PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shal, A; Nguyen, ML; Wagstaff, J; Jiang, YH; Lambert, PF				Shal, A.; Nguyen, M. L.; Wagstaff, J.; Jiang, Y-h; Lambert, P. F.			HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP	ONCOGENE			English	Article						E6; E6AP; p53	HUMAN-PAPILLOMAVIRUS TYPE-16; UBIQUITIN-PROTEIN LIGASE; CELL-CYCLE REGULATION; EPITHELIAL HYPERPLASIA; MEDIATED DEGRADATION; P53 PROTEIN; HPV-16 E6; ONCOPROTEIN; E6-AP; GENE	High-risk human papillomaviruses are the causative agents of cervical and other anogenital cancers. In these cancers, two viral oncogenes, E6 and E7, are expressed. E6 is best known for its ability to inactivate the tumor suppressor p53, which is thought to arise through ubiquitin-mediated degradation of p53 and involve a ternary complex between E6, p53 and the E3 ligase, E6AP. In mice transgenic for wild-type HPV16 E6, its expression leads to epithelial hyperplasia and an abrogation of normal cellular responses to DNA damage. Whereas only the latter phenotype is dependent upon E6's inactivation of p53, both are reduced in transgenic mice expressing an E6 mutant severely reduced in its binding to E6AP and other cellular proteins that bind E6 through a shared alpha-helix motif. Here, we investigated whether E6AP is required for the induction of the above phenotypes through the use of both E6AP-mutant and E6AP-null mice. E6, in the absence of E6AP retains an ability to induce epithelial hyperplasia, abrogate DNA damage responses and inhibit the induction (of p53 protein following exposure to ionizing radiation. We conclude that E6 is able to induce both p53-dependent and p53-independent phenotypes through E6AP-independent pathways in the mouse.	Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Dept Canc Biol, Madison, WI 53706 USA; Caroinas Med Ctr, Dept Pediat, Charlotte, NC USA; Baylor Univ, Baylor Coll Med, Dept Mol & Human Genet, Houston, TX USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor University	Lambert, PF (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, McArdle Lab Canc Res, Dept Canc Biol, 1400 Univ Ave, Madison, WI 53706 USA.	plambert@wisc.edu	Lambert, Paul F/F-3747-2012		NCI NIH HHS [R01 CA098428, T32 CA009135, P01 CA022443, P01 CA022443-300006, CA022443, P30 CA014520, R01 CA098428-04S1, R01 CA098428-04, P01 CA022443-290006, CA009135, R01 CA098428-05, P01 CA022443-310006, CA098428, CA014520] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098428, P01CA022443, P30CA014520, T32CA009135] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Cooper B, 2003, VIROLOGY, V306, P87, DOI 10.1016/S0042-6822(02)00012-0; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Gao QS, 2002, CANCER RES, V62, P3315; Gewin L, 2001, J VIROL, V75, P7198, DOI 10.1128/JVI.75.15.7198-7201.2001; Gillison ML, 2001, CURR OPIN ONCOL, V13, P183, DOI 10.1097/00001622-200105000-00009; Grm HS, 2004, J GEN VIROL, V85, P2815, DOI 10.1099/vir.0.80035-0; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Hengstermann A, 2005, J VIROL, V79, P9296, DOI 10.1128/JVI.79.14.9296-9300.2005; Herber R, 1996, J VIROL, V70, P1873, DOI 10.1128/JVI.70.3.1873-1881.1996; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar A, 2002, MOL CELL BIOL, V22, P5801, DOI 10.1128/MCB.22.16.5801-5812.2002; Lee DC, 2004, J COMMUN NETW-S KOR, V6, P78, DOI 10.1109/JCN.2004.6596990; Liu XF, 2005, J BIOL CHEM, V280, P10807, DOI 10.1074/jbc.M410343200; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; Matsumoto Y, 2006, J MED VIROL, V78, P501, DOI 10.1002/jmv.20568; Matsuura T, 1997, NAT GENET, V15, P74, DOI 10.1038/ng0197-74; Miura K, 2002, NEUROBIOL DIS, V9, P149, DOI 10.1006/nbdi.2001.0463; MUNGER K, 1989, J VIROL, V63, P4417; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAO M, 1994, HUM MOL GENET, V3, P309, DOI 10.1093/hmg/3.2.309; Nguyen M, 2002, J VIROL, V76, P13039, DOI 10.1128/JVI.76.24.13039-13048.2002; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Nguyen MM, 2003, MOL CELL BIOL, V23, P8970, DOI 10.1128/MCB.23.24.8970-8981.2003; Nomine Y, 2006, MOL CELL, V21, P665, DOI 10.1016/j.molcel.2006.01.024; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Riley RR, 2003, CANCER RES, V63, P4862; Salvat C, 2004, J BIOL CHEM, V279, P18935, DOI 10.1074/jbc.M312201200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Simonson SJS, 2005, CANCER RES, V65, P8266, DOI 10.1158/0008-5472.CAN-05-1651; Song S, 2000, VIROLOGY, V267, P141, DOI 10.1006/viro.1999.0106; Song SY, 1999, J VIROL, V73, P5887, DOI 10.1128/JVI.73.7.5887-5893.1999; Song SY, 1998, P NATL ACAD SCI USA, V95, P2290, DOI 10.1073/pnas.95.5.2290; TAKETO M, 1991, P NATL ACAD SCI USA, V88, P2065, DOI 10.1073/pnas.88.6.2065; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Traidej M, 2000, ANTISENSE NUCLEIC A, V10, P17, DOI 10.1089/oli.1.2000.10.17; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	55	21	22	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3321	3328		10.1038/sj.onc.1210130	http://dx.doi.org/10.1038/sj.onc.1210130			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130828	Green Accepted			2022-12-28	WOS:000246579600002
J	Si, ML; Zhu, S; Wu, H; Lu, Z; Wu, F; Mo, YY				Si, M.-L.; Zhu, S.; Wu, H.; Lu, Z.; Wu, F.; Mo, Y.-Y.			miR-21-mediated tumor growth	ONCOGENE			English	Article						miRNA; miR-21; post-transcriptional regulation; Bcl-2; MCF-7	HUMAN MICRORNA GENES; SMALL RNAS; C-ELEGANS; RT-PCR; EXPRESSION; ACCUMULATION; INHIBITION; BIOGENESIS; MECHANISMS; MIRNAS	MicroRNAs (miRNAs) are B22 nucleotide non-coding RNA molecules that dregulate gene expression post-transcriptionally. Although aberrant expression of miRNAs in various human cancers suggests a role for miRNAs in tumorigenesis, it remains largely unclear as to whether knockdown of a specific miRNA affects tumor growth. In this study, we profiled miRNA expression in matched normal breast tissue and breast tumor tissues by TaqMan real-time polymerase chain reaction miRNA array methods. Consistent with previous findings, we found that miR-21 was highly overexpressed in breast tumors compared to the matched normal breast tissues among 157 human miRNAs analysed. To better evaluate the role of miR-21 in tumorigenesis, we transfected breast cancer MCF-7 cells with anti-miR-21 oligonucleotides and found that anti-miR-21 suppressed both cell growth in vitro and tumor growth in the xenograft mouse model. Furthermore, this anti-miR-21-mediated cell growth inhibition was associated with increased apoptosis and decreased cell proliferation, which could be in part owing to downregulation of the antiapoptotic Bcl-2 in anti-miR-21-treated tumor cells. Together, these results suggest that miR-21 functions as an oncogene and modulates tumorigenesis through regulation of genes such as bcl-2 and thus, it may serve as a novel therapeutic target.	So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA	Southern Illinois University System; Southern Illinois University	Mo, YY (corresponding author), So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, 801 N Rutledge,POB 19626, Springfield, IL 62794 USA.	ymo@siumed.edu	Mo, Yin-Yuan/R-8255-2019; zhu, shoumin/F-4564-2011; Mo, Yin-Yuan/B-6141-2011		NATIONAL CANCER INSTITUTE [R01CA102630] Funding Source: NIH RePORTER; NCI NIH HHS [CA102630, R01 CA102630] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Fitzgerald K, 2005, CURR OPIN DRUG DISC, V8, P557; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lao KQ, 2006, BIOCHEM BIOPH RES CO, V343, P85, DOI 10.1016/j.bbrc.2006.02.106; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Mo YY, 2004, CANCER RES, V64, P2793, DOI 10.1158/0008-5472.CAN-03-2410; Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605; Tang FC, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gnj009; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	25	1259	1403	6	154	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2799	2803		10.1038/sj.onc.1210083	http://dx.doi.org/10.1038/sj.onc.1210083			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072344				2022-12-28	WOS:000246210600014
J	Huang, W; Chang, HY; Fei, T; Wu, H; Chen, YG				Huang, W.; Chang, H. Y.; Fei, T.; Wu, H.; Chen, Y-G			GSK3 beta mediates suppression of cyclin D2 expression by tumor suppressor PTEN	ONCOGENE			English	Article						PTEN; cyclin D2; gene expression; GSK3 beta; beta-catenin; TCF	GERM-CELL TUMORS; PROTEIN-KINASE-A; BETA-CATENIN; COWDEN-DISEASE; TRANSCRIPTIONAL ACTIVATION; INDUCED PROLIFERATION; COLON-CARCINOMA; GENE; PATHWAY; SURVIVAL	PTEN, encoding a lipid phosphatase, is a tumor suppressor gene and is mutated in various types of cancers. It is reported to regulate G1 to S phase transition of the cell cycle by influencing the expression, protein stability and subcellular location of cyclin D1. Here, we provide evidence that PTEN modulates the transcription and protein stability of cyclin D2. Targeted deletion of Pten in mouse embryonic fibroblasts (MEFs) endowed cells with greater potential to overcome G1 arrest than wild-type MEFs and led to the elevated expression of cyclin D2, which was suppressed by the introduction of PTEN. We further de fined a pathway involving GSK3 beta and beta-catenin/TCF in PTEN-mediated suppression of cyclin D2 transcription. LiCl, an inhibitor of GSK3b, abolished inhibitory effect of PTEN on cyclin D2 expression, and TCF members could directly bind to the promoter of cyclin D2 and regulate its transcription in a CREB-dependent manner. Our results indicate that the downregulation of cyclin D2 expression by PTEN is mediated by the GSK3 beta/beta-catenin/TCF pathway in cooperation with CREB, and suggest a convergence from the PI-3 kinase/PTEN pathway and the Wnt pathway in modulation of cyclin D2 expression.	Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China; Stanford Univ, Sch Med, Program Epithelial Biol, Stanford, CA 94305 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Tsinghua University; Stanford University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chen, YG (corresponding author), Tsing Hua Univ, Dept Mol Biol & Biotechnol, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100084, Peoples R China.	ygchen@tsinghua.edu.cn	Chen, Ye-Guang/L-6998-2019; Fei, Teng/A-5963-2010; Fei, Teng/G-5324-2015	Fei, Teng/0000-0001-5707-0673; FEI, TENG/0000-0001-9620-0450				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Anzelon AN, 2003, NAT IMMUNOL, V4, P287, DOI 10.1038/ni892; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; Chaganti RSK, 2000, CANCER RES, V60, P1475; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Vizio D, 2005, ONCOGENE, V24, P1882, DOI 10.1038/sj.onc.1208368; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huard JMT, 1999, DEVELOPMENT, V126, P1927; Jena N, 2002, CANCER RES, V62, P535; Kioussi C, 2002, CELL, V111, P673, DOI 10.1016/S0092-8674(02)01084-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, GENE CHROMOSOME CANC, V21, P61, DOI 10.1002/(SICI)1098-2264(199801)21:1<61::AID-GCC8>3.0.CO;2-6; Mohamedali A, 2003, J LEUKOCYTE BIOL, V74, P1139, DOI 10.1189/jlb.0803363; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Piatelli MJ, 2004, J IMMUNOL, V172, P2753, DOI 10.4049/jimmunol.172.5.2753; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Radu A, 2003, MOL CELL BIOL, V23, P6139, DOI 10.1128/MCB.23.17.6139-6149.2003; RAVNIK SE, 1995, DEV GENET, V16, P171, DOI 10.1002/dvg.1020160209; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; White PC, 2006, ONCOGENE, V25, P2170, DOI 10.1038/sj.onc.1209255; Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Xu LF, 2000, GENE DEV, V14, P585; Zhu XY, 2001, CANCER RES, V61, P4569	52	65	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2471	2482		10.1038/sj.onc.1210033	http://dx.doi.org/10.1038/sj.onc.1210033			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043650				2022-12-28	WOS:000245831000007
J	Frost, P; Shi, Y; Hoang, B; Lichtenstein, A				Frost, P.; Shi, Y.; Hoang, B.; Lichtenstein, A.			AKT activity regulates the ability of mTOR inhibitors to prevent angiogenesis and VEGF expression in multiple myeloma cells	ONCOGENE			English	Article						multiple myeloma; angiogenesis; internal ribosome entry sites; cap-independent translation; drug resistance; xenograft	ENDOTHELIAL GROWTH-FACTOR; BONE-MARROW ANGIOGENESIS; MESSENGER-RNA CONTAINS; RIBOSOME ENTRY SITE; MAMMALIAN TARGET; PROGNOSTIC VALUE; CYCLIN D1; IN-VIVO; TRANSLATION; ACTIVATION	We recently demonstrated that the mammalian target of rapamycin (mTOR) inhibitor, CCI-779, curtailed the growth of a subcutaneous challenge of multiple myeloma (MM) cells in immunodeficient mice. This antitumor effect was associated with prevention of cell proliferation, induction of apoptosis and inhibition of angiogenesis. Interestingly, myeloma tumors with heightened AKT activation were particularly sensitive to a CCI-779-induced antitumor response. To investigate whether part of the differential sensitivity was due to an AKT-regulated effect on angiogenesis, we compared the effects of mTOR inhibitors against isogenic MM cell lines that only differ by their degree of AKT activity. In this model, heightened AKT activity significantly sensitized MM cells to the following inhibitory effects of mTOR inhibition: angiogenesis in vivo, vascular endothelial growth factor (VEGF) expression in vitro and in vivo and VEGF translation (but not transcription). Assessment of p70S6 kinase activity indicated that rapamycin induced comparable mTOR inhibition in both cell lines suggesting that an adverse effect on VEGF cap-dependent translation would be comparable. Internal ribosome entry site (IRES)-mediated cap-independent translation is a salvage pathway for protein expression when mTOR is inhibited, so we analyzed a possible regulatory role of AKT on VEGF IRES activity. We found that elevated AKT activity inhibited VEGF IRES function. These results support a mechanism whereby AKT prevents VEGF IRES activity in myeloma cells during mTOR inhibition resulting in a more complete abrogation of VEGF translation, and ultimately, angiogenesis.	VA W Los Angeles Hosp, Dept Hematol Oncol, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	Frost, P (corresponding author), VA W Los Angeles Hosp, Dept Hematol Oncol, W111H,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.	pfrost@ucla.edu		Frost, Patrick/0000-0003-3348-5983	NATIONAL CANCER INSTITUTE [K01CA111623, R01CA096920, R01CA111448] Funding Source: NIH RePORTER; NCI NIH HHS [K01CA111623, R01CA96920, R01CA111448] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiri G, 1998, ONCOGENE, V17, P227, DOI 10.1038/sj.onc.1202019; Bellamy WT, 1999, CANCER RES, V59, P728; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bert AG, 2006, RNA, V12, P1074, DOI 10.1261/rna.2320506; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Frost P, 2004, BLOOD, V104, P4181, DOI 10.1182/blood-2004-03-1153; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kumar S, 2004, LEUKEMIA, V18, P624, DOI 10.1038/sj.leu.2403285; Kumar S, 2003, BLOOD, V101, P1715, DOI 10.1182/blood-2002-08-2441; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; LeBlanc R, 2002, CANCER RES, V62, P4996; Miller DL, 1998, FEBS LETT, V434, P417, DOI 10.1016/S0014-5793(98)01025-4; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111; Raught B, 1999, INT J BIOCHEM CELL B, V31, P43, DOI 10.1016/S1357-2725(98)00131-9; Sezer O, 2001, EUR J HAEMATOL, V66, P83, DOI 10.1034/j.1600-0609.2001.00348.x; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Stoneley M, 2000, NUCLEIC ACIDS RES, V28, P687, DOI 10.1093/nar/28.3.687; Sugawara M, 2002, HUM PATHOL, V33, P524, DOI 10.1053/hupa.2002.124783; Tu YP, 2000, CANCER RES, V60, P6763; Yan HJ, 2006, CANCER RES, V66, P2305, DOI 10.1158/0008-5472.CAN-05-2447; Zong Q, 1999, P NATL ACAD SCI USA, V96, P10632, DOI 10.1073/pnas.96.19.10632	33	59	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2255	2262		10.1038/sj.onc.1210019	http://dx.doi.org/10.1038/sj.onc.1210019			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016437				2022-12-28	WOS:000245466000001
J	Nandi, S; Reinert, LS; Hachem, A; Mazan-Mamczarz, K; Hagner, P; He, H; Gartenhaus, RB				Nandi, S.; Reinert, L. S.; Hachem, A.; Mazan-Mamczarz, K.; Hagner, P.; He, H.; Gartenhaus, R. B.			Phosphorylation of MCT-1 by p44/42 MAPK is required for its stabilization in response to DNA damage	ONCOGENE			English	Article						lymphoma; stability; phosphorylation	KINASE SIGNALING PATHWAYS; CELL-CYCLE PROGRESSION; B-CELL; CANDIDATE ONCOGENE; PROTEIN STABILITY; APOPTOSIS; PROLIFERATION; INHIBITION; ACTIVATION; EXPRESSION	We discovered a novel oncogene in a T-cell lymphoma cell line, multiple copies in T-cell lymphoma-1 (MCT-1), that has been shown to decrease cell-doubling time, shorten the duration of G(1) transit time and/or G(1)-S transition, and transform NIH3T3 fibroblasts. We subsequently demonstrated that there were significantly increased levels of MCT-1 protein in a subset of primary diffuse large B-cell lymphomas. Levels of MCT-1 protein were shown to be increased after exposure to DNA damaging agents. This increase did not require new protein synthesis, suggesting that post-translational mechanisms were involved. Phosphorylation is one potential mechanism by which the activity of molecules involved in cell cycle/survival is rapidly modulated. The RAS/mitogen-activated/extracellular-regulated kinase (MEK)/extracellular signal-regulated kinases (ERK) pathway plays a prominent role in the regulation of cell growth and proliferation through phosphorylation-dependent regulation of several substrates. The MCT-1 protein is predicted to have numerous putative phosphorylation sites. Using a combination of genetic and pharmacological approaches, we established that phosphorylation of MCT-1 protein by p44/p42 mitogen-activated protein kinases is critical for stabilization of MCT-1 protein and for its ability to promote cell proliferation. Our data suggests that targeting the RAS/MEK/ERK signal transduction cascade may provide a potential therapeutic approach in lymphomas and related malignancies that exhibit high levels of MCT-1 protein.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Calif San Diego, Dept Med, La Jolla, CA USA	University System of Maryland; University of Maryland Baltimore; University of California System; University of California San Diego	Gartenhaus, RB (corresponding author), Univ Maryland, Greenebaum Canc Ctr, 9-011 BRB,655 W Baltimore St, Baltimore, MD 21201 USA.	rgartenhaus@som.umaryland.edu		Reinert, Line/0000-0002-8317-0886				Chang FM, 2003, INT J ONCOL, V22, P469; Chen SY, 2002, J VIROL, V76, P9556, DOI 10.1128/JVI.76.18.9556-9561.2002; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; Herbert GB, 2001, ONCOGENE, V20, P6777, DOI 10.1038/sj.onc.1204881; Hsu HL, 2005, ONCOGENE, V24, P4956, DOI 10.1038/sj.onc.1208680; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Levenson AS, 2005, CANCER RES, V65, P10651, DOI 10.1158/0008-5472.CAN-05-0845; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prosniak M, 1998, CANCER RES, V58, P4233; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538; Shi B, 2003, BLOOD, V102, P297, DOI 10.1182/blood-2002-11-3486; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Werner CA, 1997, AM J PATHOL, V151, P335; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159/000068713	21	17	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2283	2289		10.1038/sj.onc.1210030	http://dx.doi.org/10.1038/sj.onc.1210030			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016429	Bronze			2022-12-28	WOS:000245466000004
J	Tong, S; Liss, AS; You, M; Bose, HR				Tong, S.; Liss, A. S.; You, M.; Bose, H. R., Jr.			The activation of TC10, a Rho small GTPase, contributes to v-Rel-mediated transformation	ONCOGENE			English	Article						v-Rel; NF-kappa B; TC10; Rho; GTPase; transformation	STIMULATED GLUT4 TRANSLOCATION; KAPPA-B FAMILY; C-REL; DNA-BINDING; CELL-TRANSFORMATION; PROTEINS; CDC42; EXPRESSION; MUTATIONS; GENES	v-Rel is the oncogenic member of the Rel/NF-kappa B family of transcription factors and transforms hematopoietic cells and fibroblasts. Differential display was employed to identify target genes that exhibit altered expression in v-Rel transformed cells. One of the cDNAs identified encodes the chicken ortholog of TC10, a member of the Rho small GTPase family. The expression of TC10 was increased in v-Rel-transformed chicken embryonic fibroblasts (CEFs) 3 to 6-fold relative to control cells at both the RNA and protein levels. An elevated level of active, GTP-bound TC10 was also detected in v-Rel-transformed cells relative to control cells. Expression of a dominant-negative TC10 mutant (TC10T32N) decreased the colony formation potential of v-Rel-transformed cells. Furthermore, overexpression of wild-type TC10 or a gain-of-function mutant (TC10Q76L) greatly enhanced the ability of v-Rel transformed CEFs to form colonies in soft agar. In addition to enhance the transformation potential of v-Rel, the overexpression of wild-type TC10 or the gain-of-function mutant alone enhanced the saturation density of CEFs and was sufficient for their anchorage-independent growth in vitro. These results indicate that elevated TC10 activity contributes to v-Rel-mediated transformation of CEFs and demonstrate for the first time that a Rho factor alone is capable of inducing the in vitro transformation of primary cells.	Univ Texas, Sect Mol Genet & Microbiol, Austin, TX 78712 USA; Univ Texas, Inst Cellular & Mol Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Bose, HR (corresponding author), Univ Texas, Sect Mol Genet & Microbiol, 1 Univ Stn A5000, Austin, TX 78712 USA.	bose@mail.utexas.edu	Liss, Andrew/L-9696-2019		NCI NIH HHS [CA33192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham MT, 2001, LARYNGOSCOPE, V111, P1285, DOI 10.1097/00005537-200107000-00027; AKIYAMA Y, 1974, BIKEN J, V17, P105; Anastasiadis PZ, 2001, J BIOL CHEM, V276, P9050, DOI 10.1074/jbc.M006570200; Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; BABA TW, 1985, VIROLOGY, V144, P139, DOI 10.1016/0042-6822(85)90312-5; Benard V, 2002, METHOD ENZYMOL, V345, P349; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Boettner B, 2002, GENE, V286, P155, DOI 10.1016/S0378-1119(02)00426-2; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; Chang L, 2002, P NATL ACAD SCI USA, V99, P12835, DOI 10.1073/pnas.202495599; Chen J, 2005, J BIOL CHEM, V280, P29912, DOI 10.1074/jbc.M504516200; Chiang SH, 2002, J BIOL CHEM, V277, P13067, DOI 10.1074/jbc.M109471200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Clark GJ, 1997, J BIOL CHEM, V272, P1677, DOI 10.1074/jbc.272.3.1677; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; Dransart E, 2005, TRAFFIC, V6, P957, DOI 10.1111/j.1600-0854.2005.00335.x; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Ellis S, 2000, TRENDS CELL BIOL, V10, P85, DOI 10.1016/S0962-8924(99)01710-9; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Frame MC, 2002, CURR OPIN GENET DEV, V12, P36, DOI 10.1016/S0959-437X(01)00261-1; FRANKLIN RB, 1977, VIROLOGY, V83, P313, DOI 10.1016/0042-6822(77)90176-3; FRYKBERG L, 1987, ONCOGENE, V1, P415; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hrdlickova R, 2006, J VIROL, V80, P281, DOI 10.1128/JVI.80.1.281-295.2006; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P308; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; HRDLICKOVA R, 1999, ENCY VIROLOGY, V3, P1496; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Keely PJ, 2001, LANCET, V358, P1744, DOI 10.1016/S0140-6736(01)06840-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P435; MOSCOW JA, 1994, ONCOGENE, V9, P189; Murphy GA, 1999, ONCOGENE, V18, P3831, DOI 10.1038/sj.onc.1202758; Murphy GA, 2001, CELL GROWTH DIFFER, V12, P157; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; NAZERIAN K, 1977, AVIAN DIS, V21, P69, DOI 10.2307/1589365; Nehyba J, 2002, MOL CELL BIOL, V22, P3942, DOI 10.1128/MCB.22.11.3942-3957.2002; Nehyba J, 1997, ONCOGENE, V14, P2881, DOI 10.1038/sj.onc.1201150; Neudauer CL, 1998, CURR BIOL, V8, P1151, DOI 10.1016/S0960-9822(07)00486-1; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; OKUNO H, 1991, ONCOGENE, V6, P1491; Osada S, 1997, FEBS LETT, V404, P227, DOI 10.1016/S0014-5793(97)00139-7; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; PERONA R, 1993, ONCOGENE, V8, P1285; Petrenko O, 1997, ONCOGENE, V15, P1671, DOI 10.1038/sj.onc.1201334; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; RAO A, 1990, CANCER RES, V50, P4764; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Ridley AJ, 2001, J CELL SCI, V114, P2713; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Ridley AJ, 1997, INT J BIOCHEM CELL B, V29, P1225, DOI 10.1016/S1357-2725(97)00052-6; ROMERO P, 1995, J VIROL, V69, P301, DOI 10.1128/JVI.69.1.301-307.1995; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; van Golen KL, 2000, CANCER RES, V60, P5832; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; Whitmire KH, 1998, ADV ORGANOMET CHEM, V42, P1, DOI 10.1016/S0065-3055(08)60542-0; You MJ, 1998, METHODS, V16, P373, DOI 10.1006/meth.1998.0692; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; ZHANG GQ, 1995, MOL CELL BIOL, V15, P1806; ZHANG JY, 1989, J VIROL, V63, P1107, DOI 10.1128/JVI.63.3.1107-1115.1989; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	88	1	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2318	2329		10.1038/sj.onc.1210023	http://dx.doi.org/10.1038/sj.onc.1210023			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016434				2022-12-28	WOS:000245466000008
J	Chang, BH; Smith, L; Huang, J; Thayer, M				Chang, B. H.; Smith, L.; Huang, J.; Thayer, M.			Chromosomes with delayed replication timing lead to checkpoint activation, delayed recruitment of Aurora B and chromosome instability	ONCOGENE			English	Article						replication checkpoint; chromosome passenger complex; genomic instability; spindle assembly checkpoint; endoreduplication; chromosome instability	DNA-DAMAGE; ARREST; TRANSLOCATIONS; ADAPTATION; SURVIVIN; CELLS; G2	Certain chromosome rearrangements display a significant delay in chromosome replication timing (DRT) that is associated with a subsequent delay in mitotic chromosome condensation (DMC). DRT/DMC chromosomes are common in tumor cells in vitro and in vivo and occur frequently in cells exposed to ionizing radiation. A hallmark for these chromosomes is the delayed phosphorylation of serine 10 of histone H3 during mitosis. The chromosome passenger complex, consisting of multiple proteins including Aurora B kinase and INCENP is thought to be responsible for H3 phosphorylation, chromosome condensation and the subsequent segregation of chromosomes. In this report, we show that chromosomes with DRT/DMC contain phosphorylated Chk1, consistent with activation of the S-M phase checkpoint. Furthermore, we show that INCENP is recruited to the DRT/DMC chromosomes during all phases of mitosis. In contrast, Aurora B kinase is absent on DRT/DMC chromosomes when these chromosomes lack serine 10 phosphorylation of H3. We also show that mitotic arrest deficient 2 (Mad2), a member of the spindle assembly checkpoint, is present on DRT/DMC chromosomes at a time when the normally condensed chromosomes show no Mad2 staining, indicating that DRT/DMC activates the spindle assembly checkpoint. Finally, cells with DRT/DMC chromosomes have centrosome amplication, abnormal spindle assembly, endoreduplication and significant chromosome instability.	Oregon Hlth & Sci Univ, Dept Biochem, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Thayer, M (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	thayerm@ohsu.edu		Chang, Bill/0000-0003-3783-1820; Smith, Leslie/0000-0001-6452-6624	NCI NIH HHS [CA 97021, R01 CA097021, R01 CA104693, CA 104693] Funding Source: Medline; NIGMS NIH HHS [F32 GM071176, F32 GM071176-01A1, F32-GM071176-01A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097021, R01CA104693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM071176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Breger KS, 2005, HUM MOL GENET, V14, P2813, DOI 10.1093/hmg/ddi314; Breger KS, 2004, CANCER RES, V64, P8231, DOI 10.1158/0008-5472.CAN-04-0879; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Galgoczy DJ, 2001, MOL CELL BIOL, V21, P1710, DOI 10.1128/MCB.21.5.1710-1718.2001; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kolodner RD, 2002, SCIENCE, V297, P552, DOI 10.1126/science.1075277; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lens SMA, 2003, EMBO J, V22, P2934, DOI 10.1093/emboj/cdg307; Liu QH, 2000, GENE DEV, V14, P1448; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Mills AD, 2000, NAT CELL BIOL, V2, P244, DOI 10.1038/35008670; Rajagopalan H, 2004, CANCER CHEMOTH PHARM, V54, pS65, DOI 10.1007/s00280-004-0889-8; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Smith A, 1998, PHARM SCI TECHNOL TO, V1, P47, DOI 10.1016/S1461-5347(98)00021-2; Smith L, 2001, P NATL ACAD SCI USA, V98, P13300, DOI 10.1073/pnas.241355098; Trask B, 1990, Methods Cell Biol, V33, P383; Yu KR, 2000, NAT CELL BIOL, V2, P609, DOI 10.1038/35023555	23	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1852	1861		10.1038/sj.onc.1209995	http://dx.doi.org/10.1038/sj.onc.1209995			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001311	Green Accepted			2022-12-28	WOS:000245117700003
J	Tsuchiya, A; Tashiro, E; Yoshida, M; Imoto, M				Tsuchiya, A.; Tashiro, E.; Yoshida, M.; Imoto, M.			Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression	ONCOGENE			English	Article						leptomycin B; cyclin D1; PP2A; c-jun	ANTI-FUNGAL ANTIBIOTICS; C-JUN; EXPORT SIGNALS; CELL-CYCLE; SERINE/THREONINE PHOSPHATASES; NUCLEOCYTOPLASMIC TRANSPORT; AP-1 ACTIVITY; OKADAIC ACID; HIV-1 REV; IN-VIVO	Leptomycin B (LMB) is a Streptomyces metabolite that causes the specific inhibition of the nuclear export of proteins containing a nuclear export signal (NES). LMB was reported to inhibit cell cycle progression in fission yeast and mammalian cells, however, the mechanism underlying LMB-induced cell cycle arrest is still obscure. In this study, we found that in serum-starved NIH3T3 cells, LMB inhibited serum-induced cyclin D1 expression at the level of transcription. However, this inhibition was reversed by inhibitors of protein phosphatase 2A (PP2A). Furthermore, we found that PP2A accumulated in the nucleus upon treatment with LMB. The finding prompted us to identify the functional NES in PP2A catalytic subunit a. These results indicated that LMB inhibited the chromosomal region maintenance 1(CRM1)-dependent nuclear export of PP2A, resulting in sustained dephosphorylation in the nucleus. Although phosphorylation of c-Jun at Ser-63 is required for activator protein 1 (AP-1)-dependent expression of cyclin D1, it decreased in LMB-treated cells compared to untreated cells. Moreover, the inhibitors of PP2A restored the levels of c-Jun phosphorylated at Ser-63. We propose that inhibition of cyclin D1 expression by LMB is mediated by the LMB-induced nuclear accumulation of PP2A, leading to sustained dephosphorylation of c-Jun at Ser-63, which leads to inactivation of the transcription of the AP-1-responsive cyclin D1 gene.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; RIKEN, Chem Genet Lab, Wako, Saitama 35101, Japan	Keio University; RIKEN	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyohi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp	Tashiro, Etsu/C-4903-2014; Imoto, Masaya/F-7957-2014; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Tashiro, Etsu/0000-0003-4533-623X				Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Haasen D, 1999, PLANT J, V20, P695, DOI 10.1046/j.1365-313X.1999.00644.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lecane PS, 2003, PROSTATE, V54, P258, DOI 10.1002/pros.10197; Lubert EJ, 2003, BIOCHEM BIOPH RES CO, V303, P908, DOI 10.1016/S0006-291X(03)00434-0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Ramirez CJ, 2005, J CELL BIOCHEM, V96, P170, DOI 10.1002/jcb.20520; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sigoillot FD, 2005, J BIOL CHEM, V280, P25611, DOI 10.1074/jbc.M504581200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Uchida S, 2004, BIOCHEM BIOPH RES CO, V316, P226, DOI 10.1016/j.bbrc.2004.02.039; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070	57	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1522	1532		10.1038/sj.onc.1209962	http://dx.doi.org/10.1038/sj.onc.1209962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964287				2022-12-28	WOS:000244782500002
J	Kim, KE; Song, H; Kim, TS; Yoon, D; Kim, CW; Bang, SI; Hur, DY; Park, H; Cho, DH				Kim, K-E; Song, H.; Kim, T. S.; Yoon, D.; Kim, C-w; Bang, S. I.; Hur, D. Y.; Park, H.; Cho, D-H			Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines	ONCOGENE			English	Article						ERK1/2; F-actin; IL-18; migration; tensin; VEGF	GAMMA-INDUCING FACTOR; IL-18; EXPRESSION; METASTASIS; PROTEIN; PROLIFERATION; ANGIOGENESIS; IMMUNITY; TENSIN; ACTS	Cell migration and angiogenesis are key steps in tumor metastasis. However, the mechanism of migration regulated by vascular endothelial growth factor ( VEGF), a potent regulator of angiogenesis, is not completely understood. This study examined the relationship between VEGF and migration, along with the mechanism involved in the VEGF-regulated migration of human gastric cancer cells. The level of cell migration was increased by recombinant human (rh) VEGF-165 in the VEGF receptor-2-expressing SNU-601 cells. Interleukin (IL)-18 is associated with the malignant progression of tumors. Accordingly, this study examined the effect of IL-18 on the migration of cancer cells in order to identify the factors involved in VEGF-enhanced migration. Inhibiting IL-18 markedly reduced the level of VEGF-enhanced migration, and IL-18 increased cell migration directly through filamentous-actin polymerization and tensin downregulation. It was confirmed that rhVEGF-165 increased IL-18 production significantly. An antioxidant and an extracellular signal-regulated kinase (ERK) 1/2-specific inhibitor blocked rhVEGF-165-enhanced IL-18 production. Accordingly, rhVEGF-165 increased the generation of region of interest (ROI) and activated the ERK1/2 pathway. These results suggest that rhVEGF-165 enhances IL-18 production via the generation of ROI and ERK1/2 phosphorylation, which results in the increased migration of gastric cancer cells.	Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea; Sookmyung Womens Univ, Dept Life Sci, Seoul 140742, South Korea; Inje Univ, Coll Med, Dept Anat, Pusan, South Korea; Korea Univ, Sch Life Sci & Technol, Seoul 136701, South Korea; Konkuk Univ, Grad Sch, Div Biosci & Biotechnol, Seoul, South Korea; Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea; Seoul Natl Univ, Coll Med, Tumor Immun Med Res Ctr, Seoul, South Korea; Sungkyunkwan Univ, Sch Med, Dept Plast Surg, Samsung Med Ctr, Seoul, South Korea	Catholic University of Korea; Catholic University Korea Hospital; Seoul St. Mary's Hospital; Sookmyung Women's University; Inje University; Korea University; Konkuk University; Seoul National University (SNU); Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center	Park, H (corresponding author), Catholic Univ Korea, Dept Dermatol, St Marys Hosp, Coll Med, Seoul, South Korea.	hjpark@catholic.ac.kr; cdhkor@sookmyung.ac.kr	Kim, Chul-Woo/F-7008-2011					Cao RH, 1999, FASEB J, V13, P2195, DOI 10.1096/fasebj.13.15.2195; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carrascal MT, 2003, CANCER RES, V63, P491; Chen JH, 2004, CELL COMMUN ADHES, V11, P1, DOI 10.1080/15419060490471739; Cho D, 2000, CANCER RES, V60, P2703; Cho DH, 2002, BIOCHEM BIOPH RES CO, V298, P289, DOI 10.1016/S0006-291X(02)02433-6; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Gossart S, 1996, J IMMUNOL, V156, P1540; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ishida Y, 2004, FEBS LETT, V569, P156, DOI 10.1016/j.febslet.2004.05.039; Ju DW, 2001, CANCER RES, V61, P3735; Lissoni P, 2000, J BIOL REG HOMEOS AG, V14, P275; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; Lo SH, 2004, INT J BIOCHEM CELL B, V36, P31, DOI 10.1016/S1357-2725(03)00171-7; Majima T, 2006, INT J CANCER, V118, P388, DOI 10.1002/ijc.21334; Meili R, 2003, CELL, V114, P153, DOI 10.1016/S0092-8674(03)00553-1; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Stoll S, 1997, J IMMUNOL, V159, P298; TAKAHASHI Y, 1995, CANCER RES, V55, P3964; Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Zhang B, 2004, LEUKEMIA RES, V28, P91, DOI 10.1016/S0145-2126(03)00121-8; Zhang H, 2002, WORLD J GASTROENTERO, V8, P994, DOI 10.3748/wjg.v8.i6.994	25	64	68	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1468	1476		10.1038/sj.onc.1209926	http://dx.doi.org/10.1038/sj.onc.1209926			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	17001321				2022-12-28	WOS:000244558800011
J	Laine, A; Ronai, Z				Laine, A.; Ronai, Z.			Regulation of p53 localization and transcription by the HECT domain E3 ligase WWP1	ONCOGENE			English	Article						p53; WWP1; ubiquitin; HECHT; E3 ligases; transcription	UBIQUITIN-PROTEIN LIGASE; KRUPPEL-LIKE FACTOR; DEGRADATION; STABILITY; DEATH; MDM2; ACTIVATION; PROMOTES; PATHWAY; MOTIFS	As a key cellular regulatory protein p53 is subject to tight regulation by several E3 ligases. Here, we demonstrate the role of HECT domain E3 ligase, WWP1, in regulating p53 localization and activity. WWP1 associates with p53 and induces p53 ubiquitylation. Unlike other E3 ligases, WWP1 increases p53 stability; inhibition of WWP1 expression or expression of a ligase-mutant form results in decreased p53 expression. WWP1-mediated stabilization of p53 is associated within creased accumulation of p53 in cytoplasm witha concomitant decrease in its transcriptional activities. WWP1 effects are independent of Mdm2 as they are seen in cells lacking Mdm2 expression. Whereas WWP1 limits p53 activity, p53 reduces expression of WWP1, pointing to a possible feedback loop mechanism. Taken together, these findings identify the first instance of a ubiquitin ligase that causes stabilization of p53 while inactivating its transcriptional activities.	Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ronai, Z (corresponding author), Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@burnham.org		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA78419, R01 CA078419-08, R01 CA078419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Conkright MD, 2001, J BIOL CHEM, V276, P29299, DOI 10.1074/jbc.M103670200; DORAN D, 2004, NATURE, V429, P86; Galinier R, 2002, BIOCHEMISTRY-US, V41, P14299, DOI 10.1021/bi020125b; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang K, 2000, GENE, V252, P137, DOI 10.1016/S0378-1119(00)00216-X; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kasanov J, 2001, CHEM BIOL, V8, P231, DOI 10.1016/S1074-5521(01)00005-9; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362; Martin-Serrano J, 2005, J CELL BIOL, V168, P89, DOI 10.1083/jcb.200408155; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Wang ZX, 2004, ONCOGENE, V23, P8146, DOI 10.1038/sj.onc.1207992; Xu HM, 2004, J BIOL CHEM, V279, P23495, DOI 10.1074/jbc.M400516200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	34	100	102	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1477	1483		10.1038/sj.onc.1209924	http://dx.doi.org/10.1038/sj.onc.1209924			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924229	Green Accepted			2022-12-28	WOS:000244558800012
J	Rojas, P; Cadenas, MB; Lin, PC; Benavides, F; Conti, CJ; Rodriguez-Puebla, ML				Rojas, P.; Cadenas, M. B.; Lin, P. -C; Benavides, F.; Conti, C. J.; Rodriguez-Puebla, M. L.			Cyclin D2 and cyclin D3 play opposite roles in mouse skin carcinogenesis	ONCOGENE			English	Article						cyclin D3; cyclin D2; skin; DMBA; keratinocytes; papillomas	DEPENDENT KINASE-ACTIVITY; SQUAMOUS-CELL CARCINOMA; TUMOR-DEVELOPMENT; IN-VIVO; TRANSGENIC MICE; EXPRESSION; PROLIFERATION; D1; DIFFERENTIATION; PROGRESSION	D-type cyclins are components of the cell-cycle engine that link cell signaling pathways and passage throughout G1 phase. We previously described the effects of overexpression cyclin D1, D2 or D3 in mouse epidermis and tumor development. We now asked whether cyclin D2 and/or cyclin D3 play a relevant role in ras-dependent tumorigenesis. Here, we described the effect of cyclin D3 and cyclin D2 overexpression in mouse skin tumor development. Notably, overexpression of cyclin D3 results in reduced tumor development and malignant progression to squamous cell carcinomas (SCC). Biochemical analysis of keratinocytes shows that overexpression of cyclin D3 results in strong reduction of cyclin D2 and its associated kinase activity. Furthermore, we found that reinstatement of cyclin D2 level in the cyclin D3/cyclin D2 bigenic mice results in a complete reversion of the inhibitory action of cyclin D3. Supporting these results, ablation of cyclin D2 results in reduced tumorigenesis and malignant progression. On the other hand, overexpression of cyclin D2 results in an increased number of papillomas and malignant progression. We conclude that cyclin D3 and cyclin D2 play opposite roles in mouse skin tumor development and that the suppressive activity of cyclin D3 is associated with cyclin D2 downregulation.	N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, Raleigh, NC 27606 USA; MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Div, Smithville, TX USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of North Carolina; North Carolina State University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Rodriguez-Puebla, ML (corresponding author), N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res Mol Biomed Sci, CVM, 4700 Hillsborough St, Raleigh, NC 27606 USA.	marcelo_rodriguez-puebla@ncsu.edu	Lin, Pei-Chun/A-3200-2013	Benavides, Fernando/0000-0003-1275-4320	NATIONAL CANCER INSTITUTE [R01CA116328] Funding Source: NIH RePORTER; NCI NIH HHS [CA116328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 1998, ONCOGENE, V17, P1027, DOI 10.1038/sj.onc.1202016; Cheung TH, 2001, CANCER LETT, V166, P199, DOI 10.1016/S0304-3835(01)00457-8; Ciemerych MA, 2002, GENE DEV, V16, P3277, DOI 10.1101/gad.1023602; de Marval PLM, 2004, ONCOGENE, V23, P1863, DOI 10.1038/sj.onc.1207309; DELMER A, 1995, BLOOD, V85, P2870, DOI 10.1182/blood.V85.10.2870.bloodjournal85102870; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Filipits M, 2002, CLIN CANCER RES, V8, P729; Fujii M, 2001, CANCER LETT, V172, P187, DOI 10.1016/S0304-3835(01)00651-6; Hedberg Y, 2002, ACTA ONCOL, V41, P175, DOI 10.1080/028418602753669562; HOULDSWORTH J, 1997, CELL GROWTH DIFFER, V8, P292; Ito Y, 2001, ANTICANCER RES, V21, P1043; KIESS M, 1995, ONCOGENE, V10, P159; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Mariappan I, 2005, MOL BIOL CELL, V16, P1948, DOI 10.1091/mbc.E04-02-0154; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Pruneri G, 2005, CLIN CANCER RES, V11, P242; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rodriguez-Puebla ML, 1998, CELL GROWTH DIFFER, V9, P31; Rodriguez-Puebla ML, 1999, CELL GROWTH DIFFER, V10, P467; Rodriguez-Puebla ML, 2000, AM J PATHOL, V157, P1039, DOI 10.1016/S0002-9440(10)64616-0; Rodriguez-Puebla ML, 1998, ONCOGENE, V17, P2251, DOI 10.1038/sj.onc.1202131; Rodriguez-Puebla ML, 2002, AM J PATHOL, V161, P405, DOI 10.1016/S0002-9440(10)64196-X; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1999, GENE DEV, V10, P1491; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Zhang SY, 1997, MOL CARCINOGEN, V18, P142, DOI 10.1002/(SICI)1098-2744(199703)18:3<142::AID-MC3>3.3.CO;2-J	33	18	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1723	1730		10.1038/sj.onc.1209970	http://dx.doi.org/10.1038/sj.onc.1209970			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983339				2022-12-28	WOS:000244955600006
J	Sui, Y; Yang, Z; Xiong, S; Zhang, L; Blanchard, KL; Peiper, SC; Dynan, WS; Tuan, D; Ko, L				Sui, Y.; Yang, Z.; Xiong, S.; Zhang, L.; Blanchard, K. L.; Peiper, S. C.; Dynan, W. S.; Tuan, D.; Ko, L.			Gene amplification and associated loss of 5 ' regulatory sequences of CoAA in human cancers	ONCOGENE			English	Article						gene amplification; CoAA oncogene; transcriptional coactivator	BINDING PROTEIN; CHROMOSOMAL TRANSLOCATIONS; RECEPTOR COREGULATORS; SYNOVIAL SARCOMA; DNA METHYLATION; FRAGILE SITES; COACTIVATOR; EXPRESSION; IDENTIFICATION; TRANSCRIPTION	CoAA is an RRM-containing transcriptional coactivator that stimulates transcriptional activation and regulates alternative splicing. We show that the CoAA gene is amplified at the chromosome 11q13 locus in a subset of primary human cancers including non-small cell lung carcinoma, squamous cell skin carcinoma and lymphoma. Analysis of 42 primary tumors suggests that CoAA amplifies independently from the CCND1 locus. Detailed mapping of three CoAA amplicons reveals that the amplified CoAA gene is consistently located at the 50 boundaries of the amplicons. The CoAA coding and basal promoter sequences are retained within the amplicons but upstream silencing sequences are lost. CoAA protein is overexpressed in tumors containing the amplified CoAA gene. RNA dot blot analysis of 100 cases of primary tumors suggests elevated CoAA mRNA expression. CoAA positively regulates its own basal promoter in transfection assays. Thus, gene amplification, loss of silencing sequence and positive feedback regulation may lead to drastic upregulation of CoAA protein. CoAA has transforming activities when tested in soft agar assays, and CoAA is homologous to oncoproteins EWS and TLS, which regulate alternative splicing. These data imply that CoAA may share a similar oncogenic mechanism with oncogene EWS and that CoAA deregulation may alter the alternative splicing of target genes.	Med Coll Georgia, Dept Pathol, IMMAG, Augusta, GA 30912 USA; Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Lilly Res Labs, Indianapolis, IN USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; Eli Lilly	Ko, L (corresponding author), Med Coll Georgia, Dept Pathol, IMMAG, 1120 15th St,CB2803, Augusta, GA 30912 USA.	lko@mcg.edu		Dynan, William/0000-0002-4045-5662; Ko, Lan/0000-0002-0089-9090	NATIONAL CANCER INSTITUTE [R01CA098239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073453] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA098239-03, R01 CA098239] Funding Source: Medline; NHLBI NIH HHS [R01 HL089519, R01 HL073453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; Auboeuf D, 2004, MOL CELL BIOL, V24, P442, DOI 10.1128/MCB.24.1.442-453.2004; Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Bystritskiy AA, 2004, CRIT REV EUKAR GENE, V14, P65, DOI 10.1615/CritRevEukaryotGeneExpr.v14.40; Caiafa P, 2005, J CELL BIOCHEM, V94, P257, DOI 10.1002/jcb.20325; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; Fox AH, 2002, CURR BIOL, V12, P13, DOI 10.1016/S0960-9822(01)00632-7; Gibbons R, 2005, GENOME, V48, P160, DOI 10.1139/G04-085; Grandinetti KB, 2006, ONCOGENE, V25, P706, DOI 10.1038/sj.onc.1209095; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Guan XY, 1996, CANCER RES, V56, P3446; Iwasaki T, 2001, J BIOL CHEM, V276, P33375, DOI 10.1074/jbc.M101517200; Jasinska A, 2004, FEBS LETT, V567, P136, DOI 10.1016/j.febslet.2004.03.109; Kalnina Z, 2005, GENE CHROMOSOME CANC, V42, P342, DOI 10.1002/gcc.20156; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kim J, 1999, PHYSIOL GENOMICS, V1, P127, DOI 10.1152/physiolgenomics.1999.1.3.127; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koreth J, 1999, J PATHOL, V187, P28, DOI 10.1002/(SICI)1096-9896(199901)187:1<28::AID-PATH166>3.0.CO;2-R; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; LAMMIE GA, 1991, CANCER CELL-MON REV, V3, P413; Lee JW, 2005, STEM CELLS, V23, P738, DOI 10.1634/stemcells.2004-0375; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Penalva LOF, 2003, MICROBIOL MOL BIOL R, V67, P343, DOI 10.1128/MMBR.67.3.343-359.2003; Rabbitts TH, 1999, J PATHOL, V187, P39; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Schmid CW, 1998, NUCLEIC ACIDS RES, V26, P4541, DOI 10.1093/nar/26.20.4541; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Yang L, 2000, J BIOL CHEM, V275, P37612, DOI 10.1074/jbc.M005739200; Yang XJ, 2004, NUCLEIC ACIDS RES, V32, P959, DOI 10.1093/nar/gkh252; Zainabadi K, 2005, GENOMICS, V85, P704, DOI 10.1016/j.ygeno.2005.02.014; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513	40	19	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					822	835		10.1038/sj.onc.1209847	http://dx.doi.org/10.1038/sj.onc.1209847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878147	Green Accepted			2022-12-28	WOS:000244063800004
J	Burdak-Rothkamm, S; Short, SC; Folkard, M; Rothkamm, K; Prise, KM				Burdak-Rothkamm, S.; Short, S. C.; Folkard, M.; Rothkamm, K.; Prise, K. M.			ATR-dependent radiation-induced gamma H2AX foci in bystander primary human astrocytes and glioma cells	ONCOGENE			English	Article						ATR; gamma H2AX; DNA damage; charged particle irradiation; targeted irradiation; bystander signalling	DOUBLE-STRAND BREAKS; CHARGED-PARTICLE MICROBEAM; MEDIATED INTERCELLULAR COMMUNICATION; IONIZING-RADIATION; REACTIVE OXYGEN; HUMAN FIBROBLASTS; IRRADIATED-CELLS; ALPHA-PARTICLES; HISTONE H2AX; GENOMIC INSTABILITY	Radiotherapy is an important treatment for patients suffering from high-grade malignant gliomas. Non-targeted ( bystander) effects may influence these cells' response to radiation and the investigation of these effects may therefore provide new insights into mechanisms of radiosensitivity and responses to radiotherapy as well as de. ne new targets for therapeutic approaches. Normal primary human astrocytes ( NHA) and T98G glioma cells were irradiated with helium ions using the Gray Cancer Institute microbeam facility targeting individual cells. Irradiated NHA and T98G glioma cells generated signals that induced gamma H2AX foci in neighbouring non-targeted bystander cells up to 48 h after irradiation. gamma H2AX bystander foci were also observed in co-cultures targeting either NHA or T98G cells and in medium transfer experiments. Dimethyl sulphoxide, Filipin and antitransforming growth factor (TGF)-beta 1 could suppress gamma H2AX foci in bystander cells, confirming that reactive oxygen species (ROS) and membrane-mediated signals are involved in the bystander signalling pathways. Also, TGF-beta 1 induced gamma H2AX in an ROS- dependent manner similar to bystander foci. ROS and membrane signalling-dependent differences in bystander foci induction between T98G glioma cells and normal human astrocytes have been observed. Inhibition of ataxia telangiectasia mutated (ATM) protein and DNA-PK could not suppress the induction of bystander gamma H2AX foci whereas the mutation of ATM- and rad3-related (ATR) abrogated bystander foci induction. Furthermore, ATR-dependent bystander foci induction was restricted to S-phase cells. These observations may provide additional therapeutic targets for the exploitation of the bystander effect.	Mt Vernon Hosp, Gray Canc Inst, Northwood HA6 2JR, Middx, England; Univ Oxford, Gray Canc Inst, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Burdak-Rothkamm, S (corresponding author), Mt Vernon Hosp, Gray Canc Inst, POB 100, Northwood HA6 2JR, Middx, England.	burdak-rothkamm@gci.ac.uk	Rothkamm, Kai/A-2164-2014; Prise, Kevin/N-7872-2015; Burdak-Rothkamm, Susanne/I-2553-2012	Rothkamm, Kai/0000-0001-7414-5729; Prise, Kevin/0000-0001-6134-7946; Burdak-Rothkamm, Susanne/0000-0002-3840-2844; Short, Susan/0000-0003-4423-7256				Ayache N, 2002, OSTEOARTHR CARTILAGE, V10, P344, DOI 10.1053/joca.2001.0499; Azzam EI, 2002, CANCER RES, V62, P5436; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Azzam EI, 2000, CANCER RES, V60, P2623; Bellocq A, 1999, AM J RESP CELL MOL, V21, P128, DOI 10.1165/ajrcmb.21.1.3379; Belyakov OV, 2002, RADIAT PROT DOSIM, V99, P249, DOI 10.1093/oxfordjournals.rpd.a006775; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Gerashchenko BI, 2003, CYTOM PART A, V56A, P71, DOI 10.1002/cyto.a.10092; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hsu HY, 2002, J BIOL CHEM, V277, P22131, DOI 10.1074/jbc.M111883200; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hwang YS, 2004, ONCOGENE, V23, P6603, DOI 10.1038/sj.onc.1207867; Kashino G, 2004, MUTAT RES-FUND MOL M, V556, P209, DOI 10.1016/j.mrfmmm.2004.08.009; Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598; Leach JK, 2001, CANCER RES, V61, P3894; LIAO H, 1995, J CELL BIOL, V130, P507, DOI 10.1083/jcb.130.3.507; Lyng FM, 2002, RADIAT RES, V157, P365, DOI 10.1667/0033-7587(2002)157[0365:IOAICE]2.0.CO;2; Maguire P, 2005, RADIAT RES, V163, P384, DOI 10.1667/RR3325; Mitchell SA, 2004, RADIAT RES, V161, P397, DOI 10.1667/RR3137; Morgan WF, 2003, ONCOGENE, V22, P7094, DOI 10.1038/sj.onc.1206992; Mothersill C, 2004, RADIAT RES, V161, P256, DOI 10.1667/RR3136; Mothersill CE, 2004, INT J RADIAT ONCOL, V58, P575, DOI 10.1016/j.ijrobp.2003.09.038; Nagasawa H, 2003, INT J RADIAT BIOL, V79, P35, DOI 10.1080/0955300021000019230; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Ryan KA, 2004, INFECT IMMUN, V72, P2123, DOI 10.1128/IAI.72.4.2123-2130.2004; Sawant SG, 2001, RADIAT RES, V155, P397, DOI 10.1667/0033-7587(2001)155[0397:TBEIRO]2.0.CO;2; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Shao C, 2005, INT J CANCER, V116, P45, DOI 10.1002/ijc.21003; Shao C, 2003, CANCER RES, V63, P8437; SHAO C, 2006, IN PRESS RAD RES; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, RADIAT RES, V160, P318, DOI 10.1667/RR3044; Sokolov MV, 2005, ONCOGENE, V24, P7257, DOI 10.1038/sj.onc.1208886; Souhami R, 2005, CANC ITS MANAGEMENT; Stiff T, 2004, CANCER RES, V64, P2390, DOI 10.1158/0008-5472.CAN-03-3207; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Veuger SJ, 2003, CANCER RES, V63, P6008; Wang HY, 2005, J CELL PHYSIOL, V202, P492, DOI 10.1002/jcp.20141; Ward IM, 2001, J BIOL CHEM, V276, P47759, DOI 10.1074/jbc.C100569200; Yang HY, 2005, ONCOGENE, V24, P2096, DOI 10.1038/sj.onc.1208439; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797	48	153	159	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					993	1002		10.1038/sj.onc.1209863	http://dx.doi.org/10.1038/sj.onc.1209863			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909103				2022-12-28	WOS:000244245400005
J	Lo, PHY; Leung, ACC; Kwok, CYC; Cheung, WSY; Ko, JMY; Yang, LC; Law, S; Wang, LD; Li, J; Stanbridge, EJ; Srivastava, G; Tang, JCO; Tsao, SW; Lung, ML				Lo, P. H. Y.; Leung, A. C. C.; Kwok, C. Y. C.; Cheung, W. S. Y.; Ko, J. M. Y.; Yang, L. C.; Law, S.; Wang, L. D.; Li, J.; Stanbridge, E. J.; Srivastava, G.; Tang, J. C. O.; Tsao, S. W.; Lung, M. L.			Identification of a tumor suppressive critical region mapping to 3p14.2 in esophageal squamous cell carcinoma and studies of a candidate tumor suppressor gene, ADAMTS9	ONCOGENE			English	Article						esophageal carcinoma; tumor suppressor gene; chromosome 3; microcell-mediated chromosome transfer; ADAMTS9	NASOPHARYNGEAL CARCINOMA; EPIGENETIC INACTIVATION; FUNCTIONAL EVIDENCE; CHROMOSOME 3P21.3; CANCER; LINES; EXPRESSION; HUMAN-CHROMOSOME-3; TUMORIGENICITY; ESTABLISHMENT	A gene critical to esophageal cancer has been identified. Functional studies using microcell-mediated chromosome transfer of intact and truncated donor chromosomes 3 into an esophageal cancer cell line and nude mouse tumorigenicity assays were used to identify a 1.61Mb tumor suppressive critical region (CR) mapping to chromosome 3p14.2. This CR is bounded by D3S1600 and D3S1285 microsatellite markers. One candidate tumor suppressor gene, ADAMTS9, maps to this CR. Further studies showed normal expression levels of this gene in tumor-suppressed microcell hybrids, levels that were much higher than observed in the recipient cells. Complete loss or downregulation of ADAMTS9 gene expression was found in 15 out of 16 esophageal carcinoma cell lines. Promoter hypermethylation was detected in the cell lines that do not express this gene. Re-expression of ADAMTS9 was observed after demethylation drug treatment, confirming that hypermethylation is involved in gene downregulation. Downregulation of ADAMTS9 was also found in 43.5 and 47.6% of primary esophageal tumor tissues from Hong Kong and from the high-risk region of Henan, respectively. Thus, this study identifies and provides functional evidence for a CR associated with tumor suppression on 3p14.2 and provides the first evidence that ADAMTS9, mapping to this region, may contribute to esophageal cancer development.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Canc Res, Kowloon, Hong Kong, Peoples R China; Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Zhengzhou Univ, Ctr Med Expt, Canc Res Lab, Henan Key Lab Esophageal Canc, Zhengzhou 450052, Henan, Peoples R China; Yaocun Esophageal Canc Hosp, Dept Pathol, Linzhou, Henan, Peoples R China; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Hong Kong; Zhengzhou University; University of California System; University of California Irvine; University of Hong Kong; Hong Kong Polytechnic University; University of Hong Kong	Lung, ML (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.	bomaria@ust.hk	Tang, Johnny C. O./M-9639-2014; Ko, Josephine/U-2972-2019; Law, Simon/C-4324-2009; Tang, Johnny Cheuk-on/W-7214-2019; Lung, Maria Li/C-4495-2009	Tang, Johnny C. O./0000-0002-4261-3206; Ko, Josephine/0000-0002-7997-331X; Law, Simon/0000-0002-6518-5806; Tang, Johnny Cheuk-on/0000-0002-4261-3206; Lung, Maria Li/0000-0003-2559-3626				Chen WY, 2005, CELL CYCLE, V4, P10, DOI 10.4161/cc.4.1.1361; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; CHEUNG AL, 2005, IN PRESS CANC LETT; Clark ME, 2000, GENOMICS, V67, P343, DOI 10.1006/geno.2000.6246; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Horiguchi K, 2003, ONCOGENE, V22, P7862, DOI 10.1038/sj.onc.1207082; HU CP, 1984, J NATL CANCER I, V72, P577; Hu YC, 2002, CANCER GENET CYTOGEN, V135, P120, DOI 10.1016/S0165-4608(01)00580-5; Ko JMY, 2005, GENE CHROMOSOME CANC, V43, P284, DOI 10.1002/gcc.20190; Ko JMY, 2001, CANCER LETT, V170, P131, DOI 10.1016/S0304-3835(01)00577-8; Li J Y, 1982, Natl Cancer Inst Monogr, V62, P113; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812; Lung HL, 2004, INT J CANCER, V112, P628, DOI 10.1002/ijc.20454; MOK CH, 1987, ANTICANCER RES, V7, P409; PAN Q, 1989, Proceedings of the Chinese Academy of Medical Sciences and the Peking Union Medical College, V4, P52; Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3; Qin Yan-Ru, 2005, Zhonghua Bing Li Xue Za Zhi, V34, P80; RIMESSI P, 1994, ONCOGENE, V9, P3467; Rooney D E, 1986, HUMAN CYTOGENETICS P, VFirst; Sambrook J, 1989, MOL CLONING; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; Sekine I, 2005, ONCOGENE, V24, P2735, DOI 10.1038/sj.onc.1207694; SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C; Shiomi H, 2003, CANCER GENET CYTOGEN, V147, P50, DOI 10.1016/S0165-4608(03)00159-6; Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200; Takahashi K., 1990, JPN J ORAL MAXILLOFA, V36, P307; Tanaka H, 1998, GENE CHROMOSOME CANC, V23, P123, DOI 10.1002/(SICI)1098-2264(199810)23:2<123::AID-GCC5>3.0.CO;2-4; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Uzawa N, 1998, CANCER GENET CYTOGEN, V107, P125, DOI 10.1016/S0165-4608(98)00097-1; Wang L, 1996, ONCOGENE, V12, P699; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yang Y, 2001, P NATL ACAD SCI USA, V98, P1136, DOI 10.1073/pnas.98.3.1136	37	65	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					148	157		10.1038/sj.onc.1209767	http://dx.doi.org/10.1038/sj.onc.1209767			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799631				2022-12-28	WOS:000243236500015
J	Ayrault, O; Andrique, L; Fauvin, D; Eymin, B; Gazzeri, S; Seite, P				Ayrault, O.; Andrique, L.; Fauvin, D.; Eymin, B.; Gazzeri, S.; Seite, P.			Human tumor suppressor p14(ARF) negatively regulates rRNA transcription and inhibits UBF1 transcription factor phosphorylation	ONCOGENE			English	Article						p14(ARF); rRNA promoter; UBF	POLYMERASE-I TRANSCRIPTION; RDNA TRANSCRIPTION; CELL-PROLIFERATION; TOPOISOMERASE-I; PROTEIN; GENE; P19(ARF); P53; RB; BIOGENESIS	The nucleolar Arf protein has been shown to regulate cell cycle through both p53-dependent and -independent pathways. In addition to the well-characterized Arf-mdm2-p53 pathway, several partners of Arf have recently been described that could participate in alternative regulation process. Among those is the nucleolar protein B23/NPM, involved in the sequential maturation of rRNA. p19(ARF) can interact with B23/NPM in highmolecular complexes and partially inhibit the cleavage of the 32S rRNA, whereas the human p14(ARF) protein has been shown to participate in the degradation of NPM/B23 by the proteasome. These data led to define Arf as a negative regulator of ribosomal RNA maturation. Our recent finding that the human p14ARF protein was able to specifically interact with the rRNA promoter in a p53-independent context, led us to analyse in vitro and in vivo the consequences of this interaction. Luciferase assay and pulse-chase experiments demonstrated that the rRNA transcription was strongly reduced upon p14(ARF) overexpression. Investigations on potential interactions between p14(ARF) and the transcription machinery proteins demonstrated that the upstream binding factor (UBF), required for the initiation of the transcriptional complex, was a new partner of the p14(ARF) protein. We next examined the phosphorylation status of UBF as UBF phosphorylation is required to recruit on the promoter factors involved in the transcriptional complex. Upon p14(ARF) overexpression, UBF was found hypophosphorylated, thus unable to efficiently recruit the transcription complex. Taken together, these data de. ne a new p53-independent pathway that could regulate cell cycle through the negative control of rRNA transcription.	Lab Oncol Mol, EA 3805, F-86022 Poitiers, France; Inst Albert Bonniot, Grp Rech Canc Poumon, EA 2021, INSERM,Unite U578, La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Seite, P (corresponding author), Lab Oncol Mol, EA 3805, Pole Biol Sante 40,Ave Recteur Pineau, F-86022 Poitiers, France.	paule.seite@univ-poitiers.fr	Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/U-4669-2019; gazzeri, sylvie/M-1961-2013; eymin, beatrice/U-4670-2019	Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; eymin, beatrice/0000-0002-7311-3810; Seite, Paule/0000-0002-7809-7610; Andrique, Laetitia/0000-0001-7840-8135				Andrique T, 2005, ONCOGENE, V24, P2580, DOI 10.1038/sj/onc.1208457; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Ciarmatori S, 2001, MOL CELL BIOL, V21, P5806, DOI 10.1128/MCB.21.17.5806-5814.2001; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Drakas R, 2004, P NATL ACAD SCI USA, V101, P9272, DOI 10.1073/pnas.0403328101; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; GARG LC, 1987, P NATL ACAD SCI USA, V84, P3185, DOI 10.1073/pnas.84.10.3185; Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200; Grummt I, 1999, PROG NUCLEIC ACID RE, V62, P109; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hannan KM, 2000, ONCOGENE, V19, P4988, DOI 10.1038/sj.onc.1203875; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Klein J, 1999, P NATL ACAD SCI USA, V96, P6096, DOI 10.1073/pnas.96.11.6096; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Savkur RS, 1998, NUCLEIC ACIDS RES, V26, P4508, DOI 10.1093/nar/26.19.4508; Stefanovsky VY, 2001, MOL CELL, V8, P1063, DOI 10.1016/S1097-2765(01)00384-7; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Voit R, 1999, EMBO J, V18, P1891, DOI 10.1093/emboj/18.7.1891; Voit R, 1997, MOL CELL BIOL, V17, P4230, DOI 10.1128/MCB.17.8.4230; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; Voit R, 2001, P NATL ACAD SCI USA, V98, P13631, DOI 10.1073/pnas.231071698; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000	35	62	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7577	7586		10.1038/sj.onc.1209743	http://dx.doi.org/10.1038/sj.onc.1209743			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16924243				2022-12-28	WOS:000242655500003
J	Taketo, MM				Taketo, M. M.			Wnt signaling and gastrointestinal tumorigenesis in mouse models	ONCOGENE			English	Review						Wnt; Apc; beta-catenin; colon cancer; gastric cancer	FAMILIAL ADENOMATOUS POLYPOSIS; APC(DELTA-716) KNOCKOUT MICE; MULTIPLE INTESTINAL NEOPLASIA; HYPERPLASTIC GASTRIC TUMORS; COMPOUND MUTANT MICE; COLON-CANCER CELLS; PPAR-DELTA STATUS; BETA-CATENIN; CYCLOOXYGENASE-2 INHIBITOR; TRANSGENIC MICE	The canonical Wnt signaling plays important roles in embryonic development and tumorigenesis. For the latter, induced mutations in mice have greatly contributed to our understanding of the molecular mechanisms of cancer initiation and progression. Here, I will review recent reports on gastrointestinal cancer model mice, with an emphasis on the roles of the Wnt signal pathway. They include: mouse models for familial adenomatous polyposis; modifying factors that affect mouse intestinal polyposis, including the genes that help cancer progression; Wnt target genes that affect mouse intestinal polyposis; and a mouse model of gastric cancer that mimics Helicobacter pyroli infection.	Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Kyoto 6068501, Japan	Kyoto University	Taketo, MM (corresponding author), Kyoto Univ, Grad Sch Med, Dept Pharmacol, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	taketo@mfour.med.kyoto-u.ac.jp						Ahn B, 2001, CANCER RES, V61, P8357; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; AOKI K, 2006, IN PRESS ONCOGENE; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chulada PC, 2000, CANCER RES, V60, P4705; Correa P, 2003, CANCER EPIDEM BIOMAR, V12, p238S; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; Goss KH, 2002, SCIENCE, V297, P2051, DOI 10.1126/science.1074340; Gould TD, 2003, PHARMACOL RES, V48, P49, DOI 10.1016/S0143-6618(03)00096-3; Gounari F, 2002, ONCOGENE, V21, P4099, DOI 10.1038/sj.onc.1205562; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Higuchi T, 2003, CLIN CANCER RES, V9, P4756; Jansson EA, 2005, P NATL ACAD SCI USA, V102, P1460, DOI 10.1073/pnas.0405928102; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; KINZLER KW, 1991, SCIENCE, V251, P1366, DOI 10.1126/science.1848370; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; Leow CC, 2005, ANN NY ACAD SCI, V1059, P174, DOI 10.1196/annals.1339.048; Leow CC, 2004, CANCER RES, V64, P6050, DOI 10.1158/0008-5472.CAN-04-0290; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Lickert H, 2000, DEVELOPMENT, V127, P3805; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nishanian TG, 2004, CANCER BIOL THER, V3, P667; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 1997, CANCER RES, V57, P1644; OSHIMA H, 2006, IN PRESS GASTROENTER; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Oshima M, 2002, CURR PHARM DESIGN, V8, P1021, DOI 10.2174/1381612023394953; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Reed KR, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-113; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Ristimaki A, 1997, CANCER RES, V57, P1276; Romagnolo B, 1999, CANCER RES, V59, P3875; Rudolph KL, 2001, NAT GENET, V28, P155, DOI 10.1038/88871; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Scherer SJ, 2005, BIOCHEM SOC T, V33, P689, DOI 10.1042/BST0330689; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Takeda H, 2003, CANCER RES, V63, P4872; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; Yamada T, 2003, CANCER RES, V63, P895; Yang WC, 2001, CANCER RES, V61, P565; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	70	57	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7522	7530		10.1038/sj.onc.1210058	http://dx.doi.org/10.1038/sj.onc.1210058			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143296				2022-12-28	WOS:000242514900010
J	Mallakin, A; Taneja, P; Matise, LA; Willingham, MC; Inoue, K				Mallakin, A.; Taneja, P.; Matise, L. A.; Willingham, M. C.; Inoue, K.			Expression of Dmp1 in specific differentiated, nonproliferating cells and its regulation by E2Fs	ONCOGENE			English	Article						Dmp1; Ki67; Arf; E2F; cell cycle; immunohistochemistry	ARF TUMOR-SUPPRESSOR; D-TYPE CYCLINS; TRANSCRIPTION FACTOR DMP1; CELLULAR PROLIFERATION; GENE-EXPRESSION; MYB PROMOTER; IN-VIVO; FAMILY; COMPLEXES; ARREST	Dmp1 is a Myb-like transcription factor that transmits oncogenic Ras-Raf signaling to the Arf-p53 pathway and induces cell cycle arrest. Immunohistochemical staining was performed to identify the pattern of Dmp1 expression in normal murine tissues compared with the proliferation marker, Ki67. In thymus, the nuclei of mature T lymphocytes in the medulla were strongly positive for Dmp1, whereas Ki67 was detected only in the cortex. In intestine, Dmp1 was detected in the nuclei of super. cial layers of the villi, whereas Ki67- positive cells were con. ned to the lower one- third of the crypt. Double staining for Dmp1 and Ki67 revealed that these two proteins were expressed in mutually exclusive fashion in nearly all the tissues examined. Subsets of E2Fs were speci. cally bound to the Dmp1 promoter upon mitogenic signaling and E2Fs 1- 4 inhibited the Dmp1 promoter in a reporter assay. The Dmp1 promoter was repressed when the cells entered the S to G2/ M phase of the cell cycle when both Dmp1 and Arf expressions were downregulated. The Dmp1 mRNA was not downregulated by serum in E2F- DB(+) cells, suggesting that the Dmp1 promoter repression is E2F- dependent. This explains why the Dmp1 and Ki67- positive cells are stained in mutually exclusive fashion in normal tissues.	Wake Forest Univ Hlth Sci, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ Hlth Sci, Dept Pathol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University School of Medicine; Wake Forest University; Wake Forest University School of Medicine	Inoue, K (corresponding author), Wake Forest Univ Hlth Sci, Dept Canc Biol, 2102 Gray Bldg,Med Ctr Blvd, Winston Salem, NC 27157 USA.	kinoue@wfubmc.edu			NATIONAL CANCER INSTITUTE [R01CA106314, R01CA106312, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA106314-03, CA12197-31, R01 CA106314-02, R01 CA106314, P30 CA012197, R01 CA106314-01, 5R01CA106312-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Barrett KL, 2001, J HISTOCHEM CYTOCHEM, V49, P821, DOI 10.1177/002215540104900703; Bentley HA, 2005, CLIN BIOCHEM, V38, P183, DOI 10.1016/j.clinbiochem.2004.10.009; Bertwistle D, 2004, HYBRIDOMA HYBRIDOM, V23, P293, DOI 10.1089/hyb.2004.23.293; Campanero MR, 1999, MOL CELL BIOL, V19, P8442; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Chadee DN, 1999, J BIOL CHEM, V274, P24914, DOI 10.1074/jbc.274.35.24914; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DeGregori J, 2002, BBA-REV CANCER, V1602, P131, DOI 10.1016/S0304-419X(02)00051-3; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Hirai H, 1996, MOL CELL BIOL, V16, P6457; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Inoue K, 2000, GENE DEV, V14, P1797; INOUE K, 1994, BLOOD, V84, P2672, DOI 10.1182/blood.V84.8.2672.bloodjournal8482672; Inoue K, 1998, J BIOL CHEM, V273, P29188, DOI 10.1074/jbc.273.44.29188; Inoue K, 1998, MOL CELL BIOL, V18, P1590, DOI 10.1128/MCB.18.3.1590; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KINDBLOM LG, 1995, VIRCHOWS ARCH, V427, P19; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; LOPEZ F, 1991, CYTOMETRY, V12, P42, DOI 10.1002/cyto.990120107; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Lu Z, 2006, ONCOGENE, V25, P230, DOI 10.1038/sj.onc.1209025; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Quon KC, 2001, GENE DEV, V15, P2917, DOI 10.1101/gad.949001; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sala A, 1999, J CELL PHYSIOL, V179, P245; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	41	24	25	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7703	7713		10.1038/sj.onc.1209750	http://dx.doi.org/10.1038/sj.onc.1209750			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16878159	Green Accepted			2022-12-28	WOS:000242830800005
J	Nevanlinna, H; Bartek, J				Nevanlinna, H.; Bartek, J.			The CHEK2 gene and inherited breast cancer susceptibility	ONCOGENE			English	Review						CHEK2; Chk2; DNA damage checkpoints; breast cancer; familial; cancer susceptibility	LI-FRAUMENI-SYNDROME; HEREDITARY PROSTATE-CANCER; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; COLORECTAL-CANCER; 1100DELC MUTATION; TUMOR-SUPPRESSOR; CHK2 GENE; CHEK2-ASTERISK-1100DELC VARIANT; GERMLINE MUTATIONS	Checkpoint kinase 2 (CHEK2, Chk2) emerges as an important signal transducer of cellular responses to DNA damage and a candidate tumor suppressor whose defects contribute to molecular pathogenesis of diverse types of human malignancies, both sporadic and hereditary. Here, we briefly outline the molecular properties, regulation and physiological role of CHEK2, and review in more detail its defects that predispose to tumors, with particular emphasis on familial breast cancer. The frequency, penetrance and epidemiological as well as clinical significance of the two most studied breast cancer-predisposing variants of the CHEK2 gene, 1100delC and I157T, are highlighted in more depth, and additional CHEK2 mutations and their cancer relevance are discussed as well. These recent findings are considered also from a broader perspective of CHEK2 as the integral component of the ataxia telangiectasia-mutated-CHEK2-p53 pathway within the genome integrity maintenance system and a barrier against tumor progression. Finally, the potential value of information about the CHEK2 status in family counseling and optimizition of individualized cancer treatment is discussed.	Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Biomed Helsinki, FIN-00029 Helsinki, Finland; Inst Canc Biol, Copenhagen, Denmark; Danish Canc Soc, Ctr Genotoxic Stress Res, Copenhagen, Denmark	University of Helsinki; Helsinki University Central Hospital; Danish Cancer Society	Nevanlinna, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Biomed Helsinki, POB 700, FIN-00029 Helsinki, Finland.	heli.nevanlinna@hus.fi	Bartek, Jiri/G-5870-2014	Nevanlinna, Heli/0000-0002-0916-2976				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Allinen M, 2001, BRIT J CANCER, V85, P209, DOI 10.1054/bjoc.2001.1858; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Bachinski LL, 2005, CANCER RES, V65, P427; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bartkova J, 2004, ONCOGENE, V23, P8545, DOI 10.1038/sj.onc.1207878; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Baysal BE, 2004, GYNECOL ONCOL, V95, P62, DOI 10.1016/j.ygyno.2004.07.015; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bernstein JL, 2006, CANCER EPIDEM BIOMAR, V15, P348, DOI 10.1158/1055-9965.EPI-05-0557; Bogdanova N, 2005, INT J CANCER, V116, P263, DOI 10.1002/ijc.21022; Bougeard G, 2001, J MED GENET, V38, P253, DOI 10.1136/jmg.38.4.253; Broeks A, 2004, BREAST CANCER RES TR, V83, P91, DOI 10.1023/B:BREA.0000010697.49896.03; Caligo MA, 2004, HUM MUTAT, V24, P100, DOI 10.1002/humu.20051; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; Cybulski C, 2004, CANCER RES, V64, P2677, DOI 10.1158/0008-5472.CAN-04-0341; de Bock GH, 2004, J MED GENET, V41, P731, DOI 10.1136/jmg.2004.019737; de Jong MM, 2005, GENE CHROMOSOME CANC, V43, P377, DOI 10.1002/gcc.20195; de Jong MM, 2005, EUR J CANCER, V41, P1819, DOI 10.1016/j.ejca.2005.04.035; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Dufault MR, 2004, INT J CANCER, V110, P320, DOI 10.1002/ijc.20073; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Einarsdottir K, 2006, PLOS MED, V3, P895, DOI 10.1371/journal.pmed.0030168; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Friedrichsen DM, 2004, BREAST CANCER RES, V6, pR629, DOI 10.1186/bcr933; Goode EL, 2002, CANCER RES, V62, P3052; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Huzarski T, 2005, BREAST CANCER RES TR, V90, P187, DOI 10.1007/s10549-004-3778-2; Ingvarsson S, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr435; Isinger A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-64; Johnson N, 2005, LANCET, V366, P1554, DOI 10.1016/S0140-6736(05)67627-1; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kato N, 2004, CELL DEATH DIFFER, V11, pS153, DOI 10.1038/sj.cdd.4401461; Kilpivaara O, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e110; Kilpivaara O, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.038331; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kilpivaara O, 2004, INT J CANCER, V111, P543, DOI 10.1002/ijc.20299; Kleibl Z, 2005, BREAST CANCER RES TR, V90, P165, DOI 10.1007/s10549-004-4023-8; Kuschel B, 2003, CANCER EPIDEM BIOMAR, V12, P809; Latella L, 2004, MOL CELL BIOL, V24, P6350, DOI 10.1128/MCB.24.14.6350-6361.2004; Lee SB, 2001, CANCER RES, V61, P8062; Li JJ, 2002, MOL CELL, V9, P1045, DOI 10.1016/S1097-2765(02)00527-0; Lipton L, 2003, CANCER LETT, V200, P149, DOI 10.1016/S0304-3835(03)00391-4; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2001, CANCER RES, V61, P4990; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Meijers-Heijboer H, 2003, AM J HUM GENET, V72, P1308, DOI 10.1086/375121; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Neuhausen S, 2004, INT J CANCER, V108, P477, DOI 10.1002/ijc.11385; Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1; Oldenburg RA, 2003, CANCER RES, V63, P8153; Osorio A, 2004, INT J CANCER, V108, P54, DOI 10.1002/ijc.11414; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shaag A, 2005, HUM MOL GENET, V14, P555, DOI 10.1093/hmg/ddi052; Siddiqui R, 2005, FAM CANCER, V4, P177, DOI 10.1007/s10689-004-1946-5; Sodha N, 2002, HUM MUTAT, V20, P460, DOI 10.1002/humu.10136; Sodha N, 2004, CANCER LETT, V215, P187, DOI 10.1016/j.canlet.2004.07.002; Sodha N, 2000, Science, V289, P359; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Syrjakoski K, 2004, INT J CANCER, V108, P475, DOI 10.1002/ijc.11384; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; van Puijenbroek M, 2005, J PATHOL, V206, P198, DOI 10.1002/path.1764; Wagenius M, 2006, SCAND J UROL NEPHROL, V40, P23, DOI 10.1080/00365590500368518; Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379; ZHOU BBS, 2004, NAT REV CANCER, V4, P1, DOI DOI 10.1038/NRC1296	77	150	154	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2006	25	43					5912	5919		10.1038/sj.onc.1209877	http://dx.doi.org/10.1038/sj.onc.1209877			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998506				2022-12-28	WOS:000240765900012
J	Du, W; Pogoriler, J				Du, W.; Pogoriler, J.			Retinoblastoma family genes	ONCOGENE			English	Review						Rb; E2F; development; tumorigenesis cell; proliferation and differentiation	E2F TARGET GENES; DEPENDENT KINASE INHIBITOR; TRANSCRIPTION FACTOR E2F; CELL-CYCLE PROGRESSION; RB MUTANT MICE; S-PHASE ENTRY; IN-VIVO; DROSOPHILA EMBRYOGENESIS; TUMOR-SUPPRESSOR; DNA-REPLICATION	The retinoblastoma gene Rb was the first tumor suppressor gene cloned, and it is well known as a negative regulator of the cell cycle through its ability to bind the transcription factor E2F and repress transcription of genes required for S phase. Although over 100 other proteins have been reported to interact with Rb, in most cases these interactions are much less well characterized. Therefore, this review will primarily focus on Rb and E2F interactions. In addition to cell cycle regulation, studies of Rb and E2F proteins in animal models have revealed important roles for these proteins in apoptosis and differentiation. Recent screens of Rb/E2F target genes have identified new targets in all these areas. In addition, the mechanisms determining how different subsets of target genes are regulated under different conditions have only begun to be addressed and offer exciting possibilities for future research.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA; Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Du, W (corresponding author), Univ Chicago, Ben May Inst Canc Res, 904 E 57th St, Chicago, IL 60637 USA.	wdu@huggins.bsd.uchicago.edu			NIGMS NIH HHS [R01 GM074197] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM074197] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bosco G, 2001, NAT CELL BIOL, V3, P289, DOI 10.1038/35060086; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; Caretti G, 2003, J BIOL CHEM, V278, P30435, DOI 10.1074/jbc.M304606200; Cayirlioglu P, 2001, DEVELOPMENT, V128, P5085; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; de Bruin A, 2003, J BIOL CHEM, V278, P42041, DOI 10.1074/jbc.M308105200; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; deNooij JC, 1996, CELL, V87, P1237, DOI 10.1016/S0092-8674(00)81819-X; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Du W, 1999, EMBO J, V18, P916, DOI 10.1093/emboj/18.4.916; Du W, 2000, DEVELOPMENT, V127, P367; Du W, 1996, GENE DEV, V10, P1206, DOI 10.1101/gad.10.10.1206; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Duronio RJ, 1998, MOL CELL BIOL, V18, P141, DOI 10.1128/MCB.18.1.141; DURONIO RJ, 1995, GENE DEV, V9, P1445, DOI 10.1101/gad.9.12.1445; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Firth LC, 2005, DEV CELL, V8, P541, DOI 10.1016/j.devcel.2005.01.017; Follette PJ, 1998, CURR BIOL, V8, P235, DOI 10.1016/S0960-9822(98)70089-2; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Frolov MV, 2003, GENE DEV, V17, P723, DOI 10.1101/gad.1031803; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; Giangrande PH, 2004, EMBO J, V23, P1336, DOI 10.1038/sj.emboj.7600134; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jost CA, 1996, VIROLOGY, V220, P78, DOI 10.1006/viro.1996.0288; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; KATO J, 1993, GENE DEV, V7, P331; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Landsberg RL, 2003, P NATL ACAD SCI USA, V100, P2456, DOI 10.1073/pnas.0138064100; Lane ME, 1996, CELL, V87, P1225, DOI 10.1016/S0092-8674(00)81818-8; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Masselli A, 2006, ONCOGENE, V25, P1290, DOI 10.1038/sj.onc.1209161; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moon NS, 2005, DEV CELL, V9, P463, DOI 10.1016/j.devcel.2005.08.015; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mundle SD, 2003, FASEB J, V17, P569, DOI 10.1096/fj.02-0431rev; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Royzman I, 1999, GENE DEV, V13, P827, DOI 10.1101/gad.13.7.827; Royzman I, 1997, GENE DEV, V11, P1999, DOI 10.1101/gad.11.15.1999; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Stevaux O, 2005, CELL CYCLE, V4, P1272, DOI 10.4161/cc.4.9.1982; Stevaux O, 2002, EMBO J, V21, P4927, DOI 10.1093/emboj/cdf501; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wells J, 2003, ONCOGENE, V22, P1445, DOI 10.1038/sj.onc.1206264; Weng L, 2003, EMBO J, V22, P3865, DOI 10.1093/emboj/cdg373; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Young AP, 2004, ONCOGENE, V23, P814, DOI 10.1038/sj.onc.1207187; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng N, 1999, GENE DEV, V13, P666, DOI 10.1101/gad.13.6.666; Zhou L, 2003, DEV CELL, V4, P599, DOI 10.1016/S1534-5807(03)00085-6; Zhu JW, 2001, MOL CELL BIOL, V21, P8547, DOI 10.1128/MCB.21.24.8547-8564.2001; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	118	109	118	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5190	5200		10.1038/sj.onc.1209651	http://dx.doi.org/10.1038/sj.onc.1209651			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936737	Green Accepted			2022-12-28	WOS:000240064100002
J	Felsani, A; Mileo, AM; Paggi, MG				Felsani, A.; Mileo, A. M.; Paggi, M. G.			Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins	ONCOGENE			English	Review						pRb; p107; pRb2/p130; E1A; E7; large T-Ag	HUMAN-PAPILLOMAVIRUS TYPE-16; LARGE-T-ANTIGEN; SIMIAN-VIRUS-40 LARGE-T; SV40 LARGE T; TUMOR-SUPPRESSOR PROTEIN; PRB-RELATED PROTEINS; CELL-CYCLE CONTROL; ADENOVIRUS E1A; BK VIRUS; E7 ONCOPROTEIN	RB, the most investigated tumor suppressor gene, is the founder of the RB family of growth/tumor suppressors, which comprises also p107(RBL1) and Rb2/p130 (RBL2). The protein products of these genes, pRb, p107 and pRb2/p130, respectively, are also known as 'pocket proteins', because they share a `pocket' domain responsible for most of the functional interactions characterizing the activity of this family of cellular factors. The interest in these genes and proteins springs essentially from their ability to regulate negatively cell cycle processes and for their ability to slow down or abrogate neoplastic growth. The pocket domain of the RB family proteins is dramatically hampered in its functions by the interference of a number of proteins produced by the small DNA viruses. In the last two decades, the 'viral hypothesis' of cancer has received a considerable renewed impulse from the notion that small DNA viruses, such as Adenovirus, Human papillomavirus (HPV) and Polyomavirus, produce factors that can physically interact with major cellular regulators and alter their function. These viral proteins (oncoproteins) act as multifaceted molecular devices that have evolved to perform very specific tasks. Owing to these features, viral oncoproteins have been widely employed as invaluable experimental tools for the identification of several key families of regulators, particularly of the cell cycle homeostasis. Adenovirus early-region 1A (E1A) is the most widely investigated small DNA tumor virus oncoprotein, but relevant interest in human oncology is raised by the E1A-related E7 protein from transforming HPV strains and by Polyomavirus oncoproteins, particularly large and small T antigens from Simian virus 40, JC virus and BK virus.	Regina Elena Inst Canc Res, Dept Dev Therapeut Programs, Lab C, I-00144 Rome, Italy; CNR, Ist Neurobiol & Med Mol, Rome, Italy; Temple Univ, Ctr Biotechnol, Philadelphia, PA 19122 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Consiglio Nazionale delle Ricerche (CNR); Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Dept Dev Therapeut Programs, Lab C, Via Elio Chianesi 53, I-00144 Rome, Italy.	paggi@ifo.it	Mileo, Anna Maria/J-3667-2016; Paggi, Marco G./K-3494-2018; Felsani, Armando/D-1784-2010	Mileo, Anna Maria/0000-0002-1970-3297; Felsani, Armando/0000-0001-8851-6295				Ach RA, 1997, MOL CELL BIOL, V17, P5077, DOI 10.1128/MCB.17.9.5077; Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; Arbeit JM, 1996, P NATL ACAD SCI USA, V93, P2930, DOI 10.1073/pnas.93.7.2930; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Avvakumov N, 2004, VIROLOGY, V329, P477, DOI 10.1016/j.virol.2004.08.007; Avvakumov N, 2003, ONCOGENE, V22, P3833, DOI 10.1038/sj.onc.1206562; BANKS L, 1990, ONCOGENE, V5, P1383; Barbanti-Brodano G, 2004, VIROLOGY, V318, P1, DOI 10.1016/j.virol.2003.09.004; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Ben-Porath I, 2004, J CLIN INVEST, V113, P8, DOI 10.1172/JCI200420663; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; BERGER JR, 1995, J NEUROVIROL, V1, P5, DOI 10.3109/13550289509111006; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Boffetta P, 2004, ONCOGENE, V23, P6392, DOI 10.1038/sj.onc.1207715; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; BROKAW JL, 1994, VIROLOGY, V205, P603, DOI 10.1006/viro.1994.1688; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 2000, J CELL BIOCHEM, V76, P189, DOI 10.1002/(SICI)1097-4644(20000201)76:2<189::AID-JCB3>3.0.CO;2-J; Cenciarelli C, 1999, MOL CELL BIOL, V19, P5203; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; CICCOLINI F, 1994, ONCOGENE, V9, P2633; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cole Charles N., 1996, P917; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dang-Tan T, 2004, ONCOGENE, V23, P6535, DOI 10.1038/sj.onc.1207877; Datto MB, 1997, MOL CELL BIOL, V17, P2030, DOI 10.1128/MCB.17.4.2030; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; de Villiers EM, 2004, VIROLOGY, V324, P17, DOI 10.1016/j.virol.2004.03.033; DEMERS GW, 1994, P NATL ACAD SCI USA, V91, P4382, DOI 10.1073/pnas.91.10.4382; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Engels EA, 2005, EXPERT REV VACCINES, V4, P197, DOI 10.1586/14760584.4.2.197; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; Fioriti D, 2005, J CELL PHYSIOL, V204, P402, DOI 10.1002/jcp.20300; Flores ER, 2000, J VIROL, V74, P6622, DOI 10.1128/JVI.74.14.6622-6631.2000; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; GAGE JR, 1990, J VIROL, V64, P723, DOI 10.1128/JVI.64.2.723-730.1990; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; HAWLEYNELSON P, 1989, EMBO J, V8, P3905, DOI 10.1002/j.1460-2075.1989.tb08570.x; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; HERRMANN CH, 1991, J VIROL, V65, P5848, DOI 10.1128/JVI.65.11.5848-5859.1991; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HU GY, 1995, CANCER GENE THER, V2, P19; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Klein G, 2002, ONCOGENE, V21, P1141, DOI 10.1038/sj.onc.1205173; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; KNUDSON AG, 1986, ANNU REV GENET, V20, P231; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kreimer AR, 2005, CANCER EPIDEM BIOMAR, V14, P467, DOI 10.1158/1055-9965.EPI-04-0551; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lee C, 2002, GENE DEV, V16, P3199, DOI 10.1101/gad.1046102; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; Mal A, 2000, J CELL BIOL, V149, P281, DOI 10.1083/jcb.149.2.281; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MARTELLI F, 1994, ONCOGENE, V9, P3579; MAYOL X, 1993, ONCOGENE, V8, P2561; MCCANCE DJ, 1988, P NATL ACAD SCI USA, V85, P7169, DOI 10.1073/pnas.85.19.7169; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; MOSSMAN BT, 1989, NEW ENGL J MED, V320, P1721, DOI 10.1056/NEJM198906293202604; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2004, J VIROL, V78, P11451, DOI 10.1128/JVI.78.21.11451-11460.2004; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGER K, 1989, J VIROL, V63, P4417; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Park JS, 2000, J BIOL CHEM, V275, P6764, DOI 10.1074/jbc.275.10.6764; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; Pfister Herbert, 2003, J Natl Cancer Inst Monogr, P52; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Powell AJ, 1999, ONCOGENE, V18, P7343, DOI 10.1038/sj.onc.1203154; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Reiss K, 2003, ONCOGENE, V22, P6517, DOI 10.1038/sj.onc.1206959; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Rizzo P, 1999, CANCER RES, V59, P6103; Sang NL, 2002, FRONT BIOSCI, V7, pD407, DOI 10.2741/sang; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Scheffner M, 2003, SEMIN CANCER BIOL, V13, P59, DOI 10.1016/S1044-579X(02)00100-1; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Singh M, 2005, J BIOL CHEM, V280, P37868, DOI 10.1074/jbc.M504877200; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Srinivasan A, 1997, MOL CELL BIOL, V17, P4761, DOI 10.1128/MCB.17.8.4761; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Steegenga WT, 1996, MOL CELL BIOL, V16, P2101; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiegler P, 1998, J CELL BIOCHEM, P30; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Thomas DM, 2003, CANCER BIOL THER, V2, P124, DOI 10.4161/cbt.2.2.235; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; Tweedale G, 2002, NAT REV CANCER, V2, P311, DOI 10.1038/nrc774; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOUSDEN KH, 1989, ONCOGENE, V4, P153; Wang JY, 2004, J EXP CLIN CANC RES, V23, P373; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang XY, 2005, J BIOL CHEM, V280, P33165, DOI 10.1074/jbc.M505124200; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55; Zwerschke W, 2000, ADV CANCER RES, V78, P1	174	116	120	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5277	5285		10.1038/sj.onc.1209621	http://dx.doi.org/10.1038/sj.onc.1209621			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936748				2022-12-28	WOS:000240064100013
J	Roskams, T				Roskams, T			Liver stem cells and their implication in hepatocellular and cholangiocarcinoma	ONCOGENE			English	Review						liver stem cells; liver progenitor cells; hepatocellular carcinoma; cholangiocarcinoma; dysplastic focus; dysplastic nodule	HEPATIC PROGENITOR CELLS; SMALL EPITHELIAL-CELLS; HUMAN HEPATOCARCINOGENESIS; CLINICAL-SIGNIFICANCE; OVAL CELLS; CARCINOMA; EXPRESSION; CIRRHOSIS; DISEASE; HEPATOBLASTOMA	In the liver, several cell types have the longevity that is needed to be the cell of origin of a cancer: hepatocytes, cholangiocytes and progenitor cells. The latter are located in the most peripheral branches of the biliary tree, the ductules and canals of Hering. The most important risk factors for liver cancer are chronic viral hepatitis B and C and alcoholic and non-alcoholic steatohepatitis. In these and other chronic liver diseases, progenitor cell activation is seen, rendering them a target cell population for carcinogenesis. The degree of activation is positively correlated with the in. ammatory activity and the stage of the disease. Recently, it has been shown that in the cirrhotic stage of most chronic liver diseases, the hepatocytes become senescent owing to telomere shortening. This makes it even more plausible that at least part of the hepatocellular carcinomas originate from a progenitor cell. Hepatocellular carcinomas expressing progenitor cell/ductular markers like cytokeratin 19 have a more aggressive clinical course. It is therefore important to recognize this entity.	Katholieke Univ Leuven, Liver Res Unit, Dept Morphol & Mol Pathol, B-3000 Louvain, Belgium	KU Leuven	Roskams, T (corresponding author), Katholieke Univ Leuven, Liver Res Unit, Dept Morphol & Mol Pathol, Mnderbroederstr 12, B-3000 Louvain, Belgium.	tania.roskams@uz.kuleuven.ac.be		Roskams, Tania/0000-0002-2816-1530				Alison MR, 2005, CELL PROLIFERAT, V38, P407, DOI 10.1111/j.1365-2184.2005.00354.x; Alison MR, 1996, GASTROENTEROLOGY, V110, P1182, DOI 10.1053/gast.1996.v110.pm8613008; Ding SJ, 2004, MOL CELL PROTEOMICS, V3, P73, DOI 10.1074/mcp.M300094-MCP200; Dumble ML, 2002, CARCINOGENESIS, V23, P435, DOI 10.1093/carcin/23.3.435; Falkowski O, 2003, J HEPATOL, V39, P357, DOI 10.1016/S0168-8278(03)00309-X; Fiegel HC, 2004, J HISTOCHEM CYTOCHEM, V52, P1495, DOI 10.1369/jhc.4A6297.2004; Hixson DC, 2000, EXP MOL PATHOL, V68, P152, DOI 10.1006/exmp.2000.2302; HSIA CC, 1992, HEPATOLOGY, V16, P1327, DOI 10.1002/hep.1840160604; Libbrecht L, 2000, J PATHOL, V192, P373, DOI 10.1002/1096-9896(2000)9999:9999&lt;::AID-PATH700&gt;3.0.CO;2-5; Libbrecht L, 2005, LIVER INT, V25, P16, DOI 10.1111/j.1478-3231.2005.01016.x; Lowes KN, 1999, AM J PATHOL, V154, P537, DOI 10.1016/S0002-9440(10)65299-6; Marshall A, 2005, GASTROENTEROLOGY, V128, P33, DOI 10.1053/j.gastro.2004.09.076; Nomoto K, 2006, PATHOL RES PRACT, V202, P71, DOI 10.1016/j.prp.2005.10.011; Roskams T, 2003, AM J PATHOL, V163, P1301, DOI 10.1016/S0002-9440(10)63489-X; Roskams T, 1998, SEMIN DIAGN PATHOL, V15, P259; Roskams TA, 2004, HEPATOLOGY, V39, P1739, DOI 10.1002/hep.20130; Roskams TA, 2003, SEMIN LIVER DIS, V23, P385; Ruck P, 1996, AM J PATHOL, V148, P321; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; VANEYKEN P, 1988, HUM PATHOL, V19, P562, DOI 10.1016/S0046-8177(88)80205-3; Wiemann SU, 2002, FASEB J, V16, P935, DOI 10.1096/fj.01-0977com; WILSON JW, 1958, J PATHOL BACTERIOL, V76, P441, DOI 10.1002/path.1700760213; Wu PC, 1999, J HEPATOL, V31, P965; Xiao JC, 2003, HISTOPATHOLOGY, V42, P141, DOI 10.1046/j.1365-2559.2003.01544.x; Yang SQ, 2004, HEPATOLOGY, V39, P403, DOI 10.1002/hep.20082; Yoon DS, 1999, YONSEI MED J, V40, P472, DOI 10.3349/ymj.1999.40.5.472	27	315	334	1	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3818	3822		10.1038/sj.onc.1209558	http://dx.doi.org/10.1038/sj.onc.1209558			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799623				2022-12-28	WOS:000238559600009
J	Leotlela, PD; Wade, MS; Duray, PH; Rhode, MJ; Brown, HF; Rosenthal, DT; Dissanayake, SK; Earley, R; Indig, FE; Nickoloff, BJ; Taub, DD; Kallioniemi, OP; Meltzer, P; Morin, PJ; Weeraratna, AT				Leotlela, P. D.; Wade, M. S.; Duray, P. H.; Rhode, M. J.; Brown, H. F.; Rosenthal, D. T.; Dissanayake, S. K.; Earley, R.; Indig, F. E.; Nickoloff, B. J.; Taub, D. D.; Kallioniemi, O. P.; Meltzer, P.; Morin, P. J.; Weeraratna, A. T.			Claudin-1 overexpression in melanoma is regulated by PKC and contributes to melanoma cell motility	ONCOGENE			English	Article						claudin; melanoma; PKC; motility; tissue array	PROTEIN-KINASE-C; TIGHT JUNCTION PROTEINS; OVARIAN-CANCER; INVASION; ACTIVATION; EXPRESSION; ADHESION; BARRIER; MICE	Serial analysis of gene expression followed by pathway analysis implicated the tight junction protein claudin-1 (CLDN1) in melanoma progression. Tight junction proteins regulate the paracellular transport of molecules, but staining of a tissue microarray revealed that claudin-1 was overexpressed in melanoma, and aberrantly expressed in the cytoplasm of malignant cells, suggesting a role other than transport. Indeed, melanoma cells in culture demonstrate no tight junction function. It has been shown that protein kinase C (PKC) can affect expression of claudin-1 in rat choroid plexus cells, and we observed a correlation between levels of activated PKC and claudin expression in our melanoma cells. To determine if PKC could affect the expression of CLDN1 in human melanoma, cells lacking endogenous claudin-1 were treated with 200 nM phorbol myristic acid (PMA). PKC activation by PMA caused an increase in CLDN1 transcription in 30 min, and an increase in claudin-1 protein by 12 h. Inhibition of PKC signaling in cells with high claudin-1 expression resulted in decreased claudin-1 expression. CLDN1 appears to contribute to melanoma cell invasion, as transient transfection of melanoma cells with CLDN1 increased metalloproteinase 2 (MMP-2) secretion and activation, and subsequently, motility of melanoma cells as demonstrated by wound-healing assays. Conversely, knockdown of CLDN1 by siRNA resulted in the inhibition of motility, as well as decreases in MMP-2 secretion and activation. These data implicate claudin-1 in melanoma progression.	NIA, Immunol Lab, NIH, Gerontol Res Ctr, Baltimore, MD 21224 USA; VA Healthcare Syst, Boston, MA USA; Univ Maryland Eastern Shore, MARC Scholar, Princess Anne, MD USA; Univ N Carolina, Dept Biol & Marine Biol, Wilmington, NC 28401 USA; NIA, Res Resources Branch, Gerontol Res Ctr, Baltimore, MD 21224 USA; Loyola Univ, Med Ctr, Dept Pathol, Maywood, IL 60153 USA; Univ Turku, VTT Tech Res Ctr Finland, Med Biotechnol Dept, SF-20500 Turku, Finland; Natl Human Genome Res Inst, Canc Genet Branch, Bethesda, MD USA; NIA, Lab Cellular & Mol Biol, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University System of Maryland; University of Maryland Eastern Shore; University of North Carolina; University of North Carolina Wilmington; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Loyola University Chicago; University of Turku; VTT Technical Research Center Finland; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Weeraratna, AT (corresponding author), NIA, Immunol Lab, NIH, Gerontol Res Ctr, 5600 Nathan Shock Dr,Box 21, Baltimore, MD 21224 USA.	weerarat@grc.nia.nih.gov	Kallioniemi, Olli P/H-5111-2011	Kallioniemi, Olli P/0000-0002-3231-0332	NATIONAL CANCER INSTITUTE [Z01BC010759, ZIABC010759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000395, Z01AG000615, ZICAG000615, Z01AG000395, ZIAAG000442, Z01AG000442, Z01AG000512] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Betanzos A, 2004, EXP CELL RES, V292, P51, DOI 10.1016/j.yexcr.2003.08.007; Cohn ML, 2005, J CUTAN PATHOL, V32, P533, DOI 10.1111/j.0303-6987.2005.00324.x; D'Souza T, 2005, J BIOL CHEM, V280, P26233, DOI 10.1074/jbc.M502003200; da Rocha AB, 2000, PATHOBIOLOGY, V68, P113, DOI 10.1159/000055911; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; DUMONT JA, 1992, CANCER RES, V52, P1195; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Heiskala M, 2001, TRAFFIC, V2, P92, DOI 10.1034/j.1600-0854.2001.020203.x; Lippoldt A, 2000, NEUROREPORT, V11, P1427, DOI 10.1097/00001756-200005150-00015; Miyamori H, 2001, J BIOL CHEM, V276, P28204, DOI 10.1074/jbc.M103083200; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakamura K, 2003, ANTICANCER RES, V23, P1395; Oku N, 2006, CANCER RES, V66, P5251, DOI 10.1158/0008-5472.CAN-05-4478; Park MJ, 2003, INT J ONCOL, V22, P137; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Sawada Norimasa, 2003, Medical Electron Microscopy, V36, P147, DOI 10.1007/s00795-003-0219-y; Smalley KSM, 2005, AM J PATHOL, V166, P1541, DOI 10.1016/S0002-9440(10)62370-X; Swisshelm K, 2005, ADV DRUG DELIVER REV, V57, P919, DOI 10.1016/j.addr.2005.01.006; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4	23	128	135	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3846	3856		10.1038/sj.onc.1210155	http://dx.doi.org/10.1038/sj.onc.1210155			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160014				2022-12-28	WOS:000247026400008
J	Aiyar, SE; Blair, AL; Hopkinson, DA; Bekiranov, S; Li, R				Aiyar, S. E.; Blair, A. L.; Hopkinson, D. A.; Bekiranov, S.; Li, R.			Regulation of clustered gene expression by cofactor of BRCA1 (COBRA1) in breast cancer cells	ONCOGENE			English	Article						COBRA1; clustered gene expression; estrogen; transcription; NELF	INTESTINAL TREFOIL FACTOR; TRANSCRIPTION ELONGATION-FACTOR; X-CHROMOSOME INACTIVATION; APOLIPOPROTEIN-D; PROSTATE-CANCER; TISSUE INHIBITOR; RETINOIC ACID; MESSENGER-RNA; ESTROGEN; NELF	Eucaryotic genes that are coordinately expressed tend to be clustered. Furthermore, gene clusters across chromosomal regions are often upregulated in various tumors. However, relatively little is known about how gene clusters are coordinately expressed in physiological or pathological conditions. Cofactor of BRCA1 (COBRA1), a subunit of the human negative elongation factor, has been shown to repress estrogen-stimulated transcription of trefoil factor 1 (TFF1 or pS2) by stalling RNA polymerase II. Here, we carried out a genome-wide study to identify additional physiological target genes of COBRA1 in breast cancer cells. The study identified a total of 134 genes that were either activated or repressed upon small hairpin RNA-mediated reduction of COBRA1. Interestingly, many COBRA1-regulated genes reside as clusters on the chromosomes and have been previously implicated in cancer development. Detailed examination of two such clusters on chromosome 21 (21q22) and chromosome X (Xp11) reveal s that COBRA1 is physically associated with a subset of its regulated genes in each cluster. In addition, COBRA1 was shown to regulate both estrogen-dependent and - independent transcription of the gene cluster at 21q22, which encompasses the previously identified COBRA1-regulated TFF1 (pS2) locus. Thus, COBRA1 plays a critical role in the regulation of clustered gene expression at preferred chromosomal domains in breast cancer cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	rl2t@virginia.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064604] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK064604] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anderson CL, 2002, HUM GENET, V110, P271, DOI 10.1007/s00439-002-0676-8; Anderson CL, 1999, AM J HUM GENET, V65, P699, DOI 10.1086/302556; Balleine RL, 1999, HISTOL HISTOPATHOL, V14, P571, DOI 10.14670/HH-14.571; Banerjee S, 2003, NEOPLASIA, V5, P63, DOI 10.1016/S1476-5586(03)80018-0; BLAIS Y, 1995, INT J CANCER, V62, P732, DOI 10.1002/ijc.2910620614; Bodey B, 2002, EXPERT OPIN BIOL TH, V2, P577, DOI 10.1517/14712598.2.6.577; Burton JD, 2004, CLIN CANCER RES, V10, P6606, DOI 10.1158/1078-0432.CCR-04-0182; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carsol JL, 2002, MOL ENDOCRINOL, V16, P1696, DOI 10.1210/me.16.7.1696; CHEN L, 1990, ONCOGENE, V5, P1391; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; Chinery R, 1996, GENOMICS, V32, P281, DOI 10.1006/geno.1996.0117; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Clark JW, 1999, BRIT J CANCER, V81, P1002, DOI 10.1038/sj.bjc.6690799; De Backer O, 1999, CANCER RES, V59, P3157; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Duan ZF, 2003, CLIN CANCER RES, V9, P2778; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fata JE, 2004, BREAST CANCER RES, V6, P1, DOI 10.1186/bcr634; Gallagher PG, 2003, TOXICON, V41, P429, DOI 10.1016/S0041-0101(02)00359-8; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gonzalez MA, 2003, J CLIN ONCOL, V21, P4306, DOI 10.1200/JCO.2003.04.121; Gott P, 1996, EUR J HUM GENET, V4, P308; HAHNEL E, 1994, PATHOBIOLOGY, V62, P82, DOI 10.1159/000163882; HIROTA S, 1995, LAB INVEST, V72, P64; Hoevel T, 2002, J CELL PHYSIOL, V191, P60, DOI 10.1002/jcp.10076; Hurst LD, 2004, NAT REV GENET, V5, P299, DOI 10.1038/nrg1319; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Jazaeri Amir A, 2004, J Transl Med, V2, P32, DOI 10.1186/1479-5876-2-32; Koon N, 2004, NEOPLASIA, V6, P143, DOI 10.1593/neo.03385; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lercher MJ, 2002, NAT GENET, V31, P180, DOI 10.1038/ng887; LOPEZBOADO YS, 1994, J BIOL CHEM, V269, P26871; Mashino K, 2001, BRIT J CANCER, V85, P713, DOI 10.1054/bjoc.2001.1974; May FEB, 1997, J PATHOL, V183, P4; McChesney PA, 2006, CANCER RES, V66, P1346, DOI 10.1158/0008-5472.CAN-05-3593; Mikhitarian K, 2005, CLIN CANCER RES, V11, P3697, DOI 10.1158/1078-0432.CCR-04-2164; Moggs JG, 2005, J MOL ENDOCRINOL, V34, P535, DOI 10.1677/jme.1.01677; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Nakopoulou L, 2003, APMIS, V111, P1027, DOI 10.1111/j.1600-0463.2003.apm1111105.x; Narita T, 2003, MOL CELL BIOL, V23, P1863, DOI 10.1128/MCB.23.6.1863-1873.2003; PAGANI A, 1994, VIRCHOWS ARCH, V425, P459; Palangat M, 2005, P NATL ACAD SCI USA, V102, P15036, DOI 10.1073/pnas.0409405102; Poulsom R, 1997, J PATHOL, V183, P30, DOI 10.1002/(SICI)1096-9896(199709)183:1<30::AID-PATH1085>3.0.CO;2-K; Rassart E, 2000, BBA-PROTEIN STRUCT M, V1482, P185, DOI 10.1016/S0167-4838(00)00162-X; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Schmitt H, 1996, CYTOGENET CELL GENET, V72, P299, DOI 10.1159/000134208; SHEIKH MS, 1993, MOL CELL ENDOCRINOL, V92, P153, DOI 10.1016/0303-7207(93)90002-2; Shetty A, 2005, BRIT J CANCER, V93, P1295, DOI 10.1038/sj.bjc.6602829; Singer GAC, 2005, MOL BIOL EVOL, V22, P767, DOI 10.1093/molbev/msi062; Smid M, 2006, J CLIN ONCOL, V24, P2261, DOI 10.1200/JCO.2005.03.8802; Spellman Paul T, 2002, J Biol, V1, P5, DOI 10.1186/1475-4924-1-5; Tian W, 2004, CANCER SCI, V95, P491, DOI 10.1111/j.1349-7006.2004.tb03238.x; Toi M, 1998, BREAST CANCER RES TR, V52, P113, DOI 10.1023/A:1006167202856; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; TOMASETTO C, 1992, GENOMICS, V13, P1328, DOI 10.1016/0888-7543(92)90059-2; Vestergaard EM, 2006, CLIN CANCER RES, V12, P807, DOI 10.1158/1078-0432.CCR-05-1545; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wu CH, 2005, NUCLEIC ACIDS RES, V33, P1269, DOI 10.1093/nar/gki274; Wu CH, 2003, GENE DEV, V17, P1402, DOI 10.1101/gad.1091403; Wu YM, 2005, ENDOCRINOLOGY, V146, P237, DOI 10.1210/en.2004-0889; Wurtz SO, 2005, ENDOCR-RELAT CANCER, V12, P215, DOI 10.1677/erc.1.00719; Xu XQ, 2005, J BIOL CHEM, V280, P23987, DOI 10.1074/jbc.M503869200; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zhong HJ, 2004, BIOCHEM BIOPH RES CO, V325, P568, DOI 10.1016/j.bbrc.2004.10.079; Zhou Y, 2003, CANCER RES, V63, P5781	71	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2543	2553		10.1038/sj.onc.1210047	http://dx.doi.org/10.1038/sj.onc.1210047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043641	Bronze			2022-12-28	WOS:000245831200002
J	Szabo, R; Molinolo, A; List, K; Bugge, TH				Szabo, R.; Molinolo, A.; List, K.; Bugge, T. H.			Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development	ONCOGENE			English	Article						placenta development; labyrinth formation; membrane proteolysis; trophoblast differentiation; basement membrane; protease inhibition	SERINE-PROTEASE INHIBITOR; BARRIER FUNCTION; EXPRESSION; HEPSIN; GENE; IDENTIFICATION; DEFICIENT; LETHALITY; HAI-1	Hepatocyte growth factor activator inhibitor-1 (HAI-1) is a Kunitz-type transmembrane serine protease inhibitor that forms inhibitor complexes with several trypsin-like serine proteases and is required for mouse placental development and embryo survival. Here we show that the essential function of HAI-1 in placentation and all other embryonic processes is to restrict the activity of the type II transmembrane serine protease, matriptase. Enzymatic gene trapping of matriptase combined with HAI-1 immunohistochemistry revealed that matriptase is co-expressed with HAI-1 in both extraembryonic and embryonic tissues. As early as embryonic day 8.5, matriptase and HAI-1 were expressed in a population of chorionic trophoblasts. Ablation of HAI-1 disrupted the epithelial integrity of this cell population, causing disorganized laminin deposition and altered expression of E-cadherin and beta-catenin. This led to a complete loss of undifferentiated chorionic trophoblasts after embryonic day 9.5 and prevented the formation of the placental labyrinth. Genetic ablation of matriptase activity in HAI-1-deficient embryos, however, restored the integrity of chorionic trophoblasts and enabled placental labyrinth formation and development to term. Furthermore, matriptase/HAI-1 double-deficient mice were phenotypically indistinguishable from matriptase single-deficient litter-mates. Oncogene	Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Proteases & Tissue Remodeling Unit, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ascenzi P, 2003, CURR PROTEIN PEPT SC, V4, P231, DOI 10.2174/1389203033487180; Fan B, 2005, J BIOL CHEM, V280, P34513, DOI 10.1074/jbc.M502119200; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; Gao F, 2004, DEVELOPMENT, V131, P1479, DOI 10.1242/dev.01048; Herter S, 2005, BIOCHEM J, V390, P125, DOI 10.1042/BJ20041955; Hooper JD, 2003, BIOCHEM J, V373, P689, DOI 10.1042/BJ20030390; Huang ZF, 1997, BLOOD, V90, P944, DOI 10.1182/blood.V90.3.944.944_944_951; Ishiguro K, 2000, J CLIN INVEST, V106, P873, DOI 10.1172/JCI10489; Itoh H, 2004, GASTROENTEROLOGY, V127, P1423, DOI 10.1053/j.gastro.2004.08.027; Kaufmann MH, 1999, ANATOMICAL BASIS MOU; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; Oberst MD, 2005, AM J PHYSIOL-CELL PH, V289, pC462, DOI 10.1152/ajpcell.00076.2005; Oberst MD, 2003, J BIOL CHEM, V278, P26773, DOI 10.1074/jbc.M304282200; Oberst MD, 2003, J HISTOCHEM CYTOCHEM, V51, P1017, DOI 10.1177/002215540305100805; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Ohmuraya M, 2005, GASTROENTEROLOGY, V129, P696, DOI 10.1053/j.gastro.2005.05.057; Riley P, 1998, NAT GENET, V18, P271, DOI 10.1038/ng0398-271; Shimomura T, 1997, J BIOL CHEM, V272, P6370, DOI 10.1074/jbc.272.10.6370; Szabo R, 2005, BIOCHEM J, V390, P231, DOI 10.1042/BJ20050299; Tanaka H, 2005, MOL CELL BIOL, V25, P5687, DOI 10.1128/MCB.25.13.5687-5698.2005; Velasco G, 2002, J BIOL CHEM, V277, P37637, DOI 10.1074/jbc.M203007200; Wu QY, 1998, J CLIN INVEST, V101, P321, DOI 10.1172/JCI1617; Zeeuwen PLJM, 2002, HUM MOL GENET, V11, P2867, DOI 10.1093/hmg/11.23.2867	26	107	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1546	1556		10.1038/sj.onc.1209966	http://dx.doi.org/10.1038/sj.onc.1209966			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983341				2022-12-28	WOS:000244782500004
J	Klampfer, L; Huang, J; Kaler, P; Sasazuki, T; Shirasawa, S; Augenlicht, L				Klampfer, L.; Huang, J.; Kaler, P.; Sasazuki, T.; Shirasawa, S.; Augenlicht, L.			STAT1-independent inhibition of cyclooxygenase-2 expression by IFN gamma; a common pathway of IFN gamma-mediated gene repression but not gene activation	ONCOGENE			English	Article						STAT1; COX-2; JAK; IFN; colon ucancer	COLORECTAL-CANCER PREVENTION; CELL LUNG-CANCER; INTERFERON-GAMMA; TYROSINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; SIGNALING PATHWAY; BINDING PROTEIN; DNA-BINDING; KI-RAS	Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in the synthesis of prostaglandins, promotes the development of colorectal cancer, and is a key molecular target of nonsteroidal anti-inflammatory drugs, compounds that reduce the relative risk of developing colon cancer. In this study, we showed that interferon gamma (IFN gamma) inhibits the expression of COX-2 protein in intestinal epithelial cells (IECs) through a pathway that requires Janus-activated kinase (JAK) activity. In contrast, we demonstrated that transcriptional inhibition of COX-2 by IFN beta or IFN gamma occurs in cells with silenced signal transducer and activator of transcription 1 (STAT1) expression and that IFNs retained the ability to inhibit COX-2 transcription in cells with activated RasV12, in which IFN gamma failed to induce STAT1. Thus, unlike the activity of JAK, STAT1 is not required for the inhibition of COX-2 expression by IFN gamma. In contrast to COX-2, the activation of genes in response to IFN gamma, such as interferon regulatory factor-1, was severely impaired by both STAT1 silencing and by constitutive Ras signaling. To determine whether there is a general differential requirement for STAT1 in gene activation and gene repression in response to IFN gamma in intestinal cells, we performed genome-wide analysis of IFN gamma target genes in an IEC line in which STAT1 expression was silenced by small interfering RNA. The results confirmed that the activation of the majority of genes by IFN gamma required STAT1. In contrast, the repression of several genes, as we showed for COX-2 specifically, was largely unaffected in cells with silenced STAT1. Our results therefore demonstrate that in general gene activation by IFNc is more sensitive to STAT1 deficiency than gene repression, and suggest that IFNc activates and represses gene expression via distinct pathways that can be distinguished, at least in part, by their requirement for STAT1.	Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, Bronx, NY 10467 USA; Int Med Ctr Japan, Inst Res, Shinjuku Ku, Tokyo, Japan	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; National Center for Global Health & Medicine - Japan	Klampfer, L (corresponding author), Montefiore Med Ctr, Albert Einstein Canc Ctr, Dept Oncol, 111 E 210th St, Bronx, NY 10467 USA.	lklampf@aecom.yu.edu			NATIONAL CANCER INSTITUTE [U54CA100926, R01CA111361] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA111361, U54 CA100926] Funding Source: Medline; PHS HHS [P30-13330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Araki Y, 2003, CANCER RES, V63, P728; Battcock SA, 2006, J VIROL, V80, P4422, DOI 10.1128/JVI.80.9.4422-4430.2006; Biasco G, 2002, DIGEST LIVER DIS, V34, P339, DOI 10.1016/S1590-8658(02)80127-X; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Bruewer M, 2003, J IMMUNOL, V171, P6164, DOI 10.4049/jimmunol.171.11.6164; Clifford JL, 2002, CLIN CANCER RES, V8, P2067; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Guy-Grand D, 1998, EUR J IMMUNOL, V28, P730, DOI 10.1002/(SICI)1521-4141(199802)28:02<730::AID-IMMU730>3.0.CO;2-U; Hanna N, 2004, AM J REPROD IMMUNOL, V51, P311, DOI 10.1111/j.1600-0897.2004.00162.x; Higaki S, 1999, J GASTROEN HEPATOL, V14, P709, DOI 10.1046/j.1440-1746.1999.01938.x; Hu JB, 2001, J BIOL CHEM, V276, P287, DOI 10.1074/jbc.M004885200; Janabi N, 2004, J NEUROIMMUNOL, V156, P113, DOI 10.1016/j.jneuroim.2004.07.012; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Klampfer L, 2004, J BIOL CHEM, V279, P30358, DOI 10.1074/jbc.M401359200; Klampfer L, 2003, J BIOL CHEM, V278, P46278, DOI 10.1074/jbc.M304721200; Klampfer L, 2003, MOL CANCER RES, V1, P855; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Muller-Tidow C, 2004, LUNG CANCER, V45, pS145, DOI 10.1016/j.lungcan.2004.07.000; Navarro A, 2003, J LEUKOCYTE BIOL, V73, P540, DOI 10.1189/jlb.1002508; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Ramsauer K, 2002, P NATL ACAD SCI USA, V99, P12859, DOI 10.1073/pnas.192264999; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma B, 1998, J BIOL CHEM, V273, P4642, DOI 10.1074/jbc.273.8.4642; Sheng HM, 2001, CANCER RES, V61, P2670; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sol VVD, 2005, J IMMUNOL, V174, P2825, DOI 10.4049/jimmunol.174.5.2825; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Wright KL, 2004, BRIT J PHARMACOL, V141, P1091, DOI 10.1038/sj.bjp.0705719	50	19	20	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2071	2081		10.1038/sj.onc.1210015	http://dx.doi.org/10.1038/sj.onc.1210015			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016440				2022-12-28	WOS:000245313400009
J	Kundu, CN; Balusu, R; Jaiswal, AS; Gairola, CG; Narayan, S				Kundu, C. N.; Balusu, R.; Jaiswal, A. S.; Gairola, C. G.; Narayan, S.			Cigarette smoke condensate-induced level of adenomatous polyposis coli blocks long-patchbase excision repair in breast epithelial cells	ONCOGENE			English	Article						adenomatous polyposis coli; long-patch base excision repair; benzo[a] pyrene; cigarette smoke condensate; breast carcinogenesis	RAS ONCOGENE ACTIVATION; APC GENE-EXPRESSION; TOBACCO-SMOKE; TRANSCRIPTIONAL REGULATION; CHEMICAL-COMPOSITION; PASSIVE SMOKING; ACTIVE SMOKING; DNA-ADDUCTS; CANCER RISK; MUTATIONS	Our previous studies have shown that treatment with cigarette smoke condensate (CSC) transforms normal breast epithelial cell line, MCF-10A. In the present study, the mechanism of CSC-induced transformation of breast epithelial cells was examined. We first determined whether benzo[ a] pyrene (B[a]P)- and CSC-induced levels of APC are capable of inhibiting long-patch base excision repair (LP-BER) since our earlier studies had shown that an interaction of APC with DNA polymerase beta (pol-beta) blocks strand-displacement synthesis. With the use of a novel in vivo LP-BER assay, it was demonstrated that increased and decreased APC levels in different breast cancer cell lines were associated witha decrease or increase in LP-BER activity, respectively. The effect of APC on LP-BER in malignant and pre- malignant breast epithelial cell lines was produced by either overexpression or knockdown of APC. Furthermore, it was shown that the decreased LP-BER in B[a]P- or CSC-treated premalignant breast epithelial cells is associated with an increased level of APC and decreased cell growth. Our results suggest that the decreased growth allows cells to repair the damaged DNA before mitosis, and failure to repair damaged DNA has the potential to transform premalignant breast epithelial cells.	Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Kentucky, Coll Med, Grad Ctr Toxicol, Lexington, KY USA	State University System of Florida; University of Florida; University of Kentucky	Narayan, S (corresponding author), Univ Florida, Shands Canc Ctr, Dept Anat & Cell Biol, Canc & Genet Res Complex,Room 255,POB 103633,1376, Gainesville, FL 32610 USA.	snarayan@ufscc.ufl.edu		Kundu, Chanakya/0000-0003-0297-1030	NCI NIH HHS [CA-100247-01, CA-097031-01, R01 CA100247, R01 CA097031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097031, R01CA100247] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; BARON JA, 1984, AM J EPIDEMIOL, V119, P9, DOI 10.1093/oxfordjournals.aje.a113730; Baron JA, 1996, CANCER EPIDEM BIOMAR, V5, P399; BASOLO F, 1991, MOL CARCINOGEN, V4, P25, DOI 10.1002/mc.2940040106; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Braithwaite E, 1998, CARCINOGENESIS, V19, P1239, DOI 10.1093/carcin/19.7.1239; CAVLIERI EL, 1998, HDB ENV CHEM J, V3, P81; CHAKRAVARTI D, 1995, P NATL ACAD SCI USA, V92, P10422, DOI 10.1073/pnas.92.22.10422; Chakravarti D, 1998, ONCOGENE, V16, P3203, DOI 10.1038/sj.onc.1201853; Chakravarti D, 2000, MUTAT RES-FUND MOL M, V456, P17, DOI 10.1016/S0027-5107(00)00102-0; Coates PJ, 2005, J PATHOL, V205, P221, DOI 10.1002/path.1701; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001; DEMARINI DM, 1995, CARCINOGENESIS, V16, P2535, DOI 10.1093/carcin/16.10.2535; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Egan KM, 2002, EPIDEMIOLOGY, V13, P138, DOI 10.1097/00001648-200203000-00007; ELBAYOUMY K, 1995, CARCINOGENESIS, V16, P431, DOI 10.1093/carcin/16.2.431; Fink AK, 2003, CANCER CAUSE CONTROL, V14, P497, DOI 10.1023/A:1024922824237; Gram IT, 2005, CANCER EPIDEM BIOMAR, V14, P61; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hecht SS, 2002, ENVIRON MOL MUTAGEN, V39, P119, DOI 10.1002/em.10071; HSU TC, 1991, MUTAT RES, V259, P67, DOI 10.1016/0165-1218(91)90110-8; HUSGAFVELPURSIAINEN K, 1993, INT J CANCER, V53, P250, DOI 10.1002/ijc.2910530213; Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200; Jaiswal AS, 2002, ONCOGENE, V21, P5912, DOI 10.1038/sj.onc.1205789; Jaiswal AS, 2006, CARCINOGENESIS, V27, P252, DOI 10.1093/carcin/bgi225; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; Johnson KC, 2000, CANCER CAUSE CONTROL, V11, P211, DOI 10.1023/A:1008906105790; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LONDON SJ, 1989, JNCI-J NATL CANCER I, V81, P1625, DOI 10.1093/jnci/81.21.1625; Mei JX, 2003, BREAST CANCER RES TR, V79, P95, DOI 10.1023/A:1023326121951; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Morabia A, 1996, AM J EPIDEMIOL, V143, P918, DOI 10.1093/oxfordjournals.aje.a008835; Narayan S, 1997, J BIOL CHEM, V272, P30619, DOI 10.1074/jbc.272.49.30619; Narayan S, 2005, J BIOL CHEM, V280, P6942, DOI 10.1074/jbc.M409200200; Narayan S, 2004, ONCOGENE, V23, P5880, DOI 10.1038/sj.onc.1207792; Nishikawa A, 2004, CURR DRUG METAB, V5, P363, DOI 10.2174/1389200043335441; Pachkowski BF, 2006, CANCER RES, V66, P2860, DOI 10.1158/0008-5472.CAN-05-3388; PALMER JR, 1993, EPIDEMIOL REV, V15, P145, DOI 10.1093/oxfordjournals.epirev.a036098; Patel AV, 2005, BREAST CANCER RES, V7, pR1168, DOI 10.1186/bcr1355; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PILLSBURY HC, 1972, J ASSOC OFF ANA CHEM, V55, P636; Porter PC, 2005, DNA REPAIR, V4, P341, DOI 10.1016/j.dnarep.2004.10.007; Raptis S, 2006, EXP SUPPL, V96, P303; Reynolds P, 2004, JNCI-J NATL CANCER I, V96, P29, DOI 10.1093/jnci/djh002; Roemer E, 2004, TOXICOLOGY, V195, P31, DOI 10.1016/j.tox.2003.08.006; RUSSO J, 1991, J CELL SCI, V99, P453; SHORTLE D, 1983, METHOD ENZYMOL, V100, P457; SLEBOS RJC, 1991, J NATL CANCER I, V83, P1024, DOI 10.1093/jnci/83.14.1024; Smith CJ, 2000, FOOD CHEM TOXICOL, V38, P637, DOI 10.1016/S0278-6915(00)00051-X; SOULE HD, 1990, CANCER RES, V50, P6075; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Stabbert R, 2003, J APPL TOXICOL, V23, P329, DOI 10.1002/jat.924; Steinetz BG, 2006, CARCINOGENESIS, V27, P1146, DOI 10.1093/carcin/bgi353; Terry PD, 2002, CANCER EPIDEM BIOMAR, V11, P953; Terry PD, 2006, CANCER EPIDEM BIOMAR, V15, P602, DOI 10.1158/1055-9965.EPI-05-0853; Wani MA, 2002, MUTAT RES-FUND MOL M, V505, P13, DOI 10.1016/S0027-5107(02)00107-0; WESTRA WH, 1993, CANCER-AM CANCER SOC, V72, P432, DOI 10.1002/1097-0142(19930715)72:2<432::AID-CNCR2820720219>3.0.CO;2-#; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0	59	37	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1428	1438		10.1038/sj.onc.1209925	http://dx.doi.org/10.1038/sj.onc.1209925			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924228				2022-12-28	WOS:000244558800007
J	Takada, Y; Ichikawa, H; Pataer, A; Swisher, S; Aggarwal, BB				Takada, Y.; Ichikawa, H.; Pataer, A.; Swisher, S.; Aggarwal, B. B.			Genetic deletion of PKR abrogates TNF-induced activation of I kappa B alpha kinase, JNK, Akt and cell proliferation but potentiates p44/p42 MAPK and p38 MAPK activation	ONCOGENE			English	Article						PKR; Akt; MAPK; JNK; NF-kappa B; TNF; survival; apoptosis	DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL-CELLS; INFLAMMATORY STIMULI; SIGNAL-TRANSDUCTION; UP-REGULATION; INTERFERON; EXPRESSION; APOPTOSIS	Double-stranded RNA-dependent protein kinase (PKR), a ubiquitously expressed serine/threonine kinase, has been implicated in the regulation or modulation of cell growth through multiple signaling pathways, but how PKR regulates tumor necrosis factor (TNF)-induced signaling pathways is poorly understood. In the present study, we used. broblasts derived from PKR gene-deleted mice to investigate the role of PKR in TNF-induced activation of nuclear factor-kappa B (NF-kappa B), mitogen-activated protein kinases (MAPKs) and growth modulation. We found that in wild-type mouse embryonic fibroblast (MEF), TNF induced NF-kappa B activation as measured by DNA binding but deletion of PKR abolished this activation. This inhibition was associated with suppression of inhibitory subunit of NF-kappa B (I kappa B)alpha kinase (IKK) activation, I kappa B alpha phosphorylation and degradation, p65 phosphorylation and nuclear translocation, and NF-kappa B-dependent reporter gene transcription. TNF-induced Akt activation needed for IKK activation was also abolished by deletion of PKR. NF-kappa B activation was diminished in PKR-deleted cells transfected with TNF receptor ( TNFR) 1, TNFR-associated death domain and TRAF2 plasmids; NF-kappa B activated by NF-kappa B-inducing kinase, IKK or p65, however, was minimally affected. Among the MAPKs, it was interesting that whereas TNF-induced c-Jun N-terminal kinase (JNK) activation was abolished, activation of p44/p42 MAPK and p38 MAPK was potentiated in PKR-deleted cells. TNF induced the expression of NF-kappa B-regulated gene products cyclin D1, c-Myc, matrix metalloproteinase-9, survivin, X-linked inhibitor-of-apoptosis protein (IAP), IAP1, Bcl-x(L), A1/Bfl-1 and Fas-associated death domain protein-like IL-1 beta-converting enzyme-inhibitory protein in wild-type MEF but not in PKR-/- cells. Similarly, TNF induced the proliferation of wild-type cells, but this proliferation was completely suppressed in PKR-deleted cells. Overall, our results indicate that PKR differentially regulates TNF signaling; IKK, Akt and JNK were positively regulated, whereas p44/p42 MAPK and p38 MAPK were negatively regulated.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, 1515 Holcombe Blvd,Unit 143, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NCI NIH HHS [P01 CA91844, P50CA97007] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA091844, P50CA097007] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Bandyopadhyay SK, 2000, J IMMUNOL, V164, P2077, DOI 10.4049/jimmunol.164.4.2077; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CHATURVEDI MM, 1994, J BIOL CHEM, V269, P14575; Cheshire JL, 1999, J BIOL CHEM, V274, P4801, DOI 10.1074/jbc.274.8.4801; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Deb A, 2001, J IMMUNOL, V166, P6170, DOI 10.4049/jimmunol.166.10.6170; Demarchi F, 1999, J VIROL, V73, P7080, DOI 10.1128/JVI.73.8.7080-7086.1999; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Donze O, 2004, EMBO J, V23, P564, DOI 10.1038/sj.emboj.7600078; Esteves E, 2002, MATH RES LETT, V9, P1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gil J, 2000, ONCOGENE, V19, P1369, DOI 10.1038/sj.onc.1203448; Gil J, 2004, MOL CELL BIOL, V24, P4502, DOI 10.1128/MCB.24.10.4502-4512.2004; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Gilbert SJ, 2004, ARTHRITIS RES THER, V6, pR46, DOI 10.1186/ar1024; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; GUSELLA GL, 1995, J IMMUNOL, V154, P345; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kronfeld-Kinar Y, 1999, CELL GROWTH DIFFER, V10, P201; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Maggi LB, 2003, J BIOL CHEM, V278, P16683, DOI 10.1074/jbc.M211744200; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; MUNDSCHAU LJ, 1995, J BIOL CHEM, V270, P3100, DOI 10.1074/jbc.270.7.3100; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Ozes ON, 1999, NATURE, V401, P82; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Simeonidis S, 1999, P NATL ACAD SCI USA, V96, P49, DOI 10.1073/pnas.96.1.49; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Takada Y, 2004, J BIOL CHEM, V279, P39541, DOI 10.1074/jbc.M403449200; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2004, J BIOL CHEM, V279, P15096, DOI 10.1074/jbc.M311192200; Takada Y, 2004, J BIOL CHEM, V279, P4750, DOI 10.1074/jbc.M304546200; Takada Y, 2003, J BIOL CHEM, V278, P23390, DOI 10.1074/jbc.M213237200; Takizawa T, 2002, EUR J BIOCHEM, V269, P6126, DOI 10.1046/j.1432-1033.2002.03325.x; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Verma IM, 1997, P NATL ACAD SCI USA, V94, P11758, DOI 10.1073/pnas.94.22.11758; Williams B R, 2001, Sci STKE, V2001, pre2, DOI 10.1126/stke.2001.89.re2; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Xu Z, 2000, MOL CELL BIOL, V20, P5285, DOI 10.1128/MCB.20.14.5285-5299.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhu L, 2001, FEBS LETT, V508, P369, DOI 10.1016/S0014-5793(01)03084-8; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	65	82	82	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1201	1212		10.1038/sj.onc.1209906	http://dx.doi.org/10.1038/sj.onc.1209906			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924232				2022-12-28	WOS:000244406400010
J	Baluchamy, S; Sankar, N; Navaraj, A; Moran, E; Thimmapaya, B				Baluchamy, S.; Sankar, N.; Navaraj, A.; Moran, E.; Thimmapaya, B.			Relationship between E1A binding to cellular proteins, c-myc activation and S-phase induction	ONCOGENE			English	Article						E1A; p300; c-myc repression; cell cycle	ACETYLTRANSFERASE COMPLEX; G(1) EXIT; P300; TRANSFORMATION; ACETYLATION; EXPRESSION; DEPLETION; PRB	We recently showed that p300/CREB-binding protein (CBP) plays an important role in maintaining cells in G0/G1 phase by keeping c-myc in a repressed state. Consistent with this, adenovirus E1A oncoprotein induces c-myc in a p300-dependent manner, and the c-myc induction is linked to S-phase induction. The induction of S phase by E1A is dependent on its binding to and inactivating several host proteins including p300/CBP. To determine whether there is a correlation between the host proteins binding to the N-terminal region of E1A, activation of c-myc and induction of S phase, we assayed the c-myc and S-phase induction in quiescent human cells by infecting them with Ad N-terminal E1A mutants with mutations that specifically affect binding to different chromatin-associated proteins including pRb, p300, p400 and p300/CBP-associated factor (PCAF). We show that the mutants that failed to bind to p300 or pRb were severely defective for c-myc and S-phase induction. The induction of c-myc and S phase was only moderately affected when E1A failed to bind to p400. Furthermore, analysis of the E1A mutants that fail to bind to p300, and both p300 and PCAF suggests that PCAF may also play a role in c-myc repression, and that the two chromatin-associated proteins may repress c-myc independently. In summary, these results suggest that c-myc deregulation by E1A through its interaction with these chromatin-associated proteins is an important step in the E1A-mediated cell cycle deregulation and possibly in cell transformation.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Temple Univ, Sch Med, Inst Canc Res & Mol Biol, Philadelphia, PA 19122 USA	Northwestern University; Feinberg School of Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Thimmapaya, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave,Olson 8452, Chicago, IL 60611 USA.	b-thimmapaya@northwestern.edu	Natesan, Sankar/C-9866-2015		NCI NIH HHS [CA74403, R01 CA074403] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074403] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; BARBEAU D, 1994, ONCOGENE, V9, P359; Buchmann AM, 1998, MOL CELL BIOL, V18, P4565, DOI 10.1128/MCB.18.8.4565; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; Fuchs M, 2001, CELL, V106, P297, DOI 10.1016/S0092-8674(01)00450-0; Goodman RH, 2000, GENE DEV, V14, P1553; GRISCH SM, 2002, NAT REV MOL CELL BIO, V6, P441; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Lang SE, 2003, ONCOGENE, V22, P2836, DOI 10.1038/sj.onc.1206376; Mitchell KO, 1999, CELL GROWTH DIFFER, V10, P223; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nees M, 2000, CANCER RES, V60, P4289; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Reid JL, 1998, EMBO J, V17, P4469, DOI 10.1093/emboj/17.15.4469; Santoso BY, 2006, NAT STRUCT MOL BIOL, V13, P131, DOI 10.1038/nsmb1048; SOULE HD, 1990, CANCER RES, V50, P6075; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993	24	16	17	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					781	787		10.1038/sj.onc.1209825	http://dx.doi.org/10.1038/sj.onc.1209825			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862175				2022-12-28	WOS:000243902200015
J	Oakes, SR; Robertson, FG; Kench, JG; Gardiner-Garden, M; Wand, MP; Green, JE; Ormandy, CJ				Oakes, S. R.; Robertson, F. G.; Kench, J. G.; Gardiner-Garden, M.; Wand, M. P.; Green, J. E.; Ormandy, C. J.			Loss of mammary epithelial prolactin receptor delays tumor formation by reducing cell proliferation in low-grade preinvasive lesions	ONCOGENE			English	Article						prolactin receptor; mouse; mammary; carcinogenesis; C3(1)/SV40T	TRANSGENIC MOUSE MODEL; BREAST-CANCER; GLAND DEVELOPMENT; GROWTH-HORMONE; EXPRESSION; MICE; RISK; PROSTATE; PRL; BROMOCRIPTINE	Top quartile serum prolactin levels confer a twofold increase in the relative risk of developing breast cancer. Prolactin exerts this effect at an ill defined point in the carcinogenic process, via mechanisms involving direct action via prolactin receptors within mammary epithelium and/or indirect action through regulation of other hormones such as estrogen and progesterone. We have addressed these questions by examining mammary carcinogenesis in transplants of mouse mammary epithelium expressing the SV40T oncogene, with or without the prolactin receptor, using host animals with a normal endocrine system. In prolactin receptor knockout transplants the area of neoplasia was significantly smaller (7 versus 17%; P < 0.001 at 22 weeks and 7 versus 14%; P=0.009 at 32 weeks). Low-grade neoplastic lesions displayed reduced BrdU incorporation rate (11.3 versus 17% P=0.003) but no change in apoptosis rate. Tumor latency increased (289 days versus 236 days, P < 0.001). Tumor frequency, growth rate, morphology, cell proliferation and apoptosis were not altered. Thus, prolactin acts directly on the mammary epithelial cells to increase cell proliferation in preinvasive lesions, resulting in more neoplasia and acceleration of the transition to invasive carcinoma. Targeting of mammary prolactin signaling thus provides a strategy to prevent the early progression of neoplasia to invasive carcinoma.	St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Sydney, NSW 2010, Australia; Inst Clin Pathol & Med Res, Dept Tissue Pathol, Westmead, NSW, Australia; Univ New S Wales, Sch Math, Dept Stat, Sydney, NSW, Australia; Lab Cell Regulat & Carcinogenesis, Transgen Oncogenesis Grp, Bethesda, MD USA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Ormandy, CJ (corresponding author), St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, 384 Victoria St, Sydney, NSW 2010, Australia.	c.ormandy@garvan.org.au	Ormandy, Chris/G-4165-2014; Wand, Matt P/F-9413-2012	Wand, Matt P/0000-0003-2555-896X; Oakes, Samantha/0000-0003-1838-2310; Ormandy, Christopher/0000-0002-2504-7919; Kench, James Geoffrey/0000-0001-8687-4988	NATIONAL CANCER INSTITUTE [ZIABC005740, Z01BC005740] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTIA MAM, 1966, CANCER RES, V26, P1787; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BONNETERRE J, 1987, CANCER RES, V47, P4724; BRADBURY JM, 1995, DEV BIOL, V170, P553, DOI 10.1006/dbio.1995.1236; Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chen WY, 1999, CLIN CANCER RES, V5, P3583; Clement-Lacroix P, 1999, ENDOCRINOLOGY, V140, P96, DOI 10.1210/en.140.1.96; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; DEOME KB, 1959, CANCER RES, V19, P515; Freemark M, 2001, ENDOCRINOLOGY, V142, P532, DOI 10.1210/en.142.2.532; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1996, J BIOL CHEM, V271, P16573, DOI 10.1074/jbc.271.28.16573; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; Gutzman JH, 2004, J STEROID BIOCHEM, V88, P69, DOI 10.1016/j.jsbmb.2003.10.008; Hankinson SE, 1998, JNCI-J NATL CANCER I, V90, P1292, DOI 10.1093/jnci/90.17.1292; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Horseman ND, 1997, EMBO J, V16, P6926, DOI 10.1093/emboj/16.23.6926; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Ling C, 2000, ENDOCRINOLOGY, V141, P3564, DOI 10.1210/en.141.10.3564; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; MANNI A, 1989, BREAST CANCER RES TR, V14, P289, DOI 10.1007/BF01806300; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; MERSHON J, 1995, ENDOCRINOLOGY, V136, P3619, DOI 10.1210/en.136.8.3619; Missmer SA, 2004, JNCI-J NATL CANCER I, V96, P1856, DOI 10.1093/jnci/djh336; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Naylor MJ, 2003, ENDOCRINE, V20, P111, DOI 10.1385/ENDO:20:1-2:111; Naylor MJ, 2002, DEV DYNAM, V225, P100, DOI 10.1002/dvdy.10133; Ormandy CJ, 1997, J MAMMARY GLAND BIOL, V2, P355, DOI 10.1023/A:1026395229025; Ormandy CJ, 1997, J CLIN ENDOCR METAB, V82, P3692, DOI 10.1210/jc.82.11.3692; Ormandy CJ, 1997, GENE DEV, V11, P167, DOI 10.1101/gad.11.2.167; PEYRAT JP, 1984, EUR J CANCER CLIN ON, V20, P1363, DOI 10.1016/0277-5379(84)90054-3; PINHEIRO J, 2005, R PACKAGE VERSION, V3, P1; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Robertson FG, 2003, ENDOCRINOLOGY, V144, P3196, DOI 10.1210/en.2003-0068; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Schroeder MD, 2003, ENDOCRINOLOGY, V144, P5300, DOI 10.1210/en.2003-0826; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shibata MA, 1998, TOXICOL PATHOL, V26, P177, DOI 10.1177/019262339802600121; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Vomachka AJ, 2000, ONCOGENE, V19, P1077, DOI 10.1038/sj.onc.1203348; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; WELSCH CW, 1975, BRIT J CANCER, V32, P427, DOI 10.1038/bjc.1975.243; WELSCH CW, 1977, CANCER RES, V37, P951; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	52	68	70	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					543	553		10.1038/sj.onc.1209838	http://dx.doi.org/10.1038/sj.onc.1209838			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862169				2022-12-28	WOS:000243731600007
J	Roos, WP; Batista, LFZ; Naumann, SC; Wick, W; Weller, M; Menck, CFM; Kaina, B				Roos, W. P.; Batista, L. F. Z.; Naumann, S. C.; Wick, W.; Weller, M.; Menck, C. F. M.; Kaina, B.			Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O-6-methylguanine	ONCOGENE			English	Article						apoptosis; DNA damage; DNA repair; MGMT; glioblastoma; Fas; p53	HUMAN O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; MISMATCH REPAIR; METHYLTRANSFERASE MGMT; O-6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; CLINICAL-RESPONSE; TRANSGENIC MICE; RNA-POLYMERASE; BRAIN-TUMORS; DAMAGE	Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumours (malignant gliomas). The mechanism of TMZ-induced glioma cell death is unknown. Here, we show that malignant glioma cells undergo apoptosis following treatment with the methylating agents N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and TMZ. Cell death determined by colony formation and apoptosis following methylation is greatly stimulated by p53. Transfection experiments with O-6-methylguanine-DNA methyltransferase (MGMT) and depletion of MGMT by O-6-benzylguanine showed that, in gliomas, the apoptotic signal originates from O6-methylguanine (O(6)MeG) and that repair of O6MeG by MGMT prevents apoptosis. We further demonstrate that O(6)MeG-triggered apoptosis requires Fas/CD95/Apo-1 receptor activation in p53 non-mutated glioma cells, whereas in p53 mutated gliomas the same DNA lesion triggers the mitochondrial apoptotic pathway. This occurs less effectively via Bcl-2 degradation and caspase-9, -2, -7 and -3 activation. O(6)MeG-triggered apoptosis in gliomas is a late response (occurring > 120 h after treatment) that requires extensive cell proliferation. Stimulation of cell cycle progression by the Pasteurella multocida toxin promoted apoptosis whereas serum starvation attenuated it. O(6)MeG-induced apoptosis in glioma cells was preceded by the formation of DNA double-strand breaks (DSBs), as measured by gamma H2AX formation. Glioma cells mutated in DNA-PKcs, which is involved in non-homologous endjoining, were more sensitive to TMZ-induced apoptosis, supporting the involvement of DSBs as a downstream apoptosis triggering lesion. Overall, the data demonstrate that cell death induced by TMZ in gliomas is due to apoptosis and that determinants of sensitivity of gliomas to TMZ are MGMT, p53, proliferation rate and DSB repair.	Johannes Gutenberg Univ Mainz, Dept Toxicol, D-55131 Mainz, Germany; Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil; Univ Tubingen, Sch Med, Hertie Inst Clin Brain Res, Dept Gen Neurol, Tubingen, Germany	Johannes Gutenberg University of Mainz; Universidade de Sao Paulo; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Dept Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Menck, Carlos FM/G-6321-2011; Roos, Wynand/B-4846-2008; Kaina, Bernd/AAE-4692-2020; Wick, Wolfgang/AAA-2545-2020	Menck, Carlos FM/0000-0003-1941-0694; Roos, Wynand/0000-0002-0474-7414; Wick, Wolfgang/0000-0002-6171-634X; Weller, Michael/0000-0002-1748-174X				ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Anda T, 2003, NEUROL RES, V25, P241, DOI 10.1179/016164103101201445; Balajee AS, 1997, P NATL ACAD SCI USA, V94, P4306, DOI 10.1073/pnas.94.9.4306; Becker K, 2003, CARCINOGENESIS, V24, P541, DOI 10.1093/carcin/24.3.541; Becker K, 1996, CANCER RES, V56, P3244; BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; Bobola MS, 2001, CLIN CANCER RES, V7, P613; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN JM, 1992, CARCINOGENESIS, V13, P1503; Chen ZP, 1999, CAN J NEUROL SCI, V26, P104; Debiak M, 2004, DNA REPAIR, V3, P359, DOI 10.1016/j.dnarep.2003.11.013; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; DUMENCO LL, 1993, SCIENCE, V259, P219, DOI 10.1126/science.8421782; Dunkern T, 2003, MUTAT RES-REV MUTAT, V544, P167, DOI 10.1016/j.mrrev.2003.06.005; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Esteller M, 2001, CANCER RES, V61, P3225; Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319; Gunther W, 2003, BRIT J CANCER, V88, P463, DOI 10.1038/sj.bjc.6600711; Hammond LA, 2004, CLIN CANCER RES, V10, P1645, DOI 10.1158/1078-0432.CCR-03-0174; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hermisson M, 2006, J NEUROCHEM, V96, P766, DOI 10.1111/j.1471-4159.2005.03583.x; Hickman MJ, 2004, MOL CELL, V14, P105, DOI 10.1016/S1097-2765(04)00162-5; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hirose Y, 2001, CANCER RES, V61, P5843; KAINA B, 1991, CARCINOGENESIS, V12, P1857; Kaina B, 1997, MUTAT RES-FUND MOL M, V381, P227, DOI 10.1016/S0027-5107(97)00187-5; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Komarova EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P41; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Lips J, 2001, CARCINOGENESIS, V22, P579, DOI 10.1093/carcin/22.4.579; Ljungman M, 1996, ONCOGENE, V13, P823; Margison GP, 2002, BIOESSAYS, V24, P255, DOI 10.1002/bies.10063; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; O'Connell MJ, 2005, J CELL SCI, V118, P1, DOI 10.1242/jcs.01626; Ochs K, 2000, CANCER RES, V60, P5815; Orth JHC, 2003, BIOCHEMISTRY-US, V42, P4971, DOI 10.1021/bi0272959; Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; Pepponi R, 2003, J PHARMACOL EXP THER, V304, P661, DOI 10.1124/jpet.102.043950; Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300; Preuss I, 1996, INT J CANCER, V65, P506, DOI 10.1002/(SICI)1097-0215(19960208)65:4<506::AID-IJC19>3.0.CO;2-7; PREUSS I, 1995, INT J CANCER, V61, P321, DOI 10.1002/ijc.2910610308; RENART J, 1979, P NATL ACAD SCI USA, V76, P3116, DOI 10.1073/pnas.76.7.3116; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Roos WP, 2000, INT J RADIAT BIOL, V76, P1493, DOI 10.1080/09553000050176252; SCUDIERO DA, 1984, CANCER RES, V44, P2467; Silber JR, 1999, CLIN CANCER RES, V5, P807; SKLAR R, 1981, NATURE, V289, P417, DOI 10.1038/289417a0; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; TSARYK R, 2005, IN PRESS CANC LETT; Wischhusen J, 2003, ONCOGENE, V22, P8233, DOI 10.1038/sj.onc.1207198	60	392	411	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					186	197		10.1038/sj.onc.1209785	http://dx.doi.org/10.1038/sj.onc.1209785			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819506				2022-12-28	WOS:000243398300003
J	Kikuchi, H; Ozaki, T; Furuya, K; Hanamoto, T; Nakanishi, M; Yamamoto, H; Yoshida, K; Todo, S; Nakagawara, A				Kikuchi, H.; Ozaki, T.; Furuya, K.; Hanamoto, T.; Nakanishi, M.; Yamamoto, H.; Yoshida, K.; Todo, S.; Nakagawara, A.			NF-kappa B regulates the stability and activity of p73 by inducing its proteolytic degradation through a ubiquitin-dependent proteasome pathway	ONCOGENE			English	Article						apoptosis; NF-B; p53; p73; ubiquitination	KINASE C-ABL; DNA-DAMAGE; TYROSINE KINASE; P53-RELATED PROTEIN; APOPTOTIC RESPONSE; CELL-SURVIVAL; P53; ACTIVATION; DEATH; INHIBITION	Nuclear factor kappa B (NF-kappa B), which exists as heterodimeric complexes composed of p50 and p65, has been shown to play an important role in cell survival processes. In the present study, we found for the first time that NF-kappa B has an ability to induce the ubiquitin-dependent proteasomal degradation of proapoptotic p73 alpha. The activation of NF-kappa B in tumor necrosis factor a (TNF-alpha)-stimulated H1299 cells resulted in a significant reduction in the amounts of the endogenous p73 alpha. Consistent with these results, TNF-alpha-mediated down-regulation of p73 alpha was observed in wild-type (WT) mouse embryonic fibroblasts (MEFs) but not in p65-deficient MEFs. Ectopic expression of NF-kappa B decreased a half-life of p73a by increasing its ubiquitination levels, and thereby inhibiting the transcriptional activity as well as proapoptotic function of p73a, whereas NF-kappa B had undetectable effects on p53. Immunoprecipitation experiments demonstrated that, under our experimental conditions, NF-kappa B does not bind to p73a in mammalian cultured cells. In contrast to WT p65, the COOH-terminal deletion mutant of p65 (p65 Delta C) failed to reduce the expression levels of p73a, suggesting that NF-kappa B-mediated proteolytic degradation of p73a requires the transcriptional activity of NF-kappa B. Taken together, our present results imply that NF-kappa B-mediated degradation of proapoptotic p73 is a novel inhibitory mechanism of p73 that regulates cell survival and death.	Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, Chiba 2608717, Japan; Hokkaido Univ, Dept Gen Surg, Sch Med, Kita Ku, Sapporo, Hokkaido, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr Res Inst, Div Biochem, Chuoh Ku, 666-2 Nitona, Chiba 2608717, Japan.	akiranak@chiba-cc.jp						Agami R, 1999, NATURE, V399, P809; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bayon Y, 2003, MOL CELL BIOL, V23, P1061, DOI 10.1128/MCB.23.3.1061-1074.2003; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Gong JG, 1999, NATURE, V399, P806; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kawai H, 2002, MOL CELL BIOL, V22, P6079, DOI 10.1128/MCB.22.17.6079-6088.2002; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kim JS, 2004, BIOCHEM PHARMACOL, V67, P1459, DOI 10.1016/j.bcp.2003.12.013; Kramer S, 2005, ONCOGENE, V24, P938, DOI 10.1038/sj.onc.1208257; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; Leng RP, 2003, CELL, V112, P779, DOI 10.1016/S0092-8674(03)00193-4; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Stiewe T, 2002, CELL DEATH DIFFER, V9, P237, DOI 10.1038/sj.cdd.4400995; Stiewe T, 2002, CANCER RES, V62, P3598; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; VAN AD, 1996, SCIENCE, V274, P787; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	45	16	17	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7608	7617		10.1038/sj.onc.1209748	http://dx.doi.org/10.1038/sj.onc.1209748			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16953234				2022-12-28	WOS:000242655500006
J	Gudmundsdottir, K; Ashworth, A				Gudmundsdottir, K.; Ashworth, A.			The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability	ONCOGENE			English	Review						BRCA1; BRCA2; repair; genomic stability; DSS1	STRAND BREAK REPAIR; CANCER SUSCEPTIBILITY GENE; DNA-DAMAGE RESPONSE; HOMOLOGY-DIRECTED REPAIR; TRANSCRIPTION-COUPLED REPAIR; EARLY EMBRYONIC LETHALITY; CELL-CYCLE CHECKPOINT; RNA-POLYMERASE-II; MAMMALIAN-CELLS; DEPENDENT PHOSPHORYLATION	The BRCA1 and BRCA2 proteins are important in maintaining genomic stability by promoting efficient and precise repair of double-strand breaks. The main role of BRCA2 appears to involve regulating the function of RAD51 in the repair by homologous recombination. BRCA1 has a broader role upstream of BRCA2, participating in various cellular processes in response to DNA damage. The DNA repair defect associated with mutations in BRCA1 or BRCA2 could be exploited to develop new targeted therapeutic approaches for cancer occurring in mutation carriers.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Ashworth, A (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	alan.ashworth@icr.ac.uk			Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Baldeyron C, 2002, ONCOGENE, V21, P1401, DOI 10.1038/sj.onc.1205200; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; Dantzer F, 2000, BIOCHEMISTRY-US, V39, P7559, DOI 10.1021/bi0003442; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Elliott B, 2005, MOL CELL, V17, P885, DOI 10.1016/j.molcel.2005.02.028; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Evers B, 2006, ONCOGENE, V25, P5885, DOI 10.1038/sj.onc.1209871; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fedier A, 2003, INT J ONCOL, V22, P1169; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Futamura M, 2000, CANCER RES, V60, P1531; Galkin VE, 2005, P NATL ACAD SCI USA, V102, P8537, DOI 10.1073/pnas.0407266102; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Gudmundsdottir K, 2004, EMBO REP, V5, P989, DOI 10.1038/sj.embor.7400255; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hartwell L, 1997, NATURE, V387, P855, DOI 10.1038/43072; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hefferin ML, 2005, DNA REPAIR, V4, P639, DOI 10.1016/j.dnarep.2004.12.005; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jin Y, 1997, P NATL ACAD SCI USA, V94, P12075, DOI 10.1073/pnas.94.22.12075; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Josse L, 2006, BIOCHEM J, V393, P303, DOI 10.1042/BJ20051238; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kojic M, 2003, MOL CELL, V12, P1043, DOI 10.1016/S1097-2765(03)00367-8; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Larminat F, 2002, ONCOGENE, V21, P5188, DOI 10.1038/sj.onc.1205659; Le Page F, 2000, CANCER RES, V60, P5548; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee M, 2004, ONCOGENE, V23, P865, DOI 10.1038/sj.onc.1207223; Li J, 2006, ONCOGENE, V25, P1186, DOI 10.1038/sj.onc.1209153; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin HR, 2003, J BIOL CHEM, V278, P35979, DOI 10.1074/jbc.M210659200; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ma JL, 2003, MOL CELL BIOL, V23, P8820, DOI 10.1128/MCB.23.23.8820-8828.2003; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Marston NJ, 1999, MOL CELL BIOL, V19, P4633; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; MCCABE N, 2006, IN PRESS CANC RES; McCarthy EE, 2003, MOL CELL BIOL, V23, P5056, DOI 10.1128/MCB.23.14.5056-5063.2003; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Okada S, 2003, J BIOL CHEM, V278, P2015, DOI 10.1074/jbc.M208685200; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pellegrini L, 2002, NATURE, V420, P287, DOI 10.1038/nature01230; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Saeki H, 2006, P NATL ACAD SCI USA, V103, P8768, DOI 10.1073/pnas.0600298103; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shin DS, 2004, DNA REPAIR, V3, P863, DOI 10.1016/j.dnarep.2004.03.022; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Spain BH, 1999, P NATL ACAD SCI USA, V96, P13920, DOI 10.1073/pnas.96.24.13920; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Stark JM, 2004, MOL CELL BIOL, V24, P9305, DOI 10.1128/MCB.24.21.9305-9316.2004; Takata M, 2002, ONCOGENE, V21, P1130, DOI 10.1038/sj.onc.1205168; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tarsounas M, 2003, ONCOGENE, V22, P1115, DOI 10.1038/sj.onc.1206263; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; Tutt ANJ, 2005, COLD SH Q B, V70, P139, DOI 10.1101/sqb.2005.70.012; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Wang Y, 2000, GENE DEV, V14, P927; Warren M, 2002, HUM MOL GENET, V11, P841, DOI 10.1093/hmg/11.7.841; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Westermark UK, 2003, MOL CELL BIOL, V23, P7926, DOI 10.1128/MCB.23.21.7926-7936.2003; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wong AKC, 1997, J BIOL CHEM, V272, P31941, DOI 10.1074/jbc.272.51.31941; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang HJ, 2002, SCIENCE, V297, P1837, DOI 10.1126/science.297.5588.1837; Yang HJ, 2005, NATURE, V433, P653, DOI 10.1038/nature03234; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yu DS, 2003, MOL CELL, V12, P1029, DOI 10.1016/S1097-2765(03)00394-0; Yu VPCC, 2000, GENE DEV, V14, P1400; Yuan SSF, 1999, CANCER RES, V59, P3547; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747; Zhuang J, 2006, CANCER RES, V66, P1401, DOI 10.1158/0008-5472.CAN-05-3278	119	427	448	2	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5864	5874		10.1038/sj.onc.1209874	http://dx.doi.org/10.1038/sj.onc.1209874			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998501				2022-12-28	WOS:000240765900007
J	Breuhahn, K; Longerich, T; Schirmacher, P				Breuhahn, K.; Longerich, T.; Schirmacher, P.			Dysregulation of growth factor signaling in human hepatocellular carcinoma	ONCOGENE			English	Review						hepatocellular carcinoma; growth factors; signal transduction; liver; tumorigenesis; receptors	FACTOR-I RECEPTOR; HEPATITIS-B-VIRUS; TYROSINE KINASE-ACTIVITY; BETA-CATENIN ACCUMULATION; SMALL-MOLECULE INHIBITOR; CANCER CELL-LINES; FAMILIAL ADENOMATOUS POLYPOSIS; MESSENGER-RNA EXPRESSION; FACTOR-BINDING-PROTEINS; FACTOR-INDUCED INVASION	Dysregulation of pleiotropic growth factors, receptors and their downstream signaling pathway components represent a central protumorigenic principle in human hepatocarcinogenesis. Especially the Insulin-like Growth Factor/IGF1 receptor (IGF/IGF-1R), Hepatocyte Growth Factor (HGF/MET), Wingless (Wnt/beta-catenin/FZD), Transforming Growth Factor alpha/Epidermal Growth Factor receptor (TGF alpha/EGFR) and Transforming Growth Factor beta (TGF beta/T beta R) pathways contribute to proliferation, antiapoptosis and invasive behavior of tumor cells. This review focuses on the relevant alterations in these pathways identified in human human hepatocellular carcinomas (HCCs). Resultant functional effects are modulated by multiple cross-talks between the different signaling pathways and additional tumor-relevant factors, such as cyclooxygenase-2 and p53. Several specific strategies are currently under development such as receptor kinase inhibitors, neutralizing antibodies and antagonistic proteins, which may improve the systemic treatment of human HCCs.	Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Schirmacher, P (corresponding author), Heidelberg Univ, Inst Pathol, Neuenheimer Feld 220-221, D-69120 Heidelberg, Germany.	peter.schirmacher@med.uni-heidelberg.de		Breuhahn, Kai/0000-0002-2462-1229				Abiru S, 2002, HEPATOLOGY, V35, P1117, DOI 10.1053/jhep.2002.32676; Abou-Shady M, 1999, AM J SURG, V177, P209, DOI 10.1016/S0002-9610(99)00012-4; Adachi Y, 2002, GASTROENTEROLOGY, V123, P1191, DOI 10.1053/gast.2002.36023; Aihara T, 1996, GASTROENTEROLOGY, V111, P455, DOI 10.1053/gast.1996.v111.pm8690212; Araki Y, 2003, CANCER RES, V63, P728; Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Arteaga CL, 2001, J CLIN ONCOL, V19, p32S; Bae SH, 2001, CLIN CANCER RES, V7, P1410; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; BASELGA J, 2000, DRUGS S1, V60, P1; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Behrens J, 2004, INT J DEV BIOL, V48, P477, DOI 10.1387/ijdb.041815jb; Berthou S, 2004, ONCOGENE, V23, P5387, DOI 10.1038/sj.onc.1207691; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Blum G, 2003, J BIOL CHEM, V278, P40442, DOI 10.1074/jbc.M305490200; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Bohula EA, 2003, J BIOL CHEM, V278, P15991, DOI 10.1074/jbc.M300714200; Boissan M, 2005, AM J PATHOL, V167, P869, DOI 10.1016/S0002-9440(10)62058-5; BOIX L, 1994, HEPATOLOGY, V19, P88, DOI 10.1016/0270-9139(94)90057-4; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Borowiak M, 2004, P NATL ACAD SCI USA, V101, P10608, DOI 10.1073/pnas.0403412101; Braulke T, 1999, HORM METAB RES, V31, P242, DOI 10.1055/s-2007-978725; Breuhahn K, 2004, CANCER RES, V64, P6058, DOI 10.1158/0008-5472.CAN-04-0292; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Byfield SD, 2004, MOL PHARMACOL, V65, P744, DOI 10.1124/mol.65.3.744; Byrd JC, 1999, J BIOL CHEM, V274, P24408, DOI 10.1074/jbc.274.34.24408; Cagatay T, 2002, ONCOGENE, V21, P7971, DOI 10.1038/sj.onc.1205919; CARIANI E, 1988, CANCER RES, V48, P6844; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen Bi-hua, 2003, Zhonghua Gan Zang Bing Za Zhi, V11, P487; CHEN JH, 2005, IN PRESS CANC LETT; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Cheng PL, 2004, ONCOGENE, V23, P7821, DOI 10.1038/sj.onc.1208066; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Christensen JG, 2003, CANCER RES, V63, P7345; CHUANG LY, 1991, HEPATOLOGY, V13, P1112, DOI 10.1016/0270-9139(91)92481-M; Civenni G, 2003, EMBO REP, V4, P166, DOI 10.1038/sj.embor.embor735; Cohen BD, 2005, CLIN CANCER RES, V11, P2063, DOI 10.1158/1078-0432.CCR-04-1070; Cui J, 2003, J GASTROEN HEPATOL, V18, P280, DOI 10.1046/j.1440-1746.2003.02973.x; Daveau M, 2003, MOL CARCINOGEN, V36, P130, DOI 10.1002/mc.10103; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; De Petro G, 1998, CANCER RES, V58, P2234; DErrico A, 1996, HEPATOLOGY, V24, P60, DOI 10.1002/hep.510240112; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; DESOUZA AT, 1995, ONCOGENE, V10, P1725; Devereux TR, 2001, MOL CARCINOGEN, V31, P68, DOI 10.1002/mc.1041; Devi GR, 1999, CANCER RES, V59, P4314; Di Popolo A, 2000, ONCOGENE, V19, P5517, DOI 10.1038/sj.onc.1203952; Efimova EA, 2004, EUR SURG RES, V36, P300, DOI 10.1159/000079915; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Enomoto A, 2001, J PATHOL, V195, P349; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; Fan G, 2004, APOPTOSIS, V9, P211, DOI 10.1023/B:APPT.0000018803.11260.02; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Ficari F, 2000, BRIT J CANCER, V82, P348, DOI 10.1054/bjoc.1999.0925; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; Foulstone E, 2005, J PATHOL, V205, P145, DOI 10.1002/path.1712; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Fujito T, 2004, HEPATO-GASTROENTEROL, V51, P921; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; Giannelli G, 2005, GASTROENTEROLOGY, V129, P1375, DOI 10.1053/j.gastro.2005.09.055; Girnita A, 2004, CANCER RES, V64, P236, DOI 10.1158/0008-5472.CAN-03-2522; Gong YW, 2000, MOL CELL BIOCHEM, V207, P101, DOI 10.1023/A:1007010818094; Gotzmann J, 2002, J CELL SCI, V115, P1189; Goya M, 2004, CANCER RES, V64, P6252, DOI 10.1158/0008-5472.CAN-04-0919; Grasl-Kraupp B, 2002, HEPATOLOGY, V35, P1372, DOI 10.1053/jhep.2002.33203; Gray SG, 2000, INT J MOL MED, V5, P33; GRONBORG M, 1993, J BIOL CHEM, V268, P23435; Guirouilh J, 2000, INT J ONCOL, V17, P777; Guirouilh J, 2001, J HEPATOL, V34, P78, DOI 10.1016/S0168-8278(00)00014-3; Guo L, 2003, J AM SOC MASS SPECTR, V14, P1022, DOI 10.1016/S1044-0305(03)00206-X; Hailey J, 2002, MOL CANCER THER, V1, P1349; Halder SK, 2005, NEOPLASIA, V7, P509, DOI 10.1593/neo.04640; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; Harris TM, 1998, ONCOGENE, V16, P203, DOI 10.1038/sj.onc.1201519; Hayashi T, 2004, CLIN CANCER RES, V10, P7540, DOI 10.1158/1078-0432.CCR-04-0632; Heideman DAM, 2005, CANCER GENE THER, V12, P954, DOI 10.1038/sj.cgt.7700856; Hisaka T, 1999, INT J ONCOL, V14, P453; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Hopfner M, 2004, J HEPATOL, V41, P1008, DOI 10.1016/j.jhep.2004.08.024; Hov H, 2004, CLIN CANCER RES, V10, P6686, DOI 10.1158/1078-0432.CCR-04-0874; HSIA CC, 1992, CANCER, V70, P1049, DOI 10.1002/1097-0142(19920901)70:5&lt;1049::AID-CNCR2820700507&gt;3.0.CO;2-C; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Hsu C, 2002, CANCER, V94, P415, DOI 10.1002/cncr.10180; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang SS, 2005, J CELL BIOCHEM, V96, P447, DOI 10.1002/jcb.20558; Huether A, 2005, BIOCHEM PHARMACOL, V70, P1568, DOI 10.1016/j.bcp.2005.09.007; Huether A, 2005, J HEPATOL, V43, P661, DOI 10.1016/j.jhep.2005.02.040; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; Idobe Y, 2003, HEPATO-GASTROENTEROL, V50, P54; Inagawa S, 2002, CLIN CANCER RES, V8, P450; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; INUI Y, 1994, GASTROENTEROLOGY, V107, P1799, DOI 10.1016/0016-5085(94)90823-0; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; Ito Y, 2001, BRIT J CANCER, V84, P1377, DOI 10.1054/bjoc.2000.1580; Ito Y, 2001, ONCOL REP, V8, P903; JACOBS S, 1986, ENDOCRINOLOGY, V118, P223, DOI 10.1210/endo-118-1-223; Jiang Y, 2001, BIOCHEM BIOPH RES CO, V286, P1123, DOI 10.1006/bbrc.2001.5521; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; JOHNSON M, 1993, HEPATOLOGY, V17, P1052, DOI 10.1002/hep.1840170618; Johnson M, 1995, BIOCHEM MOL BIOL INT, V36, P465; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Joo M, 2003, J KOREAN MED SCI, V18, P211, DOI 10.3346/jkms.2003.18.2.211; Kang-Park S, 2001, BIOCHEM BIOPH RES CO, V283, P303, DOI 10.1006/bbrc.2001.4767; KATO H, 1993, J BIOL CHEM, V268, P2655; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kern MA, 2004, CARCINOGENESIS, V25, P1193, DOI 10.1093/carcin/bgh110; Kern MA, 2002, HEPATOLOGY, V36, P885, DOI 10.1053/jhep.2002.36125; Kikuchi A, 2003, CANCER SCI, V94, P225, DOI 10.1111/j.1349-7006.2003.tb01424.x; Kim Hyung Gun, 2000, Korean Journal of Internal Medicine, V15, P165; Kim JH, 2002, MOL CELL BIOCHEM, V231, P155, DOI 10.1023/A:1014477218369; Kim SO, 1996, CANCER RES, V56, P3831; Kira S, 1997, LIVER, V17, P177; Kiss A, 1997, CLIN CANCER RES, V3, P1059; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; LafargeFrayssinet C, 1997, CANCER GENE THER, V4, P276; Lee John T, 2003, Curr Opin Investig Drugs, V4, P757; Lee S, 2001, VIROLOGY, V283, P167, DOI 10.1006/viro.2001.0892; Lee YI, 2003, MOL CELL ENDOCRINOL, V203, P51, DOI 10.1016/S0303-7207(03)00117-5; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Li XR, 1997, CANCER RES, V57, P2048; Lipinski KS, 2004, MOL THER, V10, P150, DOI 10.1016/j.ymthe.2004.03.021; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; Longerich T, 2004, VIRCHOWS ARCH, V445, P589, DOI 10.1007/s00428-004-1118-x; Lund P, 2004, CANCER LETT, V206, P85, DOI 10.1016/j.canlet.2003.10.018; Martin DC, 1999, J CELL BIOL, V146, P881, DOI 10.1083/jcb.146.4.881; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuo K, 2003, GENE CHROMOSOME CANC, V36, P283, DOI 10.1002/gcc.10170; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 1998, EMBO J, V17, P2736, DOI 10.1093/emboj/17.10.2736; McCawley LJ, 1998, J CELL PHYSIOL, V176, P255, DOI 10.1002/(SICI)1097-4652(199808)176:2<255::AID-JCP4>3.0.CO;2-N; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; Mendel DB, 2000, ANTI-CANCER DRUG DES, V15, P29; Menu E, 2006, BLOOD, V107, P655, DOI 10.1182/blood-2005-01-0293; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Mikami I, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-53; Min Y, 2005, GUT, V54, P591, DOI 10.1136/gut.2004.048926; Min YF, 2003, CANCER RES, V63, P6432; Mitsiades CS, 2004, CANCER CELL, V5, P221, DOI 10.1016/S1535-6108(04)00050-9; Miyamoto S, 2005, CLIN CANCER RES, V11, P3494, DOI 10.1158/1078-0432.CCR-04-1701; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Miyoshi Y, 1998, CANCER RES, V58, P2524; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Moinzadeh P, 2005, BRIT J CANCER, V92, P935, DOI 10.1038/sj.bjc.6602448; Monvoisin A, 1999, J HEPATOL, V30, P511, DOI 10.1016/S0168-8278(99)80113-5; Monvoisin A, 2002, INT J CANCER, V97, P157, DOI 10.1002/ijc.1595; Murphy LJ, 1998, J MOL ENDOCRINOL, V21, P97, DOI 10.1677/jme.0.0210097; Musch A, 2005, DIGESTION, V71, P78, DOI 10.1159/000084523; Musgrove EA, 2004, BREAST CANCER RES, V6, P65, DOI 10.1186/bcr737; Nagata K, 2001, BIOCHEM BIOPH RES CO, V289, P205, DOI 10.1006/bbrc.2001.5916; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; NAKOPOULOU L, 1994, HISTOL HISTOPATHOL, V9, P677; Nardone G, 1996, HEPATOLOGY, V23, P1304, DOI 10.1053/jhep.1996.v23.pm0008675143; Nath N, 2003, P NATL ACAD SCI USA, V100, P12584, DOI 10.1073/pnas.2134840100; Neaud V, 1997, HEPATOLOGY, V26, P1458, DOI 10.1002/hep.510260612; Ng IO, 1998, J GASTROEN HEPATOL, V13, P152, DOI 10.1111/j.1440-1746.1998.tb00630.x; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; Noguchi O, 1996, J HEPATOL, V24, P286, DOI 10.1016/S0168-8278(96)80006-7; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; Okano JI, 1999, LIVER, V19, P151, DOI 10.1111/j.1478-3231.1999.tb00025.x; Okumoto K, 2004, LIVER INT, V24, P21, DOI 10.1111/j.1478-3231.2004.00882.x; Ozaki I, 2003, HEPATOL RES, V27, P288, DOI 10.1016/S1386-6346(03)00268-7; Pang R, 2004, ONCOGENE, V23, P4182, DOI 10.1038/sj.onc.1207493; PARK BC, 1995, J HEPATOL, V22, P286, DOI 10.1016/0168-8278(95)80281-9; Park WS, 1999, CANCER RES, V59, P307; Park YN, 2004, HEPATO-GASTROENTEROL, V51, P396; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Pautsch A, 2001, STRUCTURE, V9, P955, DOI 10.1016/S0969-2126(01)00655-4; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Philip PA, 2005, J CLIN ONCOL, V23, P6657, DOI 10.1200/JCO.2005.14.696; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Prange W, 2001, ONCOL REP, V8, P727; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 2001, CLIN CANCER RES, V7, P2134; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; RESNICOFF M, 1994, CANCER RES, V54, P2218; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Sachdev D, 2003, CANCER RES, V63, P627; Sachs M, 2000, J CELL BIOL, V150, P1375, DOI 10.1083/jcb.150.6.1375; Saeki A, 2000, CANCER, V88, P1025, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1025::AID-CNCR11>3.0.CO;2-U; Sakai K, 2003, ENDOCRINOLOGY, V144, P2388, DOI 10.1210/en.2002-221133; SATO C, 1995, J INVEST DERMATOL, V104, P958, DOI 10.1111/1523-1747.ep12606221; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schausberger E, 2004, BRIT J CANCER, V91, P1955, DOI 10.1038/sj.bjc.6602191; SCHIRMACHER P, 1991, AM J PATHOL, V139, P231; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; Schirmacher P, 1996, J HEPATOL, V24, P547, DOI 10.1016/S0168-8278(96)80139-5; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Scotlandi K, 1998, CANCER RES, V58, P4127; Sedlaczek N, 2003, BRIT J CANCER, V88, P733, DOI 10.1038/sj.bjc.6600777; SELDEN C, 1994, J HEPATOL, V21, P227, DOI 10.1016/S0168-8278(05)80400-3; Seol DW, 2000, ONCOGENE, V19, P1132, DOI 10.1038/sj.onc.1203404; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Shibata T, 2003, HEPATOLOGY, V38, P178, DOI 10.1053/jhep.2003.50270; Shiota G, 1999, HEPATO-GASTROENTEROL, V46, P407; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Sohda T, 1996, LAB INVEST, V75, P307; Song BC, 2002, CANCER-AM CANCER SOC, V94, P175, DOI 10.1002/cncr.10170; Spicer J, 2004, CURR OPIN MOL THER, V6, P337; Stuart KA, 2000, INT J EXP PATHOL, V81, P17, DOI 10.1046/j.1365-2613.2000.00138.x; Su H Y, 1999, Dermatol Online J, V5, P1; SUE SR, 1995, ANN SURG, V222, P171, DOI 10.1097/00000658-199508000-00009; Sugiura R, 2003, NATURE, V424, P961, DOI 10.1038/nature01907; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; Suzuki A, 2000, HEPATOLOGY, V32, P796, DOI 10.1053/jhep.2000.17738; SUZUKI K, 1994, HEPATOLOGY, V20, P1231; Sweeney C, 2004, BRIT J CANCER, V90, P289, DOI 10.1038/sj.bjc.6601500; TABOR E, 1992, J MED VIROL, V37, P271, DOI 10.1002/jmv.1890370406; Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013; Tanaka S, 1996, DIGEST DIS SCI, V41, P208, DOI 10.1007/BF02208606; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Tavian D, 2000, INT J CANCER, V87, P644, DOI 10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.3.CO;2-N; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsai JF, 1997, MEDICINE, V76, P213, DOI 10.1097/00005792-199705000-00007; Ueki T, 1997, HEPATOLOGY, V25, P619, DOI 10.1002/hep.510250321; Ueno Y, 2005, BRIT J CANCER, V92, P1690, DOI 10.1038/sj.bjc.6602548; Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008-5472.CAN-04-1013; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Vasilcanu D, 2004, ONCOGENE, V23, P7854, DOI 10.1038/sj.onc.1208065; Vejchapipat P, 2004, J GASTROENTEROL, V39, P1182, DOI 10.1007/s00535-004-1469-8; Vernucci M, 2000, ONCOGENE, V19, P6376, DOI 10.1038/sj.onc.1204024; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; Wada I, 1999, HEPATOLOGY, V29, P1718, DOI 10.1002/hep.510290635; Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023; Wang SY, 2004, J HEPATOL, V41, P267, DOI 10.1016/j.jhep.2004.04.013; Wang XY, 2003, MOL CANCER THER, V2, P1085; Warshamana-Greene GS, 2005, CLIN CANCER RES, V11, P1563, DOI 10.1158/1078-0432.CCR-04-1544; Warshamana-Greene GS, 2004, MOL CANCER THER, V3, P527; Weihrauch M, 2001, INT ARCH OCC ENV HEA, V74, P405, DOI 10.1007/s004200100244; Weihrauch M, 2001, BRIT J CANCER, V84, P982, DOI 10.1054/bjoc.2000.1675; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wu T, 2006, CANCER TREAT REV, V32, P28, DOI 10.1016/j.ctrv.2005.10.004; Xian ZH, 2005, J CLIN PATHOL, V58, P500, DOI 10.1136/jcp.2004.023556; Xu Z, 2003, CELL RES, V13, P343, DOI 10.1038/sj.cr.7290179; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yamagamim H, 2002, CANCER, V95, P824, DOI 10.1002/cncr.10732; Yau TO, 2005, ONCOGENE, V24, P1607, DOI 10.1038/sj.onc.1208340; YEH YC, 1987, CANCER RES, V47, P896; Yuen MF, 2002, SCAND J GASTROENTERO, V37, P233, DOI 10.1080/003655202753416939; Zhang J, 2004, WORLD J GASTROENTERO, V10, P830; Zhang LJ, 1996, CANCER RES, V56, P1367; Zhang T, 2003, BIOCHEM J, V376, P457, DOI 10.1042/BJ20030668; Zhao M, 1998, HISTOL HISTOPATHOL, V13, P657, DOI 10.14670/HH-13.657; Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304-3835(03)00013-2; Zi XL, 2000, CANCER RES, V60, P5617	274	321	339	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3787	3800		10.1038/sj.onc.1209556	http://dx.doi.org/10.1038/sj.onc.1209556			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799620				2022-12-28	WOS:000238559600006
J	Cavarretta, IT; Neuwirt, H; Untergasser, G; Moser, PL; Zaki, MH; Steiner, H; Rumpold, H; Fuchs, D; Hobisch, A; Nemeth, JA; Culig, Z				Cavarretta, I. T.; Neuwirt, H.; Untergasser, G.; Moser, P. L.; Zaki, M. H.; Steiner, H.; Rumpold, H.; Fuchs, D.; Hobisch, A.; Nemeth, J. A.; Culig, Z.			The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1	ONCOGENE			English	Article						interleukin-6; anti-interleukin-6 antibody; Mc1-1; ERK1/2 mitogen-activated protein kinase; apoptosis; prostate cancer	ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; ACTIVATED PROTEIN-KINASE; HUMAN MYELOMA CELLS; ANDROGEN RECEPTOR EXPRESSION; SIGNAL-REGULATED KINASE; MULTIPLE-MYELOMA; GROWTH-FACTOR; IN-VIVO; IMMUNOHISTOCHEMICAL ANALYSIS; INTERLEUKIN-6 RECEPTOR	Levels of the proinflammatory cytokine interleukin-6 (IL-6) are increased in therapy-resistant prostate cancer. IL-6 has been considered a positive growth factor in late-stage prostate cancer cells and a potential target for therapeutic interference. Effects of inhibition of IL-6 on cell survival were studied in LNCaP-IL6+ cells, a model system for advanced prostate cancer, which produce IL-6. We show that the autocrine IL-6 loop is responsible for resistance to apoptosis and increased cellular levels of myeloid cell leukemia-1 (Mcl-1) protein, an antiapoptotic member of the Bcl-2 family. Treatment of cells with a chimeric anti-IL-6 antibody (CNTO 328) led to the induction of apoptosis and downregulation of Mcl-1 protein levels. Specific knockdown of Mcl-1 gene expression by small interfering RNA also yielded an increase in apoptosis of LNCaP-IL-6+ cells. Vice versa, inactivation of IL-6 autocrine loop had no influence on apoptosis levels in the absence of Mcl-1, thus suggesting this molecule as a mediator of the survival action of IL-6. Mcl-1 protein regulation by the endogenous cytokine directly involved the extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase pathway. Our data support the concept of anti-IL-6 targeted therapy in therapy-resistant prostate cancer.	Innsbruck Med Univ, Dept Urol, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Med, Div Hematol & Oncol, A-6020 Innsbruck, Austria; Innsbruck Med Univ, Dept Pathol, A-6020 Innsbruck, Austria; Centocor Inc, R&D, Malvern, PA 19355 USA; Innsbruck Med Univ, Bioctr, Dept Biol Chem, A-6020 Innsbruck, Austria; Gen Hosp Feldkirch, Dept Urol, Feldkirch, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Medical University of Innsbruck	Culig, Z (corresponding author), Innsbruck Med Univ, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria.	zoran.culig@uibk.ac.at	Cavarretta, Ilaria/AAN-4111-2020; Fuchs, Dietmar/AAL-8011-2021; Neuwirt, Hannes/AAF-1090-2019	Fuchs, Dietmar/0000-0003-1627-9563; Neuwirt, Hannes/0000-0003-1064-0098; Cavarretta, Ilaria/0000-0002-3531-2931				Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; BORSELLINO N, 1995, CANCER RES, V55, P4633; Borsellino N, 1999, CANCER, V85, P134, DOI 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chung DDL, 2003, MAT SCI ENG R, V42, P1, DOI 10.1016/S0927-796X(03)00037-8; Chung TDK, 1999, PROSTATE, V38, P199; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Debes JD, 2005, CANCER RES, V65, P5965, DOI 10.1158/0008-5472.CAN-04-2837; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Derouet M, 2004, J BIOL CHEM, V279, P26915, DOI 10.1074/jbc.M313875200; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Gioeli D, 1999, CANCER RES, V59, P279; Giri D, 2001, AM J PATHOL, V159, P2159, DOI 10.1016/S0002-9440(10)63067-2; GONG YW, 1995, ENDOCRINOLOGY, V136, P2172, DOI 10.1210/en.136.5.2172; Hajnoczky G, 2003, BIOCHEM BIOPH RES CO, V304, P445, DOI 10.1016/S0006-291X(03)00616-8; Hideshima T, 2005, BEST PRACT RES CL HA, V18, P509, DOI 10.1016/j.beha.2005.01.003; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 2001, CLIN CANCER RES, V7, P2941; Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kawada M, 2006, CANCER LETT, V242, P46, DOI 10.1016/j.canlet.2005.10.040; Keller ET, 1996, FRONT BIOSCI, V1, P340, DOI DOI 10.2741/A136; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Krajewska M, 1996, AM J PATHOL, V148, P1567; KRAJEWSKI S, 1995, AM J PATHOL, V146, P1309; Kramer G, 2004, CANCER RES, V64, P1751, DOI 10.1158/0008-5472.CAN-03-2455; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Lee SO, 2004, PROSTATE, V60, P178, DOI 10.1002/pros.20045; Li Jie, 2005, Curr Opin Investig Drugs, V6, P639; Lin DL, 2001, CLIN CANCER RES, V7, P1773; LOTEM J, 1992, BLOOD, V80, P1750; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; MARTIKAINEN P, 1990, PROSTATE, V17, P175, DOI 10.1002/pros.2990170302; Nakashima J, 2000, CLIN CANCER RES, V6, P2702; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Okamoto M, 1997, CANCER RES, V57, P141; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pu YS, 2004, PROSTATE, V60, P120, DOI 10.1002/pros.20057; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Royuela M, 2001, EUR CYTOKINE NETW, V12, P654; Royuela M, 2002, HUM PATHOL, V33, P299, DOI 10.1053/hupa.2002.32227; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Selzer E, 2002, MOL MED, V8, P877, DOI 10.1007/BF03402094; Shimada K, 2002, MOL CARCINOGEN, V35, P127, DOI 10.1002/mc.10084; SIEGALL CB, 1990, CANCER RES, V50, P7786; SIEGSMUND MJ, 1994, J UROLOGY, V151, P1396, DOI 10.1016/S0022-5347(17)35267-9; Smith PC, 2001, PROSTATE, V48, P47; Smith PC, 2001, CYTOKINE GROWTH F R, V12, P33, DOI 10.1016/S1359-6101(00)00021-6; Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297; Steiner H, 2004, EUR J CANCER, V40, P1066, DOI 10.1016/j.ejca.2003.11.033; Steiner H, 2003, AM J PATHOL, V162, P655, DOI 10.1016/S0002-9440(10)63859-X; STEINER H, 2006, IN PRESS CNTO, V328; Trikha M, 2003, CLIN CANCER RES, V9, P4653; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Wallner L, 2006, CANCER RES, V66, P3087, DOI 10.1158/0008-5472.CAN-05-3447; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zelivianski S, 2003, INT J CANCER, V107, P478, DOI 10.1002/ijc.11413; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	68	92	96	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2822	2832		10.1038/sj.onc.1210097	http://dx.doi.org/10.1038/sj.onc.1210097			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072336				2022-12-28	WOS:000246210800002
J	Urbanska, K; Trojanek, J; Del Valle, L; Eldeen, MB; Hofmann, F; Garcia-Echeverria, C; Khalili, K; Reiss, K				Urbanska, K.; Trojanek, J.; Del Valle, L.; Eldeen, M. B.; Hofmann, F.; Garcia-Echeverria, C.; Khalili, K.; Reiss, K.			Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3 beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines	ONCOGENE			English	Article						IGF-I receptor; NVP-AEW541; GSK3 beta; medulloblastoma; anchorage-independence	GLYCOGEN-SYNTHASE KINASE-3-BETA; INTEGRIN-LINKED KINASE; VIRUS T-ANTIGEN; TUMOR-GROWTH; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; CARCINOMA CELLS; SONIC HEDGEHOG; INSULIN; LOCALIZATION	We have previously reported that insulin-like growth factor-I (IGF-I) supports growth and survival of mouse and human medulloblastoma cell lines, and that IGF-I receptor (IGF-IR) is constitutively phosphorylated in human medulloblastoma clinical samples. Here, we demonstrate that a specific inhibitor of insulin-like growth factor-I receptor (IGF-IR), NVP-AEW541, attenuated growth and survival of mouse (BsB8) and human (D384, Daoy) medulloblastoma cell lines. Cell cycle analysis demonstrated that G1 arrest and apoptosis contributed to the action of NVP-AEW54. Interestingly, very aggressive BsB8 cells, which derive from cerebellar tumors of transgenic mice expressing viral oncoprotein (large T-antigen from human polyomavirus JC) became much more sensitive to NVP-AEW541 when exposed to anchorage-independent culture conditions. This high sensitivity to NVP-AEW54 in suspension was accompanied by the loss of GSK-3 beta constitutive phosphorylation and was independent from T-antigen-mediated cellular events (Supplementary Materials). BsB8 cells were partially rescued from NVP-AEW541 by GSK3 beta inhibitor, lithium chloride and were sensitized by GSK3b activator, sodium nitroprusside (SNP). Importantly, human medulloblastoma cells, D384, which demonstrated partial resistance to NVP-AEW541 in suspension cultures, become much more sensitive following SNP-mediated GSK3 beta dephosphorylation (activation). Our results indicate that hypersensitivity of medulloblastoma cells in anchorage-independence is linked to GSK-3 beta activity and suggest that pharmacological intervention against IGF-IR with simultaneous activation of GSK3 beta could be highly effective against medulloblastomas, which have intrinsic ability of disseminating the CNS via cerebrospinal fluid.	Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; Jagiellonian Univ, Dept Cell Biol, Fac Biotechnol, Krakow, Poland; Novartis Pharma AG, Novartis Inst Biomed Res, Basel, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jagiellonian University; Novartis	Reiss, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206; Trojanek, Joanna/0000-0002-3200-735X	NCI NIH HHS [R01CA095518-01] Funding Source: Medline; NINDS NIH HHS [P01 NS36466-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews DW, 2001, J CLIN ONCOL, V19, P2189, DOI 10.1200/JCO.2001.19.8.2189; Araki K, 2006, INT J CANCER, V118, P2602, DOI 10.1002/ijc.21653; Arevalo JC, 2005, CURR OPIN CELL BIOL, V17, P112, DOI 10.1016/j.ceb.2005.01.004; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Beurel E, 2004, EXP CELL RES, V300, P354, DOI 10.1016/j.yexcr.2004.08.001; Blackburn RV, 1998, CANCER, V82, P1137, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1137::AID-CNCR19>3.0.CO;2-7; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Cheng ZJ, 2005, J HYPERTENS, V23, P1757, DOI 10.1097/01.hjh.0000179765.48324.b4; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GLICK RP, 1993, ANN NY ACAD SCI, V692, P223; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Kurihara M, 1989, No To Shinkei, V41, P719; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; Liao HT, 2005, OLIGONUCLEOTIDES, V15, P196, DOI 10.1089/oli.2005.15.196; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Patti R, 2000, INT J ONCOL, V16, P577; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; SELL C, 1995, CANCER RES, V55, P303; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wang JY, 2004, J EXP CLIN CANC RES, V23, P373; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Zhang YH, 2005, FEBS LETT, V579, P6230, DOI 10.1016/j.febslet.2005.09.095	57	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2308	2317		10.1038/sj.onc.1210018	http://dx.doi.org/10.1038/sj.onc.1210018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016438				2022-12-28	WOS:000245466000007
J	Deshpande, AM; Akunowicz, JD; Reveles, XT; Patel, BB; Saria, EA; Gorlick, RG; Naylor, SL; Leach, RJ; Hansen, MF				Deshpande, A. M.; Akunowicz, J. D.; Reveles, X. T.; Patel, B. B.; Saria, E. A.; Gorlick, R. G.; Naylor, S. L.; Leach, R. J.; Hansen, M. F.			PHC3, a component of the hPRC-H complex, associates with E2F6 during G(0) and is lost in osteosarcoma tumors	ONCOGENE			English	Article						tumor suppressor gene; osteosarcoma; polycomb gene; polyhomeotic-like; cell cycle regulation	POLYCOMB-GROUP PROTEINS; DROSOPHILA-MELANOGASTER; GENES; CHROMATIN; IDENTIFICATION; REPRESSION; HOMOLOGS; BMI1; EED; CONSTITUENTS	Polyhomeotic-like 3 (PHC3) is a ubiquitously expressed member of the polycomb gene family and part of the human polycomb complex hPRC-H. We found that in normal cells PHC3 associated with both hPRC-H complex components and with the transcription factor E2F6. In differentiating and confluent cells, PHC3 and E2F6 showed nuclear colocalization in a punctate pattern that resembled the binding of polycomb bodies to heterochromatin. This punctate pattern was not seen in proliferating cells suggesting that PHC3 may be part of an E2F6-polycomb complex that has been shown to occupy and silence target promoters in G(0). Previous loss of heterozygosity (LoH) analyses had shown that the region containing PHC3 underwent frequent LoH in primary human osteosarcoma tumors. When we examined normal bone and human osteosarcoma tumors, we found loss of PHC3 expression in 36 of 56 osteosarcoma tumors. Sequence analysis revealed that PHC3 was mutated in nine of 15 primary osteosarcoma tumors. These findings suggest that loss of PHC3 may favor tumorigenesis by potentially disrupting the ability of cells to remain in G(0).	Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA	University of Connecticut; University of Texas System; University of Texas Health San Antonio; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore	Hansen, MF (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	mhansen@nso2.uchc.edu		GORLICK, RICHARD/0000-0001-8995-2929; Leach, Robin/0000-0002-3201-5579	NCI NIH HHS [R01 CA074802-03, CA074802, R01 CA074802-04] Funding Source: Medline; NIAMS NIH HHS [R01 AR049940-03, R01 AR049940-05, R01 AR049940-04, R01 AR049940-01A1, R01 AR049940, R01 AR049940-02, AR049940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ali JY, 2004, MOL CELL BIOL, V24, P7737, DOI 10.1128/MCB.24.17.7737-7747.2004; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEATRICK J, 1991, GENE, V105, P185, DOI 10.1016/0378-1119(91)90150-A; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Harlow E., 1988, ANTIBODIES LAB MANUA; Isono K, 2005, MOL CELL BIOL, V25, P6694, DOI 10.1128/MCB.25.15.6694-6706.2005; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; King IFG, 2002, MOL CELL BIOL, V22, P7919, DOI 10.1128/MCB.22.22.7919-7928.2002; Kruzelock RP, 1997, CANCER RES, V57, P106; Lavigne M, 2004, MOL CELL, V13, P415, DOI 10.1016/S1097-2765(04)00006-1; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasini D, 2004, CELL CYCLE, V3, P396; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Raaphorst FM, 2005, HUM MOL GENET, V14, pR93, DOI 10.1093/hmg/ddi111; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tonkin E, 2002, HUM GENET, V111, P435, DOI 10.1007/s00439-002-0814-3; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005	38	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1714	1722		10.1038/sj.onc.1209988	http://dx.doi.org/10.1038/sj.onc.1209988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001316	Green Accepted			2022-12-28	WOS:000244955600005
J	Pochampalli, MR; el Bejjani, RM; Schroeder, JA				Pochampalli, M. R.; el Bejjani, R. M.; Schroeder, J. A.			MUC1 is a novel regulator of erbB1 receptor trafficking	ONCOGENE			English	Article						erbB1; MUC1; phosphorylation; ubiquitination; breast cancer	GROWTH-FACTOR RECEPTOR; EGF RECEPTOR; C-SRC; TYROSINE KINASES; MAMMARY-GLAND; CANCER; CELLS; OVEREXPRESSION; SUPPRESSION; C-CBL/SLI-1	ErbB receptors are key regulators of cell survival and growth in normal and transformed tissues. The oncogenic glycoprotein MUC1 is a binding partner and substrate for erbB1 and MUC1 expression can potentiate erbB-dependent signal transduction. After receptor activation, erbB1 is typically downregulated via an endocytic pathway that results in receptor degradation or recycling. We report here that MUC1 expression inhibits the degradation of ligand-activated erbB1. Through the use of both RNAi-mediated knock down and overexpression constructs of MUC1, we show that MUC1 expression inhibits erbB1 degradation after ligand treatment in breast epithelial cells. This MUC1-mediated protection against erbB1 degradation can increase total cellular pools of erbB1 over time. Biotinylation of surface proteins demonstrates that cell-surface associated erbB1 receptor is protected by MUC1 against ligand-induced degradation, although this is accompanied by an increase in erbB1 internalization. The MUC1-mediated protection against degradation occurs with a decrease in EGF-stimulated ubiquitination of erbB1, and an increase in erbB1 recycling. These data indicate that MUC1 expression is a potent regulator of erbB1 receptor stability upon activation and may promote transformation through the inhibition of erbB1 degradation.	Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA; Univ Arizona, Bio5 Inst, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona; University of Arizona	Schroeder, JA (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA.	jschroeder@azcc.arizona.edu		El Bejjani, Rachid/0000-0003-2328-0773; schroeder, joyce/0000-0003-1277-5172	NATIONAL CANCER INSTITUTE [R01CA102113] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA102113-02, R01 CA102113] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Bivona TG, 2003, CURR OPIN CELL BIOL, V15, P136, DOI 10.1016/S0955-0674(03)00016-4; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811; Haj FG, 2002, SCIENCE, V295, P1708, DOI 10.1126/science.1067566; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; HILKENS J, 1995, CANCER LETT, V90, P27, DOI 10.1016/0304-3835(94)03674-8; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Kowanetz K, 2004, MOL BIOL CELL, V15, P3155, DOI 10.1091/mbc.E03-09-0683; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419, DOI 10.1152/ajpcell.1998.275.6.C1419; LAN MS, 1990, J BIOL CHEM, V265, P15294; Lee FT, 2005, CLIN CANCER RES, V11, p7080S, DOI 10.1158/1078-0432.CCR-1004-0019; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li XJ, 2005, CANCER BIOL THER, V4, P968, DOI 10.4161/cbt.4.9.1913; Li YQ, 2003, ONCOGENE, V22, P6107, DOI 10.1038/sj.onc.1206732; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LITVINOV SV, 1993, J BIOL CHEM, V268, P21364; McDermott KM, 2001, INT J CANCER, V94, P783, DOI 10.1002/ijc.1554; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Reinheckel T, 2005, J CELL SCI, V118, P3387, DOI 10.1242/jcs.02469; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Schroeder JA, 2004, ONCOGENE, V23, P5739, DOI 10.1038/sj.onc.1207713; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Schroeder JA, 1997, J MAMMARY GLAND BIOL, V2, P119, DOI 10.1023/A:1026347629876; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yan Q, 2005, EXP CELL RES, V304, P265, DOI 10.1016/j.yexcr.2004.11.003; ZOTTER S, 1988, Cancer Reviews, V11-12, P55	37	86	90	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1693	1701		10.1038/sj.onc.1209976	http://dx.doi.org/10.1038/sj.onc.1209976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983337				2022-12-28	WOS:000244955600003
J	Ramjaun, AR; Tomlinson, S; Eddaoudi, A; Downward, J				Ramjaun, A. R.; Tomlinson, S.; Eddaoudi, A.; Downward, J.			Upregulation of two BH3-only proteins, Bmf and Bim, during TGF beta-induced apoptosis	ONCOGENE			English	Article						Smad4; TGF beta; apoptosis; p38; Bmf; Bim	GROWTH-FACTOR-BETA; SMAD-DEPENDENT EXPRESSION; CYTOCHROME-C RELEASE; FAO HEPATOMA-CELLS; FAMILY-MEMBER BIM; P38 MAP KINASE; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; (TGF-BETA)-INDUCED APOPTOSIS; CASPASE ACTIVATION	Transforming growth factor-beta (TGF beta)-activated signalling pathways can lead to apoptosis, growth arrest or promotion of malignant behaviour, dependent on cellular context. The molecular mechanisms involved in TGF beta-induced apoptosis remain controversial; although changes in gene expression are thought to be pivotal to the process, several different candidate apoptotic initiators and mediators have been proposed. Smad4, a critical component of the TGF beta-induced transcriptional machinery, is shown here to be essential for induction of apoptosis. Gene expression analysis identified the proapoptotic Bcl-2 family members, Bmf and Bim, as induced by TGFb, dependent on both Smad4 and p38 function and the generation of reactive oxygen species. TGF beta-induced Bmf and Bim localize to cellular membranes implicated in apoptosis. Inhibition of the TGF beta-induced expression of both these proteins together provides significant protection of cells from apoptosis. The TGF beta-triggered cell death programme thus involves induction of multiple BH3-only proteins during the induction of apoptosis.	Canc Res UK, London Res Inst, Signal Transduct Lab, London WC2A 3PX, England; Canc Res UK, London Res Inst, Fluorescence Activated Cell Storing Labs, London WC2A 3PX, England	Cancer Research UK; Cancer Research UK	Downward, J (corresponding author), Canc Res UK, London Res Inst, Signal Transduct Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	downward@cancer.org.uk	Downward, Julian/A-3251-2012	Eddaoudi, Ayad/0000-0001-5272-6426; Downward, Julian/0000-0002-2331-4729				Arsura M, 1996, IMMUNITY, V5, P31, DOI 10.1016/S1074-7613(00)80307-6; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Conery AR, 2004, NAT CELL BIOL, V6, P366, DOI 10.1038/ncb1117; Coyle B, 2003, J BIOL CHEM, V278, P5920, DOI 10.1074/jbc.M211300200; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Edlund S, 2003, MOL BIOL CELL, V14, P529, DOI 10.1091/mbc.02-03-0037; Franz Wolfgang, 2000, PERSPEKTIVEN WIRTSCH, V1, P53, DOI DOI 10.1111/1468-2516.00005; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; Herrera B, 2001, HEPATOLOGY, V34, P548, DOI 10.1053/jhep.2001.27447; Hishikawa K, 1999, J BIOL CHEM, V274, P37461, DOI 10.1074/jbc.274.52.37461; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Jang CW, 2002, NAT CELL BIOL, V4, P51, DOI 10.1038/ncb731; Kanamaru C, 2002, HEPATOL RES, V23, P211, DOI 10.1016/S1386-6346(01)00175-9; Kang YB, 2003, MOL CELL, V11, P915, DOI 10.1016/S1097-2765(03)00109-6; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kim BC, 2002, MOL CELL BIOL, V22, P1369, DOI 10.1128/MCB.22.5.1369-1378.2002; Kim SG, 2004, MOL BIOL CELL, V15, P420, DOI 10.1091/mbc.E03-04-0201; Larisch S, 2000, NAT CELL BIOL, V2, P915, DOI 10.1038/35046566; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Liu JW, 2005, ONCOGENE, V24, P2020, DOI 10.1038/sj.onc.1208385; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nass SJ, 1996, BIOCHEM BIOPH RES CO, V227, P248, DOI 10.1006/bbrc.1996.1497; Ohgushi M, 2005, MOL CELL BIOL, V25, P10017, DOI 10.1128/MCB.25.22.10017-10028.2005; Park HJ, 2002, HEPATOLOGY, V35, P1360, DOI 10.1053/jhep.2002.33205; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; Schiffer M, 2004, J BIOL CHEM, V279, P37004, DOI 10.1074/jbc.M403534200; Schrantz N, 2001, MOL BIOL CELL, V12, P3139, DOI 10.1091/mbc.12.10.3139; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teramoto T, 1998, BIOCHEM BIOPH RES CO, V251, P56, DOI 10.1006/bbrc.1998.9411; Thannickal VJ, 1995, J BIOL CHEM, V270, P30334, DOI 10.1074/jbc.270.51.30334; Valderrama-Carvajal H, 2002, NAT CELL BIOL, V4, P963, DOI 10.1038/ncb885; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wildey GM, 2003, J BIOL CHEM, V278, P18069, DOI 10.1074/jbc.M211958200; Yang YC, 2003, P NATL ACAD SCI USA, V100, P10269, DOI 10.1073/pnas.1834070100; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366	47	101	108	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					970	981		10.1038/sj.onc.1209852	http://dx.doi.org/10.1038/sj.onc.1209852			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909112	Bronze			2022-12-28	WOS:000244245400003
J	Wuerzberger-Davis, SM; Nakamura, Y; Seufzer, BJ; Miyamoto, S				Wuerzberger-Davis, S. M.; Nakamura, Y.; Seufzer, B. J.; Miyamoto, S.			NF-kappa B activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage	ONCOGENE			English	Article						NEMO; SUMOylation; ATM; H2O2	DOUBLE-STRAND BREAKS; FIELD GEL-ELECTROPHORESIS; PROTEIN-TYROSINE KINASE; HAMSTER OVARY CELLS; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; TOPOISOMERASE-I; CLEAVABLE COMPLEXES; SIGNALING PATHWAY; GENOTOXIC STRESS	The inactive transcription factor NF-kappa B is localized in the cytoplasm and rapidly responds to a variety of extracellular factors and intracellular stress conditions to initiate multiple cellular responses. While the knowledge regarding NF-kappa B signaling pathways initiated by extracellular ligands is rapidly expanding, the mechanisms of activation by intracellular stress conditions are not well understood. We recently described a critical role for a small ubiquitin-like modifier (SUMO) modi. cation of NF-kappa B essential modulator (NEMO), the regulatory subunit of the I kappa B kinase, in response to certain genotoxic stress conditions. One important unanswered question is whether the role of this modi. cation is limited to the genotoxic agents or some other signaling pathways also employ SUMOylation of NEMO to regulate NF-kappa B activation. Here, we report that a variety of other stress conditions, including oxidative stress, ethanol exposure, heat shock and electric shock, also induce NEMO SUMOylation, thus demonstrating that DNA damage per se is not necessary for this NEMO modi. cation to occur. Moreover, combinations of certain SUMO stress and ATM (ataxia telangiectasia mutated) activation conditions lead to NF-kappa B activation without inducing DNA damage. Our study helps to conceptualize how individual or a combination of different stress conditions may funnel into this previously unappreciated signal transduction mechanism to regulate the activity of the ubiquitous NF-kappa B transcription factor.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Wisconsin, Canc Biol Program, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Miyamoto, S (corresponding author), Univ Wisconsin, Dept Pharmacol, 3795 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	smiyamot@wisc.edu			NCI NIH HHS [R01-CA77474, R01-CA81065] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081065, R01CA077474] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGER DD, 1991, RADIAT RES, V128, P150, DOI 10.2307/3578132; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banath JP, 2003, CANCER RES, V63, P4347; Barzilai A, 2002, DNA REPAIR, V1, P3, DOI 10.1016/S1568-7864(01)00007-6; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gloire G, 2006, ONCOGENE, V25, P5485, DOI 10.1038/sj.onc.1209542; Habraken Y, 2001, BIOCHEM PHARMACOL, V62, P603, DOI 10.1016/S0006-2952(01)00709-2; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hiraoka W, 1998, J CLIN INVEST, V102, P1961, DOI 10.1172/JCI3437; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; Kamata H, 2002, FEBS LETT, V519, P231, DOI 10.1016/S0014-5793(02)02712-6; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim SH, 2000, NUMER HEAT TR A-APPL, V38, P1, DOI 10.1080/10407780050134947; KINASHI Y, 1995, RADIAT RES, V141, P153, DOI 10.2307/3579042; Kretz-Remy C, 2001, J BIOL CHEM, V276, P43723, DOI 10.1074/jbc.M010821200; Kurepa J, 2003, J BIOL CHEM, V278, P6862, DOI 10.1074/jbc.M209694200; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; Lee SJ, 1998, ONCOGENE, V17, P1821, DOI 10.1038/sj.onc.1202088; Leight ER, 2001, MOL CELL BIOL, V21, P4149, DOI 10.1128/MCB.21.13.4149-4161.2001; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Michalke M, 2000, FEBS LETT, V465, P64, DOI 10.1016/S0014-5793(99)01719-6; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Connor S, 2004, MOL CELL BIOL, V24, P4895, DOI 10.1128/MCB.24.11.4895-4908.2004; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Piret B, 1996, NUCLEIC ACIDS RES, V24, P4242, DOI 10.1093/nar/24.21.4242; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sarkaria JN, 1998, CANCER RES, V58, P4375; Sauer H, 1999, J CELL BIOCHEM, V75, P710, DOI 10.1002/(SICI)1097-4644(19991215)75:4<710::AID-JCB16>3.0.CO;2-Z; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHULZEOSTHOFF K, 1995, BIOCHEM PHARMACOL, V50, P735, DOI 10.1016/0006-2952(95)02011-Z; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shi YL, 2004, P NATL ACAD SCI USA, V101, P5898, DOI 10.1073/pnas.0307718101; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667; Strumberg D, 2000, MOL CELL BIOL, V20, P3977, DOI 10.1128/MCB.20.11.3977-3987.2000; Szabo G, 2001, ALCOHOL CLIN EXP RES, V25, P1188; Tabary O, 2003, AM J PATHOL, V162, P293, DOI 10.1016/S0002-9440(10)63820-5; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Ward RJ, 1996, FEBS LETT, V389, P119, DOI 10.1016/0014-5793(96)00545-5; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wuerzberger-Davis SM, 2005, MOL CANCER RES, V3, P345, DOI 10.1158/1541-7786.MCR-05-0028; Yao Z, 2001, BONE, V28, P167, DOI 10.1016/S8756-3282(00)00425-7; Zhou WD, 2004, J BIOL CHEM, V279, P32262, DOI 10.1074/jbc.M404173200	67	60	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					641	651		10.1038/sj.onc.1209815	http://dx.doi.org/10.1038/sj.onc.1209815			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862178				2022-12-28	WOS:000243902200002
J	Braun, S; Mauch, C; Boukamp, P; Werner, S				Braun, S.; Mauch, C.; Boukamp, P.; Werner, S.			Novel roles of NM23 proteins in skin homeostasis, repair and disease	ONCOGENE			English	Article						skin; keratinocyte; NM23; wound healing; epidermis; differentiation	KERATINOCYTE GROWTH-FACTOR; NUCLEOSIDE DIPHOSPHATE KINASE; GENE-EXPRESSION; TGF-ALPHA; EPIDERMIS; ORGANIZATION; DIFFERENTIATION; STROMELYSIN-2; NEUROBLASTOMA; PROLIFERATION	Keratinocyte growth factor (KGF) is an important regulator of epidermal homeostasis and repair. Therefore, the identification of KGF target genes in keratinocytes should contribute to our understanding of the molecular mechanisms underlying these processes. In a search for KGF-regulated genes, we identified the gene encoding the nucleoside diphosphate kinase NM23-H1. Apart from a housekeeping function, NM23 proteins are involved in the regulation of many cellular processes as well as in tumor metastasis, but their functions in epidermal homeostasis and repair are largely unknown. Here, we show a high expression of NM23-H1 and NM23-H2 in the KGF-responsive keratinocytes of the hyperprotiferative epidermis of mouse skin wounds and of patients suffering from the skin disease psoriasis. To determine if this overexpression is functionally important, we generated HaCaT keratinocyte cell lines overexpressing NM23-Hl and/or-H2. Whereas the enhanced levels of NM23 did not affect cell proliferation in monoculture, NM23-H2 and double transfectants but not NM23-Hl transfectants formed a strongly hyperthickened epithelium in three-dimensional organotypic cultures. The abnormal epithelial morphology resulted from enhanced proliferation, reduced apoptosis and alterations in the differentiation pattern. These findings suggest that epidermal homeostasis depends on a tight regulation of the levels of NM23 isoforms.	ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Cologne, Dept Dermatol & Venerol, Cologne, Germany; German Canc Res Ctr, Dept Genet Skin Carcinogenesis, D-6900 Heidelberg, Germany	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Cologne; Helmholtz Association; German Cancer Research Center (DKFZ)	Werner, S (corresponding author), ETH, Inst Cell Biol, Schafmattstr 18, CH-8093 Zurich, Switzerland.	Sabine.werner@cell.biol.ethz.ch		Werner, Sabine/0000-0001-7397-8710				Beer HD, 2002, J BIOL CHEM, V277, P20740, DOI 10.1074/jbc.M111233200; BERNARD BA, 1988, J INVEST DERMATOL, V90, P801, DOI 10.1111/1523-1747.ep12462014; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chang CL, 1996, ONCOGENE, V12, P659; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Finch PW, 1997, AM J PATHOL, V151, P1619; Finch PW, 2004, ADV CANCER RES, V91, P69, DOI 10.1016/S0065-230X(04)91003-2; Fournier HN, 2003, J BIOENERG BIOMEMBR, V35, P81, DOI 10.1023/A:1023450008347; Frank S, 1997, ONCOGENE, V14, P915, DOI 10.1038/sj.onc.1200905; Gassmann MG, 1999, ONCOGENE, V18, P6667, DOI 10.1038/sj.onc.1203120; Gassmann MG, 2000, EXP CELL RES, V258, P23, DOI 10.1006/excr.2000.4904; GILLES AM, 1991, J BIOL CHEM, V266, P8784; Gromov P, 2003, MOL CELL PROTEOMICS, V2, P70, DOI 10.1074/mcp.M200051-MCP200; GROTENDORST GR, 1989, J CELL PHYSIOL, V139, P617, DOI 10.1002/jcp.1041390323; HAILAT N, 1991, J CLIN INVEST, V88, P341, DOI 10.1172/JCI115299; IGAWA M, 1994, CANCER RES, V54, P1313; KADUNCE DP, 1995, DERMATOL CLIN, V13, P723, DOI 10.1016/S0733-8635(18)30037-8; Kanitakis J, 1997, J CUTAN PATHOL, V24, P151, DOI 10.1111/j.1600-0560.1997.tb01569.x; KEIM D, 1992, J CLIN INVEST, V89, P919, DOI 10.1172/JCI115672; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kimura N, 2000, J BIOENERG BIOMEMBR, V32, P309, DOI 10.1023/A:1005549315846; KING LE, 1990, J INVEST DERMATOL, V95, pS10, DOI 10.1111/1523-1747.ep12505661; Krampert M, 2004, MOL BIOL CELL, V15, P5242, DOI 10.1091/mbc.E04-02-0109; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LAKSO M, 1992, CELL GROWTH DIFFER, V3, P873; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; Narayanan R, 2003, J BIOENERG BIOMEMBR, V35, P49, DOI 10.1023/A:1023441806530; Ornitz DM, 2001, GENOME BIOL, V2; Postel EH, 2003, J BIOENERG BIOMEMBR, V35, P31, DOI 10.1023/A:1023485505621; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; Sato Y, 2000, PATHOL INT, V50, P200, DOI 10.1046/j.1440-1827.2000.01030.x; Schoop VM, 1999, J INVEST DERMATOL, V112, P343, DOI 10.1046/j.1523-1747.1999.00524.x; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; STAHL JA, 1991, CANCER RES, V51, P445; Stark Hans-Jurgen, 2004, Biol Proced Online, V6, P55, DOI 10.1251/bpo72; STEEG PS, 1993, BREAST CANCER RES TR, V25, P175, DOI 10.1007/BF00662142; STEEG PS, 1989, INVAS METAST, V9, P351; Wei SJ, 2004, J BIOL CHEM, V279, P5993, DOI 10.1074/jbc.M310820200; WEINSTEIN GD, 1985, J INVEST DERMATOL, V85, P579, DOI 10.1111/1523-1747.ep12283594; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; Werner S, 1998, CYTOKINE GROWTH F R, V9, P153, DOI 10.1016/S1359-6101(98)00010-0; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WERNER S, 1992, P NATL ACAD SCI USA, V89, P6896, DOI 10.1073/pnas.89.15.6896; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	49	19	25	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					532	542		10.1038/sj.onc.1209822	http://dx.doi.org/10.1038/sj.onc.1209822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862176				2022-12-28	WOS:000243731600006
J	Laiho, P; Kokko, A; Vanharanta, S; Salovaara, R; Sammalkorpi, H; Jarvinen, H; Mecklin, JP; Karttunen, TJ; Tuppurainen, K; Davalos, V; Schwartz, S; Arango, D; Makinen, MJ; Aaltonen, LA				Laiho, P.; Kokko, A.; Vanharanta, S.; Salovaara, R.; Sammalkorpi, H.; Jarvinen, H.; Mecklin, J-P; Karttunen, T. J.; Tuppurainen, K.; Davalos, V.; Schwartz, S., Jr.; Arango, D.; Makinen, M. J.; Aaltonen, L. A.			Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis	ONCOGENE			English	Article						molecular classification; microarray; serrated colorectal cancer; EPHB2	CPG ISLAND METHYLATION; CELL NEVUS SYNDROME; MICROSATELLITE INSTABILITY; GENE-EXPRESSION; HYPERPLASTIC POLYPOSIS; HUMAN HOMOLOG; ADENOMAS; NEOPLASIA; PATHWAYS; HEDGEHOG	Serrated colorectal carcinomas (CRCs) are morphologically different from conventional CRCs and have been proposed to follow a distinct pathway of CRC formation. Despite studies of single molecular events in this tumor type, the diagnosis of serrated CRC relies on morphology and the putative unique biological character of these tumors has not been established. Here we show that the gene expression pro. ling of 37 CRCs separated serrated and conventional CRCs into two distinct branches in unsupervised hierarchical clustering (P-value 7.8 x 10(-7)), and revealed 201 differentially expressed genes representing potential biomarkers for serrated CRC. Immunohistochemistry was utilized to verify the key findings in the 37 CRCs examined by express ion profiling, and a separate validation set of 37 serrated and 86 conventional CRCs was examined to evaluate the candidate biomarkers in an extended sample material. Ephrin receptor B2, hypoxia-inducible factor 1-alpha and patched appeared as proteins important for genesis of serrated CRC. This study establishes serrated CRCs as a biologically distinct subclass of CRC and represents a step forward in the molecular classification of these cancers. The study also provides a platform to understand the molecular basis of serrated CRC and in long term may contribute to the development of specific treatment options for this tumor type.	Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol & Canc Biol Res Program, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00014 Helsinki, Finland; Jyvaskyla Cent Hosp, Dept Surg, Jyvaskyla, Finland; Univ Oulu, Dept Pathol, Oulu, Finland; Hosp Gen Valle Hebron, Res Inst, CIBBIM, Mol Biol & Biochem Res Ctr, Barcelona, Spain	University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital; University of Oulu; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)	Aaltonen, LA (corresponding author), Univ Helsinki, Dept Med Genet, Biomedicum Helsinki, Room B520A,POB 63, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Arango, Diego/M-5667-2016; Mecklin, Jukka-Pekka/AAB-5378-2020; Schwartz, Simo/H-7776-2012; Arango, Diego/AFW-0125-2022; Aaltonen, Lauri/A-5375-2010; Davalos, Veronica/AAR-8547-2020; Davalos, Veronica/S-1668-2016	Arango, Diego/0000-0003-2953-3284; Mecklin, Jukka-Pekka/0000-0003-4895-2249; Arango, Diego/0000-0003-2953-3284; Aaltonen, Lauri/0000-0001-6839-4286; Davalos, Veronica/0000-0003-4077-5137; Schwartz, Simo/0000-0001-8297-7971; Karttunen, Tuomo/0000-0002-8843-7957; Stefanius, Karoliina/0000-0002-9456-1954				Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Chan AOO, 2002, AM J PATHOL, V160, P529, DOI 10.1016/S0002-9440(10)64872-9; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Higuchi T, 2004, J CLIN PATHOL, V57, P682, DOI 10.1136/jcp.2003.015230; Hoffman EP, 2004, NAT REV GENET, V5, P229, DOI 10.1038/nrg1297; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Iino H, 1999, J CLIN PATHOL, V52, P5, DOI 10.1136/jcp.52.1.5; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Lazarus R, 2005, AM J CLIN PATHOL, V123, P349, DOI 10.1309/VBAGV3BR96N2EQTR; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; LONGACRE TA, 1990, AM J SURG PATHOL, V14, P524, DOI 10.1097/00000478-199006000-00003; Makinen MJ, 2001, J PATHOL, V193, P286, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH800>3.0.CO;2-2; Mullor JL, 2002, TRENDS CELL BIOL, V12, P562, DOI 10.1016/S0962-8924(02)02405-4; Narita T, 2000, DEVELOPMENT, V127, P981; Oldak M, 2001, INT J MOL MED, V8, P445; Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032; Park SJ, 2003, AM J PATHOL, V162, P815, DOI 10.1016/S0002-9440(10)63878-3; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Sawyer EJ, 2002, GUT, V51, P200, DOI 10.1136/gut.51.2.200; SCHWARTZ RA, 1978, NEW ENGL J MED, V299, P49; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Tateyama H, 2002, AM J SURG PATHOL, V26, P249, DOI 10.1097/00000478-200202000-00013; Tuppurainen K, 2005, J PATHOL, V207, P285, DOI 10.1002/path.1850; Yashiro M, 2005, CANCER EPIDEM BIOMAR, V14, P2253, DOI 10.1158/1055-9965.EPI-04-0790; Zeeberg BR, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-4-r28; Zhong H, 1999, CANCER RES, V59, P5830	45	115	119	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					312	320		10.1038/sj.onc.1209778	http://dx.doi.org/10.1038/sj.onc.1209778			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819509				2022-12-28	WOS:000243398300016
J	Singh, P; Wu, H; Clark, C; Owlia, A				Singh, P.; Wu, H.; Clark, C.; Owlia, A.			Annexin II binds progastrin and gastrin-like peptides, and mediates growth factor effects of autocrine and exogenous gastrins on colon cancer and intestinal epithelial cells	ONCOGENE			English	Article						Mr of gastrin-binding proteins; SELDI-TOFMS; antisense and sense Annexin II RNA	GLYCINE-EXTENDED GASTRIN; C-OXIDASE VB; TRANSGENIC MICE; CALPACTIN-I; TENASCIN-C; ENHANCED EXPRESSION; SIGNALING PATHWAYS; PANCREATIC CANCERS; INSULIN-RECEPTOR; GENE-EXPRESSION	We and others have reported the presence of novel progastrin (PG)/gastrin receptors on normal and cancerous intestinal cells. We had earlier reported the presence of 33 - 36 kDa gastrin-binding proteins on cellular membranes of colon cancer cells. The goal of the current study was to identify the protein(s) in the 33 - 36 kDa band, and analyse its functional significance. A carbodiimide crosslinker was used for crosslinking radio-labeled gastrins to membrane proteins from gastrin/PG responsive cell lines. Native membrane proteins, crosslinked to the ligand, were solubulized and enriched by > 1000-fold, and analysed by surface-enhanced laser desorption/ionization-time of light-mass spectrometry. The peptide masses were researched against the NCBInr database using the ProFound search engine. Annexin II (ANX II) was identified, and confirmed by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry. As HCT-116 cells express autocrine PG, the in situ association of PG with ANX II was demonstrated in pulldown assays. Direct binding of PG with ANX II was confirmed in an in vitro binding assay. In order to confirm a functional importance of these observations, sense and anti-sense (AS) ANX II RNA-expressing clones of intestinal epithelial (IEC-18) and human colon cancer (HCT-116) cell lines were generated. AS clones demonstrated a significant loss in the growth response to exogenous (IEC-18) and autocrine (HCT-116) PG. We have thus discovered that membrane-associated ANX II binds PG/gastrins, and partially mediates growth factor effects of the peptides.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA; Ciphergen Biosyst Inc, Fremont, CA USA	University of Texas System; University of Texas Medical Branch Galveston	Singh, P (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 10-104 Med Res Bldg,Route 1043, Galveston, TX 77555 USA.	posingh@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA097959, R01CA072992] Funding Source: NIH RePORTER; NCI NIH HHS [CA72992, CA097959, R01 CA097959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Biener Y, 1996, J BIOL CHEM, V271, P29489, DOI 10.1074/jbc.271.46.29489; BRAMBILLA R, 1991, BIOCHEM J, V278, P447, DOI 10.1042/bj2780447; Brown D, 2003, ENDOCRINOLOGY, V144, P201, DOI 10.1210/en.2002-220501; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Chiang YP, 1999, MOL CELL BIOCHEM, V199, P139, DOI 10.1023/A:1006942128672; CHIANG YP, 1993, CANCER RES, V53, P6017; CHICONE L, 1989, BIOCHEM BIOPH RES CO, V164, P512, DOI 10.1016/0006-291X(89)91749-X; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Cobb S, 2004, CANCER-AM CANCER SOC, V100, P1311, DOI 10.1002/cncr.20094; Das S, 2005, J PROTEOME RES, V4, P920, DOI 10.1021/pr050023i; Dockray GJ, 1996, PHYSIOL REV, V76, P767, DOI 10.1152/physrev.1996.76.3.767; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978; FROHLICH M, 1990, MOL CELL BIOL, V10, P3216, DOI 10.1128/MCB.10.6.3216; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GINSBERG BH, 1978, BIOCHIM BIOPHYS ACTA, V542, P88, DOI 10.1016/0304-4165(78)90235-0; GOULD KL, 1986, MOL CELL BIOL, V6, P2738, DOI 10.1128/MCB.6.7.2738; GOULD RJ, 1981, BIOCHEMISTRY-US, V20, P6776, DOI 10.1021/bi00527a006; Hajjar KA, 2000, ANN NY ACAD SCI, V902, P265; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; KEUTZER JC, 1990, EXP CELL RES, V188, P153, DOI 10.1016/0014-4827(90)90291-H; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Kucharczak J, 2001, ONCOGENE, V20, P7021, DOI 10.1038/sj.onc.1204882; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Laumonnier Y, 2006, BLOOD, V107, P3342, DOI 10.1182/blood-2005-07-2840; Lei S, 2004, J BIOL CHEM, V279, P42492, DOI 10.1074/jbc.M404025200; Mettouchi A, 1997, MOL CELL BIOL, V17, P3202, DOI 10.1128/MCB.17.6.3202; NALDINI L, 1990, BIOCHEMISTRY-US, V29, P5153, DOI 10.1021/bi00473a022; NARAYAN S, 1992, MOL CELL BIOCHEM, V112, P163; Ottewell PD, 2005, AM J PHYSIOL-GASTR L, V288, pG541, DOI 10.1152/ajpgi.00268.2004; OYAMA F, 1991, CANCER RES, V51, P4876; OZAKI T, 1993, ONCOGENE, V8, P1707; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rengifo-Cam W, 2005, GASTROENTEROLOGY, V128, pA485; Rengifo-Cam W, 2004, CURR PHARM DESIGN, V10, P2345, DOI 10.2174/1381612043383999; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; Siddheshwar RK, 2001, GUT, V48, P47, DOI 10.1136/gut.48.1.47; SINGH P, 1994, AM J PHYSIOL, V267, pG235, DOI 10.1152/ajpgi.1994.267.2.G235; SINGH P, 1987, CANCER RES, V47, P5000; Singh P, 2000, GASTROENTEROLOGY, V119, P162, DOI 10.1053/gast.2000.8527; Singh P, 1996, CANCER RES, V56, P4111; SINGH P, 1995, J BIOL CHEM, V270, P8429, DOI 10.1074/jbc.270.15.8429; Singh P, 2000, AM J PHYSIOL-GASTR L, V278, pG390, DOI 10.1152/ajpgi.2000.278.3.G390; Singh P, 2003, AM J PHYSIOL-GASTR L, V284, pG328, DOI 10.1152/ajpgi.00351.2002; SINGH P, 1994, CANCER RES, V54, P6563; SINGH P, 1994, AM J PHYSIOL, V267, P608; STAROS JV, 1986, ANAL BIOCHEM, V156, P220, DOI 10.1016/0003-2697(86)90176-4; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; VISHWANATHA JK, 1993, CARCINOGENESIS, V14, P2575, DOI 10.1093/carcin/14.12.2575; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wang TC, 1996, J CLIN INVEST, V98, P1918, DOI 10.1172/JCI118993; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; Wu H, 2000, J BIOL CHEM, V275, P32491, DOI 10.1074/jbc.M002458200; Wu H, 2003, AM J PHYSIOL-GASTR L, V285, pG1097, DOI 10.1152/ajpgi.00216.2003; ZHANG QX, 1994, BBA-GENE STRUCT EXPR, V1219, P567, DOI 10.1016/0167-4781(94)90091-4	61	63	73	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					425	440		10.1038/sj.onc.1209798	http://dx.doi.org/10.1038/sj.onc.1209798			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832341				2022-12-28	WOS:000243544000011
J	Akiyama, T; Kawasaki, Y				Akiyama, T.; Kawasaki, Y.			Wnt signalling and the actin cytoskeleton	ONCOGENE			English	Review						tumour suppressor; colon tumour; APC; cytoskeleton; kinesin-2; Asef	ADENOMATOUS POLYPOSIS-COLI; CELL-CELL ADHESION; TUMOR-SUPPRESSOR PROTEIN; APC PROTEIN; EPITHELIAL-CELLS; IN-VIVO; MICROTUBULES; CDC42; ASSOCIATION; MIGRATION	The tumour suppressor adenomatous polyposis coli (APC) is mutated in sporadic and familial colorectal tumours. APC binds to beta-catenin, a key component of the Wnt signalling pathway, and induces its degradation. In addition to this role, there is increasing evidence for additional roles of APC, including the organization of cytoskeletal networks. APC interacts with microtubules and accumulates at their plus ends in membrane protrusions. Also, it has been reported that APC is associated with the plasma membrane in an actin-dependent manner. Moreover, APC interacts with IQGAP1, an effector of Rac1 and Cdc42, and APC-stimulated guanine nucleotide exchange factor (Asef), a Rac1-specific guanine nucleotide exchange factor (GEF). IQGAP1 mediates association of APC with cortical actin in the leading edge of migrating cell and both proteins are required for cell polarization and directional migration. APC interacts with Asef and stimulates its activity, thereby regulating the actin cytoskeletal network, cell morphology, adhesion and migration. Truncated mutant APCs present in colorectal tumour cells activate Asef constitutively and contribute to their aberrant migratory properties, which may be important for adenoma formation as well as tumour progression to invasive malignancy.	Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan	University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.	akiyama@imcbns.iam.u-tokyo.ac.jp						Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 2004, CURR OPIN CELL BIOL, V16, P528, DOI 10.1016/j.ceb.2004.08.001; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; Briggs MW, 2003, FEBS LETT, V542, P7, DOI 10.1016/S0014-5793(03)00333-8; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; CADIGAN KM, 1997, GENE DEV, V11, P3052; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Fukata M, 2002, CELL, V109, P873, DOI 10.1016/S0092-8674(02)00800-0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Langford KJ, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-3; Mateer SC, 2003, CELL MOTIL CYTOSKEL, V55, P147, DOI 10.1002/cm.10118; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; MIYASHIRO I, 1995, ONCOGENE, V11, P89; MUNEMITSU S, 1994, CANCER RES, V54, P3676; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Oshima H, 1997, CANCER RES, V57, P1644; Polakis P, 2000, GENE DEV, V14, P1837; Reilein A, 2005, NAT CELL BIOL, V7, P463, DOI 10.1038/ncb1248; Rosin-Arbesfeld R, 2001, EMBO J, V20, P5929, DOI 10.1093/emboj/20.21.5929; Samowitz WS, 1999, CANCER RES, V59, P1442; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Scholey JM, 1996, J CELL BIOL, V133, P1, DOI 10.1083/jcb.133.1.1; Sharma M, 2006, J BIOL CHEM, V281, P17140, DOI 10.1074/jbc.M513027200; SU LK, 1995, CANCER RES, V55, P2972; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	45	96	97	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7538	7544		10.1038/sj.onc.1210063	http://dx.doi.org/10.1038/sj.onc.1210063			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143298				2022-12-28	WOS:000242514900012
J	Segditsas, S; Tomlinson, I				Segditsas, S.; Tomlinson, I.			Colorectal cancer and genetic alterations in the Wnt pathway	ONCOGENE			English	Review						APC; beta-catenin; 'just right'	FAMILIAL ADENOMATOUS POLYPOSIS; MUTATION CLUSTER REGION; BETA-CATENIN MUTATIONS; SOMATIC MUTATIONS; APC GENE; COLON-CANCER; CELL-LINES; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; GERMLINE MUTATION	In colorectal tumours, Wnt pathway genetics continues to be dominated by mutations in the adenomatous polyposis coli (APC) gene. Germline mutations cause familial adenomatous polyposis and at least two-thirds of sporadic colorectal tumours also acquire APC mutations, quite possibly as the initiating events in tumorigenesis. These mutations almost always cause loss of the C-terminal functions of the APC protein - probably involved in microtubule binding, cell polarity and chromosome segregation - and deletion of the SAMP repeats that are important for binding to axin and formation of the beta-catenin phosphorylation complex. The truncated APC proteins are, in general, stable and almost certainly retain some activity in beta-catenin binding. The 'two hits' at APC are coselected so as to produce an optimal activation of Wnt signalling (just-right hypothesis). In a minority of colorectal tumours, Wnt activation can occur through mutations that affect phosphorylation sites within exon 3 of beta-catenin, causing protein stabilization. In other tumours, epigenetic transcriptional silencing or mutation of the secreted frizzled-related proteins may modulate Wnt levels. Mutations in the Wnt components AXIN1, AXIN2 and TCF4 have been found in microsatellite-unstable colon cancers, but it is not clear in every case whether these changes are functional. Therapeutic modulation of the Wnt pathway remains an attractive therapeutic possibility for colorectal carcinomas.	Canc Res UK, London Res Inst, Mol & Populat Genet Lab, London WC2A 3PX, England	Cancer Research UK	Tomlinson, I (corresponding author), Canc Res UK, London Res Inst, Mol & Populat Genet Lab, 44,Lincolns Inn Fields, London WC2A 3PX, England.	ian.tomlinson@cancer.org.uk						Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Batra S, 2006, BIOCHEM BIOPH RES CO, V342, P1228, DOI 10.1016/j.bbrc.2006.02.084; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Crabtree MD, 2002, GUT, V51, P420, DOI 10.1136/gut.51.3.420; Crabtree MD, 2001, GUT, V49, P540, DOI 10.1136/gut.49.4.540; Dihlmann S, 1999, CANCER RES, V59, P1857; Duval A, 2000, CANCER RES, V60, P3872; Esteller M, 2000, CANCER RES, V60, P4366; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fearnhead NS, 2004, P NATL ACAD SCI USA, V101, P15992, DOI 10.1073/pnas.0407187101; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x; Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8; Gryfe R, 1999, AM J HUM GENET, V64, P378, DOI 10.1086/302262; Ilyas M, 1997, P NATL ACAD SCI USA, V94, P10330, DOI 10.1073/pnas.94.19.10330; Johnson V, 2005, GUT, V54, P264, DOI 10.1136/gut.2004.048132; Knudsen Anne Lyster, 2003, Fam Cancer, V2, P43, DOI 10.1023/A:1023286520725; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293; Laurent-Puig P, 1998, NUCLEIC ACIDS RES, V26, P269, DOI 10.1093/nar/26.1.269; Li JN, 2005, GASTROENTEROLOGY, V128, P1907, DOI 10.1053/j.gastro.2005.02.067; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NUGENT KP, 1994, GUT, V35, P1622, DOI 10.1136/gut.35.11.1622; Rubinfeld B, 1997, CANCER RES, V57, P4624; Schneikert J, 2006, INT J CANCER, V119, P74, DOI 10.1002/ijc.21826; Shimizu Y, 2002, GENE CHROMOSOME CANC, V33, P73, DOI 10.1002/gcc.1226; Sieber O, 2003, J PATHOL, V199, P137, DOI 10.1002/path.1272; Sieber OM, 2006, GUT, V55, P1440, DOI 10.1136/gut.2005.087106; Sieber OM, 2002, P NATL ACAD SCI USA, V99, P2954, DOI 10.1073/pnas.042699199; Slattery ML, 2001, CANCER RES, V61, P1000; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; Spirio LN, 1998, NAT GENET, V20, P385, DOI 10.1038/3865; Sturt NJH, 2004, GUT, V53, P1832, DOI 10.1136/gut.2004.042705; Su LK, 2000, AM J HUM GENET, V67, P582, DOI 10.1086/303058; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Webster MT, 2000, GENE CHROMOSOME CANC, V28, P443	44	454	466	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7531	7537		10.1038/sj.onc.1210059	http://dx.doi.org/10.1038/sj.onc.1210059			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143297				2022-12-28	WOS:000242514900011
J	Bubici, C; Papa, S; Dean, K; Franzoso, G				Bubici, C.; Papa, S.; Dean, K.; Franzoso, G.			Mutual cross-talk between reactive oxygen species and nuclear factor-kappa B: molecular basis and biological significance	ONCOGENE			English	Review						NF-kappa B; ROS; JNK; TNF; apoptosis; necrosis	TUMOR-NECROSIS-FACTOR; MANGANESE SUPEROXIDE-DISMUTASE; ALPHA-INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION PATHWAY; NECROTIC CELL-DEATH; RIBOSOMAL S6 KINASE; OXIDATIVE-STRESS; TRANSCRIPTION FACTOR; REDOX REGULATION; TNF-ALPHA	Reactive oxygen species (ROS) are emerging as key effectors in signal transduction. This role of ROS is especially evident in the pathways leading to programmed cell death (PCD) elicited in response to certain stress stimuli and cytokines. In these pathways, cytotoxic ROS signaling appears to be mediated in part by activation of the c-Jun-N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) cascade. Another pathway that is under ROS-mediated control in some systems is that leading to activation of transcription factor nuclear factor-kappa B (NF-kappa B), which is a central regulator of immunity, inflammation and cell survival. Remarkably, new evidence has unveiled the existence of a reciprocal, negative control that NF-kappa B exerts on ROS and JNK activities. This NF-kappa B-imposed restraint on ROS and JNK signaling is crucial for antagonism of PCD elicited by the proinflammatory cytokine tumor necrosis factor (TNF)alpha and likely other triggers. Effectors of this antagonistic cross-talk between NF-kappa B and ROS/JNK pathways have recently been identified. Because of the key roles that the prosurvival function of NF-kappa B plays in organismal physiology and disease, gaining a further mechanistic understanding of this cross-talk and NF-kappa B-dependent survival may be key to developing new therapies for the treatment of widespread human illnesses, such as cancer and chronic inflammatory conditions.	Univ Chicago, Ben May Inst Canc Res, Chicago, IL 60637 USA	University of Chicago	Franzoso, G (corresponding author), Univ Chicago, Ben May Inst Canc Res, 924 E 57th St, Chicago, IL 60637 USA.	gfranzos@midway.uchicago.edu	Franzoso, Guido/GRR-8628-2022; Papa, Salvatore/J-9413-2012	Papa, Salvatore/0000-0002-8369-6538; Bubici, Concetta/0000-0002-8074-4661; Franzoso, Guido/0000-0002-0778-988X	NATIONAL CANCER INSTITUTE [R01CA084040, R01CA098583] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA098583, R01-CA84040] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Aoki M, 2001, HYPERTENSION, V38, P48, DOI 10.1161/01.HYP.38.1.48; Arosio P, 2002, FREE RADICAL BIO MED, V33, P457, DOI 10.1016/S0891-5849(02)00842-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Beraud C, 1999, P NATL ACAD SCI USA, V96, P429, DOI 10.1073/pnas.96.2.429; Bernard D, 2001, CANCER RES, V61, P2656; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Bonizzi G, 1996, EUR J BIOCHEM, V242, P544, DOI 10.1111/j.1432-1033.1996.0544r.x; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Bottero V, 2006, CELL DEATH DIFFER, V13, P785, DOI 10.1038/sj.cdd.4401888; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Brasseres D.S., 2006, ONCOGENE, V25, P6817; Brennan P, 1996, BIOCHEM J, V320, P975, DOI 10.1042/bj3200975; BRENNAN P, 1995, BBA-GENE STRUCT EXPR, V1260, P167, DOI 10.1016/0167-4781(94)00186-7; Brigelius-Flohe R, 2004, ARCH BIOCHEM BIOPHYS, V423, P66, DOI 10.1016/j.abb.2003.12.008; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen F, 2003, CANCER RES, V63, P7689; Chen F, 2002, ENVIRON HEALTH PERSP, V110, P807, DOI 10.1289/ehp.02110s5807; Claudio E, 2006, CELL DEATH DIFFER, V13, P697, DOI 10.1038/sj.cdd.4401894; Courtois G, 2006, CELL DEATH DIFFER, V13, P843, DOI 10.1038/sj.cdd.4401841; Curtin JF, 2002, J IMMUNOL METHODS, V265, P49, DOI 10.1016/S0022-1759(02)00070-4; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Franzoso G, 2003, CELL DEATH DIFFER, V10, P13, DOI 10.1038/sj.cdd.4401154; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore Thomas D, 2003, Cancer Treat Res, V115, P241; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; GLOIRE G, 2006, IN PRESS BIOCH PHARM; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; Haddad JJ, 2002, CELL SIGNAL, V14, P879, DOI 10.1016/S0898-6568(02)00053-0; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hentze MW, 2004, CELL, V117, P285, DOI 10.1016/S0092-8674(04)00343-5; Hirota K, 2001, FEBS LETT, V489, P134, DOI 10.1016/S0014-5793(01)02094-4; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jaspers I, 2001, AM J RESP CELL MOL, V24, P769, DOI 10.1165/ajrcmb.24.6.4344; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kabe Y, 2005, ANTIOXID REDOX SIGN, V7, P395, DOI 10.1089/ars.2005.7.395; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2005, IUBMB LIFE, V57, P283, DOI 10.1080/15216540500097111; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Korn SH, 2001, J BIOL CHEM, V276, P35693, DOI 10.1074/jbc.M104321200; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Kumar A, 2004, J MOL MED, V82, P434, DOI 10.1007/s00109-004-0555-y; Lamb JA, 2003, MOL CELL, V11, P1479, DOI 10.1016/S1097-2765(03)00203-X; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lee CJ, 2004, NAT STRUCT MOL BIOL, V11, P1179, DOI 10.1038/nsmb856; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Liu CY, 2003, BLOOD, V101, P295, DOI 10.1182/blood-2001-12-0266; Livolsi A, 2001, EUR J BIOCHEM, V268, P1508, DOI 10.1046/j.1432-1327.2001.02028.x; Luo YQ, 1999, MOL PHARMACOL, V56, P254, DOI 10.1124/mol.56.2.254; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; MOLITOR JA, 1991, NEW BIOL, V3, P987; MOYNAGH PN, 1994, J IMMUNOL, V153, P2681; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nishi T, 2002, J BIOL CHEM, V277, P44548, DOI 10.1074/jbc.M202970200; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; ODONNELL VB, 1995, BIOCHEM J, V310, P133, DOI 10.1042/bj3100133; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; PAHL HL, 1999, ONCOGENE, V65, P704; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; ROYALL JA, 1992, ARCH BIOCHEM BIOPHYS, V294, P686, DOI 10.1016/0003-9861(92)90742-F; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Sasazuki T, 2004, MOL IMMUNOL, V41, P547, DOI 10.1016/j.molimm.2004.03.030; Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHIEVEN GL, 1994, J BIOL CHEM, V269, P20718; SCHMIDT KN, 1995, J BIOL CHEM, V270, P27136, DOI 10.1074/jbc.270.45.27136; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Schoonbroodt S, 2000, BIOCHEM PHARMACOL, V60, P1075, DOI 10.1016/S0006-2952(00)00371-3; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Shou Y, 2000, TOXICOL APPL PHARM, V164, P196, DOI 10.1006/taap.2000.8900; Shrivastava A, 1999, ANTIOXID REDOX SIGN, V1, P181, DOI 10.1089/ars.1999.1.2-181; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; STORZ P, 2006, SCI STKE, V332, pRE3, DOI DOI 10.1126/STKE.3322006RE3; SUZUKI YJ, 1995, BIOCHEM BIOPH RES CO, V210, P537, DOI 10.1006/bbrc.1995.1693; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Torti FM, 2002, BLOOD, V99, P3505, DOI 10.1182/blood.V99.10.3505; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; Vanden Berghe T, 2003, J BIOL CHEM, V278, P5622, DOI 10.1074/jbc.M208925200; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Victor VM, 2004, INT IMMUNOPHARMACOL, V4, P327, DOI 10.1016/j.intimp.2004.01.020; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Vulcano M, 2000, INT J IMMUNOPHARMACO, V22, P635, DOI 10.1016/S0192-0561(00)00026-6; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Weil R, 2006, CELL DEATH DIFFER, V13, P826, DOI 10.1038/sj.cdd.4401856; Wood MJ, 2004, NATURE, V430, P917, DOI 10.1038/nature02790; Xie CC, 2005, MOL CELL BIOL, V25, P6673, DOI 10.1128/MCB.25.15.6673-6681.2005; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Zhang J, 2001, ANTIOXID REDOX SIGN, V3, P493, DOI 10.1089/15230860152409121; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhang YD, 2004, CANCER RES, V64, P1902, DOI 10.1158/0008-5472.CAN-03-3361	154	329	336	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6731	6748		10.1038/sj.onc.1209936	http://dx.doi.org/10.1038/sj.onc.1209936			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072325				2022-12-28	WOS:000241666700005
J	Calin, GA; Croce, CM				Calin, G. A.; Croce, C. M.			MicroRNAs and chromosomal abnormalities in cancer cells	ONCOGENE			English	Review						microRNAs; chromosom al aberrations; cancer	CHRONIC LYMPHOCYTIC-LEUKEMIA; HUMAN LUNG CANCERS; C-MYC; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; CHAIN GENE; EXPRESSION; LOCUS; TRANSLOCATION; 13Q14	Over the past five decades, a plethora of nonrandom chromosomal abnormalities have been consistently reported in malignant cells facilitating the identification of cancer-associated protein coding oncogenes and tumor suppressors. The genetic dissection of hot spots for chromosomal abnormalities in the age of the sequenced human genome resulted in the discovery that microRNA ( miRNA) genes, encoding for a class of small noncoding RNAs, frequently resides in such genomic regions. The combination of nonrandom chromosomal abnormalities and other types of genetic alterations or epigenetic events contribute to downregulation or overexpression of miRNAs. The consequent abnormal expression of miRNAs affect cell cycle, survival and differentiation programs and selective targeting of these noncoding genes could provide novel therapeutic options for killing the malignant cells.	Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Croce, CM (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Dept Mol Virol Immunol & Med Genet, Wiseman Hall Room 385K,400 12th Ave, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Calin, George/E-9390-2011; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Calin, George/0000-0001-6704-5615				ADACHI M, 1990, J EXP MED, V171, P559, DOI 10.1084/jem.171.2.559; Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Arlt MF, 2003, CYTOGENET GENOME RES, V100, P92, DOI 10.1159/000072843; Barlund M, 2000, CANCER RES, V60, P5340; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Berezikov E, 2005, HUM MOL GENET, V14, pR183, DOI 10.1093/hmg/ddi271; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bullrich F, 2001, CANCER RES, V61, P6640; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, LEUKEMIA RES, V30, P653, DOI 10.1016/j.leukres.2005.10.017; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Calin GA, 2005, NEW ENGL J MED, V352, P1667, DOI 10.1056/NEJMoa042280; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; CROCE CM, 1985, BLOOD, V65, P1; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Czech MP, 2006, NEW ENGL J MED, V354, P1194, DOI 10.1056/NEJMcibr060065; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; di Iasio MG, 1999, ONCOGENE, V18, P1635, DOI 10.1038/sj.onc.1202453; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; ETIEMBLE J, 1989, ONCOGENE, V4, P51; GAUWERKY CE, 1989, P NATL ACAD SCI USA, V86, P8867, DOI 10.1073/pnas.86.22.8867; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Harfe BD, 2005, CURR OPIN GENET DEV, V15, P410, DOI 10.1016/j.gde.2005.06.012; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Migliazza A, 2001, BLOOD, V97, P2098, DOI 10.1182/blood.V97.7.2098; MORRIS JPI, 2005, SCI STKE, V297, P1; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pekarsky Y, 2005, CURR TOP MICROBIOL, V294, P51, DOI 10.1007/3-540-29933-5_4; Phan RT, 2004, NATURE, V432, P635, DOI 10.1038/nature03147; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; ROLDO C, 2006, IN PRESS J CLIN ONCO; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; RUSSO G, 1988, CELL, V53, P137, DOI 10.1016/0092-8674(88)90495-3; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73; Sonoki T, 2005, LEUKEMIA, V19, P2009, DOI 10.1038/sj.leu.2403938; Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tam W, 2006, GENE CHROMOSOME CANC, V45, P211, DOI 10.1002/gcc.20282; Tsuchiya E, 2000, JPN J CANCER RES, V91, P589, DOI 10.1111/j.1349-7006.2000.tb00986.x; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhao XT, 2003, CANCER LETT, V190, P221, DOI 10.1016/S0304-3835(02)00622-5	90	203	225	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6202	6210		10.1038/sj.onc.1209910	http://dx.doi.org/10.1038/sj.onc.1209910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028600				2022-12-28	WOS:000241158900009
J	Mamane, Y; Petroulakis, E; LeBacquer, O; Sonenberg, N				Mamane, Y.; Petroulakis, E.; LeBacquer, O.; Sonenberg, N.			MTOR, translation initiation and cancer	ONCOGENE			English	Review						mTOR; translation; cancer; eIF4G	CAP-DEPENDENT TRANSLATION; ACTIVATED PROTEIN-KINASE; TOP MESSENGER-RNAS; FACTOR 4E; C-MYC; MALIGNANT-TRANSFORMATION; PHOSPHORYLATION SITES; 4E-BINDING PROTEINS; MAMMALIAN TARGET; CELL-DEATH	Control of mRNA translation plays a fundamental role in many aspects of cell metabolism. It constitutes a critical step in the control of gene expression, and consequently cell growth, proliferation and differentiation. Translation is regulated in response to nutrient availability, hormones, mitogenic and growth factor stimulation and is coupled with cell cycle progression and cell growth. Signaling by the PI3K/Akt/mTOR pathway profoundly affects mRNA translation through phosphorylation of downstream targets such as 4E-BP and S6K. Inhibitors of this pathway and thus cap-dependent translation are emerging as promising therapeutic options for the treatment of cancer.	McGill Univ, Dept Biochem, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada	McGill University	Sonenberg, N (corresponding author), McGill Univ, Dept Biochem, McGill Canc Ctr, McIntyre Med Sci Bldg,3655 Drummond St,Rm 807, Montreal, PQ H3G 1Y6, Canada.	nahum.sonenberg@mcgill.ca	Le Bacquer, Olivier/AIE-6480-2022	Le Bacquer, Olivier/0000-0003-3805-973X				Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bauer C, 2002, INT J CANCER, V98, P181, DOI 10.1002/ijc.10180; Bauer C, 2001, CANCER, V92, P822, DOI 10.1002/1097-0142(20010815)92:4<822::AID-CNCR1388>3.0.CO;2-A; Brass N, 1997, HUM MOL GENET, V6, P33, DOI 10.1093/hmg/6.1.33; Clemens MJ, 2001, J CELL MOL MED, V5, P221, DOI 10.1111/j.1582-4934.2001.tb00157.x; De Virgilio C, 2006, INT J BIOCHEM CELL B, V38, P1476, DOI 10.1016/j.biocel.2006.02.013; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; DUNCAN R, 1987, J BIOL CHEM, V262, P380; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Grolleau A, 2002, J BIOL CHEM, V277, P22175, DOI 10.1074/jbc.M202014200; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Keiper BD, 1999, INT J BIOCHEM CELL B, V31, P37, DOI 10.1016/S1357-2725(98)00130-7; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2003, CURR TOP MICROBIOL, V279, P259; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Li SN, 2002, MOL CELL BIOL, V22, P2853, DOI 10.1128/MCB.22.8.2853-2861.2002; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Marcotrigiano J, 1999, MOL CELL, V3, P707, DOI 10.1016/S1097-2765(01)80003-4; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Okamoto H, 2003, HEPATOLOGY, V38, P1242, DOI 10.1053/jhep.2003.50457; Oridate N, 2005, CANCER BIOL THER, V4, P318, DOI 10.4161/cbt.4.3.1504; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; Panner A, 2006, CELL CYCLE, V5, P147, DOI 10.4161/cc.5.2.2359; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peterson TR, 2005, MOL CELL, V20, P655, DOI 10.1016/j.molcel.2005.11.016; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Poulin F, 1998, J BIOL CHEM, V273, P14002, DOI 10.1074/jbc.273.22.14002; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Rousseau D, 1996, ONCOGENE, V13, P2415; Rowinsky EK, 2004, CURR OPIN ONCOL, V16, P564, DOI 10.1097/01.cco.0000143964.74936.d1; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Savinainen KJ, 2004, BRIT J CANCER, V90, P1041, DOI 10.1038/sj.bjc.6601648; Schmalfeldt B, 2001, CLIN CANCER RES, V7, P2396; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shi J, 2006, ONCOGENE, V25, P4923, DOI 10.1038/sj.onc.1209495; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shuda M, 2000, ANTICANCER RES, V20, P2489; Skinner HD, 2004, J BIOL CHEM, V279, P45643, DOI 10.1074/jbc.M404097200; Stephens L, 2005, CURR OPIN PHARMACOL, V5, P357, DOI 10.1016/j.coph.2005.03.002; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tan A, 2000, ONCOGENE, V19, P1437, DOI 10.1038/sj.onc.1203446; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Thomas GV, 2006, CURR OPIN GENET DEV, V16, P78, DOI 10.1016/j.gde.2005.12.003; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Wang FQ, 2006, INT J CANCER, V118, P879, DOI 10.1002/ijc.21421; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yan HJ, 2006, CANCER RES, V66, P2305, DOI 10.1158/0008-5472.CAN-05-2447; Young DA, 2005, CURR OPIN PHARMACOL, V5, P418, DOI 10.1016/j.coph.2005.03.004; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404	85	500	508	2	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6416	6422		10.1038/sj.onc.1209888	http://dx.doi.org/10.1038/sj.onc.1209888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041626				2022-12-28	WOS:000241380700007
J	Mathew, CG				Mathew, C. G.			Fanconi anaemia genes and susceptibility to cancer	ONCOGENE			English	Review						Fanconi anaemia; chromosomal instability; leukaemia, squamous cell carcinoma	DNA-REPAIR DEFECT; BREAST-CANCER; COMPLEMENTATION GROUP; PANCREATIC-CANCER; MUTATION ANALYSIS; HELICASE BRIP1; BRCA PATHWAY; PROTEIN; BACH1; FAMILIES	Fanconi anaemia (FA) is a rare recessive disorder associated with chromosomal fragility, aplastic anaemia, congenital abnormalities and a high risk of cancer, including acute myeloid leukaemia and squamous cell carcinomas. The identification of 11 different FA genes has revealed a complex web of interacting proteins that are involved in the recognition or repair of DNA interstrand crosslinks and perhaps other forms of DNA damage. Bi- allelic mutations in BRCA2 are associated with a rare and highly cancer-prone form of FA, and the DNA helicase BRIP1 (formerly BACH1) is mutated in FA group J. There is little convincing evidence that FA heterozygotes are at increased risk of cancer, but larger studies are needed to address the possibility of modest risk effects. Somatic inactivation of the FA pathway by mutation or epigenetic silencing has been observed in several different types of sporadic cancer, and this may have important implications for targeted chemotherapy. Inhibition of this pathway represents a possible route to sensitization of tumours to DNA crosslinking drugs such as cisplatin.	Kings Coll London, Sch Med, Div Med & Mol Genet, Guys Hosp, London SE5 9PJ, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Mathew, CG (corresponding author), Guys Hosp, Dept Med & Mol Genet, 8th Floor Guys Tower, London SE1 9RT, England.	christopher.mathew@genetics.kcl.ac.uk	Mathew, Christopher G/G-3434-2015	Mathew, Christopher G/0000-0003-4178-1838				Adachi D, 2002, HUM MOL GENET, V11, P3125, DOI 10.1093/hmg/11.25.3125; Alter BP, 2005, ARCH OTOLARYNGOL, V131, P635, DOI 10.1001/archotol.131.7.635; Alter BP, 2003, CANCER-AM CANCER SOC, V97, P425, DOI 10.1002/cncr.11046; Barber LM, 2003, BRIT J HAEMATOL, V121, P57, DOI 10.1046/j.1365-2141.2003.04234.x; BARROSO E, 2006, IN PRESS CARCIN 0505; Bridge WL, 2005, NAT GENET, V37, P953, DOI 10.1038/ng1627; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Callen E, 2005, BLOOD, V105, P1946, DOI 10.1182/blood-2004-07-2588; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carreau M, 2004, BLOOD, V103, P2430, DOI 10.1182/blood-2003-11-3946; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; Chirnomas D, 2006, MOL CANCER THER, V5, P952, DOI 10.1158/1535-7163.MCT-05-0493; Condie A, 2002, LEUKEMIA LYMPHOMA, V43, P1849, DOI 10.1080/1042819021000009274; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Couch FJ, 2005, CANCER RES, V65, P383; Cumming RC, 2001, NAT MED, V7, P814, DOI 10.1038/89937; Djuzenova CS, 2001, LAB INVEST, V81, P185, DOI 10.1038/labinvest.3780226; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; Faivre L, 2000, BLOOD, V96, P4064; FANCONI G., 1967, SEMINARS HAMATOL, V4, P233; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Ferrer M, 2004, CANCER GENE THER, V11, P539, DOI 10.1038/sj.cgt.7700734; Friedman LS, 1998, CANCER RES, V58, P1338; Futaki M, 2000, BLOOD, V95, P1493, DOI 10.1182/blood.V95.4.1493.004k35_1493_1498; Garcia-Closas M, 2006, HUM GENET, V119, P376, DOI 10.1007/s00439-006-0135-z; Gillio AP, 1997, BLOOD, V90, P105; Hirsch B, 2004, BLOOD, V103, P2554, DOI 10.1182/blood-2003-06-1970; HODGSON SV, 2004, AM SOC HUM GEN M TOR; HOUGHTALING S, 2003, GENE DEV, V17, P1933; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Hussain S, 2006, DNA REPAIR, V5, P629, DOI 10.1016/j.dnarep.2006.02.007; Joenje H, 2001, NAT REV GENET, V2, P446, DOI 10.1038/35076590; Karppinen SM, 2003, EUR J CANCER, V39, P366, DOI 10.1016/S0959-8049(02)00498-7; Kutler DI, 2003, J NATL CANCER I, V95, P1718, DOI 10.1093/jnci/djg091; Kutler DI, 2003, ARCH OTOLARYNGOL, V129, P106, DOI 10.1001/archotol.129.1.106; Kutler DI, 2003, BLOOD, V101, P1249, DOI 10.1182/blood-2002-07-2170; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Levitus M, 2004, BLOOD, V103, P2498, DOI 10.1182/blood-2003-08-2915; Levitus M, 2005, NAT GENET, V37, P934, DOI 10.1038/ng1625; Levran O, 2005, NAT GENET, V37, P931, DOI 10.1038/ng1624; Lewis AG, 2005, BREAST CANCER RES, V7, pR1005, DOI 10.1186/bcr1336; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Luo LP, 2002, INT J CANCER, V98, P638, DOI 10.1002/ijc.10214; Lyakhovich A, 2006, CANCER LETT, V232, P99, DOI 10.1016/j.canlet.2005.07.038; Marsit CJ, 2004, ONCOGENE, V23, P1000, DOI 10.1038/sj.onc.1207256; Meetei AR, 2005, NAT GENET, V37, P958, DOI 10.1038/ng1626; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Meetei AR, 2004, NAT GENET, V36, P1219, DOI 10.1038/ng1458; Meyer S, 2006, BRIT J HAEMATOL, V133, P284, DOI 10.1111/j.1365-2141.2006.05985.x; Morgan NV, 2005, BLOOD, V105, P3542, DOI 10.1182/blood-2004-10-3968; Mosedale G, 2005, NAT STRUCT MOL BIOL, V12, P763, DOI 10.1038/nsmb981; Narayan G, 2004, CANCER RES, V64, P2994, DOI 10.1158/0008-5472.CAN-04-0245; Offit K, 2003, JNCI-J NATL CANCER I, V95, P1548, DOI 10.1093/jnci/djg072; Pearson T, 2001, CANCER GENET CYTOGEN, V126, P52, DOI 10.1016/S0165-4608(00)00388-5; POTTER NU, 1983, CANCER GENET CYTOGEN, V9, P61, DOI 10.1016/0165-4608(83)90025-0; Reid S, 2005, J MED GENET, V42, P147, DOI 10.1136/jmg.2004.022673; Reuter TY, 2003, EXP CELL RES, V289, P211, DOI 10.1016/S0014-4827(03)00261-1; Rogers CD, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.024851; Rogers CD, 2004, CANCER BIOL THER, V3, P167, DOI 10.4161/cbt.3.2.609; Rosenberg PS, 2003, BLOOD, V101, P822, DOI 10.1182/blood-2002-05-1498; Rosenberg PS, 2005, BLOOD, V105, P67, DOI 10.1182/blood-2004-04-1652; ROSENDORFF J, 1987, AM J MED GENET, V27, P793, DOI 10.1002/ajmg.1320270408; Rutter JL, 2003, HUM MUTAT, V22, P121, DOI 10.1002/humu.10238; SCHROEDER TM, 1964, HUMANGENETIK, V1, P194, DOI 10.1007/BF00389636; Seal S, 2003, CANCER RES, V63, P8596; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Sigurdson AJ, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-9; Surralles Jordi, 2004, Genes Dev, V18, P1359, DOI 10.1101/gad.1216304; SWIFT M, 1980, J NATL CANCER I, V65, P863; SWIFT M, 1971, NATURE, V230, P370, DOI 10.1038/230370a0; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Taniguchi T, 2006, BLOOD, V107, P4223, DOI 10.1182/blood-2005-10-4240; THOMPSON D, 2004, GENETIC PREDISPOSITI, P256; Thompson LH, 2005, ENVIRON MOL MUTAGEN, V45, P128, DOI 10.1002/em.20109; Tipping AJ, 2001, P NATL ACAD SCI USA, V98, P5734, DOI 10.1073/pnas.091402398; Tischkowitz M, 2004, BRIT J HAEMATOL, V126, P176, DOI 10.1111/j.1365-2141.2004.05023.x; Tischkowitz M, 2003, BRIT J HAEMATOL, V123, P469, DOI 10.1046/j.1365-2141.2003.04640.x; Tischkowitz MD, 2004, LEUKEMIA, V18, P420, DOI 10.1038/sj.leu.2403280; Vahteristo P, 2005, BMC CANCER, V6, P1, DOI 10.1186/1471-2407-6-19; Van der Heijden MS, 2004, AM J PATHOL, V165, P651, DOI 10.1016/S0002-9440(10)63329-9; van der Heijden MS, 2003, CANCER RES, V63, P2585; van Zeeburg HJT, 2004, JNCI-J NATL CANCER I, V96, P968, DOI 10.1093/jnci/djh178; VERLANDER PC, 1994, AM J HUM GENET, V54, P595; VERLANDER PC, 1995, BLOOD, V86, P4034, DOI 10.1182/blood.V86.11.4034.bloodjournal86114034; Wagner JE, 2004, BLOOD, V103, P3226, DOI 10.1182/blood-2003-09-3138; Waisfisz Q, 1999, NAT GENET, V22, P379, DOI 10.1038/11956; Wang XZ, 2004, MOL CELL BIOL, V24, P5850, DOI 10.1128/MCB.24.13.5850-5862.2004; WHITNEY MA, 1993, NAT GENET, V4, P202, DOI 10.1038/ng0693-202; Xie Y, 2000, BRIT J HAEMATOL, V111, P1057, DOI 10.1111/j.1365-2141.2000.02450.x; Yamamoto K, 2003, MOL CELL BIOL, V23, P5421, DOI 10.1128/MCB.23.15.5421-5430.2003; Yamashita T, 1996, BLOOD, V87, P4424, DOI 10.1182/blood.V87.10.4424.bloodjournal87104424	92	148	155	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5875	5884		10.1038/sj.onc.1209878	http://dx.doi.org/10.1038/sj.onc.1209878			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998502				2022-12-28	WOS:000240765900008
J	Helmbold, H; Deppert, W; Bohn, W				Helmbold, H.; Deppert, W.; Bohn, W.			Regulation of cellular senescence by Rb2/p130	ONCOGENE			English	Review						Rb2; p53; senescence	RETINOBLASTOMA SUSCEPTIBILITY GENE; HUMAN TUMOR-CELLS; CYCLE ARREST; HISTONE DEACETYLASE; FAMILY-MEMBERS; PROTEIN P130; TRANSCRIPTIONAL REPRESSION; DEPENDENT PHOSPHORYLATION; POCKET PROTEINS; E2F1 PROMOTER	Growth regulatory functions of Rb2/p130, which aim at a sustained arrest such as in quiescent or differentiated cells, qualify the protein also to act as a central regulator of growth arrest in cellular senescence. In this respect, Rb2/ p130 functions are connected to signaling pathways induced by p53, which is a master regulator in cellular senescence. Here, we summarize the pathways, which specify pRb2/p130 to control this arrest program and distinguish its functions from those of pRb/p105.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany	Heinrich Pette Institute; University of Hamburg	Bohn, W (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.	wolfgang.bohn@hpi.uni-hamburg.de						Alexander K, 2001, MOL CELL BIOL, V21, P3616, DOI 10.1128/MCB.21.11.3616-3631.2001; Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Bates S, 1998, ONCOGENE, V17, P1691, DOI 10.1038/sj.onc.1202104; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Bruce JL, 2000, MOL CELL, V6, P737, DOI 10.1016/S1097-2765(00)00072-1; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Campisi J, 2001, EXP GERONTOL, V36, P607, DOI 10.1016/S0531-5565(00)00230-8; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coisy M, 2004, MOL CELL, V15, P43, DOI 10.1016/j.molcel.2004.06.022; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HAUPT Y, 1995, ONCOGENE, V10, P1563; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; Howard CM, 2000, CANCER RES, V60, P2737; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; Ichimura K, 2000, GENE, V251, P37, DOI 10.1016/S0378-1119(00)00193-1; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kapic A, 2006, CELL DEATH DIFFER, V13, P324, DOI 10.1038/sj.cdd.4401756; KIESS M, 1995, CELL GROWTH DIFFER, V6, P1287; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Li Qiang, 2004, Brain Tumor Pathol, V21, P121, DOI 10.1007/BF02482187; Liu DX, 2005, GENE DEV, V19, P719, DOI 10.1101/gad.1296405; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; OSIFCHIN NE, 1994, J BIOL CHEM, V269, P6383; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Peeper DS, 2001, NAT CELL BIOL, V3, P198, DOI 10.1038/35055110; Psyrri A, 2004, CANCER RES, V64, P3079, DOI 10.1158/0008-5472.CAN-03-3739; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Steiner MS, 2000, ONCOGENE, V19, P1297, DOI 10.1038/sj.onc.1203428; Stiegler P, 1998, CANCER RES, V58, P5049; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Timmermann S, 1998, ONCOGENE, V17, P3445, DOI 10.1038/sj.onc.1202244; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YC, 1998, ONCOGENE, V17, P1923, DOI 10.1038/sj.onc.1202113; YEUNG RS, 1993, ONCOGENE, V8, P3465; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	92	24	27	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5257	5262		10.1038/sj.onc.1209613	http://dx.doi.org/10.1038/sj.onc.1209613			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936745				2022-12-28	WOS:000240064100010
J	Brenner, C; Grimm, S				Brenner, C.; Grimm, S.			The permeability transition pore complex in cancer cell death	ONCOGENE			English	Review						mitochondria; apoptosis; adenine nucleotide translocator; cyclophilin D; VDAC	ADENINE-NUCLEOTIDE TRANSLOCATOR; PERIPHERAL BENZODIAZEPINE-RECEPTOR; CYTOCHROME-C RELEASE; DEPENDENT ANION CHANNEL; INNER MITOCHONDRIAL-MEMBRANE; INTERMEMBRANE JUNCTIONAL COMPLEXES; HUMAN-BREAST-CANCER; CYCLOPHILIN-D; BAX TRANSLOCATION; OXIDATIVE STRESS	The permeability transition pore (PTP) is a multi-protein complex at contact sites of the inner with the outer mitochondrial membrane. Research over the past years has led to the concept that the PTP occupies a central role in cell death induction. Numerous apoptosis signals convert this protein aggregate into an unspecific pore, thus activating mitochondria for the cellular self-destruction process. Here, we describe the evidence for this and the various approaches being undertaken to elucidate its subunit composition and mode of regulation. In particular, we review data that indicate a role of specific PTP subunits for apoptosis inhibition during tumorigenesis.	Univ Versailles, CNRS, FRE 2445, F-78035 Versailles, France; Imperial Coll London, Hammersmith Campus, London W12 0NN, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Imperial College London	Brenner, C (corresponding author), Univ Versailles, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	catherinebrenner@yahoo.com			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Barros LF, 2001, COMP BIOCHEM PHYS A, V130, P401, DOI 10.1016/S1095-6433(01)00438-X; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Biaglow JE, 2005, CANCER BIOL THER, V4, P6; Boisvieux-Ulrich E, 2005, EXP CELL RES, V307, P76, DOI 10.1016/j.yexcr.2005.02.005; Bonod-Bidaud C, 2001, MITOCHONDRION, V1, P217, DOI 10.1016/S1567-7249(01)00017-4; BRDICZKA D, 1991, BIOCHIM BIOPHYS ACTA, V1071, P291, DOI 10.1016/0304-4157(91)90018-R; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cassarino DS, 1999, BRAIN RES REV, V29, P1, DOI 10.1016/S0165-0173(98)00046-0; Catasus L, 2000, CANCER, V88, P2290, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2290::AID-CNCR13>3.3.CO;2-9; Cesar MD, 2004, ARCH BIOCHEM BIOPHYS, V422, P191, DOI 10.1016/j.abb.2003.12.030; Chakraborti T, 1999, CELL SIGNAL, V11, P77, DOI 10.1016/S0898-6568(98)00025-4; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Clarke SJ, 2002, J BIOL CHEM, V277, P34793, DOI 10.1074/jbc.M202191200; Clement MV, 1999, FREE RADICAL RES, V30, P247, DOI 10.1080/10715769900300271; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Decaudin D, 2002, CANCER RES, V62, P1388; DELUCA M, 1981, BIOCHEM BIOPH RES CO, V99, P189, DOI 10.1016/0006-291X(81)91731-9; DENIAUD A, 2006, IN PRESS CURR PHARM; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Dvorakova K, 2002, MOL CANCER THER, V1, P185; Eldering E, 2004, EUR J IMMUNOL, V34, P1950, DOI 10.1002/eji.200324817; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Elmore SP, 2001, FASEB J, V15, P2286, DOI 10.1096/fj.01-0206fje; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; FaureVigny H, 1996, MOL CARCINOGEN, V16, P165, DOI 10.1002/(SICI)1098-2744(199607)16:3<165::AID-MC7>3.0.CO;2-G; Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Friberg H, 2002, BIOCHIMIE, V84, P241, DOI 10.1016/S0300-9084(02)01381-0; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Genini D, 2000, BLOOD, V96, P3537; Gewies A, 2003, CANCER RES, V63, P682; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; GUDNASON V, 1984, INT J CANCER, V34, P63, DOI 10.1002/ijc.2910340111; Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a; Halestrap AP, 2004, CARDIOVASC RES, V61, P372, DOI 10.1016/S0008-6363(03)00533-9; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; Halestrap AP, 2004, NATURE, V430, DOI 10.1038/nature02816; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; HALLIWELL B, 1999, FREE RADICALS BIOL; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haouzi D, 2002, APOPTOSIS, V7, P395, DOI 10.1023/A:1020026923038; Hardwick M, 1999, CANCER RES, V59, P831; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Heerdt BG, 2003, CANCER RES, V63, P6311; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Inoue K, 2001, LEUKEMIA RES, V25, P275, DOI 10.1016/S0145-2126(00)00121-1; Ionov Y, 2000, P NATL ACAD SCI USA, V97, P10872, DOI 10.1073/pnas.190210897; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; KATZ Y, 1990, CLIN SCI, V78, P155, DOI 10.1042/cs0780155; Kim JS, 2003, CURR MOL MED, V3, P527, DOI 10.2174/1566524033479564; Kim JS, 2003, GASTROENTEROLOGY, V124, P494, DOI 10.1053/gast.2003.50059; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kon K, 2004, HEPATOLOGY, V40, P1170, DOI 10.1002/hep.20437; Kornblau SM, 1999, CLIN CANCER RES, V5, P1758; Kowaltowski AJ, 1997, BBA-BIOENERGETICS, V1318, P395, DOI 10.1016/S0005-2728(96)00111-9; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Levin E, 2005, BIOCHEMISTRY-US, V44, P9924, DOI 10.1021/bi050150s; Li YM, 2004, BIOCHEM J, V383, P101, DOI 10.1042/BJ20040669; Lin DT, 2002, J BIOL CHEM, V277, P31134, DOI 10.1074/jbc.M112035200; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Maaser K, 2005, BIOCHEM BIOPH RES CO, V332, P646, DOI 10.1016/j.bbrc.2005.05.005; Maaser K, 2005, CLIN CANCER RES, V11, P1751, DOI 10.1158/1078-0432.CCR-04-1955; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madeo F, 2004, CURR OPIN MICROBIOL, V7, P655, DOI 10.1016/j.mib.2004.10.012; Manion MK, 2003, CANCER BIOL THER, V2, pS105; Marchetti P, 1999, CANCER RES, V59, P6257; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Marzo I, 1998, FEBS LETT, V427, P198, DOI 10.1016/S0014-5793(98)00424-4; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; MIETTINEN H, 1995, CANCER RES, V55, P2691; Morgan J, 2004, BRIT J DERMATOL, V151, P846, DOI 10.1111/j.1365-2133.2004.06198.x; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakamura Y, 2002, J BIOL CHEM, V277, P8492, DOI 10.1074/jbc.M109760200; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; NIEMINEN AL, 1995, BIOCHEM J, V307, P99, DOI 10.1042/bj3070099; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PETRONILLI V, 1989, FEBS LETT, V259, P137, DOI 10.1016/0014-5793(89)81513-3; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Piret JP, 2004, MITOCHONDRION, V3, P261, DOI 10.1016/j.mito.2004.01.001; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; PRATT R, 1987, PATHOLOGY, V19, P162, DOI 10.3109/00313028709077128; Precht TA, 2005, CELL DEATH DIFFER, V12, P255, DOI 10.1038/sj.cdd.4401552; Prevarskaya N, 2004, BIOCHEM BIOPH RES CO, V322, P1326, DOI 10.1016/j.bbrc.2004.08.037; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rauen U, 2004, J HEPATOL, V40, P607, DOI 10.1016/j.jhep.2003.12.021; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Rempel A, 1996, CANCER RES, V56, P2468; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Rostovtseva TK, 2005, J BIOENERG BIOMEMBR, V37, P129, DOI 10.1007/s10863-005-6566-8; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Sakurai K, 2001, J BIOL CHEM, V276, P26942, DOI 10.1074/jbc.M102029200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schempp CM, 2002, ONCOGENE, V21, P1242, DOI 10.1038/sj.onc.1205190; Schinzel AC, 2005, P NATL ACAD SCI USA, V102, P12005, DOI 10.1073/pnas.0505294102; SCHNEIDER MD, 2005, SCI STKE, pPE26; Schoenfeld N, 2004, FASEB J, V18, P158, DOI 10.1096/fj.03-0420fje; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; Shinohara Y, 2000, EUR J BIOCHEM, V267, P6067, DOI 10.1046/j.1432-1327.2000.01687.x; Shoshan-Barmatz V, 2003, CELL BIOCHEM BIOPHYS, V39, P279, DOI 10.1385/CBB:39:3:279; Smaili SS, 2001, CELL DEATH DIFFER, V8, P909, DOI 10.1038/sj.cdd.4400889; SOURDEVAL M, IN PRESS APOPTOSIS; Sowter HM, 2001, CANCER RES, V61, P6669; SZABO I, 1991, J BIOL CHEM, V266, P3376; SZABO I, 1992, J BIOENERG BIOMEMBR, V24, P111, DOI 10.1007/BF00769537; Tafani M, 2001, CANCER RES, V61, P2459; Tanveer A, 1996, EUR J BIOCHEM, V238, P166, DOI 10.1111/j.1432-1033.1996.0166q.x; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Townson JL, 2003, CURR MOL MED, V3, P631, DOI 10.2174/1566524033479483; Troyano A, 2003, CELL DEATH DIFFER, V10, P889, DOI 10.1038/sj.cdd.4401249; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Valentijn AJ, 2003, J CELL BIOL, V162, P599, DOI 10.1083/jcb.200302154; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; VAYSSIERE JL, 1994, P NATL ACAD SCI USA, V91, P11752, DOI 10.1073/pnas.91.24.11752; Venturini I, 1998, LIFE SCI, V63, P1269, DOI 10.1016/S0024-3205(98)00388-9; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisinger G, 2004, BIOCHEMISTRY-US, V43, P12315, DOI 10.1021/bi030251v; Wondrak GT, 2006, J PHARMACOL EXP THER, V316, P805, DOI 10.1124/jpet.105.094953; Yang JC, 1998, BIOCHEM BIOPH RES CO, V250, P454, DOI 10.1006/bbrc.1998.9333; Yasuda S, 2004, J HEPATOL, V40, P117, DOI 10.1016/S0168-8278(03)00503-8; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739; ZUNINO S, 2005, EPUB CANC LETT	195	161	169	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4744	4756		10.1038/sj.onc.1209609	http://dx.doi.org/10.1038/sj.onc.1209609			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892087				2022-12-28	WOS:000239687000011
J	Keller, JW; Haigis, KM; Franklin, JL; Whitehead, RH; Jacks, T; Coffey, RJ				Keller, J. W.; Haigis, K. M.; Franklin, J. L.; Whitehead, R. H.; Jacks, T.; Coffey, R. J.			Oncogenic K-RAS subverts the antiapoptotic role of N-RAS and alters modulation of the N-RAS: gelsolin complex	ONCOGENE			English	Article						K-RAS; N-RAS; survival; gelsolin	PLASMA-MEMBRANE; H-RAS; PROTEIN-KINASE; REGULATORY PROTEIN; CAAX MOTIF; APOPTOSIS; CANCER; TRANSFORMATION; GROWTH; MOUSE	Activating mutations in members of the RAS family of genes are among the most common genetic events in human tumorigenesis. Once thought to be functionally interchangeable, it is increasingly recognized that the classical members of this protein family ( H-RAS, N-RAS and K-RAS4B) exhibit unique and shared functions that are highly context-dependent. Herein, we demonstrate that the presence of an oncogenic KRAS allele results in elevated levels of GTP-bound N-RAS ( N-RAS.GTP) in two human colorectal cancer cell lines, HCT 116 and DLD-1, compared to their isogenic counterparts in which the mutant KRAS allele has been disrupted by homologous recombination. N-RAS subserves an antiapoptotic role in cells expressing wild-type K-RAS; this function is compromised, however, by the presence of mutant K-RAS, and these cells display increased sensitivity to apoptotic stimuli. We additionally identify a physical interaction between N-RAS and gelsolin, a factor that has been shown to promote survival and show that the N-RAS: gelsolin complex is modulated differently in wild-type and mutant K-RAS environments following apoptotic challenge. These findings represent the first biochemical evidence of a functional relationship between endogenous RAS proteins and identify a dynamic physical interaction between endogenous N-RAS and gelsolin that correlates with survival.	Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; MIT, Canc Res Ctr, Howard Hughes Med Inst, Cambridge, MA 02139 USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Vanderbilt University; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Coffey, RJ (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Suite 4140,MRB3,465 21st Ave S, Nashville, TN 37232 USA.	robert.coffey@vanderbilt.edu			NATIONAL CANCER INSTITUTE [P50CA095103, U01CA084239, R01CA046413] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA046413, R01 CA46413, P50 CA095103, R01 CA046413-19, U01 CA084239-09, U01 CA084239, P50 CA095103-06] Funding Source: Medline; PHS HHS [U01 084239, P50 95103] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; Archer SY, 1999, CURR OPIN GENET DEV, V9, P171, DOI 10.1016/S0959-437X(99)80026-4; BOS JL, 1989, CANCER RES, V49, P4682; CANTRELL DA, 1985, P NATL ACAD SCI USA, V82, P8158, DOI 10.1073/pnas.82.23.8158; Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Diaz R, 2002, CANCER RES, V62, P4514; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hamilton M, 1998, ONCOGENE, V16, P1417, DOI 10.1038/sj.onc.1201653; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Klampfer L, 2005, ONCOGENE, V24, P3932, DOI 10.1038/sj.onc.1208552; Klampfer L, 2004, J BIOL CHEM, V279, P36680, DOI 10.1074/jbc.M405197200; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Koya RC, 2000, J BIOL CHEM, V275, P15343, DOI 10.1074/jbc.275.20.15343; Kusano H, 2000, ONCOGENE, V19, P4807, DOI 10.1038/sj.onc.1203868; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Ohtsu M, 1997, EMBO J, V16, P4650, DOI 10.1093/emboj/16.15.4650; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, J CELL SCI, V114, P1603; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Roy S, 2005, MOL CELL BIOL, V25, P6722, DOI 10.1128/MCB.25.15.6722-6733.2005; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITEHEAD RH, 1987, IN VITRO CELL DEV B, V23, P436; WILLUMSEN BM, 1984, NATURE, V310, P583, DOI 10.1038/310583a0; Wolfman JC, 2000, J BIOL CHEM, V275, P19315, DOI 10.1074/jbc.M000250200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	39	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3051	3059		10.1038/sj.onc.1210103	http://dx.doi.org/10.1038/sj.onc.1210103			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130841				2022-12-28	WOS:000246395400010
J	Nilsson, LM; Keller, UB; Yang, C; Nilsson, JA; CLeveland, JL; Roussel, MF				Nilsson, L. M.; Keller, U. B.; Yang, C.; Nilsson, J. A.; CLeveland, J. L.; Roussel, M. F.			Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis	ONCOGENE			English	Article						p18(Ink4c); Arf; Myc; lymphomagenesis	CDK INHIBITOR P18(INK4C); INDUCED APOPTOSIS; CYCLE ARREST; EXPRESSION; MICE; INDUCTION; GROWTH; GENE; DIFFERENTIATION; PROLIFERATION	p18(Ink4c) functions as a dedicated inhibitor of cyclin-D-dependent kinases. Loss of Ink4c predisposes mice to tumor development and, in a dose-dependent manner, complements the tumor-promoting effects of various oncogenes. We have now addressed whether Ink4c loss impacts B-cell tumor development in the E mu-Myc transgenic mouse, a model of human Burkitt lymphoma. Loss of one or both alleles did not influence the onset of lymphoma in E mu-Myc transgenics, and did not appreciably affect Myc's proliferative or apoptotic responses in precancerous B cells. Nevertheless, Ink4c loss modulated the effects of Myc-induced transformation by decreasing the frequency of Arf loss, an ordinarily common event in E mu-Myc-induced lymphomas.	St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Umea Univ, Dept Mol Biol, Umea, Sweden	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Umea University	Roussel, MF (corresponding author), St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, 332 N Lauderdale St, Memphis, TN 38105 USA.	martine.roussel@stjude.org	Nilsson, Jonas/E-5346-2013; Roussel, Martine F/F-1469-2016	Roussel, Martine F/0000-0002-1740-8139; Nilsson, Jonas/0000-0003-0346-6837	NCI NIH HHS [CA-21765, R01 CA-76379, CA-71907] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA076379, P01CA071907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; Bai F, 2003, MOL CELL BIOL, V23, P1269, DOI 10.1128/MCB.23.4.1269-1277.2003; Baudino TA, 2003, MOL CELL, V11, P905, DOI 10.1016/S1097-2765(03)00102-3; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Damo LA, 2005, MOL CARCINOGEN, V42, P109, DOI 10.1002/mc.20068; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2002, CANCER RES, V62, P2184; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franciotta D, 1998, CEPHALALGIA, V18, P4, DOI 10.1046/j.1468-2982.1998.1801001-5.x; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; JACOBSEN KA, 1994, BLOOD, V84, P2784; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kulkarni MS, 2002, LEUKEMIA, V16, P127, DOI 10.1038/sj.leu.2402328; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maclean KH, 2003, MOL CELL BIOL, V23, P7256, DOI 10.1128/MCB.23.20.7256-7270.2003; Morishita A, 2004, HEPATOLOGY, V40, P677, DOI 10.1002/hep.20337; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; NOWAK NJ, 2005, CURRENT PROTOCOLS HU; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; QUELLE DE, 1995, CELL, V83, P993; ROUSSEL MF, 1991, NATURE, V353, P361, DOI 10.1038/353361a0; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Sanchez-Aguilera A, 2004, BLOOD, V103, P2351, DOI 10.1182/blood-2003-07-2356; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Snijders AM, 2005, GENOME RES, V15, P302, DOI 10.1101/gr.2902505; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tourigny MR, 2002, IMMUNITY, V17, P179, DOI 10.1016/S1074-7613(02)00364-3; Uziel T, 2005, GENE DEV, V19, P2656, DOI 10.1101/gad.1368605; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yang Y, 2001, BLOOD CELL MOL DIS, V27, P1, DOI 10.1006/bcmd.2000.0344; Zindy F, 2003, CANCER RES, V63, P5420	52	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2833	2839		10.1038/sj.onc.1210104	http://dx.doi.org/10.1038/sj.onc.1210104			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099725				2022-12-28	WOS:000246210800003
J	Sengupta, S; Kim, KS; Berk, MP; Oates, R; Escobar, P; Belinson, J; Li, W; Lindner, DJ; Williams, B; Xu, Y				Sengupta, S.; Kim, K. S.; Berk, M. P.; Oates, R.; Escobar, P.; Belinson, J.; Li, W.; Lindner, D. J.; Williams, B.; Xu, Y.			Lysophosphatidic acid downregulates tissue inhibitor of metalloproteinases, which are negatively involved in lysophosphatidic acid-induced cell invasion	ONCOGENE			English	Article						lysophosphatidic acid; LPA receptors; metastasis; ovarian cancer; tissue inhibitor of metalloproteinases	OVARIAN-CANCER CELLS; ENDOTHELIAL GROWTH-FACTOR; IN-VITRO; CARCINOMA CELLS; MIGRATION; EXPRESSION; LYSOPHOSPHOLIPIDS; PATHWAY; KINASE; LPA	Ovarian cancer is a highly metastatic disease. Lysophosphatidic acid (LPA) levels are elevated in ascites from ovarian cancer patients, but its potential role in ovarian cancer metastasis has just begun to be revealed. In this work, we show that LPA stimulates invasion of primary ovarian cancer cells, but not ovarian epithelial or borderline ovarian tumor cells, although these benign cells indeed respond to LPA in cell migration. We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs). TIMP2 and TIMP3 play functional role in LPA-induced invasion as negative regulators. G(i) protein, phosphatidylinositol-3 kinase (PI3K), p38 mitogen-activated protein kinase (MAPK), cytosolic phospholipase A(2) and urokinase type plasminogen activator (uPA) are required for LPA-induced cells invasion. TIMP3 may affect two independent downstream targets, vascular endothelial growth factor receptor and p38 MAPK. In vivo, LPA stimulates tumor metastasis in an orthotopic ovarian tumor model, which can be inhibited by a PI3K inhibitor, LY294002. In summary, LPA is likely a key component for promoting ovarian metastasis in vivo. LPA downregulates TIMP3, which may have targets other than metalloproteinases. Our in vivo metastasis mouse model is useful for studying the efficacy of therapeutic regimes of ovarian cancer.	Indiana Univ, Dept Obstet & Gynecol, Indianapolis, IN 46202 USA; Cleveland Clin, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44106 USA; Cleveland Clin, Dept Obstet & Gynecol, Cleveland, OH 44106 USA; Chonbuk Natl Univ, Sch Med, Dept Obstet & Gynecol, Chonju, Chonbuk, South Korea; Cleveland Clin, Taussig Canc Ctr, Dept Drug Discovery & Dev, Cleveland, OH 44106 USA; Harvard Univ, Sch Med, Harvard Inst Proteom, Cambridge, MA 02138 USA; Monash Inst Med Res, Clayton, Vic, Australia	Indiana University System; Indiana University-Purdue University Indianapolis; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Jeonbuk National University; Cleveland Clinic Foundation; Harvard University; Harvard Medical School; Monash University	Xu, Y (corresponding author), Indiana Univ, Dept Obstet & Gynecol, 975 W Walnut St IB355A, Indianapolis, IN 46202 USA.	xu2@iupui.eud	Williams, Bryan R. G./A-5021-2009; Lindner, Daniel/ABB-5440-2020; Berk, Michael/M-7891-2013; Berk, Michael/M-3585-2019	Williams, Bryan R. G./0000-0002-4969-1151; Berk, Michael/0000-0002-5554-6946; Berk, Michael/0000-0002-5554-6946	NCI NIH HHS [R01 CA095042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Bian D, 2006, ONCOGENE, V25, P2234, DOI 10.1038/sj.onc.1209261; Bian DF, 2004, CANCER RES, V64, P4209, DOI 10.1158/0008-5472.CAN-04-0060; Cai Wei, 2002, Ai Zheng, V21, P91; Casey RC, 2003, CLIN EXP METASTAS, V20, P343, DOI 10.1023/A:1024009131191; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fishman DA, 2001, CANCER RES, V61, P3194; Hartsough MT, 2000, J BIOENERG BIOMEMBR, V32, P301, DOI 10.1023/A:1005597231776; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hu LM, 2002, CANCER RES, V62, P1087; Hu LM, 2000, CLIN CANCER RES, V6, P880; Hu Xiao-Xia, 2004, Ai Zheng, V23, P1194; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; KIM KS, 2006, CANCER RES, V66, P3006; Krol J, 2003, BIOL CHEM, V384, P1097, DOI 10.1515/BC.2003.122; KROO J, 2003, BIOL CHEM, V384, P1085; Li HB, 2005, J BIOL CHEM, V280, P10564, DOI 10.1074/jbc.M412152200; Manenti L, 2003, EUR J CANCER, V39, P1948, DOI 10.1016/S0959-8049(03)00427-1; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Qian L, 2003, J MED CHEM, V46, P5575, DOI 10.1021/jm034207p; Rauvala M, 2005, GYNECOL ONCOL, V99, P656, DOI 10.1016/j.ygyno.2005.07.009; Ren J, 2006, CANCER RES, V66, P3006, DOI 10.1158/0008-5472.CAN-05-1292; Sakamaki Y, 2002, ECOL RES, V17, P673, DOI 10.1046/j.1440-1703.2002.00525.x; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2003, FASEB J, V17, P1570, DOI 10.1096/fj.02-1145fje; Sengupta S, 2004, SEMIN CELL DEV BIOL, V15, P503, DOI 10.1016/j.semcdb.2004.05.003; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; So J, 2005, GYNECOL ONCOL, V97, P870, DOI 10.1016/j.ygyno.2005.03.004; So J, 2004, GYNECOL ONCOL, V95, P314, DOI 10.1016/j.ygyno.2004.08.001; Sugimoto N, 2006, EXP CELL RES, V312, P1899, DOI 10.1016/j.yexcr.2006.02.020; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Wang XP, 2005, J TRANSL MED, V3, DOI 10.1186/1479-5876-3-25; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223	44	57	59	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2894	2901		10.1038/sj.onc.1210093	http://dx.doi.org/10.1038/sj.onc.1210093			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17130843				2022-12-28	WOS:000246210800009
J	Wang, L; Kurosaki, T; Corey, SJ				Wang, L.; Kurosaki, T.; Corey, S. J.			Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway	ONCOGENE			English	Article						Lyn; STAT; Jak; B-cell antigen receptor	STIMULATING FACTOR-RECEPTOR; TYROSINE KINASE; BCR-ABL; NUCLEAR EXPRESSION; PROTEIN; SRC; PHOSPHORYLATION; REGIONS; SITE; SYK	Engagement of the B-cell antigen receptor (BCR) initiated by the Src kinase Lyn triggers rapid signaling cascades, leading to proliferation, differentiation or growth arrest of B cells. The Janus kinase (JAK)-STAT (signal transducer and activator of transcription) pathway, activated through cytokine receptors, mediates similar responses. Hypothesizing that Src and JAK pathways engage in crosstalk in B-cell signaling, we studied wild-type and Lyn-null B-cell lines, which express BCR. We found that activated BCR results in tyrosine phosphorylation of JAK-STAT, which required Lyn. To confirm that STAT activation is not due to JAK, we cloned the chicken homologs of JAK1 and JAK2 and made their antisense constructs. In cells expressing antisense JAK1 and JAK2, tyrosine phosphorylation of STAT was not inhibited following BCR stimulation. Using activation loop-specific phosphotyrosine antibodies, we did not detect phospho-JAK1 and phospho-JAK2 after BCR stimulation. The JAK inhibitor AG490 did not inhibit the tyrosine phosphorylation of Lyn or STAT after BCR simulation. An in vitro phosphorylation assay showed that Lyn directly phosphorylates STAT3. In an electrophoretic mobility shift assay, BCR stimulation led to enhanced DNA binding of the STAT3 in DT40, but not in the Lyn-null cells. We conclude that BCR engagement activates the STAT pathway via Lyn, independent of JAK.	Univ Texas, MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA; RIKEN, Lymphocyte Differentiat Res Ctr Allergy & Immunol, Yokohama, Kanagawa, Japan	University of Texas System; UTMD Anderson Cancer Center; RIKEN	Corey, SJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Div Pediat, 1515 Holcombe Blvd,Unit 853, Houston, TX 77030 USA.	sjcorey@mdanderson.org	Kurosaki, Tomohiro/D-1306-2009	Kurosaki, Tomohiro/0000-0002-6352-304X				Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chin H, 1998, BLOOD, V91, P3734; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Coppo P, 2003, ONCOGENE, V22, P4102, DOI 10.1038/sj.onc.1206607; Corey SJ, 1998, J BIOL CHEM, V273, P3230, DOI 10.1074/jbc.273.6.3230; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; DeFranco AL, 1995, ANN NY ACAD SCI, V766, P195, DOI 10.1111/j.1749-6632.1995.tb26662.x; Dorsey JF, 2002, LEUKEMIA, V16, P1589, DOI 10.1038/sj.leu.2402678; Fan H, 2001, EUR J IMMUNOL, V31, P665, DOI 10.1002/1521-4141(200102)31:2<665::AID-IMMU665>3.0.CO;2-1; FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; Ihle J N, 1995, Semin Immunol, V7, P247, DOI 10.1006/smim.1995.0029; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Ishikawa H, 2002, BLOOD, V99, P2172, DOI 10.1182/blood.V99.6.2172; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Karras JG, 1996, J IMMUNOL, V157, P2299; Karras JG, 1996, J IMMUNOL, V157, P39; Keshvara LM, 1998, J IMMUNOL, V161, P5276; Koay DC, 2002, CELL SIGNAL, V14, P239, DOI 10.1016/S0898-6568(01)00237-6; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Mirnics ZK, 2004, J IMMUNOL, V172, P4133, DOI 10.4049/jimmunol.172.7.4133; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; NICHOLSON SE, 1995, BLOOD, V86, P3698, DOI 10.1182/blood.V86.10.3698.bloodjournal86103698; Okutani Y, 2001, ONCOGENE, V20, P6643, DOI 10.1038/sj.onc.1204807; Pereira S, 2003, J IMMUNOL, V171, P1319, DOI 10.4049/jimmunol.171.3.1319; Saharinen P, 2003, MOL BIOL CELL, V14, P1448, DOI 10.1091/mbc.E02-06-0342; SAOUAF SJ, 1994, P NATL ACAD SCI USA, V91, P9524, DOI 10.1073/pnas.91.20.9524; Sarmay G, 1997, IMMUNOL LETT, V57, P159, DOI 10.1016/S0165-2478(97)00055-2; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Sternberg DW, 2004, J CLIN ONCOL, V22, P361, DOI 10.1200/JCO.2004.10.124; Su L, 1999, J BIOL CHEM, V274, P31770, DOI 10.1074/jbc.274.45.31770; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TWEARDY DJ, 1995, BLOOD, V86, P4409, DOI 10.1182/blood.V86.12.4409.bloodjournal86124409; Wahl MI, 1997, P NATL ACAD SCI USA, V94, P11526, DOI 10.1073/pnas.94.21.11526; Winding P, 2001, J IMMUNOL METHODS, V249, P1, DOI 10.1016/S0022-1759(00)00333-1; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 1997, J IMMUNOL, V159, P5206; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	43	42	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2851	2859		10.1038/sj.onc.1210092	http://dx.doi.org/10.1038/sj.onc.1210092			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146444				2022-12-28	WOS:000246210800005
J	Bloch, M; Ousingsawat, J; Simon, R; Schraml, P; Gasser, TC; Mihatsch, MJ; Kunzelmann, K; Bubendorf, L				Bloch, M.; Ousingsawat, J.; Simon, R.; Schraml, P.; Gasser, T. C.; Mihatsch, M. J.; Kunzelmann, K.; Bubendorf, L.			KCNMA1 gene amplification promotes tumor cell proliferation in human prostate cancer	ONCOGENE			English	Article						prostate cancer; progression; amplification; BK channel; KCNMA1	COMPARATIVE GENOMIC HYBRIDIZATION; ACTIVATED POTASSIUM CHANNELS; MAXI-K CHANNELS; LARGE-CONDUCTANCE; EPITHELIAL-CELLS; UROKINASE GENE; BREAST-CANCER; BK CHANNELS; RECEPTOR; KINASE	Molecular mechanisms of prostate cancer progression are poorly understood. Here, we studied gene amplification of the large conductance calcium-activated potassium channel alpha subunit (KCNMA1), which is located at the chromosomal region 10q22. Fluorescence in situ hybridization ( FISH) revealed KCNMA1 amplification in 16% of 119 late-stage human prostate cancers and in the hormone-insensitive prostate cancer cell line PC-3. In contrast, KCNMA1 amplification was absent in 33 benign controls, 32 precursor lesions and in 105 clinically organ-confined prostate cancers. Amplification was associated with mRNA and protein overexpression as well as increased density of BK channel protein and beta-estradiol-insensitive BK currents in PC-3 cells as compared to non-amplified control cell lines. Specific blockade of BK channels by iberiotoxin or RNA(i) significantly inhibited K+ currents and growth of PC-3 cells. The data demonstrate that 10q22 amplification drives KCNMA1 expression and cell proliferation. Thus, KCNMA1 qualifies as a promising diagnostic and therapeutic target in patients with prostate cancer.	Univ Basel Hosp, Inst Pathol, CH-4003 Basel, Switzerland; Univ Regensburg, Dept Physiol, D-8400 Regensburg, Germany; Univ Basel, Dept Urol, Liestal, Switzerland	University of Basel; University of Regensburg; University of Basel	Bubendorf, L (corresponding author), Univ Basel Hosp, Inst Pathol, Schonbeinstr 40, CH-4003 Basel, Switzerland.	lbubendorf@uhbs.ch	Bubendorfl, Lukas/H-5880-2011; Bubendorf, Lukas/G-5299-2015	Bubendorf, Lukas/0000-0001-5970-1803; Kunzelmann, Karl/0000-0002-4583-7037				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Amberg GC, 2003, J CLIN INVEST, V112, P717, DOI 10.1172/JC1200318684; Amberg GC, 2003, CIRC RES, V93, P965, DOI 10.1161/01.RES.0000100068.43006.36; Basrai D, 2002, NEUROREPORT, V13, P403, DOI 10.1097/00001756-200203250-00008; Bernardino J, 1997, CANCER GENET CYTOGEN, V96, P123, DOI 10.1016/S0165-4608(96)00258-0; Calderone V, 2002, CURR MED CHEM, V9, P1385, DOI 10.2174/0929867023369871; Christow SP, 1999, EUR J BIOCHEM, V265, P264, DOI 10.1046/j.1432-1327.1999.00729.x; Coiret G, 2005, FEBS LETT, V579, P2995, DOI 10.1016/j.febslet.2005.02.085; Conti DJ, 2004, AM J TRANSPLANT, V4, P166; Davies AG, 2003, CELL, V115, P655, DOI 10.1016/S0092-8674(03)00979-6; El Gedaily A, 2001, PROSTATE, V46, P184; GALVEZ A, 1990, J BIOL CHEM, V265, P11083; HAYWARD SW, 1995, IN VITRO CELL DEV-AN, V31, P14; Helenius MA, 2006, BJU INT, V97, P404, DOI 10.1111/j.1464-410X.2005.05912.x; Helenius MA, 2001, CANCER RES, V61, P5340; Henke G, 2004, J CELL PHYSIOL, V199, P194, DOI 10.1002/jcp.10430; Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1&lt;60::AID-IJC11&gt;3.0.CO;2-B; KAIGHN ME, 1979, INVEST UROL, V17, P16; Kauraniemi P, 2001, CANCER RES, V61, P8235; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Koochekpour S, 2005, GENE CHROMOSOME CANC, V44, P351, DOI 10.1002/gcc.20249; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lau KM, 2000, CANCER RES, V60, P3175; MCCOBB DP, 1995, AM J PHYSIOL, V269, P767; O'Grady SM, 2005, INT J BIOCHEM CELL B, V37, P1578, DOI 10.1016/j.biocel.2005.04.002; O'Malley D, 2004, MOL PHARMACOL, V65, P1352, DOI 10.1124/mol.65.6.1352; Olsen ML, 2005, J NEUROSCI RES, V81, P179, DOI 10.1002/jnr.20543; Orio P, 2002, NEWS PHYSIOL SCI, V17, P156, DOI 10.1152/nips.01387.2002; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 2004, PHYSIOLOGY, V19, P285, DOI 10.1152/physiol.00011.2004; Parihar AS, 2003, EUR J PHARMACOL, V471, P157, DOI 10.1016/S0014-2999(03)01825-9; Pei L, 2003, P NATL ACAD SCI USA, V100, P7803, DOI 10.1073/pnas.1232448100; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Quirk JC, 2001, NEURON, V32, P13, DOI 10.1016/S0896-6273(01)00444-5; Rebhan M, 1997, TRENDS GENET, V13, P163, DOI 10.1016/S0168-9525(97)01103-7; Reiter RE, 2000, GENE CHROMOSOME CANC, V27, P95, DOI 10.1002/(SICI)1098-2264(200001)27:1<95::AID-GCC12>3.0.CO;2-3; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Sausbier M, 2006, J AM SOC NEPHROL, V17, P1275, DOI 10.1681/ASN.2005101111; TSENGCRANK J, 1994, NEURON, V13, P1315, DOI 10.1016/0896-6273(94)90418-9; Valverde MA, 1999, SCIENCE, V285, P1929, DOI 10.1126/science.285.5435.1929; Van Coppenolle F, 2004, BIOCHEM J, V377, P569, DOI 10.1042/BJ20030859; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Wang ZG, 2004, PFLUG ARCH EUR J PHY, V448, P274, DOI 10.1007/s00424-004-1258-5; Weaver AK, 2004, J NEUROSCI RES, V78, P224, DOI 10.1002/jnr.20240; Zhou XB, 2000, AM J PHYSIOL-CELL PH, V279, pC1751, DOI 10.1152/ajpcell.2000.279.6.C1751	48	101	108	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2525	2534		10.1038/sj.onc.1210036	http://dx.doi.org/10.1038/sj.onc.1210036			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17146446				2022-12-28	WOS:000245831000014
J	Vincan, E; Darcy, PK; Farrelly, CA; Faux, MC; Brabletz, T; Ramsay, RG				Vincan, E.; Darcy, P. K.; Farrelly, C. A.; Faux, M. C.; Brabletz, T.; Ramsay, R. G.			Frizzled-7 dictates three-dimensional organization of colorectal cancer cell carcinoids	ONCOGENE			English	Article						frizzled-7; Wnt signalling; colorectal cancer; carcinoma morphogenesis	EPITHELIAL-MESENCHYMAL TRANSITIONS; LAMININ-5 GAMMA-2 CHAIN; BETA-CATENIN EXPRESSION; TRANSCRIPTIONAL ACTIVATION; EPIGENETIC INACTIVATION; SIGNALING CONTROLS; WNT; DIFFERENTIATION; RECEPTOR; XENOPUS	Progression of colorectal cancer (CRC) involves spatial and temporal occurrences of epithelial-mesenchymal transition (EMT), whereby tumour cells acquire a more invasive and metastatic phenotype. Subsequently, the disseminated mesenchymal tumour cells must undergo a reverse transition (mesenchymal-epithelial transition, MET) at the site of metastases, as most metastases recapitulate the pathology of their corresponding primary tumours. Importantly, initiation of tumour growth at the secondary site is the rate-limiting step in metastasis. However, investigation of this dynamic reversible EMT and MET that underpins CRC morphogenesis has been hindered by a lack of suitable in vitro models. To this end, we have established a unique in vitro model of CRC morphogenesis, which we term LIM1863-Mph (morphogenetic). LIM1863-Mph cells spontaneously undergo cyclic transitions between two-dimensional monolayer (migratory, mesenchymal) and three-dimensional sphere (carcinoid, epithelial) states. Using RNAi, we demonstrate that FZD7 is necessary for MET of the monolayer cells as loss of FZD7 results in the persistence of a mesenchymal state (increased SNAI2/decreased E-cadherin). Moreover, FZD7 is also required for migration of the LIM1863-Mph monolayer cells. During development, FZD7 orchestrates either migratory or epithelialization events depending on the context. Our findings strongly implicate similar functional diversity for FZD7 during CRC morphogenesis.	Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3001, Australia; Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3052, Australia; Ludwig Inst Canc Res, Parkville, Vic, Australia; Univ Erlangen Nurnberg, Dept Pathol, Erlangen, Germany	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Ludwig Institute for Cancer Research; University of Erlangen Nuremberg	Vincan, E (corresponding author), Peter MacCallum Canc Ctr, Div Res, St Andrews Pl, Melbourne, Vic 3001, Australia.	Elizabeth.Vincan@petermac.org	Ramsay, Robert G/C-3291-2015	Ramsay, Robert G/0000-0001-5003-0433; Darcy, Phillip/0000-0002-5303-9561; Vincan, Elizabeth/0000-0002-8607-4849				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; BATES R, 2005, 2 EMT M VANC; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Burstyn-Cohen T, 2004, DEVELOPMENT, V131, P5327, DOI 10.1242/dev.01424; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carroll TJ, 2005, DEV CELL, V9, P283, DOI 10.1016/j.devcel.2005.05.016; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; De Calisto J, 2005, DEVELOPMENT, V132, P2587, DOI 10.1242/dev.01857; Djiane A, 2000, DEVELOPMENT, V127, P3091; Eckhardt BL, 2005, MOL CANCER RES, V3, P1; Frisch SM, 1997, BIOESSAYS, V19, P705, DOI 10.1002/bies.950190811; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gilles C, 2001, J CELL SCI, V114, P2967; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; HAYWARD IP, 1995, IMMUNOL CELL BIOL, V73, P249, DOI 10.1038/icb.1995.41; HAYWARD IP, 1992, INT J CANCER, V50, P752, DOI 10.1002/ijc.2910500515; Heath JK, 1997, P NATL ACAD SCI USA, V94, P469, DOI 10.1073/pnas.94.2.469; Hlubek F, 2004, INT J CANCER, V108, P321, DOI 10.1002/ijc.11522; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kao KR, 1998, BIOL CELL, V90, P585, DOI 10.1016/S0248-4900(99)80016-1; Kirchner T, 2000, AM J PATHOL, V157, P1113, DOI 10.1016/S0002-9440(10)64626-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2002, SEMIN CELL DEV BIOL, V13, P243, DOI 10.1016/S1084-9521(02)00050-2; Linker C, 2005, DEVELOPMENT, V132, P3895, DOI 10.1242/dev.01961; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Minobe S, 2000, DEV GENES EVOL, V210, P258, DOI 10.1007/s004270050312; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; PYKE C, 1995, CANCER RES, V55, P4132; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Schmidt C, 2004, DEV BIOL, V271, P198, DOI 10.1016/j.ydbio.2004.03.016; Schubert FR, 2002, MECH DEVELOP, V114, P143, DOI 10.1016/S0925-4773(02)00039-4; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; THOMPSON EW, 1993, CLIN EXP METASTAS, V11, P15, DOI 10.1007/BF00880062; Thompson MA, 1998, CANCER RES, V58, P5168; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Vincan E, 2005, DIFFERENTIATION, V73, P142, DOI 10.1111/j.1432-0436.2005.00015.x; Vincan E, 2004, FRONT BIOSCI-LANDMRK, V9, P1023, DOI 10.2741/1311; WHITEHEAD RH, 1987, CANCER RES, V47, P2683; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621	53	53	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2340	2352		10.1038/sj.onc.1210026	http://dx.doi.org/10.1038/sj.onc.1210026			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016432				2022-12-28	WOS:000245466000010
J	Berlingieri, MT; Pallante, P; Guida, M; Nappi, C; Masciullo, V; Scambia, G; Ferraro, A; Leone, V; Sboner, A; Barbareschi, M; Ferro, A; Troncone, G; Fusco, A				Berlingieri, M. T.; Pallante, P.; Guida, M.; Nappi, C.; Masciullo, V.; Scambia, G.; Ferraro, A.; Leone, V.; Sboner, A.; Barbareschi, M.; Ferro, A.; Troncone, G.; Fusco, A.			UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas	ONCOGENE			English	Article						UbcH10; ovarian; carcinomas; immunohistochemistry	CANCER; OVEREXPRESSION; BREAST	The UbcH10 gene codes for a protein that belongs to the ubiquitin-conjugating enzyme family. Previous studies of our group suggest UbcH10 expression as a valid indicator of the proliferative and aggressive status of thyroid carcinomas. Therefore, to better understand the process of ovarian carcinogenesis, and to look for possible tools to be used as prognostic markers in these neoplasias, we decided to extend the analysis of the UbcH10 expression to the ovarian neoplastic disease. We found that the UbcH10 gene was upregulated in some ovarian carcinoma cell lines analysed. Then, immunohistochemical studies demonstrate that UbcH10 expression significantly correlates with the tumor grade and the undifferentiated histotype of the ovarian carcinomas. Furthermore, a significant relationship between UbcH10 expression and overall survival was observed. Finally, the block of UbcH10 protein synthesis by RNA interference inhibited the growth of ovarian carcinoma cell lines, suggesting a role of UbcH10 overexpression in ovarian carcinogenesis. Therefore, all these data taken together suggest the possibility to use UbcH10 detection as a marker for the diagnosis and prognosis of these neoplastic diseases and open the perspective of a therapy of some ovarian carcinomas based on the suppression of the UbcH10 synthesis and/or function.	Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Mol, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Ginecol & Ostetr, I-80131 Naples, Italy; Univ Naples Federico II, Fac Med, Dipartimento Fisiopatol Riproduz Umana, I-80131 Naples, Italy; Univ Naples Federico II, Chirurg Napoli, I-80131 Naples, Italy; Univ Cattolica S Cuore, Ist Clin Ostet & Ginecol, Rome, Italy; European Sch Mol Med, SEMM, Naples, Italy; Naples Oncogenom Ctr, CEINGE, NOGEC, Naples, Italy; Ctr Sci & Technol Res, SRA Div ITC Irst, Trento, Italy; UO Anatomia Patol Osped S Chiara Largo Medaglie O, Trento, Italy; Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Anat Patol & Citopatol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; University of Naples Federico II; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; CEINGE Biotecnologie Avanzate; University of Naples Federico II	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, Dipartimento Biol & Patol Cellulare, Ist Endocrinol & Oncol Sperimenatle,CNR, I-80131 Naples, Italy.	afusco@napoli.com	Ferro, Antonella/AAA-8241-2020; Pallante, Pierlorenzo/AAX-8758-2020; Ferraro, Angelo/A-4172-2014; Sboner, Andrea/C-6487-2008; Barbareschi, Mattia/AAF-2043-2020; Ferraro, Angelo/H-3193-2019	Ferro, Antonella/0000-0003-4109-6769; Ferraro, Angelo/0000-0002-2044-7569; Sboner, Andrea/0000-0001-6915-3070; Ferraro, Angelo/0000-0002-2044-7569; Fusco, Alfredo/0000-0003-3332-5197				ALDOVINI D, 2006, INT J CANCER, P27; [Anonymous], 2003, WHO CLASSIFICATION T; Benedet JL, 2000, INT J GYNECOL OBSTET, V70, P209; Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Liu Xueli, 2004, J Biopharm Stat, V14, P671, DOI 10.1081/BIP-200025657; Masciullo V, 2003, CARCINOGENESIS, V24, P1191, DOI 10.1093/carcin/bgg075; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Pallante P, 2005, BRIT J CANCER, V93, P464, DOI 10.1038/sj.bjc.6602721; PIERANTONI GM, 2005, CELL DEATH DIFFER, P1; *R DEV COR TEAM, 2004, LANG ENV STAT COMP; Troncone G, 2003, J CLIN PATHOL, V56, P587, DOI 10.1136/jcp.56.8.587; VACHERLAVENU MC, 1993, B CANCER, V80, P135; Wagner KW, 2004, ONCOGENE, V23, P6621, DOI 10.1038/sj.onc.1207861; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705	17	63	72	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2136	2140		10.1038/sj.onc.1210010	http://dx.doi.org/10.1038/sj.onc.1210010			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016443				2022-12-28	WOS:000245313400016
J	Bhatt, KV; Hu, R; Spofford, LS; Aplin, AE				Bhatt, K. V.; Hu, R.; Spofford, L. S.; Aplin, A. E.			Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27(Kip1) in human melanoma cells	ONCOGENE			English	Article						adhesion; cell cycle; melanocyte; proteasome	CDK INHIBITOR P27; UBIQUITIN LIGASE; S-PHASE; DEPENDENT DEGRADATION; MALIGNANT-MELANOMA; NUCLEAR EXPORT; BRAF MUTATIONS; SKP2; EXPRESSION; PROGRESSION	Levels of cyclins and cyclin-dependent kinase (Cdk) inhibitors are tightly controlled during normal cell proliferation and are frequently dysregulated in cancerous cells. In melanoma, cyclin D1 is highly expressed and downregulation of the Cdk inhibitor, p27(Kip1), is associated with a poor prognosis. Mutant B-RAF is frequently expressed in melanoma and overrides growth factor and matrix adhesion control of cyclin D1 and p27(Kip1) levels in human melanocytes. Here, we demonstrate that p27(Kip1) expression is regulated by multiple mechanisms in melanoma cells. B-RAF regulates p27(Kip1) mRNA abundance independently of cyclin D1. Additionally, B-RAF and cyclin D1 control the levels of S-phase kinase-associated protein 2 (Skp2) that directs ubiquitin-mediated proteolysis of p27(Kip1). The cofactor for Skp2, Cdc kinase subunit 1 (Cks1) controls levels of Skp2 in melanoma cells and acts jointly with Skp2 to regulate p27(Kip1) levels. Importantly, expression of Cks1 is regulated by B-RAF and cyclin D1 at the mRNA level. Reduced Cks1 or Skp2 expression and enhanced p27(Kip1) levels inhibit melanoma cell growth. In summary, p27(Kip1) expression in melanoma is regulated by B-RAF at the mRNA level, and via B-RAF and cyclin D1 control of Cks1/Skp2- mediated proteolysis.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Aplin, AE (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, MC-165,47 New Scotland Ave, Albany, NY 12208 USA.	aplina@mail.amc.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067893] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM067893] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Bond M, 2004, J BIOL CHEM, V279, P37304, DOI 10.1074/jbc.M404307200; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Collisson EA, 2003, CANCER RES, V63, P5669; Conner SR, 2003, J BIOL CHEM, V278, P34548, DOI 10.1074/jbc.M305797200; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Delmas C, 2003, J BIOL CHEM, V278, P12443, DOI 10.1074/jbc.M209523200; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Florenes VA, 1998, AM J PATHOL, V153, P305, DOI 10.1016/S0002-9440(10)65572-1; Galan JM, 1999, P NATL ACAD SCI USA, V96, P9124, DOI 10.1073/pnas.96.16.9124; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Garriga J, 2003, MOL CELL BIOL, V23, P5165, DOI 10.1128/MCB.23.15.5165-5173.2003; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Henriet P, 2000, P NATL ACAD SCI USA, V97, P10026, DOI 10.1073/pnas.170290997; Hingorani SR, 2003, CANCER RES, V63, P5198; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Ishida N, 2002, J BIOL CHEM, V277, P14355, DOI 10.1074/jbc.C100762200; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kamura T, 2003, P NATL ACAD SCI USA, V100, P10231, DOI 10.1073/pnas.1831009100; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Katagiri Y, 2006, J DERMATOL SCI, V42, P215, DOI 10.1016/j.jdermsci.2005.12.016; Kawana H, 1998, AM J PATHOL, V153, P505, DOI 10.1016/S0002-9440(10)65593-9; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li Q, 2004, J CUTAN PATHOL, V31, P633, DOI 10.1111/j.0303-6987.2004.00243.x; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Mirza AM, 2004, MOL CELL BIOL, V24, P10868, DOI 10.1128/MCB.24.24.10868-10881.2004; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Mori M, 1997, NAT MED, V3, P593, DOI 10.1038/nm0697-593; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sauter ER, 2002, CANCER RES, V62, P3200; Shapira M, 2004, CANCER-AM CANCER SOC, V100, P1615, DOI 10.1002/cncr.20172; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Sumimoto H, 2006, INT J CANCER, V118, P472, DOI 10.1002/ijc.21286; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang W, 2004, ONCOGENE, V23, P1064, DOI 10.1038/sj.onc.1207204; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Woenckhaus C, 2005, HISTOL HISTOPATHOL, V20, P501, DOI 10.14670/HH-20.501; Zhu XH, 2004, MOL CELL BIOL, V24, P6058, DOI 10.1128/MCB.24.13.6058-6066.2004	68	59	59	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1056	1066		10.1038/sj.onc.1209861	http://dx.doi.org/10.1038/sj.onc.1209861			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16924241				2022-12-28	WOS:000244245400012
J	Singh, AP; Chauhan, SC; Andrianifahanana, M; Moniaux, N; Meza, JL; Copin, MC; van Seuningen, I; Hollingsworth, MA; Aubert, JP; Batra, SK				Singh, A. P.; Chauhan, S. C.; Andrianifahanana, M.; Moniaux, N.; Meza, J. L.; Copin, M. C.; van Seuningen, I.; Hollingsworth, M. A.; Aubert, J. P.; Batra, S. K.			MUC4 expression is regulated by cystic fibrosis transmembrane conductance regulator in pancreatic adenocarcinoma cells via transcriptional and post-translational mechanisms	ONCOGENE			English	Article						MUC4; CFTR; pancreatic adenocarcinoma	KAPPA-B ACTIVATION; GENE-EXPRESSION; MUC4/SIALOMUCIN COMPLEX; SIALOMUCIN COMPLEX; SIGNALING PATHWAY; EPITHELIAL-CELLS; CANCER-CELLS; TUMOR-CELLS; DUCT CELLS; T84 CELLS	MUC4 mucin is a high molecular weight transmembrane glycoprotein that plays important roles in tumour biology. It is aberrantly expressed in pancreatic adenocarcinoma, while not being detectable in the normal pancreas. Previous studies have demonstrated that the cystic. brosis transmembrane conductance regulator (CFTR), a chloride channel that is defective in CF, is implicated in multiple cellular functions, including gene regulation. In the present study, using a CFTR-defective pancreatic cancer cell line and its derived subline expressing functional CFTR, we report that MUC4 expression is negatively regulated by CFTR. Short-interfering RNA (siRNA)mediated silencing of CFTR also leads to an increased expression of MUC4. Additionally, our results suggest that CFTR-mediated regulation of MUC4 is cell density-dependent and is achieved by transcriptional and post-translational mechanisms. Moreover, in a panel of pancreatic cancer cell lines and normal pancreas, we observed that CFTR was downregulated in pancreatic cancer cells and negatively correlated with MUC4 in most cases. An aberrant expression of MUC4 was also detected in the CF pancreas. Downregulation of CFTR in pancreatic adenocarcinoma and its inverse association with the tumour-linked mucin, MUC4, indicate novel function(s) of CFTR in pancreatic tumour biology and suggest the implication of new signalling pathway(s) in MUC4 regulation.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Biostat Sect, Omaha, NE 68198 USA; INSERM, U560, F-59045 Lille, France	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm)	Batra, SK (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.	sbatra@unmc.edu	Moniaux, Nicolas/Y-3243-2018; Singh, Ajay/AAF-4414-2020; VAN SEUNINGEN, Isabelle/N-6176-2016	Moniaux, Nicolas/0000-0001-9718-1386; VAN SEUNINGEN, Isabelle/0000-0002-3131-2694; Singh, Ajay/0000-0003-3492-6330	NCI NIH HHS [R01 CA78590] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078590] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham EH, 1996, NAT MED, V2, P593, DOI 10.1038/nm0596-593; Andrianifahanana M, 2001, CLIN CANCER RES, V7, P4033; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BREUER W, 1993, J BIOL CHEM, V268, P13935; Buisine MP, 1998, GUT, V43, P519, DOI 10.1136/gut.43.4.519; Buisine MP, 2000, J HISTOCHEM CYTOCHEM, V48, P1667, DOI 10.1177/002215540004801210; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Davenport SE, 1996, BIOCHEM BIOPH RES CO, V229, P663, DOI 10.1006/bbrc.1996.1861; Debailleul V, 1998, J BIOL CHEM, V273, P881, DOI 10.1074/jbc.273.2.881; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; DRUMM ML, 1990, CELL, V62, P1227, DOI 10.1016/0092-8674(90)90398-X; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Estell K, 2003, MOL CELL BIOL, V23, P594, DOI 10.1128/MCB.23.2.594-606.2003; Gonzalez-Guerrico AM, 2002, J BIOL CHEM, V277, P17239, DOI 10.1074/jbc.M112456200; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinojosa-Kurtzberg AM, 2003, AM J PHYSIOL-GASTR L, V284, pG853, DOI 10.1152/ajpgi.00326.2002; Hokari R, 2005, AM J PHYSIOL-GASTR L, V289, pG949, DOI 10.1152/ajpgi.00142.2005; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacobuzio-Donahue CA, 2003, CANCER RES, V63, P8614; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Karan D, 2003, BIOCHEM BIOPH RES CO, V305, P598, DOI 10.1016/S0006-291X(03)00823-4; Komatsu M, 2001, ONCOGENE, V20, P461, DOI 10.1038/sj.onc.1204106; Komatsu M, 1999, CANCER RES, V59, P2229; Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO;2-6; Malats N, 2001, GUT, V48, P70, DOI 10.1136/gut.48.1.70; MALMBERG EK, 2006, IN PRESS AM J PHYSL; Mariette C, 2004, BIOCHEM J, V377, P701, DOI 10.1042/BJ20031132; McWilliams R, 2005, GUT, V54, P1661, DOI 10.1136/gut.2005.074534; Namkung W, 2003, J BIOL CHEM, V278, P200, DOI 10.1074/jbc.M207199200; NEGLIA JP, 1995, NEW ENGL J MED, V332, P494, DOI 10.1056/NEJM199502233320803; Park Hee-Ug, 2003, Pancreas, V26, pe48, DOI 10.1097/00006676-200304000-00022; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHOUMACHER RA, 1990, P NATL ACAD SCI USA, V87, P4012, DOI 10.1073/pnas.87.10.4012; SHELDON CD, 1993, BRIT J CANCER, V68, P1025, DOI 10.1038/bjc.1993.474; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; Soto P, 2003, J BIOL CHEM, V278, P20338, DOI 10.1074/jbc.M301886200; Steagall WK, 2000, AM J RESP CELL MOL, V22, P45, DOI 10.1165/ajrcmb.22.1.3789; Swartz MJ, 2002, AM J CLIN PATHOL, V117, P791; Tabary O, 1999, AM J PATHOL, V155, P473, DOI 10.1016/S0002-9440(10)65143-7; Thomsson KA, 2002, BIOCHEM J, V367, P609, DOI 10.1042/BJ20020371; Uribe JM, 2002, AM J PHYSIOL-GASTR L, V283, pG923, DOI 10.1152/ajpgi.00237.2002; WARREN N, 1991, BRIT MED J, V302, P760, DOI 10.1136/bmj.302.6779.760; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINPENNY JP, 1995, AM J PHYSIOL-CELL PH, V268, pC823, DOI 10.1152/ajpcell.1995.268.4.C823; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	49	46	46	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					30	41		10.1038/sj.onc.1209764	http://dx.doi.org/10.1038/sj.onc.1209764			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799633				2022-12-28	WOS:000243236500004
J	Bourette, RP; Grasset, MF; Mouchiroud, G				Bourette, R. P.; Grasset, M-F; Mouchiroud, G.			E2a/Pbx1 oncogene inhibits terminal differentiation but not myeloid potential of pro-T cells	ONCOGENE			English	Article						leukemia; hematopoiesis; differentiation	STIMULATING FACTOR-RECEPTOR; HEMATOPOIETIC PROGENITORS; ACUTE LEUKEMIAS; TRANSCRIPTION FACTORS; INTERACTING PROTEIN; LINEAGE COMMITMENT; MARROW CULTURES; FDC-P1 CELLS; IN-VITRO; GENE	E2a/Pbx1 is a fusion oncoprotein resulting from the t(1; 19) translocation found in human pre-B acute lymphocytic leukemia and in a small number of acute T-lymphoid and myeloid leukemias. It was previously suggested that E2a/Pbx1 could cooperate with normal or oncogenic signaling pathways to immortalize myeloid and lymphoid progenitor cells. To address this question, we introduced the receptor of the macrophage-colony-stimulating factor (M-CSF-R) in pro-T cells immortalized by a conditional, estradiol-dependent, E2a/Pbx1-protein, and continuously proliferating in response to stem cell factor and interleukin-7. We asked whether M-CSF-R would be functional in an early T progenitor cell and influence the fate of E2a/Pbx1-immortalized cells. E2a-Pbx1 immortalized pro-T cells could proliferate and shifted from lymphoid to myeloid lineage after signaling through exogenously expressed M-CSF-R, irrespective of the presence of estradiol. However, terminal macrophage differentiation of the cells was obtained only when estradiol was withdrawn from cultures. This demonstrated that M-CSF-R is functional for proliferation and differentiation signaling in a T-lymphoid progenitor cell, which, in addition, unveiled myeloid potential of pro-T progenitors. Moreover, the block of differentiation induced by the E2a/Pbx1 oncogene could be modulated by hematopoietic cytokines such as M-CSF, suggesting plasticity of leukemic progenitor cells. Finally, additional experiments suggested that PU.1 and eight twenty-one transcriptional regulators might be implicated in the mechanisms of oncogenesis by E2a/Pbx1.	CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS)	Bourette, RP (corresponding author), CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue Dubois, F-69622 Villeurbanne, France.	bourette@biomserv.univ-lyon1.fr	Bourette, Roland/ABB-3343-2020; Mouchiroud, Guy/K-1153-2018	Bourette, Roland/0000-0003-2074-4878				ARNAUD S, 2002, BMC IMMUNOL, V3, P15; Bakri Y, 2005, BLOOD, V105, P2707, DOI 10.1182/blood-2004-04-1448; Balciunaite G, 2005, BLOOD, V105, P1930, DOI 10.1182/blood-2004-08-3087; Beutler B, 2003, J LEUKOCYTE BIOL, V74, P479, DOI 10.1189/jlb.0203082; BORZILLO GV, 1989, MOL CELL BIOL, V9, P3973, DOI 10.1128/MCB.9.9.3973; Bourette RP, 2000, GROWTH FACTORS, V17, P155, DOI 10.3109/08977190009001065; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourgin C, 2000, FEBS LETT, V480, P113, DOI 10.1016/S0014-5793(00)01906-2; Calabi F, 2001, MOL CELL BIOL, V21, P5658, DOI 10.1128/MCB.21.16.5658-5666.2001; Carnicer MJ, 2004, LEUKEMIA RES, V28, P19, DOI 10.1016/S0145-2126(03)00125-5; CARROLL AJ, 1984, BLOOD, V63, P721; Chen D, 2001, EXP HEMATOL, V29, P971, DOI 10.1016/S0301-472X(01)00670-1; CHENG GY, 1986, J EXP MED, V163, P414, DOI 10.1084/jem.163.2.414; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Du Y, 2002, EXP HEMATOL, V30, P649, DOI 10.1016/S0301-472X(02)00817-2; Duval D, 2000, FASEB J, V14, P1577, DOI 10.1096/fj.14.11.1577; Erickson PF, 1996, BLOOD, V88, P1813; Follows GA, 2005, ONCOGENE, V24, P3643, DOI 10.1038/sj.onc.1208655; Fukuyama T, 2001, ONCOGENE, V20, P6225, DOI 10.1038/sj.onc.1204794; Gilliland D Gary, 2004, Hematology Am Soc Hematol Educ Program, P80; Gosse SG, 2005, CELL SIGNAL, V17, P1352, DOI 10.1016/j.cellsig.2005.02.002; HOFFBRAND AV, 1988, BLOOD REV, V2, P9, DOI 10.1016/0268-960X(88)90003-3; Ibanez V, 2004, CANCER RES, V64, P4547, DOI 10.1158/0008-5472.CAN-03-3689; Iwasaki-Arai J, 2003, J EXP MED, V197, P1311, DOI 10.1084/jem.20021843; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1994, ONCOGENE, V9, P3159; Katsura Y, 2002, NAT REV IMMUNOL, V2, P127, DOI 10.1038/nri721; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; King AG, 2002, P NATL ACAD SCI USA, V99, P4508, DOI 10.1073/pnas.072087899; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kondo M, 2000, NATURE, V407, P383, DOI 10.1038/35030112; Krause DS, 2002, ONCOGENE, V21, P3262, DOI 10.1038/sj.onc.1205316; Lacaud G, 2002, BLOOD, V100, P458, DOI 10.1182/blood-2001-12-0321; Lee CK, 2001, J IMMUNOL, V166, P5964, DOI 10.4049/jimmunol.166.10.5964; Lindberg SR, 2005, EXP HEMATOL, V33, P189, DOI 10.1016/j.exphem.2004.10.011; Lodie TA, 1997, J IMMUNOL, V158, P1848; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; Matsuoka T, 2003, MOL CELL BIOL, V23, P6049, DOI 10.1128/MCB.23.17.6049-6062.2003; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Nutt SL, 2005, J EXP MED, V201, P221, DOI 10.1084/jem.20041535; Pawlak G, 2000, EXP HEMATOL, V28, P1164, DOI 10.1016/S0301-472X(00)00522-1; Rochford JJ, 2004, MOL CELL BIOL, V24, P9863, DOI 10.1128/MCB.24.22.9863-9872.2004; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; Scheijen B, 2002, ONCOGENE, V21, P3314, DOI 10.1038/sj.onc.1205317; STANLEY ER, 1994, STEM CELLS, V12, P15; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sykes DB, 2004, MOL CELL BIOL, V24, P1256, DOI 10.1128/MCB.24.3.1256-1269.2004; Sykes DB, 2003, LEUKEMIA LYMPHOMA, V44, P1187, DOI 10.1080/1042819031000090273; Sykes DB, 2001, BLOOD, V98, P2308, DOI 10.1182/blood.V98.8.2308; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; TORRES H, 1990, LEUKEMIA, V4, P673; TROUSSARD X, 1995, BRIT J HAEMATOL, V89, P516, DOI 10.1111/j.1365-2141.1995.tb08357.x; Zheng R, 2004, LEUKEMIA RES, V28, P121, DOI 10.1016/S0145-2126(03)00184-X; Zheng R, 2004, BLOOD, V103, P267, DOI 10.1182/blood-2003-06-1969; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	63	15	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					234	247		10.1038/sj.onc.1209777	http://dx.doi.org/10.1038/sj.onc.1209777			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819510				2022-12-28	WOS:000243398300007
J	Lallemand, C; Blanchard, B; Palmieri, M; Lebon, P; May, E; Tovey, MG				Lallemand, C.; Blanchard, B.; Palmieri, M.; Lebon, P.; May, E.; Tovey, M. G.			Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB	ONCOGENE			English	Article						NOXA; p53; IRF-1; IRF-3; virus	INDEPENDENT PHOSPHOLIPASE A(2); OXIDE SYNTHASE EXPRESSION; REGULATORY FACTOR-I; GENE-EXPRESSION; ANTIVIRAL RESPONSE; BH3-ONLY PROTEINS; FACTOR DRAF1; INTERFERON; CELLS; ACTIVATION	To characterize the mechanisms underlying apoptosis induced by viral infection, transcriptional activation of genes encoding members of the 'BH3-only' family of proteins was analysed during the course of virus infection. Among these genes, only NOXA is transcriptionally activated by vesicular stomatitis virus (VSV), sendai virus (SV), measles virus, herpes simplex virus, or dsRNA and required for efficient apoptosis of cells. Transcriptional activation of NOXA by VSV or SV is independent of p53, but requires the presence of interferon regulatory factor 1 (IRF-1), IRF-3 and cAMP-responsive element binding protein (CREB). Binding to and transactivation of the NOXA promoter by each of these transcription factors is governed by post-translational modi. cation involving different pathways for each factor. Thus, SV infection activates IRF-3and CREB by phosphorylation triggered by Toll like receptor 3 signalling, and a pathway involving calcium-independent phopholipase A2, respectively. In addition transactivation induced by IRF-1 during viral infection correlates with a 10 kDa increase in its molecular weight, suggesting a covalent linkage with a previously unknown regulatory polypeptide.	Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, F-94801 Villejuif, France; Univ Verona, Sez Chim Biol, Dipartimento Sci Morfol Biomed, I-37100 Verona, Italy; Univ Paris 05, Hop Cochin, Virol Lab, Paris, France	Centre National de la Recherche Scientifique (CNRS); University of Verona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Lallemand, C (corresponding author), Inst Andre Lwoff, Lab Viral Oncol, UPR 9045, CNRS, 7 Rue Guy Moquet, F-94801 Villejuif, France.	lalleman@vjf.cnrs.fr		lallemand, christophe/0000-0001-5965-2482; Tovey, Michael/0000-0002-3058-0494				Biron CA, 1999, ANNU REV IMMUNOL, V17, P189, DOI 10.1146/annurev.immunol.17.1.189; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chow WA, 2000, J IMMUNOL, V164, P3512, DOI 10.4049/jimmunol.164.7.3512; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; Licata JM, 2003, INT REV IMMUNOL, V22, P451, DOI 10.1080/08830180305217; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lyles DS, 2000, MICROBIOL MOL BIOL R, V64, P709, DOI 10.1128/MMBR.64.4.709-724.2000; Maggi LB, 2002, J BIOL CHEM, V277, P38449, DOI 10.1074/jbc.M206247200; Marques JT, 2005, J VIROL, V79, P11105, DOI 10.1128/JVI.79.17.11105-11114.2005; Martinson BD, 2003, J LIPID RES, V44, P1686, DOI 10.1194/jlr.M300018-JLR200; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miro-Mur F, 2003, ONCOGENE, V22, P5451, DOI 10.1038/sj.onc.1206538; Moehler M, 2001, CANCER GENE THER, V8, P158, DOI 10.1038/sj.cgt.7700288; Moran JM, 2005, J BIOL CHEM, V280, P28162, DOI 10.1074/jbc.M500013200; Moro A, 2000, BIOCHEM BIOPH RES CO, V269, P31, DOI 10.1006/bbrc.2000.2256; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Nakagawa K, 2000, EUR J BIOCHEM, V267, P1680, DOI 10.1046/j.1432-1327.2000.01163.x; Nakagawa K, 2002, FEBS LETT, V530, P204, DOI 10.1016/S0014-5793(02)03486-5; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; Puthalakath H, 2002, CELL DEATH DIFFER, V9, P505, DOI 10.1038/sj.cdd.4400998; Ruiz-Ruiz C, 2004, J BIOL CHEM, V279, P19712, DOI 10.1074/jbc.M313023200; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sun YP, 2005, J BIOL CHEM, V280, P15561, DOI 10.1074/jbc.m412630200; Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Tanaka N, 1998, GENES CELLS, V3, P29, DOI 10.1046/j.1365-2443.1998.00164.x; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Weaver BK, 1998, MOL CELL BIOL, V18, P1359, DOI 10.1128/MCB.18.3.1359; Weaver BK, 2001, FASEB J, V15, P501, DOI 10.1096/fj.00-0222com; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Xie RL, 2001, J BIOL CHEM, V276, P18624, DOI 10.1074/jbc.M010391200; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yoneyama Mitsutoshi, 2004, Uirusu, V54, P161, DOI 10.2222/jsv.54.161	41	45	46	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					328	338		10.1038/sj.onc.1209795	http://dx.doi.org/10.1038/sj.onc.1209795			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832344				2022-12-28	WOS:000243544000002
J	Domchek, SM; Weber, BL				Domchek, S. M.; Weber, B. L.			Clinical management of BRCA1 and BRCA2 mutation carriers	ONCOGENE			English	Review						BRCA1; BRCA2; oophorectomy; breast cancer; ovarian cancer; management	BREAST-CANCER RISK; HORMONE-REPLACEMENT THERAPY; SURGICAL ADJUVANT BREAST; BILATERAL PROPHYLACTIC OOPHORECTOMY; REDUCING SALPINGO-OOPHORECTOMY; ORAL-CONTRACEPTIVE USE; OVARIAN-CANCER; POSTMENOPAUSAL WOMEN; INHERITED MUTATIONS; ENDOMETRIAL CANCER	The cancer susceptibility genes BRCA1 and BRCA2 appear to be responsible for virtually all hereditary breast ovarian families, and a smaller subset of hereditary site-specific breast cancer families. Fortunately, effective strategies have been developed to reduce the risk for the development of breast and ovarian cancer in women with BRCA1/2 mutations, making genetic testing for these mutations an important part of the management at women with a strong family history of these diseases. Here, we review the current evidence for risk reduction strategies and outline future research directions.	Univ Penn, Abramson Canc Ctr, Canc Risk Evaluat Program, Philadelphia, PA 19104 USA; GlaxoSmithKline Inc, Philadelphia, PA USA	University of Pennsylvania; GlaxoSmithKline	Domchek, SM (corresponding author), Univ Penn, Abramson Canc Ctr, Canc Risk Evaluat Program, 3400 Spruce St, Philadelphia, PA 19104 USA.	susan.domchek@uphs.upenn.edu						Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; Andrieu N, 2006, JNCI-J NATL CANCER I, V98, P535, DOI 10.1093/jnci/djj132; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Aziz S, 2001, GYNECOL ONCOL, V80, P341, DOI 10.1006/gyno.2000.6095; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Beral V, 2005, LANCET, V365, P1543, DOI 10.1016/S0140-6736(05)66455-0; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Brose MS, 2002, J NATL CANCER I, V94, P1365, DOI 10.1093/jnci/94.18.1365; Carcangiu ML, 2004, INT J GYNECOL PATHOL, V23, P35, DOI 10.1097/01.pgp.0000101082.35393.84; Casey MJ, 2005, GYNECOL ONCOL, V97, P457, DOI 10.1016/j.ygyno.2005.01.039; Cass I, 2003, CANCER, V97, P2187, DOI 10.1002/cncr.11310; Colgan TJ, 2002, GYNECOL ONCOL, V85, P397, DOI 10.1006/gyno.2002.6638; Colgan TJ, 2001, AM J SURG PATHOL, V25, P1283, DOI 10.1097/00000478-200110000-00009; COMCHEK SM, 2006, LANCET ONCOL, V7, P223; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Eitan R, 2006, GYNECOL ONCOL, V102, P315, DOI 10.1016/j.ygyno.2005.12.021; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Haffty BG, 2002, LANCET, V359, P1471, DOI 10.1016/S0140-6736(02)08434-9; Hartmann LC, 2001, JNCI-J NATL CANCER I, V93, P1633, DOI 10.1093/jnci/93.21.1633; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; Jernstrom H, 2004, JNCI-J NATL CANCER I, V96, P1094, DOI 10.1093/jnci/djh211; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; Kennedy RD, 2004, JNCI-J NATL CANCER I, V96, P1659, DOI 10.1093/jnci/djh312; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kramer JL, 2005, J CLIN ONCOL, V23, P8629, DOI 10.1200/JCO.2005.02.9199; Kriege M, 2004, NEW ENGL J MED, V351, P427, DOI 10.1056/NEJMoa031759; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lavie O, 2004, GYNECOL ONCOL, V92, P521, DOI 10.1016/j.ygyno.2003.11.009; Leach MO, 2005, LANCET, V365, P1769, DOI 10.1016/S0140-6736(05)66481-1; Lu KH, 2000, J CLIN ONCOL, V18, P2728, DOI 10.1200/JCO.2000.18.14.2728; McEwen AR, 2004, GYNECOL ONCOL, V92, P992, DOI 10.1016/j.ygyno.2003.12.003; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; Milne RL, 2005, CANCER EPIDEM BIOMAR, V14, P350, DOI 10.1158/1055-9965.EPI-04-0376; Modan B, 2001, NEW ENGL J MED, V345, P235, DOI 10.1056/NEJM200107263450401; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Narod SA, 2006, LANCET ONCOL, V7, P402, DOI 10.1016/S1470-2045(06)70624-6; Pierce LJ, 2006, J CLIN ONCOL, V24, P2437, DOI 10.1200/JCO.2005.02.7888; Pierce LJ, 2000, J CLIN ONCOL, V18, P3360, DOI 10.1200/JCO.2000.18.19.3360; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; Powell CB, 2005, J CLIN ONCOL, V23, P127, DOI 10.1200/JCO.2005.04.109; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Rebbeck TR, 2004, J CLIN ONCOL, V22, P1055, DOI 10.1200/JCO.2004.04.188; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Rutter JL, 2003, JNCI-J NATL CANCER I, V95, P1072, DOI 10.1093/jnci/95.14.1072; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warner E, 2004, JAMA-J AM MED ASSOC, V292, P1317, DOI 10.1001/jama.292.11.1317; Whittemore AS, 2004, BRIT J CANCER, V91, P1911, DOI 10.1038/sj.bjc.6602239	66	51	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5825	5831		10.1038/sj.onc.1209881	http://dx.doi.org/10.1038/sj.onc.1209881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998496				2022-12-28	WOS:000240765900002
J	Caracciolo, V; Reiss, K; Khalili, K; De Falco, G; Giordano, A				Caracciolo, V.; Reiss, K.; Khalili, K.; De Falco, G.; Giordano, A.			Role of the interaction between large T antigen and Rb family members in the oncogenicity of JC virus	ONCOGENE			English	Review						JCV T antigen; retinoblastoma family proteins; cell cycle	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RETINOBLASTOMA GENE FAMILY; TUMOR-SUPPRESSOR PROTEIN; GROWTH IN-VIVO; CELL-CYCLE; HISTONE DEACETYLASE; DNA-SEQUENCES; E2F FAMILY; PRB-FAMILY; REPRESS TRANSCRIPTION	Human polyomaviruses (JC virus, BK virus and simian virus 40) are causative agents of some human diseases and, interestingly, are involved in processes of cell transformation and oncogenesis. These viruses need the cell cycle machinery of the host cell to complete their replication; so they evolved mechanisms that can interfere with the growth control of infected cells and force them into DNA replication. The retinoblastoma family of proteins (pRb), which includes pRb/p105, p107 and pRb2/p130, acts as one of the most important regulators of the G1/S transition of the cell cycle. Rb proteins represent an important target for viral oncoproteins. Early viral T antigens can bind all members of the pRb family, promoting the activation of the E2F family of transcription factors, thus inducing the expression of genes required for the entry to the S phase. The interaction between early viral antigens and cell cycle regulators represents an important mechanism through which viruses deregulate cell cycle and lead to cell transformation. In this review, we will discuss the effects of the interaction between large T antigen and Rb proteins in JC virus-mediated oncogenesis.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Dept Biol, Philadelphia, PA 19122 USA; Temple Univ, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Dept Biol, 1900 N 12th St,BioLife Sci Bldg, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				ARIZA A, 1994, HUM PATHOL, V25, P1341, DOI 10.1016/0046-8177(94)90095-7; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Barbanti-Brodano G, 1998, ADV VIRUS RES, V50, P69, DOI 10.1016/S0065-3527(08)60806-4; Berger JR, 1998, ANN NEUROL, V44, P341, DOI 10.1002/ana.410440309; Boldorini R, 1998, J NEUROVIROL, V4, P242, DOI 10.3109/13550289809114524; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Caldarelli-Stefano R, 2000, HUM PATHOL, V31, P394, DOI 10.1016/S0046-8177(00)80256-7; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Casini B, 2005, ANTICANCER RES, V25, P1079; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; CINATL J, 2001, MECH DNA TUMOR VIRUS; Cinti C, 2000, CANCER RES, V60, P383; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Croul S, 2003, J NEUROVIROL, V9, P173, DOI 10.1080/13550280390194055; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Del Valle L, 2000, ANN NEUROL, V48, P932, DOI 10.1002/1531-8249(200012)48:6<932::AID-ANA15>3.0.CO;2-E; Del Valle L, 2005, CANCER-AM CANCER SOC, V103, P516, DOI 10.1002/cncr.20806; Del Valle L, 2002, CLIN CANCER RES, V8, P3332; Del Valle L, 2001, CANCER RES, V61, P4287; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dorries K, 1998, DEV BIOLOGICALS, V94, P71; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisque RJ, 2003, J NEUROVIROL, V9, P15, DOI 10.1080/13550280390195270; Frisque RJ, 2001, J NEUROVIROL, V7, P293, DOI 10.1080/13550280152537120; FRISQUE RJ, 1984, J VIROL, V51, P458, DOI 10.1128/JVI.51.2.458-469.1984; Frisque RJ, 1992, MOL NEUROVIROLOGY PA, P25; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; GJOERUP OV, 1994, P NATL ACAD SCI USA, V91, P12125; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helt AM, 2003, CARCINOGENESIS, V24, P159, DOI 10.1093/carcin/24.2.159; HOLMAN PS, 1994, J VIROL, V68, P668, DOI 10.1128/JVI.68.2.668-673.1994; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; Howes SH, 1996, J VIROL, V70, P3581, DOI 10.1128/JVI.70.6.3581-3588.1996; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Klucky B, 2004, ONCOGENE, V23, P4707, DOI 10.1038/sj.onc.1207640; Knudsen ES, 1998, ONCOGENE, V16, P1655, DOI 10.1038/sj.onc.1201682; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; LONDON WT, 1978, SCIENCE, V201, P1246, DOI 10.1126/science.211583; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nemethova M, 2004, MOL CELL BIOL, V24, P10986, DOI 10.1128/MCB.24.24.10986-10994.2004; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Rencic A, 1996, P NATL ACAD SCI USA, V93, P7352, DOI 10.1073/pnas.93.14.7352; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Seth P, 2003, J NEUROVIROL, V9, P236, DOI 10.1080/13550280390194019; Sheng Q, 1997, J VIROL, V71, P9410, DOI 10.1128/JVI.71.12.9410-9416.1997; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SIMA AAF, 1983, ANN NEUROL, V14, P183, DOI 10.1002/ana.410140205; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Stiegler P, 1998, J CELL BIOCHEM, P30; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trojanek J, 2006, J CELL PHYSIOL, V206, P35, DOI 10.1002/jcp.20425; TROJANEK J, 2006, INT J CANC      0329; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; WHITE MK, 2006, IN PRESS ONCOGENE; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	90	45	48	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5294	5301		10.1038/sj.onc.1209681	http://dx.doi.org/10.1038/sj.onc.1209681			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936750				2022-12-28	WOS:000240064100015
J	Tong, WM; Yang, YG; Cao, WH; Galendo, D; Frappart, L; Shen, Y; Wang, ZQ				Tong, W. M.; Yang, Y. G.; Cao, W. H.; Galendo, D.; Frappart, L.; Shen, Y.; Wang, Z. Q.			Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice	ONCOGENE			English	Article						breast cancer; DNA damage response; PARP-1; p53; BRCA1	DNA-DAMAGE RESPONSE; HUMAN BREAST-CANCER; TUMOR-FORMATION; HISTONE H2AX; P53; BRCA1; PARP-1; PHOSPHORYLATION; SUSCEPTIBILITY; DEFICIENT	The DNA strand break-binding molecule, poly(ADPribose) polymerase-1 (PARP-1), plays a role in DNA repair, chromosomal stability, transcription and cell death. Accumulating evidence suggests that dysfunction of PARP-1 contributes to tumorigenesis. Here, we report that PARP-1 deficiency causes mammary carcinoma formation in female mice, and that the introduction of Trp53 mutations accelerates the onset and shortens the latency of mammary tumorigenesis. We show that PARP1 deficiency results in chromosomal aneuploidy and centrosome amplification, which are substantiated by the inactivation of Trp53 in primary mammary epithelial (PME) cells. In addition, PARP-1 deficiency compromises p53 activation and impairs BRCA1 recruitment to the sites of DNA damage in PME cells. PARP-1 complementation partly rescues the defective DNA damage response mediated by p53 and BRCA1. The present study thus identifies a role of PARP-1 in suppressing mammary tumorigenesis in vivo and suggests that dysfunction of PARP-1 may be a risk factor for breast cancer in humans.	IARC, Pathol Grp, F-69008 Lyon, France; Chinese Acad Med Sci, Inst Basic Med Sci, Natl Lab Med Mol Biol, Beijing 100037, Peoples R China; Peking Union Med Coll, Beijing, Peoples R China; Hosp Edouard Herriot, Dept Pathol, Lyon, France	World Health Organization; International Agency for Research on Cancer (IARC); Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; bioMerieux; CHU Lyon	Tong, WM (corresponding author), IARC, Pathol Grp, 150 Cours Albert Thomas, F-69008 Lyon, France.	tong@iarc.fr						Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Beneke R, 2001, ONCOGENE, V20, P8136, DOI 10.1038/sj.onc.1205056; Bieche I, 1996, CLIN CANCER RES, V2, P1163; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cressman VL, 1999, CELL GROWTH DIFFER, V10, P1; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; De Soto Joseph A, 2006, Int J Med Sci, V3, P117; De Soto JA, 2006, INT J BIOL SCI, V2, P179; Deng CX, 2002, ONCOGENE, V21, P6222, DOI 10.1038/sj.onc.1205713; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards PAW, 1996, J MAMMARY GLAND BIOL, V1, P75, DOI 10.1007/BF02096304; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hao BT, 2004, CANCER RES, V64, P4378, DOI 10.1158/0008-5472.CAN-04-0372; Helleday T, 2005, CELL CYCLE, V4, P1176, DOI 10.4161/cc.4.9.2031; Herceg Z, 1999, MOL CELL BIOL, V19, P5124; Hu JJ, 1997, PHARMACOGENETICS, V7, P309, DOI 10.1097/00008571-199708000-00006; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Kanai M, 2003, MOL CELL BIOL, V23, P2451, DOI 10.1128/MCB.23.7.2451-2462.2003; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Lebel M, 2003, AM J PATHOL, V162, P1559, DOI 10.1016/S0002-9440(10)64290-3; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lockett KL, 2004, CANCER RES, V64, P6344, DOI 10.1158/0008-5472.CAN-04-0338; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; MALKIN D, 1998, LI FRAUMENI SYNDROME, P393; Masutani M, 2003, GENE CHROMOSOME CANC, V38, P339, DOI 10.1002/gcc.10250; McCabe N, 2005, CANCER BIOL THER, V4, P934, DOI 10.4161/cbt.4.9.2141; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Nozaki T, 2003, CANCER SCI, V94, P497, DOI 10.1111/j.1349-7006.2003.tb01472.x; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rajaee-Behbahani N, 2002, INT J CANCER, V98, P780, DOI 10.1002/ijc.10234; Shibata A, 2005, ONCOGENE, V24, P1328, DOI 10.1038/sj.onc.1208289; Shiokawa M, 2005, JPN J CLIN ONCOL, V35, P97, DOI 10.1093/jjco/hyi028; STEWART BW, 2003, BREAST CANC WORLD CA; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Tong WM, 2003, AM J PATHOL, V162, P343, DOI 10.1016/S0002-9440(10)63825-4; Tong WM, 2001, BBA-REV CANCER, V1552, P27, DOI 10.1016/S0304-419X(01)00035-X; Tong WM, 2002, CANCER RES, V62, P6990; Tsutsumi M, 2001, CARCINOGENESIS, V22, P1, DOI 10.1093/carcin/22.1.1; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Zhang XM, 2005, CANCER RES, V65, P722	48	65	70	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3857	3867		10.1038/sj.onc.1210156	http://dx.doi.org/10.1038/sj.onc.1210156			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160013				2022-12-28	WOS:000247026400009
J	Iotti, G; Ferrari-Amorotti, G; Rosafio, C; Corradini, F; Lidonnici, MR; Ronchetti, M; Bardini, M; Zhang, Y; Martinez, R; Blasi, F; Calabretta, B				Iotti, G.; Ferrari-Amorotti, G.; Rosafio, C.; Corradini, F.; Lidonnici, M. R.; Ronchetti, M.; Bardini, M.; Zhang, Y.; Martinez, R.; Blasi, F.; Calabretta, B.			Expression of CCL9/MIP-1 gamma is repressed by BCR/ABL and its restoration suppresses in vivo leukemogenesis of 32D-BCR/ABL cells	ONCOGENE			English	Article						CML; STI571; CCL9; transcription regulation; chemokine production; in vivo leukemogenesis	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; MULTIPOTENT HEMATOPOIETIC-CELLS; C/EBP-ALPHA EXPRESSION; PROTEIN-KINASE PATHWAY; BCR-ABL; CHEMOTACTIC RESPONSE; TRANSCRIPTION-FACTOR; IMATINIB MESYLATE; MOLECULAR-CLONING	Transformation of hematopoietic cells by the BCR/ABL oncogene is caused by perturbation of signal transduction pathways leading to altered patterns of gene expression and activity. By oligonucleotide microarray hybridization of polysomal RNA of untreated and STI571-treated 32DBCR/ABL cells, we identified the beta-chemokine CCL9 as a gene regulated by BCR/ABL in a tyrosine kinasedependent manner. BCR/ABL repressed CCL9 expression at the transcriptional level by mechanisms involving suppression of p38 MAP kinase, and modulation of the activity of CDP/cut and C/EBP alpha, two transcription regulators of myeloid differentiation. However, repression of C/EBP-dependent transcription did not prevent the induction of CCL9 expression by STI571, suggesting that C/EBP alpha is involved in maintaining rather than in inducing CCL9 expression. Restoration of CCL9 expression in 32D-BCR/ABL cells had no effect on the in vitro proliferation of these cells, but reduced their leukemogenic potential in vivo, possibly by recruitment of CD3-positive immune cells. Together, these findings suggest that downregulation of chemokine expression may be involved in BCR/ABL-dependent leukemogenesis by altering the relationship between transformed cells and the microenvironment.	Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; FIRC Inst Mol Oncol, IFOM, Milan, Italy; Wyeth Genet Inst, Cambridge, MA USA	Jefferson University; Universita di Modena e Reggio Emilia; IFOM - FIRC Institute of Molecular Oncology; Pfizer	Calabretta, B (corresponding author), Thomas Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, 233 S 10th St, Philadelphia, PA 19107 USA.	B_Calabretta@mail.jci.tju.edu	Lidonnici, Maria Rosa/AAN-2208-2020	Lidonnici, Maria Rosa/0000-0003-3413-8414; Blasi, Francesco/0000-0001-9406-1784; BARDINI, MICHELA/0000-0002-6942-2274	PHS HHS [P01 78890] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BEN-NERIAH Y, 1986, SCIENCE, V233, P212, DOI 10.1126/science.3460176; Berahovich RD, 2005, J IMMUNOL, V174, P7341, DOI 10.4049/jimmunol.174.11.7341; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; EAVES CJ, 1993, P NATL ACAD SCI USA, V90, P12015, DOI 10.1073/pnas.90.24.12015; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Ferrari-Amorotti G, 2006, BLOOD, V108, P1353, DOI 10.1182/blood-2006-01-011833; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Geay JF, 2005, CANCER RES, V65, P2676, DOI 10.1158/0008-5472.CAN-04-2152; Guerzoni C, 2006, BLOOD, V107, P4080, DOI 10.1182/blood-2005-08-3181; HARA T, 1995, J IMMUNOL, V155, P5352; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Jongen-Lavrencic M, 2005, LEUKEMIA, V19, P373, DOI 10.1038/sj.leu.2403626; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KANTARJIAN HM, 1993, BLOOD, V82, P691; Khanna-Gupta A, 2003, BLOOD, V101, P3460, DOI 10.1182/blood-2002-09-2767; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; Lane CM, 1999, MOL MED, V5, P55, DOI 10.1007/BF03402139; Lawson ND, 1998, BLOOD, V91, P2517, DOI 10.1182/blood.V91.7.2517.2517_2517_2524; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; Mohamadzadeh M, 1996, J IMMUNOL, V156, P3102; Nepveu A, 2001, GENE, V270, P1, DOI 10.1016/S0378-1119(01)00485-1; Okuda K, 1996, ONCOGENE, V13, P1147; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Pierce A, 2002, ONCOGENE, V21, P3068, DOI 10.1038/sj.onc.1205424; POLTORAK AN, 1995, J INFLAMM, V45, P207; Ptasznik A, 2002, J EXP MED, V196, P667, DOI 10.1084/jem.20020519; Salgia R, 1999, BLOOD, V94, P4233; Sattler M, 2003, SEMIN HEMATOL, V40, P4, DOI 10.1053/shem.2003.50034; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schuster C, 2003, BLOOD, V101, P655, DOI 10.1182/blood-2002-01-0043; Tavor S, 2003, J BIOL CHEM, V278, P52651, DOI 10.1074/jbc.M307077200; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Wark G, 1998, ONCOGENE, V16, P1319, DOI 10.1038/sj.onc.1201914; Wong S, 2003, BLOOD, V101, P4088, DOI 10.1182/blood-2002-11-3376; YOUN BS, 1995, J IMMUNOL, V155, P2661	42	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3482	3491		10.1038/sj.onc.1210146	http://dx.doi.org/10.1038/sj.onc.1210146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160016				2022-12-28	WOS:000246799200004
J	Yuan, L; Siegel, M; Choi, K; Khosla, C; Miller, CR; Jackson, EN; Piwnica-Worms, D; Rich, KM				Yuan, L.; Siegel, M.; Choi, K.; Khosla, C.; Miller, C. R.; Jackson, E. N.; Piwnica-Worms, D.; Rich, K. M.			Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy	ONCOGENE			English	Article						apoptosis; brain tumor; tissue transglutaminase 2 inhibitors; stroma; U87MG; BCNU	TISSUE TRANSGLUTAMINASE; CELL-DEATH; BRAIN-TUMORS; IN-VIVO; ED-B; EXPRESSION; CANCER; APOPTOSIS; RESISTANCE; INDUCTION	Transglutaminase 2 (TG2, a.k.a. tissue transglutaminase) belongs to a family of transglutaminase enzymes that stabilize proteins by affecting covalent crosslinking via formation of amide bonds. Cell surface TG2 is directly involved as an adhesive receptor in cell-extracellular matrix (ECM) interactions. Here, we show that TG2 activity is elevated in glioblastomas compared with non-neoplastic brain. Immunouorescent studies showed increased staining of. bronectin colocalized with TG2 in the ECM in glioblastomas. In addition, small clusters of invading human glioblastoma cells present in non- neoplastic brain parenchyma secrete high levels of TG2 and. bronectin that distinguish them from normal brain stroma. Downregulation of TG2 in U87MG glioblastoma cells with RNAi demonstrated decreased assembly of. bronectin in the ECM. Treatment with KCC009 blocked the remodeling of. bronectin in the ECM in glioblastomas in both in vitro and in vivo studies. KCC009 treatment in mice harboring orthotopic glioblastomas (DBT-FG) sensitized the tumors to N, N-1-bis(2-chloroethyl)-N-nitrosourea chemotherapy, as measured by reduced bioluminescence, increased apoptosis and prolonged survival. The ability of KCC009 to interfere with the permissive remodeling of. bronectin in the ECM in glioblastomas suggests a novel target to enhance sensitivity to chemotherapy directed not only at the tumor mass, but also invading glioblastoma cells.	Washington Univ, Sch Med, Dept Neurol Surg, St Louis, MO 63110 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Washington Univ, Sch Med, Div Neuropathol, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63130 USA; Washington Univ, Sch Med, Dept Radiol, St Louis, MO 63130 USA	Washington University (WUSTL); Stanford University; Stanford University; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Rich, KM (corresponding author), Washington Univ, Sch Med, Dept Neurol Surg, 660 S Euclid Ave,Box 8057, St Louis, MO 63110 USA.	richk@nsurg.wustl.edu	Miller, Ryan/B-9365-2008	Miller, Ryan/0000-0002-0096-8762; Khosla, Chaitan/0000-0001-6529-495X; Choi, Kihang/0000-0001-5196-4107	NCI NIH HHS [P50 CA94056, T32CA009547, P30 CA91842] Funding Source: Medline; NIDDK NIH HHS [R01 DK63158] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA091842, T32CA009547, P50CA094056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063158] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; Castellani P, 2002, AM J PATHOL, V161, P1695, DOI 10.1016/S0002-9440(10)64446-X; Castro MG, 2003, PHARMACOL THERAPEUT, V98, P71, DOI 10.1016/S0163-7258(03)00014-7; Chicoine MR, 2001, NEUROSURGERY, V48, P607, DOI 10.1097/00006123-200103000-00032; Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Gross S, 2005, METHOD ENZYMOL, V399, P512, DOI 10.1016/S0076-6879(05)99035-6; Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247; Jiang ZH, 2004, J NEUROCHEM, V89, P168, DOI 10.1111/j.1471-4159.2004.02319.x; Jiang ZH, 2003, J NEUROCHEM, V84, P273, DOI 10.1046/j.1471-4159.2003.01522.x; KUMANISHI T, 1967, JPN J EXP MED, V37, P461; Madden HL, 2000, AM J RESP CRIT CARE, V162, P1553, DOI 10.1164/ajrccm.162.4.2001015; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MEHTA K, 1994, INT J CANCER, V58, P400, DOI 10.1002/ijc.2910580316; Midulla M, 2000, CANCER RES, V60, P164; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; NICOLO G, 1990, CELL DIFFER DEV, V32, P401, DOI 10.1016/0922-3371(90)90056-3; Ohnishi T, 1998, CLIN EXP METASTAS, V16, P729, DOI 10.1023/A:1006532812408; Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Verderio EAM, 2003, J BIOL CHEM, V278, P42604, DOI 10.1074/jbc.M303303200; Wernert N, 1997, VIRCHOWS ARCH, V430, P433, DOI 10.1007/s004280050053; Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328; Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863	30	117	119	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2563	2573		10.1038/sj.onc.1210048	http://dx.doi.org/10.1038/sj.onc.1210048			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17099729				2022-12-28	WOS:000245831200004
J	Han, W; Wu, L; Chen, S; Bao, L; Zhang, L; Jiang, E; Zhao, Y; Xu, A; Hei, TK; Yu, Z				Han, W.; Wu, L.; Chen, S.; Bao, L.; Zhang, L.; Jiang, E.; Zhao, Y.; Xu, A.; Hei, T. K.; Yu, Z.			Constitutive nitric oxide acting as a possible intercellular signaling molecule in the initiation of radiation-induced DNA double strand breaks in non-irradiated bystander cells	ONCOGENE			English	Article						constitutive nitric oxide; radiation-induced bystander effects; DNA double strand breaks; initiation process	IONIZING-RADIATION; TYROSINE PHOSPHORYLATION; UNIRRADIATED CELLS; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; OPIATE RECEPTOR; HISTONE H2AX; SYNTHASE; PEROXYNITRITE; IRRADIATION	The initiation and propagation of the early processes of bystander signaling induced by low-dose alpha-particle irradiation are very important for understanding the underlying mechanism of the bystander process. Our previous investigation showed that the medium collected from cell culture exposed to low-dose alpha-particle rapidly induced phosphorylated form of H2AX protein foci formation among the non-irradiated medium receptor cells in a time-dependent manner. Using N-G-methyl-L-arginine, 4-amino-5-methylamino-2',7'-difluorofluorescein diacetate and N-omega-nitro-L-arginine (L-NNA) treatment before exposure to 1 cGy alpha-particle, we showed in the present study that nitric oxide (NO center dot) produced in the irradiated cells was important and necessary for the DNA double strand break inducing activity (DIA) of conditioned medium and the generation of NO center dot in irradiated confluent AG1522 cells is in a time-dependent manner and that almost all NO center dot was generated within 15 min post-irradiation. Concurrently, the kinetics of NO center dot production in the medium of irradiated cells after irradiation was rapid and in a time-dependent manner as well, with a maximum yield observed at 10 min after irradiation with electron spin resonance analysis. Furthermore, our results that 7-Nitroindazole and L-NNA, but not aminoguanidine hemisulfate, treatment before exposure to 1 cGy alpha-particle significantly decrease the DIA of the conditioned medium suggested that constitutive NO center dot from the irradiated cells possibly acted as an intercellular signaling molecule to initiate and activate the early process ( <= 30 min) of bystander response after low-dose irradiation.	Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, Hefei 230031, Anhui, Peoples R China; Columbia Univ Coll Phys & Surg, Ctr Radiol Res, New York, NY 10032 USA	Chinese Academy of Sciences; Hefei Institutes of Physical Science, CAS; Columbia University	Wu, L (corresponding author), Chinese Acad Sci, Inst Plasma Phys, Key Lab Ion Beam Bioengn, POB 1126,Shushanhu Rd 350, Hefei 230031, Anhui, Peoples R China.	ljw@ipp.ac.cn	Zhao, Ye/V-6986-2019; Zhao, Ye/H-9713-2013	Zhao, Ye/0000-0003-1384-6024; Zhao, Ye/0000-0003-1384-6024	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES009089, R01ES012888] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES012888, ES09089] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Azzam EI, 2004, CURR CANCER DRUG TAR, V4, P53, DOI 10.2174/1568009043481641; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; AZZAM EI, 2003, BIOL EFF LOW LEVEL E, V11, P2; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Chen HT, 2000, SCIENCE, V290, P1962, DOI 10.1126/science.290.5498.1962; Dahm-Daphi J, 2000, INT J RADIAT BIOL, V76, P67, DOI 10.1080/095530000139023; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; FAGAGNA FF, 2003, NATURE, V426, P194, DOI DOI 10.1038/NATURE02118; Femandes E, 2005, LIFE SCI, V77, P1983, DOI 10.1016/j.lfs.2005.02.018; HAN W, 2007, BR J RADIOL; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hu B, 2005, RADIAT RES, V164, P286, DOI 10.1667/RR3415.1; Hu BR, 2006, CARCINOGENESIS, V27, P245, DOI 10.1093/carcin/bgi224; Iyer R, 2000, CANCER RES, V60, P1290; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; JOURDHEUIL D, 1997, FRONT BIOSCI, V2, P189; Kiang JG, 2003, J CELL BIOCHEM, V89, P1030, DOI 10.1002/jcb.10564; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; Kojima H, 1999, ANGEW CHEM INT EDIT, V38, P3209, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3209::AID-ANIE3209>3.0.CO;2-6; Lacza Z, 2003, FREE RADICAL BIO MED, V35, P1217, DOI 10.1016/S0891-5849(03)00510-0; Leach JK, 2002, J BIOL CHEM, V277, P15400, DOI 10.1074/jbc.M110309200; Lewis DA, 2001, RADIAT RES, V156, P251, DOI 10.1667/0033-7587(2001)156[0251:PODDAN]2.0.CO;2; Li NZ, 2003, J NEUROSCI, V23, P10302; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Liu SX, 2005, CANCER RES, V65, P3236, DOI 10.1158/0008-5472.CAN-05-0424; Lyng FM, 2000, BRIT J CANCER, V83, P1223, DOI 10.1054/bjoc.2000.1433; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Matsumoto H, 2000, INT J RADIAT BIOL, V76, P1649; Minetti M, 2002, FREE RADICAL BIO MED, V33, P744, DOI 10.1016/S0891-5849(02)00891-2; Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Murad F, 1998, RECENT PROG HORM RES, V53, P43; Nagar S, 2003, CANCER RES, V63, P324; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Pfeiffer S, 1997, FREE RADICAL BIO MED, V22, P787, DOI 10.1016/S0891-5849(96)00407-8; Qu XW, 2001, FASEB J, V15, P439, DOI 10.1096/fj.99-0343com; Rao CV, 2002, CANCER RES, V62, P165; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2004, INT J RADIAT BIOL, V80, P927, DOI 10.1080/09553000400017648; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2003, CANCER RES, V63, P8437; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 2004, P NATL ACAD SCI USA, V101, P13495, DOI 10.1073/pnas.0404930101; Shao CL, 2003, FASEB J, V17, P1422, DOI 10.1096/fj.02-1115com; Stefano GB, 1998, J NEUROIMMUNOL, V83, P70, DOI 10.1016/S0165-5728(97)00223-3; Stefano GB, 2000, PROG NEUROBIOL, V60, P513, DOI 10.1016/S0301-0082(99)00038-6; Stefano GB, 1995, J BIOL CHEM, V270, P30290, DOI 10.1074/jbc.270.51.30290; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Vodovotz Y, 1999, CANCER RES, V59, P2142; Xiong QH, 2001, J INTERF CYTOK RES, V21, P529, DOI 10.1089/10799900152434411	57	75	80	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2330	2339		10.1038/sj.onc.1210024	http://dx.doi.org/10.1038/sj.onc.1210024			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016433				2022-12-28	WOS:000245466000009
J	Cai, C; Chen, SY; Zheng, Z; Omwancha, J; Lin, MF; Balk, SP; Shemshedini, L				Cai, C.; Chen, S-Y; Zheng, Z.; Omwancha, J.; Lin, M-F; Balk, S. P.; Shemshedini, L.			Androgen regulation of soluble guanylyl cyclase alpha 1 mediates prostate cancer cell proliferation	ONCOGENE			English	Article						androgen receptor; soluble guanylyl cyclase; prostate cancer; proliferation	NITRIC-OXIDE; ACID-PHOSPHATASE; GENE-EXPRESSION; RECEPTOR; LNCAP; PROGRESSION; ANTIGEN; INHIBITION; BIOLOGY; DEATH	The growth and progression of prostate cancer are dependent on androgens and androgen receptor (AR), which act by modulating gene expression. Utilizing a gene microarray approach, we have identified the alpha 1-subunit gene of soluble guanylyl cyclase (sGC) as a novel androgen-regulated gene. A heterodimeric cytoplasmic protein composed of one alpha and one beta subunit, sGC mediates the widespread cellular effects of nitric oxide (NO). We report here that, in prostate cancer cells, androgens stimulate the expression of sGC alpha 1. A cloned human sGC alpha 1 promoter is activated by androgen in an AR-dependent manner, suggesting that sGC alpha 1 may be a direct AR target gene. Disruption of sGC alpha 1 expression severely compromises the growth of both androgen-dependent and androgen-independent AR-positive prostate cancer cells. Overexpression of sGC alpha 1 alone is sufficient for stimulating prostate cancer cell proliferation. Interestingly, the major growth effect of sGC alpha 1 is independent of NO and cyclic guanosine monophosphate, a major mediator of the sGC enzyme. These data strongly suggest that sGC alpha 1 acts in prostate cancer via a novel pathway that does not depend on sGC beta 1. Tissue studies show that sGC alpha 1 expression is significantly elevated in advanced prostate cancer. Thus, sGC alpha 1 may be an important mediator of the procarcinogenic effects of androgens.	Univ Toledo, Dept Biol Sci, Toledo, OH 43606 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Nebraska, Coll Med, Ctr Med, Dept Biochem & Mol Biol, Omaha, NE 68198 USA	University System of Ohio; University of Toledo; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Nebraska System	Shemshedini, L (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	lshemsh@utnet.utoledo.edu	Cai, Changmeng/AAE-6835-2020; CHEN, Shaoyong/ABF-3357-2021	Cai, Changmeng/0000-0002-8701-2586				Arnold JT, 2002, ENDOCR-RELAT CANCER, V9, P61, DOI 10.1677/erc.0.0090061; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008; Chen ME, 1998, J BIOL CHEM, V273, P17618, DOI 10.1074/jbc.273.28.17618; CHEN SY, 2006, IN PRESS ONCOGE 0529; Chen ZJ, 2002, CANCER LETT, V177, P181, DOI 10.1016/S0304-3835(01)00788-1; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; Eder IE, 2002, CANCER GENE THER, V9, P117, DOI 10.1038/sj.cgt.7700416; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Han GZ, 2005, P NATL ACAD SCI USA, V102, P1151, DOI 10.1073/pnas.0408925102; Heisler LE, 1997, MOL CELL ENDOCRINOL, V126, P59, DOI 10.1016/S0303-7207(96)03970-6; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Igawa T, 2002, PROSTATE, V50, P222, DOI 10.1002/pros.10054; ISAACS JT, 1994, VITAM HORM, V49, P433; ISAACS JT, 1984, PROSTATE, V5, P545, DOI 10.1002/pros.2990050510; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jenster G, 1999, SEMIN ONCOL, V26, P407; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang J, 2004, CHINESE MED J-PEKING, V117, P684; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Koksal IT, 2002, PATHOLOGY, V34, P233, DOI 10.1080/00313020220131282; Krumenacker J, 2004, BRAIN RES BULL, V62, P505, DOI 10.1016/S0361-9230(03)00102-3; KRUMENACKER JS, 2001, P NATL ACAD SCI USA, V23, P170; LEE C, 1995, ENDOCRINOLOGY, V136, P796, DOI 10.1210/en.136.2.796; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Meehan KL, 2003, FRONT BIOSCI-LANDMRK, V8, pD780, DOI 10.2741/1063; Mimeault M, 2005, PROSTATE, V62, P187, DOI 10.1002/pros.20138; Papandreou CN, 1998, NAT MED, V4, P50, DOI 10.1038/nm0198-050; Postovit LM, 2002, J BIOL CHEM, V277, P35730, DOI 10.1074/jbc.M204529200; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Shenk JL, 2001, J BIOL CHEM, V276, P38472, DOI 10.1074/jbc.M103652200; Sinnaeve P, 2001, CIRC RES, V88, P103, DOI 10.1161/01.RES.88.1.103; Trapman J, 1997, SEMIN CANCER BIOL, V8, P29, DOI 10.1006/scbi.1997.0050; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; YOUNG CYF, 1994, ONCOL RES, V6, P203; YUAN SX, 1993, CANCER RES, V53, P1304	37	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1606	1615		10.1038/sj.onc.1209956	http://dx.doi.org/10.1038/sj.onc.1209956			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964290				2022-12-28	WOS:000244782500010
J	Corral, RS; Iniguez, MA; Duque, J; Lopez-Perez, R; Fresno, M				Corral, R. S.; Iniguez, M. A.; Duque, J.; Lopez-Perez, R.; Fresno, M.			Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells	ONCOGENE			English	Article						cyclooxygenase-2; NFAT; bombesin; migration; colon carcinoma	GASTRIN-RELEASING-PEPTIDE; RECEPTOR TYROSINE KINASE; CANCER CELLS; TRANSCRIPTIONAL REGULATION; INVASION; INHIBITION; MOTILITY; GROWTH; NFAT; INDUCTION	Cyclooxygenase-2 (Cox-2), the gastrin-release peptide (GRP) and its cognate receptor (GRP-R) are over-expressed in a significant percentage of colorectal carcinomas and are associated with cell growth, invasiveness and tumor progression. However, a molecular link between all of them in adenocarcinomas has not been established. Here, we show that bombesin (BBS), a GRP homolog, stimulates the expression of Cox-2 mRNA and protein in human colon adenocarcinoma Caco-2 cells, resulting in enhanced release of prostaglandin E-2. These effects were markedly inhibited by the specific BBS antagonist RC-3940-II. BBS promotes the activation of the nuclear factor of activated T cells (NFAT) through a Ca2+/calcineurin (Cn)linked pathway. Upon BBS stimulation, the NFATc1 isoform translocates into the nucleus witha concomitant increase in NFATc1 binding to two specific recognition sites in the promoter region of the Cox-2 gene. Furthermore, inhibition of Cn activity by the immunosuppressive drug cyclosporin A impaired NFAT activation and diminished Cox-2 expression in BBS-stimulated cells. Interestingly, BBS pretreatment strongly enhances the invasive capacity of carcinoma cells, effect which was inhibited by a Cox-2-specific inhibitor. These. findings provide the. first evidence for the involvement of the Ca2+/Cn/NFAT pathway in BBS-mediated induction of genes involved in colon carcinoma invasiveness such as Cox-2.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Fresno, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.	mfresno@cbm.uam.es	Peña, Miguel Angel Iñiguez/J-8518-2012	Peña, Miguel Angel Iñiguez/0000-0001-8262-6119; Lopez-Perez, Ricardo/0000-0001-9495-8604; Fresno Escudero, Manuel/0000-0002-9223-5477				ALBINI A, 1987, CANCER RES, V47, P3239; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Boss V, 1996, J BIOL CHEM, V271, P10429, DOI 10.1074/jbc.271.18.10429; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; CAI RZ, 1994, P NATL ACAD SCI USA, V91, P12664, DOI 10.1073/pnas.91.26.12664; Carroll RE, 2000, MOL PHARMACOL, V58, P601, DOI 10.1124/mol.58.3.601; Carroll RE, 1999, AM J PHYSIOL-GASTR L, V276, pG655, DOI 10.1152/ajpgi.1999.276.3.G655; Chan TA, 2002, LANCET ONCOL, V3, P166, DOI 10.1016/S1470-2045(02)00680-0; Chen M, 2005, ONCOGENE, V24, P5125, DOI 10.1038/sj.onc.1208729; Cheng HF, 2002, J BIOL CHEM, V277, P45638, DOI 10.1074/JBC.m206040200; CUTTITTA F, 1985, NATURE, V316, P823, DOI 10.1038/316823a0; Dixon DA, 2004, CURR PHARM DESIGN, V10, P635, DOI 10.2174/1381612043453171; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Engle MJ, 1998, J CELL PHYSIOL, V174, P362, DOI 10.1002/(SICI)1097-4652(199803)174:3<362::AID-JCP10>3.0.CO;2-B; Fenwick SW, 2003, GASTROENTEROLOGY, V125, P716, DOI 10.1016/S0016-5085(03)01061-8; Festuccia C, 1998, INT J CANCER, V75, P418, DOI 10.1002/(SICI)1097-0215(19980130)75:3<418::AID-IJC16>3.0.CO;2-4; Festuccia C, 2002, EXP CELL RES, V280, P1, DOI 10.1006/excr.2002.5609; Glover S, 2005, AM J PHYSIOL-GASTR L, V288, pG1274, DOI 10.1152/ajpgi.00108.2004; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; Gupta RA, 2001, NAT REV CANCER, V1, P11, DOI 10.1038/35094017; Hecht JR, 1997, PROSTAG OTH LIPID M, V54, P757, DOI 10.1016/S0090-6980(97)00162-7; Hellmich MR, 1999, J BIOL CHEM, V274, P23901, DOI 10.1074/jbc.274.34.23901; Hernandez GL, 2001, J EXP MED, V193, P607, DOI 10.1084/jem.193.5.607; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Holzmann K, 2004, CANCER RES, V64, P4428, DOI 10.1158/0008-5472.CAN-04-0431; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Iishi H, 2003, CLIN EXP METASTAS, V20, P555, DOI 10.1023/A:1025883129932; Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Inoue H, 2002, ARTERIOSCL THROM VAS, V22, P1415, DOI 10.1161/01.ATV.0000028816.13582.13; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Jensen JAG, 2001, PEPTIDES, V22, P689, DOI 10.1016/S0196-9781(01)00380-1; Kanashiro CA, 2003, P NATL ACAD SCI USA, V100, P15836, DOI 10.1073/pnas.2536558100; Kawai N, 2002, PROSTAG OTH LIPID M, V68-9, P187, DOI 10.1016/S0090-6980(02)00030-8; Kermorgant S, 2001, CARCINOGENESIS, V22, P1035, DOI 10.1093/carcin/22.7.1035; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Levine L, 2003, CANCER RES, V63, P3495; Liu WV, 2003, CANCER RES, V63, P3632; Liu ZM, 2004, J BIOL CHEM, V279, P41218, DOI 10.1074/jbc.M406917200; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Munoz-Najar UM, 2006, ONCOGENE, V25, P2379, DOI 10.1038/sj.onc.1209273; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Pai R, 2003, FASEB J, V17, P1640, DOI 10.1096/fj.02-1011com; PRESTON SR, 1995, BRIT J CANCER, V71, P1087, DOI 10.1038/bjc.1995.210; Ramsay RG, 2003, INT J IMMUNOPATH PH, V16, P59; Robida AM, 2000, MOL PHARMACOL, V58, P701, DOI 10.1124/mol.58.4.701; Rozengurt E, 2002, EUR J SURG, V168, P23; Ryan FR, 1999, J PHARMACOL EXP THER, V290, P1202; Saurin JC, 2002, CANCER RES, V62, P4829; Saurin JC, 1999, CANCER RES, V59, P962; Shao JY, 2004, J BIOL CHEM, V279, P14287, DOI 10.1074/jbc.M313276200; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Singh B, 2005, INT J ONCOL, V26, P1393; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sun YJ, 2005, MOL CANCER THER, V4, P51; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Williams CS, 1996, GASTROENTEROLOGY, V111, P1134, DOI 10.1016/S0016-5085(96)70083-5; Yegen BC, 2003, CURR PHARM DESIGN, V9, P1013, DOI 10.2174/1381612033455134; Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200	62	32	33	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					958	969		10.1038/sj.onc.1209856	http://dx.doi.org/10.1038/sj.onc.1209856			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909108	Bronze			2022-12-28	WOS:000244245400002
J	Rokaeus, N; Klein, G; Wiman, KG; Szekely, L; Mattsson, K				Rokaeus, N.; Klein, G.; Wiman, K. G.; Szekely, L.; Mattsson, K.			PRIMA-1(MET) induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins	ONCOGENE			English	Article						mutant p53; PRIMA-; nucleolus; PML odies; Hsp70	ACUTE PROMYELOCYTIC LEUKEMIA; POLYMERASE-I TRANSCRIPTION; DNA-DAMAGE; PREMATURE SENESCENCE; DEPENDENT APOPTOSIS; ONCOGENIC RAS; C-MYC; CELLS; DEGRADATION; INHIBITION	We have previously identified PRIMA-1, a low molecular weight compound that restores the transcriptional transactivation function to mutant p53 and induction of apoptosis. To explore the molecular mechanism for PRIMA-1-induced mutant p53-dependent apoptosis, we examined the intracellular distribution of mutant p53 upon treatment with PRIMA-1(MET) by immunofluorescence staining. We found that PRIMA-1(MET) induced nucleolar translocation of mutant p53 and the promyelocytic leukemia (PML) nuclear body-associated proteins PML, CBP and Hsp70. Levels of Hsp70 were significantly enhanced by PRIMA-1(MET) treatment. PRIMA-Dead, a compound structurally related to PRIMA-1 but unable to induce mutant p53-dependent apoptosis, failed to induce nucleolar translocation of mutant p53. Our results suggest that redistribution of mutant p53 to nucleoli plays a role in PRIMA-1-induced apoptosis.	Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, SE-17176 Stockholm, Sweden; Karolinska Inst, MTC, Microbiol & Tumor Biol Ctr, S-10401 Stockholm, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet	Wiman, KG (corresponding author), Karolinska Univ Hosp, Karolinska Inst, CCK, Dept Oncol Pathol, R8-04, SE-17176 Stockholm, Sweden.	Klas.Wiman@ki.se	Szekely, Laszlo/B-1268-2009; Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Szekely, Laszlo/0000-0001-6144-6573				Amin HM, 2001, BRIT J HAEMATOL, V115, P287, DOI 10.1046/j.1365-2141.2001.03123.x; Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225; Arabi A, 2003, J CELL SCI, V116, P1707, DOI 10.1242/jcs.00370; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Drouin A, 2001, EXP CELL RES, V271, P277, DOI 10.1006/excr.2001.5377; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Mattsson K, 2001, P NATL ACAD SCI USA, V98, P1012, DOI 10.1073/pnas.031566998; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Olson MOJ, 2005, HISTOCHEM CELL BIOL, V123, P203, DOI 10.1007/s00418-005-0754-9; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pespeni M, 2005, METHODS, V35, P158, DOI 10.1016/j.ymeth.2004.08.006; Pokrovskaja K, 2001, J GEN VIROL, V82, P345, DOI 10.1099/0022-1317-82-2-345; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Rehman A, 2005, BREAST CANCER RES, V7, pR765, DOI 10.1186/bcr1290; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Visintin R, 1999, NATURE, V398, P818, DOI 10.1038/19775; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	48	22	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					982	992		10.1038/sj.onc.1209858	http://dx.doi.org/10.1038/sj.onc.1209858			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909106				2022-12-28	WOS:000244245400004
J	Yang, G; Xu, Y; Chen, X; Hu, G				Yang, G.; Xu, Y.; Chen, X.; Hu, G.			IFITM1 plays an essential role in the antiproliferative action of interferon-gamma	ONCOGENE			English	Article						control of cell cycle progression; IFITM1; interferon-gamma; p53; extracellular signal-regulated kinase	SIGNAL-TRANSDUCTION PATHWAYS; BREAST-CANCER PROGRESSION; CYCLIN-DEPENDENT KINASE; MYC MESSENGER-RNA; GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; CELL-GROWTH; C-MYC; DIFFERENTIAL RESPONSE	Interferon-gamma (IFN-gamma) is a pleiotropic cytokine involved in antiproliferative and anti-virus responses, immune surveillance and tumor suppression. These biological responses to IFN-gamma are mainly mediated by the regulation of gene expression. It has been reported that growth-inhibitory role of IFN-gamma is dependent on activation of signal transducers and activators of transcription 1 (STAT1); however, the molecular basis downstream of STAT1 remains unclear. Here, we report that an IFN-gamma-induced gene, interferon-induced transmembrane protein 1 (IFITM1), plays a key role in the antiproliferative action of IFN-gamma. Overexpression of IFITM1 negatively regulated cell growth, whereas suppression of IFITM1 blocked the antiproliferative effect of IFN-gamma, accelerated the cell growth rate and conferred tumorigenicity to a nonmalignant hepatocyte in nude mice. Further, IFITM1 could inhibit the activity of extracellular signal-regulated kinase, enhance the transcriptional activity of p53 and stabilize the p53 protein by inhibiting p53 phosphorylation on Thr55. Suppression of p53 reduced the growth-inhibitory capacity of both IFITM1 and IFN-gamma. Therefore, these findings indicated that the antiproliferative action of IFN-gamma requires the induction of IFITM1, and provided a crosstalk between two well-known signaling mediators, STAT1 and p53, both of which play critical roles in tumor suppression.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Hu, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai 200031, Peoples R China.	hgxgene@sunm.shcnc.ac.cn						Abba MC, 2004, BREAST CANCER RES, V6, pR499, DOI 10.1186/bcr899; ACKRILL AM, 1991, NUCLEIC ACIDS RES, V19, P591, DOI 10.1093/nar/19.3.591; Akyerli CB, 2005, LEUKEMIA RES, V29, P283, DOI 10.1016/j.leukres.2004.07.007; Alber D, 1996, J INTERF CYTOK RES, V16, P375, DOI 10.1089/jir.1996.16.375; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Buard A, 1998, CANCER RES, V58, P840; Catchpoole D, 1997, J MED GENET, V34, P353, DOI 10.1136/jmg.34.5.353; CHEN YX, 1984, J IMMUNOL, V133, P2496; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DEBLANDRE GA, 1995, J BIOL CHEM, V270, P23860, DOI 10.1074/jbc.270.40.23860; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVANS SS, 1990, BLOOD, V76, P2583; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Halaschek-Wiener J, 2004, CELL SIGNAL, V16, P1319, DOI 10.1016/j.cellsig.2004.04.003; Huang HT, 2000, CANCER RES, V60, P6868; Huang RM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0687com; Kano A, 1999, BIOCHEM BIOPH RES CO, V257, P672, DOI 10.1006/bbrc.1999.0276; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Karnik P, 1998, HUM MOL GENET, V7, P895, DOI 10.1093/hmg/7.5.895; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; Kominsky SL, 2000, CANCER RES, V60, P3904; Li HH, 2004, MOL CELL, V13, P867, DOI 10.1016/S1097-2765(04)00123-6; LIU MK, 1994, INFECT IMMUN, V62, P2722, DOI 10.1128/IAI.62.7.2722-2731.1994; Lu KH, 1997, CANCER RES, V57, P387; MAIER JAM, 1995, BIOCHEM BIOPH RES CO, V214, P582, DOI 10.1006/bbrc.1995.2325; Mandal M, 1998, ONCOGENE, V16, P217, DOI 10.1038/sj.onc.1201529; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Matsushita K, 2006, CANCER SCI, V97, P57, DOI 10.1111/j.1349-7006.2006.00137.x; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NEGRINI M, 1995, CANCER RES, V55, P3003; Nguyen DT, 2004, MOL BIOL CELL, V15, P4248, DOI 10.1091/mbc.E03-11-0851; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; OBriant KC, 1997, GENE CHROMOSOME CANC, V18, P111, DOI 10.1002/(SICI)1098-2264(199702)18:2<111::AID-GCC5>3.0.CO;2-5; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rodig S, 1998, EUR CYTOKINE NETW, V9, P49; ROUSSEL MF, 1994, ONCOGENE, V9, P405; Sakatsume M, 1998, J BIOL CHEM, V273, P3021, DOI 10.1074/jbc.273.5.3021; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; SELIGER B, 1991, J VIROL, V65, P6307, DOI 10.1128/JVI.65.11.6307-6311.1991; Stancato LF, 1998, J BIOL CHEM, V273, P18701, DOI 10.1074/jbc.273.30.18701; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Tran YK, 1996, CANCER RES, V56, P2916; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yeh PY, 2004, ONCOGENE, V23, P3580, DOI 10.1038/sj.onc.1207426; Yeh PY, 2001, BIOCHEM BIOPH RES CO, V284, P880, DOI 10.1006/bbrc.2001.5043; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	60	101	107	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					594	603		10.1038/sj.onc.1209807	http://dx.doi.org/10.1038/sj.onc.1209807			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16847454				2022-12-28	WOS:000243731600011
J	Walker, SR; Nelson, EA; Frank, DA				Walker, S. R.; Nelson, E. A.; Frank, D. A.			STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas	ONCOGENE			English	Article						STAT5; BCL6; transcription; chromatin	B-CELL LYMPHOMA; AFFECTING BAND 3Q27; CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVE ACTIVATION; SIGNAL TRANSDUCER; GENE-EXPRESSION; SELF-RENEWAL; DIFFERENTIATION; TRANSLOCATIONS; IDENTIFICATION	Deregulated expression of BCL6 is a pathogenic event in many lymphomas. BCL6 blocks cellular differentiation by repressing transcription of its target genes, and this may promote tumorigenesis. Conversely, the transcription factor signal transducers and activators of transcription (STAT) 5 promotes differentiation in many systems. STAT5 upregulates a number of genes repressed by BCL6, raising the possibility that STAT5 and BCL6 have opposing roles in transcriptional regulation. Therefore, we sought to determine the effects of STAT5 activation on BCL6 expression and function. We found that activation of STAT5 downregulates BCL6 expression in B-lymphoma cells and other hematopoietic cell lines. We identified two potential STAT-binding regions in the first exon and first intron of BCL6 that fell within regions of high interspecies homology, suggesting conservation of regulatory function. STAT5 can bind inducibly and regulate transcription at one of these regions, identifying BCL6 as a STAT5 target gene. Additionally, STAT5-mediated downregulation of BCL6 results in loss of BCL6 repression of its target genes, confirming that STAT5 is a negative regulator of BCL6 function. The STAT5 responsive region of the BCL6 gene is mutated frequently in B-cell lymphomas, suggesting that loss of the repressive effects of STAT5 on BCL6 might contribute to the pathogenesis of these cancers.	Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Frank, DA (corresponding author), Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, 44 Binney St,M522B, Boston, MA 02115 USA.	david_frank@dfci.harvard.edu						Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; BajalicaLagercrantz S, 1997, LEUKEMIA, V11, P594, DOI 10.1038/sj.leu.2400577; Baron BW, 2004, P NATL ACAD SCI USA, V101, P14198, DOI 10.1073/pnas.0406138101; BARON BW, 1993, P NATL ACAD SCI USA, V90, P5262, DOI 10.1073/pnas.90.11.5262; Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brudno M, 2004, GENOME RES, V14, P685, DOI 10.1101/gr.2067704; Buitenhuis M, 2003, BLOOD, V101, P134, DOI 10.1182/blood-2002-03-0740; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Chaganti SR, 1998, GENE CHROMOSOME CANC, V23, P323, DOI 10.1002/(SICI)1098-2264(199812)23:4<323::AID-GCC7>3.3.CO;2-V; Chen WY, 1998, BLOOD, V91, P603, DOI 10.1182/blood.V91.2.603.603_603_607; Cui Y, 2004, MOL CELL BIOL, V24, P8037, DOI 10.1128/MCB.24.18.8037-8047.2004; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; de Mattos SF, 2004, MOL CELL BIOL, V24, P10058, DOI 10.1128/MCB.24.22.10058-10071.2004; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Frank DA, 1999, MOL MED, V5, P432; FRANK DA, 1995, P NATL ACAD SCI USA, V92, P7779, DOI 10.1073/pnas.92.17.7779; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; HAPP B, 1993, J STEROID BIOCHEM, V47, P21, DOI 10.1016/0960-0760(93)90053-Y; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ichinohasama R, 1998, CANCER GENET CYTOGEN, V104, P19, DOI 10.1016/S0165-4608(97)00412-3; Ilaria RL, 1999, BLOOD, V93, P4154, DOI 10.1182/blood.V93.12.4154.412k15_4154_4166; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Leong PL, 2002, ONCOGENE, V21, P2846, DOI 10.1038/sj.onc.1205385; Lin TS, 2000, ONCOGENE, V19, P2496, DOI 10.1038/sj.onc.1203486; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Melzner I, 2005, BLOOD, V105, P2535, DOI 10.1182/blood-2004-09-3701; Messika EJ, 1998, J EXP MED, V188, P515, DOI 10.1084/jem.188.3.515; Migliazza A, 1995, P NATL ACAD SCI USA, V92, P12520, DOI 10.1073/pnas.92.26.12520; Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010; Nakajima H, 2001, EMBO J, V20, P6836, DOI 10.1093/emboj/20.23.6836; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Niu HF, 2003, J EXP MED, V198, P211, DOI 10.1084/jem.20021395; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; OHASHI K, 1995, BIOCHEM BIOPH RES CO, V214, P461, DOI 10.1006/bbrc.1995.2309; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Otaki JM, 2005, NEUROSCI RES, V53, P189, DOI 10.1016/j.neures.2005.06.018; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Scheeren FA, 2005, NAT IMMUNOL, V6, P303, DOI 10.1038/ni1172; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Xi SC, 2003, CANCER RES, V63, P6763; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BHH, 1993, CANCER RES, V53, P2732; Zhou G, 2005, EXP MOL PATHOL, V78, P25, DOI 10.1016/j.yexmp.2004.08.008	62	91	91	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					224	233		10.1038/sj.onc.1209775	http://dx.doi.org/10.1038/sj.onc.1209775			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819511				2022-12-28	WOS:000243398300006
J	Wang, X; Zhao, J				Wang, X.; Zhao, J.			KLF8 transcription factor participates in oncogenic transformation	ONCOGENE			English	Article						KLF8; transformation; v-Src	FOCAL ADHESION KINASE; TUMOR-SUPPRESSOR GENE; CELL-CYCLE; COLORECTAL-CANCER; PROSTATE-CANCER; OVARIAN-CANCER; HUMAN BREAST; FAK; PROGRESSION; EXPRESSION	Kruppel-like factor 8 (KLF8) is a member of the family of KLF transcription factors. Several KLF members have been shown to play a role in oncogenesis. We have previously demonstrated that KLF8 mediates cell cycle progression downstream of focal adhesion kinase (FAK) by upregulating cyclin D1. FAK plays a critical role in transformation and tumorigenesis and is aberrantly upregulated in many types of human cancer. Little is known about the function of KLF8 in these regards. Here we provide evidence suggesting a novel role of KLF8 in oncogenic transformation. We show that KLF8 expression is elevated in several types of human cancer cells and primary tumor tissues. Induced expression of ectopic KLF8 causes serum-independent growth and morphological transformation in NIH3T3 cells and enhances anchorage-independent growth of v-Src-transformed cells. In contrast, expression of a dominant-negative mutant of KLF8 dramatically suppresses the transformed phenotypes induced by v-Src. In addition, the KLF8-enhanced transformation in the v-Src cells was prevented by ablating cyclin D1 expression. Overall, these results indicate that KLF8 is required for v-Src-induced transformation and may play a role in tumor progression of human cancer.	Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA	Albany Medical College	Zhao, J (corresponding author), Albany Med Coll, Ctr Cell Biol & Canc Res, 47 New Scotland Ave,Mail Code 165,MS338, Albany, NY 12208 USA.	zhaojh@mail.amc.edu						Benlimame N, 2005, J CELL BIOL, V171, P505, DOI 10.1083/jcb.200504124; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Dong JT, 2001, CANCER METAST REV, V20, P173, DOI 10.1023/A:1015575125780; Ellenrieder V, 2004, GASTROENTEROLOGY, V127, P607, DOI 10.1053/j.gastro.2004.05.018; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589; Ghaleb AM, 2005, CELL RES, V15, P92, DOI 10.1038/sj.cr.7290271; Grisaru-Granovsky S, 2005, INT J CANCER, V113, P372, DOI 10.1002/ijc.20607; Kimmelman AC, 2004, ONCOGENE, V23, P5077, DOI 10.1038/sj.onc.1207662; Leslie K, 2006, CANCER RES, V66, P2544, DOI 10.1158/0008-5472.CAN-05-2203; Lim KH, 2004, MOL CELL, V15, P491, DOI 10.1016/j.molcel.2004.08.014; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; McLean GW, 2004, GENE DEV, V18, P2998, DOI 10.1101/gad.316304; Nandan MO, 2004, ONCOGENE, V23, P3404, DOI 10.1038/sj.onc.1207397; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Sood AK, 2004, AM J PATHOL, V165, P1087, DOI 10.1016/S0002-9440(10)63370-6; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Zhao J, 2001, MOL BIOL CELL, V12, P4066, DOI 10.1091/mbc.12.12.4066; Zhao JH, 2000, J CELL SCI, V113, P3063; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	32	88	102	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					456	461		10.1038/sj.onc.1209796	http://dx.doi.org/10.1038/sj.onc.1209796			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832343				2022-12-28	WOS:000243544000014
J	Tsumura, H; Yoshida, T; Saito, H; Imanaka-Yoshida, K; Suzuki, N				Tsumura, H.; Yoshida, T.; Saito, H.; Imanaka-Yoshida, K.; Suzuki, N.			Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice	ONCOGENE			English	Article						pleomorphic rhabdomyosarcoma; K-ras; p53	SOFT-TISSUE SARCOMAS; N-RAS; SKELETAL-MUSCLE; H-RAS; P53-DEFICIENT MICE; POINT MUTATIONS; CRE RECOMBINASE; STEM-CELL; IN-VIVO; GENE	Human rhabdomyosarcomas (RMSs) frequently demonstrate genetic alterations in ras and p53. To investigate their possible involvement in the tumorigenesis, we generated a knock- in mouse line with oncogenic K- ras, conditionally expressed by Cre/ LoxP system on a background of p53 alteration. Electroporation of Cre expression vector in skeletal muscle tissues resulted in the generation of tumor in adults with tumor incidences of 100% at 10 weeks and 40% at 15 weeks, in p53(-/-) and p53(-/-) backgrounds, respectively. The tumor histology was pleomorphic RMS with characteristic bizarre giant cells, positive for desmin and alpha-sarcomeric actin and exhibiting remarkable increase in total and phosphorylated extracellular signal- regulated protein kinase (ERK) 1 and ERK2. Loss of the wild- type p53 was detected in K- rasG12V- expressed tumors of p53(-/+) mice. Early lesions 3 weeks after electroporation consisted of proliferating populations of myogenic progenitors, including stem cells positive for ScaI antigen, immature cells positive for desmin and neural cell adhesion molecule- positive myotubes. Thus, cooperation of oncogenic K- ras and p53 deficiency resulted in the development of pleomorphic RMS in adult mice, providing a useful mouse model for further detailed studies.	Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, Tsu, Mie 5148507, Japan; Mie Univ, Grad Sch Med, Tsu, Mie 5148507, Japan	Mie University; Mie University	Suzuki, N (corresponding author), Mie Univ, Life Sci Res Ctr, Dept Anim Genom, Funct Genom Inst, 2-174 Edobashi, Tsu, Mie 5148507, Japan.	nsuzuki@doc.medic.mie-u.ac.jp	Yoshida, Toshimichi/H-6204-2013	Yoshida, Toshimichi/0000-0001-8935-8217				BIRCH JM, 1990, CANCER-AM CANCER SOC, V66, P2239, DOI 10.1002/1097-0142(19901115)66:10<2239::AID-CNCR2820661034>3.0.CO;2-Q; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Durieux AC, 2004, J GENE MED, V6, P809, DOI 10.1002/jgm.534; Fedorov YV, 2002, MOL CELL BIOL, V22, P1140, DOI 10.1128/MCB.22.4.1140-1149.2002; FELIX CA, 1992, CANCER RES, V52, P2243; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Garcia JM, 2000, BRIT J CANCER, V82, P1183; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Hawkins WG, 2001, CANCER-AM CANCER SOC, V91, P794, DOI 10.1002/1097-0142(20010215)91:4<794::AID-CNCR1066>3.0.CO;2-Q; Hingorani SR, 2003, CURR OPIN GENET DEV, V13, P6, DOI 10.1016/S0959-437X(02)00017-5; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; KOYABU S, 1994, CELL MOTIL CYTOSKEL, V29, P259, DOI 10.1002/cm.970290309; LaBarge MA, 2002, CELL, V111, P589, DOI 10.1016/S0092-8674(02)01078-4; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Linardic CM, 2005, CANCER RES, V65, P4490, DOI 10.1158/0008-5472.CAN-04-3194; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; Nanni P, 2003, CANCER RES, V63, P2728; OLSON EN, 1987, MOL CELL BIOL, V7, P2104, DOI 10.1128/MCB.7.6.2104; Patel S R, 2000, Curr Treat Options Oncol, V1, P258, DOI 10.1007/s11864-000-0037-6; Saito H, 2005, BIOCHEM BIOPH RES CO, V331, P1216, DOI 10.1016/j.bbrc.2005.04.043; Sakai K, 1995, BIOCHEM BIOPH RES CO, V217, P393, DOI 10.1006/bbrc.1995.2789; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; STRATTON MR, 1989, CANCER RES, V49, P6324; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; TSUKADA T, 1993, ONCOGENE, V8, P3313; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; WEXLER LH, 1994, CA-CANCER J CLIN, V44, P211, DOI 10.3322/canjclin.44.4.211; White JD, 2002, INT J DEV BIOL, V46, P577; WILKE W, 1993, MODERN PATHOL, V6, P129; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; Yoo J, 1999, CANCER, V86, P58, DOI 10.1002/(SICI)1097-0142(19990701)86:1<58::AID-CNCR10>3.3.CO;2-J	38	62	64	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7673	7679		10.1038/sj.onc.1209749	http://dx.doi.org/10.1038/sj.onc.1209749			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785989				2022-12-28	WOS:000242830800002
J	Honrado, E; Osorio, A; Palacios, J; Benitez, J				Honrado, E.; Osorio, A.; Palacios, J.; Benitez, J.			Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations	ONCOGENE			English	Review						immunohistochemistry; profile; microarrays	BASAL EPITHELIAL PHENOTYPE; GERMLINE BRCA1; ESTROGEN-RECEPTOR; CANCER SUSCEPTIBILITY; CHEK2-ASTERISK-1100DELC VARIANT; IMMUNOHISTOCHEMICAL MARKERS; HISTOPATHOLOGICAL FEATURES; TRANSCRIPTIONAL ACTIVITY; TISSUE MICROARRAY; OVARIAN-CANCER	Tumors arising in BRCA1 and BRCA2 mutation carriers appear to have specific pathological and gene expression profiles, which show a high level of concordance. BRCA1 tumors are high-grade, negative for hormone receptors, have a high proliferation rate, and are positive for some cell cycle promoter genes. BRCA2 tumors present a phenotype opposite to BRCA1 tumors but very similar to sporadic tumors, except that BRCA2 overexpress some DNA repair markers such as CHEK2, show high cytoplasmic expression of RAD51, and are negative for HER-2 amplification and expression. Some of these characteristics have also been found in cDNA expression studies, although more analysis are necessary in order to obtain new markers that can be associated with a germ line mutation in BRCA1 or BRCA2. In this way, some studies in normal tissues of BRCA1/2 carriers suggest that differences exist in the level of expression of some genes when compared with noncarriers. Finally, IHC studies in tumors carrying a mutation in CHEK2 are rare and show contradictory results, probably due to the low number of these cases. However, they represent an example showing how different mutations of the same gene may be associated with specific histological subtypes of cancer.	CNIO, Spanish Natl Canc Ctr, Human Genet Grp, E-28029 Madrid, Spain; CNIO, Spanish Natl Canc Ctr, Breast & Gynecol Canc Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Benitez, J (corresponding author), CNIO, Spanish Natl Canc Ctr, Human Genet Grp, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	jbenitez@cnio.es	Osorio, Ana/I-4324-2014; Palacios, Jose/AAV-3765-2020	Osorio, Ana/0000-0001-8124-3984; Honrado Franco, Emiliano/0000-0001-5668-4083				Adem C, 2004, GENE CHROMOSOME CANC, V41, P1, DOI 10.1002/gcc.20057; Agnarsson BA, 1998, BREAST CANCER RES TR, V47, P121, DOI 10.1023/A:1005853022804; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; Armes JE, 1999, CANCER RES, V59, P2011; Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; ARNOLD K, 2006, CANC LETT, V28, P1; Brekelmans CTM, 2001, J CLIN ONCOL, V19, P924, DOI 10.1200/JCO.2001.19.4.924; Caligo MA, 2004, HUM MUTAT, V24, P100, DOI 10.1002/humu.20051; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cavalli LR, 2004, CANCER GENET CYTOGEN, V149, P38, DOI 10.1016/S0165-4608(03)00282-6; Chang JC, 2003, LANCET, V362, P362, DOI 10.1016/S0140-6736(03)14023-8; Chappuis PO, 2005, ANN ONCOL, V16, P735, DOI 10.1093/annonc/mdi149; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; de Bock GH, 2004, J MED GENET, V41, P731, DOI 10.1136/jmg.2004.019737; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Eisinger F, 1999, INT J CANCER, V84, P263, DOI 10.1002/(SICI)1097-0215(19990621)84:3<263::AID-IJC11>3.0.CO;2-G; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, CANCER, V98, P1569, DOI 10.1002/cncr.11688; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Gillett CE, 1998, J PATHOL, V184, P396; Goffin JR, 2003, CANCER-AM CANCER SOC, V97, P527, DOI 10.1002/cncr.11080; Greenblatt MS, 2001, CANCER RES, V61, P4092; Gretarsdottir S, 1998, CANCER RES, V58, P859; Grushko TA, 2002, CANCER RES, V62, P1481; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Hoogerbrugge N, 2003, J CLIN ONCOL, V21, P41, DOI 10.1200/JCO.2003.02.137; Huzarski T, 2005, BREAST CANCER RES TR, V90, P187, DOI 10.1007/s10549-004-3778-2; Isaacs C, 2004, BREAST CANCER RES TR, V84, P99, DOI 10.1023/B:BREA.0000018406.03679.2e; Jacquemier J, 2005, J PATHOL, V207, P260, DOI 10.1002/path.1845; Jekimovs CR, 2005, BRIT J CANCER, V92, P784, DOI 10.1038/sj.bjc.6602381; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kauff ND, 2003, CANCER-AM CANCER SOC, V97, P1601, DOI 10.1002/cncr.11225; Kilpivaara O, 2005, INT J CANCER, V113, P575, DOI 10.1002/ijc.20638; Kleibl Z, 2005, BREAST CANCER RES TR, V90, P165, DOI 10.1007/s10549-004-4023-8; Kote-Jarai Z, 2004, CLIN CANCER RES, V10, P958, DOI 10.1158/1078-0432.CCR-1067-3; Lakhani S R, 1999, Breast Cancer Res, V1, P31, DOI 10.1186/bcr10; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2000, CLIN CANCER RES, V6, P782; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lakhani SR, 1997, LANCET, V349, P1505; Lakhani SR, 1999, J PATHOL, V189, P496, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;496::AID-PATH485&gt;3.0.CO;2-D; Larson PS, 2005, J CLIN ONCOL, V23, P8613, DOI 10.1200/JCO.2005.02.1451; Linke SP, 2006, CLIN CANCER RES, V12, P1175, DOI 10.1158/1078-0432.CCR-05-1562; Lynch BJ, 1998, HUM PATHOL, V29, P1140, DOI 10.1016/S0046-8177(98)90427-0; Marcus JN, 1997, BREAST CANCER RES TR, V44, P275, DOI 10.1023/A:1005830230664; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitchell G, 2005, BREAST CANCER RES, V7, pR1122, DOI 10.1186/bcr1348; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Nielsen TO, 2004, CANCER RES, V64, P286, DOI 10.1158/0008-5472.CAN-03-1242; Noguchi S, 1999, CANCER-AM CANCER SOC, V85, P2200, DOI 10.1002/(SICI)1097-0142(19990515)85:10<2200::AID-CNCR14>3.0.CO;2-S; Offit Kenneth, 2003, BMC Med Genet, V4, P1, DOI 10.1186/1471-2350-4-1; Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230; Oldenburg RA, 2003, CANCER RES, V63, P8153; Ongusaha PP, 2003, ONCOGENE, V22, P3749, DOI 10.1038/sj.onc.1206439; Osin P, 1998, EUR J CANCER, V34, P1683, DOI 10.1016/S0959-8049(98)00248-2; Osin P P, 1999, Breast Cancer Res, V1, P36, DOI 10.1186/bcr11; Osorio A, 2004, INT J CANCER, V108, P54, DOI 10.1002/ijc.11414; Palacios J, 2003, CLIN CANCER RES, V9, P3606; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Palacios J, 2004, JNCI-J NATL CANCER I, V96, P712, DOI 10.1093/jnci/djh115; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips KA, 1999, J NATL CANCER I, V91, P469, DOI 10.1093/jnci/91.5.469; PINILLA SM, 2006, BREAST CANC RES 0316; Quenneville LA, 2002, CANCER-AM CANCER SOC, V95, P2068, DOI 10.1002/cncr.10949; Rashid MU, 2005, EUR J CANCER, V41, P2896, DOI 10.1016/j.ejca.2005.04.049; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621; Robson M, 1998, CANCER RES, V58, P1839; Robson ME, 2004, BREAST CANCER RES, V6, pR8, DOI 10.1186/bcr658; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Ruiz C, 2006, INT J CANCER, V118, P2190, DOI 10.1002/ijc.21581; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Signoretti S, 2002, J CLIN INVEST, V110, P633, DOI 10.1172/JCI200215795; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STARK GR, 1993, ADV CANCER RES, V61, P87, DOI 10.1016/S0065-230X(08)60956-2; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van der Groep P, 2004, JNCI-J NATL CANCER I, V96, P712, DOI 10.1093/jnci/djh114; van Slooten HJ, 1998, BRIT J CANCER, V77, P789, DOI 10.1038/bjc.1998.128; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Warren M, 2003, HUM MOL GENET, V12, P2645, DOI 10.1093/hmg/ddg277; Weber F, 2005, BRIT J CANCER, V92, P1922, DOI 10.1038/sj.bjc.6602557; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	104	74	75	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5837	5845		10.1038/sj.onc.1209875	http://dx.doi.org/10.1038/sj.onc.1209875			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998498				2022-12-28	WOS:000240765900004
J	Narod, SA				Narod, S. A.			Modifiers of risk of hereditary breast cancer	ONCOGENE			English	Review						BRCA1; BRCA2; penetrance; risk factors; genetic counseling; breast cancer	BRCA2 MUTATION CARRIERS; BILATERAL PROPHYLACTIC OOPHORECTOMY; SURGICAL ADJUVANT BREAST; OVARIAN-CANCER; ORAL-CONTRACEPTIVES; INHERITED MUTATIONS; WOMEN; PENETRANCE; PREVENTION; TAMOXIFEN	Mutations in the BRCA1 and BRCA2 genes confer a high lifetime risk of breast and ovarian cancer. The risk varies from individual to individual, and it appears that the risk has increased in recent generations. These observations imply that non-genetic factors may modify the inherited risk. To date, the factors that appear most strongly to modify the risk include reproductive histories and exogenous hormones. Oral contraceptives are associated with a profound reduction in the risk of ovarian cancer, and with little or no increase in the risk of breast cancer. Other modifying factors include age of menarche, parity, breastfeeding and oophorectomy. The effect of parity is different in BRCA1 and BRCA2 carriers. Multiparity appears to be protective in BRCA1 carriers, but is associated with an increase in risk in BRCA2 carriers. Oophorectomy has been associated with reductions in both the risk of breast and ovarian cancer. Knowledge of these risk factors will be useful for managing risk and for developing prevention strategies.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750A, Toronto, ON M5G 1N8, Canada.	steven.narod@wchospital.ca	Narod, Steven A/AAA-6112-2022					Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; Clarke M, 1998, LANCET, V351, P1451; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Eisen A, 2005, J CLIN ONCOL, V23, P7491, DOI 10.1200/JCO.2004.00.7138; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Friedman E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1387; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Jernstrom H, 2003, CARCINOGENESIS, V24, P991, DOI 10.1093/carcin/bgg047; JERNSTROM H, 2004, JNCI-J NATL CANCER I, V96, P209; Kauff ND, 2002, NEW ENGL J MED, V346, P1609, DOI 10.1056/NEJMoa020119; King MC, 2001, JAMA-J AM MED ASSOC, V286, P2251, DOI 10.1001/jama.286.18.2251; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kotsopoulos J, 2005, CANCER CAUSE CONTROL, V16, P125, DOI 10.1007/s10552-004-2593-8; Kotsopoulos J, 2005, CANCER CAUSE CONTROL, V16, P667, DOI 10.1007/s10552-005-1724-1; KOTSOPOULOS J, 2006, UNPUB AGE 1 BRITH RI; Kowalska E, 2005, CANCER EPIDEM BIOMAR, V14, P1302, DOI 10.1158/1055-9965.EPI-03-0448; LevyLahad E, 1997, AM J HUM GENET, V60, P1059; Mazoyer S, 1996, NAT GENET, V14, P253, DOI 10.1038/ng1196-253; Meijers-Heijboer H, 2001, NEW ENGL J MED, V345, P159, DOI 10.1056/NEJM200107193450301; NAROD S, 1993, LANCET, V341, P1101, DOI 10.1016/0140-6736(93)92468-9; Narod SA, 2002, JNCI-J NATL CANCER I, V94, P1773, DOI 10.1093/jnci/94.23.1773; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; NKONDJOCK A, 2006, INT J CANCER, V18, P1852; Phelan CM, 1996, NAT GENET, V12, P309, DOI 10.1038/ng0396-309; Rebbeck TR, 1999, AM J HUM GENET, V64, P1371, DOI 10.1086/302366; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 2005, J CLIN ONCOL, V23, P7804, DOI 10.1200/JCO.2004.00.8151; Rebbeck TR, 2001, CANCER RES, V61, P5420; Risch HA, 2001, AM J HUM GENET, V68, P700, DOI 10.1086/318787; Runnebaum IB, 2001, PHARMACOGENETICS, V11, P635, DOI 10.1097/00008571-200110000-00010; RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517; RUSSO J, 2001, BREAST J, V7, P277; Thompson D, 2001, AM J HUM GENET, V68, P410, DOI 10.1086/318181; Thorlacius S, 1997, AM J HUM GENET, V60, P1079; Tryggvadottir L, 2006, JNCI-J NATL CANCER I, V98, P116, DOI 10.1093/jnci/djj012; Weitzel JN, 2005, CANCER EPIDEM BIOMAR, V14, P1534, DOI 10.1158/1055-9965.EPI-05-0070	39	85	90	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5832	5836		10.1038/sj.onc.1209870	http://dx.doi.org/10.1038/sj.onc.1209870			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998497				2022-12-28	WOS:000240765900003
J	Chen, E; Kwon, YT; Lim, MS; Dube, ID; Hough, MR				Chen, E.; Kwon, Y. T.; Lim, M. S.; Dube, I. D.; Hough, M. R.			Loss of Ubr1 promotes aneuploidy and accelerates B-cell lymphomagenesis in TLX1/HOX11-transgenic mice	ONCOGENE			English	Article						HOX11; homeobox; B cell lymphoma; aneuploidy; chromosome missegregation	END RULE PATHWAY; LINEAGE LYMPHOMAS; UBIQUITIN LIGASES; HOMEOBOX GENE; HOX11; DEGRADATION; INTERACTS; COMPONENT; ONCOGENE; SUBUNIT	The TLX1/HOX11 homeobox gene was originally identified at the recurrent t(10;14)(q24;q11) translocation breakpoint, a chromosomal abnormality observed in 5-7% of T-cell acute lymphoblastic leukemias (T-ALLs). Proviral insertional mutagenesis studies performed on transgenic mice ectopically expressing TLX1/HOX11 in B lymphocytes (IgH mu-HOX11(Tg) mice) revealed the Ubr1 gene locus as a frequent site of proviral insertion, concomitant with accelerated development of diffuse large B-cell lymphoma. Insertion into this genomic region was confirmed by Southern blotting and by the ability to generate a polymerase chain reaction (PCR) amplicon across the viral-genome junction. Western immunoblot and semiquantitative reverse transcriptase-PCR analysis revealed downregulated expression of the Ubr1 gene product subsequent to viral integration. Loss or reduced levels of Ubr1 expression was associated with 5/14 spontaneous B-cell lymphomas in IgH mu-HOX11(Tg) mice and one of nine primary human T-ALLs. To gain mechanistic insight into the cooperativity between TLX1/HOX11 and Ubr1, IgH(mu)-HOX11(Tg)/Ubr1(+/-) mice were generated. IgH mu-HOX11(Tg)/Ubr1(+/-) mice exhibited a modest but statistically significant acceleration of disease onset relative to IgH mu-HOX11(Tg)/Ubr1(+/-) mice. Moreover, micronucleus assays to detect for chromosome missegregation were conducted and revealed increased presence of micronuclei in IgH mu-HOX11(Tg)/Ubr1(-/-) primary B lymphocyte cultures, and in both TLX1/HOX11-overexpressing T cell lines and fibroblast cultures following transfection with short interfering RNAs (siRNAs) targeting Ubr1. Karyotyping of primary B lymphocyte cultures revealed increased incidences of hypodiploid karyotypes. Finally, mitotic figures analysed from Ubr1 siRNA-transfected fibroblast cultures revealed no defects in chromosome congression to the metaphase plate, but increased incidences of atypical anaphase figures, including the development of anaphase bridges and lagging chromosomes. Based on these findings, we identify a synergistic role between TLX1/HOX11 overexpression and Ubr1 inactivation in promoting chromosome missegregation, permitting the accrual of additional chromosome losses and cytogenic abnormalities en route to malignancy.	Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, Toronto, ON M4N 3M5, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; Univ Pittsburgh, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Pharm, Ctr Pharmacogenet, Pittsburgh, PA 15260 USA; Univ Utah, Dept Pathol, Salt Lake City, UT USA; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utah System of Higher Education; University of Utah; University of Toronto	Hough, MR (corresponding author), Sunnybrook & Womens Coll Hlth Sci Ctr, Dept Mol & Cellular Biol, 2075 Bayview Ave,Room S232, Toronto, ON M4N 3M5, Canada.	margaret.hough@sw.ca	Hough, Margaret/AAA-1026-2019	Hough, Margaret/0000-0001-8539-6398; Lim, Megan/0000-0002-0415-2867; Chen, Edwin/0000-0003-0742-9734	NIGMS NIH HHS [GM69482] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069482] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen E, 2006, ONCOGENE, V25, P2575, DOI 10.1038/sj.onc.1209285; DEGROOT RJ, 1991, P NATL ACAD SCI USA, V88, P8967, DOI 10.1073/pnas.88.20.8967; Ditzel M, 2003, NAT CELL BIOL, V5, P467, DOI 10.1038/ncb984; DUBE ID, 1986, BLOOD, V67, P1181; DUBE ID, 1991, BLOOD, V78, P2996; Hamilton MH, 2003, P NATL ACAD SCI USA, V100, P5081, DOI 10.1073/pnas.0831228100; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HAWLEY RG, 1994, ONCOGENE, V9, P1; Hawley RG, 1997, CANCER RES, V57, P337; Hough MR, 1998, P NATL ACAD SCI USA, V95, P13853, DOI 10.1073/pnas.95.23.13853; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Keller G, 1998, BLOOD, V92, P877, DOI 10.1182/blood.V92.3.877.415k11_877_887; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; KLINKEN SP, 1988, J IMMUNOL, V140, P1123; Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898; Kwon YT, 2003, MOL CELL BIOL, V23, P8255, DOI 10.1128/MCB.23.22.8255-8271.2003; Kwon YT, 2002, SCIENCE, V297, P96, DOI 10.1126/science.1069531; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lawson TG, 1999, J BIOL CHEM, V274, P9871, DOI 10.1074/jbc.274.14.9871; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Mulder LCF, 2000, J BIOL CHEM, V275, P29749, DOI 10.1074/jbc.M004670200; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Riz I, 2005, ONCOGENE, V24, P5561, DOI 10.1038/sj.onc.1208727; Tasaki T, 2005, MOL CELL BIOL, V25, P7120, DOI 10.1128/MCB.25.16.7120-7136.2005; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Yin JH, 2004, HUM MOL GENET, V13, P2421, DOI 10.1093/hmg/ddh269; Yoshida S, 2002, PLANT J, V32, P129, DOI 10.1046/j.1365-313X.2002.01407.x	27	9	9	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5752	5763		10.1038/sj.onc.1209573	http://dx.doi.org/10.1038/sj.onc.1209573			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16862188				2022-12-28	WOS:000240765800006
J	Pulukuri, SM; Rao, JS				Pulukuri, S. M.; Rao, J. S.			CpG island promoter methylation and silencing of 14-3-3 sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2	ONCOGENE			English	Article						CpG methylation; 14-3-3 sigma; MBD2; prostate cancer	DNA METHYLATION; BREAST-CANCER; TRANSCRIPTIONAL REPRESSION; EPIGENETIC INACTIVATION; UPA PROMOTER; HYPERMETHYLATION; CARCINOMA; CHROMATIN; MECHANISM; GROWTH	14-3-3 sigma proteins regulate numerous cellular processes that are important to cancer development. One of its biological roles involves G2 cell-cycle arrest following DNA damage. It has also been reported that the loss of 14-3-3 sigma expression via CpG methylation may contribute to malignant transformation by impairing the G2 cell-cycle checkpoint function, thereby allowing an accumulation of genetic defects. However, how the CpG methylation-dependent silencing mechanism works in relation to promoter methylation associated with methyl-CpG-binding proteins (MeCPs) is still unclear. To better understand the mechanism, we first examined the methylation status of the 14-3-3 sigma promoter-associated CpG islands and 14-33 sigma gene expression in a subset of prostate cancer cell lines using methylation-specific PCR (MSP), an HhaI-based DNA methylation assay, and reverse transcription-PCR (RT-PCR). We found that the 14-3-3 sigma expression is lost in LNCaP and Tramp-Cl prostate cancer cell lines and that this expression is restored after treatment with epigenetic silencing modifiers 5-aza-2'-deoxycytidine (5-aza) and trichostatin A (TSA). These results imply transcriptional silencing via promoter-associated CpG methylation. Chromatin immunroprecipitation analysis revealed that methyl-CpG-binding protein 2 (MBD2) is associated preferentially to the methylated CpG island in the 14-3-3 sigma promoter in LNCaP and Tramp-Cl cells but not in 14-3-3 sigma-expressing PC3 and DU145 cells, which contain an unmethylated CpG island in the 14-3-3 sigma promoter region. The 14-3-3 sigma gene silencing because of CpG methylation correlates with binding of MBD2. In addition, the activation of 14-3-3 sigma gene expression by a combination of 5-aza and TSA also involves the release of the MBD2 from the 14-3-3 sigma promoter-methylated CpG island in LNCaP and Tramp-C1 cells. Furthermore, MBD2 knockdown by siRNA stimulated 14-3-3 sigma expression in LNCaP cells. We also investigated whether the loss of 14-3-3 sigma expression in LNCaP and Tramp-Cl cells affects cell proliferation by MTT assays. Interestingly, we observed that 14-3-3 sigma-inactivated LNCaP and Tramp-Cl cells had markedly decreased cell proliferation and protein expression of proliferation cell nuclear antigen (PCNA) after restoration of 14-3-3 sigma expression with 5-aza and TSA treatment. On the other hand, the same treatment did not significantly affect 14-3-3 sigma-active PC3 and DU145 cells, which normally express 14-3-3 sigma. Finally, 14-3-3 sigma knockdown by siRNA resulted in increased proliferation in PC3 and DU145 cells. These findings suggest that the transcriptional silencing of the 14-3-3 sigma gene is caused by promoter CpG island methylation associated with MBD2, and that this may play an important role in prostate cancer progression during the invasive and metastatic stages of the disease.	Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, Peoria, IL 61656 USA; Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Program Canc Biol, Dept Biomed & Therapeut Sci, 1 Illini Dr,Box 1649, Peoria, IL 61656 USA.	jsrao@uic.edu			NCI NIH HHS [R01 CA095058, R01 CA092393, R01 CA116708, R01 CA075557, CA 75557, CA 116708, CA 95058, CA 92393] Funding Source: Medline; NINDS NIH HHS [NS 47699, R01 NS047699] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095058, R01CA092393, R01CA116708, R01CA075557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047699] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cheng L, 2004, CLIN CANCER RES, V10, P3064, DOI 10.1158/1078-0432.CCR-03-0652; Darwanto A, 2003, CANCER SCI, V94, P442, DOI 10.1111/j.1349-7006.2003.tb01462.x; De Smet C, 2004, MOL CELL BIOL, V24, P4781, DOI 10.1128/MCB.24.11.4781-4790.2004; Dougherty MK, 2004, J CELL SCI, V117, P1875, DOI 10.1242/jcs.01171; Ego T, 2005, ONCOGENE, V24, P1914, DOI 10.1038/sj.onc.1208394; Esteller M, 2001, CANCER RES, V61, P4689; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Galm O, 2005, ONCOGENE, V24, P4799, DOI 10.1038/sj.onc.1208599; Goodman PA, 2003, ONCOGENE, V22, P2504, DOI 10.1038/sj.onc.1206313; Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230; Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaneuchi M, 2004, BIOCHEM BIOPH RES CO, V316, P1156, DOI 10.1016/j.bbrc.2004.02.171; Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787; Konduri SD, 2003, ONCOGENE, V22, P4509, DOI 10.1038/sj.onc.1206695; Lin XH, 2003, CANCER RES, V63, P498; Lodygin D, 2004, ONCOGENE, V23, P9034, DOI 10.1038/sj.onc.1208004; Lodygin D, 2003, ONCOGENE, V22, P5519, DOI 10.1038/sj.onc.1206854; Lodygin D, 2005, CELL RES, V15, P237, DOI 10.1038/sj.cr.7290292; McKie AB, 2005, ONCOGENE, V24, P2166, DOI 10.1038/sj.onc.1208371; Mhawech P, 2005, CELL RES, V15, P228, DOI 10.1038/sj.cr.7290291; Mhawech P, 2005, MODERN PATHOL, V18, P340, DOI 10.1038/modpathol.3800240; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakagawachi T, 2003, ONCOGENE, V22, P8835, DOI 10.1038/sj.onc.1207183; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200; Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5; Relchelt J, 2002, J CELL SCI, V115, P2639; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011; Singal R, 1999, BLOOD, V93, P4059, DOI 10.1182/blood.V93.12.4059; Singal R, 2001, CANCER RES, V61, P4820; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Tanaka K, 2004, INT J ONCOL, V25, P1591; TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Urano T, 2004, BIOCHEM BIOPH RES CO, V319, P795, DOI 10.1016/j.bbrc.2004.05.056; Woodcock JM, 2003, J BIOL CHEM, V278, P36323, DOI 10.1074/jbc.M304689200; Yatabe Y, 2002, ONCOGENE, V21, P8310, DOI 10.1038/sj.onc.1206014; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 2004, J BIOL CHEM, V279, P34353, DOI 10.1074/jbc.M401300200	57	34	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4559	4572		10.1038/sj.onc.1209462	http://dx.doi.org/10.1038/sj.onc.1209462			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786000	Green Accepted			2022-12-28	WOS:000239457500006
J	Romano, PR; McCallus, DE; Pachuk, CJ				Romano, P. R.; McCallus, D. E.; Pachuk, C. J.			RNA interference-mediated prevention and therapy for hepatocellular carcinoma	ONCOGENE			English	Review						HCC; HBV; HCV; RNAi; shRNA; siRNA	HEPATITIS-C VIRUS; ENDOTHELIAL GROWTH-FACTOR; DOUBLE-STRANDED-RNA; B-VIRUS; GENE-EXPRESSION; NUCLEOSIDE ANALOGS; MESSENGER-RNA; HBV ACTIVITY; CELL-LINES; IN-VIVO	Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related death and is on the increase worldwide. Hepatocellular carcinoma results from chronic liver disease and cirrhosis most commonly associated with chronic hepatitis B (HBV) or hepatitis C (HCV) infection. The highest incidences of HCC are found in China and Africa, where chronic HBV infection is the major risk component. In the United States, Europe and Japan, the significant increase in HCC and HCC-related deaths within the last three decades is mainly attributed to the rise in the number of HCV-infected individuals; smaller increases of HCC are associated with HBV. Given that HCV and HBV infection account for the majority of HCCs, therapeutic and prophylactic approaches to control or eliminate virus infection may prove effective in reducing the occurrence of HCC. Although anti-viral therapies exist for both HBV and HCV infections, they are ineffective for a significant number of patients. In addition, some treatments such as interferon therapy are dose limiting owing to toxic side effects. Clearly, new approaches are needed. RNA interference (RNAi)-based approaches may meet this need and have already shown promising preclinical results in cell culture and animal models. Although this paper focuses on the potential of RNAi as a prophylactic for HCC development, the potential use of RNAi-mediated approaches for HCC therapy will also be discussed.	Nucleonics, Horsham, PA 19044 USA		Pachuk, CJ (corresponding author), Nucleonics, 702 Elect Dr, Horsham, PA 19044 USA.	cpachuk@nucleonicsinc.com						Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Blanc JF, 2005, PROTEOMICS, V5, P3778, DOI 10.1002/pmic.200401194; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; BUKH J, 1995, SEMIN LIVER DIS, V15, P41, DOI 10.1055/s-2007-1007262; Cai ZH, 2005, J VIROL, V79, P13963, DOI 10.1128/JVI.79.22.13963-13973.2005; Chayama K, 1995, J HEPATOL, V23, P648, DOI 10.1016/0168-8278(95)80029-8; Chen M, 2005, J VIROL, V79, P3016, DOI 10.1128/JVI.79.5.3016-3027.2005; ENOMOTO N, 1995, J CLIN INVEST, V96, P224, DOI 10.1172/JCI118025; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Ghany MG, 2000, HEPATOLOGY, V32, p376A, DOI 10.1053/jhep.2000.17912; Giladi H, 2003, MOL THER, V8, P769, DOI 10.1016/S1525-0016(03)00244-2; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Guo Y, 2005, J VIROL, V79, P14392, DOI 10.1128/JVI.79.22.14392-14403.2005; Hamasaki K, 2003, FEBS LETT, V543, P51, DOI 10.1016/S0014-5793(03)00400-9; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hisaka T, 1999, INT J ONCOL, V14, P453; HUANG ZM, 1993, J VIROL, V67, P7032, DOI 10.1128/JVI.67.12.7032-7040.1993; Ito Y, 1998, HEPATOLOGY, V27, P951, DOI 10.1002/hep.510270409; Kapadia SB, 2003, P NATL ACAD SCI USA, V100, P2014, DOI 10.1073/pnas.252783999; KAWABATA K, 1995, PHARMACEUT RES, V12, P825, DOI 10.1023/A:1016248701505; Klein C, 2003, GASTROENTEROLOGY, V125, P9, DOI 10.1016/S0016-5085(03)00720-0; Korf M, 2005, J HEPATOL, V43, P225, DOI 10.1016/j.jhep.2005.02.046; Kronke J, 2004, J VIROL, V78, P3436, DOI 10.1128/JVI.78.7.3436-3446.2004; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Leonard JN, 2006, GENE THER, V13, P532, DOI 10.1038/sj.gt.3302645; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Lohmann V, 2000, J VIRAL HEPATITIS, V7, P167; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; LUI F, 1999, GENE THER, V6, P1258; Mao HJ, 2005, WORLD J GASTROENTERO, V11, P2811, DOI 10.3748/wjg.v11.i18.2811; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; McCaffrey AP, 2002, NATURE, V418, P38, DOI 10.1038/418038a; McCaffrey AP, 2003, NAT BIOTECHNOL, V21, P639, DOI 10.1038/nbt824; Mendy ME, 1999, BRIT J BIOMED SCI, V56, P34; Miura H, 1997, J HEPATOL, V27, P854, DOI 10.1016/S0168-8278(97)80323-6; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702; Papatheodoridis GV, 2002, AM J GASTROENTEROL, V97, P1618, DOI 10.1111/j.1572-0241.2002.05819.x; Prabhu R, 2005, J MED VIROL, V76, P511, DOI 10.1002/jmv.20391; Radhakrishnan SK, 2004, VIROLOGY, V323, P173, DOI 10.1016/j.virol.2004.02.021; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Randall G, 2003, P NATL ACAD SCI USA, V100, P235, DOI 10.1073/pnas.0235524100; Ren GL, 2005, BIOCHEM BIOPH RES CO, V335, P1051, DOI 10.1016/j.bbrc.2005.07.170; Schmidt CM, 1997, BIOCHEM BIOPH RES CO, V236, P54, DOI 10.1006/bbrc.1997.6840; Shlomai A, 2003, HEPATOLOGY, V37, P764, DOI 10.1053/jhep.2003.50146; Simmonds P, 1999, J HEPATOL, V31, P54, DOI 10.1016/S0168-8278(99)80375-4; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; Suzuki K, 1996, CANCER RES, V56, P3004; Uprichard SL, 2005, P NATL ACAD SCI USA, V102, P773, DOI 10.1073/pnas.0409028102; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wilson JA, 2005, J VIROL, V79, P7050, DOI 10.1128/JVI.79.11.7050-7058.2005; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Wong N, 2005, CLIN CANCER RES, V11, P1319; Wu HL, 2005, GASTROENTEROLOGY, V128, P708, DOI 10.1053/j.gastro.2004.12.007; Yang PL, 2002, P NATL ACAD SCI USA, V99, P13825, DOI 10.1073/pnas.202398599; Ying CX, 2003, BIOCHEM BIOPH RES CO, V309, P482, DOI 10.1016/j.bbrc.2003.08.021; Yokota T, 2003, EMBO REP, V4, P602, DOI 10.1038/sj.embor.embor840; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zhang G, 2004, GENE THER, V11, P675, DOI 10.1038/sj.gt.3302210; Zhang XN, 2004, WORLD J GASTROENTERO, V10, P2967; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	66	30	34	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3857	3865		10.1038/sj.onc.1209549	http://dx.doi.org/10.1038/sj.onc.1209549			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799627				2022-12-28	WOS:000238559600013
J	Vesely, DL; Hoffman, B; Liebermann, DA				Vesely, D. L.; Hoffman, B.; Liebermann, D. A.			Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells	ONCOGENE			English	Article						p53; PI3K/Akt; IL-6; apoptosis; Mcl-1; NF-kappa B	NF-KAPPA-B; WILD-TYPE P53; IN-VITRO; DEATH; DIFFERENTIATION; INHIBITION; EXPRESSION; GROWTH; FAS/APO-1; CANCER	M1 myeloid leukemic cells were used to dissect the molecular mechanisms of myeloid cell survival and apoptosis. A salient feature of M1 cells is that they respond to the physiological survival factor interleukin-6 ( IL-6), yet lack the tumor suppressor gene p53. Functional wild-type activation of temperature-sensitive p53 protein ( p53 val) at permissive temperature in M1-t-p53 cells results in rapid apoptosis, which is blocked by IL-6. How p53 induces M1 apoptosis and how IL-6 protects against p53-induced apoptosis are not fully understood. Here it is shown that p53-mediated apoptosis of M1 cells involves rapid activation of the proapoptotic Fas/CD95 death pathway, which activates caspases 8 and 10. Functional p53 also targets the mitochondria, causing upregulation of proapoptotic Bax, downregulation of prosurvival Bcl-2 and activation of caspase 9. IL-6 was found to protect against p53-induced apoptosis via activation of the PI3K/Akt survival pathway, which in turn counters both the Fas/CD95 and mitochondrial apoptotic pathways and activates the prosurvival transcription factor nuclear factor- kappaB ( NF-kappa B). Taken together, this work supports a novel model for leukemic progression where cells that acquire the ability to produce an autocrine survival factor, such as IL-6, can bypass normal p53 surveillance function by targeting Akt, which in turn can exert effects on the regulators of apoptosis, such as the Fas/CD95 pathway, the mitochondria and NF-kappa B.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NCI NIH HHS [R01 CA081168-06] Funding Source: Medline; NHLBI NIH HHS [1 R01 HL70530-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gottlieb RA, 2000, CRIT REV EUKAR GENE, V10, P231; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hu LM, 2000, CLIN CANCER RES, V6, P880; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lotem J, 2003, P NATL ACAD SCI USA, V100, P6718, DOI 10.1073/pnas.1031695100; Lotem J, 2004, P NATL ACAD SCI USA, V101, P16022, DOI 10.1073/pnas.0406966101; Manakova TE, 2001, B EXP BIOL MED+, V132, P633, DOI 10.1023/A:1012559724283; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moqattash S, 1998, P SOC EXP BIOL MED, V219, P8; Niho Y, 1998, Curr Opin Hematol, V5, P163, DOI 10.1097/00062752-199805000-00002; O'Connor L, 2000, CANCER RES, V60, P1217; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Takahashi S, 2005, LEUKEMIA RES, V29, P893, DOI 10.1016/j.leukres.2005.01.008; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang J, 2004, IUBMB LIFE, V56, P395, DOI 10.1080/15216540400008929; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	43	11	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3041	3050		10.1038/sj.onc.1210109	http://dx.doi.org/10.1038/sj.onc.1210109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099722				2022-12-28	WOS:000246395400009
J	Kweon, MH; Afaq, F; Bhat, KMR; Setaluri, V; Mukhtar, H				Kweon, M-H; Afaq, F.; Bhat, K. M. R.; Setaluri, V.; Mukhtar, H.			A novel antioxidant 3-O-Caffeoyl-1-methylquinic acid enhances ultraviolet A-mediated apoptosis in immortalized HaCaT keratinocytes via Sp1-dependent transcriptional activation of p21(WAF1/Cip1)	ONCOGENE			English	Article						MCGA3; UVA; p21; Sp1; iron chelation	SIGNAL-REGULATED KINASE; CELL-CYCLE ARREST; IRON CHELATION; GROWTH ARREST; HYPOXIA; UVA; EXPRESSION; INDUCTION; P53; PROLIFERATION	It has become clearthat ultraviolet A (UVA) radiation from the solar spectrum is a major environmental challenge to the skin. This necessitates developing novel mechanism- based agents capable of ameliorating UVAinduced effects in the skin. We recently described a novel antioxidant, 3-O-Caffeoyl-1-methylquinic acid (MCGA3) from leaves of bamboo. Here, we investigated the photochemopreventive effects of MCGA3 against UVA mediated apoptosis in immortalized HaCaT keratinocytes. Pretreatment of MCGA3 rendered cells more sensitive to subsequent UVA irradiation-induced apoptosis as well as completely reversed UVA-induced sustained phosphorylation of extracellular signal-regulated kinase 1/2 and protein kinase C alpha, downregulation of p21, and reactive oxygen species generation. Interestingly, MCGA3 itself effectively induced p21 protein and mRNA levels. Silencing of p21 by RNA interference revealed a pivotal role of p21 in generating G(1)-S arrest and in enhancing UVA-mediated apoptosis. Transcriptional activation of p21 by MCGA3 was mediated through the proximal region of multiple Sp1 sites regardless of p53-binding site in p21 promoter, and this effect was augmented by desferroioxamine, an iron chelating agent. Additional studies suggested that iron chelation-driven hypoxia by MCGA3 may function in activation of p21. MCGA3 could be a useful agent to prevent photocarcinogenesis via apoptotic elimination of p53 mutant and DNA- repair defective cells caused by UVA radiation.	Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Madison, WI 53706 USA; Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea	University of Wisconsin System; University of Wisconsin Madison; Korea University	Mukhtar, H (corresponding author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, 1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu	Bhat, Kumar/AAD-8831-2019	Bhat, Kumar/0000-0003-1805-3453; Bhat, Kumar MR/0000-0002-2346-6634	NCI NIH HHS [R01 CA78809, R01 CA101039] Funding Source: Medline; NIDDK NIH HHS [P50 DK065303] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078809, R01CA101039] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK065303] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe RD, 2001, CARCINOGENESIS, V22, P1607, DOI 10.1093/carcin/22.10.1607; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Baby SM, 2003, HISTOCHEM CELL BIOL, V120, P343, DOI 10.1007/s00418-003-0588-2; Bachelor MA, 2004, SEMIN CANCER BIOL, V14, P131, DOI 10.1016/j.semcancer.2003.09.017; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bossenmeyer-Pourie C, 2002, NEUROSCIENCE, V114, P869, DOI 10.1016/S0306-4522(02)00324-X; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Catalano A, 2005, EMBO J, V24, P170, DOI 10.1038/sj.emboj.7600502; Chung JH, 2003, FASEB J, V17, P1913, DOI 10.1096/fj.02-0914fje; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Fan LJ, 2001, CANCER RES, V61, P1073; FUKUCHI K, 1995, BIOL CHEM H-S, V376, P627; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; He YY, 2004, J BIOL CHEM, V279, P53867, DOI 10.1074/jbc.M405781200; Jiao Y, 2006, FREE RADICAL BIO MED, V40, P1152, DOI 10.1016/j.freeradbiomed.2005.11.003; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Koutsodontis G, 2002, BIOCHEMISTRY-US, V41, P12771, DOI 10.1021/bi026141q; Kweon MH, 2006, FREE RADICAL BIO MED, V40, P1349, DOI 10.1016/j.freeradbiomed.2005.12.002; Kweon MH, 2004, FREE RADICAL BIO MED, V36, P40, DOI 10.1016/j.freeradbiomed.2003.09.023; Kweon MH, 2001, J AGR FOOD CHEM, V49, P4646, DOI 10.1021/jf010514x; Martin BD, 1998, CHEM RES TOXICOL, V11, P1402, DOI 10.1021/tx9801559; Mukherjee S, 2005, J BIOL CHEM, V280, P17617, DOI 10.1074/jbc.M502278200; Patel V, 2002, CANCER RES, V62, P1401; Reagan-Shaw S, 2006, MOL CANCER THER, V5, P418, DOI 10.1158/1535-7163.MCT-05-0250; Song HJ, 2005, J PHARMACOL EXP THER, V312, P391, DOI 10.1124/jpet.104.074401; Valencia A, 2006, FREE RADICAL BIO MED, V40, P641, DOI 10.1016/j.freeradbiomed.2005.09.036; Wang SW, 2000, AM J PHYSIOL-CELL PH, V279, pC868, DOI 10.1152/ajpcell.2000.279.3.C868; Wanner R, 2002, J MOL MED, V80, P61, DOI 10.1007/s00109-001-0288-0	34	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3559	3571		10.1038/sj.onc.1210135	http://dx.doi.org/10.1038/sj.onc.1210135			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146435				2022-12-28	WOS:000246799200012
J	Beltran, A; Parikh, S; Liu, Y; Cuevas, BD; Johnson, GL; Futscher, BW; Blancafort, P				Beltran, A.; Parikh, S.; Liu, Y.; Cuevas, B. D.; Johnson, G. L.; Futscher, B. W.; Blancafort, P.			Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors	ONCOGENE			English	Article						maspin; SERPINB5; metastatic cells; methylation; zinc-fingers; artificial transcription factors	ZINC-FINGER DOMAINS; BREAST-CANCER CELLS; DNA-SEQUENCES; MAMMALIAN-CELLS; EXPRESSION; RECOGNITION; FAMILY; CONSTRUCTION; ANGIOGENESIS; METHYLATION	The controlled and specific re-activation of endogenous tumor suppressors in cancer cells represents an important therapeutic strategy to block tumor growth and subsequent progression. Other than ectopic delivery of tumor suppressor-encoded cDNA, there are no therapeutic tools able to specifically re-activate tumor suppressor genes that are silenced in tumor cells. Herein, we describe a novel approach to specifically regulate dormant tumor suppressors in aggressive cancer cells. We have targeted the Mammary Serine Protease Inhibitor (maspin) (SERPINB5) tumor suppressor, which is silenced by transcriptional and aberrant promoter methylation in aggressive epithelial tumors. Maspin is a multifaceted protein, regulating tumor cell homeostasis through inhibition of cell growth, motility and invasion. We have constructed artificial transcription factors (ATFs) made of six zinc-finger (ZF) domains targeted against 18-base pair (bp) unique sequences in the maspin promoter. The ZFs were linked to the activator domain VP64 and delivered in breast tumor cells. We found that the designed ATFs specifically interact with their cognate targets in vitro with high affinity and selectivity. One ATF was able to re-activate maspin in cell lines that comprise a maspin promoter silenced by epigenetic mechanisms. Consistently, we found that this ATF was a powerful inducer of apoptosis and was able to knock down tumor cell invasion in vitro. Moreover, this ATF was able to suppress MDA-MB-231 growth in a xenograft breast cancer model in nude mice. Our work suggests that ATFs could be used in cancer therapeutics as novel molecular switches to re-activate dormant tumor suppressors.	Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ USA; Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Arizona Center Cancer Care; University of Arizona; University of Arizona	Blancafort, P (corresponding author), Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA.	pilar_blancafort@med.unc.edu	Blancafort, Pilar/K-9029-2012	Blancafort, Pilar/0000-0002-3881-7396	NCI NIH HHS [R01 CA125273] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871] Funding Source: Medline; NIGMS NIH HHS [R01 GM030324] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA125273] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628; Beltran A, 2006, ASSAY DRUG DEV TECHN, V4, P317, DOI 10.1089/adt.2006.4.317; Blancafort P, 2004, MOL PHARMACOL, V66, P1361, DOI 10.1124/mol.104.002758; Blancafort P, 2003, NAT BIOTECHNOL, V21, P269, DOI 10.1038/nbt794; Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Dreier B, 2005, J BIOL CHEM, V280, P35588, DOI 10.1074/jbc.M506654200; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Dreier B, 2000, J MOL BIOL, V303, P489, DOI 10.1006/jmbi.2000.4133; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Garber K, 2004, NAT BIOTECHNOL, V22, P364, DOI 10.1038/nbt0404-364; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Khalkhali-Ellis Z, 2004, CLIN CANCER RES, V10, P449, DOI 10.1158/1078-0432.CCR-1002-03; Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568; Lockett J, 2006, J CELL BIOCHEM, V97, P651, DOI 10.1002/jcb.20721; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Royer Y, 2004, DNA CELL BIOL, V23, P355, DOI 10.1089/104454904323145245; Sager R, 1997, ADV EXP MED BIOL, V425, P77; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Seftor REB, 1998, CANCER RES, V58, P5681; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Shi HY, 2002, MOL THER, V5, P755, DOI 10.1006/mthe.2002.0602; Stege JT, 2002, PLANT J, V32, P1077, DOI 10.1046/j.1365-313X.2002.01492.x; Tan SY, 2003, P NATL ACAD SCI USA, V100, P11997, DOI 10.1073/pnas.2035056100; Watanabe M, 2005, HUM GENE THER, V16, P699, DOI 10.1089/hum.2005.16.699; YIN S, 2006, CANCER RES, V15, P4173; Zardo G, 2005, CELL RES, V15, P679, DOI 10.1038/sj.cr.7290337; Zhang M, 2000, ONCOGENE, V19, P6053, DOI 10.1038/sj.onc.1204006; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang WG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-50; ZHOU Z, 2000, J BIOL CHEM, V9, P6051; ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962	40	68	75	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2791	2798		10.1038/sj.onc.1210072	http://dx.doi.org/10.1038/sj.onc.1210072			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057734				2022-12-28	WOS:000246210600013
J	Cosaceanu, D; Budiu, RA; Carapancea, M; Castro, J; Lewensohn, R; Dricu, A				Cosaceanu, D.; Budiu, R. A.; Carapancea, M.; Castro, J.; Lewensohn, R.; Dricu, A.			Ionizing radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-DNA binding and by modulating Ku86 expression via a p38 kinase-dependent mechanism	ONCOGENE			English	Article						insulin-like growth factor 1 receptor; ionizing radiation; p38 kinase; Ku86; lung cancer	GROWTH-FACTOR-I; HUMAN LUNG-CANCER; PROTEIN-KINASE; CELL-LINES; PHOSPHATIDYLINOSITOL 3-KINASE; INTRINSIC RADIOSENSITIVITY; SURVIVAL PATHWAY; CARCINOMA-CELLS; S6 KINASE; RECEPTOR	Ionizing radiation exposure results in the activation of several tyrosine kinase receptors that participate in radiation-induced DNA damage response and radioresistance. We previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition enhanced radiosensitivity of non-small-cell lung cancer (NSCLC) cells. In this paper, we demonstrate that in U1810 NSCLC cells gamma-radiation activates IGF-1R within 10 min, with a maximal activation effect 2 h post-irradiation. Impairment of IGF-1R tyrosine kinase activity enhances human lung cancer cells radiosensitivity by a mechanism that involves phosphatidylinositol 3-kinase (PI3-K) and p38 kinase. In an active form, IGF-1R binds and activates p38 kinase, promoting receptor signaling. Conversely, inhibition of IGF-1R phosphorylation results in IGF-1R/p38 complex disruption and p38 kinase inactivation. We have also demonstrated that in insulin-like growth factor-1-stimulated cells, Ku-DNA-binding activation is induced by ionizing radiation within 4 h, reaches a maximum level at 12 h and remains active up to 72 h. Blockade of IGF-1R activity or its downstream signaling through p38 kinase induces a decrease in radiation-mediated Ku-DNA-binding activation and downregulates the level of Ku86, without affecting Ku70 expression in the nucleus of U1810 cells. The IGF-1R signaling via PI3-K does not interfere with the p38 signaling, the Ku-DNA-binding activity or the level of Ku86. Our present study demonstrates for the first time that ionizing radiation activates IGF-1R. Inhibition of IGF-1R signaling via p38 kinase induces radiosensitivity by a novel mechanism involving nuclear Ku86.	Canc Ctr Karolinska, Dept Oncol Pathol, S-17176 Stockholm, Sweden; Radiumhemmet Karolinska Inst Hosp, S-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Dricu, A (corresponding author), Canc Ctr Karolinska, Dept Oncol Pathol, R8-00, S-17176 Stockholm, Sweden.	anica.dricu@ki.se						Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Barlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; Bostedt KT, 2001, EXP CELL RES, V271, P368, DOI 10.1006/excr.2001.5388; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Bredin CG, 1999, INT J CANCER, V82, P338, DOI 10.1002/(SICI)1097-0215(19990730)82:3<338::AID-IJC6>3.0.CO;2-Y; BRODIN O, 1991, ACTA ONCOL, V30, P967, DOI 10.3109/02841869109088251; CARNEY DN, 1983, CANCER RES, V43, P2806; Contessa JN, 2002, ONCOGENE, V21, P4032, DOI 10.1038/sj.onc.1205500; Cosaceanu D, 2005, CANCER LETT, V222, P173, DOI 10.1016/j.canlet.2004.10.002; Dent P, 2003, RADIAT RES, V159, P283, DOI 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2; Dowell JE, 2005, NEW ENGL J MED, V352, P830, DOI 10.1056/NEJMe058033; Dricu A, 1997, CANCER RES, V57, P543; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Fegley AJ, 2003, J SURG RES, V113, P32, DOI 10.1016/S0022-4804(03)00120-3; GIRINSKY T, 1993, INT J RADIAT ONCOL, V25, P3, DOI 10.1016/0360-3016(93)90137-K; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Greenberg AK, 2002, AM J RESP CELL MOL, V26, P558, DOI 10.1165/ajrcmb.26.5.4689; Griffin RJ, 2002, CANCER RES, V62, P1702; Gupta AK, 2004, LUNG, V182, P151, DOI 10.1007/S00408/004/0310-8; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; Jung, 1996, Semin Radiat Oncol, V6, P268, DOI 10.1016/S1053-4296(96)80022-1; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; LICHTER AS, 1995, NEW ENGL J MED, V332, P371, DOI 10.1056/NEJM199502093320607; Mazzarelli P, 2003, J INVEST DERMATOL, V121, P628, DOI 10.1046/j.1523-1747.2003.12416.x; Park SJ, 2004, J BIOL CHEM, V279, P6046, DOI 10.1074/jbc.M311054200; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Quinn KA, 1996, J BIOL CHEM, V271, P11477, DOI 10.1074/jbc.271.19.11477; Reiss K, 2006, J CELL PHYSIOL, V206, P295, DOI 10.1002/jcp.20455; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shimizu T, 1999, EXP CELL RES, V251, P424, DOI 10.1006/excr.1999.4582; Sirzen F, 1999, EUR J CANCER, V35, P111, DOI 10.1016/S0959-8049(98)00289-5; SODERDAHL G, 1988, INT J CANCER, V41, P636, DOI 10.1002/ijc.2910410426; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Wan YS, 2001, INT J ONCOL, V18, P461; Watanabe H, 2004, INT J RADIAT BIOL, V80, P451, DOI 10.1080/09553000410001702355; Wen B, 2001, BRIT J CANCER, V85, P2017, DOI 10.1054/bjoc.2001.2171; WEST CML, 1993, BRIT J CANCER, V68, P819, DOI 10.1038/bjc.1993.434; Yamagishi S, 2003, MOL BRAIN RES, V119, P184, DOI 10.1016/j.molbrainres.2003.09.009; Yu D, 2003, BIOCHEM BIOPH RES CO, V311, P174, DOI 10.1016/j.bbrc.2003.09.195; Yu D, 2002, J RADIAT RES, V43, P325, DOI 10.1269/jrr.43.325; Zingg D, 2004, CANCER RES, V64, P5398, DOI 10.1158/0008-5472.CAN-03-3369	53	80	84	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2423	2434		10.1038/sj.onc.1210037	http://dx.doi.org/10.1038/sj.onc.1210037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043647				2022-12-28	WOS:000245831000003
J	Janssen, K; Hofmann, TG; Jans, DA; Hay, RT; Schulze-Osthoff, K; Fischer, U				Janssen, K.; Hofmann, T. G.; Jans, D. A.; Hay, R. T.; Schulze-Osthoff, K.; Fischer, U.			Apoptin is modified by SUMO conjugation and targeted to promyelocytic leukemia protein nuclear bodies	ONCOGENE			English	Article						apoptin; apoptosis; PML; SUMO; HipK2	CHICKEN-ANEMIA-VIRUS; INDUCED CELL-DEATH; INDUCED APOPTOSIS; GENE-THERAPY; P53 ACTIVITY; TUMOR-CELLS; PML; ACCUMULATION; SUPPRESSOR; EXPRESSION	Apoptin, a protein of the chicken anemia virus (CAV), represents a novel potential anticancer therapeutic, because it induces apoptotic death specifically in tumor but not normal cells. The cellular localization appears to be crucial for apoptin's selective toxicity. In normal cells apoptin remains in the cytoplasm, whereas in transformed cells it migrates into the nucleus and kills the cell. However, the manner by which apoptin is able to distinguish between tumor and normal cells is unknown. Here, we report for the first time that apoptin interacts directly with the promyelocytic leukemia protein (PML) in tumor cells and accumulates in PML nuclear bodies (NBs), which are involved in apoptosis induction and viral replication. We also demonstrate that apoptin is sumoylated and that a sumoylation-deficient apoptin mutant is no longer recruited to PML-NBs, but localizes in the nuclear matrix. This mutant fails to bind PML, but can still induce apoptosis as efficiently as wild-type apoptin. Moreover, apoptin kills also PML-/- cells and promyelocytic leukemia cells with defective PML expression. Our results therefore suggest that apoptin kills tumor cells independently of PML and sumoylation, however, the interaction of apoptin with PML and small ubiquitin-like modifier (SUMO) proteins might be relevant for CAV replication.	Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; Deutsch Krebsforschungszentrum, Res Grp Cellular Senescence, D-6900 Heidelberg, Germany; Monash Univ, Dept Biochem & Mol Biol, Nucl Signaling Lab, Clayton, Vic 3168, Australia; Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 4HN, Scotland	Heinrich Heine University Dusseldorf; Helmholtz Association; German Cancer Research Center (DKFZ); Monash University; University of Dundee	Fischer, U (corresponding author), Univ Dusseldorf, Inst Mol Med, Bldg 23-12,Univ Str 1, D-40225 Dusseldorf, Germany.	Ute.Fischer@uni-duesseldorf.de	Hay, Ronald/S-3233-2019; Hay, Ronald T/F-9338-2011; Schulze-Osthoff, Klaus/N-9025-2013	Hay, Ronald/0000-0001-7113-9024; Hay, Ronald T/0000-0001-7113-9024; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Jans, David/0000-0001-5115-4745				Adair BM, 2000, DEV COMP IMMUNOL, V24, P247, DOI 10.1016/S0145-305X(99)00076-2; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Burek M, 2006, ONCOGENE, V25, P2213, DOI 10.1038/sj.onc.1209258; Chen A, 2006, J CELL BIOCHEM, V98, P895, DOI 10.1002/jcb.20703; Danen-van Oorschot AAAM, 2003, J BIOL CHEM, V278, P27729, DOI 10.1074/jbc.M303114200; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Engels IH, 2005, MOL CELL BIOL, V25, P2808, DOI 10.1128/MCB.25.7.2808-2818.2005; Everett RD, 2001, ONCOGENE, V20, P7266, DOI 10.1038/sj.onc.1204759; Fischer U, 2005, PHARMACOL REV, V57, P187, DOI 10.1124/pr.57.2.6; Fischer U, 2005, ONCOGENE, V24, P1231, DOI 10.1038/sj.onc.1208290; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Ishov AM, 1996, J CELL BIOL, V134, P815, DOI 10.1083/jcb.134.4.815; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; KOKEN MHM, 1995, ONCOGENE, V10, P1315; Leliveld SR, 2003, EUR J BIOCHEM, V270, P3619, DOI 10.1046/j.1432-1033.2003.03750.x; Leliveld SR, 2003, J BIOL CHEM, V278, P9042, DOI 10.1074/jbc.M210803200; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NOTEBORN MHM, 1994, J VIROL, V68, P346, DOI 10.1128/JVI.68.1.346-351.1994; Oro C, 2004, CURR DRUG TARGETS, V5, P179, DOI 10.2174/1389450043490631; Peters MA, 2006, J GEN VIROL, V87, P823, DOI 10.1099/vir.0.81468-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pietersen AM, 1999, GENE THER, V6, P882, DOI 10.1038/sj.gt.3300876; Poon IH, 2005, CANCER RES, V65, P7059, DOI 10.1158/0008-5472.CAN-05-1370; Poon IKH, 2005, J VIROL, V79, P1339, DOI 10.1128/JVI.79.2.1339-1341.2005; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Renshaw RW, 1996, J VIROL, V70, P8872, DOI 10.1128/JVI.70.12.8872-8878.1996; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Ryu SW, 2000, BIOCHEM BIOPH RES CO, V279, P6, DOI 10.1006/bbrc.2000.3882; Schoop RAL, 2004, INT J CANCER, V109, P38, DOI 10.1002/ijc.11675; Song J, 2005, J BIOL CHEM, V280, P40122, DOI 10.1074/jbc.M507059200; Steffan JS, 2004, SCIENCE, V304, P100, DOI 10.1126/science.1092194; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tavassoli M, 2005, APOPTOSIS, V10, P717, DOI 10.1007/s10495-005-0930-3; van der Eb MM, 2002, CANCER GENE THER, V9, P53, DOI 10.1038/sj.cgt.7700397; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0; Zhang YH, 1999, CANCER RES, V59, P3010; Zhuang SM, 1995, CARCINOGENESIS, V16, P2939, DOI 10.1093/carcin/16.12.2939	49	31	33	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1557	1566		10.1038/sj.onc.1209923	http://dx.doi.org/10.1038/sj.onc.1209923			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16924230				2022-12-28	WOS:000244782500005
J	Liu, YE; Pu, W; Jiang, Y; Shi, D; Dackour, R; Shi, YE				Liu, Y. E.; Pu, W.; Jiang, Y.; Shi, D.; Dackour, R.; Shi, Y. E.			Chaperoning of estrogen receptor and induction of mammary gland proliferation by neuronal protein synuclein gamma	ONCOGENE			English	Article						synuclein gamma (SNCG); estrogen receptor; chaperone; hyperplasia; breast cancer; transgenic mouse	BREAST-CANCER CELLS; INHIBITOR-RELATED GENE; HEAT-SHOCK-PROTEIN; ABERRANT EXPRESSION; PARKINSONS-DISEASE; ALZHEIMER-DISEASE; GROWTH INHIBITOR; ALPHA-SYNUCLEIN; METASTASIS; PROMOTES	Synucleins are emerging as central players in the formation of pathologically insoluble deposits characteristic of neurodegenerative diseases. However, synuclein c (SNCG), previously identified as a breast cancer specific gene (BCSG1), is also highly associated with breast cancer progression. Using transgenic mouse model, we demonstrated a role of SNCG in induction of highly proliferative pregnancy-like phenotype of mammary epithelial cells and branching morphology. SNCG participated in the heat shock protein-based multiprotein chaperone complex for steroid receptor signaling. Expression of SNCG in mammary epithelium resulted in a significant stimulation of ER alpha transcriptional activity. SNCG-induced mammary gland proliferation can be effectively blocked by antiestrogen and ovariectomy, indicating that the induced proliferation is mediated by ERa signaling and requires estrogen stimulation. These data indicate the chaperone activity of SNCG on stimulation of steroid receptor signaling in mammary gland and, thus induces extensive mammary gland proliferation and contributes to the hormonal impact on mammary tumorigenesis.	Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; Sichuan Univ, W China Hosp, State Key Lab, Div Mol Oncol, Chengdu 610064, Peoples R China	Northwell Health; Sichuan University	Shi, YE (corresponding author), Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA.	eshi@lij.edu						Bruening W, 2000, CANCER-AM CANCER SOC, V88, P2154, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; Geisler H, 2003, J STEROID BIOCHEM, V86, P245, DOI 10.1016/S0960-0760(03)00364-9; Gupta A, 2003, ONCOGENE, V22, P7593, DOI 10.1038/sj.onc.1206880; Gupta A, 2003, CANCER RES, V63, P664; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Ji HJ, 1997, CANCER RES, V57, P759; Jia TL, 1999, CANCER RES, V59, P742; Jiang YF, 2003, CANCER RES, V63, P3899; Jiang YF, 2004, CANCER RES, V64, P4539, DOI 10.1158/0008-5472.CAN-03-3650; Lavedan C, 1998, HUM GENET, V103, P106, DOI 10.1007/s004390050792; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LU A, 2000, J BIOL CHEM, V277, P31364; Lu AP, 2001, ONCOGENE, V20, P5173, DOI 10.1038/sj.onc.1204668; Ninkina NN, 1998, HUM MOL GENET, V7, P1417, DOI 10.1093/hmg/7.9.1417; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Shi YE, 1997, CANCER RES, V57, P3084; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wang MS, 2000, CANCER RES, V60, P6482; Wang MS, 2003, J BIOL CHEM, V278, P47319, DOI 10.1074/jbc.M308131200; WU K, 2006, BREAST CANC RES TREA; Wu KJ, 2003, CANCER EPIDEM BIOMAR, V12, P920; Xiao GW, 1999, P NATL ACAD SCI USA, V96, P3700, DOI 10.1073/pnas.96.7.3700; YOSHIMOTO M, 1995, P NATL ACAD SCI USA, V92, P9141, DOI 10.1073/pnas.92.20.9141	31	20	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2115	2125		10.1038/sj.onc.1210000	http://dx.doi.org/10.1038/sj.onc.1210000			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016445				2022-12-28	WOS:000245313400013
J	Wang, DM; Sevcikova, S; Wen, H; Roberts, S; Lipsick, JS				Wang, D-M; Sevcikova, S.; Wen, H.; Roberts, S.; Lipsick, J. S.			v-Myb represses the transcription of Ets-2	ONCOGENE			English	Article						Myb; Ets; repression	MYELOMONOCYTIC GROWTH-FACTOR; AVIAN-MYELOBLASTOSIS VIRUS; DNA-BINDING ACTIVITY; C-MYB; TARGET GENE; TRANS-ACTIVATION; ONCOGENE PRODUCT; E26 VIRUS; B-MYB; EXPRESSION	The v-Myb oncogene causes monoblastic leukemia and transforms only myelomonocytic cells in culture. The vMyb protein is nuclear and binds to specific DNA sequences. To identify genes regulated by v-Myb, we utilized primary cells transformed by a retrovirus encoding a v-Myb-estrogen receptor (ER) fusion protein. The Ets-2 gene was not expressed in v-Myb-ER transformed cells in the presence of estradiol, but was expressed within 4 h after estradiol withdrawal. The expression of Ets-2 also increased dramatically following phorbol ester-induced differentiation of the v-Myb-transformed BM2 cell line. Conversely, CRYP-alpha, encoding a transmembrane tyrosine phosphatase, was expressed in the presence but not the absence of estradiol in v-Myb-ER transformed cells. CRYP-alpha was downregulated during the phorbol ester-induced differentiation of BM2 cells. Although LIM-3 expression was estradiol-inducible in v-Myb-ER transformed monoblasts, LIM-3 was expressed neither in primary yolk sac cells transformed by unfused v-Myb nor in BM2 cells. We conclude that although v-Myb has been intensively studied as a transcriptional activator, v-Myb can repress biologically relevant genes such as Ets-2, which promotes macrophage differentiation. In addition, we have shown that some genes that are regulated by a v-Myb-ER fusion protein may not be relevant to the biological function of the unfused v-Myb protein.	Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Dept Pathol, Sch Med, 300 Pasteur Dr, Stanford, CA 94305 USA.	lipsick@stanford.edu	Sevcikova, Sabina/AAB-4267-2021	Wen, Hong/0000-0001-8739-4572	NATIONAL CANCER INSTITUTE [T32CA009151, R01CA043592] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43592, T32 CA09151] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aperlo C, 1996, MOL CELL BIOL, V16, P6851; Bartley PA, 2003, ONCOGENE, V22, P7570, DOI 10.1038/sj.onc.1207136; Begue A, 1997, GENE EXPRESSION, V6, P333; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; Braas D, 2004, NUCLEIC ACIDS RES, V32, P4750, DOI 10.1093/nar/gkh808; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; Burk O, 1997, EMBO J, V16, P1371, DOI 10.1093/emboj/16.6.1371; Chen J, 2002, ONCOGENE, V21, P1859, DOI 10.1038/sj.onc.1205003; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DINI PW, 1995, J VIROL, V69, P2515, DOI 10.1128/JVI.69.4.2515-2524.1995; Engelke U, 1997, J VIROL, V71, P3760, DOI 10.1128/JVI.71.5.3760-3766.1997; Ferrao P, 1997, BLOOD, V90, P4539; GARCIA A, 1991, ONCOGENE, V6, P265; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; IBANEZ CE, 1988, J VIROL, V62, P4398, DOI 10.1128/JVI.62.11.4398-4402.1988; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KU DH, 1993, J BIOL CHEM, V268, P2255; Lang G, 2005, ONCOGENE, V24, P1375, DOI 10.1038/sj.onc.1208301; Lei WL, 2004, J BIOL CHEM, V279, P29519, DOI 10.1074/jbc.M403133200; LEUTZ A, 1989, EMBO J, V8, P175, DOI 10.1002/j.1460-2075.1989.tb03362.x; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Lisitsyn N A, 1993, Mol Gen Mikrobiol Virusol, P26; Liu F, 2006, ONCOGENE, V25, P795, DOI 10.1038/sj.onc.1209105; MELOTTI P, 1994, J BIOL CHEM, V269, P25303; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; PESSANO S, 1979, NEW MICROBIOL, V2, P379; Rushton JJ, 2003, ONCOGENE, V22, P308, DOI 10.1038/sj.onc.1206131; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Wei G, 2004, J IMMUNOL, V173, P1374, DOI 10.4049/jimmunol.173.2.1374; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; White JR, 2000, ONCOGENE, V19, P1196, DOI 10.1038/sj.onc.1203394; Worpenberg S, 1997, ONCOGENE, V15, P213, DOI 10.1038/sj.onc.1201179	42	6	6	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1238	1244		10.1038/sj.onc.1209868	http://dx.doi.org/10.1038/sj.onc.1209868			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909100				2022-12-28	WOS:000244406400014
J	Kuo, AH; Stoica, GE; Riegel, AT; Wellstein, A				Kuo, A. H.; Stoica, G. E.; Riegel, A. T.; Wellstein, A.			Recruitment of insulin receptor substrate-1 and activation of NF-kappa B essential for midkine growth signaling through anaplastic lymphoma kinase	ONCOGENE			English	Article						ALK; MK; IRS-1; NF-kappa B; autocrine	IGF-I RECEPTOR; LEUKOCYTE TYROSINE KINASE; FUNCTIONAL-ANALYSIS; ALK KINASE; ATIC-ALK; GENE; PLEIOTROPHIN; EXPRESSION; TRANSFORMATION; TRANSCRIPTION	Anaplastic lymphoma kinase (ALK) is a transmembrane receptor tyrosine kinase in the insulin receptor superfamily. We recently demonstrated that the growth factors pleiotrophin (PTN) and midkine (MK) are ligands for ALK and that upon ALK activation, insulin receptor substrate-1 (IRS-1) and other substrates are phosphorylated. Here, the role of IRS-1 in ligand-mediated ALK signaling is investigated in interleukin-3 (IL-3)-dependent 32D murine myeloid cells. These cells do not express ALK and IRS family members, and do not respond to exogenously added PTN or MK. We show that expression of ALK plus IRS-1 renders these cells independent of IL-3 owing to the activation of ALK by endogenous MK. Mutational analysis reveals that this transformed phenotype of 32D cells requires kinase-active ALK as well as the interaction of ALK with IRS-1. Furthermore, 32D/IRS-1/ALK cells display an enhanced activation of mitogen-activated protein kinase and PI3-kinase pathways, and a selective transcriptional activation of nuclear factor (NF)-kappa B. Small interfering RNA-mediated knockdown of the endogenous MK or p65/NF-kappa B revealed that both these are rate limiting for the transformed phenotype induced by ALK plus IRS-1. We conclude that the recruitment of IRS-1 to activated ALK and the activation of NF-kappa B are essential for the autocrine growth and survival signaling of MK.	Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Georgetown University	Wellstein, A (corresponding author), Georgetown Univ, Lombardi Canc Ctr, Dept Oncol, Res Bldg E311,3970 Reservoir Rd, Washington, DC 20007 USA.	wellstea@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA101811] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [C06RR014567] Funding Source: NIH RePORTER; NCI NIH HHS [CA101811] Funding Source: Medline; NCRR NIH HHS [C06 RR14567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Ballinger MD, 1999, NAT BIOTECHNOL, V17, P1199, DOI 10.1038/70746; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 2000, GROWTH HORM IGF RES, V10, pS43, DOI 10.1016/S1096-6374(00)90021-2; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Bowden ET, 2002, J BIOL CHEM, V277, P35862, DOI 10.1074/jbc.M203963200; Burks DJ, 2001, DIABETES, V50, pS140, DOI 10.2337/diabetes.50.2007.S140; Chang Q, 2002, CANCER RES, V62, P6035; Colleoni GWB, 2000, AM J PATHOL, V156, P781, DOI 10.1016/S0002-9440(10)64945-0; Cristofanelli B, 2000, ONCOGENE, V19, P3245, DOI 10.1038/sj.onc.1203664; Czubayko F, 1996, P NATL ACAD SCI USA, V93, P14753, DOI 10.1073/pnas.93.25.14753; Delsol G, 1997, BLOOD, V89, P1483, DOI 10.1182/blood.V89.5.1483.1483_1483_1490; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FANG WJ, 1992, J BIOL CHEM, V267, P25889; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Freeman M, 2003, NATURE, V425, P468, DOI 10.1038/425468a; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; Hernandez L, 1999, BLOOD, V94, P3265; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lawrence B, 2000, AM J PATHOL, V157, P377, DOI 10.1016/S0002-9440(10)64550-6; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Li XQ, 2004, HUM PATHOL, V35, P711, DOI 10.1016/j.humpath.2003.12.004; Lu KV, 2005, J BIOL CHEM, V280, P26953, DOI 10.1074/jbc.M502614200; Ma ZG, 2000, BLOOD, V95, P2144, DOI 10.1182/blood.V95.6.2144; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mirkin BL, 2005, ONCOGENE, V24, P4965, DOI 10.1038/sj.onc.1208671; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Ozes ON, 1999, NATURE, V401, P82; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; Pulford K, 2004, J CELL PHYSIOL, V199, P330, DOI 10.1002/jcp.10472; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richmond A, 2002, NAT REV IMMUNOL, V2, P664, DOI 10.1038/nri887; Romano MF, 1999, BLOOD, V94, P4060, DOI 10.1182/blood.V94.12.4060.424k23_4060_4066; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sachdev D, 2001, ENDOCR-RELAT CANCER, V8, P197, DOI 10.1677/erc.0.0080197; Scharf JG, 2003, HORM METAB RES, V35, P685; Schulte AM, 1997, TUMOUR ANGIOGENESIS, P273; Schulte AM, 1996, P NATL ACAD SCI USA, V93, P14759, DOI 10.1073/pnas.93.25.14759; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Surmacz E, 2004, J EXP CLIN CANC RES, V23, P385; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Touriol C, 2000, BLOOD, V95, P3204, DOI 10.1182/blood.V95.10.3204.010k04_3204_3207; Trinei M, 2000, CANCER RES, V60, P793; Ueno H, 1996, J BIOL CHEM, V271, P27707, DOI 10.1074/jbc.271.44.27707; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 2002, AM J PHYSIOL-ENDOC M, V283, pE413, DOI 10.1152/ajpendo.00514.2001; White MF, 1998, RECENT PROG HORM RES, V53, P119; Zamorano J, 2001, INT IMMUNOL, V13, P1479, DOI 10.1093/intimm/13.12.1479; Zhang N, 1999, Curr Opin Hematol, V6, P44, DOI 10.1097/00062752-199901000-00008; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	69	42	46	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					859	869		10.1038/sj.onc.1209840	http://dx.doi.org/10.1038/sj.onc.1209840			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878150				2022-12-28	WOS:000244063800007
J	Nouvion, AL; Thibaut, J; Lohez, OD; Venet, S; Colas, P; Gillet, G; Lalle, P				Nouvion, A-L; Thibaut, J.; Lohez, O. D.; Venet, S.; Colas, P.; Gillet, G.; Lalle, P.			Modulation of Nr-13 antideath activity by peptide aptamers	ONCOGENE			English	Article						Bcl-2; Nr-13; peptide aptamer; apoptosis; ligand	ANTIAPOPTOTIC PROTEIN NR-13; BCL-2 FAMILY; BH3 DOMAIN; APOPTOTIC FUNCTION; STRUCTURAL BASIS; TUMOR-CELLS; BAX; INHIBITOR; CANCER; IDENTIFICATION	Tumor cells are characterized by deregulated proliferation and resistance to proapoptotic stimuli. The Bcl-2 family of antiapoptotic proteins is overexpressed in a large number of chemoresistant tumors. Downregulation or inhibition of antiapoptotic proteins might result in the sensitization of cancer cells to chemotherapeutic agents. In the present study, we took advantage of the peptide aptamer strategy to target Nr-13, a Bcl-2 antiapoptotic protein involved in neoplastic transformation by the Rous sarcoma virus. We isolated peptide aptamers that behave as Nr-13 regulators, in vitro and in mammalian cells in culture. Some of these aptamers have potential proapoptotic activities. These data suggest that peptide aptamers targeting the Bcl-2 family of apoptosis inhibitors may be useful for the development of anticancer molecules.	Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, F-69367 Lyon 07, France; Aptanomics SA, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gillet, G (corresponding author), Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	LALLE, Philippe/G-7734-2018; gillet, germain/A-9095-2013	Lohez, Olivier/0000-0001-9446-9915; Colas, Pierre/0000-0001-7436-3718; GILLET, Germain/0000-0002-1514-327X				Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; AOUACHERIA A, 2003, RRD MOLEC CELL BIOL, V4, P59; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cotter FE, 1999, BBA-GENE STRUCT EXPR, V1489, P97, DOI 10.1016/S0167-4781(99)00139-6; Cui QQ, 2005, ONCOGENE, V24, P3864, DOI 10.1038/sj.onc.1208556; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Girard-Egrot A, 2004, J MOL BIOL, V335, P321, DOI 10.1016/j.jmb.2003.10.028; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Juin P, 2004, BBA-MOL CELL RES, V1644, P251, DOI 10.1016/j.bbamcr.2003.10.010; Klevenz B, 2002, CELL MOL LIFE SCI, V59, P1993, DOI 10.1007/PL00012521; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Kurtz SE, 2003, BIOTECHNOL BIOENG, V82, P38, DOI 10.1002/bit.10538; Lalle P, 2002, BIOCHEM J, V368, P213, DOI 10.1042/BJ20020836; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Mangeney M, 1996, ONCOGENE, V13, P1441; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; Moradi-Ameli M, 2002, BIOCHEMISTRY-US, V41, P8540, DOI 10.1021/bi0110286; Nauenburg S, 2001, FASEB J, V15, P592; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092	50	12	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					701	710		10.1038/sj.onc.1209832	http://dx.doi.org/10.1038/sj.onc.1209832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909120				2022-12-28	WOS:000243902200007
J	Wu, Y; McRoberts, K; Berr, SS; Frierson, HF; Conaway, M; Theodorescu, D				Wu, Y.; McRoberts, K.; Berr, S. S.; Frierson, H. F., Jr.; Conaway, M.; Theodorescu, D.			Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia	ONCOGENE			English	Article						neoplasm metastasis; endothelial growth factors; bladder neoplasms; gene expression profiling; xenograft model antitumor assays	HUMAN BLADDER-CANCER; ENDOTHELIN AXIS; PROSTATE-CANCER; CELLS; PROGRESSION; EXPRESSION; INVASION; GENE; IDENTIFICATION; RECEPTORS	Most deaths from urinary bladder cancer are owing to metastatic disease. A reduction in Rho GDP Dissociation Inhibitor 2 (RhoGDI2) protein has been associated with increased risk of metastasis in patients with locally advanced bladder cancer, whereas in animal models, RhoGDI2 reconstitution in cells without expression results in lung metastasis suppression. Recently, we noted an inverse correlation between tumor RhoGDI2 and Neuromedin U (NMU) expression, suggesting that NMU might be a target of the lung metastasis suppressor effect of RhoGDI2. Here we evaluated whether NMU is regulated by RhoGDI2 and is functionally important in tumor progression. We used small interfering RNA knockdown of endogenous RhoGDI2 in poorly tumorigenic and non-metastatic human bladder cancer T24 cells and observed increased NMU RNA expression. Although NMU overexpression did not increase the monolayer growth of T24 or related T24T poorly metastatic human bladder cancer cells, it did augment anchorage-independent growth for the latter. Overexpression of NMU in T24 and T24T cells significantly promoted tumor formation of both cell lines in nude mice, but did not alter the growth rate of established tumors. Furthermore, NMU-overexpressing xenografts were associated with lower animal body weight than control tumors, indicating a possible role of NMU in cancer cachexia. NMU overexpression in T24T cells significantly enhanced their lung metastatic ability. Bioluminescent in vivo imaging revealed that lung metastases in T24T grew faster than the same tumors in the subcutaneous microenvironment. In conclusion, NMU is a RhoGDI2-regulated gene that appears important for tumorigenicity, lung metastasis and cancer cachexia, and thus a promising therapeutic target in cancer.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiol, Charlottesville, VA USA; Univ Virginia, Dept Pathol, Charlottesville, VA USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA	University of Virginia; University of Virginia; University of Virginia; University of Virginia	Theodorescu, D (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, Box 800422, Charlottesville, VA 22908 USA.	dt9d@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA075115, R29CA075115] Funding Source: NIH RePORTER; NCI NIH HHS [CA075115] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHAI E, 2002, NAT REV CANCER, V2, P133; Alevizos I, 2001, ONCOGENE, V20, P6196, DOI 10.1038/sj.onc.1204685; Brighton PJ, 2004, PHARMACOL REV, V56, P231, DOI 10.1124/pr.56.2.3; Cameron MD, 2000, CANCER RES, V60, P2541; Cao CQ, 2003, PAIN, V104, P609, DOI 10.1016/S0304-3959(03)00118-0; Chan ISF, 1999, BIOMETRICS, V55, P1202, DOI 10.1111/j.0006-341X.1999.01202.x; Chung LWK, 2005, J UROLOGY, V173, P10, DOI 10.1097/01.ju.0000141582.15218.10; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Euer NI, 2005, ONCOL REP, V13, P375; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Gildea JJ, 2002, CANCER RES, V62, P6418; Gildea JJ, 2000, GENE CHROMOSOME CANC, V27, P252, DOI 10.1002/(SICI)1098-2264(200003)27:3<252::AID-GCC5>3.0.CO;2-9; Hanada R, 2004, NAT MED, V10, P1067, DOI 10.1038/nm1106; Harding MA, 2002, CANCER RES, V62, P6981; Howard AD, 2000, NATURE, V406, P70, DOI 10.1038/35017610; Ida T, 2005, ENDOCRINOLOGY, V146, P4217, DOI 10.1210/en.2005-0107; Im JH, 2004, CANCER RES, V64, P8613, DOI 10.1158/0008-5472.CAN-04-2078; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P745, DOI 10.1023/B:CLIN.0000006817.25962.87; Johnson EN, 2004, J IMMUNOL, V173, P7230, DOI 10.4049/jimmunol.173.12.7230; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2003, BJU INT, V91, P234, DOI 10.1046/j.1464-410X.2003.03063.x; Kowalski TJ, 2005, J ENDOCRINOL, V185, P151, DOI 10.1677/joe.1.05948; Martignoni Marcus E, 2003, Mol Cancer, V2, P36, DOI 10.1186/1476-4598-2-36; Moriyama M, 2006, BIOCHEM BIOPH RES CO, V341, P1149, DOI 10.1016/j.bbrc.2006.01.075; Moriyama M, 2005, J EXP MED, V202, P217, DOI 10.1084/jem.20050248; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Oxford G, 2003, J UROLOGY, V170, P1987, DOI 10.1097/01.ju.0000088670.02905.78; Robinson Victoria L, 2004, Cancer Treat Res, V118, P1; Seraj MJ, 2001, CLIN EXP METASTAS, V18, P519, DOI 10.1023/A:1011819621859; Shetzline SE, 2004, BLOOD, V104, P1833, DOI 10.1182/blood-2003-10-3577; Shousha S, 2006, NEUROSCI LETT, V391, P87, DOI 10.1016/j.neulet.2005.08.033; Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967; STRASSMANN G, 1995, CYTOKINES MOL THER, V1, P107; Theodorescu D, 2004, CLIN CANCER RES, V10, P3800, DOI 10.1158/1078-0432.CCR-03-0653; Tisdale MJ, 2005, PHYSIOLOGY, V20, P340, DOI 10.1152/physiol.00019.2005; Titus B, 2005, CANCER RES, V65, P7320, DOI 10.1158/0008-5472.CAN-05-1403; Welch DR, 2004, BREAST CANCER RES, V6, P61, DOI 10.1186/bcr736; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Yu XH, 2003, NEUROSCIENCE, V120, P467, DOI 10.1016/S0306-4522(03)00300-2; Zheng XX, 2005, BIOORG MED CHEM LETT, V15, P4531, DOI 10.1016/j.bmcl.2005.07.003; Zhou XW, 2004, RADIAT RES, V162, P287, DOI 10.1667/RR3220	42	46	49	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					765	773		10.1038/sj.onc.1209835	http://dx.doi.org/10.1038/sj.onc.1209835			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878152				2022-12-28	WOS:000243902200013
J	Inoue, Y; Itoh, Y; Abe, K; Okamoto, T; Daitoku, H; Fukamizu, A; Onozaki, K; Hayashi, H				Inoue, Y.; Itoh, Y.; Abe, K.; Okamoto, T.; Daitoku, H.; Fukamizu, A.; Onozaki, K.; Hayashi, H.			Smad3 is acetylated by p300/CBP to regulate its transactivation activity	ONCOGENE			English	Article						acetylation; CBP; p300; Smad2; Smad3; TGF-beta	GROWTH-FACTOR-BETA; TRANSCRIPTIONAL COACTIVATOR P/CAF; TGF-BETA; DNA-BINDING; RECEPTOR; PHOSPHORYLATION; ACTIVATION; IDENTIFICATION; SUPERFAMILY; ANTAGONIST	Smad proteins are crucial for the intracellular signaling of transforming growth factor-P (TGF-beta). Upon their receptor-induced activation, Smad proteins are phosphorylated and translocated to the nucleus to activate the transcription of a select set of target genes. Here, we show that the co-activator p300/CBP bound and acetylated Smad3 as well as Smad2 in vivo, and that the acetylation was stimulated by TGF-beta. A major acetylation site of Smad3 by p300/CBP is Lys-378 in the MH2 domain (Smad3C) known to be critical for the regulation of transcriptional activity. Replacement of Lys-378 with Arg decreased the transcriptional activity of GAL4-Smad3C in a luciferase assay. Moreover, p300/CBP potentiated the transcriptional activity of GAL4-Smad3C, but not the acetylation-resistant GAL4-Smad3C(K378R) mutant. These results suggest that acetylation of Smad3 by p300/CBP regulates positively its transcriptional activity.	Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Nagoya City Univ, Grad Sch Med Sci, Dept Mol & Cellular Biol, Mizuho Ku, Nagoya, Aichi 4678603, Japan; Univ Tsukuba, Inst Appl Biochem, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 305, Japan	Nagoya City University; Nagoya City University; University of Tsukuba	Hayashi, H (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Mol Hlth Sci, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hhayashi@phar.nagoya-cu.ac.jp	fukamizu, akiyoshi/J-5350-2012	fukamizu, akiyoshi/0000-0002-8786-6020				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Callahan JF, 2002, J MED CHEM, V45, P999, DOI 10.1021/jm010493y; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Enari M, 2006, GENE DEV, V20, P1087, DOI 10.1101/gad.1381906; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Freiman RN, 2003, CELL, V112, P11, DOI 10.1016/S0092-8674(02)01278-3; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Inoue Y, 2004, J INTERF CYTOK RES, V24, P43, DOI 10.1089/107999004772719909; Itoh S, 2000, NUCLEIC ACIDS RES, V28, P4291, DOI 10.1093/nar/28.21.4291; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Kawabata H, 2002, J BIOL CHEM, V277, P8099, DOI 10.1074/jbc.M108250200; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Miyazono K, 2000, J CELL SCI, V113, P1101; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nishihara A, 1998, GENES CELLS, V3, P613, DOI 10.1046/j.1365-2443.1998.00217.x; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Takahashi N, 2002, EUR J BIOCHEM, V269, P4559, DOI 10.1046/j.1432-1033.2002.03157.x; Wu JW, 2001, MOL CELL, V8, P1277, DOI 10.1016/S1097-2765(01)00421-X; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521	34	107	116	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					500	508		10.1038/sj.onc.1209826	http://dx.doi.org/10.1038/sj.onc.1209826			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862174				2022-12-28	WOS:000243731600003
J	Hwang, SI; Thumar, J; Lundgren, DH; Rezaul, K; Mayya, V; Wu, L; Eng, J; Wright, ME; Han, DK				Hwang, S-I; Thumar, J.; Lundgren, D. H.; Rezaul, K.; Mayya, V.; Wu, L.; Eng, J.; Wright, M. E.; Han, D. K.			Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues	ONCOGENE			English	Article						direct tissue proteomics (DTP); LC-MS/MS; prostate cancer; Wnt; formalin-fixed paraffin-embedded tissues; prostate-specific antigen (PSA)	PROSTATE-SPECIFIC ANTIGEN; ANDROGEN RECEPTOR; MASS-SPECTROMETRY; STATISTICAL-MODEL; GENE-EXPRESSION; LUNG-CANCER; PROTEIN; IDENTIFICATION; SPECIFICITY; PREVENTION	Successful treatment of multiple cancer types requires early detection and identification of reliable biomarkers present in specific cancer tissues. To test the feasibility of identifying proteins from archival cancer tissues, we have developed a methodology, termed direct tissue proteomics (DTP), which can be used to identify proteins directly from formalin-fixed paraffin-embedded prostate cancer tissue samples. Using minute prostate biopsy sections, we demonstrate the identification of 428 prostate-expressed proteins using the shotgun method. Because the DTP method is not quantitative, we employed the absolute quanti. cation method and demonstrate picogram level quantification of prostate-specific antigen. In depth bioinformatics analysis of these expressed proteins affords the categorization of metabolic pathways that may be important for distinct stages of prostate carcinogenesis. Furthermore, we validate Wnt-3 as an upregulated protein in cancerous prostate cells by immunohistochemistry. We propose that this general strategy provides a roadmap for successful identification of critical molecular targets of multiple cancer types.	Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, Farmington, CT 06030 USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of Connecticut; Fred Hutchinson Cancer Center; University of California System; University of California Davis	Han, DK (corresponding author), Univ Connecticut, Sch Med, Ctr Vasc Biol, Dept Cell Biol, 263 Farmington Ave, Farmington, CT 06030 USA.	han@nso.uchc.edu	Eng, Jimmy K/I-4202-2012	Eng, Jimmy K/0000-0001-6352-6737; Mayya, Viveka/0000-0001-5668-9124; Wright, Michael/0000-0002-4243-2931	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR019436] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL070694, R01HL067569] Funding Source: NIH RePORTER; NCRR NIH HHS [RR019436] Funding Source: Medline; NHLBI NIH HHS [HL 67569, P01 HL70694] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Cantin GT, 2004, J CHROMATOGR A, V1053, P7, DOI 10.1016/j.chroma.2004.06.046; Coombs GS, 1998, CHEM BIOL, V5, P475, DOI 10.1016/S1074-5521(98)90004-7; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Cronauer MV, 2005, INT J ONCOL, V26, P1033; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FORD TF, 1985, BRIT J UROL, V57, P50, DOI 10.1111/j.1464-410X.1985.tb08984.x; George DJ, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01589-3; Gerber SA, 2003, P NATL ACAD SCI USA, V100, P6940, DOI 10.1073/pnas.0832254100; Gleason D F, 1988, NCI Monogr, P15; GLEASON DF, 1992, HUM PATHOL, V23, P273, DOI 10.1016/0046-8177(92)90108-F; Griffin TJ, 2003, ANAL CHEM, V75, P867, DOI 10.1021/ac026127j; Gupta A, 2004, J UROLOGY, V171, P2384, DOI 10.1097/01.ju.0000124331.16739.12; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Han DK, 2001, NAT BIOTECHNOL, V19, P946, DOI 10.1038/nbt1001-946; Hood BL, 2005, MOL CELL PROTEOMICS, V4, P1741, DOI 10.1074/mcp.M500102-MCP200; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Lundgren DH, 2003, MOL CELL PROTEOMICS, V2, P1164, DOI 10.1074/mcp.M300059-MCP200; Mayya V, 2005, MOL CELL PROTEOMICS, V4, P214, DOI 10.1074/mcp.T400015-MCP200; Meyerson M, 2005, J CLIN ONCOL, V23, P3219, DOI 10.1200/JCO.2005.15.511; Nantermet PV, 2004, J BIOL CHEM, V279, P1310, DOI 10.1074/jbc.M310206200; Nelson PS, 2000, ELECTROPHORESIS, V21, P1823; Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261; Parnes HL, 2005, J CLIN ONCOL, V23, P368, DOI 10.1200/JCO.2005.08.027; Patterson SD, 2004, ARTHRITIS RHEUM-US, V50, P3741, DOI 10.1002/art.20796; Peng JM, 2003, J PROTEOME RES, V2, P43, DOI 10.1021/pr025556v; Petricoin EF, 2002, NAT REV DRUG DISCOV, V1, P683, DOI 10.1038/nrd891; Posadas EM, 2005, ANN ONCOL, V16, P16, DOI 10.1093/annonc/mdi004; Raben David, 2004, Clin Lung Cancer, V6, P48, DOI 10.3816/CLC.2004.n.021; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Sawyers CL, 2002, CURR OPIN GENET DEV, V12, P111, DOI 10.1016/S0959-437X(01)00273-8; Sharpless NE, 2005, NATURE, V436, P636, DOI 10.1038/436636a; Smith RA, 2005, CA-CANCER J CLIN, V55, P31, DOI 10.3322/canjclin.55.1.31; Stephens P, 2005, NAT GENET, V37, P590, DOI 10.1038/ng1571; Sweat GT, 2005, POSTGRAD MED, V117, P45, DOI 10.3810/pgm.2005.04.1618; TANNEBERGER S, 1977, ARCH GESCHWULSTFORSC, V47, P755; Tarro G, 2005, J CELL PHYSIOL, V203, P1, DOI 10.1002/jcp.20195; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Velasco AM, 2004, ENDOCRINOLOGY, V145, P3913, DOI 10.1210/en.2004-0311; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Wardwell NR, 2005, SEMIN ONCOL, V32, P259, DOI 10.1053/j.seminoncol.2005.02.009; Wilson JF, 2004, ANN INTERN MED, V140, P317, DOI 10.7326/0003-4819-140-4-200402170-00036; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wright ME, 2005, MOL CELL PROTEOMICS, V4, P545, DOI 10.1074/mcp.R500008-MCP200; Wright ME, 2004, GENOME BIOL, V5; Zangar RC, 2004, DIS MARKERS, V20, P135, DOI 10.1155/2004/754640; Zhu HN, 2004, CANCER RES, V64, P7918, DOI 10.1158/0008-5472.CAN-04-2704	47	105	110	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					65	76		10.1038/sj.onc.1209755	http://dx.doi.org/10.1038/sj.onc.1209755			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799640				2022-12-28	WOS:000243236500007
J	Martin, PM; Aeder, SE; Chrestensen, CA; Sturgill, TW; Hussaini, IM				Martin, P. M.; Aeder, S. E.; Chrestensen, C. A.; Sturgill, T. W.; Hussaini, I. M.			Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta	ONCOGENE			English	Article						PKC; PKC-eta; p70S6K; glioblastoma; rapamycin	BREAST-CANCER CELLS; MESSENGER-RNA TRANSLATION; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PHOSPHORYLATION; PATHWAY; MTOR	Previously, we have shown that PKC-eta (protein kinase Ceta) positively regulates glioblastoma proliferation and confers resistance to irradiation-induced apoptosis. In this study, we investigated the efficacy of rapamycin in inhibiting cell proliferation in two glioblastoma cell lines U-251MG (PKC-eta expressing) and U-1242MG (PKC-eta deficient) following PKC-eta activation. In U-251MG cells, rapamycin (10 nM) treatment was less effective as an antiproliferative agent when cells were concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent activator of PKC isozymes. Rapamycin-insensitive growth was owing to PKC-eta, as U-1242MG and U-251MG cells infected with a kinase-dead form of PKC-eta (U-251kr) were susceptible to rapamycin-induced inhibition of cell proliferation. Furthermore, U-251MG cells transfected with PKC-eta antisense oligonucleotides were sensitive to rapamycin. PKC-eta-expressing cells stimulated with PMA maintained p70S6K phosphorylation on Thr389 and phosphorylation of rpS6 (ser235/36), suggesting p70S6K kinase activity was still intact. Inhibition of p70S6K expression with small interfering RNA oligonucleotides inhibited cell proliferation greater than 50% in the presence of a combination of PMA and serum. Additionally, p70S6K co-precipitated with PKC-eta, suggesting a physical interaction between PKC-eta and p70S6K regulates the observed phosphorylation. Taken together, these data demonstrate that rapamycin-insensitive glioblastoma proliferation involves PKC-eta signaling.	Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Martin, PM (corresponding author), Fisk Univ, Dept Biol, Nashville, TN 37208 USA.	pmartin@fisk.edu			NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062890] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NIGMS NIH HHS [GM62890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Aspeslet LJ, 2000, CLIN THER, V22, pB86, DOI 10.1016/S0149-2918(00)89025-6; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choe G, 2003, CANCER RES, V63, P2742; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Dutcher Janice P, 2004, Curr Oncol Rep, V6, P111, DOI 10.1007/s11912-004-0022-5; Eshleman JS, 2002, CANCER RES, V62, P7291; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feldkamp MM, 1997, J NEURO-ONCOL, V35, P223, DOI 10.1023/A:1005800114912; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Geoerger B, 2001, CANCER RES, V61, P1527; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Hussaini IA, 2002, NEURO-ONCOLOGY, V4, P9, DOI 10.1093/neuonc/4.1.9; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiffar T, 2004, LEUKEMIA, V18, P505, DOI 10.1038/sj.leu.2403275; Lang D, 1995, NEUROSCI LETT, V201, P199, DOI 10.1016/0304-3940(95)12178-1; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy EI, 2004, J NEUROSURG, V100, P688, DOI 10.3171/jns.2004.100.4.0688; Maasho K, 2004, J IMMUNOL METHODS, V284, P133, DOI 10.1016/j.jim.2003.10.010; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, CANCER BIOL THER, V2, P242, DOI 10.4161/cbt.2.3.369; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Newton Herbert B, 2004, Expert Rev Anticancer Ther, V4, P105, DOI 10.1586/14737140.4.1.105; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rodriguez Alfredo E, 2003, J Invasive Cardiol, V15, P515; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schlegel J, 2002, ANN NY ACAD SCI, V973, P224, DOI 10.1111/j.1749-6632.2002.tb04638.x; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schondorf T, 2004, ANTI-CANCER DRUG, V15, P265, DOI 10.1097/01.cad.0000119457.84063.cb; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Xu G, 2004, INT J ONCOL, V24, P893; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					407	414		10.1038/sj.onc.1209791	http://dx.doi.org/10.1038/sj.onc.1209791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832347				2022-12-28	WOS:000243544000009
J	Jovanovic, M; Hengartner, MO				Jovanovic, M.; Hengartner, M. O.			miRNAs and apoptosis: RNAs to die for	ONCOGENE			English	Review						apoptosis; miRNA; cancer; miRNA targets; Drosophila; proliferation	CELL-DEATH; C-MYC; NUCLEAR EXPORT; MICRO RNAS; DROSOPHILA; GENE; EXPRESSION; TARGET; INTERFERENCE; LET-7	MicroRNAs (miRNAs) are small non-coding RNAs of about 18-24 nucleotides in length that negatively regulate gene expression. Discovered only recently, it has become clear that they are involved in many biological processes such as developmental timing, differentiation and cell death. Data that connect miRNAs to various kinds of diseases, particularly cancer, are accumulating. miRNAs can influence cancer development in many ways, including the regulation of cell proliferation, cell transformation, and cell death. In this review, we focus on miRNAs that have been shown to play a role in the regulation of apoptosis. We first describe in detail how Drosophila has been utilized as a model organism to connect several miRNAs with the cell death machinery. We discuss the genetic approaches that led to the identification of those miRNAs and subsequent work that helped to establish their function. In the second part of the review article, we focus on the involvement of miRNAs in apoptosis regulation in mammals. Intriguingly, many of the miRNAs that regulate apoptosis have been shown to affect cancer development. In the end, we discuss a virally encoded miRNA that influences the cell death response in the mammalian host cell. In summary, the data gathered over the recent years clearly show the potential and important role of miRNAs to regulate apoptosis at various levels and in several organisms.	Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; ETH, Zurich, Switzerland; Univ Zurich, PhD Program Mol Life Sci, CH-8057 Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich	Hengartner, MO (corresponding author), Univ Zurich, Inst Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	michael.hengartner@molbio.unizh.ch	Hengartner, Michael O/E-6235-2011	Hengartner, Michael/0000-0002-7584-596X				Alvarez-Garcia I, 2005, DEVELOPMENT, V132, P4653, DOI 10.1242/dev.02073; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen P, 1996, GENE DEV, V10, P1773, DOI 10.1101/gad.10.14.1773; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doench JG, 2003, GENE DEV, V17, P438, DOI 10.1101/gad.1064703; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909; Enright AJ, 2004, GENOME BIOL, V5; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Hay BA, 2000, CELL DEATH DIFFER, V7, P1045, DOI 10.1038/sj.cdd.4400765; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hipfner DR, 2002, GENETICS, V161, P1527; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Kim VN, 2005, MOL CELLS, V19, P1; Knight SW, 2001, SCIENCE, V293, P2269, DOI 10.1126/science.1062039; Kornbluth S, 2005, J CELL SCI, V118, P1779, DOI 10.1242/jcs.02377; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Leaman D, 2005, CELL, V121, P1097, DOI 10.1016/j.cell.2005.04.016; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Lisi S, 2000, GENETICS, V154, P669; Llave C, 2002, PLANT CELL, V14, P1605, DOI 10.1105/tpc.003210; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Nairz K, 2006, DEV BIOL, V291, P314, DOI 10.1016/j.ydbio.2005.11.047; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nordstrom W, 1996, DEV BIOL, V180, P213, DOI 10.1006/dbio.1996.0296; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Perng GC, 2000, SCIENCE, V287, P1500, DOI 10.1126/science.287.5457.1500; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Salvesen GS, 2004, ONCOGENE, V23, P2774, DOI 10.1038/sj.onc.1207522; Schuetz S, 2006, VIROLOGY, V344, P151, DOI 10.1016/j.virol.2005.09.034; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Sullivan CS, 2005, MOL CELL, V20, P3, DOI 10.1016/j.molcel.2005.09.012; Teleman AA, 2005, DEV CELL, V9, P271, DOI 10.1016/j.devcel.2005.07.004; Telernan AA, 2006, GENE DEV, V20, P417, DOI 10.1101/gad.374406; Tittel JN, 2000, GENOME BIOL, V1, pS3; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Wolff Tanya, 1993, P1277; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zeng Y, 2003, P NATL ACAD SCI USA, V100, P9779, DOI 10.1073/pnas.1630797100; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5	108	420	439	0	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6176	6187		10.1038/sj.onc.1209912	http://dx.doi.org/10.1038/sj.onc.1209912			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028597				2022-12-28	WOS:000241158900006
J	Galluzzi, L; Larochette, N; Zamzami, N; Kroemer, G				Galluzzi, L.; Larochette, N.; Zamzami, N.; Kroemer, G.			Mitochondria as therapeutic targets for cancer chemotherapy	ONCOGENE			English	Review						apoptosis; Bcl-2; caspases; cell death; p53; permeability transition	PERMEABILITY TRANSITION-PORE; CYTOCHROME-C RELEASE; APOPTOSIS-INDUCING FACTOR; ADENINE-NUCLEOTIDE TRANSLOCATOR; DEPENDENT ANION CHANNEL; PERIPHERAL BENZODIAZEPINE-RECEPTOR; RAT-LIVER MITOCHONDRIA; MANGANESE SUPEROXIDE-DISMUTASE; DRUG-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA	Mitochondria are vital for cellular bioenergetics and play a central role in determining the point-of-no-return of the apoptotic process. As a consequence, mitochondria exert a dual function in carcinogenesis. Cancer-associated changes in cellular metabolism (the Warburg effect) influence mitochondrial function, and the invalidation of apoptosis is linked to an inhibition of mitochondrial outer membrane permeabilization (MOMP). On theoretical grounds, it is tempting to develop specific therapeutic interventions that target the mitochondrial Achilles' heel, rendering cancer cells metabolically unviable or subverting endogenous MOMP inhibitors. A variety of experimental therapeutic agents can directly target mitochondria, causing apoptosis induction. This applies to a heterogeneous collection of chemically unrelated compounds including positively charged alpha-helical peptides, agents designed to mimic the Bcl-2 homology domain 3 of Bcl-2-like proteins, ampholytic cations, metals and steroid-like compounds. Such MOMP inducers or facilitators can induce apoptosis by themselves (monotherapy) or facilitate apoptosis induction in combination therapies, bypassing chemoresistance against DNA-damaging agents. In addition, it is possible to design molecules that neutralize inhibitor of apoptosis proteins (IAPs) or heat shock protein 70 (HSP70). Such IAP or HSP70 inhibitors can mimic the action of mitochondrion-derived mediators (Smac/DIABLO, that is, second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with a low isoelectric point, in the case of IAPs; AIF, that is apoptosis-inducing factor, in the case of HSP70) and exert potent chemosensitizing effects.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	Galluzzi, Lorenzo/AAG-6432-2019; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAG-6294-2019; LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi, Lorenzo/K-2709-2012	KROEMER, Guido/0000-0002-9334-4405; LAROCHETTE, Nathanael/0000-0002-7936-678X; Galluzzi, Lorenzo/0000-0003-2257-8500				Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; AOKI H, 2002, IN PRESS J BIOL CHEM; Aqeilan R, 1999, FEBS LETT, V457, P271, DOI 10.1016/S0014-5793(99)01050-9; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Becker JW, 2004, J MED CHEM, V47, P2466, DOI 10.1021/jm0305523; Belostotsky R, 2001, J IMMUNOL, V167, P4719, DOI 10.4049/jimmunol.167.8.4719; Belzacq AS, 2003, CANCER RES, V63, P541; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; Belzacq AS, 2001, CANCER RES, V61, P1260; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Boya P, 2003, ONCOGENE, V22, P6220, DOI 10.1038/sj.onc.1206827; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Brustovetsky N, 2002, BIOCHEMISTRY-US, V41, P11804, DOI 10.1021/bi0200110; Cahuana GM, 2004, EXP CELL RES, V293, P22, DOI 10.1016/j.yexcr.2003.10.004; Cande C, 2004, J CELL SCI, V117, P4461, DOI 10.1242/jcs.01356; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428; Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Casellas P, 2002, NEUROCHEM INT, V40, P475, DOI 10.1016/S0197-0186(01)00118-8; Castedo M, 2002, J EXP MED, V196, P1121, DOI 10.1084/jem.20021758; Castilho RF, 1997, INT J BIOCHEM CELL B, V29, P1005, DOI 10.1016/S1357-2725(97)00041-1; Castilho RF, 1998, ARCH BIOCHEM BIOPHYS, V354, P151, DOI 10.1006/abbi.1998.0657; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Chen J, 2003, NUCLEIC ACIDS RES, V31, P474, DOI 10.1093/nar/gkg086; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chilin A, 2005, J MED CHEM, V48, P192, DOI 10.1021/jm0493919; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chiu SM, 2005, APOPTOSIS, V10, P1357, DOI 10.1007/s10495-005-2217-0; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Chun KH, 2003, CANCER RES, V63, P3826; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Da Lozzo EJ, 1998, J BIOCHEM MOL TOXIC, V12, P291, DOI 10.1002/(SICI)1099-0461(1998)12:5<291::AID-JBT5>3.0.CO;2-G; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; de Pablo MA, 1999, APOPTOSIS, V4, P81, DOI 10.1023/A:1009694124241; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Decaudin D, 2002, CANCER RES, V62, P1388; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dilda PJ, 2005, JNCI-J NATL CANCER I, V97, P1539, DOI 10.1093/jnci/dji316; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Dolder M, 2003, J BIOL CHEM, V278, P17760, DOI 10.1074/jbc.M208705200; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Donald SP, 2001, CANCER RES, V61, P1810; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fantin VR, 2005, CANCER RES, V65, P6891, DOI 10.1158/0008-5472.CAN-05-0395; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Fulda S, 2005, NEOPLASIA, V7, P162, DOI 10.1593/neo.04442; Fulda S, 1998, CANCER RES, V58, P4453; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Garofalo T, 2005, CELL DEATH DIFFER, V12, P1378, DOI 10.1038/sj.cdd.4401672; Genini D, 2000, BLOOD, V96, P3537; Gincel D, 2004, J BIOENERG BIOMEMBR, V36, P179, DOI 10.1023/B:JOBB.0000023621.72873.9e; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Giordano A, 2005, CELL DEATH DIFFER, V12, P603, DOI 10.1038/sj.cdd.4401636; Giraud S, 1998, J MOL BIOL, V281, P409, DOI 10.1006/jmbi.1998.1955; Gogvadze V, 2001, J BIOL CHEM, V276, P19066, DOI 10.1074/jbc.M100614200; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Grinberg M, 2002, J BIOL CHEM, V277, P12237, DOI 10.1074/jbc.M104893200; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Gurbuxani S, 2003, ONCOGENE, V22, P6669, DOI 10.1038/sj.onc.1206794; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Haridas V, 2001, P NATL ACAD SCI USA, V98, P11557, DOI 10.1073/pnas.191363498; Haworth RA, 2000, J BIOENERG BIOMEMBR, V32, P91, DOI 10.1023/A:1005568630151; He YW, 2005, CANCER RES, V65, P10016, DOI 10.1158/0008-5472.CAN-05-1688; Heerdt BG, 2003, CANCER RES, V63, P6311; Heerdt BG, 2005, CANCER RES, V65, P9861, DOI 10.1158/0008-5472.CAN-05-2444; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; HERMESLIMA M, 1995, FREE RADICAL BIO MED, V19, P381, DOI 10.1016/0891-5849(95)00015-P; Hirsch T, 1998, EXP CELL RES, V241, P426, DOI 10.1006/excr.1998.4084; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jan G, 2002, CELL DEATH DIFFER, V9, P179, DOI 10.1038/sj.cdd.4400935; Johnson H, 2003, BLOOD, V101, P3093, DOI 10.1182/blood-2002-08-2485; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Klamt F, 2005, J BIOL CHEM, V280, P21346, DOI 10.1074/jbc.M501170200; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Konopleva M, 2004, CANCER RES, V64, P7927, DOI 10.1158/0008-5472.CAN-03-2402; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kudla G, 2000, J BIOL CHEM, V275, P22713, DOI 10.1074/jbc.M003807200; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kumar S, 2003, MOL PHARMACOL, V63, P276, DOI 10.1124/mol.63.2.276; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Lemeshko VV, 2005, J BIOL CHEM, V280, P15579, DOI 10.1074/jbc.M414064200; LENARTOWICZ E, 1991, J BIOENERG BIOMEMBR, V23, P679, DOI 10.1007/BF00785817; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li XX, 2005, BIOPHYS J, V88, P2577, DOI 10.1529/biophysj.104.049403; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Machida K, 2002, J BIOL CHEM, V277, P31243, DOI 10.1074/jbc.M204564200; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Manion MK, 2004, J BIOL CHEM, V279, P2159, DOI 10.1074/jbc.M306021200; Marchetti P, 1999, CANCER RES, V59, P6257; Martinvalet D, 2005, IMMUNITY, V22, P355, DOI 10.1016/j.immuni.2005.02.004; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Matsuda K, 2002, CANCER RES, V62, P2883; McJilton MA, 2003, ONCOGENE, V22, P7958, DOI 10.1038/sj.onc.1206795; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; Miccoli L, 1998, CANCER RES, V58, P5777; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Motoori S, 2001, CANCER RES, V61, P5382; Muscarella DE, 2003, TOXICOL SCI, V74, P66, DOI 10.1093/toxsci/kfg052; Nagahara Y, 2000, J IMMUNOL, V165, P3250, DOI 10.4049/jimmunol.165.6.3250; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nakamura Y, 2002, J BIOL CHEM, V277, P8492, DOI 10.1074/jbc.M109760200; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Notario B, 2003, MOL PHARMACOL, V63, P224, DOI 10.1124/mol.63.1.224; Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Orsini F, 2004, J BIOL CHEM, V279, P25689, DOI 10.1074/jbc.M401844200; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Palmeira CM, 1997, TOXICOL APPL PHARM, V143, P338, DOI 10.1006/taap.1996.8099; Pardo J, 2001, J IMMUNOL, V167, P1222, DOI 10.4049/jimmunol.167.3.1222; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Peixoto F, 2004, PLANTA MED, V70, P1064, DOI 10.1055/s-2004-832648; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Perfettini JL, 2004, J EXP MED, V199, P629, DOI 10.1084/jem.20031216; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; PFEIFFER DR, 1995, J BIOL CHEM, V270, P4923, DOI 10.1074/jbc.270.9.4923; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Ren J, 2006, ONCOGENE, V25, P20, DOI 10.1038/sj.onc.1209012; Ricci JE, 2003, J CELL BIOL, V160, P65, DOI 10.1083/jcb.200208089; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Risso A, 2002, MOL CELL BIOL, V22, P1926, DOI 10.1128/MCB.22.6.1926-1935.2002; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rodrigues CMP, 2000, MOL MED, V6, P936, DOI 10.1007/BF03401828; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Sakurai K, 2001, J BIOL CHEM, V276, P26942, DOI 10.1074/jbc.M102029200; Salvi M, 2003, BIOCHEM PHARMACOL, V66, P2375, DOI 10.1016/j.bcp.2003.08.023; Salvi M, 2005, ENDOCRINOLOGY, V146, P2306, DOI 10.1210/en.2004-1128; Sandra F, 2005, CANCER RES, V65, P8286, DOI 10.1158/0008-5472.CAN-04-1913; Schempp CM, 2002, ONCOGENE, V21, P1242, DOI 10.1038/sj.onc.1205190; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schlattner U, 2006, BBA-MOL BASIS DIS, V1762, P164, DOI 10.1016/j.bbadis.2005.09.004; Schlattner U, 2001, J BIOL CHEM, V276, P48027, DOI 10.1074/jbc.M106524200; Schmitt E, 2003, CANCER RES, V63, P8233; Schubert A, 2004, CANCER RES, V64, P85, DOI 10.1158/0008-5472.CAN-03-0476; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577; Stoebner PE, 2001, CELL DEATH DIFFER, V8, P747, DOI 10.1038/sj.cdd.4400861; Sugiyama T, 2002, ONCOGENE, V21, P4944, DOI 10.1038/sj.onc.1205621; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takuma K, 2001, J BIOL CHEM, V276, P48093, DOI 10.1074/jbc.M108622200; Tan KO, 2005, P NATL ACAD SCI USA, V102, P14623, DOI 10.1073/pnas.0503524102; Tanaka T, 2002, EMBO J, V21, P1695, DOI 10.1093/emboj/21.7.1695; Thierbach R, 2005, HUM MOL GENET, V14, P3857, DOI 10.1093/hmg/ddi410; Tolcher Anthony W, 2005, Clin Adv Hematol Oncol, V3, P635; TOLCHER AW, 2005, CLIN ADV HEMATOL ONC, V3, P662; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vahsen N, 2006, ONCOGENE, V25, P1763, DOI 10.1038/sj.onc.1209206; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Vieira HLA, 2001, ONCOGENE, V20, P4305, DOI 10.1038/sj.onc.1204575; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walter RB, 2005, BLOOD, V106, P3584, DOI 10.1182/blood-2005-02-0711; Walter RB, 2004, BLOOD, V103, P4276, DOI 10.1182/blood-2003-11-3825; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Wang Y, 2006, INT J ONCOL, V28, P161; Wang Y, 2005, ANTI-CANCER DRUG, V16, P953, DOI 10.1097/01.cad.0000180123.24031.5a; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O. H., 1930, METABOLISM TUMOURS I; Watabe M, 2000, CANCER RES, V60, P5214; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Waterhouse NJ, 2005, J BIOL CHEM, V280, P4476, DOI 10.1074/jbc.M410985200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wu CC, 2005, MOL CANCER THER, V4, P1277, DOI 10.1158/1535-7163.MCT-05-0027; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Wudarczyk J, 1996, ARCH BIOCHEM BIOPHYS, V327, P215, DOI 10.1006/abbi.1996.0112; Xue L, 2002, P NATL ACAD SCI USA, V99, P6925, DOI 10.1073/pnas.102182299; Xue LY, 2001, ONCOGENE, V20, P3420, DOI 10.1038/sj.onc.1204441; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Yu CJ, 2006, GENE THER, V13, P313, DOI 10.1038/sj.gt.3302672; Yu R, 2000, MOL PHARMACOL, V58, P431, DOI 10.1124/mol.58.2.431; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	260	281	296	1	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4812	4830		10.1038/sj.onc.1209598	http://dx.doi.org/10.1038/sj.onc.1209598			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892093				2022-12-28	WOS:000239687000017
J	Feng, JT; Shang, S; Beretta, L				Feng, J. T.; Shang, S.; Beretta, L.			Proteomics for the early detection and treatment of hepatocellular carcinoma	ONCOGENE			English	Review						proteomics; hepatocellular carcinoma; biomarkers; diagnostics; therapeutics	HEPATITIS-C-VIRUS; DIFFERENCE GEL-ELECTROPHORESIS; CHROMATOGRAPHY-MASS-SPECTROMETRY; PRIMARY LIVER-CANCER; PROTEIN IDENTIFICATION; 2-DIMENSIONAL ELECTROPHORESIS; SHOTGUN PROTEOMICS; ALPHA-FETOPROTEIN; UNITED-STATES; TUMOR-MARKERS	The prognosis for hepatocellular carcinoma (HCC) is poor and has not improved in recent years, largely owing to lack of early diagnosis, frequent recurrence after surgery and resistance to chemotherapy. Proteomics holds the promise of improving our understanding of HCC carcinogenesis and progression as well as of discovering novel diagnostics and therapeutics. Proteomic analyses of HCC cell lines, animal models and serum and tumor tissue from patients with HCC have been performed to date. Proteomic technologies have greatly improved in the past few years as reviewed here. It is anticipated that with the recent development of protein tagging, protein separation methods and mass spectrometry sensitivity, proteomic studies of HCC will allow the identification of diagnostic and prognostic biomarkers as well as therapeutic targets, which could greatly improve the clinical management of HCC patients.	Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Beretta, L (corresponding author), Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, 1100 Fairview Ave N,M5-A864,POB 19024, Seattle, WA 98109 USA.	lberetta@fhcrc.org		Laura, Beretta/0000-0002-2054-684X				Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007-MCP200; Block TM, 2005, P NATL ACAD SCI USA, V102, P779, DOI 10.1073/pnas.0408928102; Cagney G, 2002, NAT BIOTECHNOL, V20, P163, DOI 10.1038/nbt0202-163; Chignard N, 2004, GASTROENTEROLOGY, V127, pS120, DOI 10.1053/j.gastro.2004.09.025; CHIGNARD N, 2006, IN PRESS GASTROERTER; Cho SY, 2002, PROTEOMICS, V2, P1104, DOI 10.1002/1615-9861(200209)2:9<1104::AID-PROT1104>3.0.CO;2-Q; Chu RY, 2002, GENE EXPRESSION, V10, P165, DOI 10.3727/000000002783992460; Comunale MA, 2004, PROTEOMICS, V4, P826, DOI 10.1002/pmic.200300625; Cui JF, 2004, J CANCER RES CLIN, V130, P615, DOI 10.1007/s00432-004-0576-5; Daniele B, 2004, GASTROENTEROLOGY, V127, pS108, DOI 10.1053/j.gastro.2004.09.023; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Ding SJ, 2004, PROTEOMICS, V4, P982, DOI 10.1002/pmic.200300653; El-Serag HB, 2001, HEPATOLOGY, V33, P62, DOI 10.1053/jhep.2001.21041; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Feng JT, 2005, PROTEOMICS, V5, P4581, DOI 10.1002/pmic.200401309; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Fernandez-Irigoyen J, 2005, PROTEOMICS, V5, P4964, DOI 10.1002/pmic.200500070; Fujii K, 2005, PROTEOMICS, V5, P1411, DOI 10.1002/pmic.200401004; Gu S, 2004, J PROTEOME RES, V3, P1191, DOI 10.1021/pr049893a; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hanash S, 2004, MOL CELL PROTEOMICS, V3, P298, DOI 10.1074/mcp.R400004-MCP200; Hanash S, 2002, MOL CELL PROTEOMICS, V1, P413, DOI 10.1074/mcp.R200002-MCP200; He FC, 2005, MOL CELL PROTEOMICS, V4, P1841, DOI 10.1074/mcp.R500013-MCP200; Hippo Y, 2004, CANCER RES, V64, P2418, DOI 10.1158/0008-5472.CAN-03-2191; Iida M, 2003, CARCINOGENESIS, V24, P757, DOI 10.1093/carcin/bgg011; Kang SM, 2005, PROTEOMICS, V5, P2227, DOI 10.1002/pmic.200401093; KARAS M, 1988, ANAL CHEM, V60, P2299, DOI 10.1021/ac00171a028; Kim J, 2002, ELECTROPHORESIS, V23, P4142, DOI 10.1002/elps.200290032; Kim W, 2003, CLIN CANCER RES, V9, P5493; Le Naour F, 2002, MOL CELL PROTEOMICS, V1, P197, DOI 10.1074/mcp.M100029-MCP200; Lee CL, 2003, PROTEOMICS, V3, P2472, DOI 10.1002/pmic.200300586; Li C, 2005, PROTEOMICS, V5, P1125, DOI 10.1002/pmic.200401141; Li C, 2004, MOL CELL PROTEOMICS, V3, P399, DOI 10.1074/mcp.M300133-MCP200; Liang CRMY, 2005, PROTEOMICS, V5, P2258, DOI 10.1002/pmic.200401256; Lim SO, 2002, BIOCHEM BIOPH RES CO, V291, P1031, DOI 10.1006/bbrc.2002.6547; Liotta L, 2000, NAT REV GENET, V1, P48, DOI 10.1038/35049567; MacBeath G, 2002, NAT GENET, V32, P526, DOI 10.1038/ng1037; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Mehta AI, 2003, DIS MARKERS, V19, P1; Melle C, 2004, INT J ONCOL, V24, P885; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Orchard S, 2004, EXPERT REV PROTEOMIC, V1, P179, DOI 10.1586/14789450.1.2.179; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Parent R, 2005, J HEPATOL, V43, P177, DOI 10.1016/j.jhep.2005.04.001; Park KS, 2002, HEPATOLOGY, V35, P1459, DOI 10.1053/jhep.2002.33204; Park KS, 2002, INT J CANCER, V97, P261, DOI 10.1002/ijc.1585; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Pedrioli PGA, 2004, NAT BIOTECHNOL, V22, P1459, DOI 10.1038/nbt1031; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Poon TCW, 2003, CLIN CHEM, V49, P752, DOI 10.1373/49.5.752; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Schwegler EE, 2005, HEPATOLOGY, V41, P634, DOI 10.1002/hep.20577; Shalhoub P, 2001, DIS MARKERS, V17, P217, DOI 10.1155/2001/210580; Shui WQ, 2005, J PROTEOME RES, V4, P83, DOI 10.1021/pr049850u; Srisomsap C, 2004, PROTEOMICS, V4, P1135, DOI 10.1002/pmic.200300651; Steel LF, 2003, PROTEOMICS, V3, P601, DOI 10.1002/pmic.200300399; Suriawinata A, 2004, SEMIN LIVER DIS, V24, P77; Syka JEP, 2004, J PROTEOME RES, V3, P621, DOI 10.1021/pr0499794; Takashima M, 2005, PROTEOMICS, V5, P1686, DOI 10.1002/pmic.200401022; Takashima M, 2003, PROTEOMICS, V3, P2487, DOI 10.1002/pmic.200300621; Tan TL, 2005, J CLIN VIROL, V33, P293, DOI 10.1016/j.jcv.2004.12.015; Tannapfel A, 2003, J PATHOL, V201, P238, DOI 10.1002/path.1420; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Van den Bergh G, 2004, CURR OPIN BIOTECH, V15, P38, DOI 10.1016/j.copbio.2003.12.001; Wang H, 2005, MASS SPECTROM REV, V24, P413, DOI 10.1002/mas.20018; Wang H, 2003, J CHROMATOGR B, V787, P11, DOI 10.1016/S1570-0232(02)00335-5; WIRTH PJ, 1995, ELECTROPHORESIS, V16, P1946, DOI 10.1002/elps.11501601321; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Yates JR, 1998, J MASS SPECTROM, V33, P1; Yates JR, 2004, ANNU REV BIOPH BIOM, V33, P297, DOI 10.1146/annurev.biophys.33.111502.082538; Yokoo H, 2004, HEPATOLOGY, V40, P609, DOI 10.1002/hep.20372; Yokoyama Y, 2004, PROTEOMICS, V4, P2111, DOI 10.1002/pmic.200300712; Yu YL, 2004, PROTEOMICS, V4, P3112, DOI 10.1002/pmic.200300837; Zeindl-Eberhart E, 2004, HEPATOLOGY, V39, P540, DOI 10.1002/hep.20060; Zeindl-Eberhart E, 2001, ELECTROPHORESIS, V22, P3009, DOI 10.1002/1522-2683(200108)22:14<3009::AID-ELPS3009>3.0.CO;2-V; Zhang J, 2004, ELECTROPHORESIS, V25, P2374, DOI 10.1002/elps.200405956; Zhang LH, 2005, WORLD J GASTROENTERO, V11, P463, DOI 10.3748/wjg.v11.i4.463; Zhang Y, 2005, WORLD J GASTROENTERO, V11, P3485, DOI 10.3748/wjg.v11.i22.3485; Zhu H, 2003, CURR OPIN CHEM BIOL, V7, P55, DOI 10.1016/S1367-5931(02)00005-4; Zwickl H, 2005, ELECTROPHORESIS, V26, P2779, DOI 10.1002/elps.200410387	84	56	63	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3810	3817		10.1038/sj.onc.1209551	http://dx.doi.org/10.1038/sj.onc.1209551			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799622				2022-12-28	WOS:000238559600008
J	Fischer, ANM; Fuchs, E; Mikula, M; Huber, H; Beug, H; Mikulits, W				Fischer, A. N. M.; Fuchs, E.; Mikula, M.; Huber, H.; Beug, H.; Mikulits, W.			PDGF essentially links TGF-beta signaling to nuclear beta-catenin accumulation in hepatocellular carcinoma progression	ONCOGENE			English	Article						hepatocyte; epithelial to mesenchymal transition; TGF-beta; PDGF; beta-catenin	GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; TUMOR PROGRESSION; CANCER PROGRESSION; DOWN-REGULATION; LIVER-INJURY; STEM-CELLS; PROLIFERATION; HEPATOCYTES; PATHWAY	The cooperation of Ras - extracellular signal-regulated kinase/mitogen-activated protein kinase and transforming growth factor (TGF)-beta signaling provokes an epithelial to mesenchymal transition (EMT) of differentiated p19(ARF) null hepatocytes, which is accompanied by a shift in malignancy and gain of metastatic properties. Upon EMT, TGF-beta induces the secretion and autocrine regulation of platelet-derived growth factor (PDGF) by upregulation of PDGF-A and both PDGF receptors. Here, we demonstrate by loss-of-function analyses that PDGF provides adhesive and migratory properties in vitro as well as proliferative stimuli during tumor formation. PDGF signaling resulted in the activation of phosphatidylinositol-3 kinase, and furthermore associated with nuclear beta-catenin accumulation upon EMT. Hepatocytes expressing constitutively active beta-catenin or its negative regulator Axin were employed to study the impact of nuclear beta-catenin. Unexpectedly, active P-catenin failed to accelerate proliferation during tumor formation, but in contrast, correlated with growth arrest. Nuclear localization of beta-catenin was accompanied by strong expression of the Cdk inhibitor p16(INK4A) and the concomitant induction of the beta-catenin target genes cyclin D1 and c-myc. In addition, active beta-catenin revealed protection of malignant hepatocytes against anoikis, which provides a prerequisite for the dissemination of carcinoma. From these data, we conclude that TGF-beta acts tumor progressive by induction of PDGF signaling and subsequent activation of beta-catenin, which endows a subpopulation of neoplastic hepatocytes with features of cancer stem cells.	Med Univ Vienna, Inst Canc Res, Dept Med 1 Div, A-1090 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Mikulits, W (corresponding author), Med Univ Vienna, Inst Canc Res, Dept Med 1 Div, Borschke Gasse 8A, A-1090 Vienna, Austria.	wolfgang.mikulits@meduniwien.ac.at	Mikulits, Wolfgang/AAH-4043-2021	Mikula, Mario/0000-0001-5782-0681; Mikulits, Wolfgang/0000-0003-4612-7106				Artemenko Y, 2005, J CELL PHYSIOL, V204, P646, DOI 10.1002/jcp.20314; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; BATTEGAY EJ, 1994, J CELL BIOL, V125, P917, DOI 10.1083/jcb.125.4.917; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Friedl J, 2000, CANCER BIOTHER RADIO, V15, P477, DOI 10.1089/cbr.2000.15.477; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Galli A, 2000, HEPATOLOGY, V31, P101, DOI 10.1002/hep.510310117; Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083; Gotzmann J, 2002, J CELL SCI, V115, P1189; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Lu DS, 2005, P NATL ACAD SCI USA, V102, P18567, DOI 10.1073/pnas.0509316102; Lu ZM, 2003, CANCER CELL, V4, P499, DOI 10.1016/S1535-6108(03)00304-0; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Matsuzaki K, 2000, CANCER RES, V60, P1394; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Mikula M, 2006, J CELL PHYSIOL, V209, P560, DOI 10.1002/jcp.20772; Mikula M, 2004, HEPATOLOGY, V39, P628, DOI 10.1002/hep.20084; Nijhara R, 2001, J VIROL, V75, P10348, DOI 10.1128/JVI.75.21.10348-10358.2001; Pinzani M, 1996, AM J PATHOL, V148, P785; Proell V, 2005, BBA-MOL CELL RES, V1744, P76, DOI 10.1016/j.bbamcr.2004.12.009; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rossmanith W, 2001, MICROSC RES TECHNIQ, V52, P430, DOI 10.1002/1097-0029(20010215)52:4<430::AID-JEMT1028>3.0.CO;2-3; Saldanha G, 2004, BRIT J DERMATOL, V151, P157, DOI 10.1111/j.1365-2133.2004.06048.x; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsuboi Y, 2004, LIVER INT, V24, P432, DOI 10.1111/j.1478-3231.2004.0940.x; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Weng ZG, 2002, J BIOL CHEM, V277, P18677, DOI 10.1074/jbc.M105331200; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yu JH, 2000, J BIOL CHEM, V275, P19076, DOI 10.1074/jbc.M910329199; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhou L, 2003, CANCER LETT, V193, P161, DOI 10.1016/S0304-3835(03)00013-2	50	123	127	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3395	3405		10.1038/sj.onc.1210121	http://dx.doi.org/10.1038/sj.onc.1210121			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130832				2022-12-28	WOS:000246579600009
J	Ivanov, I; Lo, KC; Hawthorn, L; Cowell, JK; Ionov, Y				Ivanov, I.; Lo, K. C.; Hawthorn, L.; Cowell, J. K.; Ionov, Y.			Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells	ONCOGENE			English	Article						nonsense-mediated decay; mutations; caffeine; GINI	SHORT MONONUCLEOTIDE REPEATS; ESTROGEN-RECEPTOR-ALPHA; MICROSATELLITE INSTABILITY; FAMILIAL PREDISPOSITION; INTERNATIONAL CRITERIA; INSTITUTE WORKSHOP; ALTERED EXPRESSION; COLORECTAL-CANCER; MUTATIONS; PROTEIN	Inhibition of the nonsense-mediated decay (NMD) mechanism in cells results in stabilization of transcripts carrying premature translation termination codons. A strategy referred to as gene identification by NMD inhibition (GINI) has been proposed to identify genes carrying nonsense mutations. Genes containing frameshift mutations in colon cancer cell line have been identified using a modified version of GINI. To increase the efficiency of identifying mutant genes using GINI, we have now further improved the strategy. In this approach, inhibition of NMD with emetine is complemented with inhibiting NMD by blocking the phosphorylation of the hUpf1 protein with caffeine. In addition, to enhance the GINI strategy, comparing mRNA level alterations produced by inhibiting transcription alone or inhibiting transcription together with NMD following caffeine pretreatment were used for the efficient identification of false positives produced as a result of stress response to NMD inhibition. To demonstrate the improved efficiency of this approach, we analysed colon cancer cell lines showing microsatellite instability. Bi-allelic inactivating mutations were found in the FXR1, SEC31L1, NCOR1, BAT3, PHF14, ZNF294, C19ORF5 genes as well as genes coding for proteins with yet unknown functions.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Ionov, Y (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	Yurij.Ionov@RoswellPark.org	Martinez, Octavio/B-7375-2009; Ivanov, Igor/N-7609-2019	Ivanov, Igor/0000-0002-4942-1987; Hawthorn, Lesleyann/0000-0001-8179-0937; Cowell, John/0000-0002-2079-5950	NCI NIH HHS [1R01 CA109256-01, CA16056] Funding Source: Medline; NINDS NIH HHS [NS054543] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA109256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS054543] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Boland CR, 1998, CANCER RES, V58, P5248; Brumbaugh KM, 2004, MOL CELL, V14, P585, DOI 10.1016/j.molcel.2004.05.005; CHEN JS, 1995, CANCER RES, V55, P174; Duval A, 2002, ONCOGENE, V21, P8062, DOI 10.1038/sj.onc.1206013; Duval A, 2001, HUM MOL GENET, V10, P513, DOI 10.1093/hmg/10.5.513; El-Bchiri J, 2005, HUM MOL GENET, V14, P2435, DOI 10.1093/hmg/ddi245; Fang S, 2003, SEMIN CANCER BIOL, V13, P5, DOI 10.1016/S1044-579X(02)00095-0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Garnon J, 2005, J BIOL CHEM, V280, P5750, DOI 10.1074/jbc.M401988200; Girault I, 2003, CLIN CANCER RES, V9, P1259; Holbrook JA, 2004, NAT GENET, V36, P801, DOI 10.1038/ng1403; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; Ionov Y, 2004, P NATL ACAD SCI USA, V101, P1273, DOI 10.1073/pnas.0307276101; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Ishigaki Y, 2001, CELL, V106, P607, DOI 10.1016/S0092-8674(01)00475-5; Keeton EK, 2005, MOL ENDOCRINOL, V19, P1543, DOI 10.1210/me.2004-0395; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu LY, 2005, BIOCHEM BIOPH RES CO, V332, P670, DOI 10.1016/j.bbrc.2005.05.006; Liu LY, 2005, CANCER RES, V65, P4191, DOI 10.1158/0008-5472.CAN-04-3865; Liu LY, 2005, CANCER RES, V65, P1830, DOI 10.1158/0008-5472.CAN-04-3896; Liu LY, 2002, IN VITRO CELL DEV-AN, V38, P582; Maquat LE, 2005, J CELL SCI, V118, P1773, DOI 10.1242/jcs.01701; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Naef F, 2002, GENOME BIOL, V3; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; Ohnishi T, 2003, MOL CELL, V12, P1187, DOI 10.1016/S1097-2765(03)00443-X; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Perucho M, 1999, CANCER RES, V59, P249; PERUCHO M, 1999, CANCER RES, V58, P5248; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Rossi MR, 2005, CANCER GENET CYTOGEN, V161, P97, DOI 10.1016/j.cancergencyto.2005.02.006; Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56; Suzuki K, 2002, CANCER RES, V62, P1961; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Usuki F, 2004, ANN NEUROL, V55, P740, DOI 10.1002/ana.20107; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Weischenfeldt J, 2005, CURR BIOL, V15, pR559, DOI 10.1016/j.cub.2005.07.002; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; WU Z, 2004, 1 J HOPK U DEP BIOST; Zhang L, 2001, CANCER RES, V61, P3801; Zhang ZH, 2006, CANCER LETT, V237, P123, DOI 10.1016/j.canlet.2005.05.046	53	75	79	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2873	2884		10.1038/sj.onc.1210098	http://dx.doi.org/10.1038/sj.onc.1210098			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086209				2022-12-28	WOS:000246210800007
J	Basaki, Y; Hosoi, F; Oda, Y; Fotovati, A; Maruyama, Y; Oie, S; Ono, M; Izumi, H; Kohno, K; Sakai, K; Shimoyama, T; Nishio, K; Kuwano, M				Basaki, Y.; Hosoi, F.; Oda, Y.; Fotovati, A.; Maruyama, Y.; Oie, S.; Ono, M.; Izumi, H.; Kohno, K.; Sakai, K.; Shimoyama, T.; Nishio, K.; Kuwano, M.			Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells	ONCOGENE			English	Article						Akt; microarray; ovarian carcinoma; Y-box-binding protein-1	TRANSCRIPTION FACTOR YB-1; CHEMOKINE RECEPTORS; PROGNOSTIC-FACTOR; GENE-EXPRESSION; MESSENGER-RNA; TUMOR-GROWTH; DNA; CXCR4; INVOLVEMENT; INHIBITOR	Y-box-binding protein 1 (YB-1), which is a member of the DNA-binding protein family containing a cold-shock domain, has pleiotropic functions in response to various environmental stimuli. As we previously showed that YB-1 is a global marker of multidrug resistance in ovarian cancer and other tumor types. To identify YB-1-regulated genes in ovarian cancers, we investigated the expression profile of YB-1 small-interfering RNA (siRNA)-transfected ovarian cancer cells using a high-density oligonucleotide array. YB-1 knockdown by siRNA upregulated 344 genes, including MDR1, thymidylate synthetase, S100 calcium binding protein and cyclin B, and downregulated 534 genes, including CXCR4, N-myc downstream regulated gene 1, E-cadherin and phospholipase C. Exogenous serum addition stimulated YB-1 translocation from the cytoplasm to the nucleus, and treatment with Akt inhibitors as well as Akt siRNA and integrin-linked kinase (ILK) siRNA specifically blocked YB-1 nuclear localization. Inhibition of Akt activation downregulated CXCR4 and upregulated MDR1 (ABCB1) gene expression. Administration of Akt inhibitor resulted in decrease in nuclear YB-1-positive cancer cells in a xenograft animal model. Akt activation thus regulates the nuclear translocation of YB-1, affecting the expression of drug-resistance genes and other genes associated with the malignant characteristics in ovarian cancer cells. Therefore, the Akt pathway could be a novel target of disrupting the nuclear translocation of YB-1 that has important implications for further development of therapeutic strategy against ovarian cancers.	Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol Anat, Fukuoka 8128582, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan; Univ Occupat & Environm Hlth, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan; Natl Canc Ctr, Res Inst, Div Pharmacol, Tokyo 104, Japan	Kyushu University; Kyushu University; Kurume University; University of Occupational & Environmental Health - Japan; National Cancer Center - Japan	Basaki, Y (corresponding author), Kyushu Univ, Stn Collaborat Res 2, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yubasaki@yahoo.co.jp						Altomare DA, 2004, ONCOGENE, V23, P5853, DOI 10.1038/sj.onc.1207721; ASAKUNO K, 1994, BIOCHEM BIOPH RES CO, V199, P1428, DOI 10.1006/bbrc.1994.1390; Ashizuka M, 2002, MOL CELL BIOL, V22, P6375, DOI 10.1128/MCB.22.18.6375-6383.2002; Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Darash-Yahana M, 2004, FASEB J, V18, P1240, DOI 10.1096/fj.03-0935fje; Dooley S, 2006, J BIOL CHEM, V281, P1784, DOI 10.1074/jbc.M510215200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; En-Nia A, 2005, J BIOL CHEM, V280, P7702, DOI 10.1074/jbc.M413353200; Evdokimova V, 2001, EMBO J, V20, P5491, DOI 10.1093/emboj/20.19.5491; Fukuda T, 2004, NUCLEIC ACIDS RES, V32, P611, DOI 10.1093/nar/gkh223; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; Holm PS, 2002, J BIOL CHEM, V277, P10427, DOI 10.1074/jbc.M106955200; Hu LM, 2000, CLIN CANCER RES, V6, P880; Huang Jing, 2004, Human Genomics, V1, P287; Ise T, 1999, CANCER RES, V59, P342; Jiang YP, 2006, GYNECOL ONCOL, V103, P226, DOI 10.1016/j.ygyno.2006.02.036; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Koike K, 1997, FEBS LETT, V417, P390, DOI 10.1016/S0014-5793(97)01296-9; Kryczek I, 2005, CANCER RES, V65, P465; Kuwano M, 2004, MOL CANCER THER, V3, P1485; LADOMERY M, 1995, BIOESSAYS, V17, P9, DOI 10.1002/bies.950170104; Maruyama Y, 2006, CANCER RES, V66, P6233, DOI 10.1158/0008-5472.CAN-06-0183; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mossink MH, 2003, ONCOGENE, V22, P7458, DOI 10.1038/sj.onc.1206947; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2002, CANCER RES, V62, P7328; Ohga T, 1998, J BIOL CHEM, V273, P5997, DOI 10.1074/jbc.273.11.5997; Ohga T, 1996, CANCER RES, V56, P4224; Porcile C, 2005, EXP CELL RES, V308, P241, DOI 10.1016/j.yexcr.2005.04.024; Robledo MM, 2001, J BIOL CHEM, V276, P45098, DOI 10.1074/jbc.M106912200; Scotton CJ, 2001, CANCER RES, V61, P4961; Scotton CJ, 2002, CANCER RES, V62, P5930; Sorokin AV, 2005, EMBO J, V24, P3602, DOI 10.1038/sj.emboj.7600830; Stein U, 2005, ONCOGENE, V24, P3606, DOI 10.1038/sj.onc.1208386; Stein U, 2001, J BIOL CHEM, V276, P28562, DOI 10.1074/jbc.M100311200; Stenina OI, 2000, J CLIN INVEST, V106, P579, DOI 10.1172/JCI9075; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590	42	109	118	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2736	2746		10.1038/sj.onc.1210084	http://dx.doi.org/10.1038/sj.onc.1210084			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072343				2022-12-28	WOS:000246210600008
J	Ma, C; Zhang, J; Durrin, LK; Lv, J; Zhu, D; Han, X; Sun, Y				Ma, C.; Zhang, J.; Durrin, L. K.; Lv, J.; Zhu, D.; Han, X.; Sun, Y.			The BCL2 major breakpoint region (mbr) regulates gene expression	ONCOGENE			English	Article						BCL2; mbr; t(14;18); homologous recombination; gene regulation	T(14/18) LYMPHOMA-CELLS; MAR-BINDING PROTEIN; AU-RICH ELEMENT; HEMATOPOIETIC-CELLS; CODING SEQUENCE; DOWN-REGULATION; MESSENGER-RNA; APOPTOSIS; SATB1; SITE	BCL2 expression is finely tuned by a variety of environmental and endogenous stimuli and regulated at both transcriptional and post-transcriptional levels. Our previous investigations demonstrated that the BCL2 major breakpoint region (mbr) in the 30-UTR upregulates reporter gene expression, which implies that this region possessed intrinsic regulatory function. However, the effect of the mbr on BCL2 expression, and the underlying regulatory mechanisms, remain to be elucidated. To assess the direct effect of the mbr on the transcriptional activity of the BCL2 gene, we employed targeted homologous recombination to establish a mbr(+) / mbr(-) heterozygous Nalm-6 cell line and then compared the transcriptional activity and apoptotic effect on transcription between the wild type and targeted alleles. We found that deletion of the mbr significantly decreased the transcriptional activity of the corresponding allele in the mbr(+)/mbr(-) cell. The BCL2 allele deleted of the mbr had a slower response to apoptotic stimuli than did the wild type allele. The regulatory function of the mbr was mediated through SATB1. Overexpression of SATB1 increased BCL2 expression, while knockdown of SATB1 with RNAi decreased BCL2 expression. Our results clearly indicated that the mbr could positively regulate BCL2 gene expression and this regulatory function was closely related to SATB1.	Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Nanjing 210029, Peoples R China; Nanjing Med Univ, Dept Cell Biol & Med Genet, Nanjing 210029, Peoples R China; Nanjing Med Univ, Sch Pharm, Nanjing 210029, Peoples R China; City Hope Natl Med Ctr, Dept Mol Med, Duarte, CA 91010 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; City of Hope	Sun, Y (corresponding author), Nanjing Med Univ, Coll Basic Med, Key Lab Human Funct Genom & Jiangsu Province, Hangzhong Rd 140, Nanjing 210029, Peoples R China.	hanxiao@njmu.edu.cn; yujiesun@njmu.edu.cn						Adams JM, 1999, COLD SPRING HARB SYM, V64, P351, DOI 10.1101/sqb.1999.64.351; Alvarez JD, 2000, GENE DEV, V14, P521; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; CHEN HM, 1995, MOL CELL BIOL, V15, P3840; CHEN M, 1995, CANCER RES, V55, P991; DELIC J, 1991, BIOCHEM BIOPH RES CO, V181, P818, DOI 10.1016/0006-291X(91)91263-C; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; DICROCE PA, 1995, P NATL ACAD SCI USA, V92, P10137, DOI 10.1073/pnas.92.22.10137; Donnini M, 2004, J BIOL CHEM, V279, P20154, DOI 10.1074/jbc.M314071200; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRIGORIEV M, 1992, J BIOL CHEM, V267, P3389; Heckman CA, 2000, J BIOL CHEM, V275, P6499, DOI 10.1074/jbc.275.9.6499; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; KATO M, 1992, J BIOCHEM-TOKYO, V112, P492, DOI 10.1093/oxfordjournals.jbchem.a123927; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; Lang G, 2005, IMMUNOLOGY, V114, P25, DOI 10.1111/j.1365-2567.2004.02073.x; MIYASHITA T, 1994, CANCER RES, V54, P3131; Narla RK, 2001, LEUKEMIA LYMPHOMA, V41, P625, DOI 10.3109/10428190109060353; Patrone G, 2000, BIOTECHNIQUES, V29, P1012, DOI 10.2144/00295st02; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Raghavan SC, 2005, J BIOL CHEM, V280, P22749, DOI 10.1074/jbc.M502952200; Ramakrishnan M, 2000, MOL CELL BIOL, V20, P868, DOI 10.1128/MCB.20.3.868-877.2000; SATO N, 1994, J NEUROBIOL, V25, P1227, DOI 10.1002/neu.480251005; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sun YJ, 2006, CELL BIOL INT, V30, P244, DOI 10.1016/j.cellbi.2005.10.025; Suzuki A, 1996, ONCOGENE, V13, P31; Tong X, 2005, J BIOL CHEM, V280, P15503, DOI 10.1074/jbc.M411978200; Tsurusawa M, 1997, INT J HEMATOL, V66, P79; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Wilson BE, 1996, MOL CELL BIOL, V16, P5546; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; Zhang JJ, 2006, GENE, V379, P127, DOI 10.1016/j.gene.2006.05.002; Zhang MX, 2005, P NATL ACAD SCI USA, V102, P16967, DOI 10.1073/pnas.0503853102	36	29	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2649	2657		10.1038/sj.onc.1210069	http://dx.doi.org/10.1038/sj.onc.1210069			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057736				2022-12-28	WOS:000245831200012
J	Chen, C; Sun, X; Guo, P; Dong, XY; Sethi, P; Zhou, W; Zhou, Z; Petros, J; Frierson, HF; Vessella, RL; Atfi, A; Dong, JT				Chen, C.; Sun, X.; Guo, P.; Dong, X-Y; Sethi, P.; Zhou, W.; Zhou, Z.; Petros, J.; Frierson, H. F., Jr.; Vessella, R. L.; Atfi, A.; Dong, J-T			Ubiquitin E3 ligase WWP1 as an oncogenic factor in human prostate cancer	ONCOGENE			English	Article						WWP1; amplification; overexpression; prostate cancer; KLF5; TGF beta	GROWTH-FACTOR-BETA; KLF5 TRANSCRIPTION FACTOR; TGF-BETA; EPITHELIAL-CELLS; NEDD4 FAMILY; EXPRESSION; DEGRADATION; GENE; CARCINOMA; PROTEIN	The gene for E3 ubiquitin ligase WWP1 is located at 8q21, a region frequently amplified in human cancers, including prostate cancer. Recent studies have shown that WWP1 negatively regulates the TGFb tumor suppressor pathway by inactivating its molecular components, including Smad2, Smad4 and T beta R1. These findings suggest an oncogenic role of WWP1 in carcinogenesis, but direct supporting evidence has been lacking. In this study, we examined WWP1 for gene dosage, mRNA expression, mutation and functions in a number of human prostate cancer samples. We found that the WWP1 gene had copy number gain in 15 of 34 (44%) xenografts and cell lines from prostate cancer and 15 of 49 (31%) clinical prostate cancer samples. Consistently, WWP1 was over-expressed in 60% of xenografts and cell lines from prostate cancer. Mutation of WWP1 occurred infrequently in prostate cancer. Functionally, WWP1 overexpression promoted colony formation in the 22Rv1 prostate cancer cell line. In PC-3 prostate cancer cells, WWP1 knockdown significantly suppressed cell proliferation and enhanced TGF beta-mediated growth inhibition. These findings suggest that WWP1 is an oncogene that undergoes genomic amplification at 8q21 in human prostate cancer, and WWP1 overexpression is a common mechanism involved in the inactivation of TGFb function in human cancer.	Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Hematol & Oncol, Atlanta, GA 30322 USA; Albany Med Coll, Ctr Cell Biol & Canc Res, Albany, NY 12208 USA; Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA; Atlanta VA Med Ctr, Decatur, GA USA; Univ Virginia, Hlth Syst, Dept Pathol, Charlottesville, VA USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Hop St Antoine, INSERM, U482, Paris, France; Nankai Univ, Coll Life Sci, Dept Genet & Cell Biol, Tianjin, Peoples R China	Emory University; Emory University; Albany Medical College; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Atlanta VA Medical Center; University of Virginia; University of Washington; University of Washington Seattle; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Nankai University	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365 Clifton Rd,Room C4080, Atlanta, GA 30322 USA.	jdong2@emory.edu	guo, peng/AAG-4052-2019; Guo, Peng/GWC-0572-2022	Dong, Jin-Tang/0000-0003-2349-5782	NATIONAL CANCER INSTITUTE [R01CA087921] Funding Source: NIH RePORTER; NCI NIH HHS [CA87921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen C, 2002, ONCOGENE, V21, P6567, DOI 10.1038/sj.onc.1205817; Chen C, 2003, PROSTATE, V55, P81, DOI 10.1002/pros.10205; Chen CS, 2005, J BIOL CHEM, V280, P41553, DOI 10.1074/jbc.M506183200; Chen CS, 2005, ONCOGENE, V24, P3319, DOI 10.1038/sj.onc.1208497; Chen CS, 2003, AM J PATHOL, V162, P1349, DOI 10.1016/S0002-9440(10)63930-2; Danielpour D, 2005, EUR J CANCER, V41, P846, DOI 10.1016/j.ejca.2004.12.027; Dong JT, 2000, CANCER RES, V60, P3880; Dong JT, 2006, J CELL BIOCHEM, V97, P433, DOI 10.1002/jcb.20696; Drobnjak M, 2003, CLIN CANCER RES, V9, P2613; Flasza M, 2002, BIOCHEM BIOPH RES CO, V290, P431, DOI 10.1006/bbrc.2001.6206; Gu ZN, 2005, CLIN CANCER RES, V11, P2237, DOI 10.1158/1078-0432.CCR-04-0356; Ingham RJ, 2004, ONCOGENE, V23, P1972, DOI 10.1038/sj.onc.1207436; Kim IY, 1996, CANCER RES, V56, P44; Komuro A, 2004, ONCOGENE, V23, P6914, DOI 10.1038/sj.onc.1207885; Leite KRM, 2001, MODERN PATHOL, V14, P428, DOI 10.1038/modpathol.3880330; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Malbert-Colas L, 2003, PFLUG ARCH EUR J PHY, V447, P35, DOI 10.1007/s00424-003-1152-6; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moren A, 2005, J BIOL CHEM, V280, P22115, DOI 10.1074/jbc.M414027200; Mu ZM, 2004, PROSTATE, V60, P187, DOI 10.1002/pros.20044; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Porkka K, 2002, LAB INVEST, V82, P629, DOI 10.1038/labinvest.3780457; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Rubin MA, 2004, CANCER RES, V64, P3814, DOI 10.1158/0008-5472.CAN-03-3881; Seo SR, 2004, EMBO J, V23, P3780, DOI 10.1038/sj.emboj.7600398; Sun SY, 1997, CANCER RES, V57, P4931; Sun XD, 2005, NAT GENET, V37, P407, DOI 10.1038/ng1528; van Dekken H, 2003, LAB INVEST, V83, P789, DOI 10.1097/01.LAB.0000074889.76221.49; Van der Poel HG, 2004, J UROLOGY, V172, P1333, DOI 10.1097/01.ju.0000138829.97838.19; Verdecia MA, 2003, MOL CELL, V11, P249, DOI 10.1016/S1097-2765(02)00774-8; Wang RX, 2004, CANCER RES, V64, P1589, DOI 10.1158/0008-5472.CAN-03-3331; Zhang XL, 2004, BIOCHEM BIOPH RES CO, V316, P139, DOI 10.1016/j.bbrc.2004.02.033; Zhang Z, 2003, P NATL ACAD SCI USA, V100, P11636, DOI 10.1073/pnas.1934692100; Zitzelsberger H, 1998, VIRCHOWS ARCH, V433, P297, DOI 10.1007/s004280050252	35	97	106	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2386	2394		10.1038/sj.onc.1210021	http://dx.doi.org/10.1038/sj.onc.1210021			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016436				2022-12-28	WOS:000245466000015
J	Bagella, L; Sun, A; Tonini, T; Abbadessa, G; Cottone, G; Paggi, MG; De Luca, A; Claudio, PP; Giordano, A				Bagella, L.; Sun, A.; Tonini, T.; Abbadessa, G.; Cottone, G.; Paggi, M. G.; De Luca, A.; Claudio, P. P.; Giordano, A.			A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo	ONCOGENE			English	Article						pRb2/p130; small molecules; peptides; cdk2 inhibitor; kinase activity	DEPENDENT KINASES; CANCER-CELLS; LUNG-CANCER; RETINOBLASTOMA PROTEIN; FLAVOPIRIDOL; EXPRESSION; INDUCTION; GENE; P107; SUPPRESSION	One strategy in the development of anticancer therapeutics has been to arrest malignant proliferation through inhibition of the enzymatic activity of cyclin-dependent kinases (cdks), which are key regulatory molecules of the cell cycle. Over the past few years, numerous compounds with remarkable cdk inhibitory activity have been studied in cancer therapy, although it is very difficult to point out the best cdk to target. An excellent candidate appears to be cdk2, whose alteration is a pathogenic hallmark of tumorigenesis. The small molecule described in our study showed an inhibitory effect on the kinase activity of cdk2, a significant growth arrest observed in a colony formation assay and a reduction in the size of the tumor in nude mice, thus suggesting its potential role as a promising new type of mechanism-based antitumor drug, also for the treatment of hyperproliferative disorders.	Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Sassari, Dept Biomed Sci, Div Biochem, I-07100 Sassari, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C, Rome, Italy; Univ Naples 2, Dept Med & Publ Hlth, Sect Clin Anat, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Sassari; University of Siena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010; Sun, Ang/G-1537-2015; De Luca, Antonio/AAD-9562-2020; Claudio, Pier Paolo/AAW-7282-2021; Paggi, Marco G./K-3494-2018	Giordano, Antonio/0000-0002-5959-016X; Sun, Ang/0000-0002-8644-0407; De Luca, Antonio/0000-0002-3905-6154; Claudio, Pier Paolo/0000-0001-7790-1622; BAGELLA, Luigi/0000-0003-2815-037X				Al-Aynati MM, 2004, CLIN CANCER RES, V10, P6598, DOI 10.1158/1078-0432.CCR-04-0524; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Andrews MJI, 2004, ORG BIOMOL CHEM, V2, P2735, DOI 10.1039/b409157d; BAGELLA L, 2006, J CELL BIOCH; BATES S, 1994, ONCOGENE, V9, P71; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Carlson BA, 1996, CANCER RES, V56, P2973; Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Fischer PM, 2003, EXPERT OPIN INV DRUG, V12, P955, DOI 10.1517/eoid.12.6.955.21792; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Genovese C, 2006, ONCOGENE, V25, P5201, DOI 10.1038/sj.onc.1209652; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Howard CM, 2000, CANCER RES, V60, P2737; Hsu YL, 2004, LIFE SCI, V75, P2303, DOI 10.1016/j.lfs.2004.04.027; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee HR, 1999, INT J ONCOL, V15, P161; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Li YW, 2000, INT J ONCOL, V17, P755; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAYOL X, 1993, ONCOGENE, V8, P2561; Merola E, 2006, J CELL PHYSIOL, V207, P512, DOI 10.1002/jcp.20590; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Olofsson A, 2004, INT J ONCOL, V25, P1349; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pepper C, 2001, BRIT J HAEMATOL, V114, P70, DOI 10.1046/j.1365-2141.2001.02895.x; Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Song YC, 2004, BIOCHEM BIOPH RES CO, V317, P128, DOI 10.1016/j.bbrc.2004.03.019; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yu CH, 2004, BIOCHEM PHARMACOL, V67, P1907, DOI 10.1016/j.bcp.2004.02.004; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	64	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1829	1839		10.1038/sj.onc.1209987	http://dx.doi.org/10.1038/sj.onc.1209987			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043661				2022-12-28	WOS:000245117700001
J	Lim, YP; Lim, TT; Chan, YL; Song, ACM; Yeo, BH; Vojtesek, B; Coomber, D; Rajagopal, G; Lane, D				Lim, Y. P.; Lim, T. T.; Chan, Y. L.; Song, A. C. M.; Yeo, B. H.; Vojtesek, B.; Coomber, D.; Rajagopal, G.; Lane, D.			The p53 knowledgebase: an integrated information resource for p53 research	ONCOGENE			English	Article						database; p53; web portal	CELL-CYCLE ARREST; NUCLEAR ACCUMULATION; PROTEIN; INDUCTION; SELECTION; DATABASE; ANTIGEN	The p53 tumor suppressor protein plays a central role in maintaining genomic integrity by occupying a nodal point in the DNA damage control pathway. Here it integrates a wide variety of signals, responding in one of several ways, that is, cell cycle arrest, senescence or programmed cell death (apoptosis). Mutations in the tumor suppressor gene tp53, which affects the key transcriptional regulatory processes in cell growth and death, occur frequently in cancer and helps explain why p53 has been called the guardian of the genome. There is a vast body of published knowledge on all aspects of p53's role in cancer. To facilitate research, it would be helpful if this information could be collected, curated and updated in a format that is easily accessible to the user community. To this end, we initiated the p53 knowledgebase project (http://p53.bii.a-star.edu.sg). The p53 knowledgebase is a user-friendly web portal incorporating visualization and analysis tools that integrates information from the published literature with other manually curated information to facilitate knowledge discovery. This includes curated information on sequence, structural, mutation, polymorphisms, protein-protein interactions, transcription factors, transcriptional targets, antibodies and post-translational modifications that involve p53. The goal is to collect and maintain all relevant data on p53 and present it in an easily accessible format that will be useful to researchers in the field.	Inst Mol & Cell Biol, Singapore 138673, Singapore; Matrix, Bioinformat Inst, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII)	Lane, D (corresponding author), Inst Mol & Cell Biol, 61 Biopolis St, Singapore 138673, Singapore.	d.p.lane@imcb.a-star.edu.sg	Lim, Elaine/H-9032-2016; Lane, David P/C-4920-2008	Rajagopal, Gunaretnam/0000-0003-0111-1936; Lane, David/0000-0003-0551-3545				Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Beroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; FRITSCHE M, 1993, ONCOGENE, V8, P307; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; KASTAN MB, 1991, CANCER RES, V51, P6304; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VOGELSTEIN B, 1990, NATURE, V348, P681, DOI 10.1038/348681a0; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Zhang K, 2005, BIOINFORMATICS, V21, P131, DOI 10.1093/bioinformatics/bth482; Zhao LL, 2005, J SOL-GEL SCI TECHN, V33, P103, DOI 10.1007/s10971-005-6708-9	25	34	35	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1517	1521		10.1038/sj.onc.1209952	http://dx.doi.org/10.1038/sj.onc.1209952			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953220				2022-12-28	WOS:000244782500001
J	Kilic, M; Kasperczyk, H; Fulda, S; Debatin, KM				Kilic, M.; Kasperczyk, H.; Fulda, S.; Debatin, K-M			Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance	ONCOGENE			English	Article						hypoxia; apoptosis; Hif-1 alpha; rhabdomyosarcoma; Ewing sarcoma	PANCREATIC-CANCER CELLS; HIF-1; GENE; HIF-1-ALPHA; EXPRESSION; FACTOR-1-ALPHA; ACTIVATION; SUPPRESSION; MECHANISM; PATHWAY	Hypoxia inducible factor-1 (HIF-1) is the major transcription factor and key regulator of adoptive responses to hypoxia. Although it usually promotes tumor cell survival under hypoxia, it has also been implied to trigger apoptosis. Although the impact of hypoxia has been extensively studied in many adult solid tumors, its role in most childhood tumors, for example, in rhabdomyosarcoma (RMS) or Ewing sarcoma (ES), has not yet been addressed. Here, we report that hypoxia protects A204 RMS and A673 ES cells against anticancer drug- or tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis and that Hif-1 alpha plays a key role in conferring apoptosis resistance under hypoxia. Although a functional HIF-1 pathway and proapoptotic proteins such as p53 and Bcl-2/E1B 19 kDa interacting protein 3 were activated under hypoxia in both A204 RMS and A673 ES cells, these cells remained refractory to apoptosis. Concomitant analysis of antiapoptotic proteins revealed that hypoxia induced expression of Bcl-2 and inhibitor of apoptosis proteins (IAP)-2 as well as proteins associated with anaerobic metabolism such as the glucose transporter protein GLUT-1 and the glycolytic enzyme Aldolase A. Specific downregulation of Hif-1 alpha by RNA interference significantly enhanced apoptosis under hypoxia by preventing the hypoxia-mediated increase in GLUT-1 expression without altering expression levels of the antiapoptotic proteins Bcl-2 or cIAP-2. Moreover, glucose deprivation-induced apoptosis of A204 RMS and A673 ES cells was inhibited under hypoxic conditions in a Hif-1 alpha-dependent manner. As GLUT-1 was induced via Hif-1 alpha under hypoxia in A204 RMS and A673 ES, these findings suggest that the Hif-1 alpha-mediated increase in glucose uptake plays an important role in conferring apoptosis resistance. Thus, hypoxia-inducible genes may represent novel targets for therapeutic intervention in some pediatric tumors, which warrants further investigation.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de; klaus-michael.debatin@uniklinik-ulm.de	Debatin, Klaus-Michael/J-9704-2014; Fulda, Simone/D-5864-2011	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Akakura N, 2001, CANCER RES, V61, P6548; Alvarez-Tejado M, 2001, J BIOL CHEM, V276, P22368, DOI 10.1074/jbc.M011688200; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Blum R, 2005, CANCER RES, V65, P999; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Dagher R, 1999, Oncologist, V4, P34; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Dong Z, 2003, AM J PATHOL, V163, P663, DOI 10.1016/S0002-9440(10)63693-0; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; Fulda S, 1997, CANCER RES, V57, P3823; Ganjavi H, 2005, CANCER GENE THER, V12, P397, DOI 10.1038/sj.cgt.7700798; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hochachka PW, 2001, COMP BIOCHEM PHYS B, V130, P435, DOI 10.1016/S1096-4959(01)00408-0; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim M, 2004, CANCER RES, V64, P4078, DOI 10.1158/0008-5472.CAN-04-0284; Lin ZW, 2000, AM J PHYSIOL-ENDOC M, V278, pE958, DOI 10.1152/ajpendo.2000.278.5.E958; Mackall CL, 2002, CANCER CELL, V2, P175, DOI 10.1016/S1535-6108(02)00132-0; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MERRALL NW, 1993, CELL SIGNAL, V5, P667, DOI 10.1016/0898-6568(93)90028-K; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Murphy BJ, 1999, CANCER RES, V59, P1315; ORMEROD MG, 1992, FLOW CYTOMETRY PRACT; Pappo AS, 1997, PEDIATR CLIN N AM, V44, P953, DOI 10.1016/S0031-3955(05)70539-3; Park SY, 2002, BIOCHEM BIOPH RES CO, V291, P150, DOI 10.1006/bbrc.2002.6421; Piret JP, 2004, EXP CELL RES, V295, P340, DOI 10.1016/j.yexcr.2004.01.024; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2000, ADV EXP MED BIOL, V475, P123; Sowter HM, 2003, CANCER RES, V63, P6130; Sowter HM, 2001, CANCER RES, V61, P6669; Webster KA, 2000, ADV EXP MED BIOL, V475, P161; West DC, 2000, CURR OPIN ONCOL, V12, P323, DOI 10.1097/00001622-200007000-00008; Zhang QZ, 2004, INT J CANCER, V111, P849, DOI 10.1002/ijc.20334; Zhong H, 1999, CANCER RES, V59, P5830	48	130	140	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2027	2038		10.1038/sj.onc.1210008	http://dx.doi.org/10.1038/sj.onc.1210008			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043658	Bronze			2022-12-28	WOS:000245313400005
J	Mitchell, DC; Stafford, LJ; Li, D; Bar-Eli, M; Liu, M				Mitchell, D. C.; Stafford, L. J.; Li, D.; Bar-Eli, M.; Liu, M.			Transcriptional regulation of KiSS-1 gene expression in metastatic melanoma by specificity protein-1 and its coactivator DRIP-130	ONCOGENE			English	Article						KiSS1; GPR54; Sp1; CRSP3; cancer metastasis	ENDOTHELIAL GROWTH-FACTOR; PANCREATIC-CANCER CELLS; COFACTOR COMPLEX CRSP; HUMAN GASTRIC-CANCER; COUPLED RECEPTOR; SUPPRESSOR GENE; FACTOR SP1; ACTIVATOR PROTEIN-2-ALPHA; FACTOR FAMILY; I-RECEPTOR	Loss of the metastasis suppressor gene, KiSS-1 has been strongly correlated to the progression of metastases in numerous types of cancers. The mechanism through which KiSS-1 is lost during metastasis, however, is still not completely known. Previous studies have shown that genetic material on human chromosome 6q16.3-q23 is essential for KiSS-1 expression in normal tissues. Additionally, microcell-mediated transfer of this chromosome in cancerous tissue results in rescued expression of KiSS-1 and reduced metastatic phenotype. Here, we show that loss of Sp1-coactivator protein DRIP-130, which is encoded by human chromosome 6q16.3-q23, results in reduced KiSS-1 promoter activation in highly malignant melanoma cells. Co-expression of Sp1 and DRIP-130 not only rescues KiSS-1 expression, but also induces an inhibition of the invasive and migratory behavior in highly metastatic melanoma cells, similar to the overexpression of KiSS-1 metastasis suppressor gene in those cells. Furthermore, we demonstrate that KiSS-1 expression is regulated by Sp1 elements within the first 100-bp region of the KiSS-1 promoter and that targeted deletion of a single GC-rich region spanning -93 to -58 interrupts Sp1- and DRIP-130-modulated transcriptional control of KiSS-1 expression. Our results thus suggest that DRIP-130 is a key regulator in KiSS-1 transactivation in normal tissue, and that the loss of DRIP-130 expression, as a result of the gross loss of human chromosome 6q16.3-q23, provokes increased tumor metastasis.	Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX 77030 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Mol & Cellular Med, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; University of Texas System; UTMD Anderson Cancer Center	Liu, M (corresponding author), Texas A&M Univ, Syst Hlth Sci Ctr, Inst Biosci & Technol, 2121 W Holcombe Blvd, Houston, TX 77030 USA.	mliu@ibt.tamhsc.edu			NCI NIH HHS [1R01CA106479] Funding Source: Medline; NHLBI NIH HHS [5R01HL064792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA106479] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Goldberg SF, 2003, CANCER RES, V63, P432; Ikeguchi M, 2004, CLIN CANCER RES, V10, P1379, DOI 10.1158/1078-0432.CCR-1519-02; Ji CH, 1997, J BIOL CHEM, V272, P21260, DOI 10.1074/jbc.272.34.21260; Jiang Y, 2005, CLIN EXP METASTAS, V22, P369, DOI 10.1007/s10585-005-8186-4; Jiang YX, 2004, CLIN EXP METASTAS, V21, P755, DOI 10.1007/s10585-005-1198-2; Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1997, INT J CANCER, V71, P1035, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1035::AID-IJC20>3.3.CO;2-T; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Masui T, 2004, BIOCHEM BIOPH RES CO, V315, P85, DOI 10.1016/j.bbrc.2004.01.021; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Muir AI, 2001, J BIOL CHEM, V276, P28969, DOI 10.1074/jbc.M102743200; Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135; Ryu SJ, 1999, NATURE, V397, P446, DOI 10.1038/17141; Ryu SJ, 1999, P NATL ACAD SCI USA, V96, P7137, DOI 10.1073/pnas.96.13.7137; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sanchez-Carbayo M, 2003, AM J PATHOL, V162, P609, DOI 10.1016/S0002-9440(10)63854-0; Shi Q, 2001, CANCER RES, V61, P4143; Shirasaki F, 2001, CANCER RES, V61, P7422; Stafford LJ, 2002, CANCER RES, V62, P5399; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Taatjes DJ, 2004, MOL CELL, V14, P675, DOI 10.1016/j.molcel.2004.05.014; Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200; Wang J, 2005, J NEUROCHEM, V93, P474, DOI 10.1111/j.1471-4159.2005.03051.x; Wang LW, 2003, CLIN CANCER RES, V9, P6371; Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628; Zhu GH, 2002, ONCOGENE, V21, P8477, DOI 10.1038/sj.onc.1206030	36	45	52	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1739	1747		10.1038/sj.onc.1209963	http://dx.doi.org/10.1038/sj.onc.1209963			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964286				2022-12-28	WOS:000244955600008
J	Ivanova, IA; Dagnino, L				Ivanova, I. A.; Dagnino, L.			Activation of p38-and CRM1-dependent nuclear export promotes E2F1 degradation during keratinocyte differentiation	ONCOGENE			English	Article						keratinocyte; E2F; differentiation	TRANSCRIPTION FACTORS; EPIDERMAL-KERATINOCYTES; EXPRESSION PATTERNS; WOUND REPAIR; PROLIFERATION; PROTEIN; KINASE; FAMILY; PRB; LOCALIZATION	E2F factors modulate a plethora of cell functions, including proliferation, differentiation, DNA repair and apoptosis. We have shown that differentiation in primary epidermal keratinocytes leads to E2F1 downregulation via activation of protein kinase C and p38 mitogen-activated protein kinase. We now demonstrate that E2F1 downregulation in differentiating keratinocytes involves its ubiquitination, as well as proteasomal degradation subsequent to CRM1-dependent nuclear export. E2F1 nuclear export specifically in response to differentiation requires regions adjacent to the cyclin A-binding domain in the N-terminusof this protein. Significantly, inhibition of p38 interferes with nuclear export and degradation of E2F1 during differentiation, but has no effect on E2F1 in undifferentiated cells. Thus, induction of differentiation in epidermal keratinocytes activates a specific program for post-transcriptional downregulation of E2F1, which involves signaling through p38 and activation of nuclear export pathways.	Univ Western Ontario, Dept Physiol & Pharmacol & Regulatory Biol, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Paediat, Child Hlth Res Inst, London, ON N6A 5C1, Canada; Univ Western Ontario, Lawson Hlth Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Dagnino, L (corresponding author), Univ Western Ontario, Dept Physiol & Pharmacol, Med Sci Bldg, London, ON N6A 5C1, Canada.	ldagnino@uwo.ca		Dagnino, Lina/0000-0003-1483-5159				Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Asher G, 2005, CELL CYCLE, V4, P1015, DOI 10.4161/cc.4.8.1900; Byrne C, 2003, J ANAT, V202, P113, DOI 10.1046/j.1469-7580.2003.00142.x; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chang WY, 2004, J BIOL CHEM, V279, P51343, DOI 10.1074/jbc.M408635200; D'Souza SJA, 2002, J BIOL CHEM, V277, P10626, DOI 10.1074/jbc.M111956200; D'Souza SJA, 2001, J BIOL CHEM, V276, P23531, DOI 10.1074/jbc.M100780200; Dagnino L, 1997, MECH DEVELOP, V66, P13, DOI 10.1016/S0925-4773(97)00083-X; Dagnino L, 1997, CELL GROWTH DIFFER, V8, P553; Dicker AJ, 2000, ONCOGENE, V19, P2887, DOI 10.1038/sj.onc.1203610; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Fajas L, 2002, DEV CELL, V3, P39, DOI 10.1016/S1534-5807(02)00190-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; GOMEZ DA, 2000, J BIOL CHEM, V275, P13872; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Ivanova IA, 2006, ONCOGENE, V25, P430, DOI 10.1038/sj.onc.1208999; Jones SJ, 1997, J INVEST DERMATOL, V109, P187, DOI 10.1111/1523-1747.ep12319308; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Muller H, 1997, MOL CELL BIOL, V17, P5508; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2006, CELL CYCLE, V5, P625, DOI 10.4161/cc.5.6.2580; Vespa A, 2005, MOL BIOL CELL, V16, P4084, DOI 10.1091/mbc.e05-02-0087	25	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1147	1154		10.1038/sj.onc.1209894	http://dx.doi.org/10.1038/sj.onc.1209894			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924238				2022-12-28	WOS:000244406400005
J	Motamed-Khorasani, A; Jurisica, I; Letarte, M; Shaw, PA; Parkes, RK; Zhang, X; Evangelou, A; Rosen, B; Murphy, KJ; Brown, TJ				Motamed-Khorasani, A.; Jurisica, I.; Letarte, M.; Shaw, P. A.; Parkes, R. K.; Zhang, X.; Evangelou, A.; Rosen, B.; Murphy, K. J.; Brown, T. J.			Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression	ONCOGENE			English	Article						ovarian cancer; androgen; BRCA1; BRCA2; BACH2; acetylcholinesterase	PROTEIN-INTERACTION NETWORK; MESSENGER-RNA EXPRESSION; SIGNALING PATHWAY; CONSTITUTIVE ACTIVATION; PROGESTERONE-RECEPTORS; SURFACE EPITHELIUM; BREAST; TUMORS; CARCINOMA; BETA	Epidemiological studies have implicated androgens in the etiology and progression of epithelial ovarian cancer. We previously reported that some androgen responses were dysregulated in malignant ovarian epithelial cells relative to control, non-malignant ovarian surface epithelial (OSE) cells. Moreover, dysregulated androgen responses were observed in OSE cells derived from patients with germline BRCA-1 or -2 mutations (OSEb), which account for the majority of familial ovarian cancer predisposition, and such altered responses may be involved in ovarian carcinogenesis or progression. In the present study, gene expression pro. ling using cDNA microarrays identified 17 genes differentially expressed in response to continuous androgen exposure in OSEb cells and ovarian cancer cells as compared to OSE cells derived from control patients. A subset of these differentially affected genes was selected and verified by quantitative real-time reverse transcription -polymerase chain reaction. Six of the gene products mapped to the OPHID protein -protein interaction database, and five were networked within two interacting partners. Basic leucine zipper transcription factor 2 (BACH2) and acetylcholinesterase (ACHE), which were upregulated by androgen in OSEb cells relative to OSE cells, were further investigated using an ovarian cancer tissue microarray from a separate set of 149 clinical samples. Both cytoplasmic ACHE and BACH2 immunostaining were significantly increased in ovarian cancer relative to benign cases. High levels of cytoplasmic ACHE staining correlated with decreased survival, whereas nuclear BACH2 staining correlated with decreased time to disease recurrence. The finding that products of genes differentially responsive to androgen in OSEb cells may predict survival and disease progression supports a role for altered androgen effects in ovarian cancer. In addition to BACH2 and ACHE, this study highlights a set of potentially functionally related genes for further investigation in ovarian cancer.	Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Div Signaling Biol, Toronto, ON, Canada; Univ Toronto, Dept Comp Sci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1X8, Canada; Univ Toronto, Hosp Sick Children, Canc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Div Pathol,Ontario Canc Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst,Div Gynecol Oncol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Brown, TJ (corresponding author), Mt Sinai Hosp, Dept Obstet & Gynecol, Samuel Lunenfeld Res Inst, Room 876,600 Univ Ave, Toronto, ON M5G 1X5, Canada.	brown@mshri.on.ca	Brown, Theodore J./E-2192-2013	Brown, Theodore J./0000-0002-3074-4516				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; AUERSPERG N, 1994, LAB INVEST, V71, P510; Auersperg N, 1997, J CELL PHYSIOL, V173, P261, DOI 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G; Barrios-Rodiles M, 2005, SCIENCE, V307, P1621, DOI 10.1126/science.1105776; Beheshti B, 2003, NEOPLASIA, V5, P53, DOI 10.1016/S1476-5586(03)80017-9; Brown KR, 2005, BIOINFORMATICS, V21, P2076, DOI 10.1093/bioinformatics/bti273; Buchholz TA, 2002, INT J CANCER, V97, P557, DOI 10.1002/ijc.10109; Camp RL, 2000, LAB INVEST, V80, P1943, DOI 10.1038/labinvest.3780204; Cardillo MR, 1998, J EXP CLIN CANC RES, V17, P231; CHADHA S, 1993, HUM PATHOL, V24, P90, DOI 10.1016/0046-8177(93)90067-Q; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P717; Deng CX, 2000, BIOESSAYS, V22, P728; EASTON DF, 1995, AM J HUM GENET, V56, P265; Edmondson R, 2002, BRIT J CANCER, V86, P879, DOI 10.1038/sj.bjc.6600154; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evangelou A, 2003, CANCER RES, V63, P2416; Evangelou A, 2000, CANCER RES, V60, P929; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Foss DL, 1998, ANIM BIOTECHNOL, V9, P67, DOI 10.1080/10495399809525893; GRAY RJ, 1992, J AM STAT ASSOC, V87, P942, DOI 10.2307/2290630; Hage JJ, 2000, GYNECOL ONCOL, V76, P413, DOI 10.1006/gyno.1999.5720; HELZLSOUER KJ, 1995, JAMA-J AM MED ASSOC, V274, P1926, DOI 10.1001/jama.274.24.1926; Hirashima Y, 2003, J BIOL CHEM, V278, P26793, DOI 10.1074/jbc.M212187200; HIRTE HW, 1992, GYNECOL ONCOL, V44, P223, DOI 10.1016/0090-8258(92)90046-L; Hu W, 2000, ANTICANCER RES, V20, P729; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Imaoka S, 2001, CANCER LETT, V166, P119, DOI 10.1016/S0304-3835(00)00572-3; Isern J, 2003, BIOCHEM BIOPH RES CO, V307, P139, DOI 10.1016/S0006-291X(03)01081-7; Johnson G, 2000, INT J DEV NEUROSCI, V18, P781, DOI 10.1016/S0736-5748(00)00049-6; Johnson G, 2000, APPL BIOCHEM BIOTECH, V83, P131, DOI 10.1385/ABAB:83:1-3:131; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42; King MC, 2003, SCIENCE, V302, P643, DOI 10.1126/science.1088759; Kobayashi A, 2000, MOL CELL BIOL, V20, P1733, DOI 10.1128/MCB.20.5.1733-1746.2000; Kohonen T., 2001, SELF ORG MAPS, P501; KRUK PA, 1994, EXP CELL RES, V215, P97, DOI 10.1006/excr.1994.1320; KUHNEL R, 1987, J STEROID BIOCHEM, V26, P393, DOI 10.1016/0022-4731(87)90106-3; KUHNEL R, 1988, ANTICANCER RES, V8, P281; Lau KM, 1999, P NATL ACAD SCI USA, V96, P5722, DOI 10.1073/pnas.96.10.5722; Li AJ, 2005, CANCER EPIDEM BIOMAR, V14, P2919, DOI 10.1158/1055-9965.EPI-05-0540; Li AJ, 2003, CLIN CANCER RES, V9, P3667; LINSLEY PS, 1986, CANCER RES, V46, P6380; Lu J, 2002, ACTA BIOCH BIOPH SIN, V34, P95; Lutz LB, 2003, MOL ENDOCRINOL, V17, P1106, DOI 10.1210/me.2003-0032; Marks A, 1999, BRIT J CANCER, V80, P569, DOI 10.1038/sj.bjc.6690393; Modugno F, 2001, ANN EPIDEMIOL, V11, P568, DOI 10.1016/S1047-2797(01)00213-7; Muto A, 2002, J BIOL CHEM, V277, P20724, DOI 10.1074/jbc.M112003200; Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130; OTASEK D, 2006, SIAM C DAT MIN 22 AP, P1; Park JJ, 2000, CANCER RES, V60, P5946; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Rask K, 2003, BRIT J CANCER, V89, P1298, DOI 10.1038/sj.bjc.6601265; Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943; Risch HA, 1998, JNCI-J NATL CANCER I, V90, P1774, DOI 10.1093/jnci/90.23.1774; Robertson DM, 2004, ENDOCR-RELAT CANCER, V11, P35, DOI 10.1677/erc.0.0110035; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schildkraut JM, 1996, OBSTET GYNECOL, V88, P554, DOI 10.1016/0029-7844(96)00226-8; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully RE, 1995, J CELL BIOCHEM, P208; Shaw PA, 2001, GYNECOL ONCOL, V80, P132, DOI 10.1006/gyno.2000.6068; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; SULTAN M, 2002, BIOINFORMATICS, V18, P111; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Vidal CJ, 2005, CHEM-BIOL INTERACT, V157, P227, DOI 10.1016/j.cbi.2005.10.035; Windmill KF, 1997, MUTAT RES-FUND MOL M, V376, P153, DOI 10.1016/S0027-5107(97)00038-9; Yang LV, 2001, MECH DEVELOP, V104, P105, DOI 10.1016/S0925-4773(01)00376-8; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; ZAKUT H, 1990, J CLIN INVEST, V86, P900, DOI 10.1172/JCI114791	73	31	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					198	214		10.1038/sj.onc.1209773	http://dx.doi.org/10.1038/sj.onc.1209773			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832351				2022-12-28	WOS:000243398300004
J	Zhang, YW; Staal, B; Su, Y; Swiatek, P; Zhao, P; Cao, B; Resau, J; Sigler, R; Bronson, R; Vande Woude, GF				Zhang, Y-W; Staal, B.; Su, Y.; Swiatek, P.; Zhao, P.; Cao, B.; Resau, J.; Sigler, R.; Bronson, R.; Vande Woude, G. F.			Evidence that MIG-6 is a tumor-suppressor gene	ONCOGENE			English	Article						MIG-6; mutation; lung carcinogenesis; signal transduction; EGF; HGF/SF	CELL LUNG-CANCER; EGF RECEPTOR; ENDOGENOUS INHIBITOR; ALLELIC LOSS; C-MET; EXPRESSION; MUTATIONS; GROWTH; ACTIVATION; P73	Mitogen-inducible gene 6 (MIG-6) is located in human chromosome 1p36, a locus frequently associated with human lung cancer. MIG-6 is a negative regulator of epidermal growth factor (EGF) signaling, and we show that Mig-6 - like EGF - is induced by hepatocyte growth factor/scatter factor (HGF/SF) in human lung cancer cell lines. Frequently, the receptors for both factors, EGFR and Met, are expressed in same lung cancer cell line, and MIG-6 is induced by both factors in a mitogen-activated protein kinase-dependent fashion. However, not all tumor lines express MIG-6 in response to either EGF or HGF/SF. In these cases, we. nd missense and nonsense mutations in the MIG-6 coding region, as well as evidence for MIG-6 transcriptional silencing. Moreover, germline disruption of Mig-6 in mice leads to the development of animals with epithelial hyperplasia, adenoma, and adenocarcinoma in organs like the lung, gallbladder, and bile duct. These data suggests that MIG-6 is a tumor-suppressor gene and is therefore a candidate gene for the frequent 1p36 genetic alterations found in lung cancer.	Andel Res Inst, Mol Oncol Lab, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Germline Modificat, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Antibody Technol, Grand Rapids, MI 49503 USA; Andel Res Inst, Lab Analyt Cellular & Mol Microscopy, Grand Rapids, MI 49503 USA; Div Pfizer, Esper Therapeut, Ann Arbor, MI USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Pfizer; Harvard University; Harvard Medical School	Zhang, YW (corresponding author), Andel Res Inst, Mol Oncol Lab, 333 Bostwick NE, Grand Rapids, MI 49503 USA.	yu-wen.zhang@vai.org; george.vandewoude@vai.org						Amatschek S, 2004, CANCER RES, V64, P844, DOI 10.1158/0008-5472.CAN-03-2361; Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anastasi S, 2003, ONCOGENE, V22, P4221, DOI 10.1038/sj.onc.1206516; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Ferby I, 2006, NAT MED, V12, P568, DOI 10.1038/nm1401; Fiorentino L, 2000, MOL CELL BIOL, V20, P7735, DOI 10.1128/MCB.20.20.7735-7750.2000; Fujii T, 2002, CANCER RES, V62, P3340; Girard L, 2000, CANCER RES, V60, P4894; Herzog CR, 2002, CANCER RES, V62, P6424; HERZOG CR, 1995, ONCOGENE, V11, P1811; Keeton AB, 2005, J CELL BIOCHEM, V94, P1190, DOI 10.1002/jcb.20370; Keeton AB, 2004, BBA-GENE STRUCT EXPR, V1679, P248, DOI 10.1016/j.bbaexp.2004.07.002; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; Koo HM, 1999, CANCER RES, V59, P6057; Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650; Ma PC, 2003, CANCER RES, V63, P6272; Mai M, 1998, CANCER RES, V58, P2347; Makkinje A, 2000, J BIOL CHEM, V275, P17838, DOI 10.1074/jbc.M909735199; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Nomoto S, 1998, CANCER RES, V58, P1380; Nomoto S, 2000, GENE CHROMOSOME CANC, V28, P342, DOI 10.1002/1098-2264(200007)28:3<342::AID-GCC13>3.0.CO;2-A; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013; Ragnarsson G, 1999, BRIT J CANCER, V79, P1468, DOI 10.1038/sj.bjc.6690234; Sargent LM, 2002, CANCER RES, V62, P1152; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Tokuchi Y, 1999, BRIT J CANCER, V80, P1623, DOI 10.1038/sj.bjc.6690572; Tsunoda T, 2002, CANCER RES, V62, P5668; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; WICK M, 1995, EXP CELL RES, V219, P527, DOI 10.1006/excr.1995.1261; Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200; Xu J, 2005, BREAST CANCER RES TR, V91, P207, DOI 10.1007/s10549-005-1040-1; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zhang YW, 2005, P NATL ACAD SCI USA, V102, P11740, DOI 10.1073/pnas.0505171102; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100; Zochbauer-Muller S, 2002, ANNU REV PHYSIOL, V64, P681, DOI 10.1146/annurev.physiol.64.081501.155828	40	101	108	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					269	276		10.1038/sj.onc.1209790	http://dx.doi.org/10.1038/sj.onc.1209790			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819504				2022-12-28	WOS:000243398300010
J	Huang, Y; Li, X; Jiang, J; Frank, SJ				Huang, Y.; Li, X.; Jiang, J.; Frank, S. J.			Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells	ONCOGENE			English	Article; Proceedings Paper	86th Annual Meeting of the Endocrine-Society	JUN 12-15, 2004	New Orleans, LA	Endocrine Soc		prolactin; EGFR; signaling; phosphorylation; synergy	JAK2 TYROSINE KINASE; EGF-RECEPTOR; MAMMARY-GLAND; ERBB RECEPTORS; ACTIVATING PROTEIN-1; EPITHELIAL-CELLS; MESSENGER-RNA; HORMONE; INVOLVEMENT; EXPRESSION	Prolactin (PRL) is a polypeptide hormone produced by the anterior pituitary gland and other sites that acts both systemically and locally to cause lactation and other biological effects by interacting with the PRL receptor, a Janus kinase (JAK)2-coupled cytokine receptor family member, and activating downstream signal pathways. Recent evidence suggests PRL is a player in the pathogenesis and progression of breast cancer. Epidermal growth factor (EGF) also has effects on breast tissue, working through its receptors, epidermal growth factor receptor (EGFR) and ErbB-2 (c-neu, HER2), both intrinsic tyrosine kinase growth factor receptors. EGFR promotes pubertal breast ductal morphogenesis in mice, and both EGFR and ErbB-2 are relevant in pathogenesis and behavior of breast and other human cancers. Previous studies showed that PRL and EGF synergize to enhance motility in the human breast cancer cell line, T47D. In this study, we explored crosstalk between the PRL and EGF signaling pathways in T47D cells, with an ultimate aim of understanding how these two important factors might work together in vivo to affect breast cancer behavior. Both PRL and EGF caused robust signaling in T47D cells; PRL acutely activated JAK2, signal transducer and activator of transcription-5 (STAT5), and extracellular signal-regulated kinase-1 and -2 (ERK1 and ERK2), whereas EGF caused EGFR activation and consequent src homology collagen (SHC) activation and ERK activation. Notably, PRL also caused phosphorylation of the EGFR and ErbB-2 at sites detected by PTP101, an antibody that recognizes threonine phosphorylation at consensus motifs for ERK-induced phosphorylation. PRL-induced PTP101-reactive phosphorylation was prevented by pretreatment with PD98059, an ERK pathway inhibitor. Furthermore, PRL synergized with EGF in activating SHC and ERK and transactivating a luciferase reporter driven by c-fos gene enhancer elements, suggesting that PRL allowed markedly enhanced EGF signaling. This was accompanied by substantial inhibition of EGF-induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone. This effect of PRL was abrogated by ERK pathway inhibitor pretreatment. Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR.	Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Endocrinol Sect, Med Serv, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Frank, SJ (corresponding author), Univ Alabama Birmingham, Dept Med, Div Endocrinol Diabet & Metab, 1530 3rd Ave S,BDB 861, Birmingham, AL 35294 USA.	sjfrank@uab.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R29DK046395, R01DK046395] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46395] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acosta JJ, 2003, MOL ENDOCRINOL, V17, P2268, DOI 10.1210/me.2002-0422; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; ANDERSON E, 1993, EUR J CANCER, V29A, P209, DOI 10.1016/0959-8049(93)90178-I; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Badache A, 2001, CANCER RES, V61, P383; Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3; BenJonathan N, 1996, ENDOCR REV, V17, P639, DOI 10.1210/er.17.6.639; BERGER MS, 1988, CANCER RES, V48, P1238; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; BONNETERRE J, 1988, EUR J CANCER CLIN ON, V24, P1851, DOI 10.1016/0277-5379(88)90097-1; BOONSTRA J, 1995, CELL BIOL INT, V19, P413, DOI 10.1006/cbir.1995.1086; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chen NY, 2002, INT J ONCOL, V20, P813; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Clevenger CV, 2001, LUPUS, V10, P706, DOI 10.1191/096120301717164949; Das R, 1996, BREAST CANCER RES TR, V40, P141, DOI 10.1007/BF01806209; Das R, 1996, ONCOGENE, V13, P1139; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eisenberg A, 2004, FEBS LETT, V565, P139, DOI 10.1016/j.febslet.2004.03.089; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FENTON SE, 1993, MOL BIOL CELL, V4, P773, DOI 10.1091/mbc.4.8.773; Fenton SE, 1997, EXP CELL RES, V236, P285, DOI 10.1006/excr.1997.3727; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; GINSBURG E, 1995, CANCER RES, V55, P2591; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Goffin V, 1999, MOL CELL ENDOCRINOL, V151, P79, DOI 10.1016/S0303-7207(99)00023-4; Goffin V, 2002, ANNU REV PHYSIOL, V64, P47, DOI 10.1146/annurev.physiol.64.081501.131049; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grimm SL, 2002, MOL ENDOCRINOL, V16, P2675, DOI 10.1210/me.2002-0239; Gutzman JH, 2005, MOL ENDOCRINOL, V19, P1765, DOI 10.1210/me.2004-0339; Gutzman JH, 2004, MOL ENDOCRINOL, V18, P3064, DOI 10.1210/me.2004-0187; Hankinson SE, 1999, J NATL CANCER I, V91, P629, DOI 10.1093/jnci/91.7.629; Haraguchi S, 1997, MOL CELL ENDOCRINOL, V129, P145, DOI 10.1016/S0303-7207(97)04053-7; Harari PM, 2004, ENDOCR-RELAT CANCER, V11, P689, DOI 10.1677/erc.1.00600; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; Horseman ND, 1999, J MAMMARY GLAND BIOL, V4, P79, DOI 10.1023/A:1018708704335; Hovey RC, 2001, DEV DYNAM, V222, P192, DOI 10.1002/dvdy.1179; Huang Y, 2004, ENDOCRINOLOGY, V145, P3297, DOI 10.1210/en.2003-1658; Huang Y, 2004, MOL ENDOCRINOL, V18, P1471, DOI 10.1210/me.2003-0418; Huang Y, 2003, J BIOL CHEM, V278, P18902, DOI 10.1074/jbc.M300939200; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Johnson JL, 1996, J BIOL CHEM, V271, P21574, DOI 10.1074/jbc.271.35.20981; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kassenbrock CK, 2002, J BIOL CHEM, V277, P24967, DOI 10.1074/jbc.M201026200; Kim SO, 2002, ENDOCRINOLOGY, V143, P4856, DOI 10.1210/en.2002-220565; Kim SO, 1999, J BIOL CHEM, V274, P36015, DOI 10.1074/jbc.274.50.36015; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laskin JJ, 2004, CANCER TREAT REV, V30, P1, DOI 10.1016/j.ctrv.2003.10.002; LI X, 2005, ENDOCRINE SOC PROGRA, P3; Lichtner RB, 2003, BIOMED PHARMACOTHER, V57, P447, DOI 10.1016/j.biopha.2003.09.006; Lichtner RB, 2001, CANCER RES, V61, P5790; LIN CR, 1984, SCIENCE, V224, P843, DOI 10.1126/science.6326261; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Llovera M, 2000, ONCOGENE, V19, P4695, DOI 10.1038/sj.onc.1203846; Llovera M, 2000, EXP GERONTOL, V35, P41, DOI 10.1016/S0531-5565(99)00078-9; Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447; MCMURRAY RW, 1995, J RHEUMATOL, V22, P2084; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; PLOWMAN GD, 1993, NATURE, V366, P473, DOI 10.1038/366473a0; Qiu Y, 1998, NATURE, V393, P83, DOI 10.1038/30012; Quijano VJ, 1998, J BIOL CHEM, V273, P1200, DOI 10.1074/jbc.273.2.1200; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; RUI H, 1994, J BIOL CHEM, V269, P5364; RUI H, 2000, CYTOKINE REFERENCE O, P267; Schroeder MD, 2002, MOL ENDOCRINOL, V16, P45, DOI 10.1210/me.16.1.45; Shilo BZ, 2003, EXP CELL RES, V284, P140, DOI 10.1016/S0014-4827(02)00094-0; Stern DF, 2000, BREAST CANCER RES, V2, P176, DOI 10.1186/bcr51; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Touraine P, 1998, J CLIN ENDOCR METAB, V83, P667, DOI 10.1210/jc.83.2.667; Vonderhaar BK, 1999, ENDOCR-RELAT CANCER, V6, P389, DOI 10.1677/erc.0.0060389; Wennbo H, 1997, ENDOCRINOLOGY, V138, P4410, DOI 10.1210/en.138.10.4410; Wiepz GJ, 1997, J CELL PHYSIOL, V173, P44, DOI 10.1002/(SICI)1097-4652(199710)173:1<44::AID-JCP6>3.0.CO;2-J; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wiley HS, 2003, TRENDS CELL BIOL, V13, P43; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yamauchi T, 1998, ENDOCR J, V45, pS27, DOI 10.1507/endocrj.45.Suppl_S27	100	47	48	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7565	7576		10.1038/sj.onc.1209740	http://dx.doi.org/10.1038/sj.onc.1209740			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16785991				2022-12-28	WOS:000242655500002
J	Wang, J; Ou, ZL; Hou, YF; Luo, JM; Shen, ZZ; Ding, J; Shao, ZM				Wang, J.; Ou, Z-L; Hou, Y-F; Luo, J-M; Shen, Z-Z; Ding, J.; Shao, Z-M			Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential	ONCOGENE			English	Article						breast cancer; metastasis; Duffy antigen receptor for chemokines (DARC)	ENDOTHELIAL-CELLS; PROSTATE-CANCER; NEGATIVE INDIVIDUALS; TUMOR REJECTION; BINDING PROTEIN; ANGIOGENESIS; INTERLEUKIN-8; TUMORIGENICITY; IDENTIFICATION; GENE	In addition to the role in regulating leukocyte trafficking, chemokines recently have been shown to be involved in cancer growth and metastasis. Chemokine network in tumor neovascularity may be regulated by decoy receptors. Duffy antigen receptor for chemokines (DARC) is a specific decoy receptor binding with the angiogenic CC and CXC chemokines. To investigate the effects of DARC on the tumorigenesis and the metastasis potential of human breast cancer cells, human DARC cDNA was reintroduced into the MDA-MB-231 and MDA-MB-435HM cells which have a high capability of spontaneous pulmonary metastasis. We demonstrated that DARC overexpression induced inhibition of tumorigenesis and/ or metastasis through interfering with the tumor angiogenesis in vivo. This inhibition is associated with decreasing CCL2 protein levels, and MVD and MMP-9 expression in xenograft tumors. In human breast cancer samples, we also demonstrated that low expression of the DARC protein is significantly associated with estrogen receptor (ER) status, MVD, lymph node metastasis, distant metastasis and poor survival. Our results suggest for the first time that DARC is a negative regulator of growth in breast cancer, mainly by sequestration of angiogenic chemokines and subsequent inhibition of tumor neovascularity.	Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS	Shao, ZM (corresponding author), Fudan Univ, Canc Hosp,Shanghai Med Coll, Inst Canc,Dept Oncol, Dept Breast Surg,Breast Canc Inst, 399 Ling Ling Rd, Shanghai 200032, Peoples R China.	zhimingshao@yahoo.com						Addison CL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-28; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Braun SE, 2000, J IMMUNOL, V164, P4025, DOI 10.4049/jimmunol.164.8.4025; Castilho L, 2004, VOX SANG, V87, P190, DOI 10.1111/j.1423-0410.2004.00554.x; Chaudhuri A, 2004, BRIT J HAEMATOL, V127, P356, DOI 10.1111/j.1365-2141.2004.05208.x; Chaudhuri A, 1997, BLOOD, V89, P701, DOI 10.1182/blood.V89.2.701; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; Comerford L, 2005, IMMUNOL LETT, V96, P163, DOI 10.1016/j.imlet.2004.08.018; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Du JG, 2002, J LEUKOCYTE BIOL, V71, P141; Giovarelli M, 2000, J IMMUNOL, V164, P3200, DOI 10.4049/jimmunol.164.6.3200; HORUK R, 1994, J BIOL CHEM, V269, P17730; Inoue K, 2000, CLIN CANCER RES, V6, P2104; Kawakami K, 2001, J EXP MED, V194, P1743, DOI 10.1084/jem.194.12.1743; Kim SJ, 2001, NEOPLASIA, V3, P33, DOI 10.1038/sj.neo.7900124; Lentsch AB, 2002, FASEB J, V16, P1093, DOI 10.1096/fj.02-0066hyp; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; NEOTE K, 1994, BLOOD, V84, P44; NEOTE K, 1993, J BIOL CHEM, V268, P12247; Nibbs R, 2003, SEMIN IMMUNOL, V15, P287, DOI 10.1016/j.smim.2003.08.006; PEIPER SC, 1995, J EXP MED, V181, P1311, DOI 10.1084/jem.181.4.1311; Saji H, 2001, CANCER, V92, P1085, DOI 10.1002/1097-0142(20010901)92:5<1085::AID-CNCR1424>3.0.CO;2-K; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; Schutyser E, 2002, J BIOL CHEM, V277, P24584, DOI 10.1074/jbc.M112275200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; SZABO MC, 1995, J BIOL CHEM, V270, P25348, DOI 10.1074/jbc.270.43.25348; Tang T, 1998, DNA SEQUENCE, V9, P129, DOI 10.3109/10425179809072188; Tournamille C, 2004, IMMUNOGENETICS, V55, P682, DOI 10.1007/s00251-003-0633-2; TOURNAMILLE C, 1995, NAT GENET, V10, P224, DOI 10.1038/ng0695-224; Urquidi V, 2002, CLIN CANCER RES, V8, P61; Vicari AP, 2002, CYTOKINE GROWTH F R, V13, P143, DOI 10.1016/S1359-6101(01)00033-8	32	105	115	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	54					7201	7211		10.1038/sj.onc.1209703	http://dx.doi.org/10.1038/sj.onc.1209703			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	105QH	16785997				2022-12-28	WOS:000242046900009
J	Dutta, J; Fan, Y; Gupta, N; Fan, G; Gelinas, C				Dutta, J.; Fan, Y.; Gupta, N.; Fan, G.; Gelinas, C.			Current insights into the regulation of programmed cell death by NF-kappa B	ONCOGENE			English	Review						NF-kappaB; apoptosis; necrosis; transcription factor; cancer	MEDIATED UP-REGULATION; CHICKEN SPLEEN-CELLS; NECROSIS-FACTOR TNF; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; RELA P65; BCL-X; DOWN-REGULATION; V-REL	The nuclear factor-kappaB (NF-kappa B) transcription factors have emerged as major regulators of programmed cell death (PCD) whether via apoptosis or necrosis. In this context, NF-kappa B's activity has important rami. cations for normal tissue development, homoeostasis and the physiological functions of various cell systems including the immune, hepatic, epidermal and nervous systems. However, improper regulation of PCD by NF-kappa B can have severe pathologic consequences, ranging from neurodegeneration to cancer, where its activity often precludes effective therapy. Although NF-kappa B generally protects cells by inducing the expression genes encoding antiapoptotic and antioxidizing proteins, its role in apoptosis and necrosis can vary markedly in different cell contexts, and NF-kappa B can sensitize cells to death-inducing stimuli in some instances. This article describes our current knowledge of the role of NF-kappa B in apoptosis and necrosis, and focuses on the many advances since we last reviewed this rapidly evolving topic in Oncogene 3 years ago. There has been substantial progress in understanding NF-kappa B's mode of action in apoptosis and necrosis and the mechanisms that regulate its anti- vs proapoptotic activities. These recent developments shed new light on the role of NF-kappa B in many disease conditions including tumor development, tumor progression and anticancer treatment.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, CABM, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Grad Program Biochem & Mol Biol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Gelinas, C (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, CABM, 679 Hoes Lane, Piscataway, NJ 08854 USA.	gelinas@cabm.rutgers.edu	Fan, gaofeng/H-2996-2013	Fan, gaofeng/0000-0002-6729-2867; Bundy, Anita/0000-0003-4743-9144	NCI NIH HHS [CA54999, CA83937] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054999, R29CA054999, R01CA083937] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham MC, 2004, TRENDS CELL BIOL, V14, P184, DOI 10.1016/j.tcb.2004.03.002; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Albensi BC, 2000, SYNAPSE, V35, P151; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Ashikawa K, 2004, BIOCHEM PHARMACOL, V67, P353, DOI 10.1016/j.bcp.2003.08.039; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899; Bailey ST, 2005, NAT IMMUNOL, V6, P966, DOI 10.1038/ni1005-966; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bernard D, 2002, ONCOGENE, V21, P4392, DOI 10.1038/sj.onc.1205536; Bernard D, 2001, J BIOL CHEM, V276, P27322, DOI 10.1074/jbc.M011183200; Bernard D, 2001, CANCER RES, V61, P2656; Bertoni F, 2006, J CLIN INVEST, V116, P22, DOI 10.1172/JCI27476; Beyaert R, 2000, BIOCHEM PHARMACOL, V60, P1143, DOI 10.1016/S0006-2952(00)00404-4; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brown HJ, 2003, J VIROL, V77, P8532, DOI 10.1128/JVI.77.15.8532-8540.2003; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Burstein E, 2005, J BIOL CHEM, V280, P22222, DOI 10.1074/jbc.M501928200; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Campbell KJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-101; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Cavin LG, 2004, CANCER RES, V64, P7030, DOI 10.1158/0008-5472.CAN-04-1647; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen F, 2003, CANCER RES, V63, P7689; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chen XF, 2003, CANCER RES, V63, P1059; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Claudio E, 2006, CELL DEATH DIFFER, V13, P697, DOI 10.1038/sj.cdd.4401894; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; de Visser KE, 2005, CANCER IMMUNOL IMMUN, V54, P1143, DOI 10.1007/s00262-005-0702-5; Delhalle S, 2002, ONCOGENE, V21, P3917, DOI 10.1038/sj.onc.1205489; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Duckett Colin S, 2005, Biochem J, V385, pe1; Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Egan LJ, 2004, P NATL ACAD SCI USA, V101, P2452, DOI 10.1073/pnas.0306734101; FAN Y, 2006, IN PRESS PROGRAMMED; Fan Yongjun, 2006, P112; Feng B, 2004, CELL IMMUNOL, V232, P9, DOI 10.1016/j.cellimm.2005.01.006; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Ganesh L, 2006, MOL CELL BIOL, V26, P3864, DOI 10.1128/MCB.26.10.3864-3874.2006; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Gilmore T, 2002, CANCER LETT, V181, P1, DOI 10.1016/S0304-3835(01)00795-9; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grimm T, 2005, BLOOD, V105, P3263, DOI 10.1182/blood-2004-07-2752; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Gugasyan R, 2006, CELL DEATH DIFFER, V13, P1235, DOI 10.1038/sj.cdd.4401858; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harlin H, 2001, MOL CELL BIOL, V21, P3604, DOI 10.1128/MCB.21.10.3604-3608.2001; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; He ZM, 2000, CANCER RES, V60, P1845; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Hrdlickova R, 2006, J VIROL, V80, P281, DOI 10.1128/JVI.80.1.281-295.2006; Hu P, 2006, MOL CELL BIOL, V26, P3071, DOI 10.1128/MCB.26.8.3071-3084.2006; Hu SM, 2006, J CLIN INVEST, V116, P174, DOI 10.1172/JCI25641; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Ikeda F, 2006, CELL, V125, P643, DOI 10.1016/j.cell.2006.05.003; Jaattela M, 2003, NAT IMMUNOL, V4, P416, DOI 10.1038/ni0503-416; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jin RG, 2002, DNA CELL BIOL, V21, P491, DOI 10.1089/104454902320219059; John GR, 2003, NEUROSCIENTIST, V9, P10, DOI 10.1177/1073858402239587; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kasof GM, 2001, ONCOGENE, V20, P7965, DOI 10.1038/sj.onc.1204985; Kaur S, 2005, J BIOL CHEM, V280, P38599, DOI 10.1074/jbc.M505671200; Kawakami H, 2005, INT J CANCER, V115, P967, DOI 10.1002/ijc.20954; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Kreuz S, 2004, J CELL BIOL, V166, P369, DOI 10.1083/jcb.200401036; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee RM, 1999, GENE DEV, V13, P718, DOI 10.1101/gad.13.6.718; Lee SK, 2005, J DERMATOL SCI, V40, P95, DOI 10.1016/j.jdermsci.2005.06.008; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Levenson JM, 2004, J NEUROSCI, V24, P3933, DOI 10.1523/JNEUROSCI.5646-03.2004; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu N, 2003, EMBO J, V22, P5313, DOI 10.1093/emboj/cdg510; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; Luo JL, 2005, J CLIN IMMUNOL, V25, P541, DOI 10.1007/s10875-005-8217-6; Malewicz M, 2003, J BIOL CHEM, V278, P32825, DOI 10.1074/jbc.M304000200; Massoumi R, 2006, J INVEST DERMATOL, V126, P1182, DOI 10.1038/sj.jid.5700218; Matsui K, 1998, J IMMUNOL, V161, P3469; Matsuzawa A, 2005, ANTIOXID REDOX SIGN, V7, P472, DOI 10.1089/ars.2005.7.472; Matta H, 2005, CANCER BIOL THER, V4, P77, DOI 10.4161/cbt.4.1.1379; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2006, CELL DEATH DIFFER, V13, P852, DOI 10.1038/sj.cdd.4401837; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mittal A, 2006, J IMMUNOL, V176, P2183, DOI 10.4049/jimmunol.176.4.2183; Munzert G, 2004, LEUKEMIA LYMPHOMA, V45, P1181, DOI 10.1080/10428190310001657326; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Papa S, 2006, CELL DEATH DIFFER, V13, P712, DOI 10.1038/sj.cdd.4401865; Park MY, 2004, J BIOL CHEM, V279, P2544, DOI 10.1074/jbc.M304565200; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Prendes M, 2003, J IMMUNOL, V171, P3963, DOI 10.4049/jimmunol.171.8.3963; Ravi R, 2001, NAT CELL BIOL, V3, P409, DOI 10.1038/35070096; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Rivera-Walsh I, 2001, J BIOL CHEM, V276, P40385, DOI 10.1074/jbc.C100501200; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rudolph D, 2000, GENE DEV, V14, P854; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Santoro MG, 2003, EMBO J, V22, P2552, DOI 10.1093/emboj/cdg267; Schauvliege R, 2002, J BIOL CHEM, V277, P41624, DOI 10.1074/jbc.M207852200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schwenzer R, 1999, J BIOL CHEM, V274, P19368, DOI 10.1074/jbc.274.27.19368; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; Shen L, 2006, J BIOL CHEM, V281, P15304, DOI 10.1074/jbc.M600054200; Shin HM, 2006, EMBO J, V25, P129, DOI 10.1038/sj.emboj.7600902; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shishodia S, 2006, CLIN CANCER RES, V12, P1828, DOI 10.1158/1078-0432.CCR-05-2044; Shou Y, 2002, J NEUROCHEM, V81, P842, DOI 10.1046/j.1471-4159.2002.00880.x; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Siegmund D, 2001, J BIOL CHEM, V276, P43708, DOI 10.1074/jbc.M106421200; Song YJ, 2006, P NATL ACAD SCI USA, V103, P2689, DOI 10.1073/pnas.0511096103; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; STROZYK E, 2006, IN PRESS ONCOGENE; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Takahashi R, 1998, J BIOL CHEM, V273, P7787, DOI 10.1074/jbc.273.14.7787; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tao YM, 2006, MOL CELL BIOL, V26, P1038, DOI 10.1128/MCB.26.3.1038-1050.2006; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; White DW, 1996, ONCOGENE, V13, P891; Wilkinson JC, 2004, J BIOL CHEM, V279, P51082, DOI 10.1074/jbc.M408655200; Wolff B, 1999, ONCOGENE, V18, P2663, DOI 10.1038/sj.onc.1202617; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251; WU HY, 1994, J BIOL CHEM, V269, P20067; Wu LM, 2006, J BIOL CHEM, V281, P2162, DOI 10.1074/jbc.M505903200; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yamazaki T, 2003, NAT IMMUNOL, V4, P780, DOI 10.1038/ni949; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; You ZB, 2002, J BIOL CHEM, V277, P36671, DOI 10.1074/jbc.M203213200; Yu MC, 2004, HEPATOLOGY, V40, P1312, DOI 10.1002/hep.20488; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zazzeroni F, 2003, NATURE, V424, P742, DOI 10.1038/424742a; Zeh HJ, 2005, J IMMUNOTHER, V28, P1, DOI 10.1097/00002371-200501000-00001; Zhang JY, 2005, J CELL BIOL, V168, P561, DOI 10.1083/jcb.200411060; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006; Zheng Y, 2001, J IMMUNOL, V166, P4949, DOI 10.4049/jimmunol.166.8.4949; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	246	337	389	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6800	6816		10.1038/sj.onc.1209938	http://dx.doi.org/10.1038/sj.onc.1209938			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072329				2022-12-28	WOS:000241666700009
J	Galderisi, U; Cipollaro, M; Giordano, A				Galderisi, U.; Cipollaro, M.; Giordano, A.			The retinoblastoma gene is involved in multiple aspects of stem cell biology	ONCOGENE			English	Review						self-renewal; cell cycle; senescence; apoptosis differentiation	TARGETED DISRUPTION; CYCLE REGULATION; G(1) CONTROL; RB; PROTEIN; PRB; DIFFERENTIATION; FAMILY; P107; PHOSPHORYLATION	Genetic programs controlling self-renewal and multipotentiality of stem cells have overlapping pathways with cell cycle regulation. Components of cell cycle machinery can play a key role in regulating stem cell self-renewal, proliferation, differentiation and aging. Among the negative regulators of cell cycle progression, the RB family members play a prominent role in controlling several aspects of stem cell biology. Stem cells contribute to tissue homeostasis and must have molecular mechanisms that prevent senescence and hold 'stemness'. RB can induce senescence-associated changes in gene expression and its activity is downregulated in stem cells to preserve self-renewal. Several reports evidenced that RB could play a role in lineage specification of several types of stem cells. RB has a role in myogenesis as well as in cardiogenesis. These effects are not only related to its role in suppressing E2F-responsive genes but also to its ability to modulate the activity of tissue-specific transcription factors. RB is also involved in adipogenesis through a strict control of lineage commitment and differentiation of adipocytes as well in determining the switch between brown and white adipocytes. Also, hematopoietic progenitor cells utilize the RB pathway to modulate cell commitment and differentiation. In this review, we will also discuss the role of the other two RB family members: Rb2/p130 and p107 showing that they have both specific and overlapping functions with RB gene.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA; Univ Naples 2, Excellence Res Ctr Cardiovasc Dis, Sect Biotechnol & Mol Biol, Dept Expt Med, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli	Galderisi, U (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Philadelphia, PA 19122 USA.	umberto.galderisi@unina2.it	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Cipollaro, Marilena/0000-0003-4350-4324; GALDERISI, Umberto/0000-0003-0909-7403				Bergh G, 1999, BLOOD, V94, P1971; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cole KA, 2004, AM J PHYSIOL-CELL PH, V286, pC349, DOI 10.1152/ajpcell.00255.2003; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Galderisi U, 2006, CELL DEATH DIFFER, V13, P5, DOI 10.1038/sj.cdd.4401757; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hoshikawa Y, 1998, P NATL ACAD SCI USA, V95, P8574, DOI 10.1073/pnas.95.15.8574; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jori FP, 2004, J CELL PHYSIOL, V200, P201, DOI 10.1002/jcp.20026; JORI FP, 2006, IN PRESS; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Morrison SJ, 1997, CELL, V88, P287, DOI 10.1016/S0092-8674(00)81867-X; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Papadimou E, 2005, EMBO J, V24, P1750, DOI 10.1038/sj.emboj.7600652; Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101; Rosen ED, 2000, GENE DEV, V14, P1293; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seigel GM, 2005, MOL VIS, V11, P729; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; SPARKS RL, 1986, CANCER RES, V46, P5312; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Stiegler P, 1998, J CELL BIOCHEM, P30; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Vanderluit JL, 2004, J CELL BIOL, V166, P853, DOI 10.1083/jcb.200403156; WANG H, 1993, CELL PROLIFERAT, V26, P55, DOI 10.1111/j.1365-2184.1993.tb00006.x; Watanabe Y, 1999, BRAIN RES, V842, P342, DOI 10.1016/S0006-8993(99)01844-2; White J, 2005, MOL BIOL CELL, V16, P2018, DOI 10.1091/mbc.e04-12-1056; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; Zheng L, 2002, CANCER RES, V62, P2498; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	52	61	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5250	5256		10.1038/sj.onc.1209736	http://dx.doi.org/10.1038/sj.onc.1209736			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936744				2022-12-28	WOS:000240064100009
J	Brandon, M; Baldi, P; Wallace, DC				Brandon, M.; Baldi, P.; Wallace, D. C.			Mitochondrial mutations in cancer	ONCOGENE			English	Review						mtDNA; cancer; OXPHOS; adaptation; Warburg	HEREDITARY OPTIC NEUROPATHY; HIGH AEROBIC GLYCOLYSIS; RENAL-CELL CARCINOMA; DNA CONTROL REGION; D-LOOP; SOMATIC MUTATIONS; PROSTATE-CANCER; OXIDATIVE STRESS; MTDNA MUTATIONS; BREAST-CANCER	The metabolism of solid tumors is associated with high lactate production while growing in oxygen ( aerobic glycolysis) suggesting that tumors may have defects in mitochondrial function. The mitochondria produce cellular energy by oxidative phosphorylation (OXPHOS), generate reactive oxygen species (ROS) as a by-product, and regulate apoptosis via the mitochondrial permeability transition pore (mtPTP). The mitochondria are assembled from both nuclear DNA (nDNA) and mitochondrial DNA ( mtDNA) genes. The mtDNA codes for 37 genes essential of OXPHOS, is present in thousands of copies per cell, and has a very high mutations rate. In humans, severe mtDNA mutations result in multisystem disease, while some functional population-specific polymorphisms appear to have permitted humans to adapt to new environments. Mutations in the nDNA-encoded mitochondrial genes for fumarate hydratase and succinate dehydrogenase have been linked to uterine leiomyomas and paragangliomas, and cancer cells have been shown to induce hexokinase II which harnesses OXPHOS adenosine triphosphate (ATP) production to drive glycolysis. Germline mtDNA mutations at nucleotides 10398 and 16189 have been associated with breast cancer and endometrial cancer. Tumor mtDNA somatic mutations range from severe insertion-deletion and chain termination mutations to mild missense mutations. Surprisingly, of the 190 tumor-specific somatic mtDNA mutations reported, 72% are also mtDNA sequence variants found in the general population. The se include 52% of the tumor somatic mRNA missense mutations, 83% of the tRNA mutations, 38% of the rRNA mutations, and 85% of the control region mutations. Some associations might reflect mtDNA sequencing errors, but analysis of several of the tumor-specific somatic missense mutations with population counterparts appear legitimate. Therefore, mtDNA mutations in tumors may fall into two main classes: (1) severe mutations that inhibit OXPHOS, increase ROS production and promote tumor cell proliferation and (2) milder mutations that may permit tumors to adapt to new environments. The former may be lost during subsequent tumor oxygenation while the latter may become fixed. Hence, mitochondrial dysfunction does appear to be a factor in cancer etiology, an insight that may suggest new approaches for diagnosis and treatment.	Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, MAMMAG, Irvine, CA 92697 USA; Univ Calif Irvine, Inst Genom & Bioinformat, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Comp Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Ecol & Evolut Biol, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Wallace, DC (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, MAMMAG, Hewitt Hall,Room 2014, Irvine, CA 92697 USA.	dwallace@uci.edu	Brandon, Marty C/A-1699-2009		NHLBI NIH HHS [HL64017] Funding Source: Medline; NIA NIH HHS [AG13154, AG24373] Funding Source: Medline; NINDS NIH HHS [NS21328, NS41650] Funding Source: Medline; NLM NIH HHS [LM07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064017] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG024373, R01AG013154] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [T15LM007443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072; Birnbaum MJ, 2004, DEV CELL, V7, P781, DOI 10.1016/j.devcel.2004.11.016; BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144; BRANDON MC, 2005, NUCLEIC ACIDS RES, V1, P33; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; BROCKINGTON M, 1993, NAT GENET, V4, P67, DOI 10.1038/ng0593-67; Brown MD, 1998, AM J HUM GENET, V63, P1852, DOI 10.1086/302155; Brown MD, 1997, AM J HUM GENET, V60, P381; Brown MD, 2001, HUM GENET, V109, P33, DOI 10.1007/s004390100538; BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428; Chen JJZ, 2003, CARCINOGENESIS, V24, P1481, DOI 10.1093/carcin/bgg102; Chen JJZ, 2002, CANCER RES, V62, P6470; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; CLAYTON DA, 1970, J MOL BIOL, V47, P137, DOI 10.1016/0022-2836(70)90335-9; Copeland WC, 2002, CANCER INVEST, V20, P557, DOI 10.1081/CNV-120002155; Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; GLAICHENHAUS N, 1986, EMBO J, V5, P1261, DOI 10.1002/j.1460-2075.1986.tb04355.x; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N; Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; JOHNSON MJ, 1983, J MOL EVOL, V19, P255, DOI 10.1007/BF02099973; Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014; Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6; Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375; Krieg RC, 2004, PROTEOMICS, V4, P2789, DOI 10.1002/pmic.200300796; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Kurtz A, 2004, MOL CANCER RES, V2, P433; LaBiche R A, 1992, In Vivo, V6, P317; LABICHE RA, 1988, J CELL BIOCHEM, V36, P393, DOI 10.1002/jcb.240360408; Lee HC, 2004, MUTAT RES-FUND MOL M, V547, P71, DOI 10.1016/j.mrfmmm.2003.12.011; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Liu VWS, 2003, HUM MUTAT, V22, P173, DOI 10.1002/humu.10244; Liu VWS, 2001, CANCER RES, V61, P5998; Lott M.T., 2002, EMERY RIMOINS PRINCI, P299; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807; Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Nomoto S, 2002, CLIN CANCER RES, V8, P481; Parrella P, 2001, CANCER RES, V61, P7623; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866; Poulton J, 1998, TRENDS GENET, V14, P387, DOI 10.1016/S0168-9525(98)01529-7; Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434; RUIZRESINI E, 2006, IN PRESS HUM MUT; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; TAIRA M, 1983, NUCLEIC ACIDS RES, V11, P1635, DOI 10.1093/nar/11.6.1635; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tong BC, 2003, J SURG ONCOL, V82, P170, DOI 10.1002/jso.10202; Torroni A, 1997, AM J HUM GENET, V60, P1107; TORRONI A, 1994, AM J HUM GENET, V55, P760; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; Trounce I., 1995, American Journal of Human Genetics, V57, pA252; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479; Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4; Wang QX, 2004, AM J MED GENET A, V131A, P50, DOI 10.1002/ajmg.a.30323; Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O., 1931, METABOLISM TUMORS; Wu CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213; Yanagihara M, 2005, CANCER SCI, V96, P620, DOI 10.1111/j.1349-7006.2005.00088.x; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; Yoneyama H, 2005, MOL CANCER RES, V3, P14; Zhang J, 2003, P NATL ACAD SCI USA, V100, P1116, DOI 10.1073/pnas.242719399	92	601	641	2	102	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4647	4662		10.1038/sj.onc.1209607	http://dx.doi.org/10.1038/sj.onc.1209607			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892079				2022-12-28	WOS:000239687000003
J	Robey, RB; Hay, N				Robey, R. B.; Hay, N.			Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt	ONCOGENE			English	Review						hexokinase; mitochondria; apoptosis; Akt; metabolism	RAT-BRAIN HEXOKINASE; C-TERMINAL HALVES; RECOMBINANT YEAST MITOCHONDRIA; TYPE-1 GLUCOSE-TRANSPORTER; DEPENDENT ANION CHANNEL; BOUND HEXOKINASE; CYTOCHROME-C; INTRAMITOCHONDRIAL COMPARTMENTS; FUNCTIONAL-ORGANIZATION; BINDING PROTEIN	Cell survival has been closely linked to both trophic growth factor signaling and cellular metabolism. Such couplings have obvious physiologic and pathophysiologic implications, but their underlying molecular bases remain incompletely defined. As a common mediator of both the metabolic and anti-apoptotic effects of growth factors, the serine/threonine kinase Akt - also known as protein kinase B or PKB - is capable of regulating and coordinating these inter-related processes. The glucose dependence of the antiapoptotic effects of growth factors and Akt plus a strong correlation between Akt-regulated mitochondrial hexokinase association and apoptotic susceptibility suggest a major role for hexokinases in these effects. Mitochondrial hexokinases catalyse the first obligatory step of glucose metabolism and directly couple extramitochondrial glycolysis to intramitochondrial oxidative phosphorylation, and are thus well suited to play this role. The ability of Akt to regulate energy metabolism appears to have evolutionarily preceded the capacity to control cell survival. This suggests that Akt-dependent metabolic regulatory functions may have given rise to glucose-dependent antiapoptotic effects that evolved as an adaptive sensing system involving hexokinases and serve to ensure mitochondrial homeostasis, thereby coupling metabolism to cell survival. We hypothesize that the enlistment of Akt and hexokinase in the control of mammalian cell apoptosis evolved as a response to the recruitment of mitochondria to the apoptotic cascade. The central importance of mitochondrial hexokinases in cell survival also suggests that they may represent viable therapeutic targets in cancer.	Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; White River Junct VA Med Ctr, Res & Dev Serv, White River Jct, VT USA; Dartmouth Med Sch, Dept Med, Lebanon, NH USA; Dartmouth Med Sch, Dept Physiol, Lebanon, NH USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dartmouth College; Dartmouth College	Hay, N (corresponding author), Univ Illinois, Dept Biochem & Mol Genet, 900 S Ashland Ave M-C 669, Chicago, IL 60607 USA.	R.Brooks.Robey@Dartmouth.edu; NHay@uic.edu	Robey, R. Brooks/J-7099-2013	Robey, R. Brooks/0000-0001-5059-3965	NATIONAL CANCER INSTITUTE [R01CA090764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016927] Funding Source: NIH RePORTER; NCI NIH HHS [CA090764] Funding Source: Medline; NIA NIH HHS [AG016927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aleshin AE, 1998, STRUCTURE, V6, P39, DOI 10.1016/S0969-2126(98)00006-9; ALLEN CB, 1998, CELL MOL PHYSL, V274, pL320; ANDERSON JW, 1971, AM J CLIN NUTR, V24, P642; ARDAIL D, 1990, J BIOL CHEM, V265, P18797; Ardehali H, 1996, J BIOL CHEM, V271, P1849, DOI 10.1074/jbc.271.4.1849; Ardehali H, 1999, J BIOL CHEM, V274, P15986, DOI 10.1074/jbc.274.23.15986; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Azoulay-Zohar H, 2000, EUR J BIOCHEM, V267, P2973; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Azoulay-Zohar H, 1999, J BIOENERG BIOMEMBR, V31, P569, DOI 10.1023/A:1005469028274; BELTRANDELRIO H, 1991, ARCH BIOCHEM BIOPHYS, V286, P183, DOI 10.1016/0003-9861(91)90026-F; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V296, P667, DOI 10.1016/0003-9861(92)90625-7; BELTRANDELRIO H, 1992, ARCH BIOCHEM BIOPHYS, V299, P116, DOI 10.1016/0003-9861(92)90252-R; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; Bustamante E, 2005, BIOCHEM BIOPH RES CO, V334, P907, DOI 10.1016/j.bbrc.2005.06.174; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Cesar MD, 1998, ARCH BIOCHEM BIOPHYS, V350, P109; Cesar MD, 1995, ARCH BIOCHEM BIOPHYS, V324, P9, DOI 10.1006/abbi.1995.9936; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Colowick SP., 1973, ENZYMES, V9, P1, DOI DOI 10.1016/S1874-6047(08)60113-4; Coy PE, 2002, AM J PHYSIOL-RENAL, V283, pF271, DOI 10.1152/ajprenal.00093.2001; CRANE RK, 1953, J BIOL CHEM, V203, P273; da-Silva WS, 2004, J BIOL CHEM, V279, P39846, DOI 10.1074/jbc.M403835200; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; DEPINTO V, 1993, J BIOL CHEM, V268, P12977; DEPINTO V, 1985, BIOCHIM BIOPHYS ACTA, V813, P230; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; EASTERBY JS, 1973, EUR J BIOCHEM, V38, P201, DOI 10.1111/j.1432-1033.1973.tb03051.x; EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; Fico A, 2004, CELL DEATH DIFFER, V11, P823, DOI 10.1038/sj.cdd.4401420; FIEK C, 1982, BIOCHIM BIOPHYS ACTA, V688, P429, DOI 10.1016/0005-2736(82)90354-6; Gao ZH, 2005, J BIOL CHEM, V280, P38271, DOI 10.1074/jbc.M506488200; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; GELB BD, 1992, P NATL ACAD SCI USA, V89, P202, DOI 10.1073/pnas.89.1.202; Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231; Gottlieb E, 2002, P NATL ACAD SCI USA, V99, P12801, DOI 10.1073/pnas.202477599; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GUMAA KA, 1969, BIOCHEM BIOPH RES CO, V36, P771, DOI 10.1016/0006-291X(69)90676-7; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hashimoto M, 2000, ARCH BIOCHEM BIOPHYS, V384, P163, DOI 10.1006/abbi.2000.2085; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Horvitz HR, 2003, CHEMBIOCHEM, V4, P697, DOI 10.1002/cbic.200300614; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Jiang XJ, 2004, ANNU REV BIOCHEM, V73, P87, DOI 10.1146/annurev.biochem.73.011303.073706; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1988, ARCH BIOCHEM BIOPHYS, V262, P626, DOI 10.1016/0003-9861(88)90415-8; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kurata M, 2000, COMP HAEMATOL INT, V10, P59, DOI 10.1007/s005800070009; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; LATERVEER F, 1993, ARCH BIOCHEM BIOPHYS, V306, P285, DOI 10.1006/abbi.1993.1513; Le Goffe C, 2002, BIOCHEM J, V364, P349, DOI 10.1042/BJ20011856; Le Goffe C, 1999, BIOCHEM J, V344, P643, DOI 10.1042/0264-6021:3440643; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; Lucken-Ardjomande S, 2005, CR BIOL, V328, P616, DOI 10.1016/j.crvi.2005.05.002; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Lutter M, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471-2121-2-22; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; MALAISSELAGAE F, 1988, BIOCHEM MED METAB B, V39, P80, DOI 10.1016/0885-4505(88)90061-8; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; Miccoli L, 1998, CANCER RES, V58, P5777; Moley KH, 2000, APOPTOSIS, V5, P99, DOI 10.1023/A:1009697908332; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; OSTLUND AK, 1983, BIOCHEM MED METAB B, V30, P231, DOI 10.1016/0006-2944(83)90089-3; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; PARRY DM, 1984, J BIOL CHEM, V259, P8917; PARRY DM, 1983, J BIOL CHEM, V258, P904; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Riddle SR, 2000, AM J PHYSIOL-LUNG C, V278, pL407, DOI 10.1152/ajplung.2000.278.2.L407; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Robey RB, 2003, J LEUKOCYTE BIOL, V74, P307, DOI 10.1189/jlb.0403165; Robey RB, 2002, J BIOL CHEM, V277, P14370, DOI 10.1074/jbc.M111722200; ROSE IA, 1967, J BIOL CHEM, V242, P1635; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Sebastian S, 1997, CYTOGENET CELL GENET, V77, P266, DOI 10.1159/000134593; Shinohara Y, 2001, BBA-MOL CELL RES, V1499, P242, DOI 10.1016/S0167-4889(00)00125-7; Shinohara Y, 1997, BBA-BIOENERGETICS, V1319, P319, DOI 10.1016/S0005-2728(97)00002-9; SHINOHARA Y, 1994, CANCER LETT, V82, P27, DOI 10.1016/0304-3835(94)90142-2; Skaff DA, 2005, J BIOL CHEM, V280, P38403, DOI 10.1074/jbc.M506943200; Smit J, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-4; SOCHOR M, 1979, ARCH BIOCHEM BIOPHYS, V198, P632, DOI 10.1016/0003-9861(79)90541-1; Taneja N, 2004, AM J PHYSIOL-CELL PH, V287, pC548, DOI 10.1152/ajpcell.00126.2003; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tsai HJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P183, DOI 10.1006/abbi.1996.9850; Tsai HJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P149, DOI 10.1006/abbi.1999.1326; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; Tu S, 2006, NAT CELL BIOL, V8, P72, DOI 10.1038/ncb1340; URETA T, 1983, BIOCHEM INT, V7, P585; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, MOL CELL, V3, P159; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Vyssokikh MY, 2001, BIOCHEM J, V358, P349, DOI 10.1042/0264-6021:3580349; Vyssokikh MY, 1999, BIOCHEMISTRY-MOSCOW+, V64, P390; VYSSOKIKH MY, 2003, ACTA BIOCHIM POL, V50, P398; Wagner KW, 2004, J BIOL CHEM, V279, P35047, DOI 10.1074/jbc.M400708200; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WHITE TK, 1987, ARCH BIOCHEM BIOPHYS, V259, P402, DOI 10.1016/0003-9861(87)90506-6; Whitesell RR, 2005, BIOCHEM J, V386, P245, DOI 10.1042/BJ20040901; WILSON JE, 1973, ARCH BIOCHEM BIOPHYS, V159, P543, DOI 10.1016/0003-9861(73)90486-4; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Wilson JE, 1997, J BIOENERG BIOMEMBR, V29, P97, DOI 10.1023/A:1022472124746; WILSON JE, 1978, TRENDS BIOCHEM SCI, V3, P124, DOI 10.1016/S0968-0004(78)80029-2; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WILSON JE, 1977, MOL CELL BIOCHEM, V18, P39, DOI 10.1007/BF00215278; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103; Wilson JE, 1985, REGULATION CARBOHYDR, P45; XIE GC, 1990, ARCH BIOCHEM BIOPHYS, V276, P285, DOI 10.1016/0003-9861(90)90040-6; XU LZ, 1995, J BIOL CHEM, V270, P9939, DOI 10.1074/jbc.270.17.9939; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191	146	391	417	2	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4683	4696		10.1038/sj.onc.1209595	http://dx.doi.org/10.1038/sj.onc.1209595			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892082				2022-12-28	WOS:000239687000006
J	Feng, FY; Varambally, S; Tomlins, SA; Chun, PY; Lopez, CA; Li, X; Davis, MA; Chinnaiyan, AM; Lawrence, TS; Nyati, MK				Feng, F. Y.; Varambally, S.; Tomlins, S. A.; Chun, P. Y.; Lopez, C. A.; Li, X.; Davis, M. A.; Chinnaiyan, A. M.; Lawrence, T. S.; Nyati, M. K.			Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity	ONCOGENE			English	Article						gemcitabine; EGFR; head and neck neoplasm	SQUAMOUS-CELL CARCINOMA; NECK-CANCER; PHASE-II; EGF RECEPTOR; RADIATION CONCURRENT; SIGNALING NETWORK; DOWN-REGULATION; KINASE-ACTIVITY; ADVANCED HEAD; TGF-ALPHA	We have recently reported that treatment with gemcitabine, a potent chemotherapeutic agent and radiation sensitizer, stimulates phosphorylation of the epidermal growth factor receptor (EGFR). Because phosphorylation of EGFR is known to precede receptor degradation, we hypothesized that gemcitabine treatment may also result in EGFR degradation. In two human head and neck cancer cell lines, UMSCC-1 and UMSCC-6, we demonstrated an approximately 80% decrease in total EGFR levels at 72 h after a 2-h treatment with 1 mu m gemcitabine. Neither cisplatin nor 5-fluorouracil, which are used to treat head and neck cancer, caused EGFR degradation. EGFR downregulation did not occur at the level of transcription, as assessed by reverse transcription-polymerase chain reaction (RT-PCR), but instead occurred via phosphorylation and ubiquitination of the receptor along a proteosome/lysosome-mediated pathway. Inhibition of EGFR degradation, by either pretreatment with the EGFR tyrosine kinase inhibitor gefitinib or by exposure to the proteosome/lysosome inhibitor MG132, significantly reduced gemcitabine-induced cell death. These results suggest that EGFR degradation may be a novel mechanism for gemcitabine-mediated cell death. These findings also indicate that caution should be exercised when combining gemcitabine with agents that may prevent EGFR degradation, such as EGFR tyrosine kinase inhibitors administered in a suboptimal sequence or proteosome inhibitors.	Univ Michigan, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nyati, MK (corresponding author), Univ Michigan, Dept Radiat Oncol, Room 3011,1331 E Ann St, Ann Arbor, MI 48109 USA.	nyati@umich.edu		Varambally, Sooryanarayana/0000-0002-2277-1127	NCI NIH HHS [5 P30 CA46592, P50 CA097248, 1 P50 CA97248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046592, P50CA097248] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABBRUZZESE JL, 1991, J CLIN ONCOL, V9, P491, DOI 10.1200/JCO.1991.9.3.491; Ang KK, 2002, CANCER RES, V62, P7350; Baselga J, 2005, J CLIN ONCOL, V23, P5568, DOI 10.1200/JCO.2005.07.119; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Chinnaiyan P, 2005, INT J RADIAT ONCOL, V62, P223, DOI 10.1016/j.ijrobp.2004.12.088; Chun PY, 2006, CANCER RES, V66, P981, DOI 10.1158/0008-5472.CAN-05-2665; Cohen EEW, 2003, J CLIN ONCOL, V21, P1980, DOI 10.1200/JCO.2003.10.051; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Eisbruch A, 2001, J CLIN ONCOL, V19, P792, DOI 10.1200/JCO.2001.19.3.792; Eisbruch A, 2002, INT J RADIAT ONCOL, V53, P23, DOI 10.1016/S0360-3016(02)02712-8; FELDER S, 1990, CELL, V61, P623, DOI 10.1016/0092-8674(90)90474-S; GRANDIS JR, 1993, CANCER RES, V53, P3579; Grandis JR, 1998, JNCI-J NATL CANCER I, V90, P824, DOI 10.1093/jnci/90.11.824; Grandis JR, 1996, NAT MED, V2, P237, DOI 10.1038/nm0296-237; He YY, 2003, J BIOL CHEM, V278, P42457, DOI 10.1074/jbc.M303376200; LAWRENCE TS, 1992, CANCER RES, V52, P3698; Lawrence TS, 2001, CLIN CANCER RES, V7, P314; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Macabeo-Ong M, 2002, MODERN PATHOL, V15, P979, DOI 10.1097/01.MP.0000026054.62220.FC; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; MIZUNO H, 2005, MOL CARCINOG; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Nyati MK, 2004, CLIN CANCER RES, V10, P691, DOI 10.1158/1078-0432.CCR-1041-03; Oksvold MP, 2003, ONCOGENE, V22, P8509, DOI 10.1038/sj.onc.1207117; Pignon JP, 2000, LANCET, V355, P949, DOI 10.1016/S0140-6736(00)90011-4; Pomerantz RG, 2004, SEMIN ONCOL, V31, P734, DOI 10.1053/j.seminoncol.2004.09.015; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; SATO KI, 1995, BIOCHEM BIOPH RES CO, V215, P1078, DOI 10.1006/bbrc.1995.2574; Shewach DS, 1996, INVEST NEW DRUG, V14, P257, DOI 10.1007/BF00194528; Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075; Supino-Rosin L, 2000, J BIOL CHEM, V275, P21850, DOI 10.1074/jbc.M001834200; Tempero M, 2003, J CLIN ONCOL, V21, P3402, DOI 10.1200/JCO.2003.09.140; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhuang SG, 2003, ONCOGENE, V22, P4413, DOI 10.1038/sj.onc.1206604	40	61	63	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3431	3439		10.1038/sj.onc.1210129	http://dx.doi.org/10.1038/sj.onc.1210129			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146438				2022-12-28	WOS:000246579600013
J	Shepard, CR; Kassis, J; Whaley, DL; Kim, HG; Wells, A				Shepard, C. R.; Kassis, J.; Whaley, D. L.; Kim, H. G.; Wells, A.			PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors	ONCOGENE			English	Article						phospholipase C-gamma; tumor dissemination; lung metastases; breast carcinoma; polyoma middle T antigen; TRAMP mouse	EPIDERMAL-GROWTH-FACTOR; PHOSPHOLIPASE C-GAMMA; CANCER CELL-MIGRATION; FACTOR RECEPTOR; EGF RECEPTOR; MOTILITY; INVASION; KINASE; CARCINOMA; PROTEIN	Phospholipase C-gamma ( PLC gamma) has been implicated in tumor cell motility required for invasiveness and metastasis. Diminished tumor dissemination has been demonstrated in xenograft models, but studies in naturally-occurring tumors are lacking, having been limited by the timing of the interventions. Therefore, we generated mice that express a doxycycline ( DOX)-inducible dominant-negative fragment of PLC gamma, PLCz; this approach avoids the in utero lethality caused by the absence of PLC gamma. As we targeted two de novo-occurring carcinomas of the mammary ( MMTV-driven polyoma middle T antigen model, PyVmT) and prostate ( TRAMP model) glands, we limited expression to these epithelial cells by driving DOX transactivator from the prostatein C3 promoter. This avoids the confounding variable of potentially abrogating motility in stromal and endothelial cells. These mice developed normally in the presence of DOX, except for limited mammary development if treated before 6 weeks and immaturity of the prostate gland if treated before 2 weeks of age. DOX-mediated induction of PLCz from age 8 to 16 weeks in PyVmT mice decreased the number of lung metastases by > 10-fold ( P < 0.06) without a detectable effect on in situ tumor cell proliferation or tumor size. Lung metastases were also significantly decreased in the TRAMP model in which the mice expressed the PLCz fragment ( P < 0.05). DOX treatment itself had no effect on tumor size or metastasis in control mice, nor did it affect tumor dissemination in nontransgenic littermates. In conclusion, abrogation of the PLC gamma signaling pathway can limit the metastatic potential of carcinomas.	Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Vet Affairs Med Ctr, Dept Pathol, Pittsburgh, PA USA; Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Alabama System; University of Alabama Birmingham	Wells, A (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, 3550 Terrace St,Scaife Hall,S-713, Pittsburgh, PA 15261 USA.	wellsa@upmc.edu		Wells, Alan/0000-0002-1637-8150				Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10; BORNFELDT KE, 1994, J CLIN INVEST, V93, P1266, DOI 10.1172/JCI117081; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Carpenter G, 1999, EXP CELL RES, V253, P15, DOI 10.1006/excr.1999.4671; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CLAESSENS F, 1989, BIOCHEM BIOPH RES CO, V164, P833, DOI 10.1016/0006-291X(89)91534-9; Dittmar T, 2002, FASEB J, V16, P1823, DOI 10.1096/fj.02-0096fje; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; Glading A, 2000, J BIOL CHEM, V275, P2390, DOI 10.1074/jbc.275.4.2390; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; HOMMA Y, 1992, J BIOL CHEM, V267, P21844; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; JAKOBSSON PA, 1973, ACTA RADIOL THER PHY, V12, P1; Ji GS, 1998, MOL BIOL CELL, V9, P749, DOI 10.1091/mbc.9.4.749; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Kassis J, 2001, SEMIN CANCER BIOL, V11, P105, DOI 10.1006/scbi.2000.0362; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Price JT, 1999, CANCER RES, V59, P5475; Reddy CC, 1996, J CELL PHYSIOL, V166, P512, DOI 10.1002/(SICI)1097-4652(199603)166:3<512::AID-JCP6>3.0.CO;2-S; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Tehranian A, 1996, AM J PATHOL, V149, P1177; Thomas Sufi Mary, 2002, Proceedings of the American Association for Cancer Research Annual Meeting, V43, P542; Turner T, 1997, CLIN CANCER RES, V3, P2275; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Webster MA, 1998, ONCOGENE, V16, P1963, DOI 10.1038/sj.onc.1201707; Wells A, 2000, ADV CANCER RES, V78, P31; Wells A, 2002, ACTA ONCOL, V41, P124, DOI 10.1080/028418602753669481; XIE H, 1995, CLIN EXP METASTAS, V13, P407, DOI 10.1007/BF00118180	38	48	52	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3020	3026		10.1038/sj.onc.1210115	http://dx.doi.org/10.1038/sj.onc.1210115			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130835				2022-12-28	WOS:000246395400007
J	Khatlani, TS; Wislez, M; Sun, M; Srinivas, H; Iwanaga, K; Ma, L; Hanna, AE; Liu, D; Girard, L; Kim, YH; Pollack, JR; Minna, JD; Wistuba, II; Kurie, JM				Khatlani, T. S.; Wislez, M.; Sun, M.; Srinivas, H.; Iwanaga, K.; Ma, L.; Hanna, A. E.; Liu, D.; Girard, L.; Kim, Y. H.; Pollack, J. R.; Minna, J. D.; Wistuba, I. I.; Kurie, J. M.			c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells	ONCOGENE			English	Article						c-Jun N-terminal kinase; lung cancer; cellular transformation	METASTASIS SUPPRESSOR GENE; NH2-TERMINAL KINASE; SIGNAL-TRANSDUCTION; BREAST; GROWTH; JNK; MUTATIONS; MKK4; PROLIFERATION; EXPRESSION	c-Jun N-terminal kinase (JNK) has been reported to either potentiate or inhibit oncogenesis, depending upon the cellular context, but its role in lung neoplasia is unclear. Here we sought to de. ne the role of JNK in lung neoplasia by examining evidence of JNK phosphorylation in non-small-cell lung cancer (NSCLC) biopsy samples and by using genetic and pharmacologic approaches to modulate JNK expression and activity in cultured cells. Immunohistochemical staining for JNK phosphorylation was detected in 114 (45%) of 252 NSCLC biopsy samples and was predominantly nuclear, providing evidence of JNK activation in a subset of NSCLC cases. Introduction of a doxycycline-inducible, constitutively active, mutant mitogen-activated protein kinase kinase 4 (MKK4) into the human bronchial epithelial cell lines BEAS-2B and HB56B increased the cells' proliferation, migration, invasion and clonogenicity. Depletion of JNK in MKK4 mutant-transformed BEAS-2B cells by introduction of JNK1/2 short hairpin RNA reversed the transformed phenotype, indicating that JNK activation is oncogenic and MKK4 confers neoplastic properties in these cells. The proliferation of NSCLC cell lines HCC827 and H2009, in which JNK and its substrate c-Jun are constitutively phosphorylated, was inhibited by SP600125, a JNK kinase inhibitor. We conclude that JNK is activated in a subset of NSCLC biopsy samples and promotes oncogenesis in the bronchial epithelium, suggesting that strategies to inhibit the JNK pathway should be considered for the prevention and treatment of NSCLC.	Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Hop Tenon, AP HP, Dept Pulmonol, F-75970 Paris, France; Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	University of Texas System; UTMD Anderson Cancer Center; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University	Kurie, JM (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Box 0432,1515 Holcombe Blvd, Houston, TX 77030 USA.	jkurie@mdanderson.org		wislez, marie/0000-0001-7518-7859	NATIONAL CANCER INSTITUTE [R01CA105155, P50CA070907] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA70907, R01 CA105155, P50 CA070907] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachmeier BE, 2005, THROMB HAEMOSTASIS, V93, P761, DOI 10.1160/TH04-09-0601; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Bost F, 1999, MOL CELL BIOL, V19, P1938; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; Cazillis M, 2004, ONCOGENE, V23, P4735, DOI 10.1038/sj.onc.1207619; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GEQIANG L, 2004, J BIOL CHEM, V279, P1123; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kennedy NJ, 2003, GENE DEV, V17, P629, DOI 10.1101/gad.1062903; Kennedy NJ, 2003, CELL CYCLE, V2, P199, DOI 10.4161/cc.2.3.388; Kim HL, 2001, CANCER RES, V61, P2833; Kim MH, 2005, BIOCHEM BIOPH RES CO, V333, P874, DOI 10.1016/j.bbrc.2005.06.002; Lee HY, 2003, J BIOL CHEM, V278, P23630, DOI 10.1074/jbc.M300997200; Lee HY, 2002, CLIN CANCER RES, V8, P2970; Liu YM, 2004, ONCOGENE, V23, P8238, DOI 10.1038/sj.onc.1207889; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lu CH, 2005, ONCOGENE, V24, P6516, DOI 10.1038/sj.onc.1208905; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Nishina H, 1999, DEVELOPMENT, V126, P505; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Potapova O, 2000, J BIOL CHEM, V275, P24767, DOI 10.1074/jbc.M904591199; Rangaswami H, 2005, J BIOL CHEM, V280, P19381, DOI 10.1074/jbc.M414204200; REDDEL RR, 1991, INT J CANCER, V48, P764, DOI 10.1002/ijc.2910480522; REDDEL RR, 1988, CANCER RES, V48, P1904; SUGIO K, 1992, CANCER RES, V52, P339; Teng DHF, 1997, CANCER RES, V57, P4177; Vicent S, 2004, CLIN CANCER RES, V10, P3639, DOI 10.1158/1078-0432.CCR-03-0771; Wang L, 2004, ONCOGENE, V23, P5978, DOI 10.1038/sj.onc.1207802; Xiao L, 2000, CANCER RES, V60, P400; Yamada SD, 2002, CANCER RES, V62, P6717; Yang YM, 2003, CLIN CANCER RES, V9, P391; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	45	60	62	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2658	2666		10.1038/sj.onc.1210050	http://dx.doi.org/10.1038/sj.onc.1210050			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17057737				2022-12-28	WOS:000245831200013
J	Mangala, LS; Fok, JY; Zorrilla-Calancha, IR; Verma, A; Mehta, K				Mangala, L. S.; Fok, J. Y.; Zorrilla-Calancha, I. R.; Verma, A.; Mehta, K.			Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells	ONCOGENE			English	Article						metastasis; integrins; cell migration; invasion; transglutaminase; fibronectin	GELATIN-BINDING DOMAIN; SWISS 3T3 FIBROBLASTS; FOCAL-ADHESION KINASE; DRUG-RESISTANT; RETINOIC ACID; CROSS-LINKING; MCF-7 CELLS; IN-VITRO; FIBRONECTIN; MIGRATION	Distant metastasis is frequently observed in patients with breast cancer and is a major cause of cancer-related deaths in these patients. Currently, very little is known about the mechanisms that underlie the development of the metastatic phenotype in breast cancer cells. We previously found that metastatic breast cancer cells express high levels of tissue transglutaminase (TG2), but established no direct link between TG2 and metastasis. In this study, we hypothesized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells. The results obtained suggested that increased expression of TG2 in breast cancer cells contributes to their increased survival, invasion and motility. We further found that TG2 protein in a metastatic breast cancer MDA-MB231 cells was present on the cell surface in close association with integrins beta 1, beta 4 and beta 5. Downregulation of endogenous TG2 by small interfering RNA inhibited. bronectin (Fn)mediated cell attachment, survival and invasion. Conversely, ectopic expression of TG2 augmented invasion of breast cancer cells and attachment to Fn-coated surfaces. We conclude that TG2 expression in breast cancer cells plays an important role in the development of the metastatic phenotype.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Mehta, K (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Unit 326,1515 Holcombe Blvd, Houston, TX 77030 USA.	kmehta@mdanderson.org			NCI NIH HHS [CA 16672-29, CA 092115] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aeschlimann D, 2000, CONNECT TISSUE RES, V41, P1, DOI 10.3109/03008200009005638; Akimov SS, 2001, J CELL SCI, V114, P2989; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Baek KJ, 2001, J BIOL CHEM, V276, P5591, DOI 10.1074/jbc.M008252200; Balklava Z, 2002, J BIOL CHEM, V277, P16567, DOI 10.1074/jbc.M109836200; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; Chandrashekar R, 1998, P NATL ACAD SCI USA, V95, P531, DOI 10.1073/pnas.95.2.531; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Chen JSK, 2004, J CELL PHYSIOL, V200, P223, DOI 10.1002/jcp.20014; Chen JSK, 2002, BREAST CANCER RES TR, V71, P237, DOI 10.1023/A:1014461832403; Cordes N, 2003, INT J RADIAT BIOL, V79, P709, DOI 10.1080/09553000310001610240; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Han JA, 1999, J CANCER RES CLIN, V125, P89, DOI 10.1007/s004320050247; Hang J, 2005, J BIOL CHEM, V280, P23675, DOI 10.1074/jbc.M503323200; Herman JF, 2006, ONCOGENE, V25, P3049, DOI 10.1038/sj.onc.1209324; Janiak A, 2006, MOL BIOL CELL, V17, P1606, DOI 10.1091/mbc.E05-06-0549; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Jiang DF, 2003, PROTEOMICS, V3, P724, DOI 10.1002/pmic.200300411; Jiang WG, 2003, ONCOL REP, V10, P2039; Joshi S, 2006, ONCOGENE, V25, P240, DOI 10.1038/sj.onc.1209027; Korah R, 2004, CANCER RES, V64, P4514, DOI 10.1158/0008-5472.CAN-03-3853; Leroy P, 2004, J LEUKOCYTE BIOL, V75, P680, DOI 10.1189/jlb.0503246; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Longtin R, 2004, J NATL CANCER I, V96, P6, DOI 10.1093/jnci/96.1.6; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Mauro L, 1999, EXP CELL RES, V252, P439, DOI 10.1006/excr.1999.4639; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Mehta K, 2005, PROG EXP TUMOR RES, V38, P1; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2006, J BIOL CHEM, V281, P5532, DOI 10.1074/jbc.M506864200; Mishra S, 2006, BIOCHEM BIOPH RES CO, V339, P726, DOI 10.1016/j.bbrc.2005.11.071; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Mohan K, 2003, J IMMUNOL, V171, P3179, DOI 10.4049/jimmunol.171.6.3179; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Parker BS, 2003, CANCER BIOL THER, V2, P14; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Priglinger SG, 2004, INVEST OPHTH VIS SCI, V45, P955, DOI 10.1167/iovs.03-0210; Singh US, 2001, EMBO J, V20, P2413, DOI 10.1093/emboj/20.10.2413; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Yoneda T, 2000, J Orthop Sci, V5, P75, DOI 10.1007/s007760050012; Zemskov EA, 2006, FRONT BIOSCI-LANDMRK, V11, P1057, DOI 10.2741/1863; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	47	121	123	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2459	2470		10.1038/sj.onc.1210035	http://dx.doi.org/10.1038/sj.onc.1210035			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043648				2022-12-28	WOS:000245831000006
J	Chauhan, D; Velankar, M; Brahmandam, M; Hideshima, T; Podar, K; Richardson, P; Schlossman, R; Ghobrial, I; Raje, N; Munshi, N; Anderson, KC				Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K. C.			A novel Bcl-2/Bcl-X-L/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; mitochondria; apoptosis; Bcl-2	BCL-2 FAMILY; INDUCED APOPTOSIS; CELLS; DEXAMETHASONE; ACTIVATION; MCL-1	Bcl-2 or Bcl-X-L confers resistance to chemotherapy in multiple myeloma ( MM). Here we characterized the effects of ABT-737, a potent small-molecule inhibitor of antiapoptotic proteins Bcl-2, Bcl-X-L and Bcl-w with markedly higher affinity than previously reported compounds, on human MM cells. ABT-737 induces apoptosis in MM cells, including those resistant to conventional therapy. Examination of purified patient MM cells demonstrated similar results, without significant toxicity against normal peripheral blood mononuclear cells and MM bone marrow stromal cells. Importantly, ABT-737 decreases the viability of bortezomib-, dexamethasone-(Dex) and thalidomide-refractory patient MM cells. Additionally, ABT-737 abrogates MM cell growth triggered by interleukin-6 or insulin-like growth factor-1. Mechanistic studies show that ABT-737-induced apoptosis is associated with activation of caspase-8, caspase-9 and caspase-3, followed by poly(ADP-ribose) polymerase cleavage. Combining ABT- 737 with proteasome inhibitor bortezomib, melphalan or dexamethasone induces additive anti-MM activity. Taken together, our study provides the rationale for clinical protocols evaluating ABT-737, alone and together with botezomib, mephalan or dexamethasone, to enhance MM cell killing, overcome drug resistance conferred by Bcl-2 and improve patient outcome in MM.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Anderson, KC (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.	Kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021; Podar, Klaus/ABD-1112-2020	Podar, Klaus/0000-0002-7414-3632	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50CA10070, P0-1 CA 78373, R0-1 CA50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1999, MUTAT RES-DNA REPAIR, V434, P243, DOI 10.1016/S0921-8777(99)00032-4; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cory S, 2005, CANCER CELL, V8, P5, DOI 10.1016/j.ccr.2005.06.012; Dalton WS, 2002, CLIN CANCER RES, V8, P3643; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Gazitt Y, 1998, INT J ONCOL, V13, P397; HARDIN J, 1994, BLOOD, V84, P3063; Jelinek DF, 1997, J IMMUNOL, V159, P487; Kluck RM, 1997, APOPTOSIS, V2, P337; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; Liu Q, 2003, BLOOD, V101, P4105, DOI 10.1182/blood-2002-10-3067; Mitsiades N, 2003, BLOOD, V101, P4055, DOI 10.1182/blood-2002-11-3514; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perez-Galan P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; van de Donk NWCJ, 2003, LEUKEMIA, V17, P211, DOI 10.1038/sj.leu.2402768; Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365-2141.1997.592708.x; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	27	177	183	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2374	2380		10.1038/sj.onc.1210028	http://dx.doi.org/10.1038/sj.onc.1210028			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016430				2022-12-28	WOS:000245466000013
J	Mazzieri, R; Furlan, F; D'Alessio, S; Zonari, E; Talotta, F; Verde, P; Blasi, F				Mazzieri, R.; Furlan, F.; D'Alessio, S.; Zonari, E.; Talotta, F.; Verde, P.; Blasi, F.			A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts	ONCOGENE			English	Article						urokinase receptor; cell proliferation; Ras; E1A; Ink4a	CELL-SURFACE RECEPTOR; TUMOR-GROWTH; CANCER; PROLIFERATION; METASTASIS; INHIBITION; INVASION; AP-1; ANTAGONISTS; CARCINOMA	In addition to its role in invasion and metastasis of several tumors, the multifunctional urokinase receptor uPAR ( urokinase plasminogen activator receptor) is directly involved in the growth of several cancer cells in vitro and in vivo. We have compared growth rate and oncogenic transformation in wild-type (wt) or uPAR(-/-) mouse embryonic fibroblasts (MEFs). Surprisingly, uPAR(-/-) MEFs grew faster than wt MEFs. This agreed with elevated levels of cell cycle mediators like extracellular signal-regulated protein kinase, p38, AP1 and Cyclin D1. Infection with a uPAR retrovirus reverted the effect, decreasing the growth rate. When MEFs were transformed with H-Ras(V12) and E1A oncogenes, the efficiency of transformation in uPAR(-/-) MEFs was higher than in wt. UPAR(-/-) MEFs grew faster at low serum, produced more colonies in agar and produced tumors in vivo in nude mice with a lower latency period. The properties of the heterozygous uPAR(-/-) MEFs were always intermediate. We conclude therefore that in MEFs uPAR concentration controls cell proliferation and the transforming activity of some oncogenes.	IFOM, FIRC, Inst Mol Oncol, Washington, DC 20016 USA; Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Gen, Milan, Italy	Vita-Salute San Raffaele University	Blasi, F (corresponding author), IFOM, FIRC, Inst Mol Oncol, Via Adamello 16, Washington, DC 20016 USA.	francesco.blasi@ifom-ieo-campus.it	Mazzieri, Roberta/C-9773-2015; Zonari, Erika/K-9638-2016; Danese, Silvio/ABH-9571-2020	Mazzieri, Roberta/0000-0002-5172-0927; Zonari, Erika/0000-0002-7915-3995; Danese, Silvio/0000-0001-7341-1351; Blasi, Francesco/0000-0001-9406-1784				Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; BEHRENDT N, 1991, J BIOL CHEM, V266, P7842; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021; Dano K, 2005, THROMB HAEMOSTASIS, V93, P676, DOI 10.1160/TH05-01-0054; Dewerchin M, 1996, J CLIN INVEST, V97, P870, DOI 10.1172/JCI118489; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; Huai Q, 2006, SCIENCE, V311, P656, DOI 10.1126/science.1121143; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Lakka SS, 2001, CLIN CANCER RES, V7, P1087; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Mazzieri R, 2006, MOL BIOL CELL, V17, P367, DOI 10.1091/mbc.E05-07-0635; Mazzieri R, 2005, THROMB HAEMOSTASIS, V93, P641, DOI 10.1160/TH05-01-0021; Min HY, 1996, CANCER RES, V56, P2428; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Ploug M, 2001, BIOCHEMISTRY-US, V40, P12157, DOI 10.1021/bi010662g; Reuning U, 1998, INT J ONCOL, V13, P893; Selleri C, 2005, BLOOD, V105, P2198, DOI 10.1182/blood-2004-06-2424; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; WILHELM O, 1994, FEBS LETT, V337, P131, DOI 10.1016/0014-5793(94)80259-9	38	13	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					725	732		10.1038/sj.onc.1209833	http://dx.doi.org/10.1038/sj.onc.1209833			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878153				2022-12-28	WOS:000243902200009
J	Wu, X; Shell, SM; Liu, Y; Zou, Y				Wu, X.; Shell, S. M.; Liu, Y.; Zou, Y.			ATR-dependent checkpoint modulates XPA nuclear import in response to UV irradiation	ONCOGENE			English	Article						XPA; ATR; nuclear accumulation; DNA damage response; nucleotide excision repair	NUCLEOTIDE EXCISION-REPAIR; PIGMENTOSUM GROUP-A; CYCLOBUTANE PYRIMIDINE DIMERS; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE; S-PHASE; RADIOSENSITIZING AGENT; ATAXIA-TELANGIECTASIA; IONIZING IRRADIATION; KINASE-ACTIVITY	In response to DNA damage, mammalian cells activate various DNA repair pathways to remove DNA lesions and, meanwhile, halt cell cycle progressions to allow sufficient time for repair. The nucleotide excision repair (NER) and the ATR-dependent cell cycle checkpoint activation are two major cellular responses to DNA damage induced by UV irradiation. However, how these two processes are coordinated in the response is poorly understood. Here we showed that the essential NER factor XPA (xeroderma pigmentosum group A) underwent nuclear accumulation upon UV irradiation, and strikingly, such an event occurred in an ATR (Ataxia-Telangiectasia mutated and RAD3-related)-dependent manner. Either treatment of cells with ATR kinase inhibitors or transfection of cells with small interfering RNA targeting ATR compromised the UV-induced XPA nuclear translocation. Consistently, the ATR-deficient cells displayed no substantial XPA nuclear translocation while the translocation remained intact in ATM (AtaxiaTelangiectasia mutated)-deficient cells in response to UV irradiation. Moreover, we found that ATR is required for the UV-induced nuclear focus formation of XPA. Taken together, our results suggested that the ATR checkpoint pathway may modulate NER activity through the regulation of XPA redistribution in human cells upon UV irradiation.	E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, Johnson City, TN 37614 USA	East Tennessee State University	Zou, Y (corresponding author), E Tennessee State Univ, James H Quillen Coll Med, Dept Biochem & Mol Biol, 100 CR Rd,Box 70581, Johnson City, TN 37614 USA.	zouy@etsu.edu	Zou, Yue/ABA-8429-2020		NATIONAL CANCER INSTITUTE [R01CA086927, R56CA086927] Funding Source: NIH RePORTER; NCI NIH HHS [R56 CA086927, R01 CA086927-04, R56 CA086927-06A1, R01 CA086927, R01 CA086927-05, CA86927] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017; Dart DA, 2004, J BIOL CHEM, V279, P16433, DOI 10.1074/jbc.M314212200; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Ford JM, 2005, MUTAT RES-FUND MOL M, V577, P195, DOI 10.1016/j.mrfmmm.2005.04.005; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Gately DP, 1998, MOL BIOL CELL, V9, P2361, DOI 10.1091/mbc.9.9.2361; Giannattasio M, 2004, EMBO J, V23, P429, DOI 10.1038/sj.emboj.7600051; Guzder SN, 2006, MOL CELL BIOL, V26, P1135, DOI 10.1128/MCB.26.3.1135-1141.2006; Iakoucheva LM, 2001, PROTEIN SCI, V10, P1353, DOI 10.1110/ps.40101; Jiang H, 1999, CANCER RES, V59, P4529; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Koberle B, 2006, DNA REPAIR, V5, P641, DOI 10.1016/j.dnarep.2005.12.001; Liu Y, 2005, BIOCHEMISTRY-US, V44, P7361, DOI 10.1021/bi047598y; MIURA N, 1991, J BIOL CHEM, V266, P19786; MIYAMOTO I, 1992, J BIOL CHEM, V267, P12182; Neecke H, 1999, EMBO J, V18, P4485, DOI 10.1093/emboj/18.16.4485; Nghiem P, 2002, J BIOL CHEM, V277, P4428, DOI 10.1074/jbc.M106113200; Nitta M, 2000, NUCLEIC ACIDS RES, V28, P4212, DOI 10.1093/nar/28.21.4212; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Neill T, 2000, J BIOL CHEM, V275, P22719, DOI 10.1074/jbc.M001002200; Rademakers S, 2003, MOL CELL BIOL, V23, P5755, DOI 10.1128/MCB.23.16.5755-5767.2003; Riedl T, 2003, EMBO J, V22, P5293, DOI 10.1093/emboj/cdg489; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Thomas RK, 2003, MARK HEALTH SERV, V23, P38; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang J, 2006, CANCER RES, V66, P1906, DOI 10.1158/0008-5472.CAN-05-3444; Wright JA, 1998, P NATL ACAD SCI USA, V95, P7445, DOI 10.1073/pnas.95.13.7445; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Wu XM, 2005, ONCOGENE, V24, P4728, DOI 10.1038/sj.onc.1208674; Wu YM, 2005, J CELL BIOCHEM, V96, P751, DOI 10.1002/jcb.20577; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yu SR, 2001, MUTAT RES-DNA REPAIR, V485, P229, DOI 10.1016/S0921-8777(01)00061-1; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zou L, 2002, GENE DEV, V16, P198, DOI 10.1101/gad.950302	44	71	74	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					757	764		10.1038/sj.onc.1209828	http://dx.doi.org/10.1038/sj.onc.1209828			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862173	Green Accepted			2022-12-28	WOS:000243902200012
J	Yuan, Z; Goetz, JA; Singh, S; Ogden, SK; Petty, WJ; Black, CC; Memoli, VA; Dmitrovsky, E; Robbins, DJ				Yuan, Z.; Goetz, J. A.; Singh, S.; Ogden, S. K.; Petty, W. J.; Black, C. C.; Memoli, V. A.; Dmitrovsky, E.; Robbins, D. J.			Frequent requirement of hedgehog signaling in non-small cell lung carcinoma	ONCOGENE			English	Article						non-small cell lung carcinoma; hedgehog signaling; GLI; hedgehog target genes	SMALL-MOLECULE INHIBITOR; GROWTH-FACTOR RECEPTOR; SONIC HEDGEHOG; STEM-CELLS; PATHWAY; CANCER; TARGET; MEDULLOBLASTOMA; GLI; IDENTIFICATION	Although it had previously been suggested that the hedgehog (HH) pathway might be activated in some lung tumors, the dependence of non-small cell lung carcinomas (NSCLC) for HH activity had not been comprehensively studied. During a screen of a panel of 60 human tumor cell lines with an HH antagonist, we observed that the proliferation of a subset of NSCLC cell lines was inhibited. These NSCLC cell lines express HH, as well as key HH target genes, consistent with them being activated through an autocrine mechanism. Interestingly, we also identified a number of NSCLC cell lines that express high levels of the downstream transcription factor GLI1 and harbor enhanced levels of HH activity, but appear insensitive to known HH antagonists. We hypothesized that the high levels of GLI1 in these cells would function downstream of the HH antagonist target, allowing them to bypass the antagonist-mediated block in proliferation. Consistent with this hypothesis, when the levels of GLI1 are knocked down in such cells, they become sensitive to these inhibitors. We go on to show that a large percentage of primary NSCLC samples express GLI1, consistent with constitutive activation of the HH pathway in these samples. Taken together, these results establish the involvement of the HH signaling pathway in a subset of NSCLCs.	Dartmouth Med Sch, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Med Sch, Dept Med, Hanover, NH 03755 USA; Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC 27109 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pathol, Hanover, NH 03756 USA; Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Norris Cotton Canc Ctr, Hanover, NH 03756 USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Dartmouth College; Dartmouth College; Wake Forest University; Dartmouth College; Dartmouth College; Norris Cotton Cancer Center; Dartmouth College	Robbins, DJ (corresponding author), Dartmouth Med Sch, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	david.j.robbins@dartmouth.edu	Ogden, Stacey K/N-2528-2018; Ogden, Stacey K/P-9585-2019; Singh, Samer/H-8468-2013	Ogden, Stacey K/0000-0001-8991-3065; Singh, Samer/0000-0002-0921-1686	NATIONAL CANCER INSTITUTE [R01CA087546, P30CA023108, T32CA009658, R01CA111422, R01CA062275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064011] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA09658-14, T32 CA009658, P30 CA023108, R01 CA111422, R01 CA62275, R01 CA87546] Funding Source: Medline; NIGMS NIH HHS [R01 GM64011] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanell J, 1997, JNCI-J NATL CANCER I, V89, P1609, DOI 10.1093/jnci/89.21.1609; Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 1999, TRENDS GENET, V15, P418, DOI 10.1016/S0168-9525(99)01840-5; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Borzillo GV, 2005, CURR TOP MED CHEM, V5, P147, DOI 10.2174/1568026053507732; Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Cooper MK, 1998, SCIENCE, V280, P1603, DOI 10.1126/science.280.5369.1603; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Goetz JA, 2002, BIOESSAYS, V24, P157, DOI 10.1002/bies.10056; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Incardona JP, 1998, DEVELOPMENT, V125, P3553; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Kubo M, 2004, CANCER RES, V64, P6071, DOI 10.1158/0008-5472.CAN-04-0416; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Ogden SK, 2004, BIOCHEM PHARMACOL, V67, P805, DOI 10.1016/j.bcp.2004.01.002; Petty WJ, 2004, CLIN CANCER RES, V10, P7547, DOI 10.1158/1078-0432.CCR-04-1169; Petty WJ, 2003, LUNG CANCER, V41, pS155, DOI 10.1016/S0169-5002(03)00159-4; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Robbins DJ, 2005, CURR CANCER THER REV, V1, P277, DOI 10.2174/157339405774574243; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Rusch V, 1997, CLIN CANCER RES, V3, P515; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sheng T, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-29; SINGH S, 2006, SONIC HEDGEHOG, DOI DOI 10.1038/MP.A002208.01; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thayer SP, 2003, NATURE, V425, P851, DOI 10.1038/nature02009; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watkins DN, 2004, BIOCHEM PHARMACOL, V68, P1055, DOI 10.1016/j.bcp.2004.04.025; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; Williams JA, 2003, P NATL ACAD SCI USA, V100, P4616, DOI 10.1073/pnas.0732813100; Zhu YH, 2004, CANCER LETT, V207, P205, DOI 10.1016/j.canlet.2003.10.025	47	139	147	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1046	1055		10.1038/sj.onc.1209860	http://dx.doi.org/10.1038/sj.onc.1209860			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909105				2022-12-28	WOS:000244245400011
J	Obeid, D; Nguyen, J; Lesavre, P; Bauvois, B				Obeid, D.; Nguyen, J.; Lesavre, P.; Bauvois, B.			Differential regulation of tumor necrosis factor-alpha-converting enzyme and angiotensin-converting enzyme by type I and II interferons in human normal and leukemic myeloid cells	ONCOGENE			English	Article						interferon; ACE; TACE; monocyte; leukemia; ADAM-17	ENDOTHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; IFN-GAMMA; INHIBITORS; CANCER; MATRIX-METALLOPROTEINASE-9; ADHESION; GROWTH; INTERNALIZATION	The transmembrane metalloproteases angiotensin-converting enzyme (ACE) and tumor necrosis factor-alpha (TNF-alpha)-converting enzyme (TACE/ADAM-17) have been associated with inflammation, cancer progression and angiogenesis. Few investigations into the regulation of these enzymes by physiological stimuli have been reported. In this study, we investigated the influence of interferons (IFNs) type I (alpha, beta) and II (gamma) on ACE and TACE expression of human leukemic NB4 cells and monocytes. We assessed the expression of proteases by reverse transcriptase-polymerase chain reaction, enzyme-linked immunosorbent assay and immunofluorescence analyses. IFN gamma, but not type I IFNs, upregulated membrane ACE in a dose- and time-dependency and this was reflected by the increase of ACE enzymatic activity and ACE mRNA. ACE upregulation was dependent on protein synthesis. Treatment of the interferon responsive factor 1 (IRF1)-unresponsive HepG2 cell line with IFN gamma did not affect ACE expression, thus suggesting the participation of the IRF1 signaling pathway in IFN gamma-mediated ACE upregulation in myeloid cells. In contrast, both types of IFNs, in a dose- and time-dependent manner, downregulated surface TACE without affecting TACE transcript. Soluble TACE was not detected in the medium of IFN-treated cells. IFN gamma-mediated decrease of surface TACE in NB4 cells was reversible, and correlated with an increase in intracellular TACE, suggesting that cell surface TACE was internalized in response to IFNs. These findings, showing the presence of IFN-dependent controlled mechanisms by which ACE and TACE levels are regulated in human normal and leukemic myeloid cells, may have implications in the context of current investigations on the therapeutic potential of IFNs.	Hop Necker Enfants Malad, INSERM 507, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Bauvois, B (corresponding author), Hop Necker Enfants Malad, INSERM 507, Batiment Lavoisier,161 Rue Sevres, F-75015 Paris, France.	bauvois@necker.fr	Bauvois, Brigitte/F-6776-2013	Bauvois, Brigitte/0000-0002-1751-6922				Bauvois B, 1996, EXP CELL RES, V222, P209, DOI 10.1006/excr.1996.0026; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; Bauvois B, 2004, ONCOGENE, V23, P317, DOI 10.1038/sj.onc.1207124; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Borden EC, 2005, J INTERF CYTOK RES, V25, P511, DOI 10.1089/jir.2005.25.511; Bzowska M, 2004, EUR J BIOCHEM, V271, P2808, DOI 10.1111/j.1432-1033.2004.04215.x; Caceres William, 2003, P R Health Sci J, V22, P149; Chawla-Sarkar M, 2003, APOPTOSIS, V8, P237, DOI 10.1023/A:1023668705040; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009; Doedens JR, 2000, J BIOL CHEM, V275, P14598, DOI 10.1074/jbc.275.19.14598; Eyries M, 2002, CIRC RES, V91, P899, DOI 10.1161/01.RES.0000042703.39845.B4; Fuchs S, 2004, CURR HYPERTENS REP, V6, P124, DOI 10.1007/s11906-004-0087-4; Garton KJ, 2003, J BIOL CHEM, V278, P37459, DOI 10.1074/jbc.M305877200; Golikov P P, 1998, Klin Lab Diagn, P11; Guilhot F, 2004, HEMATOL ONCOL CLIN N, V18, P585, DOI 10.1016/j.hoc.2004.03.002; HOLMQUIST B, 1979, ANAL BIOCHEM, V95, P540, DOI 10.1016/0003-2697(79)90769-3; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; KAPLAN G, 1982, J EXP MED, V156, P1101, DOI 10.1084/jem.156.4.1101; Le Page C, 2000, Rev Immunogenet, V2, P374; Levin JI, 2004, CURR TOP MED CHEM, V4, P1289, DOI 10.2174/1568026043387935; Lindberg H, 2004, ACTA ONCOL, V43, P142, DOI 10.1080/02841860310022346; Lindner Daniel J, 2002, Curr Oncol Rep, V4, P510, DOI 10.1007/s11912-002-0065-4; Lindner DJ, 1997, J INTERF CYTOK RES, V17, P681, DOI 10.1089/jir.1997.17.681; Lovering F, 2005, CNS NEUROL DISORD-DR, V4, P161, DOI 10.2174/1568007053544147; MAGUIRE GA, 1985, ANN CLIN BIOCHEM, V22, P204, DOI 10.1177/000456328502200218; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Matikainen S, 1998, LEUKEMIA LYMPHOMA, V30, P63, DOI 10.3109/10428199809050930; Moschos S, 2005, CANC TREAT, V126, P207, DOI 10.1007/0-387-24361-5_9; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; NEWTON RC, 2001, ANN RHEUM DIS     S3, V60, P25; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nguyen J, 2005, FEBS LETT, V579, P5487, DOI 10.1016/j.febslet.2005.09.012; OHMANN HB, 1990, LYMPHOKINE RES, V9, P43; OKABE T, 1987, BIOCHEM BIOPH RES CO, V145, P1211, DOI 10.1016/0006-291X(87)91566-X; Rocken C, 2005, CLIN CANCER RES, V11, P2526, DOI 10.1158/1078-0432.CCR-04-1922; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Saijonmaa O, 2001, J VASC RES, V38, P370, DOI 10.1159/000051068; Saijonmaa O, 2001, AM J PHYSIOL-HEART C, V280, pH885, DOI 10.1152/ajpheart.2001.280.2.H885; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Taki S, 2002, CYTOKINE GROWTH F R, V13, P379, DOI 10.1016/S1359-6101(02)00023-0; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; Tsakadze NL, 2006, J BIOL CHEM, V281, P3157, DOI 10.1074/jbc.M510797200; Worley JR, 2003, J BIOL CHEM, V278, P51340, DOI 10.1074/jbc.M310865200; Yoshiji H, 2004, CURR CANCER DRUG TAR, V4, P555, DOI 10.2174/1568009043332790	50	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					102	110		10.1038/sj.onc.1209779	http://dx.doi.org/10.1038/sj.onc.1209779			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799629				2022-12-28	WOS:000243236500010
J	Goodrich, DW				Goodrich, D. W.			The retinoblastoma tumor-suppressor gene, the exception that proves the rule	ONCOGENE			English	Review						tumor-suppressor gene; cell cycle; differentiation; DNA damage repair; apoptosis	CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; PHOSPHORYLATION SITES; SUSCEPTIBILITY GENE; NERVOUS-SYSTEM; RB MUTANT; IN-VIVO; TRANSCRIPTIONAL COACTIVATOR	The retinoblastoma tumor-suppressor gene (Rb1) is centrally important in cancer research. Mutational inactivation of Rb1 causes the pediatric cancer retinoblastoma, while deregulation of the pathway in which it functions is common in most types of human cancer. The Rb1-encoded protein (pRb) is well known as a general cell cycle regulator, and this activity is critical for pRb-mediated tumor suppression. The main focus of this review, however, is on more recent evidence demonstrating the existence of additional, cell type-specific pRb functions in cellular differentiation and survival. These additional functions are relevant to carcinogenesis suggesting that the net effect of Rb1 loss on the behavior of resulting tumors is highly dependent on biological context. The molecular mechanisms underlying pRb functions are based on the cellular proteins it interacts with and the functional consequences of those interactions. Better insight into pRb-mediated tumor suppression and clinical exploitation of pRb as a therapeutic target will require a global view of the complex, interdependent network of pocket protein complexes that function simultaneously within given tissues.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Goodrich, DW (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	david.goodrich@roswellpark.org			NCI NIH HHS [R01 CA070292-07, R01 CA070292, CA70292] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070292] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adegbola O, 2005, J BIOL CHEM, V280, P15497, DOI 10.1074/jbc.M411382200; Agah R, 1997, J CLIN INVEST, V100, P2722, DOI 10.1172/JCI119817; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Balsitis SJ, 2003, MOL CELL BIOL, V23, P9094, DOI 10.1128/MCB.23.24.9094-9103.2003; Barrientes S, 2000, ONCOGENE, V19, P562, DOI 10.1038/sj.onc.1203332; Batsche E, 2005, J BIOL CHEM, V280, P19746, DOI 10.1074/jbc.M413428200; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; BOOKSTEIN R, 1991, Critical Reviews in Oncogenesis, V2, P211; Borges HL, 2005, P NATL ACAD SCI USA, V102, P15587, DOI 10.1073/pnas.0503925102; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Brown VD, 1999, MOL CELL BIOL, V19, P3246; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen PL, 1996, P NATL ACAD SCI USA, V93, P465, DOI 10.1073/pnas.93.1.465; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; Clark AJ, 2004, BLOOD, V104, P1324, DOI 10.1182/blood-2004-02-0618; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Denchi EL, 2005, EMBO REP, V6, P661, DOI 10.1038/sj.embor.7400452; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Donovan SL, 2004, VISION RES, V44, P3323, DOI 10.1016/j.visres.2004.08.007; DRYJA TP, 1986, P NATL ACAD SCI USA, V83, P7391, DOI 10.1073/pnas.83.19.7391; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo J, 2005, J BIOL CHEM, V280, P35992, DOI 10.1074/jbc.M504583200; Guo Z, 2001, CANCER RES, V61, P8395; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 2001, ARCH OPHTHALMOL-CHIC, V119, P1699; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hou ST, 2002, J BIOL CHEM, V277, P48764, DOI 10.1074/jbc.M206336200; HU NP, 1994, ONCOGENE, V9, P1021; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang Z, 2002, J CELL BIOL, V156, P185, DOI 10.1083/jcb.200106084; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Li FQ, 2000, MOL CELL BIOL, V20, P5129, DOI 10.1128/MCB.20.14.5129-5139.2000; LOHMANN DR, 1994, HUM GENET, V94, P349; Lohmann DR, 2004, AM J MED GENET C, V129C, P23, DOI 10.1002/ajmg.c.30024; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; MacLellan WR, 2005, MOL CELL BIOL, V25, P2486, DOI 10.1128/MCB.25.6.2486-2497.2005; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Macleod KF, 1996, EMBO J, V15, P6178, DOI 10.1002/j.1460-2075.1996.tb01006.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marino S, 2000, GENE DEV, V14, P994; Marino S, 2003, DEVELOPMENT, V130, P3359, DOI 10.1242/dev.00553; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; McConkey DJ, 1996, ONCOGENE, V13, P1693; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Nath N, 2003, ONCOGENE, V22, P5986, DOI 10.1038/sj.onc.1206843; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; Paggi MG, 2001, CANCER RES, V61, P4651; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Schweers BA, 2005, VISUAL NEUROSCI, V22, P553, DOI 10.1017/S0952523805225026; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shan B, 1996, P NATL ACAD SCI USA, V93, P679, DOI 10.1073/pnas.93.2.679; Sherr CJ, 2000, CANCER RES, V60, P3689; Simpson MTW, 2001, J NEUROSCI, V21, P7089, DOI 10.1523/JNEUROSCI.21-18-07089.2001; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Spike BT, 2004, EMBO J, V23, P4319, DOI 10.1038/sj.emboj.7600432; Sun HF, 2006, MOL CELL BIOL, V26, P1527, DOI 10.1128/MCB.26.4.1527-1537.2006; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Takaki T, 2005, J BIOCHEM, V137, P381, DOI 10.1093/jb/mvi050; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vidal M, 2005, FEBS LETT, V579, P1834, DOI 10.1016/j.febslet.2005.02.030; Vooijs M, 1998, ONCOGENE, V17, P1, DOI 10.1038/sj.onc.1202169; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Xiao H, 2005, ONCOGENE, V24, P8105, DOI 10.1038/sj.onc.1208958; Yamamoto H, 1999, CLIN CANCER RES, V5, P1805; Yu BD, 2003, P NATL ACAD SCI USA, V100, P14881, DOI 10.1073/pnas.2431391100; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Zhou ZX, 2005, CANCER RES, V65, P787; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	142	108	111	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5233	5243		10.1038/sj.onc.1209616	http://dx.doi.org/10.1038/sj.onc.1209616			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936742	Green Accepted			2022-12-28	WOS:000240064100006
J	Levrero, M				Levrero, M.			Viral hepatitis and liver cancer: the case of hepatitis C	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis C; HCV core; NS5A; Wnt/beta-catenin pathway; p53-family; p73	VIRUS CORE PROTEIN; NF-KAPPA-B; GENE-EXPRESSION PROFILES; ENDOTHELIAL GROWTH-FACTOR; NONSTRUCTURAL 5A PROTEIN; NECROSIS-FACTOR-ALPHA; P53 TUMOR-SUPPRESSOR; BETA-CATENIN GENE; HEPATOCELLULAR-CARCINOMA; ENDOPLASMIC-RETICULUM	Chronic infection with the hepatitis C virus (HCV) is a major risk factor for the development of hepatocellular carcinoma (HCC) worldwide. The pathogenesis of HCC in HCV infection has extensively been analysed. Hepatitis C virus-induced chronic inflammation and the effects of cytokines in the development of fibrosis and liver cell proliferation are considered as one of the major pathogenic mechanisms. Increasing experimental evidence suggests that HCV contributes to HCC by directly modulating pathways that promote the malignant transformation of hepatocytes. Hepatitis C virus is an RNA virus that does not integrate into the host genome but HCV proteins interact with many host-cell factors well beyond their roles in the viral life cycle and are involved in a wide range of activities, including cell signaling, transcription, cell proliferation, apoptosis, membrane rearrangements, vesicular trafficking and translational regulation. At least four of the HCV gene products, namely HCV core, NS3, NS4B and NS5A, have been shown to exhibit transformation potential in tissue culture and several potentially oncogenic pathways have been shown to be altered by the expression of HCV proteins. Both HCV core and NS5A induce the accumulation of wild-type beta-catenin and the Wnt-beta-catenin pathway emerges as a common target for HCV (and HBV) in human HCCs, also independently from axin/beta-catenin gene mutations. Induction of both endoplasmic reticulum stress and oxidative stress by HCV proteins might also contribute to HCV transformation. Most of the putative transforming functions of the HCV proteins have been defined in artificial cellular systems, which may not be applicable to HCV infection in vivo, and still need to be established in relevant infection and disease models.	Univ Roma La Sapienza, Dept Internal Med, I-00161 Rome, Italy; Fdn Andrea Cesalpino, Lab Gene Express, Rome, Italy; Regina Elena Canc Ctr, AIRC Ctr Mol Oncogenom, Rome, Italy; Regina Elena Canc Ctr, Dept Expt Oncol, Rome, Italy	Sapienza University Rome	Levrero, M (corresponding author), Univ Roma La Sapienza, Dept Internal Med, Viale Policlin 155, I-00161 Rome, Italy.	Massimo.levrero@uniroma1.it	Levrero, Massimo/G-5680-2016	Levrero, Massimo/0000-0002-4978-0875				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; Alam SS, 2002, ACTA MED OKAYAMA, V56, P141; Alisi A, 2003, ONCOGENE, V22, P2573, DOI 10.1038/sj.onc.1206333; [Anonymous], 2002, NIH Consens State Sci Statements, V19, P1; Aoki H, 2000, J VIROL, V74, P1736, DOI 10.1128/JVI.74.4.1736-1741.2000; Arima N, 2001, J BIOL CHEM, V276, P12675, DOI 10.1074/jbc.M008329200; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Bataller R, 2004, GASTROENTEROLOGY, V126, P529, DOI 10.1053/j.gastro.2003.11.018; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Blindenbacher A, 2003, GASTROENTEROLOGY, V124, P1465, DOI 10.1016/S0016-5085(03)00290-7; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boige V, 1997, CANCER RES, V57, P1986; Borowski P, 1999, J CLIN VIROL, V13, P61, DOI 10.1016/S1386-6532(99)00007-4; Borowski P, 1999, ARCH VIROL, V144, P687, DOI 10.1007/s007050050536; Borowski P, 1999, J BIOL CHEM, V274, P30722, DOI 10.1074/jbc.274.43.30722; Bosch FX, 1999, SEMIN LIVER DIS, V19, P271, DOI 10.1055/s-2007-1007117; Brass V, 2002, J BIOL CHEM, V277, P8130, DOI 10.1074/jbc.M111289200; Brechot C, 1998, J HEPATOL, V29, P173, DOI 10.1016/S0168-8278(98)80001-9; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Breuhahn K, 2004, CANCER RES, V64, P6058, DOI 10.1158/0008-5472.CAN-04-0292; Brunt EM, 2004, HUM PATHOL, V35, P1070, DOI 10.1016/j.humpath.2004.04.017; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; CHANG SC, 1994, BIOCHEM BIOPH RES CO, V205, P1284, DOI 10.1006/bbrc.1994.2804; Chen CJ, 2002, HEPATOLOGY, V36, P1046, DOI 10.1053/jhep.2002.37084; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cho JW, 2001, BBA-MOL CELL RES, V1538, P59, DOI 10.1016/S0167-4889(00)00137-3; Chung KM, 2000, J VIROL, V74, P5233, DOI 10.1128/JVI.74.11.5233-5241.2000; Crotta S, 2002, J EXP MED, V195, P35, DOI 10.1084/jem.20011124; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Delpuech O, 2002, ONCOGENE, V21, P2926, DOI 10.1038/sj.onc.1205392; Deuffic S, 1998, LANCET, V351, P214, DOI 10.1016/S0140-6736(05)78179-4; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Disson O, 2004, GASTROENTEROLOGY, V126, P859, DOI 10.1053/j.gastro.2003.12.005; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Erhardt A, 2002, VIROLOGY, V292, P272, DOI 10.1006/viro.2001.1227; Farazi PA, 2003, CANCER RES, V63, P5021; Foy E, 2003, SCIENCE, V300, P1145, DOI 10.1126/science.1082604; Fukuda K, 2001, HEPATOLOGY, V33, P159, DOI 10.1053/jhep.2001.20794; Fukutomi T, 2005, HEPATOLOGY, V41, P1096, DOI 10.1002/hep.20668; FURUYA K, 1988, CANCER, V61, P99, DOI 10.1002/1097-0142(19880101)61:1<99::AID-CNCR2820610117>3.0.CO;2-U; Gale M, 1999, J VIROL, V73, P6506, DOI 10.1128/JVI.73.8.6506-6516.1999; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Giambartolomei S, 2001, ONCOGENE, V20, P2606, DOI 10.1038/sj.onc.1204372; Goh PY, 2001, VIROLOGY, V290, P224, DOI 10.1006/viro.2001.1195; Gong GZ, 2001, P NATL ACAD SCI USA, V98, P9599, DOI 10.1073/pnas.171311298; Guo JT, 2001, J VIROL, V75, P8516, DOI 10.1128/JVI.75.18.8516-8523.2001; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; Henry SH, 1999, SCIENCE, V286, P2453, DOI 10.1126/science.286.5449.2453; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda A, 1999, J MED VIROL, V59, P281, DOI 10.1002/(SICI)1096-9071(199911)59:3<281::AID-JMV4>3.0.CO;2-S; Hope RG, 2002, J BIOL CHEM, V277, P4261, DOI 10.1074/jbc.M108798200; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Ide Y, 1996, GENE, V182, P203, DOI 10.1016/S0378-1119(96)00555-0; Iizuka N, 2002, CANCER RES, V62, P3939; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Ishido S, 1998, FEBS LETT, V438, P258, DOI 10.1016/S0014-5793(98)01312-X; Ishido S, 1997, BIOCHEM BIOPH RES CO, V230, P431, DOI 10.1006/bbrc.1996.5980; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Jordan R, 2002, J VIROL, V76, P9588, DOI 10.1128/JVI.76.19.9588-9599.2002; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawamura T, 1997, HEPATOLOGY, V25, P1014, DOI 10.1002/hep.510250437; Kinoshita T, 2002, BBA-MOL CELL RES, V1592, P303, DOI 10.1016/S0167-4889(02)00323-3; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; Koike K, 1997, P NATL ACAD SCI USA, V94, P233, DOI 10.1073/pnas.94.1.233; Kojiro M, 2005, BEST PRACT RES CL GA, V19, P39, DOI 10.1016/j.bpg.2004.10.007; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 1998, BLOOD, V91, P3841, DOI 10.1182/blood.V91.10.3841.3841_3841_3849; Levrero M, 2000, J CELL SCI, V113, P1661; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lohmann V, 2001, J VIROL, V75, P1437, DOI 10.1128/JVI.75.3.1437-1449.2001; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lu W, 1999, VIROLOGY, V264, P134, DOI 10.1006/viro.1999.9979; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Macdonald GA, 1998, HEPATOLOGY, V28, P90, DOI 10.1002/hep.510280114; Machida K, 2001, J BIOL CHEM, V276, P12140, DOI 10.1074/jbc.M010137200; Majumder M, 2003, FEBS LETT, V555, P528, DOI 10.1016/S0014-5793(03)01337-1; Majumder M, 2002, VIROLOGY, V294, P94, DOI 10.1006/viro.2001.1309; Majumder M, 2001, J VIROL, V75, P1401, DOI 10.1128/JVI.75.3.1401-1407.2001; Mamiya N, 1999, J BIOL CHEM, V274, P15751, DOI 10.1074/jbc.274.22.15751; Marcellin P, 2002, HEPATOLOGY, V36, pS47, DOI 10.1053/jhep.2002.36993; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Matsumoto M, 1997, J VIROL, V71, P1301, DOI 10.1128/JVI.71.2.1301-1309.1997; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Ming L, 2002, HEPATOLOGY, V36, P1214, DOI 10.1053/jhep.2002.36366; Mise M, 1996, HEPATOLOGY, V23, P455; Mitsuhashi N, 2003, HEPATOLOGY, V37, P1105, DOI 10.1053/jhep.2003.50204; Miyoshi Y, 1998, CANCER RES, V58, P2524; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; MORADPOUR D, 2002, MOL PATHOGENESIS HEP; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Moriya K, 2001, CANCER RES, V61, P4365; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nam SW, 2005, HEPATOLOGY, V42, P809, DOI 10.1002/hep.20878; Nelson DR, 1997, J VIRAL HEPATITIS, V4, P29, DOI 10.1046/j.1365-2893.1997.00124.x; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Neuman MG, 2002, CYTOKINE, V17, P108, DOI 10.1006/cyto.2001.0997; NISHIDA N, 1994, CANCER RES, V54, P3107; Ohata K, 2003, CANCER-AM CANCER SOC, V97, P3036, DOI 10.1002/cncr.11427; Okabe H, 2001, CANCER RES, V61, P2129; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Otsuka M, 2000, J BIOL CHEM, V275, P34122, DOI 10.1074/jbc.M000578200; Owsianka AM, 1999, VIROLOGY, V257, P330, DOI 10.1006/viro.1999.9659; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; PALESCANDOLO E, 2006, UNPUB; Park JS, 2000, BIOCHEM BIOPH RES CO, V267, P581, DOI 10.1006/bbrc.1999.1999; Pasquinelli C, 1997, HEPATOLOGY, V25, P719, DOI 10.1002/hep.510250338; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Pavio N, 2005, ONCOGENE, V24, P6119, DOI 10.1038/sj.onc.1208749; Perlemuter G, 2002, FASEB J, V16, P185, DOI 10.1096/fj.01-0396com; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Piao Z, 2000, INT J ONCOL, V17, P507; Pietschmann T, 2002, J VIROL, V76, P4008, DOI 10.1128/JVI.76.8.4008-4021.2002; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; Polyak SJ, 1998, J VIROL, V72, P4288, DOI 10.1128/JVI.72.5.4288-4296.1998; Polyak SJ, 2001, J VIROL, V75, P6095, DOI 10.1128/JVI.75.13.6095-6106.2001; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Qadri I, 2002, BBA-MOL CELL RES, V1592, P193, DOI 10.1016/S0167-4889(02)00315-4; RAVAGGI A, 1994, J HEPATOL, V20, P833, DOI 10.1016/S0168-8278(05)80157-6; Ray RB, 2002, VIRUS RES, V87, P21, DOI 10.1016/S0168-1702(02)00046-1; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Ruster B, 2001, J MED VIROL, V63, P128, DOI 10.1002/1096-9071(20000201)63:2&lt;128::AID-JMV1007&gt;3.0.CO;2-S; Sabile A, 1999, HEPATOLOGY, V30, P1064, DOI 10.1002/hep.510300429; SAKAMURO D, 1995, J VIROL, V69, P3893, DOI 10.1128/JVI.69.6.3893-3896.1995; SantoniRugiu E, 1996, P NATL ACAD SCI USA, V93, P9577, DOI 10.1073/pnas.93.18.9577; Satoh S, 2000, VIROLOGY, V270, P476, DOI 10.1006/viro.2000.0287; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shi ST, 2002, VIROLOGY, V292, P198, DOI 10.1006/viro.2001.1225; SHIMODA R, 1994, CANCER RES, V54, P3171; Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smith MW, 2003, CANCER RES, V63, P859; Soo HM, 2002, VIROLOGY, V303, P253, DOI 10.1006/viro.2002.1617; Squadrito G, 2006, CANCER-AM CANCER SOC, V106, P1326, DOI 10.1002/cncr.21702; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Sumida Y, 2000, J HEPATOL, V33, P616, DOI 10.1034/j.1600-0641.2000.033004616.x; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; Tan SL, 1999, P NATL ACAD SCI USA, V96, P5533, DOI 10.1073/pnas.96.10.5533; Tanaka S, 1999, J CLIN INVEST, V103, P341, DOI 10.1172/JCI4891; Taniguchi H, 2004, J MED VIROL, V72, P52, DOI 10.1002/jmv.10545; Tanimoto A, 1997, BIOCHEM BIOPH RES CO, V236, P360, DOI 10.1006/bbrc.1997.6967; Tardif KD, 2002, J VIROL, V76, P7453, DOI 10.1128/JVI.76.15.7453-7459.2002; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; TaylorRobinson SD, 1997, LANCET, V350, P1142, DOI 10.1016/S0140-6736(05)63789-0; Tellinghuisen TL, 2002, CURR OPIN MICROBIOL, V5, P419, DOI 10.1016/S1369-5274(02)00341-7; TERADA T, 1993, VIRCHOWS ARCH A, V422, P381, DOI 10.1007/BF01605457; Thimme R, 2002, P NATL ACAD SCI USA, V99, P15661, DOI 10.1073/pnas.202608299; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Thorgeirsson SS, 2006, HEPATOLOGY, V43, pS145, DOI 10.1002/hep.21063; Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6; Tseng CTK, 2002, J EXP MED, V195, P43, DOI 10.1084/jem.20011145; Tsuchihara K, 2000, FEBS LETT, V478, P299, DOI 10.1016/S0014-5793(00)01838-X; Tu H, 1999, VIROLOGY, V263, P30, DOI 10.1006/viro.1999.9893; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Vossio S, 2002, ONCOGENE, V21, P3796, DOI 10.1038/sj.onc.1205465; Wakita T, 1998, J BIOL CHEM, V273, P9001, DOI 10.1074/jbc.273.15.9001; Wakita T, 2000, J MED VIROL, V62, P308, DOI 10.1002/1096-9071(200011)62:3<308::AID-JMV2>3.0.CO;2-6; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Wang F, 2000, BIOCHEM BIOPH RES CO, V273, P479, DOI 10.1006/bbrc.2000.2970; Waris G, 2002, BIOCHEM PHARMACOL, V64, P1425, DOI 10.1016/S0006-2952(02)01300-X; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yamaguchi R, 1998, HEPATOLOGY, V28, P68, DOI 10.1002/hep.510280111; Yamanaka T, 2002, BIOCHEM BIOPH RES CO, V294, P521, DOI 10.1016/S0006-291X(02)00507-7; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843; Yoshida T, 2002, J EXP MED, V196, P641, DOI 10.1084/jem.20012127; You LR, 1999, J VIROL, V73, P2841, DOI 10.1128/JVI.73.4.2841-2853.1999; Zhao LJ, 2005, EXP CELL RES, V305, P23, DOI 10.1016/j.yexcr.2004.12.024; Zhou TL, 1997, CANCER RES, V57, P2749; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998; Zhu NL, 2001, VIROLOGY, V283, P178, DOI 10.1006/viro.2001.0896	191	309	327	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3834	3847		10.1038/sj.onc.1209562	http://dx.doi.org/10.1038/sj.onc.1209562			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799625	Green Published			2022-12-28	WOS:000238559600011
J	Zhao, J; Yart, A; Frigerio, S; Perren, A; Schraml, P; Weisstanner, C; Stallmach, T; Krek, W; Moch, H				Zhao, J.; Yart, A.; Frigerio, S.; Perren, A.; Schraml, P.; Weisstanner, C.; Stallmach, T.; Krek, W.; Moch, H.			Sporadic human renal tumors display frequent allelic imbalances and novel mutations of the HRPT2 gene	ONCOGENE			English	Article						LOH; HRPT2 mutation; parafibromin; renal tumor	COMPARATIVE GENOMIC HYBRIDIZATION; HISTOLOGY WILMS-TUMORS; SUPPRESSOR GENE; CELL CARCINOMA; SOMATIC MUTATIONS; PRIMARY HYPERPARATHYROIDISM; PARATHYROID TUMORS; HEREDITARY HYPERPARATHYROIDISM; MET PROTOONCOGENE; HUMAN PAF1	Inactivation of the HRPT2 gene encoding parafibromin was recently linked to the familial hyperparathyroidism-jaw tumor syndrome. Patients with this syndrome carry an increased risk of parathyroid and renal tumors. To determine the relevance of HRPT2 for sporadic renal tumors, clear cell, papillary and chromophobe renal cell carcinomas as well as oncocytomas and Wilms tumors were analysed for HRPT2 gene alterations. Loss of heterozygosity (LOH) of HRPT2 was found in seven of 56 (12.5%) clear cell, three of 14 (21%) papillary, six of 10 (60%) chromophobe renal cell carcinomas, three of eight (38%) oncocytomas and four of 10 (40%) Wilms tumors. In addition, two novel HRPT2 point mutations, causing K34Q and R292K changes in parafibromin, were detected in one clear cell carcinoma and one Wilms tumor, respectively. These tumors displayed LOH of the remaining wild-type allele, but interestingly no von Hippel-Lindau (VHL) mutation. Functional analysis revealed that the K34Q mutant species of parafibromin is, unlike wild-type protein, defective in suppressing cyclin D1 expression in vivo. Taken together, these results suggest that renal cancer-associated mutations in parafibromin occur in the absence of VHL mutation, which in turn may contribute to constitutively elevated cyclin D1 expression and abnormal cell proliferation.	Univ Zurich Hosp, Inst Surg Pathol, Dept Pathol, CH-8091 Zurich, Switzerland; Swiss Fed Inst Technol, Inst Cell Biol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; Swiss Federal Institutes of Technology Domain; ETH Zurich	Zhao, J (corresponding author), Univ Zurich Hosp, Inst Surg Pathol, Dept Pathol, Schmelzberger 12, CH-8091 Zurich, Switzerland.	jianming.zhao@usz.ch	Perren, Aurel/N-5979-2019; YART, Armelle/A-5656-2016; Perren, Aurel/A-9383-2018	Perren, Aurel/0000-0002-6819-6092; YART, Armelle/0000-0002-2412-9840; Perren, Aurel/0000-0002-6819-6092; Weisstanner, Christian/0000-0003-2830-1000				Brauch H, 2000, CANCER RES, V60, P1942; Bugert P, 1997, LAB INVEST, V76, P203; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Carling T, 2001, TRENDS ENDOCRIN MET, V12, P53, DOI 10.1016/S1043-2760(00)00345-3; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2004, J CLIN ENDOCR METAB, V89, P1747, DOI 10.1210/jc.2003-031016; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; Cetani F, 2004, J CLIN ENDOCR METAB, V89, P5583, DOI 10.1210/jc.2004-0294; Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172; Eble JN, 2004, PATHOLOGY GENETICS T, P359; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Fuzesi L, 2005, CANCER GENET CYTOGEN, V160, P120, DOI 10.1016/j.cancergencyto.2004.12.010; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; GRUNDY PE, 1994, CANCER RES, V54, P2331; Grundy RG, 1998, BRIT J CANCER, V78, P1181, DOI 10.1038/bjc.1998.651; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; JACKSON CE, 1990, SURGERY, V108, P1006; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jiang F, 1998, AM J PATHOL, V153, P1467, DOI 10.1016/S0002-9440(10)65734-3; KAKINUMA A, 1994, INTERNAL MED, V33, P123, DOI 10.2169/internalmedicine.33.123; Khoo SK, 2003, CANCER RES, V63, P4583; Kiuru M, 2002, CANCER RES, V62, P4554; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; KOVACS A, 1992, GENE CHROMOSOME CANC, V4, P267, DOI 10.1002/gcc.2870040313; KOVACS G, 1991, GENE CHROMOSOME CANC, V3, P249, DOI 10.1002/gcc.2870030403; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Law MH, 1997, CANCER GENET CYTOGEN, V97, P54, DOI 10.1016/S0165-4608(96)00342-1; Maiti S, 2000, CANCER RES, V60, P6288; MELONI AM, 1992, CANCER GENET CYTOGEN, V61, P108, DOI 10.1016/0165-4608(92)90382-I; Moch H, 1996, CANCER RES, V56, P27; Moch H, 1998, CANCER RES, V58, P2304; Mosimann C, 2006, CELL, V125, P327, DOI 10.1016/j.cell.2006.01.053; Nagy A, 2004, HISTOPATHOLOGY, V44, P542, DOI 10.1111/j.1365-2559.2004.01884.x; Natrajan R, 2006, J PATHOL, V210, P49, DOI 10.1002/path.2021; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Pavlovich CP, 2004, NAT REV CANCER, V4, P381, DOI 10.1038/nrc1364; Perren A, 2004, ENDOCR-RELAT CANCER, V11, P855, DOI 10.1677/erc.1.00841; Presti JC, 1996, GENE CHROMOSOME CANC, V17, P199, DOI 10.1002/(SICI)1098-2264(199612)17:4<199::AID-GCC1>3.0.CO;2-Z; Reutzel D, 2001, CYTOGENET CELL GENET, V93, P221, DOI 10.1159/000056987; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; SHUIN T, 1994, CANCER RES, V54, P2852; SPEICHER MR, 1994, AM J PATHOL, V145, P356; SZABO J, 1995, AM J HUM GENET, V56, P944; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; Wang PF, 2005, HORM METAB RES, V37, P380, DOI 10.1055/s-2005-870150; Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005	63	38	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3440	3449		10.1038/sj.onc.1210131	http://dx.doi.org/10.1038/sj.onc.1210131			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130827				2022-12-28	WOS:000246579600014
J	Man, C; Rosa, J; Lee, LTO; Lee, VHY; Chow, BKC; Lo, KW; Doxsey, S; Wu, ZG; Kwong, YL; Jin, DY; Cheung, ALM; Tsao, SW				Man, C.; Rosa, J.; Lee, L. T. O.; Lee, V. H. Y.; Chow, B. K. C.; Lo, K. W.; Doxsey, S.; Wu, Z. G.; Kwong, Y. L.; Jin, D. Y.; Cheung, A. L. M.; Tsao, S. W.			Latent membrane protein 1 suppresses RASSF1A expression, disrupts microtubule structures and induces chromosomal aberrations in human epithelial cells	ONCOGENE			English	Article						Epstein-Barr virus; LMP1; microtubules; RASSF1A; NF-kappa B; nasopharyngeal epithelial cells	EPSTEIN-BARR-VIRUS; ENCODED LATENT MEMBRANE-PROTEIN-1; PAPILLOMAVIRUS TYPE-16 E6; NF-KAPPA-B; NASOPHARYNGEAL CARCINOMA; TUMOR-SUPPRESSOR; CPG ISLAND; HONG-KONG; LARGE T; GENE	Epstein-Barr virus ( EBV) infection is closely associated with nasopharyngeal carcinoma ( NPC) and can be detected in early premalignant lesions of nasopharyngeal epithelium. The latent membrane protein 1 ( LMP1) is an oncoprotein encoded by the EBV and is believed to play a role in transforming premalignant nasopharyngeal epithelial cells into cancer cells. RASSF1A is a tumor-suppressor gene commonly inactivated in many types of human cancer including NPC. In this study, we report a novel function of LMP1, in down-regulating RASSF1A expression in human epithelial cells. Downregulation of RASSF1A expression by LMP1 is dependent on the activation of intracellular signaling of NF-kappa B involving the C-terminal activating regions ( CTARs) of LMP1. LMP1 expression also suppresses the transcriptional activity of the RASSF1A core promoter. RASSF1A stabilizes microtubules and regulates mitotic events. Aberrant mitotic spindles and chromosome aberrations are reported phenotypes in RASSF1A inactivated cells. In this study, we observed that LMP1 expression in human epithelial cells could induce aberrant mitotic spindles, disorganized interphase microtubules and aneuploidy. LMP1 expression could also suppress microtubule dynamics as exemplified by tracking movements of the growing tips of microtubules in live cells by transfecting EGFP-tagged EB1 into cells. The aberrant mitotic spindles and interphase microtubule organization induced by LMP1 could be rescued by transfecting RASSF1A expression plasmid into cells. Downregulation of RASSF1A expression by LMP1 may facilitate its role in transformation of premalignant nasopharyngeal epithelial cells into cancer cells.	Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Li Ka Shing Fac Med, Dept Biochem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Fac Sci, Dept Zool, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Shatin, Hong Kong, Peoples R China; Univ Massachusetts, Sch Med, Dept Mol Med, Worcester, MA 01605 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; University of Massachusetts System; University of Massachusetts Worcester; Hong Kong University of Science & Technology	Tsao, SW (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, L01-53,Lab Block,Li Ka Shing Fac Med,21 Sassoon R, Hong Kong, Hong Kong, Peoples R China.	gswtsao@hkucc.hku.hk	Kwong, Yok Lam/C-4296-2009; Tsao, George/C-4422-2009; Lee, Tsz On/D-3095-2009; Chow, Billy/D-3064-2009; Lee, Leo T.O./AAB-1581-2021; /C-4230-2009	Chow, Billy/0000-0003-3390-0307; /0000-0003-3217-1456; Wu, Zhenguo/0000-0003-3049-8324				Balsitis S, 2005, J VIROL, V79, P11392, DOI 10.1128/JVI.79.17.11392-11402.2005; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; Cheung ST, 1998, INT J CANCER, V76, P399, DOI 10.1002/(SICI)1097-0215(19980504)76:3<399::AID-IJC18>3.0.CO;2-6; Chow LSN, 2006, ONCOGENE, V25, P310, DOI 10.1038/sj.onc.1209001; Chow LSN, 2004, INT J CANCER, V109, P839, DOI 10.1002/ijc.20079; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; DOXSEY SJ, 1994, CELL, V76, P639, DOI 10.1016/0092-8674(94)90504-5; Duensing S, 2002, CANCER RES, V62, P7075; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; HUANG DP, 1980, INT J CANCER, V26, P127, DOI 10.1002/ijc.2910260202; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Kang GH, 2002, AM J PATHOL, V160, P787, DOI 10.1016/S0002-9440(10)64901-2; Karsenti E, 2001, SCIENCE, V294, P543, DOI 10.1126/science.1063488; Li HM, 2006, INT J CANCER, V119, P1567, DOI 10.1002/ijc.22032; Li HM, 2004, ONCOGENE, V23, P4488, DOI 10.1038/sj.onc.1207580; Liu LM, 2003, ONCOGENE, V22, P8125, DOI 10.1038/sj.onc.1206984; Liu MT, 2004, ONCOGENE, V23, P2531, DOI 10.1038/sj.onc.1207375; Lo AKF, 2004, INT J CANCER, V109, P919, DOI 10.1002/ijc.20051; Lo AKF, 2003, LAB INVEST, V83, P697, DOI 10.1097/01.LAB.0000067480.44925.10; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Mathe E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117; Patel D, 2004, CANCER RES, V64, P1299, DOI 10.1158/0008-5472.CAN-03-2917; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; RONG R, 2004, ONCOGENE, V23, P8126; Rosa J, 2006, MOL BIOL CELL, V17, P1483, DOI 10.1091/mbc.e05-08-0723; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; VOS MD, 2004, CANCER RES, V12, P4112; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Wu LM, 2006, J BIOL CHEM, V281, P2162, DOI 10.1074/jbc.M505903200; Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29; Zhang H, 2004, CANCER GENET CYTOGEN, V150, P144, DOI 10.1016/j.cancergencyto.2003.09.007	38	30	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3069	3080		10.1038/sj.onc.1210106	http://dx.doi.org/10.1038/sj.onc.1210106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099724				2022-12-28	WOS:000246395400012
J	Liu, J; Kumar, KGS; Yu, D; Molton, SA; McMahon, M; Herlyn, M; Thomas-Tikhonenko, A; Fuchs, SY				Liu, J.; Kumar, K. G. Suresh; Yu, D.; Molton, S. A.; McMahon, M.; Herlyn, M.; Thomas-Tikhonenko, A.; Fuchs, S. Y.			Oncogenic BRAF regulates beta-Trcp expression and NF-kappa B activity in human melanoma cells	ONCOGENE			English	Article						BRAF; melanoma; beta-Trcp; NF-kappa B; I kappa B kinase	MALIGNANT-MELANOMA; SIGNALING PATHWAYS; COLORECTAL TUMORS; KINASE ACTIVATION; RAF; TRANSFORMATION; MUTATIONS; APOPTOSIS; PHOSPHORYLATION; INHIBITION	Mutational activation of BRAF is a frequent event in human malignant melanomas suggesting that BRAF-dependent signaling is conducive to melanoma cell growth and survival. Previously published work reported that melanoma cells exhibit constitutive anti-apoptotic nuclear factor kappa B (NF-kappa B) transcription factor activation triggered by proteolysis of its inhibitor I kappa B. I kappa B degradation is dependent upon its phosphorylation by the I kappa B kinase (IKK) complex and subsequent ubiquitination facilitated by beta-Trcp E3 ubiquitin ligase. Here, we report that melanocytes expressing a conditionally oncogenic form of BRAF(V600E) exhibit enhanced beta-Trcp expression, increased IKK activity and a concomitant increase in the rate of I kappa B alpha degradation. Conversely, inhibition of BRAF signaling using either a broad-spectrum Raf inhibitor (BAY 43-9006) or by selective knock-down of BRAF(V600E) expression by RNA interference in human melanoma cells leads to decreased IKK activity and beta-Trcp expression, stabilization of I kappa B, inhibition of NF-kappa B transcriptional activity and sensitization of these cells to apoptosis. Taken together, these data support a model in which mutational activation of BRAF in human melanomas contributes to constitutive induction of NF-kappa B activity and to increased survival of melanoma cells.	Univ Penn, Sch Vet Med, Dept Biol Anim, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Inst Canc Res, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of California System; University of California San Francisco; University of California System; University of California San Francisco; The Wistar Institute	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Biol Anim, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu	Thomas-Tikhonenko, Andrei/E-5329-2011	Thomas-Tikhonenko, Andrei/0000-0002-2739-2206; Liu, Jianghuai/0000-0002-2382-9140	NCI NIH HHS [R01 CA092900, CA092900, R01 CA102709, CA25874, CA108972, CA102709, P01 CA025874, P50 CA093372, CA93372, R01 CA108972] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102709, R01CA092900, R01CA108972, P50CA093372, P01CA025874] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amiri KI, 2005, CANCER METAST REV, V24, P301, DOI 10.1007/s10555-005-1579-7; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Fuchs SY, 2004, ONCOGENE, V23, P2028, DOI 10.1038/sj.onc.1207389; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoeflich MP, 2006, CANCER RES, V66, P999, DOI 10.1158/0008-5472.CAN-05-2720; Ikenoue T, 2004, CANCER RES, V64, P3428, DOI 10.1158/0008-5472.CAN-03-3591; Ikenoue T, 2003, CANCER RES, V63, P8132; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Panka DJ, 2006, CANCER RES, V66, P1611, DOI 10.1158/0008-5472.CAN-05-0808; Satyamoorthy K, 2003, CANCER RES, V63, P756; Sharma A, 2005, CANCER RES, V65, P2412, DOI 10.1158/0008-5472.CAN-04-2423; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2005, ANN NY ACAD SCI, V1059, P16, DOI 10.1196/annals.1339.005; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Yang JM, 2006, CLIN CANCER RES, V12, P950, DOI 10.1158/1078-0432.CCR-05-1220; Yang JM, 2001, CANCER RES, V61, P4901; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	22	70	71	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1954	1958		10.1038/sj.onc.1209994	http://dx.doi.org/10.1038/sj.onc.1209994			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001349	Green Accepted			2022-12-28	WOS:000245117700013
J	Wong, YF; Cheung, TH; Lo, KWK; Yim, SF; Siu, NSS; Chan, SCS; Ho, TWF; Wong, KWY; Yu, MY; Wang, VW; Li, C; Gardner, GJ; Bonome, T; Johnson, WB; Smith, DI; Chung, TKH; Birrer, MJ				Wong, Y. F.; Cheung, T. H.; Lo, K. W. K.; Yim, S. F.; Siu, N. S. S.; Chan, S. C. S.; Ho, T. W. F.; Wong, K. W. Y.; Yu, M. Y.; wang, V. W.; Li, C.; Gardner, G. J.; Bonome, T.; Johnson, W. B.; Smith, D. I.; Chung, T. K. H.; Birrer, M. J.			Identification of molecular markers and signaling pathway in endometrial cancer in Hong Kong Chinese women by genome-wide gene expression profiling	ONCOGENE			English	Article						endometrioid endometrial cancer; signaling pathway; gene expression profiling	DIFFERENT HISTOLOGIC TYPES; CLEAR-CELL-CARCINOMA; MATRIX-METALLOPROTEINASE; BREAST-CANCER; SEROUS CARCINOMA; MESSENGER-RNA; CYCLIN-E; NUCLEAR TRANSLOCATION; ENDOGENOUS INHIBITOR; MICROARRAY ANALYSIS	Endometrial cancer is the third most common gynecologic malignancy and the ninth most common malignancy for females overall in Hong Kong. Approximately 80% or more of these cancers are endometrioid endometrial adenocarcinomas. The aim of this study was to reveal genes contributing to the development of endometrioid endometrial cancer, which may impact diagnosis, prognosis and treatment of the disease. Whole-genome gene expression analysis was completed for a set of 55 microdissected sporadic endometrioid endometrial adenocarcinomas and 29 microdissected normal endometrium specimens using the Affymetrix Human U133 Plus 2.0 oligonucleotide microarray. Selected genes of interest were validated by quantitative real-time-polymerase chain reaction (qRT-PCR). Pathway analysis was performed to reveal gene interactions involved in endometrial tumorigenesis. Unsupervised hierarchical clustering displayed a distinct separation between the endometrioid adenocarcinomas and normal endometrium samples. Supervised analysis identified 117 highly differentially regulated genes (>= 4.0-fold change), which distinguished the endometrial cancer specimens from normal endometrium. Twelve novel genes including DKK4, ZIC1, KIF1A, SAA2, LOC16378, ALPP2, CCL20, CXCL5, BST2, OLFM1, KLRC1 and MBC45780 were deregulated in the endometrial cancer, and further validated in an independent set of 56 cancer and 29 normal samples using qRT-PCR. In addition, 10 genes were differentially regulated in late-stage cancer, as compared to early-stage disease, and may be involved in tumor progression. Pathway analysis of the expression data from this tumor revealed an interconnected network consisting of 21 aberrantly regulated genes involved in angiogenesis, cell proliferation and chromosomal instability. The results of this study highlight the molecular features of endometrioid endometrial cancer and provide insight into the events underlying the development and progression of endometrioid endometrial cancer.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China; Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biostat, Boston, MA 02115 USA; NCI, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Mayo Clin, Sch Med, Dept Expt Pathol, Rochester, MN USA	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Mayo Clinic	Wong, YF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China.	yickfuwong@cuhk.edu.hk		CHUNG, Tony/0000-0002-6362-8546; Lo, Kwok Wai/0000-0002-3488-6124				ABELER VM, 1991, GYNECOL ONCOL, V40, P207; Acs G, 2004, INT J GYNECOL PATHOL, V23, P110, DOI 10.1097/00004347-200404000-00004; Albright CD, 2001, EXP MOL PATHOL, V70, P71, DOI 10.1006/exmp.2000.2354; Amant F, 2005, LANCET, V366, P491, DOI 10.1016/S0140-6736(05)67063-8; [Anonymous], 2005, HONG KONG CANC STAT; Bein K, 2000, J BIOL CHEM, V275, P32167, DOI 10.1074/jbc.M003834200; Bein K, 1998, J BIOL CHEM, V273, P21423, DOI 10.1074/jbc.273.33.21423; BONOME T, 2000, CANCER RES, V65, P10602; Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195; Cao QJ, 2004, INT J GYNECOL PATHOL, V23, P321, DOI 10.1097/01.pgp.0000139646.32997.3a; Cha HJ, 1998, ONCOGENE, V16, P771, DOI 10.1038/sj.onc.1201587; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Dhanesuan N, 2002, BREAST CANCER RES TR, V75, P73, DOI 10.1023/A:1016536725958; Duncan RE, 2004, J BIOL CHEM, V279, P33079, DOI 10.1074/jbc.M400732200; Ferguson SE, 2005, CLIN CANCER RES, V11, P2252, DOI 10.1158/1078-0432.CCR-04-1353; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hegde SP, 1998, MOL CELL BIOL, V18, P2729, DOI 10.1128/MCB.18.5.2729; HENDRICKSON M, 1982, AM J SURG PATHOL, V6, P93, DOI 10.1097/00000478-198203000-00002; Hojilla CV, 2003, BRIT J CANCER, V89, P1817, DOI 10.1038/sj.bjc.6601327; Hrzenjak A, 2004, J PATHOL, V204, P19, DOI 10.1002/path.1616; Ilvan S, 2004, GYNECOL ONCOL, V94, P232, DOI 10.1016/j.ygyno.2004.04.005; Kalsheker N, 2002, BIOCHEM SOC T, V30, P93, DOI 10.1042/bst0300093; Kamochi J, 2003, ONCOL REP, V10, P881; Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.3.CO;2-L; LI C, 2003, DNA CHIP ANAL CHIP A; Liu WM, 1999, CANCER RES, V59, P5695; LIU YH, 1991, J BIOL CHEM, V266, P21880; Loeb DM, 2002, J BIOL CHEM, V277, P19627, DOI 10.1074/jbc.M201336200; Massaad-Massade L, 2004, FEBS LETT, V559, P89, DOI 10.1016/S0014-5793(04)00032-8; Maxwell GL, 2005, CLIN CANCER RES, V11, P4056, DOI 10.1158/1078-0432.CCR-04-2001; MCCANN S, 1995, J BIOL CHEM, V270, P23785, DOI 10.1074/jbc.270.40.23785; Milde-Langosch K, 2001, J CANCER RES CLIN, V127, P537, DOI 10.1007/s004320100256; Miyashita R, 2004, INT IMMUNOL, V16, P163, DOI 10.1093/intimm/dxh013; Mizumoto H, 2002, INT J CANCER, V100, P401, DOI 10.1002/ijc.10504; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; MULLER PT, 1903, J CHIM PHYS PCB, V1, P190; Murphy G, 1997, MATRIX BIOL, V15, P511, DOI 10.1016/S0945-053X(97)90025-1; Mutter GL, 2001, GYNECOL ONCOL, V83, P177, DOI 10.1006/gyno.2001.6352; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Reeves R, 2001, MOL CELL BIOL, V21, P575, DOI 10.1128/MCB.21.2.575-594.2001; Risinger JI, 2005, CANCER RES, V65, P5031, DOI 10.1158/0008-5472.CAN-04-0850; Risinger JI, 2003, CANCER RES, V63, P6; RUTANEN EM, 1994, INT J CANCER, V59, P307, DOI 10.1002/ijc.2910590303; Saidi SA, 2004, ONCOGENE, V23, P6677, DOI 10.1038/sj.onc.1207562; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Sivak JM, 2004, MOL CELL BIOL, V24, P245, DOI 10.1128/MCB.24.1.245-257.2004; Smid-Koopman E, 2004, GYNECOL ONCOL, V93, P292, DOI 10.1016/j.ygyno.2004.01.022; Stetler-Stevenson WG, 2005, TRENDS MOL MED, V11, P97, DOI 10.1016/j.molmed.2005.01.007; Streit M, 1999, P NATL ACAD SCI USA, V96, P14888, DOI 10.1073/pnas.96.26.14888; Suzumori N, 2004, FERTIL STERIL, V81, P305, DOI 10.1016/j.fertnstert.2003.08.011; Takeba Y, 2001, J RHEUMATOL, V28, P2176; Tanaka T, 1998, J BIOL CHEM, V273, P26772, DOI 10.1074/jbc.273.41.26772; Tashiro H, 1997, AM J PATHOL, V150, P177; Tong W, 1999, MOL CELL BIOL, V19, P2251; WALMER DK, 1995, CANCER RES, V55, P1168; Warren CD, 2002, MOL BIOL CELL, V13, P3029, DOI 10.1091/mbc.E02-04-0203; Yan L, 2001, J BIOL CHEM, V276, P37258, DOI 10.1074/jbc.M106089200; Yang JJ, 2002, BIOCHEM BIOPH RES CO, V297, P105, DOI 10.1016/S0006-291X(02)02123-X; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yoshida S, 2002, J CLIN ENDOCR METAB, V87, P2376, DOI 10.1210/jc.87.5.2376; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903	67	90	99	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1971	1982		10.1038/sj.onc.1209986	http://dx.doi.org/10.1038/sj.onc.1209986			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043662				2022-12-28	WOS:000245117700015
J	Wang, H; Yan, C; Asangani, I; Allgayer, H; Boyd, DD				Wang, H.; Yan, C.; Asangani, I.; Allgayer, H.; Boyd, D. D.			Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression	ONCOGENE			English	Article						urokinase receptor; enhancer; gene expression	PLASMINOGEN-ACTIVATOR RECEPTOR; TRANSCRIPTION FACTOR-BINDING; IV COLLAGENASE EXPRESSION; INVASIVE COLON-CANCER; GENE-EXPRESSION; IN-VIVO; COLORECTAL-CANCER; CELL-MIGRATION; PROTEIN-KINASE; POSTTRANSCRIPTIONAL REGULATION	The transcriptionally regulated urokinase-type plasminogen activator receptor (u-PAR) contributes to cancer progression. Although previous studies have identified multiple 50 regulatory elements, these cis motifs cannot fully account for u-PAR expression prompting a search for hitherto uncharacterized regulatory elements. DNase I hypersensitivity and chromatin immunoprecipitation assays using u-PAR-expressing colon cancer cells indicated a hypersensitive region (+665/+2068) in intron 1 enriched with acetylated histone 3 (H3) and H3 methylated at lysine 4, markers of regulatory regions. The +665/+2068 region increased transcription from a u-PAR-promoter in an orientation- and distance-independent manner fulfilling the criteria of an enhancer. Optimal stimulation of the u-PAR promoter by phorbol ester required this enhancer. Systematic truncations combined with DNase I footprinting revealed two protected regions (+1060/+1099 and +1123/+1134) with deletion of the latter practically abolishing enhancer activity. The +1123/+1134 region harbored non-consensus activator protein-1 and Ets1 binding sites bound with c-Jun (and/or the related JunD/JunB) and c-Fos (and/or the related FosB/Fra-1/Fra-2) as revealed with chromatin immunoprecipitation. Further, nuclear extract from resected colon cancers showed elevated protein binding to a +1123/_1134- spanning probe coordinate with elevated u-PAR protein. Thus, we have defined a novel intragenic enhancer in the u-PAR gene required for constitutive and inducible expression.	MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; Univ Heidelberg, Dept Expt Mol Surg, D-6900 Heidelberg, Germany	University of Texas System; UTMD Anderson Cancer Center; Ruprecht Karls University Heidelberg	Boyd, DD (corresponding author), MD Anderson Canc Ctr, Dept Canc Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org		asangani, irfan/0000-0001-5381-1702; Yan, Chunhong/0000-0002-3974-7991	NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [DE10845] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Ahnen DJ, 1998, CANCER RES, V58, P1149; Allgayer H, 1999, J BIOL CHEM, V274, P4702, DOI 10.1074/jbc.274.8.4702; Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Bass R, 2005, J BIOL CHEM, V280, P14811, DOI 10.1074/jbc.M414189200; BOS JL, 1989, CANCER RES, V49, P4682; CASEY JR, 1994, BLOOD, V84, P1151; DeLong CJ, 2005, BIOCHEM BIOPH RES CO, V338, P53, DOI 10.1016/j.bbrc.2005.07.184; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Ibanez-Tallon I, 1999, ONCOGENE, V18, P2836, DOI 10.1038/sj.onc.1202644; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; JONES LG, 1994, J BIOL CHEM, V269, P23790; Kleinjan DA, 2005, AM J HUM GENET, V76, P8, DOI 10.1086/426833; Lakka SS, 2003, CANCER RES, V63, P2454; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101; Licato LL, 1997, GASTROENTEROLOGY, V113, P1589, DOI 10.1053/gast.1997.v113.pm9352861; Lin CY, 2004, GENE, V334, P63, DOI 10.1016/j.gene.2004.03.016; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; LUND LR, 1995, BIOCHEM J, V310, P345, DOI 10.1042/bj3100345; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Mahoney TS, 2001, P NATL ACAD SCI USA, V98, P10284, DOI 10.1073/pnas.181201398; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Nair RR, 2005, ONCOL RES, V15, P265, DOI 10.3727/096504005776404571; Nestl A, 2001, CANCER RES, V61, P1569; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Palii SS, 2004, J BIOL CHEM, V279, P3463, DOI 10.1074/jbc.M310483200; PYKE C, 1991, AM J PATHOL, V138, P1059; Rabbani SA, 2002, CANCER RES, V62, P2390; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; REITER LS, 1993, INT J CANCER, V53, P444, DOI 10.1002/ijc.2910530316; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Schaner ME, 2003, MOL BIOL CELL, V14, P4376, DOI 10.1091/mbc.e03-05-0279; Schewe DM, 2003, CLIN CANCER RES, V9, P2267; Shanahan F, 1999, MOL CELL BIOL, V19, P1460; Shetty S, 2005, MOL CELL BIOCHEM, V272, P107, DOI 10.1007/s11010-005-7644-2; Shetty S, 1997, MOL CELL BIOL, V17, P1075, DOI 10.1128/MCB.17.3.1075; Shields JM, 1998, NUCLEIC ACIDS RES, V26, P796, DOI 10.1093/nar/26.3.796; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Shitoh K, 2001, GENE CHROMOSOME CANC, V30, P32, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1065>3.0.CO;2-I; SORAVIA E, 1995, BLOOD, V86, P624, DOI 10.1182/blood.V86.2.624.bloodjournal862624; SOZERI O, 1992, ONCOGENE, V7, P2259; Stephens RW, 1999, JNCI-J NATL CANCER I, V91, P869, DOI 10.1093/jnci/91.10.869; Suzuki S, 1998, GUT, V43, P798, DOI 10.1136/gut.43.6.798; Trisciuoglio D, 2004, J BIOL CHEM, V279, P6737, DOI 10.1074/jbc.M308938200; Wang AY, 2000, EUR J BIOCHEM, V267, P3248, DOI 10.1046/j.1432-1327.2000.01350.x; Wang H, 2004, J BIOL CHEM, V279, P22674, DOI 10.1074/jbc.M401257200; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	66	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2058	2070		10.1038/sj.onc.1210003	http://dx.doi.org/10.1038/sj.onc.1210003			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001307				2022-12-28	WOS:000245313400008
J	Alli, E; Yang, JM; Hait, WN				Alli, E.; Yang, J-M; Hait, W. N.			Silencing of stathmin induces tumor-suppressor function in breast cancer cell lines harboring mutant p53	ONCOGENE			English	Article						stathmin; cell-cycle arrest; mitosis; apoptosis; breast cancer	DOWN-REGULATION; CYCLE ARREST; EXPRESSION; OVEREXPRESSION; CHECKPOINT; MUTATIONS; GENES; ONCOPROTEIN-18; APOPTOSIS; NETWORK	Cancers harboring dominant-negative p53 mutations are often aggressive and difficult to treat. Direct attempts to restore wild-type p53 function have produced little clinical benefit. We investigated whether targeting a p53-target gene could induce certain tumor-suppressor characteristics. We found that inhibition of stathmin, a microtubule regulator that can be transcriptionally repressed by wildtype p53, restored certain wild-type functions to cancer cells with mutant p53. Silencing of stathmin by small interfering RNA ( siRNA) in mutant p53 cell lines lowered expression to that observed following activation of wildtype p53 by DNA damage in wild-type p53 cell lines. siRNA-induced repression of stathmin decreased cell proliferation, viability and clonogenicity in mutant p53 cell lines. Furthermore, knockdown of stathmin partially restored cell-cycle regulation and activation of apoptosis. Therefore, targeting stathmin, a gene product that is overexpressed in the presence of mutant p53, may represent a novel approach to treating cancers with aberrant p53 function.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Hait, WN (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Pharmacol, 195 Little Albany St, New Brunswick, NJ 08901 USA.	jyang@umdnj.edu; haitwn@umdnj.edu			NCI NIH HHS [CA 78695, CA 72720] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078695, P30CA072720] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alaiya AA, 1997, INT J CANCER, V73, P678, DOI 10.1002/(SICI)1097-0215(19971127)73:5<678::AID-IJC11>3.0.CO;2-2; Alli E, 2002, CANCER RES, V62, P6864; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Bieche I, 2003, MOL BRAIN RES, V114, P55, DOI 10.1016/S0169-328X(03)00132-3; Bossi G, 2004, ONCOGENE, V23, P418, DOI 10.1038/sj.onc.1207042; Brattsand G, 2000, BRIT J CANCER, V83, P311, DOI 10.1054/bjoc.2000.1264; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chang CL, 2001, PROTEOMICS, V1, P1415, DOI 10.1002/1615-9861(200111)1:11<1415::AID-PROT1415>3.3.CO;2-6; Curmi PA, 2000, BRIT J CANCER, V82, P142, DOI 10.1054/bjoc.1999.0891; FAILLE A, 1994, BRIT J CANCER, V69, P1145, DOI 10.1038/bjc.1994.225; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; FRIEDRICH B, 1995, PROSTATE, V27, P102, DOI 10.1002/pros.2990270207; FUJIWARA T, 1994, J NATL CANCER I, V86, P1458, DOI 10.1093/jnci/86.19.1458; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Meek DW, 2000, PATHOL BIOL, V48, P246; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Oesterreich S, 1999, ENDOCR-RELAT CANCER, V6, P405, DOI 10.1677/erc.0.0060405; Pietenpol JA, 2002, TOXICOLOGY, V181, P475, DOI 10.1016/S0300-483X(02)00460-2; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Price DK, 2000, CANCER INVEST, V18, P722, DOI 10.3109/07357900009012204; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SOBEL A, 1983, J BIOL CHEM, V258, P312; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; Thompson DA, 1997, ONCOGENE, V15, P3025, DOI 10.1038/sj.onc.1201495; Vecil GG, 2003, J NEURO-ONCOL, V65, P237, DOI 10.1023/B:NEON.0000003653.45635.32; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Zhou Jun, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P65, DOI 10.2174/1568011053352569	43	91	103	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1003	1012		10.1038/sj.onc.1209864	http://dx.doi.org/10.1038/sj.onc.1209864			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909102				2022-12-28	WOS:000244245400006
J	Ameri, K; Hammond, EM; Culmsee, C; Raida, M; Katschinski, DM; Wenger, RH; Wagner, E; Davis, RJ; Hai, T; Denko, N; Harris, AL				Ameri, K.; Hammond, E. M.; Culmsee, C.; Raida, M.; Katschinski, D. M.; Wenger, R. H.; Wagner, E.; Davis, R. J.; Hai, T.; Denko, N.; Harris, A. L.			Induction of activating transcription factor 3 by anoxia is independent of p53 and the hypoxic HIF signalling pathway	ONCOGENE			English	Article						ATF3; hypoxia; anoxia; HIF; p53; MKK7/JNK	VASCULAR ENDOTHELIAL-CELLS; JUN NH2-TERMINAL KINASE; GENE-EXPRESSION; ATF3 GENE; C-JUN; INDUCIBLE FACTOR-1; STRESS RESPONSES; OVER-EXPRESSION; MESSENGER-RNA; BINDING	Solid tumors often have an inadequate blood supply, which results in large regions that are subjected to hypoxic or anoxic stress. Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that regulates much of the transcriptional response of cells to hypoxia. Activating transcription factor 3 (ATF3) is another transcription factor that responds to a variety of stresses and is often upregulated in cancer. We investigated the regulation of ATF3 by oxygen deprivation. ATF3 induction occurred most robustly under anoxia, is common, and it is not dependent on presence of HIF-1 or p53, but is sensitive to the inhibition of c-Jun NH2-terminal kinase activation and the antioxidant N-acetylcystein. ATF3 could also be induced by desferrioxamine but not by the mitochondrial poison cyanide or the nonspecific 2-oxoglutarate dioxygenase inhibitor dimethyloxalylglycine. We also show that anoxic ATF3 mRNA is more stable than normoxic mRNA providing a mechanism for this induction. Thus, this study demonstrates that the regulation of ATF3 under anoxia is independent of 2-oxoglutarate dioxygenase, HIF-1 and p53, presumably involving multiple regulatory pathways.	Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, Stanford, CA 94305 USA; Ctr Drug Res, Dept Pharm, Munich, Germany; Univ Leipzig, Dept Hematol Oncol, D-7010 Leipzig, Germany; Univ Gottingen, Ctr Physiol & Pathophysiol, Dept Heart & Circulatory Physiol, D-3400 Gottingen, Germany; Univ Zurich, Inst Physiol, Zurich, Switzerland; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Ctr Mol Neurobiol, Columbus, OH 43210 USA; Univ Oxford, John Radcliffe Hosp, Canc Res UK, Weatherall Inst Mol Med, Oxford OX3 9DU, England	Stanford University; University of Munich; Leipzig University; University of Gottingen; University of Zurich; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University System of Ohio; Ohio State University; Cancer Research UK; University of Oxford	Ameri, K (corresponding author), Stanford Univ, Dept Radiat Oncol, Div Radiat & Canc Biol, Sch Med, CCSR-S,269 Campus Dr, Stanford, CA 94305 USA.	kameri@stanford.edu	Wagner, Ernst/A-7435-2012; Wagner, Ernst/ABB-5976-2020; Culmsee, Carsten/ABC-3120-2021; Hai, Tsonwin/H-4480-2011; Harris, Adrian L/ABA-3343-2020; Hai, Tsonwin/E-3185-2011; Wenger, Roland H./B-7953-2009; denko, nicholas/F-8444-2010	Wagner, Ernst/0000-0001-8413-0934; Wagner, Ernst/0000-0001-8413-0934; Culmsee, Carsten/0000-0002-5121-5015; Hai, Tsonwin/0000-0003-4510-0315; Harris, Adrian L/0000-0003-1376-8409; Hai, Tsonwin/0000-0003-4510-0315; Wenger, Roland H./0000-0001-7592-4839; Davis, Roger/0000-0002-0130-1652; Hammond, Ester/0000-0002-2335-3146	NIDDK NIH HHS [DK59605] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059605] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfranca A, 2002, MOL CELL BIOL, V22, P12, DOI 10.1128/MCB.22.1.12-22.2002; Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bottone FG, 2005, J PHARMACOL EXP THER, V315, P668, DOI 10.1124/jpet.105.089607; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Chilov D, 1999, J CELL SCI, V112, P1203; Culmsee C, 2003, J NEUROSCI, V23, P8586; Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200; Fan FY, 2002, ONCOGENE, V21, P7488, DOI 10.1038/sj.onc.1205896; Francis JS, 2004, MOL BRAIN RES, V124, P199, DOI 10.1016/j.molbrainres.2003.10.027; Goldberg-Cohen I, 2002, J BIOL CHEM, V277, P13635, DOI 10.1074/jbc.M108703200; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hammond EM, 2006, MOL CELL BIOL, V26, P3492, DOI 10.1128/MCB.26.9.3492-3504.2006; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hartman MG, 2004, MOL CELL BIOL, V24, P5721, DOI 10.1128/MCB.24.13.5721-5732.2004; Inoue K, 2004, GENES CELLS, V9, P59, DOI 10.1111/j.1356-9597.2004.00707.x; Ishiguro T, 2000, ONCOL RES, V12, P181; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kaelin WG, 2005, CELL METAB, V1, P357, DOI 10.1016/j.cmet.2005.05.006; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Le QT, 2004, CANCER METAST REV, V23, P293, DOI 10.1023/B:CANC.0000031768.89246.d7; Liang GS, 1996, J BIOL CHEM, V271, P1695, DOI 10.1074/jbc.271.3.1695; Lu D, 2006, J BIOL CHEM, V281, P10473, DOI 10.1074/jbc.M509278200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Okamoto A, 2006, MOL CELL BIOL, V26, P1087, DOI 10.1128/MCB.26.3.1087-1097.2006; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Papandreou I, 2005, CANCER RES, V65, P3171, DOI 10.1158/0008-5472.CAN-04-3395; Ryan HE, 2000, CANCER RES, V60, P4010; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958, DOI 10.1164/ajrccm.158.3.9712130; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; Vecsey-Semjen B, 2002, ONCOGENE, V21, P4646, DOI 10.1038/sj.onc.1205577; Vengellur A, 2005, PHYSIOL GENOMICS, V22, P308, DOI 10.1152/physiolgenomics.00045.2004; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	41	61	63	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					284	289		10.1038/sj.onc.1209781	http://dx.doi.org/10.1038/sj.onc.1209781			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847457	Green Accepted			2022-12-28	WOS:000243398300012
J	Cowell, LN; D Graham, J; Bouton, AH; Clarke, CL; O'Neill, GM				Cowell, L. N.; D Graham, J.; Bouton, A. H.; Clarke, C. L.; O'Neill, G. M.			Tamoxifen treatment promotes phosphorylation of the adhesion molecules, p130Cas/BCAR1, FAK and Src, via an adhesion-dependent pathway	ONCOGENE			English	Article						p130Cas/BCAR1; Src kinase; estrogen receptor; adhesion; tamoxifen; FAK	BREAST-CANCER CELLS; CRK-ASSOCIATED SUBSTRATE; DOMAIN TYROSINE PHOSPHORYLATION; HUMAN ESTROGEN-RECEPTOR; DOCKING PROTEIN HEF1; C-SRC; ANTIESTROGEN RESISTANCE; TRANSFORMED-CELLS; FAMILY KINASES; IN-VIVO	Reports that the adhesion-associated molecule p130Cas/BCAR1 promotes resistance to tamoxifen suggested that adhesion-mediated signalling may be altered by tamoxifen treatment. We find that p130Cas/BCAR1 phosphorylation is enhanced in tamoxifen-treated estrogen receptor (ER)positive MCF-7 breast cancer cells. The effects of estrogen and tamoxifen were assessed independently and in combination, and the results demonstrate that tamoxifen antagonizes estrogen regulation of p130Cas/BCAR1 phosphorylation. Phosphorylation correlates with tamoxifen ER antagonist effects, as phosphorylation effects are replicated by the pure antiestrogen ICI 182, 780. Correspondingly, phosphorylation is not changed in ER-negative cells exposed to tamoxifen. We show that deletion of the p130Cas/BCAR1 substrate domain substantially reduces tamoxifen-induced phosphorylation of p130Cas/BCAR1 and confers enhanced sensitivity to tamoxifen. P130Cas/BCAR1 forms a phosphorylation-dependent signalling complex with focal adhesion kinase (FAK) and Src kinase that promotes adhesion-mediated cell survival. Therefore, we examined the kinetics of p130Cas/BCAR1, Src and FAK phosphorylation over a 14-day time course and find sustained phosphorylation of these molecules after 7 days exposure to tamoxifen. Inhibition of Src kinase is shown to reduce tamoxifen-promoted p130Cas/BCAR1 phosphorylation and reduce cell viability. Stimulation of the Src/FAK/p130Cas/BCAR1 adhesion signalling pathway in tamoxifen-treated MCF-7 cells does not cause increased migration; however, there is Src-dependent phosphorylation of the cell survival molecule Akt. Correspondingly, Akt inhibition reduces cell viability in cells treated with tamoxifen. We propose that prolonged activation of adhesion-dependent signalling may confer a survival advantage in response to additional cellular insults or alternatively, may poise cells to develop a migratory phenotype in response to additional cellular cues.	Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia; Univ Sydney, Discipline Paediat & Child Hlth, Westmead, NSW 2145, Australia; Univ Sydney, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA USA; Univ Virginia Hlth Syst, Ctr Canc, Charlottesville, VA USA	University of Sydney; University of Sydney; University of Sydney; Westmead Institute for Medical Research; University of Virginia; University of Virginia	O'Neill, GM (corresponding author), Univ Sydney, Focal Adhes Biol Grp, Oncol Res Unit, Childrens Hosp, Westmead, NSW 2145, Australia.	geraldio@chw.edu.au	O'Neill, Geraldine/F-3112-2014	O'Neill, Geraldine/0000-0001-9997-8794; Clarke, Christine/0000-0001-7568-111X	NCI NIH HHS [CA096846] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096846] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Arnold SF, 1997, MOL ENDOCRINOL, V11, P48, DOI 10.1210/me.11.1.48; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; Bartholomew PJ, 1998, J STEROID BIOCHEM, V67, P241, DOI 10.1016/S0960-0760(98)00098-3; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Brabek J, 2005, MOL CANCER RES, V3, P307, DOI 10.1158/1541-7786.MCR-05-0015; Brabek J, 2004, ONCOGENE, V23, P7406, DOI 10.1038/sj.onc.1207965; Brinkman A, 2000, JNCI-J NATL CANCER I, V92, P112, DOI 10.1093/jnci/92.2.112; Cabodi S, 2004, J CELL SCI, V117, P1603, DOI 10.1242/jcs.01025; Cai DP, 1999, J IMMUNOL, V163, P2104; Cai DP, 2003, CANCER RES, V63, P6802; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; Chodniewicz D, 2004, BBA-MOL CELL RES, V1692, P63, DOI 10.1016/j.bbamcr.2004.03.006; Clemons M, 2002, CANCER TREAT REV, V28, P165, DOI 10.1016/S0305-7372(02)00036-1; DORSSERS LCJ, 1993, MOL ENDOCRINOL, V7, P870, DOI 10.1210/me.7.7.870; Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004; Fonseca PM, 2004, CELL SIGNAL, V16, P621, DOI 10.1016/j.cellsig.2003.10.004; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; GIERTHY JF, 1991, J CELL BIOCHEM, V45, P177, DOI 10.1002/jcb.240450209; Goldberg GS, 2003, J BIOL CHEM, V278, P46533, DOI 10.1074/jbc.M307526200; Hamasaki K, 1996, BIOCHEM BIOPH RES CO, V222, P338, DOI 10.1006/bbrc.1996.0745; Hiscox S, 2004, CLIN EXP METASTAS, V21, P201, DOI 10.1023/B:CLIN.0000037697.76011.1d; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; Howell A, 2000, CANCER-AM CANCER SOC, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Huang JH, 2002, J BIOL CHEM, V277, P27265, DOI 10.1074/jbc.M203063200; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kim H, 2005, ONCOGENE, V24, P5629, DOI 10.1038/sj.onc.1208718; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Korb T, 2004, EXP CELL RES, V299, P236, DOI 10.1016/j.yexcr.2004.06.001; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Migliaccio A, 2002, ANN NY ACAD SCI, V963, P185; Migliaccio A, 2000, EMBO J, V19, P5406, DOI 10.1093/emboj/19.20.5406; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Osborne CK, 2005, J CLIN ONCOL, V23, P1616, DOI 10.1200/JCO.2005.10.036; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Pratt SJ, 2005, J CELL BIOL, V168, P813, DOI 10.1083/jcb.200406083; Riggins RB, 2003, J BIOL CHEM, V278, P28264, DOI 10.1074/jbc.M303535200; Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776; Ruest PJ, 2001, MOL CELL BIOL, V21, P7641, DOI 10.1128/MCB.21.22.7641-7652.2001; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Shin NY, 2004, J BIOL CHEM, V279, P38331, DOI 10.1074/jbc.M404675200; Sisci D, 2004, ONCOGENE, V23, P8920, DOI 10.1038/sj.onc.1208098; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; van Agthoven T, 1998, EMBO J, V17, P2799, DOI 10.1093/emboj/17.10.2799; van der Flier S, 2000, JNCI-J NATL CANCER I, V92, P120, DOI 10.1093/jnci/92.2.120; Vuori K, 1996, MOL CELL BIOL, V16, P2606	56	42	45	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7597	7607		10.1038/sj.onc.1209747	http://dx.doi.org/10.1038/sj.onc.1209747			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799644				2022-12-28	WOS:000242655500005
J	Kimelman, D; Xu, W				Kimelman, D.; Xu, W.			beta-Catenin destruction complex: insights and questions from a structural perspective	ONCOGENE			English	Review						beta-catenin; destruction complex; Wnt signaling; colon cancer; stem cells	WNT SIGNALING PATHWAY; PROTEIN PHOSPHATASE 2A; SYNTHASE KINASE 3-BETA; POLYPOSIS-COLI PROTEIN; CRYSTAL-STRUCTURE; CANONICAL WNT; SUBCELLULAR-LOCALIZATION; PLASMA-MEMBRANE; BINDING DOMAIN; NAKED CUTICLE	At the heart of the canonical Wnt signaling pathway is the beta-catenin destruction complex, which functions in the absence of Wnt signaling to keep the cytosolic and nuclear levels of beta-catenin very low by promoting the phosphorylation and ubiquitination of beta-catenin. Structural studies, combined with other experimental approaches, have begun to provide important insights into the mechanism of the destruction complex. We suggest a working model for the destruction complex based on the existing structural and experimental data, and focus on the questions that this model and other studies have raised about the function of the complex in both the normal and Wnt-inhibited states.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	kimelman@u.washington.edu	高, 雨莉/HGU-8187-2022	Xu, Wenqing/0000-0002-2884-3101	NCI NIH HHS [CA90351] Funding Source: Medline; NICHD NIH HHS [HD27262] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA090351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Bajpai R, 2004, DEVELOPMENT, V131, P1007, DOI 10.1242/dev.00980; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Cong F, 2004, MOL CELL BIOL, V24, P2000, DOI 10.1128/MCB.24.5.2000-2011.2004; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; Creyghton MP, 2006, P NATL ACAD SCI USA, V103, P5397, DOI 10.1073/pnas.0507237103; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Dajani R, 2003, EMBO J, V22, P494, DOI 10.1093/emboj/cdg068; Dale T, 2006, NAT STRUCT MOL BIOL, V13, P9, DOI 10.1038/nsmb0106-9; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Ferkey DM, 2002, J BIOL CHEM, V277, P16147, DOI 10.1074/jbc.M112363200; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 2000, MOL CELL BIOL, V20, P2228, DOI 10.1128/MCB.20.6.2228-2238.2000; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; Kikuchi A, 2006, EXP MOL MED, V38, P1, DOI 10.1038/emm.2006.1; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu J, 2006, J MOL BIOL, V360, P133, DOI 10.1016/j.jmb.2006.04.064; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Matsubayashi H, 2004, MOL CELL BIOL, V24, P2012, DOI 10.1128/MCB.24.5.2012-2024.2004; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Nusse R, 2005, NATURE, V438, P747, DOI 10.1038/438747a; Park TJ, 2005, CURR BIOL, V15, P1039, DOI 10.1016/j.cub.2005.04.062; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rothbacher U, 2000, EMBO J, V19, P1010, DOI 10.1093/emboj/19.5.1010; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Schweizer L, 2003, BMC CELL BIOL, V4, DOI 10.1186/1471-2121-4-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Sobrado P, 2005, J CELL BIOCHEM, V94, P217, DOI 10.1002/jcb.20350; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097-2765(03)00484-2; Tickenbrock L, 2003, J MOL BIOL, V327, P359, DOI 10.1016/S0022-2836(03)00144-X; van Amerongen R, 2005, CELL CYCLE, V4, pE89; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; Wallingford JB, 2005, DEVELOPMENT, V132, P4421, DOI 10.1242/dev.02068; Wharton KA, 2003, DEV BIOL, V253, P1, DOI 10.1006/dbio.2002.0869; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Xing Y, 2004, MOL CELL, V15, P523, DOI 10.1016/j.molcel.2004.08.001; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603; Yanagawa S, 2002, EMBO J, V21, P1733, DOI 10.1093/emboj/21.7.1733; Yang J, 2003, DEVELOPMENT, V130, P5569, DOI 10.1242/dev.00762; Yang J, 2006, J BIOL CHEM, V281, P17751, DOI 10.1074/jbc.M600831200; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419	72	475	508	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7482	7491		10.1038/sj.onc.1210055	http://dx.doi.org/10.1038/sj.onc.1210055			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143292				2022-12-28	WOS:000242514900006
J	Mikels, AJ; Nusse, R				Mikels, A. J.; Nusse, R.			Wnts as ligands: processing, secretion and reception	ONCOGENE			English	Review						Wnt; receptors; secretion; signaling	HEPARAN-SULFATE PROTEOGLYCANS; SEGMENT POLARITY GENES; CYSTEINE-RICH DOMAIN; LONG-RANGE ACTION; SIGNALING PATHWAY; REQUIRES RETROMER; FRIZZLED FAMILY; PORCUPINE GENE; LIPID RAFTS; WINGLESS	Cell to cell communication is vital throughout the development of multicellular organisms and during adult homeostasis. One way in which communication is achieved is through the secretion of signaling molecules that are received by neighboring responding cells. Wnt ligands comprise a large family of secreted, hydrophobic, glycoproteins that control a variety of developmental and adult processes in all metazoan organisms. By binding to various receptors present on receiving cells, Wnts initiate intracellular signaling cascades resulting in changes in gene transcription. Misregulation of Wnt signaling contributes to cancer and other degenerative disorders; thus, much effort has been made to understand the ways in which the pathway is controlled. Although ample research into the regulatory mechanisms that influence intracellular signaling events has proved fruitful, a great deal still remains to be elucidated regarding the mechanisms that control Wnt protein processing and secretion from cells, transport through the extracellular space, and protein reception on neighboring cells. This review attempts to consolidate the current data regarding these essential processes.	Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	Nusse, R (corresponding author), Stanford Univ, Sch Med, Beckman Ctr, Howard Hughes Med Inst,Dept Dev Biol, Stanford, CA 94305 USA.	rnusse@stanford.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067834] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baeg GH, 2001, DEVELOPMENT, V128, P87; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Binari RC, 1997, DEVELOPMENT, V124, P2623; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BURRUS LW, 1995, EXP CELL RES, V220, P363, DOI 10.1006/excr.1995.1327; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Carron C, 2003, J CELL SCI, V116, P2541, DOI 10.1242/jcs.00451; Chen CM, 2004, P NATL ACAD SCI USA, V101, P15961, DOI 10.1073/pnas.0407103101; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Ching W, 2006, CELL, V125, P432, DOI 10.1016/j.cell.2006.04.018; Clevers H, 2006, CANCER RES, V66, P2, DOI 10.1158/0008-5472.CAN-05-3849; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Coudreuse DYM, 2006, SCIENCE, V312, P921, DOI 10.1126/science.1124856; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; de Iongh RU, 2006, FRONT BIOSCI-LANDMRK, V11, P2442, DOI 10.2741/1982; Djiane A, 2000, DEVELOPMENT, V127, P3091; DU SJ, 1995, MOL CELL BIOL, V15, P2625; Forrester WC, 2004, GENETICS, V168, P1951, DOI 10.1534/genetics.104.031781; Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018-002-8407-9; Fox S, 2006, FRONT BIOSCI-LANDMRK, V11, P2106, DOI 10.2741/1953; Greco V, 2001, CELL, V106, P633, DOI 10.1016/S0092-8674(01)00484-6; Hacker U, 1997, DEVELOPMENT, V124, P3565; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hofmann K, 2000, TRENDS BIOCHEM SCI, V25, P111, DOI 10.1016/S0968-0004(99)01539-X; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Kadowaki T, 1996, GENE DEV, V10, P3116, DOI 10.1101/gad.10.24.3116; Katanaev VL, 2005, CELL, V120, P111, DOI 10.1016/j.cell.2004.11.014; KITAMI Y, 1992, BLOOD PRESSURE S3, V1, P12; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Kroiher M, 2001, BIOESSAYS, V23, P69, DOI 10.1002/1521-1878(200101)23:1<69::AID-BIES1009>3.3.CO;2-B; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Li Yonghe, 2005, Future Oncol, V1, P673, DOI 10.2217/14796694.1.5.673; Liepinsh E, 2006, J MOL BIOL, V357, P942, DOI 10.1016/j.jmb.2006.01.047; Lin XH, 2002, GLYCOCONJUGATE J, V19, P363, DOI 10.1023/A:1025329323438; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu WG, 2004, CELL, V119, P97, DOI 10.1016/j.cell.2004.09.019; Manoukian AS, 1995, DEVELOPMENT, V121, P4037; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; Matsuda T, 2001, MECH DEVELOP, V105, P153, DOI 10.1016/S0925-4773(01)00383-5; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NOORDERMEER J, 1995, MECH DEVELOP, V51, P145, DOI 10.1016/0925-4773(95)00348-7; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Nusse R, 2003, DEVELOPMENT, V130, P5297, DOI 10.1242/dev.00821; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Panakova D, 2005, NATURE, V435, P58, DOI 10.1038/nature03504; Polakis P, 2000, GENE DEV, V14, P1837; Povelones M, 2005, EMBO J, V24, P3493, DOI 10.1038/sj.emboj.7600817; Prasad BC, 2006, DEVELOPMENT, V133, P1757, DOI 10.1242/dev.02357; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Schulte G, 2005, J NEUROCHEM, V92, P1550, DOI 10.1111/j.1471-4159.2004.03022.x; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Spellman PT, 2002, GENOME BIOL, V3; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tanaka K, 2002, J BIOL CHEM, V277, P12816, DOI 10.1074/jbc.M200187200; Tanaka K, 2000, EUR J BIOCHEM, V267, P4300, DOI 10.1046/j.1432-1033.2000.01478.x; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; Verges M, 2004, NAT CELL BIOL, V6, P763, DOI 10.1038/ncb1153; Wang HY, 2004, CELL MOL LIFE SCI, V61, P69, DOI 10.1007/s00018-003-3165-x; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211; Yoda A, 2003, J RECEPT SIG TRANSD, V23, P1, DOI 10.1081/RRS-120018757; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185; Zhai L, 2004, J BIOL CHEM, V279, P33220, DOI 10.1074/jbc.M403407200	81	241	263	0	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7461	7468		10.1038/sj.onc.1210053	http://dx.doi.org/10.1038/sj.onc.1210053			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143290				2022-12-28	WOS:000242514900004
J	Candeias, MM; Powell, DJ; Roubalova, E; Apcher, S; Bourougaa, K; Vojtesek, B; Bruzzoni-Giovanelli, H; Fahraeus, R				Candeias, M. M.; Powell, D. J.; Roubalova, E.; Apcher, S.; Bourougaa, K.; Vojtesek, B.; Bruzzoni-Giovanelli, H.; Fahraeus, R.			Expression of p53 and p53/47 are controlled by alternative mechanisms of messenger RNA translation initiation	ONCOGENE			English	Article						p53; p53/47; stress response; alternative translation initiation	RIBOSOME-ENTRY-SITE; TUMOR-SUPPRESSOR; MEDIATED TRANSLATION; PROTEIN; MDM2; INDUCTION; APOPTOSIS; ISOFORM; DOMAIN; STABILITY	P53 controls the growth and survival of cells by acting in response to a multitude of cellular stresses. It is, however, not yet fully understood how different p53 activation pathways result in either cell cycle arrest or apoptosis. We and others have described an N-terminally truncated p53 protein (p53/47) originating from a second translation initiation site in the p53 messenger RNA ( mRNA), which can interact with p53 and impose altered stability and transactivation properties to p53 complexes. Here we show that cap-dependent and cap-independent mechanisms of initiation govern the translation of the p53 mRNA. Changes in synthesis of full-length p53 or p53/47 are regulated through distinct cell stress-induced pathways acting through separate regions of the p53 mRNA. We also show that some cytotoxic drugs require the presence of full-length p53 to induce apoptosis, whereas for others p53/47 is sufficient. This indicates that by harbouring alternative translation initiation sites, the p53 mRNA gives rise to different levels of the p53 isoforms which help to orchestrate the cell biological outcome of p53 activation in response to different types of cell stress. This sheds new light into the way p53 can integrate and differentiate a large multiplicity of changes in the cellular environment.	Hop St Louis, INSERM, Inst Mol Genet, U716, F-75010 Paris, France; Masaryk Mem Canc Inst, Brno, Czech Republic	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Masaryk Memorial Cancer Institute	Fahraeus, R (corresponding author), Hop St Louis, INSERM, Inst Mol Genet, U716, 27 Rue Juliette Dodu, F-75010 Paris, France.	robinfahraeus@yahoo.co.uk	Powell, Darren Jmaes/GOE-5236-2022; Hajduskova, Eva/G-9780-2014; Apcher, Sebastien/B-6356-2015; fahraeus, robin/K-8726-2014; Apcher, Sebastien/P-2590-2018	Powell, Darren Jmaes/0000-0001-9439-5880; Bourougaa, Karima/0000-0003-0339-962X; , robin/0000-0003-0402-8492				Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Creancier L, 2001, MOL CELL BIOL, V21, P1833, DOI 10.1128/MCB.21.5.1833-1840.2001; de Rozieres S, 2000, ONCOGENE, V19, P1691, DOI 10.1038/sj.onc.1203468; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Fu LN, 1999, ONCOGENE, V18, P6419, DOI 10.1038/sj.onc.1203064; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; Hansen S, 1998, J MOL BIOL, V275, P575, DOI 10.1006/jmbi.1997.1507; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson RJ, 2000, COLD SPRING HARBOR M, V39, P127; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222; MOSNER J, 1995, EMBO J, V14, P4442, DOI 10.1002/j.1460-2075.1995.tb00123.x; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032; Schneider R, 2001, MOL CELL BIOL, V21, P8238, DOI 10.1128/MCB.21.23.8238-8246.2001; Spriggs KA, 2005, CELL DEATH DIFFER, V12, P585, DOI 10.1038/sj.cdd.4401642; Stoneley M, 2004, ONCOGENE, V23, P3200, DOI 10.1038/sj.onc.1207551; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Venot C, 1999, ONCOGENE, V18, P2405, DOI 10.1038/sj.onc.1202539; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; WAZER DE, 1994, MOL CELL BIOL, V14, P2468, DOI 10.1128/MCB.14.4.2468; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	41	79	81	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6936	6947		10.1038/sj.onc.1209996	http://dx.doi.org/10.1038/sj.onc.1209996			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16983332				2022-12-28	WOS:000241732300004
J	Oeggerli, M; Schraml, P; Ruiz, C; Bloch, M; Novotny, H; Mirlacher, M; Sauter, G; Simon, R				Oeggerli, M.; Schraml, P.; Ruiz, C.; Bloch, M.; Novotny, H.; Mirlacher, M.; Sauter, G.; Simon, R.			E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer	ONCOGENE			English	Article						E2F3; 6p22; bladder cancer; amplification target gene	TUMOR-CELL PROLIFERATION; MAMMALIAN-CELLS; AMPLIFICATION; OVEREXPRESSION; EXPRESSION; GROWTH	Amplification of 6p22 occurs in about 10-20% of bladder cancers and is associated with enhanced tumour cell proliferation. Candidate target genes for the 6p22 amplicon include E2F3 and the adjacent gene NM_017774. To clarify which gene is representing the main target, we compared the prevalence of the amplification and the functional role of both genes. Ampli.cation of E2F3 and NM_017774 was analysed by fluorescence in situ hybridization on a bladder cancer tissue microarray composed of 2317 cancer samples. Both genes showed amplification in 104 of 893 (11.6%) interpretable tumours and were exclusively found co-amplified. Additional gene expression analysis by real-time polymerase chain reaction in 12 tumour-derived cell lines revealed that amplification of 6p22 was always associated with co-overexpression of E2F3 and NM_017774. Furthermore, RNA interference was used to study the influence of reduced gene expression on cell growth. In tumour cells with and without the 6p22 amplicon, knockdown of E2F3 always lead to unequivocal reduction of proliferation, whereas knockdown of NM_017774 was only capable to slow down cell proliferation in non-amplified cells. Our findings point out that E2F3 but not NM_017774 is driving enhanced proliferation of 6p22 amplified tumour cells. We conclude that E2F3 must be responsible for the growth advantage of 6p22 amplified bladder cancer cells.	Univ Basel Hosp, Inst Pathol, Dept Mol Pathol, CH-4031 Basel, Switzerland; Univ Zurich, Dept Pathol, Zurich, Switzerland; Univ Hamburg, Med Ctr, Dept Pathol, Hamburg, Germany	University of Basel; University of Zurich; University of Hamburg	Oeggerli, M (corresponding author), Univ Basel Hosp, Inst Pathol, Dept Mol Pathol, Schonbeinstr 40, CH-4031 Basel, Switzerland.	martin.oeggerli@unibas.ch						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bruch J, 2000, CANCER RES, V60, P4526; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Lee JM, 2003, GENOME RES, V13, P875, DOI 10.1101/gr.737703; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindl T., 1989, ZELL GEWEBEKULTUR; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Tomovska S, 2001, INT J ONCOL, V18, P1239; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; WANG WW, 1995, GENOMICS, V26, P563, DOI 10.1016/0888-7543(95)80176-M	17	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6538	6543		10.1038/sj.onc.1209946	http://dx.doi.org/10.1038/sj.onc.1209946			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16953223	Bronze			2022-12-28	WOS:000241395100010
J	Kent, OA; Mendell, JT				Kent, O. A.; Mendell, J. T.			A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes	ONCOGENE			English	Review						microRNA; tumor suppressor; oncogene; tumorigenesis; cancer	VIRUS-INDUCED LYMPHOMAS; HUMAN LUNG CANCERS; AU-RICH ELEMENT; C-MYC; MESSENGER-RNA; CELL-PROLIFERATION; CHROMOSOME 13Q; HEPATOCELLULAR-CARCINOMA; DOWN-REGULATION; TARGET GENES	The known classes of genes that function as tumor suppressors and oncogenes have recently been expanded to include the microRNA (miRNA) family of regulatory molecules. miRNAs negatively regulate the stability and translation of target messenger RNAs (mRNA) and have been implicated in diverse processes such as cellular differentiation, cell-cycle control and apoptosis. Examination of tumor-specific miRNA expression profiles has revealed widespread dysregulation of these molecules in diverse cancers. Although studies addressing their role in cancer pathogenesis are at an early stage, it is apparent that loss- or gain-of-function of specific miRNAs contributes to cellular transformation and tumorigenesis. The available evidence clearly demonstrates that these molecules are intertwined with cellular pathways regulated by classical oncogenes and tumor suppressors such as MYC, RAS and p53. Incorporation of miRNA regulation into current models of molecular cancer pathogenesis will be essential to achieve a complete understanding of this group of diseases.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University	Mendell, JT (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, 733 N Broadway,BRB 471, Baltimore, MD 21205 USA.	jmendell@jhmi.edu		Kent, Oliver/0000-0001-6494-4383				Alexandrow MG, 1997, J CELL BIOCHEM, V66, P427, DOI 10.1002/(SICI)1097-4644(19970915)66:4<427::AID-JCB1>3.3.CO;2-Y; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Dong JT, 2001, PROSTATE, V49, P166, DOI 10.1002/pros.1131; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hatfield SD, 2005, NATURE, V435, P974, DOI 10.1038/nature03816; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Honda S, 2003, ENDOCR J, V50, P309, DOI 10.1507/endocrj.50.309; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; KIM VN, 2005, NAT REV MOLL CELL BI; Koo SH, 2003, CANCER GENET CYTOGEN, V146, P139, DOI 10.1016/S0165-4608(03)00133-X; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lai EC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-115; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li YY, 2003, COMMUN PUR APPL ANAL, V2, P1; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lin YW, 1999, EUR J CANCER, V35, P1730, DOI 10.1016/S0959-8049(99)00205-1; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martin MM, 2006, J BIOL CHEM, V281, P18277, DOI 10.1074/jbc.M601496200; Matsumura I, 2003, CELL CYCLE, V2, P333, DOI 10.4161/cc.2.4.428; Michael MZ, 2003, MOL CANCER RES, V1, P882; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Richter J, 1999, CANCER RES, V59, P5687; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Sulis ML, 2003, TRENDS CELL BIOL, V13, P478, DOI 10.1016/S0962-8924(03)00175-2; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Tam W, 2002, J VIROL, V76, P4275, DOI 10.1128/JVI.76.9.4275-4286.2002; Tam W, 1997, MOL CELL BIOL, V17, P1490, DOI 10.1128/MCB.17.3.1490; Ten Dijke PT, 2002, J CELL PHYSIOL, V191, P1, DOI 10.1002/jcp.10066; Tsang YS, 1999, INT J CANCER, V83, P305, DOI 10.1002/(SICI)1097-0215(19991029)83:3<305::AID-IJC3>3.0.CO;2-D; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	78	574	609	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6188	6196		10.1038/sj.onc.1209913	http://dx.doi.org/10.1038/sj.onc.1209913			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028598				2022-12-28	WOS:000241158900007
J	Easton, JB; Houghton, PJ				Easton, J. B.; Houghton, P. J.			mTOR and cancer therapy	ONCOGENE			English	Review						mTOR; cancer therapy; rapamycin; stem cells; autophagy; hypoxia	INITIATION-FACTOR 4E; BREAST-CANCER; MAMMALIAN TARGET; PROTEIN-SYNTHESIS; KINASE INHIBITOR; PHASE-II; C-MYC; EMBRYONIC-DEVELOPMENT; TEMSIROLIMUS CCI-779; MESSENGER-RNA	Proteins regulating the mammalian target of rapamycin (mTOR), as well as some of the targets of the mTOR kinase, are overexpressed or mutated in cancer. Rapamycin, the naturally occurring inhibitor of mTOR, along with a number of recently developed rapamycin analogs (rapalogs) consisting of synthetically derived compounds containing minor chemical modi. cations to the parent structure, inhibit the growth of cell lines derived from multiple tumor types in vitro, and tumor models in vivo. Results from clinical trials indicate that the rapalogs may be useful for the treatment of subsets of certain types of cancer. The sporadic responses from the initial clinical trials, based on the hypothesis of general translation inhibition of cancer cells are now beginning to be understood owing to a more complete understanding of the dynamics of mTOR regulation and the function of mTOR in the tumor microenvironment. This review will summarize the preclinical and clinical data and recent discoveries of the function of mTOR in cancer and growth regulation.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.Houghton@stjude.org	Houghton, Peter/E-3265-2011	Easton, John/0000-0003-4503-6608	NATIONAL CANCER INSTITUTE [P30CA021765, P01CA023099, R01CA077776] Funding Source: NIH RePORTER; NCI NIH HHS [CA23099, CA77776, CA96966, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Bader AG, 2003, P NATL ACAD SCI USA, V100, P12384, DOI 10.1073/pnas.2135336100; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Chan S, 2005, J CLIN ONCOL, V23, P5314, DOI 10.1200/JCO.2005.66.130; Choi Jai-Pil, 1996, EUROPEAN J POLITICAL, V12, P273, DOI DOI 10.1016/0176-2680(95)00017-8; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; Costa LF, 2006, BLOOD, V107, P285, DOI 10.1182/blood-2005-06-2208; Couch FJ, 1999, CANCER RES, V59, P1408; Crew JP, 2000, BRIT J CANCER, V82, P161; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Edwards E, 2002, CANCER RES, V62, P4671; Gemmill RM, 2005, BRIT J CANCER, V92, P2266, DOI 10.1038/sj.bjc.6602646; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Hamanaka Y, 2005, BIOCHEM BIOPH RES CO, V330, P318, DOI 10.1016/j.bbrc.2005.02.163; Haydon MS, 2000, CANCER-AM CANCER SOC, V88, P2803, DOI 10.1002/1097-0142(20000615)88:12<2803::AID-CNCR20>3.0.CO;2-5; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Huang JL, 2001, SPECTROSC SPECT ANAL, V21, P1; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Huang SL, 2001, CANCER RES, V61, P3373; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Li BDL, 2002, ANN SURG, V235, P732, DOI 10.1097/00000658-200205000-00016; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li SY, 2006, BREAST CANCER RES TR, V96, P91, DOI 10.1007/s10549-005-9048-0; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lieberthal W, 2001, AM J PHYSIOL-RENAL, V281, pF693, DOI 10.1152/ajprenal.2001.281.4.F693; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Paglin S, 2005, CANCER RES, V65, P11061, DOI 10.1158/0008-5472.CAN-05-1083; Paglin S, 2001, CANCER RES, V61, P439; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Raje N, 2004, BLOOD, V104, P4188, DOI 10.1182/blood-2004-06-2281; Risinger JI, 1997, CANCER RES, V57, P4736; Rosenwald IB, 1996, CANCER LETT, V102, P113, DOI 10.1016/0304-3835(96)04171-7; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Scott PAE, 1998, BRIT J CANCER, V77, P2120, DOI 10.1038/bjc.1998.356; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; SHANTZ LM, 1994, CANCER RES, V54, P2313; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Shi YJ, 2005, J BIOL CHEM, V280, P10964, DOI 10.1074/jbc.M407874200; Shinohara ET, 2005, ONCOGENE, V24, P5414, DOI 10.1038/sj.onc.1208715; Sorrells DL, 1999, J SURG RES, V85, P37, DOI 10.1006/jsre.1999.5653; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Thimmaiah KN, 2005, J BIOL CHEM, V280, P31924, DOI 10.1074/jbc.M507057200; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Wang ST, 2001, THYROID, V11, P1101, DOI 10.1089/10507250152740939; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Witzig TE, 2005, J CLIN ONCOL, V23, P5347, DOI 10.1200/JCO.2005.13.466; Woltman AM, 2003, BLOOD, V101, P1439, DOI 10.1182/blood-2002-06-1688; Wong AST, 2001, GYNECOL ONCOL, V82, P305, DOI 10.1006/gyno.2001.6280; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Yan HJ, 2006, CANCER RES, V66, P2305, DOI 10.1158/0008-5472.CAN-05-2447; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	89	397	418	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6436	6446		10.1038/sj.onc.1209886	http://dx.doi.org/10.1038/sj.onc.1209886			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041628				2022-12-28	WOS:000241380700009
J	Leoncini, L; Bellan, C; De Falco, G				Leoncini, L.; Bellan, C.; De Falco, G.			Retinoblastoma gene family expression in lymphoid tissues	ONCOGENE			English	Review						RB family; cell cycle; lymphoma	E2F TRANSCRIPTIONAL NETWORK; CELL-CYCLE CONTROL; MALIGNANT-LYMPHOMAS; DISTINCT MECHANISMS; PROTEIN EXPRESSION; CDK INHIBITORS; RB FAMILY; IN-VIVO; P107; PRB	It appears more and more clear that retinoblastoma (RB) family of proteins represents key molecules in tumour suppression. This family consists of pRb/p105, p107 and pRb2/p130, which participate in a gene regulatory network that governs the cellular response to antimitogenic signals, and whose deregulation constitutes one of the hallmarks of cancer. Irrespective of their structural and biochemical similarities, RB proteins carry out different functional tasks. The expression of RB gene family in the reactive lymphoid tissues again confirms the different role of each member in cell cycle control and differentiation of normal cells. These different functional properties appear to be maintained in tumours lymphoid tissues, where alterations of the RB/p105 gene appear to be relatively rare. In this review, we will summarize the current knowledge about the role of the RB proteins in reactive and neoplastic lymphoid tissue.	Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Leoncini, L (corresponding author), Univ Siena, Dept Human Pathol & Oncol, Via Laterina 8, I-53100 Siena, Italy.	leoncinil@unisi.it	leoncini, lorenzo/P-8361-2018; BELLAN, CRISTIANA/ABG-4750-2021; LEONCINI, Lorenzo/U-4413-2019; BELLAN, CRISTIANA/L-3903-2013	leoncini, lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007; LEONCINI, Lorenzo/0000-0002-7457-300X; BELLAN, CRISTIANA/0000-0001-6119-9007				Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; BARTEK J, 1992, ONCOGENE, V7, P101; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Decker T, 2002, LEUKEMIA, V16, P327, DOI 10.1038/sj.leu.2402389; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; Dreyling MH, 1997, CANCER RES, V57, P4608; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Erlanson M, 1998, BLOOD, V92, P770; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Garcia JF, 2003, BLOOD, V101, P681, DOI 10.1182/blood-2002-04-1128; Guo SX, 2000, LEUKEMIA RES, V24, P39, DOI 10.1016/S0145-2126(99)00158-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HOANG AT, 1995, MOL CELL BIOL, V15, P4031; Jares P, 1996, AM J PATHOL, V148, P1591; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kramer AK, 2002, LEUKEMIA, V16, P1844, DOI 10.1038/sj.leu.2402609; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Leoncini L, 1999, CLIN CANCER RES, V5, P4065; Lindstrom MS, 2002, SEMIN CANCER BIOL, V12, P381, DOI 10.1016/S1044-579X(02)00058-5; Moller MB, 2000, LEUKEMIA, V14, P898, DOI 10.1038/sj.leu.2401761; Nakayama K, 2000, LEUKEMIA RES, V24, P299, DOI 10.1016/S0145-2126(99)00186-1; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Putzer BM, 1997, J VIROL, V71, P9538; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Sanchez-Beato M, 2003, BLOOD, V101, P1220, DOI 10.1182/blood-2002-07-2009; SanchezBeato M, 1996, BRIT J CANCER, V74, P1056, DOI 10.1038/bjc.1996.489; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiegler P, 1998, J CELL BIOCHEM, P30; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Zukerberg LR, 1996, BLOOD, V88, P268, DOI 10.1182/blood.V88.1.268.bloodjournal881268	48	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5309	5314		10.1038/sj.onc.1209619	http://dx.doi.org/10.1038/sj.onc.1209619			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936752				2022-12-28	WOS:000240064100017
J	Scambia, G; Lovergine, S; Masciullo, V				Scambia, G.; Lovergine, S.; Masciullo, V.			RB family members as predictive and prognostic factors in human cancer	ONCOGENE			English	Review						pRb; pRb2; p130; prognostic factor; predictive factor	RETINOBLASTOMA GENE-PRODUCT; NUCLEAR ANTIGEN-EXPRESSION; PROTEIN EXPRESSION; CYCLIN D1; ALTERED EXPRESSION; DIFFERENTIAL EXPRESSION; REGULATORY PROTEINS; SUSCEPTIBILITY GENE; ABERRANT EXPRESSION; BREAST-CARCINOMA	The retinoblastoma family members - pRb, pRb2/p130 and p107- are tumor suppressor genes involved in controlling four major cellular processes: growth arrest, apoptosis, differentiation and angiogenesis. Molecular genetic studies have identified abnormalities of these tumor suppressor genes in a large proportion of human cancers. These genetic alterations have emerged as significant factors in the pathogenesis and progression of many types of tumors and are therefore likely to provide relevant information to assess risk in cancer patients. There is a pressing clinical need to identify prognostic and predictive factors for patients with cancer, because there is an undeniable importance in being able to determine which patients will have a favorable outcome without further therapy ( prognostic factor) and which will need some additional treatment ( predictive factor). This review examines the predictive and/or prognostic role of each retinoblastoma family member in human cancer.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Cattolica Sacro Cuore, Div Gynecol Oncol, Rome, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Masciullo, V (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bld,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	masciull@temple.edu						Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; Barrett MT, 1996, ONCOGENE, V12, P1873; Bartkova J, 1996, CANCER RES, V56, P5475; Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO;2-D; Bianchi S., 1994, Pathologica (Genoa), V86, P146; Bieche I, 2000, MOL CARCINOGEN, V29, P151, DOI 10.1002/1098-2744(200011)29:3<151::AID-MC4>3.3.CO;2-Y; CANCE WG, 1990, NEW ENGL J MED, V323, P1457, DOI 10.1056/NEJM199011223232105; Ceccarelli C, 1998, J CLIN PATHOL, V51, P818, DOI 10.1136/jcp.51.11.818; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Chan MKM, 1998, GYNECOL ONCOL, V68, P156, DOI 10.1006/gyno.1997.4914; Chen JT, 2001, LUNG CANCER, V31, P163, DOI 10.1016/S0169-5002(00)00191-4; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 2004, CLIN CANCER RES, V10, P3509, DOI 10.1158/1078-0432.CCR-03-0662; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; CLAUDIO PP, 1994, CANCER RES, V54, P5556; CORDONCARDO C, 1992, J NATL CANCER I, V84, P1251, DOI 10.1093/jnci/84.16.1251; Cote RJ, 1998, CANCER RES, V58, P1090; Cui X, 2004, HUM PATHOL, V35, P1189, DOI 10.1016/j.humpath.2004.06.010; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DODSON MK, 1994, CANCER RES, V54, P610; Dokiya F, 1998, ACTA OTO-LARYNGOL, V118, P759; Dong Y, 1997, INT J CANCER, V74, P407, DOI 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z; Feakins RM, 2003, HUM PATHOL, V34, P1276, DOI 10.1016/j.humpath.2003.07.005; Feugeas O, 1996, J CLIN ONCOL, V14, P467, DOI 10.1200/JCO.1996.14.2.467; Fung Y K, 1992, Cancer Treat Res, V61, P59; GERADTS J, 1994, INT J CANCER, V58, P161, DOI 10.1002/ijc.2910580203; Girod SC, 1998, BRIT J ORAL MAX SURG, V36, P252, DOI 10.1016/S0266-4356(98)90708-2; Goldstein NS, 2000, ANN THORAC SURG, V69, P1648, DOI 10.1016/S0003-4975(00)01269-8; Guenova M, 1999, MODERN PATHOL, V12, P1062; Hashiguchi Y, 2004, HUM PATHOL, V35, P165, DOI 10.1016/j.humpath.2003.07.018; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HENSEL CH, 1990, CANCER RES, V50, P3067; Hommura F, 1999, BRIT J CANCER, V81, P696, DOI 10.1038/sj.bjc.6690750; Hui AM, 1999, INT J CANCER, V84, P604, DOI 10.1002/(SICI)1097-0215(19991222)84:6<604::AID-IJC11>3.0.CO;2-Y; Ikeguchi M, 2000, J SURG ONCOL, V73, P104, DOI 10.1002/(SICI)1096-9098(200002)73:2<104::AID-JSO9>3.0.CO;2-7; Ishii H, 1997, AM J HEMATOL, V55, P46, DOI 10.1002/(SICI)1096-8652(199705)55:1<46::AID-AJH9>3.0.CO;2-3; Jahnson S, 1998, J UROLOGY, V160, P1291, DOI 10.1016/S0022-5347(01)62518-7; KARPEH MS, 1995, BRIT J CANCER, V72, P986, DOI 10.1038/bjc.1995.447; KIM TM, 1994, CANCER RES, V54, P605; Kusume T, 1999, CLIN CANCER RES, V5, P4152; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LI WW, 1995, P NATL ACAD SCI USA, V92, P10436, DOI 10.1073/pnas.92.22.10436; LIU Y, 1994, INT J CANCER, V58, P663, DOI 10.1002/ijc.2910580508; LOGOTHETIS CJ, 1992, J NATL CANCER I, V84, P1256, DOI 10.1093/jnci/84.16.1256; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Masciullo V, 2000, INT J ONCOL, V17, P897; Massaro-Giordano M, 1999, CLIN CANCER RES, V5, P1455; Milde-Langosch K, 2003, INT J GYNECOL PATHOL, V22, P168, DOI 10.1097/00004347-200304000-00009; Milde-Langosch K, 2001, BRIT J CANCER, V85, P546, DOI 10.1054/bjoc.2001.1923; Minimo C, 1999, PATHOL RES PRACT, V195, P67, DOI 10.1016/S0344-0338(99)80072-7; Mizokami H, 1999, MODERN PATHOL, V12, P47; Morente MM, 1997, BLOOD, V90, P2429; MUNGER K, 1992, CANCER SURV, V12, P197; Nakahara Y, 2000, CANCER LETT, V160, P3, DOI 10.1016/S0304-3835(00)00546-2; Omura K, 1997, J CLIN ONCOL, V15, P3458, DOI 10.1200/JCO.1997.15.12.3458; PIETILAINEN T, 1995, EUR J CANCER, V31A, P329, DOI 10.1016/0959-8049(94)00463-F; Pinto AE, 2005, PATHOLOGY, V37, P45, DOI 10.1080/00313020400011250; Pollack A, 1997, CLIN CANCER RES, V3, P1823; Poller DN, 1997, BRIT J CANCER, V75, P87, DOI 10.1038/bjc.1997.14; Puduvalli VK, 2000, INT J ONCOL, V17, P963; Rolfe KJ, 2001, INT J GYNECOL CANCER, V11, P381, DOI 10.1046/j.1525-1438.2001.01039.x; Russo G, 2005, CLIN CANCER RES, V11, P3265, DOI 10.1158/1078-0432.CCR-04-2508; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Sanchez E, 1998, J CLIN ONCOL, V16, P1931, DOI 10.1200/JCO.1998.16.5.1931; Sartor M, 1999, BRIT J CANCER, V80, P79, DOI 10.1038/sj.bjc.6690505; SAWAN A, 1992, J PATHOL, V168, P23, DOI 10.1002/path.1711680105; SCHEMPER M, 1993, STAT MED, V12, P2377, DOI 10.1002/sim.4780122413; Semczuk A, 2000, PATHOL RES PRACT, V196, P41, DOI 10.1016/S0344-0338(00)80020-5; Skomedal H, 1999, GYNECOL ONCOL, V73, P223, DOI 10.1006/gyno.1999.5346; Song Hong Suk, 2005, Korean Journal of Internal Medicine, V20, P1; SPANDIDOS DA, 1992, ANTICANCER RES, V12, P81; SUN Y, 1993, ONCOGENE, V8, P791; Susini T, 2001, HUM PATHOL, V32, P360, DOI 10.1053/hupa.2001.23514; Susini T, 1998, J CLIN ONCOL, V16, P1085, DOI 10.1200/JCO.1998.16.3.1085; Tonini T, 2004, CLIN CANCER RES, V10, P8085, DOI 10.1158/1078-0432.CCR-04-0996; TRUDEL M, 1992, HUM PATHOL, V23, P1388, DOI 10.1016/0046-8177(92)90059-C; WADAYAMA B, 1994, CANCER RES, V54, P3042; Wakasugi E, 1997, J CLIN PATHOL, V50, P407, DOI 10.1136/jcp.50.5.407; WALTHER MM, 1995, J UROLOGY, V153, P2050, DOI 10.1016/S0022-5347(01)67400-7; WEIDE R, 1994, LEUKEMIA, V8, P97; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Wurl P, 1999, CANCER LETT, V139, P159, DOI 10.1016/S0304-3835(99)00034-8; Wurl P, 1998, LANGENBECK ARCH SURG, V383, P99, DOI 10.1007/s004230050099; Xu HJ, 1996, CLIN CANCER RES, V2, P1169; XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695; Yamamoto Y, 1998, ONCOL REP, V5, P447; Zamparelli A, 2001, HUM PATHOL, V32, P4, DOI 10.1053/hupa.2001.20371; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zojer N, 2000, BLOOD, V95, P1925, DOI 10.1182/blood.V95.6.1925	93	32	34	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5302	5308		10.1038/sj.onc.1209620	http://dx.doi.org/10.1038/sj.onc.1209620			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936751				2022-12-28	WOS:000240064100016
J	Alirol, E; Martinou, JC				Alirol, E.; Martinou, J. C.			Mitochondria and cancer: is there a morphological connection?	ONCOGENE			English	Review						mitochondrial morphology; apoptosis; energy metabolism; cancer	CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; LINKED MECHANICAL-ACTIVITY; BCL-X-L; CELL-CYCLE; SUCCINATE-DEHYDROGENASE; LACTATE-DEHYDROGENASE; ULTRASTRUCTURAL BASES; MEMBRANE; PROTEIN	Mitochondria are key players in several cellular functions including growth, division, energy metabolism, and apoptosis. The mitochondrial network undergoes constant remodelling and these morphological changes are of direct relevance for the role of this organelle in cell physiology. Mitochondrial dysfunction contributes to a number of human disorders and may aid cancer progression. Here, we summarize the recent contributions made in the field of mitochondrial dynamics and discuss their impact on our understanding of cell function and tumorigenesis.	Univ Geneva, Dept Cell Biol, CH-1211 Geneva 4, Switzerland	University of Geneva	Martinou, JC (corresponding author), Univ Geneva, Dept Cell Biol, Quai Ernest Ansermet 30, CH-1211 Geneva 4, Switzerland.	Jean-Claude.Martinou@cellbio.unige.ch		martinou, Jean-claude/0000-0002-9847-2051; Alirol, Emilie/0000-0001-8691-3991				Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Barni S, 1996, BIOTECH HISTOCHEM, V71, P66, DOI 10.3109/10520299609117135; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; CRESCENZI M, 1988, P NATL ACAD SCI USA, V85, P4869, DOI 10.1073/pnas.85.13.4869; Cristea IM, 2004, CHEM PHYS LIPIDS, V129, P133, DOI 10.1016/j.chemphyslip.2004.02.002; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Danino D, 2004, J STRUCT BIOL, V147, P259, DOI 10.1016/j.jsb.2004.04.005; Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Deshmukh M, 2000, J CELL BIOL, V150, P131, DOI 10.1083/jcb.150.1.131; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Epand RF, 2003, BIOCHEMISTRY-US, V42, P14576, DOI 10.1021/bi035348w; Epand RF, 2002, BIOCHEM BIOPH RES CO, V298, P744, DOI 10.1016/S0006-291X(02)02544-5; Epand RF, 2002, J BIOL CHEM, V277, P32632, DOI 10.1074/jbc.M202396200; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Esposti MD, 2001, MOL CELL BIOL, V21, P7268, DOI 10.1128/MCB.21.21.7268-7276.2001; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; FADOK VA, 1992, J IMMUNOL, V148, P2207; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Gallop JL, 2005, NATURE, V438, P675, DOI 10.1038/nature04136; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gatenby RA, 1996, CANCER RES, V56, P5745; Gemin A, 2005, BIOCHEM BIOPH RES CO, V332, P1122, DOI 10.1016/j.bbrc.2005.05.061; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1968, J CELL BIOL, V37, P345, DOI 10.1083/jcb.37.2.345; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Heerdt BG, 1997, CELL GROWTH DIFFER, V8, P523; Hervouet E, 2005, CARCINOGENESIS, V26, P531, DOI 10.1093/carcin/bgi001; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; John GB, 2005, MOL BIOL CELL, V16, P1543, DOI 10.1091/mbc.e04-08-0697; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; King MA, 2002, CYTOMETRY, V49, P106, DOI 10.1002/cyto.10156; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kozlovsky Y, 2002, BIOPHYS J, V83, P2634, DOI 10.1016/S0006-3495(02)75274-0; Krajewska M, 2002, CELL DEATH DIFFER, V9, P145, DOI 10.1038/sj/cdd/4400934; Krebs H A, 1972, Essays Biochem, V8, P1; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; LEPRAT P, 1990, EXP CELL RES, V186, P130, DOI 10.1016/0014-4827(90)90219-Z; Liu JH, 2005, BIOCHEM BIOPH RES CO, V330, P865, DOI 10.1016/j.bbrc.2005.03.048; Lucken-Ardjomande S, 2005, CR BIOL, V328, P616, DOI 10.1016/j.crvi.2005.05.002; Lucken-Ardjomande S, 2005, J CELL SCI, V118, P473, DOI 10.1242/jcs.01654; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandal S, 2005, DEV CELL, V9, P843, DOI 10.1016/j.devcel.2005.11.006; Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Mattenberger Y, 2003, FEBS LETT, V538, P53, DOI 10.1016/S0014-5793(03)00124-8; Messner KR, 2002, J BIOL CHEM, V277, P42563, DOI 10.1074/jbc.M204958200; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Muschen M, 2000, IMMUNOLOGY, V99, P69, DOI 10.1046/j.1365-2567.2000.00921.x; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087; NUNEZ G, 1990, J IMMUNOL, V144, P3602; Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Petros AM, 2004, BBA-MOL CELL RES, V1644, P83, DOI 10.1016/j.bbamcr.2003.08.012; Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149; Reed JC, 2002, MOL CELL, V9, P1, DOI 10.1016/S1097-2765(02)00437-9; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Santel A, 2001, J CELL SCI, V114, P867; Schinzel A, 2004, BBA-MOL CELL RES, V1644, P95, DOI 10.1016/j.bbamcr.2003.09.006; Schornack PA, 2003, NEOPLASIA, V5, P135, DOI 10.1016/S1476-5586(03)80005-2; Schulz TJ, 2006, J BIOL CHEM, V281, P977, DOI 10.1074/jbc.M511064200; Scorrano L, 2005, J BIOENERG BIOMEMBR, V37, P165, DOI 10.1007/s10863-005-6572-x; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Stojanovski D, 2004, J CELL SCI, V117, P1201, DOI 10.1242/jcs.01058; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Tondera D, 2004, J BIOL CHEM, V279, P31544, DOI 10.1074/jbc.M404704200; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VANDENBOGERT C, 1992, J CELL PHYSIOL, V152, P632, DOI 10.1002/jcp.1041520323; VANDENBOGERT C, 1986, CANCER LETT, V32, P41, DOI 10.1016/0304-3835(86)90037-6; VANDENBOGERT C, 1988, EXP CELL RES, V178, P143, DOI 10.1016/0014-4827(88)90385-0; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Yang L, 2003, CANCER RES, V63, P6815; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	131	120	123	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4706	4716		10.1038/sj.onc.1209600	http://dx.doi.org/10.1038/sj.onc.1209600			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892084				2022-12-28	WOS:000239687000008
J	Shields, JD; Emmett, MS; Dunn, DBA; Joory, KD; Sage, LM; Rigby, H; Mortimer, PS; Orlando, A; Levick, JR; Bates, DO				Shields, J. D.; Emmett, M. S.; Dunn, D. B. A.; Joory, K. D.; Sage, L. M.; Rigby, H.; Mortimer, P. S.; Orlando, A.; Levick, J. R.; Bates, D. O.			Chemokine-mediated migration of melanoma cells towards lymphatics - a mechanism contributing to metastasis	ONCOGENE			English	Article						chemotactic metastasis; melanoma; chemokine; CCL21; lymphangiogenesis	BREAST-CANCER METASTASIS; MALIGNANT-MELANOMA; NODE METASTASIS; TUMOR LYMPHANGIOGENESIS; CUTANEOUS MELANOMA; RECEPTOR CCR7; EXPRESSION; PROMOTES; SPREAD; SKIN	The mechanisms that cause tumors such as melanomas to metastasize into peripheral lymphatic capillaries are poorly defined. Non-mutually-exclusive mechanisms are lymphatic endothelial cell ( LEC) chemotaxis and proliferation in response to tumor cells ( chemotaxis-lymphangiogenesis hypothesis) or LECs may secrete chemotactic agents that attract cancer cells ( chemotactic metastasis hypothesis). Using migration assays, we found evidence supporting both hypotheses. Conditioned medium ( CM) from metastatic malignant melanoma ( MMM) cell lines attracted LEC migration, consistent with the lymphangiogenesis hypothesis. Conversely, CM from mixed endothelial cells or LECs, but not blood endothelial cells, attracted MMM cells but not non-metastatic melanoma cells, consistent with the chemotactic metastasis hypothesis. MMM cell lines expressed CCR7 receptors for the lymphatic chemokine CCL21 and CCL21 neutralizing antibodies prevented MMM chemotaxis in vitro. To test for chemotactic metastasis in vivo tumor cells were xenotransplanted into nude mice similar to 1 cm from an injected LEC depot. Two different MMM grew directionally towards the LECs, whereas non-metastatic melanomas did not. These observations support the hypothesis that MMM cells grow towards regions of high LEC density owing to chemotactic LEC secretions, including CCL21. This chemotactic metastasis may contribute to the close association between metastasizing tumor cells and peritumor lymphatic density and promote lymphatic invasion.	Univ Bristol, Microvasc Res Labs, Dept Physiol, Preclin Vet Sch, Bristol BS2 8EJ, Avon, England; Frenchay Hosp, Dept Pathol, Bristol BS16 1LE, Avon, England; St George Hosp, Sch Med, Dept Cardiac & Vasc Sci, Dermatol Unit, London, England; Frenchay Hosp, Dept Plast Surg, Bristol BS16 1LE, Avon, England; St George Hosp, Sch Med, London, England	University of Bristol; St Georges University London; St Georges University London	Bates, DO (corresponding author), Univ Bristol, Microvasc Res Labs, Dept Physiol, Preclin Vet Sch, Southwell St, Bristol BS2 8EJ, Avon, England.	dave.bates@bris.ac.uk		Bates, David/0000-0003-4850-2360	Wellcome Trust [66011, 62951] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Achen MG, 2001, J PATHOL, V193, P147, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH757>3.0.CO;2-G; Agarwal B, 2005, AM J SURG PATHOL, V29, P1449, DOI 10.1097/01.pas.0000174269.99459.9d; Akagi K, 2000, BRIT J CANCER, V83, P887, DOI 10.1054/bjoc.2000.1396; Dadras SS, 2003, AM J PATHOL, V162, P1951, DOI 10.1016/S0002-9440(10)64328-3; ELIAS EG, 1977, SURG GYNECOL OBSTET, V144, P327; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Lubach D, 1996, BRIT J DERMATOL, V135, P733; Luther SA, 2002, J IMMUNOL, V169, P424, DOI 10.4049/jimmunol.169.1.424; Mashino K, 2002, CANCER RES, V62, P2937; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; PODGRABINSKA S, 2002, P NATL ACAD SCI USA, V22, P22; Saeki H, 1999, J IMMUNOL, V162, P2472; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2001-11-0017; Shields JD, 2004, BRIT J CANCER, V90, P693, DOI 10.1038/sj.bjc.6601571; Sipos B, 2005, J PATHOL, V207, P301, DOI 10.1002/path.1840; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Stanton AWB, 1999, MICROVASC RES, V57, P320, DOI 10.1006/mvre.1998.2141; Stanton AWB, 1997, MICROVASC RES, V54, P156, DOI 10.1006/mvre.1997.2035; Takanami I, 2003, INT J CANCER, V105, P186, DOI 10.1002/ijc.11063; Takeuchi H, 2004, CLIN CANCER RES, V10, P2351, DOI 10.1158/1078-0432.CCR-03-0195; Wagner JD, 2000, PLAST RECONSTR SURG, V105, P1774, DOI 10.1097/00006534-200004050-00028; Wang J, 2004, CANCER RES, V64, P1861, DOI 10.1158/0008-5472.CAN-03-2968; White RR, 2002, ANN SURG, V235, P879, DOI 10.1097/00000658-200206000-00017; Wiley HE, 2001, J NATL CANCER I, V93, P1638, DOI 10.1093/jnci/93.21.1638; Yan C, 2004, WORLD J GASTROENTERO, V10, P783	28	120	127	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					2997	3005		10.1038/sj.onc.1210114	http://dx.doi.org/10.1038/sj.onc.1210114			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130836				2022-12-28	WOS:000246395400005
J	Dormoy-Raclet, V; Markovits, J; Malato, Y; Huet, S; Lagarde, P; Montaudon, D; Jacquemin-Sablon, A; Jacquemin-Sablon, H				Dormoy-Raclet, V.; Markovits, J.; Malato, Y.; Huet, S.; Lagarde, P.; Montaudon, D.; Jacquemin-Sablon, A.; Jacquemin-Sablon, H.			Unr, a cytoplasmic RNA-binding protein with cold-shock domains, is involved in control of apoptosis in ES and HuH7 cells	ONCOGENE			English	Article						Unr; RNA-binding protein; ES and HuH7 cells; gamma-irradiation; apoptosis; proliferation	RIBOSOME ENTRY SITES; NUCLEIC-ACID BINDING; Y-BOX PROTEIN; MESSENGER-RNA; DNA-DAMAGE; N-RAS; TRANSLATIONAL REPRESSION; GLOBAL ANALYSIS; IN-VITRO; P53	Unr (upstream of N-ras) is a cytoplasmic RNA-binding protein involved in the regulation of messenger RNA stability and internal initiation of translation. We have used Unr-deficient murine embryonic stem (ES) cells to analyse Unr role in cell proliferation and response to stress. Disruption of both unr gene copies had no effect on ES cell proliferation. However, after ionizing radiation (IR), clonogenic survival of unr(-/-) ES cells was similar to 3-fold enhanced as compared to unr(+/+) cells. We further determined that IR-induced apoptosis was decreased in unr2/2 ES cells, and that reintroduction of the unr gene in unr(+/+) cells restored normal IR-induced apoptosis. Three pro-apoptotic genes, p53, caspase-3 and Gadd45 gamma, were downregulated in unr(-/-) ES cells, indicating that Unr, as other cytoplasmic RNA-binding proteins, regulates a complex genetic program, promoting cell death after IR. In contrast, in the human hepatoma cell line HuH7, Unr knockdown using unr-specific small interfering RNAs induced apoptosis, both in untreated and c-irradiated cells. Thus, our results establish that Unr acts as a positive or negative regulator of cell death, depending on the cell type. Manipulating the level of Unr may constitute a specific approach to sensitize cancer cells to anticancer treatments.	Univ Bordeaux 2, INSERM E362, GREF, F-33076 Bordeaux, France; Inst Bergonie, CNRS, FRE 2618, Bordeaux, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Institut Bergonie	Jacquemin-Sablon, H (corresponding author), Univ Bordeaux 2, INSERM E362, GREF, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	helene.jacquemin-sablon@gref.u-bordeaux2.fr						Abaza I, 2006, GENE DEV, V20, P380, DOI 10.1101/gad.371906; Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002; Boussadia O, 1997, FEBS LETT, V420, P20, DOI 10.1016/S0014-5793(97)01479-8; Boussadia O, 2003, J VIROL, V77, P3353, DOI 10.1128/JVI.77.6.3353-3359.2003; Brown EC, 2004, J GEN VIROL, V85, P2279, DOI 10.1099/vir.0.80045-0; CARTER MS, 2000, J BIOL CHEM, V276, P37916; Chang TC, 2004, GENE DEV, V18, P2010, DOI 10.1101/gad.1219104; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chung HK, 2003, J CLIN ENDOCR METAB, V88, P3913, DOI 10.1210/jc.2002-022031; Corbet SW, 1999, ONCOGENE, V18, P1537, DOI 10.1038/sj.onc.1202436; Dinur M, 2006, MOL ENDOCRINOL, V20, P1652, DOI 10.1210/me.2005-0333; DORMOYRACLET V, 2005, RNA BIOL, V2, P112; Duncan K, 2006, GENE DEV, V20, P368, DOI 10.1101/gad.371406; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evans JR, 2003, ONCOGENE, V22, P8012, DOI 10.1038/sj.onc.1206645; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Grosset C, 2000, CELL, V103, P29, DOI 10.1016/S0092-8674(00)00102-1; Hawkins DS, 1996, CANCER RES, V56, P892; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Heyer BS, 2000, GENE DEV, V14, P2072; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirose T, 2003, ONCOGENE, V22, P7762, DOI 10.1038/sj.onc.1207091; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Hong YL, 2004, P NATL ACAD SCI USA, V101, P14443, DOI 10.1073/pnas.0401346101; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keene JD, 2002, MOL CELL, V9, P1161, DOI 10.1016/S1097-2765(02)00559-2; Kim JM, 2002, EMBO J, V21, P2168, DOI 10.1093/emboj/21.9.2168; KOHN KW, 1981, DNA REPAIR LABORATOR, P379; Kohno K, 2003, BIOESSAYS, V25, P691, DOI 10.1002/bies.10300; Kubicka S, 1997, HEPATOLOGY, V25, P867, DOI 10.1002/hep.510250414; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; LOPEZFERNANDEZ LA, 1995, BBA-GENE STRUCT EXPR, V1263, P10, DOI 10.1016/0167-4781(95)00065-O; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; MARKOVITS J, 1989, CANCER RES, V49, P5111; Masuda K, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar427; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; Mazan-Mamczarz K, 2003, P NATL ACAD SCI USA, V100, P8354, DOI 10.1073/pnas.1432104100; Mitchell SA, 2001, MOL CELL BIOL, V21, P3364, DOI 10.1128/MCB.21.10.3364-3374.2001; Mukhopadhyay D, 2003, MOL CELL, V11, P113, DOI 10.1016/S1097-2765(03)00012-1; NAKABAYASHI H, 1984, GANN, V75, P151; NICOLAIEW N, 1991, ONCOGENE, V6, P721; Ohga T, 1996, CANCER RES, V56, P4224; Patry C, 2003, CANCER RES, V63, P7679; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Sheikh MS, 2000, BIOCHEM PHARMACOL, V59, P43, DOI 10.1016/S0006-2952(99)00291-9; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Swamynathan SK, 2002, BIOCHEM BIOPH RES CO, V296, P451, DOI 10.1016/S0006-291X(02)00875-6; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Thieringer HA, 1997, NUCLEIC ACIDS RES, V25, P4764, DOI 10.1093/nar/25.23.4764; TINTON S, 2004, BIOCHEM J, V385, P155; Triqueneaux G, 1999, NUCLEIC ACIDS RES, V27, P1926, DOI 10.1093/nar/27.8.1926; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; VERBENKO N, 2003, RUSS J GENET, V39, P748; Wilson HL, 2003, BLOOD, V102, P1661, DOI 10.1182/blood-2002-08-2426; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yamanaka K, 1998, MOL MICROBIOL, V27, P247, DOI 10.1046/j.1365-2958.1998.00683.x; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yoshida T, 2005, ONCOL REP, V14, P1299; Zerbini LF, 2004, P NATL ACAD SCI USA, V101, P13618, DOI 10.1073/pnas.0402069101	73	37	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2595	2605		10.1038/sj.onc.1210068	http://dx.doi.org/10.1038/sj.onc.1210068			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17086213				2022-12-28	WOS:000245831200007
J	Demidov, ON; Kek, C; Shreeram, S; Timofeev, O; Fornace, AJ; Appella, E; Bulavin, DV				Demidov, O. N.; Kek, C.; Shreeram, S.; Timofeev, O.; Fornace, A. J.; Appella, E.; Bulavin, D. V.			The role of the MKK6/p38 MAPK pathway in Wip1-dependent regulation of ErbB2-driven mammary gland tumorigenesis	ONCOGENE			English	Article						Wip1 phosphatase; p38 MAPK; MKK6; breast cancer; ErbB2; proliferation; MMTV	TUMOR-SUPPRESSOR ACTIVITY; WIP1 PHOSPHATASE; BREAST-CANCER; PROTEIN PHOSPHATASE; IN-VIVO; PPM1D; AMPLIFICATION; KINASE; P53; ACTIVATION	There is increasing evidence for the role of wild-type p53 induced phosphatase 1( Wip1) phosphatase in the regulation of tumorigenesis. To evaluate Wip1 as a breast cancer oncogene, we generated a mouse strain with targeted expression of Wip1 to the breast epithelium. We found that these mice are prone to cancer when intercrossed with transgenics expressing the ErbB2 oncogene but not conditional knockouts for Brca2. This tumor-prone phenotype of Wip1 is fully eliminated through attenuation of proliferation by activating the MKK6/p38 mitogen-activated protein kinases ( MAPK) cascade in mice bearing a constitutively active form of MKK6. We propose that Wip1 phosphatase operates within the MKK6/p38 MAPK signaling pathway to promote ErbB2-driven mammary gland tumorigenesis.	Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, Singapore 138673, Singapore; NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	Bulavin, DV (corresponding author), Natl Univ Singapore, Inst Mol & Cell Biol, Cell Cycle Control & Tumorigenesis Grp, 61 Biopolis Dr, Singapore 138673, Singapore.	dvbulavin@imcb.a-star.edu.sg	Demidov, Oleg/U-2050-2017; Fornace, Albert J/A-7407-2008; Demidov, Oleg/AAC-4462-2021	Demidov, Oleg/0000-0003-4323-7174; Fornace, Albert J/0000-0001-9695-085X; Demidov, Oleg/0000-0003-4323-7174; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Timofeev, Oleg/0000-0002-3114-6403	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Timofeev O, 2005, CELL CYCLE, V4, P118, DOI 10.4161/cc.4.1.1342; Trost TM, 2005, CANCER RES, V65, P840; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634	20	82	89	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2502	2506		10.1038/sj.onc.1210032	http://dx.doi.org/10.1038/sj.onc.1210032			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17016428				2022-12-28	WOS:000245831000010
J	Habens, F; Lapham, AS; Dallman, CL; Pickering, BM; Michels, J; Marcusson, EG; Johnson, PWM; Packham, G				Habens, F.; Lapham, A. S.; Dallman, C. L.; Pickering, B. M.; Michels, J.; Marcusson, E. G.; Johnson, P. W. M.; Packham, G.			Distinct promoters mediate constitutive and inducible Bcl-X-L expression in malignant lymphocytes	ONCOGENE			English	Article						Bcl-X-L; Ets; lymphoma; transcription	EPSTEIN-BARR-VIRUS; REL/NF-KAPPA-B; CELL-DEATH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; FAMILY PROTEINS; POOR-PROGNOSIS	Bcl-X-L is a Bcl-2-related survival protein that is essential for normal development. Bcl-X-L expression is rapidly induced by a wide range of survival signals and many cancer cells constitutively express high levels. The Bcl-X gene has a complex organization with multiple promoters giving rise to RNAs with alternate 5' non-codingexons. Here we have investigated the mechanisms that control basal and induced expression of Bcl-X-L in B-lymphoma cells. Antisense experiments demonstrated that Bcl-X-L was essential for survival of Akata6 B-lymphoma cells. The levels of RNAs containing the IB Bcl-X non-coding exon, derived from the distal 1B promoter, correlated with basal expression of Bcl-X-L in primary malignant B cells and this promoter was highly active in B-cell lines. The activity of this promoter was largely dependent on a single Ets binding site and Ets family proteins were bound at this promoter in intact cells. CD40 ligand (CD40L)-induced cell survival was associated with increased Bcl-X-L expression and accumulation of exon IA-containing RNAs, derived from the proximal 1A promoter. Nuclear factor-kappaB (NF-kappa B) inhibition prevented induction of Bcl-X-L protein and exon IA-containingRNAs by CD40L. Therefore, the distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells, whereas NF-kappa B plays a central role in the induction of Bcl-X-L in response to CD40 signalling via the proximal 1A promoter.	Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Southampton SO16 6YD, Hants, England; ISIS Pharmaceut, Antisense Drug Discovery, Carlsbad, CA 92008 USA	Cancer Research UK; University of Southampton; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Somers Canc Res Bldg,MP824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691; Marcusson, Eric/0000-0002-0504-8674				Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Dallman C, 2005, METH MOLEC MED, V115, P1; de Nigris F, 2001, CANCER RES, V61, P2267; Deng G, 1998, MOL MED, V4, P158, DOI 10.1007/BF03401913; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallis M, 1997, LEUKEMIA, V11, P945, DOI 10.1038/sj.leu.2400705; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pena JC, 1998, CANCER RES, V58, P2111; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tian CX, 2003, BLOOD, V101, P2235, DOI 10.1182/blood-2002-04-1217; Tu YP, 1998, CANCER RES, V58, P256; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; WANG ZH, 1995, J IMMUNOL, V155, P3722; Wu LX, 2005, J IMMUNOL, V174, P180, DOI 10.4049/jimmunol.174.1.180; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	55	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1910	1919		10.1038/sj.onc.1209979	http://dx.doi.org/10.1038/sj.onc.1209979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983335				2022-12-28	WOS:000245117700008
J	Pecquet, C; Nyga, R; Penard-Lacronique, V; Smithgall, TE; Murakami, H; Regnier, A; Lassoued, K; Gouilleux, F				Pecquet, C.; Nyga, R.; Penard-Lacronique, V.; Smithgall, T. E.; Murakami, H.; Regnier, A.; Lassoued, K.; Gouilleux, F.			The Src tyrosine kinase Hck is required for Tel-Abl- but not for Tel-Jak2-induced cell transformation	ONCOGENE			English	Article						Tel-Abl; Tel-Jak2; Src kinases; Hck; signal transduction; oncogenes	KAPPA-B PATHWAY; BCR-ABL; FUSION PROTEINS; LEUKEMIA-CELLS; C-SRC; ACTIVATION; GENE; FAMILY; LYN; RECEPTOR	Tel-Abl and Tel-Jak2 are fusion proteins associated with human haematologic neoplasms. They possess constitutive tyrosine kinase activity and activate common downstream signalling pathways like Stat-5, PI3-K/Akt, Ras/MapK and NF-kappa B. In this study, we showed the specific requirement of Src family members for the Tel-Abl-mediated cell growth, activation of Stat5, PI3-K/Akt and Ras/MapK while dispensable for Tel-Jak2. Hck was found strongly phosphorylated in Tel-Abl-expressing Ba/F3 cells and sensitive to imatinib mesylate treatment, providing evidence that Hck is a target of Tel-Abl tyrosine kinase activity. Overexpression of a kinase dead form of Hck inhibits the proliferation of Ba/F3 cells expressing Tel-Abl as the phosphorylation of Akt and Erk1/2. These results argue for an important role of Hck in Tel-Abl oncogenic signalling.	Univ Picardie, INSERM, E351, F-80036 Amiens, France; Hop Necker Enfants Malad, INSERM, E210, Paris, France; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA; Okayama Univ, Dept Biotechnol, Okayama 7008530, Japan	Institut National de la Sante et de la Recherche Medicale (Inserm); Picardie Universites; Universite de Picardie Jules Verne (UPJV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Okayama University	Gouilleux, F (corresponding author), Univ Picardie, INSERM, E351, 3 Rue Louvels, F-80036 Amiens, France.	fabrice.gouilleux@sa.u-picardie.fr	Penard-Lacronique, Virginie/E-5729-2016; Penard-Lacronique, Virginie/R-1938-2019	Penard-Lacronique, Virginie/0000-0001-9435-7331; Penard-Lacronique, Virginie/0000-0001-9435-7331; Christian, Pecquet/0000-0002-8623-3483; Gouilleux, Fabrice/0000-0001-6047-1718	NCI NIH HHS [CA101828] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA101828] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Carron C, 2000, BLOOD, V95, P3891; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chin H, 1998, BLOOD, V91, P3734; Dai Y, 2004, J BIOL CHEM, V279, P34227, DOI 10.1074/jbc.M402290200; DanhauserRiedl S, 1996, CANCER RES, V56, P3589; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; dos Santos NR, 2006, LEUKEMIA, V20, P182, DOI 10.1038/sj.leu.2404026; ERNST TJ, 1994, J BIOL CHEM, V269, P5764; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Ho JMY, 2002, BLOOD, V100, P1438; Hu YG, 2004, NAT GENET, V36, P453, DOI 10.1038/ng1343; Keung YK, 2002, CANCER GENET CYTOGEN, V138, P139, DOI 10.1016/S0165-4608(02)00609-X; Klejman A, 2002, EMBO J, V21, P5766, DOI 10.1093/emboj/cdf562; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Kuno Y, 2001, BLOOD, V97, P1050, DOI 10.1182/blood.V97.4.1050; Lacronique V, 2000, BLOOD, V95, P2076, DOI 10.1182/blood.V95.6.2076; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Lionberger JM, 2000, J BIOL CHEM, V275, P18581, DOI 10.1074/jbc.C000126200; Malinge S, 2006, ONCOGENE, V25, P3589, DOI 10.1038/sj.onc.1209390; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Million RP, 2004, MOL CELL BIOL, V24, P4685, DOI 10.1128/MCB.24.11.4685-4695.2004; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; Omura T, 2002, EUR J BIOCHEM, V269, P381, DOI 10.1046/j.0014-2956.2001.02661.x; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Santos SCR, 2000, ONCOGENE, V19, P1164, DOI 10.1038/sj.onc.1203418; Santos SCR, 2001, FEBS LETT, V497, P148; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; Spiekermann K, 2002, EXP HEMATOL, V30, P262, DOI 10.1016/S0301-472X(01)00787-1; Stanglmaier M, 2003, LEUKEMIA, V17, P283, DOI 10.1038/sj.leu.2402778; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tatosyan AG, 2000, BIOCHEMISTRY-MOSCOW+, V65, P49; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Tilbrook PA, 2001, CANCER RES, V61, P2453; Van Limbergen H, 2001, GENE CHROMOSOME CANC, V30, P274, DOI 10.1002/1098-2264(2000)9999:9999<1::AID-GCC1089>3.3.CO;2-T; Voss J, 2000, ONCOGENE, V19, P1684, DOI 10.1038/sj.onc.1203467; Warmuth M, 2003, BLOOD, V101, P664, DOI 10.1182/blood-2002-01-0288; Warmuth M, 1997, J BIOL CHEM, V272, P33260, DOI 10.1074/jbc.272.52.33260; Wilson MB, 2002, ONCOGENE, V21, P8075, DOI 10.1038/sj.onc.1206008	46	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1577	1585		10.1038/sj.onc.1209949	http://dx.doi.org/10.1038/sj.onc.1209949			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953222	Green Published			2022-12-28	WOS:000244782500007
J	Kuang, SQ; Ling, X; Sanchez-Gonzalez, B; Yang, H; Andreeff, M; Garcia-Manero, G				Kuang, S-Q; Ling, X.; Sanchez-Gonzalez, B.; Yang, H.; Andreeff, M.; Garcia-Manero, G.			Differential tumor suppressor properties and transforming growth factor-beta responsiveness of p57KIP2 in leukemia cells with aberrant p57KIP2 promoter DNA methylation	ONCOGENE			English	Article						p57KIP2; DNA methylation; leukemia; cell cycle; transforming growth factor-beta	ACUTE LYMPHOCYTIC-LEUKEMIA; BECKWITH-WIEDEMANN-SYNDROME; DEPENDENT KINASE INHIBITOR; CYCLE REGULATORY PATHWAY; ACUTE MYELOID-LEUKEMIA; CDK INHIBITOR; MULTIPLE GENES; P57(KIP2) GENE; VALPROIC ACID; HYPERMETHYLATION	To investigate if the tumor suppressor properties of p57KIP2 are dependent on its DNA methylation status, we studied the impact of several stress stimuli in leukemic cell lines with different p57KIP2 promoter DNA methylation levels. p57KIP2 reactivation was observed after stimulation with transforming growth factor-beta, other cytokines, high-density culture or serum withdrawal in p57KIP2 promoter unmethylated cells but not in methylated cells. In these cells, p57KIP2 reactivation required the use of a hypomethylating agent or a histone deacetylase inhibitor. Overexpression of p57KIP2 in p57KIP2 promoter methylated leukemic cell lines resulted in cell growth arrest and the induction of apoptosis. In contrast, overexpression of p57KIP2 in partially methylated cells only resulted in a moderate inhibition of cell growth and had no impact on apoptosis. Transduction of unmethylated cells expressing high levels of p57KIP2 with p57KIP2 short hairpin RNA resulted in increased cell proliferation. These results suggest that the tumor suppressive properties of p57KIP2 in leukemia may depend on the intrinsic promoter DNA methylation status of the gene.	Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Blood & Marrow Transplantat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Garcia-Manero, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Box 428,1515 Holcombe Blvd, Houston, TX 77030 USA.	ggarciam@mdanderson.org			NATIONAL CANCER INSTITUTE [R21CA105771, R21CA100067] Funding Source: NIH RePORTER; NCI NIH HHS [CA100067, CA105771] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonilla F, 1998, INT J ONCOL, V12, P583; Bueso-Ramos C, 2005, J CLIN ONCOL, V23, P3932, DOI 10.1200/JCO.2005.02.998; Canalli AA, 2005, LEUKEMIA RES, V29, P881, DOI 10.1016/j.leukres.2004.11.023; Garcia-Manero G, 2004, BLOOD, V104, p78A; Garcia-Manero G, 2003, CANCER, V97, P695, DOI 10.1002/cncr.11090; Garcia-Manero G, 2002, CLIN CANCER RES, V8, P2217; Gutierrez MI, 2003, LEUKEMIA, V17, P1845, DOI 10.1038/sj.leu.2403060; Hatada I, 1996, NAT GENET, V14, P171, DOI 10.1038/ng1096-171; Kikuchi T, 2002, ONCOGENE, V21, P2741, DOI 10.1038/sj.onc.1205376; Kondo M, 1996, ONCOGENE, V12, P1365; Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200; Lam WWK, 1999, J MED GENET, V36, P518; Li JQ, 2003, INT J ONCOL, V23, P1537; Ling XY, 2005, CANCER RES, V65, P2532, DOI 10.1158/0008-5472.CAN-04-2425; Ling XY, 2003, CANCER RES, V63, P298; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; Matsuoka S, 1996, P NATL ACAD SCI USA, V93, P3026, DOI 10.1073/pnas.93.7.3026; Melki JR, 1999, CANCER RES, V59, P3730; OHTA M, 1987, NATURE, V329, P539, DOI 10.1038/329539a0; Orlow I, 1996, CANCER RES, V56, P1219; Roman-Gomez J, 2004, BLOOD, V104, P2492, DOI 10.1182/blood-2004-03-0954; Scandura JM, 2004, P NATL ACAD SCI USA, V101, P15231, DOI 10.1073/pnas.0406771101; Shen LL, 2003, BLOOD, V101, P4131, DOI 10.1182/blood-2002-08-2466; Sherr CJ, 2000, CANCER RES, V60, P3689; Sui L, 2002, ANTICANCER RES, V22, P3191; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; Taniguchi T, 1997, ONCOGENE, V14, P1201, DOI 10.1038/sj.onc.1200934; Tokino T, 1996, HUM GENET, V97, P625, DOI 10.1007/s004390050106; Toyota M, 2001, BLOOD, V97, P2823, DOI 10.1182/blood.V97.9.2823; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang H, 2005, LEUKEMIA RES, V29, P739, DOI 10.1016/j.leukres.2004.11.022	33	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1439	1448		10.1038/sj.onc.1209907	http://dx.doi.org/10.1038/sj.onc.1209907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936778				2022-12-28	WOS:000244558800008
J	Wang, F; Liu, R; Lee, SW; Sloss, CM; Couget, J; Cusack, JC				Wang, F.; Liu, R.; Lee, S. W.; Sloss, C. M.; Couget, J.; Cusack, J. C.			Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance	ONCOGENE			English	Article						HB-EGF; EGFR; NF-kappa B; c-fos; chemotherapy resistance	NF-KAPPA-B; HB-EGF; PROHB-EGF; METALLOPROTEINASE-CLEAVAGE; CELL-PROLIFERATION; SIGNALING CASCADES; CARCINOMA-CELLS; INHIBITION; CHEMORESISTANCE; ACTIVATION	We have shown that one of the principle mechanisms of chemotherapy resistance involves the activation of nuclear factor kappa-B (NF-kappa B). In an effort to identify NF- kappa-B-regulated chemotherapy response genes, we performed a microarray assay and observed that heparin-binding EGF-like growth factor (HB-EGF) was significantly upregulated by SN38 (a strong inducer of NF-kappa B activity) in colon cancer cells. Further studies revealed that HB-EGF was rapidly induced following a variety of chemotherapy treatments. Using RNA interference, we demonstrated that the chemotherapy-induced HB-EGF was largely dependent on activator protein-1 (AP-1) and NF-kappa B activation. Constitutive HB-EGF expression rescued AP-1/NF-kappa B small interfering RNA (siRNA) cells from chemotherapy-induced apoptosis. Meanwhile, we found that the enzymatic shedding of HB-EGF was also regulated by chemotherapy treatment, resulting in the elevated release of soluble HB-EGF from the cellular membrane. Induction of HB-EGF expression and ectodomain shedding synergistically led to robust epidermal growth factor receptor (EGFR) phosphorylation, whereas inhibition of HB-EGF expression by use of the HB-EGF inhibitor (CRM197) or siRNA resulted in the suppression of chemotherapyinduced EGFR phosphorylation. These results suggest that the chemotherapy-induced EGFR activation is regulated by HB-EGF. Finally, we demonstrated that overexpression of HB-EGF led to apoptotic resistance to chemotherapy, whereas suppression of HB-EGF expression by siRNA resulted in a dramatic increase in cell death. In summary, our study suggests that chemotherapy-induced HB-EGF activation represents a critical mechanism of inducible chemotherapy resistance. Therefore, therapeutic intervention aimed at inhibiting HB-EGF activity may be useful in cancer prevention and treatments.	Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Boston, MA 02114 USA; Harvard Univ, Bauer Ctr Genom Res, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University	Cusack, JC (corresponding author), Massachusetts Gen Hosp, Div Surg Oncol, 55 Fruit St,7th Floor, Boston, MA 02114 USA.	jcusack@partners.org			NATIONAL CANCER INSTITUTE [K08CA077278, R01CA098871] Funding Source: NIH RePORTER; NCI NIH HHS [CA98871-01, CA77278-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armant DR, 2006, DEVELOPMENT, V133, P751, DOI 10.1242/dev.02237; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bode AM, 2004, MUTAT RES-FUND MOL M, V555, P33, DOI 10.1016/j.mrfmmm.2004.05.018; Cusack JC, 2001, CANCER RES, V61, P3535; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; Higashiyama S, 2005, BBA-PROTEINS PROTEOM, V1751, P110, DOI 10.1016/j.bbapap.2004.11.009; Hirata M, 2001, BIOCHEM BIOPH RES CO, V283, P915, DOI 10.1006/bbrc.2001.4879; Ito Y, 2001, INT J PANCREATOL, V29, P47, DOI 10.1385/IJGC:29:1:47; Ito Y, 2001, ONCOL REP, V8, P903; Itoh Y, 2005, CYTOKINE, V29, P275, DOI 10.1016/j.cyto.2004.11.005; Kanda N, 2005, AM J PHYSIOL-CELL PH, V288, pC813, DOI 10.1152/ajpcell.00483.2004; Kishida O, 2005, CANCER CHEMOTH PHARM, V55, P393, DOI 10.1007/s00280-004-0904-0; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nishi E, 2004, GROWTH FACTORS, V22, P253, DOI 10.1080/08977190400008448; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Park JM, 1999, AM J PHYSIOL-CELL PH, V277, pC294, DOI 10.1152/ajpcell.1999.277.2.C294; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Suganuma K, 2003, CANCER SCI, V94, P355, DOI 10.1111/j.1349-7006.2003.tb01446.x; Takenobu H, 2003, J BIOL CHEM, V278, P17255, DOI 10.1074/jbc.M211835200; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yang XP, 2005, MOL CELLS, V20, P263; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066	26	65	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2006	2016		10.1038/sj.onc.1209999	http://dx.doi.org/10.1038/sj.onc.1209999			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001310				2022-12-28	WOS:000245313400003
J	Menon, SG; Goswami, PC				Menon, S. G.; Goswami, P. C.			A redox cycle within the cell cycle: ring in the old with the new	ONCOGENE			English	Review						redox; antioxidant enzymes; cell cycle; cyclin D1; MnSOD	UBIQUITIN-CONJUGATING ENZYMES; DENSITY-DEPENDENT REGULATION; NORMAL HUMAN FIBROBLASTS; TOPOISOMERASE-II-ALPHA; GROWTH-FACTOR RECEPTOR; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; PROTEIN-KINASE	In recent years, the intracellular oxidation-reduction ( redox) state has gained increasing attention as a critical mediator of cell signaling, gene expression changes and proliferation. This review discusses the evidence for a redox cycle ( i. e., fluctuation in the cellular redox state) regulating the cell cycle. The presence of redox-sensitive motifs ( cysteine residues, metal co-factors in kinases and phosphatases) in several cell cycle regulatory proteins indicate periodic oscillations in intracellular redox state could play a central role in regulating progression from G(0)/G(1) to S to G(2) and M cell cycle phases. Fluctuations in the intracellular redox state during cell cycle progression could represent a fundamental mechanism linking oxidative metabolic processes to cell cycle regulatory processes. Proliferative disorders are central to a variety of human pathophysiological conditions thought to involve oxidative stress. Therefore, a more complete understanding of redox control of the cell cycle could provide a biochemical rationale for manipulating aberrant cell proliferation.	Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Med Labs, Iowa City, IA 52242 USA	University of Iowa	Goswami, PC (corresponding author), Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Med Labs, B180,500 Newton Rd, Iowa City, IA 52242 USA.	prabhat-goswami@uiowa.edu	Menon, Sarita/B-5609-2012	Goswami, Prabhat/0000-0002-5700-2096; Menon, Sarita/0000-0001-9548-149X	NCI NIH HHS [CA 111365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA111365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bloomfield G, 2003, J CELL SCI, V116, P3387, DOI 10.1242/jcs.00649; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; Burch PM, 2005, ANTIOXID REDOX SIGN, V7, P741, DOI 10.1089/ars.2005.7.741; BURDON RH, 1989, FREE RADICAL RES COM, V6, P345, DOI 10.3109/10715768909087918; BURDON RH, 1990, FREE RADICAL RES COM, V11, P65, DOI 10.3109/10715769009109669; BURDON RH, 1993, FREE RADICAL RES COM, V19, P203, DOI 10.3109/10715769309111603; BURDON RH, 1989, FREE RADICAL RES COM, V7, P149, DOI 10.3109/10715768909087937; Chang TS, 2002, J BIOL CHEM, V277, P25370, DOI 10.1074/jbc.M110432200; Chiarugi P, 2003, J CELL BIOL, V161, P933, DOI 10.1083/jcb.200211118; Conour JE, 2004, PHYSIOL GENOMICS, V18, P196, DOI 10.1152/physiolgenomics.00058.2004; Demasi M, 2003, J BIOL CHEM, V278, P679, DOI 10.1074/jbc.M209282200; DeYulia GJ, 2005, P NATL ACAD SCI USA, V102, P5044, DOI 10.1073/pnas.0501154102; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DI MASCIO P, 1991, AM J CLIN NUTR, V53, pS194, DOI 10.1093/ajcn/53.1.194S; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; EVANS T, 1983, CELL, V33, P389, DOI 10.1016/0092-8674(83)90420-8; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Go YM, 2004, J BIOL CHEM, V279, P5837, DOI 10.1074/jbc.M307547200; Goswami PC, 1996, MOL CELL BIOL, V16, P1500; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; GRANA X, 1995, ONCOGENE, V11, P211; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HARTWELL LH, 1970, P NATL ACAD SCI USA, V66, P352, DOI 10.1073/pnas.66.2.352; Havre PA, 2002, CANCER RES, V62, P1443; Humphries KM, 2005, J BIOL CHEM, V280, P2750, DOI 10.1074/jbc.M410242200; Hutter DE, 1997, EXP CELL RES, V232, P435, DOI 10.1006/excr.1997.3527; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; JANSSEN YMW, 1995, CANCER RES, V55, P2085; Jonas CR, 2002, FREE RADICAL BIO MED, V33, P1499, DOI 10.1016/S0891-5849(02)01081-X; Jones DP, 2004, FASEB J, V18, P1246, DOI 10.1096/fj.03-0971fje; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; KAWAMURA N, 1960, EXP CELL RES, V20, P127, DOI 10.1016/0014-4827(60)90229-9; Kim KY, 2001, J BIOL CHEM, V276, P40591, DOI 10.1074/jbc.M100975200; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Knapp LT, 2000, J BIOL CHEM, V275, P24136, DOI 10.1074/jbc.M002043200; Kyaw M, 2004, J PHARMACOL SCI, V95, P483, DOI 10.1254/jphs.SC0040061; Laurent A, 2005, CANCER RES, V65, P948; Li N, 1998, J CELL PHYSIOL, V177, P148, DOI 10.1002/(SICI)1097-4652(199810)177:1<148::AID-JCP16>3.0.CO;2-9; Liberto M, 2000, CANCER LETT, V154, P151, DOI 10.1016/S0304-3835(00)00378-5; Limoli CL, 2004, P NATL ACAD SCI USA, V101, P16052, DOI 10.1073/pnas.0407065101; Liu M, 1999, CARCINOGENESIS, V20, P1869, DOI 10.1093/carcin/20.9.1869; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MANOME Y, 1993, BIOCHEMISTRY-US, V32, P10607, DOI 10.1021/bi00091a010; MASSEY V, 1969, BIOCHEM BIOPH RES CO, V36, P891, DOI 10.1016/0006-291X(69)90287-3; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; MAURO F, 1969, BIOPHYS J, V9, P1377, DOI 10.1016/S0006-3495(69)86460-X; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Menendez S, 2003, J BIOL CHEM, V278, P18720, DOI 10.1074/jbc.M211007200; Menon SG, 2005, ANTIOXID REDOX SIGN, V7, P711, DOI 10.1089/ars.2005.7.711; Menon SG, 2003, CANCER RES, V63, P2109; Munoz CM, 2001, CELL MOL LIFE SCI, V58, P990, DOI 10.1007/PL00013204; Murata H, 2003, J BIOL CHEM, V278, P50226, DOI 10.1074/jbc.M310171200; NEVINS JR, 1992, SCIENCE, V258, P424; OBERLEY TD, 1995, FREE RADICAL BIO MED, V19, P53, DOI 10.1016/0891-5849(95)00012-M; OBERLEY TD, 1990, AM J PATHOL, V137, P199; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; OHBA M, 1994, J CELL BIOL, V126, P1079, DOI 10.1083/jcb.126.4.1079; Okuyama H, 2001, J BIOL CHEM, V276, P28274, DOI 10.1074/jbc.M102995200; Pan WJ, 2001, CANCER RES, V61, P2885; Pani G, 2000, J BIOL CHEM, V275, P38891, DOI 10.1074/jbc.M007319200; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Rapkine L., 1931, ANN PHYSICOCHIM BIOL, V7, P382; Rhee SG, 1999, EXP MOL MED, V31, P53, DOI 10.1038/emm.1999.9; Rhee SG, 1999, BIOFACTORS, V10, P207, DOI 10.1002/biof.5520100218; Sarsour EH, 2005, J BIOL CHEM, V280, P18033, DOI 10.1074/jbc.M501939200; Savitsky PA, 2002, J BIOL CHEM, V277, P20535, DOI 10.1074/jbc.M201589200; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schrader M, 2004, HISTOCHEM CELL BIOL, V122, P383, DOI 10.1007/s00418-004-0673-1; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; SHERR CJ, 1995, P ASSOC AM PHYSICIAN, V107, P181; STIRPE F, 1991, EXP CELL RES, V192, P635, DOI 10.1016/0014-4827(91)90086-A; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Tanaka T, 2000, FREE RADICAL RES, V33, P851, DOI 10.1080/10715760000301361; TEMIN HM, 1971, J CELL PHYSIOL, V78, P161, DOI 10.1002/jcp.1040780202; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; Wang HP, 2003, FREE RADICAL RES, V37, P621, DOI 10.1080/1071576031000088283; YAMAMOTO K, 1988, EUR J CELL BIOL, V46, P129; Yamauchi A, 1997, BLOOD, V89, P4092, DOI 10.1182/blood.V89.11.4092; Zangar RC, 2004, TOXICOL APPL PHARM, V199, P316, DOI 10.1016/j.taap.2004.01.018; Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200	98	205	213	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1101	1109		10.1038/sj.onc.1209895	http://dx.doi.org/10.1038/sj.onc.1209895			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924237				2022-12-28	WOS:000244406400001
J	Chua, HL; Bhat-Nakshatri, P; Clare, SE; Morimiya, A; Badve, S; Nakshatri, H				Chua, H. L.; Bhat-Nakshatri, P.; Clare, S. E.; Morimiya, A.; Badve, S.; Nakshatri, H.			NF-kappa B represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2	ONCOGENE			English	Article						NF-kappa B; breast cancer; EMT; ZEB-1; p63	BREAST-CANCER CELLS; GENE-EXPRESSION; ESTROGEN-RECEPTOR; STEM-CELL; TRANSCRIPTIONAL REPRESSOR; MYOEPITHELIAL CELLS; ACTIVATION; SNAIL; METASTASIS; CARCINOMA	The transcription factor nuclear factor kappa B (NF-kappa B) is constitutively active in both cancer cells and stromal cells of breast cancer; however, the precise role of activated NF-kappa B in cancer progression is not known. Using parental MCF10A cells and a variant that expresses the myoepithelial marker p63 stably overexpressing the constitutively active p65 subunit of NF-kappa B (MCF10A/p65), we show that NF-kappa B suppresses the expression of epithelial specific genes E-cadherin and desmoplakin and induces the expression of the mesenchymal specific gene vimentin. P65 also suppressed the expression of p63 and the putative breast epithelial progenitor marker cytokeratin 5/6. MCF10A/p65 cells were phenotypically similar to cells undergoing epithelial to mesenchymal transition (EMT). MCF10A/p65 cells failed to form characteristic acini in three-dimensional Matrigel. Analysis of parental and MCF10A/p65 cells for genes previously shown to be involved in EMT revealed elevated expression of ZEB-1 and ZEB-2 in MCF10A/p65 cells compared to parental cells. In transient transfection assays, p65 increased ZEB-1 promoter activity. Furthermore, MCF10A cells overexpressing ZEB-1 showed reduced E-cadherin and p63 expression and displayed an EMT phenotype. The siRNA against ZEB-1 or ZEB-2 reduced the number of viable MCF10A/p65 but not parental cells, suggesting the dependence of MCF10A/p65 cells to ZEB-1 and ZEB-2 for cell cycle progression or survival. MCF10A cells chronically exposed to tumor necrosis factor alpha (TNF alpha), a potent NF-kappa B inducer, also exhibited the EMT-like phenotype and ZEB-1/ZEB-2 induction, both of which were reversed following TNFa withdrawal.	Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46204 USA; Walther Canc Inst, Indianapolis, IN USA; Indiana Univ, Sch Med, Dept Pathol, Indianapolis, IN 46204 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46204 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Nakshatri, H (corresponding author), Indiana Canc Res Inst, 1044 W Walnut St,R4-202, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052; Badve, Sunil/0000-0001-8861-9980				Adriance MC, 2005, BREAST CANCER RES, V7, P190, DOI 10.1186/bcr1286; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243; Bhat-Nakshatri P, 1998, P NATL ACAD SCI USA, V95, P6971, DOI 10.1073/pnas.95.12.6971; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Boecker W, 2002, J PATHOL, V198, P458, DOI 10.1002/path.1241; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Clarke CL, 2004, J PATHOL, V204, P147, DOI 10.1002/path.1647; Clarkson RWE, 2000, J BIOL CHEM, V275, P12737, DOI 10.1074/jbc.275.17.12737; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; IP MM, 1992, ENDOCRINOLOGY, V130, P2833, DOI 10.1210/en.130.5.2833; Irie HY, 2005, J CELL BIOL, V171, P1023, DOI 10.1083/jcb.200505087; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Jonkers J, 2004, CANCER CELL, V6, P535, DOI 10.1016/j.ccr.2004.12.002; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim DW, 2000, CARCINOGENESIS, V21, P871, DOI 10.1093/carcin/21.5.871; Kumar S, 2003, AM J PATHOL, V163, P2531, DOI 10.1016/S0002-9440(10)63608-5; Kuphal S, 2004, ONCOGENE, V23, P8509, DOI 10.1038/sj.onc.1207831; Kurose K, 2002, NAT GENET, V32, P355, DOI 10.1038/ng1013; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; McKeon F, 2004, GENE DEV, V18, P465, DOI 10.1101/gad.1190504; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nozaki S, 2000, BIOCHEM BIOPH RES CO, V275, P60, DOI 10.1006/bbrc.2000.3241; Ozturk N, 2006, P NATL ACAD SCI USA, V103, P2178, DOI 10.1073/pnas.0510877103; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Radisky DC, 2004, SCIENCE, V303, P775, DOI 10.1126/science.1094412; Rapp UR, 2006, CANCER CELL, V9, P9, DOI 10.1016/j.ccr.2005.12.022; Rizki A, 2004, CANCER CELL, V6, P1, DOI 10.1016/j.ccr.2004.06.019; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Shin SR, 2006, CANCER RES, V66, P2570, DOI 10.1158/0008-5472.CAN-05-3056; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; TAIT L, 1990, CANCER RES, V50, P6087; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tickle C, 1998, NATURE, V392, P547, DOI 10.1038/33276; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Villadsen R, 2005, APMIS, V113, P903, DOI 10.1111/j.1600-0463.2005.apm_344.x; Welm B, 2003, CELL PROLIFERAT, V36, P17, DOI 10.1046/j.1365-2184.36.s.1.3.x; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; [No title captured], DOI DOI 10.1126/STKE.2882005PE27	70	490	520	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					711	724		10.1038/sj.onc.1209808	http://dx.doi.org/10.1038/sj.onc.1209808			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862183				2022-12-28	WOS:000243902200008
J	Delarue, FL; Adnane, J; Joshi, B; Blaskovich, MA; Wang, DA; Hawker, J; Bizouarn, F; Ohkanda, J; Zhu, K; Hamilton, AD; Chellappan, S; Sebti, SM				Delarue, F. L.; Adnane, J.; Joshi, B.; Blaskovich, M. A.; Wang, D-A; Hawker, J.; Bizouarn, F.; Ohkanda, J.; Zhu, K.; Hamilton, A. D.; Chellappan, S.; Sebti, S. M.			Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter	ONCOGENE			English	Article						RhoB; farnesyltransferase inhibitors; geranylgeranyltransferase inhibitors; HDAC1 dissociation; HAT association; histone acetylation	FARNESYL-PROTEIN TRANSFERASE; HUMAN CANCER-CELLS; HUMAN TUMOR-GROWTH; GTPASE RHOB; ANTITUMOR-ACTIVITY; TRANSGENIC MICE; NUDE-MICE; K-RAS; N-RAS; PRENYLATION	Recently, we have shown that RhoB suppresses EGFR-, ErbB2-, Ras- and Akt-mediated malignant transformation and metastasis. In this paper, we demonstrate that the novel antitumor agents farnesyltransferase inhibitors (FTIs) and geranylgeranyltransferase I inhibitors (GGTIs) upregulate RhoB expression in a wide spectrum of human cancer cells including those from pancreatic, breast, lung, colon, bladder and brain cancers. RhoB induction by FTI-277 and GGTI-298 occurs at the transcriptional level and is blocked by actinomycin D. Reverse transcription-PCR experiments documented that the increase in RhoB protein levels is due to an increase in RhoB transcription. Furthermore, treatment with FTIs and GGTIs of cancer cells results in HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter. Thus, promoter acetylation is a novel mechanism by which RhoB expression levels are regulated following treatment with the anticancer agents FTIs and GGTIs.	H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; Univ S Florida, Dept Biochem, Tampa, FL USA; Univ S Florida, Dept Oncol, Tampa, FL USA; Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL USA; Yale Univ, Dept Chem, New Haven, CT USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Yale University	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr,SRB3-DRDIS, Tampa, FL 33612 USA.	sebti@moffitt.usf.edu	Ohkanda, Junko/I-6102-2019	Ohkanda, Junko/0000-0001-9663-5104; Zhu, Kuichun/0000-0002-3594-5616				Adnane J, 2002, CLIN CANCER RES, V8, P2225; Adnane J, 2000, ONCOGENE, V19, P5525, DOI 10.1038/sj.onc.1203920; Baron R, 2000, P NATL ACAD SCI USA, V97, P11626, DOI 10.1073/pnas.97.21.11626; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Benjamin D, 2001, NUCLEIC ACIDS RES, V29, P3603, DOI 10.1093/nar/29.17.3603; Chaya D, 2001, J BIOL CHEM, V276, P44385, DOI 10.1074/jbc.M108214200; Chen Z, 2000, J BIOL CHEM, V275, P17974, DOI 10.1074/jbc.C000145200; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Dasgupta P, 2004, J BIOL CHEM, V279, P38762, DOI 10.1074/jbc.M312273200; Dey A, 2003, P NATL ACAD SCI USA, V100, P8758, DOI 10.1073/pnas.1433065100; Du W, 1999, CANCER RES, V59, P5492; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, ANTICANCER RES, V19, P1681; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Holstein SA, 2002, BIOCHEMISTRY-US, V41, P13698, DOI 10.1021/bi026251x; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; Hunt JT, 2000, J MED CHEM, V43, P3587, DOI 10.1021/jm000248z; Jiang K, 2004, ONCOGENE, V23, P1136, DOI 10.1038/sj.onc.1207236; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Liu M, 1998, CANCER RES, V58, P4947; MAZIERES J, 2004, CLIN CANCER RES, V10, P2472; NAGASU T, 1995, CANCER RES, V55, P5310; Pan JX, 2005, CANCER RES, V65, P3671, DOI 10.1158/0008-5472.CAN-04-2744; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Sebti SM, 2000, EXPERT OPIN INV DRUG, V9, P2767, DOI 10.1517/13543784.9.12.2767; Sebti SM, 2003, NAT REV CANCER, V3, P945, DOI 10.1038/nrc1234; Sun JZ, 1998, ONCOGENE, V16, P1467, DOI 10.1038/sj.onc.1201656; Vogt A, 1997, J BIOL CHEM, V272, P27224, DOI 10.1074/jbc.272.43.27224; Wang SW, 2003, ONCOGENE, V22, P6204, DOI 10.1038/sj.onc.1206653; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	43	52	54	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	5					633	640		10.1038/sj.onc.1209819	http://dx.doi.org/10.1038/sj.onc.1209819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909123				2022-12-28	WOS:000243902200001
J	Olsson, AY; Feber, A; Edwards, S; Poele, RT; Giddings, I; Merson, S; Cooper, CS				Olsson, A. Y.; Feber, A.; Edwards, S.; Poele, R. te; Giddings, I.; Merson, S.; Cooper, C. S.			Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells	ONCOGENE			English	Article						cDNA microarray; cellular proliferation; bladder; prostate; cancer; siRNA	COMPARATIVE GENOMIC HYBRIDIZATION; URINARY-BLADDER; CHROMOSOMAL IMBALANCES; GENETIC ALTERATIONS; COPY NUMBER; AMPLIFICATION; CARCINOMA; TUMORS; RB; SPECIFICITY	cation and overexpression of the E2F3 gene at 6p22 in human bladder cancer is associated with increased tumour stage, grade and proliferation index, and in prostate cancer E2F3 overexpression is linked to tumour aggressiveness. We first used small interfering RNA technology to confirm the potential importance of E2F3 overexpression in bladder cancer development. Knockdown of E2F3 expression in bladder cells containing the 6p22 amplicon strongly reduced the extent of bromodeoxyuridine ( BrdU) incorporation and the rate of cellular proliferation. In contrast, knockdown of CDKAL1/FLJ20342, another proposed oncogene, from this amplicon had no effect. Expression cDNA microarray analysis on bladder cancer cells following E2F3 knockdown was then used to identify genes regulated by E2F3, leading to the identification of known E2F3 targets such as Cyclin A and CDC2 and novel targets including pituitary tumour transforming gene 1, Polo-like kinase 1 (PLK1) and Caveolin-2. For both bladder and prostate cancer, we have proposed that E2F3 protein overexpression may cooperate with removal of the E2F inhibitor retinoblastoma tumor suppressor protein (pRB) to drive cellular proliferation. In support of this model, we found that ectopic expression of E2F3a enhanced the BrdU incorporation, a marker of cellular proliferation rate, of prostate cancer DU145 cells, which lack pRB, but had no effect on the proliferation rate of PC3 prostate cancer cells that express wild-type pRB. BrdU incorporation in PC3 cells could, however, be increased by overexpressing E2F3a in cells depleted of pRB. When taken together, these observations indicate that E2F3 levels have a critical role in modifying cellular proliferation rate in human bladder and prostate cancer.	MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, Sutton SM2 5NG, Surrey, England; CRUK Ctr Canc Therapeut, Inst Canc Res, Male Urol Canc Res Ctr, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Olsson, AY (corresponding author), MUCRC, Inst Canc Res, Sect Mol Carcinogenesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	yvonne.olsson@icr.ac.uk		Giddings, Ian/0000-0003-1078-5780; Feber, Andrew/0000-0001-5282-0498	Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bidus MA, 2006, CLIN CANCER RES, V12, P83, DOI 10.1158/1078-0432.CCR-05-0835; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Black EP, 2005, P NATL ACAD SCI USA, V102, P15948, DOI 10.1073/pnas.0504300102; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Bruch J, 2000, CANCER RES, V60, P4526; Chakravarti A, 2003, J CLIN ONCOL, V21, P3328, DOI 10.1200/JCO.2003.12.151; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Denchi EL, 2005, MOL CELL BIOL, V25, P2660, DOI 10.1128/MCB.25.7.2660-2672.2005; Dolbeare F, 1996, HISTOCHEM J, V28, P531, DOI 10.1007/BF02331377; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Hovey RM, 1998, CANCER RES, V58, P3555; Humbert PO, 2000, GENE DEV, V14, P690; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Karan D, 2003, INT J CANCER, V103, P285, DOI 10.1002/ijc.10813; Knowles MA, 2001, J CLIN PATHOL-MOL PA, V54, P215, DOI 10.1136/mp.54.4.215; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Maddison LA, 2004, CANCER RES, V64, P6018, DOI 10.1158/0008-5472.CAN-03-2509; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Nogawa M, 2005, J CLIN INVEST, V115, P978, DOI 10.1172/JCI200523043; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; PHILLIPS SMA, 1994, BRIT J CANCER, V70, P1252, DOI 10.1038/bjc.1994.482; Prat E, 2001, UROLOGY, V57, P986, DOI 10.1016/S0090-4295(01)00909-8; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Richter J, 1999, CANCER RES, V59, P5687; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sambrook J., 2001, MOL CLONING LAB MANU; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Simon R, 2000, INT J ONCOL, V17, P1025; Terracciano L, 1999, J PATHOL, V189, P230, DOI 10.1002/(SICI)1096-9896(199910)189:2<230::AID-PATH407>3.0.CO;2-8; Theodorescu D, 1997, J UROLOGY, V158, P131, DOI 10.1097/00005392-199707000-00040; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Tomovska S, 2001, INT J ONCOL, V18, P1239; Veltman JA, 2003, CANCER RES, V63, P2872; Weichert W, 2004, PROSTATE, V60, P240, DOI 10.1002/pros.20050; WILKINSON M, 1988, NUCLEIC ACIDS RES, V16, P10934, DOI 10.1093/nar/16.22.10934; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593	43	93	98	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1028	1037		10.1038/sj.onc.1209854	http://dx.doi.org/10.1038/sj.onc.1209854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909110	Bronze			2022-12-28	WOS:000244245400009
J	Bejsovec, A				Bejsovec, A.			Flying at the head of the pack: Wnt biology in Drosophila	ONCOGENE			English	Review						wingless; Wnt; Drosophila; patterning; signal transduction	SEGMENT POLARITY GENE; WINGLESS SIGNALING PATHWAY; MAMMARY ONCOGENE INT-1; CATENIN-TCF COMPLEX; BETA-CATENIN; EMBRYONIC-DEVELOPMENT; NEGATIVE REGULATION; PLASMA-MEMBRANE; PROTEIN; ARMADILLO	The fruitfly, Drosophila melanogaster, has been of central importance in analysing the mechanics of cellular processes. Classic forward genetic screens in the fly have identified many of the genes that de. ne critical cell signaling pathways, for example. Our understanding of the Wnt pathway, in particular, has benefited from the many advantages that the fly offers as a model system. Here, I review the history of these discoveries and highlight the utility of the fly in dissecting the molecular workings of Wnt signal transduction.	Duke Univ, Dept Biol, Durham, NC 27708 USA	Duke University	Bejsovec, A (corresponding author), Duke Univ, Dept Biol, Box 91000,B336 LSRC,Res Dr, Durham, NC 27708 USA.	bejsovec@duke.edu		Bejsovec, Amy/0000-0002-8019-5789				Adler PN, 2002, DEV CELL, V2, P525, DOI 10.1016/S1534-5807(02)00176-4; Adler PN, 2001, CURR OPIN CELL BIOL, V13, P635, DOI 10.1016/S0955-0674(00)00263-5; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; BABU P, 1977, MOL GEN GENET, V151, P289, DOI 10.1007/BF00268792; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhanot P, 1999, DEVELOPMENT, V126, P4175; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Brunner E, 1999, DEV BIOL, V206, P178, DOI 10.1006/dbio.1998.9136; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DasGupta R, 2005, SCIENCE, V308, P826, DOI 10.1126/science.1109374; Dierick HA, 1998, DEVELOPMENT, V125, P4729; Hamada F, 1999, SCIENCE, V283, P1739, DOI 10.1126/science.283.5408.1739; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Jones WM, 2005, GENETICS, V169, P2075, DOI 10.1534/genetics.104.039735; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; Lawrence PA, 1995, DEVELOPMENT, V121, P4303; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; McCartney BM, 1999, J CELL BIOL, V146, P1303, DOI 10.1083/jcb.146.6.1303; McCartney BM, 2006, DEVELOPMENT, V133, P2407, DOI 10.1242/dev.02398; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Moline MM, 2000, CURR BIOL, V10, P1127, DOI 10.1016/S0960-9822(00)00697-7; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; Morgan T. H., 1936, YB CARNEGIE I WASH, V35, P289; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; Pai LM, 1997, DEVELOPMENT, V124, P2255; Parker DS, 2002, DEVELOPMENT, V129, P2565; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PERRIMON N, 1989, GENETICS, V121, P333; PERRIMON N, 1983, DEV BIOL, V100, P365, DOI 10.1016/0012-1606(83)90231-2; Polakis P, 2000, GENE DEV, V14, P1837; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; RIGGLEMAN B, 1990, CELL, V63, P549, DOI 10.1016/0092-8674(90)90451-J; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Rulifson EJ, 2000, MOL CELL, V6, P117, DOI 10.1016/S1097-2765(00)00013-7; SHARMA RP, 1976, DEV BIOL, V48, P461, DOI 10.1016/0012-1606(76)90108-1; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; Smits R, 2000, GENE CHROMOSOME CANC, V29, P229, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1033>3.0.CO;2-R; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, DEVELOPMENT, V126, P4165; Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1; Wu CH, 2002, J BIOL CHEM, V277, P41762, DOI 10.1074/jbc.M207850200; Yu X, 1999, NAT CELL BIOL, V1, P144, DOI 10.1038/11064	76	33	35	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7442	7449		10.1038/sj.onc.1210051	http://dx.doi.org/10.1038/sj.onc.1210051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143288				2022-12-28	WOS:000242514900002
J	Ohashi, S; Sakashita, G; Ban, R; Nagasawa, M; Matsuzaki, H; Murata, Y; Taniguchi, H; Shima, H; Furukawa, K; Urano, T				Ohashi, S.; Sakashita, G.; Ban, R.; Nagasawa, M.; Matsuzaki, H.; Murata, Y.; Taniguchi, H.; Shima, H.; Furukawa, K.; Urano, T.			Phospho-regulation of human protein kinase Aurora-A: analysis using anti-phospho-Thr288 monoclonal antibodies	ONCOGENE			English	Article						aurora-A; autophosphorylation; upstream kinase; phospho-specific antibody; monoclonal antibody; substrate specificity	CELL-CYCLE; SUSCEPTIBILITY GENE; CATALYTIC SUBUNIT; SIGNALING PATHWAY; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; CLEAVAGE FURROW; CENP-A; PHOSPHORYLATION; ACTIVATION	Mammalian Aurora- A is related to a serine/threonine protein kinase that was originally identified by its close homology with Saccharomyces cerevisiae IpI1p and Drosophila melanogaster aurora that are key regulators in the orchestration of mitotic events. The protein level of Aurora-A, its peak kinase activity during mitosis, and its activation have been attributed to phosphorylation. Here we show that this enzyme is an arginine-directed kinase and de. ne its substrate specificity. We also found that Thr288 within the activation loop is a critical residue for activating phosphorylation events in vitro and that it is spatiotemporally restricted to a brief window at mitosis on duplicated centrosomes and on spindle microtubules proximal to the poles in vivo. Immunodepletion assays indicated that an upstream kinase( s) of Aurora- A might exist in mammalian cells in addition to autophosphorylation. Furthermore, human activated Aurora- A forms complexes with the negative regulator protein serine/ threonine phosphatase type 1 ( PP1) that was negatively phosphorylated on Thr320. Interestingly, phospho- specific Aurora- A monoclonal antibodies restrain Aurora- A kinase activity in vitro, providing further therapeutic avenues to explore.	Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan; RIKEN, Harima Inst, Spring 8, Synchrotron Radiat Res Network,Membrane Dynam Pro, Sayo, Hyogo, Japan; Miyagi Prefectural Canc Ctr, Inst Res, Div Canc Chemotherapy, Natori, Miyagi, Japan	Nagoya University; Japan Synchrotron Radiation Research Institute; RIKEN	Urano, T (corresponding author), Nagoya Univ, Dept Biochem 2, Grad Sch Med, Showa Ku, 65 Tsurumai Machi, Nagoya, Aichi 4668550, Japan.	turano@med.nagoya-u.ac.jp	Murata, Yasunobu/Y-5799-2019	Murata, Yasunobu/0000-0001-5757-2497; Urano, Takeshi/0000-0003-3383-3554				Adams RR, 2001, TRENDS CELL BIOL, V11, P49, DOI 10.1016/S0962-8924(00)01880-8; Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; Ban R, 2004, J BIOL CHEM, V279, P16394, DOI 10.1074/jbc.M313257200; Bayliss R, 2003, MOL CELL, V12, P851, DOI 10.1016/S1097-2765(03)00392-7; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Castro A, 2002, EMBO REP, V3, P457, DOI 10.1093/embo-reports/kvf095; CHAN CSM, 1993, GENETICS, V135, P677; Cheeseman LM, 2002, CELL, V111, P163, DOI 10.1016/S0092-8674(02)00973-X; Cheetham GMT, 2002, J BIOL CHEM, V277, P42419, DOI 10.1074/jbc.C200426200; Ditchfield C, 2003, J CELL BIOL, V161, P267, DOI 10.1083/jcb.200208091; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Du J, 2004, P NATL ACAD SCI USA, V101, P8975, DOI 10.1073/pnas.0308484101; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Eyers PA, 2003, CURR BIOL, V13, P691, DOI 10.1016/S0960-9822(03)00166-0; Eyers PA, 2004, J BIOL CHEM, V279, P9008, DOI 10.1074/jbc.M312424200; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Goto H, 2002, GENES CELLS, V7, P11, DOI 10.1046/j.1356-9597.2001.00498.x; Goto H, 2003, J BIOL CHEM, V278, P8526, DOI 10.1074/jbc.M210892200; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Haydon CE, 2003, MOL CELL PROTEOMICS, V2, P1055, DOI 10.1074/mcp.M300054-MCP200; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Honda R, 2003, MOL BIOL CELL, V14, P3325, DOI 10.1091/mbc.E02-11-0769; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; Kawajiri A, 2003, MOL BIOL CELL, V14, P1489, DOI 10.1091/mbc.E02-09-0612; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kennelly PJ, 2002, FEMS MICROBIOL LETT, V206, P1, DOI 10.1016/S0378-1097(01)00479-7; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Li XY, 2004, J BIOL CHEM, V279, P47201, DOI 10.1074/jbc.M403029200; Littlepage LE, 2002, P NATL ACAD SCI USA, V99, P15440, DOI 10.1073/pnas.202606599; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; Minoshima Y, 2003, DEV CELL, V4, P549, DOI 10.1016/S1534-5807(03)00089-3; Murata-Hori M, 2000, J BIOCHEM-TOKYO, V128, P903, DOI 10.1093/oxfordjournals.jbchem.a022840; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Nowakowski J, 2002, STRUCTURE, V10, P1659, DOI 10.1016/S0969-2126(02)00907-3; Ohi R, 2004, MOL BIOL CELL, V15, P2895, DOI 10.1091/mbc.E04-02-0082; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Puntoni F, 1997, MOL CELL BIOCHEM, V171, P115, DOI 10.1023/A:1006892103306; Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246; Sakai H, 2002, J BIOL CHEM, V277, P48714, DOI 10.1074/jbc.M208461200; Sausville EA, 2004, NAT MED, V10, P234, DOI 10.1038/nm0304-234; Sessa F, 2005, MOL CELL, V18, P379, DOI 10.1016/j.molcel.2005.03.031; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; Sugiyama K, 2002, ONCOGENE, V21, P3103, DOI 10.1038/sj.onc.1205432; Taguchi S, 2002, FEBS LETT, V519, P59, DOI 10.1016/S0014-5793(02)02711-4; Tanaka M, 2002, J BIOL CHEM, V277, P10719, DOI 10.1074/jbc.M108252200; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Walter AO, 2000, ONCOGENE, V19, P4906, DOI 10.1038/sj.onc.1203847; Wheatley SP, 2004, J BIOL CHEM, V279, P5655, DOI 10.1074/jbc.M311299200; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Xu ZB, 2004, J BIOL CHEM, V279, P50401, DOI 10.1074/jbc.M409216200; YAMANO H, 1994, EMBO J, V13, P5310, DOI 10.1002/j.1460-2075.1994.tb06865.x; Yasui Y, 2004, J BIOL CHEM, V279, P12997, DOI 10.1074/jbc.M311128200; Yu CTR, 2005, MOL CELL BIOL, V25, P5789, DOI 10.1128/MCB.25.14.5789-5800.2005; Zeitlin SG, 2001, J CELL BIOL, V155, P1147, DOI 10.1083/jcb.200108125; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	79	75	79	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7691	7702		10.1038/sj.onc.1209754	http://dx.doi.org/10.1038/sj.onc.1209754			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785988				2022-12-28	WOS:000242830800004
J	Winograd-Katz, SE; Levitzki, A				Winograd-Katz, S. E.; Levitzki, A.			Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor	ONCOGENE			English	Article						therapy; cisplatin; p38; EGPR; phosphorylation	GROWTH-FACTOR RECEPTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; THREONINE PHOSPHORYLATION; INDEPENDENT MECHANISMS; PI3K/AKT PATHWAY; CELLS; P38; RESISTANCE; SIGNAL	Cisplatin is an effective DNA-damaging antitumor agent employed for the treatment of various human cancers. In this study, we report that Cisplatin activates PKB/Akt in several cancer cell lines and that this activation is mediated by EGFR, Src and PI3-kinase. Inhibition of PI3-kinase activity decreases the survival of the cells exposed to Cisplatin, suggesting that Cisplatin-induced PKB/Akt activation may lead to Cisplatin resistance. While investigating the EGFR-dependent PKB/Akt activation in MDA-MB-468 cells, we found that the EGFR receptor undergoes a gel mobility shift upon Cisplatin treatment, which is mediated by p38(MAPK). An EGFR, in which threonine 669 was mutated to alanine (A669), is phosphorylated by p38MAPK to a much lesser extent, suggesting that threonine 669 is a p38 phosphorylation site. We found that Cisplatin induces EGFR internalization, which is mediated by p38(MAPK-) dependent phosphorylation of the receptor on threonine 669. Our results identify the EGFR as a new substrate of p38 and identify threonine 669 as a new phosphorylation site that regulates EGFR internalization. Together, these results suggest that Cisplatin has side effects, which may alter the signaling pattern of cancer cells and modulate the desired effects of Cisplatin treatment.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Unit Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il						Bagowski CP, 1999, EMBO J, V18, P5567, DOI 10.1093/emboj/18.20.5567; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Bell M, 2001, J BIOL CHEM, V276, P25351, DOI 10.1074/jbc.M101818200; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Benhar M, 2001, MOL CELL BIOL, V21, P6913, DOI 10.1128/MCB.21.20.6913-6926.2001; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Deschesnes RG, 2001, MOL BIOL CELL, V12, P1569, DOI 10.1091/mbc.12.6.1569; Fan MY, 2001, DRUG RESIST UPDATE, V4, P253, DOI 10.1054/drup.2001.0214; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Hayakawa J, 2000, CANCER RES, V60, P5988; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kaushal GP, 2001, KIDNEY INT, V60, P1726, DOI 10.1046/j.1523-1755.2001.00026.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LITMAN P, 2006, UNPUB; MORRISON P, 1993, J BIOL CHEM, V268, P15536; NORTHWOOD IC, 1991, J BIOL CHEM, V266, P15266; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; TAKISHIMA K, 1988, BIOCHEM BIOPH RES CO, V157, P740, DOI 10.1016/S0006-291X(88)80312-7; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	37	143	148	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7381	7390		10.1038/sj.onc.1209737	http://dx.doi.org/10.1038/sj.onc.1209737			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785992	Bronze			2022-12-28	WOS:000242419100007
J	Bos, CL; Kodach, LL; van den Brink, GR; Diks, SH; van Santen, MM; Richel, DJ; Peppelenbosch, MP; Hardwick, JCH				Bos, C. L.; Kodach, L. L.; van den Brink, G. R.; Diks, S. H.; van Santen, M. M.; Richel, D. J.; Peppelenbosch, M. P.; Hardwick, J. C. H.			Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A	ONCOGENE			English	Article						aspirin; Wnt/beta-catenin; PP2A; colon cancer; chemoprevention	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLON-CANCER CELLS; FAMILIAL ADENOMATOUS POLYPOSIS; NF-KAPPA-B; BETA-CATENIN; COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITOR; SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT; OKADAIC ACID	Nonsteroidal anti-inflammatory drugs show chemopreventive efficacy in colon cancer, but the mechanism behind this remains unclear. Elucidating this mechanism is seen as vital to the development of new chemopreventive agents. We studied the effects of aspirin on the oncogenic Wnt/beta-catenin pathway activity in colorectal cancer cell lines and observed that aspirin dose-dependently decreased the activity of this pathway, as judged by TCF-driven luciferase activity, reduced Wnt target gene expression and increased phosphorylation of beta-catenin by immunoblotting. Furthermore, the ubiquitination and cytoplasmic levels of beta-catenin were assessed by immunoblotting, and also the localization of b-catenin was shown by green fluorescent protein-tagged beta-catenin and time-lapse fluorescent imaging. Importantly, aspirin treatment caused increased phosphorylation of protein phosphatase 2A (PP2A), an event associated with inhibition of PP2A enzymatic activity, which was confirmed by a reduction in enzymatic PP2A activity. Moreover, this inhibition of PP2A enzymatic activity was essential for the effects of aspirin on the Wnt/beta-catenin pathway as shown by transient transfection with PP2A constructs. The findings in this article provide a molecular explanation for the efficacy of aspirin in chemoprevention of colorectal cancer and shows biochemical evidence that PP2A is an important regulator of Wnt/beta-catenin pathway activity in these cells.	Univ Amsterdam, Lab Expt Oncol & Radiobiol, Amsterdam, Netherlands; Univ Amsterdam, Dept Oncol, Amsterdam, Netherlands; Univ Amsterdam, Lab Expt Internal Med, Amsterdam, Netherlands; Univ Amsterdam, Dept Gastroenterol, Amsterdam, Netherlands; Univ Groningen, Dept Cell Biol, Groningen, Netherlands	University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Amsterdam; University of Groningen	Hardwick, JCH (corresponding author), Acad Med Ctr, Dept Gastroenterol, C2-112,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	j.c.hardwick@amc.uva.nl	; Hardwick, James/J-4862-2013	Peppelenbosch, Maikel/0000-0001-9112-6028; Hardwick, James/0000-0002-9575-5099; Kodach, Liudmila/0000-0003-2487-3204				Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; Boon EMJ, 2002, CANCER RES, V62, P5126; Charalambous D, 1996, J GASTROEN HEPATOL, V11, P307, DOI 10.1111/j.1440-1746.1996.tb01376.x; Chung HY, 1999, BIOCHEMISTRY-US, V38, P10371, DOI 10.1021/bi990902g; Dihlmann S, 2003, MOL CANCER THER, V2, P509; Dihlmann S, 2001, ONCOGENE, V20, P645, DOI 10.1038/sj.onc.1204123; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; GIOVANNUCCI E, 1995, NEW ENGL J MED, V333, P609, DOI 10.1056/NEJM199509073331001; Green DW, 2001, J SURG RES, V101, P16, DOI 10.1006/jsre.2001.6241; Gupta RA, 1998, GASTROENTEROLOGY, V114, P1095, DOI 10.1016/S0016-5085(98)70330-0; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Husain SS, 2002, AM J GASTROENTEROL, V97, P542; Kishimoto Y, 2000, GUT, V47, P812, DOI 10.1136/gut.47.6.812; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nunbhakdi-Craig V, 2002, J CELL BIOL, V158, P967, DOI 10.1083/jcb.200206114; Orena SJ, 2000, J BIOL CHEM, V275, P15765, DOI 10.1074/jbc.M910002199; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Oshima H, 1997, CANCER RES, V57, P1644; POLAKIS P, 1997, BIOCHIM BIOPHYS ACTA, V1332, P127; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Roh H, 2001, CANCER RES, V61, P6563; Schonthal AH, 2001, CANCER LETT, V170, P1, DOI 10.1016/S0304-3835(01)00561-4; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Smal C, 2004, BIOCHEM PHARMACOL, V68, P95, DOI 10.1016/j.bcp.2004.02.031; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Stark LA, 2001, FASEB J, V15, P1273, DOI 10.1096/fj.00-0529fje; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tegeder I, 2001, FASEB J, V15, P2057, DOI 10.1096/fj.01-0390rev; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Xie HQ, 1998, BRAIN RES, V798, P173, DOI 10.1016/S0006-8993(98)00407-7	42	118	123	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 19	2006	25	49					6447	6456		10.1038/sj.onc.1209658	http://dx.doi.org/10.1038/sj.onc.1209658			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16878161				2022-12-28	WOS:000241395100001
J	Vitagliano, D; Portella, G; Troncone, G; Francione, A; Rossi, C; Bruno, A; Giorgini, A; Coluzzi, S; Nappi, TC; Rothstein, JL; Pasquinelli, R; Chiappetta, G; Terracciano, D; Macchia, V; Melillo, RM; Fusco, A; Santoro, M				Vitagliano, D.; Portella, G.; Troncone, G.; Francione, A.; Rossi, C.; Bruno, A.; Giorgini, A.; Coluzzi, S.; Nappi, T. C.; Rothstein, J. L.; Pasquinelli, R.; Chiappetta, G.; Terracciano, D.; Macchia, V.; Melillo, R. M.; Fusco, A.; Santoro, M.			Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas	ONCOGENE			English	Article						kinase; carcinoma; thyroid; ras; progression; differentiation	TISSUE-SPECIFIC EXPRESSION; PAPILLARY CARCINOMAS; RAS ONCOGENE; THYROGLOBULIN PROMOTER; RET/PTC1 ONCOGENE; PCCL3 CELLS; MUTATIONS; CANCER; INSTABILITY; DEDIFFERENTIATION	Ras oncogenes are frequently mutated in thyroid carcinomas. To verify the role played by N-ras in thyroid carcinogenesis, we generated transgenic mice in which a human N-ras(Gln61Lys) oncogene (Tg-N-ras) was expressed in the thyroid follicular cells.Tg-N-ras mice developed thyroid follicular neoplasms; 11% developed follicular adenomas and similar to 40% developed invasive follicular carcinomas, in some cases with a mixed papillary/follicular morphology. About 25% of the Tg-N-ras carcinomas displayed large, poorly differentiated areas, featuring vascular invasion and forming lung, bone or liver distant metastases. N-ras(Gln61Lys) express ion in cultured PC Cl 3 thyrocytes induced thyroid-stimulating hormone-independent proliferation and genomic instability with micronuclei formation and centrosome amplification. These findings support the notion that mutated ras oncogenes could be able to drive the formation of thyroid tumors that can progress to poorly differentiated, metastatic carcinomas.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Sci Biomorfol & Funzionali, I-80131 Naples, Italy; Consorzio Mario Negri Sud, Chieti, Italy; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol Immunol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Otolaryngol Head & Neck Surg, Philadelphia, PA 19107 USA; Fdn Pascale, Ist Nazl Tumori, Funt Genom Unit, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consorzio Mario Negri Sud; Jefferson University; Jefferson University; IRCCS Fondazione Pascale	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Fac Med, CNR,Ist Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Portella, Giuseppe/AFU-6826-2022; vitagliano, donata/B-8976-2012; melillo, rosa marina/O-5255-2015; Terracciano, Daniela/AAB-9521-2022	Terracciano, Daniela/0000-0003-4296-429X; PORTELLA, Giuseppe/0000-0001-8276-9769; Fusco, Alfredo/0000-0003-3332-5197; Coluzzi, Sabrina/0000-0003-4483-6232; MELILLO, Rosa Marina/0000-0002-9233-5275				CARCANGIU ML, 1984, AM J SURG PATHOL, V8, P655, DOI 10.1097/00000478-198409000-00005; DELELLIS RA, 2004, TUMOURS ENDOCRINE OR, P51; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X; Fagin JA, 2004, J ENDOCRINOL, V183, P249, DOI 10.1677/joe.1.05895; Fagin JA, 2002, MOL ENDOCRINOL, V16, P903, DOI 10.1210/me.16.5.903; Garcia-Rostan G, 2003, J CLIN ONCOL, V21, P3226, DOI 10.1200/JCO.2003.10.130; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; GRECO A, 1992, ONCOGENE, V7, P237; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; JOKINEN MP, 1994, PATHOLOGY TUMOURS LA, V2, P565; Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; Ledent C, 1996, EXP CLIN ENDOCR DIAB, V104, P43, DOI 10.1055/s-0029-1211683; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Motoi O, 2000, PATHOL RES PRACT, V196, P1; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P2318, DOI 10.1210/jc.2002-021907; Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838; Postiglione MP, 2002, P NATL ACAD SCI USA, V99, P15462, DOI 10.1073/pnas.242328999; Powell DJ, 1998, CANCER RES, V58, P5523; Rochefort P, 1996, ONCOGENE, V12, P111; Russell JP, 2000, ONCOGENE, V19, P5729, DOI 10.1038/sj.onc.1203922; Saavedra HI, 2000, ONCOGENE, V19, P3948, DOI 10.1038/sj.onc.1203723; SANTELLI G, 1993, CANCER RES, V53, P5523; Santoro M, 1996, ONCOGENE, V12, P1821; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Tallini G, 2002, ENDOCR PATHOL, V13, P271, DOI 10.1385/EP:13:4:271; Vasko V, 2003, J CLIN ENDOCR METAB, V88, P2745, DOI 10.1210/jc.2002-021186; Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978; Zhu ZW, 2003, AM J CLIN PATHOL, V120, P71, DOI 10.1309/ND8D9LAJTRCTG6QD	35	55	56	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	39					5467	5474		10.1038/sj.onc.1209527	http://dx.doi.org/10.1038/sj.onc.1209527			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	078ZI	16785999				2022-12-28	WOS:000240144900011
J	Wong, KK; Maser, RS; Sahin, E; Bailey, ST; Xia, H; Ji, H; McNamara, K; Naylor, M; Bronson, RT; Ghosh, S; Welsh, R; DePinho, RA				Wong, K-K; Maser, R. S.; Sahin, E.; Bailey, S. T.; Xia, H.; Ji, H.; McNamara, K.; Naylor, M.; Bronson, R. T.; Ghosh, S.; Welsh, R.; DePinho, R. A.			Diminished lifespan and acute stress-induced death in DNA-PKcs-deficient mice with limiting telomeres	ONCOGENE			English	Article						DNAPKcs; telomere; telomerase; stress; aging; cytokines	NF-KAPPA-B; ACTIVATION; REPAIR; AGE; KU; RESTRICTION; MAINTENANCE; DYSFUNCTION; IMMUNITY; LACKING	An adequate and appropriate response to physiological and pathophysiological stresses is critical for long-term homeostasis and viability of the aging organism. Previous work has pointed to the immune system, telomeres and DNA repair pathways as important and distinct determinants of a normal healthy lifespan. In this study, we explored the genetic interactions of telomeres and DNA-PKcs, a protein involved in non-homologous end-joining (NHEJ) and immune responses, in the context of a key aspect of aging and lifespan - the capacity to mount an acute and appropriate immune-mediated stress response. We observed that the combination of DNA-PKcs deficiency and telomere dysfunction resulted in a shortened lifespan that was reduced further following viral infection or experimental activation of the innate immune response. Analysis of the innate immune response in the DNA-PKcs-deficient mice with short dysfunctional telomeres revealed high basal serum levels of tumor necrosis factor alpha (TNF alpha) and hyper-active cytokine responses upon challenge with polyinosinic-polycytidylic acid (poly-IC). We further show that serum cytokine levels become elevated in telomere dysfunctional mice as a function of age. These results raise speculation that these genetic factors may contribute to misdirected immune responses of the aged under conditions of acute and chronic stress.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Harvard Univ, Sch Med, Dept Genet & Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA; Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Yale University; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yale University; Yale University; University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,M413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu	Bailey, Shannon/B-8045-2014; Maser, Richard/B-2970-2012	DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [P01CA095616, R01CA034461, U01CA084313, R01CA084628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84313, P01 CA95616, R01 CA84628, CA34461] Funding Source: Medline; NIA NIH HHS [K08 AG2400401] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bruunsgaard H, 2003, AM J MED, V115, P278, DOI 10.1016/S0002-9343(03)00329-2; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; DAYNES RA, 1993, J IMMUNOL, V150, P5219; ERSHLER WB, 1993, LYMPHOKINE CYTOK RES, V12, P225; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Karpova AY, 2002, P NATL ACAD SCI USA, V99, P2818, DOI 10.1073/pnas.052713899; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Maser RS, 2004, DNA REPAIR, V3, P979, DOI 10.1016/j.dnarep.2004.05.009; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Salminen A, 1997, BIOCHEM BIOPH RES CO, V238, P712, DOI 10.1006/bbrc.1997.7371; Smogorzewska A, 2002, CURR BIOL, V12, P1635, DOI 10.1016/S0960-9822(02)01179-X; Um JH, 2003, MECH AGEING DEV, V124, P967, DOI 10.1016/S0047-6374(03)00169-6; WOLLSCHEIDLENGE.E, 2004, SCI AGING KNOWL ENV, pPE2; Wong KK, 2000, NAT GENET, V26, P85, DOI 10.1038/79232; Wong KK, 2003, NATURE, V421, P643, DOI 10.1038/nature01385	24	5	6	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2815	2821		10.1038/sj.onc.1210099	http://dx.doi.org/10.1038/sj.onc.1210099			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072335				2022-12-28	WOS:000246210800001
J	Huang, HC; Hu, CH; Tang, MC; Wang, WS; Chen, PM; Su, Y				Huang, H.-C.; Hu, C.-H.; Tang, M.-C.; Wang, W.-S.; Chen, P.-M.; Su, Y.			Thymosin beta 4 triggers an epithelial-mesenchymal transition in colorectal carcinoma by upregulating integrin-linked kinase	ONCOGENE			English	Article						thymosin beta 4; E-cadherin; beta-catenin; integrin-linked kinase; epithelial-mesenchymal transition	E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; REPRESSES E-CADHERIN; CELL-CELL-ADHESION; COLON-CANCER; TUMOR-CELLS; CATENIN; GENE; PHOSPHORYLATION; INVASION	The epithelial-mesenchymal transition (EMT) is crucial for the invasion and metastasis of many epithelial tumors including colorectal carcinoma (CRC). In the present study, a scattering and fibroblastic morphology with reduced intercellular contacts was found in the SW480 colon cancer cells overexpressing the gene encoding thymosin beta 4 (T beta(4)), which was accompanied by a loss of E-cadherin as well as a cytosolic accumulation of beta-catenin, two most prominent markers of EMT. Whereas E-cadherin downregulation was likely to be accounted by a ZEB1-mediated transcriptional repression, the accumulation of beta-catenin was a result of glycogen synthase kinase-3 beta inactivation mediated by integrin-linked kinase (ILK) and/or its downstream effector, Akt. Intriguingly, ILK upregulation in T beta(4)-overexpressing SW480 cells seemed to be attributed mainly to a stabilization of this kinase by complexing with particularly interesting new Cys-His protein (PINCH) more efficiently. In the meantime, a strong correlation between the expression levels of T beta(4), ILK and E-cadherin in CRC patients was also revealed by immunohistochemical analysis. Taken together, these data suggest a novel role of T beta(4) in promoting CRC progression by inducing an EMT in tumor cells via upregulating ILK and consequentially its signal transduction.	Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan; Natl Taiwan Ocean Univ, Coll Life Sci, Inst Biosci & Biotechnol, Chilung, Taiwan; Taipei Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan	National Yang Ming Chiao Tung University; National Taiwan Ocean University; Taipei Veterans General Hospital	Su, Y (corresponding author), Natl Yang Ming Univ, Coll Life Sci, Inst Biopharmaceut Sci, Taipei 112, Taiwan.	yeusu@ym.edu.tw						Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Brakebusch C, 2003, EMBO J, V22, P2324, DOI 10.1093/emboj/cdg245; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hajra KM, 2002, CANCER RES, V62, P1613; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Ito K, 1999, ONCOGENE, V18, P7080, DOI 10.1038/sj.onc.1203191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Keller SH, 2003, BIOCHEM BIOPH RES CO, V307, P215, DOI 10.1016/S0006-291X(03)01143-4; Kemler R, 1992, Semin Cell Biol, V3, P149; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Noe V, 2001, J CELL SCI, V114, P111; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Pecina-Slaus N, 2005, PATHOL RES PRACT, V201, P557, DOI 10.1016/j.prp.2005.07.001; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Potter E, 1999, ENDOCR REV, V20, P207, DOI 10.1210/er.20.2.207; Provost E, 2003, J BIOL CHEM, V278, P31781, DOI 10.1074/jbc.M304953200; RISINGER JI, 1994, NAT GENET, V7, P98, DOI 10.1038/ng0594-98; SANDERS MC, 1992, P NATL ACAD SCI USA, V89, P4678, DOI 10.1073/pnas.89.10.4678; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sawhney RS, 2004, J BIOL CHEM, V279, P47379, DOI 10.1074/jbc.M402031200; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura G, 2000, J NATL CANCER I, V92, P569, DOI 10.1093/jnci/92.7.569; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wang WS, 2004, ONCOGENE, V23, P6666, DOI 10.1038/sj.onc.1207888; Wang WS, 2003, ONCOGENE, V22, P3297, DOI 10.1038/sj.onc.1206404; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yang SP, 2005, MOL CELL BIOCHEM, V272, P97, DOI 10.1007/s11010-005-7642-4; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	57	88	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2781	2790		10.1038/sj.onc.1210078	http://dx.doi.org/10.1038/sj.onc.1210078			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072345				2022-12-28	WOS:000246210600012
J	Zhong, S; Fields, CR; Su, N; Pan, YX; Robertson, KD				Zhong, S.; Fields, C. R.; Su, N.; Pan, Y-X; Robertson, K. D.			Pharmacologic inhibition of epigenetic modi. cations, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer	ONCOGENE			English	Article						lung cancer; DNA methylation; 5-aza-2 '-deoxycytidine; trichostatin A; histone acetylation; microarray	PROMOTER HYPERMETHYLATION; EARLY EVENT; TUMOR; MARKER; ADENOCARCINOMA; EPIGENOME; OXYTOCIN; BINDING; OCCURS; CELLS	Lung cancer is the leading cause of cancer-related deaths in the United States due, in large part, to the lack of early detection methods. Lung cancer arises from a complex series of genetic and epigenetic changes leading to uncontrolled cell growth and metastasis. Unlike genetic changes, epigenetic changes, such as DNA methylation and histone acetylation, are reversible with currently available pharmaceuticals and are early events in lung tumorigenesis detectable by non-invasive methods. In order to better understand how epigenetic changes contribute to lung cancer, and to identify new disease biomarkers, we combined pharmacologic inhibition of DNA methylation and histone deacetylation in non-small cell lung cancer (NSCLC) cell lines, with genome-wide expression proling. Of the more than 200 genes upregulated by these treatments, three of these, neuronatin, metallothionein 3 and cystatin E/M, were frequently hypermethylated and transcriptionally down-regulated in NSCLC cell lines and tumors. Interestingly, four other genes, cylindromatosis, CD9, activating transcription factor 3 and oxytocin receptor, were dominantly regulated by histone deacetylation and were also frequently down-regulated in lung tumors. The majority of these genes also suppressed NSCLC growth in culture when ectopically expressed. This study therefore reveals new putative NSCLC growth regulatory genes and epigenetic disease biomarkers that may enhance early detection strategies and serve as therapeutic targets.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Genet Inst, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Robertson, KD (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, UF Shands Canc Ctr Program Canc Genet Epigenet &, Gainesville, FL 32610 USA.	keithr@ufl.edu	Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367; Robertson, Keith/0000-0002-7508-3328	NCI NIH HHS [K22CA084535, R01CA114229] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K22CA084535, R01CA114229] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576; Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432; Belinsky SA, 2003, CANCER RES, V63, P7089; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bottone FG, 2003, J BIOL CHEM, V278, P25790, DOI 10.1074/jbc.M301002200; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cassoni P, 2004, J NEUROENDOCRINOL, V16, P362, DOI 10.1111/j.0953-8194.2004.01165.x; Chen H, 2004, J BIOL CHEM, V279, P50829, DOI 10.1074/jbc.M409173200; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dutta R, 2002, PROSTATE, V52, P89, DOI 10.1002/pros.10097; Eickhoff B, 2000, BIOL CHEM, V381, P107, DOI 10.1515/BC.2000.015; Espada J, 2004, J BIOL CHEM, V279, P37175, DOI 10.1074/jbc.M404842200; Esteller M, 1999, CANCER RES, V59, P67; Evans HK, 2001, GENOMICS, V77, P99, DOI 10.1006/geno.2001.6612; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Fiegl H, 2005, CANCER RES, V65, P1141, DOI 10.1158/0008-5472.CAN-04-2438; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029; Hai T, 1999, GENE EXPRESSION, V7, P321; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Karpf AR, 1999, P NATL ACAD SCI USA, V96, P14007, DOI 10.1073/pnas.96.24.14007; Kim MS, 2003, CANCER RES, V63, P7291; Kim TY, 2006, CANCER RES, V66, P7490, DOI 10.1158/0008-5472.CAN-05-4552; Kuerbitz SJ, 2002, CARCINOGENESIS, V23, P559, DOI 10.1093/carcin/23.4.559; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; Pequeux C, 2005, LUNG CANCER, V50, P177, DOI 10.1016/j.lungcan.2005.05.027; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sato N, 2003, JNCI-J NATL CANCER I, V95, P327, DOI 10.1093/jnci/95.4.327; Schrump DS, 2005, SEMIN ONCOL, V32, P488, DOI 10.1053/j.seminoncol.2005.07.007; Somech R, 2004, CANCER TREAT REV, V30, P461, DOI 10.1016/j.ctrv.2004.04.006; Suh YH, 2005, BIOCHEM BIOPH RES CO, V337, P481, DOI 10.1016/j.bbrc.2005.09.078; Topaloglu O, 2004, CLIN CANCER RES, V10, P2284, DOI 10.1158/1078-0432.CCR-1111-3; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712	51	104	108	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2621	2634		10.1038/sj.onc.1210041	http://dx.doi.org/10.1038/sj.onc.1210041			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043644				2022-12-28	WOS:000245831200009
J	Safina, A; Vandette, E; Bakin, AV				Safina, A.; Vandette, E.; Bakin, A. V.			ALK5 promotes tumor angiogenesis by upregulating matrix metalloproteinase-9 in tumor cells	ONCOGENE			English	Article						invasion; metastasis; MMP-9; MAPK; TGF-beta; angiogenesis	GROWTH-FACTOR-BETA; ACTIVATED PROTEIN-KINASE; BREAST-CANCER CELLS; TGF-BETA; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; MOLECULAR-BIOLOGY; METASTASIS; IDENTIFICATION; EXPRESSION	Transforming growth factor beta 1 (TGF-beta 1) is a potent tumor suppressor but, paradoxically, TGF-beta 1 enhances tumor growth and metastasis in the late stages of cancer progression. This study investigated the role of TGF-beta type I receptor, ALK5, and three mitogen-activated protein kinases (MAPKs) in metastasis by breast cancer cell line MDA-MB-231. We show that autocrine TGF-beta signaling in MDA-MB-231 cells is required for tumor cell invasion and tumor angiogenesis. Expression of kinase inactive ALK5 reduces tumor invasion and formation of new blood vessels within the tumor orthotopic xenografts in severe combined immunodeficiency (SCID) mice. In contrast, constitutively active ALK5-T204D enhances tumor invasion and angiogenesis by stimulating expression of matrix metalloproteinase MMP-9/gelatinase-B. Ablation of MMP-9 in ALK5-T204D cells by RNA interference (RNAi) reduces tumor invasion and tumor growth. Importantly, RNAi-MMP-9 reduces tumor neovasculature and increases tumor cell death. Induction of MMP-9 by TGF-beta-ALK5 signaling requires MEK-ERK but not JNK, p38 MAPK or Smad4. Dominant-negative MEK blocks and constitutively active MEK1 enhances MMP-9 expression. However, all three MAPK cascades (ERK, JNK and p38 MAPK) are required for TGF-beta-mediated cell migration. Collectively, our results show that TGF-beta-ALK5-MAPK signaling in tumor cells promotes tumor angiogenesis and MMP-9 is an important component of this program.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Bakin, AV (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.	andrei.bakin@roswellpark.org		Bakin, Andrei/0000-0002-7728-1969	NATIONAL CANCER INSTITUTE [R01CA095263, P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16056, R01 CA95263] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2004, MOL BIOL CELL, V15, P4682, DOI 10.1091/mbc.E04-04-0353; Bakin AV, 2002, J CELL SCI, V115, P3193; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; Benckert C, 2003, CANCER RES, V63, P1083; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bertolino P, 2005, CHEST, V128, p585S, DOI 10.1378/chest.128.6_suppl.585S; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bhattacharya A, 2004, CLIN CANCER RES, V10, P8005, DOI 10.1158/1078-0432.CCR-04-1306; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008-5472.CAN-03-0160; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dumon N, 2003, J BIOL CHEM, V278, P3275, DOI 10.1074/jbc.M204623200; Dumont N, 2003, BIOCHEM BIOPH RES CO, V301, P108, DOI 10.1016/S0006-291X(02)02977-7; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Eyers PA, 1998, CHEM BIOL, V5, P321, DOI 10.1016/S1074-5521(98)90170-3; Farina AR, 1998, INT J CANCER, V75, P721; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Frey RS, 1997, CANCER RES, V57, P628; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Janji B, 1999, INT J CANCER, V83, P255, DOI 10.1002/(SICI)1097-0215(19991008)83:2<255::AID-IJC18>3.3.CO;2-O; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Johansson N, 2000, J CELL SCI, V113, P227; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; LEENEN PJM, 1994, J IMMUNOL METHODS, V174, P5, DOI 10.1016/0022-1759(94)90005-1; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; PRICE JE, 1990, CANCER RES, V50, P717; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Seals DF, 2005, CANCER CELL, V7, P155, DOI 10.1016/j.ccr.2005.01.006; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Suarez-Cuervo C, 2004, CLIN EXP METASTAS, V21, P525, DOI 10.1007/s10585-004-3503-x; TARIN D, 1981, CANCER RES, V41, P3604; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Van den Steen PE, 2002, CRIT REV BIOCHEM MOL, V37, P375, DOI 10.1080/10409230290771546; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Welch DR, 2000, BREAST CANCER RES, V2, P408, DOI 10.1186/bcr87; WEXLER H, 1966, JNCI-J NATL CANCER I, V36, P641, DOI 10.1093/jnci/36.4.641; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang Wei, 2002, Angiogenesis, V5, P35, DOI 10.1023/A:1021540120521	65	78	81	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2407	2422		10.1038/sj.onc.1210046	http://dx.doi.org/10.1038/sj.onc.1210046			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17072348				2022-12-28	WOS:000245831000002
J	Yemelyanov, A; Czwornog, J; Chebotaev, D; Karseladze, A; Kulevitch, E; Yang, X; Budunova, I				Yemelyanov, A.; Czwornog, J.; Chebotaev, D.; Karseladze, A.; Kulevitch, E.; Yang, X.; Budunova, I.			Tumor suppressor activity of glucocorticoid receptor in the prostate	ONCOGENE			English	Article						prostate carcinoma; PIN; glucocorticoid receptor; PC marker; transcription factor; MAPKs	METHYLACYL-COA RACEMASE; ANDROGEN RECEPTOR; DIFFERENTIAL EXPRESSION; MOLECULAR-MECHANISMS; CANCER; APOPTOSIS; PATHWAY; KINASE; GROWTH; DEXAMETHASONE	Glucocorticoids are extensively used in combination chemotherapy of advanced prostate cancer (PC). Little is known, however, about the status of the glucocorticoid receptor (GR) in PC. We evaluated over 200 prostate samples and determined that GR expression was strongly decreased or absent in 70 - 85% of PC. Similar to PC tumors, some PC cell lines, including LNCaP, also lack GR. To understand the role of GR, we reconstituted its expression in LNCaP cells using lentiviral approach. Treatment of LNCaP-GR cells with the glucocorticoids strongly inhibited proliferation in the monolayer cultures and blocked anchorage-independent growth. This was accompanied by upregulation of p21 and p27, downregulation of cyclin D1 expression and c-Myc phosphorylation. Importantly, the activation of GR resulted in normalized expression of PC markers hepsin, AMACR, and maspin. On the signaling level, GR decreased expression and inhibited activity of the MAP-kinases (MAPKs) including p38, JNK/SAPK, Mek1/2 and Erk1/2. We also found that activation of GR inhibited activity of numerous transcription factors (TF) including AP-1, SRF, NF-kappa B, p53, ATF-2, CEBP alpha, Ets-1, Elk-1, STAT1 and others, many of which are regulated via MAPK cascade. The structural analysis of hepsin and AMACR promoters provided the mechanistic rationale for PC marker downregulation by glucocorticoids via inhibition of specific TFs. Our data suggest that GR functions as a tumor suppressor in prostate, and inhibits multiple signaling pathways and transcriptional factors involved in proliferation and transformation.	Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Chicago, IL 60611 USA; Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Dept Pathol, Moscow, Russia; Northwestern Univ, Feinberg Med Sch, Dept Pathol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; N.N. Blokhin Russian Cancer Research Center; Russian Academy of Medical Sciences; Northwestern University; Feinberg School of Medicine	Budunova, I (corresponding author), Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i_budunova@northwestern.edu						Ananthanarayanan V, 2005, PROSTATE, V63, P341, DOI 10.1002/pros.20196; Bourcier T, 2000, INVEST OPHTH VIS SCI, V41, P4133; Bruna A, 2003, EMBO J, V22, P6035, DOI 10.1093/emboj/cdg590; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Chen ZX, 2003, J UROLOGY, V169, P1316, DOI 10.1097/01.ju.0000050648.40164.0d; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Fakih M, 2002, UROLOGY, V60, P553, DOI 10.1016/S0090-4295(02)01741-7; Fixemer T, 2003, PROSTATE, V54, P79, DOI 10.1002/pros.10171; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Greenberg AK, 2002, AM J RESP CELL MOL, V27, P320, DOI 10.1165/rcmb.4710; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Jiang X, 2004, J BIOL CHEM, V279, P38480, DOI 10.1074/jbc.M403948200; Jiang Z, 2004, ADV ANAT PATHOL, V11, P316, DOI 10.1097/01.pap.0000146924.14246.be; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Klezovitch O, 2004, CANCER CELL, V6, P185, DOI 10.1016/j.ccr.2004.07.008; Koutsilieris M, 2002, EXPERT OPIN INV DRUG, V11, P283; Li CL, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P172; Maroni Paul D, 2004, Cell Commun Signal, V2, P5, DOI 10.1186/1478-811X-2-5; Mimeault M, 2003, GROWTH FACTORS, V21, P1, DOI 10.1080/0897719031000094921; Mohler JL, 1996, CLIN CANCER RES, V2, P889; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Nishimura K, 2001, J NATL CANCER I, V93, P1739, DOI 10.1093/jnci/93.22.1739; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Quinn DI, 2005, EUR J CANCER, V41, P858, DOI 10.1016/j.ejca.2004.12.035; Ray DW, 1996, J ENDOCRINOL, V149, P1, DOI 10.1677/joe.0.1490001; Ricote M, 2006, J PATHOL, V208, P401, DOI 10.1002/path.1910; ROSENBERG I, 1996, PROTEIN ANAL PURIFIC, P103; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schaefer JS, 2003, CURR MOL MED, V3, P653, DOI 10.2174/1566524033479519; SCHUG J, 2005, EUR J CANCER, V41, P858; Torlakovic E, 2005, INT J CANCER, V117, P381, DOI 10.1002/ijc.21174; Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Zha S, 2003, CANCER RES, V63, P7365	36	98	109	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1885	1896		10.1038/sj.onc.1209991	http://dx.doi.org/10.1038/sj.onc.1209991			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17016446				2022-12-28	WOS:000245117700006
J	Pastural, E; Takahashi, N; Dong, WF; Bainbridge, M; Hull, A; Pearson, D; Huang, S; Lowsky, R; DeCoteau, JF; Geyer, CR				Pastural, E.; Takahashi, N.; Dong, W-F; Bainbridge, M.; Hull, A.; Pearson, D.; Huang, S.; Lowsky, R.; DeCoteau, J. F.; Geyer, C. R.			RIZ1 repression is associated with insulin-like growth factor-1 signaling activation in chronic myeloid leukemia cell lines	ONCOGENE			English	Article						chronic myeloid leukemia; RIZ1; IGF-1; histone methyltransferase	ZINC-FINGER PROTEIN; TUMOR-SUPPRESSOR GENE; ERYTHROID-DIFFERENTIATION; PR DOMAIN; HISTONE METHYLTRANSFERASE; BINDING; IDENTIFICATION; INACTIVATION; EXPRESSION; MUTATIONS	RIZ1 is a histone methyltransferase whose expression and activity are reduced in many cancers. In chronic myelogenous leukemia (CML), blastic transformation is associated with loss of heterozygosity in the region where RIZ1 is located and with decreased RIZ1 expression. Forced RIZ1 expression in model CML blast crisis (BC) cell lines decreases proliferation, increases apoptosis and enhances differentiation. We characterized molecular mechanisms that may contribute to potential CML tumor suppressor properties of RIZ1. Several RIZ1-regulated genes involved in insulin-like growth factor-1 (IGF-1) signaling were identified using cDNA microarrays. RIZ1 was shown to associate with promoter regions of IGF-1 and to increase histone H3 lysine 9 methylation using chromatin immunoprecipitation assays. IGF-1-blocking antibody was used to demonstrate the importance of autocrine IGF-1 signaling in CML-BC cell line viability. Forced RIZ1 expression in CML-BC cell lines decreases IGF-1 receptor activation and activation of downstream signaling components extracellular signal-regulated kinase 1/2 and AKT. These results highlight the therapeutic potential of inhibiting IGF-1 pathway in the acute phase of CML.	Univ Saskatchewan, Genom Med & Pathobiol Grp, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 0W0, Canada; Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 0W0, Canada; Burnham Inst, Canc Genet & Epigenet Program, La Jolla, CA 92037 USA; Stanford Univ, Med Ctr, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; Sanford Burnham Prebys Medical Discovery Institute; Stanford University	DeCoteau, JF (corresponding author), Saskatoon Canc Ctr, 20 Campus Dr, Saskatoon, SK S7N 4H4, Canada.	john.decoteau@usask.ca; ron.geyer@usask.ca						Abbondanza C, 2000, P NATL ACAD SCI USA, V97, P3130, DOI 10.1073/pnas.050015697; Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; CHANG HW, 2004, INT J CANCER, V110, P212; Dong WF, 2003, BLOOD, V102, p579A; Du Y, 2001, CANCER RES, V61, P8094; Dumas AR, 2004, LEUKEMIA RES, V28, P1329, DOI 10.1016/j.leukres.2004.04.013; ENDO K, 1993, BRIT J HAEMATOL, V85, P653, DOI 10.1111/j.1365-2141.1993.tb03205.x; Francki A, 2003, J CELL BIOCHEM, V88, P802, DOI 10.1002/jcb.10424; Gazzerro P, 2006, EXP CELL RES, V312, P340, DOI 10.1016/j.yexcr.2005.11.002; HICKS DG, 1985, EXP HEMATOL, V13, P273; Hoeflich A, 2001, CANCER RES, V61, P8601; Huang S, 1998, J BIOL CHEM, V273, P15933, DOI 10.1074/jbc.273.26.15933; Kang CD, 1999, EXP MOL MED, V31, P76, DOI 10.1038/emm.1999.13; Kim KC, 2003, CANCER RES, V63, P7619; Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984; Medici N, 1999, BIOCHEM BIOPH RES CO, V264, P983, DOI 10.1006/bbrc.1999.1604; Mori N, 1998, BLOOD, V92, P3405, DOI 10.1182/blood.V92.9.3405.421k44_3405_3409; Muraosa Y, 1996, EUR J BIOCHEM, V235, P471, DOI 10.1111/j.1432-1033.1996.00471.x; PEPE MG, 1987, J CELL PHYSIOL, V133, P219, DOI 10.1002/jcp.1041330204; Piao Z, 2000, CANCER RES, V60, P4701; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; SHAPIRO VS, 1995, GENE, V163, P329, DOI 10.1016/0378-1119(95)00420-B; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Takahashi N, 2005, BLOOD, V106, p352A; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; VANDELOOSDRECHT AA, 1994, J IMMUNOL METHODS, V174, P311, DOI 10.1016/0022-1759(94)90034-5; Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200; Woessmann W, 2004, CELL BIOL INT, V28, P403, DOI 10.1016/j.cellbi.2004.03.009; Woessmann W, 2001, EXP CELL RES, V264, P193, DOI 10.1006/excr.2000.5124; Xie M, 1997, J BIOL CHEM, V272, P26360, DOI 10.1074/jbc.272.42.26360	34	40	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1586	1594		10.1038/sj.onc.1209959	http://dx.doi.org/10.1038/sj.onc.1209959			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953217				2022-12-28	WOS:000244782500008
J	Oliva-Trastoy, M; Berthonaud, V; Chevalier, A; Ducrot, C; Marsolier-Kergoat, MC; Mann, C; Leteurtre, F				Oliva-Trastoy, M.; Berthonaud, V.; Chevalier, A.; Ducrot, C.; Marsolier-Kergoat, M-C; Mann, C.; Leteurtre, F.			The Wip1 phosphatase (PPM1D) antagonizes activation of the Chk2 tumour suppressor kinase	ONCOGENE			English	Article						Wip1 oncogene; PPM1D; PPZC phosphatase; Chk2 tumour suppressor; DNA damage checkpoints	DNA-DAMAGE RESPONSE; PROTEIN PHOSPHATASE; IONIZING-RADIATION; PP2C PHOSPHATASES; CHECKPOINT; PHOSPHORYLATION; AUTOPHOSPHORYLATION; OLIGOMERIZATION; INACTIVATION; INTERACTS	We previously demonstrated that type 2C protein phosphatases (PP2C) Ptc2 and Ptc3 are required for DNA checkpoint inactivation after DNA double-strand break repair or adaptation in Saccharomyces cerevisiae. Here, we show the conservation of this pathway in mammalian cells. In response to DNA damage, ataxia telangiectasia mutated (ATM) phosphorylates the Chk2 tumour suppressor kinase at threonine 68 (Thr68), allowing Chk2 kinase dimerization and activation by autophosphorylations in the T-loop. The oncogenic protein Wip1, a PP2C phosphatase, binds Chk2 and dephosphorylates phospho-Thr68. Consequently, Wip1 opposes Chk2 activation by ATM after ionizing irradiation of cells. In HCT15 colorectal cancer cells corrected for functional Chk2 activity, Wip1 overexpression suppressed the contribution of Chk2 to the G2/M DNA damage checkpoint. These results indicate that Wip1 is one of the phosphatases regulating the activity of Chk2 in response to DNA damage.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; CEA Saclay, Dept Biol Joliot Curie, F-91191 Gif Sur Yvette, France; Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; Uniformed Services University of the Health Sciences - USA	Mann, C (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 144, F-91191 Gif Sur Yvette, France.	carl.mann@cea.fr; francois.leteurtre@cea.fr		Mann, Carl/0000-0001-7212-1512; Francois, Leteurtre/0000-0001-7373-6180				Ahn J, 2004, DNA REPAIR, V3, P1039, DOI 10.1016/j.dnarep.2004.03.033; Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Craig AL, 2004, ONCOGENE, V23, P8411, DOI 10.1038/sj.onc.1208035; Dozier C, 2004, BIOL CELL, V96, P509, DOI 10.1016/j.biolcel.2004.04.010; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Goodarzi AA, 2004, EMBO J, V23, P4451, DOI 10.1038/sj.emboj.7600455; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Lee SB, 2001, CANCER RES, V61, P8062; Leroy C, 2003, MOL CELL, V11, P827, DOI 10.1016/S1097-2765(03)00058-3; Liang XB, 2006, INT J MOL MED, V17, P703; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; NANNENGA B, 2006, IN PRESS MOL CARCINO; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Schwarz JK, 2003, MOL CANCER RES, V1, P598; Schweighofer A, 2004, TRENDS PLANT SCI, V9, P236, DOI 10.1016/j.tplants.2004.03.007; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Wu XL, 2003, J BIOL CHEM, V278, P36163, DOI 10.1074/jbc.M303795200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	92	96	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1449	1458		10.1038/sj.onc.1209927	http://dx.doi.org/10.1038/sj.onc.1209927			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936775				2022-12-28	WOS:000244558800009
J	Ong, CK; Leong, C; Tan, PH; Van, T; Huynh, H				Ong, C. K.; Leong, C.; Tan, P. H.; Van, T.; Huynh, H.			The role of 5 ' untranslated region in translational suppression of OKL38 mRNA in hepatocellular carcinoma	ONCOGENE			English	Article						OKL38; hepatocellular carcinoma; cell death; 5 ' untranslated region; translational suppression	OPEN READING FRAMES; GROWTH INHIBITOR; EXPRESSION; CANCER; MECHANISMS; SEQUENCES; ELEMENT; GLAND; GENE	Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. OKL38 is a pregnancy-induced growth inhibitory gene and its expression is lost in various breast cancer cell lines and kidney tumor. To determine the role of OKL38 expression in HCC, we investigated its expression in various HCC samples and liver cancer cell lines. Western blot analysis revealed that OKL38 protein was absent or reduced in 64.2% ( 18 of 28) of the HCCs examined and four liver cancer cell lines. Immunohistochemistry study demonstrated that OKL38 protein was undetectable in 41.3% ( 38 of 92) of HCC, whereas 39.1% ( 36 of 92) of HCC showed low expression of the protein. Lost or reduced expression level of OKL38 protein was significantly correlated to high tumor stages in HCC ( P = 0.0042). Overexpression of the OKL38 caused cell death in Chang liver cells. 50 Untranslated region (5'UTR) deletion studies demonstrated that OKL38 was downregulated via translation suppression associated with the 5'UTR of its mRNA. Taken together, the 5'UTRs of OKL38 might play an important role in downregulation of its protein and the absence of OKL38 could lead to the development or progression of HCC.	Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Singapore Gen Hosp, Dept Pathol, Singapore 0316, Singapore; Binh Dan Hosp, Ho Chi Minh City, Vietnam	National Cancer Centre Singapore (NCCS); Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr Singapore, Div Cellular & Mol Res, Mol Endocrinol Lab, 11 Hosp Dr, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Akriviadis EA, 1998, BRIT J SURG, V85, P1319; Altman D.G., 2000, STAT CONFIDENCE, Vsecond; CHAN ES, 2000, COCHRANE DB SYST REV, pPP199; Claudio PP, 2002, CLIN CANCER RES, V8, P1808; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; COLOMBO M, 1992, J HEPATOL, V15, P225, DOI 10.1016/0168-8278(92)90041-M; Dua K, 2001, PROTEOMICS, V1, P1191, DOI 10.1002/1615-9861(200110)1:10<1191::AID-PROT1191>3.0.CO;2-8; Gasteiger E., 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Harigai M, 1996, ONCOGENE, V12, P1369; HUGUET CSF, 2000, SURG LIVER BILLARY T, P1365; Huynh H, 2002, CELL GROWTH DIFFER, V13, P115; Huynh H, 2001, ENDOCRINOLOGY, V142, P3607, DOI 10.1210/en.142.8.3607; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Kullmann M, 2002, GENE DEV, V16, P3087, DOI 10.1101/gad.248902; LAI E, 1994, SURG LIVER BILIARY T, P1349; LAI ECS, 1995, ANN SURG, V221, P291, DOI 10.1097/00000658-199503000-00012; Meijer HA, 2002, BIOCHEM J, V367, P1, DOI 10.1042/BJ20011706; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Ong CK, 2004, ENDOCRINOLOGY, V145, P4763, DOI 10.1210/en.2004-0446; Ong CK, 2004, J BIOL CHEM, V279, P743, DOI 10.1074/jbc.M308668200; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Riou P, 2002, CLIN CANCER RES, V8, P3178; SPIESSL B, 1992, ILLUSTRATED GUIDE TN, P104; Takenaka K, 1996, ARCH SURG-CHICAGO, V131, P71; Wang T, 2005, J BIOL CHEM, V280, P4374, DOI 10.1074/jbc.M408708200; Willis AE, 1999, INT J BIOCHEM CELL B, V31, P73, DOI 10.1016/S1357-2725(98)00133-2	29	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1155	1165		10.1038/sj.onc.1209896	http://dx.doi.org/10.1038/sj.onc.1209896			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924236				2022-12-28	WOS:000244406400006
J	Weber, RG; Hoischen, A; Ehrler, M; Zipper, P; Kaulich, K; Blaschke, B; Becker, AJ; Weber-Mangal, S; Jauch, A; Radlwimmer, B; Schramm, J; Wiestler, OD; Lichter, P; Reifenberger, G				Weber, R. G.; Hoischen, A.; Ehrler, M.; Zipper, P.; Kaulich, K.; Blaschke, B.; Becker, A. J.; Weber-Mangal, S.; Jauch, A.; Radlwimmer, B.; Schramm, J.; Wiestler, O. D.; Lichter, P.; Reifenberger, G.			Frequent loss of chromosome 9, homozygous CDKN2A/p14ARF/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas	ONCOGENE			English	Article						pleomorphic xanthoastrocytomas; comparative genomic hybridization; molecular genetics; tumor-suppressor gene; DNA-microarray	COMPARATIVE GENOMIC HYBRIDIZATION; SCLEROSIS GENE TSC1; GLIOMA PROGRESSION; CELL CARCINOMA; P53 MUTATION; IMBALANCES; GROWTH; TUMORS; 9Q34	The molecular pathogenesis of pleomorphic xanthoastrocytoma (PXA), a rare astrocytic brain tumor with a relatively favorable prognosis, is still poorly understood. We characterized 50 PXAs by comparative genomic hybridization (CGH) and found the most common imbalance to be loss on chromosome 9 in 50% of tumors. Other recurrent losses affected chromosomes 17 (10%), 8, 18, 22 (4% each). Recurrent gains were identified on chromosomes X (16%), 7, 9q, 20 (8% each), 4, 5, 19 ( 4% each). Two tumors demonstrated amplifications mapping to 2p23-p25, 4p15, 12q13, 12q21, 21q21 and 21q22. Analysis of 10 PXAs with available high molecular weight DNA by high-resolution array-based CGH indicated homozygous 9p21.3 deletions involving the CDKN2A/p14(ARF)/CDKN2B loci in six tumors (60%). Interphase fluorescence in situ hybridization to tissue sections confirmed the presence of tumor cells with homozygous 9p21.3 deletions. Mutational analysis of candidate genes on 9q, PTCH and TSC1, revealed no mutations in PXAs with 9q loss and no evidence of TSC1 promoter methylation. However, PXAs consistently showed low TSC1 transcript levels. Taken together, our study identifies loss of chromosome 9 as the most common chromosomal imbalance in PXAs and suggests important roles for homozygous CDKN2A/p14ARF/CDKN2B deletion as well as low TSC1 mRNA expression in these tumors.	Univ Bonn, Dept Human Genet, D-53111 Bonn, Germany; Otto Von Guericke Univ, Dept Human Genet, Magdeburg, Germany; Univ Dusseldorf, Dept Neuropathol, D-4000 Dusseldorf, Germany; Univ Bonn, Dept Neuropathol, D-5300 Bonn, Germany; Univ Heidelberg, Dept Human Genet, D-6900 Heidelberg, Germany; German Canc Res Ctr, D-6900 Heidelberg, Germany; Univ Bonn, Dept Neurosurg, D-5300 Bonn, Germany	University of Bonn; Otto von Guericke University; Heinrich Heine University Dusseldorf; University of Bonn; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); University of Bonn	Weber, RG (corresponding author), Univ Bonn, Dept Human Genet, Wilhelmstr 31, D-53111 Bonn, Germany.	ruthild.weber@ukb.uni-bonn.de	Hoischen, Alexander/AGF-7293-2022; Becker, Albert J/F-6248-2012; Radlwimmer, Bernhard F/I-3229-2013; Hoischen, Alexander/D-1282-2013; Reifenberger, Guido/AAE-3599-2019; Weber, Ruthild/E-2906-2015	Hoischen, Alexander/0000-0002-8072-4476; Radlwimmer, Bernhard F/0000-0002-4553-7800; Hoischen, Alexander/0000-0002-8072-4476; Weber, Ruthild/0000-0001-6610-1080				Becker AJ, 2001, NEUROPATH APPL NEURO, V27, P105, DOI 10.1046/j.0305-1846.2001.00302.x; DUMANOIR S, 1993, HUM GENET, V90, P590, DOI 10.1007/BF00202476; Giannini C, 2001, NEUROGENETICS, V3, P159, DOI 10.1007/s100480100116; Giannini C, 1999, CANCER, V85, P2033, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2033::AID-CNCR22>3.3.CO;2-Q; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kaulich K, 2002, J NEUROPATH EXP NEUR, V61, P1092, DOI 10.1093/jnen/61.12.1092; Kepes JJ, 2000, WHO CLASSIFICATION T, P52; Knowles MA, 2003, CANCER RES, V63, P7652; Li YS, 1995, CANCER GENET CYTOGEN, V84, P46, DOI 10.1016/0165-4608(95)00065-8; LICHTER P, 1995, METHOD ENZYMOL, V254, P334; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Mollemann M, 2005, INT J CANCER, V113, P379, DOI 10.1002/ijc.20575; Paulus W, 1996, ACTA NEUROPATHOL, V91, P293, DOI 10.1007/s004010050428; Pei XH, 2005, ONCOGENE, V24, P2787, DOI 10.1038/sj.onc.1208611; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Reifenberger G, 2004, J MOL MED, V82, P656, DOI 10.1007/s00109-004-0564-x; Reifenberger G, 2003, ACTA NEUROPATHOL, V105, P358, DOI 10.1007/s00401-002-0652-3; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Reifenberger J, 1996, J NEUROPATH EXP NEUR, V55, P822, DOI 10.1097/00005072-199607000-00007; Sambrook J., 2002, MOL CLONING LAB MANU; SAWYER JR, 1991, CANCER GENET CYTOGEN, V55, P225, DOI 10.1016/0165-4608(91)90081-5; SAWYER JR, 1992, CANCER GENET CYTOGEN, V60, P152, DOI 10.1016/0165-4608(92)90008-V; Schwaenen C, 2004, P NATL ACAD SCI USA, V101, P1039, DOI 10.1073/pnas.0304717101; SolinasToldo S, 1997, GENE CHROMOSOME CANC, V20, P399, DOI 10.1002/(SICI)1098-2264(199712)20:4<399::AID-GCC12>3.0.CO;2-I; van den Boom J, 2003, AM J PATHOL, V163, P1033, DOI 10.1016/S0002-9440(10)63463-3; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Weber RG, 1996, ONCOGENE, V13, P983; Yin XL, 2002, CANCER GENET CYTOGEN, V132, P14, DOI 10.1016/S0165-4608(01)00512-X; Zielinski B, 2005, GENE CHROMOSOME CANC, V43, P294, DOI 10.1002/gcc.20186	32	70	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1088	1097		10.1038/sj.onc.1209851	http://dx.doi.org/10.1038/sj.onc.1209851			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909113				2022-12-28	WOS:000244245400015
J	Joshi, PP; Kulkarni, MV; Yu, BK; Smith, KR; Norton, DL; van Veelen, W; Hoppener, JWM; Franklin, DS				Joshi, P. P.; Kulkarni, M. V.; Yu, B. K.; Smith, K. R.; Norton, D. L.; van Veelen, W.; Hoppener, J. W. M.; Franklin, D. S.			Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis	ONCOGENE			English	Article						MEN; RET; cell cycle; CDKI; tumorigenesis; proliferation	MEDULLARY-THYROID CARCINOMA; RET PROTOONCOGENE MUTATIONS; ENDOCRINE NEOPLASIA TYPE-2; ACTIVATED PROTEIN-KINASE; D-DEPENDENT KINASE; GROWTH-FACTOR; CELL-CYCLE; CONTACT INHIBITION; SIGNALING PATHWAY; MEN2B MUTATION	Multiple endocrine neoplasia type 2A (MEN2A) is predisposed by mutations in the RET proto-oncogene. Low expression of the cyclin-dependent kinase inhibitor (CDKI) p27(Kip1) is present in thyroid tumors, and recent evidence demonstrates p27 downregulation by the active RET mutant, RET/PTC1, found in papillary thyroid carcinoma. This implicates decreased p27 activity as an important event during thyroid tumorigenesis. However, p27(-/-) mice develop MEN-like tumors only in combination with loss of another CDKI, p18(Ink4c). This suggests that p18 and p27 functionally collaborate in suppression of tumorigenesis, that loss of both is critical in the development of MEN tumors and that both p18 and p27 are regulated by RET. We report that induction of the constitutively active MEN2A-specific RET mutant, RET2A(C634R), correlates with reduced p18/p27, and elevated cyctin D protein levels, leading to increased CDK activity, increased pRb phosphorylation and proliferation under growth arrest conditions. Mechanistically, RET2A represses p18/p27 mRNA levels while elevating cyclin D1 mRNA levels. RET2A expression also correlates with decreased p27 protein stability. RET2A-mediated regulation of p18 and p27, but not of cyclins D1 and D2, requires functional mitogen-activated protein kinase signaling. Additionally, RET2A-dependent p18 repression is required and sufficient to increase cell proliferation. Perhaps most significantly, MEN2A adrenal tumors also display these changes in cell cycle expression profile, demonstrating the biological relevance of our cell culture studies. Our results demonstrate for the first time that RET2A regulates p18, and suggest that loss of not only p27 but also of p18 expression is a key step in MEN tumorigenesis.	Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Purdue Univ, Purdue Canc Ctr, W Lafayette, IN 47907 USA; Univ Utrecht, Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Utrecht University	Franklin, DS (corresponding author), Purdue Univ, Dept Biol Sci, 205A Hansen Life Sci Res Bldg,201 S Univ St, W Lafayette, IN 47907 USA.	franklid@purdue.edu						ACTON D, 2004, J INTERN MED, V255, P696; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Buchwald PC, 2004, CLIN ENDOCRINOL, V60, P389, DOI 10.1111/j.1365-2265.2004.01995.x; Celetti A, 2004, ONCOGENE, V23, P109, DOI 10.1038/sj.onc.1206981; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; CONDE E, 1992, ENDOCRINOLOGY, V131, P436, DOI 10.1210/en.131.1.436; Drosten M, 2004, JNCI-J NATL CANCER I, V96, P1231, DOI 10.1093/jnci/djh226; Eng C, 1996, JAMA-J AM MED ASSOC, V276, P1575, DOI 10.1001/jama.276.19.1575; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Franklin DS, 1998, GENE DEV, V12, P2899, DOI 10.1101/gad.12.18.2899; Greulich H, 1998, J BIOL CHEM, V273, P13280, DOI 10.1074/jbc.273.21.13280; Iwashita T, 1999, ONCOGENE, V18, P3919, DOI 10.1038/sj.onc.1202742; Iwashita T, 1996, ONCOGENE, V12, P481; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JUAN G, 1998, CURRENT PROTOCOLS CY, P791; Jung YD, 1999, CANCER RES, V59, P4804; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kato A, 1997, J BIOL CHEM, V272, P8065, DOI 10.1074/jbc.272.12.8065; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; Kawamoto Y, 2004, J BIOL CHEM, V279, P14213, DOI 10.1074/jbc.M312600200; Kim HS, 1998, J NEUROSCI, V18, P8247; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kodama Y, 2005, CANCER SCI, V96, P143, DOI 10.1111/j.1349-7006.2005.00023.x; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Marsh DJ, 1997, HORM RES, V47, P168, DOI 10.1159/000185461; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Phelps DE, 1998, CELL GROWTH DIFFER, V9, P595; Phelps DE, 1998, MOL CELL BIOL, V18, P2334, DOI 10.1128/MCB.18.4.2334; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schubert WH, 2001, J HYDROMETEOROL, V2, P3, DOI 10.1175/1525-7541(2001)002<0005:>2.0.CO;2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SOZZI G, 1991, ONCOGENE, V6, P339; TAKAHASHI M, 1991, ONCOGENE, V6, P297; TAKAHASHI M, 1993, ONCOGENE, V8, P2925; TISCHLER AS, 1989, INT J DEV NEUROSCI, V7, P439, DOI 10.1016/0736-5748(89)90004-X; TONG Q, 1995, ONCOGENE, V10, P1781; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; van Weering DHJ, 1998, RECENT RES CANCER, V154, P271; vanWeering DHJ, 1995, ONCOGENE, V11, P2207; Vitagliano D, 2004, CANCER RES, V64, P3823, DOI 10.1158/0008-5472.CAN-03-3918; Watanabe T, 2002, AM J PATHOL, V161, P249, DOI 10.1016/S0002-9440(10)64176-4; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Worby CA, 1996, J BIOL CHEM, V271, P23619, DOI 10.1074/jbc.271.39.23619	54	28	29	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					554	570		10.1038/sj.onc.1209811	http://dx.doi.org/10.1038/sj.onc.1209811			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16953232				2022-12-28	WOS:000243731600008
J	Hayden, MS; West, AP; Ghosh, S				Hayden, M. S.; West, A. P.; Ghosh, S.			NF-kappa B and the immune response	ONCOGENE			English	Review						NF-kappa B; T-cell receptor; B-cell receptor; inflammation; TLR; hematopoiesis	TOLL-LIKE RECEPTORS; DOUBLE-STRANDED-RNA; T-CELL-RECEPTOR; C-H TRANSCRIPTION; INTESTINAL EPITHELIAL-CELLS; SEVERE LIVER DEGENERATION; GERMINAL CENTER REACTIONS; I INTERFERON INDUCTION; MEK KINASE 1; DENDRITIC CELLS	One of the primary physiological roles of nuclear factor-kappa B (NF-kappa B) is in the immune system. In particular, NF-kappa B family members control the transcription of cytokines and antimicrobial effectors as well as genes that regulate cellular differentiation, survival and proliferation, thereby regulating various aspects of innate and adaptive immune responses. In addition, NF-kappa B also contributes to the development and survival of the cells and tissues that carry out immune responses in mammals. This review, therefore, describes the role of the NF-kappa B pathway in the development and functioning of the immune system.	Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Yale University; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Dept Immunobiol, 300 Cedar St, New Haven, CT 06510 USA.	sankar.ghosh@yale.edu	Hayden, Matthew/C-1263-2008; West, A. Phillip/W-8171-2019; West, A. Phillip/A-7867-2009	West, A. Phillip/0000-0003-2884-6895; Hayden, Matthew/0000-0003-1670-6430	NIGMS NIH HHS [GM07205] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2003, BLOOD, V101, P1477, DOI 10.1182/blood.V101.4.1477; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Banerjee D, 2005, IMMUNITY, V23, P445, DOI 10.1016/j.immuni.2005.09.012; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Caamano JH, 1996, MOL CELL BIOL, V16, P1342; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Catley MC, 2003, FEBS LETT, V547, P75, DOI 10.1016/S0014-5793(03)00672-0; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Corn RA, 2005, J IMMUNOL, V175, P2102, DOI 10.4049/jimmunol.175.4.2102; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Didierlaurent A, 2006, MOL CELL BIOL, V26, P735, DOI 10.1128/MCB.26.3.735-742.2006; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Doi TS, 1997, J EXP MED, V185, P953, DOI 10.1084/jem.185.5.953; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; ECK SL, 1993, MOL CELL BIOL, V13, P6530, DOI 10.1128/MCB.13.10.6530; Egawa T, 2003, CURR BIOL, V13, P1252, DOI 10.1016/S0960-9822(03)00491-3; Feng B, 2004, CELL IMMUNOL, V232, P9, DOI 10.1016/j.cellimm.2005.01.006; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346; Francois S, 2005, J IMMUNOL, V174, P3633, DOI 10.4049/jimmunol.174.6.3633; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; French LE, 1996, J CELL BIOL, V133, P335, DOI 10.1083/jcb.133.2.335; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Gazzinelli RT, 2004, IMMUNOL REV, V201, P9, DOI 10.1111/j.0105-2896.2004.00174.x; GHOSH P, 1993, P NATL ACAD SCI USA, V90, P1696, DOI 10.1073/pnas.90.5.1696; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Grundstrom S, 2004, J BIOL CHEM, V279, P8460, DOI 10.1074/jbc.M312398200; Hara H, 2003, IMMUNITY, V18, P763, DOI 10.1016/S1074-7613(03)00148-1; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hinton HJ, 2004, NAT IMMUNOL, V5, P539, DOI 10.1038/ni1062; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1073/pnas.0406933101; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Hueber AO, 2003, CELL DEATH DIFFER, V10, P7, DOI 10.1038/sj.cdd.4401155; Hwang ES, 2005, J EXP MED, V202, P1289, DOI 10.1084/jem.20051044; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Ivanov VN, 1997, J BIOL CHEM, V272, P8558; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jeremias I, 1998, BLOOD, V91, P4624, DOI 10.1182/blood.V91.12.4624.412k19_4624_4631; Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105-2896.2005.00329.x; Jimi E, 2005, INT IMMUNOL, V17, P815, DOI 10.1093/intimm/dxh263; Jurk M, 2002, NAT IMMUNOL, V3, P499, DOI 10.1038/ni0602-499; Kagan JC, 2006, CELL, V125, P943, DOI 10.1016/j.cell.2006.03.047; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Kajiura F, 2004, J IMMUNOL, V172, P2067, DOI 10.4049/jimmunol.172.4.2067; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; Kariko K, 2005, IMMUNITY, V23, P165, DOI 10.1016/j.immuni.2005.06.008; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Khoshnan A, 2000, J IMMUNOL, V165, P6933, DOI 10.4049/jimmunol.165.12.6933; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kinoshita D, 2006, J IMMUNOL, V176, P3995, DOI 10.4049/jimmunol.176.7.3995; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Koike R, 1996, EUR J IMMUNOL, V26, P669, DOI 10.1002/eji.1830260324; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Kraus M, 2004, CELL, V117, P787, DOI 10.1016/j.cell.2004.05.014; Kriehuber E, 2005, BLOOD, V106, P175, DOI 10.1182/blood-2004-08-3072; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lai WC, 2003, J IMMUNOL, V170, P6244, DOI 10.4049/jimmunol.170.12.6244; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; LEDERER JA, 1994, J IMMUNOL, V152, P77; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Legler DF, 2003, IMMUNITY, V18, P655, DOI 10.1016/S1074-7613(03)00092-X; Levitz SA, 2004, MICROBES INFECT, V6, P1351, DOI 10.1016/j.micinf.2004.08.014; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Lien E, 2001, J BIOL CHEM, V276, P1873, DOI 10.1074/jbc.M009040200; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 2004, SEMIN IMMUNOL, V16, P429, DOI 10.1016/j.smim.2004.08.022; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lopez CB, 2003, J INFECT DIS, V187, P1126, DOI 10.1086/368381; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Massari P, 2003, TRENDS MICROBIOL, V11, P87, DOI 10.1016/S0966-842X(02)00037-9; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; McDonald PP, 1997, BLOOD, V89, P3421, DOI 10.1182/blood.V89.9.3421; McDonald PP, 2004, ADV IMMUNOL, V82, P1, DOI 10.1016/S0065-2776(04)82001-7; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Means TK, 1999, J IMMUNOL, V163, P3920; Mebius RE, 2003, NAT REV IMMUNOL, V3, P292, DOI 10.1038/nri1054; Melmed G, 2003, J IMMUNOL, V170, P1406, DOI 10.4049/jimmunol.170.3.1406; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Miao EA, 2006, NAT IMMUNOL, V7, P569, DOI 10.1038/ni1344; Miller LS, 2005, J IMMUNOL, V174, P6137, DOI 10.4049/jimmunol.174.10.6137; Minakhina S, 2006, ONCOGENE, V25, P6749, DOI 10.1038/sj.onc.1209940; MIYAWAKI S, 1994, EUR J IMMUNOL, V24, P429, DOI 10.1002/eji.1830240224; Mizel SB, 2003, J BIOL CHEM, V278, P23624, DOI 10.1074/jbc.M303481200; Mora AL, 2001, J IMMUNOL, V167, P5628, DOI 10.4049/jimmunol.167.10.5628; Mora AL, 2001, J IMMUNOL, V166, P2218, DOI 10.4049/jimmunol.166.4.2218; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mueller T, 2006, J IMMUNOL, V176, P5805, DOI 10.4049/jimmunol.176.10.5805; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nakano H, 1999, P NATL ACAD SCI USA, V96, P9803, DOI 10.1073/pnas.96.17.9803; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Owyang AM, 2001, J IMMUNOL, V167, P4948, DOI 10.4049/jimmunol.167.9.4948; Ozinsky A, 2000, J ENDOTOXIN RES, V6, P393, DOI 10.1179/096805100101532333; Parra E, 1998, J IMMUNOL, V160, P5374; Pasare C, 2005, NATURE, V438, P364, DOI 10.1038/nature04267; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Paxian S, 2002, GASTROENTEROLOGY, V122, P1853, DOI 10.1053/gast.2002.33651; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Poligone B, 2001, J BIOL CHEM, V276, P38658, DOI 10.1074/jbc.M106599200; Prendes M, 2003, J IMMUNOL, V171, P3963, DOI 10.4049/jimmunol.171.8.3963; Pyatt DW, 1999, BLOOD, V93, P3302, DOI 10.1182/blood.V93.10.3302.410a38_3302_3308; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Rowe TM, 2006, P NATL ACAD SCI USA, V103, P5823, DOI 10.1073/pnas.0601287103; Rudolph D, 2000, GENE DEV, V14, P854; Ruefli-Brasse AA, 2004, J BIOL CHEM, V279, P1570, DOI 10.1074/jbc.C300460200; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; Saijo K, 2002, J EXP MED, V195, P1647, DOI 10.1084/jem.20020408; Samson SI, 2004, BLOOD, V103, P4573, DOI 10.1182/blood-2003-08-2975; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schmidt-Supprian M, 2004, J IMMUNOL, V173, P1612, DOI 10.4049/jimmunol.173.3.1612; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Serhan CN, 2005, NAT IMMUNOL, V6, P1191, DOI 10.1038/ni1276; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Smith KD, 2003, NAT IMMUNOL, V4, P1247, DOI 10.1038/ni1011; Snapper CM, 1996, J IMMUNOL, V156, P183; Snapper CM, 1996, J EXP MED, V184, P1537, DOI 10.1084/jem.184.4.1537; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Tada K, 2001, J BIOL CHEM, V276, P36530, DOI 10.1074/jbc.M104837200; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175; Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391; Thomassen E, 1999, CYTOKINE, V11, P389, DOI 10.1006/cyto.1998.0452; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529-0131(199811)41:11<1987::AID-ART14>3.3.CO;2-#; Vincenti MP, 2002, ARTHRITIS RES, V4, P157, DOI 10.1186/ar401; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wald D, 2003, NAT IMMUNOL, V4, P920, DOI 10.1038/ni968; Wan YSY, 2003, IMMUNITY, V18, P331, DOI 10.1016/S1074-7613(03)00053-0; Ward C, 1999, J BIOL CHEM, V274, P4309, DOI 10.1074/jbc.274.7.4309; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Weil R, 2003, IMMUNITY, V18, P13, DOI 10.1016/S1074-7613(02)00506-X; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Wetzler LM, 2003, VACCINE, V21, pS55, DOI 10.1016/S0264-410X(03)00201-9; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xiao CC, 2003, GENE DEV, V17, P2933, DOI 10.1101/gad.1145603; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zelazowski P, 1997, J IMMUNOL, V159, P3133; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	245	873	919	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6758	6780		10.1038/sj.onc.1209943	http://dx.doi.org/10.1038/sj.onc.1209943			23	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072327				2022-12-28	WOS:000241666700007
J	Scheidereit, C				Scheidereit, Claus			I kappa B kinase complexes: gateways to NF-kappa B activation and transcription	ONCOGENE			English	Review						NF-kappaB; IkappaB kinase; phosphorylation; ubiquitin; chromatin; transcription	CYCLIN D1 EXPRESSION; DEATH DOMAIN KINASE; T-CELL DEVELOPMENT; GAMMA IKK-GAMMA; NF-KAPPA-B2 P100; SIGNALING PATHWAY; GENE-EXPRESSION; NEMO/IKK-GAMMA; DEUBIQUITINATING ENZYME; NEGATIVE REGULATOR	Transcription factors of the NF-kappa B family regulate hundreds of genes in the context of multiple important physiological and pathological processes. NF-kappa B activation depends on phosphorylation-induced proteolysis of inhibitory I kappa B molecules and NF-kappa B precursors by the ubiquitin-proteasome system. Most of the diverse signaling pathways that activate NF-kappa B converge on I kappa B kinases (IKK), which are essential for signal transmission. Many important details of the composition, regulation and biological function of IKK have been revealed in the last years. This review summarizes current aspects of structure and function of the regular stoichiometric components, the regulatory transient protein interactions of IKK and the mechanisms that contribute to its activation, deactivation and homeostasis. Both phosphorylation and ubiquitinatin (destructive as well as non-destructive) are crucial post-translational events in these processes. In addition to controlling induced I kappa B degradation in the cytoplasm and processing of the NF-kappa B precursor p100, nuclear IKK components have been found to act directly at the chromatin level of induced genes and to mediate responses to DNA damage. Finally, IKK is engaged in cross talk with other pathways and confers functions independently of NF-kappa B.	Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Scheidereit, C (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13122 Berlin, Germany.	scheidereit@mdc-berlin.de						Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Agou F, 2002, J BIOL CHEM, V277, P17464, DOI 10.1074/jbc.M201964200; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Birbach A, 2002, J BIOL CHEM, V277, P10842, DOI 10.1074/jbc.M112475200; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Bracken CP, 2005, J BIOL CHEM, V280, P14240, DOI 10.1074/jbc.M409987200; Brenner D, 2005, EMBO J, V24, P4279, DOI 10.1038/sj.emboj.7600894; Broemer M, 2004, ONCOGENE, V23, P5378, DOI 10.1038/sj.onc.1207705; Bruey JM, 2004, J BIOL CHEM, V279, P51897, DOI 10.1074/jbc.M406741200; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Choi M, 2003, BLOOD, V102, P2259, DOI 10.1182/blood-2002-09-2960; Choi SH, 2006, MOL CELL BIOL, V26, P3048, DOI 10.1128/MCB.26.8.3048-3059.2006; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Correa RG, 2005, CURR BIOL, V15, P1291, DOI 10.1016/j.cub.2005.06.023; Courtois G, 2001, TRENDS MOL MED, V7, P427, DOI 10.1016/S1471-4914(01)02154-2; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ea CK, 2004, P NATL ACAD SCI USA, V101, P15318, DOI 10.1073/pnas.0404132101; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Eliopoulos AG, 2003, ONCOGENE, V22, P7557, DOI 10.1038/sj.onc.1207120; Evans Jared D, 2006, Hepatology, V43, P615, DOI 10.1002/hep.21096; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Fu DX, 2003, J BIOL CHEM, V278, P1487, DOI 10.1074/jbc.M210631200; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Gao ZG, 2002, J BIOL CHEM, V277, P48115, DOI 10.1074/jbc.M209459200; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Gringhuis SI, 2005, MOL CELL BIOL, V25, P6454, DOI 10.1128/MCB.25.15.6454-6463.2005; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hai T, 2006, J VIROL, V80, P4227, DOI 10.1128/JVI.80.9.4227-4241.2006; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heissmeyer V, 2001, MOL CELL BIOL, V21, P1024, DOI 10.1128/MCB.21.4.1024-1035.2001; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hong X, 2001, FEBS LETT, V499, P133, DOI 10.1016/S0014-5793(01)02535-2; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu WH, 2005, J BIOL CHEM, V280, P29233, DOI 10.1074/jbc.M501670200; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Huang J, 2004, J BIOL CHEM, V279, P16847, DOI 10.1074/jbc.M309491200; Huang TT, 2002, MOL CELL BIOL, V22, P5813, DOI 10.1128/MCB.22.16.5813-5825.2002; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Huang WC, 2003, J IMMUNOL, V170, P4767, DOI 10.4049/jimmunol.170.9.4767; Hur GM, 2003, GENE DEV, V17, P873, DOI 10.1101/gad.1062403; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Janssens S, 2005, CELL, V123, P1079, DOI 10.1016/j.cell.2005.09.036; Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054; Jono H, 2004, J BIOL CHEM, V279, P36171, DOI 10.1074/jbc.M406638200; Joo MS, 2005, J VIROL, V79, P7648, DOI 10.1128/JVI.79.12.7648-7657.2005; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Khoshnan A, 2004, J NEUROSCI, V24, P7999, DOI 10.1523/JNEUROSCI.2675-04.2004; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krappmann D, 2000, J BIOL CHEM, V275, P29779, DOI 10.1074/jbc.M003902200; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Kwak YT, 2005, J BIOL CHEM, V280, P33945, DOI 10.1074/jbc.M506206200; Lamberti C, 2001, J BIOL CHEM, V276, P42276, DOI 10.1074/jbc.M104227200; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lebowitz J, 2004, J BIOL CHEM, V279, P41985, DOI 10.1074/jbc.M403923200; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Lee SH, 2004, P NATL ACAD SCI USA, V101, P17416, DOI 10.1073/pnas.0408061101; Leonardi A, 2000, P NATL ACAD SCI USA, V97, P10494, DOI 10.1073/pnas.190245697; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li NX, 2001, J BIOL CHEM, V276, P8898, DOI 10.1074/jbc.M009809200; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li X, 2002, J BIOL CHEM, V277, P45129, DOI 10.1074/jbc.M205165200; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Liao GX, 2004, J BIOL CHEM, V279, P26243, DOI 10.1074/jbc.M403286200; Lin L, 2004, IMMUNITY, V21, P203, DOI 10.1016/j.immuni.2004.06.016; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Massa PE, 2005, J BIOL CHEM, V280, P14057, DOI 10.1074/jbc.M414401200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mauro C, 2003, BIOCHEM BIOPH RES CO, V309, P84, DOI 10.1016/S0006-291X(03)01532-8; May MJ, 2004, J BIOL CHEM, V279, P45528, DOI 10.1074/jbc.M408579200; May MJ, 2002, J BIOL CHEM, V277, P45992, DOI 10.1074/jbc.M206494200; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; MILLER BS, 2006, J BIOL CHEM, V281, P15268; Miranda C, 2006, J CELL PHYSIOL, V208, P154, DOI 10.1002/jcp.20644; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Nakata T, 2002, GENE CHROMOSOME CANC, V35, P30, DOI 10.1002/gcc.10095; Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116; Ohazama A, 2004, DEV CELL, V6, P219, DOI 10.1016/S1534-5807(04)00024-3; Ohmae T, 2005, J IMMUNOL, V175, P7162, DOI 10.4049/jimmunol.175.11.7162; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Otsuki T, 2002, J CELL BIOCHEM, V86, P613, DOI 10.1002/jcb.10270; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006; Park KJ, 2003, J BIOL CHEM, V278, P35272, DOI 10.1074/jbc.M305095200; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Piccolella E, 2003, J IMMUNOL, V170, P2895, DOI 10.4049/jimmunol.170.6.2895; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Pittet JF, 2005, J IMMUNOL, V174, P384, DOI 10.4049/jimmunol.174.1.384; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Prajapati S, 2004, J BIOL CHEM, V279, P1739, DOI 10.1074/jbc.M306273200; Qian YC, 2004, IMMUNITY, V21, P575, DOI 10.1016/j.immuni.2004.09.001; Ramakrishnan P, 2004, IMMUNITY, V21, P477, DOI 10.1016/j.immuni.2004.08.009; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Reiley W, 2005, MOL CELL BIOL, V25, P3886, DOI 10.1128/MCB.25.10.3886-3895.2005; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Reiley WW, 2006, NAT IMMUNOL, V7, P411, DOI 10.1038/ni1315; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saito K, 2004, STRUCTURE, V12, P1719, DOI 10.1016/j.str.2004.07.012; Saito N, 2003, J BIOL CHEM, V278, P46565, DOI 10.1074/jbc.M302549200; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Schmidt-Ullrich R, 2006, DEVELOPMENT, V133, P1045, DOI 10.1242/dev.02278; Sekine Y, 2006, J IMMUNOL, V176, P380, DOI 10.4049/jimmunol.176.1.380; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Seo T, 2004, ONCOGENE, V23, P6146, DOI 10.1038/sj.onc.1207807; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605; Shirane M, 1999, J BIOL CHEM, V274, P28169, DOI 10.1074/jbc.274.40.28169; Siebenlist U, 2005, NAT REV IMMUNOL, V5, P435, DOI 10.1038/nri1629; Sigala JLD, 2004, SCIENCE, V304, P1963, DOI 10.1126/science.1098387; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Soond SM, 2003, MOL CELL BIOL, V23, P8334, DOI 10.1128/mcb.23.22.8334-8344.2003; Stilo R, 2004, J BIOL CHEM, V279, P34323, DOI 10.1074/jbc.M402244200; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; Tegethoff S, 2003, MOL CELL BIOL, V23, P2029, DOI 10.1128/MCB.23.6.2029-2041.2003; Thome M, 2004, NAT REV IMMUNOL, V4, P348, DOI 10.1038/nri1352; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Tu Z, 2006, J BIOL CHEM, V281, P6699, DOI 10.1074/jbc.M512439200; Vacca A, 2006, EMBO J, V25, P1000, DOI 10.1038/sj.emboj.7600996; Verma UN, 2004, J BIOL CHEM, V279, P3509, DOI 10.1074/jbc.M309300200; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294; Wegener E, 2006, MOL CELL, V23, P13, DOI 10.1016/j.molcel.2006.05.027; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101; Wooten MW, 2005, J BIOL CHEM, V280, P35625, DOI 10.1074/jbc.C500237200; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu RC, 2002, MOL CELL BIOL, V22, P3549, DOI 10.1128/MCB.22.10.3549-3561.2002; Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; XIA ZP, 2005, SCI STKE, V272, pE7; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2001, EMBO J, V20, P6805, DOI 10.1093/emboj/20.23.6805; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang F, 2004, J IMMUNOL, V172, P2446, DOI 10.4049/jimmunol.172.4.2446; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Yoshida H, 2005, J BIOL CHEM, V280, P41111, DOI 10.1074/jbc.M509526200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zha FK, 2006, J IMMUNOL, V176, P1072, DOI 10.4049/jimmunol.176.2.1072; Zhang P, 2005, EMBO REP, V6, P531, DOI 10.1038/sj.embor.7400433; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhou HL, 2005, J EXP MED, V202, P1327, DOI 10.1084/jem.20051194; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	222	530	553	1	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6685	6705		10.1038/sj.onc.1209934	http://dx.doi.org/10.1038/sj.onc.1209934			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072322				2022-12-28	WOS:000241666700002
J	Mayer, C; Grummt, I				Mayer, C.; Grummt, I.			Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases	ONCOGENE			English	Review						transcription; RNA polymerase; mTOR; ribosome biogenesis; ribi regulon	REGULATES GENE-EXPRESSION; TOR-SIGNALING PATHWAY; PROTEIN GENE; I TRANSCRIPTION; MESSENGER-RNAS; S6 KINASE; TRANSLATION INITIATION; DEPENDENT REGULATION; TIF-IA; RAPAMYCIN	The target of rapamycin ( TOR) signal-transduction pathway is an important mechanism by which eucaryotic cells adjust their protein biosynthetic capacity to nutrient availability. Both in yeast and in mammals, the TOR pathway regulates the synthesis of ribosomal components, including transcription and processing of pre-rRNA, expression of ribosomal proteins and the synthesis of 5S rRNA. Expression of the genes encoding the numerous constituents of ribosomes requires transcription by all three classes of nuclear RNA polymerases. In this review, we summarize recent advances in understanding the interplay among nutrient availability, transcriptional control and ribosome biogenesis. We focus on transcription in response to nutrients, detailing the relevant downstream targets of TOR in yeast and mammals. The critical role of TOR in linking environmental cues to ribosome biogenesis provides an efficient means by which cells alter their overall protein biosynthetic capacity.	German Canc Res Ctr, Div Mol Biol Cell 2, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Grummt, I (corresponding author), German Canc Res Ctr, Div Mol Biol Cell 2, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.	grummt@dkfz-heidelberg.de		Mayer, Christine/0000-0003-3936-7670				Barth-Baus D, 2002, NUCLEIC ACIDS RES, V30, P1919, DOI 10.1093/nar/30.9.1919; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bodem J, 2000, EMBO REP, V1, P171, DOI 10.1093/embo-reports/kvd032; BUTTGEREIT D, 1985, NUCLEIC ACIDS RES, V13, P8165, DOI 10.1093/nar/13.22.8165; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cavalieri EL, 2002, HANDB ENVIRON CHEM, V3, P277; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; FERRARI S, 1990, CANCER RES, V50, P5825; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GRUMMT I, 1976, CELL, V7, P439, DOI 10.1016/0092-8674(76)90174-4; Grummt I, 2006, CURR OPIN GENET DEV, V16, P191, DOI 10.1016/j.gde.2006.02.001; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Holland EC, 2004, ONCOGENE, V23, P3138, DOI 10.1038/sj.onc.1207590; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; James MJ, 2004, J BIOL CHEM, V279, P8911, DOI 10.1074/jbc.M307735200; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kimball SR, 1999, J BIOL CHEM, V274, P11647, DOI 10.1074/jbc.274.17.11647; Laferte A, 2006, GENE DEV, V20, P2030, DOI 10.1101/gad.386106; MAHAJAN PB, 1994, INT J IMMUNOPHARMACO, V16, P711, DOI 10.1016/0192-0561(94)90091-4; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Miller G, 2001, EMBO J, V20, P1373, DOI 10.1093/emboj/20.6.1373; Moorefield B, 2000, P NATL ACAD SCI USA, V97, P4724, DOI 10.1073/pnas.080063997; Nader GA, 2005, AM J PHYSIOL-CELL PH, V289, pC1457, DOI 10.1152/ajpcell.00165.2005; Naora H, 1998, J CELL BIOL, V141, P741, DOI 10.1083/jcb.141.3.741; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Preiss T, 2003, NAT STRUCT BIOL, V10, P1039, DOI 10.1038/nsb1015; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Rohde JR, 2003, MOL CELL BIOL, V23, P629, DOI 10.1128/MCB.23.2.629-635.2003; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Xu G, 2001, DIABETES, V50, P353, DOI 10.2337/diabetes.50.2.353; Yuan XJ, 2002, EMBO REP, V3, P1082, DOI 10.1093/embo-reports/kvf212; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463	52	384	389	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6384	6391		10.1038/sj.onc.1209883	http://dx.doi.org/10.1038/sj.onc.1209883			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041624				2022-12-28	WOS:000241380700005
J	Uht, RM; Amos, S; Martin, PM; Riggan, AE; Hussaini, IM				Uht, R. M.; Amos, S.; Martin, P. M.; Riggan, A. E.; Hussaini, I. M.			The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway	ONCOGENE			English	Article						PKC-eta; AP-1; ERK; Elk-1; glioblastoma; proliferation	SIGNAL-TRANSDUCTION; HUMAN GLIOMA; TRANSCRIPTION FACTORS; IN-VITRO; RECEPTOR TRANSACTIVATION; MALIGNANT GLIOMAS; GROWTH; AP-1; INHIBITION; EXPRESSION	Glioblastoma multiforme (GBM) is the highest grade of astrocytoma. GBM pathogenesis has been linked to receptor tyrosine kinases and kinases further down signal-transduction pathways - in particular, members of the protein kinase C (PKC) family. The expression and activity of various PKC isoforms are increased in malignant astrocytomas, but not in non-neoplastic astrocytes. This suggests that PKC activity contributes to tumor progression. The level of PKC-eta expressed correlates with the degree of phorbol-12-myristate-13-acetate (PMA)-induced proliferation of two glioblastoma cell lines, U-1242 MG and U-251 MG. Normally, U-1242 cells do not express PKC-eta, and PMA inhibits their proliferation. Conversely, PMA increases proliferation of U-1242 cells that are stably transfected with PKC-eta (U-1242-PKC-eta). PMA treatment also stimulates proliferation of U-251 cells, which express PKC-eta. Here, we determined that extracellular signal-regulated kinase (ERK) and Elk-1 are downstream targets of PKC-eta. Elk-1-mediated transcriptional activity correlates with the PKC-eta-mediated mitogenic response. Pretreatment of U-1242-PKC-eta cells with inhibitors of PKC or MAPK/ERK kinase (MEK) (bisindolyl maleimide (BIM) or U0126, respectively) blocked both PMA-induced Elk-1 transcriptional activity and PMA-stimulated proliferation. An overexpressed dominant-negative PKC-eta reduced the mitogenic response in U-251 cells, as did reduction of Elk-1 by small interfering RNA. Taken together, these results strongly suggest that PKC-eta-mediated glioblastoma proliferation involves MEK/mitogen-activated protein (MAP) kinase phosphorylation, activation of ERK and subsequently of Elk-1. Elk-1 target genes involved in GBM proliferative responses have yet to be identified.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Uht, RM (corresponding author), Univ Virginia, Sch Med, Dept Pathol, MR 5,Rm 3123,415 Lane Rd, Charlottesville, VA 22908 USA.	ruht@virginia.edu		Amos, Samson/0000-0003-2780-2276	NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035122] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NINDS NIH HHS [R01 NS35122] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Amos S, 2005, J BIOL CHEM, V280, P7729, DOI 10.1074/jbc.M409056200; Baltuch GH, 1996, BRAIN RES, V710, P143, DOI 10.1016/0006-8993(95)01395-4; BALTUCH GH, 1995, CAN J NEUROL SCI, V22, P264, DOI 10.1017/S0317167100039457; BIGNER DD, 1981, J NEUROPATH EXP NEUR, V40, P201, DOI 10.1097/00005072-198105000-00001; BONGCAMRUDLOFF E, 1991, CANCER RES, V51, P1553; COULDWELL WT, 1990, J NEUROSURG, V73, P594, DOI 10.3171/jns.1990.73.4.0594; Dooley NP, 1998, NEUROREPORT, V9, P1727, DOI 10.1097/00001756-199806010-00011; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eller JL, 2005, NEUROSURGERY, V56, P155, DOI 10.1227/01.NEU.0000145865.25689.55; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Hess J, 2004, J CELL SCI, V117, P5965, DOI 10.1242/jcs.01589; Houillier C, 2006, CANCER-AM CANCER SOC, V106, P2218, DOI 10.1002/cncr.21819; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Hussaini IM, 1999, GLIA, V25, P71, DOI 10.1002/(SICI)1098-1136(19990101)25:1<71::AID-GLIA7>3.0.CO;2-0; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KLEIHEUS P, 1997, PATHOLOGY GENETICS T; Kleihues P, 1999, Neuro Oncol, V1, P44, DOI 10.1093/neuonc/1.1.44; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Mischel PS, 2003, BRAIN PATHOL, V13, P52; MISHIMA K, 1994, BIOCHEM BIOPH RES CO, V201, P363, DOI 10.1006/bbrc.1994.1710; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Sharif TR, 1999, INT J ONCOL, V14, P327; Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9; Shen L, 1998, BIOCHEM PHARMACOL, V55, P1711, DOI 10.1016/S0006-2952(98)00045-8; Szaniawska B, 1996, CANCER LETT, V107, P205, DOI 10.1016/0304-3835(96)04369-8; Tootle TL, 2005, BIOESSAYS, V27, P285, DOI 10.1002/bies.20198; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Uhrbom L, 1997, ONCOGENE, V15, P505, DOI 10.1038/sj.onc.1201227; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; *US CANC STAT WORK, 2005, US DEP HHS, P50; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036; Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6; Zellner A, 1998, CLIN CANCER RES, V4, P1797	40	61	65	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2885	2893		10.1038/sj.onc.1210090	http://dx.doi.org/10.1038/sj.onc.1210090			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17146445				2022-12-28	WOS:000246210800008
J	Jong, K; Marchiori, E; van der Vaart, A; Chin, SF; Carvalho, B; Tijssen, M; Eijk, PP; van den IJssel, P; Grabsch, H; Quirke, P; Oudejans, JJ; Meijer, GA; Caldas, C; Ylstra, B				Jong, K.; Marchiori, E.; van der Vaart, A.; Chin, S-F; Carvalho, B.; Tijssen, M.; Eijk, P. P.; van den IJssel, P.; Grabsch, H.; Quirke, P.; Oudejans, J. J.; Meijer, G. A.; Caldas, C.; Ylstra, B.			Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors	ONCOGENE			English	Article						array CGH; meta-analysis; chromosomal aberrations; cancer	COPY-NUMBER CHANGES; MICROARRAY DATA; EXPRESSION PATTERNS; COLORECTAL-CANCER; GENE-EXPRESSION; BREAST-TUMORS; PROFILES; CGH; CARCINOMA; REVEALS	A series of studies have been published that evaluate the chromosomal copy number changes of different tumor classes using array comparative genomic hybridization ( array CGH); however, the chromosomal aberrations that distinguish the different tumor classes have not been fully characterized. Therefore, we performed a meta-analysis of different array CGH data sets in an attempt to classify samples tested across different platforms. As opposed to RNA expression, a common reference is used in dual channel CGH arrays: normal human DNA, theoretically facilitating cross-platform analysis. To this aim, cell line and primary cancer data sets from three different dual channel array CGH platforms obtained by four different institutes were integrated. The cell line data were used to develop preprocessing methods, which performed noise reduction and transformed samples into a common format. The transformed array CGH profiles allowed perfect clustering by cell line, but importantly not by platform or institute. The same preprocessing procedures used for the cell line data were applied to data from 373 primary tumors pro. led by array CGH, including controls. Results indicated that there is no apparent feature related to the institute or platform and that array CGH allows for unambiguous cross-platform meta-analysis. Major clusters with common tissue origin were identified. Interestingly, tumors of hematopoietic and mesenchymal origins cluster separately from tumors of epithelial origin. Therefore, it can be concluded that chromosomal aberrations of tumors from hematopoietic and mesenchymal origin versus tumors of epithelial origin are distinct, and these differences can be picked up by meta-analysis of array CGH data. This suggests the possibility of prospectively using combined analysis of diverse copy number data sets for cancer subtype classification.	Vrije Univ Amsterdam, Med Ctr, Micro Array Core Facil, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; St James Univ Hosp, Dept Pathol & Tumour Biol, Leeds, W Yorkshire, England; Vrije Univ Amsterdam, Fac Sci, NL-1007 MB Amsterdam, Netherlands; Univ Cambridge, Canc Genom Program, Dept Oncol, MRC,Hutchison Res Ctr, Cambridge, England	Vrije Universiteit Amsterdam; Saint James's University Hospital; Vrije Universiteit Amsterdam; University of Cambridge	Ylstra, B (corresponding author), Vrije Univ Amsterdam, Med Ctr, Micro Array Core Facil, Dept Pathol, Room CCA-122,POB 7057, NL-1007 MB Amsterdam, Netherlands.	b.ylstra@vumc.nl	Caldas, Carlos/A-7543-2008; Quirke, Philip/AAI-1362-2019; Carvalho, Beatriz/GXA-0720-2022; Caldas, Carlos/U-7250-2019; Ylstra, Bauke/D-2906-2012	Caldas, Carlos/0000-0003-3547-1489; Ylstra, Bauke/0000-0001-9479-3010; Meijer, Gerrit/0000-0003-0330-3130; Quirke, Philip/0000-0002-3597-5444; chin, suet-feung/0000-0001-5697-1082				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Oostlander AE, 2004, CLIN GENET, V66, P488, DOI 10.1111/j.1399-0004.2004.00322.x; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schreurs MWJ, 2005, BLOOD, V106, P2663, DOI 10.1182/blood-2004-09-3742; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Snijders AM, 2003, ONCOGENE, V22, P4281, DOI 10.1038/sj.onc.1206621; van Dekken H, 2004, GENE CHROMOSOME CANC, V39, P249, DOI 10.1002/gcc.20001; van den IJssel P, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni191; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; Ylstra B, 2006, NUCLEIC ACIDS RES, V34, P445, DOI 10.1093/nar/gkj456; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	28	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1499	1506		10.1038/sj.onc.1209919	http://dx.doi.org/10.1038/sj.onc.1209919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936777				2022-12-28	WOS:000244558800015
J	Amorino, GP; Deeble, PD; Parsons, SJ				Amorino, G. P.; Deeble, P. D.; Parsons, S. J.			Neurotensin stimulates mitogenesis of prostate cancer cells through a novel c-Src/Stat5b pathway	ONCOGENE			English	Article						neurotensin; EGFR; Tyr(845); Src; Stat5b; prostate cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR TRANSACTIVATION; PROTEIN-COUPLED RECEPTORS; FOCAL ADHESION KINASE; NEUROENDOCRINE DIFFERENTIATION; TYROSINE KINASE; DNA-SYNTHESIS; TUMOR-CELLS; MAP-KINASE; C-SRC	Neuroendocrine (NE)-like cells are hypothesized to contribute to the progression of prostate cancer by producing factors that enhance the growth, survival or metastatic capabilities of surrounding tumor cells. Many of the factors known to be secreted by NE-like cells, such as neurotensin (NT), parathyroid hormone-related peptide, serotonin, bombesin, etc., are agonists for G-protein-coupled receptors, but the signaling pathways activated by these agonists in prostate tumor cells are not fully defined. Identification of such pathways could provide insights into novel methods of treating late-stage disease. Using conditioned culture medium (CM) from LNCaP-derived NE-like cells (as a source of these agonists) or NT (a prototypical component of CM) to treat PC3 cells, we found that the epidermal growth factor (EGF) receptor (EGFR) was transactivated and that such activation was required for maximal PC3 cell mitogenesis, as measured by 5-bromo-20-deoxy-uridine incorporation or cell number. NT also induced a time-dependent increase in EGFR Tyr(845) phosphorylation and phosphorylation of c-Src and signal transducer and activator of transcription 5b (Stat5b) (a downstream effector of Tyr845), events that were blocked by specific inhibition of c-Src (which mediates Tyr845 phosphorylation of EGFR) or of EGFR. Introduction of mutant forms of EGFR (Tyr845) or Stat5b in PC3 cells, or treatment with selective, catalytic inhibitors of EGFR, c-Src and matrix metalloproteinases (MMPs) resulted in the loss of NT-induced stimulation of DNA synthesis, relative to wild-type controls. These data indicate that the mitogenic effect of NT on prostate cancer cells requires transactivation of the EGFR by MMPs and a novel downstream pathway involving c-Src, phosphorylation of EGFR Tyr845 and activation of Stat5b.	Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Dept Radiat Oncol, Charlottesville, VA USA; Mary Baldwin Coll, Dept Biol, Staunton, VA USA	University of Virginia; University of Virginia	Parsons, SJ (corresponding author), Univ Virginia, Dept Microbiol, Hlth Sci Ctr, Ctr Canc, POB 800734, Charlottesville, VA 22908 USA.	sap@virginia.edu			NCI NIH HHS [R01 CA71449] Funding Source: Medline; NIDDK NIH HHS [T32 DK007646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrahamsson PA, 1999, PROSTATE, V39, P135, DOI 10.1002/(SICI)1097-0045(19990501)39:2<135::AID-PROS9>3.0.CO;2-S; Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Aprikian AG, 1997, INT J CANCER, V72, P498, DOI 10.1002/(SICI)1097-0215(19970729)72:3<498::AID-IJC19>3.3.CO;2-P; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLOGNA M, 1989, CANCER, V63, P1714; Cox ME, 1999, CANCER RES, V59, P3821; Cox ME, 2000, J BIOL CHEM, V275, P13812, DOI 10.1074/jbc.275.18.13812; Dal Farra C, 2001, INT J CANCER, V92, P503, DOI 10.1002/ijc.1225; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Deeble PD, 2001, MOL CELL BIOL, V21, P8471, DOI 10.1128/MCB.21.24.8471-8482.2001; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; Hassan S, 2006, REGUL PEPTIDES, V133, P105, DOI 10.1016/j.regpep.2005.09.031; Hassan S, 2004, REGUL PEPTIDES, V120, P155, DOI 10.1016/j.regpep.2004.03.004; IWAMURA M, 1994, UROLOGY, V43, P675, DOI 10.1016/0090-4295(94)90183-X; Jongsma J, 2000, PROSTATE, V42, P34, DOI 10.1002/(SICI)1097-0045(20000101)42:1<34::AID-PROS5>3.0.CO;2-2; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; Kloth MT, 2002, J BIOL CHEM, V277, P8693, DOI 10.1074/jbc.M111884200; Labbe-Jullie C, 1998, J BIOL CHEM, V273, P16351, DOI 10.1074/jbc.273.26.16351; LARRAN LJ, 2000, ACTAS UROL ESP, V24, P779; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Madarame J, 2003, PROSTATE, V57, P187, DOI 10.1002/pros.10295; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; ORELLANA SA, 1992, P NATL ACAD SCI USA, V89, P4726, DOI 10.1073/pnas.89.10.4726; Petit T, 2001, ANTI-CANCER DRUG, V12, P133, DOI 10.1097/00001813-200102000-00006; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; REILE H, 1994, PROSTATE, V25, P29, DOI 10.1002/pros.2990250105; Santiskulvong C, 2003, EXP CELL RES, V290, P437, DOI 10.1016/S0014-4827(03)00355-0; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Seethalakshmi L, 1997, PROSTATE, V31, P183, DOI 10.1002/(SICI)1097-0045(19970515)31:3<183::AID-PROS7>3.0.CO;2-M; SEHGAL I, 1994, P NATL ACAD SCI USA, V91, P4673, DOI 10.1073/pnas.91.11.4673; Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167-0115(02)00007-1; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wright JD, 1996, BBA-MOL CELL RES, V1312, P85, DOI 10.1016/0167-4889(96)00027-4; Xiao DM, 2003, CELL SIGNAL, V15, P945, DOI 10.1016/S0898-6568(03)00059-7; Xiao DM, 2002, REGUL PEPTIDES, V109, P141, DOI 10.1016/S0167-0115(02)00197-0; Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014; Zhao DZ, 2004, J BIOL CHEM, V279, P43547, DOI 10.1074/jbc.M401453200	46	66	71	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					745	756		10.1038/sj.onc.1209814	http://dx.doi.org/10.1038/sj.onc.1209814			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862179				2022-12-28	WOS:000243902200011
J	Arce, L; Yokoyama, NN; Waterman, ML				Arce, L.; Yokoyama, N. N.; Waterman, M. L.			Diversity of LEF/TCF action in development and disease	ONCOGENE			English	Review						LEF; TCF; Wnt; beta-catenin	TCR-ALPHA ENHANCER; APC TUMOR-SUPPRESSOR; DEPENDENT TRANSCRIPTIONAL ACTIVATION; TERMINAL-BINDING-PROTEIN; BETA-CATENIN; HMG-DOMAIN; FACTOR-I; NUCLEAR-LOCALIZATION; CELL DIFFERENTIATION; MINOR-GROOVE	Lymphoid enhancer factor/T cell factor proteins (LEF/TCFs) mediate Wnt signals in the nucleus by recruiting beta-catenin and its co-activators to Wnt response elements (WREs) of target genes. This activity is important during development but its misregulation plays a role in disease such as cancer, where overactive Wnt signaling drives LEF/TCFs to transform cells. The size of the LEF/TCF family is small: approximately four members in vertebrates and one orthologous form in flies, worms and hydra. However, size belies complexity. The LEF/TCF family exhibits extensive patterns of alternative splicing, alternative promoter usage and activities of repression, as well as activation. Recent work from numerous laboratories has highlighted how this complexity has important biological consequences in development and disease.	Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine	Waterman, ML (corresponding author), Univ Calif Irvine, Dept Microbiol & Mol Genet, Rm B240 Med Sci I, Irvine, CA 92697 USA.	mlwaterm@uci.edu			NATIONAL CANCER INSTITUTE [R01CA096878, R01CA083982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM064210] Funding Source: NIH RePORTER; NCI NIH HHS [CA096878, CA83982] Funding Source: Medline; NIGMS NIH HHS [GM064210] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amir AL, 2003, J BIOL CHEM, V278, P30828, DOI 10.1074/jbc.M301208200; Atcha FA, 2003, J BIOL CHEM, V278, P16169, DOI 10.1074/jbc.M213218200; Balmelle N, 2004, J IMMUNOL, V173, P5054, DOI 10.4049/jimmunol.173.8.5054; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Beland M, 2004, MOL CELL BIOL, V24, P5028, DOI 10.1128/MCB.24.11.5028-5038.2004; Bhatia M, 2006, MOL BIOL CELL, V17; Boras K, 2002, J BIOL CHEM, V277, P1120, DOI 10.1074/jbc.M109912200; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARLSSON P, 1993, GENE DEV, V7, P2418, DOI 10.1101/gad.7.12a.2418; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Cordray P, 2005, DEV DYNAM, V232, P969, DOI 10.1002/dvdy.20275; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Cuilliere-Dartigues P, 2006, ONCOGENE, V25, P4441, DOI 10.1038/sj.onc.1209471; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Dorsky RI, 2000, GENE DEV, V14, P158; Dorsky RI, 2003, DEVELOPMENT, V130, P1937, DOI 10.1242/dev.00402; Duval A, 1999, CANCER RES, V59, P4213; Duval A, 2000, CANCER RES, V60, P3872; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; Fang M, 2006, EMBO J, V25, P2735, DOI 10.1038/sj.emboj.7601153; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Gay F, 2003, GENE DEV, V17, P717, DOI 10.1101/gad.1042403; Ghogomu SM, 2006, J BIOL CHEM, V281, P1755, DOI 10.1074/jbc.M505869200; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Gradl D, 2002, J BIOL CHEM, V277, P14159, DOI 10.1074/jbc.M107055200; Graham TA, 2000, CELL, V103, P885, DOI 10.1016/S0092-8674(00)00192-6; Graham TA, 2001, NAT STRUCT BIOL, V8, P1048, DOI 10.1038/nsb718; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Hamada F, 2004, DEV CELL, V7, P677, DOI 10.1016/j.devcel.2004.08.022; Hammerlein A, 2005, CELL MOL LIFE SCI, V62, P606, DOI 10.1007/s00018-005-4507-7; Haremaki T, 2003, DEVELOPMENT, V130, P4907, DOI 10.1242/dev.00718; Hecht A, 2003, J BIOL CHEM, V278, P3776, DOI 10.1074/jbc.M210081200; Held W, 2003, EUR J IMMUNOL, V33, P1393, DOI 10.1002/eji.200323840; Hikasa H, 2004, DEVELOPMENT, V131, P4725, DOI 10.1242/dev.01369; Houston DW, 2002, DEVELOPMENT, V129, P4015; Hovanes K, 2000, NUCLEIC ACIDS RES, V28, P1994, DOI 10.1093/nar/28.9.1994; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200; Ishitani T, 2005, NAT CELL BIOL, V7, P1106, DOI 10.1038/ncb1311; Ishitani T, 2003, MOL CELL BIOL, V23, P1379, DOI 10.1128/MCB.23.4.1379-1389.2003; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kahler RA, 2003, J BIOL CHEM, V278, P11937, DOI 10.1074/jbc.M211443200; Kennell JA, 2003, MOL CELL BIOL, V23, P5366, DOI 10.1128/MCB.23.15.5366-5375.2003; Kolligs FT, 2000, GENE DEV, V14, P1319; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kunz M, 2004, DEV BIOL, V273, P390, DOI 10.1016/j.ydbio.2004.06.015; Kusano S, 2002, MOL CELL BIOL, V22, P6393, DOI 10.1128/MCB.22.18.6393-6405.2002; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; Li TWH, 2006, MOL CELL BIOL, V26, P5284, DOI 10.1128/MCB.00105-06; Liu F, 2005, DEVELOPMENT, V132, P5375, DOI 10.1242/dev.02152; Lo MC, 2004, CELL, V117, P95, DOI 10.1016/S0092-8674(04)00203-X; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Maduro MF, 2005, DEV BIOL, V285, P510, DOI 10.1016/j.ydbio.2005.06.022; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Nishita M, 2000, NATURE, V403, P781, DOI 10.1038/35001602; Okamura RM, 1998, IMMUNITY, V8, P11, DOI 10.1016/S1074-7613(00)80454-9; OOSTERWEGEL MA, 1991, INT IMMUNOL, V3, P1189, DOI 10.1093/intimm/3.11.1189; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Payre F, 1999, NATURE, V400, P271, DOI 10.1038/22330; Prieve MG, 1998, MOL CELL BIOL, V18, P4819, DOI 10.1128/MCB.18.8.4819; Pukrop T, 2001, J BIOL CHEM, V276, P8968, DOI 10.1074/jbc.M007533200; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roel G, 2002, CURR BIOL, V12, P1941, DOI 10.1016/S0960-9822(02)01280-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saito H, 2002, J BIOL CHEM, V277, P28787, DOI 10.1074/jbc.M203719200; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; Shetty P, 2005, DEV BIOL, V285, P584, DOI 10.1016/j.ydbio.2005.07.008; Shulewitz M, 2006, ONCOGENE, V25, P4361, DOI 10.1038/sj.onc.1209470; Sierra J, 2006, GENE DEV, V20, P586, DOI 10.1101/gad.1385806; Snider L, 2005, MOL CELL BIOL, V25, P5061, DOI 10.1128/MCB.25.12.5061-5072.2005; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Standley HJ, 2006, DEV BIOL, V289, P318, DOI 10.1016/j.ydbio.2005.10.012; Stankovic-Valentin N, 2006, FEBS J, V273, P2879, DOI 10.1111/j.1742-4658.2006.05301.x; Takeda H, 2006, NAT MED, V12, P395, DOI 10.1038/nm1386; Theisen H, 1996, DEVELOPMENT, V122, P3939; Tutter AV, 2001, GENE DEV, V15, P3342, DOI 10.1101/gad.946501; Vadlamudi U, 2005, J CELL SCI, V118, P1129, DOI 10.1242/jcs.01706; Valenta T, 2003, NUCLEIC ACIDS RES, V31, P2369, DOI 10.1093/nar/gkg346; Valenta T, 2006, EMBO J, V25, P2326, DOI 10.1038/sj.emboj.7601147; van Beest M, 2000, J BIOL CHEM, V275, P27266; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; van Roy FM, 2005, NAT REV CANCER, V5, P956, DOI 10.1038/nrc1752; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; Veien ES, 2005, DEV DYNAM, V233, P233, DOI 10.1002/dvdy.20330; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Waterman ML, 2004, CANCER METAST REV, V23, P41, DOI 10.1023/A:1025858928620; Weerkamp F, 2006, P NATL ACAD SCI USA, V103, P3322, DOI 10.1073/pnas.0511299103; Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006; Willinger T, 2006, J IMMUNOL, V176, P1439, DOI 10.4049/jimmunol.176.3.1439; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yasumoto K, 2002, EMBO J, V21, P2703, DOI 10.1093/emboj/21.11.2703; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	118	318	331	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7492	7504		10.1038/sj.onc.1210056	http://dx.doi.org/10.1038/sj.onc.1210056			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143293				2022-12-28	WOS:000242514900007
J	Corradetti, MN; Guan, KL				Corradetti, M. N.; Guan, K-L			Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?	ONCOGENE			English	Review						mTOR; rapamycin; Akt; cellular stress; translation; mTORC1	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; P70 S6 KINASE; GROWTH-FACTOR RECEPTOR; CELL-GROWTH; HYDROGEN-PEROXIDE; OSMOTIC-STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; REPLICATING ADENOVIRUSES; ENHANCED SENSITIVITY	The mammalian target of rapamycin ( mTOR) is a serine/threonine kinase that controls many aspects of cellular physiology, including transcription, translation, cell size, cytoskeletal organization and autophagy. Recent advances in the mTOR signaling field have found that mTOR exists in two heteromeric complexes, mTORC1 and mTORC2. The activity of mTORC1 is regulated by the integration of many signals, including growth factors, insulin, nutrients, energy availability and cellular stressors such as hypoxia, osmotic stress, reactive oxygen species and viral infection. In this review we highlight recent advances in the mTOR signaling field that relate to how the two mTOR complexes are regulated, and we discuss stress conditions linked to the mTOR signaling network that have not been extensively covered in other reviews. Given the diversity of signals that have been shown to impinge on mTOR, we also speculate on other signal-transduction pathways that may be linked to mTOR in the future.	Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Corradetti, MN (corresponding author), Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA.	mcorrade@umich.edu; kunliang@umich.edu			NICHD NIH HHS [5-T32-HD075005] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R21HD075005] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Andreoni KA, 2002, J MED VIROL, V67, P33, DOI 10.1002/jmv.2189; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Astrinidis A, 2006, HUM MOL GENET, V15, P287, DOI 10.1093/hmg/ddi444; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Bader AG, 2004, ONCOGENE, V23, P3145, DOI 10.1038/sj.onc.1207550; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Birchenall-Roberts MC, 2004, J BIOL CHEM, V279, P25605, DOI 10.1074/jbc.M402790200; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Boonstra J, 2004, GENE, V337, P1, DOI 10.1016/j.gene.2004.04.032; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dong LQ, 2005, AM J PHYSIOL-ENDOC M, V289, pE187, DOI 10.1152/ajpendo.00011.2005; Edinger AL, 2003, CANCER RES, V63, P8451; Eisen HJ, 2003, NEW ENGL J MED, V349, P847, DOI 10.1056/NEJMoa022171; Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Finlay GA, 2005, CANCER RES, V65, P10881, DOI 10.1158/0008-5472.CAN-05-1394; Finlay GA, 2004, J BIOL CHEM, V279, P23114, DOI 10.1074/jbc.M401912200; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Hansen IA, 2004, P NATL ACAD SCI USA, V101, P10626, DOI 10.1073/pnas.0403460101; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Homicsko K, 2005, CANCER RES, V65, P6882, DOI 10.1158/0008-5472.CAN-05-0309; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Iijima Y, 2002, J BIOL CHEM, V277, P23065, DOI 10.1074/jbc.M200328200; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Johnson RA, 2001, J VIROL, V75, P6022, DOI 10.1128/JVI.75.13.6022-6032.2001; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; Krause U, 2002, EUR J BIOCHEM, V269, P3751, DOI 10.1046/j.1432-1033.2002.03074.x; KRUPPA J, 1984, EMBO J, V3, P95, DOI 10.1002/j.1460-2075.1984.tb01767.x; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; LI Y, 2003, J BIOL CHEM, V11, P11; Lin L, 2005, BIOCHEM J, V392, P93, DOI 10.1042/BJ20050553; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Mahfouz MM, 2006, PLANT CELL, V18, P477, DOI 10.1105/tpc.105.035931; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008; Mata J, 2005, TRENDS BIOCHEM SCI, V30, P506, DOI 10.1016/j.tibs.2005.07.005; Menand B, 2003, CURR TOP MICROBIOL, V279, P97; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Naegele S, 2004, J BIOL CHEM, V279, P46023, DOI 10.1074/jbc.M404945200; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; O'Shea CC, 2005, CELL CYCLE, V4, P883, DOI 10.4161/cc.4.7.1791; O'Shea CC, 2005, CURR OPIN GENET DEV, V15, P18, DOI 10.1016/j.gde.2004.12.010; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patel J, 2002, EUR J BIOCHEM, V269, P3076, DOI 10.1046/j.1432-1033.2002.02992.x; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098; Ponticelli C, 2004, J NEPHROL, V17, P762; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Prendergast GC, 2003, CANCER CELL, V4, P244, DOI 10.1016/S1535-6108(03)00247-2; Proud CG, 2003, CURR TOP MICROBIOL, V279, P215; Proud CG, 2004, DNA REPAIR, V3, P927, DOI 10.1016/j.dnarep.2004.03.012; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2004, AMINO ACIDS, V27, P119, DOI 10.1007/s00726-004-0119-z; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; SABORIO JL, 1974, J MOL BIOL, V85, P195, DOI 10.1016/0022-2836(74)90360-X; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shamji AF, 2003, MOL CELL, V12, P271, DOI 10.1016/j.molcel.2003.08.016; Shaw RJ, 2005, SCIENCE, V310, P1642, DOI 10.1126/science.1120781; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Shi YJ, 2002, CANCER RES, V62, P5027; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; Shioi T, 2003, CIRCULATION, V107, P1664, DOI 10.1161/01.CIR.0000057979.36322.88; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2003, J BIOL CHEM, V278, P37288, DOI 10.1074/jbc.M303257200; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tirado OM, 2003, CANCER RES, V63, P6290; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Wang X, 2003, NATURE, V424, P456, DOI 10.1038/nature01818; Wang ZQ, 2003, J BIOL CHEM, V278, P27053, DOI 10.1074/jbc.M303723200; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Zacharek SJ, 2005, CANCER RES, V65, P11354, DOI 10.1158/0008-5472.CAN-05-2236; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	152	311	322	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6347	6360		10.1038/sj.onc.1209885	http://dx.doi.org/10.1038/sj.onc.1209885			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041621				2022-12-28	WOS:000241380700002
J	Evers, B; Jonkers, J				Evers, B.; Jonkers, J.			Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects	ONCOGENE			English	Review						BRCA1; BRCA2; breast cancer; tumor suppressor; mouse model	CANCER SUSCEPTIBILITY GENE; EMBRYONIC CELLULAR PROLIFERATION; DNA-DAMAGE RESPONSE; BREAST-CANCER; SPLICE VARIANT; GENOMIC INSTABILITY; ESTROGEN-RECEPTOR; FAMILIAL BREAST; CENTROSOME AMPLIFICATION; INDUCED TUMORIGENESIS	Germline mutations in BRCA1 and BRCA2 are responsible for a large proportion of hereditary breast and ovarian cancers. Soon after the identification of both genes in the mid-1990s, investigators set out to develop mouse models for the associated disease. Whereas conventional Brca1 and Brca2 mouse mutants did not reveal a strong phenotype in a heterozygous setting, most homozygous mutations caused embryonic lethality. Consequently, development of mouse models for BRCA-associated tumorigenesis required the generation of tissue-specific conditional knockout animals. In this review, we give an overview of the conventional and the conditional mouse models of BRCA1 and BRCA2 deficiency generated over the last decade, as well as the contribution of these models to our understanding of the biological and molecular functions of BRCA1 and BRCA2. The most advanced mouse models for BRCA1- and BRCA2-associated tumorigenesis mimic human disease to the extent that they can be used in studies addressing clinically relevant questions. These models will help to resolve yet unanswered questions and to translate our increasing knowledge of BRCA1 and BRCA2 biology into clinical practice.	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Jonkers, J (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.jonkers@nki.nl	Jonkers, Jos/AAG-3246-2019	Jonkers, Jos/0000-0002-9264-9792				Alberg Anthony J., 1997, Current Opinion in Oncology, V9, P505, DOI 10.1097/00001622-199711000-00003; Bachelier R, 2005, ONCOL REP, V14, P1117; Bae I, 2005, CELL CYCLE, V4, P1641, DOI 10.4161/cc.4.11.2152; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bennett LM, 2000, MOL CARCINOGEN, V28, P174, DOI 10.1002/1098-2744(200007)28:3<174::AID-MC6>3.0.CO;2-C; Berton TR, 2003, ONCOGENE, V22, P5415, DOI 10.1038/sj.onc.1206825; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Brodie SG, 2001, ONCOGENE, V20, P7514, DOI 10.1038/sj.onc.1204929; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cao L, 2003, GENE DEV, V17, P201, DOI 10.1101/gad.1050003; Cao L, 2006, EMBO J, V25, P2167, DOI 10.1038/sj.emboj.7601115; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chappuis PO, 2000, SEMIN SURG ONCOL, V18, P287, DOI 10.1002/(SICI)1098-2388(200006)18:4<287::AID-SSU3>3.3.CO;2-X; Chen FQ, 1997, MUTAT RES-DNA REPAIR, V384, P205, DOI 10.1016/S0921-8777(97)00020-7; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Cheung AMY, 2002, CANCER RES, V62, P6194; COLLINS N, 1995, ONCOGENE, V10, P1673; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Crook T, 1997, LANCET, V350, P638, DOI 10.1016/S0140-6736(05)63327-2; Cullinane CA, 2005, INT J CANCER, V117, P988, DOI 10.1002/ijc.21273; Daniels MJ, 2004, SCIENCE, V306, P876, DOI 10.1126/science.1102574; de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782; Dekker M, 2006, GENE THER, V13, P686, DOI 10.1038/sj.gt.3302689; Dekker M, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng027; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Donoho G, 2003, GENE CHROMOSOME CANC, V36, P317, DOI 10.1002/gcc.10148; Elledge SJ, 2002, CANCER CELL, V1, P129, DOI 10.1016/S1535-6108(02)00041-7; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fortin J, 2005, BBA-GENE STRUCT EXPR, V1731, P57, DOI 10.1016/j.bbaexp.2005.08.011; Friedman LS, 1998, CANCER RES, V58, P1338; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Greenblatt MS, 2001, CANCER RES, V61, P4092; Hakem R, 1997, NAT GENET, V16, P298, DOI 10.1038/ng0797-298; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hay T, 2005, CANCER RES, V65, P10145, DOI 10.1158/0008-5472.CAN-05-1186; Hay T, 2005, ONCOGENE, V24, P3842, DOI 10.1038/sj.onc.1208533; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Jonkers J, 2002, NAT REV CANCER, V2, P251, DOI 10.1038/nrc777; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kim SS, 2004, MOL CELL BIOL, V24, P9498, DOI 10.1128/MCB.24.21.9498-9507.2004; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lane TF, 2004, CANCER BIOL THER, V3, P528, DOI 10.4161/cbt.3.6.843; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee H, 1999, MOL CELL, V4, P1, DOI 10.1016/S1097-2765(00)80182-3; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lomonosov M, 2003, GENE DEV, V17, P3017, DOI 10.1101/gad.279003; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Lu ML, 1996, CANCER RES, V56, P4578; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ludwig T, 2001, GENE DEV, V15, P1188, DOI 10.1101/gad.879201; Mak TW, 2000, NAT IMMUNOL, V1, P77, DOI 10.1038/76950; Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McAllister KA, 2002, CANCER RES, V62, P990; McPherson JP, 2006, HUM MOL GENET, V15, P831, DOI 10.1093/hmg/ddl002; McPherson JP, 2004, GENE DEV, V18, P1144, DOI 10.1101/gad.1192704; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Metcalfe K, 2004, J CLIN ONCOL, V22, P2328, DOI 10.1200/JCO.2004.04.033; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; Morimatsu M, 1998, CANCER RES, V58, P3441; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Noruzinia M, 2005, CANCER-AM CANCER SOC, V104, P1567, DOI 10.1002/cncr.21367; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Phillips KA, 2000, J CLIN ONCOL, V18, p107S; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sharan SK, 1997, NATURE, V386, P804, DOI 10.1038/386804a0; Shen SX, 1998, ONCOGENE, V17, P3115, DOI 10.1038/sj.onc.1202243; Shin S, 2003, P NATL ACAD SCI USA, V100, P7201, DOI 10.1073/pnas.1132020100; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Spillman MA, 1996, ONCOGENE, V13, P1639; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Suzuki A, 1997, GENE DEV, V11, P1242, DOI 10.1101/gad.11.10.1242; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Turner JMA, 2004, CURR BIOL, V14, P2135, DOI 10.1016/j.cub.2004.11.032; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Tutt ANJ, 2002, EMBO REP, V3, P255, DOI 10.1093/embo-reports/kvf037; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XY, 2004, J BIOL CHEM, V279, P29606, DOI 10.1074/jbc.M312279200; Weaver Z, 2002, ONCOGENE, V21, P5097, DOI 10.1038/sj.onc.1205636; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xia F, 2001, P NATL ACAD SCI USA, V98, P8644, DOI 10.1073/pnas.151253498; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yan DH, 2004, ONCOGENE, V23, P1896, DOI 10.1038/sj.onc.1207314; Yang YP, 2003, HUM MOL GENET, V12, P2121, DOI 10.1093/hmg/ddg222	121	176	177	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5885	5897		10.1038/sj.onc.1209871	http://dx.doi.org/10.1038/sj.onc.1209871			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998503				2022-12-28	WOS:000240765900009
J	Chatterjee, A; Mambo, E; Sidransky, D				Chatterjee, A.; Mambo, E.; Sidransky, D.			Mitochondrial DNA mutations in human cancer	ONCOGENE			English	Review						mitochondria; mutation; homoplasmy; reactive oxygen species (ROS); molecular detection	RENAL-CELL CARCINOMA; NONCANCEROUS LIVER-TISSUE; PEPTIDE NUCLEIC-ACID; CYTOCHROME-C-OXIDASE; D-LOOP MUTATIONS; HEPATOCELLULAR-CARCINOMA; BREAST-CANCER; SOMATIC MUTATIONS; ENERGY-METABOLISM; PROSTATE-CANCER	Somatic mitochondrial DNA ( mtDNA) mutations have been increasingly observed in primary human cancers. As each cell contains many mitochondria with multiple copies of mtDNA, it is possible that wild-type and mutant mtDNA can co-exist in a state called heteroplasmy. During cell division, mitochondria are randomly distributed to daughter cells. Over time, the proportion of the mutant mtDNA within the cell can vary and may drift toward predominantly mutant or wild type to achieve homoplasmy. Thus, the biological impact of a given mutation may vary, depending on the proportion of mutant mtDNAs carried by the cell. This effect contributes to the various phenotypes observed among family members carrying the same pathogenic mtDNA mutation. Most mutations occur in the coding sequences but few result in substantial amino acid changes raising questions as to their biological consequence. Studies reveal that mtDNA play a crucial role in the development of cancer but further work is required to establish the functional significance of specific mitochondrial mutations in cancer and disease progression. The origin of somatic mtDNA mutations in human cancer and their potential diagnostic and therapeutic implications in cancer are discussed. This review article provides a detailed summary of mtDNA mutations that have been reported in various types of cancer. Furthermore, this review offers some perspective as to the origin of these of mutations, their functional consequences in cancer development, and possible therapeutic implications.	Johns Hopkins Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Head & Neck Canc Res Div, Baltimore, MD 21205 USA	Johns Hopkins University	Sidransky, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Head & Neck Canc Res Div, 720 Rutland Ave, Baltimore, MD 21205 USA.	dsidrans@jhmi.edu			NCI NIH HHS [CA-P01-77664] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA077664] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abnet CC, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-30; Abu-Amero KK, 2005, ONCOGENE, V24, P1455, DOI 10.1038/sj.onc.1208292; Alonso A, 1997, ELECTROPHORESIS, V18, P682, DOI 10.1002/elps.1150180504; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bando H, 2005, CLIN CANCER RES, V11, P5784, DOI 10.1158/1078-0432.CCR-05-0149; Basso D, 2004, GUT, V53, P1159, DOI 10.1136/gut.2003.024471; Beck SA, 2004, LIPIDS, V39, P1187, DOI 10.1007/s11745-004-1346-8; BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072; Blanchard JL, 1996, MOL BIOL EVOL, V13, P537, DOI 10.1093/oxfordjournals.molbev.a025614; BOITIER E, 1995, CANCER RES, V55, P3028; Boros LG, 1998, MED HYPOTHESES, V50, P501, DOI 10.1016/S0306-9877(98)90271-7; Boros LG, 2000, CANCER RES, V60, P1183; BURGART LJ, 1995, AM J PATHOL, V147, P1105; Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008; Capuano F, 1997, J BIOENERG BIOMEMBR, V29, P379, DOI 10.1023/A:1022402915431; CAVELIER L, 1995, GENOMICS, V29, P217, DOI 10.1006/geno.1995.1234; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061; Chowdhury SKR, 2005, BIOCHEM BIOPH RES CO, V333, P1139, DOI 10.1016/j.bbrc.2005.06.017; Cooper R, 2003, BRIT J CANCER, V89, P870, DOI 10.1038/sj.bjc.6601202; Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014; Cuezva JM, 2002, CANCER RES, V62, P6674; Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2; Denda A, 2002, CARCINOGENESIS, V23, P245, DOI 10.1093/carcin/23.2.245; Eigenbrodt E, 1998, ANTICANCER RES, V18, P3267; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; FARRELL LB, 1988, EUR J BIOCHEM, V173, P131, DOI 10.1111/j.1432-1033.1988.tb13976.x; FERRETTI A, 1993, ANTICANCER RES, V13, P867; Flierl A, 2003, MOL THER, V7, P550, DOI 10.1016/S1525-0016(03)00037-6; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; GEARING DP, 1986, EMBO J, V5, P3651, DOI 10.1002/j.1460-2075.1986.tb04695.x; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Griffiths J. R., 2001, Bioessays, V23, P295, DOI 10.1002/1521-1878(200103)23:3<295::AID-BIES1040>3.0.CO;2-M; GRIVELL LA, 1983, SCI AM, V248, P78, DOI 10.1038/scientificamerican0383-78; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; Ha PK, 2002, CLIN CANCER RES, V8, P2260; Habano W, 1998, ONCOGENE, V17, P1931, DOI 10.1038/sj.onc.1202112; Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N; Han CB, 2005, WORLD J GASTROENTERO, V11, P31, DOI 10.3748/wjg.v11.i1.31; Hardy S, 2003, J BIOL CHEM, V278, P31861, DOI 10.1074/jbc.M300190200; HEERDT BG, 1990, CANCER RES, V50, P1596; Hibi K, 2001, INT J CANCER, V92, P319, DOI 10.1002/ijc.1204; HOBERMAN HD, 1975, CANCER RES, V35, P3332; Hockenbery DM, 2002, ADV CANCER RES, V85, P203, DOI 10.1016/S0065-230X(02)85007-2; Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z; IRWIN CC, 1978, CANCER RES, V38, P1584; Isaacs C, 2004, BREAST CANCER RES TR, V84, P99, DOI 10.1023/B:BREA.0000018406.03679.2e; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; Jeronimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646; Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X; Jones JB, 2001, CANCER RES, V61, P1299; Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931; Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267; LAW RHP, 1990, EUR J BIOCHEM, V188, P421, DOI 10.1111/j.1432-1033.1990.tb15419.x; LAW RHP, 1988, FEBS LETT, V236, P501, DOI 10.1016/0014-5793(88)80086-3; Leij-Halfwerk S, 2000, CANCER RES, V60, P618; Liang BC, 1996, MUTAT RES-FUND MOL M, V354, P27, DOI 10.1016/0027-5107(96)00004-8; Liang BC, 1996, CANCER LETT, V105, P167, DOI 10.1016/0304-3835(96)04276-0; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Liu VWS, 2001, CANCER RES, V61, P5998; LOPEZALARCON L, 1986, CANCER RES, V46, P5589; LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x; LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504; Mambo E, 2005, INT J CANCER, V116, P920, DOI 10.1002/ijc.21110; Mambo E, 2003, P NATL ACAD SCI USA, V100, P1838, DOI 10.1073/pnas.0437910100; Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200; Mazurek S, 1997, J BIOENERG BIOMEMBR, V29, P315, DOI 10.1023/A:1022490512705; Meierhofer D, 2004, CARCINOGENESIS, V25, P1005, DOI 10.1093/carcin/bgh104; Miyazono F, 2002, ONCOGENE, V21, P3780, DOI 10.1038/sj.onc.1205532; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027; Montanini L, 2005, J NEURO-ONCOL, V74, P87, DOI 10.1007/s11060-004-4036-5; Nagy A, 2003, J PATHOL, V199, P237, DOI 10.1002/path.1273; Nagy A, 2002, GENE CHROMOSOME CANC, V35, P256, DOI 10.1002/gcc.10118; Nishikawa M, 2001, CANCER RES, V61, P1843; Nomoto S, 2002, CLIN CANCER RES, V8, P481; Nomoto Shuji, 2002, Methods Mol Biol, V197, P107, DOI 10.1385/1-59259-284-8:107; OCKNER RK, 1993, HEPATOLOGY, V18, P669, DOI 10.1002/hep.1840180327; Parrella P, 2003, CANCER LETT, V190, P73, DOI 10.1016/S0304-3835(02)00578-5; Parrella P, 2001, CANCER RES, V61, P7623; Pelicano H, 2003, J BIOL CHEM, V278, P37832, DOI 10.1074/jbc.M301546200; Peluso G, 2000, J CELL PHYSIOL, V182, P339, DOI 10.1002/(SICI)1097-4652(200003)182:3<339::AID-JCP4>3.3.CO;2-2; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Rogounovitch TI, 2002, CANCER RES, V62, P7031; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Rudlowski C, 2004, ONCOLOGY-BASEL, V66, P404, DOI 10.1159/000079489; Sakai H, 2004, FEBS LETT, V563, P151, DOI 10.1016/S0014-5793(04)00292-3; Salas A, 2005, PLOS MED, V2, P1158, DOI 10.1371/journal.pmed.0020296; Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015; Selvanayagam P, 1996, LAB INVEST, V74, P592; SHAW JHF, 1987, ANN SURG, V205, P368, DOI 10.1097/00000658-198704000-00005; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Simonnet H, 2003, CARCINOGENESIS, V24, P1461, DOI 10.1093/carcin/bgg109; SPRINGER EL, 1980, CANCER RES, V40, P803; SRIPATHMANATHAN RM, 1994, INT J CANCER, V56, P900, DOI 10.1002/ijc.2910560624; Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093; Stefaneanu L, 1979, Endocrinologie, V17, P233; SUN AS, 1980, CANCER RES, V40, P4677; SUN AS, 1981, LAB INVEST, V44, P13; Suzuki M, 2003, CLIN CANCER RES, V9, P5636; Tamori A, 2004, J GASTROENTEROL, V39, P1063, DOI 10.1007/s00535-004-1445-3; Tan DJ, 2002, CANCER RES, V62, P972; Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980; Tong BC, 2003, J SURG ONCOL, V82, P170, DOI 10.1002/jso.10202; Wang XD, 2001, GENE DEV, V15, P2922; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG O, 1995, ONCOLOGIA, V9, P75; Weber K, 2002, BIOL CHEM, V383, P283, DOI 10.1515/BC.2002.030; Wenzel U, 2005, J CELL PHYSIOL, V202, P379, DOI 10.1002/jcp.20129; Wheelhouse NM, 2005, BRIT J CANCER, V92, P1268, DOI 10.1038/sj.bjc.6602496; Wong LJC, 2003, CANCER RES, V63, P3866; Wu CW, 2005, GENE CHROMOSOME CANC, V44, P19, DOI 10.1002/gcc.20213; Xu RH, 2005, CANCER RES, V65, P613; Zhao YB, 2005, WORLD J GASTROENTERO, V11, P3304, DOI 10.3748/wjg.v11.i21.3304	123	440	473	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4663	4674		10.1038/sj.onc.1209604	http://dx.doi.org/10.1038/sj.onc.1209604			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892080				2022-12-28	WOS:000239687000004
J	Takahashi, K; Akiyama, H; Shimazaki, K; Uchida, C; Akiyama-Okunuki, H; Tomita, M; Fukumoto, M; Uchida, T				Takahashi, K.; Akiyama, H.; Shimazaki, K.; Uchida, C.; Akiyama-Okunuki, H.; Tomita, M.; Fukumoto, M.; Uchida, T.			Ablation of a peptidyl prolyl isomerase Pin1 from p53-null mice accelerated thymic hyperplasia by increasing the level of the intracellular form of Notch1	ONCOGENE			English	Article						p53; Notch1; presenilin-1; thymocytes; hyperplasia	CELL-CYCLE; RETINOBLASTOMA PROTEIN; X-CHROMOSOME; P53 PROTEIN; DNA-DAMAGE; GROWTH; APOPTOSIS; GENE; PRESENILIN-1; EXPRESSION	Tumor suppressor p53 is essential for checkpoint control in response to a variety of genotoxics tresses. DNA damage leads to phosphorylation on the Ser/Thr-Pro motifs of p53, which facilitates interaction with Pin1, a pSer/pThr-Prospeci. c peptidyl prolyl isomerase. Pin1 is required for the timely activation of p53, resulting in apoptosis or cell cycle arrest. To investigate the physiological relationship between Pin1 and p53, we created Pin1-/-p53-/-mice. These p53-deficient mice spontaneously developed lymphomas, mainly of thymic origin, as well as generalized lymphoma infiltration into other organs, including the liver, kidneys and lungs. Ablation of Pin1, in addition to p53, accelerated the thymichy perplasia, but the thymocytes in these Pin1-/-p53-/- mice did not infiltrate other organs. The thymocytes in 12-week-old Pin1-/-p53-/- mic e were CD4(-)CD8(-) (double negative) and had significantly higher levels of the intracellular form of Notch1 (NIC) than the thymocytes of p53-/- or wild- type mice. Presenilin-1, a cleavage enzyme for NIC generation from full-length Notch1 was increased in the thymocytes of Pin1-/-p53-/- mice. Pin1 depletion also inhibited the degradation of NIC by proteasomes. These results suggest that both Pin1 and p53 control the normal proliferation and differentiation of thymocytes by regulating the NIC level.	Tohoku Univ, Grad Sch Agr Sci, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Ctr Interdisciplinary Res, Sendai, Miyagi 9818555, Japan; Tohoku Univ, Inst Dev Aging & Canc, Sendai, Miyagi 9818555, Japan; Showa Univ, Sch Pharmaceut Sci, Tokyo 142, Japan; Ibaraki Univ, Univ Hlth Ctr, Mito, Ibaraki 310, Japan	Tohoku University; Tohoku University; Tohoku University; Showa University; Ibaraki University	Uchida, T (corresponding author), Tohoku Univ, Grad Sch Agr Sci, 1-1 Amamiya, Sendai, Miyagi 9818555, Japan.	uchidat@biochem.tohoku.ac.jp		Uchida, Takafumi/0000-0003-3665-4906				Akiyama H, 2005, BIOCHEM BIOPH RES CO, V336, P521, DOI 10.1016/j.bbrc.2005.08.130; Amson R, 2000, P NATL ACAD SCI USA, V97, P5346, DOI 10.1073/pnas.97.10.5346; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Beverly LJ, 2005, CANCER RES, V65, P7159, DOI 10.1158/0008-5472.CAN-05-1664; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; Deftos ML, 1998, IMMUNITY, V9, P777, DOI 10.1016/S1074-7613(00)80643-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fowlkes BJ, 2002, J IMMUNOL, V169, P1817, DOI 10.4049/jimmunol.169.4.1817; Fujimori F, 1999, BIOCHEM BIOPH RES CO, V265, P658, DOI 10.1006/bbrc.1999.1736; HAAPAJARVI T, 1995, ONCOGENE, V11, P151; Hasserjian RP, 1996, BLOOD, V88, P970, DOI 10.1182/blood.V88.3.970.bloodjournal883970; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jehn BM, 1999, J IMMUNOL, V162, P635; Katsuda K, 2002, ONCOGENE, V21, P2108, DOI 10.1038/sj.onc.1205272; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lai EC, 2002, CURR BIOL, V12, pR200, DOI 10.1016/S0960-9822(02)00749-2; Laws AM, 2004, EUR J IMMUNOL, V34, P726, DOI 10.1002/eji.200324772; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Loubat A, 1999, ONCOGENE, V18, P3324, DOI 10.1038/sj.onc.1202668; Lu KP, 1996, NATURE, V380, P544; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; Maillard I, 2003, IMMUNITY, V19, P781, DOI 10.1016/S1074-7613(03)00325-X; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Nakase H, 1996, STROKE, V27, P720, DOI 10.1161/01.STR.27.4.720; Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001; Pastorcic M, 2000, J BIOL CHEM, V275, P34938, DOI 10.1074/jbc.M005411200; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; PURDIE CA, 1994, ONCOGENE, V9, P603; Radtke F, 2004, NAT IMMUNOL, V5, P247, DOI 10.1038/ni1045; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; Robey E, 1996, CELL, V87, P483, DOI 10.1016/S0092-8674(00)81368-9; ROGEL A, 1988, BIOCHIM BIOPHYS ACTA, V950, P395; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Soussi T, 2000, ANN NY ACAD SCI, V910, P121; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; TAKAGI N, 1974, EXP CELL RES, V86, P127, DOI 10.1016/0014-4827(74)90657-0; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wahl GM, 2002, NAT CELL BIOL, V4, P328; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116	59	48	49	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 31	2007	26	26					3835	3845		10.1038/sj.onc.1210153	http://dx.doi.org/10.1038/sj.onc.1210153			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17160015				2022-12-28	WOS:000247026400007
J	Xu, J; Gao, M; Fan, S; Meng, Q; Goldberg, ID; Abounader, R; Ressom, H; Laterra, JJ; Rosen, EM				Xu, J.; Gao, M.; Fan, S.; Meng, Q.; Goldberg, I. D.; Abounader, R.; Ressom, H.; Laterra, J. J.; Rosen, E. M.			Effect of Akt inhibition on scatter factor-regulated gene expression in DU-145 human prostate cancer cells	ONCOGENE			English	Article						scatter factor (SF); hepatocyte growth factor (HGF); c-Akt; dominant-negative; gene expression; DU-145	GROWTH FACTOR/SCATTER FACTOR; C-MET RECEPTOR; FACTOR PROTECTS; INDUCED APOPTOSIS; PATHWAY; IDENTIFICATION; PROGRESSION; ACTIVATION; TARGETS; GAB1	The cytokine scatter factor (SF) (hepatocyte growth factor) transduces various biologic actions, including cell motility, invasion, angiogenesis and apoptosis inhibition. The latter is relevant to understanding the role of SF in promoting tumor cell survival in different contexts, for example, detachment from basement membrane, growth in metastatic sites and responses to chemo- and radiotherapy. Previously, we showed that SF protects cells against apoptosis owing to DNA damage, by a mechanism involving phosphoinositol-3-kinase/c-Akt signaling. Here, we used DNA microarray assays to identify c-Akt-regulated genes that might contribute to cell protection. DU-145 human prostate cancer cells were transfected+/-a dominant-negative mutant Akt, treated+/-SF and analysed for gene expression using Affymetrix arrays. These studies identified SF-regulated genes for which induction was c-Akt-dependent vs -independent. Selected microarray findings were confirmed by semiquantitative and quantitative reverse transcription-polymerase chain reaction. We tested the contribution of four SF-inducible/c-Akt-dependent genes (AMPD3, EPHB2, MX1 and WNT4) to protection against adriamycin (a DNA topoisomerase II alpha inhibitor) using RNA interference. Knockdown of each gene except EPHB2 caused a small but significant reduction in the SF cell protection. The lack of effect of EPHB2 knockdown may be due to the fact that DU-145 cells contain a single-mutant EPHB2 allele. A combination of three small interfering RNAs blocked most of the protection by SF in both DU-145 and T47D cells. These findings identify novel c-Akt-regulated genes, some of which contribute to SF-mediated cytoprotection.	Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA; Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New York, NY USA; Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Dept Neurooncol, Baltimore, MD USA	Georgetown University; Northwell Health; Yeshiva University; Johns Hopkins University; Kennedy Krieger Institute	Rosen, EM (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, 3970 Reservoir Rd,NW,Box 571469, Washington, DC 20057 USA.	emr36@georgetown.edu			NATIONAL CANCER INSTITUTE [R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043987] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA82599] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NINDS NIH HHS [R01-NS43987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; ALLEY MC, 1988, CANCER RES, V48, P589; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Barry CP, 2000, CANCER RES, V60, P1887; Beppu K, 2000, ANTICANCER RES, V20, P1263; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowers DC, 2000, CANCER RES, V60, P4277; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carter TH, 2002, J NUTR, V132, P3314, DOI 10.1093/jn/132.11.3314; Cong LN, 1997, MOL ENDOCRINOL, V11, P1881, DOI 10.1210/me.11.13.1881; Cook SA, 2002, J BIOL CHEM, V277, P22528, DOI 10.1074/jbc.M201462200; Cutforth T, 2002, TRENDS NEUROSCI, V25, P332, DOI 10.1016/S0166-2236(02)02187-2; Dworkin LD, 2004, KIDNEY INT, V65, P409, DOI 10.1111/j.1523-1755.2004.00417.x; Engelhardt OG, 2004, J GEN VIROL, V85, P2315, DOI 10.1099/vir.0.79795-0; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fan SJ, 1998, ONCOGENE, V17, P131, DOI 10.1038/sj.onc.1201943; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Futamatsu H, 2005, CIRC RES, V96, P823, DOI 10.1161/01.RES.0000163016.52653.2e; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; Huusko P, 2004, NAT GENET, V36, P979, DOI 10.1038/ng1408; Jin L, 1997, CANCER, V79, P749, DOI 10.1002/(SICI)1097-0142(19970215)79:4<749::AID-CNCR12>3.0.CO;2-#; Kannan R, 2004, FREE RADICAL BIO MED, V37, P166, DOI 10.1016/j.freeradbiomed.2004.04.011; Kim HS, 2005, FASEB J, V19, P1042, DOI 10.1096/fj.04-2841fje; Knudsen BS, 2004, ADV CANCER RES, V91, P31, DOI 10.1016/S0065-230X(04)91002-0; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Leiriao P, 2005, CELL MICROBIOL, V7, P603, DOI 10.1111/j.1462-5822.2004.00490.x; Mahnke-Zizelman DK, 2001, BIOCHEM BIOPH RES CO, V285, P489, DOI 10.1006/bbrc.2001.5180; Majumder PK, 2003, P NATL ACAD SCI USA, V100, P7841, DOI 10.1073/pnas.1232229100; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Mitsiades CS, 2004, CURR CANCER DRUG TAR, V4, P235, DOI 10.2174/1568009043333032; Rosen EM, 1997, CIBA F SYMP, V212, P215; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Wang X, 2004, J BIOL CHEM, V279, P5237, DOI 10.1074/jbc.M309271200; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yao HHC, 2004, DEV DYNAM, V230, P210, DOI 10.1002/dvdy.20042; Yuan RQ, 2001, CANCER RES, V61, P8022; Zhang YW, 2003, P NATL ACAD SCI USA, V100, P12718, DOI 10.1073/pnas.2135113100	42	8	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2925	2938		10.1038/sj.onc.1210088	http://dx.doi.org/10.1038/sj.onc.1210088			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099727				2022-12-28	WOS:000246210800012
J	Efeyan, A; Collado, M; Velasco-Miguel, S; Serrano, M				Efeyan, A.; Collado, M.; Velasco-Miguel, S.; Serrano, M.			Genetic dissection of the role of p21(Cip1/Waf1) in p53-mediated tumour suppression	ONCOGENE			English	Article						p21; p53; cancer; cell cycle; apoptosis; tumour suppression	CYCLE ARREST; DNA-DAMAGE; P21; P53; INHIBITOR; CELLS; INACTIVATION; SENSITIVITY; DEFICIENCY; P21(WAF1)	Protein p21(Cip1/Waf1) is transcriptionally activated by the tumour suppressor p53 and previous studies have shown that p21 plays a role in tumour suppression. However, the involvement of p21 in p53-mediated tumour suppression remains to be directly demonstrated in vivo. Tumour suppression mediated by p53 can be measured by comparing tumour susceptibility in animals carrying two (wild-type mice) or three (super-p53 mice) copies of the p53 gene. We have taken advantage of this genetically defined system to measure p53-mediated cell-cycle arrest, apoptosis and tumorigenesis, in a p21 wild-type and in a p21-null context. The absence of p21 significantly impaired the enhanced p53-mediated cell-cycle arrest characteristic of super-p53 cells, but did not affect the enhanced apoptosis. Importantly, in an experimental model of fibrosarcoma induction, the absence of p21 significantly decreased the tumour suppression benefit of super-p53 mice. We conclude that cell-cycle arrest through p21 plays a significant role in mediating p53-dependent cancer protection.	Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), Spanish Natl Canc Ctr, CNIO, Mol Oncol Program, 3 Melchor Fernandez Almagro St, Madrid 28029, Spain.	mserrano@cnio.es	Collado, Manuel/K-8140-2014; Efeyan, Alejo/J-8197-2016; Serrano, Manuel/H-2634-2015	Collado, Manuel/0000-0002-0330-0880; Efeyan, Alejo/0000-0002-3806-6799; Serrano, Manuel/0000-0001-7177-9312				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Bearss DJ, 2002, CANCER RES, V62, P2077; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Brugarolas J, 1998, J CELL BIOL, V141, P503, DOI 10.1083/jcb.141.2.503; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fan SJ, 1997, ONCOGENE, V14, P2127, DOI 10.1038/sj.onc.1201052; Fotedar R, 2004, CELL CYCLE, V3, P134; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Garcia-Cao I, 2002, EMBO J, V21, P6225, DOI 10.1093/emboj/cdf595; HARPER JW, 1993, CELL, V75, P805; Jackson JF, 2002, MOLEC METH PLAN ANAL, V21, P1; Jackson RJ, 2003, CANCER RES, V63, P3021; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Poole AJ, 2004, ONCOGENE, V23, P8128, DOI 10.1038/sj.onc.1207994; Samuel T, 2002, CELL CYCLE, V1, P162, DOI 10.4161/cc.1.3.118; Strathdee G, 2001, ONCOGENE, V20, P1923, DOI 10.1038/sj.onc.1204276; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vousden KH, 2005, CELL, V120, P7, DOI 10.1016/j.cell.2004.12.027; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weinberg WC, 1999, CANCER RES, V59, P2050; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang WC, 2005, AM J PATHOL, V166, P1239, DOI 10.1016/S0002-9440(10)62342-5; Yang WC, 2001, CANCER RES, V61, P565	32	28	29	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1645	1649		10.1038/sj.onc.1209972	http://dx.doi.org/10.1038/sj.onc.1209972			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964282				2022-12-28	WOS:000244782500014
J	Jackson-Bernitsas, DG; Ichikawa, H; Takada, Y; Myers, JN; Lin, XL; Darnay, BG; Chaturvedi, MM; Aggarwal, BB				Jackson-Bernitsas, D. G.; Ichikawa, H.; Takada, Y.; Myers, J. N.; Lin, X. L.; Darnay, B. G.; Chaturvedi, M. M.; Aggarwal, B. B.			Evidence that TNF-TNFR1-TRADD-TRAF2-RIP-TAK1-IKK pathway mediates constitutive NF-kappa B activation and proliferation in human head and neck squamous cell carcinoma	ONCOGENE			English	Article						head and neck squamous cell carcinoma; nuclear factor-kappa B; tumor necrosis factor; proliferation	TUMOR-NECROSIS-FACTOR; GENE-EXPRESSION; FACTOR-RECEPTOR; GROWTH-FACTOR; ALPHA; TNF; APOPTOSIS; REQUIRES; CURCUMIN; SURVIVAL	Constitutively activated nuclear factor-kappa B (NF-kappa B) has been associated with a variety of aggressive tumor types, including head and neck squamous cell carcinoma (HNSCC); however, the mechanism of its activation is not fully understood. Therefore, we investigated the molecular pathway that mediates constitutive activation of NF-kappa B in a series of HNSCC cell lines. We confirmed that NF-kappa B was constitutively active in all HNSCC cell lines (FaDu, LICR-LON-HN5 and SCC4) examined as indicated by DNA binding, immunocytochemical localization of p65, by NF-kappa B-dependent reporter gene expression and its inhibition by dominant-negative (DN)-inhibitory subunit of NF-kappa B (I kappa B alpha), the natural inhibitor of NF-kappa B. Constitutive NF-kappa B activation in HNSCC was found to be due to constitutive activation of IjBa kinase (IKK); and this correlated with constitutive expression of phosphorylated forms of I kappa B alpha and p65 proteins. All HNSCC showed the expression of p50, p52, p100 and receptor-interacting protein; all linked with NF-kappa B activation. The expression of constitutively active NF-kappa B in HNSCC is mediated through the tumor necrosis factor (TNF) signaling pathway, as NF-kappa B reporter activity was inhibited by DN-TNF receptor-associated death domain ( TRADD), DN-TNF receptor-associated factor ( TRAF) 2, DN-receptor-interacting protein ( RIP), DN-transforming growth factor-beta-activated kinase 1 (TAK1), DN-kappa-Ras, DN-AKT and DN-IKK but not by DN-TRAF5 or DN-TRAF6. Constitutive NF-kappa B activation was also associated with the autocrine expression of TNF, TNF receptors and receptor-activator of NF-kappa B and its ligand in HNSCC cells but not interleukin (IL)-1 beta. All HNSCC cell lines expressed IL-6, a NF-kappa B-regulated gene product. Furthermore, treatment of HNSCC cells with anti-TNF antibody downregulated constitutively active NF-kappa B, and this was associated with inhibition of IL-6 expression and cell proliferation. Our results clearly demonstrate that constitutive activation of NF-kappa B is mediated through the TRADD-TRAF2-RIP-TAK1-IKK pathway, making TNF a novel target in the treatment of head and neck cancer.	Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Aggarwal, BB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Cytokine Res Lab, Dept Expt Therapeut,Unit 143, 1515 Holcombe Blvd, Houston, TX 77030 USA.	aggarwal@mdanderson.org	Aggarwal, Bharat B/G-3388-2013		NATIONAL CANCER INSTITUTE [P01CA091844] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA91844] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 1996, CANCER RES, V56, P5156; Aggarwal BB, 2006, E SCHERING RES FDN W, V56, P161; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Aggarwal S, 2004, INT J CANCER, V111, P679, DOI 10.1002/ijc.20333; Bancroft CC, 2002, INT J CANCER, V99, P538, DOI 10.1002/ijc.10398; Blonska M, 2005, J BIOL CHEM, V280, P43056, DOI 10.1074/jbc.M507807200; Buchholz TA, 2005, CLIN CANCER RES, V11, P8398, DOI 10.1158/1078-0432.CCR-05-0885; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Chaturvedi MM, 2000, METHOD ENZYMOL, V319, P585; Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724; Dong G, 2001, CANCER RES, V61, P4797; Duffey DC, 1999, CANCER RES, V59, P3468; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; ESTROV Z, 1993, J EXP MED, V177, P763, DOI 10.1084/jem.177.3.763; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Izzo JG, 2006, J CLIN ONCOL, V24, P748, DOI 10.1200/JCO.2005.03.8810; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Li QT, 2000, GENE DEV, V14, P1729; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Loercher A, 2004, CANCER RES, V64, P6511, DOI 10.1158/0008-5472.CAN-04-0852; LoTempio MM, 2005, CLIN CANCER RES, V11, P6994, DOI 10.1158/1078-0432.CCR-05-0301; Majumdar S, 2002, J IMMUNOL, V168, P2644, DOI 10.4049/jimmunol.168.6.2644; Manna SK, 2000, J IMMUNOL, V165, P4927, DOI 10.4049/jimmunol.165.9.4927; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Ozes ON, 1999, NATURE, V401, P82; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Takada Y, 2004, J BIOL CHEM, V279, P26287, DOI 10.1074/jbc.M400963200; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Thomas GR, 2004, CANCER IMMUNOL IMMUN, V53, P33, DOI 10.1007/s00262-003-0433-4; Wang YF, 2002, HEAD NECK-J SCI SPEC, V24, P850, DOI 10.1002/hed.10145; Wolf JS, 2001, CLIN CANCER RES, V7, P1812; Woods KV, 1998, CANCER RES, V58, P3142	39	164	171	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1385	1397		10.1038/sj.onc.1209945	http://dx.doi.org/10.1038/sj.onc.1209945			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953224				2022-12-28	WOS:000244558800003
J	Streicher, KL; Yang, ZQ; Draghici, S; Ethier, SP				Streicher, K. L.; Yang, Z. Q.; Draghici, S.; Ethier, S. P.			Transforming function of the LSM1 oncogene in human breast cancers with the 8p11-12 amplicon	ONCOGENE			English	Article						LSM1; breast cancer; chromosome 8p11-12	MESSENGER-RNA DEGRADATION; ANTISENSE GENE-THERAPY; SM-LIKE PROTEIN; ONTO-TOOLS; CELL-LINES; PANCREATIC-CANCER; EPITHELIAL-CELLS; EXPRESSION; CASM; CONTRIBUTES	Amplification of the 8p11 - 12 region occurs in 15 - 20% of breast cancers, but the driving oncogene at this locus has yet to be definitively identified. We mapped the 8p11 - 12 amplicon in breast cancer cell lines and primary human breast cancers and identified the candidate oncogene human Sm-like protein (hLsm1, LSM1) based on increases in copy number and expression level relative to human mammary epithelial cells. To examine the oncogenic role of LSM1, we overexpressed this gene in MCF10A mammary epithelial cells and inhibited its production in the SUM44 breast cancer cell line, which has a natural amplification and overexpression of LSM1. Our data confirmed that LSM1 is an oncogene from the 8p11 - 12 amplicon by showing that hLsm1 overexpression induced growth factor-independent proliferation and soft agar colony formation in MCF10A cells, and hLsm1 inhibition in SUM44 cells dramatically reduced soft agar growth. Little is known about hLsm1 function other than its involvement in mRNA degradation; therefore, we used expression microarray analysis to investigate how hLsm1 affects cell transformation in MCF10A and SUM44 cells. We identified numerous genes altered following hLsm1 overexpression common to SUM44 breast cancer cells that play important roles in cell cycle regulation, cell proliferation and other cancer-promoting processes. Future work will continue to characterize these important changes to achieve a more complete understanding of the mechanism of hLsm1's effect on cancer progression.	Karmanos Canc Inst, Breast Canc Program, Detroit, MI 48201 USA; Wayne State Univ, Dept Comp Sci, Detroit, MI 48202 USA; Karmanos Canc Inst, Detroit, MI USA; Wayne State Univ, Sch Med, Dept Pathol, Detroit, MI 48202 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Streicher, KL (corresponding author), Karmanos Canc Inst, Breast Canc Program, 4100 John R St,815 HWCRC, Detroit, MI 48201 USA.	streiche@karmanos.org	Draghici, Sorin/B-3074-2013	Draghici, Sorin/0000-0002-0786-8377	NATIONAL CANCER INSTITUTE [P30CA022453, R21CA100740, R01CA100724] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR017857] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG003491] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R21EB000990] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045207] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA100724-01, R01 CA100724, P30 CA022453, P30 CA022453-25, R21 CA100740, R21 CA10074001, R21 CA100740-01] Funding Source: Medline; NCRR NIH HHS [1S10 RR01785701, S10 RR017857-01, S10 RR017857] Funding Source: Medline; NHGRI NIH HHS [R01 HG003491-01A1, R01 HG003491] Funding Source: Medline; NIBIB NIH HHS [R21 EB000990-01, R21 EB000990, 1R21 EB0099001] Funding Source: Medline; NINDS NIH HHS [R01 NS045207-01, 1R01NS04520701, R01 NS045207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Draghici S, 2003, GENOMICS, V81, P98, DOI 10.1016/S0888-7543(02)00021-6; Draghici S, 2003, NUCLEIC ACIDS RES, V31, P3775, DOI 10.1093/nar/gkg624; Draghici S., 2003, DATA ANAL TOOLS DNA; ETHIER SP, 1991, BREAST CANCER RES TR, V18, P73, DOI 10.1007/BF01980969; ETHIER SP, 1991, BREAST CANCER RES TR, V17, P221, DOI 10.1007/BF01806371; Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306; Forozan F, 1999, BRIT J CANCER, V81, P1328, DOI 10.1038/sj.bjc.6695007; Fraser MM, 2005, CANCER RES, V65, P6228, DOI 10.1158/0008-5472.CAN-05-0650; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; He WH, 2000, CURR OPIN CELL BIOL, V12, P346, DOI 10.1016/S0955-0674(00)00098-3; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kelley JR, 2003, ANTICANCER RES, V23, P2007; Khatri P, 2002, GENOMICS, V79, P266, DOI 10.1006/geno.2002.6698; Khatri P, 2005, NUCLEIC ACIDS RES, V33, pW762, DOI 10.1093/nar/gki472; Khatri P, 2004, NUCLEIC ACIDS RES, V32, pW449, DOI 10.1093/nar/gkh409; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Paddison PJ, 2003, CURR OPIN MOL THER, V5, P217; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Prentice LM, 2005, ONCOGENE, V24, P7281, DOI 10.1038/sj.onc.1208892; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Schweinfest CW, 1997, CANCER RES, V57, P2961; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Yan Y, 2006, MOL THER, V13, P357, DOI 10.1016/j.ymthe.2005.06.485; Yang ZQ, 2004, CANCER GENET CYTOGEN, V155, P57, DOI 10.1016/j.cancergencyto.2004.03.013; Zaric B, 2005, J BIOL CHEM, V280, P16066, DOI 10.1074/jbc.M414481200	30	42	44	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2104	2114		10.1038/sj.onc.1210002	http://dx.doi.org/10.1038/sj.onc.1210002			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001308	Green Accepted			2022-12-28	WOS:000245313400012
J	Inamoto, S; Iwata, S; Inamoto, T; Nomura, S; Sasaki, T; Urasaki, Y; Hosono, O; Kawasaki, H; Tanaka, H; Dang, NH; Morimoto, C				Inamoto, S.; Iwata, S.; Inamoto, T.; Nomura, S.; Sasaki, T.; Urasaki, Y.; Hosono, O.; Kawasaki, H.; Tanaka, H.; Dang, N. H.; Morimoto, C.			Crk-associated substrate lymphocyte type regulates transforming growth factor-beta signaling by inhibiting Smad6 and Smad7	ONCOGENE			English	Article						Cas-L; Smad6; Smad7; TGF-beta; cancer	FOCAL ADHESION KINASE; MEDIATED TYROSINE PHOSPHORYLATION; CAS-L; DOCKING PROTEIN; INTEGRIN; HEF1; CELLS; EXPRESSION; RECEPTOR; IDENTIFICATION	Crk-associated substrate lymphocyte type (Cas-L) is a 105 kDa docking protein with diverse functional properties, including regulation of cell division, proliferation, migration and adhesion. Cas-L is also involved in beta 1 integrin- or antigen receptor-mediated signaling in B and T cells. In the present study, we demonstrate that Cas-L potentiates transforming growth factor-beta (TGF-beta) signaling pathway by interacting with Smad6 and Smad7. Immunoprecipitation experiments reveal that single domain deletion of full-length Cas-L completely abolishes its docking function with Smad6 and Smad7, suggesting that the natural structure of Cas-L is necessary for its association with Smad6 and Smad7. On the other hand, both N-terminal and C-terminal deletion mutants of Smad6 and Smad7 still retain their docking ability to Cas-L, suggesting that Smad6 and Smad7 possess several binding motifs to Cas-L. Moreover, Cas-L interaction with Mad-homology (MH)2 domain, but not with MH1 domain of Smad6 or Smad7, ameliorates TGF-beta-induced signaling pathway. Finally, depletion of Cas-L by small-interfering RNA oligo attenuates TGF-beta-induced growth inhibition of Huh-7 cells, with a concomitant reduction in phosphorylation of Smad2 and Smad3. These results strongly suggest that Cas-L is a potential regulator of TGF-beta signaling pathway.	Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, Tokyo 1088639, Japan; Osaka Med Coll, Dept Med, Osaka, Japan; Nevada Canc Inst, Dept Hematol Malignancies, Las Vegas, NV USA	University of Tokyo; Osaka Medical College; University of California System; University of California San Diego	Morimoto, C (corresponding author), Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Div Clin Immunol,Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	morimoto@ims.u-tokyo.ac.jp	Iwata, Satoshi/A-8819-2011					Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; Chacko BM, 2004, MOL CELL, V15, P813, DOI 10.1016/j.molcel.2004.07.016; Datta PK, 2000, MOL CELL BIOL, V20, P3157, DOI 10.1128/MCB.20.9.3157-3167.2000; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Fashena SJ, 2002, J CELL SCI, V115, P99; Gronroos E, 2002, MOL CELL, V10, P483, DOI 10.1016/S1097-2765(02)00639-1; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ito Y, 2001, J BIOL CHEM, V276, P44163, DOI 10.1074/jbc.M011424200; Iwata S, 2005, ONCOGENE, V24, P1262, DOI 10.1038/sj.onc.1208261; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kamiguchi K, 1999, J IMMUNOL, V163, P563; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Krishnan P, 2001, DEV GROWTH DIFFER, V43, P115; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Lee HY, 2002, CANCER RES, V62, P3530; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; Liu XH, 2000, EMBO J, V19, P6759, DOI 10.1093/emboj/19.24.6759; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Miyake-Nishijima R, 2003, ARTHRITIS RHEUM, V48, P1890, DOI 10.1002/art.11047; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ohashi Y, 1999, J IMMUNOL, V163, P3727; Ohashi Y, 1998, J BIOL CHEM, V273, P6446, DOI 10.1074/jbc.273.11.6446; Ohnuma K, 2004, P NATL ACAD SCI USA, V101, P14186, DOI 10.1073/pnas.0405266101; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Sasaki T, 2005, STROKE, V36, P2457, DOI 10.1161/01.STR.0000185672.10390.30; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Sugano Y, 2003, ONCOGENE, V22, P2309, DOI 10.1038/sj.onc.1206305; Tachibana K, 1997, J BIOL CHEM, V272, P29083, DOI 10.1074/jbc.272.46.29083; Tanaka J, 1999, BIOCHEM BIOPH RES CO, V264, P938, DOI 10.1006/bbrc.1999.1617; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Xu L, 2000, NAT CELL BIOL, V2, P559, DOI 10.1038/35019649; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yagil C, 2005, CIRC RES, V96, P617, DOI 10.1161/01.RES.0000160556.52369.61; Zhang ZY, 2000, J BIOL CHEM, V275, P37219, DOI 10.1074/jbc.M001818200	42	17	21	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					893	904		10.1038/sj.onc.1209848	http://dx.doi.org/10.1038/sj.onc.1209848			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909115				2022-12-28	WOS:000244063800010
J	Raafat, A; Zoltan-Jones, A; Strizzi, L; Bargo, S; Kimura, K; Salomon, D; Callahan, R				Raafat, A.; Zoltan-Jones, A.; Strizzi, L.; Bargo, S.; Kimura, K.; Salomon, D.; Callahan, R.			Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis	ONCOGENE			English	Article						Kit; PDGFR-alpha; Notch4/Int3; Gleevec; phosphorylation; siRNA	GASTROINTESTINAL STROMAL TUMORS; TRUNCATED INT3 GENE; C-KIT; GROWTH-FACTOR; NEOPLASTIC TRANSFORMATION; ENDOTHELIAL-CELLS; BREAST-CANCER; MOUSE MODEL; STEM-CELLS; MAMMARY	Transgenic mice overexpressing Notch4 intracellular domain (Int3) under the control of the whey acidic protein (WAP) or mouse mammary tumor virus-long terminal repeat promoters, develop mammary tumors. Microarray analysis of these tumors revealed high levels of c-Kit expression. Gleevec is a tyrosine kinase inhibitor that targets c-Kit, platelet-derived growth factor receptors (PDGFRs) and c-Abl. This led us to speculate that tyrosine kinase receptor activity might be a driving force in the development of Int3 mammary tumors. WAP-Int3 tumor-bearing mice were treated with continuous release of Gleevec using subcutaneously implanted Alzet pumps. Phoshorylation of c-Kit, PDGFRs and c-Abl is inhibited in Int3 transgenic mammary tumors by Gleevec. Inhibition of these enzymes is associated with a decrease in cell proliferation and angiogenesis, and an induction of apoptosis. To examine the signaling mechanisms underlying Notch4/Int3 tumorigenesis, we employed small interfering RNA (siRNA) to knock down c-Kit, PDGFRs and c-Abl alone or in combination and observed the effects on soft agar growth of HC11 cells overexpressing Int3. Only siRNA constructs for c-Kit and/or PDGFR-alpha were able to inhibit HC11-Int3colony formation in soft agar. Our data demonstrate an inhibitory effect of Gleevec on Int3-induced transformation of HC11 cells and mammary tumors and indicate an oncogenic role for c-Kit and PDGFR-alpha tyrosine kinases in the context of Int3 signaling.	NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Callahan, R (corresponding author), NCI, Mammary Biol & Tumorigenesis Lab, Oncogenet Sect, NIH, 37 Convent Dr,Bldg 37,Rm 1118A, Bethesda, MD 20892 USA.	rc54d@nih.gov						Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Basciani S, 2005, CANCER RES, V65, P1897, DOI 10.1158/0008-5472.CAN-04-2181; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Betsholtz Christer, 2003, Birth Defects Research, V69, P272, DOI 10.1002/bdrc.10030; Callahan R, 2001, J MAMMARY GLAND BIOL, V6, P23, DOI 10.1023/A:1009512414430; Chiaramonte R, 2005, CANCER LETT, V219, P113, DOI 10.1016/j.canlet.2004.07.022; Cortes J, 2004, BLOOD, V104, P2204, DOI 10.1182/blood-2004-04-1335; Dang TP, 2000, J NATL CANCER I, V92, P1355, DOI 10.1093/jnci/92.16.1355; Dang TP, 2003, ONCOGENE, V22, P1988, DOI 10.1038/sj.onc.1206230; Das AV, 2004, DEV BIOL, V273, P87, DOI 10.1016/j.ydbio.2004.05.023; De Jong JS, 1998, J PATHOL, V184, P44; Diallo R, 2006, HUM PATHOL, V37, P205, DOI 10.1016/j.humpath.2005.10.015; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; GALLAHAN D, 1987, J VIROL, V61, P218, DOI 10.1128/JVI.61.1.218-220.1987; Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hwang RF, 2003, CLIN CANCER RES, V9, P6534; Imatani A, 2000, ONCOGENE, V19, P223, DOI 10.1038/sj.onc.1203295; Jeffries S, 2000, MOL CELL BIOL, V20, P3928, DOI 10.1128/MCB.20.11.3928-3941.2000; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kim MK, 2000, APPL IMMUNOHISTO M M, V8, P147, DOI 10.1097/00022744-200006000-00009; Lasota J, 1999, AM J PATHOL, V154, P53, DOI 10.1016/S0002-9440(10)65250-9; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; Marley SB, 2005, CLIN SCI, V109, P13, DOI 10.1042/CS20040336; Matsui J, 2004, J BIOL CHEM, V279, P18600, DOI 10.1074/jbc.M311643200; Noseda M, 2004, CIRC RES, V94, P910, DOI 10.1161/01.RES.0000124300.76171.C9; Pear WS, 2004, CURR OPIN HEMATOL, V11, P426, DOI 10.1097/01.moh.0000143965.90813.70; Raafat A, 2004, ONCOGENE, V23, P9401, DOI 10.1038/sj.onc.1208187; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; SMITH GH, 1995, CELL GROWTH DIFFER, V6, P563; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; Taniguchi M, 1999, CANCER RES, V59, P4297; Tsuda H, 2005, CANCER SCI, V96, P333, DOI 10.1111/j.1349-7006.2005.00060.x; Tsuda H, 2005, CANCER SCI, V96, P48, DOI 10.1111/j.1349-7006.2005.00009.x; Uehara H, 2003, J NATL CANCER I, V95, P458, DOI 10.1093/jnci/95.6.458; Ulivi P, 2004, BREAST CANCER RES TR, V83, P33, DOI 10.1023/B:BREA.0000010694.35023.9e; VARVALHO I, 2005, BREAST CANCER RES, V7, pR788; Wang DG, 1999, CANCER RES, V59, P1464; Weijzen S, 2002, NAT MED, V8, P979, DOI 10.1038/nm754	46	14	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					662	672		10.1038/sj.onc.1209823	http://dx.doi.org/10.1038/sj.onc.1209823			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878155				2022-12-28	WOS:000243902200004
J	Cody, NAL; Ouellet, V; Manderson, EN; Quinn, MCJ; Filali-Mouhim, A; Tellis, P; Zietarska, M; Provencher, DM; Mes-Masson, AM; Chevrette, M; Tonin, PN				Cody, N. A. L.; Ouellet, V.; Manderson, E. N.; Quinn, M. C. J.; Filali-Mouhim, A.; Tellis, P.; Zietarska, M.; Provencher, D. M.; Mes-Masson, A-M; Chevrette, M.; Tonin, P. N.			Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p	ONCOGENE			English	Article						ovarian cancer; chromosome 3p; radiation hybrids; tumor suppressor gene	ENDOTHELIAL GROWTH-FACTOR; GENE-EXPRESSION; PRIMARY CULTURES; SOLID TUMORS; TRANSCRIPTION FACTORS; LOW-GRADE; CARCINOMA; HETEROZYGOSITY; LOCUS; ADENOCARCINOMA	Multiple chromosome 3p tumor suppressor genes (TSG) have been proposed in the pathogenesis of ovarian cancer based on complex patterns of 3p loss. To attain functional evidence in support of TSGs and identify candidate regions, we applied a chromosome transfer method involving cell fusions of the tumorigenic OV90 human ovarian cancer cell line, monoallelic for 3p and an irradiated mouse cell line containing a human chromosome 3 in order to derive OV90 hybrids containing normal 3p fragments. The resulting hybrids showed complete or incomplete suppression of tumorigenicity in nude mouse xenograft assays, and varied in their ability to form colonies in soft agarose and three-dimensional spheroids in a manner consistent with alteration of their in vivo tumorigenic phenotypes. Expression microarray analysis identified a set of common differentially expressed genes, such as SPARC, DAB2 and VEGF, some of which have been shown implicated in ovarian cancer. Genotyping assays revealed that they harbored normal 3p fragments, some of which overlapped candidate TSG regions (3p25p26, 3p24 and 3p14-pcen) identified previously in loss of heterozygosity analyses of ovarian cancers. However, only the 3p12-pcen region was acquired in common by all hybrids where expression microarray analysis identified differentially expressed genes. The correlation of 3p12peen transfer and tumor suppression with a concerted reprogramming of the cellular transcriptome suggest that the putative TSG may have affected key underlying events in ovarian cancer.	McGill Univ, Dept Human Genet, Montreal, PQ H3H 1P3, Canada; McGill Univ, Res Inst, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; Univ Montreal, Inct Canc Montreal, Ctr Rech, Ctr Hosp, Montreal, PQ, Canada; Univ Montreal, Div Gynecol Oncol, Montreal, PQ, Canada; Univ Montreal, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Surg, Div Urol, Montreal, PQ H3A 2T5, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada	McGill University; McGill University; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University	Tonin, PN (corresponding author), Montreal Gen Hosp, Room L10-120,1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada.	patricia.tonin@mcgill.ca		Mes-Masson, Anne-Marie/0000-0002-6498-266X				Adams J, 2002, CURR OPIN CHEM BIOL, V6, P486, DOI 10.1016/S1367-5931(02)00357-5; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Akutagawa N, 2002, JPN J CANCER RES, V93, P644, DOI 10.1111/j.1349-7006.2002.tb01302.x; Arcand SL, 2004, MOL CARCINOGEN, V41, P17, DOI 10.1002/mc.20038; Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Bayani J, 2002, CANCER RES, V62, P3466; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chen HH, 2004, J BIOL CHEM, V279, P30800, DOI 10.1074/jbc.M400154200; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Cuthbert AP, 1999, JNCI-J NATL CANCER I, V91, P37, DOI 10.1093/jnci/91.1.37; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Davidson B, 2003, CANCER METAST REV, V22, P103, DOI 10.1023/A:1022272204045; DODSON MK, 1993, CANCER RES, V53, P4456; Doherty AMO, 2003, MAMM GENOME, V14, P583, DOI 10.1007/s00335-003-4002-0; DORIN JR, 1992, HUM MOL GENET, V1, P53, DOI 10.1093/hmg/1.1.53; EHLEN T, 1990, ONCOGENE, V5, P219; Fullwood P, 1999, CANCER RES, V59, P4662; GENTLEMAN R, 2003, VISUALIZATION ANNOTA; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Hoglund M, 2001, GENE CHROMOSOME CANC, V31, P156; Hoglund M, 2003, CANCER RES, V63, P3378; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kelm JM, 2003, BIOTECHNOL BIOENG, V83, P173, DOI 10.1002/bit.10655; KRUK PA, 1990, LAB INVEST, V63, P132; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Lacerte A, 2004, MOL ENDOCRINOL, V18, P1558, DOI 10.1210/me.2003-0470; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; Lott ST, 1998, CANCER RES, V58, P3533; Lounis H, 1998, ONCOGENE, V17, P2359, DOI 10.1038/sj.onc.1202152; LOUNIS H, 1994, EXP CELL RES, V215, P303, DOI 10.1006/excr.1994.1346; Lovell M, 1999, CANCER RES, V59, P2182; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; Manderson EN, 2002, MOL CARCINOGEN, V34, P78, DOI 10.1002/mc.10051; Manderson EN, 2002, GENOME RES, V12, P112, DOI 10.1101/gr.174202; Manning AP, 1999, MOL CARCINOGEN, V24, P218, DOI 10.1002/(SICI)1098-2744(199903)24:3<218::AID-MC8>3.0.CO;2-A; McMahon G, 2000, Oncologist, V5 Suppl 1, P3; Mertens F, 1997, CANCER RES, V57, P2765; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Mok SC, 1996, ONCOGENE, V12, P1895; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; Paley PJ, 1997, CANCER, V80, P98, DOI 10.1002/(SICI)1097-0142(19970701)80:1<98::AID-CNCR13>3.0.CO;2-A; PEJOVIC T, 1992, GENE CHROMOSOME CANC, V4, P58, DOI 10.1002/gcc.2870040108; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Presneau N, 2005, MOL CARCINOGEN, V43, P141, DOI 10.1002/mc.20096; Presneau N, 2003, ONCOGENE, V22, P1568, DOI 10.1038/sj.onc.1206219; Provencher DM, 2000, IN VITRO CELL DEV-AN, V36, P357; RIMESSI P, 1994, ONCOGENE, V9, P3467; SANCHEZ Y, 1994, P NATL ACAD SCI USA, V91, P3383, DOI 10.1073/pnas.91.8.3383; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; Simon R, 2000, GENE CHROMOSOME CANC, V28, P106, DOI 10.1002/(SICI)1098-2264(200005)28:1<106::AID-GCC13>3.3.CO;2-J; Speevak MD, 1996, MOL CELL BIOL, V16, P2214; SPEEVAK MD, 1995, CYTOGENET CELL GENET, V69, P63, DOI 10.1159/000133939; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P290, DOI 10.1002/(SICI)1098-2264(199907)25:3<290::AID-GCC12>3.0.CO;2-G; Taetle R, 1999, GENE CHROMOSOME CANC, V25, P46, DOI 10.1002/(SICI)1098-2264(199905)25:1<46::AID-GCC7>3.3.CO;2-F; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Tse C, 2002, CANCER RES, V62, P542; Wang L, 2000, GENE CHROMOSOME CANC, V27, P1, DOI 10.1002/(SICI)1098-2264(200001)27:1<1::AID-GCC1>3.0.CO;2-6; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V11, P91, DOI 10.1016/0165-4608(84)90102-X; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xiang RH, 2002, CANCER RES, V62, P2637; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Yoneda J, 1998, JNCI-J NATL CANCER I, V90, P447, DOI 10.1093/jnci/90.6.447; Yonescu R, 1996, CANCER GENET CYTOGEN, V87, P167, DOI 10.1016/0165-4608(95)00241-3; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104; ZHENG JP, 1991, CANCER RES, V51, P4045	70	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					618	632		10.1038/sj.onc.1209821	http://dx.doi.org/10.1038/sj.onc.1209821			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909122				2022-12-28	WOS:000243731600014
J	Bacon, AL; Fox, S; Turley, H; Harris, AL				Bacon, A. L.; Fox, S.; Turley, H.; Harris, A. L.			Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer	ONCOGENE			English	Article						BNIP3; hypoxia; histone deacetylation; HIF; silencing	CELL-DEATH; PROTEIN BNIP3; TUMOR HYPOXIA; EXPRESSION; NECROSIS; BREAST; P53; MEDIATOR; GROWTH; HEAD	Hypoxia, via the hypoxia-inducible factors 1 and 2 (HIF-1 and HIF-2), upregulates many genes involved in cell survival. However, proapoptotic pathways are also induced. BCL-2/adenovirus E1B-19kDa-interacting protein 3 (BNIP3) represents a paradigm of a cell death protein that is hypoxically upregulated via HIF-1 in most cancers. We found that in contrast to many other cell types, 6/8 colorectal cancer (CRC) cell lines show little hypoxic induction of BNIP3 despite an intact HIF signalling system. Colorectal tumour tissue also loses BNIP3 expression relative to matched normal samples. Downregulation of hypoxic BNIP3 in CRC cells was independent of the expression of other BCL-2 family members, or BNIP3L. That BNIP3 plays a functional role in hypoxic survival in CRC cells was demonstrated by the fact that CRC cell lines that do not upregulate BNIP3 or have been treated with BNIP3 RNA interference were insensitive to hypoxia-induced cell death. Promoter methylation and histone deacetylation were shown to silence BNIP3 in these CRC cell lines. Of significance, hypoxic induction of BNIP3 was restored in 4/6 cell lines by trichostatin-A treatment alone. These data suggest that BNIP3 plays an important role in hypoxic cell death and epigenetic mechanisms selectively silence its expression in CRC.	Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Lab, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DU, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020; Fox, Stephen/G-9719-2016	Harris, Adrian L/0000-0003-1376-8409; Fox, Stephen/0000-0002-7648-8896				Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Beasley NJP, 2002, CANCER RES, V62, P2493; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Chen G, 1997, J EXP MED, V186, P1975, DOI 10.1084/jem.186.12.1975; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012; Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hockel M, 1998, INT J CANCER, V79, P365; Kim JH, 2001, COMPOS INTERFACE, V7, P443, DOI 10.1163/156855400750262932; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Knowles HJ, 2001, BREAST CANCER RES, V3, P318, DOI 10.1186/bcr314; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298; Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rubin H, 2001, ADV CANCER RES, V83, P159, DOI 10.1016/S0065-230X(01)83006-2; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Sowter HM, 2003, J PATHOL, V201, P573, DOI 10.1002/path.1486; Sowter HM, 2001, CANCER RES, V61, P6669; Stadler P, 1999, INT J RADIAT ONCOL, V44, P749, DOI 10.1016/S0360-3016(99)00115-7; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tomes L, 2003, BREAST CANCER RES TR, V81, P61, DOI 10.1023/A:1025476722493; Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000; Wykoff CC, 2000, CANCER RES, V60, P7075; Yasuda M, 1998, J BIOL CHEM, V273, P12415, DOI 10.1074/jbc.273.20.12415; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327	39	53	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					132	141		10.1038/sj.onc.1209761	http://dx.doi.org/10.1038/sj.onc.1209761			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799636				2022-12-28	WOS:000243236500013
J	Penserga, ETP; Skorski, T				Penserga, E. T. P.; Skorski, T.			Fusion tyrosine kinases: a result and cause of genomic instability	ONCOGENE			English	Review						fusion tyrosine kinase; genomic instability; ROS; DNA damage; DNA repair; imatinib mesylate	CHRONIC MYELOID-LEUKEMIA; GROWTH-FACTOR RECEPTOR-1; DOUBLE-STRAND BREAKS; CHROMOSOMAL TRANSLOCATION MECHANISMS; IMATINIB RESISTANCE MUTATIONS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; NUCLEOTIDE EXCISION-REPAIR; HEMATOPOIETIC-CELL LINE; DNA-POLYMERASE-BETA	Reciprocal chromosomal translocations may arise as a result of unfaithful repair of spontaneous DNA double-strand breaks, most probably induced by oxidative stress, radiation, genotoxic chemicals and/or replication stress. Genes encoding tyrosine kinases are targeted by these mechanisms resulting in the generation of chimera genes encoding fusion tyrosine kinases (FTKs). FTKs display transforming activity owing to their constitutive kinase activity causing deregulated proliferation, apoptosis, differentiation and adhesion. Moreover, FTKs are able to facilitate DNA repair, prolong activation of G(2)/M and S cell cycle checkpoints, and elevate expression of antiapoptotic protein Bcl-X-L, making malignant cells less responsive to antitumor treatment. FTKs may also stimulate the generation of reactive oxygen species and enhance spontaneous DNA damage in tumor cells. Unfortunately, FTKs compromise the delity of DNA repair mechanisms, which contribute to the accumulation of additional genetic abnormalities leading to the resistance to inhibitors such as imatinib mesylate and malignant progression of the disease.	Temple Univ, Dept Microbiol & Immunol, Sch Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Skorski, T (corresponding author), Temple Univ, Dept Microbiol & Immunol, Sch Med, MRB 548A,3400 N Broad St, Philadelphia, PA 19140 USA.	tskorski@temple.edu			NIDDK NIH HHS [5R25DK059644-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R25DK059644] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abeysinghe SS, 2003, HUM MUTAT, V22, P229, DOI 10.1002/humu.10254; Akman SA, 2000, ANN NY ACAD SCI, V899, P88; ALIMENA G, 1987, CANCER GENET CYTOGEN, V26, P39, DOI 10.1016/0165-4608(87)90131-2; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Aoki M, 2001, BRIT J DERMATOL, V145, P123, DOI 10.1046/j.1365-2133.2001.04295.x; Aplan PD, 2006, TRENDS GENET, V22, P46, DOI 10.1016/j.tig.2005.10.002; Apperley JF, 2002, NEW ENGL J MED, V347, P481, DOI 10.1056/NEJMoa020150; Arlinghaus Ralph, 2004, Cancer Treat Res, V119, P239; Azam M, 2003, CELL, V112, P831, DOI 10.1016/S0092-8674(03)00190-9; BARRETT A, 1992, BONE MARROW TRANSPL, V9, P305; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Baumann H, 2003, J BIOL CHEM, V278, P16198, DOI 10.1074/jbc.M300018200; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; BEDI A, 1995, BLOOD, V86, P1148, DOI 10.1182/blood.V86.3.1148.bloodjournal8631148; BIERNAUX C, 1995, BLOOD, V86, P3118; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bose S, 1998, BLOOD, V92, P3362, DOI 10.1182/blood.V92.9.3362; Bousquet M, 2005, ONCOGENE, V24, P7248, DOI 10.1038/sj.onc.1208850; Brady N, 2003, CANCER RES, V63, P1798; Brain JM, 2003, CANCER RES, V63, P4895; Branford S, 2002, BLOOD, V99, P3472, DOI 10.1182/blood.V99.9.3472; Burgess MR, 2005, P NATL ACAD SCI USA, V102, P3395, DOI 10.1073/pnas.0409770102; Calabretta B, 2004, BLOOD, V103, P4010, DOI 10.1182/blood-2003-12-4111; Cambier N, 1998, ONCOGENE, V16, P335, DOI 10.1038/sj.onc.1201490; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Canitrot Y, 2003, BLOOD, V102, P2632, DOI 10.1182/blood-2002-10-3207; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; CHEN SJ, 1989, NUCLEIC ACIDS RES, V17, P7631, DOI 10.1093/nar/17.19.7631; CHOU CL, 1993, J IMMUNOL, V150, P5350; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; Collis SJ, 2001, NUCLEIC ACIDS RES, V29, P1534, DOI 10.1093/nar/29.7.1534; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Cross NCP, 2002, LEUKEMIA, V16, P1207, DOI 10.1038/sj.leu.2402556; Croteau DL, 1997, J BIOL CHEM, V272, P25409, DOI 10.1074/jbc.272.41.25409; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; De Keersmaecker K, 2006, LEUKEMIA, V20, P200, DOI 10.1038/sj.leu.2404064; Deininger MWN, 1998, CANCER RES, V58, P421; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Deutsch E, 2001, BLOOD, V97, P2084, DOI 10.1182/blood.V97.7.2084; Dierov J, 2004, CANCER CELL, V5, P275, DOI 10.1016/S1535-6108(04)00056-X; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Elliott B, 2005, MOL CELL, V17, P885, DOI 10.1016/j.molcel.2005.02.028; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; EPNER DE, 1990, ANN INTERN MED, V113, P3, DOI 10.7326/0003-4819-113-1-3; Fioretos T, 2001, GENE CHROMOSOME CANC, V32, P302, DOI 10.1002/gcc.1195; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; GAIGER A, 1995, BLOOD, V86, P2371, DOI 10.1182/blood.V86.6.2371.bloodjournal8662371; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; Gaymes TJ, 2002, CANCER RES, V62, P2791; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goldberg Z, 2004, CELL CYCLE, V3, P1188; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gorre ME, 2002, CURR OPIN HEMATOL, V9, P303, DOI 10.1097/00062752-200207000-00007; Greenland C, 2001, ONCOGENE, V20, P7386, DOI 10.1038/sj.onc.1204870; Heath C, 2004, J BIOL CHEM, V279, P6666, DOI 10.1074/jbc.M308743200; Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741; Hofmann WK, 2002, BLOOD, V99, P1860, DOI 10.1182/blood.V99.5.1860; Holyoake T, 1999, BLOOD, V94, P2056, DOI 10.1182/blood.V94.6.2056; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Hoser G, 2003, LEUKEMIA RES, V27, P267, DOI 10.1016/S0145-2126(02)00163-7; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Issaad C, 2000, LEUKEMIA, V14, P662, DOI 10.1038/sj.leu.2401730; Jackson AL, 2001, MUTAT RES-FUND MOL M, V477, P7, DOI 10.1016/S0027-5107(01)00091-4; Jeffs AR, 1998, HUM MOL GENET, V7, P767, DOI 10.1093/hmg/7.5.767; Johansson B, 2002, ACTA HAEMATOL-BASEL, V107, P76, DOI 10.1159/000046636; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Keeshan K, 2001, LEUKEMIA, V15, P1823, DOI 10.1038/sj.leu.2402309; KELMAN Z, 1989, BLOOD, V74, P2318; Kolibaba KS, 1997, BIOCHIM BIOPHYS ACTA, V1333, P217; KOPTYRA M, 2006, IN PRESS BLOOD, V9; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANEUVILLE P, 1992, BLOOD, V80, P1788; Laurent E, 2003, CLIN CANCER RES, V9, P3722; Lessen DS, 2005, CANCER GENET CYTOGEN, V160, P73, DOI 10.1016/j.cancergencyto.2004.11.013; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; LILLICRAP DA, 1984, LANCET, V2, P699; Limoli CL, 2003, CANCER RES, V63, P3107; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368; Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160; Martinelli G, 2000, HAEMATOLOGICA, V85, P40; Maru Y, 2001, MUTAT RES-FUND MOL M, V483, P83, DOI 10.1016/S0027-5107(01)00229-9; Matsuda T, 2003, J BIOL CHEM, V278, P25947, DOI 10.1074/jbc.C300170200; McGill CB, 1998, GENETICS, V148, P1525; Mighell AJ, 1997, FEBS LETT, V417, P1, DOI 10.1016/S0014-5793(97)01259-3; Million RP, 2002, BLOOD, V99, P4568, DOI 10.1182/blood-2001-12-0244; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Nieborowska-Skorska M, 2001, CANCER RES, V61, P6517; Nieborowska-Skorska M, 2006, CELL CYCLE, V5, P994, DOI 10.4161/cc.5.9.2722; Nishii K, 1996, ONCOGENE, V13, P2225; NOWELL PC, 1960, SCIENCE, V132, P1497; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; O'Hare T, 2004, BLOOD, V104, P2532, DOI 10.1182/blood-2004-05-1851; Ott G, 1998, GENE CHROMOSOME CANC, V22, P114, DOI 10.1002/(SICI)1098-2264(199806)22:2<114::AID-GCC5>3.0.CO;2-#; PAPADOPOULOS PC, 1990, GENE CHROMOSOME CANC, V1, P233, DOI 10.1002/gcc.2870010308; Pastink A, 2001, MUTAT RES-FUND MOL M, V480, P37, DOI 10.1016/S0027-5107(01)00167-1; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002; PRESTON DL, 1994, RADIAT RES, V137, pS68, DOI 10.2307/3578893; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Raderschall E, 2002, CANCER RES, V62, P219; Reddy EP, 2003, CANCER BIOL THER, V2, P115; Reed SH, 2005, DNA REPAIR, V4, P909, DOI 10.1016/j.dnarep.2005.04.009; Reiter A, 2005, CANCER RES, V65, P2662, DOI 10.1158/0008-5472.CAN-04-4263; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; ROWLEY JD, 1982, ADV CANCER RES, V36, P103, DOI 10.1016/S0065-230X(08)60423-6; Roy-Engel AM, 2002, J MOL BIOL, V316, P1033, DOI 10.1006/jmbi.2001.5380; RUDIGER NS, 1995, NUCLEIC ACIDS RES, V23, P256, DOI 10.1093/nar/23.2.256; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Sattler M, 1999, BLOOD, V93, P2928; SAWYERS CL, 1995, J EXP MED, V181, P307, DOI 10.1084/jem.181.1.307; Sawyers CL, 2002, CANCER CELL, V1, P13, DOI 10.1016/S1535-6108(02)00022-3; Semenza GL, 2000, CIRC RES, V86, P117, DOI 10.1161/01.RES.86.2.117; Sercan HO, 2000, LEUKEMIA LYMPHOMA, V39, P385, DOI 10.3109/10428190009065838; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Shteper P, 2001, SEMIN CANCER BIOL, V11, P313, DOI 10.1006/scbi.2001.0387; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; SKINNER AM, 2005, SCI AGING KNOWLEDGE; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SKORSKI T, 1994, J EXP MED, V179, P1855, DOI 10.1084/jem.179.6.1855; Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Slupianek A, 2001, MOL CELL, V8, P795, DOI 10.1016/S1097-2765(01)00357-4; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Slupianek A, 2002, MOL CELL BIOL, V22, P4189, DOI 10.1128/MCB.22.12.4189-4201.2002; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Stoklosa T, 2004, CELL CYCLE, V3, P1463, DOI 10.4161/cc.3.11.1229; Strick R, 2006, HUM GENET, V119, P479, DOI 10.1007/s00439-006-0146-9; Suzukawa K, 1997, GENOMICS, V42, P356, DOI 10.1006/geno.1997.4732; Takeda N, 1999, P NATL ACAD SCI USA, V96, P203, DOI 10.1073/pnas.96.1.203; Thompson LH, 2001, MUTAT RES-FUND MOL M, V477, P131, DOI 10.1016/S0027-5107(01)00115-4; TOKUHATA GK, 1968, BLOOD, V31, P216, DOI 10.1182/blood.V31.2.216.216; Tsao AS, 2002, BRIT J HAEMATOL, V119, P15, DOI 10.1046/j.1365-2141.2002.03899.x; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Varga T, 2005, DNA REPAIR, V4, P1038, DOI 10.1016/j.dnarep.2005.05.004; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Villamor N, 1999, ANN HEMATOL, V78, P478, DOI 10.1007/s002770050603; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; von Bubnoff N, 2005, BLOOD, V105, P1652, DOI 10.1182/blood-2004-06-2445; Weinstock DM, 2006, BLOOD, V107, P777, DOI 10.1182/blood-2005-06-2437; Weisberg E, 2001, DRUG RESIST UPDATE, V4, P22, DOI 10.1054/drup.2001.0180; Wlodarska I, 1998, BLOOD, V92, P2688, DOI 10.1182/blood.V92.8.2688.420a42_2688_2695; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yu TW, 1997, MUTAT RES-FUND MOL M, V379, P201, DOI 10.1016/S0027-5107(97)00141-3	161	60	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					11	20		10.1038/sj.onc.1209756	http://dx.doi.org/10.1038/sj.onc.1209756			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16785987				2022-12-28	WOS:000243236500002
J	Jannot, G; Simard, MJ				Jannot, G.; Simard, M. J.			Tumour-related microRNAs functions in Caenorhabditis elegans	ONCOGENE			English	Review						C. elegans; microRNA; miR-61; miR-84; oncogene	RNA; RAS; EXPRESSION; SEQUENCE; PATHWAY; MIR-48; ACTS; VAV1	Altering cell proliferation and differentiation are usually key events leading to cancer. As originally demonstrated by Sydney Brenner in 1960s, the nematode Caenorhabditis elegans represents an animal model of choice to study mechanisms important to maintain proper cellular behaviour. This round worm has helped to elucidate components as well as new cellular pathways required for animal development. Among them, the discovery of the programmed cell death and non-coding RNAs (microRNAs) controlling gene expression are two remarkable examples. Recently, two studies have demonstrated, once again, that using C. elegans can help gathering insights on cellular mechanisms leading to tumour formation. Two microRNAs, miR-84 and miR-61, control the expression of the oncogene orthologues Ras and Vav indicating their capacity to act as tumour suppressors. These observations demonstrate that uncovering the function of microRNAs is important to increase our understanding of cancer.	Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, CHUQ, Quebec City, PQ G1R 2J6, Canada	Laval University	Simard, MJ (corresponding author), Univ Laval, Canc Res Ctr, Hotel Dieu Quebec, CHUQ, Quebec City, PQ G1R 2J6, Canada.	Martin.Simard@crhdq.ulaval.ca		Simard, Martin/0000-0002-3189-9309				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Abrahante JE, 2003, DEV CELL, V4, P625, DOI 10.1016/S1534-5807(03)00127-8; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; DeNicola G, 2005, CANCER BIOL THER, V4, P509, DOI 10.4161/cbt.4.5.1781; Grad Y, 2003, MOL CELL, V11, P1253, DOI 10.1016/S1097-2765(03)00153-9; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grosshans H, 2005, DEV CELL, V8, P321, DOI 10.1016/j.devcel.2004.12.019; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Johnston RJ, 2005, P NATL ACAD SCI USA, V102, P12449, DOI 10.1073/pnas.0505530102; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Li M, 2005, DEV CELL, V9, P415, DOI 10.1016/j.devcel.2005.08.002; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lin SY, 2003, DEV CELL, V4, P639, DOI 10.1016/S1534-5807(03)00124-2; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Poulin G, 2004, ONCOGENE, V23, P8340, DOI 10.1038/sj.onc.1208010; Radtke F, 2003, NAT REV CANCER, V3, P756, DOI 10.1038/nrc1186; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Schumacher Bjorn, 2006, Future Oncol, V2, P145, DOI 10.2217/14796694.2.1.145; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; Sternberg PW., 2005, C ELEGANS RES COMMUN; Sundaram MV, 2005, GENE DEV, V19, P1825, DOI 10.1101/gad.1330605; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481	36	28	40	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6197	6201		10.1038/sj.onc.1209921	http://dx.doi.org/10.1038/sj.onc.1209921			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028599				2022-12-28	WOS:000241158900008
J	Chikamori, M; Fujimoto, J; Tokai-Nishizumi, N; Yamamoto, T				Chikamori, M.; Fujimoto, J.; Tokai-Nishizumi, N.; Yamamoto, T.			Identification of multiple SNT-binding sites on NPM-Alk oncoprotein and their involvement in cell transformation	ONCOGENE			English	Article						NPM-ALK; SNT; cell transformation; tyrosine phosphorylation; oncoprotein; anaplastic large-cell lymphoma	ANAPLASTIC LYMPHOMA KINASE; RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; NON-HODGKINS-LYMPHOMA; MAP KINASE; PROTEIN; ACTIVATION; GENE; FRS2; DIFFERENTIATION	The t(2;5) chromosomal translocation occurs in anaplastic large-cell lymphoma arising from activated T lymphocytes. This genomic rearrangement generates the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncoprotein that is a chimeric protein consisting of parts of the nuclear protein NPM and ALK receptor protein-tyrosine kinase. We used yeast two-hybrid screening to identify an adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT)-2 as a new partner that interacted with the cytoplasmic domain of ALK. Immunoprecipitation assay revealed that SNT-1 and SNT-2 interacted with NPM-ALK and kinase-negative NPM-ALK mutant. Y156, Y567 and a 19-amino-acid sequence (aa 631-649) of NPM-ALK were essential for this interaction. The interaction through Y156 and Y567 was dependent on phosphorylation of these tyrosines, whereas the interaction through the 19-amino- acid sequence was independent of phosphorylation. NPM-ALK mutant protein mutated at these three binding sites showed significantly reduced transforming activity. This transformation-defective NPM-ALK mutant still interacted with signal transducing proteins such as phospholipase C-gamma and phosphatidylinositol 3-kinase, which were previously reported to be relevant to NPM-ALK-dependent tumorigenesis. These observations indicate that the three SNT-binding sites of NPM-ALK are important for its transforming activity. This raises a possibility that SNT family proteins play significant roles in cellular transformation triggered by NPM-ALK, which though remains to be verified.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan; Natl Inst Radiol Sci, Res Ctr Radiat Emergency Med, Chiba 260, Japan; Univ Calif San Diego, La Jolla, CA 92093 USA	University of Tokyo; National Institutes for Quantum Science & Technology; University of California System; University of California San Diego	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan.	tyamamot@ims.u-tokyo.ac.jp						Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HERBST H, 1991, BLOOD, V78, P2666; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; McDougall K, 2001, MECH DEVELOP, V103, P145, DOI 10.1016/S0925-4773(01)00337-9; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	21	13	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2950	2954		10.1038/sj.onc.1210095	http://dx.doi.org/10.1038/sj.onc.1210095			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086210				2022-12-28	WOS:000246210800015
J	Kakinuma, S; Kodama, Y; Amasaki, Y; Yi, S; Tokairin, Y; Arai, M; Nishimura, M; Monobe, M; Kojima, S; Shimada, Y				Kakinuma, S.; Kodama, Y.; Amasaki, Y.; Yi, S.; Tokairin, Y.; Arai, M.; Nishimura, M.; Monobe, M.; Kojima, S.; Shimada, Y.			Ikaros is a mutational target for lymphomagenesis in Mlh1-deficient mice	ONCOGENE			English	Article						T-cell lymphoma; DNA mismatch repair; coding microsatellites; microsatellite instability; mutational target gene	ACUTE LYMPHOBLASTIC-LEUKEMIA; MISMATCH REPAIR DEFICIENCY; NONPOLYPOSIS COLON-CANCER; MOUSE THYMIC LYMPHOMAS; ETHYL-N-NITROSOUREA; MICROSATELLITE INSTABILITY; TRANSCRIPTION FACTOR; POINT MUTATIONS; MURINE LYMPHOMAS; GENE	Deficiencies in DNA mismatch repair (MMR) result in replication errors within key tumor suppressor genes or oncogenes, and cause hereditary nonpolyposis colorectal cancer (HNPCC). Hematological malignancy with microsatellite instability is also associated with defective MMR, but little is known about the target genes for MMR. Here we identified Ikaros, a master transcription factor of lymphoid lineage commitment and differentiation, as a mutational target in spontaneous and radiation-induced T-cell lymphomas in Mlh1-deficient mice. Three quarters of lymphomas lacked Ikaros protein expression, which resulted from a frameshift mutation that created a stop codon. Mononucleotide repeat sequences at 1029-1034(C)6 and 1567-1572(G)6 in Ikaros were mutational hot spots with a one-base deletion occurring with a frequency of 45 and 50%, respectively. Point mutations and splicing alterations were also observed. In total, 85% of the lymphomas showed aberrations in Ikaros. The characteristic of Mlh1-deficient lymphomas is harboring of multiple mutations simultaneously in the same tumor, displaying a combination of two frameshift mutations at different repeats, frameshift and point mutations, and/or deletion mutations. This is the first report of Ikaros mutations coupled with Mlh1 deficiency in lymphoma-genesis.	Natl Inst Radiol Sci, Expt Radiobiol Childrens Hlth Res Grp, Inage Ku, Chiba 2638555, Japan; Tokyo Univ Sci, Fac Pharmaceut Sci, Dept Radiat Biosci, Chiba, Japan; Tokyo Med & Dent Univ, Dept Surg, Tokyo, Japan; Japanese Fdn Canc Res, Canc Inst Hosp, Clin Lab Genet Diag, Tokyo, Japan	National Institutes for Quantum Science & Technology; Tokyo University of Science; Tokyo Medical & Dental University (TMDU); Japanese Foundation for Cancer Research	Kakinuma, S (corresponding author), Natl Inst Radiol Sci, Expt Radiobiol Childrens Hlth Res Grp, Inage Ku, 4-9-1 Anagawa, Chiba 2638555, Japan.	skakinum@nirs.go.jp; y_shimad@nirs.go.jp						Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Campbell MR, 2000, CARCINOGENESIS, V21, P2281, DOI 10.1093/carcin/21.12.2281; De Vos M, 2006, JNCI-J NATL CANCER I, V98, P358, DOI 10.1093/jnci/djj073; Duval A, 2002, CANCER RES, V62, P2447; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; Gu LY, 2002, ONCOGENE, V21, P5758, DOI 10.1038/sj.onc.1205695; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; Kakinuma S, 2005, MUTAT RES-FUND MOL M, V572, P132, DOI 10.1016/j.mrfmmm.2005.01.010; Kakinuma S, 2002, RADIAT RES, V157, P331, DOI 10.1667/0033-7587(2002)157[0331:SOZIIA]2.0.CO;2; Karlsson A, 2002, CANCER RES, V62, P2650; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lowsky R, 2000, BLOOD, V95, P1767, DOI 10.1182/blood.V95.5.1767.005k07_1767_1772; Nakanishi M, 2001, INT J RADIAT BIOL, V77, P687, DOI 10.1080/095530000110047537; Nakayama H, 1999, CANCER RES, V59, P3931; Okano H, 1999, ONCOGENE, V18, P6677, DOI 10.1038/sj.onc.1203100; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Papathanasiou P, 2003, IMMUNITY, V19, P131, DOI 10.1016/S1074-7613(03)00168-7; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Ricciardone MD, 1999, CANCER RES, V59, P290; Shimada Y, 2000, RADIAT RES, V154, P293, DOI 10.1667/0033-7587(2000)154[0293:RALOHA]2.0.CO;2; Shimada Y, 2003, INT J RADIAT BIOL, V79, P423, DOI 10.1080/0955300031000139371; Sun L, 1999, CLIN CANCER RES, V5, P2112; Sun L, 1999, P NATL ACAD SCI USA, V96, P680, DOI 10.1073/pnas.96.2.680; Tokairin Y, 2006, INT J EXP PATHOL, V87, P89, DOI 10.1111/j.0959-9673.2006.00464.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; Wang Q, 1997, INT J CANCER, V73, P831, DOI 10.1002/(SICI)1097-0215(19971210)73:6<831::AID-IJC11>3.0.CO;2-7; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; Yao X, 1999, P NATL ACAD SCI USA, V96, P6850, DOI 10.1073/pnas.96.12.6850	33	10	10	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2945	2949		10.1038/sj.onc.1210100	http://dx.doi.org/10.1038/sj.onc.1210100			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086208				2022-12-28	WOS:000246210800014
J	Montano, MM; Chaplin, LJ; Deng, H; Mesia-Vela, S; Gaikwad, N; Zahid, M; Rogan, E				Montano, M. M.; Chaplin, L. J.; Deng, H.; Mesia-Vela, S.; Gaikwad, N.; Zahid, M.; Rogan, E.			Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis	ONCOGENE			English	Article						quinone reductase; oxidative damage; estrogen receptor beta; estrogen; antiestrogens; mammary gland	TRANSCRIPTIONAL REGULATION; FUNCTIONAL IMPLICATIONS; F344 RAT; CARCINOGEN; INDUCTION; RECEPTOR; CANCER; DAMAGE; BETA; SUSCEPTIBILITY	We previously reported that antiestrogen-liganded estrogen receptor beta (ER beta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR) (NAD(P)H:quinone oxidoreductase). Further studies on the functional role of ERb-mediated upregulation of antioxidative enzymes indicated protective effects against estrogen induced oxidative DNA damage (ODD). We now report on in vivo and in vitro studies that show that ER beta-mediated upregulation of QR are involved in the protection against estrogen-induced mammary tumorigenesis. Using the August Copenhagen Irish (ACI) model of estrogen-induced carcinogenesis, we observed that increased ODD and decreased QR expression occur early in the process of estrogen-induced mammary tumorigenesis. Prevention of ACI mammary gland tumorigenesis by tamoxifen was accompanied by decreased ODD and increased QR levels. These correlative findings were supported by our findings that down regulation of QR levels led to increased levels of estrogen quinone metabolites and enhanced transformation potential of 17 beta-estradiol treated MCF10A non-tumorigenic breast epithelial cells. Concurrent expression of ER beta and treatment with 4-hydroxytamoxifen decreased tumorigenic potential of these MCF10A cells. We conclude that upregulation of QR, through induction by tamoxifen, can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a possible novel mechanism of tamoxifen prevention against breast cancer.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Columbia Univ, Med Ctr, Emphysema & Canc Act Program, New York, NY USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68182 USA	Case Western Reserve University; Columbia University; University of Nebraska System; University of Nebraska Medical Center	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg Room W367,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu		zahid, Muhammad/0000-0002-9975-9476	NCI NIH HHS [CA92440, CA80959, P01 CA49210] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092440, P01CA049210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ansell PJ, 2004, ENDOCRINOLOGY, V145, P311, DOI 10.1210/en.2003-0817; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Dawson PJ, 1996, AM J PATHOL, V148, P313; Guo M, 2001, BIOCHEM PHARMACOL, V62, P1449, DOI 10.1016/S0006-2952(01)00801-2; Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95; Jones SB, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-62; Kassie F, 2003, CARCINOGENESIS, V24, P255, DOI 10.1093/carcin/24.2.255; Li JJ, 2002, MOL CARCINOGEN, V33, P56, DOI 10.1002/mc.10022; Li SA, 2002, J ENDOCRINOL, V175, P297, DOI 10.1677/joe.0.1750297; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Matusheski NV, 2001, J AGR FOOD CHEM, V49, P5743, DOI 10.1021/jf010809a; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Thomas RD, 2006, CHEM-BIOL INTERACT, V160, P204, DOI 10.1016/j.cbi.2006.01.007	19	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3587	3590		10.1038/sj.onc.1210144	http://dx.doi.org/10.1038/sj.onc.1210144			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160017				2022-12-28	WOS:000246799200015
J	Vaira, V; Lee, CW; Goel, HL; Bosari, S; Languino, LR; Altieri, DC				Vaira, V.; Lee, C. W.; Goel, H. L.; Bosari, S.; Languino, L. R.; Altieri, D. C.			Regulation of survivin expression by IGF-1/mTOR signaling	ONCOGENE			English	Article						survivin; IGF-1; prostate cancer; mTOR; rapamycin	RECEPTOR TYROSINE KINASE; PROSTATE-CANCER CELLS; FACTOR-I RECEPTOR; WILD-TYPE P53; NF-KAPPA-B; INDUCED APOPTOSIS; AKT; PHOSPHORYLATION; PATHWAYS; GENE	Survivin is a dual regulator of cell proliferation and cell viability overexpressed in most human tumors. Although strategies to lower survivin levels have been pursued for rational cancer therapy, the molecular circuitries controlling survivin expression in tumors have not been completely elucidated. Here, we show that stimulation with insulin-like growth factor-1 (IGF-1) results in increased survivin expression in prostate cancer cells. This response is independent of de novo gene transcription, changes in mRNA expression or modi. cations of survivin protein stability. Instead, IGF-1 induced persistence and translation of a pool of survivin mRNA, in a reaction abolished by the mTOR (mammalian target of rapamycin) inhibitor, rapamycin. Forced expression of the mTOR target p70S6K1 reproduced the increase in survivin expression in prostate cancer cells, whereas acute ablation of endogenous p70S6K1 by small interfering RNA down-regulated survivin levels. Rapamycin, alone or in combination with suboptimal concentrations of taxol reduced survivin protein levels, and decreased viability of prostate cancer cells. Therefore, IGF-1/mTOR signaling elevates survivin in prostate cancer cells via rapid changes in mRNA translation. Antagonists of this pathway may be beneficial to lower an antiapoptotic threshold maintained by survivin in prostate cancer.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Ctr Canc, Worcester, MA 01605 USA; Univ Milan, AOS Paolo & Fdn Osped Maggiore Policlin Regina El, Div Pathol, Dept Med Surg & Dent, Milan, Italy	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Altieri, DC (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB428,364 Plantat St, Worcester, MA 01605 USA.	dario.altieri@umassmed.edu	Vaira, Valentina/K-6499-2016; Bosari, Silvano/K-7744-2016	Vaira, Valentina/0000-0003-4416-6216; Bosari, Silvano/0000-0002-9744-6951; Languino, Lucia/0000-0001-9011-7031	NCI NIH HHS [CA78810, F31 CA132622, CA109874, CA90917] Funding Source: Medline; NHLBI NIH HHS [HL54131] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F31CA132622, R01CA090917, R01CA078810, R01CA109874] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL054131, R01HL054131] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altieri DC, 2006, MOL CANCER THER, V5, P478, DOI 10.1158/1535-7163.MCT-05-0436; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Dan HC, 2004, ONCOGENE, V23, P706, DOI 10.1038/sj.onc.1207171; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Dohi T, 2004, J CLIN INVEST, V114, P1117, DOI 10.1172/JCI200422222; Fornaro M, 2003, J BIOL CHEM, V278, P50402, DOI 10.1074/jbc.M307627200; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Hopfner M, 2006, BIOCHEM PHARMACOL, V71, P1435, DOI 10.1016/j.bcp.2006.02.006; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1999, BIOCHEM J, V344, P305, DOI 10.1042/0264-6021:3440305; Li SW, 1996, J BIOL CHEM, V271, P12254, DOI 10.1074/jbc.271.21.12254; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Nam S, 2005, P NATL ACAD SCI USA, V102, P5998, DOI 10.1073/pnas.0409467102; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Romano G, 1999, J CELL BIOCHEM, V72, P294, DOI 10.1002/(SICI)1097-4644(19990201)72:2<294::AID-JCB14>3.0.CO;2-0; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; Stromberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306; Vong QP, 2005, SCIENCE, V310, P1499, DOI 10.1126/science.1120160; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang SX, 2006, CANCER RES, V66, P4285, DOI 10.1158/0008-5472.CAN-05-4456; Zhang M, 2005, ONCOGENE, V24, P2474, DOI 10.1038/sj.onc.1208490	38	156	166	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2678	2684		10.1038/sj.onc.1210094	http://dx.doi.org/10.1038/sj.onc.1210094			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072337				2022-12-28	WOS:000246210600002
J	Reiter, F; Hartl, M; Karagiannidis, AI; Bister, K				Reiter, F.; Hartl, M.; Karagiannidis, A. I.; Bister, K.			WS5, a direct target of oncogenic transcription factor Myc, is related to human melanoma glycoprotein genes and has oncogenic potential	ONCOGENE			English	Article						cell transformation; gene expression; C/EBP; Pmel17; GPNMB	DOXYCYCLINE-CONTROLLED EXPRESSION; CONDITIONAL CELL-TRANSFORMATION; C-MYC; V-MYC; C/EBP-ALPHA; ACTIVATION; JUN; DNA; ONCOPROTEIN; METASTASIS	We have isolated a gene (WS5) that is specifically expressed at the mRNA and protein level in avian fibroblasts transformed by the v-myc oncogene of avian acute leukemia virus MC29. In a conditional cell transformation system, WS5 gene expression was tightly correlated with v-myc activation. The WS5 gene contains 11 exons, encoding a 733-amino acid protein with a transmembrane region and a polycystic kidney disease (PKD) domain. Near the transcriptional start site, the WS5 promoter contains a cluster of four binding sites for the Myc-Max complex and a binding site for transcription factor C/EBP alpha. Electrophoretic mobility shift assays and chromatin immunoprecipitation showed that Myc, Max and C/EBP alpha bind specifically to these sites. Functional promoter analyses revealed that both the Myc-binding site cluster and the C/EBP alpha-binding site are essential for strong transcriptional activation, and that Myc and C/EBP alpha synergistically activate the WS5 promoter. Ectopic expression of WS5 led to cell transformation documented by anchorage-independent growth. The human melanoma antigen Pmel17, a type I transmembrane glycoprotein, is the mammalian protein with the highest amino acid sequence identity (38%) to WS5. The Pmel17 gene is regulated by the MITF protein, a bHLHZip transcription factor with DNA binding specificities similar to those of Myc/Max. WS5 is also related to human glycoprotein GPNMB expressed in metastatic melanoma cells and implicated in the progression of brain and liver tumors.	Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci Innsbruck, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Bister, K (corresponding author), Univ Innsbruck, Inst Biochem, Peter Mayr Str 1A, A-6020 Innsbruck, Austria.	klaus.bister@uibk.ac.at	Hartl, Markus/O-4655-2014; Bister, Klaus/AFA-9400-2022	Hartl, Markus/0000-0001-7447-5920; Bister, Klaus/0000-0001-6545-5653	Austrian Science Fund FWF [P 18148, P 17041] Funding Source: Medline	Austrian Science Fund FWF(Austrian Science Fund (FWF))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Bader AG, 2000, VIROLOGY, V270, P98, DOI 10.1006/viro.2000.0222; Ben-Porath I, 1999, MOL CELL BIOL, V19, P3529; Berson JF, 2003, J CELL BIOL, V161, P521, DOI 10.1083/jcb.200302072; Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Bycroft M, 1999, EMBO J, V18, P297, DOI 10.1093/emboj/18.2.297; Clark LA, 2006, P NATL ACAD SCI USA, V103, P1376, DOI 10.1073/pnas.0506940103; Dang CV, 1999, MOL CELL BIOL, V19, P1; Du JY, 2003, AM J PATHOL, V163, P333, DOI 10.1016/S0002-9440(10)63657-7; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; Fieber W, 2001, J MOL BIOL, V307, P1395, DOI 10.1006/jmbi.2001.4537; Grabe Niels, 2002, In Silico Biology, V2, pS1; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Hartl M, 2006, ONCOGENE, V25, P4043, DOI 10.1038/sj.onc.1209441; HARTL M, 1995, P NATL ACAD SCI USA, V92, P11731, DOI 10.1073/pnas.92.25.11731; Hartl M, 1998, ONCOGENE, V17, P2901, DOI 10.1038/sj.onc.1202219; Hartl M, 2003, J MOL BIOL, V333, P33, DOI 10.1016/j.jmb.2003.08.018; Hartl M, 2001, P NATL ACAD SCI USA, V98, P13601, DOI 10.1073/pnas.241451198; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Jing H, 2002, STRUCTURE, V10, P1453, DOI 10.1016/S0969-2126(02)00840-7; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Liu YN, 2004, ONCOGENE, V23, P278, DOI 10.1038/sj.onc.1207022; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Mink S, 1996, P NATL ACAD SCI USA, V93, P6635, DOI 10.1073/pnas.93.13.6635; Mink S, 1999, BBA-GENE STRUCT EXPR, V1447, P175, DOI 10.1016/S0167-4781(99)00168-2; MOCHII M, 1991, PIGM CELL RES, V4, P41, DOI 10.1111/j.1600-0749.1991.tb00312.x; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Oberst C, 1999, VIROLOGY, V253, P193, DOI 10.1006/viro.1998.9499; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Secombe J, 2004, CELL, V117, P153, DOI 10.1016/S0092-8674(04)00336-8; Theos AC, 2005, PIGM CELL RES, V18, P322, DOI 10.1111/j.1600-0749.2005.00269.x; Turque N, 1996, EMBO J, V15, P3338, DOI 10.1002/j.1460-2075.1996.tb00699.x; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; WETERMAN MAJ, 1995, INT J CANCER, V60, P73, DOI 10.1002/ijc.2910600111; Zhang XY, 2005, P NATL ACAD SCI USA, V102, P13968, DOI 10.1073/pnas.0502330102	47	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1769	1779		10.1038/sj.onc.1209975	http://dx.doi.org/10.1038/sj.onc.1209975			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964280				2022-12-28	WOS:000244955600011
J	Jeong, KW; Kim, HZ; Kim, S; Kim, YS; Choe, J				Jeong, K. W.; Kim, H-Z; Kim, S.; Kim, Y. S.; Choe, J.			Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation	ONCOGENE			English	Article						HPV; E6; E6AP; proteasome; ubiquitination	CERVICAL-CANCER CELLS; GOLGI PROTEIN; ADENOVIRUS E4-ORF1; EARLY GENES; HPV-18 E6; IN-VITRO; P53; IDENTIFICATION; BINDING; ONCOPROTEINS	The PDZ proteins such as hDLG, hScrib and MAGIs function as the membrane-associated protein scaffolds and have been shown to interact with the high-risk human papillomavirus (HPV) E6s. In this report, we identify a Golgi-associated PDZ protein, cystic fibrosis transmembrane regulator-associated ligand (CAL) as a cellular target of HPV16 E6 by the proteomic approach. The carboxy-terminal PDZ-binding motif of HPV16 E6 specifically interacts with the PDZ domain of CAL, and the interaction enhances proteasome-mediated degradation of CAL. HPV16 E6 interacts with CAL more strongly and degrades it better than HPV18 E6 owing to the more compatible PDZ-binding motif. CAL is ubiquitinated by the E6/E6-associated protein (E6AP) complex or by E6AP alone, albeit less efficiently, which indicates that it could be a normal target of E6AP. Although it downregulates CAL at the transcript level, small interfering RNA-induced depletion of HPV16 E6 in Caski cells stabilizes CAL at the protein level, suggesting that HPV16 E6 mediates the proteasomal degradation of CAL in HPV-positive cervical cancer cells. HPV16 E6 may tightly regulate the vesicular trafficking processes by interacting with CAL, and such a modification can contribute to the development of cervical cancer.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Yonsei University	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong Dong, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Choe, Joonho/F-3066-2011					Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Gao QS, 2002, CANCER RES, V62, P3315; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Piserchio A, 2005, BIOCHEMISTRY-US, V44, P16158, DOI 10.1021/bi0516475; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					487	499		10.1038/sj.onc.1209837	http://dx.doi.org/10.1038/sj.onc.1209837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16878151				2022-12-28	WOS:000243731600002
J	Zhang, JS; Gong, A; Young, CYF				Zhang, J-S; Gong, A.; Young, C. Y. F.			ZNF185, an actin-cytoskeleton-associated growth inhibitory LIM protein in prostate cancer	ONCOGENE			English	Article						LIM domain protein; filamentous actin; prostate cancer; tumor suppressor	GENE; DOMAIN; DIFFERENTIATION; HOMEODOMAIN; TARGETS; EPLIN; CELLS; MOTIF; LOST	We have recently identified ZNF185 as a gene that is downregulated in prostate cancer (PCa), in part via epigenetic alteration, and maybe associated with disease progression. In this study, we cloned the ZNF185 cDNA from normal human prostate tissues and investigated its biological function. We show that ZNF185 is a novel actin-cytoskeleton-associated Lin-l 1, Isl-1 and Mec-3 (LIM) domain-containing protein that localizes to F-actin structures, and is enriched at focal adhesions. We find that the NH2-terminal region, which we designate the actin-targeting domain, facilitates ZNF185 binding to actin ;in vitro and is both necessary and sufficient to mediate actin - cytoskeleton targeting of ZNF185, whereas the LIM domain, which is localized in the COOH-terminus is dispensable for this phenomenon. Interestingly, ectopic expression of full-length ZNF185, but not a mutant lacking the actin-targeting domain, could suppress proliferation and anchorage-independent growth of PCa cells. Together, our data suggest that ZNF185 may function as a tumor-suppressor protein by associating with the actin cytoskeleton.	Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, Rochester, MN 55905 USA	Mayo Clinic	Zhang, JS (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Urol, 200 1st St SW, Rochester, MN 55905 USA.	zhang.jinsan@mayo.edu			NCI NIH HHS [CA70892, CA91956] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA091956, R01CA070892] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; FREYD G, 1990, NATURE, V344, P876, DOI 10.1038/344876a0; Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015; Gonzalez HE, 2003, ARCH OTOLARYNGOL, V129, P754, DOI 10.1001/archotol.129.7.754; Heiss NS, 1997, GENOMICS, V43, P329, DOI 10.1006/geno.1997.4810; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; Labouesse M, 2003, CURR BIOL, V13, pR528, DOI 10.1016/S0960-9822(03)00448-2; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Maul RS, 1999, ONCOGENE, V18, P7838, DOI 10.1038/sj.onc.1203206; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; PAN Y, 2003, CANCER EPIDEM BIOMAR, V8, P769; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Rubin MA, 2002, JAMA-J AM MED ASSOC, V287, P1662, DOI 10.1001/jama.287.13.1662; Song YH, 2002, MOL BIOL CELL, V13, P1408, DOI 10.1091/mbc.01-08-0414; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Vanaja DK, 2003, CANCER RES, V63, P3877; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; Welsh JB, 2001, CANCER RES, V61, P5974; Wong N, 2005, CLIN CANCER RES, V11, P1319; Xu JF, 1998, NAT GENET, V20, P175, DOI 10.1038/2477; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang JS, 2005, GENE CHROMOSOME CANC, V43, P249, DOI 10.1002/gcc.20188	30	32	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					111	122		10.1038/sj.onc.1209769	http://dx.doi.org/10.1038/sj.onc.1209769			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799630				2022-12-28	WOS:000243236500011
J	Ji, Z; Degerny, C; Vintonenko, N; Deheuninck, J; Foveau, B; Leroy, C; Coll, J; Tulasne, D; Baert, JL; Fafeur, V				Ji, Z.; Degerny, C.; Vintonenko, N.; Deheuninck, J.; Foveau, B.; Leroy, C.; Coll, J.; Tulasne, D.; Baert, J-L; Fafeur, V.			Regulation of the Ets-1 transcription factor by sumoylation and ubiquitinylation	ONCOGENE			English	Article						Ets-1; transcription factor; SUMO; ubiquitin	DNA-BINDING; MOLECULAR-BIOLOGY; SUMO MODIFICATION; GENE-EXPRESSION; PHOSPHORYLATION; RECEPTOR; DOMAIN; COACTIVATOR; REPRESSION; INHIBITION	Sumoylation and ubiquitinylation reversibly regulate the activity of transcription factors through covalent attachment to lysine residues of target proteins. We examined whether the Ets-1 transcription factor is modified by sumoylation and/or ubiquitinylation. Among four potential SUMO motifs in Ets-1, we identified lysines 15 and 227 within the (LKYE)-Y-15 and IK(227)QE motifs, as being the sumoylation acceptor sites. Using transfection of Ets-1 wildtype (WT) or its sumoylation deficient version (Ets-1 K15R/K227R), as well as WT or mutant proteins of the SUMO pathway, we further demonstrated that the E2 SUMO-conjugating enzyme Ubc9 and a E3 SUMO ligase, PIASy, can enhance Ets-1 sumoylation, while a SUMO protease, SENP1, can desumoylate Ets-1. We also found that Ets-1 is modified by K48-linked polyubiquitinylation independently of the sumoylation acceptor sites and is degraded through the 26S proteasome pathway, while sumoylation of Ets-1 does not affect its stability. Finally, sumoylation of Ets-1 leads to reduced transactivation and we demonstrated that previously identified critical lysine residues in Synergistic Control motifs are the sumoylation acceptor sites of Ets-1. These data show that Ets-1 can be modified by sumoylation and/or ubiquitinylation, with sumoylation repressing transcriptional activity of Ets-1 and having no clear antagonistic action on the ubiquitin-proteasome degradation pathway.	Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fafeur, V (corresponding author), Univ Lille 1, Inst Biol Lille, CNRS, UMR 8161,Inst Pasteur Lille,Univ Lille 2, 1 Rue Calmette,BP 447, F-59021 Lille, France.	veronique.fafeur@ibl.fr	Tulasne, David/AAR-5287-2020; Fafeur, Veronique/L-9072-2018; Tulasne, David/A-8705-2008	Tulasne, David/0000-0002-6764-7242; 				Bohren KM, 2004, J BIOL CHEM, V279, P27233, DOI 10.1074/jbc.M402273200; BORIES JC, 1995, NATURE, V377, P635, DOI 10.1038/377635a0; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Cheng JK, 2004, MOL CELL BIOL, V24, P6021, DOI 10.1128/MCB.24.13.6021-6028.2004; Cowley DO, 2000, GENE DEV, V14, P366; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Dohmen RJ, 2004, BBA-MOL CELL RES, V1695, P113, DOI 10.1016/j.bbamcr.2004.09.021; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Haglund K, 2005, EMBO J, V24, P3353, DOI 10.1038/sj.emboj.7600808; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Herrera FJ, 2004, CURR BIOL, V14, pR622, DOI 10.1016/j.cub.2004.07.046; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Janknecht R, 1996, ONCOGENE, V12, P1961; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Kurihara I, 2005, J BIOL CHEM, V280, P6721, DOI 10.1074/jbc.M411820200; Leight ER, 2005, DEVELOPMENT, V132, P1047, DOI 10.1242/dev.01664; Macauley MS, 2006, J BIOL CHEM, V281, P4164, DOI 10.1074/jbc.M510488200; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Muller S, 2004, ONCOGENE, V23, P1998, DOI 10.1038/sj.onc.1207415; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Perdomo J, 2005, MOL CELL BIOL, V25, P1549, DOI 10.1128/MCB.25.4.1549-1559.2005; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; Reveneau S, 2003, ANN NY ACAD SCI, V1010, P100, DOI 10.1196/annals.1299.016; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2003, CELL MOL LIFE SCI, V60, P2561, DOI 10.1007/s00018-003-3129-1; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Tulasne D, 2004, MOL CELL BIOL, V24, P10328, DOI 10.1128/MCB.24.23.10328-10339.2004; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; van den Akker E, 2005, J BIOL CHEM, V280, P38035, DOI 10.1074/jbc.M502938200; Wasylyk C, 2005, ONCOGENE, V24, P820, DOI 10.1038/sj.onc.1208226; Wasylyk C, 1997, ONCOGENE, V14, P899, DOI 10.1038/sj.onc.1200914; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119; Xiao GH, 2001, P NATL ACAD SCI USA, V98, P247, DOI 10.1073/pnas.011532898; Yang SH, 2005, EMBO J, V24, P2161, DOI 10.1038/sj.emboj.7600690; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	53	40	41	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					395	406		10.1038/sj.onc.1209789	http://dx.doi.org/10.1038/sj.onc.1209789			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862185				2022-12-28	WOS:000243544000008
J	Guder, C; Philipp, I; Lengfeld, T; Watanabe, H; Hobmayer, B; Holstein, TW				Guder, C.; Philipp, I.; Lengfeld, T.; Watanabe, H.; Hobmayer, B.; Holstein, T. W.			The Wnt code: cnidarians signal the way	ONCOGENE			English	Review						Wnt signalling; regeneration; axis formation; Hydra; Nematostella; cnidaria	ANEMONE NEMATOSTELLA-VECTENSIS; SEA-ANEMONE; AXIS FORMATION; BETA-CATENIN; LARVAL DEVELOPMENT; SNAIL EXPRESSION; NANOS EXPRESSION; HEAD ORGANIZER; GENE FAMILY; STEM-CELLS	Cnidarians are the simplest metazoans with a nervous system. They are well known for their regeneration capacity, which is based on the restoration of a signalling centre (organizer). Recent work has identified the canonical Wnt pathway in the freshwater polyp Hydra, where it acts in organizer formation and regeneration. Wnt signalling is also essential for cnidarian embryogenesis. In the sea anemone Nematostella vectensis 11 of the 12 known wnt gene subfamilies were identified. Different wnt genes exhibit serial and overlapping expression domains along the oral-aboral axis of the embryo (the `wnt code'). This is reminiscent of the hox code (cluster) in bilaterian embryogenesis that is, however, absent in cnidarians. It is proposed that the common ancestor of cnidarians and bilaterians invented a set of wnt genes that patterned the ancient main body axis. Major antagonists of Wnt ligands (e.g. Dkk 1/2/4) that were previously known only from chordates, are also present in cnidarians and exhibit a similar conserved function. The unexpectedly high level of genetic complexity of wnt genes evolved in early multi-cellular animals about 650 Myr ago and suggests a radical expansion of the genetic repertoire, concurrent with the evolution of multi-cellularity and the diversification of eumetazoan body plans.	Heidelberg Univ, Dept Mol Evolut & Genom, D-69120 Heidelberg, Germany; Univ Innsbruck, Inst Zool, A-6020 Innsbruck, Austria; Univ Innsbruck, Ctr Mol Biosci, A-6020 Innsbruck, Austria	Ruprecht Karls University Heidelberg; University of Innsbruck; University of Innsbruck	Holstein, TW (corresponding author), Heidelberg Univ, Dept Mol Evolut & Genom, Neuenheimer Feld 230, D-69120 Heidelberg, Germany.	holstein@uni-hd.de	Watanabe, Hiroshi/GOP-0177-2022; Guder, Corina/L-8413-2014	Watanabe, Hiroshi/0000-0001-8887-5407; Guder, Corina/0000-0002-8438-5168; Holstein, Thomas/0000-0003-0480-4674				Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; [Anonymous], 2005, PLAUSIBILITY LIFE; Augustin R, 2006, DEV BIOL, V296, P62, DOI 10.1016/j.ydbio.2006.04.003; Banziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049; Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009; Brooke NM, 2003, CURR OPIN GENET DEV, V13, P599, DOI 10.1016/j.gde.2003.09.002; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Broun M, 2005, DEVELOPMENT, V132, P2907, DOI 10.1242/dev.01848; Broun M, 2002, DEVELOPMENT, V129, P875; Browne EN, 1909, J EXP ZOOL, V7, P1, DOI 10.1002/jez.1400070102; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JY, 2002, DEV BIOL, V248, P182, DOI 10.1006/dbio.2002.0714; Chourrout D, 2006, NATURE, V442, P684, DOI 10.1038/nature04863; Darling JA, 2005, BIOESSAYS, V27, P211, DOI 10.1002/bies.20181; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; Extavour CG, 2005, EVOL DEV, V7, P201, DOI 10.1111/j.1525-142X.2005.05023.x; Fedders H, 2004, DEV GENES EVOL, V214, P72, DOI 10.1007/s00427-003-0378-9; Ferrier DEK, 2001, NAT REV GENET, V2, P33, DOI 10.1038/35047605; Finnerty JR, 2004, SCIENCE, V304, P1335, DOI 10.1126/science.1091946; Fritzenwanker JH, 2004, DEV BIOL, V275, P389, DOI 10.1016/j.ydbio.2004.08.014; Frobius AC, 2003, DEV GENES EVOL, V213, P445, DOI 10.1007/s00427-003-0344-6; Garcia-Fernandez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723; Garcia-Fernandez J, 2005, HEREDITY, V94, P145, DOI 10.1038/sj.hdy.6800621; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Guder C, 2006, DEVELOPMENT, V133, P901, DOI 10.1242/dev.02265; HAND C, 1992, BIOL BULL, V182, P169, DOI 10.2307/1542110; HASSEL M, 1993, DEV BIOL, V156, P362, DOI 10.1006/dbio.1993.1083; Hayward DC, 2004, DEV GENES EVOL, V214, P257, DOI 10.1007/s00427-004-0398-0; He X, 2006, DEVELOPMENT, V133, P2597, DOI 10.1242/dev.02452; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; Hobmayer E, 1996, GENE, V172, P155, DOI 10.1016/0378-1119(96)00162-X; Holland LZ, 2001, DEV BIOL, V232, P493, DOI 10.1006/dbio.2001.0160; Holland LZ, 2002, DEV BIOL, V241, P209, DOI 10.1006/dbio.2001.0503; Holland P, 2004, SCIENCE, V304, P1255, DOI 10.1126/science.1099829; Holstein TW, 2003, DEV DYNAM, V226, P257, DOI 10.1002/dvdy.10227; Jessen JR, 2005, CELL, V120, P736, DOI 10.1016/j.cell.2005.03.005; Jones SE, 2002, BIOESSAYS, V24, P811, DOI 10.1002/bies.10136; Kamm K, 2006, CURR BIOL, V16, P920, DOI 10.1016/j.cub.2006.03.036; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; Klein RD, 1996, P NATL ACAD SCI USA, V93, P7108, DOI 10.1073/pnas.93.14.7108; Kusserow A, 2005, NATURE, V433, P156, DOI 10.1038/nature03158; Lee PN, 2006, SEMIN CELL DEV BIOL, V17, P157, DOI 10.1016/j.semcdb.2006.05.002; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Magie CR, 2005, DEV GENES EVOL, V215, P618, DOI 10.1007/s00427-005-0022-y; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Martindale MQ, 2004, DEVELOPMENT, V131, P2463, DOI 10.1242/dev.01119; Matus DQ, 2006, CURR BIOL, V16, P499, DOI 10.1016/j.cub.2006.01.052; Millar JBA, 2002, GENOME BIOL, V3; Miller DJ, 2005, TRENDS GENET, V21, P536, DOI 10.1016/j.tig.2005.08.002; Minobe S, 2000, DEV GENES EVOL, V210, P258, DOI 10.1007/s004270050312; Morris SC, 2000, P NATL ACAD SCI USA, V97, P4426, DOI 10.1073/pnas.97.9.4426; Muller WA, 2004, DEV BIOL, V275, P215, DOI 10.1016/j.ydbio.2004.08.006; Muller WA, 2004, INT J DEV BIOL, V48, P9, DOI 10.1387/ijdb.15005569; Onai T, 2004, DEV CELL, V7, P95, DOI 10.1016/j.devcel.2004.06.004; Plickert G, 2006, DEV BIOL, V298, P368, DOI 10.1016/j.ydbio.2006.06.043; Price MA, 2006, GENE DEV, V20, P399, DOI 10.1101/gad.1394306; Prud'homme B, 2002, CURR BIOL, V12, P1395, DOI 10.1016/S0960-9822(02)01068-0; Rentzsch F, 2005, DEV BIOL, V278, P1, DOI 10.1016/j.ydbio.2004.10.007; Rentzsch F, 2006, DEV BIOL, V296, P375, DOI 10.1016/j.ydbio.2006.06.003; Scholz CB, 2003, DEV GENES EVOL, V212, P563, DOI 10.1007/s00427-002-0272-x; Spring J, 2002, DEV BIOL, V244, P372, DOI 10.1006/dbio.2002.0616; Spring J, 2000, DEV BIOL, V228, P363, DOI 10.1006/dbio.2000.9956; Steele RE, 2006, P NATL ACAD SCI USA, V103, P6415, DOI 10.1073/pnas.0601983103; Strutt H, 2006, CURR BIOL, V16, P1329, DOI 10.1016/j.cub.2006.04.041; Tao QH, 2005, CELL, V120, P857, DOI 10.1016/j.cell.2005.01.013; Technau U, 2000, P NATL ACAD SCI USA, V97, P12127, DOI 10.1073/pnas.97.22.12127; Technau U, 2005, TRENDS GENET, V21, P633, DOI 10.1016/j.tig.2005.09.007; Technau U, 2003, INT J DEV BIOL, V47, P531; Technau U, 1999, DEVELOPMENT, V126, P999; Teo R, 2006, DEV BIOL, V289, P91, DOI 10.1016/j.ydbio.2005.10.009; Torras R, 2005, INT J DEV BIOL, V49, P895, DOI 10.1387/ijdb.051980rt; Torras R, 2004, EVOL DEV, V6, P362, DOI 10.1111/j.1525-142X.2004.04044.x; Tree DRP, 2002, SEMIN CELL DEV BIOL, V13, P217, DOI 10.1016/S1084-9521(02)00042-3; VANLAUE CC, 2003, THESIS DARMSTADT U T, P97; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1; Wikramanayake AH, 2003, NATURE, V426, P446, DOI 10.1038/nature02113; Wittlieb J, 2006, P NATL ACAD SCI USA, V103, P6208, DOI 10.1073/pnas.0510163103; Yang Yingzi, 2003, Birth Defects Research, V69, P305, DOI 10.1002/bdrc.10026	80	140	148	0	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7450	7460		10.1038/sj.onc.1210052	http://dx.doi.org/10.1038/sj.onc.1210052			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143289	Bronze			2022-12-28	WOS:000242514900003
J	Hui, L; Zheng, Y; Yan, Y; Bargonetti, J; Foster, DA				Hui, L.; Zheng, Y.; Yan, Y.; Bargonetti, J.; Foster, D. A.			Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D	ONCOGENE			English	Article						phospholipase D; p53; survival signals; apoptosis; breast cancer	GAIN-OF-FUNCTION; TUMOR-SUPPRESSOR GENE; WILD-TYPE; FUNCTION MUTATIONS; EXPRESSION; BINDING; MDM2; TRANSFORMATION; ACTIVATION; RESISTANCE	p53 is the most commonly mutated gene in human cancer. Although the loss of tumor suppressor functions for p53 in tumorigenesis is well characterized, gain-of-function p53 mutations observed in most cancers are not as widely appreciated. The human breast cancer cell line MDA-MB-231, which has high levels of a mutant p53, has high levels of phospholipase D (PLD) activity, which provides a survival signal in these cells when deprived of serum growth factors. We report here that the mutant p53 in MDA-MB-231 cells is stabilized by the elevated PLD activity in these cells. Surprisingly, the survival of MDA-MB-231 cells deprived of serum was dependent on the mutant p53. These data indicate that a mutant p53, stabilized by elevated PLD activity, can contribute to the suppression of apoptosis in a human breast cancer cell line and suggest a rationale for the selection of p53 mutations early in tumorigenesis to suppress apoptosis in an emerging tumor.	CUNY, Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY, Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu		Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046677, R01CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asher G, 2003, P NATL ACAD SCI USA, V100, P15065, DOI 10.1073/pnas.2436329100; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; DEB SP, 1994, ONCOGENE, V9, P1341; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; FOSTER DA, 2006, IN PRESS CURR SIGNAL, V1; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HSIAO M, 1994, AM J PATHOL, V145, P702; Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Irwin MS, 2004, CELL CYCLE, V3, P319; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; Katayose D, 1995, CLIN CANCER RES, V1, P889; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Moll UM, 2003, MOL CANCER RES, V1, P1001; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200; Peng YH, 2001, J BIOL CHEM, V276, P6874, DOI 10.1074/jbc.C000781200; Preuss U, 2000, INT J CANCER, V88, P162, DOI 10.1002/1097-0215(20001015)88:2<162::AID-IJC3>3.0.CO;2-M; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Strano S, 2003, CELL CYCLE, V2, P348, DOI 10.4161/cc.2.4.426; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	44	145	149	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7305	7310		10.1038/sj.onc.1209735	http://dx.doi.org/10.1038/sj.onc.1209735			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785993				2022-12-28	WOS:000242244700009
J	Hiscott, J; Nguyen, TLA; Arguello, M; Nakhaei, P; Paz, S				Hiscott, J.; Nguyen, T-L A.; Arguello, M.; Nakhaei, P.; Paz, S.			Manipulation of the nuclear factor-kappa B pathway and the innate immune response by viruses	ONCOGENE			English	Review						NF-kappaB; innate immunity; interferons; viral evasion; Toll-like receptors	CELL LEUKEMIA-VIRUS; VESICULAR-STOMATITIS-VIRUS; TOLL-LIKE RECEPTOR-3; DOUBLE-STRANDED-RNA; HTLV-I TAX; INTERFERON REGULATORY FACTOR-3; RESPIRATORY SYNCYTIAL VIRUS; DOMAIN-CONTAINING ADAPTER; LONG TERMINAL REPEAT; IFN-BETA PROMOTER	Viral and microbial constituents contain specific motifs or pathogen-associated molecular patterns (PAMPs) that are recognized by cell surface-and endosome-associated Toll-like receptors (TLRs). In addition, intracellular viral double-stranded RNA is detected by two recently characterized DExD/H box RNA helicases, RIG-I and Mda-5. Both TLR-dependent and -independent pathways engage the I kappa B kinase (IKK) complex and related kinases TBK-1 and IKK epsilon. Activation of the nuclear factor kappa B (NF-kappa B) and interferon regulatory factor (IRF) transcription factor pathways are essential immediate early steps of immune activation; as a result, both pathways represent prime candidates for viral interference. Many viruses have developed strategies to manipulate NF-kappa B signaling through the use of multifunctional viral proteins that target the host innate immune response pathways. This review discusses three rapidly evolving areas of research on viral pathogenesis: the recognition and signaling in response to virus infection through TLR-dependent and -independent mechanisms, the involvement of NF-kappa B in the host innate immune response and the multitude of strategies used by different viruses to short circuit the NF-kappa B pathway.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; McGill Univ, Dept Med & Oncol, Montreal, PQ, Canada	Lady Davis Institute; McGill University; McGill University; McGill University	Hiscott, J (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	john.hiscott@mcgill.ca		Paz, Suzanne/0000-0002-0465-7144				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Aizaki H, 2000, J INTERF CYTOK RES, V20, P1111, DOI 10.1089/107999000750053780; AKAGI T, 1995, BLOOD, V86, P4243, DOI 10.1182/blood.V86.11.4243.bloodjournal86114243; Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alefantis T, 2005, J BIOMED SCI, V12, P961, DOI 10.1007/s11373-005-9026-x; Alter HJ, 2000, SEMIN LIVER DIS, V20, P17, DOI 10.1055/s-2000-9505; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Atkinson PGP, 2003, J BIOL CHEM, V278, P51134, DOI 10.1074/jbc.M304771200; Aupperle KR, 2001, CELL IMMUNOL, V214, P54, DOI 10.1006/cimm.2002.1885; Azran I, 2005, ONCOGENE, V24, P4521, DOI 10.1038/sj.onc.1208645; Basler CF, 2000, P NATL ACAD SCI USA, V97, P12289, DOI 10.1073/pnas.220398297; Basler CF, 2003, J VIROL, V77, P7945, DOI 10.1128/JVI.77.14.7945-7956.2003; Bex F, 1998, METHODS, V16, P83, DOI 10.1006/meth.1998.0646; Bex F, 1999, J VIROL, V73, P738, DOI 10.1128/JVI.73.1.738-745.1999; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; Blight KJ, 2003, J VIROL, V77, P3181, DOI 10.1128/JVI.77.5.3181-3190.2003; Bonnard M, 2000, EMBO J, V19, P4976, DOI 10.1093/emboj/19.18.4976; Bossert B, 2003, J VIROL, V77, P8661, DOI 10.1128/JVI.77.16.8661-8668.2003; Bossert B, 2002, J VIROL, V76, P4287, DOI 10.1128/JVI.76.9.4287-4293.2002; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Breiman A, 2005, J VIROL, V79, P3969, DOI 10.1128/JVI.79.7.3969-3978.2005; Brinkmann MM, 2006, J GEN VIROL, V87, P1047, DOI 10.1099/vir.0.81598-0; Brzozka K, 2005, J VIROL, V79, P7673, DOI 10.1128/JVI.79.12.7673-7681.2005; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Cahir-McFarland ED, 2000, P NATL ACAD SCI USA, V97, P6055, DOI 10.1073/pnas.100119497; Cardenas WB, 2006, J VIROL, V80, P5168, DOI 10.1128/JVI.02199-05; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Cesaire R, 2006, ONCOGENE, V25, P349, DOI 10.1038/sj.onc.1209055; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chen BK, 1997, J VIROL, V71, P5495, DOI 10.1128/JVI.71.7.5495-5504.1997; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; Cheng GH, 1996, GENE DEV, V10, P963, DOI 10.1101/gad.10.8.963; Chisari FV, 2005, NATURE, V436, P930, DOI 10.1038/nature04076; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Civas A, 2006, J BIOL CHEM, V281, P4856, DOI 10.1074/jbc.M506812200; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Conzelmann KK, 2005, J VIROL, V79, P5241, DOI 10.1128/JVI.79.9.5241-5248.2005; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; Degli-Esposti MA, 2005, NAT REV IMMUNOL, V5, P112, DOI 10.1038/nri1549; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devergne O, 1996, MOL CELL BIOL, V16, P7098; Devergne O, 1998, J VIROL, V72, P7900, DOI 10.1128/JVI.72.10.7900-7908.1998; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Donelan NR, 2004, J VIROL, V78, P11574, DOI 10.1128/JVI.78.21.11574-11582.2004; DUNNE A, 2003, SCI STKE, pRE3, DOI DOI 10.1126/STKE.2003.171.RE3; Duyao M P, 1992, Curr Top Microbiol Immunol, V182, P421; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; Eshima N, 2003, MATH MED BIOL, V20, P29, DOI 10.1093/imammb/20.1.29; Ferran MC, 1997, J VIROL, V71, P371, DOI 10.1128/JVI.71.1.371-377.1997; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; FOY E, 2005, P NATL ACAD SCI USA, V79, P2689; Fujita F, 2003, MOL CELL BIOL, V23, P7780, DOI 10.1128/MCB.23.21.7780-7793.2003; Gale M, 2005, NATURE, V436, P939, DOI 10.1038/nature04078; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Garcia-Sastre A, 2006, EMERG INFECT DIS, V12, P44, DOI 10.3201/eid1201.051186; Garcia-Sastre A, 2004, CURR TOP MICROBIOL, V283, P249; Garcia-Sastre A, 2006, SCIENCE, V312, P879, DOI 10.1126/science.1125676; Geleziunas R, 1998, MOL CELL BIOL, V18, P5157, DOI 10.1128/MCB.18.9.5157; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Ghosh AK, 1999, J GEN VIROL, V80, P1179, DOI 10.1099/0022-1317-80-5-1179; Ghosh AK, 2000, J BIOL CHEM, V275, P7184, DOI 10.1074/jbc.275.10.7184; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P89; GILMORE TD, 1995, DNA PROVIRUS, P109; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; Gotoh B, 2002, REV MED VIROL, V12, P337, DOI 10.1002/rmv.357; Granja AG, 2006, J IMMUNOL, V176, P451, DOI 10.4049/jimmunol.176.1.451; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Grindstaff P, 2005, SEMIN NEUROL, V25, P315, DOI 10.1055/s-2005-917668; GROSSMAN WJ, 1995, P NATL ACAD SCI USA, V92, P1057, DOI 10.1073/pnas.92.4.1057; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Guasparri I, 2006, EMBO REP, V7, P114, DOI 10.1038/sj.embor.7400580; Guo HG, 2004, J VIROL, V78, P9336, DOI 10.1128/JVI.78.17.9336-9342.2004; Harhaj EW, 1999, ONCOGENE, V18, P1341, DOI 10.1038/sj.onc.1202405; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hatzivassiliou E, 2002, FRONT BIOSCI, V7, pD319, DOI 10.2741/hatziva; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He B, 2002, VIROLOGY, V303, P15, DOI 10.1006/viro.2002.1738; He ZM, 2000, CANCER RES, V60, P1845; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hengel H, 2005, TRENDS IMMUNOL, V26, P396, DOI 10.1016/j.it.2005.05.004; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Heylbroeck C, 2000, J VIROL, V74, P3781, DOI 10.1128/JVI.74.8.3781-3792.2000; HIMES SR, 1993, ONCOGENE, V8, P3189; HINRICHS SH, 1987, SCIENCE, V237, P1340, DOI 10.1126/science.2888191; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hiscott J, 2006, TRENDS MOL MED, V12, P53, DOI 10.1016/j.molmed.2005.12.003; HISCOTT J, 1989, J VIROL, V63, P2557, DOI 10.1128/JVI.63.6.2557-2566.1989; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Hoofnagle JH, 2002, HEPATOLOGY, V36, pS21, DOI 10.1053/jhep.2002.36227; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 2006, NATURE, V440, P949, DOI 10.1038/nature04641; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Huang YP, 2001, ONCOGENE, V20, P1094, DOI 10.1038/sj.onc.1204198; HUEN DS, 1995, ONCOGENE, V10, P549; Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x; Ishii KJ, 2006, NAT IMMUNOL, V7, P40, DOI 10.1038/ni1282; Iwanaga Y, 1999, J VIROL, V73, P1271, DOI 10.1128/JVI.73.2.1271-1277.1999; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Izumi KM, 1997, P NATL ACAD SCI USA, V94, P1447, DOI 10.1073/pnas.94.4.1447; Janeway C.A., 1999, IMMUNOBIOLOGY IMMUNE; Jeang KT, 2001, CYTOKINE GROWTH F R, V12, P207, DOI 10.1016/S1359-6101(00)00028-9; Jeong SJ, 2005, ONCOGENE, V24, P6719, DOI 10.1038/sj.onc.1208825; Jeong SJ, 2005, J BIOL CHEM, V280, P10326, DOI 10.1074/jbc.M412643200; Jiang ZF, 2004, P NATL ACAD SCI USA, V101, P3533, DOI 10.1073/pnas.0308496101; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Kaisho T, 2004, MICROBES INFECT, V6, P1388, DOI 10.1016/j.micinf.2004.08.019; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kashanchi F, 2005, ONCOGENE, V24, P5938, DOI 10.1038/sj.onc.1208973; Kato H, 2006, NATURE, V441, P101, DOI 10.1038/nature04734; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Kfoury Y, 2005, CELL DEATH DIFFER, V12, P871, DOI 10.1038/sj.cdd.4401624; Kim TK, 1997, MOL CELL, V1, P119, DOI 10.1016/S1097-2765(00)80013-1; Kishore N, 2002, J BIOL CHEM, V277, P13840, DOI 10.1074/jbc.M110474200; KIYOSAWA K, 1990, HEPATOLOGY, V12, P671, DOI 10.1002/hep.1840120409; Kolakofsky D, 1998, J VIROL, V72, P891, DOI 10.1128/JVI.72.2.891-899.1998; Kravchenko VV, 2003, J BIOL CHEM, V278, P26612, DOI 10.1074/jbc.M303001200; Krug RM, 2006, SCIENCE, V311, P1562, DOI 10.1126/science.1125998; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Kwon H, 1998, J BIOL CHEM, V273, P7431, DOI 10.1074/jbc.273.13.7431; La Rocca SA, 2005, J VIROL, V79, P7239, DOI 10.1128/JVI.79.11.7239-7247.2005; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Lamsoul I, 2005, MOL CELL BIOL, V25, P10391, DOI 10.1128/MCB.25.23.10391-10406.2005; Latz E, 2004, J ENDOTOXIN RES, V10, P406, DOI 10.1179/096805104225006525; Lee BS, 2002, J VIROL, V76, P12185, DOI 10.1128/JVI.76.23.12185-12199.2002; Lee H, 1999, J VIROL, V73, P3913, DOI 10.1128/JVI.73.5.3913-3919.1999; LeMosy EK, 1998, DEVELOPMENT, V125, P4045; LENARDO MJ, 1989, CELL, V57, P287, DOI 10.1016/0092-8674(89)90966-5; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Lenzmeier BA, 1999, J MOL BIOL, V291, P731, DOI 10.1006/jmbi.1999.2969; Lenzmeier BA, 1998, MOL CELL BIOL, V18, P721, DOI 10.1128/MCB.18.2.721; LI CCH, 1993, J VIROL, V67, P4205, DOI 10.1128/JVI.67.7.4205-4213.1993; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li SD, 2006, VIROLOGY, V349, P13, DOI 10.1016/j.virol.2006.01.005; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XD, 2005, P NATL ACAD SCI USA, V102, P17717, DOI 10.1073/pnas.0508531102; Lichty BD, 2004, HUM GENE THER, V15, P821, DOI 10.1089/1043034041839208; Lichty BD, 2004, TRENDS MOL MED, V10, P210, DOI 10.1016/j.molmed.2004.03.003; Lin RT, 2006, J VIROL, V80, P6072, DOI 10.1128/JVI.02495-05; Lin RT, 1999, MOL CELL BIOL, V19, P2465; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Lin RT, 2000, MOL CELL BIOL, V20, P6342, DOI 10.1128/MCB.20.17.6342-6353.2000; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lomvardas S, 2001, CELL, V106, P685, DOI 10.1016/S0092-8674(01)00490-1; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Luftig M, 2003, P NATL ACAD SCI USA, V100, P15595, DOI 10.1073/pnas.2136756100; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Lye E, 2004, J BIOL CHEM, V279, P40653, DOI 10.1074/jbc.M402666200; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mamane Y, 2005, J INTERF CYTOK RES, V25, P43, DOI 10.1089/jir.2005.25.43; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marriott SJ, 2005, ONCOGENE, V24, P5986, DOI 10.1038/sj.onc.1208976; Matsumoto M, 2003, J IMMUNOL, V171, P3154, DOI 10.4049/jimmunol.171.6.3154; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233, DOI 10.1073/pnas.2237236100; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Melen K, 2004, J MED VIROL, V73, P536, DOI 10.1002/jmv.20123; Merika M, 2001, CURR OPIN GENET DEV, V11, P205, DOI 10.1016/S0959-437X(00)00180-5; Merlo JJ, 2001, VIROLOGY, V279, P325, DOI 10.1006/viro.2000.0714; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012; Miller K, 2004, J INTERF CYTOK RES, V24, P391, DOI 10.1089/1079990041535647; Min JY, 2006, P NATL ACAD SCI USA, V103, P7100, DOI 10.1073/pnas.0602184103; Minakhina S, 2006, ONCOGENE, V25, P6749, DOI 10.1038/sj.onc.1209940; Mink M, 2001, GENOMICS, V74, P234, DOI 10.1006/geno.2001.6548; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; Mori N, 2002, INT J CANCER, V99, P378, DOI 10.1002/ijc.10388; MORI N, 1995, J RHEUMATOL, V22, P2049; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; Mosialos G, 2001, CYTOKINE GROWTH F R, V12, P259, DOI 10.1016/S1359-6101(00)00035-6; Munshi N, 1999, COLD SPRING HARB SYM, V64, P149, DOI 10.1101/sqb.1999.64.149; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nagai Y, 2004, CURR TOP MICROBIOL, V283, P197; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; Nicot C, 2000, BLOOD, V96, P275, DOI 10.1182/blood.V96.1.275.013k43_275_281; Nicot C, 2000, AIDS RES HUM RETROV, V16, P1629, DOI 10.1089/08892220050193065; Noah DL, 2005, ADV VIRUS RES, V65, P121, DOI 10.1016/S0065-3527(05)65004-X; Nomura F, 2000, GENES CELLS, V5, P191; Nourbakhsh M, 1997, IMMUNOBIOLOGY, V198, P65, DOI 10.1016/S0171-2985(97)80027-7; Nourbakhsh M, 1999, EMBO J, V18, P6415, DOI 10.1093/emboj/18.22.6415; Obenauer JC, 2006, SCIENCE, V311, P1576, DOI 10.1126/science.1121586; Ohno S, 2004, J GEN VIROL, V85, P2991, DOI 10.1099/vir.0.80308-0; Okamoto K, 2006, GENES CELLS, V11, P177, DOI 10.1111/j.1365-2443.2006.00927.x; Oshiumi H, 2003, J BIOL CHEM, V278, P49751, DOI 10.1074/jbc.M305820200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palese P, 2006, IMMUNITY, V24, P121, DOI 10.1016/j.immuni.2006.01.007; Palosaari H, 2003, J VIROL, V77, P7635, DOI 10.1128/JVI.77.13.7635-7644.2003; Parekh BS, 1999, MOL CELL, V3, P125, DOI 10.1016/S1097-2765(00)80181-1; Pati S, 2001, J VIROL, V75, P8660, DOI 10.1128/JVI.75.18.8660-8673.2001; PAZ S, 2006, IN PRESS CELL MOL BI, V52; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Peters RT, 2001, BBA-REV CANCER, V1471, pM57, DOI 10.1016/S0304-419X(00)00024-X; Pflugheber J, 2002, P NATL ACAD SCI USA, V99, P4650, DOI 10.1073/pnas.062055699; Pise-Masison CA, 2005, ARCH IMMUNOL THER EX, V53, P283; Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Qin BY, 2005, STRUCTURE, V13, P1269, DOI 10.1016/j.str.2005.06.011; Qin BY, 2003, NAT STRUCT BIOL, V10, P913, DOI 10.1038/nsb1002; Qu ZX, 2004, J BIOL CHEM, V279, P44563, DOI 10.1074/jbc.M403689200; Quinto I, 1999, J BIOL CHEM, V274, P17567, DOI 10.1074/jbc.274.25.17567; Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Rodriguez CI, 2002, J VIROL, V76, P3936, DOI 10.1128/JVI.76.8.3936-3942.2002; Roof P, 2002, VIROLOGY, V296, P77, DOI 10.1006/viro.2001.1397; Rosenberg S, 2001, J MOL BIOL, V313, P451, DOI 10.1006/jmbi.2001.5055; Rothe M, 1996, P NATL ACAD SCI USA, V93, P8241, DOI 10.1073/pnas.93.16.8241; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Sachdev S, 1998, MOL CELL BIOL, V18, P2524, DOI 10.1128/MCB.18.5.2524; Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato S, 2003, J IMMUNOL, V171, P4304, DOI 10.4049/jimmunol.171.8.4304; Schaefer TM, 2005, J IMMUNOL, V174, P992, DOI 10.4049/jimmunol.174.2.992; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schlender J, 2000, J VIROL, V74, P8234, DOI 10.1128/JVI.74.18.8234-8242.2000; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Senger K, 2000, MOL CELL, V6, P931, DOI 10.1016/S1097-2765(05)00081-X; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sgarbanti M, 2004, ONCOGENE, V23, P5770, DOI 10.1038/sj.onc.1207707; Shaffer JA, 2003, VIROLOGY, V315, P389, DOI 10.1016/S0042-6822(03)00537-3; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; SMITH MR, 1992, VIROLOGY, V187, P316, DOI 10.1016/0042-6822(92)90320-O; Song J, 1999, J GEN VIROL, V80, P879, DOI 10.1099/0022-1317-80-4-879; Sorokina EM, 2004, J BIOL CHEM, V279, P13469, DOI 10.1074/jbc.M305250200; Sousa CRE, 2004, SEMIN IMMUNOL, V16, P27, DOI 10.1016/j.smim.2003.10.004; Spann KM, 2004, J VIROL, V78, P4363, DOI 10.1128/JVI.78.8.4363-4369.2004; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stumper R, 2005, J VIROL, V79, P2689, DOI 10.1128/JVI.79.5.2689-2699.2005; Sun QM, 2006, IMMUNITY, V24, P633, DOI 10.1016/j.immuni.2006.04.004; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Sun SC, 2005, ONCOGENE, V24, P5952, DOI 10.1038/sj.onc.1208969; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200; Sylla BS, 1998, P NATL ACAD SCI USA, V95, P10106, DOI 10.1073/pnas.95.17.10106; Tait SWG, 2000, J BIOL CHEM, V275, P34656, DOI 10.1074/jbc.M000320200; Takahasi K, 2003, NAT STRUCT BIOL, V10, P922, DOI 10.1038/nsb1001; Tan SL, 2001, VIROLOGY, V284, P1, DOI 10.1006/viro.2001.0885; Taylor DR, 1999, SCIENCE, V285, P107, DOI 10.1126/science.285.5424.107; tenOever BR, 2006, IMMUNITY, V24, P510, DOI 10.1016/j.immuni.2006.05.006; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; THANOS D, 1995, MOL CELL BIOL, V15, P152, DOI 10.1128/MCB.15.1.152; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Thoetkiattikul H, 2005, P NATL ACAD SCI USA, V102, P11426, DOI 10.1073/pnas.0505240102; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Tissari J, 2005, J IMMUNOL, V174, P4289, DOI 10.4049/jimmunol.174.7.4289; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Tsujimura H, 2004, J IMMUNOL, V172, P6820, DOI 10.4049/jimmunol.172.11.6820; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Ulevitch RJ, 2000, IMMUNOL RES, V21, P49, DOI 10.1385/IR:21:2-3:49; Valarcher JF, 2003, J VIROL, V77, P8426, DOI 10.1128/JVI.77.15.8426-8439.2003; van Opijnen T, 2004, J VIROL, V78, P3675, DOI 10.1128/JVI.78.7.3675-3683.2004; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; VISVANATHAN KV, 1989, EMBO J, V8, P1129, DOI 10.1002/j.1460-2075.1989.tb03483.x; Wang S, 1996, CANCER RES, V56, P4610; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; Wasley A, 2000, SEMIN LIVER DIS, V20, P1, DOI 10.1055/s-2000-9506; Wieland SF, 2005, J VIROL, V79, P9369, DOI 10.1128/JVI.79.15.9369-9380.2005; Wu LM, 2006, J BIOL CHEM, V281, P2162, DOI 10.1074/jbc.M505903200; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2004, MOL IMMUNOL, V40, P861, DOI 10.1016/j.molimm.2003.10.006; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; YANEZ RJ, 1995, VIROLOGY, V208, P249, DOI 10.1006/viro.1995.1149; Yang K, 2006, MOL BIOL CELL, V17, P1461, DOI 10.1091/mbc.E05-09-0853; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yasui T, 2004, P NATL ACAD SCI USA, V101, P278, DOI 10.1073/pnas.2237224100; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Yie JM, 1997, MOL CELL BIOL, V17, P3649, DOI 10.1128/MCB.17.7.3649; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; YOSHIDA M, 1994, LEUKEMIA, V8, pS51; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	335	206	211	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6844	6867		10.1038/sj.onc.1209941	http://dx.doi.org/10.1038/sj.onc.1209941			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072332	Green Published, Bronze			2022-12-28	WOS:000241666700012
J	Hoffmann, A; Natoli, G; Ghosh, G				Hoffmann, A.; Natoli, G.; Ghosh, G.			Transcriptional regulation via the NF-kappa B signaling module	ONCOGENE			English	Review						NF-kappaB; IkappaB; transcription; signal transduction; combinatorial control; dynamic control	RAY CRYSTAL-STRUCTURE; NECROSIS-FACTOR-ALPHA; C-REL; GENE-EXPRESSION; DNA-BINDING; IKK-ALPHA; NUCLEAR RECEPTORS; RESPONSE ELEMENT; TEMPORAL CONTROL; DIMER INTERFACE	Stimulus-induced nuclear factor-kappa B (NF-kappa B) activity, the central mediator of inflammatory responses and immune function, comprises a family of dimeric transcription factors that regulate diverse gene expression programs consisting of hundreds of genes. A family of inhibitor of kappa B (I kappa B) proteins controls NF-kappa B DNA-binding activity and nuclear localization. I kappa B protein metabolism is intricately regulated through stimulus-induced degradation and feedback re-synthesis, which allows for dynamic control of NF-kappa B activity. This network of interactions has been termed the NF-kappa B signaling module. Here, we summarize the current understanding of the molecular structures and biochemical mechanisms that determine NF-kappa B dimer formation and the signal-processing characteristics of the signaling module. We identify NF-kappa B-kappa B site interaction specificities and dynamic control of NF-kappa B activityas mechanisms that generate specificity in transcriptional regulation. We discuss examples of gene regulation that illustrate how these mechanisms may interface with other transcription regulators and promoter-associated events, and how these mechanisms suggest regulatory principles for NF-kappa B-mediated gene activation.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92037 USA; Univ Calif San Diego, Signaling Syst Lab, La Jolla, CA 92093 USA; European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of California System; University of California San Diego; University of California System; University of California San Diego; IRCCS European Institute of Oncology (IEO)	Hoffmann, A (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92037 USA.	ahoffmann@ucsd.edu; gghosh@ucsd.edu	Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018	Natoli, Gioacchino/0000-0003-0711-2411	NCI NIH HHS [CA71718] Funding Source: Medline; NIGMS NIH HHS [GM071573, GM071862, GM72024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM072024, P01GM071862, R01GM071573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barken D, 2005, SCIENCE, V308, DOI 10.1126/science.1107904; BARKEN D, 2006, IN PRESS; BASAK S, 2006, IN PRESS CELL; Berkowitz B, 2002, J BIOL CHEM, V277, P24694, DOI 10.1074/jbc.M200006200; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Bosisio D, 2006, EMBO J, V25, P798, DOI 10.1038/sj.emboj.7600977; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chen YQ, 2000, STRUCT FOLD DES, V8, P419, DOI 10.1016/S0969-2126(00)00123-4; Chen-Park FE, 2002, J BIOL CHEM, V277, P24701, DOI 10.1074/jbc.M200007200; Cheong R, 2006, J BIOL CHEM, V281, P2945, DOI 10.1074/jbc.M510085200; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Cramer P, 1997, EMBO J, V16, P7078, DOI 10.1093/emboj/16.23.7078; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; Doyle SE, 2002, IMMUNITY, V17, P251, DOI 10.1016/S1074-7613(02)00390-4; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Gaudet S, 2005, MOL CELL PROTEOMICS, V4, P1569, DOI 10.1074/mcp.M500158-MCP200; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Hart DJ, 2001, J MOL BIOL, V310, P563, DOI 10.1006/jmbi.2001.4724; Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Huang DB, 2005, STRUCTURE, V13, P1365, DOI 10.1016/j.str.2005.06.018; Huang DB, 2005, J MOL BIOL, V346, P147, DOI 10.1016/j.jmb.2004.11.042; Huang DB, 2001, STRUCTURE, V9, P669, DOI 10.1016/S0969-2126(01)00635-9; Huxford T, 1999, COLD SPRING HARB SYM, V64, P533, DOI 10.1101/sqb.1999.64.533; Jacque E, 2005, P NATL ACAD SCI USA, V102, P14635, DOI 10.1073/pnas.0507342102; Janes KA, 2006, CELL, V124, P1225, DOI 10.1016/j.cell.2006.01.041; Kearns JD, 2006, J CELL BIOL, V173, P659, DOI 10.1083/jcb.200510155; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; KUNSCH C, 1992, MOL CELL BIOL, V12, P4412, DOI 10.1128/MCB.12.10.4412; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Linnell J, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh042; Malek S, 2003, J BIOL CHEM, V278, P23094, DOI 10.1074/jbc.M301022200; Maniatis T, 1998, COLD SPRING HARB SYM, V63, P609, DOI 10.1101/sqb.1998.63.609; Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Munshi N, 2001, SCIENCE, V293, P1133, DOI 10.1126/science.293.5532.1133; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Phelps CB, 2000, J BIOL CHEM, V275, P29840, DOI 10.1074/jbc.M004899200; Phelps CB, 2000, J BIOL CHEM, V275, P24392, DOI 10.1074/jbc.M003784200; Phelps CB, 2004, ONCOGENE, V23, P1229, DOI 10.1038/sj.onc.1207242; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Saccani S, 2003, MOL CELL, V11, P1563, DOI 10.1016/S1097-2765(03)00227-2; Saccani S, 2001, J EXP MED, V193, P1351, DOI 10.1084/jem.193.12.1351; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Sanjabi S, 2005, GENE DEV, V19, P2138, DOI 10.1101/gad.1329805; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schreiber J, 2006, P NATL ACAD SCI USA, V103, P5899, DOI 10.1073/pnas.0510996103; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; Senger K, 2004, MOL CELL, V13, P19, DOI 10.1016/S1097-2765(03)00500-8; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Tisne C, 1999, J MOL BIOL, V293, P139, DOI 10.1006/jmbi.1999.3157; Tisne C, 1998, J MOL BIOL, V279, P127, DOI 10.1006/jmbi.1998.1757; Udalova IA, 2002, P NATL ACAD SCI USA, V99, P8167, DOI 10.1073/pnas.102674699; VERWEIJ CL, 1991, J BIOL CHEM, V266, P14179; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wietek C, 2003, J BIOL CHEM, V278, P50923, DOI 10.1074/jbc.M308135200; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738	84	476	502	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6706	6716		10.1038/sj.onc.1209933	http://dx.doi.org/10.1038/sj.onc.1209933			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072323				2022-12-28	WOS:000241666700003
J	Acquaviva, A; Ciccolallo, L; Rondelli, R; Balistreri, A; Ancarola, R; Cozza, R; Hadjistilianou, D; De Francesco, S; Toti, P; Pastore, G; Haupt, R; Carli, M; Santoro, N; Di Cataldo, A; Fiorillo, A; Indolfi, P; Nucci, P; Sandri, A; Porta, F; Porcaro, AB; Tamaro, P; Morgese, G				Acquaviva, A.; Ciccolallo, L.; Rondelli, R.; Balistreri, A.; Ancarola, R.; Cozza, R.; Hadjistilianou, D.; De Francesco, S.; Toti, P.; Pastore, G.; Haupt, R.; Carli, M.; Santoro, N.; Di Cataldo, A.; Fiorillo, A.; Indolfi, P.; Nucci, P.; Sandri, A.; Porta, F.; Porcaro, A. B.; Tamaro, P.; Morgese, G.			Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry	ONCOGENE			English	Review						retinoblastoma; second primary neoplasm; chemotherapy; radiotherapy; mortality	NONOCULAR TUMORS; HEREDITARY; NEOPLASMS; MUTATIONS; SPECTRUM; CANCERS; GENE	Survivors of retinoblastoma (Rb) are at high risk of dying from second malignant tumour. The occurrence of second malignant neoplasm ( SMN) and related mortality in a cohort of 1111 cases from the Italian Retinoblastoma Registry was analysed, considering the possible role of both genetic and iatrogenic causes. Rb patients had a greater than 10-fold excess in overall mortality compared with the general population ( standardized mortality ratio ( SMR) 10.73, 95% CI 9.00-12.80). Their excess risk attributable to cancers other than Rb was 14.93 95% CI 10.38 - 21.49). Survivors of hereditary Rb had an SMR for all causes of 16.25 ( 95% CI 13.20 - 20.00), whereas their SMR for all cancers was 25.72 ( 95% CI 17.38 - 38.07). Survivors of unilateral sporadic Rb had an SMR of 4.12 from all cancers ( 95% CI 1.55 - 10.98) and a much higher excess for overall mortality ( SMR 13.34, 95% CI 10.74-16.56). As expected, survivors of hereditary Rb had higher mortality from cancers of the bone ( SMR 391.90, 95% CI 203.90 - 753.20) and soft tissue ( SMR 453.00, 95% CI 203.50 - 1008.40), small intestine ( SMR 1375.50, 95% CI 344.00 - 5499.70), nasal cavity ( SMR 13.71, 95% CI 1.93 - 97.35) and cancers of the brain and central nervous system ( SMR 41.14, 95% CI 13.2 - 127.55)	Univ Siena, Dept Pediat Obstet & Reprod Med, Italian Retinoblastoma Registry, I-53100 Siena, Italy; Ist Nazl Studio & Cura Tumori, Dept Prevent & Predict Med, Epidemiol Unit, I-20133 Milan, Italy; Univ Bologna, Dept Pediat, Bologna, Italy; Univ Siena, Dept Surg & Bioengn, I-53100 Siena, Italy; Bambino Gesu Pediat Hosp, Dept Pediat Oncol, Rome, Italy; Univ Siena, Dept Ophthalmol Sci, I-53100 Siena, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Univ Turin, Canc Epidemiol Unit, Childhood Canc Registry Piedmont, Turin, Italy; Ist Giannina Gaslini, Dept Hematol Oncol, I-16148 Genoa, Italy; Univ Hosp Padova, Dept Pediat, Div Hematol Oncol, Padua, Italy; Univ Bari, Dept Biomed Childhood, Bari, Italy; Univ Catania, Ctr Paediat Haematol & Oncol, Catania, Italy; Univ Naples Federico II, Dept Pediat, Naples, Italy; Univ Naples 2, Pediat Oncol Serv, Naples, Italy; Univ Milan, San Paola Hosp, Pediat Ophthalmol & Strabismus Unit, Milan, Italy; Univ Turin, Dept Pediat Oncol, Turin, Italy; Univ Brescia, Dept Pediat, Brescia, Italy; Civil Major Hosp, Dept Urol, Verona, Italy; Univ Trieste, Osped Infantile Burlo Garofolo, Dept Pediat, Trieste, Italy	University of Siena; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Bologna; University of Siena; IRCCS Bambino Gesu; University of Siena; University of Siena; University of Turin; University of Genoa; IRCCS Istituto Giannina Gaslini; University of Padua; Azienda Ospedaliera - Universita di Padova; Universita degli Studi di Bari Aldo Moro; University of Catania; University of Naples Federico II; Universita della Campania Vanvitelli; University of Milan; University of Turin; University of Brescia; IRCCS Burlo Garofolo; University of Trieste	Acquaviva, A (corresponding author), Univ Siena, Dept Pediat Obstet & Reprod Med, Italian Retinoblastoma Registry, Viale Bracci 16, I-53100 Siena, Italy.	acquaviva@unisi.it	Toti, Paolo/E-6358-2012; nucci, paolo/J-9523-2016; Haupt, Riccardo/AAA-7437-2020; Ciccolallo, Laura/F-5653-2014; Di Cataldo, Andrea/M-2509-2016; Balistreri, Alberto/P-1173-2018; Porcaro, Antonio/M-2383-2017	Toti, Paolo/0000-0002-1214-5886; nucci, paolo/0000-0002-4036-703X; Haupt, Riccardo/0000-0003-0571-8460; Di Cataldo, Andrea/0000-0002-4509-3066; Balistreri, Alberto/0000-0002-7349-9725; Ciccolallo, Laura/0000-0002-8415-7106; Porcaro, Antonio/0000-0002-7890-040X; Cozza, Raffaele/0000-0002-8502-3310; Hadjistilianou, Theodora/0000-0002-9267-2255				ABRAMSON DH, 1984, OPHTHALMOLOGY, V91, P1351; Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; ABRAMSON DH, 1979, AM J OPHTHALMOL, V87, P624, DOI 10.1016/0002-9394(79)90293-9; ACQUAVIVA A, 1985, Bollettino di Oculistica, V64, P141; Aerts I, 2004, EUR J CANCER, V40, P1522, DOI 10.1016/j.ejca.2004.03.023; BLANQUET V, 1995, HUM MOL GENET, V4, P383, DOI 10.1093/hmg/4.3.383; CHAUVEINC L, 2001, OPHTHALMOL GENET, V2, P77; DERKINDEREN DJ, 1987, OPHTHALMIC PAED GEN, V8, P23, DOI 10.3109/13816818709028511; DRAPER GJ, 1986, BRIT J CANCER, V53, P661, DOI 10.1038/bjc.1986.110; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kaye FJ, 2004, J NATL CANCER I, V96, P342, DOI 10.1093/jnci/djh080; Lohmann DR, 1996, AM J HUM GENET, V58, P940; LUEDER GT, 1986, ARCH OPHTHALMOL-CHIC, V104, P372; Matsumoto H, 2003, PEDIATR INT, V45, P728, DOI 10.1046/j.1442-200x.2003.01821.x; Moll AC, 1996, HUM GENET, V98, P109, DOI 10.1007/s004390050168; ROARTY JD, 1988, OPHTHALMOLOGY, V95, P1583; SAGERMAN RH, 1969, AMER J ROENTGENOL RA, V105, P529, DOI 10.2214/ajr.105.3.529; Stata Corporation, 2006, STAT STAT SOFTW REL; Wong FL, 1997, JAMA-J AM MED ASSOC, V278, P1262, DOI 10.1001/jama.278.15.1262	22	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5350	5357		10.1038/sj.onc.1209786	http://dx.doi.org/10.1038/sj.onc.1209786			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936757				2022-12-28	WOS:000240064100022
J	Moll, UM; Marchenko, N; Zhang, XK				Moll, U. M.; Marchenko, N.; Zhang, X-k			p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction	ONCOGENE			English	Review						p53; Nur77/ TR3; mitochondria	ORPHAN NUCLEAR RECEPTOR; RETINOID-X-RECEPTOR; OVARIAN-CARCINOMA CELLS; LUNG-CANCER; STEROID-RECEPTOR; NGFI-B; INDUCED APOPTOSIS; PROSTATE-CANCER; GENE-EXPRESSION; FATTY-ACIDS	The complex apoptotic functions of the p53 tumor suppressor are central to its antineoplastic activity in vivo. Conversely, p53 function is altered or attenuated in one way or another in the majority of human cancers. Besides its well-understood action as a transcriptional regulator of multiple apoptotic genes, p53 also exerts a direct pro-apoptotic role at the mitochondria by engaging in protein-protein interactions with anti- and pro-apoptotic Bcl2 family members, thereby executing the shortest known circuitry of p53 death signaling. Nur77, also known as TR3 or NGFI-B, is a unique transcription factor belonging to the orphan nuclear receptor superfamily. Even more extreme than p53, Nur77 can exert opposing biological activities of survival and death. Its activities are regulated by subcellular distribution, expression levels, protein modi. cation and heterodimerization with retinoid X receptor. In cancer cells, Nur77 functions in the nucleus as an oncogenic survival factor, but becomes a potent killer when certain death stimuli induce its migration to mitochondria, where it binds to Bcl2 and conformationally converts it to a killer that triggers cytochrome c release and apoptosis. This review focuses on their unexpected transcription-independent pro-death programs at mitochondria and highlights the remarkable mechanistic similarities between them. Moreover, an accumulating body of evidence provides ample rationale to further investigate how these mitochondrial p53 and Nur77 pathways could become exploitable targets for new cancer therapeutics.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; Burnham Inst Med Res, Ctr Canc, La Jolla, CA USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanford Burnham Prebys Medical Discovery Institute	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu						Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819; Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Baker KD, 2003, CELL, V113, P731, DOI 10.1016/S0092-8674(03)00420-3; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200; Bonafe M, 2004, CELL DEATH DIFFER, V11, P962, DOI 10.1038/sj.cdd.4401415; Bonini P, 2004, J NEUROSCI RES, V75, P83, DOI 10.1002/jnr.10822; Bras A, 2000, CELL DEATH DIFFER, V7, P262, DOI 10.1038/sj.cdd.4400653; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cao XH, 2004, MOL CELL BIOL, V24, P9705, DOI 10.1128/MCB.24.22.9705-9725.2004; Castro-Obregon S, 2004, J BIOL CHEM, V279, P17543, DOI 10.1074/jbc.M312363200; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; CHANG C, 1989, J STEROID BIOCHEM, V34, P391; Chen GQ, 2002, INT J CANCER, V99, P171, DOI 10.1002/ijc.10304; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; Chinnaiyan P, 2006, INT J CANCER, V118, P1041, DOI 10.1002/ijc.21465; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Culmsee C, 2005, BIOCHEM BIOPH RES CO, V331, P761, DOI 10.1016/j.bbrc.2005.03.149; Dagher PC, 2004, KIDNEY INT, V66, P506, DOI 10.1111/j.1523-1755.2004.761_7.x; Daidone MG, 1999, ENDOCR-RELAT CANCER, V6, P61, DOI 10.1677/erc.0.0060061; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Dawson MI, 2001, CANCER RES, V61, P4723; de Souza-Pinto NC, 2004, ONCOGENE, V23, P6559, DOI 10.1038/sj.onc.1207874; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; FAHRNER TJ, 1990, MOL CELL BIOL, V10, P6454, DOI 10.1128/MCB.10.12.6454; Fan YY, 2003, CARCINOGENESIS, V24, P1541, DOI 10.1093/carcin/bgg110; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Fontana JA, 2002, LEUKEMIA, V16, P463, DOI 10.1038/sj.leu.2402414; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; GASPARINI G, 1995, CLIN CANCER RES, V1, P189; Gennari A, 2002, TOXICOL APPL PHARM, V181, P27, DOI 10.1006/taap.2002.9357; Gilman CP, 2003, NEUROMOL MED, V3, P159, DOI 10.1385/NMM:3:3:159; Goldstein JT, 2003, ARCH BIOCHEM BIOPHYS, V420, P185, DOI 10.1016/j.abb.2003.09.034; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; Grandgirard D, 1998, EMBO J, V17, P1268, DOI 10.1093/emboj/17.5.1268; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HAN YH, 2006, ONCOGENE; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Igaki T, 2000, P NATL ACAD SCI USA, V97, P662, DOI 10.1073/pnas.97.2.662; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jacobs CM, 2005, BIOCHEM BIOPH RES CO, V336, P646, DOI 10.1016/j.bbrc.2005.08.143; Jeong JH, 2003, ANN NY ACAD SCI, V1010, P171, DOI 10.1196/annals.1299.029; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Katagiri Y, 2000, NAT CELL BIOL, V2, P435, DOI 10.1038/35017072; Kaufmann T, 2003, J CELL BIOL, V160, P53, DOI 10.1083/jcb.200210084; Kaul SC, 2005, J BIOL CHEM, V280, P39373, DOI 10.1074/jbc.M500022200; Ke N, 2004, CANCER RES, V64, P8208, DOI 10.1158/0008-5472.CAN-04-2134; Kelly KJ, 2003, J AM SOC NEPHROL, V14, P128, DOI 10.1097/01.ASN.0000040596.23073.01; Kochel I, 2005, BIOCHEM BIOPH RES CO, V334, P1102, DOI 10.1016/j.bbrc.2005.07.004; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; LABELLE Y, 1995, HUM MOL GENET, V4, P2219, DOI 10.1093/hmg/4.12.2219; Labelle Y, 1999, ONCOGENE, V18, P3303, DOI 10.1038/sj.onc.1202675; Le W, 1999, J NEUROCHEM, V73, P2218; Lee JM, 2004, J VIROL, V78, P12694, DOI 10.1128/JVI.78.22.12694-12697.2004; Lee JM, 2002, P NATL ACAD SCI USA, V99, P11878, DOI 10.1073/pnas.182552499; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Lengqvist J, 2004, MOL CELL PROTEOMICS, V3, P692, DOI 10.1074/mcp.M400003-MCP200; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; LIM RW, 1987, ONCOGENE, V1, P263; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Lin XF, 2004, J CELL SCI, V117, P5609, DOI 10.1242/jcs.01474; Liu D, 2003, ARTERIOSCL THROM VAS, V23, P2002, DOI 10.1161/01.ATV.0000098644.03153.6F; Liu S, 2002, WORLD J GASTROENTERO, V8, P446, DOI 10.3748/wjg.v8.i3.446; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Lotan R, 2003, J BIOL REG HOMEOS AG, V17, P13; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Martin B, 2003, BRIT J CANCER, V89, P55, DOI 10.1038/sj.bjc.6601095; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Meinke G, 1999, NAT STRUCT BIOL, V6, P471; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MOLL U, 2000, NEW P53 BASED STRATE; Mu XM, 2003, J BIOL CHEM, V278, P42840, DOI 10.1074/jbc.M305594200; Nemajerova A, 2005, FEBS LETT, V579, P6079, DOI 10.1016/j.febslet.2005.09.074; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Park KC, 2005, MOL ENDOCRINOL, V19, P12, DOI 10.1210/me.2004-0107; Pei LM, 2006, MOL ENDOCRINOL, V20, P786, DOI 10.1210/me.2005-0331; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Peng ZH, 2005, HUM GENE THER, V16, P1016, DOI 10.1089/hum.2005.16.1016; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; PETROS AM, 2004, FEBS LETT, P1; Pfahl M, 2003, ONCOGENE, V22, P9058, DOI 10.1038/sj.onc.1207109; Phillips A, 1997, MOL CELL BIOL, V17, P5946, DOI 10.1128/MCB.17.10.5946; Rajpal A, 2003, EMBO J, V22, P6526, DOI 10.1093/emboj/cdg620; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Shin HJ, 2004, CARCINOGENESIS, V25, P1467, DOI 10.1093/carcin/bgh135; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; SPEIDEL D, 2005, ONCOGENE; Srivastava RK, 1999, P NATL ACAD SCI USA, V96, P3775, DOI 10.1073/pnas.96.7.3775; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; Suzuki S, 2003, P NATL ACAD SCI USA, V100, P8276, DOI 10.1073/pnas.0932598100; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Uemura H, 1998, ENDOCRINOLOGY, V139, P2329, DOI 10.1210/en.139.5.2329; Uhlmann EJ, 1998, J BIOL CHEM, V273, P17926, DOI 10.1074/jbc.273.28.17926; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2002, J BIOL CHEM, V277, P33001, DOI 10.1074/jbc.M203572200; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Weih F, 1996, P NATL ACAD SCI USA, V93, P5533, DOI 10.1073/pnas.93.11.5533; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Wilson AJ, 2003, CANCER RES, V63, P5401; WINGATE AD, 2005, BIOCH J; WORONICZ JD, 1995, MOL CELL BIOL, V15, P6364; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Wu Q, 2002, CARCINOGENESIS, V23, P1583, DOI 10.1093/carcin/23.10.1583; Wu Q, 1997, EMBO J, V16, P1656, DOI 10.1093/emboj/16.7.1656; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG YL, 1995, P NATL ACAD SCI USA, V92, P3051, DOI 10.1073/pnas.92.7.3051; YANG YL, 1993, P NATL ACAD SCI USA, V90, P6170, DOI 10.1073/pnas.90.13.6170; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoshida Y, 2003, CANCER RES, V63, P3729; Zeimet AG, 2003, LANCET ONCOL, V4, P415, DOI 10.1016/S1470-2045(03)01139-2; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang XK, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090087; Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	164	202	209	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4725	4743		10.1038/sj.onc.1209601	http://dx.doi.org/10.1038/sj.onc.1209601			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892086				2022-12-28	WOS:000239687000010
J	Christensen, KL; Brennan, JDG; Aldridge, CS; Ford, HL				Christensen, K. L.; Brennan, J. D. G.; Aldridge, C. S.; Ford, H. L.			Cell cycle regulation of the human Six1 homeoprotein is mediated by APC(Cdh1)	ONCOGENE			English	Article						Six1; anaphase-promoting complex; Cdh1; proteasome; homeoprotein; cell cycle	ANAPHASE-PROMOTING COMPLEX; DESTRUCTION BOX; DNA-DAMAGE; AURORA-A; PROTEIN; DEGRADATION; RECOGNITION; EXPRESSION; MECHANISM; SYSTEM	The Six1 homeoprotein is an important mediator of normal development, where it is critical for the proliferation of precursor cell populations that ultimately constitute the muscle, kidney and inner ear, among other organs. Interestingly, its overexpression has been observed in numerous cancers, where it contributes to the proliferative and metastatic ability of the cancer cells. Here we show that Six1 not only regulates the cell cycle, but is itself regulated throughout the cell cycle via ubiquitin-mediated proteolysis. The protein is present from the G(1)/S boundary until mitosis, when it is degraded via the anaphase-promoting complex (APC) with its activating subunit Cdh1. However, unlike most identified APC(Cdh1) targets, Six1 does not contain functional destruction or KEN box motifs that are necessary for its degradation. Instead, the Six1 protein contains multiple, as yet undefined, sequences within its N- and C-termini responsible for its degradation, including an N-terminal region that binds to Cdh1. Cell cycle regulation of Six1 occurs both transcriptionally and post-translationally via phosphorylation; therefore, this study demonstrates a third and novel mechanism of cell cycle-specific regulation of Six1, underscoring the importance of confining its activity to a defined cell cycle window from the G(1)/S boundary to early mitosis.	Univ Colorado, Dept Obstet & Gynecol, Aurora, CO 80045 USA; Hlth Sci Ctr, Aurora, CO USA; Univ Colorado, Program Mol Biol, Denver, CO 80202 USA; Univ Colorado, Dept Biochem & Mol Genet, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Denver; University of Colorado System; University of Colorado Boulder	Ford, HL (corresponding author), Univ Colorado, Dept Obstet & Gynecol, Mailstop 8309,12800 E 19th Ave,POB 6511, Aurora, CO 80045 USA.	heide.ford@uchsc.edu			NCI NIH HHS [R01 CA095277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 2000, CELL, V102, P55, DOI 10.1016/S0092-8674(00)00010-6; Araki M, 2005, GENE DEV, V19, P2458, DOI 10.1101/gad.1361905; Brodbeck S, 2004, MECH DEVELOP, V121, P1211, DOI 10.1016/j.mod.2004.05.019; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burton JL, 2005, MOL CELL, V18, P533, DOI 10.1016/j.molcel.2005.04.022; Castro A, 2005, ONCOGENE, V24, P314, DOI 10.1038/sj.onc.1207973; Castro A, 2003, MOL CELL BIOL, V23, P4126, DOI 10.1128/MCB.23.12.4126-4138.2003; Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Eytan E, 2006, P NATL ACAD SCI USA, V103, P2081, DOI 10.1073/pnas.0510695103; Fang CH, 1998, INT J MOL MED, V1, P163; Ford HL, 1998, P NATL ACAD SCI USA, V95, P12608, DOI 10.1073/pnas.95.21.12608; FORD HL, 1995, ONCOGENE, V10, P1597; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; JAMIESON C, 1991, J IMMUNOL, V147, P416; Kawakami K, 2000, BIOESSAYS, V22, P616, DOI 10.1002/1521-1878(200007)22:7<616::AID-BIES4>3.3.CO;2-I; Kenyon KL, 2005, DEV BIOL, V286, P158, DOI 10.1016/j.ydbio.2005.07.017; Kraft C, 2005, MOL CELL, V18, P543, DOI 10.1016/j.molcel.2005.04.023; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Littlepage LE, 2002, GENE DEV, V16, P2274, DOI 10.1101/gad.1007302; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Ozaki H, 2004, DEVELOPMENT, V131, P551, DOI 10.1242/dev.00943; Park KH, 2005, BREAST CANCER RES, V7, pR238, DOI 10.1186/bcr978; Passmore LA, 2005, EMBO REP, V6, P873, DOI 10.1038/sj.embor.7400482; Peters JM, 2002, MOL CELL, V9, P931, DOI 10.1016/S1097-2765(02)00540-3; Reichenberger KJ, 2005, CANCER RES, V65, P2668, DOI 10.1158/0008-5472.CAN-04-4286; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Yamano H, 2004, MOL CELL, V13, P137, DOI 10.1016/S1097-2765(03)00480-5; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360; Zheng WM, 2003, DEVELOPMENT, V130, P3989, DOI 10.1242/dev.00628	36	29	32	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3406	3414		10.1038/sj.onc.1210122	http://dx.doi.org/10.1038/sj.onc.1210122			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130831				2022-12-28	WOS:000246579600010
J	Lemee, F; Bavoux, C; Pillaire, MJ; Bieth, A; Machado, CR; Pena, SD; Guimbaud, R; Selves, J; Hoffmann, JS; Cazaux, C				Lemee, F.; Bavoux, C.; Pillaire, M. J.; Bieth, A.; Machado, C. R.; Pena, S. D.; Guimbaud, R.; Selves, J.; Hoffmann, J. S.; Cazaux, C.			Characterization of promoter regulatory elements involved in downexpression of the DNA polymerase kappa in colorectal cancer	ONCOGENE			English	Article						DNA polymerase kappa; promoter; colorectal cancer; SP1; CRE; genetic instability	TRANSCRIPTION FACTOR; PROXIMAL PROMOTER; EXPRESSION; GENE; REPAIR; DAMAGE; CELLS; BETA; TUMORIGENESIS; LOCALIZATION	The low-fidelity DNA polymerases thought to be specialized in DNA damage processing are frequently misregulated in cancers. We show here that DNA polymerase kappa (pol kappa), prone to replicate across oxidative and aromatic adducts and known to function in nucleotide excision repair (NER), is downregulated in colorectal tumour biopsies. Contrary to the replicative pol delta and pol alpha, for which only activating domains were described, we identified an upstream 465-bp-long repressor region in the promoter of POLK. We also found an activating 237-bp region that includes stimulating protein-1 (SP1) and cyclic AMP-responsive element (CRE)-binding sites. Mutations at one CRE-binding site led to a dramatic 80% decrease in promoter activity. Alterations of the SP1-binding site also affected, to a lesser extent, the transcription. Gel shift assays confirmed the role played by CRE/SP1 recognition sequences. Moreover, ectopic expression of SP1 or CRE-binding protein (CREB) protein favoured Pol kappa transcription. Finally, we found that Pol kappa down-expression in colorectal biopsies correlated with a decreased level of CREB and SP1 transcripts. This work shows that the promoter of POLK is cis-controlled and suggests that silencing of CREB and SP1 proteins could contribute to downregulation of this repair polymerase in colorectal tumours.	Univ Toulouse 3, UMR 5089, CNRS, Inst Pharmacol & Struct Biol,Lab Genet Instabil &, F-31077 Toulouse, France; Univ Fed Minas Gerais, Dept biochem & Immunol, Belo Horizonte, MG, Brazil; Univ Toulouse 3, INSERM, U563, Ctr Physiopathol Toulouse Purpan,Federat Digest C, F-31062 Toulouse, France; Univ Toulouse 3, Dept Anat Pathol, F-31062 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universidade Federal de Minas Gerais; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Cazaux, C (corresponding author), Univ Toulouse 3, UMR 5089, CNRS, Inst Pharmacol & Struct Biol,Lab Genet Instabil &, 205 Route Narbonne, F-31077 Toulouse, France.	cazaux@ipbs.fr	MACHADO, CARLOS/AAW-1492-2020; Pillaire, Marie-Jeanne/P-1579-2014; Machado, Carlos Renato/H-1043-2015; Hoffmann, Jean-Sebastien/O-9183-2014; GUIMBAUD, Rosine/M-7503-2014	Pillaire, Marie-Jeanne/0000-0001-6866-7416; Machado, Carlos Renato/0000-0002-8724-3165; Hoffmann, Jean-Sebastien/0000-0003-2222-354X; 				Albertella MR, 2005, DNA REPAIR, V4, P583, DOI 10.1016/j.dnarep.2005.01.005; Anacleto C, 2005, NEOPLASIA, V7, P331, DOI 10.1593/neo.04502; Arita M, 2003, GENE, V306, P57, DOI 10.1016/S0378-1119(03)00385-8; Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bavoux C, 2005, BIOCHIMIE, V87, P637, DOI 10.1016/j.biochi.2005.02.007; Bavoux C, 2005, CANCER RES, V65, P325; Bergoglio V, 2003, J MOL BIOL, V331, P1017, DOI 10.1016/S0022-2836(03)00837-4; Bergoglio V, 2002, J CELL SCI, V115, P4413, DOI 10.1242/jcs.00162; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; Capp JP, 2006, NUCLEIC ACIDS RES, V34, P2998, DOI 10.1093/nar/gkl380; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Duriseti S, 2006, NEOPLASIA, V8, P250, DOI 10.1593/neo.05766; Feng YM, 2004, GENE, V330, P75, DOI 10.1016/j.gene.2004.01.006; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; KEDAR PS, 1991, P NATL ACAD SCI USA, V88, P3729, DOI 10.1073/pnas.88.9.3729; LEHMANN A, 2003, CURR BIOL, V5, P13; McElhinny SAN, 2005, MOL CELL, V19, P357, DOI 10.1016/j.molcel.2005.06.012; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Ogi T, 2005, J CELL SCI, V118, P129, DOI 10.1242/jcs.01603; Ogi T, 2006, NAT CELL BIOL, V8, P640, DOI 10.1038/ncb1417; RAY R, 1989, J CLIN INVEST, V83, P2003, DOI 10.1172/JCI114110; Servant L, 2002, J MOL BIOL, V315, P1039, DOI 10.1006/jmbi.2001.5307; Shin T, 2005, ARCH BIOCHEM BIOPHYS, V435, P291, DOI 10.1016/j.abb.2005.01.002; SINGHAL R, 2006, J BIOL CHEM, V270, P949; Velasco-Miguel S, 2003, DNA REPAIR, V2, P91, DOI 10.1016/S1568-7864(02)00189-1	31	33	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3387	3394		10.1038/sj.onc.1210116	http://dx.doi.org/10.1038/sj.onc.1210116			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17099721				2022-12-28	WOS:000246579600008
J	Shinmura, K; Bennett, RA; Tarapore, P; Fukasawa, K				Shinmura, K.; Bennett, R. A.; Tarapore, P.; Fukasawa, K.			Direct evidence for the role of centrosomally localized p53 in the regulation of centrosome duplication	ONCOGENE			English	Article						p53; centrosome; centrosome duplication	CYCLIN-E OVEREXPRESSION; NUCLEAR EXPORT SIGNAL; CHROMOSOME INSTABILITY; AMPLIFICATION; CELLS; P21; SUPPRESSION; INHIBITOR; INDUCTION; MUTANTS	Abnormal amplification of centrosomes is the major cause of mitotic defects and chromosome instability in cancer cells. Centrosomes duplicate once in each cell cycle, and abrogation of the regulatory mechanism underlying centrosome duplication leads to centrosome amplification. p53 tumor suppressor protein is involved in the regulation of centrosome duplication: loss of p53 as well as expression of certain p53 mutants result in deregulated centrosome duplication and centrosome amplification. p53 at least in part depends on its transactivation function to control centrosome duplication, primarily via upregulation of p21 cyclin-dependent kinase (CDK) inhibitor, which prevents untimely activation of CDK2/cyclin E, a key initiator of centrosome duplication. However, numerous studies have shown the presence of p53 at centrosomes, yet the role of the centrosomally localized p53 in the regulation of centrosome duplication had been enigmatic. Here, we comparatively examined wild-type p53 and p53 mutants that are transactivation(+)/centrosome-binding(-), transactivation(-)/centrosome-binding(+) and transactivation(-)/centrosome-binding(+) for their abilities to control centrosome duplication. We found that the transactivation(+)/centrosome-binding(-) and transactivation(-)/centrosome-binding(+) mutants suppress centrosome duplication only partially compared with wild-type p53. Moreover, the transactivation(-)/centrosome-binding(-) mutant almost completely lost the ability to suppress centrosome duplication. These observations provide direct evidence for the centrosomally localized p53 to participate in the regulation of centrosome duplication in a manner independent of its transactivation function in addition to its transactivation-dependent regulation of centrosome duplication.	Univ Cincinnati, Coll Med, Dept Cell Biol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Fukasawa, K (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol, POB 670521, Cincinnati, OH 45267 USA.	Kenji.Fukasawa@uc.edu	Shinmura, Kazuya/K-8940-2012; Tarapore, Pheruza/A-8876-2013	Shinmura, Kazuya/0000-0003-4963-746X; Tarapore, Pheruza/0000-0003-0911-3661	NATIONAL CANCER INSTITUTE [R01CA095925, R01CA090522] Funding Source: NIH RePORTER; NCI NIH HHS [CA95925, CA90522] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bennett RA, 2004, ONCOGENE, V23, P6823, DOI 10.1038/sj.onc.1207561; BROWN CR, 1994, J CELL PHYSIOL, V160, P47, DOI 10.1002/jcp.1041600107; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; Hinchcliffe EH, 2002, ONCOGENE, V21, P6154, DOI 10.1038/sj.onc.1205826; JOSHI HC, 1994, CURR OPIN CELL BIOL, V6, P55, DOI 10.1016/0955-0674(94)90116-3; Kaul SC, 2001, NEOPLASIA, V3, P110, DOI 10.1038/sj.neo.7900139; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Ma Z, 2006, ONCOGENE, V25, P5377, DOI 10.1038/sj.onc.1209543; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAZIA D, 1987, INT REV CYTOL, V100, P49; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Shinmura K, 2005, FEBS LETT, V579, P6621, DOI 10.1016/j.febslet.2005.10.057; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tarapore P, 2001, ONCOGENE, V20, P3173, DOI 10.1038/sj.onc.1204424; Tarapore P, 2001, ONCOGENE, V20, P6851, DOI 10.1038/sj.onc.1204848; Wadhwa R, 1998, J BIOL CHEM, V273, P29586, DOI 10.1074/jbc.273.45.29586; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZAJDEL MEB, 1988, ONCOGENE, V2, P579; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	35	71	75	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2939	2944		10.1038/sj.onc.1210085	http://dx.doi.org/10.1038/sj.onc.1210085			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072342				2022-12-28	WOS:000246210800013
J	Oyama, K; Okawa, T; Nakagawa, H; Takaoka, M; Andl, CD; Kim, SH; Klein-Szanto, A; Diehl, JA; Herlyn, M; El-Deiry, W; Rustgi, AK				Oyama, K.; Okawa, T.; Nakagawa, H.; Takaoka, M.; Andl, C. D.; Kim, S-H; Klein-Szanto, A.; Diehl, J. A.; Herlyn, M.; El-Deiry, W.; Rustgi, A. K.			AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture	ONCOGENE			English	Article						AKT; EGFR; proliferation; differentiation; organotypic culture	SIGNALING PATHWAY; IN-VITRO; KINASE-B; GROWTH; KERATINOCYTES; ACTIVATION; ARCHITECTURE; CARCINOMA; CANCER; PROLIFERATION	Epidermal growth factor receptor (EGFR) overexpression and activation is critical in the initiation and progression of cancers, especially those of epithelial origin. EGFR activation is associated with the induction of divergent signal transduction pathways and a gamut of cellular processes; however, the cell-type and tissue-type specificity conferred by certain pathways remains to be elucidated. In the context of the esophageal epithelium, a prototype stratified squamous epithelium, EGFR overexpression is relevant in the earliest events of carcinogenesis as modeled in a three-dimensional organotypic culture system. We demonstrate that the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, and not the MEK/MAPK (mitogen-activated protein kinase) pathway, is preferentially activated in EGFR-mediated esophageal epithelial hyperplasia, a premalignant lesion. The hyperplasia was abolished with direct inhibition of PI3K and of AKT but not with inhibition of the MAPK pathway. With the introduction of an inducible AKT vector in both primary and immortalized esophageal epithelial cells, we find that AKT overexpression and activation is permissive for complete epithelial formation in organotypic culture, but imposes a growth constraint in cells grown in monolayer. In organotypic culture, AKT mediates changes related to cell shape and size with an expansion of the differentiated compartment.	Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, Villanova, PA 19085 USA; Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Genet, Villanova, PA 19085 USA; Univ Penn, Div Hematol Oncol, Villanova, PA 19085 USA; Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Fox Chase Cancer Center; The Wistar Institute; University of Pennsylvania	Rustgi, AK (corresponding author), Univ Penn, Abramson Canc Ctr, Div Gastroenterol, Dept Med, 600 CRB,415 Curie Blvd, Villanova, PA 19085 USA.	anil2@mail.med.upenn.edu	El-Deiry, Wafik/AAJ-6080-2020; Klein-Szanto, A./E-6218-2010	El-Deiry, Wafik/0000-0002-9577-8266; 	NCI NIH HHS [F32-CA108657, CA 80999, F32 CA108657, R01 CA080999, P01 CA025874, CA 25874] Funding Source: Medline; NIDCR NIH HHS [P01 DE12467, P01 DE012467] Funding Source: Medline; NIDDK NIH HHS [P30 DK50306, K01 DK075379-01A1, K01 DK066205, K01 DK075379, K01-DK0662059, P30 DK050306] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA108657, P01CA025874, R01CA080999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK075379, P30DK050306, K01DK066205] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andl CD, 2003, J BIOL CHEM, V278, P1824, DOI 10.1074/jbc.M209148200; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Harada H, 2003, MOL CANCER RES, V1, P729; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; ITOIZ ME, 1985, AM J PATHOL, V119, P456; Janda E, 2002, ONCOGENE, V21, P5148, DOI 10.1038/sj.onc.1205661; Janes SM, 2004, J CELL SCI, V117, P4157, DOI 10.1242/jcs.01302; Kamei T, 2002, MOL ENDOCRINOL, V16, P1469, DOI 10.1210/me.16.7.1469; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kim YT, 2002, GYNECOL ONCOL, V87, P84, DOI 10.1006/gyno.2002.6803; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Li WJ, 2005, J BIOL CHEM, V280, P6036, DOI 10.1074/jbc.M406546200; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lo HW, 2006, BREAST CANCER RES TR, V95, P211, DOI 10.1007/s10549-005-9011-0; Mandard AM, 2000, MUTAT RES-REV MUTAT, V462, P335, DOI 10.1016/S1383-5742(00)00019-3; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045; MURPHY GF, 2005, LEVERS HISTOPATHOLOG, P13; Nelson CM, 2005, SEMIN CANCER BIOL, V15, P342, DOI 10.1016/j.semcancer.2005.05.001; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; Okano Jun-ichi, 2003, Methods Mol Biol, V222, P131; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sugatani T, 2005, J BIOL CHEM, V280, P3583, DOI 10.1074/jbc.M410480200; Xing DY, 2005, P NATL ACAD SCI USA, V102, P6936, DOI 10.1073/pnas.0502256102; Zahir N, 2004, CURR OPIN GENET DEV, V14, P71, DOI 10.1016/j.gde.2003.12.005	33	43	43	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2353	2364		10.1038/sj.onc.1210025	http://dx.doi.org/10.1038/sj.onc.1210025			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043653	Green Accepted			2022-12-28	WOS:000245466000011
J	Abdulrahman, M; Maina, EN; Morris, MR; Zatyka, M; Raval, RR; Banks, RE; Wiesener, MS; Richards, FM; Johnson, CM; Latif, F; Maher, ER				Abdulrahman, M.; Maina, E. N.; Morris, M. R.; Zatyka, M.; Raval, R. R.; Banks, R. E.; Wiesener, M. S.; Richards, F. M.; Johnson, C. M.; Latif, F.; Maher, E. R.			Identification of novel VHL targets that are associated with the development of renal cell carcinoma	ONCOGENE			English	Article						renal cell carcinoma; VHL; microarray; gene expression	HIPPEL-LINDAU-DISEASE; PROTEINASE-ACTIVATED RECEPTOR-2; HYPOXIA-INDUCIBLE FACTOR; TUMOR-SUPPRESSOR PROTEIN; CYCLIN D1; DIFFERENTIAL EXPRESSION; GERMLINE MUTATIONS; ENDOTHELIAL-CELLS; THYMOSIN BETA(4); MOUSE MODEL	von Hippel-Lindau (VHL) disease is a dominantly inherited family cancer syndrome characterized by the development of retinal and central nervous system haemangioblastomas, renal cell carcinoma (RCC) and phaeochromocytoma. Specific germline VHL mutations may predispose to haemangioblastomas, RCC and phaeochromocytoma to a varying extent. Although dysregulation of the hypoxia-inducible transcription factor-2 and JunB have been linked to the development of RCC and phaeochromocytoma, respectively, the precise basis for genotype-phenotype correlations in VHL disease have not been defined. To gain insights into the pathogenesis of RCC in VHL disease we compared gene expression microarray profiles in a RCC cell line expressing a Type 1 or Type 2B mutant pVHL (RCC-associated) to those of a Type 2A or 2C mutant (not associated with RCC). We identified 19 differentially expressed novel VHL target genes linked to RCC development. Eight targets were studied in detail by quantitative real-time polymerase chain reaction (three downregulated and five upregulated by wild-type VHL) and for six genes the effect of VHL inactivation was mimicked by hypoxia (but hypoxic-induction of smooth muscle alpha-actin 2 was specific for a RCC cell line). The potential role of four RCC-associated VHL target genes was assessed in vitro. NB thymosin beta (TMSNB) and proteinase-activated receptor 2 (PAR2) (both downregulated by wt pVHL) increased cell growth and motility in a RCC cell line, but aldehyde dehydrogenase (ALDH)1 and ALDH7 had no effect. These findings implicate TMSNB and PAR2 candidate oncogenes in the pathogenesis of VHL-associated RCC.	Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, Sch Med, Canc Res UK, Renal Mol Oncol Res Grp, Birmingham B15 2TT, W Midlands, England; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; St James Univ Hosp, Canc Res UK, Ctr Clin, Leeds LS9 7TF, W Yorkshire, England; Univ Erlangen Nurnberg, Interdisciplinary Ctr Clin Res, IZKF, Erlangen, Germany; Pfizer Globaol R&D, Discovery Biol, Sandwich, Kent, England	University of Birmingham; Cancer Research UK; University of Birmingham; University of Oxford; Wellcome Centre for Human Genetics; Cancer Research UK; Saint James's University Hospital; University of Erlangen Nuremberg; Pfizer	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	E.R.Maher@bham.ac.uk	Morris, Mark/C-6413-2008; MAHER, EAMONN R/A-9507-2008; Zatyka, Malgorzata/D-9340-2017	MAHER, EAMONN R/0000-0002-6226-6918; Zatyka, Malgorzata/0000-0003-3427-1653; Banks, Rosamonde/0000-0002-0042-8715; Johnson, Claire/0000-0003-4428-3594; Morris, Mark/0000-0002-0700-355X; Abdulrahman, Mahera/0000-0001-6271-3776				Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Bertog M, 1999, J PHYSIOL-LONDON, V521, P3, DOI 10.1111/j.1469-7793.1999.00003.x; Bindra RS, 2002, CANCER RES, V62, P3014; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; CHA HJ, 2003, J NATL CANCER I, P1674; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cocks TM, 1999, GASTROENTEROLOGY, V116, P586, DOI 10.1016/S0016-5085(99)70180-0; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Danahay H, 2001, AM J PHYSIOL-CELL PH, V280, pC1455, DOI 10.1152/ajpcell.2001.280.6.C1455; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Frungieri MB, 2002, P NATL ACAD SCI USA, V99, P15072, DOI 10.1073/pnas.232422999; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HALL AK, 1994, MED HYPOTHESES, V43, P125, DOI 10.1016/0306-9877(94)90135-X; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hollenberg MD, 2002, AM J PHYSIOL-CELL PH, V283, pC1347, DOI 10.1152/ajpcell.00304.2002; Hoogerwerf WA, 2001, J NEUROSCI, V21, P9036, DOI 10.1523/JNEUROSCI.21-22-09036.2001; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Iguchi K, 1999, BIOCHEM PHARMACOL, V57, P1105, DOI 10.1016/S0006-2952(99)00030-1; Jiang YD, 2003, MOL CANCER RES, V1, P453; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Knauth K, 2006, ONCOGENE, V25, P370, DOI 10.1038/sj.onc.1209062; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Li DS, 2004, MOL CELL BIOL, V24, P3838, DOI 10.1128/MCB.24.9.3838-3848.2004; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Maher ER, 2004, CURR MOL MED, V4, P833, DOI 10.2174/1566524043359827; MAHER ER, 1991, J MED GENET, V28, P443, DOI 10.1136/jmg.28.7.443; Maina EN, 2005, ONCOGENE, V24, P4549, DOI 10.1038/sj.onc.1208649; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Maxwell PH, 2002, SEMIN CELL DEV BIOL, V13, P29, DOI 10.1006/scdb.2001.0287; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Milia AF, 2002, CIRC RES, V91, P346, DOI 10.1161/01.RES.0000031958.92781.9E; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; NEUMANN HPH, 1995, JAMA-J AM MED ASSOC, V274, P1149; Nguyen TD, 1999, J CLIN INVEST, V103, P261, DOI 10.1172/JCI2539; Niu M, 2000, CELL ADHES COMMUN, V7, P311, DOI 10.3109/15419060009015002; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008-5472.CAN-04-4130; Webster AR, 1998, AM J HUM GENET, V63, P1025, DOI 10.1086/302037; Wiesener MS, 2001, CANCER RES, V61, P5215; Woodward ER, 1997, HUM MOL GENET, V6, P1051, DOI 10.1093/hmg/6.7.1051; Wykoff CC, 2004, BRIT J CANCER, V90, P1235, DOI 10.1038/sj.bjc.6601657; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491; Zatyka M, 2002, CANCER RES, V62, P3803; Zbar B, 1996, HUM MUTAT, V8, P348, DOI 10.1002/(SICI)1098-1004(1996)8:4<348::AID-HUMU8>3.0.CO;2-3	57	19	20	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1661	1672		10.1038/sj.onc.1209932	http://dx.doi.org/10.1038/sj.onc.1209932			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	17001320	Bronze			2022-12-28	WOS:000244782500017
J	Carretero, J; Medina, PP; Blanco, R; Smit, L; Tang, M; Roncador, G; Maestre, L; Conde, E; Lopez-Rios, F; Clevers, HC; Sanchez-Cespedes, M				Carretero, J.; Medina, P. P.; Blanco, R.; Smit, L.; Tang, M.; Roncador, G.; Maestre, L.; Conde, E.; Lopez-Rios, F.; Clevers, H. C.; Sanchez-Cespedes, M.			Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer	ONCOGENE			English	Article						LKB1; AMPK; lung cancer; energy stress	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; MAMMALIAN TARGET; UPSTREAM KINASE; DOWN-REGULATION; LKB1; AKT; GROWTH; CELLS; RAPAMYCIN	LKB1, mutated in Peutz-Jeghers and in sporadic lung tumours, phosphorylates a group of protein kinases named AMP-activated protein kinase (AMPK)-related kinases. Among them is included the AMPK, a sensor of cellular energy status. To investigate the relevance of LKB1 in lung carcinogenesis, we study several lung cancer cells with and without LKB1-inactivating mutations. We report that LKB1-mutant cells are deficient for AMPK activity and refractory to mTOR inhibition upon glucose depletion but not growth-factor deprivation. The requirement for wild-type LKB1 to properly activate AMPK is further demonstrated in genetically modified cancer cells. In addition, LKB1-deficient lung primary tumours had diminished AMPK activity, assessed by complete absence or low level of phosphorylation of its critical substrate, acetyl-CoA carboxylase. We also demonstrate that LKB1 wild-type cells are more resistant to cell death upon glucose withdrawal than their mutant counterparts. Finally, modulation of AMPK activity did not affect PI3K/AKT signalling, an advantage for the potential use of AMPK as a target for cancer therapy in LKB1 wildtype tumours. Thus, sustained abrogation of cell energetic checkpoint control, through alterations at key genes, appear to be an obligatory step in the development of some lung tumours.	Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain; Netherlands Inst Dev Biol, Hubrecht Lab, Ctr Biomed Genet, NL-3584 CT Utrecht, Netherlands; Univ Madrid, Hosp 12 Octubre, CNIO, Monoclonal Antibodies Unit, Madrid 3, Spain; Univ Madrid, Hosp 12 Octubre, Dept Pathol, Madrid 3, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Centro Nacional de Investigaciones Oncologicas (CNIO); Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre	Sanchez-Cespedes, M (corresponding author), Spanish Natl Canc Ctr, Lung Canc Grp, CNIO, Madrid 28029, Spain.	msanchez@cnio.es	Maestre, Lorena/L-1352-2014; Roncador, Giovanna/L-1764-2014; Sanchez-Cespedes, Montse/H-8485-2012; Carretero, Julian/N-5214-2014; Blanco, Raquel/M-4290-2015; Vico, Pedro Pablo Medina/D-1688-2013	Maestre, Lorena/0000-0001-8743-0422; Roncador, Giovanna/0000-0002-9807-2875; Sanchez-Cespedes, Montse/0000-0002-6045-5627; Carretero, Julian/0000-0001-7269-8506; Blanco, Raquel/0000-0001-5477-5379; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Smit, Linda/0000-0003-0025-269X				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Baas AF, 2003, EMBO J, V22, P3062, DOI 10.1093/emboj/cdg292; Boudeau J, 2003, EMBO J, V22, P5102, DOI 10.1093/emboj/cdg490; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622; Carretero J, 2004, ONCOGENE, V23, P4037, DOI 10.1038/sj.onc.1207502; Conde E, 2006, CLIN CANCER RES, V12, P710, DOI 10.1158/1078-0432.CCR-05-1362; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fernandez P, 2004, ONCOGENE, V23, P5084, DOI 10.1038/sj.onc.1207665; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003-0982; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; JEGHERS H, 1949, NEW ENGL J MED, V241, P1031, DOI 10.1056/NEJM194912292412601; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jimenez AI, 2003, CANCER RES, V63, P1382; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Manning BD, 2003, BIOCHEM SOC T, V31, P573, DOI 10.1042/BST0310573; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P17; Nakau M, 2002, CANCER RES, V62, P4549; NELLIST M, 1993, CELL, V75, P1305; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Rossi DJ, 2002, P NATL ACAD SCI USA, V99, P12327, DOI 10.1073/pnas.192301399; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Tiainen M, 1999, P NATL ACAD SCI USA, V96, P9248, DOI 10.1073/pnas.96.16.9248; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Ylikorkala A, 2001, SCIENCE, V293, P1323, DOI 10.1126/science.1062074; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	41	119	123	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1616	1625		10.1038/sj.onc.1209951	http://dx.doi.org/10.1038/sj.onc.1209951			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953221				2022-12-28	WOS:000244782500011
J	Nakai-Murakami, C; Shimura, M; Kinomoto, M; Takizawa, Y; Tokunaga, K; Taguchi, T; Hoshino, S; Miyagawa, K; Sata, T; Kurumizaka, H; Yuo, A; Ishizaka, Y				Nakai-Murakami, C.; Shimura, M.; Kinomoto, M.; Takizawa, Y.; Tokunaga, K.; Taguchi, T.; Hoshino, S.; Miyagawa, K.; Sata, T.; Kurumizaka, H.; Yuo, A.; Ishizaka, Y.			HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination	ONCOGENE			English	Article						HIV-1; Vpr; DNA double-strand breaks; homologous recombination; non-AIDS defining malignancies	VIRUS TYPE-1 VPR; AIDS-DEFINING CANCERS; DOUBLE-STRAND BREAKS; VIRAL-PROTEIN-R; DNA-DAMAGE; MICRONUCLEI FORMATION; ACCESSORY GENE; CYCLE ARREST; EARLY STEPS; P53	An ATM-dependent cellular signal, a DNA-damage response, has been shown to be involved during infection of human immunodeficiency virus type-1 (HIV-1), and a high incidence of malignant tumor development has been observed in HIV-1-positive patients. Vpr, an accessory gene product of HIV-1, delays the progression of the cell cycle at the G2/M phase, and ATR-Chk1-Wee-1, another DNA-damage signal, is a proposed cellular pathway responsible for the Vpr-induced cell cycle arrest. In this study, we present evidence that Vpr also activates ATM, and induces expression of gamma-H2AX and phosphorylation of Chk2. Strikingly, Vpr was found to stimulate the focus formation of Rad51 and BRCA1, which are involved in repair of DNA double-strand breaks (DSBs) by homologous recombination (1411), and biochemical analysis revealed that Vpr dissociates the interaction of p53 and Rad51 in the chromatin fraction, as observed under irradiation-induced DSBs. Vpr was consistently found to increase the rate of HR in the locus of I-Scel, a rare cutting-enzyme site that had been introduced into the genome. An increase of the HR rate enhanced by Vpr was attenuated by an ATM inhibitor, KU55933, suggesting that Vpr-induced DSBs activate ATM-dependent cellular signal that enhances the intracellular recombination potential. In context with a recent report that KU55933 attenuated the integration of HIV-1 into host genomes, we discuss the possible role of Vpr-induced DSBs in viral integration and also in HIV-1 associated malignancy.	Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; Int Med Ctr Japan, Dept Hematol, Shinjuku Ku, Tokyo 1628655, Japan; Natl Inst Infect Dis, Dept Pathol, Shinjuku Ku, Tokyo, Japan; Waseda Univ, Sch Sci & Engn, Shinjuku Ku, Tokyo 169, Japan; Univ Tokyo, Grad Sch Med, Sect Radiat Biol, Bunkyo Ku, Tokyo, Japan	National Center for Global Health & Medicine - Japan; National Center for Global Health & Medicine - Japan; National Institute of Infectious Diseases (NIID); Waseda University; University of Tokyo	Ishizaka, Y (corresponding author), Int Med Ctr Japan, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.imcj.go.jp	Takizawa, Yoshimasa/G-2956-2015; Tokunaga, Kenzo/Q-9914-2018	Takizawa, Yoshimasa/0000-0002-6265-4830; Tokunaga, Kenzo/0000-0002-2625-5322; Kurumizaka, Hitoshi/0000-0001-7412-3722				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Anglana M, 1999, NUCLEIC ACIDS RES, V27, P4276, DOI 10.1093/nar/27.21.4276; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Biggar RJ, 1996, INT J CANCER, V68, P754; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; Burgi A, 2005, CANCER-AM CANCER SOC, V104, P1505, DOI 10.1002/cncr.21334; Chadburn A, 1997, SEMIN DIAGN PATHOL, V14, P15; Cromie GA, 2001, MOL CELL, V8, P1163, DOI 10.1016/S1097-2765(01)00419-1; Daniel R, 2005, J VIROL, V79, P2058, DOI 10.1128/JVI.79.4.2058-2065.2005; Daniel R, 2004, J VIROL, V78, P8573, DOI 10.1128/JVI.78.16.8573-8581.2004; Daniel R, 2003, P NATL ACAD SCI USA, V100, P4778, DOI 10.1073/pnas.0730887100; Daniel R, 1999, SCIENCE, V284, P644, DOI 10.1126/science.284.5414.644; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Elder RT, 2002, FRONT BIOSCI-LANDMRK, V7, pD349, DOI 10.2741/elder; ElenitobaJohnson KSJ, 1997, SEMIN DIAGN PATHOL, V14, P35; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Groschel B, 2005, J VIROL, V79, P5695, DOI 10.1128/JVI.79.9.5695-5704.2005; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Herida M, 2003, J CLIN ONCOL, V21, P3447, DOI 10.1200/JCO.2003.01.096; HOSHINO S, 2006, UNPUB; Huang MB, 2000, J NEUROVIROL, V6, P202, DOI 10.3109/13550280009015823; HUANG X, 2006, CYTOMETER A, V67, P222; ISHIZAKA Y, 1995, P NATL ACAD SCI USA, V92, P3224, DOI 10.1073/pnas.92.8.3224; Jeanson L, 2002, VIROLOGY, V300, P100, DOI 10.1006/viro.2002.1515; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kagawa W, 2001, J BIOL CHEM, V276, P35201, DOI 10.1074/jbc.M104938200; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Khanna KK, 2001, CELL DEATH DIFFER, V8, P1052, DOI 10.1038/sj.cdd.4400874; Knowles DM, 2003, HEMATOL ONCOL CLIN N, V17, P785, DOI 10.1016/S0889-8588(03)00050-9; Kurumizaka H, 1999, J MOL BIOL, V291, P537, DOI 10.1006/jmbi.1999.2950; Lai MY, 2005, J VIROL, V79, P15443, DOI 10.1128/JVI.79.24.15443-15451.2005; Lau A, 2005, NAT CELL BIOL, V7, P493, DOI 10.1038/ncb1250; Lau A, 2004, EMBO J, V23, P3421, DOI 10.1038/sj.emboj.7600348; LAURENCE J, 1991, P NATL ACAD SCI USA, V88, P7635, DOI 10.1073/pnas.88.17.7635; LEVYDN, 1994, P NATL ACAD SCI USA, V91, P10873; Li L, 2001, EMBO J, V20, P3272, DOI 10.1093/emboj/20.12.3272; Lim Soon Thye, 2005, Curr HIV/AIDS Rep, V2, P146, DOI 10.1007/s11904-005-0008-4; Linke SP, 2003, CANCER RES, V63, P2596; Mahalingam S, 1998, P NATL ACAD SCI USA, V95, P3419, DOI 10.1073/pnas.95.7.3419; Marmorstein LY, 1998, P NATL ACAD SCI USA, V95, P13869, DOI 10.1073/pnas.95.23.13869; MAYER V, 1995, EUR J CANCER PREV, V4, P211, DOI 10.1097/00008469-199506000-00001; Nunnari G, 2005, VIROLOGY, V335, P177, DOI 10.1016/j.virol.2005.02.015; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Roshal M, 2003, J BIOL CHEM, V278, P25879, DOI 10.1074/jbc.M303948200; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; Sengupta S, 2003, EMBO J, V22, P1210, DOI 10.1093/emboj/cdg114; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Shimura M, 2005, AIDS, V19, P1434, DOI 10.1097/01.aids.0000180788.92627.e7; Shimura M, 1999, CANCER RES, V59, P2259; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Slebos RJC, 2001, BIOCHEM BIOPH RES CO, V281, P212, DOI 10.1006/bbrc.2001.4335; Straus D J, 2001, Curr Oncol Rep, V3, P260, DOI 10.1007/s11912-001-0059-7; Tachiwana H, 2006, CANCER RES, V66, P627, DOI 10.1158/0008-5472.CAN-05-3144; Taguchi T, 2004, BIOCHEM BIOPH RES CO, V320, P18, DOI 10.1016/j.bbrc.2004.05.126; Tokunaga K, 2001, J VIROL, V75, P6776, DOI 10.1128/JVI.75.15.6776-6785.2001; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; WALDMAN AS, 1987, P NATL ACAD SCI USA, V84, P5340, DOI 10.1073/pnas.84.15.5340; West SC, 2003, NAT REV MOL CELL BIO, V4, P435, DOI 10.1038/nrm1127; Yamaguchi-Iwai Y, 1998, MOL CELL BIOL, V18, P6430, DOI 10.1128/MCB.18.11.6430; Yoon D, 2004, J MOL BIOL, V336, P639, DOI 10.1016/j.jmb.2003.12.050; Yuan HD, 2004, J VIROL, V78, P8183, DOI 10.1128/JVI.78.15.8183-8190.2004; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zimmerman ES, 2004, MOL CELL BIOL, V24, P9286, DOI 10.1128/MCB.24.21.9286-9294.2004	67	41	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					477	486		10.1038/sj.onc.1209831	http://dx.doi.org/10.1038/sj.onc.1209831			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16983346				2022-12-28	WOS:000243731600001
J	Sasai, K; Kakumoto, K; Hanafusa, H; Akagi, T				Sasai, K.; Kakumoto, K.; Hanafusa, H.; Akagi, T.			The Ras-MAPK pathway downregulates Caveolin-1 in rodent fibroblast but not in human fibroblasts: implications in the resistance to oncogene-mediated transformation	ONCOGENE			English	Article						caveolin-1; hTERT; normal human diploid fibroblast; oncogenic transformation; Ras-MAPK pathway	HUMAN-DIPLOID FIBROBLASTS; CANCER; CELLS; INVASIVENESS; EXPRESSION; KINASE	Normal human diploid fibroblasts (HDFs) are refractory to oncogene-mediated transformations in vitro, compared with rodent fibroblasts. As successful oncogene-mediated transformations of normal HDFs have been reported using the human telomerase catalytic subunit, it has been considered that telomerase activity contributes to the species-specific transformability. However, these transformed HDFs are much less malignant compared with those of rodent cells, suggesting the existence of undetermined mechanisms that render HDFs resistant to malignant transformation. Here, cDNA microarray analysis identified caveolin-1 as one of the possible cellular factors involved in such mechanisms. The mitogen-activated protein kinases ( MAPK) pathway downregulates Caveolin-1 in rodent fibroblasts, transformed by coexpression of the SV40 early region and activated H-Ras. In contrast, the coexpression of these two oncogenes in HDFs failed to reduce the expression level of Caveolin-1. These results strongly suggest the presence of critical differences in events following the phosphorylation of ERK during the activation process of the MAPK signaling pathway between human and rodent cells, as the ERK protein was similarly phosphorylated in both systems. Furthermore, the small interfering RNA-mediated suppression of Caveolin-1 facilitated the oncogene-mediated transformation of normal HDFs, clearly indicating that the differences in the transformability between human and rodent cells are due, at least in part, to the mechanism responsible for the resistance to Ras-induced Caveolin-1 downregulation in HDFs.	Osaka Biosci Inst, Oncol Mol Lab, Ibaraki, Osaka 5670085, Japan		Akagi, T (corresponding author), Osaka Biosci Inst, Oncol Mol Lab, Saito Boincubator Rm204,7-7-15 Saito Asagi, Ibaraki, Osaka 5670085, Japan.	takagi@obi.or.jp						Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Akagi T, 2004, TRENDS MOL MED, V10, P542, DOI 10.1016/j.molmed.2004.09.001; Akagi T, 2003, P NATL ACAD SCI USA, V100, P13567, DOI 10.1073/pnas.1834876100; Akagi T, 2002, MOL CELL BIOL, V22, P7015, DOI 10.1128/MCB.22.20.7015-7023.2002; Chi JT, 2003, P NATL ACAD SCI USA, V100, P6343, DOI 10.1073/pnas.1037853100; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Ge SJ, 2004, J BIOL CHEM, V279, P6688, DOI 10.1074/jbc.M311769200; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kakumoto K, 2006, P NATL ACAD SCI USA, V103, P5490, DOI 10.1073/pnas.0601222103; Razani B, 2001, J BIOL CHEM, V276, P38121; Sasai K, 2003, J BIOL CHEM, V278, P25295, DOI 10.1074/jbc.M301913200; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Sukezane T, 2005, ONCOGENE, V24, P5648, DOI 10.1038/sj.onc.1208724; Tang W, 2004, MOL BIOL CELL, V15, P4043, DOI 10.1091/mbc.E04-05-0402; van den Heuvel APJ, 2005, BIOCHEM J, V385, P795, DOI 10.1042/BJ20041449; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Williams TM, 2004, J BIOL CHEM, V279, P24745, DOI 10.1074/jbc.M402064200; Zhao JJ, 2004, TRENDS MOL MED, V10, P344, DOI 10.1016/j.molmed.2004.05.005	22	16	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					449	455		10.1038/sj.onc.1209792	http://dx.doi.org/10.1038/sj.onc.1209792			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832346				2022-12-28	WOS:000243544000013
J	Engels, BM; Hutvagner, G				Engels, B. M.; Hutvagner, G.			Principles and effects of microRNA-mediated post-transcriptional gene regulation	ONCOGENE			English	Review						miRNA; RISC formation; translational repression; P-body	RNAI ENZYME COMPLEX; TARGETED MESSENGER-RNAS; CAENORHABDITIS-ELEGANS; PROCESSING BODIES; CRYSTAL-STRUCTURE; HUMAN-CELLS; C-ELEGANS; TRANSLATIONAL REPRESSION; SILENCING PATHWAYS; PROTEIN-SYNTHESIS	MicroRNAs (miRNAs) are abundant regulatory RNAs involved in the regulation of many key biological processes. Recent advances in understanding the mechanism of RNA interference and miRNA-mediated mechanisms shed light on major principals of the formation of the regulatory complex and provide models to explain how these small regulatory RNA species interfere with gene expression and how they influence the translational status of the transcriptome.	Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Hutvagner, G (corresponding author), Univ Dundee, Coll Life Sci, Div Gene Regulat & Express, Dow St, Dundee DD1 5EH, Scotland.	g.hutvagner@dundee.ac.uk		Hutvagner, Gyorgy/0000-0002-7231-9446	Wellcome Trust [076624/Z/05/Z, 076624] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agbottah E, 2005, J BIOL CHEM, V280, P3029, DOI 10.1074/jbc.M406435200; Andrei MA, 2005, RNA, V11, P717, DOI 10.1261/rna.2340405; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328; Baumberger N, 2005, P NATL ACAD SCI USA, V102, P11928, DOI 10.1073/pnas.0505461102; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Cerutti H, 2006, CURR GENET, V50, P81, DOI 10.1007/s00294-006-0078-x; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Chu CY, 2006, PLOS BIOL, V4, P1122, DOI 10.1371/journal.pbio.0040210; Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060; Ding L, 2005, MOL CELL, V19, P437, DOI 10.1016/j.molcel.2005.07.013; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Duchaine TF, 2006, CELL, V124, P343, DOI [10.1016/j.cell.2005.11.036, 10.1016/j.cel.2005.11.036]; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Enright AJ, 2004, GENOME BIOL, V5; Farh KKH, 2005, SCIENCE, V310, P1817, DOI 10.1126/science.1121158; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Hornstein E, 2005, NATURE, V438, P671, DOI 10.1038/nature04138; Hornstein E, 2006, NAT GENET, V38, pS20, DOI 10.1038/ng1803; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jakymiw A, 2005, NAT CELL BIOL, V7, P1267, DOI 10.1038/ncb1334; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Jing Q, 2005, CELL, V120, P623, DOI 10.1016/j.cell.2004.12.038; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Kedersha N, 2005, J CELL BIOL, V169, P871, DOI 10.1083/jcb.200502088; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kiriakidou M, 2004, GENE DEV, V18, P1165, DOI 10.1101/gad.1184704; Kloosterman WP, 2004, NUCLEIC ACIDS RES, V32, P6284, DOI 10.1093/nar/gkh968; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Lall S, 2006, CURR BIOL, V16, P460, DOI 10.1016/j.cub.2006.01.050; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Leuschner PJF, 2006, EMBO REP, V7, P314, DOI 10.1038/sj.embor.7400637; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu JD, 2005, NAT CELL BIOL, V7, P1261, DOI 10.1038/ncb1333; Liu JD, 2005, NAT CELL BIOL, V7, P719, DOI 10.1038/ncb1274; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Lykke-Andersen J, 2005, GENE DEV, V19, P351, DOI 10.1101/gad.1282305; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2005, CURR BIOL, V15, P2149, DOI 10.1016/j.cub.2005.10.048; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Miyoshi K, 2005, GENE DEV, V19, P2837, DOI 10.1101/gad.1370605; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nelson PT, 2004, RNA, V10, P387, DOI 10.1261/rna.5181104; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079; Pillai RS, 2004, RNA, V10, P1518, DOI 10.1261/rna.7131604; Qi Y, 2005, MOL CELL, V19, P421, DOI 10.1016/j.molcel.2005.06.014; Rajewsky N, 2004, DEV BIOL, V267, P529, DOI 10.1016/j.ydbio.2003.12.003; Rehwinkel J, 2005, RNA, V11, P1640, DOI 10.1261/rna.2191905; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Seitz H, 2003, NAT GENET, V34, P261, DOI 10.1038/ng1171; Sen GL, 2005, NAT CELL BIOL, V7, P633, DOI 10.1038/ncb1265; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Stark A, 2005, CELL, V123, P1133, DOI 10.1016/j.cell.2005.11.023; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang BB, 2006, MOL CELL, V22, P553, DOI 10.1016/j.molcel.2006.03.034; Wienholds E, 2005, FEBS LETT, V579, P5911, DOI 10.1016/j.febslet.2005.07.070; Wu LG, 2006, P NATL ACAD SCI USA, V103, P4034, DOI 10.1073/pnas.0510928103; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Yuan YR, 2005, MOL CELL, V19, P405, DOI 10.1016/j.molcel.2005.07.011; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688	106	355	380	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6163	6169		10.1038/sj.onc.1209909	http://dx.doi.org/10.1038/sj.onc.1209909			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028595	Green Submitted			2022-12-28	WOS:000241158900004
J	Reiling, JH; Sabatini, DM				Reiling, J. H.; Sabatini, D. M.			Stress and mTORture signaling	ONCOGENE			English	Review						mTOR; raptor; rictor; growth; cancer; hypoxia	ACTIVATED PROTEIN-KINASE; INITIATION-FACTOR 4E; MESSENGER-RNA TRANSLATION; TUMOR-SUPPRESSOR COMPLEX; CELL-CYCLE PROGRESSION; S6 KINASE; MAMMALIAN TARGET; HEAT-SHOCK; SKELETAL-MUSCLE; LIFE-SPAN	The TOR ( target of rapamycin) pathway is an evolutionarily conserved signaling module regulating cell growth ( accumulation of mass) in response to a variety of environmental cues such as nutrient availability, hypoxia, DNA damage and osmotic stress. Its pivotal role in cellular and organismal homeostasis is reflected in the fact that unrestrained signaling activity in mammals is associated with the occurrence of disease states including inflammation, cancer and diabetes. The existence of TOR homologs in unicellular organisms whose growth is affected by environmental factors, such as temperature, nutrients and osmolarity, suggests an ancient role for the TOR signaling network in the surveillance of stress conditions. Here, we will summarize recent advances in the TOR signaling field with special emphasis on how stress conditions impinge on insulin/insulin-like growth factor signaling/TOR signaling.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute	Sabatini, DM (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	sabatini@wi.mit.edu		/0000-0002-1446-7256				Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Bae GU, 1999, J BIOL CHEM, V274, P32596, DOI 10.1074/jbc.274.46.32596; Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; Bradley JMB, 2003, INVEST OPHTH VIS SCI, V44, P5174, DOI 10.1167/iovs.03-0213; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Brenneisen P, 2000, J BIOL CHEM, V275, P4336, DOI 10.1074/jbc.275.6.4336; Broughton SJ, 2005, P NATL ACAD SCI USA, V102, P3105, DOI 10.1073/pnas.0405775102; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Cai SL, 2006, J CELL BIOL, V173, P279, DOI 10.1083/jcb.200507119; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Clancy DJ, 2002, SCIENCE, V296, P319, DOI 10.1126/science.1069366; Colombani J, 2003, CELL, V114, P739, DOI 10.1016/S0092-8674(03)00713-X; Connolly E, 2006, MOL CELL BIOL, V26, P3955, DOI 10.1128/MCB.26.10.3955-3965.2006; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Copp J, 2005, AM J PHYSIOL-CELL PH, V288, pC403, DOI 10.1152/ajpcell.00095.2004; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Ding M, 2002, MOL CELL BIOCHEM, V234, P81, DOI 10.1023/A:1015901232124; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Drummond-Barbosa D, 2001, DEV BIOL, V231, P265, DOI 10.1006/dbio.2000.0135; Dudley R, 1998, J EXP BIOL, V201, P1043; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Feigenblum D, 1996, MOL CELL BIOL, V16, P5450; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; Fontoura BMA, 1997, MOL CELL BIOL, V17, P3146, DOI 10.1128/MCB.17.6.3146; Frazier MR, 2001, PHYSIOL BIOCHEM ZOOL, V74, P641, DOI 10.1086/322172; Frese KK, 2003, ONCOGENE, V22, P710, DOI 10.1038/sj.onc.1206151; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Fumarola C, 2005, J CELL PHYSIOL, V204, P155, DOI 10.1002/jcp.20272; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gual P, 2003, J BIOL CHEM, V278, P26550, DOI 10.1074/jbc.M212273200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hafen E, 2003, PLOS BIOL, V1, P319, DOI 10.1371/journal.pbio.0000086; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hansen IA, 2005, J BIOL CHEM, V280, P20565, DOI 10.1074/jbc.M500712200; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Holzenberger M, 2003, NATURE, V421, P182, DOI 10.1038/nature01298; Horman S, 2002, CURR BIOL, V12, P1419, DOI 10.1016/S0960-9822(02)01077-1; Hornberger TA, 2006, P NATL ACAD SCI USA, V103, P4741, DOI 10.1073/pnas.0600678103; Hornberger TA, 2006, J CELL BIOCHEM, V97, P1207, DOI 10.1002/jcb.20671; Hornberger TA, 2001, AM J PHYSIOL-CELL PH, V281, pC179, DOI 10.1152/ajpcell.2001.281.1.C179; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang CS, 2002, CANCER RES, V62, P5689; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ikeya T, 2002, CURR BIOL, V12, P1293, DOI 10.1016/S0960-9822(02)01043-6; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jung DK, 2003, EXP CELL RES, V290, P144, DOI 10.1016/S0014-4827(03)00320-3; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kaper F, 2006, CANCER RES, V66, P1561, DOI 10.1158/0008-5472.CAN-05-3375; Karuman P, 2001, MOL CELL, V7, P1307, DOI 10.1016/S1097-2765(01)00258-1; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Konishi H, 1997, FEBS LETT, V410, P493, DOI 10.1016/S0014-5793(97)00541-3; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Kraiss LW, 2001, J SURG RES, V97, P20, DOI 10.1006/jsre.2001.6091; Kwiatkowski DJ, 2005, HUM MOL GENET, V14, pR251, DOI 10.1093/hmg/ddi260; LAMPHEAR BJ, 1991, J BIOL CHEM, V266, P2789; Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513; Li W, 2003, J CELL PHYSIOL, V195, P202, DOI 10.1002/jcp.10230; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Ma L, 2005, GENE DEV, V19, P1779, DOI 10.1101/gad.1314405; Mahfouz MM, 2006, PLANT CELL, V18, P477, DOI 10.1105/tpc.105.035931; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mannova P, 2005, J VIROL, V79, P8742, DOI 10.1128/JVI.79.14.8742-8749.2005; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Meyuhas O, 2000, EUR J BIOCHEM, V267, P6321, DOI 10.1046/j.1432-1327.2000.01719.x; Moody CA, 2005, J VIROL, V79, P5499, DOI 10.1128/JVI.79.9.5499-5506.2005; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; O'Shea C, 2005, EMBO J, V24, P1211, DOI 10.1038/sj.emboj.7600597; Ohji G, 2006, J BIOCHEM, V139, P129, DOI 10.1093/jb/mvj008; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Parrott LA, 1999, J BIOL CHEM, V274, P24731, DOI 10.1074/jbc.274.35.24731; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Patel S, 2002, BIOCHEM J, V365, P537, DOI 10.1042/BJ20020266; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Peck LS, 2003, P ROY SOC B-BIOL SCI, V270, pS166, DOI 10.1098/rsbl.2003.0054; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Proud CG, 2002, EUR J BIOCHEM, V269, P5338, DOI 10.1046/j.1432-1033.2002.03292.x; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Reynolds TH, 2002, J BIOL CHEM, V277, P17657, DOI 10.1074/jbc.M201142200; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Santoro MG, 2000, BIOCHEM PHARMACOL, V59, P55, DOI 10.1016/S0006-2952(99)00299-3; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; SCHARF KD, 1982, CELL, V30, P427, DOI 10.1016/0092-8674(82)90240-9; Scott BA, 2002, SCIENCE, V296, P2388, DOI 10.1126/science.1072302; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Teleman AA, 2005, GENE DEV, V19, P1844, DOI 10.1101/gad.341505; Tettweiler G, 2005, GENE DEV, V19, P1840, DOI 10.1101/gad.1311805; Thomas G, 2002, BIOL RES, V35, P305, DOI 10.4067/S0716-97602002000200022; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tinton SA, 1999, FEBS LETT, V446, P55, DOI 10.1016/S0014-5793(99)00185-4; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Turck F, 1998, MOL CELL BIOL, V18, P2038, DOI 10.1128/MCB.18.4.2038; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Vries RGJ, 1997, J BIOL CHEM, V272, P32779, DOI 10.1074/jbc.272.52.32779; Weisman R, 2001, J BIOL CHEM, V276, P7027, DOI 10.1074/jbc.M010446200; Wu Q, 2005, P NATL ACAD SCI USA, V102, P13289, DOI 10.1073/pnas.0501914102; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; ZAPATA JM, 1991, J BIOL CHEM, V266, P16007; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	178	272	291	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2006	25	48					6373	6383		10.1038/sj.onc.1209889	http://dx.doi.org/10.1038/sj.onc.1209889			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041623				2022-12-28	WOS:000241380700004
J	Pelicano, H; Martin, DS; Xu, RH; Huang, P				Pelicano, H.; Martin, D. S.; Xu, R. -H; Huang, P.			Glycolysis inhibition for anticancer treatment	ONCOGENE			English	Review						glycolysis; Warburg effect; glycolytic inhibitor; ATP; mitochondria	AUTOCRINE MOTILITY FACTOR; MITOCHONDRIAL-DNA MUTATIONS; HIGH AEROBIC GLYCOLYSIS; DRUG-DEVELOPMENT-GROUP; TUMOR-CELL LINES; PROTEIN-KINASE-B; PHASE-II TRIAL; CANCER-CELLS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; IN-VIVO	Most cancer cells exhibit increased glycolysis and use this metabolic pathway for generation of ATP as a main source of their energy supply. This phenomenon is known as the Warburg effect and is considered as one of the most fundamental metabolic alterations during malignant transformation. In recent years, there are significant progresses in our understanding of the underlying mechanisms and the potential therapeutic implications. Biochemical and molecular studies suggest several possible mechanisms by which this metabolic alteration may evolve during cancer development. These mechanisms include mitochondrial defects and malfunction, adaptation to hypoxic tumor microenvironment, oncogenic signaling, and abnormal expression of metabolic enzymes. Importantly, the increased dependence of cancer cells on glycolytic pathway for ATP generation provides a biochemical basis for the design of therapeutic strategies to preferentially kill cancer cells by pharmacological inhibition of glycolysis. Several small molecules have emerged that exhibit promising anticancer activity in vitro and in vivo, as single agent or in combination with other therapeutic modalities. The glycolytic inhibitors are particularly effective against cancer cells with mitochondrial defects or under hypoxic conditions, which are frequently associated with cellular resistance to conventional anticancer drugs and radiation therapy. Because increased aerobic glycolysis is commonly seen in a wide spectrum of human cancers and hypoxia is present in most tumor microenvironment, development of novel glycolytic inhibitors as a new class of anticancer agents is likely to have broad therapeutic applications.	Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China	University of Texas System; UTMD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Sun Yat Sen University	Huang, P (corresponding author), Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA.	phuang@mdanderson.org	Xu, Rui-Hua/AAW-4766-2021	Xu, Rui-Hua/0000-0001-9771-8534	NCI NIH HHS [CA100428, CA109041, CA085563] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085563, R01CA109041, R01CA100428] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARORA KK, 1990, J BIOL CHEM, V265, P6481; Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; BAUMANN M, 1990, CANCER INVEST, V8, P351, DOI 10.3109/07357909009012053; BAUMANN M, 1988, CANCER RES, V48, P7018; Bayley JP, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-39; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P402, DOI 10.1006/bcmd.1997.0157; Biaglow JE, 1997, BIOCHEM BIOPH RES CO, V235, P739, DOI 10.1006/bbrc.1997.6835; Blum R, 2005, CANCER RES, V65, P999; BOARD M, 1995, CANCER RES, V55, P3278; Bolin DC, 1996, VET HUM TOXICOL, V38, P85; Boren J, 2001, J BIOL CHEM, V276, P37747; BORK P, 1993, PROTEIN SCI, V2, P31; Boros LG, 2001, PANCREAS, V22, P1, DOI 10.1097/00006676-200101000-00001; Brahimi-Horn MC, 2005, INT REV CYTOL, V242, P157; Briasoulis E, 2003, EUR J CANCER, V39, P2334, DOI 10.1016/S0959-8049(03)00629-4; BROWN J, 1962, METABOLISM, V11, P1098; Bryson JM, 2002, J BIOL CHEM, V277, P11392, DOI 10.1074/jbc.M110927200; Budihardjo II, 1998, CLIN CANCER RES, V4, P117; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Carew JS, 2003, LEUKEMIA, V17, P1437, DOI 10.1038/sj.leu.2403043; CATTANEO A, 1985, EXP CELL RES, V161, P130, DOI 10.1016/0014-4827(85)90497-5; Chen JJZ, 2004, J ENVIRON SCI HEAL C, V22, P1, DOI 10.1081/GNC-120037931; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Comin-Anduix B, 2001, EUR J BIOCHEM, V268, P4177, DOI 10.1046/j.1432-1327.2001.02329.x; Coy JF, 2005, CLIN LAB, V51, P257; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Dastoor Z, 2001, J CELL SCI, V114, P1643; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; Deprez J, 1997, J BIOL CHEM, V272, P17269, DOI 10.1074/jbc.272.28.17269; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; Dollner R, 2004, ANTICANCER RES, V24, P2947; El-Zarruk AA, 1999, CANCER LETT, V142, P185, DOI 10.1016/S0304-3835(99)00167-6; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Feo S, 2000, FEBS LETT, V473, P47, DOI 10.1016/S0014-5793(00)01494-0; FILELLA X, 1991, TUMOR BIOL, V12, P360, DOI 10.1159/000217737; FLIER JS, 1987, SCIENCE, V235, P1492, DOI 10.1126/science.3103217; FLORIDI A, 1981, J NATL CANCER I, V66, P497; Floridi A, 1998, BIOCHEM PHARMACOL, V56, P841, DOI 10.1016/S0006-2952(98)00054-9; Ford WCL, 2006, HUM REPROD UPDATE, V12, P269, DOI 10.1093/humupd/dmi053; Funasaka T, 2002, INT J CANCER, V101, P217, DOI 10.1002/ijc.10617; Funasaka T, 2001, BIOCHEM BIOPH RES CO, V285, P118, DOI 10.1006/bbrc.2001.5135; Garg AK, 2005, ANTIOXID REDOX SIGN, V7, P1630, DOI 10.1089/ars.2005.7.1630; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Geschwind Jean-Francois, 2004, Expert Rev Anticancer Ther, V4, P449, DOI 10.1586/14737140.4.3.449; Geschwind JFH, 2002, CANCER RES, V62, P3909; Giaccone G, 2004, EUR J CANCER, V40, P667, DOI 10.1016/j.ejca.2003.10.027; GolshaniHebroni SG, 1997, J BIOENERG BIOMEMBR, V29, P331, DOI 10.1023/A:1022442629543; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gottschalk S, 2004, CLIN CANCER RES, V10, P6661, DOI 10.1158/1078-0432.CCR-04-0039; GROSSE F, 1986, EUR J BIOCHEM, V160, P459, DOI 10.1111/j.1432-1033.1986.tb10062.x; HARRISON RA, 1974, ANAL BIOCHEM, V61, P500, DOI 10.1016/0003-2697(74)90417-5; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; Hirono Y, 1996, BRIT J CANCER, V74, P2003, DOI 10.1038/bjc.1996.667; Ishitani R, 1996, P NATL ACAD SCI USA, V93, P9937, DOI 10.1073/pnas.93.18.9937; Izyumov DS, 2004, BBA-BIOENERGETICS, V1658, P141, DOI 10.1016/j.bbabio.2004.05.007; Jelks KB, 2001, TOXICOL SCI, V62, P115, DOI 10.1093/toxsci/62.1.115; Jones AR, 1997, XENOBIOTICA, V27, P711, DOI 10.1080/004982597240299; Kang HT, 2006, LIFE SCI, V78, P1392, DOI 10.1016/j.lfs.2005.07.001; Karnauskas R, 2003, ONCOGENE, V22, P688, DOI 10.1038/sj.onc.1206159; KIM SU, 1973, ACTA NEUROPATHOL, V26, P259, DOI 10.1007/BF00684436; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOUTCHER JA, 1993, CANCER RES, V53, P3518; LAYZER RB, 1969, J BIOL CHEM, V244, P3823; Ledoux S, 2003, CANCER RES, V63, P7284; Li C, 2006, PROTEOMICS, V6, P547, DOI 10.1002/pmic.200500256; Lian FR, 1998, NUTR CANCER, V31, P184, DOI 10.1080/01635589809514701; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V274, pF315, DOI 10.1152/ajprenal.1998.274.2.F315; LIOTTA LA, 1986, P NATL ACAD SCI USA, V83, P3302, DOI 10.1073/pnas.83.10.3302; Little Edward, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P1; Liu H, 2001, BIOCHEMISTRY-US, V40, P5542, DOI 10.1021/bi002426w; Liu HP, 2002, BIOCHEM PHARMACOL, V64, P1745, DOI 10.1016/S0006-2952(02)01456-9; LYNCH RM, 1991, J CELL BIOL, V112, P385, DOI 10.1083/jcb.112.3.385; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; MARANGOS PJ, 1978, J NEUROCHEM, V31, P727, DOI 10.1111/j.1471-4159.1978.tb07847.x; MARTIN DS, 1994, CANCER INVEST, V12, P296, DOI 10.3109/07357909409023028; Martin DS, 1996, ANTI-CANCER DRUG, V7, P655, DOI 10.1097/00001813-199608000-00006; Martin DS, 2001, APOPTOSIS, V6, P125, DOI 10.1023/A:1009692631748; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Munoz-Pinedo C, 2003, J BIOL CHEM, V278, P12759, DOI 10.1074/jbc.M212392200; NABI IR, 1990, CANCER RES, V50, P409; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NATALI PG, 1984, ONCOLOGY, V41, P7, DOI 10.1159/000225879; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; NIEDERACHER D, 1991, EUR J BIOCHEM, V200, P311, DOI 10.1111/j.1432-1033.1991.tb16187.x; Niinaka Y, 1998, CANCER RES, V58, P2667; Niizeki H, 2002, BRIT J CANCER, V86, P1914, DOI 10.1038/sj.bjc.6600331; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Papaldo P, 2003, J CLIN ONCOL, V21, P3462, DOI 10.1200/JCO.2003.03.034; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pawlu C, 2005, FAM CANCER, V4, P49, DOI 10.1007/s10689-004-4227-4; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Penkowa M, 2004, J NEUROSCI RES, V77, P35, DOI 10.1002/jnr.20154; PERUCHO M, 1980, BIOCHIM BIOPHYS ACTA, V606, P181, DOI 10.1016/0005-2787(80)90028-3; Pirinen E, 2004, BBA-GENE STRUCT EXPR, V1676, P149, DOI 10.1016/j.bbaexp.2003.11.007; Pollard PJ, 2003, ANN MED, V35, P632, DOI 10.1080/07853890310018458; Rais B, 1999, FEBS LETT, V456, P113, DOI 10.1016/S0014-5793(99)00924-2; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Rathmell JC, 2003, MOL CELL BIOL, V23, P7315, DOI 10.1128/MCB.23.20.7315-7328.2003; Rempel A, 1996, CANCER RES, V56, P2468; Rodriguez A, 2001, BIOCHEM J, V355, P625, DOI 10.1042/bj3550625; ROSBE KW, 1989, CANCER CHEMOTH PHARM, V25, P32, DOI 10.1007/BF00694335; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; Seker H, 2000, BRIT J CANCER, V82, P629, DOI 10.1054/bjoc.1999.0974; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; SEMENZA GL, 2001, NOVART FDN SYMP, V240, P51260; Serkova N, 2005, AM J PHARMACOGENOMIC, V5, P293, DOI 10.2165/00129785-200505050-00002; Shashidharan P, 1999, NEUROREPORT, V10, P1149, DOI 10.1097/00001756-199904060-00045; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; Singh KK, 2004, ANN NY ACAD SCI, V1019, P260, DOI 10.1196/annals.1297.043; Sirover MA, 2005, J CELL BIOCHEM, V95, P45, DOI 10.1002/jcb.20399; STRUMILO SA, 1984, BIOMED BIOCHIM ACTA, V43, P159; Sun YJ, 1999, P NATL ACAD SCI USA, V96, P5412, DOI 10.1073/pnas.96.10.5412; Taguchi K, 2001, Rinsho Byori, VSuppl 116, P117; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Tretter L, 2005, PHILOS T R SOC B, V360, P2335, DOI 10.1098/rstb.2005.1764; VANDEBERG JL, 1985, ISOZYMES-CURR T BIOL, V12, P133; VANSCHAFTINGEN E, 1986, EUR J BIOCHEM, V159, P359; Varshney R, 2005, INT J RADIAT BIOL, V81, P397, DOI 10.1080/09553000500148590; Varshney R., 2003, Indian Journal of Experimental Biology, V41, P1384; Veyhl M, 1998, P NATL ACAD SCI USA, V95, P2914, DOI 10.1073/pnas.95.6.2914; VORA S, 1930, METABOLISM TUMORS; Waldron RT, 2000, J BIOL CHEM, V275, P17114, DOI 10.1074/jbc.M908959199; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WARBURG O, 2004, BIOCHEM Z, V152, P309; Watanabe H, 1996, CANCER RES, V56, P2960; Weindruch R, 2001, J GERONTOL A-BIOL, V56, P20, DOI 10.1093/gerona/56.suppl_1.20; WILLIAMS KR, 1985, P NATL ACAD SCI USA, V82, P5260, DOI 10.1073/pnas.82.16.5260; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; XU LZ, 1995, BIOCHEMISTRY-US, V34, P6083, DOI 10.1021/bi00018a011; Xu RH, 2005, CANCER RES, V65, P613; Xu RH, 2005, LEUKEMIA, V19, P2153, DOI 10.1038/sj.leu.2403968; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Zhao YB, 2005, WORLD J GASTROENTERO, V11, P3304, DOI 10.3748/wjg.v11.i21.3304; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zhou JR, 1999, J NUTR, V129, P1628, DOI 10.1093/jn/129.9.1628; Zhu WZ, 2005, CARCINOGENESIS, V26, P145, DOI 10.1093/carcin/bgh282; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	150	1067	1144	3	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4633	4646		10.1038/sj.onc.1209597	http://dx.doi.org/10.1038/sj.onc.1209597			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892078				2022-12-28	WOS:000239687000002
J	Duan, H; Heckman, CA; Boxer, LM				Duan, H.; Heckman, C. A.; Boxer, L. M.			The immunoglobulin heavy-chain gene 3 ' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells	ONCOGENE			English	Article						follicular lymphoma; bcl-2; promoter usage; IgH enhancer	LOCUS-CONTROL REGION; EXPRESSION; CHEMORESISTANCE; TRANSCRIPTION; APOPTOSIS; PROTEIN	In t(14;18) lymphomas, bcl-2 is juxtaposed to the immunoglobulin heavy-chain gene (IgH), resulting in increased bcl-2 transcription and resistance to apoptosis. Regulatory elements of both the bcl-2 promoter and the IgH enhancers are believed to play a role in the increased expression of bcl-2 in t(14;18) lymphoma cells. In addition, transcription of the translocated bcl-2 allele is deregulated with activation of the normally minor bcl-2 P2 promoter. The mechanisms involved in the promoter shift from P1 to P2 are not known. We found that the murine IgH 30 enhancers increased bcl-2 P2 promoter activity in an episomal model of the translocation, and IgH enhancer region HS12 had the greatest effect. Quantitative chromatin immunoprecipitation (ChIP) assays revealed that localized histone H3 hyperacetylation of the P2 promoter was observed on the translocated allele in t(14;18) DHL-4 cells and also on the stably transfected bcl-2 promoter-IgH enhancer episomal construct. Analysis of the HS12 enhancer region revealed that a previously identified nuclear factor-kappa B (NF-kappa B) site and a previously uncharacterized downstream Cdx site, both of which are conserved in the human and murine IgH enhancers, were important for its enhancer activity and promoter activation. ChIP assays showed that C/EBP beta bound to the HS12 Cdx site in vivo, and mutation of this site abrogated the binding of C/EBP beta. Reduced expression of C/EBP beta by transfection of small interfering RNA or interference with NF-kappa B activity decreased transcription from the bcl-2 promoters. These results demonstrate that the IgH 30 enhancers, particularly HS12, are important for the deregulation of bcl-2 promoter usage in t(14;18) lymphomas.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Stanford, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Boxer, LM (corresponding author), Stanford Univ, Sch Med, Dept Hematol, CCSR 1155,269 Campus Dr, Stanford, CA 94305 USA.	lboxer@stanford.edu		Heckman, Caroline/0000-0002-4324-8706	NCI NIH HHS [CA56764] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056764, R56CA056764] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; Decary S, 2002, MOL CELL BIOL, V22, P7877, DOI 10.1128/MCB.22.22.7877-7888.2002; DESOIZE B, 1994, ANTICANCER RES, V14, P2291; Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005; Heckman CA, 2003, CANCER RES, V63, P6666; Heckman CA, 2003, ONCOGENE, V22, P7891, DOI 10.1038/sj.onc.1206639; Heckman CA, 2002, ONCOGENE, V21, P3898, DOI 10.1038/sj.onc.1205483; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Ji L, 1996, J BIOL CHEM, V271, P22687, DOI 10.1074/jbc.271.37.22687; Khamlichi AA, 2000, ADV IMMUNOL, V75, P317, DOI 10.1016/S0065-2776(00)75008-5; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Krumm A, 1998, P NATL ACAD SCI USA, V95, P13501, DOI 10.1073/pnas.95.23.13501; MADISEN L, 1994, GENE DEV, V8, P2212, DOI 10.1101/gad.8.18.2212; Madisen L, 1998, MOL CELL BIOL, V18, P6281, DOI 10.1128/MCB.18.11.6281; REED JC, 1994, ANN ONCOL, V5, pS61, DOI 10.1093/annonc/5.suppl_1.S61; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	19	20	21	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2635	2641		10.1038/sj.onc.1210061	http://dx.doi.org/10.1038/sj.onc.1210061			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043638				2022-12-28	WOS:000245831200010
J	Jo, M; Thomas, KS; Takimoto, S; Gaultier, A; Hsieh, EH; Lester, RD; Gonias, SL				Jo, M.; Thomas, K. S.; Takimoto, S.; Gaultier, A.; Hsieh, E. H.; Lester, R. D.; Gonias, S. L.			Urokinase receptor primes cells to proliferate in response to epidermal growth factor	ONCOGENE			English	Article						urokinase receptor; epidermal growth factor; ERK; c-Src; STAT5b	C-SRC INTERACTIONS; PLASMINOGEN-ACTIVATOR; EGF RECEPTOR; TYROSINE KINASES; BREAST-CANCER; PHOSPHORYLATION; TRANSACTIVATION; BINDING; SIGNAL; INTEGRINS	Epidermal growth factor (EGF) express es mitogenic activity by a mechanism that requires the EGF receptor (EGFR). We report that murine embryonic. broblasts ( MEFs) prolifer ate in response to EGF only when these cells express the urokinase receptor (uPAR). EGFR expression was equivalent in uPAR-/- and uPAR+/+ MEFs. In response to EGF, these cells demonstrated equivalent overall EGFR tyrosine phosphorylation and ERK/MAP kinase activation; however, phosphorylation of Tyr-845 in the EGFR, which has been implicated in cell growth, was substantially decreased in uPAR-/-MEFs. STAT5b activation also was decreased. As Tyr- 845 is a c- Src target, we overexpressed c- Src in uPAR-/- MEFs and rescued EGF mitogenic activity. Rescue also was achieved by expressing murine but not human uPAR, suggesting a role for autocrine uPAR cell- signaling. In MDA-MB 231 breast cancer cells, EGF mitogenic activity was blocked by uPAR gene silencing, with antibodies that block uPA-binding to uPAR, and with a synthetic peptide that disrupts uPAR-dependent cell signaling. Again, c-Src overexpression rescued the mitogenic activity of EGF. We conclude that uPAR-dependent cell-signaling may prime cells to proliferate in response to EGF by promoting Tyr-845 phosphorylation and STAT5b activation. The importance of this pathway depends on the c-Src level in the cell.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA	University of California System; University of California San Diego; University of Virginia	Gonias, SL (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	sgonias@ucsd.edu			NCI NIH HHS [CA-94900] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094900] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Angelucci A, 2006, ENDOCR-RELAT CANCER, V13, P197, DOI 10.1677/erc.1.01100; Biscardi JS, 1998, MOL CARCINOGEN, V21, P261, DOI 10.1002/(SICI)1098-2744(199804)21:4<261::AID-MC5>3.0.CO;2-N; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; BOLLA M, 1990, BREAST CANCER RES TR, V16, P97, DOI 10.1007/BF01809293; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Duffy MJ, 1999, J SURG ONCOL, V71, P130, DOI 10.1002/(SICI)1096-9098(199906)71:2<130::AID-JSO14>3.0.CO;2-9; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; Jo M, 2003, J BIOL CHEM, V278, P1642, DOI 10.1074/jbc.M210877200; Jo MJ, 2005, J BIOL CHEM, V280, P17449, DOI 10.1074/jbc.M413141200; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Kiyan J, 2005, EMBO J, V24, P1787, DOI 10.1038/sj.emboj.7600669; Kloth MT, 2003, J BIOL CHEM, V278, P1671, DOI 10.1074/jbc.M207289200; KOSHI S, 1997, TAIWAN J MATH, V1, P1; Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Ma Z, 2002, J CELL BIOL, V159, P1061, DOI 10.1083/jcb.200207070; Ma Z, 2001, J CELL SCI, V114, P3387; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; MAZZIERI R, 2006, ONCOGENE; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; Monaghan-Benson E, 2006, J BIOL CHEM, V281, P9450, DOI 10.1074/jbc.M501901200; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Nguyen DHD, 2000, J BIOL CHEM, V275, P19382, DOI 10.1074/jbc.M909575199; Nguyen DHD, 1998, J BIOL CHEM, V273, P8502, DOI 10.1074/jbc.273.14.8502; OREILLY DR, 1986, BIOL CELL, V57, P187, DOI 10.1111/j.1768-322X.1986.tb00475.x; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Singh AB, 2005, CELL SIGNAL, V17, P1183, DOI 10.1016/j.cellsig.2005.03.026; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Weaver AM, 1997, J BIOL CHEM, V272, P14372, DOI 10.1074/jbc.272.22.14372; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yan YB, 2002, J CELL BIOL, V158, P221, DOI 10.1083/jcb.200112026	42	52	56	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2585	2594		10.1038/sj.onc.1210066	http://dx.doi.org/10.1038/sj.onc.1210066			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043637				2022-12-28	WOS:000245831200006
J	Baril, P; Gangeswaran, R; Mahon, PC; Caulee, K; Kocher, HM; Harada, T; Zhu, M; Kalthoff, H; Crnogorac-Jurcevic, T; Lemoine, NR				Baril, P.; Gangeswaran, R.; Mahon, P. C.; Caulee, K.; Kocher, H. M.; Harada, T.; Zhu, M.; Kalthoff, H.; Crnogorac-Jurcevic, T.; Lemoine, N. R.			Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta(4) integrin and the PI3k pathway	ONCOGENE			English	Article						pancreatic cancer; periostin; invasion; survival; hypoxia; PI3kinase	GROWTH-FACTOR-BETA; IN-VITRO; EXTRACELLULAR-MATRIX; ADHESION MOLECULE; ALPHA-6-BETA-4 INTEGRIN; PROGNOSTIC MARKER; SEQUENCE-ANALYSIS; SERUM LEVEL; FASCICLIN-I; EXPRESSION	Pancreatic ductal adenocarcinoma is a devastating disease, characterized by a rapid progression and poor treatment response. Using gene expression pro. ling of pancreatic cancer tissues, we previously identified periostin as a potential diagnostic and therapeutic target. In this study, we report the overexpression of periostin in a larger set of pancreatic cancer tissues and show that although the periostin transcript is exclusively expressed in tumour cells, the protein product is only detected in the extracellular matrix adjacent to cancer cells. Using an enzyme-linked immunosorbent assay (ELISA) assay, we show significantly increased levels of periostin in the sera of pancreatic cancer patients compared to non-cancer controls. We demonstrate that periostin promotes the invasiveness of tumour cells by increasing the motility of cells without inducing expression of proteases, and enhances the survival of tumour cells exposed to hypoxic conditions. At the molecular level, we provide evidence that the alpha(6)beta(4) integrin complex acts as the cell receptor of periostin in pancreatic cancer cells and that interaction promotes phosphorylation of focal adhesion kinase (FAK) and protein kinase B (AKT) though activation of the PI3 kinase pathway, but not the RAS/MEK/ERK pathway. These findings suggest an important role of periostin in pancreatic cancer and provide a rationale to study periostin for diagnostic and therapeutic applications.	Ctr Mol Oncol, Inst Canc, Barts & The London, London, England; John Vane Sci Ctr, London Sch Med & Dent, London EC1M 6BQ, England; CR UK Clin Ctr, Barts & The London, London, England; Ctr Tumour Biol, Barts & The London, Inst Canc, London, England; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA; Univ Kiel, Clin Gen Surg & Thorac Surg, D-24098 Kiel, Germany	University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of London; Queen Mary University London; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Kiel	Lemoine, NR (corresponding author), Ctr Mol Oncol, Inst Canc, Barts & The London, London, England.	nick.lemoine@cancer.org.uk	Kalthoff, Holger/B-1618-2010	Kocher, Hemant M/0000-0001-6771-1905; BARIL, Patrick/0000-0001-8290-9899				Akakura N, 2001, CANCER RES, V61, P6548; Bao SD, 2004, CANCER CELL, V5, P329, DOI 10.1016/S1535-6108(04)00081-9; Billings PC, 2002, J BIOL CHEM, V277, P28003, DOI 10.1074/jbc.M106837200; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Boukerche H, 2000, CANCER RES, V60, P5848; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; DiMagno EP, 1999, GASTROENTEROLOGY, V117, P1464, DOI 10.1016/S0016-5085(99)70298-2; Dowen SE, 2005, AM J PATHOL, V166, P81, DOI 10.1016/S0002-9440(10)62234-1; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Gibson MA, 1997, J HISTOCHEM CYTOCHEM, V45, P1683, DOI 10.1177/002215549704501212; Gillan L, 2002, CANCER RES, V62, P5358; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; HALL PA, 1991, J PATHOL, V165, P33, DOI 10.1002/path.1711650107; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; Hosotani Ryo, 2002, Pancreas, V25, pe30, DOI 10.1097/00006676-200208000-00021; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kii I, 2006, BIOCHEM BIOPH RES CO, V342, P766, DOI 10.1016/j.bbrc.2006.02.016; Kim CJ, 2005, INT J CANCER, V117, P51, DOI 10.1002/ijc.21120; Kim MO, 2003, NEUROSCI LETT, V336, P93, DOI 10.1016/S0304-3940(02)01260-0; Koninger J, 2004, BIOCHEM BIOPH RES CO, V322, P943, DOI 10.1016/j.bbrc.2004.08.008; Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; Li P, 2004, J APPL PHYSIOL, V97, P1550, DOI 10.1152/japplphysiol.01311.2003; Lindner V, 2005, ARTERIOSCL THROM VAS, V25, P77, DOI 10.1161/01.ATV.0000149141.81230.c6; Lipscomb EA, 2005, CANCER METAST REV, V24, P413, DOI 10.1007/s10555-005-5133-4; Litvin J, 2005, ANAT REC PART A, V287A, P1205, DOI 10.1002/ar.a.20237; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Rich JN, 2003, J BIOL CHEM, V278, P15951, DOI 10.1074/jbc.M211498200; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sasaki H, 2003, BREAST CANCER RES TR, V77, P245, DOI 10.1023/A:1021899904332; Sasaki H, 2002, J PEDIATR SURG, V37, P1293, DOI 10.1053/jpsu.2002.34985; Sasaki H, 2001, CANCER-AM CANCER SOC, V92, P843, DOI 10.1002/1097-0142(20010815)92:4<843::AID-CNCR1391>3.0.CO;2-P; Sasaki H, 2001, JPN J CANCER RES, V92, P869, DOI 10.1111/j.1349-7006.2001.tb01174.x; Sasaki H, 2001, CANCER LETT, V172, P37, DOI 10.1016/S0304-3835(01)00633-4; Shao R, 2004, MOL CELL BIOL, V24, P3992, DOI 10.1128/MCB.24.9.3992-4003.2004; Shi Q, 2004, J BIOL CHEM, V279, P52200, DOI 10.1074/jbc.M409630200; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Stoll V, 2005, GUT, V54, P109, DOI 10.1136/gut.2004.046706; Tai IT, 2005, CARCINOGENESIS, V26, P908, DOI 10.1093/carcin/bgi034; TAKESHITA S, 1993, BIOCHEM J, V294, P271, DOI 10.1042/bj2940271; Yoon SO, 2005, CANCER RES, V65, P2761, DOI 10.1158/0008-5472.CAN-04-4122; Zhao HR, 2004, J BIOL CHEM, V279, P8592, DOI 10.1074/jbc.M308708200; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	46	227	243	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2082	2094		10.1038/sj.onc.1210009	http://dx.doi.org/10.1038/sj.onc.1210009			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043657				2022-12-28	WOS:000245313400010
J	Perez-Caro, M; Gutierrez-Cianca, N; Gonzalez-Herrero, I; Lopez-Hernandez, I; Flores, T; Orfao, A; Sanchez-Martin, M; Gutierrez-Adan, A; Pintado, B; Sanchez-Garcia, I				Perez-Caro, M.; Gutierrez-Cianca, N.; Gonzalez-Herrero, I.; Lopez-Hernandez, I.; Flores, T.; Orfao, A.; Sanchez-Martin, M.; Gutierrez-Adan, A.; Pintado, B.; Sanchez-Garcia, I.			Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice	ONCOGENE			English	Article						cancer maintenance; dox regulation; fusion genes; cancer stem cell; mouse models	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; COMPLETE CYTOGENETIC REMISSION; IMATINIB MESYLATE TREATMENT; BCR-ABL; PHILADELPHIA-CHROMOSOME; IN-VIVO; HEMATOPOIETIC PROGENITORS; CANCER DEVELOPMENT	Pharmacological inactivation of cancer genes or products is being used as a strategy for therapy in oncology. To investigate the potential role of BCR-ABLp190 cessation in leukaemia development, we generated mice carrying a tetracycline-repressible BCR-ABLp190 transgene. These mice were morphologically normal at birth, and developed leukaemias. Disease was characterized by the presence of B-cell blasts co-expressingmyeloid markers, reminiscent of the human counterpart. BCR-ABLp190 activation can initiate leukaemia in both young and adult mice. Transitory expression of BCR-ABLp190 is enough to develop leukaemia. Suppression of the BCR-ABLp190 transgene in leukaemic CombitTA-p190 mice did not rescue the malignant phenotype, indicating that BCR-ABLp190 is not required to maintain the disease in mice. Similar results were obtained by inactivation of BCR-ABLp190 with STI571 (Gleevec; Novartis, East Hanover, NJ, USA) in leukaemic CombitTA-p190 mice. However, gradual suppression of BCR-ABLp190 in leukaemic CombitTA-p190 mice identified a minimum level of BCR-ABLp190 expression necessary to revert the specific block in B-cell differentiation in the leukaemic cells. Overall, the findings indicate that BCR-ABLp190 appears to cause epigenetic and/or genetic changes in tumour-maintaining cells that render them insensitive to BCR-ABLp190 inactivation.	Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, E-37007 Salamanca, Spain; Univ Salamanca, Serv Anat Patol, E-37007 Salamanca, Spain; Univ Salamanca, Serv Citometria, E-37007 Salamanca, Spain; Univ Salamanca, Dept Med, E-37007 Salamanca, Spain; Ctr Invest & Tecnol, Area Reprod Anim, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Salamanca; University of Salamanca; University of Salamanca	Sanchez-Garcia, I (corresponding author), Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, Lab 13, Campus Unamuno S-N, E-37007 Salamanca, Spain.	isg@usal.es	Sanchez-Martin, Manuel/N-5327-2016; Gutierrez-Adan, Alfonso/A-1485-2014; 2007, Secribsal/A-1556-2012; SANCHEZ-GARCIA, ISIDRO/A-5631-2019; González-Herrero, Inés/G-8546-2015; Orfao, Alberto/B-5801-2017; Pintado, Belen/N-3233-2014	Sanchez-Martin, Manuel/0000-0001-8370-1336; Gutierrez-Adan, Alfonso/0000-0001-9893-9179; González-Herrero, Inés/0000-0003-1142-4362; Pintado, Belen/0000-0002-8485-2520; SANCHEZ-GARCIA, ISIDRO/0000-0001-6989-9905				Bhatia R, 2003, BLOOD, V101, P4701, DOI 10.1182/blood-2002-09-2780; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; Chu S, 2005, BLOOD, V105, P2093, DOI 10.1182/blood-2004-03-1114; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; Cobaleda C, 2000, BLOOD, V95, P1007, DOI 10.1182/blood.V95.3.1007.003k35_1007_1013; Cobaleda C, 1998, BIOESSAYS, V20, P922, DOI 10.1002/(SICI)1521-1878(199811)20:11<922::AID-BIES7>3.0.CO;2-O; COPELAN EA, 1995, BLOOD, V85, P1151, DOI 10.1182/blood.V85.5.1151.bloodjournal8551151; Cox CV, 2004, BLOOD, V104, P2919, DOI 10.1182/blood-2004-03-0901; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041; FORD AM, 1983, EMBO J, V2, P997, DOI 10.1002/j.1460-2075.1983.tb01533.x; GarciaHernandez B, 1997, P NATL ACAD SCI USA, V94, P13239, DOI 10.1073/pnas.94.24.13239; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; GRIFFITHS SD, 1992, ONCOGENE, V7, P1391; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Mauro MJ, 2001, ONCOLOGIST, V6, P233, DOI 10.1634/theoncologist.6-3-233; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; O'Dwyer ME, 2001, CURR CANCER DRUG TAR, V1, P49, DOI 10.2174/1568009013334250; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; Perez-Caro M, 2005, CURR GENOMICS, V6, P81, DOI 10.2174/1389202053642276; Perez-Mancera PA, 2005, HUM MOL GENET, V14, P3449, DOI 10.1093/hmg/ddi373; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Sanchez-Garcia I, 1997, ANNU REV GENET, V31, P429, DOI 10.1146/annurev.genet.31.1.429; SANCHEZGARCIA I, 1995, P NATL ACAD SCI USA, V92, P5287, DOI 10.1073/pnas.92.12.5287; Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339; Schultze N, 1996, NAT BIOTECHNOL, V14, P499, DOI 10.1038/nbt0496-499; SECKERWALKER LM, 1991, GENE CHROMOSOME CANC, V3, P320; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; SKORSKI T, 1994, P NATL ACAD SCI USA, V91, P4504, DOI 10.1073/pnas.91.10.4504; SZCZYLIK C, 1991, SCIENCE, V253, P562, DOI 10.1126/science.1857987; Tabernero MD, 2001, LEUKEMIA, V15, P406, DOI 10.1038/sj.leu.2402060; Towatari M, 2004, BLOOD, V104, P3507, DOI 10.1182/blood-2004-04-1389; Van Etten R A, 2001, Curr Oncol Rep, V3, P228; Wendel HG, 2006, P NATL ACAD SCI USA, V103, P7444, DOI 10.1073/pnas.0602402103; Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Zhao RCH, 1997, BLOOD, V90, P4687, DOI 10.1182/blood.V90.12.4687.4687_4687_4698	48	20	23	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1702	1713		10.1038/sj.onc.1209968	http://dx.doi.org/10.1038/sj.onc.1209968			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983340				2022-12-28	WOS:000244955600004
J	Achison, M; Boylan, MT; Hupp, TR; Spruce, BA				Achison, M.; Boylan, M. T.; Hupp, T. R.; Spruce, B. A.			HIF-1 alpha contributes to tumour-selective killing by the sigma receptor antagonist rimcazole	ONCOGENE			English	Article						HIF-1 alpha; hypoxia; rimcazole; p53	HYPOXIA-INDUCIBLE FACTOR-1; GROWTH-FACTOR EXPRESSION; HUMAN CANCER-CELLS; TRANSCRIPTIONAL REPRESSION; FACTOR 1-ALPHA; P53; CARCINOMA; APOPTOSIS; HIF-1; DEATH	We have previously reported tumour-selective killing by the sigma(sigma) receptor ligand rimcazole. We now report that rimcazole elevates hypoxia inducible factor-1 alpha (HIF-1 alpha) protein levels under normoxic conditions in colorectal (HCT-116) and mammary carcinoma (MDA MB 231) cells but fails to induce HIF-1 alpha in normal fibroblasts or mammary epithelial cells. Combining the sigma-1 agonist (+)-pentazocine with rimcazole substantially reduces the accumulation of HIF-1 alpha, confirming that the effect is mediated at least partly by antagonism of sigma-1 sites. HIF-1 alpha knockdown by RNA interference attenuates rimcazole-induced cell death in both cell types. Thus, the induction of HIF-1 alpha by rimcazole contributes to tumour cell killing. In a comparison of HCT-116p53(+/+) and HCT-116p53(-/-) cells, HIF-1 alpha levels are consistently higher after rimcazole treatment in HCT-116p53(+/+) cells. Furthermore, although rimcazole kills HCT-116p53(-/-) cells, it has a more potent apoptosis-inducing effect in HCT-116p53+/+ cells. This suggests that the presence of functional p53 protein may enhance death induction by rimcazole in part through greater induction of HIF-1 alpha p53 is not required, however, for the rimcazole-induced engagement of HIF-1 alpha in proapoptotic mode as HIF-1 alpha knockdown attenuates rimcazole-induced death to comparable extents in p53 mutant and wild-type cell systems. Knowledge of HIF-1 alpha involvement may assist the re-pro. ling of rimcazole and other sigma ligands as cancer therapeutics.	Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Edinburgh, Western Gen Hosp, CRUK Canc Res Labs, Signal Transduct Unit P53, Edinburgh, Midlothian, Scotland	University of Dundee; University of Edinburgh	Spruce, BA (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland.	b.a.spruce@dundee.ac.uk						Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434; An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arends JW, 2000, J PATHOL, V190, P412; Bacon AL, 2004, ANN MED, V36, P530, DOI 10.1080/07853890410018231; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chen DL, 2003, J BIOL CHEM, V278, P13595, DOI 10.1074/jbc.C200694200; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Giaccia AJ, 1998, SCIENCE, V279, P12; Gilmore DL, 2004, CNS DRUG REV, V10, P1; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hansson LO, 2002, P NATL ACAD SCI USA, V99, P10305, DOI 10.1073/pnas.122347199; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Koumenis C, 2001, MOL CELL BIOL, V21, P1297, DOI 10.1128/MCB.21.4.1297-1310.2001; Krishnamachary B, 2003, CANCER RES, V63, P1138; Langa F, 2003, EUR J NEUROSCI, V18, P2188, DOI 10.1046/j.1460-9568.2003.02950.x; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Magnusson KP, 1998, ONCOGENE, V17, P2333, DOI 10.1038/sj.onc.1202149; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sanchez-Puig N, 2005, MOL CELL, V17, P11, DOI 10.1016/j.molcel.2004.11.019; Schmid T, 2004, BIOCHEM J, V380, P289, DOI 10.1042/BJ20031299; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Spruce BA, 2004, CANCER RES, V64, P4875, DOI 10.1158/0008-5472.CAN-03-3180; WALDMAN T, 1995, CANCER RES, V55, P5187; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Yim S, 2003, J BIOL CHEM, V278, P38260, DOI 10.1074/jbc.M306016200; Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598	34	18	20	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1137	1146		10.1038/sj.onc.1209890	http://dx.doi.org/10.1038/sj.onc.1209890			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924239				2022-12-28	WOS:000244406400004
J	Bradley, KJ; Bowl, MR; Williams, SE; Ahmad, BN; Partridge, CJ; Patmanidi, AL; Kennedy, AM; Loh, NY; Thakker, RV				Bradley, K. J.; Bowl, M. R.; Williams, S. E.; Ahmad, B. N.; Partridge, C. J.; Patmanidi, A. L.; Kennedy, A. M.; Loh, N. Y.; Thakker, R. V.			Parafibromin is a nuclear protein with a functional monopartite nuclear localization signal	ONCOGENE			English	Article						parathyroid cancer; tumour suppressor gene; uterine tumours; renal tumours; ossifying fibromas	JAW TUMOR SYNDROME; PARATHYROID CARCINOMA; GENE-PRODUCT; HUMAN PAF1; HYPERPARATHYROIDISM; HRPT2; MUTATIONS; RETINOBLASTOMA; IDENTIFICATION; DYSPLASIA	Parafibromin is a nuclear protein with a tumour suppressor role in the development of non-hereditary and hereditary parathyroid carcinomas, and the hyperparathyroidism-jaw tumour (HPT-JT) syndrome, which is associated with renal and uterine tumours. Nuclear localization signal( s), (NLS(s)), of the 61kDa parafibromin remain to be defined. Utilization of computer-prediction programmes, identified five NLSs (three bipartite ( BP) and two monopartite ( MP)). To investigate their functionality, wild-type (WT) and mutant parafibromin constructs tagged with enhanced green fluorescent protein or cMyc were transiently expressed in COS-7 cells, or human embryonic kidney 293 (HEK293) cells, and their subcellular locations determined by confocal fluorescence microscopy. Western blot analyses of nuclear and cytoplasmic fractions from the transfected cells were also performed. WT parafibromin localized to the nucleus and deletions or mutations of the three predicted BP and one of the predicted MP NLSs did not affect this localization. In contrast, deletions or mutations of a MP NLS, at residues 136-139, resulted in loss of nuclear localization. Furthermore, the critical basic residues, KKXR, of this MP NLS were found to be evolutionarily conserved, and over 60% of all parafibromin mutations lead to a loss of this NLS. Thus, an important functional domain of parafibromin, consisting of an evolutionarily conserved MP NLS, has been identified.	Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England; Univ Oxford, Diabet Res Labs, Nuffield Dept Clin Med, Dept Clin Med,Churchill Hosp,OCDEM, Oxford OX3 7LJ, England	University of Oxford; University of Oxford	Thakker, RV (corresponding author), Univ Oxford, OCDEM, Nuffield Dept Clin Med, Acad Endocrine Unit,Churchil Hosp, Oxford OX3 7LJ, England.	rajesh.thakker@ndm.ox.ac.uk		Kennedy, Ann/0000-0003-0290-396X; Piret, Sian/0000-0002-3586-7654; Patmanidi, Alexandra/0000-0003-0773-2020; Bowl, Michael/0000-0001-7971-445X; Thakker, Rajesh/0000-0002-1438-3220	Medical Research Council [G9825289] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G9825289] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Bradley KJ, 2006, CLIN ENDOCRINOL, V64, P299, DOI 10.1111/j.1365-2265.2006.02460.x; Bradley KJ, 2005, J INTERN MED, V257, P18, DOI 10.1111/j.1365-2796.2004.01421.x; Carpten JD, 2002, NAT GENET, V32, P676, DOI 10.1038/ng1048; Cavaco BM, 2001, QJM-INT J MED, V94, P213, DOI 10.1093/qjmed/94.4.213; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Fabbro M, 2003, EXP CELL RES, V282, P59, DOI 10.1016/S0014-4827(02)00019-8; Fontes MRM, 2003, J BIOL CHEM, V278, P27981, DOI 10.1074/jbc.M303275200; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Hahn MA, 2005, ONCOGENE, V24, P6241, DOI 10.1038/sj.onc.1208778; Haven CJ, 2000, J CLIN ENDOCR METAB, V85, P1449, DOI 10.1210/jc.85.4.1449; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Howell VM, 2003, J MED GENET, V40, P657, DOI 10.1136/jmg.40.9.657; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Kennedy AM, 2005, J CLIN INVEST, V115, P2832, DOI 10.1172/JCI22900; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Krauer K, 2004, J GEN VIROL, V85, P165, DOI 10.1099/vir.0.19549-0; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200; Quadrini KJ, 2002, J BIOL CHEM, V277, P32243, DOI 10.1074/jbc.M205677200; Rozenblatt-Rosen O, 2005, MOL CELL BIOL, V25, P612, DOI 10.1128/MCB.25.2.612-620.2005; Shattuck TM, 2003, NEW ENGL J MED, V349, P1722, DOI 10.1056/NEJMoa031237; SZABO J, 1995, AM J HUM GENET, V56, P944; Tan MH, 2004, CLIN CANCER RES, V10, P6629, DOI 10.1158/1078-0432.CCR-04-0493; Teh BT, 1996, J CLIN ENDOCR METAB, V81, P4204, DOI 10.1210/jc.81.12.4204; THAKKER RV, 2006, ENDOCRINOLOGY, V2, P1511; Vandenbroucke I, 2004, FEBS LETT, V560, P98, DOI 10.1016/S0014-5793(04)00078-X; Woodard GE, 2005, ONCOGENE, V24, P1272, DOI 10.1038/sj.onc.1208274; Yart A, 2005, MOL CELL BIOL, V25, P5052, DOI 10.1128/MCB.25.12.5052-5060.2005; ZACKSENHAUS E, 1993, MOL CELL BIOL, V13, P4588, DOI 10.1128/MCB.13.8.4588	30	49	49	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1213	1221		10.1038/sj.onc.1209893	http://dx.doi.org/10.1038/sj.onc.1209893			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964291				2022-12-28	WOS:000244406400011
J	Choi, YL; Tsukasaki, K; O'Neill, MC; Yamada, Y; Onimaru, Y; Matsumoto, K; Ohashi, J; Yamashita, Y; Tsutsumi, S; Kaneda, R; Takada, S; Aburatani, H; Kamihira, S; Nakamura, T; Tomonaga, M; Mano, H				Choi, Y. L.; Tsukasaki, K.; O'Neill, M. C.; Yamada, Y.; Onimaru, Y.; Matsumoto, K.; Ohashi, J.; Yamashita, Y.; Tsutsumi, S.; Kaneda, R.; Takada, S.; Aburatani, H.; Kamihira, S.; Nakamura, T.; Tomonaga, M.; Mano, H.			A genomic analysis of adult T-cell leukemia	ONCOGENE			English	Article						adult T-cell leukemia; DNA microarray; MET; artificial neural network	HEPATOCYTE GROWTH-FACTOR; VIRUS TYPE-I; C-MET PROTOONCOGENE; GENE-EXPRESSION; HOMOZYGOUS DELETIONS; HTLV-I; LYMPHOMA; IDENTIFICATION; LEUKEMIA/LYMPHOMA; FEATURES	Adult T-cell leukemia (ATL) is an intractable malignancy of CD4(+) T cells that is etiologically associated with infection by human T-cell leukemia virus-type I. Most individuals in the chronic stage of ATL eventually undergo progression to a highly aggressive acute stage. To clarify the mechanism responsible for this stage progression, we isolated CD4(+) cells from individuals in the chronic ( n =19) or acute ( n = 22) stages of ATL and subjected them to pro. ling of gene expression with DNA micro-arrays containing > 44 000 probe sets. Changes in chromosome copy number were also examined for 24 cell specimens with the use of microarrays harboring similar to 50 000 probe sets. Stage-dependent changes in gene expression pro. le and chromosome copy number were apparent. Furthermore, expression of the gene for MET, a receptor tyrosine kinase for hepatocyte growth factor (HGF), was shown to be specific to the acute stage of ATL, and the plasma concentration of HGF was increased in individuals in either the acute or chronic stage. HGF induced proliferation of a MET-positive ATL cell line, and this effect was blocked by antibodies to HGF. The HGF-MET signaling pathway is thus a potential therapeutic target for ATL.	Jichi Med Univ, Div Funct Genom, Shimotsukeshi, Tochigi 3290498, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Nagasaki 852, Japan; Univ Maryland, Dept Biol Sci, Baltimore, MD 21201 USA; Nagasaki Univ, Dept Lab Med, Grad Sch Biomed Sci, Nagasaki 852, Japan; Osaka Univ, Grad Sch Med, Div Mol Regenerat Med, Osaka, Japan; Univ Tokyo, Grad Sch Med, Dept Human Genet, Tokyo, Japan; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo, Japan	Jichi Medical University; Nagasaki University; University System of Maryland; University of Maryland Baltimore; Nagasaki University; Osaka University; University of Tokyo; University of Tokyo	Mano, H (corresponding author), Jichi Med Univ, Div Funct Genom, 3311-1 Yakushiji, Shimotsukeshi, Tochigi 3290498, Japan.	hmano@jichi.ac.jp	Matsumoto, Kunio/D-8441-2015; OHASHI, JUN/G-5907-2015	Matsumoto, Kunio/0000-0002-6532-4482; Takada, Shuji/0000-0002-9406-4683				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Ariyama Y, 1999, J HUM GENET, V44, P357, DOI 10.1007/s100380050178; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BROADUS AE, 1988, NEW ENGL J MED, V319, P556; CESARMAN E, 1992, BLOOD, V80, P3205; Choi YL, 2004, LEUKEMIA, V18, P556, DOI 10.1038/sj.leu.2403261; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; Funakoshi H, 2003, CLIN CHIM ACTA, V327, P1, DOI 10.1016/S0009-8981(02)00302-9; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; Imaizumi Y, 2003, CLIN CANCER RES, V9, P181; Lin M, 2004, BIOINFORMATICS, V20, P1233, DOI 10.1093/bioinformatics/bth069; Lockett A, 2005, J MANAGE INQUIRY, V14, P139, DOI 10.1177/1056492605276645; MATSUMOTO K, 1992, BIOCHEM BIOPH RES CO, V188, P235, DOI 10.1016/0006-291X(92)92375-8; Matsuoka M, 2003, ONCOGENE, V22, P5131, DOI 10.1038/sj.onc.1206551; MIGONE TS, 1995, SCIENCE, V269, P79, DOI 10.1126/science.7604283; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MOTOKURA T, 1988, BIOCHEM BIOPH RES CO, V154, P1182, DOI 10.1016/0006-291X(88)90265-3; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; Nosaka K, 2000, CANCER RES, V60, P1043; O'Neill MC, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-13; Oshiro A, 2006, BLOOD, V107, P4500, DOI 10.1182/blood-2005-09-3801; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Sasaki H, 2005, BLOOD, V105, P1204, DOI 10.1182/blood-2004-03-1222; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; TAJIMA K, 1990, INT J CANCER, V45, P237, DOI 10.1002/ijc.2910450206; Tamiya S, 1998, BLOOD, V91, P3935; TAMURA M, 1993, J BIOL CHEM, V268, P8140; Tsukasaki K, 2004, INT J CANCER, V109, P875, DOI 10.1002/ijc.20028; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WANO Y, 1987, J CLIN INVEST, V80, P911, DOI 10.1172/JCI113152; Yamada Y, 1996, LEUKEMIA LYMPHOMA, V21, P443, DOI 10.3109/10428199609093442; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778; Yamashita Y, 2001, J BIOL CHEM, V276, P39012, DOI 10.1074/jbc.M106249200; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	38	61	66	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1245	1255		10.1038/sj.onc.1209898	http://dx.doi.org/10.1038/sj.onc.1209898			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16909099				2022-12-28	WOS:000244406400015
J	Castellano, E; De las Rivas, J; Guerrero, C; Santos, E				Castellano, E.; De Las Rivas, J.; Guerrero, C.; Santos, E.			Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses	ONCOGENE			English	Article						H-Ras; N-Ras; microarray; genomics; transcriptome; cluster analysis; differential gene expression	K-RAS; PLASMA-MEMBRANE; DIFFERENTIAL ACTIVATION; INTERFERON-ALPHA; GENE-EXPRESSION; PROTEIN-KINASE; MOUSE; TRANSFORMATION; GROWTH; RECEPTOR	We characterized differential gene expression profiles of fibroblast cell lines harboring single or double-homozygous null mutations in H-ras and N-ras. Whereas the expression level of the individual H-, N- and K-ras genes appeared unaffected by the presence or absence of the other ras loci, significant differences were observed between the expression profiles of cells missing N-ras and/or H-ras. Absence of N-ras produced much stronger effects than absence of H-ras over the pro. le of the cellular transcriptome. N-ras(-/-) and H-ras(-/-). broblasts displayed rather antagonistic expression profiles and the transcriptome of H-ras(-/-) cells was significantly closer to that of wild-type. broblasts than to that of N- ras(-/-) cells. Classifying all differentially expressed genes into functional categories suggested specific roles for H-Ras and N-Ras. It was particularly strikingin N-ras(-/-) cells the upregulation of a remarkable number of immunity-related genes, as well as of several loci involved in apoptosis. Reverse-phase protein array assays demonstrated in the same N- ras(-/-) cells the overexpression and nuclear migration of tyrosine phosphorylated signal transducer and activator of transcription 1 (Stat1) which was concomitant with transcriptional activation mediated by interferon-stimulated response elements. Significantly enhanced numbers of apoptotic cells were also detected in cultures of N-ras(-/-) cells. Our data support the notion that different Ras isoforms play functionally distinct cellular roles and indicate that N-Ras is significantly involved in immune modulation/host defense and apoptotic responses.	Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca	Santos, E (corresponding author), Univ Salamanca, Ctr Invest Canc, CSIC, USAL,Inst Biol Mol & Celular Canc, Salamanca 37007, Spain.	esantos@usal.es	Guerrero, Carmen/F-1776-2010; 2007, Secribsal/A-1556-2012; Sánchez, Esther Castellano/AAA-8087-2020; De Las Rivas, Javier/G-5936-2014	Guerrero, Carmen/0000-0002-8747-6831; Sánchez, Esther Castellano/0000-0002-8449-4081; De Las Rivas, Javier/0000-0002-0984-9946				Barash Y, 2004, BIOINFORMATICS, V20, P839, DOI 10.1093/bioinformatics/btg487; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; BOS JL, 1989, CANCER RES, V49, P4682; Brem R, 2001, ONCOGENE, V20, P2854, DOI 10.1038/sj.onc.1204403; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Croonquist PA, 2003, BLOOD, V102, P2581, DOI 10.1182/blood-2003-04-1227; DAVIES SA, 1989, BIOCHIM BIOPHYS ACTA, V1013, P173, DOI 10.1016/0167-4889(89)90046-3; Dumaz N, 2005, FEBS J, V272, P3491, DOI 10.1111/j.1742-4658.2005.04763.x; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873; Espina V, 2003, PROTEOMICS, V3, P2091, DOI 10.1002/pmic.200300592; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Hamilton M, 1998, J BIOL CHEM, V273, P28155, DOI 10.1074/jbc.273.43.28155; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Herrmann PC, 2003, PROTEOMICS, V3, P1801, DOI 10.1002/pmic.200300461; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Improta T, 1997, CYTOKINE, V9, P383, DOI 10.1006/cyto.1996.0180; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Kisseleva T, 2002, GENE, V285, P1, DOI 10.1016/S0378-1119(02)00398-0; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; MAHER J, 1995, ONCOGENE, V11, P1639; Matallanas D, 2006, MOL CELL BIOL, V26, P100, DOI 10.1128/MCB.26.1.100-116.2006; Murtagh F., 1985, COMPSTAT LECT, V4; Ohnami S, 2003, BIOCHEM BIOPH RES CO, V309, P798, DOI 10.1016/j.bbrc.2003.08.073; Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200; Perez de Castro I, 2004, MOL CELL BIOL, V24, P3485, DOI 10.1128/MCB.24.8.3485-3496.2004; Perez de Castro I, 2003, CANCER RES, V63, P1615; Petricoin EF, 1997, NATURE, V390, P629, DOI 10.1038/37648; PINEDA JA, 1994, COGNITIVE BRAIN RES, V2, P1, DOI 10.1016/0926-6410(94)90015-9; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Plowman SJ, 2005, BBA-MOL CELL RES, V1746, P274, DOI 10.1016/j.bbamcr.2005.06.004; Plowman SJ, 2003, MOL CELL BIOL, V23, P9245, DOI 10.1128/MCB.23.24.9245-9250.2003; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rocks O, 2005, SCIENCE, V307, P1746, DOI 10.1126/science.1105654; Rojas Jose M., 2002, Current Genomics, V3, P295, DOI 10.2174/1389202023350381; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Ruiz-Vela A, 2005, EMBO REP, V6, P379, DOI 10.1038/sj.embor.7400375; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takahashi C, 2006, NAT GENET, V38, P118, DOI 10.1038/ng1703; Townsend PA, 2004, J BIOL CHEM, V279, P5811, DOI 10.1074/jbc.M302637200; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Vasseur Sophie, 2003, Mol Cancer, V2, P19, DOI 10.1186/1476-4598-2-19; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; Walsh AB, 2001, J BIOL CHEM, V276, P15609, DOI 10.1074/jbc.M010573200; Wolfman JC, 2002, MOL CELL BIOL, V22, P1589, DOI 10.1128/MCB.22.5.1589-1606.2002; Wulfkuhle JD, 2003, PROTEOMICS, V3, P2085, DOI 10.1002/pmic.200300591; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	61	25	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					917	933		10.1038/sj.onc.1209845	http://dx.doi.org/10.1038/sj.onc.1209845			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909116				2022-12-28	WOS:000244063800012
J	Lacreusette, A; Nguyen, JM; Pandolfino, MC; Khammari, A; Dreno, B; Jacques, Y; Godard, A; Blanchard, F				Lacreusette, A.; Nguyen, J-M; Pandolfino, M-C; Khammari, A.; Dreno, B.; Jacques, Y.; Godard, A.; Blanchard, F.			Loss of oncostatin M receptor beta in metastatic melanoma cells	ONCOGENE			English	Article						oncostatin M; interleukin-6; STAT3; histone acetylation; melanoma	HISTONE DEACETYLASE INHIBITORS; TUMOR-INFILTRATING LYMPHOCYTES; INDUCED GROWTH-INHIBITION; INTERLEUKIN-6; EXPRESSION; STAT3; RESPONSIVENESS; ACETYLATION; PROGRESSION; ACTIVATION	Oncostatin M (OSM) is an interleukin-6 (IL-6) type cytokine originally described by its capacity to inhibit melanoma proliferation in vitro. Here, the mechanisms involved in resistance to growth inhibition by OSM were analysed for the first time on a large panel of metastatic melanoma cell lines. OSM resistance did not strictly correlate with IL-6, interferon-gamma or tumor necrosis factor-alpha resistance. Rather, it correlated with a specific loss of the OSM receptor-beta (OSMR beta) subunit, in conjunction with a lower level of histone acetylation in the OSMR beta promoter region. Treatment of various OSM-resistant melanoma cells with the histone deacetylase inhibitor Trichostatin A increased activity and histone acetylation of the OSMR beta promoter as well as expression of OSMR beta mRNA and protein, allowing OSM to activate the signal transducer and activator of transcription 3 (STAT3) and to inhibit proliferation. Other defects associated with OSM resistance were identified at the level of OSMR beta transcription or protein expression, as well as downstream of or parallel to STAT3 activation. Altogether, our results suggest a role for OSM in the prevention of melanoma progression and that metastatic melanoma cells could escape this growth control by the epigenetic silencing of OSMR beta.	INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, F-44035 Nantes 1, France; Univ Nantes, Inst Biol, IFR26, UFR, F-44035 Nantes, France; PIMESP, Nantes, France; CHU Nantes, Unit Skin Canc, F-44035 Nantes 01, France; CHU Nantes, Biochim Lab, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Godard, A (corresponding author), INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, 0 Quai Moncousu, F-44035 Nantes 1, France.	agodard@nantes.inserm.fr; frederic.blanchard@univ-nantes.fr	Blanchard, Frederic/AAS-1930-2021; NGUYEN, JEAN-MICHEL/K-7665-2015; Blanchard, Frederic/K-8018-2015	Blanchard, Frederic/0000-0003-1055-2573; NGUYEN, JEAN-MICHEL/0000-0001-8815-7640; Blanchard, Frederic/0000-0003-1055-2573				Bani MR, 1996, CANCER RES, V56, P3075; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Blanchard F, 2003, HEPATOLOGY, V38, P1516, DOI 10.1016/j.hep.2003.09.029; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Bohm M, 2001, J INVEST DERMATOL, V117, P132, DOI 10.1046/j.0022-202x.2001.01372.x; Boing I, 2006, CELL SIGNAL, V18, P50, DOI 10.1016/j.cellsig.2005.03.015; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715; Dreno B, 2002, CANCER IMMUNOL IMMUN, V51, P539, DOI 10.1007/s00262-002-0315-1; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; GERVOIS N, 1990, EUR J IMMUNOL, V20, P825, DOI 10.1002/eji.1830200417; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEYMANN D, 1995, IMMUNOL LETT, V46, P245, DOI 10.1016/0165-2478(95)00049-B; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarry A, 2004, MOL CELL PROBE, V18, P349, DOI 10.1016/j.mcp.2004.05.004; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Labarriere N, 2002, CANCER IMMUNOL IMMUN, V51, P532, DOI 10.1007/s00262-002-0313-3; LU C, 1993, CANCER RES, V53, P2708; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Ozbek S, 2001, ONCOGENE, V20, P972, DOI 10.1038/sj.onc.1204180; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Sandor V, 2002, CLIN CANCER RES, V8, P718; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yannelli JR, 2004, VACCINE, V23, P97, DOI 10.1016/j.vaccine.2003.12.036; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	44	36	37	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					881	892		10.1038/sj.onc.1209844	http://dx.doi.org/10.1038/sj.onc.1209844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909117				2022-12-28	WOS:000244063800009
J	Lin, R; Maeda, S; Liu, C; Karin, M; Edgington, TS				Lin, R.; Maeda, S.; Liu, C.; Karin, M.; Edgington, T. S.			A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas	ONCOGENE			English	Article						large noncoding RNA; carcinoma; hepcarcin; MALAT-1	GENE-EXPRESSION; TRANSCRIPTION FACTOR; XIST GENE; H19 GENE; TUMOR; CANCER; LIVER; HEPATOCARCINOGENESIS; IDENTIFICATION; TRANSLOCATION	Tumor markers can facilitate understanding molecular cell biology of neoplasia and provide potential targets for the diagnosis and insight for intervention. We here identify a novel murine gene, hepcarcin (hcn), encoding a 7-kb mRNA-like transcript. The gene appears to be the murine ortholog of the human alpha gene, that is, MALAT-1. The gene and homologs lack credible open reading frames, consistent with a highly conserved large noncoding RNA (ncRNA). In all nodules of procarcinogen-induced murine hepatocellular carcinomas (HCCs) and human HCCs, expression was markedly elevated compared to the uninvolved liver. Quantitative analyses indicated a 6-7-fold increased RNA level in HCCs versus uninvolved liver, advancing this as a molecule of interest. This ncRNA was overexpressed in all five non-hepatic human carcinomas analysed, consistent with a potential marker for neoplastic cells and potential participant in the molecular cell biology of neoplasia.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Univ Calif San Diego, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego	Edgington, TS (corresponding author), Scripps Res Inst, Dept Immunol, 10666 N Torrey Pines Rd,SP258, La Jolla, CA 92037 USA.	ruilin@scripp.edu; tse@scripps.edu		Lin, Rui/0000-0002-1859-7904	NCI NIH HHS [CA-75924] Funding Source: Medline; NHLBI NIH HHS [HL-16411] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA075924] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014; Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100; Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Erdmann VA, 2001, NUCLEIC ACIDS RES, V29, P189, DOI 10.1093/nar/29.1.189; Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lottin S, 2002, CARCINOGENESIS, V23, P1885, DOI 10.1093/carcin/23.11.1885; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Manoharan H, 2003, MOL CARCINOGEN, V38, P40, DOI 10.1002/mc.10144; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Numata K, 2003, GENOME RES, V13, P1301, DOI 10.1101/gr.1011603; O'Neill MJ, 2005, HUM MOL GENET, V14, pR113, DOI 10.1093/hmg/ddi108; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Plath K, 2002, ANNU REV GENET, V36, P233, DOI 10.1146/annurev.genet.36.042902.092433; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Reis EM, 2004, ONCOGENE, V23, P6684, DOI 10.1038/sj.onc.1207880; SARMA DSR, 1986, CANCER SURV, V5, P781; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Willingham AT, 2005, SCIENCE, V309, P1570, DOI 10.1126/science.1115901; Xu L, 2001, CANCER RES, V61, P3176; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yamada K, 2006, CANCER SCI, V97, P106, DOI 10.1111/j.1349-7006.2006.00147.x; Yan MD, 2005, HUM MOL GENET, V14, P1465, DOI 10.1093/hmg/ddi156	36	432	485	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					851	858		10.1038/sj.onc.1209846	http://dx.doi.org/10.1038/sj.onc.1209846			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878148				2022-12-28	WOS:000244063800006
J	Taubert, H; Greither, T; Kaushal, D; Wurl, P; Bache, M; Bartel, F; Kehlen, A; Lautenschlager, C; Harris, L; Kraemer, K; Meye, A; Kappler, M; Schmidt, H; Holzhausen, HJ; Hauptmann, S				Taubert, H.; Greither, T.; Kaushal, D.; Wuerl, P.; Bache, M.; Bartel, F.; Kehlen, A.; Lautenschlaeger, C.; Harris, L.; Kraemer, K.; Meye, A.; Kappler, M.; Schmidt, H.; Holzhausen, H-J; Hauptmann, S.			Expression of the stem cell self-renewal gene Hiwi and risk of tumour-related death in patients with soft-tissue sarcoma	ONCOGENE			English	Article						Hiwi; stem cell self-renewal; soft-tissue sarcoma; prognosis; Piwi domain; mRNA expression	PIWI; PROTEINS; RECOGNITION; HOMOLOG; CANCER	Self-renewal is considered as a common property of stem cells. Dysregulation of stem cell self-renewal is likely a requirement for the development of cancer. Hiwi, the human Piwi gene, encodes a protein responsible for stem cell self-renewal. In this study, we investigated the expression of Hiwi at the RNA level by real-time quantitative PCR in 65 primary soft-tissue sarcomas (STS) and ascertained its impact on prognosis for STS patients. In a multivariate Cox's proportional hazards regression model, we found that an increased expression of Hiwi mRNA is a significant negative prognostic factor for patients with STS (P=0.017; relative risk 4.6, 95% confidence interval (CI) 1.3 - 16.1) compared to medium expression of Hiwi transcript. However, a low expression of Hiwi transcript is correlated with a 2.4- fold ( CI 0.7-8.0) increased risk, but this effect was not significant (P=0.17). Altogether, high-level expression of Hiwi mRNA identifies STS patients at high risk of tumour-related death. This is the first report showing a correlation between expression of a gene involved in stem cell self-renewal and prognosis of cancer patients.	Univ Halle Wittenberg, Fac Med, Inst Pathol, D-06097 Halle, Germany; St Jude Childrens Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; Univ Ulm, Clin Gen & Transplantat Surg, D-89069 Ulm, Germany; Univ Halle Wittenberg, Dept Radiotherapy, D-4010 Halle, Germany; Probiodrug AG, Halle, Germany; Univ Halle Wittenberg, Inst Med Biometry & Informat, Halle, Germany; St Jude Childrens Hosp, Memphis, TN 38105 USA; Tech Univ Dresden, Dept Urol, D-8027 Dresden, Germany; Univ Halle Wittenberg, Inst Pathol, Jr Res Grp, Halle, Germany	Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Ulm University; Martin Luther University Halle Wittenberg; Vivoryon Therapeutics; Martin Luther University Halle Wittenberg; St Jude Children's Research Hospital; Technische Universitat Dresden; Martin Luther University Halle Wittenberg	Taubert, H (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Pathol, Magdeburger Str 14, D-06097 Halle, Germany.	helge.taubert@medizin.uni-halle.de	Greither, Thomas/M-5334-2019; Kappler, Matthias/ABG-9644-2020	Kappler, Matthias/0000-0003-2002-0271				Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cox DN, 2000, DEVELOPMENT, V127, P503; Fetzer CP, 2002, NUCLEIC ACIDS RES, V30, P4380, DOI 10.1093/nar/gkf579; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010; Liu XY, 2006, INT J CANCER, V118, P1922, DOI 10.1002/ijc.21575; Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488; Qiao D, 2002, ONCOGENE, V21, P3988, DOI 10.1038/sj.onc.1205505; Sharma AK, 2001, BLOOD, V97, P426, DOI 10.1182/blood.V97.2.426; Soltysova A, 2005, NEOPLASMA, V52, P435; VANUNNIK JAM, 1995, HEMATOL ONCOL CLIN N, V9, P677, DOI 10.1016/S0889-8588(18)30091-1; WITTEKIND C, 1997, UICC TNM KLASSIFIKAT; Wurl P, 2002, LANCET, V359, P943, DOI 10.1016/S0140-6736(02)07990-4	14	111	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1098	1100		10.1038/sj.onc.1209880	http://dx.doi.org/10.1038/sj.onc.1209880			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953229				2022-12-28	WOS:000244245400016
J	Paltoglou, S; Roberts, BJ				Paltoglou, S.; Roberts, B. J.			HIF-1 alpha and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases	ONCOGENE			English	Article						HIF-1 alpha; HIF-2 alpha; VHL; EPAS; ubiquitin; SCF	HIPPEL-LINDAU PROTEIN; INDUCIBLE FACTOR-I; PROLYL HYDROXYLATION/; HIF-ALPHA; DEGRADATION; DOMAINS; DESTRUCTION; COMPLEX; FAMILY; SIC1	Hypoxia-inducible factor 1 alpha (HIF-1 alpha) degradation under normoxia is critical to modulating vascular growth. This degradation is mediated during normoxia by the von Hippel-Lindau tumour suppressor protein (VHL)-E3 ubiquitin ligase in partnership with the E2 enzyme UbcH5. In current models of the functionally similar Skp1, cullin, F-box (SCF)-E3 ligase, the E3 binds the target protein and the E2 catalyses ubiquitin transfer to lysines in an appropriately positioned domain. In the present study, we report that for efficient ubiquitination of HIF-1 alpha to occur, three conserved lysines are required in both the HIF-1 alpha and endothelial Per-ARNT-Sim domain protein (EPAS) sequences. The site of ubiquitin attachment via UbcH5 was mapped, and is shown to involve three HIF-1 alpha lysines, K532, K538 and K547, and the same aligned lysines in EPAS. Only one of these lysines need to be intact for full ubiquitination to occur, analogous to the mechanism of Sic1 ubiquitination by the SCF/Cdc34 complex and further strengthening the functional link between the VHL and SCF-E3 ubiquitin ligases. We also report that lysines can be moved around the HIF-1 alpha sequence with only minor losses in ubiquitination efficiency, thus suggesting HIF-1 alpha and EPAS regulation by hypoxia depends primarily on an interaction with VHL per se, rather than the highly specific positioning of flanking lysine acceptors.	Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, Adelaide, SA 5000, Australia	University of South Australia	Roberts, BJ (corresponding author), Univ S Australia, Sch Pharmaceut Mol & Biomed Sci, 4 Froome Rd, Adelaide, SA 5000, Australia.	Ben.Roberts@unisa.edu.au						Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Deffenbaugh AE, 2003, CELL, V114, P611, DOI 10.1016/S0092-8674(03)00641-X; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson PK, 2002, MOL CELL, V9, P923, DOI 10.1016/S1097-2765(02)00538-5; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Kondo K, 2001, EXP CELL RES, V264, P117, DOI 10.1006/excr.2000.5139; Lewis MD, 2004, ONCOGENE, V23, P2315, DOI 10.1038/sj.onc.1207384; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Lonser RR, 2003, LANCET, V361, P2059, DOI 10.1016/S0140-6736(03)13643-4; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pugh CW, 2003, SEMIN CANCER BIOL, V13, P83, DOI 10.1016/S1044-579X(02)00103-7; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Yu F, 2001, CANCER RES, V61, P4136; Zhou MI, 2002, J BIOL CHEM, V277, P39887, DOI 10.1074/jbc.M205040200	23	43	44	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					604	609		10.1038/sj.onc.1209818	http://dx.doi.org/10.1038/sj.onc.1209818			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862177				2022-12-28	WOS:000243731600012
J	Camilleri-Broet, S; Cremer, I; Marmey, B; Comperat, E; Viguie, F; Audouin, J; Rio, MC; Fridman, WH; Sautes-Fridman, C; Regnier, CH				Camilleri-Broet, S.; Cremer, I.; Marmey, B.; Comperat, E.; Viguie, F.; Audouin, J.; Rio, M-C; Fridman, W-H; Sautes-Fridman, C.; Regnier, C. H.			TRAF4 overexpression is a common characteristic of human carcinomas	ONCOGENE			English	Article						TRAF4; chromosome 17q11; ERBB2; amplification; lung	HUMAN BREAST-TUMORS; GENE-EXPRESSION; CDNA MICROARRAYS; COPY NUMBER; CANCER; ACTIVATION; RECEPTOR; FAMILY; IDENTIFICATION; CHROMOSOME-17	Tumor necrosis factor receptor (TNFR) associated factor 4 (TRAF4) was initially identified as a gene amplified and overexpressed in breast carcinomas. Our aim was to evaluate whether TRAF4 protein overexpression exists in other cancer types. Immunohistochemistry analysis of tumor samples from 623 patients with 20 different tumor types showed that TRAF4 was overexpressed in 268 tumors (43%), including 82 of 137 lung adenocarcinomas (60%). Interestingly, 32 primary tumors and their matching metastases exhibited mostly similar TRAF4 expression pattern. TRAF4 protein overexpression was limited to cancer cells and the subcellular localization was consistently cytoplasmic in a large majority of cases. To investigate changes in TRAF4 gene copy number, 125 cases from six different types of carcinomas were also analysed by fluorescence in situ hybridization. Out of the 28 cases (22%) showing an increased TRAF4 gene copy number, 23 (82%) were overexpressing the protein. Thus, TRAF4 gene amplification is one of the mechanisms responsible for TRAF4 protein overexpression in human cancers. Considering that TRAF4 is located at 17q11.2 in a region of amplification devoid of known oncogenes and is commonly overexpressed in cancer, our data support an oncogenic role for TRAF4.	Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, F-75006 Paris, France; Univ Paris Descartes, Fac Med, AP HP Hotel Dieu, Paris, France; Univ Paris 06, Fac Med, AP HA La Pitie Salpetriere, Paris, France; Univ Strasbourg 1, INSERM, U596,Dept Pathol Mol,IGBMC, CNRS,UPR 6520, Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Regnier, CH (corresponding author), Univ Paris 06, Ctr Rech Biomed Cordeliers, INSERM,Univ Paris Descartes, U255,Fac Med,Ctr Rech Biomed Cordeliers, 15 Rue Ecole Med, F-75006 Paris, France.	catherine.regnier@u255.bhdc.jussieu.fr	Cremer, Isabelle/D-4278-2017	Cremer, Isabelle/0000-0002-0963-1031; fridman, wolf herman/0000-0002-1332-0973; sautes-fridman, catherine/0000-0003-1735-8722; Regnier, Catherine/0000-0002-4386-1324				Abell AN, 2005, J BIOL CHEM, V280, P35793, DOI 10.1074/jbc.C500260200; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Bieche I, 1996, CANCER RES, V56, P3886; Bowers AJ, 2004, GENE, V328, P135, DOI 10.1016/j.gene.2003.12.002; Chung JY, 2002, J CELL SCI, V115, P679; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Esparza EM, 2004, CELL MOL LIFE SCI, V61, P3087, DOI 10.1007/s00018-004-4417-0; Glauner H, 2002, EUR J BIOCHEM, V269, P4819, DOI 10.1046/j.1432-1033.2002.03180.x; Hirsch FR, 2002, BRIT J CANCER, V86, P1449, DOI 10.1038/sj.bjc.6600286; Hyman E, 2002, CANCER RES, V62, P6240; Kauraniemi P, 2001, CANCER RES, V61, P8235; Krajewska M, 1998, AM J PATHOL, V152, P1549; Li JM, 2005, MOL CELL BIOL, V25, P2320, DOI 10.1128/MCB.25.6.2320-2330.2005; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Regnier CH, 2002, P NATL ACAD SCI USA, V99, P5585, DOI 10.1073/pnas.052124799; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Sax JK, 2003, J BIOL CHEM, V278, P36435, DOI 10.1074/jbc.M303191200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Takeshita F, 2005, EUR J IMMUNOL, V35, P2477, DOI 10.1002/eji.200526151; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100; Wu RF, 2005, J CELL BIOL, V171, P893, DOI 10.1083/jcb.200507004; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Ye X, 1999, J BIOL CHEM, V274, P30202, DOI 10.1074/jbc.274.42.30202	29	61	67	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					142	147		10.1038/sj.onc.1209762	http://dx.doi.org/10.1038/sj.onc.1209762			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799635				2022-12-28	WOS:000243236500014
J	Ozanne, BW; Spence, HJ; McGarry, LC; Hennigan, RF				Ozanne, B. W.; Spence, H. J.; McGarry, L. C.; Hennigan, R. F.			Transcription factors control invasion: AP-1 the first among equals	ONCOGENE			English	Review						invasion; metastasis; AP-1; Fos; Jun; transcription factors	ANCHORAGE-INDEPENDENT GROWTH; CHICKEN-EMBRYO FIBROBLASTS; TUMOR-CELL INVASION; C-FOS GENE; MULTIGENIC INVASION; SIGNAL-TRANSDUCTION; PROTEIN CAUSES; UP-REGULATION; DNA-BINDING; V-FOS	Metastasis, the aggressive spread of a malignant tumor to distant organs, is a major cause of death in cancer patients. Despite this critical role in cancer outcomes, the molecular mechanisms that control this process are just beginning to be understood. Metastasis is largely dependent upon the ability of tumor cells to invade the barrier formed by the basement membrane and to migrate through neighboring tissues. This review will summarize the evidence that tumor cell invasion is the result of oncogene-mediated signal transduction pathways that control the expression of a specific set of genes that together mediate tumor cell invasion. We focus on the role of the transcription factor AP-1 to both induce the expression of genes that function as invasion effectors and repress other genes that function as invasion suppressors. This identies AP-1 as a critical regulator of a complex program of gene expression that de. nes the invasive phenotype.	Univ Cincinnati, Dept Cell Biol, Cincinnati, OH 45267 USA; Beatson Inst Canc Res, Invas & Metastasis Lab, Glasgow G61 1BD, Lanark, Scotland	University System of Ohio; University of Cincinnati; Beatson Institute	Hennigan, RF (corresponding author), Univ Cincinnati, Dept Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Robert.Hennigan@uc.edu						ALANI R, 1991, MOL CELL BIOL, V11, P6286, DOI 10.1128/MCB.11.12.6286; Andela VB, 2003, CLIN ORTHOP RELAT R, pS75, DOI 10.1097/01.blo.0000093048.96273.aa; Andersen H, 2005, MOL CELL BIOL, V25, P9138, DOI 10.1128/MCB.25.20.9138-9150.2005; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Bahassi EM, 2004, CLIN EXP METASTAS, V21, P293, DOI 10.1023/B:CLIN.0000046132.46946.dd; Bailly M, 1998, MICROSC RES TECHNIQ, V43, P433, DOI 10.1002/(SICI)1097-0029(19981201)43:5<433::AID-JEMT9>3.0.CO;2-2; Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; BASSUK AG, 1995, IMMUNITY, V3, P223, DOI 10.1016/1074-7613(95)90092-6; Belguise K, 2005, ONCOGENE, V24, P1434, DOI 10.1038/sj.onc.1208312; Benbow U, 1997, MATRIX BIOL, V15, P519, DOI 10.1016/S0945-053X(97)90026-3; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Black EJ, 2004, ONCOGENE, V23, P2357, DOI 10.1038/sj.onc.1207377; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; Briggs J, 2002, ONCOGENE, V21, P7077, DOI 10.1038/sj.onc.1205857; BROWN R, 1984, EMBO J, V3, P1321, DOI 10.1002/j.1460-2075.1984.tb01970.x; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; CHEN LL, 1993, BIOCHEM BIOPH RES CO, V193, P167, DOI 10.1006/bbrc.1993.1605; Chen RH, 1996, ONCOGENE, V12, P1493; Cohen SB, 2001, ONCOGENE, V20, P141, DOI 10.1038/sj.onc.1204077; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, J VIROL, V42, P114, DOI 10.1128/JVI.42.1.114-122.1982; DENHARDT DT, 1987, ONCOGENE, V2, P55; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; Dong ZG, 1997, MOL CARCINOGEN, V19, P204, DOI 10.1002/(SICI)1098-2744(199707)19:3<204::AID-MC8>3.0.CO;2-D; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416; Foos G, 2000, ONCOGENE, V19, P5507, DOI 10.1038/sj.onc.1203946; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GRINNELL F, 1994, J CELL BIOL, V124, P401, DOI 10.1083/jcb.124.4.401; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; HAWKER KL, 1993, J VIROL, V67, P5487, DOI 10.1128/JVI.67.9.5487-5495.1993; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Hernandez-Alcoceba R, 2000, CELL MOL LIFE SCI, V57, P65, DOI 10.1007/s000180050499; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; JOOSS KU, 1995, ONCOGENE, V10, P603; KOVARY K, 1991, NEW BIOL, V3, P870; Kralova J, 1998, MOL CELL BIOL, V18, P2997, DOI 10.1128/MCB.18.5.2997; Kuramochi M, 2001, NAT GENET, V27, P427, DOI 10.1038/86934; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; KY M, 1996, ONCOGENE, V12, P221; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEDWITH BJ, 1990, MOL CELL BIOL, V10, P1545, DOI 10.1128/MCB.10.4.1545; LEE MS, 1993, ONCOGENE, V8, P387; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Li JJ, 1998, ONCOGENE, V16, P2711, DOI 10.1038/sj.onc.1201798; Lindholm PF, 2001, CLIN EXP METASTAS, V18, P471, DOI 10.1023/A:1011845725394; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Liu S, 2006, EXP MOL PATHOL, V80, P132, DOI 10.1016/j.yexmp.2005.07.005; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Ma ZD, 2004, MOL CELL BIOL, V24, P5496, DOI 10.1128/MCB.24.12.5496-5509.2004; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Mashimo J, 1997, CANCER LETT, V113, P213, DOI 10.1016/S0304-3835(97)04700-9; McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687; MELCHIORI A, 1990, ANTICANCER RES, V10, P37; MERCOLA D, 1987, BIOCHEM BIOPH RES CO, V147, P288, DOI 10.1016/S0006-291X(87)80119-5; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MIAO GG, 1994, MOL CELL BIOL, V14, P4295, DOI 10.1128/MCB.14.6.4295; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; MILLER AD, 1984, CELL, V36, P51; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Nguyen A, 2005, INT J ONCOL, V27, P949; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; OKUNO H, 1991, ONCOGENE, V6, P1491; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Ordway JM, 2004, ONCOGENE, V23, P3737, DOI 10.1038/sj.onc.1207483; Ordway JM, 2002, CELL GROWTH DIFFER, V13, P149; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; PARTIN AW, 1988, CANCER RES, V48, P6050; Philips A, 1998, MOL ENDOCRINOL, V12, P973, DOI 10.1210/me.12.7.973; PRICE CHG, 1972, BRIT J CANCER, V26, P15, DOI 10.1038/bjc.1972.5; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAZ A, 1989, CANCER RES, V49, P3489; REICHMANN E, 1992, CELL, V71, P1103, DOI 10.1016/S0092-8674(05)80060-1; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Sapi E, 1998, CANCER RES, V58, P1027; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Seth A, 2001, Expert Opin Ther Targets, V5, P87, DOI 10.1517/14728222.5.1.87; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Spence HJ, 2006, MOL CELL BIOL, V26, P1480, DOI 10.1128/MCB.26.4.1480-1495.2006; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stapleton G, 2002, J CELL SCI, V115, P2713; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STOLZ DB, 1994, J CELL BIOCHEM, V55, P445, DOI 10.1002/jcb.240550405; SUN HQ, 1995, J CELL BIOL, V129, P147, DOI 10.1083/jcb.129.1.147; TANIGUCHI S, 1989, CANCER RES, V49, P6738; Tkach V, 2003, ONCOGENE, V22, P5045, DOI 10.1038/sj.onc.1206570; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; WANG ZQ, 1995, CANCER RES, V55, P6244; Weissman I, 2005, JAMA-J AM MED ASSOC, V294, P1359, DOI 10.1001/jama.294.11.1359; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	116	201	206	0	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					1	10		10.1038/sj.onc.1209759	http://dx.doi.org/10.1038/sj.onc.1209759			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799638				2022-12-28	WOS:000243236500001
J	Zhang, G; Luo, X; Sumithran, E; Pua, VSC; Barnetson, RSC; Halliday, GM; Khachigian, LM				Zhang, G.; Luo, X.; Sumithran, E.; Pua, V. S. C.; Barnetson, R. St C.; Halliday, G. M.; Khachigian, L. M.			Squamous cell carcinoma growth in mice and in culture is regulated by c-Jun and its control of matrix metalloproteinase-2 and -9 expression	ONCOGENE			English	Article						c-Jun; squamous cell carcinoma; matrix metalloproteinases; angiogenesis; tumor growth	TRANSCRIPTION FACTOR; SKIN CARCINOGENESIS; TUMOR-GROWTH; DNA ENZYME; ANGIOGENESIS; ACTIVATION; AP-1; DEOXYRIBOZYMES; PROLIFERATION; PROGRESSION	Squamous cell carcinoma (SCC) is an invasive malignancy of epidermal keratinocytes. Surgical excision is currently the main treatment; however, this can cause scarring and disfigurement. There is accordingly, an acute need for alternative strategies to treat SCC. The transcription factor c-Jun is expressed in human SCC and another common form of invasive skin cancer, basal cell carcinoma together with the mitogenic marker-proliferating cell nuclear antigen. Here, we have employed DNAzymes (catalytic DNA molecules) targeting c-Jun (Dz13) to inhibit c-Jun expression in SCC cells. Dz13 inhibits SCC proliferation and suppresses solid SCC tumor growth and tumor angiogenesis in severe combined immunodeficient mice. We further demonstrate that Dz13 inhibits c-Jun, together with matrix metalloproteinase (MMP)-2 and MMP-9 expression in the tumors, consistent with DNAzyme inhibition of MMP-2 and MMP-9 gelatinolytic activity by zymography. Dz13 also suppressed the expression of vascular endothelial growth factor and fibroblast growth factor-2 in the tumors. These findings demonstrate that c-Jun regulates SCC growth and suggest that DNAzymes targeting this transcription factor may potentially be useful as inhibitors of cutaneous carcinoma.	Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW, Australia; Gribbles Pathol, Melbourne, Vic, Australia; Royal Prince Alfred Hosp, Dermatol Res Labs, Sydney, NSW, Australia; Univ Sydney, Sydney, NSW 2006, Australia	University of New South Wales Sydney; University of Sydney; University of Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Ctr Vasc Res, Dept Pathol, Sydney, NSW 2052, Australia.	l.khachigian@unsw.edu.au	Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Bernstein SC, 1996, DERMATOL SURG, V22, P243, DOI 10.1111/j.1524-4725.1996.tb00315.x; BOWDEN GT, 1994, CANCER RES, V54, pS1882; Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P453, DOI 10.1016/S0896-1549(02)00042-1; Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276; Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905; Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; Fuchs Shmuel, 2001, Int J Cardiovasc Intervent, V4, P3; Halliday GM, 2001, INT IMMUNOL, V13, P1147, DOI 10.1093/intimm/13.9.1147; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Herbst RS, 2001, EXPERT OPIN BIOL TH, V1, P719, DOI 10.1517/14712598.1.4.719; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; JOHNSON TM, 1992, J AM ACAD DERMATOL, V26, P467, DOI 10.1016/0190-9622(92)70074-P; Karamouzis M, 2004, EUR J CANCER, V40, P761, DOI 10.1016/j.ejca.2003.12.002; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Khachigian LM, 2000, J CLIN INVEST, V106, P1189, DOI 10.1172/JCI11620; Khachigian LM, 2002, CURR OPIN MOL THER, V4, P119; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kraus S, 1998, J AM ACAD DERMATOL, V38, P438, DOI 10.1016/S0190-9622(98)70502-X; Lowe HC, 2002, THROMB HAEMOSTASIS, V87, P134, DOI 10.1055/s-0037-1612956; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Patel BP, 2005, J SURG ONCOL, V90, P81, DOI 10.1002/jso.20240; Ro Young-Suck, 1995, Journal of Korean Medical Science, V10, P85; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Sato H, 1997, PHOTOCHEM PHOTOBIOL, V65, P908, DOI 10.1111/j.1751-1097.1997.tb01942.x; Schubert S, 2003, NUCLEIC ACIDS RES, V31, P5982, DOI 10.1093/nar/gkg791; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shin M, 2002, BBA-MOL CELL RES, V1589, P311, DOI 10.1016/S0167-4889(02)00195-7; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120	36	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7260	7266		10.1038/sj.onc.1209726	http://dx.doi.org/10.1038/sj.onc.1209726			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16785994	Bronze			2022-12-28	WOS:000242244700004
J	Minakhina, S; Steward, R				Minakhina, S.; Steward, R.			Nuclear factor-kappa B pathways in Drosophila	ONCOGENE			English	Review						NF-kappaB; Dorsal; Dif; Relish; immunity; embryonic polarity	REL PROTEIN DORSAL; PEPTIDOGLYCAN RECOGNITION PROTEIN; INNATE IMMUNE-RESPONSE; SIGNAL-TRANSDUCTION PATHWAY; MOSQUITO AEDES-AEGYPTI; N-TERMINAL KINASE; DORSOVENTRAL POLARITY; HOST-DEFENSE; MORPHOGEN GRADIENT; DEGRADATION ESTABLISHES	The nuclear factor kappa B (NF-kappa B) pathways in Drosophila are multi-component pathways, as in vertebrates, that regulate the expression of many genes responsible for the formation of dorsal-ventral polarity in the early embryo, the innate immune response to infection with Gram-negative and positive bacteria and fungi, the cellular immune response and hematopoiesis. Overactivation of the fly pathway can result in developmental defects, overproliferation of hemocytes and the formation of melanotic tumors or nodules. The extracellular events leading to the maturation of the ligand for initiation of the Drosophila NF-kappa B pathway is not conserved between flies and vertebrates, but the Toll receptor and downstream events are remarkably similar. NF-kappa B proteins have been identified in mollusks, and arthropods such as horseshoe crabs and beetles, indicating that this pathway has been established more than 500 million years ago. The fly NF-kappa B pathways are less complex than those in vertebrates, with the involvement of fewer proteins, but they are, nonetheless, just as important as their vertebrate counterparts for the life of the fly.	Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Steward, R (corresponding author), Rutgers State Univ, Dept Mol Biol & Biochem, Waksman Inst, 190 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	steward@waksman.rutgers.edu	Gimenez, Luis E Diaz/D-9291-2011					ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BarillasMury C, 1996, EMBO J, V15, P4691, DOI 10.1002/j.1460-2075.1996.tb00846.x; Beremendi A, 2005, NEUROSCIENCE, V134, P397, DOI 10.1016/j.neuroscience.2005.04.046; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Bhattacharya A, 2002, EMBO REP, V3, P378, DOI 10.1093/embo-reports/kvf072; Bian G, 2005, P NATL ACAD SCI USA, V102, P13568, DOI 10.1073/pnas.0502815102; Biemar F, 2005, P NATL ACAD SCI USA, V102, P15907, DOI 10.1073/pnas.0507817102; Bilak H, 2003, BIOCHEM SOC T, V31, P648, DOI 10.1042/bst0310648; Bolatto C, 2003, J NEUROBIOL, V54, P525, DOI 10.1002/neu.10179; Brandt SM, 2004, PLOS BIOL, V2, P2067, DOI 10.1371/journal.pbio.0020418; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Castillejo-Lopez C, 2005, BIOCHEM BIOPH RES CO, V338, P1075, DOI 10.1016/j.bbrc.2005.10.042; Cha GH, 2003, MOL CELL BIOL, V23, P7982, DOI 10.1128/MCB.23.22.7982-7991.2003; Charatsi I, 2003, MECH DEVELOP, V120, P219, DOI 10.1016/S0925-4773(02)00410-0; Cherry S, 2004, NAT IMMUNOL, V5, P81, DOI 10.1038/ni1019; Chisholm ST, 2006, CELL, V124, P803, DOI 10.1016/j.cell.2006.02.008; Chiu HL, 2005, DEV BIOL, V288, P60, DOI 10.1016/j.ydbio.2005.08.008; Choe KM, 2005, P NATL ACAD SCI USA, V102, P1122, DOI 10.1073/pnas.0404952102; Cornwell WD, 2001, J CELL BIOCHEM, V82, P22, DOI 10.1002/jcb.1144; Cramer P, 1999, STRUCTURE, V7, P841, DOI 10.1016/S0969-2126(99)80107-5; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Drier EA, 2000, CURR BIOL, V10, P23, DOI 10.1016/S0960-9822(99)00267-5; Dushay MS, 1996, P NATL ACAD SCI USA, V93, P10343, DOI 10.1073/pnas.93.19.10343; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; GEISLER R, 1992, CELL, V71, P613, DOI 10.1016/0092-8674(92)90595-4; Georgel P, 2001, DEV CELL, V1, P503, DOI 10.1016/S1534-5807(01)00059-4; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Govind S, 1996, BIOCHEM SOC T, V24, P39, DOI 10.1042/bst0240039; Govind S, 1996, MOL CELL BIOL, V16, P1103; GOVIND S, 1993, DEVELOPMENT, V117, P135; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Han ZS, 1999, J BIOL CHEM, V274, P21355, DOI 10.1074/jbc.274.30.21355; Hashimoto C, 2003, DEV CELL, V5, P945, DOI 10.1016/S1534-5807(03)00338-1; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; Hedengren-Olcott M, 2004, J BIOL CHEM, V279, P21121, DOI 10.1074/jbc.M313856200; Horng T, 2001, P NATL ACAD SCI USA, V98, P12654, DOI 10.1073/pnas.231471798; Hu XD, 2004, P NATL ACAD SCI USA, V101, P9369, DOI 10.1073/pnas.0307062101; Huang L, 2005, DEV BIOL, V280, P407, DOI 10.1016/j.ydbio.2005.02.006; Huguet C, 1997, ONCOGENE, V15, P2965, DOI 10.1038/sj.onc.1201471; Imler Jean-Luc, 2005, V86, P1, DOI 10.1159/000086648; IP YT, 1992, GENE DEV, V6, P1518, DOI 10.1101/gad.6.8.1518; IP YT, 1993, CELL, V75, P753, DOI 10.1016/0092-8674(93)90495-C; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; Kasai Y, 1998, GENE EXPRESSION, V7, P171; Khush RS, 2002, CURR BIOL, V12, P1728, DOI 10.1016/S0960-9822(02)01214-9; Khush RS, 2001, TRENDS IMMUNOL, V22, P260, DOI 10.1016/S1471-4906(01)01887-7; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; Kim T, 2005, NAT IMMUNOL, V6, P211, DOI 10.1038/ni1159; Kleino A, 2005, EMBO J, V24, P3423, DOI 10.1038/sj.emboj.7600807; KOSMAN D, 1991, SCIENCE, V254, P118, DOI 10.1126/science.1925551; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; LEHMING N, 1995, P NATL ACAD SCI USA, V92, P10242, DOI 10.1073/pnas.92.22.10242; LEMAITRE B, 1995, P NATL ACAD SCI USA, V92, P9465, DOI 10.1073/pnas.92.21.9465; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Leulier F, 2002, CURR BIOL, V12, P996, DOI 10.1016/S0960-9822(02)00873-4; LEVASHINA EA, 1995, EUR J BIOCHEM, V233, P694, DOI 10.1111/j.1432-1033.1995.694_2.x; Levashina EA, 1998, J MOL BIOL, V278, P515, DOI 10.1006/jmbi.1998.1705; Ligoxygakis P, 2003, CURR BIOL, V13, P2097, DOI 10.1016/j.cub.2003.10.062; Ligoxygakis P, 2002, EMBO J, V21, P6330, DOI 10.1093/emboj/cdf661; Ligoxygakis P, 2002, SCIENCE, V297, P114, DOI 10.1126/science.1072391; Liu ZP, 1997, GENE DEV, V11, P3413, DOI 10.1101/gad.11.24.3413; Lu YR, 2001, GENE DEV, V15, P104, DOI 10.1101/gad.856901; Manfruelli P, 1999, EMBO J, V18, P3380, DOI 10.1093/emboj/18.12.3380; Meister M, 2003, CELL MICROBIOL, V5, P573, DOI 10.1046/j.1462-5822.2003.00302.x; Meister S, 2005, P NATL ACAD SCI USA, V102, P11420, DOI 10.1073/pnas.0504950102; Meng XJ, 1999, GENE DEV, V13, P792, DOI 10.1101/gad.13.7.792; Mengin-Lecreulx D, 2005, J ENDOTOXIN RES, V11, P105, DOI 10.1179/096805105X35233; Minakhina S, 2003, GENES CELLS, V8, P299, DOI 10.1046/j.1365-2443.2002.00634.x; MINAKHINA S, 2006, IN PRESS GENETICS; Montagnani C, 2004, FEBS LETT, V561, P75, DOI 10.1016/S0014-5793(04)00124-3; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Moussian B, 2005, CURR BIOL, V15, pR887, DOI 10.1016/j.cub.2005.10.026; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Nappi AJ, 2005, J INSECT PHYSIOL, V51, P197, DOI 10.1016/j.jinsphys.2004.10.013; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Ooi JY, 2002, EMBO REP, V3, P82, DOI 10.1093/embo-reports/kvf004; Papatsenko D, 2005, P NATL ACAD SCI USA, V102, P4966, DOI 10.1073/pnas.0409414102; Park JM, 2003, MOL CELL BIOL, V23, P1358, DOI 10.1128/MCB.23.4.1358-1367.2003; Pelte N, 2006, INSECT BIOCHEM MOLEC, V36, P37, DOI 10.1016/j.ibmb.2005.10.004; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Qiu P, 1998, DEVELOPMENT, V125, P1909; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roth P, 2003, J CELL BIOL, V163, P701, DOI 10.1083/jcb.200304046; Roth S, 2003, PHILOS T ROY SOC B, V358, P1317, DOI 10.1098/rstb.2003.1325; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; ROTH S, 1991, DEVELOPMENT, V112, P371; ROTH S, 1994, CURR BIOL, V4, P755, DOI 10.1016/S0960-9822(00)00170-6; Royet J, 2004, CELL MOL LIFE SCI, V61, P537, DOI 10.1007/s00018-003-3243-0; Rutschmann S, 2000, NAT IMMUNOL, V1, P342, DOI 10.1038/79801; Rutschmann S, 2000, IMMUNITY, V12, P569, DOI 10.1016/S1074-7613(00)80208-3; Sagisaka A, 2004, BBA-GENE STRUCT EXPR, V1678, P85, DOI 10.1016/j.bbaexp.2004.02.001; Schneider D, 2000, SCIENCE, V288, P2376, DOI 10.1126/science.288.5475.2376; SCHUPBACH T, 1989, GENETICS, V121, P101; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; Shen BH, 2002, DEVELOPMENT, V129, P1925; Shin SW, 2005, J BIOL CHEM, V280, P16499, DOI 10.1074/jbc.M500711200; Silverman N, 2003, J BIOL CHEM, V278, P48928, DOI 10.1074/jbc.M304802200; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Stathopoulos A, 2002, CELL, V111, P687, DOI 10.1016/S0092-8674(02)01087-5; Stathopoulos A, 2002, DEV BIOL, V246, P57, DOI 10.1006/dbio.2002.0652; STEWARD R, 1989, CELL, V59, P1179, DOI 10.1016/0092-8674(89)90773-3; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; Stoven S, 2003, P NATL ACAD SCI USA, V100, P5991, DOI 10.1073/pnas.1035902100; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Takehana A, 2004, EMBO J, V23, P4690, DOI 10.1038/sj.emboj.7600466; Tanaka H, 2005, BBA-GENE STRUCT EXPR, V1730, P10, DOI 10.1016/j.bbaexp.2005.05.007; Tanji T, 2005, TRENDS IMMUNOL, V26, P193, DOI 10.1016/j.it.2005.02.006; TATEI K, 1995, MOL CELL BIOL, V15, P3627; Tsuda M, 2005, EMBO REP, V6, P1082, DOI 10.1038/sj.embor.7400537; Uv AE, 2000, GENE DEV, V14, P1945; Uvell H, 2003, MOL CELL BIOL, V23, P8272, DOI 10.1128/MCB.23.22.8272-8281.2003; Vernick KD, 2005, CURR TOP MICROBIOL, V295, P383; Vidal S, 2001, GENE DEV, V15, P1900, DOI 10.1101/gad.203301; Wang XW, 2006, P NATL ACAD SCI USA, V103, P4204, DOI 10.1073/pnas.0507044103; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yagi Y, 2005, EMBO REP, V6, P1088, DOI 10.1038/sj.embor.7400542; Yang J, 1997, P NATL ACAD SCI USA, V94, P14524, DOI 10.1073/pnas.94.26.14524; Yang YO, 1997, GENE DEV, V11, P1621, DOI 10.1101/gad.11.13.1621; Zambon RA, 2005, P NATL ACAD SCI USA, V102, P7257, DOI 10.1073/pnas.0409181102; Zhong WW, 2006, SCIENCE, V311, P1481, DOI 10.1126/science.1123287; Zhou R, 2005, J BIOL CHEM, V280, P34048, DOI 10.1074/jbc.M506655200	130	56	57	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6749	6757		10.1038/sj.onc.1209940	http://dx.doi.org/10.1038/sj.onc.1209940			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072326				2022-12-28	WOS:000241666700006
J	Ahmed, M; Rahman, N				Ahmed, M.; Rahman, N.			ATM and breast cancer susceptibility	ONCOGENE			English	Review						ATM; breast cancer susceptibility; ataxia-telangiectasia; breast cancer genes	ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE; EARLY-ONSET; MISSENSE MUTATIONS; FUNCTIONAL CONSEQUENCES; FAMILIAL BREAST; RISK; VARIANTS; HETEROZYGOTES; FREQUENCY	ATM was originally identified by positional cloning as the gene that underlies the autosomal recessive condition ataxia-telangiectasia. The encoded protein plays a central role in the complex processes that repair DNA double-strand breaks. Nearly 20 years ago, epidemiological surveys of relatives of ataxia-telangiectasia cases suggested that female relatives were at modestly increased risk of breast cancer. Subsequently, many studies have tried to clarify the role of ATM in breast cancer susceptibility, but have produced inconclusive and/or inconsistent results. Recently, large epidemiological and molecular studies have finally provided conclusive evidence that ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles.	Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England	University of London; Institute of Cancer Research - UK	Rahman, N (corresponding author), Inst Canc Res, Sect Canc Genet, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	nazneen.rahman@icr.ac.uk	Rahman, Nazneen/B-8890-2012; Rahman, Nazneen/D-2802-2013	Rahman, Nazneen/0000-0003-4376-0440				Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Allinen M, 2002, J MED GENET, V39, P192, DOI 10.1136/jmg.39.3.192; Angele S, 2003, CANCER RES, V63, P8717; Antoniou AC, 2006, ONCOGENE, V25, P5898, DOI 10.1038/sj.onc.1209879; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bay JO, 1998, INT J ONCOL, V12, P1385; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Bretsky P, 2003, CANCER EPIDEM BIOMAR, V12, P733; Broeks A, 2000, AM J HUM GENET, V66, P494, DOI 10.1086/302746; Buchholz TA, 2004, CANCER, V100, P1345, DOI 10.1002/cncr.20133; Chen JD, 1998, CANCER RES, V58, P1376; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Domchek SM, 2006, ONCOGENE, V25, P5825, DOI 10.1038/sj.onc.1209881; Dork T, 2001, CANCER RES, V61, P7608; Drumea KC, 2000, BREAST CANCER RES TR, V61, P79, DOI 10.1023/A:1006463730337; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; GATTI RA, 1988, NATURE, V336, P577, DOI 10.1038/336577a0; Geoffroy-Perez B, 2001, INT J CANCER, V93, P288, DOI 10.1002/ijc.1329; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Gutierrez-Enriquez S, 2004, GENE CHROMOSOME CANC, V40, P109, DOI 10.1002/gcc.20025; Iannuzzi CM, 2002, INT J RADIAT ONCOL, V52, P606, DOI 10.1016/S0360-3016(01)02684-0; Izatt L, 1999, GENE CHROMOSOME CANC, V26, P286, DOI 10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.0.CO;2-X; JEGGO PA, 2006, IN PRESS DNA REPAIR; Jiang XF, 2006, J BIOL CHEM, V281, P15741, DOI 10.1074/jbc.M513172200; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Laake K, 2000, BRIT J CANCER, V83, P1650, DOI 10.1054/bjoc.2000.1519; Lavin MF, 2004, DNA REPAIR, V3, P1197, DOI 10.1016/j.dnarep.2004.03.011; Lee KM, 2005, CANCER EPIDEM BIOMAR, V14, P821, DOI 10.1158/1055-9965.EPI-04-0330; Lindeman GJ, 2004, BREAST CANCER RES, V6, pR401, DOI 10.1186/bcr806; Maillet P, 2002, J MED GENET, V39, P751, DOI 10.1136/jmg.39.10.751; Meyer A, 2004, RADIOTHER ONCOL, V72, P319, DOI 10.1016/j.radonc.2004.07.010; MORRELL D, 1986, J NATL CANCER I, V77, P89; Neubauer S, 2002, RADIAT RES, V157, P312, DOI 10.1667/0033-7587(2002)157[0312:ROATAN]2.0.CO;2; Nevanlinna H, 2006, ONCOGENE, V25, P5912, DOI 10.1038/sj.onc.1209877; Offit K, 2002, CLIN CANCER RES, V8, P3813; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; OLSON JH, 2005, BRIT J CANCER, V93, P260; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; RENWICK A, 2006, IN PRESS NAT GENET; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shafman TD, 2000, GENE CHROMOSOME CANC, V27, P124, DOI 10.1002/(SICI)1098-2264(200002)27:2<124::AID-GCC2>3.0.CO;2-M; Shayeghl M, 1998, BRIT J CANCER, V78, P922, DOI 10.1038/bjc.1998.602; Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004; Sommer SS, 2003, CANCER GENET CYTOGEN, V145, P115, DOI 10.1016/S0165-4608(03)00119-5; Sommer SS, 2002, CANCER GENET CYTOGEN, V134, P25, DOI 10.1016/S0165-4608(01)00594-5; Speit G, 2000, CYTOGENET CELL GENET, V91, P261, DOI 10.1159/000056855; Spurdle AB, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr534; Stankovic T, 1998, AM J HUM GENET, V62, P334, DOI 10.1086/301706; Stewart GS, 2001, J BIOL CHEM, V276, P30133, DOI 10.1074/jbc.M103160200; SWIFT M, 1976, CANCER RES, V36, P209; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; SWIFT M, 1986, AM J HUM GENET, V39, P573; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; Szabo CI, 2004, CANCER RES, V64, P840, DOI 10.1158/0008-5472.CAN-03-2678; Tamimi RM, 2004, BREAST CANCER RES, V6, pR416, DOI 10.1186/bcr809; Taylor AMR, 2005, J CLIN PATHOL, V58, P1009, DOI 10.1136/jcp.2005.026062; Teraoka SN, 2001, CANCER-AM CANCER SOC, V92, P479, DOI 10.1002/1097-0142(20010801)92:3<479::AID-CNCR1346>3.0.CO;2-G; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson Deborah, 2005, Hum Mutat, V25, P594, DOI 10.1002/humu.9344; Thorstenson YR, 2003, CANCER RES, V63, P3325; Vorechovsky I, 1996, CANCER RES, V56, P4130	66	151	154	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5906	5911		10.1038/sj.onc.1209873	http://dx.doi.org/10.1038/sj.onc.1209873			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998505				2022-12-28	WOS:000240765900011
J	Li, J; Wood, WH; Becker, KG; Weeraratna, AT; Morin, PJ				Li, J.; Wood, W. H., III; Becker, K. G.; Weeraratna, A. T.; Morin, P. J.			Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells	ONCOGENE			English	Article						cisplatin; connexin; p53; microarrays; ovarian cancer; expression profling	P53 STATUS; INTERCELLULAR COMMUNICATION; REDUCED EXPRESSION; ANTICANCER AGENTS; CARCINOMA CELLS; LINES; IDENTIFICATION; APOPTOSIS; BCL-2; CHEMOTHERAPY	The molecular pathways activated in response to acute cisplatin exposure, as well as the mechanisms involved in the long-term development of cisplatin-resistant cancer cells remain unclear. Using whole genome oligonucleotide microarrays, we have examined the kinetics of gene expression changes in a cisplatin-sensitive cell line, A2780, and its cisplatin-resistant derivative, ACRP. Both sensitive and resistant cell lines exhibited a very similar response of p53-inducible genes as early as 16 h after treatment. This p53 response was further increased at the 24-h time point. These experiments identify p53 as the main pathway producing a large-scale transcriptional response after cisplatin treatment in these cells containing wild-type p53. Consistent with a role for the p53 response in cisplatin sensitivity, knock down of the p53 protein with small interfering RNA led to a twofold decrease in cell survival in the resistant cells. In addition, our analysis also allowed the identification of several genes that are differentially expressed between sensitive and resistant cells. These genes include GJA1 (encoding connexin 43 (Cx43)) and TWIST1, which are highly upregulated in cisplatin-resistant cells. The importance of Cx43 in drug resistance was demonstrated through functional analyses, although paradoxically, inhibition of Cx43 function in high expressing cells led to an increase in drug resistance. The pathways important in cisplatin response, as well as the genes found differentially expressed between cisplatin-resistant and -sensitive cells, may represent targets for therapy aimed at reversing drug resistance.	NIA, Gerontol Res Ctr, Cellular & Mol Biol Lab, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Resources Res Branch, Baltimore, MD 21224 USA; NIA, Gerontol Res Ctr, Immunol Lab, Baltimore, MD 21224 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21205 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Johns Hopkins University; Johns Hopkins Medicine	Morin, PJ (corresponding author), NIA, Gerontol Res Ctr, Cellular & Mol Biol Lab, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	morinp@grc.nia.nih.gov		Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [Z01AG000512] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akervall J, 2004, CLIN CANCER RES, V10, P8204, DOI 10.1158/1078-0432.CCR-04-0722; Amundson SA, 2005, ONCOGENE, V24, P4572, DOI 10.1038/sj.onc.1208653; Azzam EI, 2003, CANCER RES, V63, P7128; Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; BROWN R, 1993, INT J CANCER, V55, P678, DOI 10.1002/ijc.2910550428; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Buttitta F, 1997, BRIT J CANCER, V75, P230, DOI 10.1038/bjc.1997.38; Cheng TC, 2006, CANCER CHEMOTH PHARM, V58, P384, DOI 10.1007/s00280-005-0171-8; Dalton WS, 1999, DRUG RESIST UPDATE, V2, P285, DOI 10.1054/drup.1999.0097; DeFeudis P, 1997, BRIT J CANCER, V76, P474, DOI 10.1038/bjc.1997.412; Dong Y, 1997, INT J CANCER, V74, P407, DOI 10.1002/(SICI)1097-0215(19970822)74:4<407::AID-IJC8>3.0.CO;2-Z; Einhorn LH, 2002, P NATL ACAD SCI USA, V99, P4592, DOI 10.1073/pnas.072067999; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Fernstrom MJ, 2002, EXP MOL PATHOL, V73, P54, DOI 10.1006/exmp.2002.2436; Filmus J, 2001, GLYCOBIOLOGY, V11, p19R, DOI 10.1093/glycob/11.3.19R; Hawkins DS, 1996, CANCER RES, V56, P892; Herod JJO, 1996, CANCER RES, V56, P2178; Hough CD, 2001, CANCER RES, V61, P3869; Kang HC, 2004, CLIN CANCER RES, V10, P272, DOI 10.1158/1078-0432.CCR-1025-3; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kerley-Hamilton JS, 2005, ONCOGENE, V24, P6090, DOI 10.1038/sj.onc.1208755; Koivusalo R, 2002, CANCER RES, V62, P7364; KOPEMAIER P, 1992, CHEM-BIOL INTERACT, V82, P295; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lin HC, 1999, CANCER RES, V59, P807; Lin JHC, 2003, J NEUROSCI, V23, P430, DOI 10.1523/JNEUROSCI.23-02-00430.2003; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Moorehead RA, 2000, BIOCHEM PHARMACOL, V59, P337, DOI 10.1016/S0006-2952(99)00333-0; Morin PJ, 2003, DRUG RESIST UPDATE, V6, P169, DOI 10.1016/S1368-7646(03)00059-1; OConnor PM, 1997, CANCER RES, V57, P4285; OZOLS RF, 1984, SEMIN ONCOL, V11, P251; Pestell KE, 1998, INT J CANCER, V77, P913, DOI 10.1002/(SICI)1097-0215(19980911)77:6<913::AID-IJC19>3.0.CO;2-1; Pestell KE, 2000, MOL PHARMACOL, V57, P503, DOI 10.1124/mol.57.3.503; Reles A, 2001, CLIN CANCER RES, V7, P2984; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Sax JK, 2003, CELL DEATH DIFFER, V10, P413, DOI 10.1038/sj.cdd.4401227; Shen DW, 2004, MOL PHARMACOL, V66, P789, DOI 10.1124/mol.66.4.789; Sherman-Baust CA, 2003, CANCER CELL, V3, P377, DOI 10.1016/S1535-6108(03)00058-8; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988; Tanaka T, 2001, MOL CARCINOGEN, V30, P176, DOI 10.1002/mc.1026; Thiel G, 2002, J CELL PHYSIOL, V193, P287, DOI 10.1002/jcp.10178; Varma RR, 2005, ONCOL REP, V14, P925; Wang XH, 2004, ONCOGENE, V23, P474, DOI 10.1038/sj.onc.1207128; Wernyj RP, 2004, DRUG RESIST UPDATE, V7, P227, DOI 10.1016/j.drup.2004.08.002; Whiteside MA, 2004, ONCOGENE, V23, P744, DOI 10.1038/sj.onc.1207164; Wu GS, 1996, CLIN CANCER RES, V2, P623	51	63	67	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2860	2872		10.1038/sj.onc.1210086	http://dx.doi.org/10.1038/sj.onc.1210086			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072341				2022-12-28	WOS:000246210800006
J	Tavner, F; Frampton, J; Watson, RJ				Tavner, F.; Frampton, J.; Watson, R. J.			Targeting an E2F site in the mouse genome prevents promoter silencing in quiescent and post-mitotic cells	ONCOGENE			English	Article						B-myb promoter; cell cycle; E2F; gene silencing	B-MYB TRANSCRIPTION; IN-VIVO; CYCLE REGULATION; REGULATED EXPRESSION; REPRESSION; ACTIVATION; PRB; PHOSPHORYLATION; SENESCENCE; OCCUPATION	Previous studies have shown that the cell cycle-regulated B-myb promoter contains a conserved E2F binding site that is critical for repressing transcription in quiescent cells. To investigate its significance for permanent promoter silencing, we have inactivated this binding site in the mouse genome. Mice homozygous for the mutant B-myb(mE2F) allele were fully viable, however, B-myb transcription was derepressed during quiescence in mouse embryo fibroblasts (MEFs) derived from mutant animals. Moreover, it was found that mutation of the E2F site resulted in abnormal maintenance of B-myb expression in senescent MEFs and in differentiated brain tissue. These findings therefore reveal a direct and primary role for repressive E2F complexes in silencing gene expression in post-mitotic cells. Analysis of histone modifications at the promoter showed that histone H3 lysine 9 was constitutively acetylated throughout the cell cycle in homozygous mutant MEFs. This mouse system is the first description of an E2F site mutation in situ and will facilitate the study of E2F function in vivo.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, London W2 1PG, England; Univ Birmingham, Sch Med, Inst Biomed Res, Birmingham B15 2TT, W Midlands, England	Imperial College London; University of Birmingham	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, St Marys Campus,Norfolk Pl, London W2 1PG, England.	r.watson@imperial.ac.uk						Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bennett JD, 1996, ONCOGENE, V13, P1073; Catchpole S, 2002, J BIOL CHEM, V277, P39015, DOI 10.1074/jbc.M202960200; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Maehara K, 2005, J CELL BIOL, V168, P553, DOI 10.1083/jcb.200411093; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nagy AG, 2003, MANIPULATING MOUSE G; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Robinson C, 1996, ONCOGENE, V12, P1855; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sitzmann J, 1996, ONCOGENE, V12, P1889; Takahashi Y, 2000, GENE DEV, V14, P804; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595	27	31	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2727	2735		10.1038/sj.onc.1210087	http://dx.doi.org/10.1038/sj.onc.1210087			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072340				2022-12-28	WOS:000246210600007
J	Clark, J; Merson, S; Jhavar, S; Flohr, P; Edwards, S; Foster, CS; Eeles, R; Martin, FL; Phillips, DH; Crundwell, M; Christmas, T; Thompson, A; Fisher, C; Kovacs, G; Cooper, CS				Clark, J.; Merson, S.; Jhavar, S.; Flohr, P.; Edwards, S.; Foster, C. S.; Eeles, R.; Martin, F. L.; Phillips, D. H.; Crundwell, M.; Christmas, T.; Thompson, A.; Fisher, C.; Kovacs, G.; Cooper, C. S.			Diversity of TMPRSS2-ERG fusion transcripts in the human prostate	ONCOGENE			English	Article						prostate cancer; ERG gene; TMPRSS2 gene; ERG fusion transcripts	EWINGS-SARCOMA; MYELOID-LEUKEMIA; CANCER; IDENTIFICATION; GENES; TRANSLOCATION; TLS/FUS; RNA; ERG	TMPRSS2-ERG gene fusions have recently been reported to be present in a high proportion of human prostate cancers. In the current study, we show that great diversity exists in the precise structure of TMPRSS2-ERG hybrid transcripts found in human prostates. Fourteen distinct hybrid transcripts are characterized, each containing different combinations of sequences from the TMPRSS2 and ERG genes. The transcripts include two that are predicted to encode a normal full-length ERG protein, six that encode N-terminal truncated ERG proteins and one that encodes a TMPRSS2-ERG fusion protein. Interestingly, distinct patterns of hybrid transcripts were found in samples taken from separate regions of individual cancer-containing prostates, suggesting that TMPRSS2-ERG gene fusions may be arising independently in different regions of a single prostate.	Inst Canc Res, Male Urol Canc Res Ctr, Sutton SM2 5NG, Surrey, England; Univ Liverpool, Royal Liverpool Univ Hosp, Dept Pathol, Liverpool L69 3BX, Merseyside, England; Royal Marsden NHS Trust Fdn Hosp, Surrey, England; Univ Lancaster, Dept Biol Sci, Biomed Sci Unit, Lancaster LA1 4YW, England; Royal Devon & Exeter Hosp, Exeter EX2 5DW, Devon, England; Royal Marsden NHS Fdn Trust Hosp, Dept Urol, London, England; Univ Heidelberg, Fac Med, Oncol Mol Lab, Heidelberg, Germany	University of London; Institute of Cancer Research - UK; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; Royal Marsden NHS Foundation Trust; Lancaster University; University of Exeter; Royal Marsden NHS Foundation Trust; Ruprecht Karls University Heidelberg	Clark, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	jeremy.clark@icr.ac.uk	Martin, Francis L/J-4585-2019	Martin, Francis L/0000-0001-8562-4944; Eeles, Rosalind/0000-0002-3698-6241; Phillips, David/0000-0001-8509-3485	Medical Research Council [G0501019] Funding Source: Medline; MRC [G0501019] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		CARNEY DN, 1985, CANCER RES, V45, P2913; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; COOPER CS, 2001, TRANSLOCATIONS SOLID; de Alava E, 1998, J CLIN ONCOL, V16, P1248, DOI 10.1200/JCO.1998.16.4.1248; DELATTRE O, 2002, CHROMOSOMES TRANSLOC; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Janknecht R, 2005, GENE, V363, P1, DOI 10.1016/j.gene.2005.08.007; Jhavar SG, 2005, J CLIN PATHOL, V58, P504, DOI 10.1136/jcp.2004.021808; Kojima T, 2002, BIOL PHARM BULL, V25, P991, DOI 10.1248/bpb.25.991; Kong XT, 1997, BLOOD, V90, P1192; Lin PP, 1999, CANCER RES, V59, P1428; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Soller MJ, 2006, GENE CHROMOSOME CANC, V45, P717, DOI 10.1002/gcc.20329; Tomlins SA, 2006, CANCER RES, V66, P3396, DOI 10.1158/0008-5472.CAN-06-0168; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679	16	185	205	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2667	2673		10.1038/sj.onc.1210070	http://dx.doi.org/10.1038/sj.onc.1210070			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043636				2022-12-28	WOS:000245831200014
J	Gamble, SC; Chotai, D; Odontiadis, M; Dart, DA; Brooke, GN; Powell, SM; Reebye, V; Varela-Carver, A; Kawano, Y; Waxman, J; Bevan, CL				Gamble, S. C.; Chotai, D.; Odontiadis, M.; Dart, D. A.; Brooke, G. N.; Powell, S. M.; Reebye, V.; Varela-Carver, A.; Kawano, Y.; Waxman, J.; Bevan, C. L.			Prohibitin, a protein downregulated by androgens, represses androgen receptor activity	ONCOGENE			English	Article						prohibitin; prostate cancer; androgen receptor; corepressor; cell cycle	PROSTATE-CANCER CELLS; ESTROGEN-RECEPTOR; TRANSCRIPTIONAL ACTIVITY; NUCLEAR RECEPTOR; N-COR; MITOCHONDRIAL PROTEINS; TUMOR-SUPPRESSOR; BINDING; DOMAIN; COACTIVATOR	Prohibitin (PHB) is a cell cycle regulatory protein, known to repress E2F1-mediated gene activation via recruitment of transcriptional regulatory factors such as retinoblastoma and histone deacetylase 1 (HDAC1). We previously identified PHB as a target protein of androgen signaling in prostate cancer cells and showed that downregulation of PHB is required for androgen-induced cell cycle entry in these cells. We now present evidence that PHB, which has 54% homology at the protein level to the oestrogen receptor corepressor REA (repressor of oestrogen receptor activity), can repress androgen receptor (AR)mediated transcription and androgen-dependent cell growth. Depletion of endogenous PHB resulted in an increase in expression of the androgen-regulated prostatespecific antigen gene. The repression appears to be specific to androgen and closely related receptors, as it is also evident for the glucocorticoid and progesterone, but not oestrogen, receptors. In spite of interaction of PHB with HDAC1, HDAC activity is not required for this repression. Although AR and PHB could be co-immunoprecipitated, no direct interaction was detectable, suggesting that PHB forms part of a repressive complex with the AR. Competition with the co-activator SRC1 further suggests that formation of a complex with AR, PHB and other cofactors is the mechanism by which repression is achieved. It appears then that repression of AR activity is one mechanism by which PHB inhibits androgen-dependent growth of prostate cells. Further, this study implies that the AR itself could, by mediating downregulation of a corepressor, be involved in the progression of prostate tumours to the hormone refractory stage.	Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, London W12 0NN, England	Imperial College London	Bevan, CL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Oncol, Harris Lab Prostate Canc Res, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	charlotte.bevan@imperial.ac.uk	Bevan, Charlotte L/K-2276-2012; Brooke, Greg/ABF-4859-2020; Bevan, Charlotte/T-7769-2019; Brooke, Greg/C-9426-2013	Bevan, Charlotte L/0000-0002-7533-0552; Brooke, Greg/0000-0003-4501-4134	Medical Research Council [MC_U120084164] Funding Source: Medline; Worldwide Cancer Research [05-0613] Funding Source: Medline; MRC [MC_U120084164] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Worldwide Cancer Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adegbola O, 2005, BIOCHEM BIOPH RES CO, V334, P702, DOI 10.1016/j.bbrc.2005.06.153; Belandia B, 2003, CELL, V114, P277, DOI 10.1016/S0092-8674(03)00599-3; Berrevoets CA, 2004, BIOCHEM J, V379, P731, DOI 10.1042/BJ20031456; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Burd CJ, 2005, MOL ENDOCRINOL, V19, P607, DOI 10.1210/me.2004-0266; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Fusaro G, 2002, ONCOGENE, V21, P4539, DOI 10.1038/sj.onc.1205551; Fusaro G, 2003, J BIOL CHEM, V278, P47853, DOI 10.1074/jbc.M305171200; Gamble SC, 2004, ONCOGENE, V23, P2996, DOI 10.1038/sj.onc.1207444; HO YS, 1988, FEBS LETT, V229, P256, DOI 10.1016/0014-5793(88)81136-0; Hu X, 2000, TRENDS ENDOCRIN MET, V11, P6, DOI 10.1016/S1043-2760(99)00215-5; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; Joshi B, 2003, BIOCHEM BIOPH RES CO, V312, P459, DOI 10.1016/j.bbrc.2003.10.148; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; KALKHOVEN E, 1994, MOL CELL ENDOCRINOL, V102, P45, DOI 10.1016/0303-7207(94)90096-5; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; MCCLUNG JK, 1989, BIOCHEM BIOPH RES CO, V164, P1316, DOI 10.1016/0006-291X(89)91813-5; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; NUELL MJ, 1991, MOL CELL BIOL, V11, P1372, DOI 10.1128/MCB.11.3.1372; Rajalingam K, 2005, NAT CELL BIOL, V7, P837, DOI 10.1038/ncb1283; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Smith JR, 1997, IEEE MULTIMEDIA, V4, P12, DOI 10.1109/93.621578; Steglich G, 1999, MOL CELL BIOL, V19, P3435; Thompson WE, 2001, ENDOCRINOLOGY, V142, P4076, DOI 10.1210/en.142.9.4076; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wang L, 2004, MOL CELL BIOL, V24, P2202, DOI 10.1128/MCB.24.5.2202-2213.2004; Wang S, 1999, ONCOGENE, V18, P3501, DOI 10.1038/sj.onc.1202684; Wang S, 2004, EMBO J, V23, P2293, DOI 10.1038/sj.emboj.7600231; Wang S, 2002, ONCOGENE, V21, P8388, DOI 10.1038/sj.onc.1205944; Whitaker HC, 2004, CLIN CANCER RES, V10, P7392, DOI 10.1158/1078-0432.CCR-04-0388; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; Zhang X, 1998, MOL ENDOCRINOL, V12, P513, DOI 10.1210/me.12.4.513; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208	44	56	58	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1757	1768		10.1038/sj.onc.1209967	http://dx.doi.org/10.1038/sj.onc.1209967			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964284				2022-12-28	WOS:000244955600010
J	Shao, RX; Kato, N; Lin, LJ; Muroyama, R; Moriyama, M; Ikenoue, T; Watabe, H; Otsuka, M; Guleng, B; Ohta, M; Tanaka, Y; Kondo, S; Dharel, N; Chang, JH; Yoshida, H; Kawabe, T; Omata, M				Shao, R-X; Kato, N.; Lin, L-J; Muroyama, R.; Moriyama, M.; Ikenoue, T.; Watabe, H.; Otsuka, M.; Guleng, B.; Ohta, M.; Tanaka, Y.; Kondo, S.; Dharel, N.; Chang, J-H; Yoshida, H.; Kawabe, T.; Omata, M.			Absence of tyrosine kinase mutations in Japanese colorectal cancer patients	ONCOGENE			English	Article						tyrosine kinase; mutation; colorectal cancer	GENE	Tyrosine kinases, which are important regulators of intracellular signal-transduction pathways, have mutated forms that are often associated with oncogenesis and are attractive targets for therapeutic intervention. Recently, systematic mutational analyses of tyrosine kinases revealed that a minimum of 30% of colorectal cancer contain at least one mutation in the tyrosine kinases. To further explore these mutations, we examined all reported mutations of NTRK3, FES, KDR, EPHA3, NTRK2, JAK1, PDGFRA, EPHA7, EPHA8, ERBB4, FGFR1, MLK4 and GUCY2F genes in the 24 colorectal cancer cell lines. Unexpectedly, among 24 colorectal cancer cell lines, only two cell lines (LoVo and CaR1) harbored mutation C1408T (R470C) in MLK4 gene. The mutation rate was extremely low compared to that previously reported. Therefore, we analyzed mutations in 46 colorectal cancer samples resected from the same number of Japanese patients. Surprisingly, none of the 46 samples contained any of the mutations reported. Based on our study, we advise that a more comprehensive tyrosine kinase gene mutation assay is necessary in the future.	Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Jilin Univ, China Japan Union Hosp, Dept Gastroenterol, Changchun 130023, Jilin Province, Peoples R China; China Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Shenyang, Peoples R China	University of Tokyo; Jilin University; China Medical University	Kato, N (corresponding author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kato-2im@h.u-tokyo.ac.jp	Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881; Tanaka, Yasuo/0000-0002-2917-3365				Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shao RX, 2005, J GASTROENTEROL, V40, P918, DOI 10.1007/s00535-005-1661-5; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022	7	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2133	2135		10.1038/sj.onc.1210007	http://dx.doi.org/10.1038/sj.onc.1210007			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016444				2022-12-28	WOS:000245313400015
J	Yu, W; Imoto, I; Inoue, J; Onda, M; Emi, M; Inazawa, J				Yu, W.; Imoto, I.; Inoue, J.; Onda, M.; Emi, M.; Inazawa, J.			A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity	ONCOGENE			English	Article						DUSP26; ATC; amplification; p38; array-CGH	ACTIVATED PROTEIN-KINASE; SIGNAL-REGULATED KINASE; TUMOR-SUPPRESSOR; MICROARRAY ANALYSIS; PHOSPHATASE; EXPRESSION; APOPTOSIS; BREAST; PATHWAYS; IDENTIFICATION	Anaplastic thyroid cancer (ATC) is one of the most lethal of all human tumors, but cytogenetic information concerning ATC is extremely limited. Using our in-house array-based comparative genomic hybridization and 14 ATC cell lines with further fluorescence in situ hybridization analysis, we demonstrated ampli. cation of the DUSP26 gene, known by another report as MAP kinase phosphatase-8. DUSP26 was overexpressed in ATC cell lines and primary ATC tumor samples. When overexpressed, either exogenously or endogenously, DUSP26 promoted growth of the ATC cells. DUSP26 encodes a protein containing a dual-specificity phosphatase domain that can dephosphorylate itself. DUSP26 effectively dephosphorylates p38 and has a little effect on extracellular signal-regulated kinase in ATC cells. DUSP26 protein formed a physical complex with p38, and promoted survival of ATC cells by inhibiting p38-mediated apoptosis. Our findings suggest that DUSP26 may act as an oncogene in ATC, and might be a useful diagnostic marker and therapeutic target of this disease.	Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; 21st Century Ctr Excellence COE, Program Mol Destruct & Reconstruct Tooth & Bone, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Tokyo, Japan; Nippon Med Sch, Inst Gerontol, Dept Mol Biol, Kanagawa, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Nippon Medical School	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Dept Mol Cytogenet, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; yu, wei/B-5859-2011; Imoto, Issei/AAD-5799-2020					BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Bulavin DV, 2004, ADV CANCER RES, V92, P95, DOI 10.1016/S0065-230X(04)92005-2; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Bulavin DV, 2001, NATURE, V411, P102, DOI 10.1038/35075107; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Garcia MJ, 2005, ONCOGENE, V24, P5235, DOI 10.1038/sj.onc.1208741; Hoornaert I, 2003, ONCOGENE, V22, P7728, DOI 10.1038/sj.onc.1207089; Hu YZ, 2006, MOL CELL BIOL, V26, P3282, DOI 10.1128/MCB.26.8.3282-3294.2006; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Izumi H, 2005, HUM MOL GENET, V14, P997, DOI 10.1093/hmg/ddi092; Juretic N, 2001, J CELL BIOCHEM, V83, P92, DOI 10.1002/jcb.1211; Liu B, 2001, BRIT J CANCER, V85, P303, DOI 10.1054/bjoc.2001.1910; McMullen ME, 2005, J BIOL CHEM, V280, P20995, DOI 10.1074/jbc.M407060200; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Onda M, 2004, ENDOCR-RELAT CANCER, V11, P843, DOI 10.1677/erc.1.00818; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Passler C, 1999, LANGENBECK ARCH SURG, V384, P284, DOI 10.1007/s004230050205; Ray ME, 2004, CANCER RES, V64, P40, DOI 10.1158/0008-5472.CAN-03-1022; Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9; Simon R, 2001, CANCER RES, V61, P4514; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; Vasudevan SA, 2005, BIOCHEM BIOPH RES CO, V330, P511, DOI 10.1016/j.bbrc.2005.03.028; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Walentinsson A, 2001, CANCER RES, V61, P8263; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiseman SM, 2003, HEAD NECK-J SCI SPEC, V25, P662, DOI 10.1002/hed.10277; Wu JJ, 2005, J BIOL CHEM, V280, P16461, DOI 10.1074/jbc.M501762200; Wu W, 2004, CANCER RES, V64, P1757, DOI 10.1158/0008-5472.CAN-03-2546; Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x; Yu W, 2003, J HUM GENET, V48, P331, DOI 10.1007/s10038-003-0026-2	45	75	78	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1178	1187		10.1038/sj.onc.1209899	http://dx.doi.org/10.1038/sj.onc.1209899			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924234				2022-12-28	WOS:000244406400008
J	Iyer, NG; Xian, J; Chin, SF; Bannister, AJ; Daigo, Y; Aparicio, S; Kouzarides, T; Caldas, C				Iyer, N. G.; Xian, J.; Chin, S-F; Bannister, A. J.; Daigo, Y.; Aparicio, S.; Kouzarides, T.; Caldas, C.			p300 is required for orderly G1/S transition in human cancer cells	ONCOGENE			English	Article						RB; retinoblastoma; hyperphosphorylation; Cdk; HCT116	DNA-DAMAGE; C-MYC; RETINOBLASTOMA PROTEIN; G(1) EXIT; IN-VITRO; ACETYLATION; CBP; P53; MUTATIONS; BINDING	The role of the transcriptional coactivator p300 in cell cycle control has not been analysed in detail due to the lack of appropriate experimental systems. We have now examined cell cycle progression of p300-deficient cancer cell lines, where p300 was disrupted either by gene targeting (p300(-) cells) or knocked down using RNAi. Despite significant proliferation defects under normal growth conditions, p300(-) deficient cells progressed rapidly through G1 with premature S-phase entry. Accelerated G1/S transition was associated with early retinoblastoma (RB) hyperphosphorylation and activation of E2F targets. The p300(-) acetylase activity was dispensable since expression of a HAT-deficient p300 mutant reversed these changes. Co-immunoprecipitation showed p300/RB interaction occurs in vivo during G1, and this interaction has two peaks: in early G1 with unphosphorylated RB and in late G1 with phosphorylated RB. In vitro kinase assays showed that p300 directly inhibits cdk6-mediated RB phosphorylation, suggesting p300 acts in early G1 to prevent RB hyperphosphorylation and delay premature S-phase entry. Paradoxically, continued cycling of p300(-) cells despite prolonged serum depletion was observed, and this occurred in association with persistent RB hyperphosphorylation. Altogether, these results suggest that p300 has an important role in G1/S control, possibly by modulating RB phosphorylation.	Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Cambridge CB2 2XZ, England; Univ Cambridge, Wellcome Trust CRUK Gurdon Inst, Cambridge, England	University of Cambridge; University of Cambridge	Caldas, C (corresponding author), Univ Cambridge, Canc Genom Program, Hutchison MRC Res Ctr, Dept Oncol, Hills Rd, Cambridge CB2 2XZ, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; Caldas, Carlos/U-7250-2019	Caldas, Carlos/0000-0003-3547-1489; Kouzarides, Tony/0000-0002-8918-4162; Aparicio, Samuel/0000-0002-0487-9599; chin, suet-feung/0000-0001-5697-1082; Bannister, Andrew/0000-0002-6312-4436; Daigo, Yataro/0000-0002-0915-3025				Ait-Si-Ali S, 2000, ONCOGENE, V19, P2430, DOI 10.1038/sj.onc.1203562; Baluchamy S, 2003, P NATL ACAD SCI USA, V100, P9524, DOI 10.1073/pnas.1633700100; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dimitrova DS, 1999, J CELL BIOL, V146, P709, DOI 10.1083/jcb.146.4.709; Dolbeare F, 1990, Methods Cell Biol, V33, P207; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 2001, EUR J BIOCHEM, V268, P2773, DOI 10.1046/j.1432-1327.2001.02226.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Iyer NG, 2004, P NATL ACAD SCI USA, V101, P7386, DOI 10.1073/pnas.0401002101; Iyer NG, 2004, ONCOGENE, V23, P4225, DOI 10.1038/sj.onc.1207118; Kolli S, 2001, P NATL ACAD SCI USA, V98, P4646, DOI 10.1073/pnas.081141998; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Liu L, 1999, MOL CELL BIOL, V19, P1202; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Ozdag H, 2002, BRIT J CANCER, V87, P1162, DOI 10.1038/sj.bjc.6600554; Rajabi HN, 2005, J BIOL CHEM, V280, P361, DOI 10.1074/jbc.M408633200; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; WALDMAN T, 1995, CANCER RES, V55, P5187; Ward R, 2005, J MED GENET, V42, P514, DOI 10.1136/jmg.2004.025080; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930	33	49	50	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					21	29		10.1038/sj.onc.1209771	http://dx.doi.org/10.1038/sj.onc.1209771			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16878158				2022-12-28	WOS:000243236500003
J	Ose, T; Kadowaki, Y; Fukuhara, H; Kazumori, H; Ishihara, S; Udagawa, J; Otani, H; Takasawa, S; Okamoto, H; Kinoshita, Y				Ose, T.; Kadowaki, Y.; Fukuhara, H.; Kazumori, H.; Ishihara, S.; Udagawa, J.; Otani, H.; Takasawa, S.; Okamoto, H.; Kinoshita, Y.			Reg I-knockout mice reveal its role in regulation of cell growth that is required in generation and maintenance of the villous structure of small intestine	ONCOGENE			English	Article						Reg; knockout mice; growth factor; small intestine	TRANSGENIC MICE; FACTOR-ALPHA; REGENERATING ISLETS; MENETRIERS DISEASE; PROGENITOR CELLS; GASTRIC-MUCOSA; GENE FAMILY; STEM-CELL; PROTEIN; EXPRESSION	Reg I (regenerating gene product I) is a growth factor that plays a central role in the generation and regeneration of the gastric mucosal architecture. On the other hand, mouse Reg I mRNA is expressed at the highest levels in the small intestine among the gastrointestinal tissues. In the current study, with the aim to clarify the role of Reg I protein in the small intestine, the temporal and spatial pattern of Reg I expression and the phenotype of Reg I-knockout mice in the tissue were examined. In the wild-type mice, immunohistochemistry localized Reg I protein expression in absorptive cells located in the lower half of the intestinal villi. Reg I expression was undetectable until embryonic day 13 (E13), when the fetal intestine still lacks villous structure; however, it dramatically increased at E17 along with the formation and maturation of the fetal intestinal villi. In the small intestine of the adult Reg I-knockout mice, less densely packed, round-shaped aberrant morphology of the absorptive cells was observed light microscopically, and electron microscopical examination revealed a strikingly loose connection of these cells to the basement membrane. Antiproliferating cell nuclear antigen staining and anti-Ki67 staining demonstrated the marked decrease in the number of proliferating cells in the small intestinal mucosa of the knockout mice. The cell migration speed visualized by one shot labeling of 5-bromodeoxyuridine was significantly slower in the knockout mice. These phenotypes of Reg I-knockout mice emerged, in accordance with the temporal pattern of Reg I expression described above, from E17. Reg I was considered to be a regulator of cell growth that is required to generate and maintain the villous structure of the small intestine.	Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, Izumo, Shimane 6938501, Japan; Shimane Univ, Dept Anat, Sch Med, Izumo, Shimane 6938501, Japan; Tohoku Univ, Grad Sch Med, Dept Biochem, Sendai, Miyagi 980, Japan; Tohoku Univ, Grad Sch Med, Dept Adv Biol Sci Regenerat, Kotobiken Med Labs, Sendai, Miyagi 980, Japan	Shimane University; Shimane University; Tohoku University; Tohoku University	Kadowaki, Y (corresponding author), Shimane Univ, Dept Gastroenterol & Hepatol, Sch Med, 89-1 Enya cho, Izumo, Shimane 6938501, Japan.	y-kado@momo.so-net.ne.jp						Asahara M, 1996, GASTROENTEROLOGY, V111, P45, DOI 10.1053/gast.1996.v111.pm8698224; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Brittan M, 2004, GUT, V53, P899, DOI 10.1136/gut.2003.025478; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; Fukui H, 1998, GASTROENTEROLOGY, V115, P1483, DOI 10.1016/S0016-5085(98)70027-7; Hartupee JC, 2001, BBA-GENE STRUCT EXPR, V1518, P287, DOI 10.1016/S0167-4781(00)00284-0; Kadowaki Y, 2002, FEBS LETT, V530, P59, DOI 10.1016/S0014-5793(02)03398-7; Kaneko Y, 2000, DEV NEUROSCI-BASEL, V22, P139, DOI 10.1159/000017435; Kayahara T, 2003, FEBS LETT, V535, P131, DOI 10.1016/S0014-5793(02)03896-6; Kazumori H, 2000, GASTROENTEROLOGY, V119, P1610, DOI 10.1053/gast.2000.20262; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Lickert H, 2001, MECH DEVELOP, V105, P181, DOI 10.1016/S0925-4773(01)00390-2; Macadam RCA, 2000, BRIT J CANCER, V83, P188; Miyaoka Y, 2004, ONCOGENE, V23, P3572, DOI 10.1038/sj.onc.1207333; Perfetti R, 1996, J GERONTOL A-BIOL, V51, pB308, DOI 10.1093/gerona/51A.5.B308; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Potten CS, 2003, DIFFERENTIATION, V71, P28, DOI 10.1046/j.1432-0436.2003.700603.x; SBARBATI R, 1982, J ANAT, V135, P477; SHARP R, 1995, DEVELOPMENT, V121, P149; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TERAZONO K, 1988, J BIOL CHEM, V263, P2111; TERAZONO K, 1990, DIABETOLOGIA, V33, P250, DOI 10.1007/BF00404804; Unno M, 2002, DIABETES, V51, pS478, DOI 10.2337/diabetes.51.2007.S478; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; Walters JRF, 2005, CURR OPIN GASTROEN, V21, P135, DOI 10.1097/01.mog.0000153309.13080.8b; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; YAMAMOTO T, 1983, CELL, V35, P71, DOI 10.1016/0092-8674(83)90209-X; Zenilman ME, 1996, GASTROENTEROLOGY, V110, P1208, DOI 10.1053/gast.1996.v110.pm8613011	31	39	42	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					349	359		10.1038/sj.onc.1209799	http://dx.doi.org/10.1038/sj.onc.1209799			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909126				2022-12-28	WOS:000243544000004
J	Shiraishi, K; Yamasaki, K; Nanba, D; Inoue, H; Hanakawa, Y; Shirakata, Y; Hashimoto, K; Higashiyama, S				Shiraishi, K.; Yamasaki, K.; Nanba, D.; Inoue, H.; Hanakawa, Y.; Shirakata, Y.; Hashimoto, K.; Higashiyama, S.			Pre-B-cell leukemia transcription factor 1 is a major target of promyelocytic leukemia zinc-finger-mediated melanoma cell growth suppression	ONCOGENE			English	Article						Pbx1; PLZF; Hox; melanoma	PLZF-RAR-ALPHA; DNA-BINDING; TRANSLOCATION PROTEIN; GENE; PROLIFERATION; EXPRESSION; HOXB7; ANGIOGENESIS; REPRESSION; CARCINOMA	Promyelocytic leukemia zinc-finger ( PLZF) is a transcriptional repressor and tumor suppressor. PLZF is expressed in melanocytes but not in melanoma cells, and recovery of PLZF expression markedly suppresses melanoma cell growth. Several target genes regulated by PLZF have been identified, but the precise function of PLZF remains uncertain. Here, we searched for candidate target genes of PLZF by DNA microarray analysis. Pre-B-cell leukemia transcription factor 1 (Pbx1) was one of the prominently suppressed genes. Pbx1 was highly expressed in melanoma cells, and its expression was reduced by transduction with the PLZF gene. Moreover, the growth suppression mediated by PLZF was reversed by enforced expression of Pbx1. Knockdown of Pbx1 by specific small interfering RNAs suppressed melanoma cell growth. We also found that Pbx1 binds HoxB7. Reverse transcription-polymerase chain reaction analysis demonstrated that repression of Pbx1 by PLZF reduces the expression of HoxB7 target genes, including tumor-associated neoangiogenesis factors such as basic fibroblast growth factor, angiopoietin-2 and matrix metalloprotease 9. These findings suggest that deregulation of Pbx1 expression owing to loss of PLZF expression contributes to the progression and/or pathogenesis of melanoma.	Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan; Ehime Univ, Grad Sch Med, Dept Dermatol, Toon, Ehime 7910295, Japan; Japan Sci & Technol Corp JST, PRESTO, Kawaguchi, Saitama, Japan	Ehime University; Ehime University; Japan Science & Technology Agency (JST)	Higashiyama, S (corresponding author), Ehime Univ, Grad Sch Med, Dept Biochem & Mol Genet, Toon, Ehime 7910295, Japan.	shigeki@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				Ahmad SA, 2001, CANCER RES, V61, P1255; Barna M, 2002, DEV CELL, V3, P499, DOI 10.1016/S1534-5807(02)00289-7; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; BECKER D, 1989, EMBO J, V8, P3685, DOI 10.1002/j.1460-2075.1989.tb08543.x; Care A, 1998, ONCOGENE, V16, P3285, DOI 10.1038/sj.onc.1201875; Care A, 1996, MOL CELL BIOL, V16, P4842; Care A, 2001, CANCER RES, V61, P6532; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Etoh T, 2001, CANCER RES, V61, P2145; Felicetti F, 2004, ONCOGENE, V23, P4567, DOI 10.1038/sj.onc.1207597; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McConnell MJ, 2003, MOL CELL BIOL, V23, P9375, DOI 10.1128/MCB.23.24.9375-9388.2003; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Shanmugam K, 1997, J BIOL CHEM, V272, P19081, DOI 10.1074/jbc.272.30.19081; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Tanaka M, 2004, J BIOL CHEM, V279, P41950, DOI 10.1074/jbc.M400086200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375	27	41	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					339	348		10.1038/sj.onc.1209800	http://dx.doi.org/10.1038/sj.onc.1209800			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16862184				2022-12-28	WOS:000243544000003
J	Sun, L; Trausch-Azar, JS; Ciechanover, A; Schwartz, AL				Sun, L.; Trausch-Azar, J. S.; Ciechanover, A.; Schwartz, A. L.			E2A protein degradation by the ubiquitin-proteasome system is stage-dependent during muscle differentiation	ONCOGENE			English	Article						E2A; E12; E47; ubiquitin; proteasome; muscle differentiation	LOOP-HELIX PROTEINS; LYMPHOCYTE DEVELOPMENT; MEDIATED DEGRADATION; DNA-BINDING; TRANSCRIPTION; LOCALIZATION; E47; MYOD; ASSOCIATION; TURNOVER	The E2A proteins are basic helix-loop-helix transcription factors that regulate proliferation and differentiation in many cell types. In muscle cells, the E2A proteins form heterodimers with muscle regulatory factors such as MyoD, which then bind to DNA and regulate the transcription of target genes essential for muscle differentiation. We now demonstrate that E2A proteins are primarily localized in the nucleus in both C2C12 myoblasts and myotubes, and are degraded by the ubiquitin proteasome system evidenced by stabilization following treatment with the proteasome inhibitor, MG132. During the differentiation from myoblast to myotube, the cellular abundance of E2A proteins is relatively unaltered, despite significant changes ( each similar to 5-fold) in the relative rates of protein synthesis and protein degradation via the ubiquitin-proteasome system. The rate of ubiquitin-proteasome-mediated E2A protein degradation depends on the myogenic differentiation state (t 1/2 similar to 2 h in proliferating myoblasts versus t 1/2 > 10h in differentiated myotubes), and is also associated with cell cycle in non-muscle cells. Our findings reveal an important role for both translational and post-translational regulatory mechanisms in mediating the complex program of muscle differentiation determined by the E2A proteins.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; St Louis Childrens Hosp, St Louis, MO 63178 USA; Technion Israel Inst Technol, Fac Med, Vasc & Tumor Biol Res Ctr, Haifa, Israel	Washington University (WUSTL); Washington University (WUSTL); St. Louis Children's Hospital; Washington University (WUSTL); Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Schwartz, AL (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, 660 S Euclid Ave,CB 8116, St Louis, MO 63110 USA.	Schwartz@kids.wustl.edu	Ciechanover, Aaron J/C-9166-2017					ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Coulombe P, 2003, MOL CELL BIOL, V23, P4542, DOI 10.1128/MCB.23.13.4542-4558.2003; Dearth LR, 2003, J BIOL CHEM, V278, P11246, DOI 10.1074/jbc.M207930200; Deed RW, 1996, J BIOL CHEM, V271, P23603, DOI 10.1074/jbc.271.39.23603; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; Huggins GS, 1999, J BIOL CHEM, V274, P28690, DOI 10.1074/jbc.274.40.28690; Kho CJ, 1997, J BIOL CHEM, V272, P3845, DOI 10.1074/jbc.272.6.3845; Langlands K, 1997, J BIOL CHEM, V272, P19785, DOI 10.1074/jbc.272.32.19785; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; Lazorchak A, 2005, TRENDS IMMUNOL, V26, P334, DOI 10.1016/j.it.2005.03.011; Lingbeck JM, 2005, ONCOGENE, V24, P6376, DOI 10.1038/sj.onc.1208789; Lluis F, 2005, EMBO J, V24, P974, DOI 10.1038/sj.emboj.7600528; Nie L, 2003, EMBO J, V22, P5780, DOI 10.1093/emboj/cdg567; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Quong MW, 2002, ANNU REV IMMUNOL, V20, P301, DOI 10.1146/annurev.immunol.20.092501.162048; Riera L, 2003, FEBS LETT, V550, P23, DOI 10.1016/S0014-5793(03)00808-1; Riley RL, 2005, SEMIN IMMUNOL, V17, P330, DOI 10.1016/j.smim.2005.05.011; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Sun LP, 2005, J BIOL CHEM, V280, P26448, DOI 10.1074/jbc.M500373200; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; Van der Put E, 2004, J IMMUNOL, V173, P818, DOI 10.4049/jimmunol.173.2.818; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317	26	15	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					441	448		10.1038/sj.onc.1209793	http://dx.doi.org/10.1038/sj.onc.1209793			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909127				2022-12-28	WOS:000243544000012
J	Salatino, M; Beguelin, W; Peters, MG; Carnevale, R; Proietti, CJ; D Galigniana, M; Vedoy, CG; Schillaci, R; Charreau, EH; Sogayar, MC; Elizalde, PV				Salatino, M.; Beguelin, W.; Peters, M. G.; Carnevale, R.; Proietti, C. J.; D Galigniana, M.; Vedoy, C. G.; Schillaci, R.; Charreau, E. H.; Sogayar, M. C.; Elizalde, P. V.			Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation	ONCOGENE			English	Article						caveolin-1; breast cancer; progesterone receptor	ACTIVATED PROTEIN-KINASE; ONCOGENICALLY TRANSFORMED-CELLS; MOUSE MAMMARY ADENOCARCINOMAS; INSENSITIVE PROSTATE-CANCER; ESTROGEN-RECEPTOR-ALPHA; GROWTH-FACTOR RECEPTOR; IN-VIVO; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; MEDROXYPROGESTERONE ACETATE	Progestin regulation of gene expression was assessed in the progestin- dependent murine tumor line C4HD which requires MPA, a synthetic progestin, for in vivo growth and expresses high levels of progesterone receptor ( PR). By using suppressive subtractive hybridization, caveolin-1 was identified as a gene whose expression was increased with in vivo MPA treatment. By Northern and Western blot analysis, we further confirmed that caveolin-1 mRNA and protein expression increased in MPA- treated tumors as compared with untreated tumors. When primary cultures of C4H D cells were treated in vitro with MPA, caveolin-1 levels also increased, effect that was abolished by pre-treatment with progestin antagonist RU486. In addition, MPA promoted strong caveolin-1 promoter transcriptional activation both in mouse and human breast cancer cells. We also showed that MPA regulation of caveolin-1 expression involved in activation of two signaling pathways: MAPK and PI-3K. Short- term MPA treatment of C4HD cells led to tyrosine phosphorylation of caveolin-1 protein, where Src was the kinase involved. Additionally, we showed that MPA- induced association of caveolin- 1 and PR, which was detected by communoprecipitation and by confocal microscopy. Finally, we proved that MPA- induced proliferation of C4HD cells was inhibited by suppression ofcaveol in- 1 expression with antisense oligodeoxynucleotides to caveolin1 mRNA. Furthermore, we observed that inhibition of caveolin- 1 expression abrogated PR capacity to induced luciferase activity from a progesterone response elementdriven reporter plasmid. Comprehensively, our results demonstrated for the. rst time that caveolin- 1 expression is upregulated by progestin in breast cancer. We also demonstrated that caveolin- 1 is a downstream effector of MPA that is partially responsible for the stimulation of growth ofbreast cancer cells.	Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, RA-1428 Buenos Aires, DF, Argentina; Univ Buenos Aires, Inst Oncol Angel H Roffo, Buenos Aires, DF, Argentina; Consejo Nacl Invest Cient & Tecn, Inst Leloir, RA-1033 Buenos Aires, DF, Argentina; Univ Sao Paulo, Inst Quim, Sao Paulo, Brazil	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Institute of Biology & Experimental Medicine; University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; Universidade de Sao Paulo	Elizalde, PV (corresponding author), Consejo Nacl Invest Cient & Tecn, Lab Mol Mechanisms Carcinogenesis, Inst Biol & Med Expt, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	elizalde@dna.uba.ar	Sogayar, Mari C/B-3980-2017	Sogayar, Mari C/0000-0003-4805-4609; Elizalde, Patricia V./0000-0002-5923-9898; GALIGNIANA, MARIO/0000-0002-9130-8574; Peters, Maria/0000-0002-9271-4590				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Balana ME, 1999, ONCOGENE, V18, P6370, DOI 10.1038/sj.onc.1203028; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Cho KA, 2003, J BIOL CHEM, V278, P27789, DOI 10.1074/jbc.M208105200; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Elizalde PV, 1998, J STEROID BIOCHEM, V67, P305, DOI 10.1016/S0960-0760(98)00123-X; Engelman JA, 1998, J BIOL CHEM, V273, P20448, DOI 10.1074/jbc.273.32.20448; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Engelman JA, 1999, J BIOL CHEM, V274, P32333, DOI 10.1074/jbc.274.45.32333; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Hayashi K, 2001, CANCER RES, V61, P2361; Ho Shuk-Mei, 2003, Reprod Biol Endocrinol, V1, P73, DOI 10.1186/1477-7827-1-73; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Ismail PM, 2003, STEROIDS, V68, P779, DOI 10.1016/S0039-128X(03)00133-8; Kiss AL, 2005, MOL CELL ENDOCRINOL, V245, P128, DOI 10.1016/j.mce.2005.11.005; Kogo H, 2000, FEBS LETT, V465, P119, DOI 10.1016/S0014-5793(99)01730-5; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; KORDON E, 1990, BREAST CANCER RES TR, V17, P33, DOI 10.1007/BF01812682; Labriola L, 2003, MOL CELL BIOL, V23, P1095, DOI 10.1128/MCB.23.3.1095-1111.2003; Lange CA, 1999, MOL ENDOCRINOL, V13, P829, DOI 10.1210/me.13.6.829; Lange CA, 1998, J BIOL CHEM, V273, P31308, DOI 10.1074/jbc.273.47.31308; Lee H, 2002, AM J PATHOL, V161, P1357, DOI 10.1016/S0002-9440(10)64412-4; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Li SW, 1996, J BIOL CHEM, V271, P3863; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Lydon JP, 2000, J MAMMARY GLAND BIOL, V5, P325, DOI 10.1023/A:1009555013246; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; Montecchia MF, 1999, J STEROID BIOCHEM, V68, P11, DOI 10.1016/S0960-0760(98)00166-6; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Proietti C, 2005, MOL CELL BIOL, V25, P4826, DOI 10.1128/MCB.25.12.4826-4840.2005; Puricelli L, 2002, INT J CANCER, V100, P642, DOI 10.1002/ijc.10533; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Ross RK, 2000, JNCI-J NATL CANCER I, V92, P328, DOI 10.1093/jnci/92.4.328; Salatino M, 2004, ONCOGENE, V23, P5161, DOI 10.1038/sj.onc.1207659; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 1999, J BIOL CHEM, V274, P33551, DOI 10.1074/jbc.274.47.33551; Schlegel A, 2001, BIOCHEM J, V359, P203, DOI 10.1042/0264-6021:3590203; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Syed V, 2005, ONCOGENE, V24, P1774, DOI 10.1038/sj.onc.1207991; Tahir SA, 2001, CANCER RES, V61, P3882; Thompson TC, 1999, APOPTOSIS, V4, P233, DOI 10.1023/A:1009612708099; Timme TL, 2003, CURR DRUG TARGETS, V4, P251, DOI 10.2174/1389450033491127; Trouet D, 1999, J PHYSIOL-LONDON, V520, P113, DOI 10.1111/j.1469-7793.1999.t01-1-00113.x; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; Williams TM, 2005, J BIOL CHEM, V280, P25134, DOI 10.1074/jbc.M501186200; Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200; Yamamoto M, 1998, J BIOL CHEM, V273, P26962, DOI 10.1074/jbc.273.41.26962; Yang G, 1999, CANCER RES, V59, P5719; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2000, CLIN CANCER RES, V6, P3430	66	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7723	7739		10.1038/sj.onc.1209757	http://dx.doi.org/10.1038/sj.onc.1209757			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799639				2022-12-28	WOS:000242830800007
J	Soprano, KJ; Purev, E; Vuocolo, S; Soprano, DR				Soprano, K. J.; Purev, E.; Vuocolo, S.; Soprano, D. R.			Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid	ONCOGENE			English	Review						retinoids; ovarian cancer; protein phosphatase 2A; Rb2/p130	RESTRICTED SYNTHETIC RETINOIDS; LARGE T-ANTIGEN; NUCLEAR-LOCALIZATION; RETINOBLASTOMA PROTEIN; CANCER-CELLS; THYMIDINE KINASE; BINDING-SITE; SUBCELLULAR-LOCALIZATION; PAPILLOMAVIRUS TYPE-1; HISTONE DEACETYLASE	Despite a number of attempts to improve treatment of ovarian cancer, it remains the most common cause of death from gynecological cancers. Thus, it is very important to identify more effective drugs for treatment and prevention of ovarian cancer. All-trans-retinoic acid ( ATRA) has been shown to arrest the growth of ovarian carcinoma cells in G0/G1 and to significantly elevate levels of Rb2/p130 protein, a member of the retinoblastoma family of tumor suppressors. As ATRA treatment leads to a significant increase in the amount of Rb2/p130 protein but not mRNA, the elevated levels of Rb2/p130 protein is likely the result of increased stability. In studies to elucidate the mechanism by which ATRA alters Rb2/p130 stability in ovarian cancer cells, it was determined that PP2A, a serine/threonine phosphatase, binds and dephosphorylates Rb2/p130. Dephosphorylated Rb2/p130 exhibits decreased ubiquitination and thus is not degraded by the proteasome. The sites at which PP2A catalytic subunit (PP2Ac) interacts with Rb2/p130 have been localized to the NLS in the C-terminus of Rb2/p130. These sites are also involved in the interaction of Rb/p130 with importin beta and importin alpha, members of the nuclear transport machinery. It is known that importin a recognizes a NLS on a target protein and importin b binds the nuclear pore complex. Moreover, it has been shown that the binding of importin a to NLS significantly decreases with phosphorylation of NLS. In ATRA-treated ovarian carcinoma cells, PP2A binds to Rb2/p130 and dephosphorylates the NLS of Rb2/p130 leading to the interaction of importin a with Rb2/p130. Importin b then binds to the importin alpha-Rb2/p130 complex, leading to the translocation of the Rb2/p130 to the nucleus where it acts to arrest ovarian cancer cells in G1 and suppress proliferation.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.	sopranok@temple.edu			NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; BANKS L, 1990, ONCOGENE, V5, P1383; Bhattacharya S, 2003, ONCOGENE, V22, P2443, DOI 10.1038/sj.onc.1206339; Borriello A, 2000, ONCOGENE, V19, P51, DOI 10.1038/sj.onc.1203231; Botz J, 1996, MOL CELL BIOL, V16, P3401; Canhoto AJ, 2000, ONCOGENE, V19, P5116, DOI 10.1038/sj.onc.1203893; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; Chen MH, 2002, MECH DEVELOP, V114, P205, DOI 10.1016/S0925-4773(02)00066-7; Chestukhin A, 2002, MOL CELL BIOL, V22, P453, DOI 10.1128/MCB.22.2.453-468.2002; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Cinti C, 2000, CANCER RES, V60, P383; Claudio PP, 1996, CANCER RES, V56, P2003; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Corbeil HB, 1997, ONCOGENE, V15, P657, DOI 10.1038/sj.onc.1201224; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Craiu A, 1997, J BIOL CHEM, V272, P13437, DOI 10.1074/jbc.272.20.13437; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Daly M, 1998, SEMIN ONCOL, V25, P255; Dawson Marcia I., 1994, P5; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; DELUCA L, 1995, SCI AM, P2; DOU QP, 1994, J BIOL CHEM, V269, P1306; Dunaief JL, 2002, CURR EYE RES, V24, P392, DOI 10.1076/ceyr.24.5.392.8524; Fahrenkrog B, 2004, TRENDS BIOCHEM SCI, V29, P175, DOI 10.1016/j.tibs.2004.02.006; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Fanjul AN, 1996, J BIOL CHEM, V271, P22441, DOI 10.1074/jbc.271.37.22441; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; FORD D, 1995, AM J HUM GENET, V57, P1457; Fry CJ, 1997, MOL CELL BIOL, V17, P1966, DOI 10.1128/MCB.17.4.1966; Fukuchi K, 1999, BBA-MOL CELL RES, V1451, P206, DOI 10.1016/S0167-4889(99)00081-6; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; GRUNT TW, 1991, J CELL SCI, V100, P657; GUILHOT C, 1993, ONCOGENE, V8, P619; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; Harreman MT, 2004, J BIOL CHEM, V279, P20613, DOI 10.1074/jbc.M401720200; Hengstschlager M, 1996, ONCOGENE, V12, P1635; Holmes WF, 2003, J CELL BIOCHEM, V89, P262, DOI 10.1002/jcb.10505; Holmes WF, 2004, J CELL PHYSIOL, V199, P317, DOI 10.1002/jcp.10338; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Holmes WF, 2002, J BIOL CHEM, V277, P45408, DOI 10.1074/jbc.M204600200; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1994, RETINOIDS, P592; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; Iavarone A, 1999, MOL CELL BIOL, V19, P916; IQBAL K, 1991, MOL NEUROBIOL, V5, P399, DOI 10.1007/BF02935561; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; Kehlenbach RH, 2000, J BIOL CHEM, V275, P17848, DOI 10.1074/jbc.M001455200; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Litovchick L, 2004, MOL CELL BIOL, V24, P8970, DOI 10.1128/MCB.24.20.8970-8980.2004; Liu Y, 2000, J BIOL CHEM, V275, P30894, DOI 10.1074/jbc.M000640200; LUDLOW JW, 1993, ONCOGENE, V8, P331; Mayol X, 1996, ONCOGENE, V13, P237; Mayol X, 1997, Prog Cell Cycle Res, V3, P157; MAYOL X, 1998, FRONT BIOSCI, V3, P11; McGuire WP, 1998, CURR PROB CANCER, V22, P138, DOI 10.1016/S0147-0272(98)90005-8; MISSERO C, 1993, J CELL BIOL, V121, P1109, DOI 10.1083/jcb.121.5.1109; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MJMBY MC, 1993, PHYSIOL REV, V4, P673; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Modugno F, 2003, GYNECOL ONCOL, V91, P15, DOI 10.1016/S0090-8258(03)00254-3; Muller H, 1997, MOL CELL BIOL, V17, P5508; MUMBY M, 1995, SEMIN CANCER BIOL, V6, P229, DOI 10.1006/scbi.1995.0030; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NIELSCH U, 1991, ONCOGENE, V6, P1031; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Pergolizzi R, 1999, INT J CANCER, V81, P829; Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490; PUREV E, 2006, UNPUB; Putzer BM, 1997, J VIROL, V71, P9538; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rumpf H, 1999, VIROLOGY, V257, P45, DOI 10.1006/viro.1999.9651; Sabichi AL, 1998, J NATL CANCER I, V90, P597, DOI 10.1093/jnci/90.8.597; SAUNDERS DE, 1995, ANTI-CANCER DRUG, V6, P562, DOI 10.1097/00001813-199508000-00009; SCHMITT A, 1994, J VIROL, V68, P7051, DOI 10.1128/JVI.68.11.7051-7059.1994; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sekimoto T, 2004, EMBO J, V23, P1934, DOI 10.1038/sj.emboj.7600198; SHEIKH MS, 1995, CARCINOGENESIS, V16, P2477, DOI 10.1093/carcin/16.10.2477; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; Sidle A, 1996, CRIT REV BIOCHEM MOL, V31, P237, DOI 10.3109/10409239609106585; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spitkovsky D, 1997, CELL GROWTH DIFFER, V8, P699; Stiegler P, 1999, ANAL QUANT CYTOL, V21, P363; STOCHAJ U, 1993, J CELL SCI, V104, P89; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; Sueoka N, 1999, CANCER RES, V59, P3838; TortoleroLuna G, 1995, J CELL BIOCHEM, P200; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Um SJ, 2001, CANCER LETT, V174, P127, DOI 10.1016/S0304-3835(01)00697-8; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Vuocolo S, 2003, J BIOL CHEM, V278, P41881, DOI 10.1074/jbc.M302715200; WADE M, 1995, J BIOL CHEM, V270, P9783, DOI 10.1074/jbc.270.17.9783; Wang P, 1997, Zhonghua Fu Chan Ke Za Zhi, V32, P722; Watanabe G, 1998, MOL CELL BIOL, V18, P3212, DOI 10.1128/MCB.18.6.3212; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Young M, 2001, PHARMACOECONOMICS, V19, P1227, DOI 10.2165/00019053-200119120-00005; Zacksenhaus E, 1999, BBA-MOL CELL RES, V1451, P288, DOI 10.1016/S0167-4889(99)00103-2; Zhang DM, 2001, ONCOGENE, V20, P7935, DOI 10.1038/sj.onc.1204971; Zhang DM, 2000, J CELL PHYSIOL, V185, P1, DOI 10.1002/1097-4652(200010)185:1<1::AID-JCP1>3.0.CO;2-O	116	24	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5315	5325		10.1038/sj.onc.1209679	http://dx.doi.org/10.1038/sj.onc.1209679			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936753				2022-12-28	WOS:000240064100018
J	Mathupala, SP; Ko, YH; Pedersen, PL				Mathupala, S. P.; Ko, Y. H.; Pedersen, P. L.			Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria	ONCOGENE			English	Review						hexokinase II; glycolysis; mitochondria; cell death; 3-bromopyruvate	DEPENDENT ANION CHANNEL; ADENINE-NUCLEOTIDE TRANSLOCATOR; PERMEABILITY TRANSITION PORE; ANTITUMOR DRUG LONIDAMINE; APOPTOTIC CELL-DEATH; ASCITES TUMOR-CELLS; C-TERMINAL HALVES; GLUCOSE CATABOLISM; FUNCTIONAL-ORGANIZATION; MAMMALIAN HEXOKINASES	A key hallmark of many cancers, particularly the most aggressive, is the capacity to metabolize glucose at an elevated rate, a phenotype detected clinically using positron emission tomography(PET). This phenotype provides cancer cells, including those that participate in metastasis, a distinct competitive edge over normal cells. Specifically, after rapid entry of glucose into cancer cells on the glucose transporter, the highly glycolytic phenotype is supported by hexokinase (primarily HK II) that is overexpressed and bound to the outer mitochondrial membrane via the porin-like protein voltage-dependent anion channel (VDAC). This protein and the adenine nucleotide transporter move ATP, newly synthesized by the inner membrane located ATP synthase, to active sites on HK II. The abundant amounts of HK II bind both the ATP and the incoming glucose producing the product glucose-6-phosphate, also at an elevated rate. This critical metabolite then serves both as a biosynthetic precursor to support cell proliferation and as a precursor for lactic acid, the latter exiting cancer cells causing an unfavorable environment for normal cells. Although helping facilitate this chemical warfare, HK II via its mitochondrial location also suppresses the death of cancer cells, thus increasing their possibility for metastasis and the ultimate death of the human host. For these reasons, targeting this key enzyme is currently being investigated in several laboratories in a strategy to develop novel therapies that may turn the tide on the continuing struggle to find effective cures for cancer. One such candidate is 3-bromopyruvate that has been shown recently to eradicate advanced stage, PET positive hepatocellular carcinomas in an animal model without apparent harm to the animals.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Karmanos Canc Inst, Detroit, MI 48202 USA	Johns Hopkins University; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Pedersen, PL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.	ppederse@jhmi.edu			NCI NIH HHS [R01CA08018, R01 CA010951, R01 CA116257, R01CA010951] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116257, R01CA010951] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ardehali H, 1996, J BIOL CHEM, V271, P1849, DOI 10.1074/jbc.271.4.1849; ARORA KK, 1992, J BIOENERG BIOMEMBR, V24, P47, DOI 10.1007/BF00769530; ARORA KK, 1988, J BIOL CHEM, V263, P17422; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Bay DC, 2002, BIOCHEM CELL BIOL, V80, P551, DOI 10.1139/O02-149; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; Bustamante E, 2005, BIOCHEM BIOPH RES CO, V334, P907, DOI 10.1016/j.bbrc.2005.06.174; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Campanella ME, 2005, P NATL ACAD SCI USA, V102, P2402, DOI 10.1073/pnas.0409741102; Capano M, 2002, BIOCHEM J, V367, P169, DOI 10.1042/BJ20020805; Cesar MD, 2004, ARCH BIOCHEM BIOPHYS, V422, P191, DOI 10.1016/j.abb.2003.12.030; Cesar MD, 1998, ARCH BIOCHEM BIOPHYS, V350, P109; Chen C, 2004, J BIOL CHEM, V279, P31761, DOI 10.1074/jbc.M401353200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5; Colombini M, 2004, MOL CELL BIOCHEM, V256, P107, DOI 10.1023/B:MCBI.0000009862.17396.8d; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Danial NN, 2003, NATURE, V424, P952, DOI 10.1038/nature01825; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904; Fanciulli M, 1996, ONCOL RES, V8, P111; FELGNER PL, 1979, J BIOL CHEM, V254, P4946; Floridi A, 1998, BIOCHEM PHARMACOL, V56, P841, DOI 10.1016/S0006-2952(98)00054-9; GAUTHIER T, 1990, INT J BIOCHEM, V22, P419, DOI 10.1016/0020-711X(90)90146-T; Geschwind Jean-Francois, 2004, Expert Rev Anticancer Ther, V4, P449, DOI 10.1586/14737140.4.3.449; Geschwind JFH, 2002, CANCER RES, V62, P3909; Goel A, 2003, J BIOL CHEM, V278, P15333, DOI 10.1074/jbc.M300608200; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; GRAHAM JF, 1985, NEUROSURGERY, V17, P537, DOI 10.1227/00006123-198510000-00001; Granville DJ, 2003, CURR MED CHEM, V10, P1527, DOI 10.2174/0929867033457214; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; JOHANSSON T, 1985, BIOCHEM BIOPH RES CO, V133, P608, DOI 10.1016/0006-291X(85)90948-9; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Ko YH, 2003, J BIOL CHEM, V278, P12305, DOI 10.1074/jbc.C200703200; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; KROPP ES, 1970, BIOCHEM BIOPH RES CO, V38, P74, DOI 10.1016/0006-291X(70)91085-5; Lee MG, 2003, J BIOL CHEM, V278, P41047, DOI 10.1074/jbc.M307031200; Lemasters JJ, 2006, BBA-MOL BASIS DIS, V1762, P181, DOI 10.1016/j.bbadis.2005.10.006; Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Majewski N, 2004, MOL CELL BIOL, V24, P730, DOI 10.1128/MCB.24.2.730-740.2004; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; Mayer D, 1997, BIOCHEM SOC T, V25, P122, DOI 10.1042/bst0250122; Miccoli L, 1996, BIOCHEM J, V313, P957, DOI 10.1042/bj3130957; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Pauwels EKJ, 1998, NUCL MED BIOL, V25, P317, DOI 10.1016/S0969-8051(97)00226-6; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Penso J, 1998, EUR J PHARMACOL, V342, P113, DOI 10.1016/S0014-2999(97)01507-0; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Printz RL, 1997, BIOCHEM SOC T, V25, P107, DOI 10.1042/bst0250107; REMPEL A, 1994, BIOCHEM J, V303, P269, DOI 10.1042/bj3030269; Rempel A, 1996, CANCER RES, V56, P2468; Rempel A, 1996, FEBS LETT, V385, P233, DOI 10.1016/0014-5793(96)00399-7; REMPEL A, 1994, BBA-GENE STRUCT EXPR, V1219, P660, DOI 10.1016/0167-4781(94)90225-9; ROSE IA, 1982, ARCH BIOCHEM BIOPHYS, V213, P625, DOI 10.1016/0003-9861(82)90592-6; ROSE IA, 1967, J BIOL CHEM, V242, P1635; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Shinohara Y, 1997, BBA-BIOENERGETICS, V1319, P319, DOI 10.1016/S0005-2728(97)00002-9; Shinohara Y, 2000, EUR J BIOCHEM, V267, P6067, DOI 10.1046/j.1432-1327.2000.01687.x; Smith TAD, 1999, BRIT J BIOMED SCI, V56, P285; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; TEDESCHI H, 1989, J BIOENERG BIOMEMBR, V21, P451, DOI 10.1007/BF00762517; Tsai HJ, 1997, ARCH BIOCHEM BIOPHYS, V338, P183, DOI 10.1006/abbi.1996.9850; TSAI HJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P206, DOI 10.1006/abbi.1995.1029; Tsai HJ, 1996, ARCH BIOCHEM BIOPHYS, V329, P17, DOI 10.1006/abbi.1996.0186; Vander Heiden MG, 1999, MOL CELL, V3, P159; VISCHER U, 1987, BIOCHEM J, V241, P249, DOI 10.1042/bj2410249; Vyssokikh M, 2004, MOL CELL BIOCHEM, V256, P117, DOI 10.1023/B:MCBI.0000009863.69249.d9; Vyssokikh MY, 2003, ACTA BIOCHIM POL, V50, P389; Vyssokikh MY, 2002, MOL BIOL REP, V29, P93, DOI 10.1023/A:1020383108620; Warburg O.H., 1930, METABOLISM TUMOURS I; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WILSON JE, 1983, METHOD ENZYMOL, V97, P469; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Wilson JE, 1997, BIOCHEM SOC T, V25, P103, DOI 10.1042/bst0250103; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zhou H, 2005, EXP CELL RES, V309, P316, DOI 10.1016/j.yexcr.2005.06.014	89	561	593	2	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4777	4786		10.1038/sj.onc.1209603	http://dx.doi.org/10.1038/sj.onc.1209603			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892090	Green Accepted			2022-12-28	WOS:000239687000014
J	Yoo, YG; Na, TY; Yang, WK; Kim, HJ; Lee, IK; Kong, G; Chung, JH; Lee, MO				Yoo, Y-G; Na, T-Y; Yang, W-K; Kim, H-J; Lee, I-K; Kong, G.; Chung, J-H; Lee, M-O			6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1 alpha resulting in new vessel formation	ONCOGENE			English	Article						6-mercaptopurine; Nur77; hypoxia-inducible factor-1 alpha; vascular endothelial growth factor	HYPOXIA-INDUCIBLE-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; VASCULAR ENDOTHELIAL-CELLS; SERUM GROWTH-FACTORS; ORPHAN RECEPTOR TR3; NUCLEAR RECEPTOR; PROTEIN-KINASE; FACTOR 1-ALPHA; NGFI-B; EXPRESSION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) plays a central role in oxygen homeostasis. Previously, we reported that the orphan nuclear receptor Nur77 functions in stabilizing HIF-1 alpha. Here, we demonstrate that 6-mercaptopurine (6-MP), an activator of the NR4A family members, enhances transcriptional activity of HIF-1. 6-MP enhanced the protein-level of HIF-1 alpha as well as vascular endothelial growth factor (VEGF) in a dose- and time-dependent manner. The induction of HIF-1 alpha was abolished by the transfection of either a dominant-negative Nur77 mutant or si-Nur77, indicating a critical role of Nur77 in the 6-MP action. The HIF-1 alpha protein level remained up to 60 min in the presence of 6-MP when de novo protein synthesis was blocked by cycloheximide, suggesting that 6-MP induces stabilization of the HIF-1 alpha protein. The fact that 6-MP decreased the association of HIF-1 alpha with von Hippel - Lindau protein and the acetylation of HIF-1 alpha, may explain how 6-MP induced stability of HIF-1 alpha. Further, 6-MP induced the transactivation function of HIF-1 alpha by recruiting co-activator cyclic-AMP-response-element- binding protein. Finally, 6-MP enhanced the expression of HIF-1 alpha and VEGF, and the formation of capillary tubes in human umbilical vascular endothelial cells. Together, our results provide a new insight for 6-MP action in the stabilization of HIF-1a and imply a potential application of 6-MP in hypoxia-associated human vascular diseases.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Kyungpook National University	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Lee, In-Kyu/AAR-6374-2021					Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Cuenda A, 2000, METH MOL B, V99, P161; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Erez N, 2003, CANCER RES, V63, P8777; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim SH, 2006, BIOCHEM BIOPH RES CO, V340, P422, DOI 10.1016/j.bbrc.2005.12.018; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li MH, 2004, CLIN CANCER RES, V10, P8266, DOI 10.1158/1078-0432.CCR-04-0951; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Martinez-Gonzalez J, 2003, CIRC RES, V92, P96, DOI 10.1161/01.ES.0000050921.53008.47; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Rius J, 2006, ATHEROSCLEROSIS, V184, P276, DOI 10.1016/j.atherosclerosis.2005.04.008; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Weigel G, 1999, THROMB RES, V94, P87, DOI 10.1016/S0049-3848(98)00199-6; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	57	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3823	3834		10.1038/sj.onc.1210149	http://dx.doi.org/10.1038/sj.onc.1210149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17146432				2022-12-28	WOS:000247026400006
J	Mateos, S; Amarir, S; Laugier, D; Marx, M; Calothy, G				Mateos, S.; Amarir, S.; Laugier, D.; Marx, M.; Calothy, G.			Stable expression of intracellular Notch suppresses v-Src-induced transformation in avian neural cells	ONCOGENE			English	Article						cell transformation; differentiation; Src; Notch; tumor suppressor; paracrine activity	RETINAL PROGENITOR CELLS; QUAIL NEURORETINA CELLS; PROTEIN-KINASE; CHICK-EMBRYO; NEOPLASTIC TRANSFORMATION; TRANSCRIPTION FACTOR; VIRAL ONCOGENES; GROWTH ARREST; CANCER CELLS; CYCLE ARREST	Understanding how disruption of differentiation contributes to the cancer cell phenotype is required to identify alterations essential for malignant transformation and provide experimental basis for their correction. We investigated whether primary quail neuroretina cells, transformed by a conditional v-Src mutant (QNR/v-src(ts)), could revert to a normal phenotype, in response to the stable expression of constitutively active Notch1 intracellular domain (ICN). This model system was chosen because Notch signaling plays an instructive role in cell fate determination during NR development, and because the intrinsic capacity of QNR cultures to differentiate is blocked by v-Src.We report that stable ICN expression results in suppression of QNR/v-src(ts) cell transformation in the presence of an active oncoprotein. This phenotypic reversion coincides with a major switch in cell identity, as these undifferentiated cells acquire glial differentiation traits. Both changes appear to be mediated by CBF, a transcription factor that binds to ICN and activates target genes. Cells restored to a normal and differentiated phenotype have undergone changes in the functioning of signaling effectors, essentially regulating cell morphology and cytoskeleton organization. This dominant interference may be partially mediated by an autocrine/paracrine mechanism, as revertant cells secrete a factor(s), which inhibits transformation properties of QNR/v-src(ts) cells.	Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Calothy, G (corresponding author), Ctr Univ Paris Sud, Inst CURIE, CNTS, UMR 146, F-91405 Orsay, France.	georges.calothy@curie.u-psud.fr						ADLER V, 1992, J BIOL CHEM, V267, P17001; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bao ZZ, 1997, J NEUROSCI, V17, P1425; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BeleckyAdams T, 1997, INVEST OPHTH VIS SCI, V38, P1293; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bernardos RL, 2005, DEV BIOL, V278, P381, DOI 10.1016/j.ydbio.2004.11.018; Berset T, 2001, SCIENCE, V291, P1055, DOI 10.1126/science.1055642; BINDER LI, 1986, ANN NY ACAD SCI, V466, P145, DOI 10.1111/j.1749-6632.1986.tb38392.x; Bissell MJ, 2005, CANCER CELL, V7, P17, DOI 10.1016/j.ccr.2004.12.013; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burmeister M, 1996, NAT GENET, V12, P376, DOI 10.1038/ng0496-376; CALOTHY G, 1980, COLD SPRING HARB SYM, V44, P983, DOI 10.1101/SQB.1980.044.01.106; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Chen CB, 2002, DEVELOPMENT, V129, P2401; Chen CMA, 2000, MECH DEVELOP, V90, P293; COMBES PC, 1977, CELL TISSUE RES, V185, P159; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; Douer D, 2002, INT J HEMATOL, V76, P179, DOI 10.1007/BF03165115; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Faigle R, 2004, MOL CELL BIOL, V24, P280, DOI 10.1128/MCB.24.1.280-293.2004; FALCONE G, 1985, P NATL ACAD SCI USA, V82, P426, DOI 10.1073/pnas.82.2.426; Fincham VJ, 1999, J CELL SCI, V112, P947; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Furukawa T, 2000, NEURON, V26, P383, DOI 10.1016/S0896-6273(00)81171-X; Galy A, 2002, DEV BIOL, V248, P251, DOI 10.1006/dbio.2002.0736; Girard L, 1996, GENE DEV, V10, P1930, DOI 10.1101/gad.10.15.1930; GUERMAH M, 1990, MOL CELL BIOL, V10, P3584, DOI 10.1128/MCB.10.7.3584; GUERMAH M, 1991, P NATL ACAD SCI USA, V88, P4503, DOI 10.1073/pnas.88.10.4503; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen LA, 2000, CARCINOGENESIS, V21, P1271, DOI 10.1093/carcin/21.7.1271; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; Huang C, 2004, CELL CYCLE, V3, P4, DOI 10.4161/cc.3.1.601; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; KAHN P, 1984, P NATL ACAD SCI-BIOL, V81, P7122, DOI 10.1073/pnas.81.22.7122; KAWAI S, 1971, VIROLOGY, V46, P470, DOI 10.1016/0042-6822(71)90047-X; Kim JW, 2005, P NATL ACAD SCI USA, V102, P14308, DOI 10.1073/pnas.0501600102; Kopan R, 1996, CURR OPIN NEUROBIOL, V6, P594, DOI 10.1016/S0959-4388(96)80090-0; Kopan R, 2002, J CELL SCI, V115, P1095; LAYER PG, 1989, CELL TISSUE RES, V258, P233; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Marquardt T, 2002, TRENDS NEUROSCI, V25, P32, DOI 10.1016/S0166-2236(00)02028-2; Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; MARX M, 1988, J VIROL, V62, P4627, DOI 10.1128/JVI.62.12.4627-4633.1988; Mateos S, 2003, ONCOGENE, V22, P740, DOI 10.1038/sj.onc.1206213; Mayer T, 1999, ONCOGENE, V18, P2117, DOI 10.1038/sj.onc.1202537; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; Morimura T, 2000, J BIOL CHEM, V275, P36523, DOI 10.1074/jbc.M006415200; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; OKADA TS, 1983, CELL DIFFER DEV, V12, P85, DOI 10.1016/0045-6039(83)90060-X; Oren A, 1999, MOL CELL BIOL, V19, P1742; Pawlak G, 2002, J BIOL CHEM, V277, P26927, DOI 10.1074/jbc.M202261200; Perron M, 2000, CELL MOL LIFE SCI, V57, P215, DOI 10.1007/PL00000685; PESSAC B, 1983, NATURE, V302, P616, DOI 10.1038/302616a0; PESSAC B, 1974, SCIENCE, V185, P709, DOI 10.1126/science.185.4152.709; Peyssonnaux C, 2000, MOL CELL BIOL, V20, P7068, DOI 10.1128/MCB.20.19.7068-7079.2000; POUPONNOT C, 1995, MOL CELL BIOL, V15, P5563; Prada FA, 1995, GLIA, V15, P389, DOI 10.1002/glia.440150404; Rangarajan A, 2001, EMBO J, V20, P3427, DOI 10.1093/emboj/20.13.3427; Rohn JL, 1996, J VIROL, V70, P8071, DOI 10.1128/JVI.70.11.8071-8080.1996; Servitja JM, 2003, J BIOL CHEM, V278, P34339, DOI 10.1074/jbc.M302960200; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Souopgui J, 2002, EMBO J, V21, P6429, DOI 10.1093/emboj/cdf644; Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X; Sriuranpong V, 2001, CANCER RES, V61, P3200; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tanaka M, 1999, J NEUROBIOL, V41, P524, DOI 10.1002/(SICI)1097-4695(199912)41:4<524::AID-NEU8>3.3.CO;2-9; TROTTER J, 1989, ONCOGENE, V4, P457; Vadlamudi RK, 2005, ONCOGENE, V24, P4591, DOI 10.1038/sj.onc.1208672; Wakamatsu Y, 2000, DEVELOPMENT, V127, P2811; Waltzer L, 1995, NUCLEIC ACIDS RES, V23, P4939, DOI 10.1093/nar/23.24.4939; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Xia Y, 2004, TRENDS CELL BIOL, V14, P94, DOI 10.1016/j.tcb.2003.12.005; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555	85	5	5	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3338	3351		10.1038/sj.onc.1210124	http://dx.doi.org/10.1038/sj.onc.1210124			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146440				2022-12-28	WOS:000246579600004
J	Narisawa-Saito, M; Handa, K; Yugawa, T; Ohno, S; Fujita, M; Kiyono, T				Narisawa-Saito, M.; Handa, K.; Yugawa, T.; Ohno, S.; Fujita, M.; Kiyono, T.			HPV16 E6-mediated stabilization of ErbB2 in neoplastic transformation of human cervical keratinocytes	ONCOGENE			English	Article						HPV16 E6; ErbB2; primary human cervical keratinocytes; cervical cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; GROWTH-FACTOR RECEPTOR; PROGNOSTIC-SIGNIFICANCE; HER-2/NEU ONCOGENE; E6 ONCOPROTEIN; CARCINOMA; PROTEIN; CELLS; EXPRESSION; CANCER	Whether ErbB2 receptor tyrosine kinase contributes to cervical cancer is controversial. We have examined the effects of E6 and E7 genes of human papillomaviruses type 16 ( HPV-16) on ErbB2 expression in primary human cervical keratinocytes ( HCK) immortalized with hTERT ( HCK1T). In E6-positive cells ( HCK1T-E6 and HCK1T-E6E7), ErbB2 expression levels increased with the cell density. HCK1T-E6E7 showed impaired contact inhibition and anchorage-independent growth in soft agar which were abrogated with introduction of ErbB2-specific short hairpin RNA ( shRNA) or an ErbB2 specific inhibitor AG825. Furthermore, increased ErbB2 expression was also observed in HPV16 positive cervical cancer cell lines and this was diminished by introduction of HPV16E6- or E6AP-shRNA. At post-confluence cell densities, ErbB2 protein was stabilized in the presence of E6 whereas increased ErbB2 expression was not obvious with E6 mutants incapable of degrading p53. Furthermore, introduction of p53-shRNA to HCK1T resulted in increased ErbB2 protein stability, indicating possible ErbB2 regulation through p53. Finally, we showed that tumor formation of ErbB2-shRNA introduced SiHa cells were almost abolished. Taken together, these data indicate an important role of ErbB2 regulation by HPV16 E6 in oncogenic transformation of human cervical keratinocytes.	Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Kiyono, T (corresponding author), Natl Canc Ctr, Res Inst, Virol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tkiyono@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Al Moustafa AE, 2004, ONCOGENE, V23, P350, DOI 10.1038/sj.onc.1207148; Beger M, 2001, J MOL MED, V79, P314, DOI 10.1007/s001090100211; Bellone S, 2003, GYNECOL ONCOL, V91, P231, DOI 10.1016/S0090-8258(03)00460-8; Gewin L, 2004, GENE DEV, V18, P2269, DOI 10.1101/gad.1214704; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Ignatoski KMW, 2005, NEOPLASIA, V7, P788, DOI 10.1593/neo.05106; Kansra S, 2004, MOL BIOL CELL, V15, P4299, DOI 10.1091/mbc.E04-03-0233; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kersemaekers AMF, 1999, CLIN CANCER RES, V5, P577; KIHANA T, 1994, CANCER, V73, P148, DOI 10.1002/1097-0142(19940101)73:1<148::AID-CNCR2820730125>3.0.CO;2-C; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; KIYONO T, 1994, J VIROL, V68, P4656, DOI 10.1128/JVI.68.7.4656-4661.1994; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Nakano T, 1997, CANCER, V79, P513, DOI 10.1002/(SICI)1097-0142(19970201)79:3<513::AID-CNCR13>3.0.CO;2-6; Ndubisi B, 1997, ANN CLIN LAB SCI, V27, P396; Ngan HYS, 2001, TUMOR BIOL, V22, P176, DOI 10.1159/000050613; Niibe Y, 2003, INT J GYNECOL CANCER, V13, P849, DOI 10.1111/j.1525-1438.2003.13397.x; PINION SB, 1991, LANCET, V337, P819, DOI 10.1016/0140-6736(91)92518-7; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Rosty C, 2004, INT J GYNECOL PATHOL, V23, P13, DOI 10.1097/01.pgp.0000092137.88121.8d; Sawada M, 2004, CELL DEATH DIFFER, V11, P997, DOI 10.1038/sj.cdd.4401438; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sharma A, 1999, ONCOLOGY-BASEL, V56, P83, DOI 10.1159/000011934; Takeda Y, 2004, J GENE MED, V6, P833, DOI 10.1002/jgm.583; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	32	42	43	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2988	2996		10.1038/sj.onc.1210118	http://dx.doi.org/10.1038/sj.onc.1210118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17146442				2022-12-28	WOS:000246395400004
J	Iwamaru, A; Szymanski, S; Iwado, E; Aoki, H; Yokoyama, T; Fokt, I; Hess, K; Conrad, C; Madden, T; Sawaya, R; Kondo, S; Priebe, W; Kondo, Y				Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y.			A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo	ONCOGENE			English	Article						STAT3; apoptosis; malignant glioma	ACTIVATION; CANCER; GLIOBLASTOMA; KINASE; TUMORS; INTERLEUKIN-6; EXPRESSION; PROTEINS; MCL-1	Signal transducer and activator of transcription-3 (STAT3) is constitutively activated in a variety of cancer types, including malignant gliomas. STAT3 is activated by phosphorylation of a tyrosine residue, after which it dimerizes and translocates into the nucleus. There it regulates the expression of several genes responsible for proliferation and survival at the transcriptional level. A selective inhibitor of STAT3 phosphorylation, AG490, has been shown to inhibit growth and induce apoptosis in some cancer cell types. However, although AG490 routinely shows in vitro anticancer activity, it has not consistently demonstrated an in vivo anticancer effect in animal models. Here, we have tested WP1066, a novel inhibitor structurally related to AG490 but significantly more potent and active, against human malignant glioma U87MG and U373-MG cells in vitro and in vivo. IC50 values for WP1066 were 5.6 mu M in U87-MG cells and 3.7 mu M in U373-MG cells, which represents 18-fold and eightfold increases in potency, respectively, over that of AG490. WP1066 activated Bax, suppressed the expression of c-myc, Bcl-X-L and Mcl-1, and induced apoptosis. Systemic intraperitoneal administration of WP1066 in mice significantly (P < 0.001) inhibited the growth of subcutaneous malignant glioma xenografts during the 30-day follow-up period. Immunohistochemical analysis of the excised tumors revealed that phosphorylated STAT3 levels in the WP1066 treatment group remained inhibited at 3 weeks after the final WP1066 injection, whereas tumors from the control group expressed high levels of phosphorylated STAT3. We conclude that WP1066 holds promise as a therapeutic agent against malignant gliomas.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci Houston, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; University of Texas System	Kondo, Y (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Unit BSRB1004,1515 Holcombe Blvd, Houston, TX 77030 USA.	yaskondo@mdanderson.org	Hess, Kenneth/K-6546-2019	Hess, Kenneth/0000-0003-1377-6070	NCI NIH HHS [CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhattacharya S, 2005, BIOCHEM J, V392, P335, DOI 10.1042/BJ20050465; Bogler O, 2002, FRONT BIOSCI, V7, pE339, DOI 10.2741/bogler; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 2001, BIOESSAYS, V23, P161, DOI 10.1002/1521-1878(200102)23:2<161::AID-BIES1023>3.0.CO;2-0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kanzawa T, 2006, ONCOGENE, V25, P3638, DOI 10.1038/sj.onc.1209414; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kapoor GS, 2003, NEUROSURGERY, V52, P1425, DOI 10.1227/01.NEU.0000065135.28143.39; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Kondo Y, 2004, INT J ONCOL, V24, P1101; Konnikova L, 2005, CANCER RES, V65, P6516, DOI 10.1158/0008-5472.CAN-05-0924; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LICHTOR T, 1994, NEUROSURGERY, V34, P669, DOI 10.1227/00006123-199404000-00015; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Rahaman SO, 2002, ONCOGENE, V21, P8404, DOI 10.1038/sj.onc.1206047; Reardon DA, 2006, J CLIN ONCOL, V24, P1253, DOI 10.1200/JCO.2005.04.5302; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Song H, 2005, P NATL ACAD SCI USA, V102, P4700, DOI 10.1073/pnas.0409894102; Sonoda Y, 2001, CANCER RES, V61, P4956; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Turkson J, 2004, MOL CANCER THER, V3, P1533; VAN MEIR E, 1990, CANCER RES, V50, P6683; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Weissenberger J, 2004, ONCOGENE, V23, P3308, DOI 10.1038/sj.onc.1207455; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940	36	295	323	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2435	2444		10.1038/sj.onc.1210031	http://dx.doi.org/10.1038/sj.onc.1210031			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043651				2022-12-28	WOS:000245831000004
J	Zhang, L; Wang, C				Zhang, L.; Wang, C.			Identification of a new class of PAX3-FKHR target promoters: a role of the Pax3 paired box DNA binding domain	ONCOGENE			English	Article						oncogene; rhabdomyosarcoma; transcription; chromosomal translocation	ALVEOLAR RHABDOMYOSARCOMA; TRANSCRIPTION FACTORS; FUSION PROTEIN; MYOGENIN GENE; EXPRESSION; DIFFERENTIATION; EMBRYOGENESIS; ACTIVATION; CELLS; TRANSLOCATION	Alveolar rhabdomyosarcoma (aRMS), an aggressive skeletal muscle cancer, carries a unique t(2;13) chromosomal translocation resulting in the formation of a chimeric transcription factor PAX3-FKHR. This fusion protein contains the intact DNA-binding domains (PD:paired box binding domain; HD: paired-type homeodomain) of Pax3 fused to the activation domain of FKHR. Cells expressing Pax3 and PAX3-FKHR show vastly different gene expression patterns, despite that they share the same DNA-binding domains. We present evidence of a gain of function mechanism that allows the fusion protein to recognize and transcriptionally activate response elements containing a PD-specific binding site. This DNA recognition specificity is in contrast to the requirement for Pax3-specific target sequences that must contain a composite of PD-and HD-binding sites. Domain swapping studies suggest that an increased structural flexibility could account for the relaxed DNA targeting specificity in PAX3-FKHR. Here, we identify myogenin gene as a direct target of PD- dependent PAX3-FKHR activation pathway in vitro and in vivo. We demonstrate that PAX3-FKHR could induce myogenin expression in undifferentiated myoblasts by a MyoD independent pathway, and that PAX3-FKHR is directly involved in myogenin expression in aRMS cells.	Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,Room 530E,M-C 860, Chicago, IL 60612 USA.	chiayeng@uic.edu			NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907] Funding Source: NIH RePORTER; NCI NIH HHS [CA074907, R29 CA074907, R01 CA074907, R01 CA074907-09] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Barr FG, 1997, CURR TOP MICROBIOL, V220, P113; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; BUCHBERGER A, 1994, J BIOL CHEM, V269, P17289; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P3685, DOI 10.1073/pnas.91.9.3685; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; De Pitta C, 2006, INT J CANCER, V118, P2772, DOI 10.1002/ijc.21698; Dias P, 2000, AM J PATHOL, V156, P399, DOI 10.1016/S0002-9440(10)64743-8; DOUGLASS EC, 1987, CYTOGENET CELL GENET, V45, P148, DOI 10.1159/000132446; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Folpe AL, 2002, ADV ANAT PATHOL, V9, P198, DOI 10.1097/00125480-200205000-00003; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Hostein I, 2004, CANCER-AM CANCER SOC, V101, P2817, DOI 10.1002/cncr.20711; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lam PYP, 1999, MOL CELL BIOL, V19, P594; MALIK S, 1995, EUR J BIOCHEM, V230, P88, DOI 10.1111/j.1432-1033.1995.tb20537.x; Michelagnoli MP, 2003, MED PEDIATR ONCOL, V40, P1, DOI 10.1002/mpo.10201; Puri PL, 2000, GENE DEV, V14, P574; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Spicer DB, 1996, SCIENCE, V272, P1476, DOI 10.1126/science.272.5267.1476; Spitz F, 1998, P NATL ACAD SCI USA, V95, P14220, DOI 10.1073/pnas.95.24.14220; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Wang-Wuu S, 1988, Cancer Res, V48, P983; Weintraub M, 1997, Sarcoma, V1, P135, DOI 10.1080/13577149778218; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286	39	28	28	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1595	1605		10.1038/sj.onc.1209958	http://dx.doi.org/10.1038/sj.onc.1209958			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964289	Green Accepted			2022-12-28	WOS:000244782500009
J	Caporali, A; Wark, L; Vermolen, BJ; Garini, Y; Mai, S				Caporali, A.; Wark, L.; Vermolen, B. J.; Garini, Y.; Mai, S.			Telomeric aggregates and end-to-end chromosomal fusions require myc box II	ONCOGENE			English	Article						three-dimensional nuclear organization; telomere aggregates; c-Myc; genomic instability; telomeric fusions	C-MYC; CELL-CYCLE; NUCLEAR ARCHITECTURE; GENOMIC INSTABILITY; GENE; DYNAMICS; ORGANIZATION; ACTIVATION; MITOSIS; DOMAIN	Telomeres of tumor cells form telomeric aggregates (TAs) within the three-dimensional (3D) interphase nucleus. Some of these TAs represent end-to-end chromosomal fusions and may subsequently initiate breakage-bridge fusion cycles. Wild-type (wt) and myc box II mutant (mt) Myc induce different types of genomic instability when conditionally expressed in mouse proB cells (Ba/F3). Only wt Myc overexpressing Ba/F3 cells are capable of tumor formation in severe combined immunodeficient mice. In this study, we investigated whether telomere dysfunction leading to TA formation is linked to the genetic changes that permit wt c-Myc-dependent transformation of Ba/F3 cells. To this end, we examined the 3D organization of telomeres after the deregulated expression of deletion myc box II mutant (D106) or wt Myc. D106-Myc overexpression did not induce TAs, whereas wt-Myc deregulation did. Instead, D106-Myc remodelled the 3D telomeric organization such that telomeres aligned in the center of the 3D interphase nucleus forming a telomeric disk owing to a D106-induced G1/S cell cycle arrest. In contrast, wt-Myc overexpression led to distorted telomere distribution and TA formation. Analysis of chromosomal alterations using spectral karyotyping confirmed D106-Myc and wt-Myc-associated genomic instability. A significant number of chromosomal end-to-end fusions indicative of telomere dysfunction were noted in wt-Myc-expressing cells only. This study suggests that TAs may play a fundamental role in Myc-induced tumorigenesis and provides a novel way to dissect tumor initiation.	Univ Parma, Dipartimento Med Sperimentale, Sez Biochim Biochim Clin & Biochim Esercizio Fis, I-43100 Parma, Italy; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB, Canada; Delft Univ Technol, Fac Sci Appl, Dept Imaging Sci & Technol, Delft, Netherlands	University of Parma; University of Manitoba; University of Manitoba; Delft University of Technology	Mai, S (corresponding author), Manitoba Inst Cell Biol Physiol Biochem & Med Gen, 675 McDermot, Winnipeg, MB R3E 0V9, Canada.	smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017; Vermolen, Bart/C-4739-2008	Mai, Sabine/0000-0002-5797-2201; Garini, Yuval/0000-0002-8783-2015				Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barber CB, 1996, ACM T MATH SOFTWARE, V22, P469, DOI 10.1145/235815.235821; Chuang TCY, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-12; Cremer M, 2003, J CELL BIOL, V162, P809, DOI 10.1083/jcb.200304096; Cremer T, 2001, NAT REV GENET, V2, P292, DOI 10.1038/35066075; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Deb-Basu D, 2006, CELL CYCLE, V5, P1348, DOI 10.4161/cc.5.12.2860; DePinho RA, 2004, NAT GENET, V36, P932, DOI 10.1038/ng0904-932; Ermler S, 2004, EUR J CELL BIOL, V83, P681, DOI 10.1078/0171-9335-00430; Essers J, 2005, MOL BIOL CELL, V16, P769, DOI 10.1091/mbc.e04-10-0876; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Fest T, 2005, ONCOGENE, V24, P2944, DOI 10.1038/sj.onc.1208467; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Frye M, 2003, DEVELOPMENT, V130, P2793, DOI 10.1242/dev.00462; Fukatsu K, 1997, SEN-I GAKKAISHI, V53, P15, DOI 10.2115/fiber.53.15; Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703; Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2; Kozubek S, 1999, CHROMOSOMA, V108, P426, DOI 10.1007/s004120050394; Kuschak TI, 2002, ONCOGENE, V21, P909, DOI 10.1038/sj.onc.1205145; Kuschak TI, 1999, GENE, V238, P351, DOI 10.1016/S0378-1119(99)00341-8; KUTTLER F, 2005, GENOME DIS GENOME DY, V1, P171; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Louis SF, 2005, P NATL ACAD SCI USA, V102, P9613, DOI 10.1073/pnas.0407512102; Mai S, 2006, J CELL BIOCHEM, V97, P904, DOI 10.1002/jcb.20760; Mai S, 2005, CELL CYCLE, V4, P1327, DOI 10.4161/cc.4.10.2082; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Mai Sabine, 1999, Neoplasia (New York), V1, P241, DOI 10.1038/sj.neo.7900030; McClintock B, 1941, GENETICS, V26, P234; Molenaar C, 2003, EMBO J, V22, P6631, DOI 10.1093/emboj/cdg633; Neves H, 1999, BLOOD, V93, P1197, DOI 10.1182/blood.V93.4.1197.404k33_1197_1207; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Parada LA, 2002, CURR BIOL, V12, P1692, DOI 10.1016/S0960-9822(02)01166-1; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Poon SSS, 1999, CYTOMETRY, V36, P267, DOI 10.1002/(SICI)1097-0320(19990801)36:4<267::AID-CYTO1>3.0.CO;2-O; Schaefer LH, 2001, J MICROSC-OXFORD, V204, P99, DOI 10.1046/j.1365-2818.2001.00949.x; Solovei I, 2002, EXP CELL RES, V276, P10, DOI 10.1006/excr.2002.5513; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Trumpp A, 2001, NATURE, V414, P768, DOI 10.1038/414768a; Vermolen BJ, 2005, CYTOM PART A, V67A, P144, DOI 10.1002/cyto.a.20159; Walter J, 2003, J CELL BIOL, V160, P685, DOI 10.1083/jcb.200211103	41	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1398	1406		10.1038/sj.onc.1209928	http://dx.doi.org/10.1038/sj.onc.1209928			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953226				2022-12-28	WOS:000244558800004
J	Karp, CM; Shukla, MN; Buckley, DJ; Buckley, AR				Karp, C. M.; Shukla, M. N.; Buckley, D. J.; Buckley, A. R.			HRPAP20: a novel calmodulin-binding protein that increases breast cancer cell invasion	ONCOGENE			English	Article						HRPAP20; calmodulin; MMP-9; tumor invasion; metastasis; breast cancer	MMP-9 IMMUNOREACTIVE PROTEIN; LIGHT-CHAIN KINASE; IN-VITRO; TARGET RECOGNITION; PROGNOSTIC VALUE; TUMOR-CELLS; MATRIX; EXPRESSION; GROWTH; IDENTIFICATION	We previously reported the identification of HRPAP20 (hormone-regulated proliferation-associated protein 20), a novel hormone-regulated, proliferation-associated protein. In tumor cell lines, constitutive HRPAP20 expression enhanced proliferation and suppressed apoptosis, characteristics frequently associated with malignant progression. Here, we report that highly invasive breast cancer cell lines and human breast tumor specimens express elevated HRPAP20, which in transfection experiments in MCF-7 and MDA-MB-231 cells, increased invasion. Results from mechanistic studies revealed that HRPAP20 bound to calmodulin (CaM) via a conserved CaM-binding motif. Transfection of MCF-7 breast cancer cells with HRPAP20 harboring a mutated CaM-binding motif (HRPAP20K73A) inhibited its interaction with CaM and failed to increase invasion. Other experiments revealed that transfection with HRPAP20, but not HRPAP20K73A, increased secretion of matrix metallo-proteinase-9 (MMP-9). Moreover, knockdown of HRPAP20 with small interfering RNA in MCF-7/HRPAP20 transfectants and wild-type MDA-MB-231 cells reduced invasion and inhibited secretion of MMP-9. Together these observations suggest that HRPAP20 may be an important regulator of breast tumor cell invasion by a CaM-mediated mechanism that leads to increased MMP-9 secretion. We conclude that dysregulation of HRPAP20 expression in tumor cells may contribute to the observed phenotypic changes associated with breast cancer progression.	Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Buckley, AR (corresponding author), Univ Cincinnati, Acad Hlth Ctr, Coll Pharm, 3223 Eden Ave, Cincinnati, OH 45267 USA.	arthur.buckley@uc.edu						Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; ALBINI A, 1987, CANCER RES, V47, P3239; ARAFAH BM, 1986, CANCER RES, V46, P3268; BAGCHI IC, 1992, J BIOL CHEM, V267, P3024; Bartsch JE, 2003, J SURG RES, V110, P383, DOI 10.1016/S0022-4804(03)00007-6; Boehning D, 2004, J BIOL CHEM, V279, P30927, DOI 10.1074/jbc.C400222200; CRIVICI A, 1995, ANNU REV BIOPH BIOM, V24, P85, DOI 10.1146/annurev.bb.24.060195.000505; Di Carlo A, 2005, INT J ONCOL, V26, P1363; Dumitrescu RG, 2005, J CELL MOL MED, V9, P208, DOI 10.1111/j.1582-4934.2005.tb00350.x; Ellis MJ, 2003, ADV EXP MED BIOL, V532, P223; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; Fernandez CA, 2005, CLIN CANCER RES, V11, P5390, DOI 10.1158/1078-0432.CCR-04-2391; FITZSIMONS DP, 1992, J BIOL CHEM, V267, P23903; Garbett EA, 2000, J CLIN PATHOL-MOL PA, V53, P99, DOI 10.1136/mp.53.2.99; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Haupt LM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-18; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Karp CM, 2004, CANCER RES, V64, P1016, DOI 10.1158/0008-5472.CAN-03-0023; La Rocca G, 2004, BRIT J CANCER, V90, P1414, DOI 10.1038/sj.bjc.6601725; LEONESSA F, 1992, ACTA ONCOL, V31, P115, DOI 10.3109/02841869209088890; Li HC, 2004, BREAST CANCER RES TR, V88, P75, DOI 10.1007/s10549-004-1200-8; Mariani G, 2005, ANN ONCOL, V16, P191, DOI 10.1093/annonc/mdi719; Mendes O, 2005, CLIN EXP METASTAS, V22, P237, DOI 10.1007/s10585-005-8115-6; MIYAZAKI K, 1994, NATURE, V368, P695, DOI 10.1038/368695b0; MURPHY G, 1989, INT J CANCER, V44, P757, DOI 10.1002/ijc.2910440434; NAKAJIMA M, 1987, CANCER RES, V47, P4869; Paquette B, 2005, INT J CANCER, V113, P706, DOI 10.1002/ijc.20647; Pellikainen JM, 2004, CLIN CANCER RES, V10, P7621, DOI 10.1158/1078-0432.CCR-04-1061; PRZYBLOWSKA K, BREAST CANC RES TREA, V95, P65; Rahko E, 2004, ANTICANCER RES, V24, P4247; Ranuncolo SM, 2003, INT J CANCER, V106, P745, DOI 10.1002/ijc.11288; REICH R, 1988, CANCER RES, V48, P3307; REPESH LA, 1989, INVAS METAST, V9, P192; Rhoads AR, 1997, FASEB J, V11, P331, DOI 10.1096/fasebj.11.5.9141499; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schmitt M, 1990, Blood Coagul Fibrinolysis, V1, P695; Sliva D, 2004, CURR CANCER DRUG TAR, V4, P327, DOI 10.2174/1568009043332961; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Subramaniam Deepa S, 2005, Curr Treat Options Oncol, V6, P147, DOI 10.1007/s11864-005-0022-1; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; Talvensaari-Mattila A, 2005, CANCER LETT, V217, P237, DOI 10.1016/j.canlet.2004.06.056; Weigelt B, 2004, BRIT J CANCER, V90, P1531, DOI 10.1038/sj.bjc.6601659; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2	45	17	19	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1780	1788		10.1038/sj.onc.1209980	http://dx.doi.org/10.1038/sj.onc.1209980			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001319				2022-12-28	WOS:000244955600012
J	Morales, A; Paris, R; Villanueva, A; Llavuna, L; Garcia-Ruiz, C; Fernandez-Checa, JC				Morales, A.; Paris, R.; Villanueva, A.; Llavuna, L.; Garcia-Ruiz, C.; Fernandez-Checa, J. C.			Pharmacological inhibition or small interfering RNA targeting acid ceramidase sensitizes hepatoma cells to chemotherapy and reduces tumor growth in vivo	ONCOGENE			English	Article						cancer therapy; ceramide; sphingosine-1-phosphate; mitochondria; apoptosis	MITOCHONDRIAL PERMEABILITY TRANSITION; DAUNORUBICIN-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; SPHINGOSINE 1-PHOSPHATE; GD3 GANGLIOSIDE; SPHINGOSINE-1-PHOSPHATE; GENERATION; KINASE; DEATH; NECROSIS	Ceramidases (CDases) play a key role in cancer therapy through enhanced conversion of ceramide into sphingosine 1-phosphate (S1P), but their involvement in hepatocarcinogenesis is unknown. Here, we report that daunorubicin (DNR) activated acid CDase post-transcriptionally in established human (HepG2 cells) or mouse (Hepa1c1c7) hepatoma cell lines as well as in primary cells from murine liver tumors, but not in cultured mouse hepatocytes. Acid CDase silencing by small interfering RNA (siRNA) or pharmacological inhibition with N-oleoylethanolamine (NOE) enhanced the ceramide to S1P balance compared to DNR alone, sensitizing hepatoma cells (HepG2, Hep-3B, SK-Hep and Hepa1c1c7) to DNR-induced cell death. DNR plus NOE or acid CDase siRNA-induced cell death was preceded by ultrastructural changes in mitochondria, stimulation of reactive oxygen species generation, release of Smac/DIABLO and cytochrome c and caspase-3 activation. In addition, in vivo siRNA treatment targeting acid CDase reduced tumor growth in liver tumor xenografts of HepG2 cells and enhanced DNR therapy. Thus, acid CDase promotes hepatocarcinogenesis and its antagonism may be a promising strategy in the treatment of liver cancer.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, Barcelona 08036, Spain; IDIBELL, Inst Invest Bellvitge, Inst Catala Oncol, Lab Recerca Translac, Barcelona, Spain; CSIC, Inst Invest Biomed, Dept Expt Pathol, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Inst Invest Biomed August Pi & Sunyer,IDIBAPS, C Villarroel 170, Barcelona 08036, Spain.	checa229@yahoo.com	Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014; Morales, Albert/E-2988-2013	Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990; Morales, Albert/0000-0001-8702-2269	NIAAA NIH HHS [P50 AA11999, 1R21 AA014135-01] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R21AA014135, P50AA011999] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bielawska A, 1996, J BIOL CHEM, V271, P12646, DOI 10.1074/jbc.271.21.12646; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; Block TM, 2003, ONCOGENE, V22, P5093, DOI 10.1038/sj.onc.1206557; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Burek C, 2001, ONCOGENE, V20, P6493, DOI 10.1038/sj.onc.1204841; Colell Anna, 2001, FASEB Journal, V15, P1068; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Gruber C, 2004, BIOCHEM PHARMACOL, V67, P1859, DOI 10.1016/j.bcp.2004.01.026; Hara S, 2004, CELL DEATH DIFFER, V11, P853, DOI 10.1038/sj.cdd.4401428; HASSLER DF, 1993, ADV LIPID RES, V26, P49; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Kawaguchi K, 2005, BIOCHEM BIOPH RES CO, V329, P370, DOI 10.1016/j.bbrc.2005.01.128; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Li CM, 1999, GENOMICS, V62, P223, DOI 10.1006/geno.1999.5940; Liu YY, 2001, FASEB J, V15, P719, DOI 10.1096/fj.00-0223com; Matsko CM, 2001, BIOCHEM BIOPH RES CO, V287, P1112, DOI 10.1006/bbrc.2001.5696; Monick MM, 2004, J IMMUNOL, V173, P123, DOI 10.4049/jimmunol.173.1.123; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; Paris F, 2002, NAT MED, V8, P901, DOI 10.1038/nm0902-901; Paris R, 2002, J BIOL CHEM, V277, P49870, DOI 10.1074/jbc.M208303200; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Prinetti A, 2006, BIOCHEM J, V395, P311, DOI 10.1042/BJ20051184; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Selzner M, 2001, CANCER RES, V61, P1233; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Strelow A, 2000, J EXP MED, V192, P601, DOI 10.1084/jem.192.5.601; SUGITA M, 1975, BIOCHIM BIOPHYS ACTA, V398, P125, DOI 10.1016/0005-2760(75)90176-9; Suzuki E, 2004, P NATL ACAD SCI USA, V101, P14788, DOI 10.1073/pnas.0406536101; Yatomi Y, 1996, BIOCHEMISTRY-US, V35, P626, DOI 10.1021/bi9515533	46	83	87	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					905	916		10.1038/sj.onc.1209834	http://dx.doi.org/10.1038/sj.onc.1209834			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862171				2022-12-28	WOS:000244063800011
J	An, J; Chervin, AS; Nie, A; Ducoff, HS; Huang, Z				An, J.; Chervin, A. S.; Nie, A.; Ducoff, H. S.; Huang, Z.			Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor	ONCOGENE			English	Article						Bcl-2; HA14-1; p53; radiosensitization; apoptosis; ROS; JNK	N-TERMINAL KINASE; CYTOCHROME-C RELEASE; INDUCED APOPTOSIS; TUMOR-CELLS; DNA-DAMAGE; RADIATION; DEATH; ACTIVATION; JNK; BAX	Bcl-2 overexpression is an important mechanism underlying the aggressive behavior of prostate cancer cells and their resistance to radio- or chemotherapy. HA14-1, a recently discovered organic Bcl-2 inhibitor, potently induces apoptosis in various human cancer cells. Sequential exposure of radioresistant LNCaP (wild-type (wt) p53), LNCaP/Bcl-2 (wt p53) and PC3 (mutant p53) prostate cancer cells to a minimally cytotoxic concentration of 10 mu M HA14-1 for 1 h followed by 1-6 Gy gamma radiation, resulted in a highly synergistic (combination index < 1.0) induction of cell death as determined by an apoptosis assay at 72 h, and a clonogenicity assay at 12 days, after the initial treatment. The reverse treatment sequence did not cause a synergistic induction of cell death. When compared to individual treatments, cell death induced by the combined treatment was associated with dramatically increased reactive oxygen species (ROS) generation, c-Jun N-terminal kinase (JNK) activation, Bcl-2 phosphorylation, cytochrome c release, caspase-3 activation and DNA fragmentation. Exposure to either 200 mu g/ml of the antioxidant alpha-tocopherol or 10 mu M JNK inhibitor SP600125 before the combined treatment resulted in decreased activation of JNK and caspase-3 as well as decreased DNA fragmentation. However, treatment with the pancaspase inhibitor carbobenzoxyl-valyl-alanyl-aspartyl-[O-methyl]-fuoromethylketone before the combined treatment inhibited apoptosis without affecting JNK activation, and this inhibitory effect was enhanced in the presence of alpha-tocopherol or SP600125. Taken together, our results indicate that HA14-1 potently sensitizes radioresistant LNCaP and PC3 cells to gamma radiation, regardless of the status of p53. ROS and JNK are important early signals that trigger both caspase-dependent and -independent cell death pathways and contribute to the apoptotic synergy induced by the combined treatments.	Burnham Inst Med Res, La Jolla, CA 92037 USA; Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA	Sanford Burnham Prebys Medical Discovery Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	An, J (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jingan@burnham.org						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; An J, 2004, J BIOL CHEM, V279, P19133, DOI 10.1074/jbc.M400295200; Autorino R, 2003, UROL INT, V70, P1, DOI 10.1159/000067704; Bauer JJ, 1996, J UROLOGY, V156, P1511, DOI 10.1016/S0022-5347(01)65641-6; Belka C, 2004, INT J RADIAT ONCOL, V58, P542, DOI 10.1016/j.ijrobp.2003.09.067; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chaudhary KS, 2001, J PATHOL, V193, P522, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH821>3.0.CO;2-Y; Chendil D, 2004, ONCOGENE, V23, P1599, DOI 10.1038/sj.onc.1207284; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Denmeade SR, 1996, PROSTATE, V28, P251; DEWEY WC, 1971, P NATL ACAD SCI USA, V68, P667, DOI 10.1073/pnas.68.3.667; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Garzotto M, 1999, CANCER RES, V59, P5194; Hahn P, 1996, INT J RADIAT ONCOL, V34, P41, DOI 10.1016/0360-3016(95)02024-1; Hering F L, 2001, Sao Paulo Med J, V119, P138; Higuchi Y, 2003, BIOCHEM PHARMACOL, V66, P1527, DOI 10.1016/S0006-2952(03)00508-2; Kimura K, 1999, CANCER RES, V59, P1606; Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702; Krajewska M, 1996, AM J PATHOL, V148, P1567; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lickliter JD, 2003, LEUKEMIA, V17, P2074, DOI 10.1038/sj.leu.2403102; Lin AN, 2002, AGING CELL, V1, P112, DOI 10.1046/j.1474-9728.2002.00014.x; Lin X, 2003, CANCER RES, V63, P3413; Marchal S, 2004, BIOCHEMISTRY-MOSCOW+, V69, P45, DOI 10.1023/B:BIRY.0000016350.61894.be; McConkey DJ, 1996, CANCER RES, V56, P5594; Mikkelsen RB, 2003, ONCOGENE, V22, P5734, DOI 10.1038/sj.onc.1206663; Milella M, 2002, BLOOD, V99, P3461, DOI 10.1182/blood.V99.9.3461; Mishra KP, 2004, J ENVIRON PATHOL TOX, V23, P61, DOI 10.1615/JEnvPathToxOncol.v23.i1.60; Ortiz MA, 2001, CANCER RES, V61, P8504; Park J, 1997, J BIOL CHEM, V272, P16725, DOI 10.1074/jbc.272.27.16725; Phillips DC, 2002, ARCH BIOCHEM BIOPHYS, V407, P15, DOI 10.1016/S0003-9861(02)00496-4; RAFFO AJ, 1995, CANCER RES, V55, P4438; Reed JC, 1996, ADV EXP MED BIOL, V406, P99; Rosser CJ, 2003, INT J RADIAT ONCOL, V56, P1, DOI 10.1016/S0360-3016(02)04468-1; Scherr DS, 1999, J UROLOGY, V162, P12, DOI 10.1097/00005392-199907000-00003; Scott SL, 2002, CANCER BIOTHER RADIO, V17, P647, DOI 10.1089/108497802320970253; Shaffer DR, 2003, LANCET ONCOL, V4, P407, DOI 10.1016/S1470-2045(03)01138-0; Szostak MJ, 2000, ONCOL REP, V7, P699; Tang DG, 1997, PROSTATE, V32, P284; Tepper AD, 1999, J CLIN INVEST, V103, P971, DOI 10.1172/JCI5457; Todaro M, 2002, J CELL BIOCHEM, V86, P162, DOI 10.1002/jcb.10203; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tsuruta F, 2004, EMBO J, V23, P1889, DOI 10.1038/sj.emboj.7600194; Vivo C, 2003, J BIOL CHEM, V278, P25461, DOI 10.1074/jbc.M302161200; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Xiao D, 2004, ONCOGENE, V23, P5594, DOI 10.1038/sj.onc.1207747; Yamaguchi H, 2002, CANCER RES, V62, P466; Yu NF, 2000, TETRAHEDRON LETT, V41, P6993, DOI 10.1016/S0040-4039(00)01195-3; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310	49	85	92	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					652	661		10.1038/sj.onc.1209830	http://dx.doi.org/10.1038/sj.onc.1209830			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909121				2022-12-28	WOS:000243902200003
J	Mueller, W; Nutt, CL; Ehrich, M; Riemenschneider, MJ; von Deimling, A; van den Boom, D; Louis, DN				Mueller, W.; Nutt, C. L.; Ehrich, M.; Riemenschneider, M. J.; von Deimling, A.; van den Boom, D.; Louis, D. N.			Downregulation of RUNX3 and TES by hypermethylation in glioblastoma	ONCOGENE			English	Article						glioblastoma; glioma; methylation; 5-aza-dC; mass spectrometry	CPG ISLAND HYPERMETHYLATION; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; EPIGENETIC INACTIVATION; ASTROCYTIC GLIOMAS; MULTIPLE GENES; 14-3-3 SIGMA; CANCER; EXPRESSION	Glioblastoma, the most aggressive and least treatable form of malignant glioma, is the most common human brain tumor. Although many regions of allelic loss occur in glioblastomas, relatively few tumor suppressor genes have been found mutated at such loci. To address the possibility that epigenetic alterations are an alternative means of glioblastoma gene inactivation, we coupled pharmacological manipulation of methylation with gene profiling to identify potential methylation-regulated, tumor-related genes. Duplicates of three short-term cultured glioblastomas were exposed to 5 mu m 5-aza-dC for 96h followed by cRNA hybridization to an oligonucleotide microarray (Affymetrix U133A). We based candidate gene selection on bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR), bisulfite sequencing, methylation-specific PCR and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Two genes identified in this manner, RUNX3 and Testin (TES), were subsequently shown to harbor frequent tumor-specific epigenetic alterations in primary glioblastomas. This overall approach therefore provides a powerful means to identify candidate tumor-suppressor genes for subsequent evaluation and may lead to the identification of genes whose epigenetic dysregulation is integral to glioblastoma tumorigenesis.	Massachusetts Gen Hosp, Pathol Serv, Dept Pathol, Ctr Canc, Boston, MA 02114 USA; Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Johns Hopkins Ct, Sequenom Inc, San Diego, CA USA; Univ Hosp Charite, Dept Neuropathol, Berlin, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Sequenom; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Louis, DN (corresponding author), Massachusetts Gen Hosp, Pathol Serv, Dept Pathol, Ctr Canc, WRN2, Boston, MA 02114 USA.	louis@helix.mgh.harvard.edu	Nutt, Catherine/K-8794-2012; Reifenberger, Guido/AAE-3599-2019; von Deimling, Andreas/F-7774-2013	von Deimling, Andreas/0000-0002-5863-540X	NCI NIH HHS [CA57683] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057683] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ballestar E, 2005, PROG MOLEC, V38, P169; Bhatia K, 2003, CANCER EPIDEM BIOMAR, V12, P165; Blanc JL, 2004, J NEURO-ONCOL, V68, P275, DOI 10.1023/B:NEON.0000033385.37098.85; Ching TT, 2005, NAT GENET, V37, P645, DOI 10.1038/ng1563; CHUNG R, 1991, GENE CHROMOSOME CANC, V3, P323, DOI 10.1002/gcc.2870030502; Collins V P, 2004, J Neurol Neurosurg Psychiatry, V75 Suppl 2, pii2, DOI 10.1136/jnnp.2004.040337; Costello J F, 2000, Brain Tumor Pathol, V17, P49, DOI 10.1007/BF02482735; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Costello JF, 2002, METHODS, V27, P144, DOI 10.1016/S1046-2023(02)00067-1; Costello JF, 1996, CANCER RES, V56, P2405; Costello Joseph F, 2002, Methods Mol Biol, V200, P53; Curtis CD, 2005, METH MOLEC MED, V103, P123; Dallol A, 2003, ONCOGENE, V22, P4611, DOI 10.1038/sj.onc.1206687; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; Esteller M, 1999, CANCER RES, V59, P793; Esteller M, 2003, ADV EXP MED BIOL, V532, P39; Fan X, 2002, INT J ONCOL, V21, P667; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; Gasco M, 2002, CANCER RES, V62, P2072; Gonzalez-Gomez P, 2003, INT J MOL MED, V11, P655; Gonzalez-Gomez P, 2003, INT J ONCOL, V22, P601; Hegi ME, 2004, CLIN CANCER RES, V10, P1871, DOI 10.1158/1078-0432.CCR-03-0384; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; HENSON JW, 1994, ANN NEUROL, V36, P714, DOI 10.1002/ana.410360505; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hill C, 2003, ADV ANAT PATHOL, V10, P212, DOI 10.1097/00125480-200307000-00004; Hong CB, 2003, CANCER RES, V63, P7600; Ichimura K, 2000, CANCER RES, V60, P417; Ichimura K, 1996, ONCOGENE, V13, P1065; Imamura Y, 2005, ANTICANCER RES, V25, P2627; Ino Y, 2000, J NEUROSURG, V92, P983, DOI 10.3171/jns.2000.92.6.0983; Jain PK, 2003, ANN NY ACAD SCI, V983, P71, DOI 10.1111/j.1749-6632.2003.tb05963.x; Jeanteur P, 2000, Bull Cancer, V87, P525; Kamiryo T, 2004, NEUROSURGERY, V54, P349, DOI 10.1227/01.NEU.0000103422.51382.99; Kang GH, 2004, J PATHOL, V202, P233, DOI 10.1002/path.1503; Kato N, 2003, AM J PATHOL, V163, P387, DOI 10.1016/S0002-9440(10)63668-1; KIM DH, 1995, INT J CANCER, V60, P812, DOI 10.1002/ijc.2910600615; Kim TY, 2004, LAB INVEST, V84, P479, DOI 10.1038/labinvest.3700060; Kleihues P, 2000, PATHOLOGY GENETICS T; Kohno T, 1998, HUM GENET, V102, P258, DOI 10.1007/s004390050689; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Q, 1998, ONCOGENE, V16, P3197, DOI 10.1038/sj.onc.1201831; Li Q, 1999, ONCOGENE, V18, P3284, DOI 10.1038/sj.onc.1202663; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li QL, 2004, BIOCHEM BIOPH RES CO, V314, P223, DOI 10.1016/j.bbrc.2003.12.079; Liang G, 1998, GENOMICS, V53, P260, DOI 10.1006/geno.1998.5502; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; MATSUMURA T, 1989, EXP GERONTOL, V24, P477, DOI 10.1016/0531-5565(89)90054-5; Mohapatra G, 1998, GENE CHROMOSOME CANC, V21, P195, DOI 10.1002/(SICI)1098-2264(199803)21:3<195::AID-GCC3>3.3.CO;2-A; Mori T, 2005, LIVER INT, V25, P380, DOI 10.1111/j.1478-3231.2005.1059.x; Morris MR, 2005, CANCER RES, V65, P4598, DOI 10.1158/0008-5472.CAN-04-3371; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Osada H, 2002, ONCOGENE, V21, P2418, DOI 10.1038/sj.onc.1205303; Sarti M, 2005, CLIN CANCER RES, V11, P806; Sato N, 2004, ONCOGENE, V23, P1531, DOI 10.1038/sj.onc.1207269; Schmidt MC, 2002, J NEUROPATH EXP NEUR, V61, P321, DOI 10.1093/jnen/61.4.321; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Smiraglia DJ, 1999, GENOMICS, V58, P254, DOI 10.1006/geno.1999.5840; Stanssens P, 2004, GENOME RES, V14, P126; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stone AR, 2004, AM J PATHOL, V165, P1151, DOI 10.1016/S0002-9440(10)63376-7; Suzuki H, 2000, CANCER RES, V60, P4353; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; Tozawa T, 2004, CANCER SCI, V95, P736, DOI 10.1111/j.1349-7006.2004.tb03254.x; Ueki K, 1996, CANCER RES, V56, P150; Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438; von Deimling A, 2000, J NEUROPATH EXP NEUR, V59, P544, DOI 10.1093/jnen/59.6.544; von Deimling A, 1994, Recent Results Cancer Res, V135, P33; Wang SI, 1997, CANCER RES, V57, P4183; Watanabe T, 2002, ACTA NEUROPATHOL, V104, P357, DOI 10.1007/s00401-002-0549-1; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wooten E C, 1999, Neuro Oncol, V1, P169, DOI 10.1093/neuonc/1.3.169; Xiao WH, 2004, WORLD J GASTROENTERO, V10, P376; Yamashita K, 2002, CANCER CELL, V2, P485, DOI 10.1016/S1535-6108(02)00215-5; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	80	101	107	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					583	593		10.1038/sj.onc.1209805	http://dx.doi.org/10.1038/sj.onc.1209805			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909125				2022-12-28	WOS:000243731600010
J	Roesch-Ely, M; Nees, M; Karsai, S; Ruess, A; Bogumil, R; Warnken, U; Schnolzer, M; Dietz, A; Plinkert, PK; Hofele, C; Bosch, FX				Roesch-Ely, M.; Nees, M.; Karsai, S.; Ruess, A.; Bogumil, R.; Warnken, U.; Schnoelzer, M.; Dietz, A.; Plinkert, P. K.; Hofele, C.; Bosch, F. X.			Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer	ONCOGENE			English	Article						proteomics; SELDI-TOF-MS; HNSCC; field cancerization; protein biomarkers	SQUAMOUS-CELL CARCINOMA; GENETICALLY ALTERED FIELDS; HUMAN NEUTROPHIL PEPTIDE-1; TUMOR-DISTANT EPITHELIA; LYMPH-NODE METASTASIS; CLINICAL-IMPLICATIONS; HUMAN-PAPILLOMAVIRUS; IN-SITU; IDENTIFICATION; CANCERIZATION	Development of head and necksquamous cell carcinoma (HNSCC) is a multistep process and in many cases involves a phenomenon coined 'field cancerization'. In order to identify changes in protein expression occurring at different stages of tumorigenesis and field cancerization, we analysed 113 HNSCCs and 73 healthy, 99 tumor-distant and 18 tumor-adjacent squamous mucosae by SELDI-TOF-MS on IMAC30 ProteinChip Arrays. Forty-eight protein peaks were differentially expressed between healthy mucosa and HNSCC. Calgizarrin (S100A11), the Cystein proteinase inhibitor Cystatin A, Acyl-CoA-binding protein, Stratifin (14-3-3 sigma), Histone H4, alpha- and beta-Hemoglobin, a C-terminal fragment of beta-hemoglobin and the alpha-defensins 1-3 were identified by mass spectrometry. The alpha-defensins showed various alterations in expression as validated by immunohistochemistry (IHC). Supervised prediction analysis revealed excellent classification of healthy mucosa (94.5% correctly classified) and tumor samples (92.9% correctly classified). Application of this classifier to the tumor-adjacent and tumor-distant mucosa samples disclosed dramatic changes: only 59.6% of the tumor-distant biopsies were classified as normal, 27.3% were predicted as aberrant or HNSCC. Strikingly, 72% of the tumor-adjacent mucosae were predicted as aberrant. These data provide evidence for the existence of genetically altered fields with inconspicuous histology. Comparison of the protein profiles in the tumor-distant-samples with clinical outcome of 32 patients revealed a significant association between aberrant profiles with tumor relapse events (P = 0.018; Fisher's exact test, two-tailed). We conclude that proteomic pro. ling in conjunction with protein identification greatly outperforms histopathological diagnosis and may have significant predictive power for clinical outcome and personalized risk assessment.	Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, D-69120 Heidelberg, Germany; Ciphergan Biosyst GmbH, Berlin, Germany; German Canc Res Ctr, Prot Anal Facil, D-6900 Heidelberg, Germany; Univ Leipzig, Dept Ear Nose & Throat, D-7010 Leipzig, Germany; Univ Heidelberg, Dept Oral & Maxillofacial Surg, Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Leipzig University; Ruprecht Karls University Heidelberg	Bosch, FX (corresponding author), Univ Heidelberg, Dept Otolaryngol Head & Neck Surg, Mol Biol Lab, INF 400, D-69120 Heidelberg, Germany.	franz.bosch@med.uni-heidelberg.de	Hofele, Christof/D-4882-2015; Nees, Matthias/AAT-5577-2020; Roesch-Ely, Mariana/H-5981-2013; Nees, Matthias/W-6596-2018	Hofele, Christof/0000-0002-6332-5684; Nees, Matthias/0000-0002-9034-301X				Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ai H, 1999, MUTAT RES-GEN TOX EN, V439, P223, DOI 10.1016/S1383-5718(98)00199-5; Ai H, 2001, LARYNGOSCOPE, V111, P1853, DOI 10.1097/00005537-200110000-00034; Albrethsen J, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-8; ALHO H, 1995, CELL GROWTH DIFFER, V6, P309; Andl T, 1998, CANCER RES, V58, P5; Bedi GC, 1996, CANCER RES, V56, P2484; Braakhuis BJM, 2005, SEMIN CANCER BIOL, V15, P113, DOI 10.1016/j.semcancer.2004.08.004; Braakhuis BJM, 2002, HEAD NECK-J SCI SPEC, V24, P198, DOI 10.1002/hed.10042.abs; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Buhimschi IA, 2005, BJOG-INT J OBSTET GY, V112, P173, DOI 10.1111/j.1471-0528.2004.00340.x; Califano J, 1996, CANCER RES, V56, P2488; Carr S, 2004, MOL CELL PROTEOMICS, V3, P531, DOI 10.1074/mcp.T400006-MCP200; Chavakis T, 2004, FASEB J, V18, P1306, DOI 10.1096/fj.03-1009fje; Dellambra E, 2000, J CELL BIOL, V149, P1117, DOI 10.1083/jcb.149.5.1117; Ely MR, 2005, EUR J CELL BIOL, V84, P431, DOI 10.1016/j.ejcb.2005.01.003; Freier K, 2003, CANCER RES, V63, P1179; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Garcia SB, 1999, J PATHOL, V187, P61, DOI 10.1002/(SICI)1096-9896(199901)187:1<61::AID-PATH247>3.0.CO;2-I; Gasco M, 2002, CANCER RES, V62, P2072; Hegedus CM, 2005, LEUKEMIA, V19, P1713, DOI 10.1038/sj.leu.2403897; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Homann N, 2001, CLIN CANCER RES, V7, P290; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Le Bihan MC, 2004, PROTEOMICS, V4, P2739, DOI 10.1002/pmic.200300759; Lundy FT, 2004, ORAL ONCOL, V40, P139, DOI 10.1016/S1368-8375(03)00142-8; Melle C, 2004, CANCER RES, V64, P4099, DOI 10.1158/0008-5472.CAN-03-3807; Muller CA, 2002, AM J PATHOL, V160, P1311, DOI 10.1016/S0002-9440(10)62558-8; NEES M, 1993, CANCER RES, V53, P4189; Partridge M, 2000, CANCER RES, V60, P3893; Petrescu AD, 2003, J BIOL CHEM, V278, P51813, DOI 10.1074/jbc.M303858200; Prevo LJ, 1999, CANCER RES, V59, P4784; Shiraishi T, 1998, INT J CANCER, V79, P175, DOI 10.1002/(SICI)1097-0215(19980417)79:2<175::AID-IJC13>3.3.CO;2-P; Sinha AA, 2002, CANCER-AM CANCER SOC, V94, P3141, DOI 10.1002/cncr.10604; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; SmithMcCune K, 1997, OBSTET GYNECOL, V89, P482, DOI 10.1016/S0029-7844(97)80037-3; SODER AI, 1995, CANCER RES, V55, P5030; Tabor MP, 2004, CLIN CANCER RES, V10, P3607, DOI 10.1158/1078-0432.CCR-03-0632; Tabor MP, 2001, CLIN CANCER RES, V7, P1523; Tolson JR, 2006, PROTEOMICS, V6, P697, DOI 10.1002/pmic.200500033; Vlahou A, 2001, AM J PATHOL, V158, P1491, DOI 10.1016/S0002-9440(10)64100-4; Waridel F, 1997, ONCOGENE, V14, P163, DOI 10.1038/sj.onc.1200812; Wiesner A, 2004, CURR PHARM BIOTECHNO, V5, P45, DOI 10.2174/1389201043489675; Wilkins MR, 2006, PROTEOMICS, V6, P4, DOI 10.1002/pmic.200500856; Wolf C, 2004, LARYNGOSCOPE, V114, P698, DOI 10.1097/00005537-200404000-00019; Wright George L Jr, 2002, Expert Rev Mol Diagn, V2, P549, DOI 10.1586/14737159.2.6.549	47	94	99	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					54	64		10.1038/sj.onc.1209770	http://dx.doi.org/10.1038/sj.onc.1209770			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819514				2022-12-28	WOS:000243236500006
J	Avila, MA; Berasain, C; Sangro, B; Prieto, J				Avila, M. A.; Berasain, C.; Sangro, B.; Prieto, J.			New therapies for hepatocellular carcinoma	ONCOGENE			English	Review						hepatocellular carcinoma; molecular targets; new therapies	GROWTH-FACTOR RECEPTOR; FOCAL ADHESION KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR STEM-CELLS; INTRAHEPATIC YTTRIUM-90 MICROSPHERES; CHEMOTHERAPY-INDUCED APOPTOSIS; UBIQUITIN-PROTEASOME PATHWAY; ONCOLYTIC ADENOVIRAL VECTOR; WNT/BETA-CATENIN-PATHWAY; CYTOSINE DEAMINASE GENE	Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, is often diagnosed at an advanced stage when most potentially curative therapies such as resection, transplantation or percutaneous and transarterial interventions are of limited efficacy. The fact that HCC is resistant to conventional chemotherapy, and is rarely amenable to radiotherapy, leaves this disease with no effective therapeutic options and a very poor prognosis. Therefore, the development of more effective therapeutic tools and strategies is much needed. HCCs are phenotypically and genetically heterogeneous tumors that commonly emerge on a background of chronic liver disease. However, in spite of this heterogeneity recent insights into the biology of HCC suggest that certain signaling pathways and molecular alterations are likely to play essential roles in HCC development by promoting cell growth and survival. The identification of such mechanisms may open new avenues for the prevention and treatment of HCC through the development of targeted therapies. In this review we will describe the new potential therapeutic targets and clinical developments that have emerged from progress in the knowledge of HCC biology, In addition, recent advances in gene therapy and combined cell and gene therapy, together with new radiotherapy techniques and immunotherapy in patients with HCC will be discussed.	Univ Navarra, Div Hepatol & Gene Therapy, Ctr Appl Med Res, CIMA, E-31080 Pamplona, Spain; Univ Navarra, Clin Univ, Dept Med, E-31080 Pamplona, Spain; Univ Navarra, Clin Univ, Liver Unit, E-31080 Pamplona, Spain	University of Navarra; University of Navarra; University of Navarra	Prieto, J (corresponding author), Univ Navarra, Div Hepatol & Gene Therapy, Ctr Appl Med Res, CIMA, E-31080 Pamplona, Spain.	jprieto@unav.es	Avila, Matias A/Y-6342-2019; Berasain, Carmen/E-4139-2016; Sangro, Bruno/AFW-4106-2022	Avila, Matias A/0000-0001-6570-3557; Berasain, Carmen/0000-0001-7075-2476; Prieto, Jesus/0000-0002-1091-9593; Sangro, Bruno/0000-0002-4177-6417				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; Adjei AA, 2005, J CLIN ONCOL, V23, P5386, DOI 10.1200/JCO.2005.23.648; Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947; Alexia C, 2004, BIOCHEM PHARMACOL, V68, P1003, DOI 10.1016/j.bcp.2004.05.029; Algarra I, 2000, HUM IMMUNOL, V61, P65, DOI 10.1016/S0198-8859(99)00156-1; Amaravadi R, 2005, J CLIN INVEST, V115, P2618, DOI 10.1172/JCI26273; Antony PA, 2005, J IMMUNOTHER, V28, P120, DOI 10.1097/01.cji.0000155049.26787.45; Arsura M, 2005, CANCER LETT, V229, P157, DOI 10.1016/j.canlet.2005.07.008; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barajas M, 2001, HEPATOLOGY, V33, P52, DOI 10.1053/jhep.2001.20796; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; BEDOSSA P, 1995, HEPATOLOGY, V21, P760, DOI 10.1016/0270-9139(95)90530-8; Berasain C, 2005, J BIOL CHEM, V280, P19012, DOI 10.1074/jbc.M413344200; Berasain C, 2005, GASTROENTEROLOGY, V128, P424, DOI 10.1053/j.gastro.2004.11.006; Berasain C, 2003, HEPATOLOGY, V38, P148, DOI 10.1053/jhep.2003.50269; Beurel E, 2005, INT J ONCOL, V27, P215; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Bissell DM, 2001, EXP MOL MED, V33, P179, DOI 10.1038/emm.2001.31; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Brechot C, 2004, GASTROENTEROLOGY, V127, pS56, DOI 10.1053/j.gastro.2004.09.016; Bristol JA, 2003, MOL THER, V7, P755, DOI 10.1016/S1525-0016(03)00103-5; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Calvisi DF, 2004, LAB INVEST, V84, P1137, DOI 10.1038/labinvest.3700147; Calvisi DF, 2001, CANCER RES, V61, P2085; Camirand A, 2005, BREAST CANCER RES, V7, pR570, DOI 10.1186/bcr1028; Camp ER, 2005, CLIN CANCER RES, V11, P397; Carloni V, 2005, CLIN CANCER RES, V11, P4266, DOI 10.1158/1078-0432.CCR-04-2386; Carloni V, 2001, HEPATOLOGY, V34, P42, DOI 10.1053/jhep.2001.25224; Chan KT, 2004, CANCER CHEMOTH PHARM, V53, P519, DOI 10.1007/s00280-004-0767-4; Chung YH, 2000, CANCER, V89, P977, DOI 10.1002/1097-0142(20000901)89:5<977::AID-CNCR6>3.0.CO;2-I; Clarke MF, 2005, BIOL BLOOD MARROW TR, V11, P14, DOI 10.1016/j.bbmt.2004.11.011; Coleman WB, 2003, CURR MOL MED, V3, P573, DOI 10.2174/1566524033479546; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Deane NG, 2001, CANCER RES, V61, P5389; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609; Dikmen ZG, 2005, CANCER RES, V65, P7866, DOI 10.1158/0008-5472.CAN-05-1215; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Ding X, 2004, WORLD J GASTROENTERO, V10, P2735, DOI 10.3748/wjg.v10.i18.2735; Djojosubroto MW, 2005, HEPATOLOGY, V42, P1127, DOI 10.1002/hep.20822; Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252; Drozdzik M, 2000, J HEPATOL, V32, P279, DOI 10.1016/S0168-8278(00)80073-2; Ebert O, 2003, CANCER RES, V63, P3605; Edamoto Y, 2003, INT J CANCER, V106, P334, DOI 10.1002/ijc.11254; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Ensor CM, 2002, CANCER RES, V62, P5443; Erion MD, 2005, J PHARMACOL EXP THER, V312, P554, DOI 10.1124/jpet.104.075903; Eskens FALM, 2004, BRIT J CANCER, V90, P1, DOI 10.1038/sj.bjc.6601401; Ezquerro IJ, 2003, CYTOKINE, V22, P12, DOI 10.1016/S1043-4666(03)00101-7; Feijoo E, 2005, INT J CANCER, V116, P275, DOI 10.1002/ijc.21046; Feitelson MA, 2002, ONCOGENE, V21, P2593, DOI 10.1038/sj.onc.1205434; FEITELSON MA, 2005, CANC LETT; Fillat C., 2003, Current Gene Therapy, V3, P13, DOI 10.2174/1566523033347426; Fischer ANM, 2005, CARCINOGENESIS, V26, P931, DOI 10.1093/carcin/bgi043; Folkman J, 2003, CANCER BIOL THER, V2, pS127; Fujii T, 2004, J HEPATOL, V41, P104, DOI 10.1016/j.jhep.2004.03.029; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Geschwind JFH, 2004, GASTROENTEROLOGY, V127, pS194, DOI 10.1053/j.gastro.2004.09.034; Giannelli G, 2003, CLIN CANCER RES, V9, P3684; Giannelli G, 2004, BRIT J CANCER, V91, P1964, DOI 10.1038/sj.bjc.6602231; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Goin JE, 2005, J VASC INTERV RADIOL, V16, P205, DOI 10.1097/01.RVI.00001142592.89564.F9; Goin JE, 2005, J VASC INTERV RADIOL, V16, P195, DOI 10.1097/01.RVI.0000142602.79459.90; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Gotzmann J, 2002, J CELL SCI, V115, P1189; Graaf MR, 2004, CANCER TREAT REV, V30, P609, DOI 10.1016/j.ctrv.2004.06.010; Griscelli F, 1998, P NATL ACAD SCI USA, V95, P6367, DOI 10.1073/pnas.95.11.6367; Habib N, 2002, CANCER GENE THER, V9, P254, DOI 10.1038/sj.cgt.7700431; Habib NA, 2001, HUM GENE THER, V12, P219, DOI 10.1089/10430340150218369; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Harada K, 1999, LIVER, V19, P318, DOI 10.1111/j.1478-3231.1999.tb00056.x; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; Herraiz M, 2003, HUM GENE THER, V14, P463, DOI 10.1089/104303403321467225; Higashitsuji H, 2005, CANCER CELL, V8, P75, DOI 10.1016/j.ccr.2005.06.006; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Hopfner M, 2004, J HEPATOL, V41, P1008, DOI 10.1016/j.jhep.2004.08.024; Horie Y, 2004, J CLIN INVEST, V113, P1774, DOI 10.1172/JCI200420513; Hu KQ, 2002, J LAB CLIN MED, V139, P234, DOI 10.1067/mlc.2002.122281; Hu TH, 2003, CANCER, V97, P1929, DOI 10.1002/cncr.11266; Huang TG, 2003, MOL THER, V8, P434, DOI 10.1016/S1525-0016(03)00204-1; Huang TG, 2003, GENE THER, V10, P1241, DOI 10.1038/sj.gt.3301987; Huether A, 2005, J HEPATOL, V43, P661, DOI 10.1016/j.jhep.2005.02.040; Humphreys MJ, 2001, GENE THER, V8, P1241, DOI 10.1038/sj.gt.3301518; Huynh H, 2004, INT J ONCOL, V25, P1839; Hwang YH, 2004, HEPATOL RES, V29, P113, DOI 10.1016/j.hepres.2004.02.009; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; INUI Y, 1994, GASTROENTEROLOGY, V107, P1799, DOI 10.1016/0016-5085(94)90823-0; Irving J, 2004, CANCER GENE THER, V11, P174, DOI 10.1038/sj.cgt.7700666; Ishikawa N, 2005, CANCER RES, V65, P9176, DOI 10.1158/0008-5472.CAN-05-1556; Itoh S, 2004, CLIN CANCER RES, V10, P2812, DOI 10.1158/1078-0432.CCR-1046-03; Izzo F, 2004, J CLIN ONCOL, V22, P1815, DOI 10.1200/JCO.2004.11.120; Jakubczak JL, 2003, CANCER RES, V63, P1490; Jarnagin WR, 2003, CANCER GENE THER, V10, P215, DOI 10.1038/sj.cgt.7700558; Kakiuchi S, 2004, HUM MOL GENET, V13, P3029, DOI 10.1093/hmg/ddh331; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kawashima M, 2005, J CLIN ONCOL, V23, P1839, DOI 10.1200/JCO.2005.00.620; Kennedy AS, 2004, INT J RADIAT ONCOL, V60, P1552, DOI 10.1016/j.ijrobp.2004.09.004; Kianmanesh AR, 1997, HUM GENE THER, V8, P1807, DOI 10.1089/hum.1997.8.15-1807; Kim Y, 2005, TOXICOL PATHOL, V33, P175, DOI 10.1080/01926230590522130; Kirn D, 2001, EXPERT OPIN BIOL TH, V1, P525, DOI 10.1517/14712598.1.3.525; Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193; Kuhns MS, 2000, P NATL ACAD SCI USA, V97, P12711, DOI 10.1073/pnas.220423597; Kulik LM, 2005, LIVER TRANSPLANT, V11, P1127, DOI 10.1002/lt.20514; LAI CL, 1993, HEPATOLOGY, V17, P389; Lambert B, 2005, J NUCL MED, V46, P1326; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Lee JS, 2005, SEMIN LIVER DIS, V25, P125, DOI 10.1055/s-2005-871192; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Lee RG, 1997, HEPATOLOGY, V26, P1415; Lee WC, 2005, J IMMUNOTHER, V28, P496, DOI 10.1097/01.cji.0000171291.72039.e2; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; Libbrecht L, 2002, SEMIN CELL DEV BIOL, V13, P389, DOI 10.1016/S1084952102001258; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; Liu MD, 2004, AM SURGEON, V70, P947; Liu YQ, 2005, CANCER RES, V65, P3691, DOI 10.1158/0008-5472.CAN-04-3462; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Lozano G, 2005, CANCER CELL, V8, P3, DOI 10.1016/j.ccr.2005.06.014; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Makower D, 2003, CLIN CANCER RES, V9, P693; Mani A, 2005, J CLIN ONCOL, V23, P4776, DOI 10.1200/JCO.2005.05.081; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masaki T, 2003, HEPATOLOGY, V37, P534, DOI 10.1053/jhep.2003.50112; Matsumura T, 2001, CLIN CANCER RES, V7, P594; Mazzolini G, 2005, J CLIN ONCOL, V23, P999, DOI 10.1200/JCO.2005.00.463; Mazzolini G, 2000, HUM GENE THER, V11, P113, DOI 10.1089/10430340050016201; Mazzolini G, 2003, CURR PHARM DESIGN, V9, P1981, DOI 10.2174/1381612033454261; Mazzolini G, 2003, GENE THER, V10, P1067, DOI 10.1038/sj.gt.3301957; McCormick F, 2003, CANCER BIOL THER, V2, pS157; Melero I, 1999, GENE THER, V6, P1779, DOI 10.1038/sj.gt.3301010; Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009; Mesnil M, 2000, CANCER RES, V60, P3989; Mohr L, 2000, HEPATOLOGY, V31, P606, DOI 10.1002/hep.510310310; Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786; MORGAN DJ, 1995, CLIN PHARMACOKINET, V29, P370, DOI 10.2165/00003088-199529050-00005; Mosesson Y, 2004, SEMIN CANCER BIOL, V14, P262, DOI 10.1016/j.semcancer.2004.04.005; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Murillo O, 2003, CLIN CANCER RES, V9, P5454; Nakanishi K, 2002, CANCER RES, V62, P2971; Narvaiza I, 2000, J IMMUNOL, V164, P3112, DOI 10.4049/jimmunol.164.6.3112; Nejjari M, 2002, HEPATOLOGY, V36, P418, DOI 10.1053/jhep.2002.34611; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; O'Neal VK, 2000, MOL MED, V6, P179, DOI 10.1007/BF03402113; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Ohwada A, 1996, HUM GENE THER, V7, P1567, DOI 10.1089/hum.1996.7.13-1567; Okabe H, 2001, CANCER RES, V61, P2129; Osada S, 2005, J AM COLL SURGEONS, V201, P405, DOI 10.1016/j.jamcollsurg.2005.05.015; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Palmer DH, 2004, J CLIN ONCOL, V22, P1546, DOI 10.1200/JCO.2004.10.005; Palmieri G, 2002, AM J CLIN ONCOL-CANC, V25, P224, DOI 10.1097/00000421-200206000-00003; Park W, 2005, INT J RADIAT ONCOL, V61, P1143, DOI 10.1016/j.ijrobp.2004.08.028; Pawlik TM, 2000, CANCER RES, V60, P2790; Pei ZF, 2004, HEPATOLOGY, V39, P1371, DOI 10.1002/hep.20203; Penuelas I, 2005, GASTROENTEROLOGY, V128, P1787, DOI 10.1053/j.gastro.2005.03.024; Philip PA, 2005, J CLIN ONCOL, V23, P6657, DOI 10.1200/JCO.2005.14.696; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pinzani M, 2005, J HEPATOL, V42, pS22, DOI 10.1016/j.jhep.2004.12.008; Prieto J, 2004, EXPERT OPIN BIOL TH, V4, P1073, DOI 10.1517/14712598.4.7.1073; Putzer BM, 2001, J NATL CANCER I, V93, P472, DOI 10.1093/jnci/93.6.472; Qian C, 2002, GASTROENTEROLOGY, V123, P639, DOI 10.1053/gast.2002.35132; RANGES GE, 1987, J EXP MED, V166, P991, DOI 10.1084/jem.166.4.991; Raoul JL, 1997, HEPATOLOGY, V26, P1156; Raskopf E, 2005, HEPATOLOGY, V41, P1233, DOI 10.1002/hep.20724; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Robert C, 2005, LANCET ONCOL, V6, P491, DOI 10.1016/S1470-2045(05)70243-6; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Rumpold H, 2004, J CELL MOL MED, V8, P509, DOI 10.1111/j.1582-4934.2004.tb00475.x; Rust C, 2000, AM J MED, V108, P567, DOI 10.1016/S0002-9343(00)00370-3; Ryan AJ, 2005, BRIT J CANCER, V92, pS6, DOI 10.1038/sj.bjc.6602603; Sahin F, 2004, CLIN CANCER RES, V10, P8421, DOI 10.1158/1078-0432.CCR-04-0941; Sangro B, 2004, J CLIN ONCOL, V22, P1389, DOI 10.1200/JCO.2004.04.059; Sangro B, 1998, SURGERY, V124, P575, DOI 10.1067/msy.1998.90359; SANGRO B, 1993, HEPATOLOGY, V18, P309, DOI 10.1002/hep.1840180214; Satyanarayana A, 2004, HEPATOLOGY, V40, P276, DOI 10.1002/hep.20308; Sawai Y, 2003, J HEPATOL, V39, P991, DOI 10.1016/S0168-8278(03)00498-7; Schiffer E, 2005, HEPATOLOGY, V41, P307, DOI 10.1002/hep.20538; Schmitz V, 2002, GENE THER, V9, P1600, DOI 10.1038/sj.gt.3301805; Schmitz V, 2001, HEPATOLOGY, V34, P72, DOI 10.1053/jhep.2001.25757; Schuppan D, 2003, HEPATOLOGY, V38, P289, DOI 10.1053/jhep.2003.50338; Sell S, 2002, SEMIN CELL DEV BIOL, V13, P419, DOI 10.1016/S1084952102001295; Sgadari C, 1996, BLOOD, V87, P3877, DOI 10.1182/blood.V87.9.3877.bloodjournal8793877; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297; Strand S, 1996, NAT MED, V2, P1361, DOI 10.1038/nm1296-1361; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Strumberg D, 2005, J CLIN ONCOL, V23, P965, DOI 10.1200/JCO.2005.06.124; Stuart K, 1999, CANCER, V86, P410; Stupack DG, 2004, CURR TOP DEV BIOL, V64, P207, DOI 10.1016/S0070-2153(04)64009-9; Su MC, 2005, CANCER LETT, V224, P117, DOI 10.1016/j.canlet.2004.10.010; Sundram F, 2004, EUR J NUCL MED MOL I, V31, P250, DOI 10.1007/s00259-003-1363-2; Sutter AP, 2005, J HEPATOL, V43, P808, DOI 10.1016/j.jhep.2005.04.010; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tirapu I, 2004, INT J CANCER, V110, P51, DOI 10.1002/ijc.20093; Tirapu I., 2002, Current Gene Therapy, V2, P79, DOI 10.2174/1566523023348192; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; Valdes F, 2002, MOL CANCER RES, V1, P68; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; von Sengbusch A, 2005, AM J PATHOL, V166, P585, DOI 10.1016/S0002-9440(10)62280-8; Wallace HM, 2003, BIOCHEM SOC T, V31, P393, DOI 10.1042/BST0310393; Wang L, 2003, MOL THER, V8, P72, DOI 10.1016/S1525-0016(03)00128-X; Warren Robert S, 2002, Surg Oncol Clin N Am, V11, P571, DOI 10.1016/S1055-3207(02)00043-1; Wiesenauer CA, 2004, J AM COLL SURGEONS, V198, P410, DOI 10.1016/j.jamcollsurg.2003.10.004; Wirth T, 2003, CANCER RES, V63, P3181; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Xu GW, 1996, HEPATOLOGY, V24, P1264; Xu Z, 2003, BIOCHEM BIOPH RES CO, V312, P388, DOI 10.1016/j.bbrc.2003.10.130; Yang CQ, 2003, CANCER RES, V63, P8312; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227; Zacharoulis D, 2005, EXPERT REV ANTICANC, V5, P645, DOI 10.1586/14737140.5.4.645; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zender L, 2002, GASTROENTEROLOGY, V123, P608, DOI 10.1053/gast.2002.34756; Zhang H, 2004, CANCER SCI, V95, P878, DOI 10.1111/j.1349-7006.2004.tb02197.x; Zhang H, 2003, HEPATOLOGY, V38, P305, DOI 10.1053/jhep.2003.50345; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zou WG, 2004, ONCOGENE, V23, P457, DOI 10.1038/sj.onc.1207033	232	324	342	0	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3866	3884		10.1038/sj.onc.1209550	http://dx.doi.org/10.1038/sj.onc.1209550			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799628	Green Submitted			2022-12-28	WOS:000238559600014
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			E-cadherin repression contributes to c-Myc-induced epithelial cell transformation	ONCOGENE			English	Article						c-Myc; E-cadherin; transformation; epithelial cell; EMT	TRANSCRIPTION FACTOR SNAIL; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; METASTASIS; GROWTH	c-Myc oncoprotein is overexpressed in a significant proportion of human epithelial cancers, and experimental overexpression of c-Myc in epithelial cells promotes tumour formation. However, it is not known how c-Myc promotes epithelial cell tumour formation. We report that c-Myc expression in human mammary epithelial cells induces a dramatic change in cell morphology, with some characteristics of an 'epithelial to mesenchymal transition'. E-cadherin expression is repressed by a post-transcriptional mechanism in cells expressing c-Myc. Furthermore, E-cadherin repression is necessary for c-Myc-induced cell transformation.	Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH 03756 USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Coll Sch Med, Norris Cotton Canc Ctr, Dept Pharmacol, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA080320] Funding Source: NIH RePORTER; Medical Research Council [G0700240] Funding Source: Medline; NCI NIH HHS [CA80320] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; DiRenzo J, 2002, CANCER RES, V62, P89; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; GRAFF JR, 1995, CANCER RES, V55, P5195; Niveditha S R, 2003, Indian J Pathol Microbiol, V46, P579; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Shiio Y, 2002, EMBO J, V21, P5088, DOI 10.1093/emboj/cdf525; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	18	49	50	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3582	3586		10.1038/sj.onc.1210132	http://dx.doi.org/10.1038/sj.onc.1210132			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146437				2022-12-28	WOS:000246799200014
J	Kerr, LE; Birse-Archbold, JLA; Short, DM; McGregor, AL; Heron, I; MacDonald, DC; Thompson, J; Carlson, GJ; Kelly, JS; McCulloch, J; Sharkey, J				Kerr, L. E.; Birse-Archbold, J-L A.; Short, D. M.; McGregor, A. L.; Heron, I.; MacDonald, D. C.; Thompson, J.; Carlson, G. J.; Kelly, J. S.; McCulloch, J.; Sharkey, J.			Nucleophosmin is a novel Bax chaperone that regulates apoptotic cell death	ONCOGENE			English	Article						bcl-2 family; translocation; apoptosis; focal cerebral ischaemia; protein-protein interaction	FOCAL CEREBRAL-ISCHEMIA; MITOCHONDRIAL APOPTOSIS; BCL-2 FAMILY; CYTOSOLIC HEAT-SHOCK-PROTEIN-60; CONFORMATIONAL-CHANGE; SIGNALING PATHWAY; NEURONAL DEATH; PROTEIN B23; C-TERMINUS; P53	The proapoptotic B-cell lymphoma-2 family protein Bax is a key regulatory point in the intrinsic apoptotic pathway. However, the factors controlling the process of Bax activation and translocation to mitochondria have yet to be fully identified and characterized. We performed affinity chromatography using peptides corresponding to the mitochondrial-targeting region of Bax, which is normally sequestered within the inactive structure. The molecular chaperone nucleophosmin was identified. ed as a novel Bax-binding protein by matrix- assisted laser desorption/ionization time-of-flight mass spectrometry. Reciprocal co-immunoprecipitation and proximity assays con. confirmed the Bax-nucleophosmin protein-protein interaction and verified that nucleophosmin only bound to activated conformationally altered Bax. Confocal microscopy in a cell-based apoptosis model, demonstrated that nucleophosmin translocation from nucleolus to cytosol preceded Bax movement. Specific. c knockdown of nucleophosmin expression using RNAi attenuated apoptosis as measured by mitochondrial cytochrome c release and activation of the caspase cascade. In a mouse model of ischaemic stroke, subcellular fractionation studies veri. ed that nucleophosmin translocation occurred within 3 h, at a time before Bax translocation but after Bax conformational changes have occurred. Thus, we have elucidated a novel molecular mechanism whereby Bax becomes activated and translocates to the mitochondria to orchestrate mitochondrial dysfunction and apoptotic cell death, which opens new avenues for therapeutic intervention.	Univ Edinburgh, Astellas CNS Res Edinburgh, Edinburgh EH16 4SB, Midlothian, Scotland	University of Edinburgh	Kerr, LE (corresponding author), Univ Edinburgh, Astellas CNS Res Edinburgh, Chancellors Bldg,49 Little France Crescent, Edinburgh EH16 4SB, Midlothian, Scotland.	Lorraine.Kerr@ed.ac.uk		McGregor, Ailsa/0000-0002-8598-1535; Sharkey, John/0000-0001-8288-1857				Ahn JY, 2005, MOL CELL, V18, P435, DOI 10.1016/j.molcel.2005.04.010; Akhtar RS, 2004, BBA-MOL CELL RES, V1644, P189, DOI 10.1016/j.bbamcr.2003.10.013; Baksh S, 2005, MOL CELL, V18, P637, DOI 10.1016/j.molcel.2005.05.010; Birse-Archbold JLA, 2005, J CEREBR BLOOD F MET, V25, P1356, DOI 10.1038/sj.jcbfm.9600133; BORER RA, 1989, CELL, V56, P379, DOI 10.1016/0092-8674(89)90241-9; Cao GD, 2001, J CEREBR BLOOD F MET, V21, P321, DOI 10.1097/00004647-200104000-00001; Cartron PF, 2003, J BIOL CHEM, V278, P11633, DOI 10.1074/jbc.M208955200; Chan PK, 1999, BIOCHEM BIOPH RES CO, V264, P305, DOI 10.1006/bbrc.1999.1255; Chiesa R, 2005, P NATL ACAD SCI USA, V102, P238, DOI 10.1073/pnas.0406173102; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200; Gao YQ, 2005, J CEREBR BLOOD F MET, V25, P694, DOI 10.1038/sj.jcbfm.9600062; Gleave M, 2003, ANN NY ACAD SCI, V1002, P95, DOI 10.1196/annals.1281.020; Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Gustafsson AB, 2004, J BIOL CHEM, V279, P21233, DOI 10.1074/jbc.M400695200; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Kerr LE, 2004, APOPTOSIS, V9, P739, DOI 10.1023/B:APPT.0000045787.50848.e1; Kerr LE, 2004, CELL DEATH DIFFER, V11, P1102, DOI 10.1038/sj.cdd.4401449; Kirchhoff SR, 2002, CIRCULATION, V105, P2899, DOI 10.1161/01.CIR.0000019403.35847.23; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kurki S, 2004, CANCER CELL, V5, P465, DOI 10.1016/S1535-6108(04)00110-2; Li J, 2005, LEUKEMIA RES, V29, P1415, DOI 10.1016/j.leukres.2005.05.005; Li J, 2004, J BIOL CHEM, V279, P41275, DOI 10.1074/jbc.C400297200; Li YP, 1997, J VIROL, V71, P4098, DOI 10.1128/JVI.71.5.4098-4102.1997; Lu YY, 1996, BIOCHEM J, V317, P321, DOI 10.1042/bj3170321; Maiguel DA, 2004, MOL CELL BIOL, V24, P3703, DOI 10.1128/MCB.24.9.3703-3711.2004; MAR MSM, 2001, BIOCHEMISTRY-US, V40, P9983; Matsushita K, 1998, NEUROSCIENCE, V83, P439, DOI 10.1016/S0306-4522(97)00391-6; Nam YJ, 2004, MOL CELL, V15, P901, DOI 10.1016/j.molcel.2004.08.020; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schinzel A, 2004, J CELL BIOL, V164, P1021, DOI 10.1083/jcb.200309013; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Takahashi Y, 2005, MOL CELL BIOL, V25, P9369, DOI 10.1128/MCB.25.21.9369-9382.2005; Takemura M, 2002, EXP CELL RES, V276, P233, DOI 10.1006/excr.2002.5523; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tremblais K, 1999, BIOCHEM BIOPH RES CO, V260, P582, DOI 10.1006/bbrc.1999.0904; White FA, 1998, J NEUROSCI, V18, P1428; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291	46	66	69	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2554	2562		10.1038/sj.onc.1210044	http://dx.doi.org/10.1038/sj.onc.1210044			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072349				2022-12-28	WOS:000245831200003
J	Carvalho, G; Fabre, C; Braun, T; Grosjean, J; Ades, L; Agou, F; Tasdemir, E; Boehrer, S; Israel, A; Veron, M; Fenaux, P; Kroemer, G				Carvalho, G.; Fabre, C.; Braun, T.; Grosjean, J.; Ades, L.; Agou, F.; Tasdemir, E.; Boehrer, S.; Israel, A.; Veron, M.; Fenaux, P.; Kroemer, G.			Inhibition of NEMO, the regulatory subunit of the IKK complex, induces apoptosis in high-risk myelodysplastic syndrome and acute myeloid leukemia	ONCOGENE			English	Article						apoptosis; NF-kappa B; mitochondria	NF-KAPPA-B; MITOCHONDRIAL ALTERATIONS; PROTEIN INTERACTIONS; CELL-LINE; ACTIVATION; SYSTEM	In high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), blasts constitutively activate the antiapoptotic transcription factor nuclear factor-kappa B (NF-kappa B). Here, we show that this NF-kappa B activation relies on the constitutive activation of the I kappa B kinase (IKK) complex, which is formed by the IKK alpha, IKK beta and IKK gamma/NF-kappa B essential modulator (NEMO) subunits. A cell-permeable peptide that mimics the leucine zipper subdomain of IKK gamma, thus preventing its oligomerization, inhibited the constitutive NF-kappa B activation and induced apoptotic cell death in a panel of human MDS and AML cell lines (P39, MOLM13, THP1 and MV4-11). Small interfering RNA-mediated knockdown of the p65 NF-kappa B subunit or the three IKK subunits including IKK gamma/NEMO also induced apoptotic cell death in P39 cells. Cell death induced by the IKK gamma/NEMO-antagonistic peptide involved the caspase-independent loss of the mitochondrial transmembrane potential as well as signs of outer mitochondrial membrane permeabilization with the consequent release of cytochrome c, apoptosis-inducing factor and endonuclease G. Primary bone marrow CD34(+) cells from high-risk MDS and AML patients also succumbed to the IKK gamma/NEMO-antagonistic peptide, but not to a mutated control peptide. Altogether, these data indicate that malignant cells in high-risk MDS and AML cells critically depend on IKK gamma/NEMO to survive. Moreover, our data delineate a novel procedure for their therapeutic removal, through inhibition of IKK gamma/NEMO oligomerization.	Inst Gustave Roussy, CNRS, FRE 2939, F-94805 Villejuif, France; INSERM, Unit Apoptosis Canc & Immun, Villejuif, France; Univ Paris 11, Fac Med Paris Sud, Villejuif, France; Univ Paris 13, AP HP, Hop Avicenne, Hematol Unit, Bobigny, France; Inst Pasteur, CNRS, URA 2185, Unite Regulat Enzymat Activities Cellulaires, Paris, France; Inst Pasteur, CNRS, URA 2582, SMAC, Paris, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE 2939, Rue Camille Desmoulins,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	, AGOU/GXA-2760-2022; KROEMER, Guido/B-4263-2013; Ades, lionel/T-6882-2019; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Agou F, 2004, J BIOL CHEM, V279, P27861, DOI 10.1074/jbc.M314278200; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Braun T, 2006, CELL DEATH DIFFER, V13, P748, DOI 10.1038/sj.cdd.4401874; Braun T, 2006, BLOOD, V107, P1156; Castedo M, 2002, J IMMUNOL METHODS, V265, P39, DOI 10.1016/S0022-1759(02)00069-8; Castedo M, 1996, J IMMUNOL, V157, P512; Dev KK, 2004, NAT REV DRUG DISCOV, V3, P1047, DOI 10.1038/nrd1578; Dombret H, 2002, SEMIN HEMATOL, V39, P8, DOI 10.1053/shem.2002.33608; Estrov Z, 2003, BLOOD, V102, P987, DOI 10.1182/blood-2002-11-3550; Fenaux P, 2005, SEMIN ONCOL, V32, pS11, DOI 10.1053/j.seminoncol.2005.06.016; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GLOIRE G, 2006, BIOCH PHARM; Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Guzman ML, 2002, P NATL ACAD SCI USA, V99, P16220, DOI 10.1073/pnas.252462599; Hassan Z, 1999, EXP HEMATOL, V27, P1322, DOI 10.1016/S0301-472X(99)00066-1; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Lindberg EH, 2005, CURR DRUG TARGETS, V6, P713, DOI 10.2174/1389450054863707; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Matsuo Y, 1997, LEUKEMIA, V11, P1469, DOI 10.1038/sj.leu.2400768; Metivier D, 1998, IMMUNOL LETT, V61, P157, DOI 10.1016/S0165-2478(98)00013-3; NAGAI M, 1984, GANN, V75, P1100; Nakamori Y, 2006, J CELL BIOL, V173, P665, DOI 10.1083/jcb.200601065; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Smahi A, 2002, HUM MOL GENET, V11, P2371, DOI 10.1093/hmg/11.20.2371; Steensma DP, 2006, MAYO CLIN PROC, V81, P104, DOI 10.4065/81.1.104; Vardiman JW, 2002, BLOOD, V100, P2292, DOI 10.1182/blood-2002-04-1199; ZAMZAMI N, 2003, METH MOL B, V282, P103	30	42	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2299	2307		10.1038/sj.onc.1210043	http://dx.doi.org/10.1038/sj.onc.1210043			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043643				2022-12-28	WOS:000245466000006
J	Crosby, ME; Jacobberger, J; Gupta, D; Macklis, RM; Almasan, A				Crosby, M. E.; Jacobberger, J.; Gupta, D.; Macklis, R. M.; Almasan, A.			E2F4 regulates a stable G(2) arrest response to genotoxic stress in prostate carcinoma	ONCOGENE			English	Article						E2F4 knockdown; G(2) cell cycle arrest; apoptosis; ionizing radiation	CELL-CYCLE EXIT; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; GENETIC INSTABILITY; DOWN-REGULATION; IN-VIVO; EXPRESSION; P53; REPLICATION; CHECKPOINT	The retinoblastoma (pRB) family proteins regulate the E2F transcription factors; their complexes regulate critical transitions through the cell cycle. The function of these pRBfamily/E2F complexes, which includes p130/E2F4, in response to genotoxic agents, is not well understood. We investigated the role of E2F4 in the genotoxic stress response. Following radiation treatment, E2F4 colocalized with p130 in the nucleus during a radiation-induced stable G2-phase arrest. Arrested cells had significantly decreased expression of Cyclins A2 and B1 and decreased phosphorylation of mitotic protein monoclonal-2 (MPM-2) mitotic proteins. Small interference RNA (siRNA)-mediated knockdown of E2F4 sensitized cells to subsequent irradiation, resulting in enhanced cellular DNA damage and cell death, as determined by caspase activation and decreased clonogenic cell survival. Downstream E2F4 targets potentially involved in the progression from G2 into M phase were identified by oligonucleotide microarray expression pro. ling. Chromatin immunoprecipitation localized E2F4 at promoter regions of the Bub3 and Pttg1 mitotic genes following irradiation, which were among the downregulated genes identified by the microarray. These data suggest that in response to radiation, E2F4 becomes active in the nucleus, enforces a stable G2 arrest by target gene repression, and thus provides increased cell survival ability by minimizing propagation of cells that have irreparable DNA damage.	Cleveland Clin, Dept Canc Biol & Radiat Oncol, Cleveland, OH 44195 USA; Lerner Res Inst, Dept Canc Biol, Cleveland, OH USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Almasan, A (corresponding author), Cleveland Clin, Dept Canc Biol & Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	almasaa@ccf.org	Almasan, Alex/C-2715-2008; Jacobberger, James/P-9183-2014	Almasan, Alex/0000-0002-8916-6650; Jacobberger, James/0000-0002-3092-5157; Crosby, Meredith/0000-0002-3626-9445	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081504-08, R01 CA081504-09, R01 CA081504-07, CA82858, R01 CA082858, CA81504, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Crosby ME, 2004, J ENVIRON PATHOL TOX, V23, P67, DOI 10.1615/JEnvPathToxOncol.v23.i1.70; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Ray S, 2003, CANCER RES, V63, P4713; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takahashi Y, 2000, GENE DEV, V14, P804; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Waghray A, 2001, CANCER RES, V61, P4283; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan T, 2004, MOL CANCER THER, V3, P1147; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	46	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1897	1909		10.1038/sj.onc.1209998	http://dx.doi.org/10.1038/sj.onc.1209998			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043659	Green Accepted			2022-12-28	WOS:000245117700007
J	Burgers, WA; Blanchon, L; Pradhan, S; de Launoit, Y; Kouzarides, T; Fuks, F				Burgers, W. A.; Blanchon, L.; Pradhan, S.; de Launoit, Y.; Kouzarides, T.; Fuks, F.			Viral oncoproteins target the DNA methyltransferases	ONCOGENE			English	Article						E1A; E7; Dnmt1; DNA methyltransferase; viral oncoproteins	RETINOBLASTOMA GENE-PRODUCT; CYTOSINE-5 METHYLTRANSFERASE; ACETYLTRANSFERASE ACTIVITY; CELLULAR-TRANSFORMATION; HISTONE DEACETYLASE; DE-NOVO; E1A; METHYLATION; TRANSCRIPTION; EXPRESSION	Small DNA tumour viruses have evolved a number of mechanisms to drive nondividing cells into S phase. Virally encoded oncoproteins such as adenovirus E1A and human papillomavirus (HPV) E7 can bind an array of cellular proteins to override proliferation arrest. The DNA methyltransferase Dnmt1 is the major mammalian enzyme responsible for maintaining CpG methylation patterns in the cell following replication. One of the hallmarks of tumour cells is disrupted DNA methylation patterns, highlighting the importance of the proper regulation of DNA methyltransferases in normal cell proliferation. Here, we show that adenovirus 5 E1A and HPV-16 E7 associate in vitro and in vivo with the DNA methyltransferase Dnmt1. Consistent with this interaction, we find that E1A and E7 can purify DNA methyltransferase activity from nuclear extracts. These associations are direct and mediated by the extreme N-terminus of E1A and the CR3 zinc-finger domain of E7. Furthermore, we find that a point mutant at leucine 20 of E1A, a residue known to be critical for its transformation functions, is unable to bind Dnmt1 and DNA methyltransferase activity. Finally, both E1A and E7 can stimulate the methyltransferase activity of Dnmt1 in vitro. Our results provide the first indication that viral oncoproteins bind and regulate Dnmt1 enzymatic activity. These observations open up the possibility that this association may be used to control cellular proliferation pathways and suggest a new mechanism by which small DNA tumour viruses can steer cells through the cell cycle.	Free Univ Brussels, Fac Med, Lab Canc Epigenet, B-1070 Brussels, Belgium; Univ Cambridge, CRUK Gurdon Inst, Wellcome Trust, Cambridge CB2 1TN, England; Univ Cape Town, Fac Hlth Sci, Div Med Virol, ZA-7925 Cape Town, South Africa; Univ Lille 1, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, Lille, France; Univ Lille 2, CNRS, Inst Pasteur, Inst Biol Lille,UMR 8161, F-59800 Lille, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Cambridge; Wellcome Trust Sanger Institute; University of Cape Town; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Fuks, F (corresponding author), Free Univ Brussels, Fac Med, Lab Canc Epigenet, 808 Route Lennik, B-1070 Brussels, Belgium.	ffuks@ulb.ac.be		Burgers, Wendy/0000-0003-3396-9398; BLANCHON, LOIC/0000-0001-8842-0162; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust [092096] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; DEBUSTROS A, 1988, P NATL ACAD SCI USA, V85, P5693; Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gowher H, 2005, J BIOL CHEM, V280, P13341, DOI 10.1074/jbc.M413412200; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; McCance DJ, 2005, CURR OPIN GENET DEV, V15, P515, DOI 10.1016/j.gde.2005.08.003; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166, DOI 10.1128/MCB.18.9.5166; Ordway JM, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-19; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Sang NL, 1997, J CELL PHYSIOL, V170, P182, DOI 10.1002/(SICI)1097-4652(199702)170:2<182::AID-JCP10>3.0.CO;2-K; Slack A, 1999, J BIOL CHEM, V274, P10105, DOI 10.1074/jbc.274.15.10105; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; WANG HGH, 1993, J VIROL, V67, P4804, DOI 10.1128/JVI.67.8.4804-4813.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU JJ, 1993, P NATL ACAD SCI USA, V90, P8891, DOI 10.1073/pnas.90.19.8891	24	194	202	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1650	1655		10.1038/sj.onc.1209950	http://dx.doi.org/10.1038/sj.onc.1209950			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983344	Green Accepted, Bronze			2022-12-28	WOS:000244782500015
J	McDermott, SP; Ranheim, EA; Leatherberry, VS; Khwaja, SS; Klos, KS; Alexander, CM				McDermott, S. P.; Ranheim, E. A.; Leatherberry, V. S.; Khwaja, S. S.; Klos, K. S.; Alexander, C. M.			Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development	ONCOGENE			English	Article						syndecan-1 heparan sulfate proteoglycan; mouse tumor; DMBA	BREAST-CANCER CELLS; PROGENITOR CELLS; HEPARAN-SULFATE; STEM-CELLS; MOUSE; IDENTIFICATION; ACTIVATION; EXPRESSION; INDUCTION; RECOMMENDATIONS	We previously showed that mice with a null mutation in syndecan-1 (Sdc1; CD138) were resistant to Wnt1-induced mammary tumor initiation. The absence of Sdc1 inhibited the increase in the mammary stem cell fraction that is characteristic of preneoplasia in this model. As the tumor precursor cells are recruited from the stem/progenitor cell compartment, tumor development was also inhibited (Liu et al., 2004; PNAS 101, 4158). Although Sdc1(-/-) mice are grossly normal, they are systemically smaller, suggesting that developmental abnormalities may extend further than their mammary glands. We have therefore evaluated the multi-organ response of Sdc1(-/-) mice to carcinogen-induced tumor development (7,12-dimethylbenz[a] anthracene, DMBA), and find these mice to be resistant to tumorigenesis in all the predominant carcinogen-susceptible lineages. Thus, Sdc1(-/-) mice administered DMBA during juvenile development are resistant not only to epithelial tumors, including liver (60-80%) and lung tumors (C57BL6 mice, 60-80%), but also to lymphoma ( over 70%, depending upon strain and carcinogen dose). We demonstrate that CD138 is expressed ( heterogeneously) in the hematopoietic stem cell fraction ( and not only in pre-B and plasma cells), and that tumors arise in both myeloid and lymphoid lineages. Furthermore, carcinogen-induced mammary tumors are bilineal, implying a bipotent precursor cell. Both observations imply that the DMBA-induced tumor precursor cells are drawn from the stem/progenitor fraction, and we suggest that pathogenic activation of these cells could be abnormal in Sdc1(-/-) mice.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Pathol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Alexander, CM (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	alexander@oncology.wisc.edu	McDermott, Sean/I-2978-2013; Ranheim, Erik/AAY-6505-2021	McDermott, Sean/0000-0001-7820-2399; 	NCI NIH HHS [T32 CA09135, CA 90877] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA090877] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAMATSU Y, 1975, J NATL CANCER I, V55, P893, DOI 10.1093/jnci/55.4.893; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bunger MK, 2003, J BIOL CHEM, V278, P17767, DOI 10.1074/jbc.M209594200; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FLAKS A, 1968, European Journal of Cancer, V4, P579, DOI 10.1016/0014-2964(68)90042-X; Forsberg EC, 2005, PLOS GENET, V1, P281, DOI 10.1371/journal.pgen.0010028; Gallo R, 1996, J INVEST DERMATOL, V107, P676, DOI 10.1111/1523-1747.ep12365571; Gotte M, 2002, INVEST OPHTH VIS SCI, V43, P1135; Heidel SM, 2000, CANCER RES, V60, P3454; Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592; Kenney Nicholas J., 2001, Journal of Biomedicine and Biotechnology, V1, P133, DOI 10.1155/S1110724301000304; Kramer KL, 2003, ANNU REV GENET, V37, P461, DOI 10.1146/annurev.genet.37.061103.090226; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu BY, 2003, ONCOGENE, V22, P9243, DOI 10.1038/sj.onc.1207217; Maeda T, 2006, ONCOGENE, V25, P1408, DOI 10.1038/sj.onc.1209168; Maeda T, 2004, CANCER RES, V64, P612, DOI 10.1158/0008-5472.CAN-03-2439; Mehta RG, 2000, EUR J CANCER, V36, P1275, DOI 10.1016/S0959-8049(00)00100-3; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Paguirigan A, 2006, EUR J CANCER, V42, P1225, DOI 10.1016/j.ejca.2006.01.048; Park PW, 2001, NATURE, V411, P98, DOI 10.1038/35075100; Ranheim EA, 2005, BLOOD, V105, P2487, DOI 10.1182/blood-2004-06-2334; ROE FJC, 1968, FOOD COSMET TOXICOL, V6, P581, DOI 10.1016/0015-6264(68)90302-7; SHACKLEFORD GM, 1988, P NATL ACAD SCI USA, V85, P9655, DOI 10.1073/pnas.85.24.9655; SHACKLEFORD GM, 1993, P NATL ACAD SCI USA, V90, P740, DOI 10.1073/pnas.90.2.740; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stepp MA, 2002, J CELL SCI, V115, P4517, DOI 10.1242/jcs.00128; SUTHERLAND AE, 1991, DEVELOPMENT, V113, P339; Taylor KR, 2006, FASEB J, V20, P9, DOI 10.1096/fj.05-4682rev; VANLEEUWEN F, 1995, SEMIN CANCER BIOL, V6, P127, DOI 10.1006/scbi.1995.0018; WALTERS MA, 1966, BRIT J CANCER, V20, P148, DOI 10.1038/bjc.1966.17; Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m	37	49	49	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1407	1416		10.1038/sj.onc.1209930	http://dx.doi.org/10.1038/sj.onc.1209930			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953225				2022-12-28	WOS:000244558800005
J	Nieto, M; Barradas, M; Criado, LM; Flores, JM; Serrano, M; Llano, E				Nieto, M.; Barradas, M.; Criado, L. M.; Flores, J. M.; Serrano, M.; Llano, E.			Normal cellular senescence and cancer susceptibility in mice genetically deficient in Ras-induced senescence-1 (Ris1)	ONCOGENE			English	Article						Ris1; Ras; senescence; tumor suppression; mouse models	ONCOGENIC RAS; TUMOR SUPPRESSION; CARCINOGENESIS; IDENTIFICATION; TUMORIGENESIS; GENES; P53	Oncogenic Ras triggers a permanent cell-cycle arrest known as oncogene-induced senescence (OIS) that constitutes a relevant tumor suppressor mechanism. Ris1 (Ras-induced senescence-1) is a novel gene that was identified in a screen as specifically upregulated during Ras-induced senescence, and that is located at a chromosomal region, 3p21.3, frequently lost in human cancer. Moreover, Ris1 is highly conserved in vertebrates, does not present paralogs, and its sequence does not reveal similarities with other proteins or domains. To analyse the physiological function of Ris1 and test its putative role as a tumor suppressor gene, we have generated mutant mice deficient for this gene. Ris1-null mice are viable, fertile, develop normally and do not display any obvious abnormalities. Of relevance, Ris1-deficient mice had a normal lifespan and did not exhibit predisposition to spontaneous tumors or to tumors induced by chemical carcinogens. Finally, Ris1-deficient embryonic fibroblasts were indistinguishable from wild-type cells regarding their proliferation properties, immortalization, senescence and oncogenic transformation. These findings do not support a role of Ris1 in tumor suppression or in OIS.	Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, E-28029 Madrid, Spain; Spanish Natl Canc Ctr, Tumor Suppress Grp, CNIO, E-28029 Madrid, Spain; Univ Complutense, Sch Vet, Dept Anim Surg & Med, E-28040 Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Complutense University of Madrid	Serrano, M (corresponding author), Spanish Natl Canc Ctr, Dept Mol Oncol, CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Llano, Elena/K-1723-2014; Serrano, Manuel/H-2634-2015; Llano, Elena/AAS-5517-2021	Llano, Elena/0000-0002-2626-5723; Serrano, Manuel/0000-0001-7177-9312; Llano, Elena/0000-0002-2626-5723				Barradas M, 2002, EXP CELL RES, V273, P127, DOI 10.1006/excr.2001.5434; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Hama T, 2001, J BIOL CHEM, V276, P31929, DOI 10.1074/jbc.M100617200; Imreh S, 2003, GENE CHROMOSOME CANC, V38, P307, DOI 10.1002/gcc.10271; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Petursdottir TE, 2004, GENE CHROMOSOME CANC, V41, P232, DOI 10.1002/gcc.20072; Qin ZH, 2002, J EXP MED, V195, P1479, DOI 10.1084/jem.20011887; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Silva J, 2006, MUTAT RES-FUND MOL M, V594, P78, DOI 10.1016/j.mrfmmm.2005.07.017; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Xiang RH, 2002, CANCER RES, V62, P2637	21	5	6	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1673	1680		10.1038/sj.onc.1209978	http://dx.doi.org/10.1038/sj.onc.1209978			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964279				2022-12-28	WOS:000244955600001
J	Rinaldo, F; Li, J; Wang, E; Muders, M; Datta, K				Rinaldo, F.; Li, J.; Wang, E.; Muders, M.; Datta, K.			RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation	ONCOGENE			English	Article						RalA; VEGF-C; androgen; reactive oxygen species; prostate cancer	LYMPH-NODE METASTASIS; TUMOR LYMPHANGIOGENESIS; OXIDATIVE STRESS; EPITHELIAL-CELLS; EXPRESSION; RAS; PATHWAY; INVOLVEMENT; ACTIVATION; RECEPTOR-3	Prostate cancer mortality is primarily due to failure to cure patients with metastatic disease. In its early stages, prostate cancer growth is enhanced by androgens. As such, the primary therapy for advanced (locally extensive or metastatic) prostate cancer consists of androgen deprivation therapy by pharmacotherapeutic or surgical means. Eventually, the tumor recurs owing to a transition from androgen-dependence to a highly metastatic and androgen refractory (androgen depletion-independent) phenotype. As the detailed molecular mechanism underlying this transition to a more aggressive phenotype is poorly understood, it has been difficult to develop effective treatments for this advanced stage of the disease. We have previously reported an increase in vascular endothelial growth factor-C (VEGF-C) express ion in human prostate cancer cells after androgen withdrawal. We have also shown increased expression of the androgen receptor coactivator BAG-1L by VEGF-C, suggesting the involvement of this growth factor in transactivation of the androgen receptor, even at low concentrations of androgen. In our present study, we show that androgen deprivation of human prostate carcinoma cells activates the small GTPase, RalA, a molecule important for human oncogenesis. RalA activation leads to VEGF-C upregulation. We also show that elevated levels of intracellular reactive oxygen species in prostate cancer cells under androgen-ablated conditions is the major inducer of RalA activation and VEGF-C synthesis.	Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Datta, K (corresponding author), Mayo Clin Fdn, Mayo Clin Canc Ctr, Dept Biochem & Mol Biol, Gugg 1401B,200 1st St SW, Rochester, MN 55905 USA.	datta.kaustubh@mayo.edu	Muders, Michael/AAU-6443-2020		PHS HHS [1 PSOCA91956-3] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Collette J, 2004, INT J CANCER, V112, P190, DOI 10.1002/ijc.20398; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; DENIS L, 1993, CANCER, V72, P3888, DOI 10.1002/1097-0142(19931215)72:12+<3888::AID-CNCR2820721726>3.0.CO;2-B; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; Essers MAG, 2004, EMBO J, V23, P4802, DOI 10.1038/sj.emboj.7600476; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jennbacken K, 2005, PROSTATE, V65, P110, DOI 10.1002/pros.20276; Jia YT, 2004, WORLD J GASTROENTERO, V10, P3261, DOI 10.3748/wjg.v10.i22.3261; Karpanen T, 2001, CANCER RES, V61, P1786; Kimura Y, 2003, ONCOL REP, V10, P1747; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Li JP, 2005, ONCOGENE, V24, P5510, DOI 10.1038/sj.onc.1208693; Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Neuchrist C, 2003, HEAD NECK-J SCI SPEC, V25, P464, DOI 10.1002/hed.10235; Oh WK, 1998, J UROLOGY, V160, P1220, DOI 10.1016/S0022-5347(01)62501-1; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Sipos B, 2004, AM J PATHOL, V165, P1187, DOI 10.1016/S0002-9440(10)63379-2; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Tam NNC, 2003, AM J PATHOL, V163, P2513, DOI 10.1016/S0002-9440(10)63606-1; Tchevkina E, 2005, ONCOGENE, V24, P329, DOI 10.1038/sj.onc.1208094; Tsurusaki T, 1999, BRIT J CANCER, V80, P309, DOI 10.1038/sj.bjc.6690356; Ulku AS, 2003, MOL CANCER RES, V1, P1077; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Zeng YP, 2005, PROSTATE, V65, P222, DOI 10.1002/pros.20288	30	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1731	1738		10.1038/sj.onc.1209971	http://dx.doi.org/10.1038/sj.onc.1209971			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964283				2022-12-28	WOS:000244955600007
J	Kaur, M; Pop, M; Shi, D; Brignone, C; Grossman, SR				Kaur, M.; Pop, M.; Shi, D.; Brignone, C.; Grossman, S. R.			hHR23B is required for genotoxic-specific activation of p53 and apoptosis	ONCOGENE			English	Article						p53; hHR23; ubiquitin; proteasome; DNA damage; chromatin	NUCLEOTIDE EXCISION-REPAIR; UBIQUITIN-PROTEASOME SYSTEM; DNA-REPAIR; IN-VIVO; POLYUBIQUITIN CHAINS; UV-IRRADIATION; C PROTEIN; DEGRADATION; RAD23; DOMAINS	Rad23 proteins function in both DNA repair and protein stability regulation. As ubiquitinated forms of p53 are stabilized after DNA damage in concert with p53 functional activation, and human Rad23 proteins (hHR23A and B) regulate p53 stability in unstressed cells, the role of hHR23B in post-genotoxin regulation of p53 was investigated. Depletion of hHR23B by specific short interfering RNA before genotoxic exposure attenuated p53, p21 and bax induction, abrogated the accumulation of ubiquitinated p53 and suppressed apoptosis. Expression of ubiquitin derivatives with all lysines mutated except K48 or K63 demonstrated that K48-linked p53-ubiquitin conjugates were specifically induced after DNA damage. hHR23B, along with native and ubiquitinated p53, accumulated in chromatin after genotoxic exposure, and the accumulation of ubiquitinated p53 in chromatin was prevented by hHR23B depletion. Chromatin immunoprecipitation analysis demonstrated that hHR23B and p53 both localized to the p21 promoter shortly after DNA damage. hHR23B thus plays a critical role in the activation and function of p53 after specific genotoxic exposures.	Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Gastrointestinal Canc Program, Worcester, MA 01605 USA; Univ Massachusetts, Ctr Canc, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Grossman, SR (corresponding author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB419,364 Plantat St, Worcester, MA 01605 USA.	steven.grossman@umassmed.edu			NATIONAL CANCER INSTITUTE [R01CA107532] Funding Source: NIH RePORTER; NCI NIH HHS [CA107532, R01 CA107532] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brignone C, 2004, ONCOGENE, V23, P4121, DOI 10.1038/sj.onc.1207540; Cutts SM, 2003, MOL CANCER THER, V2, P661; Glockzin S, 2003, MOL CELL BIOL, V23, P8960, DOI 10.1128/MCB.23.24.8960-8969.2003; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hsieh HC, 2005, BIOCHEM BIOPH RES CO, V335, P181, DOI 10.1016/j.bbrc.2005.07.067; Itoh T, 2005, DNA REPAIR, V4, P1457, DOI 10.1016/j.dnarep.2005.08.008; Kruczynski A, 2004, CLIN CANCER RES, V10, P3156, DOI 10.1158/1078-0432.CCR-1305-2; Lee YJ, 2006, CARCINOGENESIS, V27, P446, DOI 10.1093/carcin/bgi254; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Ng JMY, 2003, GENE DEV, V17, P1630, DOI 10.1101/gad.260003; Ng JMY, 2002, MOL CELL BIOL, V22, P1233, DOI 10.1128/MCB.22.4.1233-1245.2002; Ortolan TG, 2004, NUCLEIC ACIDS RES, V32, P6490, DOI 10.1093/nar/gkh987; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Raasi S, 2004, J MOL BIOL, V341, P1367, DOI 10.1016/j.jmb.2004.06.057; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Robles AI, 1999, ONCOGENE, V18, P4681, DOI 10.1038/sj.onc.1202862; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Soria G, 2006, ONCOGENE, V25, P2829, DOI 10.1038/sj.onc.1209315; Sweder K., 2002, Journal of Biomedicine & Biotechnology, V2, P94, DOI 10.1155/S1110724302205033; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Verma R, 2004, CELL, V118, P99, DOI 10.1016/j.cell.2004.06.014; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang XY, 2003, SPECTROSC SPECT ANAL, V23, P42; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Xie ZW, 2004, NUCLEIC ACIDS RES, V32, P5981, DOI 10.1093/nar/gkh934	28	22	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 22	2007	26	8					1231	1237		10.1038/sj.onc.1209865	http://dx.doi.org/10.1038/sj.onc.1209865			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924240	Green Accepted			2022-12-28	WOS:000244406400013
J	Zucman-Rossi, J; Benhamouche, S; Godard, C; Boyault, S; Grimber, G; Balabaud, C; Cunha, AS; Bioulac-Sage, P; Perret, C				Zucman-Rossi, J.; Benhamouche, S.; Godard, C.; Boyault, S.; Grimber, G.; Balabaud, C.; Cunha, A. S.; Bioulac-Sage, P.; Perret, C.			Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas	ONCOGENE			English	Article						hepatocellular carcinoma; beta-catenin; Axin1; target genes; Wnt pathway	COLON-CARCINOMA; PROTEIN-KINASE; CYCLIN D1; GENE; COMPLEX; VIRUS; LIVER; IDENTIFICATION; EXPRESSION; FREQUENT	Perturbations to the Wnt signaling pathway have been implicated in a large proportion of human hepatocellular carcinomas (HCCs). Activating beta-catenin mutations and loss of function mutations in Axin1 are thought to be functionally equivalent. We examined the Wnt pathway in HCC by comparing the expression of b-catenin target genes and the level of beta-catenin-dependent transcriptional activation, in 45 HCC tumors and four cell lines. Among these samples, beta-catenin and AXIN1 were mutated in 20 and seven cases, respectively. We found a significant correlation between activated b-catenin mutations and overexpression of mRNA for the target genes glutamine synthetase (GS), G-protein-coupled receptor (GPR) 49 and glutamate transporter (GLT)-1 (P = 0.0001), but not for the genes ornithine aminotransferase, LECT2, c-myc and cyclin D1. We also showed that GS is a good immunohistochemical marker of b-catenin activation in HCC. However, we observed no induction of GS, GPR49 or GLT-1 in the five inactivated Axin1 tumors. beta-Catenin-dependent transcriptional activation in two Axin1-mutated HCC cell lines was much weaker than in beta-catenin-mutated cell lines. Our results strongly suggest that in HCC, contrary to expectation, the loss of function of Axin1 is not equivalent to the gain of function of beta-catenin. Our results also suggest that the tumor suppressor function of Axin1 in HCC may be related to another, non-Wnt pathway.	Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, F-75014 Paris, France; INSERM, U674, IFR105, CEPH, Paris, France; Ctr Hosp Univ Bordeaux, Dept Hepatol, Bordeaux, France; Ctr Hosp Univ Bordeaux, Hop Pellegrin, Serv Anat Pathol, Bordeaux, France; Univ Bordeaux 2, INSERM, E362, GREF, F-33076 Bordeaux, France; CHU Bordeaux, Hop St Andre, Serv Chirurg Digest, Bordeaux, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux	Perret, C (corresponding author), Univ Paris 05, INSERM, U567,Inst Cochin, CNRS,UMR 8104,Dept EMC,Fac Med Cochin Port Royal, 24,Bat Fac,Rue Faubourg St Jacques, F-75014 Paris, France.	perret@cochin.inserm.fr	Perret-Mayeux, Christine/L-3297-2017; j, zucman-rossi/AAV-3594-2021; cunha, antonio sa/B-5781-2012; zucman-rossi, Jessica/B-5098-2009	j, zucman-rossi/0000-0002-5687-0334; cunha, antonio sa/0000-0003-4015-5368; zucman-rossi, Jessica/0000-0002-5687-0334; Godard, Cecile/0000-0003-3016-0980; perret, christine/0000-0003-4710-7051				Befeler AS, 2002, GASTROENTEROLOGY, V122, P1609, DOI 10.1053/gast.2002.33411; Cadoret A, 2002, ONCOGENE, V21, P8293, DOI 10.1038/sj.onc.1206118; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Furuhashi M, 2001, MOL CELL BIOL, V21, P5132, DOI 10.1128/MCB.21.15.5132-5141.2001; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Miyoshi Y, 1998, CANCER RES, V58, P2524; Ovejero C, 2004, HEPATOLOGY, V40, P167, DOI 10.1002/hep.20286; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Salahshor S, 2005, J CLIN PATHOL, V58, P225, DOI 10.1136/jcp.2003.009506; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Ueta T, 2002, ONCOL REP, V9, P1197; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Yamamoto Y, 2003, HEPATOLOGY, V37, P528, DOI 10.1053/jhep.2003.50029; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	26	191	196	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					774	780		10.1038/sj.onc.1209824	http://dx.doi.org/10.1038/sj.onc.1209824			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16964294				2022-12-28	WOS:000243902200014
J	Khwaja, FW; Svoboda, P; Reed, M; Pohl, J; Pyrzynska, B; Van Meir, EG				Khwaja, F. W.; Svoboda, P.; Reed, M.; Pohl, J.; Pyrzynska, B.; Van Meir, E. G.			Proteomic identification of the wt-p53-regulated tumor cell secretome	ONCOGENE			English	Article						p53; proteomics; secretion; glioma; brain cancer; two-dimensional electrophoresis	GLIOBLASTOMA CELLS; WILD-TYPE; STROMA INTERACTIONS; P53 ALLELES; TGF-BETA; ANGIOGENESIS; EXPRESSION; CANCER; PROTEINS; PATHWAY	Tumor-stroma interactions play a major role in tumor development, maintenance and progression. Yet little is known on how the genetic alterations that underlie cell transformation elicit cell extrinsic changes modulating heterotypic cell interactions. We hypothesized that these events involve a modi. cation in the complement of secreted proteins by the cell, acting as mediators of intercellular communication. To test this hypothesis, we examined the role of wt-p53, a major tumor suppressor, on the tumor microenvironment through its regulation of secreted factors. Using a combination of 2-DE and cICAT proteomic techniques, we found a total of 111 secreted proteins, 39 of which showed enhanced and 21 inhibited secretion in response to wt-p53 expression. The majority of these were not direct targets of p53 transcription factor activity, suggesting a novel role for wt-p53 in the control of intracellular protein trafficking and/or secreted protein stability. Evidence for p53-controlled post-translational modi. cations on nine secreted proteins was also found. These findings will enhance our understanding of wt-p53 modulated interactions of the tumor with its environment.	Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, Atlanta, GA 30322 USA; Emory Univ, Dept Hematol Oncol, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Microchem & Proteom Facil, Sch Med, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Van Meir, EG (corresponding author), Emory Univ, Lab Mol NeuroOncol, Dept Neurosurg, Winship Canc Inst,Sch Med, 1365C Clifton Rd,NE,C5078, Atlanta, GA 30322 USA.	evanmei@emory.edu	Pyrzyńska, Beata/T-2187-2018	Pyrzyńska, Beata/0000-0002-0490-618X; Van Meir, Erwin G./0000-0003-2444-7707	NCI NIH HHS [CA 86335] Funding Source: Medline; NCRR NIH HHS [RR 02878, RR 12878, RR 13948] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086335] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR012878, S10RR002878, S10RR013948] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Albertoni M, 1998, ONCOGENE, V16, P321, DOI 10.1038/sj.onc.1201544; Albertoni M, 2002, ONCOGENE, V21, P4212, DOI 10.1038/sj.onc.1205610; Amzallag N, 2004, J BIOL CHEM, V279, P46104, DOI 10.1074/jbc.M404850200; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Brat DJ, 2005, NEURO-ONCOLOGY, V7, P122, DOI 10.1215/S1152851704001061; Bueter M, 2006, INT J ONCOL, V28, P519; Chiarugi V, 1998, INT J MOL MED, V2, P715; Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Fulci G, 1999, MOL NEUROBIOL, V19, P61, DOI 10.1007/BF02741378; GOLDMAN D, 1980, CLIN CHEM, V26, P1317; Gorg A, 2004, PROTEOMICS, V4, P3665, DOI 10.1002/pmic.200401031; Gygi SP, 2002, J PROTEOME RES, V1, P47, DOI 10.1021/pr015509n; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Kamemura K, 2003, PROG NUCLEIC ACID RE, V73, P107, DOI 10.1016/S0079-6603(03)01004-3; KHWAJA FW, 2006, IN PRESS CLIN CANC R; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; Mazzocca A, 2005, CANCER RES, V65, P4728, DOI 10.1158/0008-5472.CAN-04-4449; Morimoto I, 2002, GENE CHROMOSOME CANC, V33, P270, DOI 10.1002/gcc.10020; Pietras K, 2002, CANCER RES, V62, P5476; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Steer M, 2005, IEEE T MICROW THEORY, V53, P3, DOI 10.1109/TMTT.2004.839957; Stuelten CH, 2005, J CELL SCI, V118, P2143, DOI 10.1242/jcs.02334; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tenan M, 2000, J EXP MED, V191, P1789, DOI 10.1084/jem.191.10.1789; Tsai MS, 2000, CANCER RES, V60, P5603; Tsuzuki T, 1998, J CLIN PATHOL, V51, P13, DOI 10.1136/jcp.51.1.13; VAN MEIR EG, 1995, P NATL ACAD SCI USA, V92, P1008, DOI 10.1073/pnas.92.4.1008; VAN MEIR EG, 1994, NAT GENET, V8, P171, DOI 10.1038/ng1094-171; Volmer MW, 2005, PROTEOMICS, V5, P2587, DOI 10.1002/pmic.200401188; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579; Zigrino P, 2005, BIOCHIMIE, V87, P321, DOI 10.1016/j.biochi.2004.10.025	37	57	60	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7650	7661		10.1038/sj.onc.1209969	http://dx.doi.org/10.1038/sj.onc.1209969			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	17043663				2022-12-28	WOS:000242655500010
J	Timofeeva, OA; Plisov, S; Evseev, AA; Peng, S; Jose-Kampfner, M; Lovvorn, HN; Dome, JS; Perantoni, AO				Timofeeva, O. A.; Plisov, S.; Evseev, A. A.; Peng, S.; Jose-Kampfner, M.; Lovvorn, H. N.; Dome, J. S.; Perantoni, A. O.			Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis	ONCOGENE			English	Article						serine 727; STAT1; protein kinase CK2; MCL-1; HSP27; Wilms' tumor	PROTEIN-KINASE CK2; CHRONIC LYMPHOCYTIC-LEUKEMIA; TARGET GENE-EXPRESSION; SIGNAL TRANSDUCER; IFN-GAMMA; INTERFERON-GAMMA; INDUCED APOPTOSIS; CASEIN KINASE-2; CANCER-THERAPY; CELL LYMPHOMA	Wilms' tumor (WT), one of the most common pediatric solid cancers, arises in the developing kidney as a result of genetic and epigenetic changes that lead to the abnormal proliferation and differentiation of the metanephric blastema. As activation of signal transducers and activators of transcription (STATs) plays an important role in the maintenance/growth and differentiation of the metanephric blastema, and constitutively activated STATs facilitate neoplastic behaviors of a variety of cancers, we hypothesized that dysregulation of STAT signaling may also contribute to WT pathogenesis. Accordingly, we evaluated STAT phosphorylation patterns in tumors and found that STAT1 was constitutively phosphorylated on serine 727 (S727) in 19 of 21 primary WT samples and two WT cell lines. An inactivating mutation of S727 to alanine reduced colony formation of WT cells in soft agar by more than 80% and induced apoptosis under conditions of growth stress. S727-phosphorylated STAT1 provided apoptotic resistance for WT cells via upregulation of expression of the heat-shock protein (HSP) 27 and antiapoptotic protein myeloid cell leukemia (MCL)-1. The kinase responsible for STAT1 S727 phosphorylation in WT cells was identified based upon the use of selective inhibitors as protein kinase CK2, not p38, MAP-kinase kinase (MEK)1/2, phosphatidylinositol 3'-kinase, protein kinase C or Ca/calmodulin-dependent protein kinase II (CaMKII). The inhibition of CK2 blocked the anchorage-independent growth of WT cells and induced apoptosis under conditions of growth stress. Our findings suggest that serine-phosphorylated STAT1, as a downstream target of protein kinase CK2, plays a critical role in the pathogenesis of WT and possibly other neoplasms with similar STAT1 phosphorylation patterns.	NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, Frederick, MD 21702 USA; Vanderbilt Univ, Dept Pediat Surg, Nashville, TN USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University; St Jude Children's Research Hospital	Perantoni, AO (corresponding author), NCI, Lab Comparat Carcinogenesis, Canc Res Ctr, 1050 Boyless St,Bldg 538,R 205E, Frederick, MD 21702 USA.	peranton@ncifcrf.gov	Dome, Jeffrey/AAH-7825-2019		Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005093, ZIABC005093] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abril E, 1998, CANCER IMMUNOL IMMUN, V47, P113, DOI 10.1007/s002620050511; Barasch J, 1999, CELL, V99, P377, DOI 10.1016/S0092-8674(00)81524-X; Benekli M, 2003, BLOOD, V101, P2940, DOI 10.1182/blood-2002-04-1204; Bianchi L, 1999, NUCLEIC ACIDS RES, V27, P4223, DOI 10.1093/nar/27.21.4223; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Bromberg J, 2001, METHOD ENZYMOL, V333, P138; Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306; Danial NN, 2000, ONCOGENE, V19, P2523, DOI 10.1038/sj.onc.1203484; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dome JS, 2002, CURR OPIN PEDIATR, V14, P5, DOI 10.1097/00008480-200202000-00002; Ford HL, 2000, J BIOL CHEM, V275, P22245, DOI 10.1074/jbc.M002446200; Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869; Friedberg JW, 2004, LEUKEMIA RES, V28, P139, DOI 10.1016/S0145-2126(03)00213-3; Garrido C, 2003, CELL CYCLE, V2, P579, DOI 10.4161/cc.2.6.521; GESSLER M, 1994, HUM MUTAT, V3, P212, DOI 10.1002/humu.1380030307; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Heuvel GBV, 1996, KIDNEY INT, V50, P453, DOI 10.1038/ki.1996.336; Huang SY, 2002, ONCOGENE, V21, P2504, DOI 10.1038/sj.onc.1205341; Hudelist G, 2005, CANCER GENET CYTOGEN, V158, P35, DOI 10.1016/j.cancergencyto.2004.08.007; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Kabakov AE, 2003, CELL STRESS CHAPERON, V8, P335, DOI 10.1379/1466-1268(2003)008<0335:HSPOHS>2.0.CO;2; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100; Koesters R, 1999, CANCER RES, V59, P3880; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Levy DE, 2000, ONCOGENE, V19, P2505, DOI 10.1038/sj.onc.1203480; Lin WS, 2004, J NEUROSCI, V24, P10074, DOI 10.1523/JNEUROSCI.2604-04.2004; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; Maiti S, 2000, CANCER RES, V60, P6288; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Nair JS, 2002, P NATL ACAD SCI USA, V99, P5971, DOI 10.1073/pnas.052159099; Nishiu M, 2002, JPN J CANCER RES, V93, P894, DOI 10.1111/j.1349-7006.2002.tb01335.x; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Parcellier A, 2003, BIOCHEM BIOPH RES CO, V304, P505, DOI 10.1016/S0006-291X(03)00623-5; Plisov SY, 2001, DEVELOPMENT, V128, P1045; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Rigolet M, 2001, PEDIATR NEPHROL, V16, P1113, DOI 10.1007/s004670100040; Roberts D, 2005, BRIT J CANCER, V92, P1149, DOI 10.1038/sj.bjc.6602447; Ruteshouser EC, 2004, AM J MED GENET C, V129C, P29, DOI 10.1002/ajmg.c.30025; Santelli G, 1999, AM J PATHOL, V155, P799, DOI 10.1016/S0002-9440(10)65178-4; Sarno S, 2002, PHARMACOL THERAPEUT, V93, P159, DOI 10.1016/S0163-7258(02)00185-7; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sarto C, 2004, PROTEOMICS, V4, P2252, DOI 10.1002/pmic.200300797; Seldin DC, 2005, MOL CELL BIOCHEM, V274, P63, DOI 10.1007/s11010-005-3078-0; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Spiekermann K, 2001, EUR J HAEMATOL, V67, P63, DOI 10.1034/j.1600-0609.2001.t01-1-00385.x; STALTER G, 1994, BIOCHEM BIOPH RES CO, V202, P141, DOI 10.1006/bbrc.1994.1904; Stephanou A, 2003, INT J EXP PATHOL, V84, P239, DOI 10.1111/j.0959-9673.2003.00363.x; Stephanou A, 1999, J BIOL CHEM, V274, P1723, DOI 10.1074/jbc.274.3.1723; Stephanou A, 2001, J BIOL CHEM, V276, P28340, DOI 10.1074/jbc.M101177200; Stephanou A, 2000, J BIOL CHEM, V275, P10002, DOI 10.1074/jbc.275.14.10002; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; Terui K, 2004, BIOCHEM J, V380, P203, DOI 10.1042/BJ20031891; Unger GM, 2004, CURR CANCER DRUG TAR, V4, P77, DOI 10.2174/1568009043481687; Varinou L, 2003, IMMUNITY, V19, P793, DOI 10.1016/S1074-7613(03)00322-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; Wang GX, 2005, MOL CELL BIOCHEM, V274, P77, DOI 10.1007/s11010-005-3077-1; Widschwendter A, 2002, CLIN CANCER RES, V8, P3065; Xu WF, 2005, J INTERF CYTOK RES, V25, P113, DOI 10.1089/jir.2005.25.113; Yu J, 2004, CURR OPIN GENET DEV, V14, P550, DOI 10.1016/j.gde.2004.07.009; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963; Zien P, 2005, BBA-PROTEINS PROTEOM, V1754, P271, DOI 10.1016/j.bbapap.2005.07.039; Zykova TA, 2005, CARCINOGENESIS, V26, P331, DOI 10.1093/carcin/bgh334	70	73	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7555	7564		10.1038/sj.onc.1209742	http://dx.doi.org/10.1038/sj.onc.1209742			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16799645				2022-12-28	WOS:000242655500001
J	Clarke, AR				Clarke, A. R.			Wnt signalling in the mouse intestine	ONCOGENE			English	Review						Wnt; Apc; intestine	K-RAS ONCOGENE; BETA-CATENIN; COLORECTAL-CANCER; CELL DIFFERENTIATION; GENE-EXPRESSION; MAJOR MODIFIER; COLON-CANCER; SELF-RENEWAL; STEM-CELLS; E-CADHERIN	The Apc(Min/+) mouse has emerged as a powerful model of human intestinal tumour predisposition. As such, it has provided a platform for studying genetic and epigenetic modifiers of adenoma predisposition, and for assessing the chemotherapeutic potential of a plethora of different agents. The development of new conditional and hypomorphic Apc alleles, together with models carrying mutations in other Wnt pathway components, has greatly extended the scope of experimentation. Together these approaches are being used to identify and validate key critical targets of the Wnt pathway, such as Mash2, Tiam1 and the Eph/Ephrins. They have also established a fundamental role for Wnt in the development and maintenance of normal intestinal physiology, and in particular control of the stem cell niche. These activities are now being dissected at the level of individual Wnt components, with some surprising dependencies revealed. In terms of adenoma development, these models also support a 'just right' notion for tightly controlled beta-catenin activity both in normal physiology and neoplastic development. They also indicate a two-stage dependency for some Wnt pathway targets, with an initial requirement that is subsequently overcome to permit progression. Finally, these models establish that the Wnt pathway does not operate in isolation, and that both normal and diseased physiology develops in a dynamic interplay with other pathways such as the Notch, Hedgehog and BMP pathways. The comprehensive understanding arising from these studies should lead the identification of novel prognostic markers and therapeutic targets, and also open the possibility of tissue engineering in the intestine.	Cardiff Univ, Cardiff Sch Biosci, Cardiff CF10 3US, Wales	Cardiff University	Clarke, AR (corresponding author), Cardiff Univ, Cardiff Sch Biosci, Museum Ave, Cardiff CF10 3US, Wales.	clarkear@cf.ac.uk	Clarke, Alan R/A-6256-2008; clarke, alan r/P-2820-2014	Clarke, Alan/0000-0002-4281-426X	Medical Research Council [G0301154] Funding Source: Medline; MRC [G0301154] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alberici P, 2006, ONCOGENE, V25, P1841, DOI 10.1038/sj.onc.1209226; Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Andreu P, 2005, DEVELOPMENT, V132, P1443, DOI 10.1242/dev.01700; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bettess MD, 2005, MOL CELL BIOL, V25, P7868, DOI 10.1128/MCB.25.17.7868-7878.2005; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Chia IV, 2005, MOL CELL BIOL, V25, P4371, DOI 10.1128/MCB.25.11.4371-4376.2005; Corpet DE, 2003, CANCER EPIDEM BIOMAR, V12, P391; Corpet DE, 2005, EUR J CANCER, V41, P1911, DOI 10.1016/j.ejca.2005.06.006; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DORUDI S, 1993, AM J PATHOL, V142, P981; Eads CA, 2002, CANCER RES, V62, P1296; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Galceran J, 1999, GENE DEV, V13, P709, DOI 10.1101/gad.13.6.709; Giannakis M, 2006, J BIOL CHEM, V281, P11292, DOI 10.1074/jbc.M512118200; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Gregorieff A, 2004, EMBO J, V23, P1825, DOI 10.1038/sj.emboj.7600191; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gupta RA, 2004, NAT MED, V10, P245, DOI 10.1038/nm993; Hadjihannas MV, 2006, P NATL ACAD SCI USA, V103, P10747, DOI 10.1073/pnas.0604206103; Haines J, 2005, P NATL ACAD SCI USA, V102, P2868, DOI 10.1073/pnas.0500039102; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Hamamoto T, 2002, CANCER RES, V62, P5955; Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Holmberg J, 2006, CELL, V125, P1151, DOI 10.1016/j.cell.2006.04.030; Hsieh M, 2005, BIOL REPROD, V73, P1135, DOI 10.1095/biolreprod.105.042739; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Janssen KP, 2002, GASTROENTEROLOGY, V123, P492, DOI 10.1053/gast.2002.34786; Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Kim BM, 2005, DEV CELL, V8, P611, DOI 10.1016/j.devcel.2005.01.015; Kim KA, 2005, SCIENCE, V309, P1256, DOI 10.1126/science.1112521; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Leung SY, 2002, P NATL ACAD SCI USA, V99, P16203, DOI 10.1073/pnas.212646299; Li Q, 2005, CANCER RES, V65, P8622, DOI 10.1158/0008-5472.CAN-05-2145; Lickert H, 2000, DEVELOPMENT, V127, P3805; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Madison BB, 2005, DEVELOPMENT, V132, P279, DOI 10.1242/dev.01576; Malliri A, 2006, J BIOL CHEM, V281, P543, DOI 10.1074/jbc.M507582200; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Milano J, 2004, TOXICOL SCI, V82, P341, DOI 10.1093/toxsci/kfh254; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MILLS JC, 2002, GASTROENTEROLOGY, V125, P266; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Ogawa K, 2006, BIOCHEM BIOPH RES CO, V343, P159, DOI 10.1016/j.bbrc.2006.02.127; Ormestad M, 2006, DEVELOPMENT, V133, P833, DOI 10.1242/dev.02252; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Perreault N, 2005, GENE DEV, V19, P311, DOI 10.1101/gad.1260605; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103; Pretlow TP, 2003, AM J PATHOL, V163, P1757, DOI 10.1016/S0002-9440(10)63535-3; Prokhortchouk A, 2006, MOL CELL BIOL, V26, P199, DOI 10.1128/MCB.26.1.199-208.2006; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Reed KR, 2004, ONCOGENE, V23, P8992, DOI 10.1038/sj.onc.1208143; Reichling T, 2005, CANCER RES, V65, P166; Reitmair AH, 1996, CANCER RES, V56, P2922; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sansom OJ, 2005, J BIOL CHEM, V280, P28463, DOI 10.1074/jbc.M500191200; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Sansom OJ, 2006, P NATL ACAD SCI USA, V103, P14122, DOI 10.1073/pnas.0604130103; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Sieber OM, 2004, CANCER RES, V64, P8876, DOI 10.1158/0008-5472.CAN-04-2958; Silverman KA, 2002, GENOME RES, V12, P88, DOI 10.1101/gr.206002; Singla DK, 2006, BIOCHEM BIOPH RES CO, V345, P789, DOI 10.1016/j.bbrc.2006.04.125; Smits R, 2000, GASTROENTEROLOGY, V119, P1045, DOI 10.1053/gast.2000.18162; Smits R, 1997, CARCINOGENESIS, V18, P321, DOI 10.1093/carcin/18.2.321; Spring CM, 2005, EXP CELL RES, V305, P253, DOI 10.1016/j.yexcr.2005.01.007; Stappenbeck TS, 2003, P NATL ACAD SCI USA, V100, P1004, DOI 10.1073/pnas.242735899; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Takaku K, 1999, CANCER RES, V59, P6113; Takano-Maruyama M, 2006, AM J PHYSIOL-GASTR L, V291, pG163, DOI 10.1152/ajpgi.00019.2006; Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002; van Amerongen R, 2005, GENE DEV, V19, P425, DOI 10.1101/gad.326705; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van den Brink GR, 2004, NAT GENET, V36, P277, DOI 10.1038/ng1304; van Es JH, 2005, NAT CELL BIOL, V7, P381, DOI 10.1038/ncb1240; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Wilding J, 2002, CANCER RES, V62, P4562; Wong MH, 2002, J BIOL CHEM, V277, P15843, DOI 10.1074/jbc.M200184200; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504; Yamada Y, 2005, P NATL ACAD SCI USA, V102, P13580, DOI 10.1073/pnas.0506612102; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705; Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	102	58	68	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7512	7521		10.1038/sj.onc.1210065	http://dx.doi.org/10.1038/sj.onc.1210065			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143295				2022-12-28	WOS:000242514900009
J	Masuda, K; Richter, M; Song, X; Berezov, A; Masuda, K; Murali, R; Greene, MI; Zhang, H				Masuda, K.; Richter, M.; Song, X.; Berezov, A.; Masuda, K.; Murali, R.; Greene, M. I.; Zhang, H.			AHNP-streptavidin: a tetrameric bacterially produced antibody surrogate fusion protein against p185(her2/neu)	ONCOGENE			English	Article						AHNP; P185(her2/neu); streptavidin; tetramer	ESCHERICHIA-COLI; EXPRESSION; ONCOGENE; TUMOR; PHARMACOKINETICS; BIODISTRIBUTION; ADENOCARCINOMAS; PEPTIDES; C-ERBB-2; P185NEU	The anti-p185(her2/neu) peptidomimetic (AHNP) is a small exo-cyclic peptide derived from the anti-p185(her2/neu) rhumAb 4D5 (h4D5). AHNP mimics many but not all of the antitumor characteristics exhibited by h4D5. However, the pharmacokinetic profiles of AHNP are less than optimal for therapeutic or diagnostic purposes. To improve the binding affinity to p185(her2/neu) and the antitumor efficacy, we have engineered a fusion protein containing AHNP and a nonimmunoglobulin protein scaffold, streptavidin (SA). The recombinant protein, AHNP-SA (ASA) bound to p185(her2/neu) with high affinity, inhibited the proliferation of p185(her2/neu)-overexpressing cells, and reduced tumor growth induced by p185(her2/neu)-transformed cells. These data suggest that the bacterially produced tetrameric ASA can be used as an antibody-surrogate molecule. This class of molecule will play a role in the diagnosis and treatment of p185(her2/neu)-related tumors. Our studies establish a general principle by which a small biologically active synthetic exo-cyclic peptide can be engineered to enhance functional aspects by structured oligomerization and can be produced recombinantly using bacterial expression.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Greene, MI (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, 252 John Morgan Bldg,36th Hamilton Walk, Philadelphia, PA 19104 USA.	greene@reo.med.upenn.edu		Murali, Ramachandran/0000-0002-8384-2793; Zhang, Hongtao/0000-0001-9173-0049	NCI NIH HHS [5P01 CA 89480] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA089480] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berezov A, 2002, J BIOL CHEM, V277, P28330, DOI 10.1074/jbc.M202880200; Berezov A, 2001, J MED CHEM, V44, P2565, DOI 10.1021/jm000527m; BRUCK C, 1986, P NATL ACAD SCI USA, V83, P6578, DOI 10.1073/pnas.83.17.6578; Chinol M, 1998, BRIT J CANCER, V78, P189, DOI 10.1038/bjc.1998.463; COHEN JA, 1989, ONCOGENE, V4, P81; DI FP, 1987, CELL, V51, P1063; DREBIN JA, 1985, CELL, V41, P695, DOI 10.1016/S0092-8674(85)80050-7; DREBIN JA, 1984, NATURE, V312, P545, DOI 10.1038/312545a0; DREBIN JA, 1988, ONCOGENE, V2, P387; DREBIN JA, 1986, S FUND CANC RES, V381, P277; Farlow SJ, 2002, FEBS LETT, V516, P197, DOI 10.1016/S0014-5793(02)02565-6; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129; Jurado P, 2002, J MOL BIOL, V320, P1, DOI 10.1016/S0022-2836(02)00405-9; KALOFONOS HP, 1990, J NUCL MED, V31, P1791; KERN JA, 1990, CANCER RES, V50, P5184; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; KOKAI Y, 1988, PRINC TAK S, V191, P45; LODATO RF, 1990, MODERN PATHOL, V3, P449; Maynard J, 2000, ANNU REV BIOMED ENG, V2, P339, DOI 10.1146/annurev.bioeng.2.1.339; Meyer DL, 2001, PROTEIN SCI, V10, P491, DOI 10.1110/ps.19901; Murali R, 1998, IMMUNOL RES, V17, P163, DOI 10.1007/BF02786441; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; Proba K, 1997, J MOL BIOL, V265, P161, DOI 10.1006/jmbi.1996.0726; ROSEBROUGH SF, 1993, NUCL MED BIOL, V20, P663, DOI 10.1016/0969-8051(93)90037-U; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Sliwkowski MX, 1999, SEMIN ONCOL, V26, P60; WILLIAMS TM, 1991, PATHOBIOLOGY, V59, P46, DOI 10.1159/000163614; WILLIAMS WV, 1989, P NATL ACAD SCI USA, V86, P5537, DOI 10.1073/pnas.86.14.5537; Zhang HT, 2006, NAT MED, V12, P473, DOI 10.1038/nm1378	30	16	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7740	7746		10.1038/sj.onc.1209745	http://dx.doi.org/10.1038/sj.onc.1209745			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16785990				2022-12-28	WOS:000242830800008
J	Ko, K; Furukawa, K; Takahashi, T; Urano, T; Sanai, Y; Nagino, M; Nimura, Y; Furukawa, K				Ko, K.; Furukawa, K.; Takahashi, T.; Urano, T.; Sanai, Y.; Nagino, M.; Nimura, Y.; Furukawa, K.			Fundamental study of small interfering RNAs for ganglioside GD3 synthase gene as a therapeutic target of lung cancers	ONCOGENE			English	Article						small interfering RNA; GD3 synthase; lung cancer; GD2; ganglioside	DOUBLE-STRANDED-RNA; CELL-LINES; EXPRESSION; MELANOMA; INVASION; CLONING; MOTILITY; GROWTH	Gangliosides GD3 and GD2 are specifically expressed in neuro-ectoderm-derived tumors, and are considered to play roles in the malignant properties of those cells. We analysed effects of small interfering ( si) RNAs against GD3 synthase gene on the expression of ganglioside GD2 and biological phenotypes of human lung cancer cells expressing GD2. An siRNA could suppress the mRNA level of GD3 synthase gene even by single transfection, whereas repeated transfection was required to suppress GD2express ion on the cell surface. Significant reduction in the cell growth and invasion activity was observed in both lung cancer cell lines examined, when repeatedly transfected with the siRNA twice a week. DNA ladder formation was observed after third transfection, indicating the potent induction of apoptosis. Stable transfection of an RNAi expression vector with H1 RNA promoter was also examined. Transfectant cells with the RNAi expression vector showed almost equivalent suppression of GD2 expression and tumor properties in vitro. Furthermore, the stable transfectant cells showed slower cell growth than the control cells in severe combined immunodeficiency mice. These results suggested that siRNAs and/or RNAi expression vectors to generate siRNAs are promising approach to overcome human lung cancers.	Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Grad Sch Med, Dept Surg, Div Surg Oncol,Showa Ku, Nagoya, Aichi 4660065, Japan; Nagoya Univ, Grad Sch Med, Dept Mol Oncol, Showa Ku, Nagoya, Aichi 4660065, Japan; Tokyo Metropolitan Inst Med Sci, Dept Biochem Cell Res, Bunkyo Ku, Tokyo 113, Japan; Chubu Univ, Coll Life & Hlth Sci, Dept Biomed Sci, Kasugai, Aichi 487, Japan	Nagoya University; Nagoya University; Nagoya University; Tokyo Metropolitan Institute of Medical Science; Chubu University	Furukawa, K (corresponding author), Nagoya Univ, Grad Sch Med, Dept Biochem 2, Showa Ku, 65 Tsurumai, Nagoya, Aichi 4660065, Japan.	koichi@med.nagoya-u.ac.jp	Nagino, Masato/I-7342-2014; Takahashi, Takashi/I-7262-2014	Takahashi, Takashi/0000-0003-0615-7001; Urano, Takeshi/0000-0003-3383-3554				Aixinjueluo W, 2005, J BIOL CHEM, V280, P29828, DOI 10.1074/jbc.M414041200; Aoki H, 2004, FEBS LETT, V567, P203, DOI 10.1016/j.febslet.2004.04.060; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Barik S, 2004, ANN MED, V36, P540, DOI 10.1080/07853890410018817; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; CARUBIA JM, 1984, BIOCHEM BIOPH RES CO, V120, P500, DOI 10.1016/0006-291X(84)91282-8; Damstrup L, 1998, BRIT J CANCER, V78, P631, DOI 10.1038/bjc.1998.553; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P10231, DOI 10.1073/pnas.172380699; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; Hamamura K, 2005, P NATL ACAD SCI USA, V102, P11041, DOI 10.1073/pnas.0503658102; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; Hauck CR, 2002, EMBO J, V21, P6289, DOI 10.1093/emboj/cdf631; HOUGHTON AN, 1985, P NATL ACAD SCI USA, V82, P1242, DOI 10.1073/pnas.82.4.1242; Izquierdo M, 2005, CANCER GENE THER, V12, P217, DOI 10.1038/sj.cgt.7700791; Kojima Y, 2000, J BIOL CHEM, V275, P15152, DOI 10.1074/jbc.M909620199; Okada M, 1996, CANCER RES, V56, P2844; PORTOUKALIAN J, 1979, EUR J BIOCHEM, V94, P19, DOI 10.1111/j.1432-1033.1979.tb12866.x; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; SCHENGRUND CL, 1990, BRAIN RES BULL, V24, P131, DOI 10.1016/0361-9230(90)90297-D; Scherer L, 2004, CURR PHARM BIOTECHNO, V5, P355, DOI 10.2174/1389201043376724; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Yoshida S, 2001, CANCER RES, V61, P4244; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	29	27	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	52					6924	6935		10.1038/sj.onc.1209683	http://dx.doi.org/10.1038/sj.onc.1209683			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	101HQ	16862187				2022-12-28	WOS:000241732300003
J	Gilmore, TD; Herscovitch, M				Gilmore, T. D.; Herscovitch, M.			Inhibitors of NF-kappa B signaling: 785 and counting	ONCOGENE			English	Review						NF-kappa B; IKK; signal transduction; inhibition; inflammation; cancer therapy	FACTOR-INDUCED APOPTOSIS; NUCLEAR-LOCALIZATION SEQUENCE; NITRIC-OXIDE SYNTHASE; HUMAN MONOCYTIC CELLS; TRANSCRIPTION FACTOR; IN-VITRO; CYCLOSPORINE-A; KINASE-BETA; T-CELLS; EPITHELIAL-CELLS	Nuclear factor kappa B (NF-kappa B) transcription factors regulate several important physiological processes, including inflammation and immune responses, cell growth, apoptosis, and the expression of certain viral genes. Therefore, the NF-kappa B signaling pathway has also provided a focus for pharmacological intervention, primarily in situations of chronic inflammation or in cancer, where the pathway is often constitutively active and plays a key role in the disease. Now that many of the molecular details of the NF-kappa B pathway are known, it is clear that modulators of this pathway can act at several levels. As described herein, over 750 inhibitors of the NF-kappa B pathway have been identified, including a variety of natural and synthetic molecules. These compounds include antioxidants, peptides, small RNA/DNA, microbial and viral proteins, small molecules, and engineered dominant-negative or constitutively active polypeptides. Several of these molecules act as general inhibitors of NF-kappa B induction, whereas others inhibit specific pathways of induction. In addition, some compounds appear to target multiple steps in the NF-kappa B pathway. Compounds designed as specific NF-kappa B inhibitors are not yet in clinical use, but they are likely to be developed as treatments for certain cancers and neurodegenerative and inflammatory diseases. Moreover, the therapeutic and preventative effects of many natural products may, at least in part, be due to their ability to inhibit NF-kappa B.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu						Acarin L, 2000, NEUROSCI LETT, V288, P41, DOI 10.1016/S0304-3940(00)01202-7; Adams J, 2004, CANCER CELL, V5, P417, DOI 10.1016/S1535-6108(04)00120-5; AGGARWAL BB, 2006, IN PRESS BIOCH PHARM; Agou F, 2004, J BIOL CHEM, V279, P54248, DOI 10.1074/jbc.M406423200; Aguilera C, 2004, P NATL ACAD SCI USA, V101, P16537, DOI 10.1073/pnas.0404429101; Aravindan N, 2006, J CARDIOTHOR VASC AN, V20, P179, DOI 10.1053/j.jvca.2005.03.028; Azuma RW, 2004, CARDIOVASC RES, V64, P412, DOI 10.1016/j.cardiores.2004.09.014; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bentires-Alj M, 1999, CANCER RES, V59, P811; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Burke JR, 2003, J BIOL CHEM, V278, P1450, DOI 10.1074/jbc.M209677200; Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435; Camus-Bouclainville C, 2004, J VIROL, V78, P2510, DOI 10.1128/JVI.78.5.2510-2516.2004; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Catley MC, 2005, BRIT J PHARMACOL, V145, P114, DOI 10.1038/sj.bjp.0706170; Chang NS, 2002, J BIOL CHEM, V277, P10323, DOI 10.1074/jbc.M106607200; Choi SH, 2006, MOL CELL BIOL, V26, P3048, DOI 10.1128/MCB.26.8.3048-3059.2006; Collier-Hyams LS, 2002, J IMMUNOL, V169, P2846, DOI 10.4049/jimmunol.169.6.2846; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Crinelli R, 2004, CURR DRUG TARGETS, V5, P745, DOI 10.2174/1389450043345083; Cusack JC, 2001, CANCER RES, V61, P3535; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; di Meglio P, 2005, ARTHRITIS RHEUM-US, V52, P951, DOI 10.1002/art.20960; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIKSHIT P, 2006, J BIOL CHEM, V25, P6868; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Ehrlich LC, 1998, NEUROREPORT, V9, P1723, DOI 10.1097/00001756-199806010-00010; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; Fenteany G, 1998, J BIOL CHEM, V273, P8545, DOI 10.1074/jbc.273.15.8545; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; Fu DX, 2004, J BIOL CHEM, V279, P12819, DOI 10.1074/jbc.M312572200; Garcia-Pineres AJ, 2004, LIFE SCI, V75, P841, DOI 10.1016/j.lfs.2004.01.024; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; GLOIRE G, 2006, IN PRESS BIOCH PHARM; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Grimm S, 1996, J CELL BIOL, V134, P13, DOI 10.1083/jcb.134.1.13; Grisham MB, 1999, METHOD ENZYMOL, V300, P345; Hayakawa M, 2003, EMBO J, V22, P3356, DOI 10.1093/emboj/cdg332; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; HIGUCHI M, 1995, BLOOD, V86, P2248, DOI 10.1182/blood.V86.6.2248.bloodjournal8662248; Hirano F, 2003, INT IMMUNOPHARMACOL, V3, P225, DOI 10.1016/S1567-5769(02)00275-8; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ikezoe T, 2004, CANCER RES, V64, P7426, DOI 10.1158/0008-5472.CAN-03-2677; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Iordanskiy S, 2002, VIROLOGY, V302, P195, DOI 10.1006/viro.2002.1618; IQBAL M, 1995, J MED CHEM, V38, P2276, DOI 10.1021/jm00013a002; Isomura I, 2006, MICROBIOL IMMUNOL, V50, P559, DOI 10.1111/j.1348-0421.2006.tb03827.x; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Johanson V, 2005, NEUROENDOCRINOLOGY, V82, P171, DOI 10.1159/000091754; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kanegae Y, 1998, NATURE, V392, P611, DOI 10.1038/33429; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Khaled AR, 1998, CLIN IMMUNOL IMMUNOP, V86, P170, DOI 10.1006/clin.1997.4486; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; KUNZ D, 1995, BIOCHEM BIOPH RES CO, V216, P438, DOI 10.1006/bbrc.1995.2642; Kupatt C, 2002, GENE THER, V9, P518, DOI 10.1038/sj.gt.3301673; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lan CCE, 2005, BRIT J DERMATOL, V153, P725, DOI 10.1111/j.1365-2133.2005.06779.x; Lawrence DM, 2004, J VASC SURG, V40, P334, DOI 10.1016/j.jvs.2004.05.020; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Letoha T, 2005, WORLD J GASTROENTERO, V11, P990, DOI 10.3748/wjg.v11.i7.990; Li JJ, 2004, MED HYPOTHESES, V62, P499, DOI 10.1016/j.mehy.2003.12.014; Li JN, 2003, BIOCHEMISTRY-US, V42, P13476, DOI 10.1021/bi035390r; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Li Xu, 2005, World J Gastroenterol, V11, P4807; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Manna SK, 1998, J BIOL CHEM, V273, P13245, DOI 10.1074/jbc.273.21.13245; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Marienfeld R, 1997, EUR J IMMUNOL, V27, P1601, DOI 10.1002/eji.1830270703; Marquez N, 2005, ANTIVIR RES, V66, P137, DOI 10.1016/j.antiviral.2005.02.006; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; MCCAFFREY PG, 1994, NUCLEIC ACIDS RES, V22, P2134, DOI 10.1093/nar/22.11.2134; McCarty MF, 2006, INTEGR CANCER THER, V5, P252, DOI 10.1177/1534735406291499; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Meyer S, 1997, FEBS LETT, V413, P354, DOI 10.1016/S0014-5793(97)00930-7; Miyanohara T, 2000, LARYNGOSCOPE, V110, P126, DOI 10.1097/00005537-200001000-00023; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Na HK, 2006, MOL NUTR FOOD RES, V50, P152, DOI 10.1002/mnfr.200500154; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Nemeth ZH, 2004, MOL PHARMACOL, V65, P342, DOI 10.1124/mol.65.2.342; Neznanov N, 2005, J BIOL CHEM, V280, P24153, DOI 10.1074/jbc.M502303200; Nichols DB, 2006, J VIROL, V80, P578, DOI 10.1128/JVI.80.2.578-586.2006; Nishiyama S, 2005, INT IMMUNOPHARMACOL, V5, P699, DOI 10.1016/j.intimp.2004.11.018; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Olivier S, 2006, MOL PHARMACOL, V69, P1615, DOI 10.1124/mol.105.020479; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palayoor ST, 1998, CLIN CANCER RES, V4, P763; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pan Q, 2002, CANCER RES, V62, P4854; Pande V, 2005, CURR MED CHEM, V12, P357, DOI 10.2174/0929867053363180; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Powell PP, 1996, J VIROL, V70, P8527, DOI 10.1128/JVI.70.12.8527-8533.1996; Pu O, 2005, J HYPERTENS, V23, P401, DOI 10.1097/00004872-200502000-00023; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; Reddy SAG, 1997, J BIOL CHEM, V272, P29167, DOI 10.1074/jbc.272.46.29167; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Revilla Y, 1998, J BIOL CHEM, V273, P5405, DOI 10.1074/jbc.273.9.5405; REYNAERT NL, 2006, IN PRESS P NATL ACAD; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Ruan H, 2003, J BIOL CHEM, V278, P28181, DOI 10.1074/jbc.M303141200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sen CK, 1996, FEBS LETT, V385, P58, DOI 10.1016/0014-5793(96)00346-8; SEN J, 1995, J IMMUNOL, V154, P3213; SERFLING E, 1995, BBA-GENE STRUCT EXPR, V1263, P181, DOI 10.1016/0167-4781(95)00112-T; Severa M, 2005, BIOCHEM PHARMACOL, V69, P425, DOI 10.1016/j.bcp.2004.10.004; Shikama Y, 2003, EUR J IMMUNOL, V33, P1998, DOI 10.1002/eji.200324013; Shoji S, 1998, BIOCHEM BIOPH RES CO, V249, P745, DOI 10.1006/bbrc.1998.9221; Shumilla JA, 1998, ARCH BIOCHEM BIOPHYS, V349, P356, DOI 10.1006/abbi.1997.0470; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Song Xiao-yu R, 2002, Mol Interv, V2, P36, DOI 10.1124/mi.2.1.36; Swinney DC, 2002, J BIOL CHEM, V277, P23573, DOI 10.1074/jbc.M200842200; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Takigawa N, 2006, ANTICANCER RES, V26, P1869; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; TEPPER MA, 1995, J IMMUNOL, V155, P2427; Thoetkiattikul H, 2005, P NATL ACAD SCI USA, V102, P11426, DOI 10.1073/pnas.0505240102; Tomita N, 2003, CURR DRUG TARGETS, V4, P603, DOI 10.2174/1389450033490803; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Trepicchio WL, 1998, ANN NY ACAD SCI, V856, P12, DOI 10.1111/j.1749-6632.1998.tb08308.x; Uchiba M, 2004, THROMB HAEMOSTASIS, V92, P1420, DOI 10.1160/TH04-03-0139; Umezawa K, 2000, ANTI-CANCER DRUG DES, V15, P239; UMEZAWA K, 2006, IN PRESS CANC SCI; VAN AD, 1996, SCIENCE, V274, P787; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VENKATARAMAN L, 1995, J EXP MED, V181, P1091, DOI 10.1084/jem.181.3.1091; Wagner S, 2006, J MED CHEM, V49, P2241, DOI 10.1021/jm051125n; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; WECHSLER AS, 1994, J IMMUNOL, V153, P2515; Weiss T, 2004, ANTIMICROB AGENTS CH, V48, P1974, DOI 10.1128/AAC.48.6.1974-1982.2004; WEISSMANN G, 1991, HOSP PRACT, V26, P60; Weyrich AS, 2005, CIRCULATION, V111, P633, DOI 10.1161/01.CIR.0000154607.90506.45; Wolf AM, 2005, P NATL ACAD SCI USA, V102, P13622, DOI 10.1073/pnas.0501758102; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; YANG JP, 1995, FEBS LETT, V361, P89, DOI 10.1016/0014-5793(95)00157-5; Yao HW, 2004, ACTA PHARMACOL SIN, V25, P915; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yasuda H, 2006, EUR RESPIR J, V28, P51, DOI 10.1183/09031936.06.00058505; Yin MJ, 1998, NATURE, V396, P77, DOI 10.1038/23948; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang Siyuan, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P239, DOI 10.2174/1568011053765976; Zheng B, 2004, CLIN CANCER RES, V10, P3207, DOI 10.1158/1078-0432.CCR-03-0494; Zhou HL, 2005, J EXP MED, V202, P1327, DOI 10.1084/jem.20051194	172	457	482	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6887	6899		10.1038/sj.onc.1209982	http://dx.doi.org/10.1038/sj.onc.1209982			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072334				2022-12-28	WOS:000241666700014
J	Averous, J; Proud, CG				Averous, J.; Proud, C. G.			When translation meets transformation: the mTOR story	ONCOGENE			English	Review						apoptosis; mRNA translation; protein kinase; initiation; elongation; rapamycin	INITIATION-FACTOR 4E; ACTIVATED PROTEIN-KINASE; CAP-BINDING PROTEIN; MESSENGER-RNA TRANSPORT; AMINO-ACIDS; S6 KINASE; CYCLIN D1; ELONGATION-FACTOR-2 KINASE; MAMMALIAN TARGET; FACTOR EIF4E	There is currently a high level of interest in signalling through the mammalian target of rapamycin ( mTOR). This reflects both its key role in many cell functions and its involvement in disease states such as cancers. The best understood targets for mTOR signalling are proteins involved in controlling the translational machinery, including the ribosomal protein S6 kinases and proteins that regulate the initiation and elongation phases of translation. Indeed, there is compelling evidence that at least one of these targets of mTOR ( eukaryotic initiation factor eIF4E) plays a key role in tumorigenesis. It is regulated through the mTOR-dependent phosphorylation of inhibitory proteins such as eIF4E-binding protein 1. Thus, targeting mTOR signalling may be an effective anticancer strategy, in at least a significant subset of tumours. Not all effects of mTOR are sensitive to the classical anti-mTOR drug rapamycin, and this compound also interferes with other processes besides eIF4E function. Developing new approaches to targeting mTOR for cancer therapy requires more detailed knowledge of signalling downstream of mTOR. Such advances are likely to come from further work to understand the regulation of mTOR targets such as components of the translational apparatus.	Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; INRA, Unite Nutr Humaine, St Genes Champanelle, France	University of British Columbia; INRAE	Proud, CG (corresponding author), Univ British Columbia, Life Sci Ctr, Dept Biochem & Mol Biol, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	cgpr@interchange.ubc.ca		Proud, Christopher/0000-0003-0704-6442				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ali SM, 2005, J BIOL CHEM, V280, P19445, DOI 10.1074/jbc.C500125200; Arora S, 2003, CANCER RES, V63, P6894; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Avruch J, 2001, Prog Mol Subcell Biol, V26, P115; BAGAGLIO DM, 1994, CELL GROWTH DIFFER, V5, P1403; BAGAGLIO DM, 1993, CANCER RES, V53, P2260; Barlund M, 2000, CANCER RES, V60, P5340; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Bradley CA, 2002, J BIOL CHEM, V277, P12559, DOI 10.1074/jbc.M111134200; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Browne GJ, 2002, EUR J BIOCHEM, V269, P5360, DOI 10.1046/j.1432-1033.2002.03290.x; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Byrd MP, 2005, J BIOL CHEM, V280, P18610, DOI 10.1074/jbc.M414014200; Calastretti A, 2001, EUR J CANCER, V37, P2121, DOI 10.1016/S0959-8049(01)00256-8; Calastretti A, 2001, ONCOGENE, V20, P6172, DOI 10.1038/sj.onc.1204751; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CHENG EHC, 1995, CELL GROWTH DIFFER, V6, P615; Choo AY, 2006, CANCER CELL, V9, P77, DOI 10.1016/j.ccr.2006.01.021; Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544; Cohen N, 2001, EMBO J, V20, P4547, DOI 10.1093/emboj/20.16.4547; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; Constantinou C, 2005, ONCOGENE, V24, P4839, DOI 10.1038/sj.onc.1208648; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dostie J, 2000, EMBO J, V19, P3142, DOI 10.1093/emboj/19.12.3142; DSARBASSOV D, 2006, MOL CELL, V22, P159; Eberle J, 1997, INT J CANCER, V71, P396, DOI 10.1002/(SICI)1097-0215(19970502)71:3<396::AID-IJC16>3.0.CO;2-E; Fang P, 2006, EXP CELL RES, V312, P1229, DOI 10.1016/j.yexcr.2005.12.011; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Ferguson G, 2003, J BIOL CHEM, V278, P47459, DOI 10.1074/jbc.M307949200; Ferraiuolo MA, 2005, J CELL BIOL, V170, P913, DOI 10.1083/jcb.200504039; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004; FLYNN A, 1995, J BIOL CHEM, V270, P21684, DOI 10.1074/jbc.270.37.21684; FukuchiShimogori T, 1997, CANCER RES, V57, P5041; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Gingras AC, 2001, GENE DEV, V15, P2852; Graff JR, 2003, CLIN EXP METASTAS, V20, P265, DOI 10.1023/A:1022943419011; GRESSNER AM, 1974, BIOCHEM BIOPH RES CO, V60, P1482, DOI 10.1016/0006-291X(74)90365-9; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Hait WN, 2006, CLIN CANCER RES, V12, P1961, DOI 10.1158/1078-0432.CCR-06-0011; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Houghton PJ, 2003, CURR TOP MICROBIOL, V279, P339; Hui AS, 2006, FASEB J, V20, P466, DOI 10.1096/fj.05-5086com; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; JOSHI B, 1995, J BIOL CHEM, V270, P14597, DOI 10.1074/jbc.270.24.14597; Kentsis A, 2001, J MOL BIOL, V312, P609, DOI 10.1006/jmbi.2001.5003; Kimball SR, 2006, J NUTR, V136, p227S, DOI 10.1093/jn/136.1.227S; Klampfer L, 2006, CURR CANCER DRUG TAR, V6, P107, DOI 10.2174/156800906776056491; Kleijn M, 2002, FEBS LETT, V532, P319, DOI 10.1016/S0014-5793(02)03694-3; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; Koh H, 1999, ONCOGENE, V18, P5115, DOI 10.1038/sj.onc.1202895; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li S, 2003, J BIOL CHEM, V278, P3015, DOI 10.1074/jbc.M208821200; Li SN, 2004, J BIOL CHEM, V279, P21312, DOI 10.1074/jbc.M312467200; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; Ng G, 2005, MOL CARCINOGEN, V43, P183, DOI 10.1002/mc.20097; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; O'Loghlen A, 2004, EXP CELL RES, V299, P343, DOI 10.1016/j.yexcr.2004.06.006; Parmer TG, 1999, BRIT J CANCER, V79, P59, DOI 10.1038/sj.bjc.6690012; Parmer TG, 1997, CELL GROWTH DIFFER, V8, P327; Parra JL, 2005, J BIOL CHEM, V280, P37623, DOI 10.1074/jbc.M508356200; Parra-Palau JL, 2003, J BIOL CHEM, V278, P44197, DOI 10.1074/jbc.M302398200; Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Polunovsky VA, 1996, MOL CELL BIOL, V16, P6573; Polunovsky VA, 2000, J BIOL CHEM, V275, P24776, DOI 10.1074/jbc.M001938200; Proud CG, 2005, CELL DEATH DIFFER, V12, P541, DOI 10.1038/sj.cdd.4401588; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Redpath NT, 1996, EMBO J, V15, P2291, DOI 10.1002/j.1460-2075.1996.tb00582.x; Rousseau D, 1996, ONCOGENE, V13, P2415; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Ryazanov AG, 1997, P NATL ACAD SCI USA, V94, P4884, DOI 10.1073/pnas.94.10.4884; Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scheper GC, 2003, MOL CELL BIOL, V23, P5692, DOI 10.1128/MCB.23.16.5692-5705.2003; Scheper GC, 2002, EUR J BIOCHEM, V269, P5350, DOI 10.1046/j.1432-1033.2002.03291.x; Scheper GC, 2002, J BIOL CHEM, V277, P3303, DOI 10.1074/jbc.M103607200; Scheper GC, 2001, MOL CELL BIOL, V21, P743, DOI 10.1128/MCB.21.3.743-754.2001; Schmidt EV, 2004, ONCOGENE, V23, P3217, DOI 10.1038/sj.onc.1207548; Shuda M, 2000, ANTICANCER RES, V20, P2489; Slepenkov SV, 2006, J BIOL CHEM, V281, P14927, DOI 10.1074/jbc.M601653200; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Strudwick S, 2002, DIFFERENTIATION, V70, P10, DOI 10.1046/j.1432-0436.2002.700102.x; Surace EI, 2004, ANN NEUROL, V56, P295, DOI 10.1002/ana.20201; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Tee AR, 2001, CELL DEATH DIFFER, V8, P841, DOI 10.1038/sj.cdd.4400876; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Tomoo K, 2005, BBA-PROTEINS PROTEOM, V1753, P191, DOI 10.1016/j.bbapap.2005.07.023; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069; Topisirovic I, 2002, MOL CELL BIOL, V22, P6183, DOI 10.1128/MCB.22.17.6183-6198.2002; Tuhackova Z, 1999, INT J CANCER, V81, P963, DOI 10.1002/(SICI)1097-0215(19990611)81:6<963::AID-IJC20>3.0.CO;2-C; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7; Zhou HY, 2006, ENDOCRINOLOGY, V147, P2557, DOI 10.1210/en.2005-1404; Zuberek J, 2004, BIOCHEMISTRY-US, V43, P5370, DOI 10.1021/bi030266t; Zuberek J, 2003, RNA, V9, P52, DOI 10.1261/rna.2133403	134	153	162	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6423	6435		10.1038/sj.onc.1209887	http://dx.doi.org/10.1038/sj.onc.1209887			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041627				2022-12-28	WOS:000241380700008
J	Cereghetti, GM; Scorrano, L				Cereghetti, G. M.; Scorrano, L.			The many shapes of mitochondrial death	ONCOGENE			English	Review						mitochondria; cytochrome c release; fusion; fission; cristae; apoptosis	DOMINANT OPTIC ATROPHY; DYNAMIN-RELATED PROTEIN; CYTOCHROME-C RELEASE; MARIE-TOOTH NEUROPATHY; PROGRAMMED CELL-DEATH; ENDOPLASMIC-RETICULUM; OPA1 GENE; GTPASE ACTIVITY; OUTER-MEMBRANE; BAX ACTIVATION	Mitochondria integrate apoptotic signalling by releasing cytochrome c and other proapoptotic cofactors needed for activation of effector caspases. Previously overlooked morphological changes, mitochondrial fragmentation and cristae remodelling, emerged as subroutines of the mitochondrial programme of apoptosis in mammalian cells, as well as in developmental cell death of Caenorhabditis elegans. Mitochondrial morphology results from fusion and fission processes, controlled by a growing set of 'mitochondria-shaping' proteins. Their levels and function appear to influence mitochondrial pathways of cell death, but mechanisms are largely unknown. An emerging model implicates different signals converging on mitochondria-shaping proteins to activate or deactivate them during apoptosis. In turn, the se proteins can orchestrate changes in mitochondrial shape to insure cytochrome c release and progression of the apoptotic cascade. These therefore appear an appealing novel therapeutic target to modulate cell death in cancer.	Venetian Inst Mol Med, Dulbecco Telethon Inst, I-35129 Padua, Italy	Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine	Scorrano, L (corresponding author), Venetian Inst Mol Med, Dulbecco Telethon Inst, Via Orus 2, I-35129 Padua, Italy.	luca.scorrano@unipd.it	Scorrano, Luca/K-3967-2019; Scorrano, Luca/A-6652-2008	Scorrano, Luca/0000-0002-8515-8928; Scorrano, Luca/0000-0002-8515-8928	Telethon [TCP02016] Funding Source: Medline	Telethon(Fondazione Telethon)		Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944; Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681; Arnoult D, 2005, CURR BIOL, V15, P2112, DOI 10.1016/j.cub.2005.10.041; Arnoult D, 2005, J BIOL CHEM, V280, P35742, DOI 10.1074/jbc.M505970200; Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200; Bassik MC, 2004, EMBO J, V23, P1207, DOI 10.1038/sj.emboj.7600104; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; CEREGHETTI GM, 2006, UNPUB; Chami M, 2004, J BIOL CHEM, V279, P54581, DOI 10.1074/jbc.M409663200; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen KH, 2004, NAT CELL BIOL, V6, P872, DOI 10.1038/ncb1161; Chung JG, 2001, CANCER RES, V61, P8873; Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101; CIPOLAT S, 2006, UNPUB; Claeys K, 2005, J PERIPHER NERV SYST, V10, P16; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; De Vos KJ, 2005, CURR BIOL, V15, P678, DOI 10.1016/j.cub.2005.02.064; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278; Delettre C, 2001, HUM GENET, V109, P584, DOI 10.1007/s00439-001-0633-y; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Ferre M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1; FREZZA C, 2006, UNPUB; Germain M, 2005, EMBO J, V24, P1546, DOI 10.1038/sj.emboj.7600592; Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200; Harder Z, 2004, CURR BIOL, V14, P340, DOI 10.1016/j.cub.2004.02.004; Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2004, J CELL BIOL, V166, P1027, DOI 10.1083/jcb.200407046; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Li C, 2002, P NATL ACAD SCI USA, V99, P9830, DOI 10.1073/pnas.152571899; Liston P, 2003, ONCOGENE, V22, P8568, DOI 10.1038/sj.onc.1207101; LIU JP, 1994, SCIENCE, V265, P970, DOI 10.1126/science.8052858; Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488; Marchbank NJ, 2002, J MED GENET, V39, DOI 10.1136/jmg.39.8.e47; McNiven MA, 2000, MOL BIOL CELL, V11, p219A; Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612; Meeusen SL, 2005, CURR OPIN CELL BIOL, V17, P389, DOI 10.1016/j.ceb.2005.06.014; MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315; Mozdy AD, 2000, J CELL BIOL, V151, P367, DOI 10.1083/jcb.151.2.367; Neuspiel M, 2005, J BIOL CHEM, V280, P25060, DOI 10.1074/jbc.M501599200; Nutt LK, 2002, J BIOL CHEM, V277, P20301, DOI 10.1074/jbc.M201604200; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Pacher P, 2001, EMBO J, V20, P4107, DOI 10.1093/emboj/20.15.4107; Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005; Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Satoh M, 2003, BIOCHEM BIOPH RES CO, V300, P482, DOI 10.1016/S0006-291X(02)02874-7; Scorrano L, 2005, J BIOENERG BIOMEMBR, V37, P165, DOI 10.1007/s10863-005-6572-x; Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Shimizu S, 2002, JPN J OPHTHALMOL, V46, P336, DOI 10.1016/S0021-5155(02)00484-7; Sik A, 2004, J BIOL CHEM, V279, P15323, DOI 10.1074/jbc.M313756200; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sugioka R, 2004, J BIOL CHEM, V279, P52726, DOI 10.1074/jbc.M408910200; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; Szabadkai G, 2004, MOL CELL, V16, P59, DOI 10.1016/j.molcel.2004.09.026; Thiselton DL, 2002, INVEST OPHTH VIS SCI, V43, P1715; Thiselton DL, 2001, HUM GENET, V109, P498, DOI 10.1007/s004390100600; Toomes C, 2001, HUM MOL GENET, V10, P1369, DOI 10.1093/hmg/10.13.1369; Varadi A, 2004, J CELL SCI, V117, P4389, DOI 10.1242/jcs.01299; Yaffe MP, 1999, SCIENCE, V283, P1493, DOI 10.1126/science.283.5407.1493; Yoon Y, 2001, MOL BIOL CELL, V12, P2894, DOI 10.1091/mbc.12.9.2894; Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Yu TZ, 2005, J CELL SCI, V118, P4141, DOI 10.1242/jcs.02537; Zhang PJ, 2001, NAT CELL BIOL, V3, P922, DOI 10.1038/ncb1001-922; Zuchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341	87	107	110	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4717	4724		10.1038/sj.onc.1209605	http://dx.doi.org/10.1038/sj.onc.1209605			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892085				2022-12-28	WOS:000239687000009
J	Kroemer, G				Kroemer, G.			Mitochondria in cancer	ONCOGENE			English	Editorial Material							CELL-DEATH	Prominent features of cancer cells include metabolic imbalances and enhanced resistance to mitochondrial apoptosis. The fact that tumors rely heavily on glycolysis to meet their metabolic demands has been recognized since the beginning of the twentieth century, yet a complete elucidation of the so-called Warburg effect has not been achieved. Several mechanisms have been proposed to explain this phenomenon, including the upregulation of rate-limiting steps of glycolysis, the accumulation of mutations in the mitochondrial genome, the hypoxia-induced switch from mitochondrial respiration to glycolysis or the metabolic reprogramming resulting from the loss-of-function of enzymes like fumarate and succinate dehydrogenases. How aerobic glycolysis and apoptosis resistance are linked remains to be elucidated. On the one hand, these alterations may be acquired independently by cancer cells during multistep oncogenesis. On the other hand, the suppression of the intrinsic apoptotic program may be achieved through mechanisms that directly lead to the Warburg phenotype. Cancer-specific mitochondrial alterations and bioenergetics may be taken advantage for the development of two novel classes of antineoplastic agents. A first approach would target glycolysis and/or revert the Warburg phenomenon, whereas a second approach would aim at inducing apoptosis by targeting mitochondrial proteins and membranes. In both instances, encouraging pre-clinical results have been obtained.	Inst Gustave Roussy, CNRS, FRE2939, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, CNRS, FRE2939, Rue Camille Desmoulins, F-94800 Villejuif, France.		KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; 				Alirol E, 2006, ONCOGENE, V25, P4706, DOI 10.1038/sj.onc.1209600; Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604; Cheng WC, 2006, ONCOGENE, V25, P4697, DOI 10.1038/sj.onc.1209596; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Fontenay M, 2006, ONCOGENE, V25, P4757, DOI 10.1038/sj.onc.1209606; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602; Pelicano H, 2006, ONCOGENE, V25, P4633, DOI 10.1038/sj.onc.1209597; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Warburg O. H., 1930, METABOLISM TUMOURS I; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	21	155	178	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4630	4632		10.1038/sj.onc.1209589	http://dx.doi.org/10.1038/sj.onc.1209589			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892077				2022-12-28	WOS:000239687000001
J	Schagdarsurengin, U; Pfeifer, GP; Dammann, R				Schagdarsurengin, U.; Pfeifer, G. P.; Dammann, R.			Frequent epigenetic inactivation of cystatin M in breast carcinoma	ONCOGENE			English	Article						cystatin M; tumour suppressor gene; epigenetic inactivation; methylation; breast cancer; CST6	CYSTEINE PROTEINASE-INHIBITOR; SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; PROMOTER HYPERMETHYLATION; MALIGNANT PHENOTYPE; CANCER; ASSOCIATION; PROGRESSION; EXPRESSION	Cystatin M is a potent endogenous inhibitor of lysosomal cysteine proteases. In breast carcinoma, cystatin M expression is frequently downregulated. It has been shown that cystatin M expression suppressed growth and migration of breast cancer cells. We examined the methylation status of the CpG island promoter of cystatin M in four breast cancer cell lines ( MDAMB231, ZR75-1, MCF7 and T47D), in 40 primary breast carcinoma and in corresponding normal tissue probes by combined bisulphite restriction analysis. To investigate the effects of cystatin M expression on the growth of breast carcinoma, cystatin M was transfected in T47D. The cystatin M promoter was highly methylated in all four-breast cancer cell lines. Primary breast tumours were significantly more frequently methylated compared to normal tissue samples ( 60 vs 25%; P = 0.006 Fisher's exact test). Treatment of breast cancer cells with 5-aza-2'-deoxycytidine ( 5-Aza-CdR), reactivated the transcription of cystatin M. Transfection of breast carcinoma cells with cystatin M caused a 30% decrease in colony formation compared to control transfection ( P = 0.002). Our results show that cystatin M is frequently epigenetically inactivated during breast carcinogenesis and cystatin M expression suppresses the growth of breast carcinoma. These data suggest that cystatin M may encode a novel epigenetically inactivated candidate tumour suppressor gene.	Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, D-06097 Halle, Germany; City Hope Canc Ctr, Beckman Res Inst, Dept Biol, Duarte, CA USA	Martin Luther University Halle Wittenberg; City of Hope; Beckman Research Institute of City of Hope	Dammann, R (corresponding author), Univ Halle Wittenberg, Fac Med, Inst Human Genet, AWG Tumour Genet, Magdeburger Str 2, D-06097 Halle, Germany.	reinhard.dammann@medizin.uni-halle.de	Schagdarsurengin, Undraga/AAH-4346-2020; Schagdarsurengin, Undraga/AAH-4312-2020	Schagdarsurengin, Undraga/0000-0003-0127-4938	NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abrahamson M, 2003, BIOCHEM SOC SYMP, V70, P179, DOI 10.1042/bss0700179; Ahuja N, 2000, HISTOL HISTOPATHOL, V15, P835, DOI 10.14670/HH-15.835; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; CALKINS CC, 1995, BIOL CHEM H-S, V376, P71; Cheng T, 2006, J BIOL CHEM, V281, P15893, DOI 10.1074/jbc.M600694200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; Guo MZ, 2004, CLIN CANCER RES, V10, P5131, DOI 10.1158/1078-0432.CCR-03-0763; Haider AS, 2006, J INVEST DERMATOL, V126, P869, DOI 10.1038/sj.jid.5700157; Henskens YMC, 1996, BIOL CHEM H-S, V377, P71; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Krepela E, 2001, NEOPLASMA, V48, P332; Lah TT, 1998, BIOL CHEM, V379, P125; Ni J, 1997, J BIOL CHEM, V272, P10853; Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1; Shridhar R, 2004, ONCOGENE, V23, P2206, DOI 10.1038/sj.onc.1207340; Song J, 2006, BIOCHEM BIOPH RES CO, V340, P175, DOI 10.1016/j.bbrc.2005.11.171; Sotiropoulou G, 1997, J BIOL CHEM, V272, P903, DOI 10.1074/jbc.272.2.903; Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698; Stenman G, 1997, CYTOGENET CELL GENET, V76, P45, DOI 10.1159/000134512; Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005; Vigneswaran N, 2003, ORAL ONCOL, V39, P559, DOI 10.1016/S1368-8375(03)00038-1; Waki T, 2003, ONCOGENE, V22, P4128, DOI 10.1038/sj.onc.1206651; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Zeeuwen PLJM, 2004, EUR J CELL BIOL, V83, P761, DOI 10.1078/0171-9335-00388; Zeeuwen PLJM, 2002, BRIT J DERMATOL, V147, P87, DOI 10.1046/j.1365-2133.2002.04785.x; Zhang J, 2004, CANCER RES, V64, P6957, DOI 10.1158/0008-5472.CAN-04-0819	31	30	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3089	3094		10.1038/sj.onc.1210107	http://dx.doi.org/10.1038/sj.onc.1210107			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099723				2022-12-28	WOS:000246395400014
J	Toualbi, K; Guller, MC; Mauriz, JL; Labalette, C; Buendia, MA; Mauviel, A; Bernuau, D				Toualbi, K.; Guller, M. C.; Mauriz, J-L; Labalette, C.; Buendia, M-A; Mauviel, A.; Bernuau, D.			Physical and functional cooperation between AP-1 and beta-catenin for the regulation of TCF-dependent genes	ONCOGENE			English	Article						AP-1; beta-catenin; Fos; Jun; cyclin D1; hepatoma cells	GROWTH-FACTOR-BETA; ONLY PROTEIN FHL2; C-FOS EXPRESSION; NF-KAPPA-B; CYCLIN D1; TRANSCRIPTIONAL COACTIVATOR; SIGNALING PATHWAY; MESENCHYMAL TRANSITION; BINDING PROTEIN; ACTIVATION	Stabilization of cytoplasmic beta-catenin is a hallmark of a variety of cancers. The stabilized beta-catenin is able to translocate to the nucleus, where it acts as a transcriptional activator of T-cell factor (TCF)-regulated genes. beta-Catenin may cross-talk with many signalling cascades to activate target genes. Whether beta-catenin cooperates with AP-1, another transcriptional complex activated during tumorigenesis is not fully clarified. We show that alpha-catenin co-immunoprecipitates with c-Jun and c- os. GST pull-down experiments indicate a physical association of the armadillo repeat domain of b-catenin with the DNA-binding domain of c-Jun and of the C-terminal domain of beta- catenin with the N-terminal domain of c-Fos. Promoter studies indicate that overexpression of AP-1 activates the transcription of two beta-catenin target genes, cyclin D1 and c-myc, by a mechanism independent of the AP-1 site, and fully dependent on the TCF-binding site. We further demonstrate that AP-1/beta-catenin synergism is involved during serum-induced cyclin D1 transcriptional activation. We identify a TCF-binding site on the cyclin D1 promoter which binds in vivo a complex induced by serum, containing beta- catenin, TCF4, c-Fos, c-Jun, JunB and JunD. This novel mechanism of interaction between two signalling cascades might contribute to the potentiation of malignancy.	INSERM, U697, Paris, France; Univ Paris 07, Paris, France; Inst Pasteur, Unite Recombinaison & Express Genet, Paris, France; INSERM, U163, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bernuau, D (corresponding author), Hop St Louis, Unite INSERM, U 697, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	bernuau@stlouis.inserm.fr	Mauriz, Jose L/G-9970-2014; MAUVIEL, Alain/F-6251-2013	Mauriz, Jose L/0000-0003-3160-8599; Mauviel, Alain/0000-0002-0438-2793				Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; Chakladar A, 2005, BIOCHEM BIOPH RES CO, V336, P190, DOI 10.1016/j.bbrc.2005.08.061; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Eger A, 2004, ONCOGENE, V23, P2672, DOI 10.1038/sj.onc.1207416; Eger A, 2000, J CELL BIOL, V148, P173, DOI 10.1083/jcb.148.1.173; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Esufali S, 2004, ONCOGENE, V23, P8260, DOI 10.1038/sj.onc.1208007; Ferrara P, 2003, ONCOGENE, V22, P1461, DOI 10.1038/sj.onc.1206266; Ferrigno O, 2002, ONCOGENE, V21, P4879, DOI 10.1038/sj.onc.1205623; Fialka I, 1996, J CELL BIOL, V132, P1115, DOI 10.1083/jcb.132.6.1115; GIESE K, 1993, EMBO J, V12, P4667, DOI 10.1002/j.1460-2075.1993.tb06155.x; Grueneberg DA, 2003, MOL CELL BIOL, V23, P3936, DOI 10.1128/MCB.23.11.3936-3950.2003; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Iavarone C, 2003, J BIOL CHEM, V278, P50024, DOI 10.1074/jbc.M308617200; Ishikawa T, 2000, MOL CELL ENDOCRINOL, V164, P77, DOI 10.1016/S0303-7207(00)00241-0; Iwahashi H, 2000, J IMMUNOL, V164, P5403, DOI 10.4049/jimmunol.164.10.5403; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Rahmani M, 2001, ONCOGENE, V20, P5132, DOI 10.1038/sj.onc.1204678; Rivat C, 2003, FASEB J, V17, P1721, DOI 10.1096/fj.03-0132fje; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sasaki T, 2003, CANCER RES, V63, P801; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; SIMONSON MS, 1994, EXP CELL RES, V215, P137, DOI 10.1006/excr.1994.1325; Sparks AB, 1998, CANCER RES, V58, P1130; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Zhurinsky J, 2000, J CELL SCI, V113, P3127	52	64	67	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2007	26	24					3492	3502		10.1038/sj.onc.1210133	http://dx.doi.org/10.1038/sj.onc.1210133			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146436				2022-12-28	WOS:000246799200005
J	Cho, DH; Lee, HJ; Kim, HJ; Hong, SH; Pyo, JO; Cho, C; Jung, YK				Cho, D.-H.; Lee, H.-J.; Kim, H.-J.; Hong, S.-H.; Pyo, J.-O.; Cho, C.; Jung, Y.-K.			Suppression of hypoxic cell death by APIP-induced sustained activation of AKT and ERK1/2	ONCOGENE			English	Article						APIP; hypoxia; ERK1/2; AKT; caspase-9	GLUCOSE-METABOLISM; PHOSPHORYLATION; INHIBITION; CASPASE-9; PROTEIN; PATHWAY; TARGET	Apaf-1-interacting protein (APIP) was previously isolated as an inhibitor of mitochondrial cell death interacting with Apaf-1. Here, we report a hypoxia-selective antiapoptotic activity of APIP that induces the activation of AKT and extracellular signal-regulated kinase (ERK) 1/2. Stable expression of APIP in C2C12 (C2C12/APIP) cells suppressed cell death induced by hypoxia and etoposide. Unlike etoposide, however, APIP induces the sustained activation of AKT and ERK1/2 and the phosphorylation of caspase-9 during hypoxia. Inhibition of AKT and ERK1/2 activation by the treatments with phosphatidylinositol 3'-kinase and mitogen-activated protein kinase kinase (MEK) 1/2 inhibitors sensitized C2C12/APIP cells to hypoxic cell death and abolished the hypoxia-induced phosphorylation of caspase-9. Further, overexpression of phosphorylation-mimic caspase-9 mutants (caspase-9-T125E and caspase-9-S196D), but not phosphorylation-defective caspase-9 mutants (caspase-9-T125A and caspase-9-S196A), effectively suppressed hypoxia-induced death of C2C12 cells. These results elucidate a novel Apaf-1-independent antiapoptotic activity of APIP during hypoxic cell death, inducing the sustained activation of AKT and ERK1/2 and leading to caspase- 9 phosphorylation.	Seoul Natl Univ, Sch Biol Sci, Bio Max Inst, Seoul 151747, South Korea; Gwangju Inst Sci & Technol, Dept Life Sci, Kwangju, South Korea	Seoul National University (SNU); Gwangju Institute of Science & Technology (GIST)	Jung, YK (corresponding author), Seoul Natl Univ, Sch Biol Sci, Bio Max Inst, Seoul 151747, South Korea.	ykjung@snu.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jung, Yong-Keun/0000-0002-9686-3120				Allan LA, 2003, NAT CELL BIOL, V5, P647, DOI 10.1038/ncb1005; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen EY, 2001, CANCER RES, V61, P2429; Chen J, 2003, AM J PATHOL, V162, P1283, DOI 10.1016/S0002-9440(10)63924-7; Cho DH, 2004, J BIOL CHEM, V279, P39942, DOI 10.1074/jbc.M405747200; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Jiang ZJ, 2002, BIOCHEM BIOPH RES CO, V294, P726, DOI 10.1016/S0006-291X(02)00540-5; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Mottet D, 2003, J CELL PHYSIOL, V194, P30, DOI 10.1002/jcp.10176; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; Yanez AJ, 2005, J CELL PHYSIOL, V202, P743, DOI 10.1002/jcp.20183	14	31	32	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2809	2814		10.1038/sj.onc.1210080	http://dx.doi.org/10.1038/sj.onc.1210080			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17086211				2022-12-28	WOS:000246210600016
J	Saintigny, Y; Delacote, F; Boucher, D; Averbeck, D; Lopez, BS				Saintigny, Y.; Delacote, F.; Boucher, D.; Averbeck, D.; Lopez, B. S.			XRCC4 in G1 suppresses homologous recombination in S/G2, in G1 checkpoint-defective cells	ONCOGENE			English	Article						double strand break; non homologous end joining; homologous recombination; cell cycle; mammalian cell	DOUBLE-STRAND BREAKS; DNA-LIGASE-IV; MAMMALIAN RAD51; V(D)J RECOMBINATION; INDUCED REPLICATION; GENOMIC STABILITY; REPAIR PATHWAYS; BACKUP PATHWAYS; NUCLEAR FOCI; S-PHASE	Non-homologous end joining (NHEJ) and homologous recombination (HR) are two pathways that can compete or cooperate for DNA double-strand break (DSB) repair. NHEJ was previously shown to act throughout the cell cycle whereas HR is restricted to late S/G2. Paradoxically, we show here that defect in XRCC4 (NHEJ) leads to over-stimulation of HR when cells were irradiated in G1, not in G2. However, XRCC4 defect did not modify the strict cell cycle regulation for HR (i.e. in S/G2) as attested by (i) the formation of Rad51 foci in late S/G2 whatever the XRCC4 status, and (ii) the fact that neither Rad51 foci nor HR (gene conversion plus single-strand annealing) events induced by ionizing radiation were detected when cells were maintained blocked in G1. Finally, both gamma-H2AX analysis and pulse field gel electrophoresis showed that following irradiation in G1, some DSBs reached S/G2 in NHEJ-defective cells. Taken together, our results show that when cells are defective in G1/S arrest, DSB produced in G1 and left unrepaired by XRCC4 can be processed by HR but in late S/G2.	CEA, CNRS, UMR 217, F-92265 Fontenay Aux Roses, France; Ctr Univ, Inst Curie, CNRS, UMR 2027,Sect Rech, F-91405 Orsay, France	CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Lopez, BS (corresponding author), CEA, CNRS, UMR 217, 18 Route Panorama,BP6, F-92265 Fontenay Aux Roses, France.	bernard.lopez@cea.fr	Saintigny, Yannick/C-2697-2008; Lopez, Bernard S/O-7308-2017	Saintigny, Yannick/0000-0002-3839-3562; Lopez, Bernard S/0000-0001-5088-0155; Boucher, Didier/0000-0002-7964-0881				Aladjem MI, 1998, CURR BIOL, V8, P145, DOI 10.1016/S0960-9822(98)70061-2; Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899; AMOR M, 1988, P NATL ACAD SCI USA, V85, P1600, DOI 10.1073/pnas.85.5.1600; Aten JA, 2004, SCIENCE, V303, P92, DOI 10.1126/science.1088845; Audebert M, 2004, J BIOL CHEM, V279, P55117, DOI 10.1074/jbc.M404524200; Ausubel F., 1999, CURRENT PROTOCOLS MO; BELMAAZA A, 1990, NUCLEIC ACIDS RES, V18, P6385, DOI 10.1093/nar/18.21.6385; BELMAAZA A, 1994, MUTAT RES, V314, P199, DOI 10.1016/0921-8777(94)90065-5; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Bertrand P, 2003, ONCOGENE, V22, P7587, DOI 10.1038/sj.onc.1206998; Boucher D, 2004, CAN J PHYSIOL PHARM, V82, P125, DOI 10.1139/Y04-006; BROUILLETTE S, 1987, MOL CELL BIOL, V7, P2248, DOI 10.1128/MCB.7.6.2248; CHEONG N, 1994, MUTAT RES, V314, P77, DOI 10.1016/0921-8777(94)90063-9; Cohen PE, 2001, BIOESSAYS, V23, P996, DOI 10.1002/bies.1145; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Difilippantonio MJ, 2000, NATURE, V404, P510, DOI 10.1038/35006670; Esashi F, 2005, NATURE, V434, P598, DOI 10.1038/nature03404; FABRE F, 1984, MOL GEN GENET, V195, P139, DOI 10.1007/BF00332736; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Ferguson DO, 2000, COLD SPRING HARB SYM, V65, P395, DOI 10.1101/sqb.2000.65.395; Guirouilh-Barbat J, 2004, MOL CELL, V14, P611, DOI 10.1016/j.molcel.2004.05.008; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; Hinz JM, 2005, DNA REPAIR, V4, P782, DOI 10.1016/j.dnarep.2005.03.005; Ira G, 2004, NATURE, V431, P1011, DOI 10.1038/nature02964; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; JEGGO PA, 1990, MUTAT RES, V239, P1, DOI 10.1016/0165-1110(90)90028-A; JEGGO PA, 1995, BIOESSAYS, V17, P949, DOI 10.1002/bies.950171108; Johnson RD, 2000, EMBO J, V19, P3398, DOI 10.1093/emboj/19.13.3398; Jung D, 2004, CELL, V116, P299, DOI 10.1016/S0092-8674(04)00039-X; KADYK LC, 1992, GENETICS, V132, P387; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kraus E, 2001, P NATL ACAD SCI USA, V98, P8255, DOI 10.1073/pnas.151008198; Lambert S, 2000, EMBO J, V19, P3090, DOI 10.1093/emboj/19.12.3090; Lee SE, 1997, MOL CELL BIOL, V17, P1425, DOI 10.1128/MCB.17.3.1425; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Malkova A, 2005, MOL CELL BIOL, V25, P933, DOI 10.1128/MCB.25.3.933-944.2005; Mills KD, 2004, GENE DEV, V18, P1283, DOI 10.1101/gad.1204304; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; Raderschall E, 1999, P NATL ACAD SCI USA, V96, P1921, DOI 10.1073/pnas.96.5.1921; Redon C, 2002, CURR OPIN GENET DEV, V12, P162, DOI 10.1016/S0959-437X(02)00282-4; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2000, MOL CELL BIOL, V20, P9068, DOI 10.1128/MCB.20.23.9068-9075.2000; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Rothstein R, 2000, GENE DEV, V14, P1; Saintigny Y, 2001, EMBO J, V20, P3861, DOI 10.1093/emboj/20.14.3861; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; STAMATO TD, 1988, RADIAT RES, V115, P325, DOI 10.2307/3577168; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tashiro S, 2000, J CELL BIOL, V150, P283, DOI 10.1083/jcb.150.2.283; Vanasse GJ, 1999, J CLIN INVEST, V103, P1669, DOI 10.1172/JCI6658; Wang HC, 2005, CANCER RES, V65, P4020, DOI 10.1158/0008-5472.CAN-04-3055; Wang HC, 2001, NUCLEIC ACIDS RES, V29, P1653, DOI 10.1093/nar/29.8.1653; Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	63	25	27	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2769	2780		10.1038/sj.onc.1210075	http://dx.doi.org/10.1038/sj.onc.1210075			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057732	Green Published			2022-12-28	WOS:000246210600011
J	Sharif, A; Legendre, P; Prevot, V; Allet, C; Romao, L; Studler, JM; Chneiweiss, H; Junier, MP				Sharif, A.; Legendre, P.; Prevot, V.; Allet, C.; Romao, L.; Studler, J.-M.; Chneiweiss, H.; Junier, M.-P.			Transforming growth factor a promotes sequential conversion of mature astrocytes into neural progenitors and stem cells	ONCOGENE			English	Article						erbB1; differentiation; radial glia; gliogenesis; oncogenesis; EGFR	RADIAL GLIAL-CELLS; FACTOR-ALPHA; TGF-ALPHA; MOUSE; DIFFERENTIATION; EXPRESSION; PROTEIN; RECEPTOR; NEURONS; NESTIN	An instability of the mature cell phenotype is thought to participate to the formation of gliomas, primary brain tumors deriving from astrocytes and/or neural stem cells. Transforming growth factor alpha (TGF alpha) is an erbB1 ligand overexpressed in the earliest stages of gliomas, and exerts trophic effects on gliomal cells and astrocytes. Here, we questioned whether prolonged TGF alpha exposure affects the stability of the normal mature astrocyte phenotype. We first developed astrocyte cultures devoid of residual neural stem cells or progenitors. We demonstrate that days of TGF alpha treatment result in the functional conversion of a population of mature astrocytes into radial glial cells, a population of neural progenitors. TGF alpha-generated radial glial cells support embryonic neurons migration, and give birth to cells of the neuronal lineage, expressing neuronal markers and the electrophysiological properties of neuroblasts. Lengthening TGF alpha treatment to months results in the delayed appearance of cells with neural stem cells properties: they form floating cellular spheres that are self-renewing, can be clonally derived from a single cell and differentiated into cells of the neuronal lineage. This study uncovers a novel population of mature astrocytes capable, in response to a single epigenetic factor, to regress progressively into a neural stem-like cell stage via an intermediate progenitor stage.	INSERM, U752, Coll France, F-75005 Paris, France; INSERM, U114, F-75005 Paris, France; Univ Paris 05, Paris, France; Univ Paris 06, CNRS, UMR 7102, Paris, France; INSERM, U816, F-59045 Lille, France; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, Rio De Janeiro, Brazil	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade Federal do Rio de Janeiro	Junier, MP (corresponding author), INSERM, U752, Coll France, 11 Pl Marcelin Berthelot, F-75005 Paris, France.	marie-pierre.junier@college-de-france.fr	Romao, Luciana/I-4291-2015; Prevot, Vincent/E-5720-2016; Sharif, Ariane/AGW-8363-2022; herve, chneiweiss/Q-6818-2019	Prevot, Vincent/0000-0001-7185-3615; herve, chneiweiss/0000-0001-7675-5061; Sharif, Ariane/0000-0003-0810-400X; ALLET, Cecile/0000-0003-1294-9064				Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bahrey HLP, 2003, CEREB CORTEX, V13, P239, DOI 10.1093/cercor/13.3.239; BIGNAMI A, 1974, NATURE, V252, P55, DOI 10.1038/252055a0; Burrows RC, 1997, NEURON, V19, P251, DOI 10.1016/S0896-6273(00)80937-X; Chanas-Sacre G, 2000, DEV DYNAM, V219, P514, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1078>3.0.CO;2-0; Dai C, 2003, CANCER J, V9, P72, DOI 10.1097/00130404-200303000-00002; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Feldman DH, 1996, EXP NEUROL, V140, P206, DOI 10.1006/exnr.1996.0130; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Figiel M, 2003, EXP NEUROL, V183, P124, DOI 10.1016/S0014-4886(03)00134-1; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; FRISEN J, 1995, J CELL BIOL, V131, P453, DOI 10.1083/jcb.131.2.453; Fukuda S, 2003, J NEUROSCI, V23, P9357; Fukuda S, 2004, CELL DEATH DIFFER, V11, P196, DOI 10.1038/sj.cdd.4401332; Gregg C, 2003, J NEUROSCI, V23, P11587; Hack MA, 2004, MOL CELL NEUROSCI, V25, P664, DOI 10.1016/j.mcn.2003.12.012; Hadjantonakis AK, 1998, MECH DEVELOP, V76, P79, DOI 10.1016/S0925-4773(98)00093-8; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harris H, 2004, NATURE, V427, P201, DOI 10.1038/427201a; Imura T, 2006, GLIA, V53, P277, DOI 10.1002/glia.20281; Imura T, 2003, J NEUROSCI, V23, P2824; Jung M, 1998, EUR J NEUROSCI, V10, P3246, DOI 10.1046/j.1460-9568.1998.00344.x; Junier MP, 2000, PROG NEUROBIOL, V62, P443, DOI 10.1016/S0301-0082(00)00017-4; KRESSIN K, 1995, GLIA, V15, P173, DOI 10.1002/glia.440150210; Kriegstein AR, 2003, GLIA, V43, P37, DOI 10.1002/glia.10250; Laywell ED, 2000, P NATL ACAD SCI USA, V97, P13883, DOI 10.1073/pnas.250471697; Leavitt BR, 1999, EXP NEUROL, V157, P43, DOI 10.1006/exnr.1999.6982; LEE DC, 1995, PHARMACOL REV, V47, P51; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Liu B, 2004, DEV BIOL, V273, P297, DOI 10.1016/j.ydbio.2004.06.006; Marshall CAG, 2005, J NEUROSCI, V25, P7289, DOI 10.1523/JNEUROSCI.1924-05.2005; Miller S, 1996, J NEUROCHEM, V67, P1435; Muroyama Y, 2005, NATURE, V438, P360, DOI 10.1038/nature04139; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Pekny M, 1998, EXP CELL RES, V239, P332, DOI 10.1006/excr.1997.3922; Prevot V, 2005, ENDOCRINOLOGY, V146, P1465, DOI 10.1210/en.2004-1146; Raff M, 2003, ANNU REV CELL DEV BI, V19, P1, DOI 10.1146/annurev.cellbio.19.111301.143037; Rakic P, 2003, GLIA, V43, P19, DOI 10.1002/glia.10244; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Scherer SS, 1997, CURR OPIN NEUROL, V10, P386, DOI 10.1097/00019052-199710000-00006; Seaberg RM, 2005, DEV BIOL, V278, P71, DOI 10.1016/j.ydbio.2004.10.017; Sharif A, 2006, ONCOGENE, V25, P4076, DOI 10.1038/sj.onc.1209443; Sharif A, 2004, NEUROSCIENCE, V126, P263, DOI 10.1016/j.neuroscience.2004.02.039; SHARIF A, 2006, M SOC NEUR ATL US OC; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Sun Y, 2005, NEURON, V45, P873, DOI 10.1016/j.neuron.2005.01.045; Sutherland ML, 1996, J NEUROSCI, V16, P2191; Tropepe V, 1999, DEV BIOL, V208, P166, DOI 10.1006/dbio.1998.9192; Verkhratsky A, 2000, BRAIN RES REV, V32, P380, DOI 10.1016/S0165-0173(99)00093-4; Wagner B, 2006, EMBO J, V25, P752, DOI 10.1038/sj.emboj.7600988; Wechsler-Reya R, 2001, ANNU REV NEUROSCI, V24, P385, DOI 10.1146/annurev.neuro.24.1.385; Zhou RX, 2001, BRAIN RES BULL, V56, P37, DOI 10.1016/S0361-9230(01)00591-3	54	63	70	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2695	2706		10.1038/sj.onc.1210071	http://dx.doi.org/10.1038/sj.onc.1210071			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057735				2022-12-28	WOS:000246210600004
J	Barrier, A; Roser, F; Boelle, PY; Franc, B; Tse, C; Brault, D; Lacaine, F; Houry, S; Callard, P; Penna, C; Debuire, B; Flahault, A; Dudoit, S; Lemoine, A				Barrier, A.; Roser, F.; Boelle, P-Y; Franc, B.; Tse, C.; Brault, D.; Lacaine, F.; Houry, S.; Callard, P.; Penna, C.; Debuire, B.; Flahault, A.; Dudoit, S.; Lemoine, A.			Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling	ONCOGENE			English	Article						functional genomics; colon cancer; prognosis prediction; non neoplastic mucosa; cross validation; cDNA arrays	TRANSMEMBRANE-4 SUPERFAMILY; T-CELLS; TUMOR; METASTASIS; MICROARRAYS; PREDICTION; CD24	We have assessed the possibility to build a prognosis predictor (PP), based on non-neoplastic mucosa microarray gene expression measures, for stage II colon cancer patients. Non-neoplastic colonic mucosa mRNA samples from 24 patients (10 with a metachronous metastasis, 14 with no recurrence) were pro. led using the Affymetrix HGU133A GeneChip. Patients were repeatedly and randomly divided into 1000 training sets (TSs) of size 16 and validation sets (VS) of size 8. For each TS/VS split, a 70-gene PP, identified on the TS by selecting the 70 most differentially expressed genes and applying diagonal linear discriminant analysis, was used to predict the prognoses of VS patients. Mean prognosis prediction performances of the 70-gene PP were 81.8% for accuracy, 73.0% for sensitivity and 87.1% for specific city. Informative genes suggested branching signal-transduction pathways with possible extensive networks between individual pathways. They also included genes coding for proteins involved in immune surveillance. In conclusion, our study suggests that one can build an accurate PP for stage II colon cancer patients, based on non-neoplastic mucosa microarray gene expression measures.	Hop Paul Brousse, AP HP, Serv Biochim, F-94804 Villejuif, France; Hop Tenon, AP HP, Serv Chirurg Digest, F-75970 Paris, France; INSERM, UMR S707, Paris, France; Univ Paris 06, Fac Med, F-75252 Paris 05, France; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; INSERM, UMR S602, Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France; Hop Ambroise Pare, AP HP, Serv Anat Pathol, Boulogne, France; Univ Versailles, Fac Med, Boulogne, France; Hop Tenon, AP HP, Serv Biochim, F-75970 Paris, France; Hop Tenon, AP HP, Serv Anat Pathol, F-75970 Paris, France; Hop Ambroise Pare, AP HP, Serv Chirurg Digest, Boulogne, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of California System; University of California Berkeley; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Lemoine, A (corresponding author), Hop Paul Brousse, AP HP, Serv Biochim, 12 Ave Paul Vaillant Couturier, F-94804 Villejuif, France.	antoinette.lemoine@pbr.ap-hop-paris.fr		Boelle, Pierre-Yves/0000-0002-5367-8232				Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Arango D, 2005, GASTROENTEROLOGY, V129, P874, DOI 10.1053/j.gastro.2005.06.066; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Barrier A, 2005, ONCOGENE, V24, P6155, DOI 10.1038/sj.onc.1208984; BARRIER A, 2006, IN PRESS J CLIN ONCO, V24; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bolstad BM, 2005, STAT BIOL HEALTH, P13; Dudoit S, 2002, J AM STAT ASSOC, V97, P77, DOI 10.1198/016214502753479248; Dudoit S, 2005, STAT METHODOL, V2, P131, DOI [10.1016/j.stamet.2005.02.003, DOI 10.1016/J.STAMET.2005.02.003]; Figueredo A, 2004, J CLIN ONCOL, V22, P3395, DOI 10.1200/JCO.2004.03.087; Hashida H, 2003, BRIT J CANCER, V89, P158, DOI 10.1038/sj.bjc.6601015; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kitahara O, 2001, CANCER RES, V61, P3544; Kristiansen G, 2004, J MOL HISTOL, V35, P255; Li O, 2004, J EXP MED, V200, P1083, DOI 10.1084/jem.20040779; Mazzocca A, 2002, J HEPATOL, V37, P322, DOI 10.1016/S0168-8278(02)00175-7; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Notterman DA, 2001, CANCER RES, V61, P3124; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Schindelmann S, 2002, TUMOR BIOL, V23, P139, DOI 10.1159/000064030; Tanaka T, 2004, ONCOGENE, V23, P3980, DOI 10.1038/sj.onc.1207555; Wang YX, 2004, J CLIN ONCOL, V22, P1564, DOI 10.1200/JCO.2004.08.186; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	26	44	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2642	2648		10.1038/sj.onc.1210060	http://dx.doi.org/10.1038/sj.onc.1210060			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043639				2022-12-28	WOS:000245831200011
J	Cotroneo, MS; Haag, JD; Zan, Y; Lopez, CC; Thuwajit, P; Petukhova, GV; Camerini-Otero, RD; Gendron-Fitzpatrick, A; Griep, AE; Murphy, CJ; Dubielzig, RR; Gould, MN				Cotroneo, M. S.; Haag, J. D.; Zan, Y.; Lopez, C. C.; Thuwajit, P.; Petukhova, G. V.; Camerini-Otero, R. D.; Gendron-Fitzpatrick, A.; Griep, A. E.; Murphy, C. J.; Dubielzig, R. R.; Gould, M. N.			Characterizing a rat Brca2 knockout model	ONCOGENE			English	Article						Brca2; knockout; rat; carcinogenesis; tumors	DOUBLE-STRAND BREAKS; DNA-REPAIR; SYNAPTONEMAL COMPLEX; MEIOTIC CHROMOSOMES; MICE; RECOMBINATION; LOCALIZATION; RADIATION; CANCER; SUSCEPTIBILITY	Evidence exists that BRCA2 carriers may have an elevated risk of breast, ovarian, colon, prostate, and pancreatic cancer. In general, carriers are defined as individuals with protein truncating mutations within the BRCA2 gene. Many Brca2 knockout lines have been produced and characterized in the mouse. We previously produced a rat Brca2 knockout strain in which there is a nonsense mutation in exon 11 between BRC repeats 2 and 3, and a truncated protein is produced. Interestingly, while such a mutation in homozygous mice would lead to limited survival of approximately 3 months, the Brca2(-/-) rats are 100% viable and the vast majority live to over 1 year of age. Brca2(-/-) rats show a phenotype of growth inhibition and sterility in both sexes. Aspermatogenesis in the Brca2(-/-) rats is due to a failure of homologous chromosome synapsis. Long-term phenotypes include underdeveloped mammary glands, cataract formation and lifespan shortening due to the development of tumors and cancers in multiple organs. The establishment of the rat Brca2 knockout model provides a means to study the role of Brca2 in increasing cancer susceptibility and inducing a novel ocular phenotype not previously associated with this gene.	Univ Wisconsin, Canc Res Lab, Madison, WI 53706 USA; NIDDK, Genet & Biochem Branch, NIH, Bethesda, MD USA; Univ Wisconsin, Res Anim Resource Ctr, Comparat Pathol Lab, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Anat, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, Canc Res Lab, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Thuwajit, Peti/AAD-1014-2021; Gould, Michael N/C-7414-2014	Thuwajit, Peti/0000-0003-0798-1510	NATIONAL CANCER INSTITUTE [R01CA106216] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK052008, Z01DK052033, ZIADK052033] Funding Source: NIH RePORTER; NCI NIH HHS [CA106216] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allers T, 2001, CELL, V106, P47, DOI 10.1016/S0092-8674(01)00416-0; Barlow C, 1998, DEVELOPMENT, V125, P4007; Bignell G, 1997, HUM MOL GENET, V6, P53, DOI 10.1093/hmg/6.1.53; Bigsby RM, 1999, P NATL ACAD SCI USA, V96, P9328, DOI 10.1073/pnas.96.16.9328; Bork P, 1996, NAT GENET, V13, P22, DOI 10.1038/ng0596-22; BRENNER S, 1981, J CELL BIOL, V91, P95, DOI 10.1083/jcb.91.1.95; BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863; Connor F, 1997, NAT GENET, V17, P423, DOI 10.1038/ng1297-423; Cucinotta FA, 2001, RADIAT RES, V156, P460, DOI 10.1667/0033-7587(2001)156[0460:SRACIA]2.0.CO;2; Davies AA, 2001, MOL CELL, V7, P273, DOI 10.1016/S1097-2765(01)00175-7; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Dynlacht JR, 2006, RADIAT RES, V165, P9, DOI 10.1667/RR3481.1; Eijpe M, 2000, CHROMOSOMA, V109, P123, DOI 10.1007/s004120050420; Elliott B, 2002, CELL MOL LIFE SCI, V59, P373, DOI 10.1007/s00018-002-8429-3; Friedman LS, 1998, CANCER RES, V58, P1338; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; Hunter N, 2001, CELL, V106, P59, DOI 10.1016/S0092-8674(01)00430-5; Keeney S, 2001, CURR TOP DEV BIOL, V52, P1, DOI 10.1016/S0070-2153(01)52008-6; Klein BEK, 1998, ARCH OPHTHALMOL-CHIC, V116, P219, DOI 10.1001/archopht.116.2.219; Liu JG, 1996, EXP CELL RES, V226, P11, DOI 10.1006/excr.1996.0197; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; McAllister KA, 2002, CANCER RES, V62, P990; McAllister KA, 2006, TOXICOL PATHOL, V34, P187, DOI 10.1080/01926230600611794; Moens PB, 1998, CURR TOP DEV BIOL, V37, P241; Mohr U., 1994, PATHOBIOLOGY AGING R, V2; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nakazawa M, 2001, EXP ANIM TOKYO, V50, P99, DOI 10.1538/expanim.50.99; Pellegrini L, 2004, TRENDS BIOCHEM SCI, V29, P310, DOI 10.1016/j.tibs.2004.04.009; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Samuelson DJ, 2003, CARCINOGENESIS, V24, P1455, DOI 10.1093/carcin/bgg112; Sarkisian CJ, 2001, J BIOL CHEM, V276, P37640, DOI 10.1074/jbc.M106281200; Schulze W, 1999, HUM REPROD, V14, P82, DOI 10.1093/humrep/14.suppl_1.82; Sharan SK, 2004, DEVELOPMENT, V131, P131, DOI 10.1242/dev.00888; Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008; Siaud N, 2004, EMBO J, V23, P1392, DOI 10.1038/sj.emboj.7600146; Villeneuve AM, 2001, CELL, V106, P647, DOI 10.1016/S0092-8674(01)00500-1; WORGUL BV, 1991, MUTAGENESIS, V6, P495, DOI 10.1093/mutage/6.6.495; Worgul BV, 2002, P NATL ACAD SCI USA, V99, P9836, DOI 10.1073/pnas.162349699; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zan YH, 2003, NAT BIOTECHNOL, V21, P645, DOI 10.1038/nbt830; Zhoucun A, 2006, EUR J OBSTET GYN R B, V124, P61, DOI 10.1016/j.ejogrb.2005.09.001; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603; Zierhut D, 2000, INT J RADIAT ONCOL, V46, P131, DOI 10.1016/S0360-3016(99)00354-5	43	23	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1626	1635		10.1038/sj.onc.1209960	http://dx.doi.org/10.1038/sj.onc.1209960			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964288				2022-12-28	WOS:000244782500012
J	Jones, RA; Campbell, CI; Gunther, EJ; Chodosh, LA; Petrik, JJ; Khokha, R; Moorehead, RA				Jones, R. A.; Campbell, C. I.; Gunther, E. J.; Chodosh, L. A.; Petrik, J. J.; Khokha, R.; Moorehead, R. A.			Transgenic overexpression of IGF-IR disrupts mammary ductal morphogenesis and induces tumor formation	ONCOGENE			English	Article						IGF-IR; transgenic mice; mammary tumorigenesis; mammary development	GROWTH-FACTOR-I; BREAST-CANCER; GENE-EXPRESSION; FACTOR RECEPTOR; INSULIN; ACTIVATION; STAT3; MICE; RISK; PROLIFERATION	Overexpression and hyperactivation of the type I insulin-like growth factor receptor (IGF-IR) has been observed in human breast tumor biopsies. In addition, in vitro studies indicate that overexpression of IGF-IR is sufficient to transform cells such as mouse embryo fibroblasts and this receptor promotes proliferation and survival in breast cancer cell lines. To fully understand the function of the IGF-IR in tumor initiation and progression, transgenic mice containing human IGF-IR under a doxycycline-inducible MMTV promoter system were generated. Administration of 2 mg/ml doxycycline in the animals' water supply beginning at 21 days of age resulted in elevated levels of IGF-IR in mammary epithelial cells as detected by Western blotting and immunohistochemistry. Whole mount analysis of 55-day-old mouse mammary glands revealed that IGF-IR overexpression significantly impaired ductal elongation. Moreover, histological analyses revealed multiple hyperplasic lesions in the mammary glands of these 55-day-old mice. The formation of palpable mammary tumors was evident at approximately 2 months of age and was associated with increased levels of IGF-IR signaling molecules including phosphorylated Akt, Erk1/Erk2 and STAT3. Therefore, these transgenic mice provide evidence that IGF-IR overexpression is sufficient to induce mammary epithelial hyperplasia and tumor formation in vivo and provide a model to further understand the function of IGF-IR in mammary epithelial transformation.	Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada; Penn State Hershey Med Sch, Hershey, PA USA; Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Toronto, Princess Margaret Hosp, Hlth Network, Toronto, ON, Canada	University of Guelph; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Pennsylvania; Pennsylvania Medicine; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Moorehead, RA (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Room 3605, Guelph, ON N1G 2W1, Canada.	rmoorehe@uoguelph.ca		, Roger/0000-0001-9539-6295; Jones, Robert/0000-0001-7665-9301				Adams TE, 2004, GROWTH FACTORS, V22, P89, DOI 10.1080/08977190410001700998; Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; BATES P, 1995, BRIT J CANCER, V72, P1189, DOI 10.1038/bjc.1995.484; Berclaz G, 2001, INT J ONCOL, V19, P1155; Bonnette SG, 2001, ENDOCRINOLOGY, V142, P4937, DOI 10.1210/en.142.11.4937; Butler AA, 1998, CANCER RES, V58, P3021; Carboni JM, 2005, CANCER RES, V65, P3781, DOI 10.1158/0008-5472.CAN-04-4602; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Clarke M, 1998, LANCET, V351, P1451; Cowin P, 2005, CURR OPIN CELL BIOL, V17, P499, DOI 10.1016/j.ceb.2005.08.014; Diaz N, 2006, CLIN CANCER RES, V12, P20, DOI 10.1158/1078-0432.CCR-04-1749; El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559; ELLIS MJC, 1994, BREAST CANCER RES TR, V31, P249, DOI 10.1007/BF00666158; Giani C, 1996, BREAST CANCER RES TR, V41, P43, DOI 10.1007/BF01807035; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hadsell DL, 2000, ONCOGENE, V19, P889, DOI 10.1038/sj.onc.1203386; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Helle SI, 1996, ACTA ONCOL, V35, P19, DOI 10.3109/02841869609083963; Kumar R, 2005, CANCER RES, V65, P2511, DOI 10.1158/0008-5472.CAN-05-0189; Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001; Li L, 2002, J BIOL CHEM, V277, P17397, DOI 10.1074/jbc.M109962200; Linnerth NM, 2005, INT J CANCER, V114, P977, DOI 10.1002/ijc.20814; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Moorehead RA, 2001, CELL DEATH DIFFER, V8, P16, DOI 10.1038/sj.cdd.4400762; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; PAPA V, 1993, CANCER RES, V53, P3736; Pravtcheva DD, 1998, J EXP ZOOL, V281, P43, DOI 10.1002/(SICI)1097-010X(19980501)281:1<43::AID-JEZ7>3.3.CO;2-3; Resnik JL, 1998, CANCER RES, V58, P1159; Richards RG, 1998, J BIOL CHEM, V273, P11962, DOI 10.1074/jbc.273.19.11962; Richards RG, 2004, ENDOCRINOLOGY, V145, P3106, DOI 10.1210/en.2003-1112; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Ruan WF, 1999, ENDOCRINOLOGY, V140, P5075, DOI 10.1210/en.140.11.5075; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Santen RJ, 2002, J STEROID BIOCHEM, V80, P239, DOI 10.1016/S0960-0760(01)00189-3; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; Takahashi T, 1999, CIRC RES, V85, P884; Turner BC, 1997, CANCER RES, V57, P3079; Werner H, 2000, CELL MOL LIFE SCI, V57, P932, DOI 10.1007/PL00000735; Wetterau LA, 1999, MOL GENET METAB, V68, P161, DOI 10.1006/mgme.1999.2920; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	47	101	109	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1636	1644		10.1038/sj.onc.1209955	http://dx.doi.org/10.1038/sj.onc.1209955			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953219				2022-12-28	WOS:000244782500013
J	Matta, H; Surabhi, RM; Zhao, J; Punj, V; Sun, Q; Schamus, S; Mazzacurati, L; Chaudhary, PM				Matta, H.; Surabhi, R. M.; Zhao, J.; Punj, V.; Sun, Q.; Schamus, S.; Mazzacurati, L.; Chaudhary, P. M.			Induction of spindle cell morphology in human vascular endothelial cells by human herpesvirus 8-encoded viral FLICE inhibitory protein K13	ONCOGENE			English	Article						KSHV; HHV8; vFLIP; Kaposi's sarcoma; NF-kappa B; spindle cells	NF-KAPPA-B; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; INDUCED APOPTOSIS; ACTIVATION; TRANSFORMATION; EXPRESSION; HUMAN-HERPESVIRUS-8; VFLIP; GENE	Human herpesvirus 8(HHV8), also known as Kaposi's sarcoma-associated herpesvirus, is linked to the development of Kaposi's sarcoma, a disease characterized by the presence of distinctive proliferating spindle-like cells. Although HHV8 can induce spindle cell transformation of vascular endothelial cells in vitro, the viral gene(s) responsible for this phenotype remain to be identified. We demonstrate that expression of HHV8-encoded viral Fas-associated death domain protein-like IL-1 beta-converting enzyme inhibitory protein K13 is sufficient to induce spindle cell phenotype in human umbilical vein endothelial cells (HUVEC), which is associated with the activation of the nuclear factor-kappa B (NF-kappa B) pathway and can be blocked by Bay-11-7082, a specific inhibitor of this pathway. K13 induces the expression of several genes known to be upregulated in HHV8-transformed vascular endothelial cells, such as interleukin (IL)-6, IL-8, CXC ligand 3 (CXCL3), orphan G protein coupled receptor (RDC1), cyclooxygenase-2 (COX-2) and dual-specificity phosphatase 5 (DUSP5). Furthermore, similar to K13, HHV8-induced spindle cell transformation of HUVEC is associated with NF-kappa B activation and can be blocked by Bay-11-7082. Thus, ectopic expression of a single latent gene of HHV8 is sufficient for the acquisition of spindle cell phenotype by vascular endothelial cells and NF-kappa B activation plays an essential role in this process.	Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; CORBEIL J, 1991, J IMMUNOL, V146, P2972; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Hu SM, 1997, J BIOL CHEM, V272, P9621; Kennedy MM, 1998, J CLIN PATHOL-MOL PA, V51, P14, DOI 10.1136/mp.51.1.14; Liu J, 2002, J VIB CONTROL, V8, P277, DOI 10.1177/107754602023821; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0	25	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1656	1660		10.1038/sj.onc.1209931	http://dx.doi.org/10.1038/sj.onc.1209931			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16936773				2022-12-28	WOS:000244782500016
J	Liu, B; Lee, KW; Anzo, M; Zhang, B; Zi, X; Tao, Y; Shiry, L; Pollak, M; Lin, S; Cohen, P				Liu, B.; Lee, K. -W; Anzo, M.; Zhang, B.; Zi, X.; Tao, Y.; Shiry, L.; Pollak, M.; Lin, S.; Cohen, P.			Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis	ONCOGENE			English	Article						insulin-like growth factor-binding protein-3; prostate cancer; angiogenesis; apoptosis	FACTOR IGF; ENDOTHELIAL-CELLS; TARGETED DISRUPTION; TUMOR ANGIOGENESIS; BREAST-CANCER; EXPRESSION; IGFBP-3; INDUCTION; ZEBRAFISH; APOPTOSIS	Insulin-like growth factor-binding protein-3 (IGFBP-3) is a multifunctional protein that induces apoptosis utilizing both insulin-like growth factor receptor (IGF)-dependent and -independent mechanisms. We investigated the effects of IGFBP-3 on tumor growth and angiogenesis utilizing a human CaP xenograft model in severe-combined immunodeficiency mice. A 16-day course of IGFBP-3 injections reduced tumor size and increased apoptosis and also led to a reduction in the number of vessels stained with CD31. In vitro, IGFBP-3 inhibited both vascular endothelial growth factor- and IGF-stimulated human umbilical vein endothelial cells vascular network formation in a matrigel assay. This action is primarily IGF independent as shown by studies utilizing the non-IGFBP-binding IGF-1 analog Long-R3. Additionally, we used a fibroblast growth factor- enriched matrigel-plug assay and chick allantoic membrane assays to show that IGFBP-3 has potent antiangiogenic actions in vivo. Finally, overexpression of IGFBP-3 or the non-IGF-binding GGG-IGFBP-3 mutant in Zebrafish embryos confirmed that both IGFBP-3 and the non-IGF-binding mutant inhibited vessel formation in vivo, indicating that the antiangiogenic effect of IGFBP-3 is an IGF-independent phenomenon. Together, these studies provide the first evidence that IGFBP-3 has direct, IGF-independent inhibitory effects on angiogenesis providing an additional mechanism by which it exerts its tumor suppressive effects and further supporting its development for clinical use in the therapy of patients with prostate cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA; Peking Univ, Coll Life Sci, Ctr Dev Biol & Genet, Beijing 100871, Peoples R China; UCI, Dept Urol, Irvine, CA USA; UCI, Chao Family Comprehens Canc Ctr, Irvine, CA USA; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H2W 1S4, Canada; McGill Univ, Dept Oncol, Montreal, PQ H2W 1S4, Canada; INSMED Corp, Charlottesville, VA USA; Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Peking University; University of California System; University of California Irvine; University of California System; University of California Irvine; McGill University; McGill University; University of California System; University of California Los Angeles	Cohen, P (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pediat Endocrinol, Dept Pediat,Mattel Childrens Hosp, Los Angeles, CA 90095 USA.	hassy@mednet.ucla.edu	Zi, Xiaolin/D-3924-2009; Zhang, Bo/K-7162-2012; Pollak, Michael/G-9094-2011	Pollak, Michael/0000-0003-3047-0604	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD034610] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA100938, P50CA092131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020954] Funding Source: NIH RePORTER; NCI NIH HHS [P50CA92131, R01CA100938] Funding Source: Medline; NIA NIH HHS [R01AG20954] Funding Source: Medline; NICHD NIH HHS [2K12HD34610] Funding Source: Medline; NIDDK NIH HHS [R01DK054508] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acker T, 2003, CELL TISSUE RES, V314, P145, DOI 10.1007/s00441-003-0763-8; Arakawa A, 1997, PROSTATE CANCER P D, V1, P32, DOI 10.1038/sj.pcan.4500204; Bagheri-Yarmand R, 1999, CANCER RES, V59, P507; Bettencourt MC, 1998, J UROLOGY, V160, P459, DOI 10.1016/S0022-5347(01)62925-2; Bono AV, 2002, PROSTATE CANCER P D, V5, P123, DOI 10.1038/sj.pcan.4500572; Booth BA, 1996, GROWTH REGULAT, V6, P206; Brown TA, 2001, DOMEST ANIM ENDOCRIN, V20, P203, DOI 10.1016/S0739-7240(01)00092-3; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Cao YH, 1998, P NATL ACAD SCI USA, V95, P14389, DOI 10.1073/pnas.95.24.14389; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; Chan SSY, 2005, J CLIN ENDOCR METAB, V90, P6588, DOI 10.1210/jc.2005-0595; Cross LM, 2003, ARTERIOSCL THROM VAS, V23, P911, DOI 10.1161/01.ATV.0000068685.72914.7E; Dahlfors G, 2000, ENDOCRINOLOGY, V141, P2062, DOI 10.1210/en.141.6.2062; Delafontaine P, 1996, BIOCHEM BIOPH RES CO, V222, P478, DOI 10.1006/bbrc.1996.0769; Diaz-Gonzalez JA, 2005, CANCER BIOL THER, V4, P1055, DOI 10.4161/cbt.4.10.2195; Eivers E, 2004, INT J DEV BIOL, V48, P1131, DOI 10.1387/ijdb.041913ee; ERICKSON GF, 1993, ENDOCRINOLOGY, V133, P1147, DOI 10.1210/en.133.3.1147; Erondu NE, 1996, GROWTH REGULAT, V6, P1; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Franklin SL, 2003, J CLIN ENDOCR METAB, V88, P900, DOI 10.1210/jc.2002-020472; Fraser HM, 1998, HUM REPROD, V13, P2180, DOI 10.1093/humrep/13.8.2180; Fraser HM, 2000, J CLIN ENDOCR METAB, V85, P1672, DOI 10.1210/jc.85.4.1672; Grimberg A, 2005, J CLIN ENDOCR METAB, V90, P3568, DOI 10.1210/jc.2004-1213; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Huang SS, 2003, FASEB J, V17, P2068, DOI 10.1096/fj.03-0256com; Ikonen M, 2003, P NATL ACAD SCI USA, V100, P13042, DOI 10.1073/pnas.2135111100; Iwatsuki K, 2005, ONCOGENE, V24, P1129, DOI 10.1038/sj.onc.1208287; Jackson MW, 1997, J UROLOGY, V157, P2323, DOI 10.1016/S0022-5347(01)64774-8; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jones HE, 2005, ENDOCR-RELAT CANCER, V12, pS173, DOI 10.1677/erc.1.01004; Klauber N, 1997, CANCER RES, V57, P81; Koong AC, 2000, CANCER RES, V60, P883; LEE HS, 1999, J INJECTION MOLDING, V3, P11; Lee HY, 2002, CANCER RES, V62, P3530; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Liu BR, 2005, CLIN CANCER RES, V11, P4851, DOI 10.1158/1078-0432.CCR-04-2160; Odenthal J, 1996, DEVELOPMENT, V123, P103; Oh SH, 2006, CLIN CANCER RES, V12, P653, DOI 10.1158/1078-0432.CCR-05-1725; OLNEY RC, 1995, J ENDOCRINOL, V146, P279, DOI 10.1677/joe.0.1460279; PRATT SE, 1994, BIOCHEM BIOPH RES CO, V198, P292, DOI 10.1006/bbrc.1994.1041; Schmitt HJ, 2003, LANCET INFECT DIS, V3, P103, DOI 10.1016/S1473-3099(03)00519-X; Singh RP, 2003, CANCER EPIDEM BIOMAR, V12, P933; Singh RP, 2004, CLIN CANCER RES, V10, P244, DOI 10.1158/1078-0432.CCR-1080-3; Singh RP, 2004, INT J CANCER, V108, P733, DOI 10.1002/ijc.11620; Tucci M, 1998, J ENDOCRINOL, V157, P13, DOI 10.1677/joe.0.1570013; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; van Moorselaar RJA, 2002, MOL CELL ENDOCRINOL, V197, P239, DOI 10.1016/S0303-7207(02)00262-9; Voskuil DW, 2005, CANCER EPIDEM BIOMAR, V14, P195; WEIDNER N, 1993, AM J PATHOL, V143, P401; Zadeh SM, 1997, ENDOCRINOLOGY, V138, P3069, DOI 10.1210/en.138.7.3069	54	81	85	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1811	1819		10.1038/sj.onc.1209977	http://dx.doi.org/10.1038/sj.onc.1209977			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983336				2022-12-28	WOS:000244955600015
J	Zapatka, M; Zboralski, D; Radacz, Y; Bockmann, M; Arnold, C; Schoneck, A; Hoppe, S; Tannapfel, A; Schmiegel, W; Simon-Assmann, P; Schwarte-Waldhoff, I				Zapatka, M.; Zboralski, D.; Radacz, Y.; Boeckmann, M.; Arnold, C.; Schoeneck, A.; Hoppe, S.; Tannapfel, A.; Schmiegel, W.; Simon-Assmann, P.; Schwarte-Waldhoff, I.			Basement membrane component laminin-5 is a target of the tumor suppressor Smad4	ONCOGENE			English	Article						tumor suppressor Smad4; TGF-beta; laminin-5; invasion; basement membrane	STABLE RNA INTERFERENCE; GAMMA-2 CHAIN; COLORECTAL-CANCER; CARCINOMA CELLS; EXPRESSION; INVASION; DPC4; METASTASIS; LAMC2; LINES	The tumor suppressor Smad4 is involved in carcinogenesis mainly of the pancreas and colon. Functional inactivation of Smad4 is a genetically late event that occurs upon transition from premalignant stages to invasive and metastatic growth. Smad4 encodes an intracellular messenger common to all signalling cascades induced by members of the transforming growth factor-beta (TGF-beta) superfamily of cytokines. Despite extensive knowledge about the mechanisms of TGF-beta/Smadsignal transduction, little is known about Smad4 targets involved in the transition to malignancy. The hallmark of invasive growth is a breakdown of the basement membrane ( BM), a specialized sheet of extracellular matrix produced through of epithelial and stromal cells. Laminin-5, a heterotrimeric epithelial-derived BM component, is commonly lost in carcinomas but not in premalignant tumors. Herein, we report that in human colon and pancreatic tumor cells, Smad4 functions as a positive transcriptional regulator of all three genes encoding laminin-5. Coordinate re-expression of the three laminin-5 chains induced by reconstitution of Smad4 leads to secretion and deposition of the heterotrimeric molecule in BM-like structures. These data de. ne the expression control of an essential BM component as a novel function for the tumor suppressor Smad4.	Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, D-44892 Bochum, Germany; Univ Strasbourg, INSERM, U682, Strasbourg, France; Ruhr Univ Bochum, Inst Pathol, BG Kliniken Bergmannsheil, D-4630 Bochum, Germany; Ruhr Univ Bochum, Dept Gastroenterol & Hepatol, Kliniken Bergmannsheil, D-4630 Bochum, Germany	Ruhr University Bochum; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Ruhr University Bochum; Ruhr University Bochum	Schwarte-Waldhoff, I (corresponding author), Ruhr Univ Bochum, Dept Internal Med, Knappschaftskrankenhaus, IMBL, Schornau 23-25, D-44892 Bochum, Germany.	Irmgard.Schwarte-Waldhoff@ruhr-uni-bochum.de	Zapatka, Marc/G-9896-2013	Zapatka, Marc/0000-0001-8287-5967; Zboralski, Dirk/0000-0002-2224-2452				Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; BOUZIGES F, 1991, INT J CANCER, V48, P101; Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Giannelli G, 2001, CLIN EXP METASTAS, V18, P439; Givant-Horwitz V, 2005, CANCER LETT, V223, P1, DOI 10.1016/j.canlet.2004.08.030; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hlubek F, 2001, CANCER RES, V61, P8089; Imamura T, 2004, BIOCHEM BIOPH RES CO, V318, P289, DOI 10.1016/j.bbrc.2004.04.029; Jazag A, 2005, ONCOGENE, V24, P662, DOI 10.1038/sj.onc.1208102; Jonson T, 2003, GENE CHROMOSOME CANC, V36, P340, DOI 10.1002/gcc.10179; Katayama M, 2004, J MOL HISTOL, V35, P277; KORANG K, 1995, FEBS LETT, V368, P556, DOI 10.1016/0014-5793(95)00740-Z; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lohi J, 2001, INT J CANCER, V94, P763, DOI 10.1002/ijc.1539; Lu W, 2001, HISTOCHEM J, V33, P629, DOI 10.1023/A:1016350316926; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Luttges J, 2001, AM J PATHOL, V158, P1677, DOI 10.1016/S0002-9440(10)64123-5; Maitra A, 2000, AM J PATHOL, V157, P1105, DOI 10.1016/S0002-9440(10)64625-1; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; Muller N, 2002, ONCOGENE, V21, P6049, DOI 10.1038/sj.onc.1205766; Olsen J, 2003, BIOCHEM J, V371, P211, DOI 10.1042/BJ20021454; Patarroyo M, 2002, SEMIN CANCER BIOL, V12, P197, DOI 10.1016/S1044-579X(02)00023-8; PYKE C, 1995, CANCER RES, V55, P4132; PYKE C, 1994, AM J PATHOL, V145, P782; Richter M, 2002, EUR J CANCER, V38, P1937, DOI 10.1016/S0959-8049(02)00158-2; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Simon-Assmann P, 1998, ANN NY ACAD SCI, V859, P46, DOI 10.1111/j.1749-6632.1998.tb11110.x; Sordat I, 2000, INT J CANCER, V88, P708, DOI 10.1002/1097-0215(20001201)88:5<708::AID-IJC5>3.0.CO;2-J; Sordat I, 1998, J PATHOL, V185, P44, DOI 10.1002/(SICI)1096-9896(199805)185:1<44::AID-PATH46>3.0.CO;2-A; Takahashi H, 2004, CLIN CANCER RES, V10, P3772, DOI 10.1158/1078-0432.CCR-03-0120; Takahashi S, 2002, CANCER, V94, P1894, DOI 10.1002/cncr.10395; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; TELLER IC, 2001, EXPERT REV MOL MED, P1; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Volmer MW, 2004, PROTEOMICS, V4, P1324, DOI 10.1002/pmic.200300703; WAYNER EA, 1993, J CELL BIOL, V121, P1141, DOI 10.1083/jcb.121.5.1141; Wilentz RE, 2000, CANCER RES, V60, P2002; Yuen HW, 2005, EXP CELL RES, V309, P198, DOI 10.1016/j.yexcr.2005.05.013	41	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1417	1427		10.1038/sj.onc.1209918	http://dx.doi.org/10.1038/sj.onc.1209918			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953227				2022-12-28	WOS:000244558800006
J	Bignone, PA; Lee, KY; Liu, Y; Emilion, G; Finch, J; Soosay, AER; Charnock, FML; Beck, S; Dunham, I; Mungall, AJ; Ganesan, TS				Bignone, P. A.; Lee, K. Y.; Liu, Y.; Emilion, G.; Finch, J.; Soosay, A. E. R.; Charnock, F. M. L.; Beck, S.; Dunham, I.; Mungall, A. J.; Ganesan, T. S.			RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer	ONCOGENE			English	Article						ovarian cancer; RPS6KA2; chromosome 6q27; tumour suppressor gene	SIGNAL-REGULATED KINASE; COFFIN-LOWRY SYNDROME; RIBOSOMAL S6 KINASE; CELL-CYCLE ARREST; MONOALLELIC EXPRESSION; NUCLEAR TRANSLOCATION; HOMOZYGOUS DELETIONS; CHROMOSOME 6Q27; ALLELE LOSS; MAP	We had previously defined by allele loss studies a minimal region at 6q27 (between D6S264 and D6S297) to contain a putative tumour suppressor gene. The p90 ribosomal S6 kinase-3 gene (p90 Rsk-3, RPS6KA2) maps in this interval. It is a serine-threonine kinase that signals downstream of the mitogen-activated protein kinase pathway. It is expressed in normal ovarian epithelium, whereas reduced or absent in tumours or cell lines. We show that RPS6KA2 is monoallelically expressed in the ovary suggesting that loss of a single expressed allele is sufficient to cause complete loss of expression in cancer cells. Further, we have identified two new isoforms of RPS6KA2 with an alternative start codon. Homozygous deletions were identified within the RPS6KA2 gene in two cell lines. Re-expression of RPS6KA2 in ovarian cancer cell lines suppressed colony formation. In UCI101 cells, the expression of RPS6KA2 reduced proliferation, caused G1 arrest, increased apoptosis, reduced levels of phosphorylated extracellular signal-regulated kinase and altered other cell cycle proteins. In contrast, small interfering RNA against RPS6KA2 showed the opposite effect in 41M cells. The above results suggest that RPS6KA2 is a putative tumour suppressor gene to explain allele loss at 6q27.	John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Sanger Ctr, Cambridge, England	University of Oxford; Wellcome Trust Sanger Institute	Ganesan, TS (corresponding author), John Radcliffe Hosp, Mol Oncol Labs, Ovarian Canc Grp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	ganesan@cancer.org.uk	Mungall, Andrew J./U-7067-2018; GANESAN, Trivadi Sundaram/AAU-1499-2020; Soosay, Ashley/D-8060-2012; Bignone, Paola/K-3797-2012	Mungall, Andrew J./0000-0002-0905-2742; GANESAN, Trivadi Sundaram/0000-0002-4671-8099; Soosay, Ashley/0000-0002-7443-4472; Dunham, Ian/0000-0003-2525-5598; Bignone, Paola/0000-0003-2296-7039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Acquati F, 2001, ONCOGENE, V20, P980, DOI 10.1038/sj.onc.1204178; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; BJORBAEK C, 1995, J BIOL CHEM, V270, P18848, DOI 10.1074/jbc.270.32.18848; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Bruning JC, 2000, P NATL ACAD SCI USA, V97, P2462, DOI 10.1073/pnas.97.6.2462; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; Conover CA, 1998, EXP CELL RES, V238, P439, DOI 10.1006/excr.1997.3861; Cooke IE, 1996, GENE CHROMOSOME CANC, V15, P223, DOI 10.1002/(SICI)1098-2264(199604)15:4<223::AID-GCC4>3.3.CO;2-4; Cooke IE, 1996, MAMM GENOME, V7, P157, DOI 10.1007/s003359900040; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Douville E, 1997, ONCOGENE, V15, P373, DOI 10.1038/sj.onc.1201214; Dufresne SD, 2001, MOL CELL BIOL, V21, P81, DOI 10.1128/MCB.21.1.81-87.2001; Dummler BA, 2005, J BIOL CHEM, V280, P13304, DOI 10.1074/jbc.M408194200; Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; Goldmit M, 2004, IMMUNOL REV, V200, P197, DOI 10.1111/j.0105-2896.2004.00158.x; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Jirtle RL, 1999, EXP CELL RES, V248, P18, DOI 10.1006/excr.1999.4453; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; Kawada M, 1997, ONCOGENE, V15, P629, DOI 10.1038/sj.onc.1201228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVAL S, 1994, CELL GROWTH DIFFER, V5, P1173; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Lin BH, 2001, J FOOD PROD MARK, V6, P63, DOI 10.1300/J038v06n04_06; Liu Y, 2002, ONCOGENE, V21, P387, DOI 10.1038/sj.onc.1205067; Liu Y, 2002, BMC GENET, V3, DOI 10.1186/1471-2156-3-20; Liu Y, 2002, REPRODUCTION, V123, P341, DOI 10.1530/reprod/123.3.341; Lo HS, 2003, GENOME RES, V13, P1855, DOI 10.1101/gr.1006603; Luedi PP, 2005, GENOME RES, V15, P875, DOI 10.1101/gr.3303505; Modesitt SC, 2001, CLIN CANCER RES, V7, P1765; MOLLER DE, 1994, AM J PHYSIOL, V266, pC351, DOI 10.1152/ajpcell.1994.266.2.C351; Morison IM, 2005, TRENDS GENET, V21, P457, DOI 10.1016/j.tig.2005.06.008; Myers AP, 2004, MOL CELL BIOL, V24, P4255, DOI 10.1128/MCB.24.10.4255-4266.2004; Nikaido L, 2003, GENOME RES, V13, P1402, DOI 10.1101/gr.1055303; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Ohtani Naoko, 2004, J Med Invest, V51, P146, DOI 10.2152/jmi.51.146; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pineau P, 2003, INT J CANCER, V106, P216, DOI 10.1002/ijc.11214; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; Rougeulle C, 1997, NAT GENET, V17, P14, DOI 10.1038/ng0997-14; SAITO S, 1992, CANCER RES, V52, P5815; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schinelli S, 2001, J NEUROSCI, V21, P8842, DOI 10.1523/JNEUROSCI.21-22-08842.2001; Schreiber M, 1999, ONCOGENE, V18, P1663, DOI 10.1038/sj.onc.1202466; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Suzuki Y, 2004, NUCLEIC ACIDS RES, V32, pD78, DOI 10.1093/nar/gkh076; Teng DHF, 1997, CANCER RES, V57, P4177; Tibiletti MB, 2000, CLIN CANCER RES, V6, P1422; Tibiletti MG, 1996, CANCER RES, V56, P4493; Tibiletti MG, 1998, ONCOGENE, V16, P1639, DOI 10.1038/sj.onc.1201654; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Trubia M, 1997, GENOMICS, V42, P342, DOI 10.1006/geno.1997.4679; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yntema HG, 1999, GENOMICS, V62, P332, DOI 10.1006/geno.1999.6004; Yoo LI, 2002, NAT REV CANCER, V2, P529, DOI 10.1038/nrc843; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zeniou M, 2002, HUM MOL GENET, V11, P2929, DOI 10.1093/hmg/11.23.2929; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	69	77	82	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					683	700		10.1038/sj.onc.1209827	http://dx.doi.org/10.1038/sj.onc.1209827			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16878154				2022-12-28	WOS:000243902200006
J	Inoue, T; Hiratsuka, M; Osaki, M; Yamada, H; Kishimoto, I; Yamaguchi, S; Nakano, S; Katoh, M; Ito, H; Oshimura, M				Inoue, T.; Hiratsuka, M.; Osaki, M.; Yamada, H.; Kishimoto, I.; Yamaguchi, S.; Nakano, S.; Katoh, M.; Ito, H.; Oshimura, M.			SIRT2, a tubulin deacetylase, acts to block the entry to chromosome condensation in response to mitotic stress	ONCOGENE			English	Article						SIRT2; mitotic checkpoint; endoreduplication; epigenetic modi. cation; subcellular localization	DIFFERENTIALLY-EXPRESSED GENES; NUCLEAR EXPORT SIGNALS; GLIOMA-CELL-LINES; POLO-LIKE KINASES; PROMOTER HYPERMETHYLATION; SPINDLE CHECKPOINT; DOWN-REGULATION; CHFR; CYCLE; CANCERS	We previously identified SIRT2, an nicotinamide adenine dinucleotide (NAD)-dependent tubulin deacetylase, as a protein downregulated in gliomas and glioma cell lines, which are characterized by aneuploidy. Other studies reported SIRT2 to be involved in mitotic progression in the normal cell cycle. We herein investigated whether SIRT2 functions in the mitotic checkpoint in response to mitotic stress caused by microtubule poisons. By monitoring chromosome condensation, the exogenously expressed SIRT2 was found to block the entry to chromosome condensation and subsequent hyperploid cell formation in glioma cell lines with a persistence of the cyclin B/cdc2 activity in response to mitotic stress. SIRT2 is thus a novel mitotic checkpoint protein that functions in the early metaphase to prevent chromosomal instability (CIN), characteristics previously reported for the CHFR protein. We further found that histone deacetylation, but not the aberrant DNA methylation of SIRT2 5'untranslated region is involved in the downregulation of SIRT2. Although SIRT2 is normally exclusively located in the cytoplasm, the rapid accumulation of SIRT2 in the nucleus was observed after treatment with a nuclear export inhibitor, leptomycin B and ionizing radiation in normal human. fibroblasts, suggesting that nucleo-cytoplasmic shuttling regulates the SIRT2 function. Collectively, our results suggest that the further study of SIRT2 may thus provide new insights into the relationships among CIN, epigenetic regulation and tumorigenesis.	Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Grad Sch Med Sci, Dept Human Genome Sci, Yonago, Tottori 6838503, Japan; Tottori Univ, Fac Med, Dept Pathol & Microbiol, Div Organ Pathol, Yonago, Tottori 683, Japan	Tottori University; Tottori University; Tottori University	Oshimura, M (corresponding author), Tottori Univ, Grad Sch Med Sci, Inst Regenerat Med & Biofunct, Dept Biomed Sci, 86 Nichi Cho, Yonago, Tottori 6838503, Japan.	oshimura@grape.med.tottori-u.ac.jp						Alonso M, 2003, MOL CANCER THER, V2, P139; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bae NS, 2004, J BIOCHEM, V135, P695, DOI 10.1093/jb/mvh084; Bertholon J, 2003, ONCOGENE, V22, P8956, DOI 10.1038/sj.onc.1207078; Bigner SH, 1990, BRAIN PATHOL, V1, P12, DOI 10.1111/j.1750-3639.1990.tb00633.x; Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058; Chu YW, 1999, CYTOMETRY, V36, P333, DOI 10.1002/(SICI)1097-0320(19990801)36:4<333::AID-CYTO8>3.0.CO;2-F; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Cortez D, 2000, NATURE, V406, P354, DOI 10.1038/35019227; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dryden SC, 2003, MOL CELL BIOL, V23, P3173, DOI 10.1128/MCB.23.9.3173-3185.2003; Finnin MS, 2001, NAT STRUCT BIOL, V8, P621, DOI 10.1038/89668; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Honda T, 2004, BRIT J CANCER, V90, P2013, DOI 10.1038/sj.bjc.6601849; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Imai Y, 1999, JPN J CANCER RES, V90, P837, DOI 10.1111/j.1349-7006.1999.tb00824.x; Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kyrylenko S, 2003, CELL MOL LIFE SCI, V60, P1990, DOI 10.1007/s00018-003-3090-z; la Cour T, 2004, PROTEIN ENG DES SEL, V17, P527, DOI 10.1093/protein/gzh062; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402; Muhua L, 1998, NATURE, V393, P487, DOI 10.1038/31014; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307; Nitta M, 2002, GENES CELLS, V7, P151, DOI 10.1046/j.1356-9597.2001.00509.x; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Qian K, 2005, MOL HUM REPROD, V11, P245, DOI 10.1093/molehr/gah147; Roberts EC, 2001, MOL CELL BIOL, V21, P524, DOI 10.1128/MCB.21.2.524-533.2001; Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646; Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108; Serrador JM, 2004, IMMUNITY, V20, P417, DOI 10.1016/S1074-7613(04)00078-0; SHACKNEY SE, 1989, CANCER RES, V49, P3344; Takahashi T, 2004, CLIN CANCER RES, V10, P6126, DOI 10.1158/1078-0432.CCR-04-0579; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Xie SQ, 2005, ONCOGENE, V24, P277, DOI 10.1038/sj.onc.1208218; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	43	181	193	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					945	957		10.1038/sj.onc.1209857	http://dx.doi.org/10.1038/sj.onc.1209857			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909107				2022-12-28	WOS:000244245400001
J	Yang, G; Thompson, MA; Brandt, SJ; Hiebert, SW				Yang, G.; Thompson, M. A.; Brandt, S. J.; Hiebert, S. W.			Histone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein	ONCOGENE			English	Article						RUNX1; ETO; MTG8; histone deacetylase; t(8;21); corepressor	ACUTE MYELOID-LEUKEMIA; T-CELL LYMPHOMA; ABL TYROSINE KINASE; TRANS-RETINOIC ACID; ALPHA ONCOPROTEIN; TUMOR-SUPPRESSOR; ARSENIC TRIOXIDE; NUCLEAR-BODIES; CANCER-THERAPY; MURINE MODEL	The t(8; 21) chromosomal translocation that generates the fusion oncoprotein RUNX1-ETO predominates in leukemia patients of the French-American-British (FAB) class M2 subtype. The oncoprotein has the capacity to promote expansion of hematopoietic stem/progenitor cells and induces leukemia in association with other genetic alterations. Here, we show that RUNX1-ETO undergoes degradation in response to treatment with histone deacetylase inhibitors, one of which, depsipeptide (DEP), is currently undergoing phase II clinical testing in a variety of malignancies. These compounds induce turnover of RUNX1-ETO without affecting the stability of RUNX1-ETO partner proteins. In addition, RUNX1-ETO physically interacts with heat shock protein 90 (HSP90). DEP treatment interrupts the association of RUNX1-ETO with HSP90 and induces proteasomal degradation of RUNX1-ETO. DEP and the HSP90 antagonist 17-allylamino-geldanamycin (17-AAG) both triggered RUNX1-ETO degradation, but without any additive or cooperative effects. These findings may stimulate the development of more rational and effective approaches for treating t(8; 21) patients using histone deacetylase inhibitors or HSP90 inhibitors.	Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pathol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Tennessee Valley VA Healthcare Syst, Nashville, TN 37212 USA; Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; Vanderbilt University; Vanderbilt University	Hiebert, SW (corresponding author), Vanderbilt Univ, Dept Biochem, Sch Med, 512 Preston Res Bldg,23rd & Pierce Ave, Nashville, TN 37232 USA.	scott.hiebert@vanderbilt.edu	Hiebert, Scott W/C-9979-2010		NCI NIH HHS [R01-CA64140, CA68485] Funding Source: Medline; NHLBI NIH HHS [R01-HL49118] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064140, P30CA068485] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049118] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Aoyagi S, 2005, TRENDS CELL BIOL, V15, P565, DOI 10.1016/j.tcb.2005.09.003; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Byrd JC, 2005, BLOOD, V105, P959, DOI 10.1182/blood-2004-05-1693; Chen GQ, 1997, BLOOD, V89, P3345; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Fuino L, 2003, MOL CANCER THER, V2, P971; Garrido SM, 2001, EXP HEMATOL, V29, P448, DOI 10.1016/S0301-472X(01)00612-9; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; George P, 2005, BLOOD, V105, P1768, DOI 10.1182/blood-2004-09-3413; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X; Kasashima K, 2004, BIOCHIMIE, V86, P713, DOI 10.1016/j.biochi.2004.08.003; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Komori A, 1999, JPN J CANCER RES, V90, P60, DOI 10.1111/j.1349-7006.1999.tb00666.x; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Kozu T, 2000, GENES CELLS, V5, P637, DOI 10.1046/j.1365-2443.2000.00353.x; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Linggi BE, 2005, J CELL BIOCHEM, V96, P938, DOI 10.1002/jcb.20604; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x; MATSUSHITA H, 1995, BIOCHEM BIOPH RES CO, V215, P431, DOI 10.1006/bbrc.1995.2483; Muller S, 1998, BLOOD, V92, P4308, DOI 10.1182/blood.V92.11.4308.423k36_4308_4316; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Odenike OM, 2004, BLOOD, V104, p79A; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Pichardo DA, 2004, LEUKEMIA LYMPHOMA, V45, P1755, DOI 10.1080/10428190410001693560; Piekarz R, 2004, CURR PHARM DESIGN, V10, P2289, DOI 10.2174/1381612043383980; Piekarz RL, 2004, BLOOD, V103, P4636, DOI 10.1182/blood-2003-09-3068; Piekarz RL, 2001, BLOOD, V98, P2865, DOI 10.1182/blood.V98.9.2865; Prodromou C, 2003, CURR CANCER DRUG TAR, V3, P301, DOI 10.2174/1568009033481877; Raelson JV, 1996, BLOOD, V88, P2826, DOI 10.1182/blood.V88.8.2826.bloodjournal8882826; SAKAKURA C, 1994, P NATL ACAD SCI USA, V91, P11723, DOI 10.1073/pnas.91.24.11723; Sandor V, 2000, BRIT J CANCER, V83, P817, DOI 10.1054/bjoc.2000.1327; SANDRO V, 2002, CLIN CANCER RES, V8, P662; Sato N, 2004, INT J ONCOL, V24, P679; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Sutheesophon K, 2005, J CELL PHYSIOL, V203, P387, DOI 10.1002/jcp.20235; Szyrach M, 2001, EUR J BIOCHEM, V268, P3550, DOI 10.1046/j.1432-1327.2001.02259.x; Tabe Y, 2006, BLOOD, V107, P1546, DOI 10.1182/blood-2004-10-4126; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wang JX, 1999, CANCER RES, V59, P2766; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Yan M, 2004, P NATL ACAD SCI USA, V101, P17468, DOI 10.1073/pnas.0406142101; Yang GY, 2005, MOL CELL BIOL, V25, P5869, DOI 10.1128/MCB.25.14.5869-5879.2005; Yoshida H, 1996, CANCER RES, V56, P2945; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhu J, 1997, P NATL ACAD SCI USA, V94, P3978, DOI 10.1073/pnas.94.8.3978	68	54	58	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					91	101		10.1038/sj.onc.1209760	http://dx.doi.org/10.1038/sj.onc.1209760			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799637				2022-12-28	WOS:000243236500009
J	Letessier, A; Garrido-Urbani, S; Ginestier, C; Fournier, G; Esterni, B; Monville, F; Adelaide, J; Geneix, J; Xerri, L; Dubreuil, P; Viens, P; Charafe-Jauffret, E; Jacquemier, J; Birnbaum, D; Lopez, M; Chaffanet, M				Letessier, A.; Garrido-Urbani, S.; Ginestier, C.; Fournier, G.; Esterni, B.; Monville, F.; Adelaide, J.; Geneix, J.; Xerri, L.; Dubreuil, P.; Viens, P.; Charafe-Jauffret, E.; Jacquemier, J.; Birnbaum, D.; Lopez, M.; Chaffanet, M.			Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer	ONCOGENE			English	Article						Afadin; AF-6 gene; breast cancer; FRA6E; Parkin; PARK2 gene; tissue microarrays	RECESSIVE JUVENILE PARKINSONISM; ACUTE LYMPHOBLASTIC-LEUKEMIA; TUMOR-SUPPRESSOR GENE; COMMON FRAGILE SITES; CELL-CELL JUNCTIONS; LONG ARM; HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; BINDING PROTEIN; LUNG-CANCER	Common fragile sites (CFSs) are regions of chromosomal break that may play a role in oncogenesis. The most frequent alteration occurs at FRA3B, within the FHIT gene, at chromosomal region 3p14. We studied a series of breast carcinomas for break of a CFS at 6q26, FRA6E, and its associated gene PARK2, using fluorescence in situ hybridization on tissue microarrays (TMA). We found break of PARK2 in 6% of cases. We studied the PARK2-encoded protein Parkin by using immunohistochemistry on the same TMA. Loss of Parkin was found in 13% of samples but was not correlated with PARK2 break. PARK2 break but not Parkin expression was correlated with prognosis. Alteration of PARK2/FRA6E may cause haplo-insufficiency of one or several telomeric potential tumor suppressor genes (TSG). The AF-6/MLLT4 gene, telomeric of PARK2, encodes the Afadin scaffold protein, which is essential for epithelial integrity. Loss of Afadin was found in 14.5% of cases, and 36% of these cases showed PARK2 break. Loss of Afadin had prognostic impact, suggesting that AF-6 may be a TSG. Loss of Afadin was correlated with loss of FHIT expression, suggesting fragility of FRA6E and FRA3B in a certain proportion of breast tumors.	Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept Biostat, F-13009 Marseille, France; INSERM, UMR599, Dept Med Oncol, F-13009 Marseille, France; Inst J Paoli I Calmettes, Dept BioPathol, F-13009 Marseille, France; Univ Mediterranee, Fac Med, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	Birnbaum, D (corresponding author), Ctr Rech Cancerol Marseille, UMR599, Dept Mol Oncol, INSERM, 27 Bd Lei Roure, F-13009 Marseille, France.	birnbaum@marseille.inserm.fr	Letessier, Anne/M-3431-2017; CHAFFANET, Max/AAU-5743-2020; ADELAIDE, José JA/O-4390-2017; dubreuil, patrice/F-5346-2011; Ginestier, Christophe/M-8828-2017; Dubreuil, Patrice/V-4816-2019; Charafe-Jauffret, emmanuelle/P-6009-2017	Letessier, Anne/0000-0002-1894-4072; ADELAIDE, José JA/0000-0003-4364-9857; dubreuil, patrice/0000-0003-1155-1150; Ginestier, Christophe/0000-0002-7477-3837; Dubreuil, Patrice/0000-0003-1155-1150; CHAFFANET, Max/0000-0002-2344-1488; Charafe-Jauffret, emmanuelle/0000-0002-0286-1299				Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bobinnec Y, 1998, CELL MOTIL CYTOSKEL, V39, P223, DOI 10.1002/(SICI)1097-0169(1998)39:3<223::AID-CM5>3.3.CO;2-3; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; Buchert M, 1999, J CELL BIOL, V144, P361, DOI 10.1083/jcb.144.2.361; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307; Chin SF, 2003, J CLIN PATHOL-MOL PA, V56, P275, DOI 10.1136/mp.56.5.275; Delaval B, 2005, CANCER RES, V65, P7231, DOI 10.1158/0008-5472.CAN-04-4167; Denison SR, 2003, GENE CHROMOSOME CANC, V38, P40, DOI 10.1002/gcc.10236; Denison SR, 2003, ONCOGENE, V22, P8370, DOI 10.1038/sj.onc.1207072; Dhillon VS, 2003, TERATOGEN CARCIN MUT, P35, DOI 10.1002/tcm.10068; Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102; Ginestier C, 2003, INT J CANCER, V107, P854, DOI 10.1002/ijc.11462; Ginestier C, 2002, AM J PATHOL, V161, P1223, DOI 10.1016/S0002-9440(10)64399-4; Guasch G, 2004, BLOOD, V103, P309, DOI 10.1182/blood-2003-05-1690; Guler G, 2005, PATHOL INT, V55, P471, DOI 10.1111/j.1440-1827.2005.01855.x; HAYASHI Y, 1990, BLOOD, V76, P1626; Huang Tie-Jun, 2004, Hepatobiliary Pancreat Dis Int, V3, P62; Huebner K, 2003, BRIT J CANCER, V88, P1501, DOI 10.1038/sj.bjc.6600937; Huebner K, 1998, RECENT RES CANCER, V154, P200; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Ishii H, 2003, FASEB J, V17, P1768, DOI 10.1096/fj.03-0241fje; Johnson SAS, 2003, CELL CYCLE, V2, P442, DOI 10.4161/cc.2.5.493; Johnson SAS, 2003, MOL CELL BIOL, V23, P3043, DOI 10.1128/MCB.23.9.3043-3051.2003; Kerangueven F, 1997, CANCER RES, V57, P5469; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; Marin I, 2004, PHYSIOL GENOMICS, V17, P253, DOI 10.1152/physiolgenomics.00226.2003; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P26, DOI 10.1002/gcc.2870100105; Miki H, 2005, TRENDS CELL BIOL, V15, P467, DOI 10.1016/j.tcb.2005.07.006; MILLIKIN D, 1991, CANCER RES, V51, P5449; NEGRINI M, 1994, CANCER RES, V54, P1331; Noviello C, 1996, CLIN CANCER RES, V2, P1601; ORPHANOS V, 1995, BRIT J CANCER, V71, P290, DOI 10.1038/bjc.1995.58; Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898; Park SW, 2004, BRIT J CANCER, V91, P753, DOI 10.1038/sj.bjc.6602023; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; Popovici C, 1999, BLOOD, V93, P1381, DOI 10.1182/blood.V93.4.1381.404k30_1381_1389; PRASAD R, 1993, CANCER RES, V53, P5624; Richards RI, 2001, TRENDS GENET, V17, P339, DOI 10.1016/S0168-9525(01)02303-4; Rodriguez C, 2000, GENE CHROMOSOME CANC, V27, P76, DOI 10.1002/(SICI)1098-2264(200001)27:1<76::AID-GCC10>3.0.CO;2-E; Roz L, 2002, P NATL ACAD SCI USA, V99, P3615, DOI 10.1073/pnas.062030799; SAITO S, 1992, CANCER RES, V52, P5815; Sato T, 2006, J BIOL CHEM, V281, P5288, DOI 10.1074/jbc.M510070200; Seki N, 2001, INT J ONCOL, V19, P305; Smith DI, 1998, INT J ONCOL, V12, P187; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Taki T, 1996, ONCOGENE, V13, P2121; Teixeira MR, 2002, GENE CHROMOSOME CANC, V33, P1, DOI 10.1002/gcc.1206; Tibiletti MG, 1996, CANCER RES, V56, P4493; van der Burg M, 2004, LEUKEMIA, V18, P895, DOI 10.1038/sj.leu.2403340; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Whitcomb BP, 2003, CLIN CANCER RES, V9, P2277; Zhadanov AB, 1999, CURR BIOL, V9, P880, DOI 10.1016/S0960-9822(99)80392-3	61	64	65	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					298	307		10.1038/sj.onc.1209772	http://dx.doi.org/10.1038/sj.onc.1209772			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819513				2022-12-28	WOS:000243398300014
J	Vogler, M; Durr, K; Jovanovic, M; Debatin, KM; Fulda, S				Vogler, M.; Duerr, K.; Jovanovic, M.; Debatin, K-M; Fulda, S.			Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells	ONCOGENE			English	Article						apoptosis; TRAIL; pancreatic cancer; XIAP; resistance	X-LINKED INHIBITOR; DRUG-INDUCED APOPTOSIS; DOWN-REGULATION; CANCER-CELLS; EXPRESSION; PROTEINS; DEATH; BCL-2; REGRESSION; RESISTANT	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapy because of its relative tumor selectivity. However, many cancers including pancreatic cancer remain resistant towards TRAIL. To develop TRAIL for cancer therapy of pancreatic carcinoma, it will therefore be pivotal to elucidate the molecular mechanisms of TRAIL resistance. Here, we identify X-linked inhibitor of apoptosis (XIAP) as a regulator of TRAIL sensitivity in pancreatic carcinoma cells. Full activation of effector caspases, loss of mitochondrial membrane potential and cytochrome c release following TRAIL treatment were markedly impaired in pancreatic carcinoma cell lines, which poorly responded to TRAIL (PaTuII, PancTu1, ASPC1, DanG), compared to TRAIL-sensitive Colo357 pancreatic carcinoma cells. Stable downregulation of XIAP by RNA interference significantly reduced survival and enhanced TRAIL-induced apoptosis in pancreatic carcinoma cells. Also, downregulation of XIAP significantly increased CD95-induced cell death. Importantly, knockdown of XIAP strongly inhibited clonogenicity of pancreatic cancer cells treated with TRAIL indicating that XIAP promotes clonogenic survival of pancreatic carcinoma cells. Thus, our findings for the first time indicate that targeting XIAP represents a promising strategy to enhance the antitumor activity of TRAIL in pancreatic cancer, which has important clinical implications.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014; Duerr, Katharina/A-6975-2015	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Vogler, Meike/0000-0003-2650-586X; Duerr, Katharina/0000-0002-3245-4088				Amantana A, 2004, MOL CANCER THER, V3, P699; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Burstein E, 2004, EMBO J, V23, P244, DOI 10.1038/sj.emboj.7600031; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; Ehrhardt H, 2003, ONCOGENE, V22, P3842, DOI 10.1038/sj.onc.1206520; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 2004, VITAM HORM, V67, P275; Gerhard MC, 2002, BRIT J CANCER, V86, P893, DOI 10.1038/sj.bjc.6600171; Hao YY, 2004, NAT CELL BIOL, V6, P849, DOI 10.1038/ncb1159; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hinz S, 2000, ONCOGENE, V19, P5477, DOI 10.1038/sj.onc.1203936; Hu YP, 2003, CLIN CANCER RES, V9, P2826; Ibrahim SM, 2001, PANCREAS, V23, P72, DOI 10.1097/00006676-200107000-00011; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706; McManus DC, 2004, ONCOGENE, V23, P8105, DOI 10.1038/sj.onc.1207967; Mohr A, 2004, CELL DEATH DIFFER, V11, P1153, DOI 10.1038/sj.cdd.4401480; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sasaki H, 2000, CANCER RES, V60, P5659; Satoh K, 2001, PANCREAS, V23, P251, DOI 10.1097/00006676-200110000-00005; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; Trauzold A, 2001, ONCOGENE, V20, P4258, DOI 10.1038/sj.onc.1204559; Trauzold A, 2003, BRIT J CANCER, V89, P1714, DOI 10.1038/sj.bjc.6601330; Vischioni B, 2006, HUM PATHOL, V37, P78, DOI 10.1016/j.humpath.2005.09.022; Westphal Sabine, 2003, Mol Cancer, V2, P6, DOI 10.1186/1476-4598-2-6; Wolff RA, 2000, INVEST NEW DRUG, V18, P43, DOI 10.1023/A:1006383831045; Yang L, 2003, CANCER RES, V63, P6815	38	95	97	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					248	257		10.1038/sj.onc.1209776	http://dx.doi.org/10.1038/sj.onc.1209776			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832350				2022-12-28	WOS:000243398300008
J	Niehrs, C				Niehrs, C.			Function and biological roles of the Dickkopf family of Wnt modulators	ONCOGENE			English	Review						Dkk; Wnt; Kremen; embryo; Lrp6; colipase fold	RECEPTOR-RELATED PROTEIN-5; HEAD INDUCER DICKKOPF-1; HOMEOBOX GENE CLUSTERS; HIGH BONE MASS; BETA-CATENIN; SIGNALING PATHWAY; WNT/BETA-CATENIN; ANTAGONIST DICKKOPF-1; LIMB DEVELOPMENT; OSTEOBLAST DIFFERENTIATION	Dickkopf (Dkk) genes comprise an evolutionary conserved small gene family of four members (Dkk1-4) and a unique Dkk3-related gene, Dkkl1 (soggy). They encode secreted proteins that typically antagonize Wnt/beta-catenin signaling, by inhibiting the Wnt coreceptors Lrp5 and 6. Additionally, Dkks are high affinity ligands for the transmembrane proteins Kremen1 and 2, which also modulate Wnt signaling. Dkks play an important role in vertebrate development, where they locally inhibit Wnt regulated processes such as antero-posterior axial patterning, limb development, somitogenesis and eye formation. In the adult, Dkks are implicated in bone formation and bone disease, cancer and Alzheimer's disease.	German Canc Res Ctr, Dept Mol Embryol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), German Canc Res Ctr, Dept Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	Niehrs@DKFZ-Heidelberg.DE						Abarzua F, 2005, CANCER RES, V65, P9617, DOI 10.1158/0008-5472.CAN-05-0829; Adamska M, 2004, DEV BIOL, V272, P134, DOI 10.1016/j.ydbio.2004.04.026; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946-4955.2005; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; Aravind L, 1998, CURR BIOL, V8, pR477, DOI 10.1016/S0960-9822(98)70309-4; Aulehla A, 2004, GENE DEV, V18, P2060, DOI 10.1101/gad.1217404; Aulehla A, 2003, DEV CELL, V4, P395, DOI 10.1016/S1534-5807(03)00055-8; Aung PP, 2006, ONCOGENE, V25, P2546, DOI 10.1038/sj.onc.1209279; Babij P, 2003, J BONE MINER RES, V18, P960, DOI 10.1359/jbmr.2003.18.6.960; Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081; Barrantes ID, 2006, MOL CELL BIOL, V26, P2317, DOI 10.1128/MCB.26.6.2317-2326.2006; Barrantes ID, 2003, GENE DEV, V17, P2239, DOI 10.1101/gad.269103; Barrow JR, 2003, GENE DEV, V17, P394, DOI 10.1101/gad.1044903; Boisbouvier J, 1998, J MOL BIOL, V283, P205, DOI 10.1006/jmbi.1998.2057; Boyden LM, 2002, NEW ENGL J MED, V346, P1513, DOI 10.1056/NEJMoa013444; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Bullock CM, 2004, MOL PHARMACOL, V65, P582, DOI 10.1124/mol.65.3.582; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 2006, J CELL SCI, V119, P395, DOI 10.1242/jcs.02826; Cappuccio I, 2005, J NEUROSCI, V25, P2647, DOI 10.1523/JNEUROSCI.5230-04.2005; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Caricasole A, 2003, J BIOL CHEM, V278, P37024, DOI 10.1074/jbc.M300191200; Carter M, 2005, P NATL ACAD SCI USA, V102, P12843, DOI 10.1073/pnas.0501963102; Chamorro MN, 2005, EMBO J, V24, P73, DOI 10.1038/sj.emboj.7600460; Chapman SC, 2004, DEV DYNAM, V229, P668, DOI 10.1002/dvdy.10491; Church VL, 2002, INT J DEV BIOL, V46, P927; Davidson G, 2005, NATURE, V438, P867, DOI 10.1038/nature04170; Davidson G, 2002, DEVELOPMENT, V129, P5587, DOI 10.1242/dev.00154; De Robertis EM, 2004, ANNU REV CELL DEV BI, V20, P285, DOI 10.1146/annurev.cellbio.20.011403.154124; Diep DB, 2004, DEV BRAIN RES, V153, P261, DOI 10.1016/j.devbrainres.2004.09.008; Esteve P, 2006, CURR OPIN NEUROBIOL, V16, P13, DOI 10.1016/j.conb.2006.01.001; Fedders H, 2004, DEV GENES EVOL, V214, P72, DOI 10.1007/s00427-003-0378-9; Fedi P, 1999, J BIOL CHEM, V274, P19465, DOI 10.1074/jbc.274.27.19465; Fjeld K, 2005, DEV DYNAM, V233, P161, DOI 10.1002/dvdy.20285; Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092-8674(01)00571-2; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Greco TL, 1996, GENE DEV, V10, P313, DOI 10.1101/gad.10.3.313; Gregory CA, 2005, J BIOL CHEM, V280, P2309, DOI 10.1074/jbc.M406275200; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; Grotewold L, 1999, MECH DEVELOP, V89, P151, DOI 10.1016/S0925-4773(99)00194-X; Guder C, 2006, DEVELOPMENT, V133, P901, DOI 10.1242/dev.02265; Hashimoto H, 2000, DEV BIOL, V217, P138, DOI 10.1006/dbio.1999.9537; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hino K, 2003, DEV GENES EVOL, V213, P264, DOI 10.1007/s00427-003-0318-8; Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952; Holmen SL, 2005, BIOCHEM BIOPH RES CO, V328, P533, DOI 10.1016/j.bbrc.2005.01.009; Holmen SL, 2004, J BONE MINER RES, V19, P2033, DOI 10.1359/JBMR.040907; Hsieh SY, 2004, ONCOGENE, V23, P9183, DOI 10.1038/sj.onc.1208138; Idkowiak J, 2004, DEV GENES EVOL, V214, P591, DOI 10.1007/s00427-004-0436-y; Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674; Kaneko KJ, 2000, NUCLEIC ACIDS RES, V28, P3982, DOI 10.1093/nar/28.20.3982; Kaser A, 2003, EMBO REP, V4, P469, DOI 10.1038/sj.embor.embor830; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; KAWANO Y, 2006, ONCOGENE; Kazanskaya O, 2000, DEVELOPMENT, V127, P4981; Kelly OG, 2004, DEVELOPMENT, V131, P2803, DOI 10.1242/dev.01137; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Kobayashi K, 2002, GENE, V282, P151, DOI 10.1016/S0378-1119(01)00838-1; Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022; Kohn MJ, 2005, MOL REPROD DEV, V71, P516, DOI 10.1002/mrd.20314; Kokubu C, 2004, DEVELOPMENT, V131, P5469, DOI 10.1242/dev.01405; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Kurose K, 2004, J UROLOGY, V171, P1314, DOI 10.1097/01.ju.0000101047.64379.d4; Lee AY, 2004, BIOCHEM BIOPH RES CO, V323, P1246, DOI 10.1016/j.bbrc.2004.09.001; Leonard DM, 2000, J BIOL CHEM, V275, P25194, DOI 10.1074/jbc.M002036200; Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614; Liu GZ, 2005, MOL CELL BIOL, V25, P3475, DOI 10.1128/MCB.25.9.3475-3482.2005; Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407; Lovicu FJ, 2005, DEV BIOL, V280, P1, DOI 10.1016/j.ydbio.2005.01.020; Luke GN, 2003, P NATL ACAD SCI USA, V100, P5292, DOI 10.1073/pnas.0836141100; MacDonald BT, 2004, DEVELOPMENT, V131, P2543, DOI 10.1242/dev.01126; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Marvin MJ, 2001, GENE DEV, V15, P316, DOI 10.1101/gad.855501; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Mikheev AM, 2004, CARCINOGENESIS, V25, P47, DOI 10.1093/carcin/bgg190; Monaghan AP, 1999, MECH DEVELOP, V87, P45, DOI 10.1016/S0925-4773(99)00138-0; Montero-Pedrazuela A, 2003, ENDOCRINOLOGY, V144, P1045, DOI 10.1210/en.2002-220823; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311; Mukhopadhyay M, 2001, DEV CELL, V1, P423, DOI 10.1016/S1534-5807(01)00041-7; Mukhopadhyay M, 2006, DEVELOPMENT, V133, P2149, DOI 10.1242/dev.02381; Nakamura T, 2001, BBA-GENE STRUCT EXPR, V1518, P63, DOI 10.1016/S0167-4781(01)00168-3; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; Nie XG, 2005, J MOL HISTOL, V36, P367, DOI 10.1007/s10735-005-9008-3; Nie XG, 2005, J MOL HISTOL, V36, P419, DOI 10.1007/s10735-005-9014-5; Niehrs C, 2004, NAT REV GENET, V5, P425, DOI 10.1038/nrg1347; Niehrs C, 2004, DEV CELL, V6, P453, DOI 10.1016/S1534-5807(04)00102-9; Nozaki I, 2001, INT J ONCOL, V19, P117; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Orme MH, 2003, MOL CELL NEUROSCI, V24, P673, DOI 10.1016/S1044-7431(03)00229-X; Pandur P, 2002, NATURE, V418, P636, DOI 10.1038/nature00921; Patil MA, 2005, ONCOGENE, V24, P3737, DOI 10.1038/sj.onc.1208479; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Polakis P, 2000, GENE DEV, V14, P1837; Politou MC, 2006, INT J CANCER, V119, P1728, DOI 10.1002/ijc.22033; Pollard SL, 2000, CURR BIOL, V10, P1059, DOI 10.1016/S0960-9822(00)00676-X; Roman-Gomez J, 2004, BRIT J CANCER, V91, P707, DOI 10.1038/sj.bjc.6602008; Schneider VA, 2001, GENE DEV, V15, P304, DOI 10.1101/gad.855601; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Shinya M, 2000, MECH DEVELOP, V98, P3, DOI 10.1016/S0925-4773(00)00433-0; Shou J, 2002, ONCOGENE, V21, P878, DOI 10.1038/sj.onc.1205138; Soshnikova N, 2003, GENE DEV, V17, P1963, DOI 10.1101/gad.263003; Szeto TH, 2000, TOXICON, V38, P429, DOI 10.1016/S0041-0101(99)00174-9; Tada M, 2002, SEMIN CELL DEV BIOL, V13, P251, DOI 10.1016/S1084-9521(02)00052-6; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Tsuji T, 2000, BIOCHEM BIOPH RES CO, V268, P20, DOI 10.1006/bbrc.1999.2067; van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614; Van Raay TJ, 2004, DEV NEUROSCI-BASEL, V26, P352, DOI 10.1159/000082277; van Tilbeurgh H, 1999, BBA-MOL CELL BIOL L, V1441, P173, DOI 10.1016/S1388-1981(99)00149-3; Wang J, 2000, ONCOGENE, V19, P1843, DOI 10.1038/sj.onc.1203503; Wirths O, 2003, LAB INVEST, V83, P429, DOI 10.1097/01.LAB.0000059926.66359.BD; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; Yamaguchi Y, 2004, J CELL BIOL, V165, P275, DOI 10.1083/jcb.200311122; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522; Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	126	738	800	5	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7469	7481		10.1038/sj.onc.1210054	http://dx.doi.org/10.1038/sj.onc.1210054			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143291				2022-12-28	WOS:000242514900005
J	Mullan, PB; Quinn, JE; Harkin, DP				Mullan, P. B.; Quinn, J. E.; Harkin, D. P.			The role of BRCA1 in transcriptional regulation and cell cycle control	ONCOGENE			English	Review						BRCA1; transcription; cell cycle	RNA-POLYMERASE-II; ESTROGEN-RECEPTOR ACTIVITY; SUSCEPTIBILITY GENE BRCA1; ZINC-FINGER PROTEIN; DIRECTED DNA-REPAIR; C-TERMINAL REGION; INTERACT IN-VIVO; BREAST-CANCER; S-PHASE; IONIZING IRRADIATION	The exact functions of BRCA1 have not been fully described but it now seems apparent that it has roles in DNA damage repair, transcriptional regulation, cell cycle control and most recently in ubiquitylation. These functions of BRCA1 are most likely interdependent but this review will focus on the role of BRCA1 in relation to transcriptional regulation and in particular how this impacts upon cell cycle control. We will (i) describe the structure of BRCA1 and how it may contribute to its transcription function; (ii) describe the interaction of BRCA1 with the core transcriptional machinery ( RNA polII); (iii) describe how BRCA1 may regulate transcription at an epigenetic level through chromatin modi. cation; (iv) discuss the role of BRCA1 in modulating transcription through its association with sequence-specific transcription factors. Finally, we will discuss the possible effects of BRCA1 transcriptional regulation on downstream targets with known roles in cell cycle control.	Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Belfast BT9 7AB, Antrim, North Ireland	Belfast City Hospital; Queens University Belfast	Harkin, DP (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast City Hosp, Univ Floor,Lisburn Rd, Belfast BT9 7AB, Antrim, North Ireland.	d.harkin@qub.ac.uk			MRC [G0200103] Funding Source: UKRI; Medical Research Council [G0200103] Funding Source: Medline; Breast Cancer Now [2003:596] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Breast Cancer Now		Ahmad N, 2000, BIOCHEM BIOPH RES CO, V275, P328, DOI 10.1006/bbrc.2000.3297; Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bernabei P, 2003, BLOOD, V102, P2933, DOI 10.1182/blood-2003-01-0100; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Cabart P, 2004, ONCOGENE, V23, P5316, DOI 10.1038/sj.onc.1207684; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen GC, 2001, BIOCHEM BIOPH RES CO, V284, P507, DOI 10.1006/bbrc.2001.5003; Chen YM, 1996, CANCER RES, V56, P3168; Chiba N, 2002, CANCER RES, V62, P4222; Fabbro M, 2004, J BIOL CHEM, V279, P31251, DOI 10.1074/jbc.M405372200; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2002, CANCER RES, V62, P141; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Feng ZH, 2004, J BIOL CHEM, V279, P28574, DOI 10.1074/jbc.M404137200; Gilmore PM, 2004, CANCER RES, V64, P4148, DOI 10.1158/0008-5472.CAN-03-4080; Haile DT, 1999, J BIOL CHEM, V274, P2113, DOI 10.1074/jbc.274.4.2113; Hashizume R, 2001, J BIOL CHEM, V276, P14537, DOI 10.1074/jbc.C000881200; Hulka BS, 2001, MATURITAS, V38, P103, DOI 10.1016/S0378-5122(00)00196-1; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; Ikeda T, 2002, J LEUKOCYTE BIOL, V72, P1198; Jin SQ, 2000, ONCOGENE, V19, P4050, DOI 10.1038/sj.onc.1203759; Kadam S, 2000, GENE DEV, V14, P2441, DOI 10.1101/gad.828000; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kleiman FE, 2005, GENE DEV, V19, P1227, DOI 10.1101/gad.1309505; Krum SA, 2003, J BIOL CHEM, V278, P52012, DOI 10.1074/jbc.M308418200; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; MacLachlan TK, 2000, J BIOL CHEM, V275, P31869, DOI 10.1074/jbc.M003338200; MacLachlan TK, 2000, J BIOL CHEM, V275, P2777, DOI 10.1074/jbc.275.4.2777; MacLachlan TK, 2002, MOL CELL BIOL, V22, P4280, DOI 10.1128/MCB.22.12.4280-4292.2002; Manke IA, 2003, SCIENCE, V302, P636, DOI 10.1126/science.1088877; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moisan A, 2004, MOL CELL BIOL, V24, P6947, DOI 10.1128/MCB.24.16.6947-6956.2004; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; Mullan PB, 2005, ONCOGENE, V24, P5492, DOI 10.1038/sj.onc.1208698; Mullan PB, 2001, ONCOGENE, V20, P6123, DOI 10.1038/sj.onc.1204712; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Oishi H, 2006, J BIOL CHEM, V281, P20, DOI 10.1074/jbc.M510157200; Ongusaha PP, 2003, ONCOGENE, V22, P3749, DOI 10.1038/sj.onc.1206439; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Quinn JE, 2003, CANCER RES, V63, P6221; Razandi M, 2004, MOL CELL BIOL, V24, P5900, DOI 10.1128/MCB.24.13.5900-5913.2004; Ree AH, 2003, ONCOGENE, V22, P8952, DOI 10.1038/sj.onc.1207000; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Tan W, 2004, J BIOL CHEM, V279, P55153, DOI 10.1074/jbc.M410926200; Tan W, 2004, J BIOL CHEM, V279, P6576, DOI 10.1074/jbc.M312270200; Wada O, 2004, ONCOGENE, V23, P6000, DOI 10.1038/sj.onc.1207786; Wang CG, 2005, CANCER RES, V65, P6557, DOI 10.1158/0008-5472.CAN-05-0486; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Williams RS, 2003, J BIOL CHEM, V278, P2630, DOI 10.1074/jbc.M210019200; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Xiong JB, 2003, MOL CELL BIOL, V23, P8668, DOI 10.1128/MCB.23.23.8668-8690.2003; Xu B, 2002, CANCER RES, V62, P4588; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu JW, 2005, ENDOCRINOLOGY, V146, P2031, DOI 10.1210/en.2004-0409; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yun JH, 2003, MOL CELL BIOL, V23, P7305, DOI 10.1128/MCB.23.20.7305-7314.2003; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang XT, 2005, MOL CELL, V19, P89, DOI 10.1016/j.molcel.2005.05.015; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200	88	214	218	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 25	2006	25	43					5854	5863		10.1038/sj.onc.1209872	http://dx.doi.org/10.1038/sj.onc.1209872			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998500				2022-12-28	WOS:000240765900006
J	Cooper, K				Cooper, K.			Rb, whi it's not just for metazoans anymore	ONCOGENE			English	Review						cyclin; cyclin dependent kinases; retinoblastoma; heterodimeric transcription factors; cell cycle; G1 progression	START-SPECIFIC TRANSCRIPTION; YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; MATING-PHEROMONE; S-PHASE; CLN3-CDC28 KINASE; PROTEIN-KINASE; BUDDING YEAST; G(1) CONTROL; E2F	The E2F family of heterodimeric transcription factors controls the expression of genes required in G1 for cell cycle progression. The retinoblastoma ( Rb) family of pocket proteins which, upon binding to E2F, inhibit this complex from initiating transcription. Upon mitogen stimulation, this repression is relieved by hyperphosphorylation of Rb by the cyclin D Cdk4/6 complex. Initiation of the cell cycle in yeast is similar. The heterodimeric transcription factor SBF controls most G1-specific transcription. Its activation is dependent upon the removal of Whi5; a functional homolog of Rb. Similar to Rb, disassociation of Whi5 from SBF is controlled by G1 cyclin/Cdk-dependent phosphorylation. Although Rb and Whi5 play similar roles in regulating G1 gene expression, they exhibit no sequence homology. This review will discuss the difference and similarities between how these proteins play similar roles in controlling G1 progression.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Cooper, K (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	cooperka@umdnj.edu						AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bean CJ, 2001, HUM MOL GENET, V10, P963, DOI 10.1093/hmg/10.9.963; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flick JS, 1998, GENETICS, V148, P33; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Harrington LA, 1996, NUCLEIC ACIDS RES, V24, P558, DOI 10.1093/nar/24.4.558; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kato M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r56; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 2005, PHILOS T R SOC B, V360, P483, DOI 10.1098/rstb.2004.1604; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wang XC, 1997, T NONFERR METAL SOC, V7, P45; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	55	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5228	5232		10.1038/sj.onc.1209630	http://dx.doi.org/10.1038/sj.onc.1209630			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936741	Bronze			2022-12-28	WOS:000240064100007
J	Seeff, LB; Hoofnagle, JH				Seeff, L. B.; Hoofnagle, J. H.			Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B; hepatitis C	CHRONIC LIVER-DISEASE; UNITED-STATES; WORLDWIDE INCIDENCE; VIRAL-HEPATITIS; VIRUS; CANCER; TRENDS; POPULATION; BURDEN; PREVALENCE	Hepatocellular carcinoma (HCC) ranks among the 10 most common cancers worldwide. It evolves from several chronic liver diseases, most of which culminate in cirrhosis. As the most common causes, other than alcoholic cirrhosis, are chronic hepatitis B and C infections, its prevalence worldwide is linked to the prevalence of these two viruses. Thus, the highest rates are in southeast Asia and sub-Saharan Africa, the world's most populous nations, where hepatitis B virus infection is endemic. In most western countries, hepatitis C virus infection is the predominant cause, and hepatitis B-related liver cancer occurs largely among immigrants from countries of high hepatitis B endemicity. In most western countries, the incidence and mortality from HCC is increasing as a consequence of the chronic sequelae of the 'epidemic' of hepatitis C of the 1960 - 1980s. In the US, modeling of this infection predicts a continued rise in liver cancer over the next decade. Surveillance by the National Cancer Institute and the Centers for Disease Control confirms the increasing incidence of and mortality from HCC to the year 2000, although subsequent analyses suggest a slowing or possibly decline in the rate of increase. Whether this trend will continue requires further evaluation.	NIDDK, Liver Dis Res Branch, Div Digest Dis & Nutr, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Seeff, LB (corresponding author), NIDDK, Liver Dis Res Branch, Div Digest Dis & Nutr, NIH, 27A Ctr Dr,Room 9A27, Bethesda, MD 20892 USA.	seeffL@EXTRA.NIDDK.NIH.GOV						Armstrong GL, 2000, HEPATOLOGY, V31, P777, DOI 10.1002/hep.510310332; BEASLEY RP, 1981, LANCET, V2, P1129; BLUMBERG BS, 1965, J AMER MED ASSOC, V191, P541, DOI 10.1001/jama.1965.03080070025007; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; BRUIX J, 1989, LANCET, V2, P1004; Caldwell SH, 2004, GASTROENTEROLOGY, V127, pS97, DOI 10.1053/j.gastro.2004.09.021; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020; Delarocque-Astagneau E, 2005, ANN EPIDEMIOL, V15, P551, DOI 10.1016/j.annepidem.2004.12.006; Deuffic S, 1999, J VIRAL HEPATITIS, V6, P411, DOI 10.1046/j.1365-2893.1999.00178.x; Dyer Z, 2005, ALIMENT PHARM THER, V22, P17, DOI 10.1111/j.1365-2036.2005.02504.x; Edwards BK, 2005, JNCI-J NATL CANCER I, V97, P1407, DOI 10.1093/jnci/dji289; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; El-Serag HB, 2002, J CLIN GASTROENTEROL, V35, pS72, DOI 10.1097/00004836-200211002-00002; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Hankey BF, 1999, CANCER EPIDEM BIOMAR, V8, P1117; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; HUTTON MD, 2001, J REGISTRY MANAGE, V28, P113; Kim HJ, 2000, STAT MED, V19, P335, DOI 10.1002/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z; Lavanchy D, 2004, J VIRAL HEPATITIS, V11, P97, DOI 10.1046/j.1365-2893.2003.00487.x; Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939; McGlynn KA, 2001, INT J CANCER, V94, P290, DOI 10.1002/ijc.1456; *NAT CANC I, 2005, SEER; *NAT CTR CHRON DIS, 2005, NAT PROGR CANC REG C; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; REIS LAG, 2005, SEER CANC STAT REV 1; Warren JL, 2002, MED CARE, V40, P3; Wong JB, 2000, AM J PUBLIC HEALTH, V90, P1562, DOI 10.2105/AJPH.90.10.1562; World Health Organization, 2003, WORLD HLTH REP SHAP	33	123	135	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3771	3777		10.1038/sj.onc.1209560	http://dx.doi.org/10.1038/sj.onc.1209560			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799618				2022-12-28	WOS:000238559600004
J	Murkoster, SS; Werbing, V; Sipos, B; Debus, MA; Witt, M; Grossmann, M; Leisner, D; Kotteritzsch, J; Kappes, H; Kloppel, G; Altevogt, P; Folsch, UR; Schafer, H				Muerkoester, S. Sebens; Werbing, V.; Sipos, B.; Debus, M. A.; Witt, M.; Grossmann, M.; Leisner, D.; Koetteritzsch, J.; Kappes, H.; Kloeppel, G.; Altevogt, P.; Foelsch, U. R.; Schaefer, H.			Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells	ONCOGENE			English	Article						chemoresistance; pancreatic ductal adenocarcinoma; L1CAM; NO	CARCINOMA-CELLS; OVARIAN CARCINOMAS; CANCER CELLS; TUMOR-GROWTH; L1 CD171; MIGRATION; PROGRESSION; INHIBITION; BINDING	Pancreatic ductal adenocarcinoma (PDAC) is characterized by rapid tumor progression, high metastatic potential and profound chemoresistance. We recently reported that induction of a chemoresistant phenotype in the PDAC cell line PT45-P1 by long-term chemotherapy involves an increased interleukin 1 beta (IL1b)-dependent secretion of nitric oxide (NO) accounting for efficient caspase inhibition. In the present study, we elucidated the involvement of L1CAM, an adhesion molecule previously found in other malignancies, in this NO-dependent chemoresistance. Chemoresistant PT45-P1res cells, but not chemosensitive parental PT45-P1 cells, express high levels of L1CAMin an IL beta-dependent fashion. PT45-P1res cells subjected to short interfering RNA (siRNA)- mediated L1CAM knock-down exhibited reduced inducible nitric oxide synthase expression and NO secretion, as well as a significant increase of anticancer drug-induced caspase activation, an effect reversed by the NO donor S-nitroso-N-acetyl-D,L-penicillamine. Conversely, overexpression of L1CAMin PT45-P1 cells conferred anti-apoptotic protection to anti-cancer drug treatment. Interestingly, L1CAM ectodomain shedding, in example, by ADAM10, as reported for other L1CAM-related activities, seemed to be dispensable for antiapoptotic protection by L1CAM. Neither the shedded L1CAM ectodomain was detected in chemoresistant L1CAM-expressing PT45-P1 cells nor did the administration of various metalloproteinase inhibitors affect L1CAM-dependent chemoresistance. Immunohistochemical analysis revealed L1CAM expression in 80% of pancreatic cancer specimens, supporting a potential role of L1CAMin the malignancy of this tumor. These findings substantiate our understanding of the molecular mechanisms leading to chemoresistance in PDAC cells and indicate the importance of L1CAMin this scenario.	UKHS, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, D-24105 Kiel, Germany; UKHS, Dept Pathol, Kiel, Germany; German Canc Res Ctr, Tumor Immunol Programme, D-6900 Heidelberg, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ)	Schafer, H (corresponding author), UKHS, Clin Internal Med, Lab Mol Gastroenterol & Hepatol, Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Sebens, Susanne/C-1222-2010					Arlt A, 2002, CANCER RES, V62, P910; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Arlt MJE, 2006, CANCER RES, V66, P936, DOI 10.1158/0008-5472.CAN-05-1818; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Castellani V, 2002, EMBO J, V21, P6348, DOI 10.1093/emboj/cdf645; Fogel M, 2003, LANCET, V362, P869, DOI 10.1016/S0140-6736(03)14342-5; Fukahi K, 2004, CLIN CANCER RES, V10, P581, DOI 10.1158/1078-0432.CCR-0930-03; Gast D, 2005, INT J CANCER, V115, P658, DOI 10.1002/ijc.20869; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Hortsch M, 2000, MOL CELL NEUROSCI, V15, P1, DOI 10.1006/mcne.1999.0809; Izumoto S, 1996, CANCER RES, V56, P1440; Kaifi JT, 2006, MODERN PATHOL, V19, P399, DOI 10.1038/modpathol.3800547; Kaifi JT, 2006, WORLD J GASTROENTERO, V12, P94, DOI 10.3748/wjg.v12.i1.94; KALTHOFF H, 1993, ONCOGENE, V8, P289; Lockhart AC, 2005, GASTROENTEROLOGY, V128, P1642, DOI 10.1053/j.gastro.2005.03.039; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Maretzky T, 2005, MOL CELL BIOL, V25, P9040, DOI 10.1128/MCB.25.20.9040-9053.2005; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Meier F, 2006, INT J CANCER, V119, P549, DOI 10.1002/ijc.21880; Miyamoto H, 2004, PANCREAS, V28, P38, DOI 10.1097/00006676-200401000-00006; MOOS M, 1988, NATURE, V334, P701, DOI 10.1038/334701a0; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Muerkoster SS, 2006, ONCOGENE, V25, P4628, DOI 10.1038/sj.onc.1209806; Schachner M, 1997, CURR OPIN CELL BIOL, V9, P627, DOI 10.1016/S0955-0674(97)80115-9; Schafer H, 1999, BIOCHEM BIOPH RES CO, V262, P139, DOI 10.1006/bbrc.1999.1131; Schneider G, 2005, GASTROENTEROLOGY, V128, P1606, DOI 10.1053/j.gastro.2005.04.001; St Croix Brad, 1997, Current Opinion in Oncology, V9, P549; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663	28	94	97	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2759	2768		10.1038/sj.onc.1210076	http://dx.doi.org/10.1038/sj.onc.1210076			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17086212				2022-12-28	WOS:000246210600010
J	Avivi, A; Ashur-Fabian, O; Joel, A; Trakhtenbrot, L; Adamsky, K; Goldstein, I; Amariglio, N; Rechavi, G; Nevo, E				Avivi, A.; Ashur-Fabian, O.; Joel, A.; Trakhtenbrot, L.; Adamsky, K.; Goldstein, I.; Amariglio, N.; Rechavi, G.; Nevo, E.			P53 in blind subterranean mole rats - loss-of-function versus gain-offunction activities on newly cloned Spalax target genes	ONCOGENE			English	Article						subterranean mole rat; hypoxia; p53; apaf1; mdm2	ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; APOPTOSIS; TOLERANCE; MUTANTS; CELLS; ERYTHROPOIETIN; ACTIVATION; CANCER; APAF-1	A tumor suppressor gene, p53, controls cellular responses to a variety of stress conditions, including DNA damage and hypoxia, leading to growth arrest and/or apoptosis. Recently, we demonstrated that in blind subterranean mole rats, Spalax, a model organism for hypoxia tolerance, the p53 DNA-binding domain contains a specific Arg174Lys amino acid substitution. This substitution reduces the p53 effect on the transcription of apoptosis genes ( apaf1, puma, pten and noxa) and enhances it on human cell cycle arrest and p53 stabilization/homeostasis genes (mdm2, pten, p21 and cycG). In the current study, we cloned Spalax apaf1 promoter and mdm2 intronic regions containing consensus p53-responsive elements. We compared the Spalax-responsive elements to those of human, mouse and rat and investigated the transcriptional activity of Spalax and human Arg174Lys-mutated p53 on target genes of both species. Spalax and human-mutated p53 lost induction of apaf1 transcription, and increased induction of mdm2 transcription. We conclude that Spalax evolved hypoxia-adaptive mechanisms, analogous to the alterations acquired by cancer cells during tumor development, with a bias against apoptosis while favoring cell arrest and DNA repair.	Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel; Safra Childrens Hosp, Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	University of Haifa; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, Aba Hushi Blv, IL-31905 Haifa, Israel.	aaron@research.haifa.ac.il	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182				Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2005, FASEB J, V19, P1314, DOI 10.1096/fj.04-3414fje; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein G, 2004, CELL DEATH DIFFER, V11, P13, DOI 10.1038/sj.cdd.4401342; Kuramochi H, 2006, CLIN CANCER RES, V12, P29, DOI 10.1158/1078-0432.CCR-05-1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E., 2001, ADAPTIVE RAD BLIND S; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Shams I, 2005, FASEB J, V19, P1749, DOI 10.1096/fj.05-3975fje; Shams I, 2004, FASEB J, V18, P307, DOI 10.1096/fj.04-2758fje; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062	33	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2507	2512		10.1038/sj.onc.1210045	http://dx.doi.org/10.1038/sj.onc.1210045			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043642				2022-12-28	WOS:000245831000011
J	Brauweiler, A; Lorick, KL; Lee, JP; Tsai, YC; Chan, D; Weissman, AM; Drabkin, HA; Gemmill, RM				Brauweiler, A.; Lorick, K. L.; Lee, J. P.; Tsai, Y. C.; Chan, D.; Weissman, A. M.; Drabkin, H. A.; Gemmill, R. M.			RING-dependent tumor suppression and G2/M arrest induced by the TRC8 hereditary kidney cancer gene	ONCOGENE			English	Article						ubiquitin ligase; SREBP; clear-cell renal carcinoma; RING-H2	RENAL-CELL CARCINOMA; ELEMENT-BINDING PROTEIN; CHOLESTEROL; EXPRESSION; GROWTH; TRANSLOCATION; ACTIVATION; MECHANISMS; COMPLEX; DOMAIN	TRC8/RNF139 and von Hippel-Lindau (VHL) both encode E3 ubiquitin (Ub) ligases mutated in clear-cell renal carcinomas (ccRCC). VHL, inactivated in nearly 70% of ccRCCs, is a tumor suppressor encoding the targeting subunit for a Ub ligase complex that down-regulates hypoxia-inducible factor-alpha. TRC8/RNF139 is a putative tumor suppressor containing a sterol-sensing domain and a RING-H2 motif essential for Ub ligase activity. Here we report that human kidney cells are growth inhibited by TRC8. Inhibition is manifested by G2/M arrest, decreased DNA synthesis and increased apoptosis and is dependent upon the Ub ligase activity of the RING domain. Tumor formation in a nude mouse model is inhibited by TRC8 in a RING-dependent manner. Expression of TRC8 represses genes involved in cholesterol and fatty acid biosynthesis that are transcriptionally regulated by the sterol response element binding proteins (SREBPs). Expression of activated SREBP-1a partially restores the growth of TRC8-inhibited cells. These data suggest that TRC8 modulation of SREBP activity comprises a novel regulatory link between growth control and the cholesterol/lipid homeostasis pathway.	Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, Aurora, CO 80045 USA; Univ Colorado, Ctr Canc, Aurora, CO 80045 USA; NCI, Lab Prot Dynam & Signaling, Frederick, MD 21701 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gemmill, RM (corresponding author), Univ Colorado Denver & Hlth Sci Ctr, Div Med Oncol, Dept Med, 12801 E 17th Ave,Mail Stop 8117,POB 6511, Aurora, CO 80045 USA.	robert.gemmill@uchsc.edu		Tsai, Yien Che/0000-0001-9624-1092	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA076035] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076035, Z01BC009392] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ciechanover A, 2006, NEUROLOGY, V66, pS7, DOI 10.1212/01.wnl.0000192261.02023.b8; CLAYMAN RV, 1986, CANCER RES, V46, P2958; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; COHEN AJ, 1979, NEW ENGL J MED, V301, P592, DOI 10.1056/NEJM197909133011107; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; GEBHARD RL, 1987, J LIPID RES, V28, P1177; Gemmill RM, 2002, ONCOGENE, V21, P3507, DOI 10.1038/sj.onc.1205437; Gemmill RM, 2005, ONCOGENE, V24, P3503, DOI 10.1038/sj.onc.1208509; Gemmill RM, 1998, P NATL ACAD SCI USA, V95, P9572, DOI 10.1073/pnas.95.16.9572; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Hughes AL, 2005, CELL, V120, P831, DOI 10.1016/j.cell.2005.01.012; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kaelin WG, 2004, CLIN CANCER RES, V10, p6290S, DOI 10.1158/1078-0432.CCR-sup-040025; Katoh S, 2003, J BIOL CHEM, V278, P15341, DOI 10.1074/jbc.M210531200; LI FP, 1993, ANN INTERN MED, V118, P106, DOI 10.7326/0003-4819-118-2-199301150-00005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma DQ, 2005, CANCER RES, V65, P5523, DOI 10.1158/0008-5472.CAN-04-2582; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Ohira T, 2003, P NATL ACAD SCI USA, V100, P10429, DOI 10.1073/pnas.1734137100; Todd BL, 2006, MOL CELL BIOL, V26, P2817, DOI 10.1128/MCB.26.7.2817-2831.2006; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	28	29	30	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2263	2271		10.1038/sj.onc.1210017	http://dx.doi.org/10.1038/sj.onc.1210017			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016439	Bronze			2022-12-28	WOS:000245466000002
J	Seng, TJ; Low, JSW; Li, H; Cui, Y; Goh, HK; Wong, MLY; Srivastava, G; Sidransky, D; Califano, J; Steenbergen, RDM; Rha, SY; Tan, J; Hsieh, WS; Ambinder, RF; Lin, X; Chan, ATC; Tao, Q				Seng, T. J.; Low, J. S. W.; Li, H.; Cui, Y.; Goh, H. K.; Wong, M. L. Y.; Srivastava, G.; Sidransky, D.; Califano, J.; Steenbergen, R. D. M.; Rha, S. Y.; Tan, J.; Hsieh, W-S; Ambinder, R. F.; Lin, X.; Chan, A. T. C.; Tao, Q.			The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation	ONCOGENE			English	Article						DLC1; 8p22; tumor suppressor gene; methylation; nasopharyngeal carcinoma; esophageal carcinoma; cervical carcinoma	EPSTEIN-BARR-VIRUS; COMPARATIVE GENOMIC HYBRIDIZATION; STRESS-RESPONSIVE GENE; HUMAN BREAST-CANCER; PROMOTER HYPERMETHYLATION; P53 GENE; EPIGENETIC INACTIVATION; SUSCEPTIBILITY LOCUS; TSLC1 GENE; MULTIPLE	Identification of tumor suppressor genes (TSG) silenced by methylation uncovers mechanisms of tumorigenesis and identifies new epigenetic tumor markers for early cancer detection. Both nasopharyngeal carcinoma (NPC) and esophageal carcinoma are major tumors in Southern China and Southeast Asia. Through expression subtraction of NPC, we identified Deleted in Liver Cancer 1 (DLC1)/ARHGAP7 (NM_006094) - an 8p22 TSG as a major downregulated gene. Although expressed in all normal tissues, DLC1 was silenced or downregulated in 11/12 (91%) NPC, 6/15 (40%) esophageal, 5/8 (63%) cervical and 3/9 (33%) breast carcinoma cell lines. No genetic deletion of DLC1 was detected in NPC although a hemizygous deletion at 8p22-11 was found by 1-Mb array-CGH in some cell lines. We then located the functional DLC1 promoter by 5'-RACE and promoter activity assays. This promoter was frequently methylated in all downregulated cell lines and in a large collection of primary tumors including 89% (64/72) NPC (endemic and sporadic types), 51% (48/94) esophageal, 87% (7/8) cervical and 36% (5/14) breast carcinomas, but seldom in paired surgical marginal tissues and not in any normal epithelial tissue. The transcriptional silencing of DLC1 could be reversed by 5-aza-20-deoxycytidine or genetic double knock-out of DNMT1 and DNMT3B. Furthermore, ectopic expression of DLC1 in NPC and esophageal carcinoma cells strongly inhibited their colony formation. We thus found frequent epigenetic silencing of DLC1 in NPC, esophageal and cervical carcinomas, and a high correlation of methylation with its downregulation, suggesting a predominant role of epigenetic inactivation. DLC1 appears to be a major TSG implicated in the pathogenesis of these tumors, and should be further tested as a molecular biomarker in patients with these cancers.	Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Singapore, Biopolis, Singapore, Singapore; Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; Johns Hopkins Med Inst, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA; Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HV Amsterdam, Netherlands; Yonsei Univ, Coll Med, Ctr Canc, Seoul 120749, South Korea; Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Chinese University of Hong Kong; Prince of Wales Hospital; Johns Hopkins University; Johns Hopkins Medicine; University of Hong Kong; Johns Hopkins University; Johns Hopkins Medicine; Vrije Universiteit Amsterdam; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Tao, Q (corresponding author), Chinese Univ Hong Kong, Ctr Canc, Canc Epigenet Lab, Dept Clin Oncol,PWH, Hong Kong, Hong Kong, Peoples R China.	qtao@clo.cuhk.edu.hk	Tao, Qian/T-4743-2018; Chan, Anthony Tak Cheung/R-3940-2018	Tao, Qian/0000-0001-5383-4808; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Rha, Sun Young/0000-0002-2512-4531; Steenbergen, Renske/0000-0002-2327-9839	NATIONAL CANCER INSTITUTE [P01CA015396] Funding Source: NIH RePORTER; NCI NIH HHS [P01CA15396] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chen YJ, 1999, GENE CHROMOSOME CANC, V25, P169, DOI 10.1002/(SICI)1098-2264(199906)25:2<169::AID-GCC13>3.3.CO;2-9; Cheng Y, 2002, GENE CHROMOSOME CANC, V34, P97, DOI 10.1002/gcc.10048; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Deng W, 2004, ONCOGENE, V23, P9090, DOI 10.1038/sj.onc.1208119; EFFERT P, 1992, J VIROL, V66, P3768, DOI 10.1128/JVI.66.6.3768-3775.1992; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Feng BJ, 2002, NAT GENET, V31, P395, DOI 10.1038/ng932; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GLASER R, 1989, P NATL ACAD SCI USA, V86, P9524, DOI 10.1073/pnas.86.23.9524; Gulley ML, 1998, AM J PATHOL, V152, P865; HILDESHEIM A, 1993, EPIDEMIOL REV, V15, P466, DOI 10.1093/oxfordjournals.epirev.a036130; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; Hui ABY, 2003, MOL CARCINOGEN, V38, P170, DOI 10.1002/mc.10156; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Kim TM, 2005, CLIN CANCER RES, V11, P79; Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573; Lo KW, 2000, CANCER RES, V60, P3348; LO KW, 1995, CANCER RES, V55, P2039; LU SJ, 1990, NATURE, V346, P470, DOI 10.1038/346470a0; Moon SY, 2003, TRENDS CELL BIOL, V13, P13, DOI 10.1016/S0962-8924(02)00004-1; Murray PG, 2004, ONCOGENE, V23, P1326, DOI 10.1038/sj.onc.1207313; PATHMANATHAN R, 1995, NEW ENGL J MED, V333, P693, DOI 10.1056/NEJM199509143331103; Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Raab-Traub N, 2002, SEMIN CANCER BIOL, V12, P431, DOI 10.1016/S1044579X0200086X; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; SPRUCK CH, 1992, CANCER RES, V52, P4787; Srivastava G, 2000, BLOOD, V95, P2443, DOI 10.1182/blood.V95.7.2443.007k18_2443_2445; Steenbergen RDM, 2004, JNCI-J NATL CANCER I, V96, P294, DOI 10.1093/jnci/djh031; Steenbergen RDM, 1996, ONCOGENE, V13, P1249; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; Tang JCO, 2001, CANCER GENET CYTOGEN, V124, P36, DOI 10.1016/S0165-4608(00)00317-4; Tao Q, 1999, AM J PATHOL, V155, P619, DOI 10.1016/S0002-9440(10)65157-7; Tao Q, 1998, J VIROL, V72, P7075, DOI 10.1128/JVI.72.9.7075-7083.1998; Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091; Tao Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2672, DOI 10.2741/2000; Teramoto A, 2004, ONCOL REP, V12, P141; Tsao SW, 2002, BBA-MOL CELL RES, V1590, P150, DOI 10.1016/S0167-4889(02)00208-2; Wang DZM, 1997, CANCER RES, V57, P2478; Wilson PJ, 2000, HUM MUTAT, V15, P156, DOI 10.1002/(SICI)1098-1004(200002)15:2<156::AID-HUMU4>3.0.CO;2-4; Wong CM, 2003, CANCER RES, V63, P7646; Wong ML, 2006, INT J ONCOL, V28, P767; Xiong W, 2004, CANCER RES, V64, P1972, DOI 10.1158/0008-5472.CAN-03-3253; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Ying JM, 2005, CLIN CANCER RES, V11, P6442, DOI 10.1158/1078-0432.CCR-05-0267; Yu MC, 2002, SEMIN CANCER BIOL, V12, P421, DOI 10.1016/S1044579X02000858; Yuan BZ, 1998, CANCER RES, V58, P2196; Yuan BZ, 2003, CANCER GENET CYTOGEN, V140, P113, DOI 10.1016/S0165-4608(02)00674-X; Yuan BZ, 2004, ONCOGENE, V23, P1405, DOI 10.1038/sj.onc.1207291; Yuan BZ, 2003, ONCOGENE, V22, P445, DOI 10.1038/sj.onc.1206064; Zhou L, 2005, NEOPLASIA, V7, P809, DOI 10.1593/neo.05217	53	104	118	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					934	944		10.1038/sj.onc.1209839	http://dx.doi.org/10.1038/sj.onc.1209839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862168				2022-12-28	WOS:000244063800013
J	Adam, SJ; Rund, LA; Kuzmuk, KN; Zachary, JF; Schook, LB; Counter, CM				Adam, S. J.; Rund, L. A.; Kuzmuk, K. N.; Zachary, J. F.; Schook, L. B.; Counter, C. M.			Genetic induction of tumorigenesis in Swine	ONCOGENE			English	Article						porcine; cancer; model	CUTANEOUS MELANOMAS; RAS ONCOGENESIS; HUMAN CANCER; TUMOR-CELLS; IN-VIVO; TELOMERASE; TRANSFORMATION; MODELS; GROWTH; REQUIREMENTS	The transition from basic to clinical cancer research for a number of experimental therapeutics is hampered by the lack of a genetically malleable, large animal model. To this end, we genetically engineered primary porcine cells to be tumorigenic by expression of proteins known to perturb pathways commonly corrupted in human cancer. Akin to human cells, these porcine cells were quite resistant to transformation, requiring multiple genetic changes. Moreover, the transformed porcine cells produced tumors when returned to the isogenic host animal. The ability to now rapidly and reproducibly genetically induce tumors of sizes similar to those treated clinically in a large mammal similar to humans in many respects will provide a robust cancer model for preclinical studies dependant on generating large tumors.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, Durham, NC 27710 USA; Univ Illinois, Dept Anim Sci, Chicago, IL 60680 USA; Univ Illinois, Inst Genom Biol, Chicago, IL 60680 USA; Univ Illinois, Coll Vet Med, Dept Pathobiol, Urbana, IL 61801 USA	Duke University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Urbana-Champaign	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Dept Radiat Oncol, 3813,LSRC Bldg,Room C225,Res Dr, Durham, NC 27710 USA.	schook@uiuc.edu; count004@mc.duke.edu		rund, laurie/0000-0003-0761-7196; Schook, Lawrence/0000-0002-6580-8364; Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA094184] Funding Source: NIH RePORTER; NCI NIH HHS [CA94184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON LJ, 1968, CANCER, V22, P398, DOI 10.1002/1097-0142(196808)22:2<398::AID-CNCR2820220218>3.0.CO;2-2; Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BOS JL, 1989, CANCER RES, V49, P4682; BROWN DG, 1970, J AM VET MED ASSOC, V157, P1914; Chudnovsky Y, 2005, NAT GENET, V37, P745, DOI 10.1038/ng1586; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; DEWHIRST MD, 2000, TUMOR MODELS CANC RE, P565; FIEBIG HH, 2000, TUMOR MODELS CANC RE, P113; Goessel G, 2005, P NATL ACAD SCI USA, V102, P15599, DOI 10.1073/pnas.0409730102; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Kendall SD, 2006, CELL CYCLE, V5, P1074, DOI 10.4161/cc.5.10.2734; Kendall SD, 2005, CANCER RES, V65, P9824, DOI 10.1158/0008-5472.CAN-05-1543; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lim KH, 2004, MOL CELL, V15, P491, DOI 10.1016/j.molcel.2004.08.014; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; O'Hayer KM, 2006, METHOD ENZYMOL, V407, P637, DOI 10.1016/S0076-6879(05)07050-3; OXENHANDLER RW, 1982, AM J PATHOL, V109, P259; Pathak S, 2000, INT J ONCOL, V17, P1219; Perez J, 2002, VET PATHOL, V39, P445, DOI 10.1354/vp.39-4-445; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Shay JW, 2002, CANCER CELL, V2, P257, DOI 10.1016/S1535-6108(02)00159-9; Stewart SA, 2000, SEMIN CANCER BIOL, V10, P399, DOI 10.1006/scbi.2000.0339; Swanson KS, 2004, EXP BIOL MED, V229, P866, DOI 10.1177/153537020422900902; Van Dyke T, 2002, CELL, V108, P135, DOI 10.1016/S0092-8674(02)00621-9; Vincent-Naulleau S, 2004, PIGM CELL RES, V17, P24, DOI 10.1046/j.1600-0749.2003.00101.x; WARGOVICH MJ, 1991, J COMP PATHOL, V105, P271, DOI 10.1016/S0021-9975(08)80195-8; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; Xie W, 2002, DRUG DISCOV TODAY, V7, P509, DOI 10.1016/S1359-6446(02)02251-1; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	31	48	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1038	1045		10.1038/sj.onc.1209892	http://dx.doi.org/10.1038/sj.onc.1209892			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16964292				2022-12-28	WOS:000244245400010
J	Wallez, Y; Cand, F; Cruzalegui, F; Wernstedt, C; Souchelnytskyi, S; Vilgrain, I; Huber, P				Wallez, Y.; Cand, F.; Cruzalegui, F.; Wernstedt, C.; Souchelnytskyi, S.; Vilgrain, I.; Huber, P.			Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site	ONCOGENE			English	Article						angiogenesis; adherens junctions; VE-cadherin; tyrosine kinases	FOCAL ADHESION KINASE; VE-CADHERIN; C-SRC; INDUCED ANGIOGENESIS; BETA-CATENIN; CELL; PROTEIN; BINDING; ASSOCIATION; FAMILY	Src-family tyrosine kinases are regulatory proteins that play a pivotal role in the disorganization of cadherin-dependent cell-cell contacts. We previously showed that Src was associated with vascular endothelial (VE)cadherin and that tyrosine phosphorylation level of VE-cadherin was dramatically increased in angiogenic tissues as compared to quiescent tissues. Here, we examined whether VE-cadherin was a direct substrate for Src in vascular endothelial growth factor ( VEGF)induced VE-cadherin phosphorylation, and we identified the target tyrosine sites. Co-transfections of Chinese hamster ovary cells (CHO) cells with VE-cadherin and constitutively active Src (Y530F) resulted in a robust tyrosine phosphorylation of VE-cadherin that was not detected with kinase-dead Src (K298M). In an in vitro Src assay, the VE-cadherin cytoplasmic domain is directly phosphorylated by purified Src as well as the tyrosine residue 685 (Tyr)685-containing peptide RPSLY(685)AQVQ. VE-cadherin peptide mapping from human umbilical vein endothelial cells stimulated by VEGF and VE-cadherin-CHO cells transfected with active Src revealed that Y685 was the unique phosphorylated site. The presence of Phospho Y685 was confirmed by its ability to bind to C-terminal Src kinase-SH2 domain in a pull-down assay. Finally, we found that in a VEGF-induced wound-healing assay, cadherin adhesive activity was impaired by Src kinase inhibitors. These data identify that VEGF-induced-VE- cadherin tyrosine phosphorylation is mediated by Src on Y685, a process that appears to be critical for VEGF-induced endothelial cell migration.	Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, F-38054 Grenoble 9, France; SERVIER, Inst Rech, Croissy, Croissy Sur Seine, France; Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Servier; Ludwig Institute for Cancer Research	Vilgrain, I (corresponding author), Univ Grenoble 1, ISERE, CEA Grenoble,INSERM,Dept Rech & Dynam Cellulaires, EMI 0219,Lab Dev & Viellissement Endothelium, 17 Rue Martyrs, F-38054 Grenoble 9, France.	ivilgrain@cea.fr	Souchelnytskyi, Serhiy/J-9446-2014; Wallez, Yann/H-1033-2013; Souchelnytskyi, Serhiy/G-6491-2011; Huber, Philippe/C-7971-2019	Souchelnytskyi, Serhiy/0000-0001-8243-9276; Huber, Philippe/0000-0002-4153-7694; VILGRAIN, Isabelle/0000-0002-5511-5871; Wallez, Yann/0000-0001-9654-6187				Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Calcerrada MC, 2002, NEUROCHEM RES, V27, P313, DOI 10.1023/A:1014911329489; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; Corada M, 1999, P NATL ACAD SCI USA, V96, P9815, DOI 10.1073/pnas.96.17.9815; DEJANA E, 1995, FASEB J, V9, P910, DOI 10.1096/fasebj.9.10.7615160; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41; Esser S, 1998, J CELL SCI, V111, P1853; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Hudry-Clergeon H, 2005, FASEB J, V19, P512, DOI 10.1096/fj.04-2202com; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kouklis P, 2003, J BIOL CHEM, V278, P16230, DOI 10.1074/jbc.M212591200; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lampugnani MG, 1999, METH MOL B, V96, P177; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Lauder H, 1998, Angiogenesis, V2, P67, DOI 10.1023/A:1009006527462; Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029; Lindquist JA, 2003, IMMUNOL REV, V191, P165, DOI 10.1034/j.1600-065X.2003.00007.x; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Pawson T, 2004, CELL, V116, P191, DOI 10.1016/S0092-8674(03)01077-8; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Su WH, 2002, BLOOD, V100, P3597, DOI 10.1182/blood-2002-01-0303; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Wallez Y, 2006, TRENDS CARDIOVAS MED, V16, P55, DOI 10.1016/j.tcm.2005.11.008; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	42	152	157	4	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1067	1077		10.1038/sj.onc.1209855	http://dx.doi.org/10.1038/sj.onc.1209855			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909109				2022-12-28	WOS:000244245400013
J	Oliveira, C; Velho, S; Moutinho, C; Ferreira, A; Preto, A; Domingo, E; Capelinha, AF; Duval, A; Hamelin, R; Machado, JC; Schwartz, S; Carneiro, F; Seruca, R				Oliveira, C.; Velho, S.; Moutinho, C.; Ferreira, A.; Preto, A.; Domingo, E.; Capelinha, A. F.; Duval, A.; Hamelin, R.; Machado, J. C.; Schwartz, S., Jr.; Carneiro, F.; Seruca, R.			KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression	ONCOGENE			English	Article						KRAS; BRAF; colorectal carcinoma; instability; MAP kinase; lymph node metastases	RAS POINT MUTATIONS; CELL-CYCLE ARREST; K-RAS; COLON-CANCER; WILD-TYPE; EXPRESSION; ASSOCIATION; ACTIVATION; MELANOMA; PATTERNS	In sporadic colorectal cancer (CRC), KRAS are alternative to BRAF mutations and occur, respectively, in 30 and 10% of cases. Few reports addressed the association between KRAS - BRAF mutations and tumour progression specifically in sporadic microsatellite-stable (MSS) CRC. We screened KRAS and BRAF in 250 MSS primary CRC and 45 lymph node (LN) metastases and analysed the pathological features of the cases to understand the involvement of KRAS - BRAF activation in progression and metastasis. Forty-five per cent of primary MSS CRCs carried mutations in at least one of these genes and mutations were associated with wall invasion (P = 0.02), presence and number of LN metastases (P = 0.02 and P = 0.03, respectively), distant metastases (P = 0.004) and advanced stage (P = 0.01). We demonstrated that KRAS and BRAF are alternative events in Tis and T1 MSS CRC and, KRAS rather than BRAF mutations, contributed to the progression of MSS CRC. The frequency of KRAS and/or BRAF mutations was higher in LN metastases than in primary carcinomas (P = 0.0002). Mutated LN metastases displayed KRAS associated or not with BRAF mutations. BRAF mutations were never present as a single event. Concomitant KRAS and BRAF mutations increased along progression of MSS CRCs, suggesting that activation of both genes is likely to harbour a synergistic effect.	Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4200465 Oporto, Portugal; Hosp Univ Vall Hebron, CIBBIM, Barcelona, Spain; Hosp Sao Joao, Dept Pathol, Oporto, Portugal; INSERM, U762, CEPH, Paris, France; Univ Porto, Fac Med, P-4100 Oporto, Portugal	Universidade do Porto; Hospital Universitari Vall d'Hebron; Sao Joao Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universidade do Porto	Seruca, R (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, Rua Roberto Frias S-N, P-4200465 Oporto, Portugal.	rseruca@ipatimup.pt	Oliveira, Carla/F-8188-2011; Carneiro, Fatima/AAV-8677-2021; Preto, Ana/H-8112-2012; seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Machado, Jose Carlos/C-5907-2009; Velho, Sérgia/B-8501-2013; Domingo, Enric/A-9099-2018; Carneiro, Fatima/J-6432-2013	Oliveira, Carla/0000-0001-8340-2264; Carneiro, Fatima/0000-0002-1964-1006; Preto, Ana/0000-0002-7302-0630; Machado, Jose Carlos/0000-0003-4741-8415; Velho, Sérgia/0000-0002-7104-8234; Domingo, Enric/0000-0003-4390-8767; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166; Ferreira, Ana/0000-0001-6290-1320; Schwartz, Simo/0000-0001-8297-7971				Al-Mulla F, 1998, J PATHOL, V185, P130, DOI 10.1002/(SICI)1096-9896(199806)185:2<130::AID-PATH85>3.0.CO;2-M; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Carter JH, 2004, CLIN CANCER RES, V10, P3448, DOI 10.1158/1078-0432.CCR-03-0210; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Deng GR, 2004, CLIN CANCER RES, V10, P191, DOI 10.1158/1078-0432.CCR-1118-3; Domingo E, 2004, GENE CHROMOSOME CANC, V39, P138, DOI 10.1002/gcc.10310; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINKELSTEIN SD, 1993, CANCER, V71, P3827, DOI 10.1002/1097-0142(19930615)71:12<3827::AID-CNCR2820711207>3.0.CO;2-N; Fransen K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049; Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229; Hingorani SR, 2003, CANCER RES, V63, P5198; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Ikehara N, 2005, INT J CANCER, V115, P943, DOI 10.1002/ijc.20957; Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174; Kerkhoff E, 1998, CANCER RES, V58, P1636; Koinuma K, 2004, INT J CANCER, V108, P237, DOI 10.1002/ijc.11523; Kumar R, 2003, CLIN CANCER RES, V9, P3362; Liao JH, 2003, J BIOL CHEM, V278, P31871, DOI 10.1074/jbc.M301931200; Lipton L, 2003, CANCER RES, V63, P7595; Lubomierski N, 2005, CANCER-AM CANCER SOC, V104, P952, DOI 10.1002/cncr.21266; MARSHALL M, 1995, MOL REPROD DEV, V42, P493, DOI 10.1002/mrd.1080420418; Melillo RM, 2005, J CLIN INVEST, V115, P1068, DOI 10.1172/JCI22758; MOERKERK P, 1994, CANCER RES, V54, P3376; Nagasaka T, 2004, J CLIN ONCOL, V22, P4584, DOI 10.1200/JCO.2004.02.154; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061; Oliveira C, 2004, HUM MOL GENET, V13, P2303, DOI 10.1093/hmg/ddh238; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schramm K, 2000, INT J CANCER, V87, P155, DOI 10.1002/1097-0215(20000715)87:2<155::AID-IJC1>3.0.CO;2-J; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Span M, 1996, INT J CANCER, V69, P241, DOI 10.1002/(SICI)1097-0215(19960621)69:3<241::AID-IJC15>3.3.CO;2-D; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wang L, 2003, CANCER RES, V63, P5209; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504; Yan ZF, 1997, J BIOL CHEM, V272, P30928, DOI 10.1074/jbc.272.49.30928; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Yuen ST, 2002, CANCER RES, V62, P6451	52	139	143	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					158	163		10.1038/sj.onc.1209758	http://dx.doi.org/10.1038/sj.onc.1209758			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16953233				2022-12-28	WOS:000243236500016
J	Rockstroh, A; Kleinert, A; Kramer, M; Grosse, F; Soe, K				Rockstroh, A.; Kleinert, A.; Kramer, M.; Grosse, F.; Soe, K.			Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner	ONCOGENE			English	Article						apoptosis; damage response; p53; topoisomerase I; colcemid; TNF alpha	CLEAVAGE COMPLEXES; HYDROGEN-PEROXIDE; INDUCED APOPTOSIS; INDUCTION; CELLS; FRAGMENTATION; POLYMERASE; CASPASE-3; ADDUCTS; REPAIR	The 'human topoisomerase I (htopoI) damage response' was reported to be triggered by various kinds of DNA lesions. Also, a high and persistent level of htopoI cleavage complexes correlated with apoptosis. In the present study, we demonstrate that DNA damage-independent induction of cell death using colcemid and tumor necrosis factor a is also accompanied by a strong htopoI response that correlates with the onset of apoptotic hallmarks. Consequently, these results suggest that htopoI cleavage complex formation may be caused by signaling pathways independent of the kind of cellular stress. Thus, protein interactions or signaling cascades induced by DNA damage or cellular stress might lead to the formation of stabilized cleavage complexes rather than the DNA lesion itself. Finally, we show that p53 not only plays a key role in the regulation of the htopoI response to UV-C irradiation but also to treatment with colcemid.	Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, D-07745 Jena, Germany	Leibniz Institut fur Alternsforschung - Fritz-Lipmann-Institut (FLI)	Soe, K (corresponding author), Fritz Lipmann Inst eV, Leibniz Inst Age Res, Biochem, Beutenbergstr 11, D-07745 Jena, Germany.	kent@fli-leibniz.de	Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X				ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Daroui P, 2004, J BIOL CHEM, V279, P14587, DOI 10.1074/jbc.M311370200; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; Huppertz B, 1999, ANAT EMBRYOL, V200, P1, DOI 10.1007/s004290050254; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2003, DNA REPAIR, V2, P1115, DOI 10.1016/S1568-7864(03)00122-8; Pommier Y, 2002, J BIOL CHEM, V277, P13666, DOI 10.1074/jbc.M200209200; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P2040, DOI 10.1073/pnas.040397497; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2002, CLIN CANCER RES, V8, P2499; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; Pourquier P, 1998, J BIOL CHEM, V273, P27245, DOI 10.1074/jbc.273.42.27245; ROSEN A, 1995, J EXP MED, V181, P1557, DOI 10.1084/jem.181.4.1557; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; SHERWOOD SW, 1994, EXP CELL RES, V215, P373, DOI 10.1006/excr.1994.1354; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Sordet O, 2004, J BIOL CHEM, V279, P50499, DOI 10.1074/jbc.M410277200; Sordet O, 2004, J BIOL CHEM, V279, P33968, DOI 10.1074/jbc.M404620200; STEWART AF, 1990, CELL, V60, P141; Subramanian D, 1998, CANCER RES, V58, P976; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651	33	4	4	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					123	131		10.1038/sj.onc.1209766	http://dx.doi.org/10.1038/sj.onc.1209766			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799632				2022-12-28	WOS:000243236500012
J	Mathur, M; Samuels, HH				Mathur, M.; Samuels, H. H.			Role of PSF-TFE3 oncoprotein in the development of papillary renal cell carcinomas	ONCOGENE			English	Article						PSF-TFE3; siRNA; growth inhibition; apoptosis; transformation; dedifferentiation	PROXIMAL TUBULE CELLS; SOFT PART SARCOMA; TUMOR-CELLS; GENE FUSION; CLEAR-CELL; TFE3; CLASSIFICATION; CONTEXT; TYPE-1; GROWTH	A subset of papillary renal cell carcinomas (RCC) is characterized by the expression of a TFE3 fusion protein, where the fusion partner can be any of the several proteins identified so far such as PSF (PTB associated splicing factor), NonO, PRCC, CLTC and ASPL. These proteins result from chromosomal translocations involving the TFE3 gene located on the X chromosome. Our present study documents the central role of PSF-TFE3 in oncogenic transformation. We show that the inhibition of PSF-TFE3 expression through siRNA or shRNA leads to impaired growth, proliferation, invasion potential and long-term survival of UOK-145 papillary renal carcinoma-derived cells, which endogenously express PSF-TFE3. The oncogenic potential of PSF-TFE3 became evident by stable expression of PSF-TFE3 in NIH-3T3 mouse fibroblast cells, which leads to the acquisition of anchorage-independent growth as revealed by soft agar assay. In addition, the expression of PSF-TFE3 in normal renal proximal tubular epithelial cells from where such tumors originate leads to dedifferentiation and loss of some key functional proteins, which may reflect an initial step in the multistep process of tumor development. This suggests that the expression of PSF-TFE3 in renal epithelial cells plays an important role in the initiation and maintenance of oncogenic phenotype in papillary RCC.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Med, New York, NY 10016 USA	New York University; New York University	Mathur, M (corresponding author), NYU, Sch Med, Dept Pharmacol, MSB-411,550 1st Ave, New York, NY 10016 USA.	mathum01@med.nyu.edu; herbert.samuels@med.nyu.edu			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002083] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK016636, R37DK016636, R01DK016636] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR02083] Funding Source: Medline; NIDDK NIH HHS [DK16636] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBINI A, 1987, CANCER RES, V47, P3239; Argani P, 2003, ONCOGENE, V22, P5374, DOI 10.1038/sj.onc.1206686; Argani P, 2001, AM J PATHOL, V159, P179, DOI 10.1016/S0002-9440(10)61684-7; Bennicelli JL, 2002, CURR OPIN ONCOL, V14, P412, DOI 10.1097/00001622-200207000-00008; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bodmer D, 2002, HUM MOL GENET, V11, P2489, DOI 10.1093/hmg/11.20.2489; Gao CF, 2005, P NATL ACAD SCI USA, V102, P10528, DOI 10.1073/pnas.0504367102; Guo Hong-feng, 2004, Zhonghua Wai Ke Za Zhi, V42, P196; Kolb RJ, 2004, HYPERTENSION, V44, P352, DOI 10.1161/01.HYP.0000136645.90116.1a; Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G; Ladanyi M, 2001, ONCOGENE, V20, P48, DOI 10.1038/sj.onc.1204074; Le TH, 2004, PHYSIOL GENOMICS, V18, P290, DOI 10.1152/physiolgenomics.00120.2003; Lindor NM, 2001, GENET TEST, V5, P101, DOI 10.1089/109065701753145547; Mathur M, 2003, ONCOGENE, V22, P5031, DOI 10.1038/sj.onc.1206643; Morrissey C, 2001, CANCER RES, V61, P7277; Murer H, 2000, PHYSIOL REV, V80, P1373, DOI 10.1152/physrev.2000.80.4.1373; Orosz DE, 2004, IN VITRO CELL DEV-AN, V40, P22; Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360; Sanders ME, 2002, AM J PATHOL, V161, P997, DOI 10.1016/S0002-9440(10)64260-5; Skalsky YM, 2001, ONCOGENE, V20, P178, DOI 10.1038/sj.onc.1204056; Storkel S, 1997, CANCER, V80, P987, DOI 10.1002/(SICI)1097-0142(19970901)80:5<987::AID-CNCR24>3.0.CO;2-R; Weterman MAJ, 2001, ONCOGENE, V20, P1414, DOI 10.1038/sj.onc.1204213; Weterman MAJ, 2001, P NATL ACAD SCI USA, V98, P13808, DOI 10.1073/pnas.241304198; Wiesener MS, 2001, CANCER RES, V61, P5215; Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491	25	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					277	283		10.1038/sj.onc.1209783	http://dx.doi.org/10.1038/sj.onc.1209783			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832349				2022-12-28	WOS:000243398300011
J	Quignon, F; Rozier, L; Lachages, AM; Bieth, A; Simili, M; Debatisse, M				Quignon, F.; Rozier, L.; Lachages, A. -M.; Bieth, A.; Simili, M.; Debatisse, M.			Sustained mitotic block elicits DNA breaks: one-step alteration of ploidy and chromosome integrityin mammalian cells	ONCOGENE			English	Article						double strand breaks; chromosome rearrangements; mitotic slippage; DNA damage checkpoint; spindle checkpoint; tetraploidy	GENOMIC INSTABILITY; P53; TETRAPLOIDY; INHIBITION; ANEUPLOIDY; REREPLICATION; FIBROBLASTS; CHECKPOINTS; MECHANISM; APOPTOSIS	Following prolonged mitotic spindle disruption by microtubule poisons, mammalian cells delay their entry into anaphase, then progressively slip out of mitosis and become tetraploid. Normal cells then stop cycling before S-phase onset, but the mechanisms underlying this arrest are still unclear. Here we show that a double block prevents endo-reduplication. First, cells that exit mitosis without a functional microtubule network are driven toward G0. Reconstitution of the network unmasks a second block that relies on DNA double-strand breaks occurring early in the G1 phase that follows the mitotic block. We propose that a stress signal elicited upon mitotic impairment triggers breakage, which couples the leaky spindle checkpoint to the stringent DNA damage response. Consistent with this finding, cells defective for the damage response continue cycling and acquire, within a single cell cycle, both chromosome rearrangements and abnormal chromosome numbers that remarkably mimic the complex genetic hallmark of tumorigenesis.	Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, F-75248 Paris 05, France; CNR, Inst Fisiol Clin, Area Ric, I-56100 Pisa, Italy	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Consiglio Nazionale delle Ricerche (CNR)	Debatisse, M (corresponding author), Univ Paris 06, Sect Rech, UMR 7147, Inst Curie,CNRS, 26 Rue Ulm, F-75248 Paris 05, France.	michelle.debatisse@curie.fr	Quignon, Frédérique/P-4249-2017	Lachages, Anne-Marie/0000-0003-1771-1880				Aardema MJ, 1998, MUTAT RES-REV MUTAT, V410, P3, DOI 10.1016/S1383-5742(97)00029-X; Anglana M, 2001, J BIOL CHEM, V276, P36639, DOI 10.1074/jbc.M104501200; Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Halappanavar SS, 2004, CELL CYCLE, V3, P335; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Jallepalli PV, 2001, NAT REV CANCER, V1, P109, DOI 10.1038/35101065; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Mantel CR, 2002, CELL CYCLE, V1, P327, DOI 10.4161/cc.1.5.150; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Martin SS, 2004, BBA-MOL CELL RES, V1692, P145, DOI 10.1016/j.bbamcr.2004.02.008; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; STUBBLEFIELD ELTON, 1964, SYMP INT SOC CELL BIOL, V3, P223; TOLEDO F, 1992, EMBO J, V11, P2665, DOI 10.1002/j.1460-2075.1992.tb05332.x; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Tsuiki H, 2001, ONCOGENE, V20, P420, DOI 10.1038/sj.onc.1204126; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6	31	47	47	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					165	172		10.1038/sj.onc.1209787	http://dx.doi.org/10.1038/sj.onc.1209787			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16832348				2022-12-28	WOS:000243398300001
J	Ferretti, E; Di Marcotullio, L; Gessi, M; Mattei, T; Greco, A; Po, A; De Smaele, E; Giangaspero, F; Riccardi, R; Di Rocco, C; Pazzaglia, S; Maroder, M; Alimandi, M; Screpanti, I; Gulino, A				Ferretti, E.; Di Marcotullio, L.; Gessi, M.; Mattei, T.; Greco, A.; Po, A.; De Smaele, E.; Giangaspero, F.; Riccardi, R.; Di Rocco, C.; Pazzaglia, S.; Maroder, M.; Alimandi, M.; Screpanti, I.; Gulino, A.			Alternative splicing of the ErbB-4 cytoplasmic domain and its regulation by hedgehog signaling identify distinct medulloblastoma subsets	ONCOGENE			English	Article						medulloblastoma; ErbB-4; alternative splicing; hedgehog; Gli1	CHILDHOOD MEDULLOBLASTOMA; EXPRESSION; ISOFORM; CELLS; CANCER; PROLIFERATION; TRANSCRIPTION; RECEPTORS; RENKCTD11; VARIANTS	Medulloblastoma (MB) results from aberrant development of cerebellar neurons in which altered hedgehog (Hh) signalling plays a major role. We investigated the possible influence of Hh signalling on ErbB-receptor expression in MB, in particular that of the ErbB-4 CYT-1 and CYT-2 isoforms generated by alternative splicing of the cytoplasmic domain. ErbB-4 expression was downregulated in Hh-induced MBs from Patched- 1(+/-) mice. Hh signalling (reflected by enhanced expression of the Gli1 transcription factor) inhibited ErbB-4 expression in mouse cerebellar granule progenitors and human MB cells. Analysis of 26 human primary MBs revealed a subset of 11 tumors characterized by low Gli1 levels, upregulated ErbB-4 expression and increased CYT-1: CYT-2 ratios. Interestingly, CYT-1 and Gli1 levels were inversely correlated. ErbB-4 CYT-1 and CYT-2 had different phenotypic effects in cultured MB cells: in response to neuregulin treatment, CYT-2 overexpression inhibited proliferation whereas CYT-1, which includes a phosphatidylinositol 3-kinase (PI3K)-binding site that is missing in CYT-2, enhanced resistance to starvation- and etoposide-induced apoptosis by activating PI3K/Akt signalling. CYT-1: CYT-2 ratios displayed correlation with tumor histotype and ErbB-2 levels, which are established prognostic indices for MB. These findings demonstrate that low-level Hh signalling in human MB is associated with the selective maintenance of high ErbB-4 CYT-1 expression, an alteration that exerts tumor-promoting effects.	Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy; Natl Neurol Inst C Besta, Div Neuropathol, Milan, Italy; Neuromed Inst, Isernia, Italy; Catholic Univ Rome, Dept Pediat, Rome, Italy; Catholic Univ Rome, Inst Neurosurg, Rome, Italy; ENEA CR, Biotechnol Unit, Rome, Italy; Cenci Bolognetti Fdn, Inst Pasteur, Rome, Italy	Sapienza University Rome; IRCCS Istituto Neurologico Besta; IRCCS Neuromed; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Italian National Agency New Technical Energy & Sustainable Economics Development; Fondazione Cenci Bolognetti	Gulino, A (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, 324 Viale Regina Elena, I-00161 Rome, Italy.	alberto.gulino@uniroma1.it	Po, Agnese/AEQ-0192-2022; Giangaspero, Felice/Z-4961-2019; Mattei, Tobias A./U-7166-2019; Gessi, Marco/K-2572-2018; Giangaspero, Felice/AAH-9253-2020; De Smaele, Enrico/C-1124-2013; Alimandi, Maurizio/AAG-9246-2019; Po, Agnese/G-8754-2015; Ferretti, Elisabetta/G-5413-2013	Po, Agnese/0000-0002-9346-8782; Giangaspero, Felice/0000-0001-5382-2380; Giangaspero, Felice/0000-0001-5382-2380; De Smaele, Enrico/0000-0003-4524-4423; Alimandi, Maurizio/0000-0002-1409-6803; Po, Agnese/0000-0002-9346-8782; RICCARDI, RICCARDO/0000-0001-7515-6622; Ferretti, Elisabetta/0000-0001-7265-6429; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178	Telethon [GGP04168] Funding Source: Medline	Telethon(Fondazione Telethon)		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Argenti B, 2005, J NEUROSCI, V25, P8338, DOI 10.1523/JNEUROSCI.2438-05.2005; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Di Marcotullio L, 2004, P NATL ACAD SCI USA, V101, P10833, DOI 10.1073/pnas.0400690101; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Elenius K, 1999, ONCOGENE, V18, P2607, DOI 10.1038/sj.onc.1202612; Ferretti E, 2005, TRENDS MOL MED, V11, P537, DOI 10.1016/j.molmed.2005.10.005; Fox IJ, 2005, J NEUROSCI RES, V79, P584, DOI 10.1002/jnr.20381; Gajjar A, 2004, J CLIN ONCOL, V22, P984, DOI 10.1200/JCO.2004.06.032; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GIANGASPERO F, 2002, PATHOLOGY GENETICS T, P129; Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146; Gilbertson RJ, 1998, CANCER RES, V58, P3932; Gilbertson RJ, 1997, CANCER RES, V57, P3272; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Junttila TT, 2003, CLIN CANCER RES, V9, P5346; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Marti E, 2002, TRENDS NEUROSCI, V25, P89, DOI 10.1016/S0166-2236(02)02062-3; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Omerovic J, 2004, EXP CELL RES, V294, P469, DOI 10.1016/j.yexcr.2003.12.002; Ozaki M, 1998, NEUROSCI RES, V30, P351, DOI 10.1016/S0168-0102(98)00013-3; Pazzaglia S, 2002, ONCOGENE, V21, P7580, DOI 10.1038/sj.onc.1205973; Rieff HI, 1999, J NEUROSCI, V19, P10757, DOI 10.1523/JNEUROSCI.19-24-10757.1999; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562	29	39	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	55					7267	7273		10.1038/sj.onc.1209716	http://dx.doi.org/10.1038/sj.onc.1209716			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16878160				2022-12-28	WOS:000242244700005
J	Cowger, JJM; Zhao, Q; Isovic, M; Torchia, J				Cowger, J. J. M.; Zhao, Q.; Isovic, M.; Torchia, J.			Biochemical characterization of the zinc-finger protein 217 transcriptional repressor complex: identification of a ZNF217 consensus recognition sequence	ONCOGENE			English	Article						ZNF217; zinc-finger; CoREST; breast cancer; CAST	EPITHELIAL-MESENCHYMAL TRANSITIONS; BREAST-CANCER; E-CADHERIN; COREST; COMPONENT; GENE; CTBP; COREPRESSOR; REGION; 20Q13	Zinc-finger protein 217 (ZNF217) is a Kruppel-like zinc-finger protein located at 20q13.2, within a region of recurrent maximal amplification. Here, we demonstrate that ZNF217 is a transcriptional repressor protein and report the purification and characterization of a ZNF217 complex. The purified ZNF217 complex consists of approximately six proteins and contains the transcriptional co-repressors CoREST, BHC110/LSD1, histone deacetylase (HDAC) 2 and C-terminal binding protein (CtBP1). The purified ZNF217 complex possesses deacetylase activity as well as lysine 4 histone H3-specific demethylase activity that is most likely mediated by the BHC110/LSD1 component. To determine if ZNF217 is a sequence-specific binding protein, we have made use of cyclic amplification and selection of targets (CAST) assay and identify for the first time a ZNF217 DNA consensus recognition sequence (CRS) that is highly conserved in the human E-cadherin promoter. Chromatin immunoprecipitation (ChIP) experiments demonstrate that ZNF217, as well as the other components of the ZNF217 complex, are found on the region of the proximal E-cadherin promoter that contains the identified ZNF217 CRS in vivo. Using a combination of transient transfections and small interfering RNA, we demonstrate that ZNF217 represses the E-cadherin promoter. Collectively, our results implicate ZNF217 and its associated proteins in a novel pathway that may have profound effects on cancer progression.	Univ Western Ontario, London Reg Canc Program, Dept Oncol, London, ON N6A 3K7, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 3K7, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), London Reg Canc Program, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.	jtorchia@uwo.ca	Zhao, Qingshi/H-9839-2013					Andres ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873; AUSUBEL FM, 2002, CURRENT PROTOCOLS MO; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bukholm IK, 2000, J PATHOL, V190, P15; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Collins C, 2001, GENOME RES, V11, P1034, DOI 10.1101/gr.GR1743R; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dellaire G, 2002, MOL CELL BIOL, V22, P5141, DOI 10.1128/MCB.22.14.5141-5156.2002; Elrod-Erickson M, 1999, J BIOL CHEM, V274, P19281, DOI 10.1074/jbc.274.27.19281; Grimes JA, 2000, J BIOL CHEM, V275, P9461, DOI 10.1074/jbc.275.13.9461; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hakimi MA, 2003, J BIOL CHEM, V278, P7234, DOI 10.1074/jbc.M208992200; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Huang GQ, 2005, HUM MOL GENET, V14, P3219, DOI 10.1093/hmg/ddi352; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Nishimura G, 2002, ONCOL REP, V9, P479; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Quinlan KGR, 2006, MOL CELL BIOL, V26, P8159, DOI 10.1128/MCB.00680-06; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANNER MM, 1994, CANCER RES, V54, P4257; Tanner MM, 1995, CLIN CANCER RES, V1, P1455; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454	30	77	80	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3378	3386		10.1038/sj.onc.1210126	http://dx.doi.org/10.1038/sj.onc.1210126			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130829				2022-12-28	WOS:000246579600007
J	Kuninaka, S; Iida, SI; Hara, T; Nomura, M; Naoe, H; Morisaki, T; Nitta, M; Arima, Y; Mimori, T; Yonehara, S; Saya, H				Kuninaka, S.; Iida, S-I; Hara, T.; Nomura, M.; Naoe, H.; Morisaki, T.; Nitta, M.; Arima, Y.; Mimori, T.; Yonehara, S.; Saya, H.			Serine protease Omi/HtrA2 targets WARTS kinase to control cell proliferation	ONCOGENE			English	Article						apoptosis; serine protease; mitotic kinase; staurosporine; cell cycle; PDZ domain	ANTI-APOPTOTIC PROTEIN; TUMOR-SUPPRESSOR; CHECKPOINT FUNCTION; PROMOTES APOPTOSIS; MITOTIC APPARATUS; GENOMIC INTEGRITY; CASPASE ACTIVITY; HUMAN HOMOLOG; DROSOPHILA; INHIBITOR	The serine protease Omi/HtrA2 was initially regarded as a proapoptotic molecule that proteolyses several proteins to induce cell death. Recent studies, however, indicate that loss of Omi protease activity increases susceptibility to stress-induced cell death. These complicated findings suggest that the protease activity of Omi is involved not only in apoptosis but also in cellular homeostasis. However, the targets which Omi uses to mediate this novel process are unknown. Previously, we showed that WARTS (WTS)/large tumor-suppressor 1 mitotic kinase interacts with the protein/discs-large protein/zonula (PDZ) domain of Omi and promotes its protease activity. We nowreport that WTS is a substrate for Omi protease activity, thus it is not only a regulator but also a downstream target of this protease. Interaction with Omi PDZ domain is required for WTS to be proteolysed. When caspase-9-deficient mouse embryonic. broblasts (MEFs) were treated with staurosporine, WTS was proteolysed by activated endogenous Omi without induction of cell death. Therefore, protease activity of Omi and proteolysis of WTS are not necessarily required for cell death. We found that depletion of Omi from HeLa cells results in accelerated cell proliferation despite no significant change in the duration of mitosis. The depletion of WTS showed the same effect on S phase progression. Therefore, WTS proteolytic fragment(s) generated by Omi may act as an inhibitor of G1/S progression. Our data reveal a role for Omi-mediated processing of WTS in negative regulation of cell cycle progression at interphase, suggesting a novel function of Omi other than apoptosis.	Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto 8608556, Japan; Kyoto Univ, Inst Virus Res, Mol & Cellular Biol Lab, Kyoto 606, Japan	Kumamoto University; Kyoto University	Kuninaka, S (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, 1-1-1 Honjo, Kumamoto 8608556, Japan.	hsaya@gpo.kumamoto-u.ac.jp	Kuninaka, Shinji/J-7158-2013; Saya, Hideyuki/J-4325-2013; Arima, Yoshimi/J-8057-2013	Naoe, Hideaki/0000-0003-4274-8220; Arima, Yoshimi/0000-0002-2384-1406				Bardin AJ, 2001, NAT REV MOL CELL BIO, V2, P815, DOI 10.1038/35099020; Cilenti L, 2004, J BIOL CHEM, V279, P50295, DOI 10.1074/jbc.M406006200; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Hirota T, 2000, J CELL BIOL, V149, P1073, DOI 10.1083/jcb.149.5.1073; Hockley D, 1998, JAVA REP, V3, P6; Iida S, 2004, ONCOGENE, V23, P5266, DOI 10.1038/sj.onc.1207623; Jones JM, 2003, NATURE, V425, P721, DOI 10.1038/nature02052; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuninaka S, 2005, ONCOGENE, V24, P5287, DOI 10.1038/sj.onc.1208682; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Martins LM, 2004, MOL CELL BIOL, V24, P9848, DOI 10.1128/MCB.24.22.9848-9862.2004; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Nishiyama Y, 1999, FEBS LETT, V459, P159, DOI 10.1016/S0014-5793(99)01224-7; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Sudo T, 2001, EMBO J, V20, P6499, DOI 10.1093/emboj/20.22.6499; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Yang QH, 2003, GENE DEV, V17, P1487, DOI 10.1101/gad.1097903; Yang XL, 2004, NAT CELL BIOL, V6, P609, DOI 10.1038/ncb1140	35	29	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2395	2406		10.1038/sj.onc.1210042	http://dx.doi.org/10.1038/sj.onc.1210042			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17130845				2022-12-28	WOS:000245831000001
J	Wan, X; Harkavy, B; Shen, N; Grohar, P; Helman, LJ				Wan, X.; Harkavy, B.; Shen, N.; Grohar, P.; Helman, L. J.			Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism	ONCOGENE			English	Article						mTOR; rapamycin; Akt; IGF-1R; rhabdomyosarcoma	GROWTH-FACTOR-II; INSULIN-RESISTANCE; MTOR; RECEPTOR; PHOSPHORYLATION; SURVIVAL; PATHWAY; TARGET; RHABDOMYOSARCOMA; DOWNSTREAM	Rapamycin and several analogs, such as CCI-779 and RAD001, are currently undergoing clinical evaluation as anticancer agents. In this study, we show that inhibition of mammalian target of rapamycin ( mTOR) signaling by rapamycin leads to an increase of Akt phosphorylation in Rh30 and RD human rhabdomyosarcoma cell lines and xenografts, and insulin-like growth factor (IGF)-II-treated C2C12 mouse myoblasts and IGF-II-overexpressing Chinese hamster ovary cells. RNA interference-mediated knockdown of S6K1 also results in an increase of Akt phosphorylation. These data suggest that mTOR/S6K1 inhibition either by rapamycin or small interfering RNA ( siRNA) triggers a negative feedback loop, resulting in the activation of Akt signaling. We next sought to investigate the mechanism of this negative feedback regulation from mTOR to Akt. Suppression of insulin receptor substrate (IRS)-1 and tuberous sclerosis complex-1 by siRNAs failed to abrogate rapamycin-induced upregulation of Akt phosphorylation in both Rh30 and RD cells. However, pretreatment with h7C10 antibody directed against insulin-like growth factor-1 receptor (IGF-1R) led to a blockade of rapamycin-induced Akt activation. Combined mTOR and IGF-1R inhibition with rapamycin and h7C10 antibody, respectively, resulted in additive inhibition of cell growth and survival. These data suggest that rapamycin mediates Akt activation through an IGF-1R-dependent mechanism. Thus, combining an mTOR inhibitor and an IGF-1R antibody/inhibitor may be an appropriate strategy to enhance mTOR-targeted anticancer therapy.	NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH,Ctr Canc Res, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wan, X (corresponding author), NCI, Mol Oncol Sect, Pediat Oncol Branch, NIH,Ctr Canc Res, Bldg 10,Rm CRC 1W 3750, Bethesda, MD 20892 USA.	xiaolinw@mail.nih.gov	Grohar, Patrick/V-2557-2018		NATIONAL CANCER INSTITUTE [ZIASC006892, Z01SC006892] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Dagher R, 1999, Oncologist, V4, P34; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Goetsch L, 2005, INT J CANCER, V113, P316, DOI 10.1002/ijc.20543; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2005, CANCER CELL, V8, P179, DOI 10.1016/j.ccr.2005.08.008; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hidalgo M, 2000, ONCOGENE, V19, P6680, DOI 10.1038/sj.onc.1204091; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Lawlor MA, 2001, J CELL SCI, V114, P2903; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Manning BD, 2004, J CELL BIOL, V167, P399, DOI 10.1083/jcb.200408161; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MINNITI CP, 1995, CELL GROWTH DIFFER, V6, P263; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; PAPPO AS, 1995, J CLIN ONCOL, V13, P2123, DOI 10.1200/JCO.1995.13.8.2123; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; Tremblay F, 2001, J BIOL CHEM, V276, P38052; Wan XL, 2005, CANCER RES, V65, P2406, DOI 10.1158/0008-5472.CAN-04-3135; Wan XL, 2003, ONCOGENE, V22, P8205, DOI 10.1038/sj.onc.1206878; Wan XL, 2002, NEOPLASIA, V4, P400, DOI 10.1038/sj.neo.7900242; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Womer RB, 2000, CURR OPIN ONCOL, V12, P337, DOI 10.1097/00001622-200007000-00010; Zhang LJ, 1999, J BIOL CHEM, V274, P13118, DOI 10.1074/jbc.274.19.13118	37	611	632	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1932	1940		10.1038/sj.onc.1209990	http://dx.doi.org/10.1038/sj.onc.1209990			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001314				2022-12-28	WOS:000245117700010
J	Hess, F; Estrugo, D; Fischer, A; Belka, C; Cordes, N				Hess, F.; Estrugo, D.; Fischer, A.; Belka, C.; Cordes, N.			Integrin-linked kinase interacts with caspase-9 and-8 in an adhesion-dependent manner for promoting radiation-induced apoptosis in human leukemia cells	ONCOGENE			English	Article						apoptosis; ILK; caspase-8; caspase-9; ECM; radiation	RESISTANCE CAM-DR; LUNG-CANCER CELLS; IN-VITRO; PROTEIN-KINASE; IONIZING-RADIATION; ALPHA-4-BETA-1 INTEGRIN; CD95-INDUCED APOPTOSIS; RNA INTERFERENCE; CYTOTOXIC DRUGS; SURVIVAL	Integrin-mediated adhesion of leukemia cells to extracellular matrix proteins reduces apoptosis following radiation-induced genotoxic injury. To evaluate the role of integrin-linked kinase ( ILK) in this process, HL60 human acute promyelocytic leukemia cells were stably transfected with ILK wild-type or kinase-hyperactive overexpression vectors. Suspension or. bronectin (FN) adhesion cultures were irradiated with X-rays and processed for measurement of apoptosis, mitochondrial transmembrane potential and caspase activation. Adhesion to FN pronouncedly reduced radiation-induced apoptosis of HL60 cells and vector controls. Intriguingly, overexpressed ILK enhanced apoptosis after irradiation by combined activation of caspase-3 through caspase-8 and -9 in irradiated FN cultures. Irradiation of ILK suspension cultures lacked caspase-8 activation, but showed serial cleavage of caspase-9, -3 and poly (ADPribose) polymerase. These findings further characterize the cell death-promoting function of ILK in DNA-damaged cells. Moreover, ILK might represent a potential therapeutic target for innovative chemo- and radiooncological approaches in hematological malignancies.	Tech Univ Dresden, Fac Med, D-01307 Dresden, Germany; Bundeswehr Inst Radiobiol, Munich, Germany; Univ Tubingen, Dept Radiat Oncol, Tubingen, Germany	Technische Universitat Dresden; Eberhard Karls University of Tubingen	Cordes, N (corresponding author), Tech Univ Dresden, Fac Med, Fetscherstasse 74-PF, D-01307 Dresden, Germany.	nils.cordes@oncoray.de		Cordes, Nils/0000-0001-5684-629X				Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Chanan-Khan Asher, 2004, Curr Treat Options Oncol, V5, P261, DOI 10.1007/s11864-004-0017-3; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cordes N, 2006, ONCOGENE, V25, P1378, DOI 10.1038/sj.onc.1209164; Cordes N, 2004, STRAHLENTHER ONKOL, V180, P157, DOI 10.1007/s00066-004-1144-2; Cordes N, 2004, CANCER RES, V64, P5683, DOI 10.1158/0008-5472.CAN-04-1056; Cordes N, 2004, INT J RADIAT ONCOL, V58, P453, DOI 10.1016/j.ijrobp.2003.09.069; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cordes N, 2003, STRAHLENTHER ONKOL, V179, P337, DOI 10.1007/s00066-003-1074-4; Damiano JS, 2001, LEUKEMIA, V15, P1232, DOI 10.1038/sj.leu.2402179; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; de la Fuente MT, 2002, J LEUKOCYTE BIOL, V71, P495; Duxbury MS, 2005, CLIN CANCER RES, V11, P3433, DOI 10.1158/1078-0432.CCR-04-1510; Eke I, 2006, RADIOTHER ONCOL, V80, P178, DOI 10.1016/j.radonc.2006.07.028; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Finkelstein LD, 2000, BIOCHEM J, V345, P385, DOI 10.1042/0264-6021:3450385; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gendron S, 2003, J BIOL CHEM, V278, P48633, DOI 10.1074/jbc.M305169200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jan YW, 2004, CELL, V116, P751, DOI 10.1016/S0092-8674(04)00204-1; Kasahara T, 2002, ANTIOXID REDOX SIGN, V4, P491, DOI 10.1089/15230860260196290; Kinbara K, 2003, NAT REV MOL CELL BIO, V4, P767, DOI 10.1038/nrm1229; Kremer CL, 2006, PROSTATE, V66, P88, DOI 10.1002/pros.20316; Legate KR, 2006, NAT REV MOL CELL BIO, V7, P20, DOI 10.1038/nrm1789; Matter ML, 2001, J BIOL CHEM, V276, P27757, DOI 10.1074/jbc.M102014200; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Nardi V, 2004, CURR OPIN HEMATOL, V11, P35, DOI 10.1097/00062752-200401000-00006; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Peter ME, 2003, CELL DEATH DIFFER, V10, P26, DOI 10.1038/sj.cdd.4401186; Riedl SJ, 2004, NAT REV MOL CELL BIO, V5, P897, DOI 10.1038/nrm1496; Seidler J, 2005, RADIOTHER ONCOL, V76, P129, DOI 10.1016/j.radonc.2005.06.018; Sethi T, 1999, NAT MED, V5, P662, DOI 10.1038/9511; Shain KH, 2002, J IMMUNOL, V168, P2544, DOI 10.4049/jimmunol.168.5.2544; Soldatenkov VA, 2000, INT J CANCER, V90, P59, DOI 10.1002/(SICI)1097-0215(20000420)90:2<59::AID-IJC1>3.0.CO;2-4; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun EW, 2001, PHARMACOL THERAPEUT, V92, P135, DOI 10.1016/S0163-7258(01)00164-4; Tamagiku Y, 2004, BIOCHEM BIOPH RES CO, V323, P445, DOI 10.1016/j.bbrc.2004.08.115; Zhang H, 2002, CANCER, V95, P896, DOI 10.1002/cncr.10751	47	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1372	1384		10.1038/sj.onc.1209947	http://dx.doi.org/10.1038/sj.onc.1209947			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936772				2022-12-28	WOS:000244558800002
J	Rose, PP; Carroll, JM; Carroll, PA; DeFilippis, VR; Lagunoff, M; Moses, AV; Roberts, CT; Fruh, K				Rose, P. P.; Carroll, J. M.; Carroll, P. A.; DeFilippis, V. R.; Lagunoff, M.; Moses, A. V.; Roberts, C. T., Jr.; Fruh, K.			The insulin receptor is essential for virus-induced tumorigenesis of Kaposi's sarcoma	ONCOGENE			English	Article						Kaposi's sarcoma; endothelial cell; tumorigenesis; insulin; insulin-like growth factor	GENE-EXPRESSION; ENDOTHELIAL-CELLS; IGF-II; HERPESVIRUS; GROWTH; TRANSFORMATION; INFECTION; ISOFORM; ESTABLISHMENT; DISEASES	Kaposi sarcoma (KS), a multifocal neoplasm of the skin that can spread to visceral organs, is the most prevalent malignant tumor in acquired immuno deficiency syndrome (AIDS) patients. KS-associated herpesvirus (KSHV or HHV8) is considered the primary etiological factor of this malignancy, as well as of primary effusion lymphoma and multicentric Castleman's disease. KS lesions are characterized by proliferating spindle cells of endothelial cell (EC) origin. The action of the insulin-like growth factor (IGF) system has been implicated in many malignancies, and recent data have demonstrated that the IGF-I receptor (IGF-IR) is required for in vitro growth of the KS-derived KSIMM cell line. To examine whether the IGF pathway is also involved in KSHV-mediated transformation of ECs, we examined the expression and function of the IGF system in KSHV-infected, immortalized dermal microvascular EC (E-DMVEC). The expression of the insulin receptor (IR) was strongly induced in latently infected E-DMVEC, whereas the expression levels of the IGF-IR remained unchanged. Gene knockdown of IR, but not IGF-IR, prevented the characteristic focus formation seen in KSHV-infected E-DMVEC. Similarly, treatment with the IR-specific small-molecule inhibitor HNMPA-(AM(3)) inhibited post-confluent growth. These data suggest a role for the IR, but not the IGF-IR, in KSHV-induced transformation of vascular ECs.	Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Beaverton, OR 97006 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle	Fruh, K (corresponding author), Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, 505 NW 185th ave, Beaverton, OR 97006 USA.	fruehk@ohsu.edu	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772; Frueh, Klaus/0000-0001-8014-3877; Carroll, Patrick/0000-0001-8147-5750	NATIONAL CANCER INSTITUTE [R01CA099906] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007781] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA099906, R01 CA097934] Funding Source: Medline; NHLBI NIH HHS [T32 HL007781-13] Funding Source: Medline; NCHHSTP CDC HHS [PS1-RR00163] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCHHSTP CDC HHS		Albini A, 1997, AIDS, V11, P713, DOI 10.1097/00002030-199706000-00003; BALTENSPERGER K, 1992, P NATL ACAD SCI USA, V89, P7885, DOI 10.1073/pnas.89.17.7885; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Catrina SB, 2005, BRIT J CANCER, V92, P1467, DOI 10.1038/sj.bjc.6602408; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; Denley A, 2004, MOL ENDOCRINOL, V18, P2502, DOI 10.1210/me.2004-0183; Denley A, 2003, HORM METAB RES, V35, P778; Flamand L, 1996, J ACQ IMMUN DEF SYND, V13, P194, DOI 10.1097/00042560-199610010-00011; Grundhoff A, 2004, J CLIN INVEST, V113, P124, DOI 10.1172/JCI200417803; Hailey J, 2002, MOL CANCER THER, V1, P1349; Jenner RG, 2002, BBA-REV CANCER, V1602, P1, DOI 10.1016/S0304-419X(01)00040-3; Lagunoff M, 2002, J VIROL, V76, P2440, DOI 10.1128/JVI.76.5.2440-2448.2002; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LUNARDIISKANDAR Y, 1995, JNCI-J NATL CANCER I, V87, P974, DOI 10.1093/jnci/87.13.974; McAllister SC, 2004, BLOOD, V103, P3465, DOI 10.1182/blood-2003-08-2781; Moses AV, 2002, J VIROL, V76, P8383, DOI 10.1128/JVI.76.16.8383-8399.2002; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Orem J, 2004, CURR OPIN ONCOL, V16, P468, DOI 10.1097/00001622-200409000-00010; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; Parravicini C, 2000, AM J PATHOL, V156, P743, DOI 10.1016/S0002-9440(10)64940-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; Sharma-Walia N, 2005, J VIROL, V79, P10308, DOI 10.1128/JVI.79.16.10308-10329.2005; Staskus KA, 1997, J VIROL, V71, P715, DOI 10.1128/JVI.71.1.715-719.1997; Surmacz E, 2003, ONCOGENE, V22, P6589, DOI 10.1038/sj.onc.1206772; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang HW, 2004, NAT GENET, V36, P687, DOI 10.1038/ng1384	31	29	30	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1995	2005		10.1038/sj.onc.1210006	http://dx.doi.org/10.1038/sj.onc.1210006			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001305				2022-12-28	WOS:000245313400002
J	Trivedi, AK; Bararia, D; Christopeit, M; PeerZada, AA; Singh, SM; Kieser, A; Hiddemann, W; Behre, HM; Behre, G				Trivedi, A. K.; Bararia, D.; Christopeit, M.; PeerZada, A. A.; Singh, S. M.; Kieser, A.; Hiddemann, W.; Behre, H. M.; Behre, G.			Proteomic identification of C/EBP-DBD multiprotein complex: JNK1 activates stem cell regulator C/EBP alpha by inhibiting its ubiquitination	ONCOGENE			English	Article						JNK1; C/EBP alpha; ubiquitination; AML and proteomics	BINDING-PROTEIN-ALPHA; ACUTE MYELOID-LEUKEMIA; C-JUN EXPRESSION; GRANULOCYTIC DIFFERENTIATION; DNA-BINDING; TRANSCRIPTION FACTORS; LINEAGE COMMITMENT; DOWN-REGULATION; PHOSPHORYLATION; KINASE	Functional inactivation of transcription factors in hematopoietic stem cell development is involved in the pathogenesis of acute myeloid leukemia (AML). Stem cell regulator C/enhancer binding protein (EBP)alpha is among such transcription factors known to be inactive in AML. This is either due to mutations or inhibition by protein-protein interactions. Here, we applied a mass spectrometry-based proteomic approach to systematically identify putative co-activator proteins interacting with the DNA-binding domain (DBD) of C/EBP transcription factors. In our proteomic screen, we identified c-Jun N-terminal kinase (JNK) 1 among others such as PAK6, MADP-1, calmodulin-like skin proteins and ZNF45 as proteins interacting with DBD of C/EBPs from nuclear extract of myelomonocytic U937 cells. We show that kinase JNK1 physically interacts with DBD of C/EBP alpha in vitro and in vivo. Furthermore, we show that active JNK1 inhibits ubiquitination of C/EBP alpha possibly by phosphorylating in its DBD. Consequently, JNK1 prolongs C/EBP alpha protein half-life leading to its enhanced transactivation and DNA-binding capacity. In certain AML patients, however, the JNK1 mRNA expression and its kinase activity is decreased which suggests a possible reason for C/EBP alpha inactivation in AML. Thus, we report the first proteomic screen of C/EBP-interacting proteins, which identifies JNK1 as positive regulator of C/EBP alpha.	Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany; GSF Natl Res Ctr Environm & Hlth, Dept Gene Vectors, Munich, Germany; Univ Munich, Dept Internal Med 3, D-80539 Munich, Germany; Univ Halle Wittenberg, Androl Sect, D-4010 Halle, Germany	Martin Luther University Halle Wittenberg; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich; Martin Luther University Halle Wittenberg	Behre, G (corresponding author), Univ Halle Wittenberg, Bone Marrow Transplantat Sect, Dept Internal Med 4, State Ctr Cell & Gene Therapy, Halle, SA, Germany.	gerhard.behre@medizin.uni-halle.de	Kieser, Arnd/M-4616-2014; Trivedi, Arun Kumar/W-1883-2019	Kieser, Arnd/0000-0003-0783-1950; Trivedi, Arun Kumar/0000-0002-6316-0947; Christopeit, Maximilian/0000-0003-4627-0412				BALKHI MY, 2006, EPUB ONCOGENE, V29; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Behre Gerhard, 2002, Expert Opin Ther Targets, V6, P491, DOI 10.1517/14728222.6.4.491; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Cleaves R, 2004, ONCOGENE, V23, P716, DOI 10.1038/sj.onc.1207172; Cristea IM, 2004, BLOOD, V103, P3624, DOI 10.1182/blood-2003-09-3295; D'Alo F, 2003, BLOOD, V102, P3163, DOI 10.1182/blood-2003-02-0479; Friedman AD, 1996, CANCER RES, V56, P3250; Frohling S, 2004, J CLIN ONCOL, V22, P624, DOI 10.1200/JCO.2004.06.060; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Fuchs SY, 1996, ONCOGENE, V13, P1531; Gombart AF, 2002, BLOOD, V99, P1332, DOI 10.1182/blood.V99.4.1332; Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI12466; Hattori T, 2003, ONCOGENE, V22, P1273, DOI 10.1038/sj.onc.1206204; Iakova P, 2003, CELL, V113, P495, DOI 10.1016/S0092-8674(03)00318-0; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Mann M, 2001, ANNU REV BIOCHEM, V70, P437, DOI 10.1146/annurev.biochem.70.1.437; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388; Muller C, 2004, J BIOL CHEM, V279, P7353, DOI 10.1074/jbc.M312709200; Muller C, 1995, EMBO J, V14, P6127, DOI 10.1002/j.1460-2075.1995.tb00303.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Pabst T, 2001, NAT GENET, V27, P263, DOI 10.1038/85820; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Perrotti D, 2004, J CLIN ONCOL, V22, P582, DOI 10.1200/JCO.2004.12.965; Perrotti D, 2002, NAT GENET, V30, P48, DOI 10.1038/ng791; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Rangatia J, 2002, MOL CELL BIOL, V22, P8681, DOI 10.1128/MCB.22.24.8681-8694.2002; Reddy VA, 2002, BLOOD, V100, P483, DOI 10.1182/blood.V100.2.483; Ronai Z, 2004, MOL CELL, V15, P843, DOI 10.1016/j.molcel.2004.09.011; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Schoch C, 2002, P NATL ACAD SCI USA, V99, P10008, DOI 10.1073/pnas.142103599; SCOTT LM, 1992, BLOOD, V80, P1725; Shim M, 2003, J BIOL CHEM, V278, P19674, DOI 10.1074/jbc.M301356200; Sieweke MH, 1998, CURR OPIN GENET DEV, V8, P545, DOI 10.1016/S0959-437X(98)80009-9; Smith ML, 2004, NEW ENGL J MED, V351, P2403, DOI 10.1056/NEJMoa041331; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; TERRANCE A, 2002, LEUKEMIA RES, V26, P55; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Wang HM, 2001, MOL CELL, V8, P817, DOI 10.1016/S1097-2765(01)00366-5; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yoon K, 2004, MOL CELL BIOL, V24, P10650, DOI 10.1128/MCB.24.24.10650-10660.2004; Zada AAP, 2003, ONCOGENE, V22, P2296, DOI 10.1038/sj.onc.1206330; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zheng R, 2004, BLOOD, V103, P1883, DOI 10.1182/blood-2003-06-1978	53	43	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1789	1801		10.1038/sj.onc.1209964	http://dx.doi.org/10.1038/sj.onc.1209964			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983342				2022-12-28	WOS:000244955600013
J	Leong, CTC; Ong, CK; Tay, SK; Huynh, H				Leong, C. T. C.; Ong, C. K.; Tay, S. K.; Huynh, H.			Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro	ONCOGENE			English	Article						HuUO-44; CUB; zona pellucida; cisplatin; RNAi and ovarian cancer	GENE-EXPRESSION; APOPTOSIS; INHIBITION; PACLITAXEL; PROTEIN; LINES; RESISTANCE; THERAPY; UTERUS; GROWTH	Ovarian cancer is currently the second leading cause of gynecological malignancy and cisplatin or cisplatin-based regimens have been the standard of care for the treatment of advance epithelial ovarian cancers. However, the efficacy of cisplatin treatment is often limited by the development of drug resistance either through the inhibition of apoptotic genes or activation of antiapoptotic genes. We have previously reported the overexpression of human UO-44 (HuUO-44) in ovarian cancers and the HuUO-44 antisera markedly inhibitedNIH-OVCAR3 ovarian cancer cell attachment and proliferation (Oncogene 23: 5707-5718, 2004). In the present study, we observed through the cancer cell line pro. ling array that the expression of HuUO-44 was suppressed in the ovarian cancer cell line (SKOV-3) after treatment with several chemotherapeutic drugs. Similarly, this suppression in HuUO-44 expression was also correlated to the cisplatin sensitivity in two other ovarian cancer cell lines NIH-OVCAR3 and OV-90 in a dose-dependent manner. To elucidate the function of HuUO-44 in cisplatin chemoresistance in ovarian cancer cell, small interfering RNAs (siRNAs) were employed to mediate HuUO-44 silencing in ovarian cancer cell line, NIH-OVCAR3. HuUO-44 RNA interference (RNAi) resulted in the inhibition of cell growth and proliferation. Importantly, HuUO-44 RNAi significantly increased sensitivity of NIH-OVCAR3 to cytotoxic stress induced by cisplatin (P < 0.01). Strikingly, we have also demonstrated that overexpression of HuUO-44 significantly conferred cisplatin resistance in NIH-OVCAR3 cells (P < 0.05). Taken together, UO-44 is involved in conferring cisplatin resistance; the described HuUO-44-specific siRNA oligonucleotides that can potently silence HuUO-44 gene expression may prove to be valuable pretreatment targets for antitumor therapy or other pathological conditions that involves aberrant HuUO-44 expression.	Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore; Natl Univ Singapore, Dept Pharmacol, Singapore 117548, Singapore; Singapore Gen Hosp, Dept Obstet & Gynaecol, Singapore 0316, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore; Singapore General Hospital	Huynh, H (corresponding author), Natl Canc Ctr, Div Cellular & Mol Res, Mol Endocrinol Lab, Singapore 169610, Singapore.	cmrhth@nccs.com.sg		Ong, Choon Kiat/0000-0001-6402-4288				Chen JY, 1999, ELECTROCHEM COMMUN, V1, P274, DOI 10.1016/S1388-2481(99)00056-9; Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497; Cioca DP, 2003, CANCER GENE THER, V10, P125, DOI 10.1038/sj.cgt.7700544; DEVI GR, 2006, IN PRESS CANC GENE T; Duan ZF, 2004, MOL CANCER THER, V3, P833; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Harborth J, 2001, J CELL SCI, V114, P4557; Huynh H, 2001, ENDOCRINOLOGY, V142, P2985, DOI 10.1210/en.142.7.2985; Imamura T, 2002, J BIOL CHEM, V277, P50725, DOI 10.1074/jbc.M204159200; Judson PL, 1999, CANCER RES, V59, P2425; July LV, 2004, MOL CANCER THER, V3, P223; Kasik JW, 1998, BIOCHEM J, V330, P947; Leong CTC, 2004, ONCOGENE, V23, P5707, DOI 10.1038/sj.onc.1207754; McGuire WP, 2003, BRIT J CANCER, V89, pS3, DOI 10.1038/sj.bjc.6601494; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Miyamoto S, 2004, CANCER RES, V64, P5720, DOI 10.1158/0008-5472.CAN-04-0811; Muggia FM, 2000, J CLIN ONCOL, V18, P106, DOI 10.1200/JCO.2000.18.1.106; Ryther RCC, 2005, GENE THER, V12, P5, DOI 10.1038/sj.gt.3302356; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tebes SJ, 2005, GYNECOL ONCOL, V99, P736, DOI 10.1016/j.ygyno.2005.08.031; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; vanEngeland M, 1996, CYTOMETRY, V24, P131, DOI 10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200	25	14	15	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					870	880		10.1038/sj.onc.1209836	http://dx.doi.org/10.1038/sj.onc.1209836			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16862170				2022-12-28	WOS:000244063800008
J	Syed, DN; Afaq, F; Kweon, MH; Hadi, N; Bhatia, N; Spiegelman, VS; Mukhtar, H				Syed, D. N.; Afaq, F.; Kweon, M-H; Hadi, N.; Bhatia, N.; Spiegelman, V. S.; Mukhtar, H.			Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappa B activation in normal human bronchial epithelial cells	ONCOGENE			English	Article						(-)-epigallocatechin-3-gallate; cigarette smoke condensate; normal human bronchial epithelial cells; nuclear factor-kappa B	LUNG-CANCER; NITRIC-OXIDE; GROWTH; EXPRESSION; TARGET; TUMOR; PROLIFERATION; INFLAMMATION; INDUCTION; TUMORIGENESIS	Cigarette smoke is a powerful inducer of inflammatory responses resulting in disruption of major cellular pathways with transcriptional and genomic alterations driving the cells towards carcinogenesis. Cell culture and animal model studies indicate that (-)-epigallocatechin-3-gallate (EGCG), the major polyphenol present in green tea, possesses potent anti-inflammatory and antiproliferative activity capable of selectively inhibiting cell growth and inducing apoptosis in cancer cells without adversely affecting normal cells. Here, we demonstrate that EGCG pretreatment (20-80 mu M) of normal human bronchial epithelial cells (NHBE) resulted in significant inhibition of cigarette smoke condensate (CSC)-induced cell proliferation. Nuclear factor-kappa B (NF-kappa B) controls the transcription of genes involved in immune and inflammatory responses. In most cells, NF-kappa B prevents apoptosis by mediating cell survival signals. Pretreatment of NHBE cells with EGCG suppressed CSC-induced phosphorylation of I kappa B alpha, and activation and nuclear translocation of NF-kappa B/p65. NHBE cells transfected with a luciferase reporter plasmid containing an NF-kappa B-inducible promoter sequence showed an increased reporter activity after CSC exposure that was specifically inhibited by EGCG pretreatment. Immunoblot analysis showed that pretreatment of NHBE cells with EGCG resulted in a significant downregulation of NF-kappa B-regulated proteins cyclin D1, MMP-9, IL-8 and iNOS. EGCG pretreatment further inhibited CSC-induced phosphorylation of ERK1/2, JNK and p38 MAPKs and resulted in a decreased expression of PI3K, AKT and mTOR signaling molecules. Taken together, our data indicate that EGCG can suppress NF-kappa B activation as well as other pro-survival pathways such as PI3K/AKT/mTOR and MAPKs in NHBE cells, which may contribute to its ability to suppress inflammation, proliferation and angiogenesis induced by cigarette smoke.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Mukhtar, H (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Room B25,1300 Univ Ave, Madison, WI 53706 USA.	hmukhtar@wisc.edu		Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA078809, P30CA014520, R01CA101039] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 78809, R01 CA 101039, 5P30 CA 14520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson GP, 2003, TRENDS PHARMACOL SCI, V24, P71, DOI 10.1016/S0165-6147(02)00052-4; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Doss MX, 2005, J NUTR BIOCHEM, V16, P259, DOI 10.1016/j.jnutbio.2004.11.003; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ho YS, 2005, TOXICOL APPL PHARM, V205, P133, DOI 10.1016/j.taap.2004.09.019; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Jin ZH, 2004, J BIOL CHEM, V279, P23837, DOI 10.1074/jbc.M402566200; Johnson MK, 2000, MUTAT RES-DNA REPAIR, V459, P211, DOI 10.1016/S0921-8777(99)00074-9; Kisley LR, 2002, CANCER RES, V62, P6850; Konopka TE, 2001, CANCER RES, V61, P3182; Kurie JM, 1996, CLIN CANCER RES, V2, P1787; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Magnani M., 2000, Current Drug Targets, V1, P387, DOI 10.2174/1389450003349056; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miller DP, 2003, INT J CANCER, V104, P758, DOI 10.1002/ijc.10989; Mossman BT, 2006, AM J RESP CELL MOL, V34, P666, DOI 10.1165/rcmb.2006-0047SF; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189, DOI 10.1165/ajrcmb.20.2.3305; Ozlu T, 2005, TUBERK TORAK, V53, P200; Patel JD, 2005, J CLIN ONCOL, V23, P3212, DOI 10.1200/JCO.2005.11.486; PERRY WJ, 2003, LUNG CANCER S1, V41, pS155; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Rao CV, 2004, MUTAT RES-FUND MOL M, V555, P107, DOI 10.1016/j.mrfmmm.2004.05.022; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; Sahnoun Z, 1998, THERAPIE, V53, P315; Sasco AJ, 2004, LUNG CANCER, V45, pS3, DOI 10.1016/j.lungcan.2004.07.998; Shiraga M, 2002, CANCER RES, V62, P5967; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165, DOI 10.1152/ajplung.2001.280.1.L165; Tsao AS, 2003, CANCER EPIDEM BIOMAR, V12, P660; Tsurutani J, 2005, CARCINOGENESIS, V26, P1182, DOI 10.1093/carcin/bgi072; Valen G, 2001, J AM COLL CARDIOL, V38, P307, DOI 10.1016/S0735-1097(01)01377-8; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Vlahos R, 2006, AM J PHYSIOL-LUNG C, V290, pL931, DOI 10.1152/ajplung.00201.2005; West KA, 2003, J CLIN INVEST, V111, P81, DOI 10.1172/JCI200316147; Wislez M, 2005, CANCER RES, V65, P3226, DOI 10.1158/0008-5472.CAN-04-4420; Wistuba II, 2002, ONCOGENE, V21, P7298, DOI 10.1038/sj.onc.1205806; Xu WM, 2002, CELL RES, V12, P311, DOI 10.1038/sj.cr.7290133; Yamamoto T, 2003, J PHARMACOL EXP THER, V307, P230, DOI 10.1124/jpet.103.054676; Yang CS, 2005, EXP LUNG RES, V31, P135, DOI 10.1080/01902140490495525; Zhang Q, 2005, AM J RESP CELL MOL, V32, P72, DOI 10.1165/rcmb.2004-0198OC; Zhong CY, 2005, CARCINOGENESIS, V26, P2187, DOI 10.1093/carcin/bgi189	43	107	120	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					673	682		10.1038/sj.onc.1209829	http://dx.doi.org/10.1038/sj.onc.1209829			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16862172				2022-12-28	WOS:000243902200005
J	Wozniak, RJ; Klimecki, WT; Lau, SS; Feinstein, Y; Futscher, BW				Wozniak, R. J.; Klimecki, W. T.; Lau, S. S.; Feinstein, Y.; Futscher, B. W.			5-Aza-2 '-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3K9 di-methylation levels are linked to tumor suppressor gene reactivation	ONCOGENE			English	Article						5-aza-2 '-deoxycytidine; H3K9 methylation; cytosine methylation; tumor suppressor; breast cancer; G9A histone methyltransferase	ABERRANT CYTOSINE METHYLATION; RISK MYELODYSPLASTIC SYNDROME; CPG-BINDING-PROTEIN; HUMAN BREAST-CANCER; DNA METHYLATION; PROMOTER HYPERMETHYLATION; HYPOMETHYLATING AGENT; COLORECTAL-CANCER; BRCA1 PROMOTER; LUNG-CANCER	The epigenetic silencing of tumor suppressor genes is a common event during carcinogenesis, and often involves aberrant DNA methylation and histone modi. cation of gene regulatory regions, resulting in the formation of a transcriptionally repressive chromatin state. Two examples include the antimetastatic, tumor suppressor genes, desmocollin 3 (DSC3) and MASPIN, which are frequently silenced in this manner in human breast cancer. Treatment of the breast tumor cell lines MDA-MB-231 and UACC 1179 with 5-aza-20-deoxycytidine (5-aza-CdR) induced transcriptional reactivation of both genes in a dose-dependent manner. Importantly, DSC3 and MASPIN reactivation was closely and consistently linked with significant decreases in promoter H3 K9 di-methylation. Moreover, 5-aza-CdR treatment also resulted in global decreases in H3 K9 di-methylation, an effect that was linked to its ability to mediate dose-dependent, post-transcriptional decreases in the key enzyme responsible for this epigenetic modification, G9A. Finally, small interfering RNA (siRNA)-mediated knockdown of G9A and DNMT1 led to increased MASPIN expression in MDA-MB-231 cells, to levels that were supra-additive, verifying the importance of these enzymes in maintaining multiple layers of epigenetic repression in breast tumor cells. These results highlight an additional, complimentary mechanism of action for 5-aza-CdR in the reactivation of epigenetically silenced genes, in a manner that is independent of its effects on DNA methylation, further supporting an important role for H3 K9 methylation in the aberrant repression of tumor suppressor genes in human cancer.	Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, Tucson, AZ 85724 USA; Univ Arizona, Arizona Resp Sci Ctr, Tucson, AZ USA; Univ Arizona, Arizona Canc Ctr, SW Environm Hlth Sci Ctr Prote Core, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; Arizona Center Cancer Care; University of Arizona	Futscher, BW (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Pharmacol & Toxicol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	bfutscher@azcc.arizona.edu			NCI NIH HHS [R01 CA065662, T32-CA09213, CA65662] Funding Source: Medline; NIEHS NIH HHS [P30 ES006694, P30 ES06694, T32 ES007091, ES007091] Funding Source: Medline; PHS HHS [P30023074] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065662, R29CA065662, T32CA009213] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006694, T32ES007091] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAYLIN SB, 1986, CANCER RES, V46, P2917; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bender CM, 1998, CANCER RES, V58, P95; Bovenzi V, 2001, CANCER CHEMOTH PHARM, V48, P71, DOI 10.1007/s002800100294; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699; Coombes MM, 2003, ONCOGENE, V22, P8902, DOI 10.1038/sj.onc.1207050; CREUSOT F, 1982, J BIOL CHEM, V257, P2041; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5; Fahrner JA, 2002, CANCER RES, V62, P7213; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200; Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115; Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Geiman TM, 2004, BIOCHEM BIOPH RES CO, V318, P544, DOI 10.1016/j.bbrc.2004.04.058; GONZALEZZULUETA M, 1995, CANCER RES, V55, P4531; Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Hsi LC, 2005, MOL CANCER THER, V4, P1740, DOI 10.1158/1535-7163.MCT-05-0218; Huang C, 2003, CURR OPIN GENET DEV, V13, P246, DOI 10.1016/S0959-437X(03)00054-6; Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006; Kantarjian HM, 2003, CANCER, V98, P522, DOI 10.1002/cncr.11543; Karpf AR, 2002, ONCOGENE, V21, P5496, DOI 10.1038/sj.onc.1205602; KOCH PJ, 1994, CURR OPIN CELL BIOL, V6, P682, DOI 10.1016/0955-0674(94)90094-9; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Kondo Y, 2004, P NATL ACAD SCI USA, V101, P7398, DOI 10.1073/pnas.0306641101; Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Lubbert M, 2001, BRIT J HAEMATOL, V114, P349, DOI 10.1046/j.1365-2141.2001.02933.x; Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005; MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076; MOMPARLER RL, 1985, LEUKEMIA RES, V9, P1361, DOI 10.1016/0145-2126(85)90123-7; Mund C, 2005, CANCER RES, V65, P7086, DOI 10.1158/0008-5472.CAN-05-0695; Nguyen CT, 2002, CANCER RES, V62, P6456; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Oshiro MM, 2005, BREAST CANCER RES, V7, pR669, DOI 10.1186/bcr1273; Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; PLIML J, 1964, COLLECT CZECH CHEM C, V29, P2576; Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761; Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rosenfeld CS, 2005, SEMIN ONCOL, V32, P465, DOI 10.1053/j.seminoncol.2005.07.002; Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118; Santini V, 2001, ANN INTERN MED, V134, P573, DOI 10.7326/0003-4819-134-7-200104030-00011; Scott SA, 2006, LEUKEMIA RES, V30, P69, DOI 10.1016/j.leukres.2005.05.010; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099; TAMAME M, 1983, MOL CELL BIOL, V3, P2287, DOI 10.1128/MCB.3.12.2287; TAMAME M, 1988, MOL CELL BIOL, V8, P3043, DOI 10.1128/MCB.8.8.3043; TRENT J, 1993, GENE CHROMOSOME CANC, V7, P194, DOI 10.1002/gcc.2870070403; Wijermans P, 2000, J CLIN ONCOL, V18, P956, DOI 10.1200/JCO.2000.18.5.956; Zhu WG, 2001, ONCOGENE, V20, P7787, DOI 10.1038/sj.onc.1204970	65	159	170	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 4	2007	26	1					77	90		10.1038/sj.onc.1209763	http://dx.doi.org/10.1038/sj.onc.1209763			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16799634				2022-12-28	WOS:000243236500008
J	Chen, YJ; Chang, JT; Lee, L; Wang, HM; Liao, CT; Chiu, CC; Chen, PJ; Cheng, AJ				Chen, Y-J; Chang, J. T.; Lee, L.; Wang, H-M; Liao, C-T; Chiu, C-C; Chen, P-J; Cheng, A-J			DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis	ONCOGENE			English	Article						DSG3; head neck cancer; clinical association; migration and invasion; therapeutic target	SQUAMOUS-CELL CARCINOMA; INTERMEDIATE FILAMENTS; PEMPHIGUS-VULGARIS; EXPRESSION; DESMOGLEIN; ADHESION; TELOMERASE	To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer ( HNC), we employed differential display analysis to compare the gene expression profiles between HNC and histopathologically normal epithelial tissues. Using reverse transcription - polymerase chain reaction and Western blot analysis, desmoglein 3 (DSG3) was identified as being differentially expressed at both the RNA and protein levels. Of 56 patients assayed, 34 (61%) had overexpression of DSG3, which correlated statistically with T stage (P=0.009), N stage (P = 0.047), overall stage (P = 0.011), tumor depth (P = 0.009) and extracapsular spread in lymph nodes (P = 0.044), suggesting that DSG3 participates in carcinogenesis of HNC. Consistent with the clinical findings, inhibition of DSG3 by RNA interference (RNAi) significantly reduced cell growth and colony formation to 57 - 21% in three HNC cell lines. Use of an in vitro wound healing and Matrigel invasion assays, we found that cell migration and invasive ability were also inhibited to 30 - 48% in three cell lines tested. An in vivo xenograft study showed that administration of DSG3-RNAi plasmid significantly inhibited tumor growth for 2 months in BALB/C nude mice. In conclusion, DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.	Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan; Chang Gung Mem Hosp, Dept Radiat Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Surg Pathol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Internal Med, Div Hematol Oncol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Dept Otorhinolaryngol Head & Neck Surg, Tao Yuan, Taiwan; Chang Gung Univ, Grad Inst Med Biotechnol, Tao Yuan 333, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University	Cheng, AJ (corresponding author), Chang Gung Univ, Sch Med Technol, Grad Inst Basic Med Sci, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	ajchen@mail.cgu.edu.tw	Cheng, Ann-Joy/AAI-4374-2020; Chun-Ta, Liao/B-9589-2011; Chiu, Ching-Chi/AAB-3093-2020	Chiu, Ching-Chi/0000-0002-1827-8049; Cheng, Ann-Joy/0000-0002-1317-0725				AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Amagai M, 1998, J CLIN INVEST, V102, P775, DOI 10.1172/JCI3647; Chang JT, 2006, BRIT J CANCER, V94, P870, DOI 10.1038/sj.bjc.6603008; Chang JT, 2005, INT J CANCER, V114, P942, DOI 10.1002/ijc.20663; Chang JT, 2002, CLIN BIOCHEM, V35, P591, DOI 10.1016/S0009-9120(02)00403-4; Chung CH, 2004, CANCER CELL, V5, P489, DOI 10.1016/S1535-6108(04)00112-6; CLAYMAN GL, 1996, CANC MED, P1645; DECKER J, 1982, NEW ENGL J MED, V306, P1151, DOI 10.1056/NEJM198205133061905; Garrod DR, 2002, CURR OPIN CELL BIOL, V14, P537, DOI 10.1016/S0955-0674(02)00366-6; Gordon LA, 2003, INT J CANCER, V106, P8, DOI 10.1002/ijc.11172; Green KJ, 2000, NAT REV MOL CELL BIO, V1, P208, DOI 10.1038/35043032; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P1231, DOI 10.1046/j.1523-1747.2002.19648.x; Hanakawa Y, 2002, J INVEST DERMATOL, V119, P27, DOI 10.1046/j.1523-1747.2002.01780.x; Harada H, 1996, ACTA DERM-VENEREOL, V76, P417; IMAI K, 1995, HEAD NECK-J SCI SPEC, V17, P204, DOI 10.1002/hed.2880170307; Krunic ALJ, 1996, ACTA DERM-VENEREOL, V76, P394; Liao CT, 2004, HEAD NECK-J SCI SPEC, V26, P504, DOI 10.1002/hed.20007; Liao SK, 1998, CANCER GENET CYTOGEN, V103, P52, DOI 10.1016/S0165-4608(97)00416-0; VOKES EE, 1993, NEW ENGL J MED, V328, P184, DOI 10.1056/NEJM199301213280306; Yang C C, 2001, Zhonghua Yi Xue Za Zhi (Taipei), V64, P357; Yin TF, 2004, SEMIN CELL DEV BIOL, V15, P665, DOI 10.1016/j.semcdb.2004.09.005	21	89	91	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					467	476		10.1038/sj.onc.1209802	http://dx.doi.org/10.1038/sj.onc.1209802			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878157				2022-12-28	WOS:000243544000016
J	Davalos, V; Dopeso, H; Velho, S; Ferreira, AM; Cirnes, L; Diaz-Chico, N; Bilbao, C; Ramirez, R; Rodriguez, G; Falcon, O; Leon, L; Niessen, RC; Keller, G; Dallenbach-Hellweg, G; Espin, E; Armengol, M; Plaja, A; Perucho, M; Imai, K; Yamamoto, H; Gebert, JF; Diaz-Chico, JC; Hofstra, RM; Woerner, SM; Seruca, R; Schwartz, S; Arango, D				Davalos, V.; Dopeso, H.; Velho, S.; Ferreira, A. M.; Cirnes, L.; Diaz-Chico, N.; Bilbao, C.; Ramirez, R.; Rodriguez, G.; Falcon, O.; Leon, L.; Niessen, R. C.; Keller, G.; Dallenbach-Hellweg, G.; Espin, E.; Armengol, M.; Plaja, A.; Perucho, M.; Imai, K.; Yamamoto, H.; Gebert, J. F.; Diaz-Chico, J. C.; Hofstra, R. M.; Woerner, S. M.; Seruca, R.; Schwartz, S., Jr.; Arango, D.			High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability	ONCOGENE			English	Article						EPHB2; cancer; microsatellite instability; colorectal; stomach; endometrium	RECEPTOR TYROSINE KINASE; FRAMESHIFT MUTATIONS; COLORECTAL TUMORS; TARGET GENES; CANCER; EXPRESSION	The EPH/EFN family of receptor tyrosine kinases regulates cell adhesion and migration and has an important role in controlling cell positioning in the normal intestinal epithelium. Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI). In this study, we extended these analyses to extracolonic MSI cancers, and found frameshift EPHB2 mutations in 39% (25/64) of gastric tumors and 14% (8/56) of endometrial tumors. Regression analysis of these EPHB2 mutation data on the basis of our previously proposed statistical model identified EPHB2 as a selective target of frameshift mutations in MSI gastric cancers but not in MSI endometrial carcinomas. These results suggest a functional role for EPHB2 in gastric tumor progression, and emphasize the differences between the tumorigenic processes in MSI gastrointestinal and endometrial cancer.	Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Valle Hebron Hosp Res Inst, Mol Oncol Program, Mol Oncol & Aging Grp, Barcelona 08035, Spain; Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4100 Oporto, Portugal; Univ Groningen, Med Ctr, Dept Genet, Groningen, Netherlands; Canc Res Inst Canary Isl, Endometrial Canc Study Grp, ICIC, Canary Isl, Spain; Univ Las Palmas Gran Canaria, Fac Hlth Sci, Dept Biochem & Physiol, Las Palmas Gran Canaria, Canary Islands, Spain; Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany; Hosp Univ Materno Infantil Canarias, Dept Obstet & Gynecol, Las Palmas Gran Canaria, Canary Islands, Spain; Dr Falcon Gynecol Inst, Las Palmas Gran Canaria, Canary Islands, Spain; Hosp Univ Materno Infantil Canarias, Dept Pathol, Las Palmas Gran Canaria, Canary Islands, Spain; Inst Pathol, Mannheim, Germany; Vall Hebron Hosp Res Inst, CIBBIM, Program Cytogenet & Epigenet, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Burnham Inst Med Res, La Jolla, CA USA; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Inst Pathol, ATB, Dept Appl Tumor Biol, Heidelberg, Germany	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universidade do Porto; University of Groningen; Universidad de Las Palmas de Gran Canaria; Technical University of Munich; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Sanford Burnham Prebys Medical Discovery Institute; Sapporo Medical University	Arango, D (corresponding author), Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	darango@ir.vhebron.net	seruca, raquel/F-8187-2011; Schwartz, Simo/H-7776-2012; Dopeso, Higinio/H-7575-2019; Arango, Diego/AFW-0125-2022; Diaz-Chico, Juan/H-1527-2015; Ramírez, Raquel/GSO-1079-2022; Ramirez-Moreno, Raquel/J-4905-2018; SIEYRO, CRISTINA BILBAO/R-6779-2018; Velho, Sérgia/B-8501-2013; Woerner, Stefan/A-2187-2010; Davalos, Veronica/AAR-8547-2020; Arango, Diego/M-5667-2016; Davalos, Veronica/S-1668-2016	Dopeso, Higinio/0000-0003-0060-1861; Arango, Diego/0000-0003-2953-3284; Diaz-Chico, Juan/0000-0002-0944-990X; Ramirez-Moreno, Raquel/0000-0002-0351-9073; SIEYRO, CRISTINA BILBAO/0000-0002-4796-1445; Velho, Sérgia/0000-0002-7104-8234; Arango, Diego/0000-0003-2953-3284; Perucho, Manuel/0000-0002-2169-2662; Rodriguez Gonzalez, Francisco G/0000-0002-8509-0804; Espin-Basany, Eloy/0000-0002-9139-4548; Schwartz, Simo/0000-0001-8297-7971; Ferreira, Ana/0000-0001-6290-1320; Davalos, Veronica/0000-0003-4077-5137; Diaz Chico, Bonifacio Nicolas/0000-0001-5633-6185; Hofstra, Robert/0000-0001-7498-3829; Armengol, Manuel/0000-0002-3211-3195; Seruca, Raquel/0000-0002-8851-4166	NCI NIH HHS [R37 CA63585] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA063585] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; Duval A, 2002, CANCER RES, V62, P1609; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; Huet S., 2003, STAT TOOLS NONLINEAR; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Schwartz S, 1999, CANCER RES, V59, P2995; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yamamoto H, 1999, J EXP CLIN CANC RES, V18, P103	15	35	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					308	311		10.1038/sj.onc.1209780	http://dx.doi.org/10.1038/sj.onc.1209780			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819508				2022-12-28	WOS:000243398300015
J	de Nigris, F; Botti, C; Rossiello, R; Crimi, E; Sica, V; Napoli, C				de Nigris, F.; Botti, C.; Rossiello, R.; Crimi, E.; Sica, V.; Napoli, C.			Cooperation between Myc and YY1 provides novel silencing transcriptional targets of alpha 3 beta 1-integrin in tumour cells	ONCOGENE			English	Article						YY1; integrin; c-myc; tumours	C-MYC; IN-VIVO; OSTEOSARCOMA CELLS; SIGNALING PATHWAYS; OVER-EXPRESSION; INTEGRINS; CANCER; MECHANISMS; BETA-1-INTEGRIN; ACTIVATION	We show that human osteosarcoma cells (Saos-2) have downregulation of alpha 3 beta 1-integrin compared to normal bone cells; this was further described in human osteosarcomas and in a primary murine sarcoma. The alpha 3 gene was silenced in Saos-2 cells causing a low expression of alpha 3 beta 1-integrin and reduction in collagen attachment with increasing migratory capacity. Chromatin immunoprecipitation assay performed on alpha 3 promoter established that Myc and Yin Yang protein (YY1) cooperate in tandem to downregulate the alpha 3 gene. This silencing mechanism involves the binding of Myc and YY1 to DNA and formation of complexes among Myc/Max, YY1, CREB-binding protein and deacetylation activity. The promoter containing deletions of E-boxes or YY1 cassettes failed to downregulate the transcription of a reporter gene as well as the inhibition of deacetylation activity. Overexpression of both Myc and YY1 was necessary to determine the alpha 3-integrin promoter downregulation in normal osteoblasts. This downregulation of alpha 3 beta 1-integrin can contribute to the acquisition of a more aggressive phenotype. YY1 regulated negatively the Myc activity through a direct interaction with the Myc/Max and deacetylase complexes. This represents a novel silencing mechanism with broad implications in the transcription machinery of tumours.	Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, I-80138 Naples, Italy; Univ Naples 2, Sch Med 2, Div Human Pathol, I-80138 Naples, Italy; Berkshire Med Ctr, Dept Internal Med, Pittsfield, MA USA	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Napoli, C (corresponding author), Univ Naples 2, Sch Med 1, Dept Gen Pathol, Div Clin Pathol, Via Luigi Crecchio 7,Complesso S Maria Dame, I-80138 Naples, Italy.	claudio.napoli@unina2.it		Napoli, Claudio/0000-0002-5455-555X				Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Brockbank EC, 2005, BRIT J CANCER, V92, P102, DOI 10.1038/sj.bjc.6602255; Dang CV, 1997, J BIOMED SCI, V4, P269, DOI 10.1007/BF02258350; Davie JR, 1998, J CELL BIOCHEM, P203; de Nigris F, 2000, CIRCULATION, V102, P2111, DOI 10.1161/01.CIR.102.17.2111; de Nigris F, 2002, BRIT J CANCER, V87, P1479, DOI 10.1038/sj.bjc.6600636; de Nigris F, 2001, CANCER RES, V61, P2267; de Nigris F, 2003, CELL CYCLE, V2, P325, DOI 10.4161/cc.2.4.414; Donohoe ME, 1999, MOL CELL BIOL, V19, P7237; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; Galvin KM, 1997, MOL CELL BIOL, V17, P3723, DOI 10.1128/MCB.17.7.3723; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Judware R, 1997, CLIN EXP METASTAS, V15, P228, DOI 10.1023/A:1018417330479; Judware R, 1995, ONCOGENE, V11, P2599; Kawashima A, 2001, CELL BIOL INT, V25, P319, DOI 10.1006/cbir.2000.0652; LEE TC, 1994, ONCOGENE, V9, P1047; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2002, NEOPLASIA, V4, P185, DOI 10.1038/sj.neo.7900232; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; PULVERER BJ, 1994, ONCOGENE, V9, P59; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SCHWARTZ MA, 1993, CANCER RES, V53, P1503; Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117; Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; SHRIVASTAVA A, 1994, NUCLEIC ACIDS RES, V22, P5151, DOI 10.1093/nar/22.24.5151; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Ye JP, 1996, MOL CELL BIOL, V16, P4744	34	35	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					382	394		10.1038/sj.onc.1209804	http://dx.doi.org/10.1038/sj.onc.1209804			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16878156				2022-12-28	WOS:000243544000007
J	Kong, LJ; Chang, JT; Bild, AH; Nevins, JR				Kong, L-J; Chang, J. T.; Bild, A. H.; Nevins, J. R.			Compensation and specificity of function within the E2F family	ONCOGENE			English	Article						E2F; cell cycle; expression signatures	TRANSCRIPTION FACTOR; DNA-REPLICATION; CELL-CYCLE; S-PHASE; EXPRESSION; PROLIFERATION; INDUCTION; PATHWAY; CANCER; LEADS	Functions encoded by single genes in lower organisms are often represented by multiple related genes in the mammalian genome. An example is the retinoblastoma and E2F families of proteins that regulate transcription during the cell cycle. Analysis of gene function using germline mutations is often confounded by overlapping function resulting in compensation. Indeed, in cells deleted of the E2F1 or E2F3 genes, there is an increase in the expression of the other family member. To avoid complications of compensatory effects, we have used small-interfering RNAs that target individual E2F proteins to generate a temporary loss of E2F function. We find that both E2F1 and E2F3 are required for cells to enter the S phase from a quiescent state, whereas only E2F3 is necessary for the S phase in growing cells. We also find that the acute loss of E2F3 activity affects the expression of genes encoding DNA replication and mitotic activities, whereas loss of E2F1 affects a limited number of genes that are distinct from those regulated by E2F3. We conclude that the long-term loss of E2F activity does lead to compensation by other family members and that the analysis of acute loss of function reveals specific and distinct roles for these proteins.	Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA	Duke University	Nevins, JR (corresponding author), Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Inst Genome Sci & Policy, Durham, NC 27710 USA.	j.nevins@duke.edu			NCI NIH HHS [CA104663, CA106520, CA112952] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA104663, R01CA106520] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Giangrande PH, 2003, MOL CELL BIOL, V23, P3707, DOI 10.1128/MCB.23.11.3707-3720.2003; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Humbert PO, 2000, GENE DEV, V14, P690; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller M J, 2001, Obes Rev, V2, P15; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nevins JR, 1997, METHOD ENZYMOL, V283, P205; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rempel RE, 2000, MOL CELL, V6, P293, DOI 10.1016/S1097-2765(00)00030-7; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yu JY, 2002, P NATL ACAD SCI USA, V99, P6047, DOI 10.1073/pnas.092143499; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	28	69	72	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					321	327		10.1038/sj.onc.1209817	http://dx.doi.org/10.1038/sj.onc.1209817			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16909124				2022-12-28	WOS:000243544000001
J	Barolo, S				Barolo, S.			Transgenic Wnt/TCF pathway reporters: all you need is Lef?	ONCOGENE			English	Review						Wnt; beta-catenin; Tcf/Lef; transgenic reporter; cell signaling pathway; transcription	BETA-CATENIN; TRANSCRIPTION FACTORS; AXIS SPECIFICATION; SIGNALING PATHWAY; GENE-EXPRESSION; TARGET GENE; STEM-CELLS; IN-VIVO; WNT; DROSOPHILA	The Wnt signaling pathway controls a large and diverse set of cell fate decisions in embryonic development, adult organ maintenance and disease. At the transcriptional level, Wnt/beta-catenin signaling is primarily mediated by the T-cell factor (TCF)/Lef-1 family of transcription factors, referred to here as TCFs. In order to track Wnt pathway activity during animal development, several laboratories have built transgenic reporter constructs containing multimerized TCF binding sites. Most of these reporters are active at multiple known sites of Wnt signaling, and several act as faithful reporters of pathway activity in specific contexts. However, multimerized TCF reporters should not be assumed to give a complete or definitive readout of Wnt signaling in vivo. Direct comparisons reveal discrepancies among reporters; in addition, there is good reason to expect that some important types of pathway activity, including target gene de-repression and TCF-independent Wnt or beta-catenin signaling, will not be accurately reported by such constructs. This review will discuss various transgenic Wnt/beta-catenin/TCF reporters, address the fidelity and completeness of their Wnt responsiveness, and contrast their in vivo transcriptional responses with those of natural Wnt target genes. Finally, three caveats to the interpretation of multimerized TCF reporter expression patterns will be proposed.	Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Barolo, S (corresponding author), Univ Michigan, Sch Med, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA.	sbarolo@umich.edu						Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3; Barolo S, 2000, BIOTECHNIQUES, V29, P726, DOI 10.2144/00294bm10; Barolo S, 2002, GENE DEV, V16, P1167, DOI 10.1101/gad.976502; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Carr M, 2005, DEV GENES EVOL, V215, P402, DOI 10.1007/s00427-005-0488-7; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen AE, 2005, NATURE, V433, P317, DOI 10.1038/nature03126; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; DasGupta R, 1999, DEVELOPMENT, V126, P4557; De Langhe SP, 2005, DEV BIOL, V277, P316, DOI 10.1016/j.ydbio.2004.09.023; Denayer T, 2006, FEBS LETT, V580, P393, DOI 10.1016/j.febslet.2005.11.084; Dessimoz J, 2005, CURR BIOL, V15, P1677, DOI 10.1016/j.cub.2005.08.037; Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515; Fathke C, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-4; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Geng X, 2003, FEBS LETT, V547, P1, DOI 10.1016/S0014-5793(03)00639-2; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Halfon MS, 2000, CELL, V103, P63, DOI 10.1016/S0092-8674(00)00105-7; Hatini V, 2001, MOL CELL, V7, P151, DOI 10.1016/S1097-2765(01)00163-0; Haynes TL, 1996, NUCLEIC ACIDS RES, V24, P5034, DOI 10.1093/nar/24.24.5034; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Hernandez-Munain C, 1998, MOL CELL BIOL, V18, P3223, DOI 10.1128/MCB.18.6.3223; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Hurlstone AFL, 2003, NATURE, V425, P633, DOI 10.1038/nature02028; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jian HY, 2006, GENE DEV, V20, P666, DOI 10.1101/gad.1388806; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; Knirr S, 2001, DEV BIOL, V238, P13, DOI 10.1006/dbio.2001.0397; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Labbe E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697; Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200; Lie DC, 2005, NATURE, V437, P1370, DOI 10.1038/nature04108; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maduro MF, 2005, DEV BIOL, V285, P510, DOI 10.1016/j.ydbio.2005.06.022; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Merrill BJ, 2004, DEVELOPMENT, V131, P263, DOI 10.1242/dev.00935; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Mohamed OA, 2004, DEV DYNAM, V231, P416, DOI 10.1002/dvdy.20135; Nakaya MA, 2005, DEVELOPMENT, V132, P5425, DOI 10.1242/dev.02149; Newfeld SJ, 2002, GENETICS, V161, P685; O'Brien WT, 2004, J NEUROSCI, V24, P6791, DOI 10.1523/JNEUROSCI.4753-03.2004; Park JI, 2005, DEV CELL, V8, P843, DOI 10.1016/j.devcel.2005.04.010; Pradeep A, 2004, ONCOGENE, V23, P3689, DOI 10.1038/sj.onc.1207454; Prieve MG, 1999, MOL CELL BIOL, V19, P4503; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; ROBERTSON LM, 1995, NEURON, V14, P241, DOI 10.1016/0896-6273(95)90282-1; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; ROOSE J, 1999, THESIS U HOSP UTRECH; SHTUTMAN M, 1999, P NATL ACAD SCI USA, V275, P21203; Shu WG, 2005, DEV BIOL, V283, P226, DOI 10.1016/j.ydbio.2005.04.014; Spychala J, 1999, J BIOL CHEM, V274, P22705, DOI 10.1074/jbc.274.32.22705; Staal FJT, 2004, J IMMUNOL, V172, P1099, DOI 10.4049/jimmunol.172.2.1099; Staal FJT, 2001, EUR J IMMUNOL, V31, P285, DOI 10.1002/1521-4141(200101)31:1<285::AID-IMMU285>3.3.CO;2-4; Theil T, 2002, DEVELOPMENT, V129, P3045; van Beest M, 2000, J BIOL CHEM, V275, P27266; VOLK T, 1994, DEVELOPMENT, V120, P59; Watabe T, 1995, GENE DEV, V9, P3038, DOI 10.1101/gad.9.24.3038; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Yang X, 2000, DEVELOPMENT, V127, P3695; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021; Ziemer LT, 2001, MOL CELL BIOL, V21, P562, DOI 10.1128/MCB.21.2.562-574.2001	63	123	128	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2006	25	57					7505	7511		10.1038/sj.onc.1210057	http://dx.doi.org/10.1038/sj.onc.1210057			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143294				2022-12-28	WOS:000242514900008
J	De Ferrari, GV; Moon, RT				De Ferrari, G. V.; Moon, R. T.			The ups and downs of Wnt signaling in prevalent neurological disorders	ONCOGENE			English	Review						Wnt signaling; autism; schizophrenia; Alzheimer's disease; apolipoprotein E; genetic variation	GLYCOGEN-SYNTHASE KINASE-3-BETA; FETAL VALPROATE SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; HOMEOBOX-TRANSCRIPTION-FACTOR; DISEASE-LIKE PHOSPHORYLATION; AMYLOID PRECURSOR PROTEIN; ONSET ALZHEIMER-DISEASE; GENOME-WIDE SCAN; ALPHA-T-CATENIN; BETA-CATENIN	In order to function properly, the brain must be wired correctly during critical periods in early development. Mistakes in this process are hypothesized to occur in disorders like autism and schizophrenia. Later in life, signaling pathways are essential in maintaining proper communication between neuronal and non-neuronal cells, and disrupting this balance may result in disorders like Alzheimer's disease. The Wnt/beta-catenin pathway has a well-established role in cancer. Here, we review recent evidence showing the involvement of Wnt/beta-catenin signaling in neurodevelopment as well as in neurodegenerative diseases. We suggest that the onset/development of such pathological conditions may involve the additive effect of genetic variation within Wnt signaling components and of molecules that modulate the activity of this signaling cascade.	Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98115 USA; Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98115 USA; Univ Concepcion, Fac Ciencias Biol, Dept Bioquim & Biol Mol, Concepcion, Chile	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Universidad de Concepcion	De Ferrari, GV (corresponding author), Univ Washington, Sch Med, Howard Hughes Med Inst, Dept Pharmacol, Seattle, WA 98115 USA.	gdeferrari@udec.cl; rtmoon@u.washington.edu	Moon, Randall T/B-1743-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; De Ferrari, Giancarlo/0000-0003-0932-125X				Abu-Khalil A, 2004, J COMP NEUROL, V474, P276, DOI 10.1002/cne.20112; Ahn YM, 2005, INT J NEUROPSYCHOPH, V8, P607, DOI 10.1017/S1461145705005353; Alimohamad H, 2005, J NEUROCHEM, V95, P513, DOI 10.1111/j.1471-4159.2005.03388.x; Alimohamad H, 2005, BIOL PSYCHIAT, V57, P533, DOI 10.1016/j.biopsych.2004.11.036; Alvarez AR, 2004, EXP CELL RES, V297, P186, DOI 10.1016/j.yexcr.2004.02.028; Alvarez G, 2002, BIPOLAR DISORD, V4, P153, DOI 10.1034/j.1399-5618.2002.01150.x; Baader SL, 1998, J NEUROSCI, V18, P1763; Bailer U, 2002, BIOL PSYCHIAT, V52, P40, DOI 10.1016/S0006-3223(02)01320-3; Bailey A, 1998, HUM MOL GENET, V7, P571; Barrett S, 1999, AM J MED GENET, V88, P609; Bartlett CW, 2005, INT J DEV NEUROSCI, V23, P221, DOI 10.1016/j.ijdevneu.2004.10.004; Beasley C, 2001, NEUROSCI LETT, V302, P117, DOI 10.1016/S0304-3940(01)01688-3; Benayed R, 2005, AM J HUM GENET, V77, P851, DOI 10.1086/497705; Benedetti F, 2005, NEUROSCI LETT, V376, P51, DOI 10.1016/j.neulet.2004.11.022; Benedetti F, 2004, NEUROSCI LETT, V368, P123, DOI 10.1016/j.neulet.2004.06.050; Benedetti F, 2004, NEUROSCI LETT, V355, P37, DOI 10.1016/j.neulet.2003.10.021; Blacker D, 2003, HUM MOL GENET, V12, P23, DOI 10.1093/hmg/ddg007; Blomqvist MEL, 2004, NEUROSCI LETT, V358, P220, DOI 10.1016/j.neulet.2004.01.032; Blouin JL, 1998, NAT GENET, V20, P70, DOI 10.1038/1734; Brown SP, 1998, J AGING PHYS ACTIV, V6, P248, DOI 10.1123/japa.6.3.248; Bug G, 2005, CANCER RES, V65, P2537, DOI 10.1158/0008-5472.CAN-04-3011; Busby V, 2004, NEUROMOL MED, V5, P133, DOI 10.1385/NMM:5:2:133; Buxbaum JD, 2001, AM J HUM GENET, V68, P1514, DOI 10.1086/320588; Caricasole A, 2004, J NEUROSCI, V24, P6021, DOI 10.1523/JNEUROSCI.1381-04.2004; Caricasole A, 2003, TRENDS PHARMACOL SCI, V24, P233, DOI 10.1016/S0165-6147(03)00100-7; Chakravarti A, 2001, NATURE, V409, P822, DOI 10.1038/35057281; Chen G, 1999, J NEUROCHEM, V72, P1327, DOI 10.1046/j.1471-4159.2000.0721327.x; Chen JY, 2006, J BIOL CHEM, V281, P11910, DOI 10.1074/jbc.M511920200; Chenn A, 2002, SCIENCE, V297, P365, DOI 10.1126/science.1074192; Chenn A, 2003, CEREB CORTEX, V13, P599, DOI 10.1093/cercor/13.6.599; CHRISTIANSON AL, 1994, DEV MED CHILD NEUROL, V36, P361; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Collaborative Linkage Study of Autism, 2001, Am J Med Genet, V105, P609; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cotter D, 1998, NEUROREPORT, V9, P1379, DOI 10.1097/00001756-199805110-00024; Courchesne E, 2004, CURR OPIN NEUROL, V17, P489, DOI 10.1097/01.wco.0000137542.14610.b4; Courchesne E, 2003, JAMA-J AM MED ASSOC, V290, P337, DOI 10.1001/jama.290.3.337; Courchesne E, 2001, NEUROLOGY, V57, P245, DOI 10.1212/WNL.57.2.245; Daw EW, 2000, AM J HUM GENET, V66, P196, DOI 10.1086/302710; De Ferrari GV, 2003, MOL PSYCHIATR, V8, P195, DOI 10.1038/sj.mp.4001208; De Ferrari GV, 2000, BRAIN RES REV, V33, P1, DOI 10.1016/S0165-0173(00)00021-7; Emamian ES, 2004, NAT GENET, V36, P131, DOI 10.1038/ng1296; Ertekin-Taner N, 2003, HUM MOL GENET, V12, P3133, DOI 10.1093/hmg/ddg343; Fatemi SH, 2002, CELL MOL NEUROBIOL, V22, P171, DOI 10.1023/A:1019861721160; Folstein S. E., 2003, NOVART FDN SYMP, V251, P281; Folstein S. E., 2003, NOVART FDN SYMP, V251, P80; Folstein S. E., 2003, NOVART FDN SYMP, V251, P109; Folstein SE, 2001, NAT REV GENET, V2, P943, DOI 10.1038/35103559; Folstein SE, 2003, NOVART FDN SYMP, V251, P70; Ftouh S, 2005, J NEUROCHEM, V94, P520, DOI 10.1111/j.1471-4159.2005.03239.x; Gharani N, 2004, MOL PSYCHIATR, V9, P474, DOI 10.1038/sj.mp.4001498; Grove EA, 1998, DEVELOPMENT, V125, P2315; Gurling HMD, 2001, AM J HUM GENET, V68, P661, DOI 10.1086/318788; Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116; Hall AC, 2002, MOL CELL NEUROSCI, V20, P257, DOI 10.1006/mcne.2002.1117; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Hey PJ, 1998, GENE, V216, P103, DOI 10.1016/S0378-1119(98)00311-4; Houart C, 2002, NEURON, V35, P255, DOI 10.1016/S0896-6273(02)00751-1; Hu-Lince D, 2005, AM J PHARMACOGENOMIC, V5, P233, DOI 10.2165/00129785-200505040-00004; Ide M, 2004, BIOL PSYCHIAT, V56, P462, DOI 10.1016/j.biopsych.2004.06.039; Ingram JL, 2000, NEUROTOXICOL TERATOL, V22, P319, DOI 10.1016/S0892-0362(99)00083-5; Jeong SH, 2006, PSYCHIAT RES, V143, P1, DOI 10.1016/j.psychres.2005.07.026; JOYNER AL, 1991, SCIENCE, V251, P1239, DOI 10.1126/science.1672471; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Katsu T, 2003, NEUROSCI LETT, V353, P53, DOI 10.1016/j.neulet.2003.09.017; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kendler KS, 2000, AM J PSYCHIAT, V157, P402, DOI 10.1176/appi.ajp.157.3.402; Kim DH, 1998, J BIOCHEM-TOKYO, V124, P1072, DOI 10.1093/oxfordjournals.jbchem.a022223; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Kozlovsky N, 2000, AM J PSYCHIAT, V157, P831, DOI 10.1176/appi.ajp.157.5.831; Kozlovsky N, 2001, SCHIZOPHR RES, V52, P101, DOI 10.1016/S0920-9964(00)00174-2; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Lako M, 1998, HUM MOL GENET, V7, P813, DOI 10.1093/hmg/7.5.813; Lau KF, 1999, J PEPT RES, V54, P85, DOI 10.1034/j.1399-3011.1999.00083.x; Lee SMK, 2000, DEVELOPMENT, V127, P457; Leroy K, 1999, J CHEM NEUROANAT, V16, P279, DOI 10.1016/S0891-0618(99)00012-5; Li J, 2004, AM J MED GENET B, V126B, P51, DOI 10.1002/ajmg.b.20122; Li X, 2006, J NEURAL TRANSM, V113, P93, DOI 10.1007/s00702-005-0303-7; Li YH, 2001, MOL NEUROBIOL, V23, P53; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Magoori K, 2003, J BIOL CHEM, V278, P11331, DOI 10.1074/jbc.M211987200; Mak BC, 2005, AM J PATHOL, V167, P107, DOI 10.1016/S0002-9440(10)62958-6; Mak BC, 2004, CANCER INVEST, V22, P588, DOI 10.1081/CNV-200027144; Mak BC, 2003, J BIOL CHEM, V278, P5947, DOI 10.1074/jbc.C200473200; Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; Mateo I, 2006, DEMENT GERIATR COGN, V21, P228, DOI 10.1159/000091044; Mayeux R, 2002, AM J HUM GENET, V70, P237, DOI 10.1086/324773; McCoy PA, 2002, AM J MED GENET, V114, P106, DOI 10.1002/ajmg.10182; McGrew LL, 1999, MECH DEVELOP, V87, P21, DOI 10.1016/S0925-4773(99)00136-7; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MILLEN KJ, 1994, DEVELOPMENT, V120, P695; Miyaoka T, 1999, SCHIZOPHR RES, V38, P1, DOI 10.1016/S0920-9964(98)00179-0; Miyazaki K, 2005, INT J DEV NEUROSCI, V23, P287, DOI 10.1016/j.ijdevneu.2004.05.004; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Moore SJ, 2000, J MED GENET, V37, P489, DOI 10.1136/jmg.37.7.489; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Mudher A, 2001, J NEUROSCI, V21, P4987, DOI 10.1523/JNEUROSCI.21-14-04987.2001; Myers A, 2002, AM J MED GENET, V114, P235, DOI 10.1002/ajmg.10183; Packard M, 2002, CELL, V111, P319, DOI 10.1016/S0092-8674(02)01047-4; Palferman S, 2001, AM J HUM GENET, V69, P570; Panakova D, 2005, NATURE, V435, P58, DOI 10.1038/nature03504; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; PETIT E, 1995, J MED GENET, V32, P269, DOI 10.1136/jmg.32.4.269; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Philippe A, 1999, HUM MOL GENET, V8, P805, DOI 10.1093/hmg/8.5.805; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; PULVER AE, 1995, AM J MED GENET, V60, P252, DOI 10.1002/ajmg.1320600316; Rapoport JL, 2005, MOL PSYCHIATR, V10, P434, DOI 10.1038/sj.mp.4001642; Rebeck GW, 2002, J ALZHEIMERS DIS, V4, P145, DOI 10.3233/JAD-2002-4304; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; RITVO ER, 1986, AM J PSYCHIAT, V143, P862; Rodier PM, 1997, REPROD TOXICOL, V11, P417, DOI 10.1016/S0890-6238(97)80001-U; Rogaeva E, 1998, JAMA-J AM MED ASSOC, V280, P614, DOI 10.1001/jama.280.7.614; Russ C, 2002, MOL PSYCHIATR, V7, P104, DOI 10.1038/sj/mp/4000941; Russ C, 2001, MOL PSYCHIATR, V6, P320, DOI 10.1038/sj.mp.4000852; Sala CF, 2000, BIOCHEM BIOPH RES CO, V273, P27, DOI 10.1006/bbrc.2000.2882; Salinas PC, 1999, BIOCHEM SOC SYMP, V65, P101; Salinas PC, 2005, J NEUROBIOL, V64, P435, DOI 10.1002/neu.20159; Sato S, 2002, J BIOL CHEM, V277, P42060, DOI 10.1074/jbc.M202241200; Saunders AJ, 2003, HUM MOL GENET, V12, P2765, DOI 10.1093/hmg/ddg310; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Scassellati C, 2004, NEUROPSYCHOBIOLOGY, V50, P16, DOI 10.1159/000077936; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; Scott WK, 2000, AM J HUM GENET, V66, P922, DOI 10.1086/302828; Serajee FJ, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.4.e42; SHAW A, 1998, CHINA NEW INVESTOR, V3, P3; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sun X, 2002, NEUROSCI LETT, V321, P61, DOI 10.1016/S0304-3940(01)02583-6; Svenningsson P, 2003, SCIENCE, V302, P1412, DOI 10.1126/science.1089681; Takashima A, 1998, NEUROSCI RES, V31, P317, DOI 10.1016/S0168-0102(98)00061-3; Takashima A, 1998, P NATL ACAD SCI USA, V95, P9637, DOI 10.1073/pnas.95.16.9637; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; Teter B, 2002, J ALZHEIMERS DIS, V4, P155, DOI 10.3233/JAD-2002-4305; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; van Meurs JBJ, 2006, J BONE MINER RES, V21, P141, DOI 10.1359/JBMR.050904; Vogel MW, 1996, DEV BRAIN RES, V96, P210; Vorstman JAS, 2006, MOL PSYCHIATR, V11, P18, DOI 10.1038/sj.mp.4001757; Wang JM, 2003, NAT NEUROSCI, V6, P1017, DOI 10.1038/nn1128; Wang YS, 2002, J NEUROSCI, V22, P8563; Wassink TH, 2001, AM J MED GENET, V105, P406, DOI 10.1002/ajmg.1401; Wehrli M, 2000, NATURE, V407, P527, DOI 10.1038/35035110; Williams G, 2001, DEV MED CHILD NEUROL, V43, P202, DOI 10.1017/S001216220100038X; Williams PG, 1997, DEV MED CHILD NEUROL, V39, P632; Wilson SW, 2004, DEV CELL, V6, P167, DOI 10.1016/S1534-5807(04)00027-9; Wiznitzer M, 2004, J CHILD NEUROL, V19, P675, DOI 10.1177/08830738040190090701; Wu WS, 1998, JAMA-J AM MED ASSOC, V280, P619, DOI 10.1001/jama.280.7.619; Yang JZ, 2003, BIOL PSYCHIAT, V54, P1298, DOI 10.1016/S0006-3223(03)00291-9; Ylisaukko-oja T, 2004, MOL PSYCHIATR, V9, P161, DOI 10.1038/sj.mp.4001385; Zhang YB, 2004, AM J MED GENET B, V129B, P16, DOI 10.1002/ajmg.b.30076; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhou CJ, 2004, J NEUROSCI, V24, P7632, DOI 10.1523/JNEUROSCI.2123-04.2004; Zhou JH, 1997, NEUROREPORT, V8, P2085, DOI 10.1097/00001756-199705260-00054	164	179	209	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2006	25	57					7545	7553		10.1038/sj.onc.1210064	http://dx.doi.org/10.1038/sj.onc.1210064			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GX	17143299				2022-12-28	WOS:000242514900013
J	Lotem, J; Sachs, L				Lotem, J.; Sachs, L.			Epigenetics and the plasticity of differentiation in normal and cancer stem cells	ONCOGENE			English	Review						epigenetics; differentiation plasticity; normal embryonic and adult stem cells; cancer stem cells; transcription accessibility	ACUTE MYELOID-LEUKEMIA; MARROW STROMAL CELLS; HISTONE DEACETYLASE INHIBITION; COLONY-STIMULATING FACTOR; GENE-EXPRESSION PROFILES; SYNUCLEIN-GAMMA-GENE; NORMAL MAST-CELLS; HEMATOPOIETIC STEM; BONE-MARROW; DNA METHYLATION	Embryonic stem cells are characterized by their differentiation to all cell types during embryogenesis. In adult life, different tissues also have somatic stem cells, called adult stem cells, which in specific niches can undergo multipotent differentiation. The use of these adult stem cells has considerable therapeutic potential for the regeneration of damaged tissues. In both embryonic and adult stem cells, differentiation is controlled by epigenetic mechanisms, and the plasticity of differentiation in these cells is associated with transcription accessibility for genes expressed in different normal tissues. Abnormalities in genetic and/ or epigenetic controls can lead to development of cancer, which is maintained by self- renewing cancer stem cells. Although the genetic abnormalities produce defects in growth and differentiation in cancer stem cells, these cells have not always lost the ability to undergo differentiation through epigenetic changes that by- pass the genomic abnormalities, thus creating the basis for differentiation therapy. Like normal stem cells, cancer stem cells can show plasticity for differentiation. This plasticity of cancer stem cells is also associated with transcription accessibility for genes that are normally expressed in different tissues, including tissues other than those from which the cancers originated. This broad transcription accessibility can also contribute to the behavior of cancer cells by overexpressing genes that promote cell viability, growth and metastasis.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Sachs, L (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	leo.sachs@weizmann.ac.il						Adams SP, 2002, LEUKEMIA, V16, P2238, DOI 10.1038/sj.leu.2402732; Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; Alonso L, 2003, GENE DEV, V17, P1189, DOI 10.1101/gad.1086903; Altieri DC, 2003, ADV CANCER RES, V88, P31, DOI 10.1016/S0065-230X(03)88303-3; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Amoh Y, 2005, P NATL ACAD SCI USA, V102, P17734, DOI 10.1073/pnas.0508440102; Andersson A, 2005, P NATL ACAD SCI USA, V102, P19069, DOI 10.1073/pnas.0506637102; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; Baba Y, 2005, IMMUNITY, V23, P599, DOI 10.1016/j.immuni.2005.10.009; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bailey AS, 2004, BLOOD, V103, P13, DOI 10.1182/blood-2003-05-1684; BAIN G, 1994, BIOESSAYS, V16, P343, DOI 10.1002/bies.950160509; Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Behbod F, 2005, CARCINOGENESIS, V26, P703, DOI 10.1093/carcin/bgh293; Bhattacharya B, 2004, BLOOD, V103, P2956, DOI 10.1182/blood-2003-09-3314; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bjerkvig R, 2005, NAT REV CANCER, V5, P899, DOI 10.1038/nrc1740; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blasco T, 2003, AM J PHYSIOL-RENAL, V285, pF799, DOI 10.1152/ajprenal.00149.2003; Bonnet D, 2005, BRIT J HAEMATOL, V130, P469, DOI 10.1111/j.1365-2141.2005.05596.x; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Boon EMJ, 2004, BRIT J CANCER, V90, P224, DOI 10.1038/sj.bjc.6601505; Cairns BR, 2001, TRENDS CELL BIOL, V11, pS15, DOI 10.1016/S0962-8924(01)02125-0; Calaluce R, 2004, NEOPLASIA, V6, P468, DOI 10.1593/neo.03499; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; Camargo FD, 2003, NAT MED, V9, P1520, DOI 10.1038/nm963; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Cao BH, 2003, NAT CELL BIOL, V5, P640, DOI 10.1038/ncb1008; Carlone DL, 2005, MOL CELL BIOL, V25, P4881, DOI 10.1128/MCB.25.12.4881-4891.2005; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Chung Y, 2006, NATURE, V439, P216, DOI 10.1038/nature04277; CICCARONE V, 1989, CANCER RES, V49, P219; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; Corbel SY, 2003, NAT MED, V9, P1528, DOI 10.1038/nm959; Cox DN, 1998, GENE DEV, V12, P3715, DOI 10.1101/gad.12.23.3715; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902; Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763; Deng W, 2002, DEV CELL, V2, P819, DOI 10.1016/S1534-5807(02)00165-X; Dezawa M, 2005, SCIENCE, V309, P314, DOI 10.1126/science.1110364; Dezawa M, 2004, J CLIN INVEST, V113, P1701, DOI 10.1172/JCI200420935; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dore BT, 1998, CANCER CHEMOTH PHARM, V41, P275, DOI 10.1007/s002800050740; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Dusenbery KE, 2003, J PEDIAT HEMATOL ONC, V25, P760, DOI 10.1097/00043426-200310000-00004; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fan GP, 2005, DEVELOPMENT, V132, P3345, DOI 10.1242/dev.01912; Fang JY, 2001, J GASTROEN HEPATOL, V16, P960, DOI 10.1046/j.1440-1746.2001.02554.x; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fischbach NA, 2005, BLOOD, V105, P1456, DOI 10.1182/blood-2004-04-1583; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; FRANK D, 1991, NATURE, V351, P239, DOI 10.1038/351239a0; Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Geiger TR, 2005, CANCER RES, V65, P7033, DOI 10.1158/0008-5472.CAN-05-0709; Georgantas RW, 2004, CANCER RES, V64, P4434, DOI 10.1158/0008-5472.CAN-03-3247; Gidekel S, 2002, J BIOL CHEM, V277, P34521, DOI 10.1074/jbc.M203338200; GINSBURG H, 1963, J NATL CANCER I, V31, P1; Golan-Mashiach M, 2004, FASEB J, V18, P147, DOI 10.1096/fj.04-2417fje; Goldmit M, 2005, NAT IMMUNOL, V6, P198, DOI 10.1038/ni1154; Goolsby J, 2003, P NATL ACAD SCI USA, V100, P14926, DOI 10.1073/pnas.2434383100; Granziero L, 2003, BLOOD, V101, P1962, DOI 10.1182/blood-2002-05-1339; GRIESINGER F, 1989, J EXP MED, V169, P1101, DOI 10.1084/jem.169.3.1101; Guan K, 2006, NATURE, V440, P1199, DOI 10.1038/nature04697; Guinn BA, 2005, BIOCHEM BIOPH RES CO, V333, P703, DOI 10.1016/j.bbrc.2005.05.161; Gupta A, 2003, CANCER RES, V63, P664; HANADA M, 1993, BLOOD, V82, P1820; Harrell PC, 2005, EXP CELL RES, V303, P308, DOI 10.1016/j.yexcr.2004.09.020; Harris RG, 2004, SCIENCE, V305, P90, DOI 10.1126/science.1098925; Hasumi H, 2005, INT J CANCER, V115, P911, DOI 10.1002/ijc.20967; Havt A, 2005, P NATL ACAD SCI USA, V102, P17424, DOI 10.1073/pnas.0506844102; HAYASHI M, 1974, INT J CANCER, V14, P40, DOI 10.1002/ijc.2910140106; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herzog EL, 2003, BLOOD, V102, P3483, DOI 10.1182/blood-2003-05-1664; Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504; Hong SH, 2001, MOL CELL BIOL, V21, P7172, DOI 10.1128/MCB.21.21.7172-7182.2001; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Hsu CL, 2006, P NATL ACAD SCI USA, V103, P672, DOI 10.1073/pnas.0510304103; ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488; Inaba S, 2005, BREAST CANCER RES TR, V94, P25, DOI 10.1007/s10549-005-6938-0; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004; Jang YY, 2004, NAT CELL BIOL, V6, P532, DOI 10.1038/ncb1132; Jarzab B, 2005, CANCER RES, V65, P1587, DOI 10.1158/0008-5472.CAN-04-3078; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kanatsu-Shinohara M, 2004, CELL, V119, P1001, DOI 10.1016/j.cell.2004.11.011; Kaneda A, 2004, CANCER SCI, V95, P58, DOI 10.1111/j.1349-7006.2004.tb03171.x; Kaneda A, 2005, CANCER RES, V65, P11236, DOI 10.1158/0008-5472.CAN-05-2959; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0; KLEINSMITH LJ, 1964, CANCER RES, V24, P1544; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Kocher O, 1996, AM J PATHOL, V149, P493; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Kondo T, 2006, NEUROREPORT, V17, P1, DOI 10.1097/01.wnr.0000192732.00535.ff; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kubota H, 2004, P NATL ACAD SCI USA, V101, P16489, DOI 10.1073/pnas.0407063101; Kurisu S, 2005, ONCOGENE, V24, P1309, DOI 10.1038/sj.onc.1208177; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LeBrun DP, 2003, FRONT BIOSCI, V8, pS206, DOI 10.2741/1030; Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430; Lee S, 2006, P NATL ACAD SCI USA, V103, P1030, DOI 10.1073/pnas.0509878103; LEVAN A, 1953, J NATL CANCER I, V14, P1; Li L, 2003, CANCER RES, V63, P2733; Li LH, 2005, ANNU REV CELL DEV BI, V21, P605, DOI 10.1146/annurev.cellbio.21.012704.131525; Liu HY, 2005, CANCER RES, V65, P7635, DOI 10.1158/0008-5472.CAN-05-1089; Liu JW, 2000, BREAST CANCER RES TR, V62, P99, DOI 10.1023/A:1006418219012; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; Lotem J, 2004, P NATL ACAD SCI USA, V101, P16022, DOI 10.1073/pnas.0406966101; Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8; Lotem J, 2005, P NATL ACAD SCI USA, V102, P18556, DOI 10.1073/pnas.0509360102; LOTEM J, 1978, P NATL ACAD SCI USA, V75, P3781, DOI 10.1073/pnas.75.8.3781; Lubbert M, 1996, BLOOD, V87, P447, DOI 10.1182/blood.V87.2.447.bloodjournal872447; Luce MJ, 1999, GENE, V231, P121, DOI 10.1016/S0378-1119(99)00093-1; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; MAKINO S, 1953, J NATL CANCER I, V13, P1213; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028; MARTIN GR, 1975, P NATL ACAD SCI USA, V72, P1441, DOI 10.1073/pnas.72.4.1441; Martin-Rendon E, 2003, BRIT J HAEMATOL, V122, P877, DOI 10.1046/j.1365-2141.2003.04576.x; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Meshorer E, 2006, DEV CELL, V10, P105, DOI 10.1016/j.devcel.2005.10.017; Miyata Y, 2001, BIOCHEM BIOPH RES CO, V283, P655, DOI 10.1006/bbrc.2001.4840; Mohri T, 2006, J BIOL CHEM, V281, P6442, DOI 10.1074/jbc.M508969200; MONK M, 1987, DEVELOPMENT, V99, P371; Muller C, 2001, CURR OPIN GENET DEV, V11, P167, DOI 10.1016/S0959-437X(00)00175-1; Munster PN, 2001, CANCER RES, V61, P8492; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; NAKAMURA M, 1991, CANCER RES, V51, P1940; Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307; Ogasawara S, 2004, ONCOGENE, V23, P1117, DOI 10.1038/sj.onc.1207211; Ogishima T, 2005, ONCOGENE, V24, P6765, DOI 10.1038/sj.onc.1208811; Okutsu J, 2002, MOL CANCER THER, V1, P1035; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Pan ZZ, 2002, J BIOL CHEM, V277, P35050, DOI 10.1074/jbc.M201650200; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; Pinto do O P, 1998, EMBO J, V17, P5744, DOI 10.1093/emboj/17.19.5744; PLUZNIK DH, 1966, EXP CELL RES, V43, P553, DOI 10.1016/0014-4827(66)90026-7; PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309; Porter D, 2003, P NATL ACAD SCI USA, V100, P10931, DOI 10.1073/pnas.1932980100; Pui CH, 1998, BLOOD, V92, P411, DOI 10.1182/blood.V92.2.411.414k34_411_415; Rabbitts T. H., 1997, Leukemia (Basingstoke), V11, P271; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Rangel LBA, 2003, ONCOGENE, V22, P7225, DOI 10.1038/sj.onc.1207008; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Rekasi Z, 2005, P NATL ACAD SCI USA, V102, P3435, DOI 10.1073/pnas.0410006102; Rippon HJ, 2004, CELL PROLIFERAT, V37, P23, DOI 10.1111/j.1365-2184.2004.00298.x; Robbins MJ, 2002, MOL BRAIN RES, V106, P136, DOI 10.1016/S0169-328X(02)00420-5; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Roloff TC, 2005, EUR J CELL BIOL, V84, P123, DOI 10.1016/j.ejcb.2004.12.013; Romero-Ramos M, 2002, J NEUROSCI RES, V69, P894, DOI 10.1002/jnr.10374; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; Roumier C, 2003, LEUKEMIA, V17, P9, DOI 10.1038/sj.leu.2402766; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742; SACHS L, 1987, PROC R SOC SER B-BIO, V231, P289, DOI 10.1098/rspb.1987.0045; SACHS L, 1987, CANCER RES, V47, P1981; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SACHS L, 1955, J NATL CANCER I, V15, P1267; SACHS L, 1995, ADV CANCER RES, V66, P1, DOI 10.1016/S0065-230X(08)60250-X; SACHS L, 1964, ANNU REV GENET, V4, P246; SACHS L, 1964, NEW PERSPECT BIO, V4, P246; Sakatani T, 2005, SCIENCE, V307, P1976, DOI 10.1126/science.1108080; Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0; Sato N, 2003, CANCER RES, V63, P4158; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Schmittwolf C, 2005, EMBO J, V24, P554, DOI 10.1038/sj.emboj.7600546; Seshi B, 2003, BLOOD CELL MOL DIS, V31, P268, DOI 10.1016/S1079-9796(03)00150-5; Shachaf CM, 2004, NATURE, V431, P1112, DOI 10.1038/nature03043; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sigurjonsson OE, 2005, P NATL ACAD SCI USA, V102, P5227, DOI 10.1073/pnas.0501029102; Simonsson S, 2005, CELL CYCLE, V4, P513, DOI 10.4161/cc.4.4.1581; Simonsson S, 2004, NAT CELL BIOL, V6, P984, DOI 10.1038/ncb1176; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Singh SK, 2003, CANCER RES, V63, P5821; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Sotiriou C, 2004, CURR OPIN ONCOL, V16, P211, DOI 10.1097/00001622-200405000-00003; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; Steidl U, 2004, BLOOD, V104, P81, DOI 10.1182/blood-2004-01-0373; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tagoh H, 2004, BLOOD, V103, P2950, DOI 10.1182/blood-2003-09-3323; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theocharis SE, 2004, HISTOPATHOLOGY, V45, P103, DOI 10.1111/j.1365-2559.2004.01922.x; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; van der Heyden MAG, 2003, CARDIOVASC RES, V58, P292, DOI 10.1016/S0008-6363(02)00771-X; VanMolle W, 1997, J IMMUNOL, V159, P3555; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VELCICH A, 1995, CELL GROWTH DIFFER, V6, P749; Villalba JM, 2000, ANTIOXID REDOX SIGN, V2, P213, DOI 10.1089/ars.2000.2.2-213; Wang JX, 1999, CANCER RES, V59, P2766; Wang WS, 2006, CARCINOGENESIS, V27, P1113, DOI 10.1093/carcin/bgi351; Watt PM, 2000, GENE CHROMOSOME CANC, V29, P371, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1050>3.0.CO;2-Y; WEIH F, 1991, EMBO J, V10, P2559, DOI 10.1002/j.1460-2075.1991.tb07796.x; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wolffe AP, 2001, ONCOGENE, V20, P2988, DOI 10.1038/sj.onc.1204322; Woodbury D, 2002, J NEUROSCI RES, V69, P908, DOI 10.1002/jnr.10365; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu HK, 1996, ONCOGENE, V12, P1205; Wurmser AE, 2004, NATURE, V430, P350, DOI 10.1038/nature02604; Xi RW, 2005, SCIENCE, V310, P1487, DOI 10.1126/science.1120140; Xie HF, 2004, CELL, V117, P663, DOI 10.1016/S0092-8674(04)00419-2; Xu H, 1999, GENOMICS, V62, P281, DOI 10.1006/geno.1999.6009; YAMAGUCHI A, 1991, J CELL BIOL, V113, P681, DOI 10.1083/jcb.113.3.681; Yepes M, 2000, BLOOD, V96, P569; Yoon YS, 2005, J CLIN INVEST, V115, P326, DOI 10.1172/JCI200522326; Yoshida M, 2004, BLOOD, V103, P2753, DOI 10.1182/blood-2003-07-2482; Yu CD, 2005, WORLD J GASTROENTERO, V11, P2390, DOI 10.3748/wjg.v11.i16.2390; Zeitler P, 2002, ENDOCRINE, V18, P85, DOI 10.1385/ENDO:18:1:85; Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041; Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	243	66	69	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7663	7672		10.1038/sj.onc.1209816	http://dx.doi.org/10.1038/sj.onc.1209816			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16847453				2022-12-28	WOS:000242830800001
J	Midorikawa, Y; Yamamoto, S; Ishikawa, S; Kamimura, N; Igarashi, H; Sugimura, H; Makuuchi, M; Aburatani, H				Midorikawa, Y.; Yamamoto, S.; Ishikawa, S.; Kamimura, N.; Igarashi, H.; Sugimura, H.; Makuuchi, M.; Aburatani, H.			Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays	ONCOGENE			English	Article						liver cancer; oligonucleotide array; SNP; allelic imbalance; copy number	COMPARATIVE GENOMIC HYBRIDIZATION; UNIPARENTAL PATERNAL DISOMY; HIGH-RESOLUTION ANALYSIS; COPY NUMBER VARIATION; HETEROZYGOSITY ANALYSIS; MICROARRAY ANALYSIS; ANALYSIS REVEALS; CPG ISLANDS; CANCER; DNA	Genomic amplification of oncogenes and inactivation of suppressor genes are critical in the pathogenesis of human cancer. To identify chromosomal alterations associated with hepatocarcinogenesis, we performed allelic gene dosage analysis on 36 hepatocellular carcinomas (HCCs). Data from high-density single-nucleotide polymorphism arrays were analysed using the Genome Imbalance Map (GIM) algorithm, which simultaneously detects DNA copy number alterations and loss of heterozygosity (LOH) events. Genome Imbalance Map analysis identified allelic imbalance regions, including uniparental disomy, and predicted the coexistence of a heterozygous population of cancer cells. We observed that gains of 1q, 5p, 5q, 6p, 7q, 8q, 17q and 20q, and LOH of 1p, 4q, 6q, 8p, 10q, 13q, 16p, 16q and 17p were significantly associated with HCC. On 6q24-25, which contains imprinting gene clusters, we observed reduced levels of PLAGL1 expression owing to loss of the unmethylated allele. Finally, we integrated the copy number data with gene expression intensity, and found that genome dosage is correlated with alteration in gene expression. These observations indicated that high-resolution GIM analysis can accurately determine the localizations of genomic regions with allelic imbalance, and when integrated with epigenetic information, a mechanistic basis for inactivation of a tumor suppressor gene in HCC was elucidated.	Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, Tokyo 1538904, Japan; Hamamatsu Univ Sch Med, Dept Pathol 1, Shizuoka, Japan; Univ Tokyo, Hepato Biliary Pancreat Surg Div, Tokyo, Japan	University of Tokyo; Hamamatsu University School of Medicine; University of Tokyo	Aburatani, H (corresponding author), Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan.	haburata-tky@umin.ac.jp	幕内, 雅敏 m/A-2140-2012					Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200; Benetkiewicz M, 2005, GENE CHROMOSOME CANC, V42, P228, DOI 10.1002/g.cc.20128; Bignell GR, 2004, GENOME RES, V14, P287, DOI 10.1101/gr.2012304; Boige V, 1997, CANCER RES, V57, P1986; Buckley PG, 2005, CANCER RES, V65, P2653, DOI 10.1158/0008-5472.CAN-04-3651; Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051; ENGEL E, 1993, AM J MED GENET, V46, P670, DOI 10.1002/ajmg.1320460613; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; GRUNDY P, 1994, AM J HUM GENET, V54, P282; Hashimoto K, 2004, MODERN PATHOL, V17, P617, DOI 10.1038/modpathol.3800107; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hoque MO, 2003, CANCER RES, V63, P2216; Ishikawa S, 2005, BIOCHEM BIOPH RES CO, V333, P1309, DOI 10.1016/j.bbrc.2005.06.040; Janne PA, 2004, ONCOGENE, V23, P2716, DOI 10.1038/sj.onc.1207329; Jou YS, 2004, CANCER RES, V64, P3030, DOI 10.1158/0008-5472.CAN-03-2320; KALLIONIEMI A, 1992, SCIENCE, V258, P818, DOI 10.1126/science.1359641; Kano M, 2003, PHYSIOL GENOMICS, V13, P31, DOI 10.1152/physiolgenomics.00116.2002; Katoh H, 2005, J HEPATOL, V43, P863, DOI 10.1016/j.jhep.2005.05.033; Kennedy GC, 2003, NAT BIOTECHNOL, V21, P1233, DOI 10.1038/nbt869; Kitayama Y, 2003, LAB INVEST, V83, P1311, DOI 10.1097/01.LAB.0000087622.80751.C5; Kondo Y, 2000, HEPATOLOGY, V32, P970, DOI 10.1053/jhep.2000.19797; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lieberfarb ME, 2003, CANCER RES, V63, P4781; Lindblad-Toh K, 2000, NAT BIOTECHNOL, V18, P1001, DOI 10.1038/79269; Lucito R, 2003, GENOME RES, V13, P2291, DOI 10.1101/gr.1349003; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Midorikawa Y, 2002, JPN J CANCER RES, V93, P636, DOI 10.1111/j.1349-7006.2002.tb01301.x; Midorikawa Y, 2004, CANCER RES, V64, P7263, DOI 10.1158/0008-5472.CAN-04-1275; Murthy SK, 2002, MODERN PATHOL, V15, P1241, DOI 10.1097/01.MP.0000032535.62750.D1; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nannya Y, 2005, CANCER RES, V65, P6071, DOI 10.1158/0008-5472.CAN-05-0465; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; Niketeghad F, 2001, BRIT J CANCER, V85, P697, DOI 10.1054/bjoc.2001.1963; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Raghavan M, 2005, CANCER RES, V65, P375; Sano T, 2006, PATHOL INT, V56, P117, DOI 10.1111/j.1440-1827.2006.01940.x; TAGUCHI T, 1993, CANCER RES, V53, P4349; TEMPLE IK, 1995, NAT GENET, V9, P110, DOI 10.1038/ng0295-110; THRASHBINGHAM CA, 1995, CANCER RES, V55, P6189; Upender MB, 2004, CANCER RES, V64, P6941, DOI 10.1158/0008-5472.CAN-04-0474; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308	53	81	86	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5581	5590		10.1038/sj.onc.1209537	http://dx.doi.org/10.1038/sj.onc.1209537			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16785998				2022-12-28	WOS:000240370400012
J	Fontenay, M; Cathelin, S; Amiot, M; Gyan, E; Solary, E				Fontenay, M.; Cathelin, S.; Amiot, M.; Gyan, E.; Solary, E.			Mitochondria in hematopoiesis and hematological diseases	ONCOGENE			English	Review						mitochondria; sideroblastic anemia; leukemia; myelodysplastic syndromes; apoptosis	LINKED SIDEROBLASTIC ANEMIA; MULTIPLE-MYELOMA CELLS; CYTOCHROME-C RELEASE; BCL-2 ANTISENSE OLIGONUCLEOTIDE; LYMPHOCYTIC-LEUKEMIA CELLS; DEPENDENT KINASE INHIBITOR; FAS-LIGAND EXPRESSION; BONE-MARROW-CELLS; NF-KAPPA-B; MYELODYSPLASTIC SYNDROMES	Mitochondria are involved in hematopoietic cell homeostasis through multiple ways such as oxidative phosphorylation, various metabolic processes and the release of cytochrome c in the cytosol to trigger caspase activation and cell death. In erythroid cells, the mitochondrial steps in heme synthesis, iron (Fe) metabolism and Fe-sulfur (Fe-S) cluster biogenesis are of particular importance. Mutations in the specifc delta-aminolevulinic acid synthase (ALAS) 2 isoform that catalyses the first and rate-limiting step in heme synthesis pathway in the mitochondrial matrix, lead to ineffective erythropoiesis that characterizes X-linked sideroblastic anemia (XLSA), the most common inherited sideroblastic anemia. Mutations in the adenosine triphosphate-binding cassette protein ABCB7, identified in XLSA with ataxia (XLSA-A), disrupt the maturation of cytosolic (Fe-S) clusters, leading to mitochondrial Fe accumulation. In addition, large deletions in mitochondrial DNA, whose integrity depends on a specific DNA polymerase, are the hallmark of Pearson's syndrome, a rare congenital disorder with sideroblastic anemia. In acquired myelodysplastic syndromes at early stage, exacerbation of physiological pathways involving caspases and the mitochondria in erythroid differentiation leads to abnormal activation of a mitochondria-mediated apoptotic cell death pathway. In contrast, oncogenesis-associated changes at the mitochondrial level can alter the apoptotic response of transformed hematopoietic cells to chemotherapeutic agents. Recent findings in mitochondria metabolism and functions open new perspectives in treating hematopoietic cell diseases, for example various compounds currently developed to trigger tumor cell death by directly targeting the mitochondria could prove efficient as either cytotoxic drugs or chemosensitizing agents in treating hematological malignancies.	Fac Med, INSERM, U 517, F-21000 Dijon, France; Inst Biol, INSERM U601, Nantes, France; Inst Cochin, Dept Hematol, INSERM U567, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Solary, E (corresponding author), Fac Med, INSERM, U 517, 7 Blvd Jeanne Arc, F-21000 Dijon, France.	esolary@u-bourgogne.fr		Fontenay, Michaela/0000-0002-5492-6349; GYAN, Emmanuel/0000-0002-7651-9189; Solary, Eric/0000-0002-8629-1341				Aerbajinai W, 2003, BLOOD, V102, P712, DOI 10.1182/blood-2002-11-3324; Astner I, 2005, EMBO J, V24, P3166, DOI 10.1038/sj.emboj.7600792; Azzouz M, 2000, HUM MOL GENET, V9, P803, DOI 10.1093/hmg/9.5.803; Banker DE, 2002, LEUKEMIA RES, V26, P91, DOI 10.1016/S0145-2126(01)00112-6; Becattini B, 2004, CHEM BIOL, V11, P1107, DOI 10.1016/j.chembiol.2004.05.022; Becker EM, 2002, BLOOD, V99, P3813, DOI 10.1182/blood.V99.10.3813; Belzacq AS, 2001, CANCER RES, V61, P1260; Benesch M, 2003, LEUKEMIA, V17, P2460, DOI 10.1038/sj.leu.2403180; Berger G, 2001, Hematol J, V2, P87, DOI 10.1038/sj.thj.6200086; Bombrun A, 2003, J MED CHEM, V46, P4365, DOI 10.1021/jm034107j; Bouchier-Hayes L, 2005, J CLIN INVEST, V115, P2640, DOI 10.1172/JCI26274; Bouscary D, 1997, LEUKEMIA, V11, P839, DOI 10.1038/sj.leu.2400654; Bouscary D, 2000, EXP HEMATOL, V28, P784, DOI 10.1016/S0301-472X(00)00179-X; Bowen D, 2002, BRIT J HAEMATOL, V118, P345, DOI 10.1046/j.1365-2141.2002.03576_2.x; Braun T, 2006, BLOOD, V107, P1156; CAMPOS L, 1993, BLOOD, V81, P3091; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Carlsson G, 2004, BLOOD, V103, P3355, DOI 10.1182/blood-2003-04-1011; Cazzola M, 2003, BLOOD, V101, P1996, DOI 10.1182/blood-2002-07-2006; Chandra J, 2002, BLOOD, V99, P655, DOI 10.1182/blood.V99.2.655; Chauhan D, 2004, BLOOD, V103, P3158, DOI 10.1182/blood-2003-08-2873; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9; Chou WC, 2004, P NATL ACAD SCI USA, V101, P4578, DOI 10.1073/pnas.0306687101; Claessens YE, 2005, BLOOD, V105, P4035, DOI 10.1182/blood-2004-08-3166; Claessens YE, 2003, BLOOD, V102, p144A; Claessens YE, 2002, BLOOD, V99, P1594, DOI 10.1182/blood.V99.5.1594; Cotter PD, 1999, BLOOD, V93, P1757, DOI 10.1182/blood.V93.5.1757.405a12_1757_1769; COX TC, 1994, NEW ENGL J MED, V330, P675, DOI 10.1056/NEJM199403103301004; Craven SE, 2005, BLOOD, V105, P3528, DOI 10.1182/blood-2004-03-1089; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; De Maria R, 1999, BLOOD, V93, P796, DOI 10.1182/blood.V93.3.796.403k23_796_803; Decaudin D, 2002, CANCER RES, V62, P1388; del Rio G, 2001, FEBS LETT, V494, P213, DOI 10.1016/S0014-5793(01)02348-1; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Fadeel B, 1999, LEUKEMIA, V13, P719, DOI 10.1038/sj.leu.2401411; FELLOUS R, 1988, CANCER RES, V48, P6542; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fleming MD, 2001, GENE DEV, V15, P652, DOI 10.1101/gad.873001; Friedman JS, 2004, BLOOD, V104, P2565, DOI 10.1182/blood-2003-11-3858; Furuyama K, 1997, BLOOD, V90, P822, DOI 10.1182/blood.V90.2.822.822_822_830; Furuyama K, 2000, J CLIN INVEST, V105, P757, DOI 10.1172/JCI6816; Gattermann N, 2000, LEUKEMIA RES, V24, P141, DOI 10.1016/S0145-2126(99)00160-5; Gattermann N, 2002, BRIT J HAEMATOL, V119, P1139, DOI 10.1046/j.1365-2141.2002.03942_3.x; Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972; Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x; Genini D, 2000, BLOOD, V96, P3537; Gersuk GM, 1996, BLOOD, V88, P1122, DOI 10.1182/blood.V88.3.1122b.bloodjournal8831122b; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Gomez-Bougie P, 2005, ONCOGENE, V24, P8076, DOI 10.1038/sj.onc.1208949; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; GRASSO JA, 1980, BRIT J HAEMATOL, V46, P57; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Gupta P, 1999, LEUKEMIA, V13, P44, DOI 10.1038/sj.leu.2401233; Hafid-Medheb K, 2003, BLOOD, V101, P2575, DOI 10.1182/blood-2002-02-0478; Harigae H, 2003, BLOOD, V101, P1188, DOI 10.1182/blood-2002-01-0309; He L, 2003, LEUKEMIA, V17, P2487, DOI 10.1038/sj.leu.2403146; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265; Hishita T, 2001, CANCER RES, V61, P2878; Houwerzijl EJ, 2005, BLOOD, V105, P3472, DOI 10.1182/blood-2004-06-2108; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jonasova A, 1998, BRIT J HAEMATOL, V100, P304, DOI 10.1046/j.1365-2141.1998.00551.x; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Jourdan M, 2003, ONCOGENE, V22, P2950, DOI 10.1038/sj.onc.1206423; Kang TB, 2004, J IMMUNOL, V173, P2976, DOI 10.4049/jimmunol.173.5.2976; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kerbauy DMB, 2005, BLOOD, V106, P3917, DOI 10.1182/blood-2005-04-1424; Kitagawa M, 1998, LEUKEMIA, V12, P486, DOI 10.1038/sj.leu.2400980; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Kostic V, 1997, SCIENCE, V277, P559, DOI 10.1126/science.277.5325.559; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lacour S, 2003, ONCOGENE, V22, P1807, DOI 10.1038/sj.onc.1206127; Larochette N, 1999, EXP CELL RES, V249, P413, DOI 10.1006/excr.1999.4519; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Le Gouill S, 2004, BLOOD, V104, P2886, DOI 10.1182/blood-2004-05-1760; Letai A, 2004, CANCER CELL, V6, P241, DOI 10.1016/j.ccr.2004.07.011; Letai A, 2005, J CLIN INVEST, V115, P2648, DOI 10.1172/JCI26250; Lill R, 2000, TRENDS BIOCHEM SCI, V25, P352, DOI 10.1016/S0968-0004(00)01589-9; Lindberg EH, 2001, BRIT J HAEMATOL, V112, P714, DOI 10.1046/j.1365-2141.2001.02581.x; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Logette E, 2005, MOL CELL BIOL, V25, P9621, DOI 10.1128/MCB.25.21.9621-9631.2005; Marchetti P, 1999, CANCER RES, V59, P6257; Marczin N, 2003, ARCH BIOCHEM BIOPHYS, V420, P222, DOI 10.1016/j.abb.2003.08.037; Matthes TW, 2000, BRIT J HAEMATOL, V111, P843, DOI 10.1046/j.1365-2141.2000.02425.x; Matthes TW, 2002, LEUKEMIA, V16, P1319, DOI 10.1038/sj.leu.2402527; Meijerink JPP, 1998, BLOOD, V91, P2991, DOI 10.1182/blood.V91.8.2991.2991_2991_2997; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Michels J, 2005, INT J BIOCHEM CELL B, V37, P267, DOI 10.1016/j.biocel.2004.04.007; Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood-2003-06-1984; Moshynska O, 2004, JNCI-J NATL CANCER I, V96, P673, DOI 10.1093/jnci/djh122; Motoyama N, 1999, J EXP MED, V189, P1691, DOI 10.1084/jem.189.11.1691; Mufti GJ, 2004, BEST PRACT RES CL HA, V17, P543, DOI 10.1016/j.beha.2004.08.007; Nakajima O, 1999, EMBO J, V18, P6282, DOI 10.1093/emboj/18.22.6282; Napier I, 2005, BLOOD, V105, P1867, DOI 10.1182/blood-2004-10-3856; Nencioni A, 2005, BLOOD, V105, P3255, DOI 10.1182/blood-2004-10-3984; Nie GJ, 2005, BLOOD, V105, P2161, DOI 10.1182/blood-2004-07-2722; Ogasawara Y, 2005, BLOOD, V106, P3271, DOI 10.1182/blood-2005-01-0150; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Opferman JT, 2003, NATURE, V426, P671, DOI 10.1038/nature02067; Oren Z, 2002, EUR J BIOCHEM, V269, P3869, DOI 10.1046/j.1432-1033.2002.03080.x; Oudard S, 2003, J NEURO-ONCOL, V63, P81, DOI 10.1023/A:1023756707900; Pandolfo Massimo, 2003, Semin Pediatr Neurol, V10, P163, DOI 10.1016/S1071-9091(03)00025-1; Parker JE, 2000, BLOOD, V96, P3932, DOI 10.1182/blood.V96.12.3932.h8003932_3932_3938; PASANEN AVO, 1981, SCAND J HAEMATOL, V27, P35; PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3; Ponka P, 1999, AM J MED SCI, V318, P241, DOI 10.1097/00000441-199910000-00004; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; RAZA A, 1995, BLOOD, V86, P268, DOI 10.1182/blood.V86.1.268.bloodjournal861268; Reddy PL, 2002, BRIT J HAEMATOL, V116, P564, DOI 10.1046/j.0007-1048.2001.03323.x; Richardson DR, 1996, BLOOD, V87, P3477, DOI 10.1182/blood.V87.8.3477.bloodjournal8783477; ROTIG A, 1991, GENOMICS, V10, P502, DOI 10.1016/0888-7543(91)90342-C; Rudin CM, 2004, J CLIN ONCOL, V22, P1110, DOI 10.1200/JCO.2004.10.148; SANDRELLI A, 1992, EUR J CANCER, V28A, P1633, DOI 10.1016/0959-8049(92)90057-9; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Schiller AB, 2002, CYTOMETRY, V50, P203, DOI 10.1002/cyto.10091; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serkova N, 2004, MOL INTERV, V4, P97, DOI 10.1124/mi.4.2.7; Shetty V, 2002, BRIT J HAEMATOL, V116, P817, DOI 10.1046/j.0007-1048.2002.03366.x; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Shin MG, 2004, BLOOD, V103, P553, DOI 10.1182/blood-2003-05-1724; Shin MG, 2003, BLOOD, V101, P3118, DOI 10.1182/blood-2002-06-1825; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Shirihai OS, 2000, EMBO J, V19, P2492, DOI 10.1093/emboj/19.11.2492; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sordet O, 2001, BLOOD, V97, P3931, DOI 10.1182/blood.V97.12.3931; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Taketani S, 2003, BLOOD, V101, P3274, DOI 10.1182/blood-2002-04-1212; Tehranchi R, 2005, CLIN CANCER RES, V11, P6291, DOI 10.1158/1078-0432.CCR-04-1850; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Testa U, 2004, LEUKEMIA, V18, P1176, DOI 10.1038/sj.leu.2403383; Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517; TURA S, 1984, ONCOLOGY, V41, P90, DOI 10.1159/000225894; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Waldmeier PC, 2002, MOL PHARMACOL, V62, P22, DOI 10.1124/mol.62.1.22; Walker A, 1997, CANCER RES, V57, P1939; Walsh M, 2002, BLOOD, V99, P3439, DOI 10.1182/blood.V99.9.3439; Wang JL, 2000, CANCER RES, V60, P1498; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Watabe M, 2000, CANCER RES, V60, P5214; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Weisberg EL, 1996, CANCER RES, V56, P551; Weisleder N, 2004, P NATL ACAD SCI USA, V101, P769, DOI 10.1073/pnas.0303202101; Woo M, 2003, NAT IMMUNOL, V4, P1016, DOI 10.1038/ni976; Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514; Yamamoto K, 2004, LEUKEMIA RES, V28, P1203, DOI 10.1016/j.leukres.2004.03.020; Yamamoto M, 2000, INT J HEMATOL, V72, P157; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zhang B, 2003, ONCOGENE, V22, P1848, DOI 10.1038/sj.onc.1206358; Zhivotovsky B, 2005, BIOCHEM BIOPH RES CO, V331, P859, DOI 10.1016/j.bbrc.2005.03.191; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	163	64	66	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4757	4767		10.1038/sj.onc.1209606	http://dx.doi.org/10.1038/sj.onc.1209606			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892088				2022-12-28	WOS:000239687000012
J	Andersen, JB; Li, XL; Judge, CS; Zhou, A; Jha, BK; Shelby, S; Zhou, L; Silverman, RH; Hassel, BA				Andersen, J. B.; Li, X. L.; Judge, C. S.; Zhou, A.; Jha, B. K.; Shelby, S.; Zhou, L.; Silverman, R. H.; Hassel, B. A.			Role of 2-5A-dependent RNase-L in senescence and longevity	ONCOGENE			English	Article						RNase-L; senescence; apoptosis; 2 '-5 '-oligoadenylate; aging	CELLULAR SENESCENCE; SIGNALING PATHWAY; INTERFERON ACTION; L INHIBITOR; CANCER; ACTIVATION; APOPTOSIS; EXPRESSION; GENES; CELLS	Senescence is a permanent growth arrest that restricts the lifespan of primary cells in culture, and represents an in vitro model for aging. Senescence functions as a tumor suppressor mechanism that can be induced independent of replicative crisis by diverse stress stimuli. RNase-L mediates antiproliferative activities and functions as a tumor suppressor in prostate cancer, therefore, we examined a role for RNase-L in cellular senescence and aging. Ectopic expression of RNase-L induced a senescent morphology, a decrease in DNA synthesis, an increase in senescence-associated beta-galactosidase activity, and accelerated replicative senescence. In contrast, senescence was retarded in RNase-L-null fibroblasts compared with wildtype fibroblasts. Activation of endogenous RNase-L by 2-5A transfection induced distinct senescent and apoptotic responses in parental and Simian virus 40-transformed WI38 fibroblasts, respectively, demonstrating cell type specific differences in the antiproliferative response to RNase-L activation. Replicative senescence is a model for in vivo aging; therefore, genetic disruption of senescence effectors may impact lifespan. RNase-L-/- mice survived 31.7% ( P < 0.0001) longer than strain-matched RNase-L+/+ mice providing evidence for a physiological role for RNase-L in aging. These findings identify a novel role for RNase-L in senescence that may contribute to its tumor suppressive function and to the enhanced longevity of RNase-L-/- mice.	Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Program Mol & Cell Biol, College Pk, MD 20742 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; No Arizona Univ, Dept Chem & Biochem, Flagstaff, AZ 86011 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland College Park; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation; Northern Arizona University; University System of Maryland; University of Maryland Baltimore	Hassel, BA (corresponding author), Univ Maryland, Marlene & Stewart Greenebaum Canc Ctr, 655 W Baltimore St,9th Floor BRB, Baltimore, MD 21201 USA.	bhassel@som.umaryland.edu	jha, babal k/B-1803-2010	jha, babal k/0000-0002-7660-5255; Andersen, Jesper B/0000-0003-1760-5244	NATIONAL CANCER INSTITUTE [R01CA044059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG020355] Funding Source: NIH RePORTER; NCI NIH HHS [CA044059] Funding Source: Medline; NIA NIH HHS [AG20355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BISBAL C, 1995, J BIOL CHEM, V270, P13308, DOI 10.1074/jbc.270.22.13308; Bisbal C, 2000, MOL CELL BIOL, V20, P4959, DOI 10.1128/MCB.20.14.4959-4969.2000; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Carpten J, 2002, NAT GENET, V30, P181, DOI 10.1038/ng823; Casey G, 2002, NAT GENET, V32, P582, DOI 10.1038/ng1021; Castelli JC, 1997, J EXP MED, V186, P967, DOI 10.1084/jem.186.6.967; Chase BI, 2003, J INTERF CYTOK RES, V23, P565, DOI 10.1089/107999003322485062; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DiazGuerra M, 1997, VIROLOGY, V236, P354, DOI 10.1006/viro.1997.8719; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DONG BH, 1995, J BIOL CHEM, V270, P4133, DOI 10.1074/jbc.270.8.4133; FLOYDSMITH G, 1988, P SOC EXP BIOL MED, V189, P329; Hardy K, 2005, MOL BIOL CELL, V16, P943, DOI 10.1091/mbc.E04-05-0392; HASSEL BA, 1993, EMBO J, V12, P3297, DOI 10.1002/j.1460-2075.1993.tb05999.x; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kubota K, 2004, J BIOL CHEM, V279, P37832, DOI 10.1074/jbc.M400089200; Kulaeva OI, 2003, ONCOGENE, V22, P4118, DOI 10.1038/sj.onc.1206594; Leszczyniecka M, 2003, GENE, V316, P143, DOI 10.1016/S0378-1119(03)00752-2; Li GQ, 2004, J BIOL CHEM, V279, P1123, DOI 10.1074/jbc.M305893200; Malathi K, 2005, P NATL ACAD SCI USA, V102, P14533, DOI 10.1073/pnas.0507551102; Malathi K, 2004, CANCER RES, V64, P9144, DOI 10.1158/0008-5472.CAN-04-2226; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; QUARRIE JK, 2004, SCI AGING KNOWLEDGE, V31, pRE5; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Shay JW, 2004, ONCOGENE, V23, P2919, DOI 10.1038/sj.onc.1207518; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; Shou JY, 2002, P NATL ACAD SCI USA, V99, P2830, DOI 10.1073/pnas.052705299; Silverman RH, 2003, BIOCHEMISTRY-US, V42, P1805, DOI 10.1021/bi027147i; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; TAHARA H, 1995, ONCOGENE, V11, P1125; Untergasser G, 2002, CANCER RES, V62, P6255; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; Xin H, 2004, ONCOGENE, V23, P6209, DOI 10.1038/sj.onc.1207836; Yoon IK, 2004, EXP GERONTOL, V39, P1369, DOI 10.1016/j.exger.2004.07.002; Zhou AM, 1997, EMBO J, V16, P6355, DOI 10.1093/emboj/16.21.6355	41	34	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3081	3088		10.1038/sj.onc.1210111	http://dx.doi.org/10.1038/sj.onc.1210111			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130839	Green Submitted			2022-12-28	WOS:000246395400013
J	Hawcroft, G; Ko, CWS; Hull, MA				Hawcroft, G.; Ko, C. W. S.; Hull, M. A.			Prostaglandin E-2-EP4 receptor signalling promotes tumorigenic behaviour of HT-29 human colorectal cancer cells	ONCOGENE			English	Article						colorectal cancer; cyclic AMP; EP receptor; prostaglandin E-2	GROWTH-FACTOR RECEPTOR; ELEMENT-BINDING PROTEIN; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INTESTINAL EPITHELIAL-CELLS; EP4 PROSTANOID RECEPTORS; CARCINOMA CELLS; ADENOCARCINOMA CELLS; ADENOMA GROWTH; CYCLIC-AMP; E-2	The predominant product of cyclooxygenase ( COX) activity in the colon, prostaglandin ( PG) E-2 promotes intestinal tumorigenesis. Expression of the PGE(2) receptor EP4 is upregulated during colorectal carcinogenesis. Therefore, we investigated the role of elevated PGE(2)-EP4 receptor signalling in the protumorigenic activity of PGE2 by increasing EP4 receptor expression in HT-29 human colorectal cancer ( CRC) cells ( HT-29-EP4) by stable transfection. Elevated PGE(2)-induced EP4 receptor activity in HT-29 cells increased resistance to spontaneous apoptosis and promoted anchorage-independent growth, but had no effect on proliferation of HT-29-EP4 cells. EP4 receptor activation by PGE(2) in HT-29-EP4 cells also led to development of fluid-filled cysts, which was associated with increased tight junction protein ( occludin and zonula occludens-1) expression. Overexpression of the EP4 receptor in HT-29 cells led to basal EP4 receptor signalling in the absence of exogenous PGE(2), which was explained by autocrine activity of endogenous, COX-2-derived PGE(2) and constitutive, ligand-independent EP4 receptor activity. The predominant signalling pathway mediating antiapoptotic activity downstream of PGE(2)-EP4 receptor activation in HT-29-EP4 cells was elevation of cyclic adenosine monophosphate ( cAMP) levels, which was associated with phosphorylation of cAMP-response element binding protein. EP4 receptor activation led to a small increase in phosphorylated extracellular signal-regulated kinase ( ERK) 2 protein levels but inhibition of ERK phosphorylation did not abrogate the antiapoptotic activity of PGE(2). However, PGE(2)-EP4 receptor signalling did not lead to trans-activation of the epidermal growth factor receptor in HT-29 cells. Inhibition of protumorigenic PGE(2)-EP4 receptor signalling represents a potential strategy for anti-CRC therapy that may avoid the toxicity associated with systemic COX inhibition.	Univ Leeds, St James Univ Hosp, Inst Mol Med, Sect Mol Gastroenterol, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hawcroft, G (corresponding author), Univ Leeds, St James Univ Hosp, Inst Mol Med, Sect Mol Gastroenterol, Leeds LS9 7TF, W Yorkshire, England.	medgha@leeds.ac.uk			Medical Research Council [G116/146] Funding Source: Medline; MRC [G116/146] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adamson RH, 1998, AM J PHYSIOL-HEART C, V274, pH1885, DOI 10.1152/ajpheart.1998.274.6.H1885; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Buchanan FG, 2003, J BIOL CHEM, V278, P35451, DOI 10.1074/jbc.M302474200; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Cahlin C, 2005, INT J ONCOL, V27, P913; Cassano G, 2000, CANCER LETT, V152, P217, DOI 10.1016/S0304-3835(00)00339-6; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chell SD, 2006, CANCER RES, V66, P3106, DOI 10.1158/0008-5472.CAN-05-3702; Colucci R, 2005, BRIT J PHARMACOL, V144, P338, DOI 10.1038/sj.bjp.0706053; Desai S, 2001, FEBS LETT, V501, P156, DOI 10.1016/S0014-5793(01)02640-0; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fujino H, 2006, MOL PHARMACOL, V69, P13, DOI 10.1124/mol.105.017749; Fujino H, 2005, MOL PHARMACOL, V68, P251, DOI 10.1124/mol.105.011833; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2003, J BIOL CHEM, V278, P12151, DOI 10.1074/jbc.M212665200; Gardner SH, 2004, BRIT J CANCER, V91, P153, DOI 10.1038/sj.bjc.6601901; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Han C, 2005, J BIOL CHEM, V280, P24053, DOI 10.1074/jbc.M500562200; Han C, 2006, J CELL PHYSIOL, V207, P261, DOI 10.1002/jcp.20560; Holla VR, 2006, J BIOL CHEM, V281, P2676, DOI 10.1074/jbc.M507752200; Hoshino T, 2003, J BIOL CHEM, V278, P12752, DOI 10.1074/jbc.M212097200; Hsi LC, 2000, EXP CELL RES, V256, P563, DOI 10.1006/excr.2000.4863; Hull MA, 2004, MOL CANCER THER, V3, P1031; Hull MA, 2005, EUR J CANCER, V41, P1854, DOI 10.1016/j.ejca.2005.04.013; Kato K, 2005, INT J APPL CERAM TEC, V2, P64, DOI 10.1111/j.1744-7402.2005.02006.x; Keese M, 2005, J BIOL CHEM, V280, P27826, DOI 10.1074/jbc.M504485200; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; Ko SC, 2002, ONCOGENE, V21, P7175, DOI 10.1038/sj.onc.1205869; Krause W, 2000, PROSTAG OTH LIPID M, V61, P145, DOI 10.1016/S0090-6980(00)00069-1; Ma XR, 2006, CANCER RES, V66, P2923, DOI 10.1158/0008-5472.CAN-05-4348; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mendez M, 2005, AM J PHYSIOL-HEART C, V288, pH2111, DOI 10.1152/ajpheart.00838.2004; Misra UK, 2005, J BIOL CHEM, V280, P38276, DOI 10.1074/jbc.M507332200; Mutoh M, 2002, CANCER RES, V62, P28; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; Nishihara H, 2004, J BIOL CHEM, V279, P26176, DOI 10.1074/jbc.M313346200; Ophir I, 1995, TISSUE CELL, V27, P659, DOI 10.1016/S0040-8166(05)80021-7; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pavlovic S, 2006, J BIOL CHEM, V281, P3321, DOI 10.1074/jbc.M506846200; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Regan JW, 2003, LIFE SCI, V74, P143, DOI 10.1016/j.lfs.2003.09.031; Sales KJ, 2004, MOL ENDOCRINOL, V18, P1533, DOI 10.1210/me.2004-0022; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shao JY, 2000, J BIOL CHEM, V275, P33951, DOI 10.1074/jbc.M002324200; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shoji Y, 2004, GUT, V53, P1151, DOI 10.1136/gut.2003.028787; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Wright CW, 2005, J CLIN INVEST, V115, P2673, DOI 10.1172/JCI26251	51	60	61	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3006	3019		10.1038/sj.onc.1210113	http://dx.doi.org/10.1038/sj.onc.1210113			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130837				2022-12-28	WOS:000246395400006
J	He, H; Sun, Y				He, H.; Sun, Y.			Ribosomal protein S27L is a direct p53 target that regulates apoptosis	ONCOGENE			English	Article						RPS27L; p53; apoptosis; ribosomal protein; gene expression and siRNA silencing	BREAST-CANCER; TUMOR-MARKER; DNA-DAMAGE; GROWTH; CARCINOMA; ACTIVATION; METALLOPANSTIMULIN; INHIBITION; EXPRESSION; CELLS	Ribosomal proteins were recently shown to regulate p53 activity by abrogating Mdm2-induced p53 degradation (L23, L11, L5) or by enhancing p53 translation (L26). Here, we report that a novel ribosomal protein, RPS27L (S27-like protein), is a direct p53 target. RPS27L, but not its family member RPS27, was identified as a p53 inducible gene in a genome-wide chip-profiling study. Further characterization revealed a p53-dependent induction of RPS27L in multiple cancer cell models. Indeed, a consensus p53-binding site was identified in the first intron of the RPS27L gene and a direct binding of p53 to this site was demonstrated both in vitro and in vivo. Characterization of a luciferase reporter driven by the RPS27L intron fragment revealed a p53-binding site-dependent transaction by wild-type p53, but not by several transactivating-deficient p53 mutants. This transactivation was enhanced by etoposide, a DNA damaging agent that activates p53 and was completely blocked by a dominant-negative p53 mutant. Functionally, overexpression of RPS27L within the physiological inducible levels promoted, whereas siRNA silencing of RPS27L inhibited, apoptosis induced by etoposide. This is the first report, to our knowledge, that p53 directly induces the expression of a ribosomal protein, RPS27L, which in turn promotes apoptosis.	Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Sun, Y (corresponding author), Univ Michigan, Ctr Comprehens Canc, Dept Radiat Oncol, Div Canc Biol, 4304 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	sunyi@umich.edu	Sun, Yi/K-1025-2014	Sun, Yi/0000-0002-5841-4287	NATIONAL CANCER INSTITUTE [R01CA111554] Funding Source: NIH RePORTER; NCI NIH HHS [1R01-CA111554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atsuta Y, 2002, CANCER LETT, V182, P101, DOI 10.1016/S0304-3835(02)00068-X; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Bian JH, 1997, P NATL ACAD SCI USA, V94, P14753, DOI 10.1073/pnas.94.26.14753; Bian JH, 1997, MOL CELL BIOL, V17, P6330, DOI 10.1128/MCB.17.11.6330; Bockbrader KM, 2005, ONCOGENE, V24, P7381, DOI 10.1038/sj.onc.1208888; CHAN YL, 1993, NUCLEIC ACIDS RES, V21, P649, DOI 10.1093/nar/21.3.649; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Duan HJ, 1999, MOL CELL BIOL, V19, P3145; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FernandezPol JA, 1997, ANTICANCER RES, V17, P1519; FERNANDEZPOL JA, 1993, J BIOL CHEM, V268, P21198; FERNANDEZPOL JA, 1994, CELL GROWTH DIFFER, V5, P811; FernandezPol JA, 1996, ANTICANCER RES, V16, P2177; Ganger DR, 1997, ANTICANCER RES, V17, P1993; Ganger DR, 2001, CANCER DETECT PREV, V25, P231; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Lee WJ, 2004, OTOLARYNG HEAD NECK, V131, P466, DOI 10.1016/j.otohns.2004.03.011; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li J, 2005, NEOPLASIA, V7, P312, DOI 10.1593/neo.04325; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Robinson M, 2003, CANCER BIOL THER, V2, P406, DOI 10.4161/cbt.2.4.437; Stack Brendan C Jr, 2004, World J Surg Oncol, V2, P45, DOI 10.1186/1477-7819-2-45; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; SUN Y, 1992, CANCER RES, V52, P1907; SUN Y, 1993, MOL CARCINOGEN, V8, P49, DOI 10.1002/mc.2940080111; SUN Y, 1993, FASEB J, V7, P944, DOI 10.1096/fasebj.7.10.8344492; Sun YJ, 2006, IEEE T CIRCUITS-II, V53, P409, DOI 10.1109/TCSII.2006.869913; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wallingford JB, 1997, CURR BIOL, V7, P747, DOI 10.1016/S0960-9822(06)00333-2; WONG JM, 1993, CANCER RES, V53, P1916; Yoo YA, 2005, MOL CELL BIOL, V25, P6603, DOI 10.1128/MCB.25.15.6603-6616.2005	38	72	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2707	2716		10.1038/sj.onc.1210073	http://dx.doi.org/10.1038/sj.onc.1210073			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057733				2022-12-28	WOS:000246210600005
J	Nanjundan, M; Zhang, F; Schmandt, R; Smith-McCune, K; Mills, GB				Nanjundan, M.; Zhang, F.; Schmandt, R.; Smith-McCune, K.; Mills, G. B.			Identification of a novel splice variant of AML1b in ovarian cancer patients conferring loss of wild-type tumor suppressive functions	ONCOGENE			English	Article						AML1; splicing; ovarian cancers	ACUTE MYELOID-LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; E-CADHERIN; NUCLEAR-MATRIX; CELL-MIGRATION; BETA-CATENIN; EXPRESSION; GENE; TRANSACTIVATION; ASSOCIATION	Acute myeloid leukemia (AML) 1 is often disrupted by chromosomal translocations generating oncogenic fusions in human leukemias. However, its role in epithelial cancers has not been extensively investigated. Herein, we show a marked accumulation of AML1 transcripts including a high frequency of a novel alternatively spliced AML1b transcript lacking exon 6 (AML1b(Del179-242)) in ovarian cancer patients. The increases in RNA transcripts for total wild-type AML1 and AML1b(Del179-242) are associated with poor patient outcomes. We have shown that although both wild-type AML1b and AML1b(Del179-242) are localized to nuclear speckles, AML1b(Del179-242) was observed to have dramatically reduced transactivation potential with the plasminogen activator inhibitor-1 promoters and behaved as a weak dominant negative of wild-type AML1b. Wild-type AML1b was found to inhibit the growth of immortalized ovarian epithelial cells (T29) decreasing colony-forming ability. Moreover, we have identified a novel function of AML1b where it inhibits ovarian cell migration. In contrast, AML1b(Del179-242) has lost the ability to inhibit both ovarian cell proliferation and migration indicating that the functional effects observed with wild-type AML1b are dependent on amino acids 179-242. Collectively, these studies suggest that deregulated alternative splicing of AML1b transcripts may potentially contribute to the pathophysiology of ovarian cancers.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77054 USA; Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77054 USA; Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California San Francisco	Nanjundan, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, 7435 Fannin St, Houston, TX 77054 USA.	mnanjund@mdanderson.org			NATIONAL CANCER INSTITUTE [P30CA016672, P50CA083639, P01CA064602] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA16672, P50 CA083639, P01 CA64602] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; Bartel F, 2002, CANCER CELL, V2, P9, DOI 10.1016/S1535-6108(02)00091-0; Berger R, 1997, CANCER GENET CYTOGEN, V94, P8, DOI 10.1016/S0165-4608(96)00351-2; Biggs JR, 2005, MOL CANCER RES, V3, P391, DOI 10.1158/1541-7786.MCR-04-0184; Dairkee SH, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-47; Faleiro-Rodrigues C, 2004, HUM PATHOL, V35, P663, DOI 10.1016/j.humpath.2004.01.024; Fowler M, 2006, J CELL BIOCHEM, V97, P1, DOI 10.1002/jcb.20664; Fujioka T, 2001, ONCOL REP, V8, P249; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; Harrison S., 2002, SMALL SCALE EC MANAG, V1, P1, DOI [DOI 10.1007/S11842-002-0001-3, 10.1007/s11842-002-0001-3]; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; INOUE M, 1992, AM J CLIN PATHOL, V98, P76, DOI 10.1093/ajcp/98.1.76; Kirschnerova G, 2006, NEOPLASMA, V53, P150; Levanon D, 1996, DNA CELL BIOL, V15, P175, DOI 10.1089/dna.1996.15.175; Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991; Mikhail FM, 2006, J CELL PHYSIOL, V207, P582, DOI 10.1002/jcp.20538; MIYOSHI H, 1995, NUCLEIC ACIDS RES, V23, P2762, DOI 10.1093/nar/23.14.2762; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Orban TI, 2003, J CLIN PATHOL-MOL PA, V56, P191, DOI 10.1136/mp.56.4.191; Robinson HM, 2003, LEUKEMIA, V17, P2249, DOI 10.1038/sj.leu.2403140; Sun LX, 2001, CANCER RES, V61, P4994; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Whitley BR, 2004, EXP CELL RES, V296, P151, DOI 10.1016/j.yexer.2004.02.022; Yamagata T, 2005, INT J HEMATOL, V82, P1, DOI 10.1532/IJH97.05075; Yamaguchi Y, 2004, J BIOL CHEM, V279, P15630, DOI 10.1074/jbc.M400355200; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zeng CM, 1998, P NATL ACAD SCI USA, V95, P1585, DOI 10.1073/pnas.95.4.1585; Zhang YW, 1997, MOL CELL BIOL, V17, P4133, DOI 10.1128/MCB.17.7.4133	28	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2574	2584		10.1038/sj.onc.1210067	http://dx.doi.org/10.1038/sj.onc.1210067			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072347				2022-12-28	WOS:000245831200005
J	Chu, CY; Cha, ST; Chang, CC; Hsiao, CH; Tan, CT; Lu, YC; Jee, SH; Kuo, ML				Chu, C-Y; Cha, S-T; Chang, C-C; Hsiao, C-H; Tan, C-T; Lu, Y-C; Jee, S-H; Kuo, M-L			Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells	ONCOGENE			English	Article						collagenase-3; CXCR4; basal cell carcinoma; invasion; MMP-13; SDF-1 alpha	SIGNAL-REGULATED KINASES-1/2; CHEMOKINE RECEPTOR; COLLAGENASE-3 EXPRESSION; TUMOR-GROWTH; CXCR4; ACTIVATION; MIGRATION; SKIN; PROLIFERATION; ANGIOGENESIS	Basal cell carcinoma (BCC) is one of the most common skin neoplasms in humans and is usually characterized by local aggressiveness with little metastatic potential, although deep invasion, recurrence, and regional and distant metastases may occur. Here, we studied the mechanism of BCC invasion. We found that human BCC tissues and a BCC cell line had significant expression of CXCR4, which was higher in invasive than non-invasive BCC types. Further, of 19 recurrent tumors among 390 BCCs diagnosed during the past 12 years, 17/ 19 (89.5%) had high CXCR4 expression. We found that the CXCR4 ligand, stromal-cell-derived factor 1a (SDF1a), directed BCC invasion and that this was mediated by time-dependent upregulation of mRNA expression and gelatinase activity of matrix metalloproteinase-13 (MMP-13). The transcriptional regulation of MMP-13 by SDF-1 alpha was mediated by phosphorylation of extracellular signal-related kinase 1/2 and activation of the AP-1 component c-Jun. Finally, CXCR4-transfected BCC cells injected into nude mice induced aggressive BCCs that co-expressed CXCR4 and MMP-13. The identification of SDF-1a/CXCR4 as an important factor in BCC invasiveness may contribute insight into mechanisms involved in the aggressive potential of human BCC and may improve therapy for invasive BCCs.	Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, Taipei 100, Taiwan; Natl Taiwan Univ, Angiogenesis Res Ctr, Taipei 100, Taiwan; Natl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Pathol, Taipei, Taiwan; Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital	Kuo, ML (corresponding author), Natl Taiwan Univ, Lab Mol & Cellular Toxicol, Inst Toxicol, Coll Med, 1 Sect 1 Jen Ai Rd, Taipei 100, Taiwan.	toxkml@ha.mc.ntu.edu.tw	Kuo, Min-Liang/C-4872-2009	KUO, MIN-LIANG/0000-0002-7139-0144; CHU, CHIA-YU/0000-0002-9370-3279; Tan, Ching-Ting/0000-0001-8317-2235; JEE, SHIOU-HWA/0000-0001-6737-6297				Airola K, 1997, J INVEST DERMATOL, V109, P225, DOI 10.1111/1523-1747.ep12319441; Ala-Aho R, 2005, BIOCHIMIE, V87, P273, DOI 10.1016/j.biochi.2004.12.009; Avniel S, 2006, J INVEST DERMATOL, V126, P468, DOI 10.1038/sj.jid.5700069; Bachelder RE, 2002, CANCER RES, V62, P7203; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Barbero S, 2003, CANCER RES, V63, P1969; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Brand S, 2005, EXP CELL RES, V310, P117, DOI 10.1016/j.yexcr.2005.07.006; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chen GS, 2006, BRIT J DERMATOL, V154, P910, DOI 10.1111/j.1365-2133.2006.07150.x; De Clercq E, 2003, NAT REV DRUG DISCOV, V2, P581, DOI 10.1038/nrd1134; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dumas V, 1999, ANTICANCER RES, V19, P2929; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fernandis AZ, 2004, ONCOGENE, V23, P157, DOI 10.1038/sj.onc.1206910; Forsyth CB, 2002, ARTHRITIS RHEUM, V46, P2368, DOI 10.1002/art.10502; Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014-5793(02)03143-5; Jee SH, 2004, J INVEST DERMATOL, V123, P1169, DOI 10.1111/j.0022-202X.2004.23497.x; Jee SH, 2002, J INVEST DERMATOL, V119, P1121, DOI 10.1046/j.1523-1747.2002.19503.x; JIMENEZ J, 1999, RRD MICROBIOL 1, V3, P1; Kerkela E, 2003, EXP DERMATOL, V12, P109, DOI 10.1034/j.1600-0625.2003.120201.x; Kijima T, 2002, CANCER RES, V62, P6304; Lapteva N, 2005, CANCER GENE THER, V12, P84, DOI 10.1038/sj.cgt.7700770; Lear JT, 1998, J ROY SOC MED, V91, P585, DOI 10.1177/014107689809101110; Leeman MF, 2002, CRIT REV BIOCHEM MOL, V37, P149, DOI 10.1080/10409230290771483; Menu E, 2006, HAEMATOLOGICA, V91, P605; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Neuhaus T, 2003, CELL PROLIFERAT, V36, P75, DOI 10.1046/j.1365-2184.2003.00262.x; Ohira S, 2006, AM J PATHOL, V168, P1155, DOI 10.2353/ajpath.2006.050204; Payne AS, 2002, J INVEST DERMATOL, V118, P915, DOI 10.1046/j.1523-1747.2002.01725.x; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Pendas AM, 2000, CLIN CHIM ACTA, V291, P137, DOI 10.1016/S0009-8981(99)00225-9; Phillips RJ, 2003, AM J RESP CRIT CARE, V167, P1676, DOI 10.1164/rccm.200301-071OC; POULSOM R, 1993, J CLIN PATHOL, V46, P429, DOI 10.1136/jcp.46.5.429; Rippey JJ, 1998, HISTOPATHOLOGY, V32, P393; Saur D, 2005, GASTROENTEROLOGY, V129, P1237, DOI 10.1053/j.gastro.2005.06.056; Singh S, 2004, LAB INVEST, V84, P1666, DOI 10.1038/labinvest.3700181; Strieter RM, 2001, NAT IMMUNOL, V2, P285, DOI 10.1038/86286; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Uria JA, 1997, CANCER RES, V57, P4882; Varani J, 2000, BRIT J CANCER, V82, P657, DOI 10.1054/bjoc.1999.0978; Walling HW, 2004, CANCER METAST REV, V23, P389, DOI 10.1023/B:CANC.0000031775.04618.30; Woodhouse EC, 1997, CANCER-AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1529::AID-CNCR2>3.0.CO;2-F; Yen HT, 1996, ARCH DERMATOL RES, V288, P157, DOI 10.1007/BF02505826; Yucel T, 2005, EXP MOL PATHOL, V79, P151, DOI 10.1016/j.yexmp.2005.05.003; Zhang LB, 2005, J SOC GYNECOL INVEST, V12, P2, DOI 10.1016/j.jsgi.2004.09.004; Zhang SP, 2002, J MOL BIOL, V324, P271, DOI 10.1016/S0022-2836(02)01044-6; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	54	68	68	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2491	2501		10.1038/sj.onc.1210040	http://dx.doi.org/10.1038/sj.onc.1210040			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17099730				2022-12-28	WOS:000245831000009
J	Dow, LE; Kauffman, JS; Caddy, J; Peterson, AS; Jane, SM; Russell, SM; Humbert, PO				Dow, L. E.; Kauffman, J. S.; Caddy, J.; Peterson, A. S.; Jane, S. M.; Russell, S. M.; Humbert, P. O.			The tumour-suppressor Scribble dictates cell polarity during directed epithelial migration: regulation of Rho GTPase recruitment to the leading edge	ONCOGENE			English	Article						scribble; polarity; migration; wound healing; epithelium	DISCS LARGE; DIFFERENTIAL EXPRESSION; CDC42 CONTROLS; HUMAN HOMOLOG; PROTEIN; DROSOPHILA; ACTIVATION; COMPLEX; ACTIN; MOUSE	Altered expression of human Scribble is associated with invasive epithelial cancers, however, its role in tumour development remains unclear. Mutations in Drosophila Scribble result in loss of polarity, overproliferation and 3D-tumourous overgrowth of epithelial cells. Using complementation studies in Drosophila we recently demonstrated that expression of human Scribble can also regulate polarity and restrict tissue overgrowth. Here, we have undertaken a detailed study of human Scribble function in the polarized mammary cell line, MCF10A. We show that although Scribble does not seem to be required for apical-basal polarity or proliferation control in MCF10A cells, Scribble is essential for the control of polarity associated with directed epithelial cell migration. Scribble-depleted MCF10A cells show defective in vitro wound closure and chemotactic movement. The cells at the wound edge fail to polarize, show reduced lamellipodia formation and impaired recruitment of Cdc42 and Rac1 to the leading edge. Furthermore, we show that this function is relevant in vivo as Scribble mutant mice show defective epidermal wound healing. This data identifies an essential role for mammalian Scribble in the regulation of the polarity specifically involved in directed epithelial migration.	Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic 8006, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic, Australia; Rotary Bone Marrow Res Labs, Parkville, Vic, Australia; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Peter MacCallum Canc Ctr, Immune Signalling Lab, Melbourne, Vic, Australia; Swinburne Univ Technol, Fac Engn & Ind Sci, Ctr Microphoton, Cell Biol Lab, Hawthorn, Vic 3122, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Peter Maccallum Cancer Center; University of Melbourne; Roche Holding; Genentech; Peter Maccallum Cancer Center; Swinburne University of Technology; University of Melbourne	Humbert, PO (corresponding author), Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	patrick.humbert@petermac.org	Humbert, Patrick O/L-4264-2016; Russell, Sarah M/B-9341-2009; Jane, Stephen/D-6659-2011	Humbert, Patrick O/0000-0002-1366-6691; Russell, Sarah M/0000-0001-5826-9641; Dow, Lukas/0000-0001-7048-1418; Jane, Stephen Marsden/0000-0002-1045-0481	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL053749] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL53749-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; Bilder D, 2004, GENE DEV, V18, P1909, DOI 10.1101/gad.1211604; Bilder D, 2003, NAT CELL BIOL, V5, P53, DOI 10.1038/ncb897; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Boussioutas A, 2003, CANCER RES, V63, P2569; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Cau JL, 2005, J CELL SCI, V118, P2579, DOI 10.1242/jcs.02385; Cavatorta AL, 2004, INT J CANCER, V111, P373, DOI 10.1002/ijc.20275; Chen XY, 2005, NAT CELL BIOL, V7, P262, DOI 10.1038/ncb1226; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dow LE, 2003, ONCOGENE, V22, P9225, DOI 10.1038/sj.onc.1207154; Etienne-Manneville S, 2005, J CELL BIOL, V170, P895, DOI 10.1083/jcb.200412172; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Gomes ER, 2005, CELL, V121, P451, DOI 10.1016/j.cell.2005.02.022; Hall A, 2005, BIOCHEM SOC T, V33, P891, DOI 10.1042/BST0330891; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; HUMBERT PO, 2006, IN PRESS TRENDS CELL; Legouis R, 2000, NAT CELL BIOL, V2, P415, DOI 10.1038/35017046; Legouis R, 2003, EMBO REP, V4, P1096, DOI 10.1038/sj.embor.7400006; Lin HT, 2004, GYNECOL ONCOL, V93, P422, DOI 10.1016/j.ygyno.2004.01.025; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MCCLUSKEY J, 1993, TISSUE CELL, V25, P173, DOI 10.1016/0040-8166(93)90017-F; Mine N, 2005, DEVELOPMENT, V132, P4317, DOI 10.1242/dev.02030; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; Nakagawa S, 2004, BRIT J CANCER, V90, P194, DOI 10.1038/sj.bjc.6601465; Navarro C, 2005, ONCOGENE, V24, P4330, DOI 10.1038/sj.onc.1208632; Nishiya N, 2005, NAT CELL BIOL, V7, P343, DOI 10.1038/ncb1234; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pinheiro EM, 2004, DEVELOPMENT, V131, P5243, DOI 10.1242/dev.01412; Qin Y, 2005, J CELL BIOL, V171, P1061, DOI 10.1083/jcb.200506094; Redvers RP, 2004, METH MOL B, V289, P15; Shin I, 2005, J BIOL CHEM, V280, P14675, DOI 10.1074/jbc.M411625200; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Ting SB, 2005, SCIENCE, V308, P411, DOI 10.1126/science.1107511; Wada H, 2005, DEVELOPMENT, V132, P2273, DOI 10.1242/dev.01810; Watanabe T, 2004, DEV CELL, V7, P871, DOI 10.1016/j.devcel.2004.10.017; Watson RA, 2002, CARCINOGENESIS, V23, P1791, DOI 10.1093/carcin/23.11.1791; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zenz R, 2003, DEV CELL, V4, P879, DOI 10.1016/S1534-5807(03)00161-8	48	138	140	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2272	2282		10.1038/sj.onc.1210016	http://dx.doi.org/10.1038/sj.onc.1210016			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043654				2022-12-28	WOS:000245466000003
J	Cronauer, MV; Ince, Y; Engers, R; Rinnab, L; Weidemann, W; Suschek, CV; Burchardt, M; Kleinert, H; Wiedenmann, J; Sies, H; Ackermann, R; Kroncke, KD				Cronauer, M. V.; Ince, Y.; Engers, R.; Rinnab, L.; Weidemann, W.; Suschek, C. V.; Burchardt, M.; Kleinert, H.; Wiedenmann, J.; Sies, H.; Ackermann, R.; Kroencke, K.-D.			Nitric oxide-mediated inhibition of androgen receptor activity: possible implications for prostate cancer progression	ONCOGENE			English	Article						androgen receptor; nitric oxide; prostate cancer; prostate specific antigen; zinc-finger	CARCINOMA-CELL LINE; GROWTH-FACTOR; UP-REGULATION; ZINC RELEASE; TUMOR-GROWTH; SYNTHASE-II; EXPRESSION; TRANSCRIPTION; PROTEIN; METALLOTHIONEIN	Chronic inflammation increases the risk of cancer and many cancers, including prostate cancer, arise at sites of chronic inflammation. Inducible nitric oxide synthase ( iNOS) is an enzyme dominantly expressed during inflammatory reactions. Although synthesis of high amounts of nitric oxide (NO) by iNOS has been demonstrated in pathophysiological processes, such as acute or chronic inflammation, autoimmune diseases or tumorigenesis, the role of iNOS activity in most of these diseases is poorly understood. Analysing prostate cancer biopsies by immunohistochemistry we found iNOS protein expression in tumor cells strongly paralleled by nitrotyrosine suggesting that iNOS is fully active. In vitro, NO inhibits androgen receptor-dependent promoter activity and prostate specific antigen production as well as DNA-binding activity of the androgen receptor (AR) in a concentration-dependent manner. Inhibition of the activity of androgen receptor-dependent reporter constructs is neither owing to diminished AR protein levels nor owing to an inhibition of its nuclear import. In addition, NO inhibits the proliferation of androgen receptor-positive prostate cancer cells significantly more efficiently than proliferation of androgen receptor-negative prostate cancer cells. In summary, our findings suggest that intratumoral iNOS activity favors development of prostate cancer cells that are able to proliferate androgen receptor-independently, thereby promoting prostate tumor progression.	Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, D-40225 Dusseldorf, Germany; Univ Ulm, Dept Gen Zool & Endocrinol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Inst Pathol, D-4000 Dusseldorf, Germany; Univ Ulm, Dept Urol & Pediat Urol, D-89069 Ulm, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 2, D-4000 Dusseldorf, Germany; Johannes Gutenberg Univ Mainz, Dept Pharmacol, D-6500 Mainz, Germany	Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ulm University; Heinrich Heine University Dusseldorf; Johannes Gutenberg University of Mainz	Kroncke, KD (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 1, Dept Urol, Univ Str 1, D-40225 Dusseldorf, Germany.	kroencke@uni-duesseldorf.de	Cronauer, Marcus/AAG-7457-2021; Kleinert, Hartmut/M-2988-2018; Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Kleinert, Hartmut/0000-0003-2202-3548; Sies, Helmut/0000-0002-1000-3198				Aaltomaa SH, 2001, ANTICANCER RES, V21, P3101; Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Attardi BJ, 2004, MOL CELL ENDOCRINOL, V222, P121, DOI 10.1016/j.mce.2004.04.013; Baltaci S, 2001, BJU INT, V88, P100, DOI 10.1046/j.1464-410x.2001.02231.x; Berendji D, 1997, FEBS LETT, V405, P37, DOI 10.1016/S0014-5793(97)00150-6; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Craft N, 1999, CANCER RES, V59, P5030; Cronauer MV, 2000, BRIT J CANCER, V82, P39; Cronauer MV, 2005, INT J ONCOL, V26, P1033; Cronauer MV, 2004, ONCOGENE, V23, P3541, DOI 10.1038/sj.onc.1207346; Cronauer MV, 2003, INT J ONCOL, V23, P1095; Ekmekcioglu S, 2005, CURR CANCER DRUG TAR, V5, P103, DOI 10.2174/1568009053202072; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Garban HJ, 2005, P NATL ACAD SCI USA, V102, P2632, DOI 10.1073/pnas.0409854102; Garban HJ, 2001, J IMMUNOL, V167, P75, DOI 10.4049/jimmunol.167.1.75; GAST A, 1995, MOL CELL ENDOCRINOL, V111, P93, DOI 10.1016/0303-7207(95)03554-K; Gradini R, 1999, J PATHOL, V189, P224; Grune T, 2003, BIOCHEM BIOPH RES CO, V305, P709, DOI 10.1016/S0006-291X(03)00809-X; Hobisch A, 1996, PROSTATE, V28, P129; Hobisch A, 1998, CANCER RES, V58, P4640; Hongo F, 2005, BIOCHEM BIOPH RES CO, V336, P692, DOI 10.1016/j.bbrc.2005.08.150; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Hrabie JA, 2000, J ORG CHEM, V65, P5745, DOI 10.1021/jo000600g; Huguenin S, 2004, PROSTATE, V61, P132, DOI 10.1002/pros.20081; Keefer LK, 1996, METHOD ENZYMOL, V268, P281; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Klotz T, 1998, CANCER, V82, P1897, DOI 10.1002/(SICI)1097-0142(19980515)82:10<1897::AID-CNCR12>3.0.CO;2-O; Kroncke KD, 2000, ANTIOXID REDOX SIGN, V2, P585, DOI 10.1089/15230860050192341; Kroncke KD, 2000, FASEB J, V14, P166; Kroncke KD, 2001, NITRIC OXIDE-BIOL CH, V5, P289, DOI 10.1006/niox.2001.0354; KRONCKE KD, 1994, BIOCHEM BIOPH RES CO, V200, P1105, DOI 10.1006/bbrc.1994.1564; Le XD, 2005, P NATL ACAD SCI USA, V102, P8758, DOI 10.1073/pnas.0409581102; MARTH C, 1990, CANCER RES, V50, P7037; Michalaki V, 2004, BRIT J CANCER, V90, P2312, DOI 10.1038/sj.bjc.6601814; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nelson William G, 2004, J Urol, V172, pS6, DOI 10.1097/01.ju.0000142058.99614.ff; Nienhaus GU, 2006, PHOTOCHEM PHOTOBIOL, V82, P351, DOI 10.1562/2005-05-19-RA-533; Olson MV, 2006, CANCER GENE THER, V13, P676, DOI 10.1038/sj.cgt.7700941; PARK JG, 1987, CANCER RES, V47, P6710; Pearce LL, 2000, P NATL ACAD SCI USA, V97, P477, DOI 10.1073/pnas.97.1.477; Royle JS, 2004, J UROLOGY, V172, P338, DOI 10.1097/01.ju.0000132367.02834.41; Rudeck M, 2000, IUBMB LIFE, V49, P451; Sramkoski RM, 1999, IN VITRO CELL DEV-AN, V35, P403; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; Tepper CG, 2002, CANCER RES, V62, P6606; Thomsen LL, 1998, CANCER METAST REV, V17, P107, DOI 10.1023/A:1005912906436; Wang JZ, 2003, UROL ONCOL-SEMIN ORI, V21, P117, DOI 10.1016/S1078-1439(02)00208-9; Wiedenmann J, 2004, P NATL ACAD SCI USA, V101, P15905, DOI 10.1073/pnas.0403668101	50	54	56	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1875	1884		10.1038/sj.onc.1209984	http://dx.doi.org/10.1038/sj.onc.1209984			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983333				2022-12-28	WOS:000245117700005
J	Chen, SL; Lin, ST; Tsai, TC; Hsiao, WC; Tsao, YP				Chen, S-L; Lin, S-T; Tsai, T-C; Hsiao, W-C; Tsao, Y-P			ErbB4 (JM-b/CYT-1)-induced expression and phosphorylation of c-Jun is abrogated by human papillomavirus type 16 E5 protein	ONCOGENE			English	Article						c-jun; ErbB4; HPV-16 E5; phosphorylation; proliferation	EPIDERMAL-GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; FACTOR RECEPTOR; TRANSCRIPTIONAL ACTIVITY; PRODUCTIVE INTERACTION; TRANSMEMBRANE MUTANTS; GENE-EXPRESSION; MESSENGER-RNA; MICE LACKING; HA-RAS	Human papillomavirus type 16 E5 (HPV-16 E5) is a highly hydrophobic membrane protein with weak-transforming activity, which is associated with ErbB4 receptor in HPV-16-infected cervical lesions. Presently, we investigated the transforming mechanisms of E5 involving ErbB4 signaling. Firstly, we report a role for ErbB4 (JM-b/CYT-1) receptor that activates c-jun gene expression and phosphorylating at Ser63 and Ser73 of the c-Jun protein in ligand-independent and Ras-c-jun NH2-terminal kinase-dependent pathway. Secondly, we show that HPV-16 E5 protein can form a complex with ErbB4 via binding to the extracellular and transmembrane domains of ErbB4 (JM-b/CYT-1). When co-expressing HPV-16 E5 and ErbB4 in cells, E5 can abrogate ErbB4-induced c-Jun protein expression and phosphorylation resulted in increasing cell proliferation compared to ErbB4-expressing cells. The interaction between of HPV-16 E5 and ErbB4 provides more insight into the mechanisms of HPV-16 E5 transformation induction.	Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, Taipei, Taiwan; Natl Def Univ, Natl Def Med Ctr, Dept Microbiol & Immunol, Taipei, Taiwan; Asia Univ, Dept Biotechnol & Bioinformat, Taichung, Taiwan; Mackay Mem Hosp, Dept Ophthalmol, Taipei, Taiwan	National Taiwan University; National Defense Medical Center; National Defense University - Taiwan; Asia University Taiwan; Mackay Memorial Hospital	Chen, SL (corresponding author), Natl Taiwan Univ, Grad Inst Microbiol, Coll Med, Dept Microbiol, 7F,1,Sec 1,Jen Ai Rd, Taipei, Taiwan.	showlic@ha.mc.ntu.edu.tw						Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Bacus SS, 1996, AM J PATHOL, V148, P549; BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; Bouyain S, 2005, P NATL ACAD SCI USA, V102, P15024, DOI 10.1073/pnas.0507591102; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; Chang JL, 2001, J BIOMED SCI, V8, P206, DOI 10.1007/BF02256414; Chen SL, 1998, VIROLOGY, V244, P521, DOI 10.1006/viro.1998.9109; Chen XM, 1996, J BIOL CHEM, V271, P7620, DOI 10.1074/jbc.271.13.7620; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; CULOUSCOU JM, 1995, J BIOL CHEM, V270, P12857, DOI 10.1074/jbc.270.21.12857; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DiMaio D, 2001, ONCOGENE, V20, P7866, DOI 10.1038/sj.onc.1204915; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Gambarotta G, 2004, J BIOL CHEM, V279, P48808, DOI 10.1074/jbc.M408374200; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Golding JP, 2000, NAT CELL BIOL, V2, P103, DOI 10.1038/35000058; Graber HU, 1999, INT J CANCER, V84, P24, DOI 10.1002/(SICI)1097-0215(19990219)84:1<24::AID-IJC5>3.0.CO;2-2; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; Hsieh CH, 2000, ARCH VIROL, V145, P2273, DOI 10.1007/s007050070020; HWANG ES, 1995, VIROLOGY, V211, P227, DOI 10.1006/viro.1995.1395; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; Junttila TT, 2005, CANCER RES, V65, P1384, DOI 10.1158/0008-5472.CAN-04-3150; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; Knowlden JM, 1998, ONCOGENE, V17, P1949, DOI 10.1038/sj.onc.1202107; Komuro A, 2003, J BIOL CHEM, V278, P33334, DOI 10.1074/jbc.M305597200; Lai CC, 2005, J VIROL, V79, P1924, DOI 10.1128/JVI.79.3.1924-1929.2005; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; Li BS, 2002, EMBO J, V21, P324, DOI 10.1093/emboj/21.3.324; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Lyne JC, 1997, CANCER J SCI AM, V3, P21; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Memon AA, 2004, BRIT J CANCER, V91, P2034, DOI 10.1038/sj.bjc.6602251; Mendrola JM, 2002, J BIOL CHEM, V277, P4704, DOI 10.1074/jbc.M108681200; Nappi VM, 2002, J BIOL CHEM, V277, P47149, DOI 10.1074/jbc.M209582200; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Riese DJ, 1996, ONCOGENE, V12, P345; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1994, EMBO J, V13, P6006, DOI 10.1002/j.1460-2075.1994.tb06946.x; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; TALOR P, 2006, IN PRESS J CELL 0303; Thomasson M, 2004, ACTA ONCOL, V43, P453, DOI 10.1080/02841860410028574; Tsai TC, 2003, ARCH VIROL, V148, P1445, DOI 10.1007/s00705-003-0111-z; TSAO YP, 1995, CANCER LETT, V95, P201, DOI 10.1016/0304-3835(95)03894-3; Tsao YP, 1996, J VIROL, V70, P7535, DOI 10.1128/JVI.70.11.7535-7539.1996; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Weiss FU, 1997, J CELL PHYSIOL, V173, P187, DOI 10.1002/(SICI)1097-4652(199711)173:2<187::AID-JCP19>3.0.CO;2-D; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Williams SMG, 2005, CANCER RES, V65, P6534, DOI 10.1158/0008-5472.CAN-05-0083; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	66	32	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 4	2007	26	1					42	53		10.1038/sj.onc.1209768	http://dx.doi.org/10.1038/sj.onc.1209768			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122OO	16819515				2022-12-28	WOS:000243236500005
J	Lee, HJ; Yun, CH; Lim, SH; Kim, BC; Baik, KG; Kim, JM; Kim, WH; Kim, SJ				Lee, H-J; Yun, C-H; Lim, S. H.; Kim, B-C; Baik, K. G.; Kim, J-M; Kim, W-H; Kim, S-J			SRF is a nuclear repressor of Smad3-mediated TGF-beta signaling	ONCOGENE			English	Article						SRF; TGF-beta; Smad; signaling; transcription; suppression	SERUM RESPONSE FACTOR; GROWTH-FACTOR-BETA; CELL-CYCLE ARREST; DNA-BINDING ACTIVITY; PHOSPHORYLATION SITES; CDK INHIBITOR; C-MYC; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATORS; RECEPTOR COMPLEX	Serum response factor (SRF) is a widely expressed transcription factor involved in immediate-early and tissue-specific gene expression, cell proliferation and differentiation. We defined a new role of SRF as a nuclear repressor of the tumor growth factor beta 1 (TGF-beta 1) growth-inhibitory signal during cell proliferation. We show that SRF significantly inhibits the TGF-beta 1/Smad-dependent transcription by associating with Smad3. SRF causes resistance to the TGF-beta 1 cytostatic response by directly repressing the Smad transcriptional activity and Smad binding to DNA. Furthermore, we demonstrated that overexpression of SRF markedly decreases the level of Smad3 complex binding to the promoters of Smad3 target genes, p15(INK4b) and p21(Cip1). This leads to the inhibition of expression of TGF-beta 1-responsive genes. SRF therefore acts as a nuclear repressor of Smad3-mediated TGF-beta 1 signaling.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; KRIBB, Div Mol Therapeut, Taejon, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Kangweon Natl Univ, Div Life Sci, Chunchon, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Advanced Institute of Science & Technology (KAIST); Kangwon National University; Seoul National University (SNU)	Kim, SJ (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.	kims@mail.nih.gov	Kim, Wooho/G-3703-2011	Lim, Seunghwan/0000-0001-8920-0890	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC005617] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM SE, 1992, MOL BIOL CELL, V3, P655, DOI 10.1091/mbc.3.6.655; ALEXANDROW MG, 1995, P NATL ACAD SCI USA, V92, P3239, DOI 10.1073/pnas.92.8.3239; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chai J, 2002, J PHYSIOL PHARMACOL, V53, P147; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Depoortere F, 2000, MOL BIOL CELL, V11, P1061, DOI 10.1091/mbc.11.3.1061; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Feng XH, 2002, MOL CELL, V9, P133, DOI 10.1016/S1097-2765(01)00430-0; GARRIGUEANTAR L, 1995, J IMMUNOL METHODS, V186, P267, DOI 10.1016/0022-1759(95)00151-Y; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Iavarone A, 1997, NATURE, V387, P417; Iyer D, 2006, P NATL ACAD SCI USA, V103, P4516, DOI 10.1073/pnas.0505338103; Iyer D, 2003, BIOCHEMISTRY-US, V42, P7477, DOI 10.1021/bi030045n; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; Kang SH, 1999, BRIT J CANCER, V80, P1144, DOI 10.1038/sj.bjc.6690478; Kim BC, 2004, MOL CELL BIOL, V24, P2251, DOI 10.1128/MCB.24.6.2251-2262.2004; KIM JH, 1994, J BIOL CHEM, V269, P13740; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Lee DK, 2002, J BIOL CHEM, V277, P38557, DOI 10.1074/jbc.M206786200; Lee HJ, 2004, J BIOL CHEM, V279, P2666, DOI 10.1074/jbc.M310591200; Lee MH, 2003, CANCER METAST REV, V22, P435, DOI 10.1023/A:1023785332315; LIU SH, 1993, J BIOL CHEM, V268, P21147; Mack CP, 1999, CIRC RES, V84, P852; MANAK JR, 1991, MOL CELL BIOL, V11, P3652, DOI 10.1128/MCB.11.7.3652; Massague J, 2000, GENE DEV, V14, P627; Miano JM, 2003, J MOL CELL CARDIOL, V35, P577, DOI 10.1016/S0022-2828(03)00110-X; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; Qiu P, 2003, J MOL CELL CARDIOL, V35, P1407, DOI 10.1016/j.yjmcc.2003.09.002; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Schratt G, 2001, MOL CELL BIOL, V21, P2933, DOI 10.1128/MCB.21.8.2933-2943.2001; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Warner BJ, 1999, MOL CELL BIOL, V19, P5913; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CYTOKINE GROWTH F R, V11, P5, DOI 10.1016/S1359-6101(99)00024-6; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1	51	31	32	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					173	185		10.1038/sj.onc.1209774	http://dx.doi.org/10.1038/sj.onc.1209774			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819512				2022-12-28	WOS:000243398300002
J	Amiri, KI; Ha, HC; Smulson, ME; Richmond, A				Amiri, K. I.; Ha, H. C.; Smulson, M. E.; Richmond, A.			Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1	ONCOGENE			English	Article						PARP-1; CXCL1; NF-kappa B; transcription; melanoma	NF-KAPPA-B; DNA-BINDING; GENE-EXPRESSION; CHROMATIN-STRUCTURE; GRO-ALPHA; ACTIVATION; PARP-1; IL-8; INTERLEUKIN-8; INHIBITION	The continuous production of the CXC ligand 1 ( CXCL1) chemokine by melanoma cells is a major effector of tumor growth. We have previously shown that the constitutive expression of this chemokine is dependent upon transcription factors nuclear factor- kappa B ( NF- kappa B), stimulating protein-1 (SP1), high- mobility group-I/Y ( HMGI/Y), CAAT displacement protein ( CDP) and poly( ADPribose) polymerase- 1 ( PARP-1). In this study, we demonstrate for the first time the mechanism of transcriptional regulation of CXCL1 through PARP-1 in melanoma cells. In its inactive state, PARP- 1 binds to the CXCL1 promoter in a sequence-specific manner and prevents binding of NF- kappa B ( p65/ p50) to its element. However, activation of the PARP- 1 enzymatic activity enhances CXCL1 expression, owing to the loss of PARP1 binding to the CXCL1 promoter, accompanied by enhanced binding of p65 to the promoter. The delineation of the role of NF-kappa B- interacting factors in the putative CXCL1 enhanceosome will provide key information in developing strategies to block constitutive expression of this and other chemokines in cancer and to develop targeted therapy.	Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Vet Affairs, Nashville, TN 37232 USA; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA; Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC USA	Vanderbilt University; Vanderbilt University; Meharry Medical College; Georgetown University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Canc Biol, 771 PRB,23rd Ave S Pierce, Nashville, TN 37232 USA.	ann.richmond@vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NCI NIH HHS [P01CA-74175, CA-56704, R01 CA116021, R01 CA116021-03, R01 CA116021-02] Funding Source: Medline; BLRD VA [IK6 BX005225] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA116021, R01CA056704, P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarez-Gonzalez R, 1999, J BIOL CHEM, V274, P32122, DOI 10.1074/jbc.274.45.32122; BALENTIEN E, 1991, ONCOGENE, V6, P1115; Boulares AH, 2003, AM J RESP CELL MOL, V28, P322, DOI 10.1165/rcmb.2001-0015OC; Burkle A, 2001, BIOESSAYS, V23, P795, DOI 10.1002/bies.1115; Cayuela ML, 2001, BIOCHEM BIOPH RES CO, V285, P289, DOI 10.1006/bbrc.2001.5178; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Ha HC, 2004, P NATL ACAD SCI USA, V101, P5087, DOI 10.1073/pnas.0306895101; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hassa PO, 1999, BIOL CHEM, V380, P953, DOI 10.1515/BC.1999.118; Huang K, 2004, BIOCHEMISTRY-US, V43, P217, DOI 10.1021/bi0301800; Kameoka M, 2000, BIOCHEM J, V346, P641, DOI 10.1042/0264-6021:3460641; Keane MP, 1997, J IMMUNOL, V159, P1437; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Li AH, 2001, CLIN CANCER RES, V7, P3298; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Olbina G, 1996, ANTICANCER RES, V16, P3525; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Richards BL, 1997, AM J SURG, V174, P507; Schadendorf D, 1996, BRIT J CANCER, V74, P194, DOI 10.1038/bjc.1996.337; Schadendorf M, 1994, J IMMUNOL, V153, P3360; SHATTUCK RL, 1994, MOL CELL BIOL, V14, P791, DOI 10.1128/MCB.14.1.791; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Smulson ME, 2000, ADV ENZYME REGUL, V40, P183, DOI 10.1016/S0065-2571(99)00024-2; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; STRIETER RM, 1995, J BIOL CHEM, V270, P27348, DOI 10.1074/jbc.270.45.27348; Szabo E, 2001, J INVEST DERMATOL, V117, P74, DOI 10.1046/j.0022-202x.2001.01388.x; Takamori H, 2000, PANCREAS, V21, P52, DOI 10.1097/00006676-200007000-00051; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Tulin A, 2003, CURR TOP DEV BIOL, V56, P55, DOI 10.1016/S0070-2153(03)01007-X; WOOD LD, 1995, NUCLEIC ACIDS RES, V23, P4210, DOI 10.1093/nar/23.20.4210; Yang JM, 2001, CANCER RES, V61, P4901; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	36	43	46	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2006	25	59					7714	7722		10.1038/sj.onc.1209751	http://dx.doi.org/10.1038/sj.onc.1209751			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799643	Green Accepted			2022-12-28	WOS:000242830800006
J	Yang, Y; Pan, X; Lei, W; Wang, J; Song, J				Yang, Y.; Pan, X.; Lei, W.; Wang, J.; Song, J.			Transforming growth factor-beta 1 induces epithelial-to-mesenchymal transition and apoptosis via a cell cycle-dependent mechanism	ONCOGENE			English	Article						PKD; EMT; cell cycle; TGF-beta; apoptosis; signaling	PROTEIN-KINASE-D; GROWTH-FACTOR-BETA; CONFERS RESISTANCE; TRANSDIFFERENTIATION; ACTIVATION; PLASTICITY; MIGRATION; P38; HEPATOCYTES; PROGRESSION	Apoptosis and epithelial-to-mesenchymal transition (EMT) have been implicated in a variety of biological processes, such as embryonic development, fibrosis and tumor progression. Transforming growth factor-beta (TGF-beta) can induce simultaneously both EMT and apoptotic response of epithelial cells. However, the underlying mechanism of these biological events remains not well understood. In the present study, we show that TGF-beta 1 induces apoptosis and EMT in AML-12 cells in a cell cycle-related manner, in which apoptosis and EMT took place at G2/M and G1/S phases, respectively. TGF-beta 1-induced apoptosis was correlated with different extent of caspase activation at different cell cycle phases. Interestingly, increased phosphorylation of protein kinase D (PKD) can be observed in G1/S phase in response to TGF-beta 1, and inhibition of PKD by inhibitor or by small interference RNA blocked EMT but not apoptosis. Our data suggest a previously unrecognized role of cell cycle state in the regulation of TGF-beta-induced EMT and apoptosis, and demonstrate that PKD is involved in the TGF-beta 1-induced EMT.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Song, J (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Mol Cell Biol Lab, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	jgsong@sibs.ac.cn	Yang, Yanan/F-1592-2010; Lei, Weiwei/H-4997-2012					Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bakin AV, 2002, J CELL SCI, V115, P3193; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bollag WB, 2004, DRUG NEWS PERSPECT, V17, P117, DOI 10.1358/dnp.2004.17.2.829045; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kennett SB, 2004, J BIOL CHEM, V279, P3300, DOI 10.1074/jbc.M305734200; Lemonnier J, 2004, J BIOL CHEM, V279, P259, DOI 10.1074/jbc.M308665200; Liao JH, 2001, CELL RES, V11, P89, DOI 10.1038/sj.cr.7290072; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Piek E, 1999, J CELL SCI, V112, P4557; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Schuster N, 2002, CELL TISSUE RES, V307, P1, DOI 10.1007/s00441-001-0479-6; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Twomey C, 2005, J CELL MOL MED, V9, P345, DOI 10.1111/j.1582-4934.2005.tb00360.x; Valdes F, 2002, MOL CANCER RES, V1, P68; Van Lint J, 2002, INT J BIOCHEM CELL B, V34, P577, DOI 10.1016/S1357-2725(01)00163-7; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Yang Y, 2004, INT J BIOCHEM CELL B, V36, P223, DOI 10.1016/S1357-2725(03)00215-2; Zhao S, 2004, J CELL PHYSIOL, V199, P47, DOI 10.1002/jcp.10453	32	84	88	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	55					7235	7244		10.1038/sj.onc.1209712	http://dx.doi.org/10.1038/sj.onc.1209712			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	108MU	16799646				2022-12-28	WOS:000242244700002
J	Turner, NC; Reis, JS				Turner, N. C.; Reis-Filho, J. S.			Basal-like breast cancer and the BRCA1 phenotype	ONCOGENE			English	Review						breast cancer; basal-like; BRCA1; molecular genetics; cancer genetics; EGFR	COMPARATIVE GENOMIC HYBRIDIZATION; GENE-EXPRESSION PROFILES; CARCINOMA IN-SITU; INVASIVE DUCTAL CARCINOMAS; CENTRAL ACELLULAR ZONES; ESTROGEN-RECEPTOR; EPITHELIAL PHENOTYPE; IMMUNOHISTOCHEMICAL MARKERS; HISTOPATHOLOGICAL FEATURES; MOLECULAR CLASSIFICATION	Breast cancers arising in germline carriers of BRCA1 mutations have a characteristic phenotype that has been shown in many studies to differentiate BRCA1 tumours from sporadic tumours. Recently, it has become clear that the characteristic phenotype of BRCA1 tumours is due to expression of the basal-like phenotype. We review-these phenotypes, the evidence for BRCA1 pathway dysfunction in sporadic basal-like cancers, and discuss the clinical significance of the basal-like phenotype for cancer genetics and treatment.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Turner, NC (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, Fulham Rd, London SW3 6JB, England.	nicholas.turner@icr.ac.uk; jorge.reis-filho@icr.ac.uk		Turner, Nicholas/0000-0001-8937-0873	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.3.CO;2-E; Armes JE, 1999, CANCER RES, V59, P2011; Arnes JB, 2005, CLIN CANCER RES, V11, P4003, DOI 10.1158/1078-0432.CCR-04-2064; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Buerger H, 1999, J PATHOL, V189, P521, DOI 10.1002/(SICI)1096-9896(199912)189:4<521::AID-PATH472>3.0.CO;2-B; Buerger H, 1999, J PATHOL, V187, P396, DOI 10.1002/(SICI)1096-9896(199903)187:4<396::AID-PATH286>3.0.CO;2-L; Buerger H, 2001, J PATHOL, V194, P165, DOI 10.1002/path.875; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254; Chenevix-Trench G, 2006, CANCER RES, V66, P2019, DOI 10.1158/0008-5472.CAN-05-3546; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; DAIRKEE SH, 1987, LANCET, V1, P514; Eerola H, 2005, BREAST CANCER RES, V7, pR465, DOI 10.1186/bcr1025; Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Foulkes WD, 2004, CANCER RES, V64, P830, DOI 10.1158/0008-5472.CAN-03-2970; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Fulford LG, 2006, HISTOPATHOLOGY, V49, P22, DOI 10.1111/j.1365-2559.2006.02453.x; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; GOULD VE, 1990, AM J PATHOL, V137, P1143; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudmundsdottir K, 2006, ONCOGENE, V25, P5864, DOI 10.1038/sj.onc.1209874; Gusterson BA, 2005, BREAST CANCER RES, V7, P143, DOI 10.1186/bcr1041; Hamperl H, 1970, Curr Top Pathol, V53, P161; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Hnasko Robert, 2003, Mol Interv, V3, P445, DOI 10.1124/mi.3.8.445; Honrado E, 2006, ONCOGENE, V25, P5837, DOI 10.1038/sj.onc.1209875; Honrado E, 2005, J CLIN ONCOL, V23, P7503, DOI 10.1200/JCO.2005.01.3698; Honrado E, 2005, MODERN PATHOL, V18, P1305, DOI 10.1038/modpathol.3800453; Honrado E, 2006, CRIT REV ONCOL HEMAT, V59, P27, DOI 10.1016/j.critrevonc.2006.01.006; Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Hwang ES, 2004, CLIN CANCER RES, V10, P5160, DOI 10.1158/1078-0432.CCR-04-0165; Jacquemier J, 2005, J PATHOL, V207, P260, DOI 10.1002/path.1845; Jones C, 2004, CANCER RES, V64, P3037, DOI 10.1158/0008-5472.CAN-03-2028; Jones C, 2001, BRIT J CANCER, V85, P422, DOI 10.1054/bjoc.2001.1869; Jones C, 2004, CLIN CANCER RES, V10, P5988, DOI 10.1158/1078-0432.CCR-03-0731; Jones LP, 2005, ONCOGENE, V24, P3554, DOI 10.1038/sj.onc.1208426; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Korsching E, 2002, LAB INVEST, V82, P1525, DOI 10.1097/01.LAB.0000038508.86221.B3; Laakso M, 2005, MODERN PATHOL, V18, P1321, DOI 10.1038/modpathol.3800456; Lacroix M, 2004, ENDOCR-RELAT CANCER, V11, P497, DOI 10.1677/erc.1.00758; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lakhani SR, 2001, BREAST CANCER RES, V3, P1, DOI 10.1186/bcr260; Lakhani SR, 1998, JNCI-J NATL CANCER I, V90, P1138, DOI 10.1093/jnci/90.15.1138; Lakhani SR, 2001, NAT MED, V7, P408, DOI 10.1038/86464; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Lou ZK, 2005, NAT STRUCT MOL BIOL, V12, P589, DOI 10.1038/nsmb953; Malzahn K, 1998, VIRCHOWS ARCH, V433, P119, DOI 10.1007/s004280050226; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Matos I, 2005, VIRCHOWS ARCH, V447, P688, DOI 10.1007/s00428-005-0010-7; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Moyano JV, 2006, J CLIN INVEST, V116, P261, DOI 10.1172/JCI25888; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Osin P, 2003, INT J SURG PATHOL, V11, P153, DOI 10.1177/106689690301100301; Page MJ, 1999, P NATL ACAD SCI USA, V96, P12589, DOI 10.1073/pnas.96.22.12589; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polychronis A, 2005, LANCET ONCOL, V6, P383, DOI 10.1016/S1470-2045(05)70176-5; Quenneville LA, 2002, CANCER-AM CANCER SOC, V95, P2068, DOI 10.1002/cncr.10949; RAYMOND WA, 1989, J PATHOL, V157, P299, DOI 10.1002/path.1711570406; Reis JS, 2006, J PATHOL, V209, P445, DOI 10.1002/path.2004; Reis JS, 2006, J CLIN PATHOL, V59, P225, DOI 10.1136/jcp.2005.028324; Reis JS, 2006, MODERN PATHOL, V19, P307, DOI 10.1038/modpathol.3800542; Reis JS, 2005, BREAST CANCER RES, V7, pR1028, DOI 10.1186/bcr1341; Reis JS, 2005, PATHOL RES PRACT, V201, P713, DOI 10.1016/j.prp.2005.05.013; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Reis JS, 2006, MODERN PATHOL, V19, P999, DOI 10.1038/modpathol.3800621; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Pinilla SMR, 2006, BREAST CANCER RES TR, V99, P85, DOI 10.1007/s10549-006-9184-1; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Roylance R, 1999, CANCER RES, V59, P1433; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691; Simpson PT, 2004, J PATHOL, V202, P274, DOI 10.1002/path.1530; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tirkkonen M, 1999, GENE CHROMOSOME CANC, V24, P56, DOI 10.1002/(SICI)1098-2264(199901)24:1<56::AID-GCC8>3.0.CO;2-X; Tsuda H, 1999, HUM PATHOL, V30, P1134, DOI 10.1016/S0046-8177(99)90028-X; Tsuda H, 2000, AM J SURG PATHOL, V24, P197, DOI 10.1097/00000478-200002000-00005; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; van Beers EH, 2005, CANCER RES, V65, P822; van de Rijn M, 2002, AM J PATHOL, V161, P1991, DOI 10.1016/S0002-9440(10)64476-8; van der Groep P, 2004, JNCI-J NATL CANCER I, V96, P712, DOI 10.1093/jnci/djh114; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Vos CBJ, 1999, BRIT J CANCER, V81, P1410, DOI 10.1038/sj.bjc.6693372; Waldman FM, 2000, JNCI-J NATL CANCER I, V92, P313, DOI 10.1093/jnci/92.4.313; Wang ZGC, 2004, CANCER RES, V64, P64, DOI 10.1158/0008-5472.CAN-03-2570; Wessels LFA, 2002, CANCER RES, V62, P7110; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Zheng L, 2001, P NATL ACAD SCI USA, V98, P9587, DOI 10.1073/pnas.171174298	107	334	351	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5846	5853		10.1038/sj.onc.1209876	http://dx.doi.org/10.1038/sj.onc.1209876			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998499				2022-12-28	WOS:000240765900005
J	Giacinti, C; Giordano, A				Giacinti, C.; Giordano, A.			RB and cell cycle progression	ONCOGENE			English	Review						Rb; cell cycle; E2F; cancer; Rb2/p130; tumor suppressor	DEPENDENT TRANSCRIPTIONAL REPRESSION; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; HISTONE DEACETYLASE; DIFFERENTIAL REGULATION; GENE RB2/P130; PRB-FAMILY; E2F; CANCER; EXPRESSION	The Rb protein is a tumor suppressor, which plays a pivotal role in the negative control of the cell cycle and in tumor progression. It has been shown that Rb protein (pRb) is responsible for a major G1 checkpoint, blocking S-phase entry and cell growth. The retinoblastoma family includes three members, Rb/p105, p107 and Rb2/p130, collectively referred to as 'pocket proteins'. The pRb protein represses gene transcription, required for transition from G1 to S phase, by directly binding to the transactivation domain of E2F and by binding to the promoter of these genes as a complex with E2F. pRb represses transcription also by remodeling chromatin structure through interaction with proteins such as hBRM, BRG1, HDAC1 and SUV39H1, which are involved in nucleosome remodeling, histone acetylation/deacetylation and methylation, respectively. Loss of pRb functions may induce cell cycle deregulation and so lead to a malignant phenotype. Gene inactivation of pRB through chromosomal mutations is one of the principal reasons for retinoblastoma tumor development. Functional inactivation of pRb by viral oncoprotein binding is also shown in many neoplasias such as cervical cancer, mesothelioma and AIDS-related Burkitt's lymphoma.	Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; GIACINTI, Cristina/0000-0002-5596-6967				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Baldi A, 1996, P NATL ACAD SCI USA, V93, P4629, DOI 10.1073/pnas.93.10.4629; BIGNON YJ, 1993, B CANCER, V80, P704; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Cinti C, 2000, AM J PATHOL, V156, P751, DOI 10.1016/S0002-9440(10)64941-3; CINTI C, 2000, EMERGING THER TARGET, V4, P765; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; Condorelli G, 1997, J CELL BIOCHEM, V67, P423, DOI 10.1002/(SICI)1097-4644(19971215)67:4<423::AID-JCB1>3.0.CO;2-U; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; De Falco G, 2003, ONCOGENE, V22, P6214, DOI 10.1038/sj.onc.1206637; DEFALCO G, 2006, ONCOGENE; delaLuna S, 1996, J CELL SCI, V109, P2443; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; DIMOVA DK, 2005, ONCOGENE, V44, P30; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DUNN JM, 1988, SCIENCE, V241, P1797, DOI 10.1126/science.3175621; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Gagrica S, 2004, EMBO J, V23, P4627, DOI 10.1038/sj.emboj.7600470; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Geng Y, 2001, P NATL ACAD SCI USA, V98, P13138, DOI 10.1073/pnas.231487798; HARBOUR JW, 2000, CELL, V101, P79; HELIN K, 1993, MOL CELL BIOL, V13, P3149; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Hitomi M, 1999, CURR BIOL, V9, P1075, DOI 10.1016/S0960-9822(99)80476-X; HOPBNEFER R, 2000, CANCER RES, V1, P121; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ichimura K, 2000, GENE, V251, P37, DOI 10.1016/S0378-1119(00)00193-1; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878; Johnson David G., 1998, Frontiers in Bioscience, V3, pD447; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; KEYOMARSI K, 1995, ONCOGENE, V11, P941; Kim SJ, 2005, TECH PHYS LETT+, V31, P597, DOI 10.1134/1.2001065; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES WH, 1993, MOL CELL BIOL, V2, P1194; Liu HP, 2004, CURR OPIN GENET DEV, V14, P55, DOI 10.1016/j.gde.2003.11.005; LUDLOW JW, 1993, MOL CELL BIOL, V13, P367, DOI 10.1128/MCB.13.1.367; Lundberg AS, 1999, EUR J CANCER, V35, P531; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Ma DD, 2003, J BIOL CHEM, V278, P19358, DOI 10.1074/jbc.M301761200; Macaluso M, 2005, SEMIN ONCOL, V32, P452, DOI 10.1053/j.seminoncol.2005.07.009; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Puri PL, 1999, MOLECULAR BASIS OF CELL CYCLE AND GROWTH CONTROL, P15; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; REN S, 2004, DEV CELL, V6, P607; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SHAO ZH, 1995, ONCOGENE, V10, P221; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; Stiegler P, 1998, CANCER RES, V58, P5049; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Young AP, 2004, ONCOGENE, V23, P2587, DOI 10.1038/sj.onc.1207330; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	86	783	822	1	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5220	5227		10.1038/sj.onc.1209615	http://dx.doi.org/10.1038/sj.onc.1209615			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936740				2022-12-28	WOS:000240064100005
J	Kansaku, A; Hirabayashi, S; Mori, H; Fujiwara, N; Kawata, A; Ikeda, M; Rokukawa, C; Kurihara, H; Hata, Y				Kansaku, A.; Hirabayashi, S.; Mori, H.; Fujiwara, N.; Kawata, A.; Ikeda, M.; Rokukawa, C.; Kurihara, H.; Hata, Y.			Ligand-of-Numb protein X is an endocytic scaffold for junctional adhesion molecule 4	ONCOGENE			English	Article						endocytosis; scaffold; cell adhesion	HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHOSPHOTYROSINE-BINDING DOMAIN; ASYMMETRIC CELL-DIVISION; FATE DETERMINANT NUMB; MAMMALIAN NUMB; TIGHT JUNCTION; FAMILY PROTEINS; MDCK CELLS; TGF-BETA	Junctional adhesion molecule 4 (JAM4) is a cell adhesion molecule that interacts with a tight junction protein, membrane-associated guanylate kinase inverted 1 (MAGI-1). Our previous studies suggest that JAM4 is implicated in the regulation of paracellular permeability and the signalings of hepatocyte growth factor. In this study, we performed yeast two-hybrid screening to search for an unidentified JAM4-binding protein and obtained one isoform of Ligand-of-Numb protein X1 (LNX1), LNXp70, that is an interactor of Numb. Ligand-of-Numb protein X1 is expressed in kidney glomeruli and intestinal epithelial cells, where JAM4 is also detected. Immunoprecipitation from kidney lysates supports the in vivo interaction of proteins. Biochemical studies reveal that JAM4 directly binds the second PDZ domain of LNX1 through its carboxyl terminus. Junctional adhesion molecule 4, LNX1 and Numb form a tripartite complex in vitro and are partially colocalized in heterologous cells. Ligand-of-Numb protein X1 facilitates endocytosis of JAM4 and is involved in transforming growth factor beta-induced redistribution of JAM4 in mammary epithelial cells. Experiments using dominant-negative constructs and RNA interference insure that Numb is necessary for the LNX1-mediated endocytosis of JAM4. All these findings indicate that LNX1 provides an endocytic scaffold for JAM4 that is implicated in the reorganization of cell junctions.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Anat, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU); Juntendo University	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, 15-45 Yushima, Tokyo, Japan.	yuhammch@med.tmd.ac.jp						Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Coyne CB, 2005, ADV DRUG DELIVER REV, V57, P869, DOI 10.1016/j.addr.2005.01.007; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Heiz M, 2004, J BIOL CHEM, V279, P31149, DOI 10.1074/jbc.M403587200; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Mandell KJ, 2005, ADV DRUG DELIVER REV, V57, P857, DOI 10.1016/j.addr.2005.01.005; McCright B, 2001, DEVELOPMENT, V128, P491; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mirza M, 2005, EXP CELL RES, V309, P110, DOI 10.1016/j.yexcr.2005.05.023; Mori H, 2004, GENES CELLS, V9, P811, DOI 10.1111/j.1365-2443.2004.00765.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nie J, 2004, J BIOL CHEM, V279, P20807, DOI 10.1074/jbc.M311396200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Pollack AL, 2004, AM J PHYSIOL-CELL PH, V286, pC482, DOI 10.1152/ajpcell.00377.2003; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rice DS, 2001, MOL CELL NEUROSCI, V18, P525, DOI 10.1006/mcne.2001.1024; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; STOKER M, 1985, J CELL SCI, V77, P209; Tajima M, 2003, GENES CELLS, V8, P759, DOI 10.1046/j.1365-2443.2003.00673.x; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANITALLIE CM, 2005, ANN REV PHYSL; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	57	35	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5071	5084		10.1038/sj.onc.1209468	http://dx.doi.org/10.1038/sj.onc.1209468			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16832352	Bronze			2022-12-28	WOS:000240063700001
J	Ohta, S				Ohta, S.			Contribution of somatic mutations in the mitochondrial genome to the development of cancer and tolerance against anticancer drugs	ONCOGENE			English	Review						apoptosis; cybrid; codon; mitochondrial disease; transplantation	CELLS LACKING MTDNA; DNA MUTATIONS; HELA-CELLS; BIOENERGETIC SIGNATURE; PATHOGENIC MUTATIONS; PROTEIN-SYNTHESIS; GENE; APOPTOSIS; DISEASE; STRESS	Mitochondrial defects have long been suspected to play an important role in the development of cancer. Although most cancer cells harbor somatic mutations in mitochondrial DNA (mtDNA), the question of whether such mutations positively contribute to the development of cancer remained unclear. To clarify the role of mutant mtDNA excluding effects by the nuclear background, we focus on a method of transmitochondrial cybrids. Tumors were formed by transplanting cybrids with or without mutant mtDNA into nude mice and compared each size, revealing that mutant cybrids enhanced tumorigenesis. Next, we discuss a method for excluding the possibility of secondary nuclear mutations that may affect tumorigenesis. Mitochondrial genes that had been converted from mitochondrial to nuclear codons and equipped with a mitochondrial-targeting sequence were introduced into the nucleus of mutant cybrids. The gene products complemented the dysfunction, and reduced the promotion of tumors. By these methods, we concluded that mutant mitochondria positively and directly contribute to tumorigenesis. Since apoptosis occurred less frequently in the mutant versus wild-type cybrids in tumors, pathogenic mtDNA mutations contribute to the promotion of tumors by preventing apoptosis. Finally, we discuss the role of mutant mtDNA in conferring tolerance against anticancer drugs.	Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol,Nakahara Ku, Kawasaki, Kanagawa 2118533, Japan	Nippon Medical School	Ohta, S (corresponding author), Nippon Med Sch, Grad Sch Med, Inst Dev & Aging Sci, Dept Biochem & Cell Biol,Nakahara Ku, 1-396 Kosugi Cho, Kawasaki, Kanagawa 2118533, Japan.	ohta@nms.ac.jp						Amuthan G, 2001, EMBO J, V20, P1910, DOI 10.1093/emboj/20.8.1910; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2; Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng100; Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Cuezva JM, 2002, CANCER RES, V62, P6674; D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017; Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221; Geschickter C.F., 1930, J CHEM EDUC, DOI [10.1021/ed007p179, DOI 10.1021/ED007P179]; Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200; Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354; HAYASHI J, 1990, BIOCHEM BIOPH RES CO, V167, P216, DOI 10.1016/0006-291X(90)91753-F; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584; HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159; HAYASHI JI, 1991, PROGR NEUROPATHOLOGY, P93; HOLT IJ, 1990, AM J HUM GENET, V46, P428; Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; Klein Theodore M., 1993, Current Opinion in Biotechnology, V4, P583, DOI 10.1016/0958-1669(93)90081-7; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3; Linnartz B, 2004, CANCER RES, V64, P1966, DOI 10.1158/0008-5472.CAN-03-2956; Liu VWS, 2001, CANCER RES, V61, P5998; Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851; Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200; Maximo V, 2002, AM J PATHOL, V160, P1857, DOI 10.1016/S0002-9440(10)61132-7; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; Michiels C, 2002, FREE RADICAL BIO MED, V33, P1231, DOI 10.1016/S0891-5849(02)01045-6; Moraes CT, 2001, METHOD CELL BIOL, V65, P397, DOI 10.1016/S0091-679X(01)65023-4; MORAIS R, 1994, CANCER RES, V54, P3889; Nakano K, 2003, MITOCHONDRION, V3, P21, DOI 10.1016/S1567-7249(03)00056-4; Nakashima-Kamimura N, 2005, J CELL SCI, V118, P5357, DOI 10.1242/jcs.02645; Nishikawa M, 2001, CANCER RES, V61, P1843; Ohta S, 2003, CURR MED CHEM, V10, P2485, DOI 10.2174/0929867033456440; Parrella P, 2001, CANCER RES, V61, P7623; Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102; Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108; Qian W, 2005, AM J PHYSIOL-CELL PH, V289, pC1466, DOI 10.1152/ajpcell.00265.2005; Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012; Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Takamatsu C, 2002, EMBO REP, V3, P451, DOI 10.1093/embo-reports/kvf099; Tan DJ, 2002, CANCER RES, V62, P972; Tang JT, 1999, ANTICANCER RES, V19, P4959; TATUCH Y, 1992, AM J HUM GENET, V50, P852; Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wong LJC, 2003, CANCER RES, V63, P3866; Xu RH, 2005, CANCER RES, V65, P613; Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; YONEDA M, 1995, BIOCHEM BIOPH RES CO, V209, P723, DOI 10.1006/bbrc.1995.1559; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	67	64	69	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4768	4776		10.1038/sj.onc.1209602	http://dx.doi.org/10.1038/sj.onc.1209602			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892089				2022-12-28	WOS:000239687000013
J	Laurent-Puig, P; Zucman-Rossi, J				Laurent-Puig, P.; Zucman-Rossi, J.			Genetics of hepatocellular tumors	ONCOGENE			English	Review						hepatocellular carcinoma; hepatocellular adenoma; chromosome instability; gene mutation; tumor suppressor gene	HEPATITIS-B-VIRUS; BETA-CATENIN GENE; COMPARATIVE GENOMIC HYBRIDIZATION; P53 GENE; SHORT ARM; RETINOBLASTOMA PROTEIN; SEGREGATION ANALYSIS; GROWTH-SUPPRESSION; LIVER-CIRRHOSIS; ALLELIC LOSSES	Numerous genetic alterations are accumulated during the process of hepatocarcinogenesis. These genetic alterations can be divided into two groups. The first set of genetic alterations is specific of hepatocellular tumor risk factors. It includes integration of hepatitis B virus (HBV) DNA, R249S TP53 (tumor protein p53) mutation in aflatoxin B1-exposed patients, KRAS mutations related to vinyl chloride exposure, hepatocyte nuclear factor 1 alpha (HNF1 alpha) mutations associated to hepatocellular adenomas and adenomatosis polyposis coli (APC) germline mutations predisposing to hepatoblastomas. The second set of genetic alterations are etiological nonspecific, it includes recurrent gains and losses of chromosomes, alteration of TP53 gene, activation of WNT/beta-catenin pathway through CTNNB1/beta-catenin and AXIN (axis inhibition protein) mutations, inactivation of retinoblastoma and IGF2R (insulin-like growth factor 2 receptor) pathways through inactivation of RB1 (retinoblastoma 1), P16 and IGF2R. Comprehensive analyses of these genetic alterations have defined two pathways of hepatocarcinogenesis according to the presence or the absence of chromosomal instability. Hepatitis B virus and poorly differentiated tumors are related to chromosome instable tumors associated with frequent TP53 mutations, whereas non-HBV and well-differentiated tumors are related to chromosomal stable samples that are frequently beta-catenin activated. These classifications have clinical relevance as genetic alterations may also be related to prognosis.	INSERM, U674, F-75010 Paris, France; Univ Paris 05, Paris, France; INSERM, U775, Paris, France; Univ Paris 07, Inst Hematol, CEPH, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Zucman-Rossi, J (corresponding author), INSERM, U674, 27 Rue Juliette Dodu, F-75010 Paris, France.	zucman@cephb.fr	Laurent-Puig, Pierre/K-3641-2019; zucman-rossi, Jessica/B-5098-2009; laurent-puig, pierre/B-2226-2013; j, zucman-rossi/AAV-3594-2021	Laurent-Puig, Pierre/0000-0001-8475-5459; zucman-rossi, Jessica/0000-0002-5687-0334; laurent-puig, pierre/0000-0001-8475-5459; j, zucman-rossi/0000-0002-5687-0334				Andrisani OM, 1999, INT J ONCOL, V15, P373; Aoki H, 1996, P NATL ACAD SCI USA, V93, P7300, DOI 10.1073/pnas.93.14.7300; Bacq Y, 2003, GASTROENTEROLOGY, V125, P1470, DOI 10.1016/j.gastro.2003.07.012; Baek MJ, 2000, CANCER, V89, P60, DOI 10.1002/1097-0142(20000701)89:1<60::AID-CNCR9>3.0.CO;2-3; Balsara BR, 2001, GENE CHROMOSOME CANC, V30, P245, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1083>3.0.CO;2-M; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; Biden K, 1997, HEPATOLOGY, V25, P593, DOI 10.1002/hep.510250317; Bluteau O, 2002, ONCOGENE, V21, P1225, DOI 10.1038/sj.onc.1205197; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boige V, 1997, CANCER RES, V57, P1986; BRESSAC B, 1991, NATURE, V350, P429, DOI 10.1038/350429a0; Buendia MA, 2002, MED PEDIATR ONCOL, V39, P530, DOI 10.1002/mpo.10180; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cai RL, 2003, WORLD J GASTROENTERO, V9, P2428; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; Cetta F, 2003, MED PEDIATR ONCOL, V41, P496, DOI 10.1002/mpo.10362; Chen YW, 2002, HEPATOLOGY, V36, P927, DOI 10.1053/jhep.2002.36126; CHIU JH, 1992, J CLIN INVEST, V89, P539, DOI 10.1172/JCI115618; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Collonge-Rame MA, 2001, CANCER GENET CYTOGEN, V127, P49, DOI 10.1016/S0165-4608(00)00421-0; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; EDMONDSON HA, 1976, NEW ENGL J MED, V294, P470, DOI 10.1056/NEJM197602262940904; EDMONDSON HA, 1983, SEMIN ROENTGENOL, V18, P75, DOI 10.1016/0037-198X(83)90005-6; ESSIGMANN JM, 1977, P NATL ACAD SCI USA, V74, P1870, DOI 10.1073/pnas.74.5.1870; EZAKI T, 1988, CANCER, V61, P106, DOI 10.1002/1097-0142(19880101)61:1<106::AID-CNCR2820610118>3.0.CO;2-R; FEITELSON MA, 1993, ONCOGENE, V8, P1109; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FUJIMOTO J, 1991, CANCER, V67, P939, DOI 10.1002/1097-0142(19910215)67:4<939::AID-CNCR2820670414>3.0.CO;2-J; FUJIMOTO Y, 1994, CANCER RES, V54, P281; FURUYA K, 1988, CANCER, V61, P99, DOI 10.1002/1097-0142(19880101)61:1<99::AID-CNCR2820610117>3.0.CO;2-U; GRAEF E, 1994, ONCOGENE, V9, P81; GROOPMAN JD, 1981, P NATL ACAD SCI-BIOL, V78, P5445, DOI 10.1073/pnas.78.9.5445; Guan XY, 2000, GENE CHROMOSOME CANC, V29, P110; Hickman ES, 2002, CURR OPIN GENET DEV, V12, P60, DOI 10.1016/S0959-437X(01)00265-9; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Horikawa I, 2003, CARCINOGENESIS, V24, P1167, DOI 10.1093/carcin/bgg085; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; HSU IC, 1991, NATURE, V350, P427, DOI 10.1038/350427a0; Huang H, 1999, AM J PATHOL, V155, P1795, DOI 10.1016/S0002-9440(10)65496-X; Ishizaki Y, 2004, INT J ONCOL, V24, P1077; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; Koch A, 2004, J PATHOL, V204, P546, DOI 10.1002/path.1662; Koch A, 1999, CANCER RES, V59, P269; Kondo Y, 1999, JPN J CANCER RES, V90, P1301, DOI 10.1111/j.1349-7006.1999.tb00712.x; Koyama M, 1999, JPN J CANCER RES, V90, P951, DOI 10.1111/j.1349-7006.1999.tb00840.x; KUROKI T, 1995, GENE CHROMOSOME CANC, V13, P163, DOI 10.1002/gcc.2870130305; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Lee JW, 2005, ONCOGENE, V24, P1477, DOI 10.1038/sj.onc.1208304; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Lin Y., 1996, Annals Academy of Medicine Singapore, V25, P22; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; Marchio A, 1997, GENE CHROMOSOME CANC, V18, P59, DOI 10.1002/(SICI)1098-2264(199701)18:1<59::AID-GCC7>3.0.CO;2-0; Marchio AS, 2000, ONCOGENE, V19, P3733, DOI 10.1038/sj.onc.1203713; MARTIN CN, 1977, NATURE, V267, P863, DOI 10.1038/267863a0; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; MCGLYNN KA, 1995, P NATL ACAD SCI USA, V92, P2384, DOI 10.1073/pnas.92.6.2384; MILLER C, 1986, NATURE, V319, P783, DOI 10.1038/319783a0; MILLER EC, 1978, CANCER RES, V38, P1479; Miyoshi Y, 1998, CANCER RES, V58, P2524; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Motyka B, 2000, CELL, V103, P491, DOI 10.1016/S0092-8674(00)00140-9; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; NISHIDA N, 1992, INT J CANCER, V51, P862, DOI 10.1002/ijc.2910510605; Nishimura T, 2002, GENE CHROMOSOME CANC, V35, P329, DOI 10.1002/gcc.10126; Oka Y, 2002, HEPATOLOGY, V35, P1153, DOI 10.1053/jhep.2002.32669; Okabe H, 2000, HEPATOLOGY, V31, P1073, DOI 10.1053/he.2000.6409; Okabe H, 2001, CANCER RES, V61, P2129; Paradis V, 1998, HEPATOLOGY, V28, P953, DOI 10.1002/hep.510280409; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Piao Z, 1999, CANCER LETT, V138, P227, DOI 10.1016/S0304-3835(99)00019-1; Piao Z, 1998, INT J CANCER, V75, P29, DOI 10.1002/(SICI)1097-0215(19980105)75:1<29::AID-IJC5>3.3.CO;2-#; Piao Z, 1997, LIVER, V17, P251; Pineau P, 1999, ONCOGENE, V18, P3127, DOI 10.1038/sj.onc.1202648; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SHEN FM, 1991, AM J HUM GENET, V49, P88; Shirota Y, 2001, HEPATOLOGY, V33, P832, DOI 10.1053/jhep.2001.23003; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; Sun CA, 2001, CARCINOGENESIS, V22, P1289, DOI 10.1093/carcin/22.8.1289; TANAKA S, 1993, CANCER RES, V53, P2884; Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591; TERADA T, 1993, VIRCHOWS ARCH A, V422, P381, DOI 10.1007/BF01605457; TERAMOTO T, 1994, CANCER RES, V54, P231; Terris B, 1999, ONCOGENE, V18, P6583, DOI 10.1038/sj.onc.1203051; THOMAS RM, 1992, HUM PATHOL, V23, P496, DOI 10.1016/0046-8177(92)90126-N; TSUDA H, 1990, P NATL ACAD SCI USA, V87, P6791, DOI 10.1073/pnas.87.17.6791; Van Nhieu JT, 1999, AM J PATHOL, V155, P703, DOI 10.1016/S0002-9440(10)65168-1; Vautier G, 1999, GASTROENTEROLOGY, V117, P154, DOI 10.1016/S0016-5085(99)70562-7; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; Wei Y, 2000, ONCOGENE, V19, P498, DOI 10.1038/sj.onc.1203356; Weihrauch M, 2001, BRIT J CANCER, V84, P982, DOI 10.1054/bjoc.2000.1675; WEINBERG AG, 1983, HUM PATHOL, V14, P512, DOI 10.1016/S0046-8177(83)80005-7; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Wong N, 2000, HEPATOLOGY, V32, P1060, DOI 10.1053/jhep.2000.19349; Xu XR, 2001, P NATL ACAD SCI USA, V98, P15089, DOI 10.1073/pnas.241522398; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; Yakicier MC, 2001, ONCOGENE, V20, P5232, DOI 10.1038/sj.onc.1204674; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0; Yeh SH, 2001, GASTROENTEROLOGY, V121, P699, DOI 10.1053/gast.2001.27211; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225; Yu MW, 2000, J NATL CANCER I, V92, P1159, DOI 10.1093/jnci/92.14.1159; ZHANG X, 1994, CANCER RES, V54, P4177; Zucman-Rossi J, 2006, HEPATOLOGY, V43, P515, DOI 10.1002/hep.21068	112	268	280	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3778	3786		10.1038/sj.onc.1209547	http://dx.doi.org/10.1038/sj.onc.1209547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799619				2022-12-28	WOS:000238559600005
J	Amiri, A; Noei, F; Jeganathan, S; Kulkarni, G; Pinke, DE; Lee, JM				Amiri, A.; Noei, F.; Jeganathan, S.; Kulkarni, G.; Pinke, D. E.; Lee, J. M.			eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration	ONCOGENE			English	Article						eEF1A2; Akt; filopodia; protein translation; actin; cell motility	ELONGATION-FACTOR EEF1A2; BINDING PROTEIN; CELL-MIGRATION; FACTOR 1A; TRANSLATION; KINASES; GROWTH; GENE; OVEREXPRESSION; FACTOR-1-ALPHA	eEF1A2 ( eukaryotic protein elongation factor 1 alpha 2) is a protein translation factor that is likely a human oncogene by virtue of its capacity to transform mammalian cells and its high expression in tumors of the ovary, breast and lung. Here, we show that expression of eEF1A2 is sufficient to stimulate the formation of filopodia in BT 549 human breast cancer cells and non-transformed Rat2 cells. Filopodia formation in eEF1A2-expressing cells is dependent on the activity of phosphatidylinositol-3 kinase ( PI3K), and the ROCK and Akt kinases. Furthermore, eEF1A2 expression is sufficient to activate Akt in a PI3K-dependent fashion and inactivation of eEF1A2 by short interfering RNA reduces Akt activity. Using breast cancer cell line BT 549, we show that eEF1A2 expression stimulates cell migration and invasion in a largely PI3K- and Akt-dependent manner. These results suggest that eEF1A2 regulates oncogenesis through Akt and PI3K-dependent cytoskeletal remodeling.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	University of Ottawa	Lee, JM (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jlee@uottawa.ca						ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Anand N, 2002, NAT GENET, V31, P301, DOI 10.1038/ng904; Arboleda MJ, 2003, CANCER RES, V63, P196; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; CHANG R, 2006, J CELL BIOCH; Chen J, 2004, P NATL ACAD SCI USA, V101, P14479, DOI 10.1073/pnas.0404438101; Chodniewicz D, 2004, EXP CELL RES, V301, P31, DOI 10.1016/j.yexcr.2004.08.006; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; CREWS CM, 1994, J BIOL CHEM, V269, P15411; Edmonds BT, 1996, J CELL SCI, V109, P2705; Enomoto A, 2005, DEV CELL, V9, P389, DOI 10.1016/j.devcel.2005.08.001; Fitzsimmons S, 2003, ONCOGENE, V22, P1737, DOI 10.1038/sj.onc.1206295; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gross SR, 2005, NAT STRUCT MOL BIOL, V12, P772, DOI 10.1038/nsmb979; Heilmeyer LMG, 2003, IUBMB LIFE, V55, P59, DOI 10.1080/1521654031000090896; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; Jimeno J, 2004, ANTI-CANCER DRUG, V15, P321, DOI 10.1097/00001813-200404000-00003; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; KNUDSEN SM, 1993, EUR J BIOCHEM, V215, P549, DOI 10.1111/j.1432-1033.1993.tb18064.x; KULKARNI G, 2006, BREAST CANC RES TREA; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Lau J, 2006, MOL CELL BIOCHEM, V286, P17, DOI 10.1007/s11010-005-9006-5; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; LEE S, 1993, J BIOL CHEM, V268, P24453; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Meijer HJG, 2003, ANNU REV PLANT BIOL, V54, P265, DOI 10.1146/annurev.arplant.54.031902.134748; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Munshi R, 2001, GENETICS, V157, P1425; Nathrath MH, 2002, ONCOGENE, V21, P5975, DOI 10.1038/sj.onc.1205764; Overduin M, 2001, Mol Interv, V1, P150; OWEN CH, 1992, J STRUCT BIOL, V109, P248, DOI 10.1016/1047-8477(92)90037-B; PENCIL SD, 1993, BREAST CANCER RES TR, V25, P165, DOI 10.1007/BF00662141; Pendaries C, 2006, EMBO J, V25, P1024, DOI 10.1038/sj.emboj.7601001; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; REINHARD M, 1992, EMBO J, V11, P2063, DOI 10.1002/j.1460-2075.1992.tb05264.x; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rodrigues SP, 2005, MOL CANCER RES, V3, P183; Svitkina TM, 2003, J CELL BIOL, V160, P409, DOI 10.1083/jcb.200210174; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tomlinson VAL, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-113; Tornieri K, 2006, CELL MOTIL CYTOSKEL, V63, P173, DOI 10.1002/cm.20115; Verhagen PCMS, 2002, INT J CANCER, V102, P142, DOI 10.1002/ijc.10677; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002; YANG F, 1990, NATURE, V347, P494, DOI 10.1038/347494a0; Yang L, 2004, CANCER RES, V64, P4394, DOI 10.1158/0008-5472.CAN-04-0343; YANG WN, 1993, J BIOL CHEM, V268, P392; Zhou GL, 2003, MOL CELL BIOL, V23, P8058, DOI 10.1128/MCB.23.22.8058-8069.2003	50	105	110	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3027	3040		10.1038/sj.onc.1210101	http://dx.doi.org/10.1038/sj.onc.1210101			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130842				2022-12-28	WOS:000246395400008
J	Dabbeekeh, JTS; Faitar, SL; Dufresne, CP; Cowell, JK				Dabbeekeh, J. T. S.; Faitar, S. L.; Dufresne, C. P.; Cowell, J. K.			The EVI5 TBC domain provides the GTPase-activating protein motif for RAB11	ONCOGENE			English	Article						EVI5; TBC domain; GAP; RAB 11; GTPase	RECYCLING ENDOSOME; CLEAVAGE FURROW; CYTOKINESIS; FAMILY; RECEPTOR; COMPLEX; BINDS	The human EVI5 gene was originally isolated through its involvement with a constitutional chromosome translocation in a patient with stage 4S neuroblastoma. Recently, it has been shown that EVI5 is a centrosomal protein in interphase cells, which relocalizes to the midbody during late phases of mitosis. Disruption of its function leads to incomplete cell division and the formation of multinucleate cells. The EVI5 protein contains a TBC (TRE2/BUB/CDC16 homology) motif located in the N-terminal region. Proteins containing a TBC domain have been shown in some cases to act as GTPase-activating proteins (GAPs) and function through the interaction with Rab-like small G proteins. Despite the identification of over 50 TBC-containing proteins, and over 70 Rab-like proteins, only three combinations have been shown to have Rab/GAP activity to date. In this study, using linear ion trap mass spectroscopy, we have demonstrated that EVI5 exists in a protein complex with Rab11. Further, using a specific Rab-binding assay, we have shown that EVI5 preferentially interacts with the guanosine triphosphate-bound form of Rab11, and in a GAP activity assay, we have confirmed that EVI5 functions as a GAP for the Rab11 GTPase.	Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Cowell, JK (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet, Elm & Carlton St, Buffalo, NY 14263 USA.	John.Cowell@RoswellPark.org		Cowell, John/0000-0002-2079-5950				Bernards A, 2005, GROWTH FACTORS, V23, P143, DOI 10.1080/08977190500130480; Bottger G, 1996, J BIOL CHEM, V271, P29191, DOI 10.1074/jbc.271.46.29191; Cuif MH, 1999, EMBO J, V18, P1772, DOI 10.1093/emboj/18.7.1772; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Faitar SL, 2006, EXP CELL RES, V312, P2325, DOI 10.1016/j.yexcr.2006.03.032; Faitar SL, 2005, GENOMICS, V86, P594, DOI 10.1016/j.ygeno.2005.06.002; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; Haas AK, 2005, NAT CELL BIOL, V7, P887, DOI 10.1038/ncb1290; Horgan CP, 2004, BIOCHEM BIOPH RES CO, V319, P83, DOI 10.1016/j.bbrc.2004.04.157; Junutula JR, 2004, J BIOL CHEM, V279, P33430, DOI 10.1074/jbc.M404633200; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; Pereira-Leal JB, 2001, J MOL BIOL, V313, P889, DOI 10.1006/jmbi.2001.5072; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Ward ES, 2005, MOL BIOL CELL, V16, P2028, DOI 10.1091/mbc.E04-08-0735; Wilcke M, 2000, J CELL BIOL, V151, P1207, DOI 10.1083/jcb.151.6.1207; Wilson GM, 2005, MOL BIOL CELL, V16, P849, DOI 10.1091/mbc.e04-10-0927; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	20	44	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2804	2808		10.1038/sj.onc.1210081	http://dx.doi.org/10.1038/sj.onc.1210081			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17099728				2022-12-28	WOS:000246210600015
J	Ghaleb, AM; Katz, JP; Kaestner, KH; Du, JX; Yang, VW				Ghaleb, A. M.; Katz, J. P.; Kaestner, K. H.; Du, J. X.; Yang, V. W.			Kruppel-like factor 4 exhibits antiapoptotic activity following gamma-radiation-induced DNA damage	ONCOGENE			English	Article						apoptosis; cell cycle; KLF4; p53; BAX; p21(WAF1/CIP1)	P53 TUMOR-SUPPRESSOR; CELL-CYCLE ARREST; APOPTOSIS; GENE; KLF4; DIFFERENTIATION; IDENTIFICATION; PROLIFERATION; EXPRESSION; PROGRESSION	In response to gamma-radiation- induced DNA damage, organisms either activate cell cycle checkpoint and repair machinery or undergo apoptosis to eliminate damaged cells. Although previous studies indicated that the tumor suppressor p53 is critically involved in mediating both responses, how a cell decides which pathway to take is not well established. The zinc-finger-containing transcription factor, Kruppel-like factor 4 (KLF4), is a crucial mediator for the checkpoint functions of p53 after gamma-irradiation and does so by inhibiting the transition from the G1 to S and G(2) to M phases of the cell cycle. Here, we determined the role of KLF4 in modulating the apoptotic response following c-irradiation. In three independent cell systems including colorectal cancer cells and mouse embryo fibroblasts in which expression of KLF4 could be manipulated, we observed that gamma-irradiated cells underwent apoptosis if KLF4 was absent. In the presence of KLF4, the degree of apoptosis was significantly reduced and cells resorted to checkpoint arrest. The mechanism by which KLF4 accomplished this antiapoptotic effect is by activating expression of the cell cycle arrest gene, p21(WAF1/CIP1), and by inhibiting the ability of p53 to transactivate expression of the proapoptotic gene, BAX. Results of our study illustrate an unexpected antiapoptotic function of KLF4, heretofore considered a tumor suppressor in colorectal cancer, and suggest that KLF4 may be an important determinant of cell fate following gamma-radiation- induced DNA damage.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Univ Penn, Sch Med, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Emory Univ, Sch Med, Winship Canc Inst, Dept Hematol & Oncol, Atlanta, GA 30322 USA	Emory University; University of Pennsylvania; University of Pennsylvania; Emory University	Yang, VW (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 201 Whitehead Res Bldg,615 Michael St, Atlanta, GA 30322 USA.	vyang@emory.edu			NCI NIH HHS [R01 CA084197-07, R01 CA084197-09, R01 CA084197-08, R01 CA084197, CA84197] Funding Source: Medline; NIDDK NIH HHS [R24 DK064399-03, R01 DK052230-11, R01 DK052230, R01 DK052230-09, DK52230, DK64399, R24 DK064399, R24 DK064399-05, R24 DK064399-04, R01 DK052230-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052230, R24DK064399] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brodsky MH, 2004, MOL CELL BIOL, V24, P1219, DOI 10.1128/MCB.24.3.1219-1231.2004; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chan TA, 2000, GENE DEV, V14, P1584; Chen XM, 2001, J BIOL CHEM, V276, P30423, DOI 10.1074/jbc.M101194200; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Katz JP, 2005, GASTROENTEROLOGY, V128, P935, DOI 10.1053/j.gastro.2005.02.022; Katz JP, 2002, DEVELOPMENT, V129, P2619; Lewanski CR, 2001, LANCET ONCOL, V2, P455; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; MIYASHITA T, 1995, CELL, V80, P293; Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780; Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei DY, 2005, CANCER RES, V65, P2746, DOI 10.1158/0008-5472.CAN-04-3619; Yoon HS, 2005, ONCOGENE, V24, P4017, DOI 10.1038/sj.onc.1208576; Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yu J, 2003, CANCER BIOL THER, V2, P694; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zhang WQ, 1998, J BIOL CHEM, V273, P17917, DOI 10.1074/jbc.273.28.17917; Zhao WD, 2004, ONCOGENE, V23, P395, DOI 10.1038/sj.onc.1207067	42	83	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2365	2373		10.1038/sj.onc.1210022	http://dx.doi.org/10.1038/sj.onc.1210022			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016435	Green Accepted			2022-12-28	WOS:000245466000012
J	Chin, SF; Wang, Y; Thorne, NP; Teschendorff, AE; Pinder, SE; Vias, M; Naderi, A; Roberts, I; Barbosa-Morais, NL; Garcia, MJ; Iyer, NG; Kranjac, T; Robertson, JFR; Aparicio, S; Tavare, S; Ellis, I; Brenton, JD; Caldas, C				Chin, S-F; Wang, Y.; Thorne, N. P.; Teschendorff, A. E.; Pinder, S. E.; Vias, M.; Naderi, A.; Roberts, I.; Barbosa-Morais, N. L.; Garcia, M. J.; Iyer, N. G.; Kranjac, T.; Robertson, J. F. R.; Aparicio, S.; Tavare, S.; Ellis, I.; Brenton, J. D.; Caldas, C.			Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers	ONCOGENE			English	Article						breast cancer; array-CGH; amplification; deletion	HISTOLOGICAL GRADE; GENE; MICROARRAY; IDENTIFICATION; CARCINOMAS; PATTERNS; AMPLIFICATION; SUBGROUPS; REVEALS; CGH	We analysed 148 primary breast cancers using BAC-arrays containing 287 clones representing cancer-related gene/loci to obtain genomic molecular portraits. Gains were detected in 136 tumors (91.9%) and losses in 123 tumors (83.1%). Eight tumors (5.4%) did not have any genomic aberrations in the 281 clones analysed. Common (more than 15% of the samples) gains were observed at 8q11-qtel, 1q21-qtel, 17q11-q12 and 11q13, whereas common losses were observed at 16q12-qtel, 11ptel-p15.5, 1p36-ptel, 17p11.2-p12 and 8ptel-p22. Patients with tumors registering either less than 5% (median value) or less than 11% (third quartile) total copy number changes had a better overall survival (log-rank test: P = 0.0417 and P = 0.0375, respectively). Unsupervised hierarchical clustering based on copy number changes identified four clusters. Women with tumors from the cluster with amplification of three regions containing known breast oncogenes (11q13, 17q12 and 20q13) had a worse prognosis. The good prognosis group (Nottingham Prognostic Index (NPI) <= 3.4) tumors had frequent loss of 16q24-qtel. Genes significantly associated with estrogen receptor (ER), Grade and NPI were used to build k-nearest neighbor (KNN) classifiers that predicted ER, Grade and NPI status in the test set with an average misclassification rate of 24.7, 25.7 and 35.7%, respectively. These data raise the prospect of generating a molecular taxonomy of breast cancer based on copy number pro. ling using tumor DNA, which may be more generally applicable than expression microarray analysis.	Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Cambridge CB2 2XZ, Cambs, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Hutchison MRC, Res Ctr, Canc Cell Unit, Cambridge, England; Inst Mol Med, Lisbon, Portugal; Univ Nottingham, Nottingham NG7 2RD, England	University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Universidade de Lisboa; University of Nottingham	Caldas, C (corresponding author), Univ Cambridge, Hutchison MRC Res Ctr, Dept Oncol, Canc Genom Program, Hill Rd, Cambridge CB2 2XZ, Cambs, England.	cc234@cam.ac.uk	Caldas, Carlos/A-7543-2008; García, María J/G-1361-2016; Wang, Yanzhong/GRY-3114-2022; Barbosa-Morais, Nuno L/I-2743-2013; Brenton, James D/B-3174-2008; Caldas, Carlos/U-7250-2019	García, María J/0000-0002-2236-9912; Barbosa-Morais, Nuno L/0000-0002-1215-0538; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Naderi, Ali/0000-0001-7142-7616; Aparicio, Samuel/0000-0002-0487-9599; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474; Wang, Yanzhong/0000-0002-0768-1676; chin, suet-feung/0000-0001-5697-1082				Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Bogliolo M, 2002, MUTAGENESIS, V17, P529, DOI 10.1093/mutage/17.6.529; Callagy G, 2005, J PATHOL, V205, P388, DOI 10.1002/path.1694; Chin SF, 2001, BRIT J CANCER, V84, P193, DOI 10.1054/bjoc.2000.1577; Cingoz S, 2003, CANCER GENET CYTOGEN, V145, P108, DOI 10.1016/S0165-4608(03)00094-3; Daigo Y, 2001, AM J PATHOL, V158, P1623, DOI 10.1016/S0002-9440(10)64118-1; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Forozan F, 1997, TRENDS GENET, V13, P405, DOI 10.1016/S0168-9525(97)01244-4; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; GILCHRIST KW, 1985, BREAST CANCER RES TR, V5, P3, DOI 10.1007/BF01807642; Glinsky GV, 2004, CLIN CANCER RES, V10, P2272, DOI 10.1158/1078-0432.CCR-03-0522; Gunther K, 2001, J PATHOL, V193, P40, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH745>3.0.CO;2-N; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771; James LA, 1997, ONCOGENE, V14, P1059, DOI 10.1038/sj.onc.1200923; Jones C, 2004, CLIN CANCER RES, V10, P5988, DOI 10.1158/1078-0432.CCR-03-0731; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Korsching E, 2004, BRIT J CANCER, V90, P1422, DOI 10.1038/sj.bjc.6601658; Landi MT, 2005, J NATL CANCER I, V97, P998, DOI 10.1093/jnci/dji176; Loo LWM, 2004, CANCER RES, V64, P8541, DOI 10.1158/0008-5472.CAN-04-1992; Maass N, 2002, CANCER LETT, V185, P219, DOI 10.1016/S0304-3835(02)00286-0; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356; Nessling M, 2005, CANCER RES, V65, P439; Nupponen NN, 2000, GENE CHROMOSOME CANC, V28, P203; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; PIPER J, 2002, P 3 EUR QUANT MOL CY, P109; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rennstam K, 2003, CANCER RES, V63, P8861; Reyal F, 2005, CANCER RES, V65, P1376, DOI 10.1158/0008-5472.CAN-04-2706; Roylance R, 1999, CANCER RES, V59, P1433; Smyth Gordon K, 2003, Methods Mol Biol, V224, P111; Soares R, 2004, MOL ENDOCRINOL, V18, P2333, DOI 10.1210/me.2003-0362; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stange DE, 2006, CLIN CANCER RES, V12, P345, DOI 10.1158/1078-0432.CCR-05-1633; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tirkkonen M, 1998, GENE CHROMOSOME CANC, V21, P177, DOI 10.1002/(SICI)1098-2264(199803)21:3<177::AID-GCC1>3.3.CO;2-C; Tsarouha H, 1999, CANCER GENET CYTOGEN, V113, P156, DOI 10.1016/S0165-4608(99)00016-3; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang DY, 2004, MOL ENDOCRINOL, V18, P402, DOI 10.1210/me.2003-0202; WENGER CR, 1993, BREAST CANCER RES TR, V28, P9, DOI 10.1007/BF00666351; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069	44	83	88	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1959	1970		10.1038/sj.onc.1209985	http://dx.doi.org/10.1038/sj.onc.1209985			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001317				2022-12-28	WOS:000245117700014
J	Rother, K; Kirschner, R; Sanger, K; Bohlig, L; Mossner, J; Engeland, K				Rother, K.; Kirschner, R.; Saenger, K.; Boehlig, L.; Moessner, J.; Engeland, K.			p53 downregulates expression of the G(1)/S cell cycle phosphatase Cdc25A	ONCOGENE			English	Article						p53; Cdc25A; G(1) to S transition; repression; tumor suppressor; transcription	SUPPRESSOR PROTEIN P53; P63; HOMOLOG; TRANSCRIPTION; ACTIVATION; PHOSPHORYLATION; P73; IDENTIFICATION; REQUIREMENT; INHIBITION	Overexpression of Cdc25A phosphatase is often observed in cancer and results in poor prognosis. Cdc25A mainly dephosphorylates and thereby activates Cyclin-dependent kinase 2 and thus induces progression in the cell cycle from G(1) to S phase. Here, we demonstrate that the tumor suppressor p53 downregulates expression from the Cdc25A gene. In a p53-inducible cell system, Cdc25A expression on the mRNA and protein level is downregulated upon p53 expression. Promoter-reporter assays show that this regulation is dependent on the Cdc25A promoter. Mutant p53 fails to reduce Cdc25A transcription. In contrast to p53, neither p63 nor p73 can repress Cdc25A transcription. The Cdc25A promoter displays no p53 binding site, and p53 does not bind directly to the promoter DNA as shown by chromatin immunoprecipitation assays. Previously, the contribution of p53 to G1/S arrest has been mostly linked to activating the expression of the Cdk inhibitor p21(WAF1/CIP1). By downregulating Cdc25A expression, p53 may impair transition from G1 to S phase independently of p21(WAF1/CIP1). Therefore, the data suggest that, as long as p53 is intact, Cdc25A transcriptional downregulation might play a role in cancer prevention.	Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, D-04103 Leipzig, Germany; Univ Leipzig, IZKF, Max Burger Forschungszentrum, D-7010 Leipzig, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Leipzig University	Engeland, K (corresponding author), Univ Leipzig, Med Klin & Poliklin 2, Max Burger Forschungszentrum, Johannisallee, D-04103 Leipzig, Germany.	engeland@medizin.uni-leipzig.de	Engeland, Kurt/AAW-9965-2020; Rother, Karen/GQI-3786-2022	Engeland, Kurt/0000-0003-3525-0440; Rother, Karen/0000-0002-0074-7329				Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Broggini M, 2000, ANTICANCER RES, V20, P4835; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Katoh I, 2000, ONCOGENE, V19, P3126, DOI 10.1038/sj.onc.1203644; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lammer C, 1998, J CELL SCI, V111, P2445; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Moll UM, 2004, MOL CANCER RES, V2, P371; NAGATA A, 1991, NEW BIOL, V3, P959; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; SADHU K, 1990, P NATL ACAD SCI USA, V87, P5139, DOI 10.1073/pnas.87.13.5139; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; STRAUSFELD U, 1994, J BIOL CHEM, V269, P5989; Tschop K, 2006, FEBS J, V273, P1681, DOI 10.1111/j.1742-4658.2006.05184.x; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Wasner M, 2003, GENE, V312, P225, DOI 10.1016/S0378-1119(03)00618-8; Wasner M, 2003, FEBS LETT, V536, P66, DOI 10.1016/S0014-5793(03)00028-0; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhu JH, 1998, CANCER RES, V58, P5061	45	49	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1949	1953		10.1038/sj.onc.1209989	http://dx.doi.org/10.1038/sj.onc.1209989			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001315				2022-12-28	WOS:000245117700012
J	Saigusa, K; Imoto, I; Tanikawa, C; Aoyagi, M; Ohno, K; Nakamura, Y; Inazawa, J				Saigusa, K.; Imoto, I.; Tanikawa, C.; Aoyagi, M.; Ohno, K.; Nakamura, Y.; Inazawa, J.			RGC32, a novel p53-inducible gene, is located on centrosomes during mitosis and results in G2/M arrest	ONCOGENE			English	Article						RGC32; p53; Plk1; glioma; array-CGH	COMPARATIVE GENOMIC HYBRIDIZATION; POLO-LIKE KINASES; MULTIPLE-MYELOMA; CHROMOSOME 13Q; CANCER-CELLS; TUMOR; PLK1; P53; AMPLIFICATION; GLIOBLASTOMAS	To identify target genes for the hemizygous deletions of chromosome 13 that are recurrently observed in malignant gliomas, we performed genome-wide DNA copy-number analysis using array-based comparative genomic hybridization and gene expression analysis using an oligonucleotide-array. The response gene to complement 32 (RGC32) at 13q14.11 was identified as a deletion target, and its expression was frequently silenced in glioma cell lines compared with normal brain. Levels of RGC32 mRNA tended to decrease toward higher grades of primary astrocytomas, especially in tumors with mutations of p53. Expression of RGC32 mRNA was dramatically increased by exogenous p53 in a p53-mutant glioma cell line, and also by endogenous p53 in response to DNA damage in p53(+/+) colon-cancer cells, but not in isogenic p53(-/-) cells. Chromatin immunoprecipitation and reporter assays demonstrated binding of endogenous p53 protein to the promoter region of the RGC32 gene, implying p53-dependent transcriptional activity. Transiently and stably overexpressed RGC32 suppressed the growth of glioma cells, probably owing to induction of G2/M arrest. Immunocytochemical analysis revealed a concentration of RGC32 protein at the centrosome during mitosis. RGC32 formed a protein complex with polo-like kinase 1 and was phosphorylated in vitro. These observations implied a novel mechanism by which p53 might negatively regulate cell-cycle progression by way of this newly identified transcriptional target. Our results provide the first evidence that RGC32 might be a possible tumor-suppressor for glioma, that it is directly induced by p53, and that it mediates the arrest of mitotic progression.	Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch, Dept Neurosurg, Tokyo 1138510, Japan; Japan Sci & Technol Corp, JST, CREST, Tokyo, Japan; Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1138510, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Tokyo, Japan; Tokyo Med & Dent Univ, Century Ctr Excellence Program Mol Destruct & Rec, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); University of Tokyo; Tokyo Medical & Dental University (TMDU)	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Imoto, Issei/AAD-5799-2020	Tanikawa, Chizu/0000-0003-4759-4793				Badea T, 2002, J BIOL CHEM, V277, P502, DOI 10.1074/jbc.M109354200; Badea TC, 1998, J BIOL CHEM, V273, P26977, DOI 10.1074/jbc.273.41.26977; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Burns KL, 1998, J NEUROPATH EXP NEUR, V57, P122, DOI 10.1097/00005072-199802000-00003; Dietzmann K, 2001, J NEURO-ONCOL, V53, P1, DOI 10.1023/A:1011808200978; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elez R, 2000, BIOCHEM BIOPH RES CO, V269, P352, DOI 10.1006/bbrc.2000.2291; Gumireddy K, 2005, CANCER CELL, V7, P275, DOI 10.1016/j.ccr.2005.02.009; Holland EC, 2001, NAT REV GENET, V2, P120, DOI 10.1038/35052535; Imoto I, 2003, CANCER RES, V63, P5691; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inda MD, 2003, MOL CARCINOGEN, V36, P6, DOI 10.1002/mc.10085; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; Jongsma APM, 2002, J CLIN PATHOL-MOL PA, V55, P305, DOI 10.1136/mp.55.5.305; Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kunwar S, 2001, CANCER RES, V61, P7683; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Liu XQ, 2003, P NATL ACAD SCI USA, V100, P5789, DOI 10.1073/pnas.1031523100; Lu W, 2006, PROSTATE, V66, P405, DOI 10.1002/pros.20363; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Marumoto T, 2002, GENES CELLS, V7, P1173, DOI 10.1046/j.1365-2443.2002.00592.x; Misawa A, 2005, CANCER RES, V65, P10233, DOI 10.1158/0008-5472.CAN-05-1073; MIYASHITA T, 1995, CELL, V80, P293; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nakamura M, 2001, CARCINOGENESIS, V22, P1715, DOI 10.1093/carcin/22.10.1715; Nishizaki T, 1998, GENE CHROMOSOME CANC, V21, P340, DOI 10.1002/(SICI)1098-2264(199804)21:4<340::AID-GCC8>3.0.CO;2-Z; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Okamoto Y, 2004, ACTA NEUROPATHOL, V108, P49, DOI 10.1007/s00401-004-0861-z; Pan HJ, 2005, CANCER RES, V65, P1664, DOI 10.1158/0008-5472.CAN-04-3297; Saigusa K, 2005, CANCER SCI, V96, P676, DOI 10.1111/j.1349-7006.2005.00099.x; SATO T, 1991, CANCER RES, V51, P5794; Shaughnessy J, 2000, BLOOD, V96, P1505, DOI 10.1182/blood.V96.4.1505.h8001505_1505_1511; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	41	59	62	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1110	1121		10.1038/sj.onc.1210148	http://dx.doi.org/10.1038/sj.onc.1210148			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	17146433				2022-12-28	WOS:000244406400002
J	Wang, Z; Wade, P; Mandell, KJ; Akyildiz, A; Parkos, CA; Mrsny, RJ; Nusrat, A				Wang, Z.; Wade, P.; Mandell, K. J.; Akyildiz, A.; Parkos, C. A.; Mrsny, R. J.; Nusrat, A.			Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor Slug	ONCOGENE			English	Article						TJ; occluding; Slug; Raf 1	EPITHELIAL-MESENCHYMAL TRANSITIONS; MEMBRANE-PROTEIN; DOWN-REGULATION; FACTOR SNAIL; TUMOR-CELLS; CANCER; KINASE; BREAST; RAS; DIFFERENTIATION	Although dysregulation of tight junction (TJ) proteins is observed in epithelial malignancy, their participation in epithelial transformation is poorly understood. Recently we demonstrated that expression of oncogenic Raf 1 in Pa4 epithelial cells disrupts TJs and induces an oncogenic phenotype by downregulating expression of the TJ protein, occludin. Here we report the mechanism by which Raf 1 regulates occludin expression. Raf 1 inhibited occludin transcription by repressing a minimal segment of the occludin promoter in concert with upregulation of the transcriptional repressor, Slug without influencing the well-documented transcriptional repressor, Snail. Overexpression of Slug in Pa4 cells recapitulated the effect of Raf 1 on occludin expression, and depletion of Slug by small interfering RNA abrogated the effect of Raf 1 on occludin. Finally, chromatin immunoprecipitation assays and site- directed mutagenesis demonstrated a direct interaction between Slug and an E-box within the minimal Raf 1-responsive segment of the occludin promoter. These findings support a role of Slug in mediating Raf 1-induced transcriptional repression of occludin and subsequent epithelial to mesenchymal transition.	Emory Univ, Dept Pathol, Epithelial Pathobiol Res Unit, Atlanta, GA 30322 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; Unity Pharmaceut, Los Altos Hills, CA USA	Emory University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Nusrat, A (corresponding author), Emory Univ, Sch Med, Dept Pathol & Lab Med, Epithelial Pathobiol Res Unit, 615 Michael St,Room 105E, Atlanta, GA 30322 USA.	anusrat@emory.edu	Nusrat, Asma/B-3887-2009; Parkos, Charles a/B-3896-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059888, R01DK061379] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES101965] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008169] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NIDDK NIH HHS [DK 61379, DK 59888] Funding Source: Medline; NIGMS NIH HHS [T32 GM008169] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1993, J CELL SCI, P159; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULKHOLM IK, 1998, J PATHOL, V185, P262; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Gonzalez-Mariscal L, 2003, PROG BIOPHYS MOL BIO, V81, P1, DOI 10.1016/S0079-6107(02)00037-8; Hoover KB, 1998, AM J PATHOL, V153, P1767, DOI 10.1016/S0002-9440(10)65691-X; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kimura Y, 1997, AM J PATHOL, V151, P45; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; Lan MD, 2004, CARCINOGENESIS, V25, P2385, DOI 10.1093/carcin/bgh248; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Locascio A, 2002, J BIOL CHEM, V277, P38803, DOI 10.1074/jbc.M205358200; Matter K, 2005, CURR OPIN CELL BIOL, V17, P453, DOI 10.1016/j.ceb.2005.08.003; Matter K, 2003, NAT REV MOL CELL BIO, V4, P225, DOI 10.1038/nrm1055; Matter K, 1998, J CELL SCI, V111, P511; McCarthy KM, 1996, J CELL SCI, V109, P2287; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nottage M, 2002, CURR PHARM DESIGN, V8, P2231, DOI 10.2174/1381612023393107; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Ruch RJ, 1998, EXP LUNG RES, V24, P523, DOI 10.3109/01902149809087384; Tobioka H, 2004, VIRCHOWS ARCH, V445, P472, DOI 10.1007/s00428-004-1054-9; Tobioka H, 2004, HUM PATHOL, V35, P159, DOI 10.1016/j.humpath.2003.09.013; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wang ZL, 2005, ONCOGENE, V24, P4412, DOI 10.1038/sj.onc.1208634; Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498	37	58	66	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1222	1230		10.1038/sj.onc.1209902	http://dx.doi.org/10.1038/sj.onc.1209902			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924233				2022-12-28	WOS:000244406400012
J	Vegran, F; Boidot, R; Oudin, C; Defrain, C; Rebucci, M; Lizard-Nacol, S				Vegran, F.; Boidot, R.; Oudin, C.; Defrain, C.; Rebucci, M.; Lizard-Nacol, S.			Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer	ONCOGENE			English	Article						survivin expression; alternative splicing; p53 status; breast cancer	ANTI-APOPTOSIS GENE; WILD-TYPE P53; TRANSCRIPTIONAL REPRESSION; SURVIVIN-DELTA-EX3; INDUCTION; CELLS; INHIBITOR; MUTATIONS	Survivin, a member of the inhibitory apoptosis protein family, gives rise, by an alternative splicing, to four variants with different functions. Many experimental studies indicate that p53 can regulate the expression of survivin and some of its splice variants. Although both the expression of survivin splice variants and the p53 gene were frequently altered in human cancers, nothing is known about their interactions in in vivo tumour samples. Here, we report that, in 162 breast carcinomas, p53 mutations are significantly associated with an increased expression of survivin and, in particular, its antiapoptotic splice variants (survivin-Delta Ex3 and survivin-3B). The upregulation of these variant expressions is particularly related to p53 mutations occurring in the residues belonging to the tetramerization domain. The loss of heterozygosity in the p53 gene is also associated with an increased expression of the survivin-Delta Ex3 variant. The expression of the proapoptotic variants (survivin-2B and survivin-2 alpha) is not affected by any of these alterations. Our results provide for the first time in vivo evidence that, in human breast cancer, the survivin expression as well as its splicing depends on the p53 status. The results also suggest that the upregulation of antiapoptotic survivin variant expression by the mutant p53 may increase breast cancer cells survival and resistance to therapy.	Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, F-21034 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Georges-Francois Leclerc	Lizard-Nacol, S (corresponding author), Ctr Georges Francois Leclerc, INSERM, Mol Genet Lab, U 517, 1 Rue Prof Marion, F-21034 Dijon, France.	slizard@dijon.fnclcc.fr	VEGRAN, Frédérique/H-4792-2017; VEGRAN, Frederique/O-9986-2018	VEGRAN, Frederique/0000-0002-4377-1441				Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; Badran A, 2004, BIOCHEM BIOPH RES CO, V314, P902, DOI 10.1016/j.bbrc.2003.12.178; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Caldas H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-11; CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Esteve PO, 2005, P NATL ACAD SCI USA, V102, P1000, DOI 10.1073/pnas.0407729102; Franco N, 2003, ARCH SURG-CHICAGO, V138, P291, DOI 10.1001/archsurg.138.3.291; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Mahotka C, 1999, CANCER RES, V59, P6097; Maxwell SA, 1999, APOPTOSIS, V4, P109, DOI 10.1023/A:1009618811038; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Moyret-Lalle C, 2001, CANCER RES, V61, P486; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; NASU S, 2002, ANTICANCER RES, V22, P2613; O'Driscoll L, 2003, CANCER LETT, V201, P225, DOI 10.1016/S0304-3835(03)00518-4; Punga T, 2003, FEBS LETT, V552, P214, DOI 10.1016/S0014-5793(03)00927-X; Ryan B, 2005, BRIT J CANCER, V92, P120, DOI 10.1038/sj.bjc.6602314; Sommer KW, 2003, ONCOGENE, V22, P4266, DOI 10.1038/sj.onc.1206509; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399; Tsuji N, 2004, BREAST CANCER RES TR, V87, P23, DOI 10.1023/B:BREA.0000041575.73262.aa; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vegran F, 2005, INT J ONCOL, V27, P1151; Xu H, 2003, ONCOL RES, V13, P429; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Zhou XL, 1999, CANCER RES, V59, P843; Zhu NX, 2004, ONCOGENE, V23, P7545, DOI 10.1038/sj.onc.1208038	33	59	63	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					290	297		10.1038/sj.onc.1209784	http://dx.doi.org/10.1038/sj.onc.1209784			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16847456	Bronze			2022-12-28	WOS:000243398300013
J	Perkins, ND				Perkins, N. D.			Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway	ONCOGENE			English	Review						NF-kappa B; IKK; I kappa B; phosphorylation; ubiquitination; modification	TUMOR-NECROSIS-FACTOR; REQUIRES TYROSINE PHOSPHORYLATION; FACTOR-ALPHA ACTIVATION; A RECOGNITION SEQUENCE; T-CELL COSTIMULATION; TERMINAL PEST DOMAIN; IKK-BETA; C-REL; PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY	The diverse cellular and biological functions of the nuclear factor kappa B (NF-kappa B) pathway, together with the catastrophic consequences of its aberrant regulation, demand specific and highly regulated control of its activity. As described in this review, regulation of the NF-kappa B pathway is brought about through multiple post-translational modi. cations that control the activity of the core components of NF-kappa B signaling: the I kappa B kinase (IKK) complex, the I kappa B proteins and the NF-kappa B subunits themselves. These regulatory modi. cations, which include phosphorylation, ubiquitination, acetylation, sumoylation and nitrosylation, can vary, depending on the nature of the NF-kappa B-inducing stimulus. Moreover, they frequently have distinct, sometimes antagonistic, functional consequences and the same modi. cation can have different effects depending on the context. Given the important role of NF-kappa B in human health and disease, understanding these pathways will not only provide valuable insights into mechanism and function, but could also lead to new drug targets and the development of diagnostic and prognostic biomarkers for many pathological conditions.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI-WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk			Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032; Abu-Amer Y, 1998, J BIOL CHEM, V273, P29417, DOI 10.1074/jbc.273.45.29417; Amir RE, 2004, ONCOGENE, V23, P2540, DOI 10.1038/sj.onc.1207366; Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Babu GR, 2006, BBA-MOL CELL RES, V1763, P174, DOI 10.1016/j.bbamcr.2005.12.010; Beinke S, 2003, MOL CELL BIOL, V23, P4739, DOI 10.1128/MCB.23.14.4739-4752.2003; Bohuslav J, 2004, J BIOL CHEM, V279, P26115, DOI 10.1074/jbc.M313509200; Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008; Bui NT, 2001, J CELL BIOL, V152, P753, DOI 10.1083/jcb.152.4.753; Burns KA, 2004, CURR BIOL, V14, pR1040, DOI 10.1016/j.cub.2004.11.040; Buss H, 2004, J BIOL CHEM, V279, P55633, DOI 10.1074/jbc.M409825200; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Campbell KJ, 2006, CANCER RES, V66, P929, DOI 10.1158/0008-5472.CAN-05-2234; Carter RS, 2005, J BIOL CHEM, V280, P43272, DOI 10.1074/jbc.M508656200; Carter RS, 2003, J BIOL CHEM, V278, P19642, DOI 10.1074/jbc.M301705200; Chen E, 1998, J BIOL CHEM, V273, P35201, DOI 10.1074/jbc.273.52.35201; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chen ZJ, 2006, CELL DEATH DIFFER, V13, P687, DOI 10.1038/sj.cdd.4401869; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Chu ZL, 1996, MOL CELL BIOL, V16, P5974; Cohen S, 2004, MOL CELL BIOL, V24, P475, DOI 10.1128/MCB.24.1.475-486.2004; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Demarchi F, 2003, J BIOL CHEM, V278, P39583, DOI 10.1074/jbc.M305676200; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Deng WG, 2006, BLOOD, V108, P518, DOI 10.1182/blood-2005-09-3691; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DRUKER BJ, 1994, J BIOL CHEM, V269, P5387; Duran A, 2003, EMBO J, V22, P3910, DOI 10.1093/emboj/cdg370; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Fan CG, 2003, J BIOL CHEM, V278, P2072, DOI 10.1074/jbc.M206718200; Fischer C, 1999, J BIOL CHEM, V274, P24625, DOI 10.1074/jbc.274.35.24625; Fognani C, 2000, ONCOGENE, V19, P2224, DOI 10.1038/sj.onc.1203543; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gapuzan MER, 2003, BIOCHEM BIOPH RES CO, V307, P92, DOI 10.1016/S0006-291X(03)01123-9; Garcia-Pineres AJ, 2004, LIFE SCI, V75, P841, DOI 10.1016/j.lfs.2004.01.024; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Glineur C, 2000, BIOCHEM J, V352, P583, DOI 10.1042/0264-6021:3520583; Guan HC, 2005, J BIOL CHEM, V280, P9957, DOI 10.1074/jbc.M412180200; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Gustin JA, 2006, J BIOL CHEM, V281, P16473, DOI 10.1074/jbc.M507373200; Haller D, 2002, J BIOL CHEM, V277, P38168, DOI 10.1074/jbc.M205737200; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hoberg JE, 2004, MOL CELL, V16, P245, DOI 10.1016/j.molcel.2004.10.010; Hou SH, 2003, J BIOL CHEM, V278, P45994, DOI 10.1074/jbc.M307971200; Hu J, 2005, MOL CANCER RES, V3, P100, DOI 10.1158/1541-7786.MCR-04-0070; Huang QJ, 2004, NAT IMMUNOL, V5, P98, DOI 10.1038/ni1014; Huang TT, 2003, CELL, V115, P565, DOI 10.1016/S0092-8674(03)00895-X; Huang WC, 2003, J BIOL CHEM, V278, P9944, DOI 10.1074/jbc.M208521200; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200; Kang JL, 2003, MOL CELL BIOCHEM, V248, P17, DOI 10.1023/A:1024163630166; Kato T, 2003, MOL CELL, V12, P829, DOI 10.1016/S1097-2765(03)00358-7; Kiernan R, 2003, J BIOL CHEM, V278, P2758, DOI 10.1074/jbc.M209572200; KOONG AC, 1994, CANCER RES, V54, P1425; Krappmann D, 2005, EMBO REP, V6, P321, DOI 10.1038/sj.embor.7400380; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lang V, 2003, MOL CELL BIOL, V23, P402, DOI 10.1128/MCB.23.1.402-413.2003; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee KY, 2005, SCIENCE, V308, P114, DOI 10.1126/science.1107107; Liang CY, 2006, CELL SIGNAL, V18, P1309, DOI 10.1016/j.cellsig.2005.10.011; Liang MC, 2006, BIOCHEM PHARMACOL, V71, P634, DOI 10.1016/j.bcp.2005.11.013; LIANG MC, 2006, IN PRESS CANC LETT; Lin L, 1998, CELL, V92, P819, DOI 10.1016/S0092-8674(00)81409-9; Lin RT, 1996, MOL CELL BIOL, V16, P1401; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Liu JJ, 2002, J IMMUNOL, V169, P581, DOI 10.4049/jimmunol.169.1.581; Mahabeleshwar GH, 2003, J BIOL CHEM, V278, P52598, DOI 10.1074/jbc.M308941200; Maier HJ, 2003, J BIOL CHEM, V278, P39242, DOI 10.1074/jbc.M301521200; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; McKinsey TA, 1997, J BIOL CHEM, V272, P22377, DOI 10.1074/jbc.272.36.22377; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILLER BS, 2006, J BIOL CHEM, V281, P15268; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; Mukhopadhyay A, 2000, J BIOL CHEM, V275, P8549, DOI 10.1074/jbc.275.12.8549; Na HK, 2006, MOL CARCINOGEN, V45, P368, DOI 10.1002/mc.20225; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; NEUMANN M, 1992, ONCOGENE, V7, P2095; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Ozes ON, 1999, NATURE, V401, P82; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park MH, 2005, BIOCHEMISTRY-US, V44, P8326, DOI 10.1021/bi050156h; Park SW, 2005, MOL CELL PROTEOMICS, V4, P300, DOI 10.1074/mcp.M400195-MCP200; Pellegatta F, 2003, AM J CLIN NUTR, V77, P1220, DOI 10.1093/ajcn/77.5.1220; Perkins ND, 2006, CELL DEATH DIFFER, V13, P759, DOI 10.1038/sj.cdd.4401838; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Quivy V, 2004, BIOCHEM PHARMACOL, V68, P1221, DOI 10.1016/j.bcp.2004.05.039; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Romieu-Mourez R, 2002, CANCER RES, V62, P6770; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Schoonbroodt S, 2000, J IMMUNOL, V164, P4292, DOI 10.4049/jimmunol.164.8.4292; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Singh S, 1996, J BIOL CHEM, V271, P31049, DOI 10.1074/jbc.271.49.31049; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takada Y, 2003, J BIOL CHEM, V278, P24233, DOI 10.1074/jbc.M212389200; Tanaka H, 2005, J BIOL CHEM, V280, P40965, DOI 10.1074/jbc.M506235200; Tang ED, 2003, J BIOL CHEM, V278, P37297, DOI 10.1074/jbc.M303389200; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Waterfield M, 2004, MOL CELL BIOL, V24, P6040, DOI 10.1128/MCB.24.13.6040-6048.2004; Weil R, 1997, J BIOL CHEM, V272, P9942; Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yeh PY, 2004, J BIOL CHEM, V279, P26143, DOI 10.1074/jbc.M402362200; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang LP, 2005, CANCER RES, V65, P457; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	141	541	557	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6717	6730		10.1038/sj.onc.1209937	http://dx.doi.org/10.1038/sj.onc.1209937			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072324				2022-12-28	WOS:000241666700004
J	Shimanuki, T; Hara, T; Furuya, T; Imamura, T; Miyazono, K				Shimanuki, T.; Hara, T.; Furuya, T.; Imamura, T.; Miyazono, K.			Modulation of the functional binding sites for TGF-beta on the type II receptor leads to suppression of TGF-beta signaling	ONCOGENE			English	Article						tGF-beta; TGF-beta receptor; homology modeling; antagonist	GROWTH-FACTOR-BETA; DEPENDENT KINASE INHIBITOR; CRYSTAL-STRUCTURE; TRANSFORMING GROWTH-FACTOR-BETA-2; SMAD PROTEINS; ACTIVIN; COMPLEX; SUPERFAMILY; FLAVOPIRIDOL; MEMBRANE	Transforming growth factor-beta (TGF-beta) binds to two different types of serine/threonine kinase receptors termed type II (T beta R-II) and type I (T beta R-I). TGF-beta is unable to bind to T beta R-I in the absence of T beta R-II, and initiates receptor assembly by binding with high affinity to T beta beta R-II. Previous structural analysis of the TGF-beta 3-T beta R-II complex has suggested that two charged amino acid residues, D55 and E142 of T beta R-II, are binding sites of TGF-beta. In the present study, we have shown that mutations of the amino-acid residues, D55 and E142 of T beta R-II, resulted in loss of TGF-beta binding and downstream signaling activity. Moreover, we found that 3,5,7,2',4'-pentahydroxyflavone (Morin) inhibits TGF-beta binding to T beta R-II, and suppresses phosphorylation of Smad2 and expression of a TGF-beta target gene Smad7 induced by TGF-beta. Our findings may thus provide useful information for designing therapeutic agents for various diseases induced by TGF-beta, including advanced cancers.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Tokyo, Japan; JFCR, Canc Inst, Koto Ku, Tokyo, Japan; POLA Chem Inst Ltd, Cutaneous Drug Res, Totsuka Ku, Kanagawa, Japan; PharmaDesign Inc, Chuo Ku, Tokyo, Japan	University of Tokyo; University of Tokyo; Japanese Foundation for Cancer Research; Pola Chemical Industries Inc.	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	miyazono-ind@umin.ac.jp						Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103; Bandyopadhyay A, 2006, CANCER RES, V66, P6714, DOI 10.1158/0008-5472.CAN-05-3565; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; BIRT DF, 1990, CHEMOPREVENTION NONN, P221; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DAOPIN S, 1992, SCIENCE, V257, P369, DOI 10.1126/science.1631557; DE AWJ, 1996, P NATL ACAD SCI USA, V93, P2735; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ebisawa T, 1999, J CELL SCI, V112, P3519; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; EWING T, 1998, DOCK VERSION 4 0 REF; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Goumans MJ, 2003, MOL CELL, V12, P817, DOI 10.1016/S1097-2765(03)00386-1; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Harrison CA, 2003, J BIOL CHEM, V278, P21129, DOI 10.1074/jbc.M302015200; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hinck AP, 1996, BIOCHEMISTRY-US, V35, P8517, DOI 10.1021/bi9604946; Hsiang CY, 2005, BIOCHEM PHARMACOL, V69, P1603, DOI 10.1016/j.bcp.2005.03.008; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Kelland LR, 2000, EXPERT OPIN INV DRUG, V9, P2903, DOI 10.1517/13543784.9.12.2903; Kirsch T, 2000, NAT STRUCT BIOL, V7, P492; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Mittl PRE, 1996, PROTEIN SCI, V5, P1261, DOI 10.1002/pro.5560050705; Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365-2443.2002.00599.x; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oeda E, 1998, J BIOL CHEM, V273, P9353, DOI 10.1074/jbc.273.16.9353; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Qian SW, 1996, J BIOL CHEM, V271, P30656, DOI 10.1074/jbc.271.48.30656; Qian SW, 1999, GROWTH FACTORS, V17, P63, DOI 10.3109/08977199909001063; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Schwartz GK, 2001, J CLIN ONCOL, V19, P1985, DOI 10.1200/JCO.2001.19.7.1985; Senderowicz AM, 1999, INVEST NEW DRUG, V17, P313, DOI 10.1023/A:1006353008903; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; Tojo M, 2005, CANCER SCI, V96, P791, DOI 10.1111/j.1349-7006.2005.00103.x; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	39	6	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 17	2007	26	23					3311	3320		10.1038/sj.onc.1210123	http://dx.doi.org/10.1038/sj.onc.1210123			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146441				2022-12-28	WOS:000246579600001
J	Liu, W; Wei, W; Winer, D; Bamberger, AM; Bamberger, C; Wagener, C; Ezzat, S; Asa, SL				Liu, W.; Wei, W.; Winer, D.; Bamberger, A.-M.; Bamberger, C.; Wagener, C.; Ezzat, S.; Asa, S. L.			CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases	ONCOGENE			English	Article						CEACAM1; thyroid cancer; cell adhesion; tumor invasion; metastases	CELL-ADHESION MOLECULE; CARCINOEMBRYONIC ANTIGEN FAMILY; BILIARY GLYCOPROTEIN GENE; C-CAM; TUMOR-SUPPRESSOR; PROSTATE-CANCER; CD66A BGP; CYTOPLASMIC DOMAIN; ENHANCES INVASION; EPITHELIAL-CELLS	CEACAM1, also known as biliary glycoprotein (BGP), CD66a, pp120 and C-CAM1, is a member of the CEA immunoglobulin superfamily. CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma. However, CEACAM1 is overexpressed in some tumors such as non-small cell lung cancer. To clarify the mechanism of action of this cell adhesion molecule, we studied thyroid carcinoma that has a spectrum of morphologies and variable behavior allowing separation of proliferation from invasion and metastasis. CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior. Introduction of CEACAM1 into endogenously deficient WRO cells resulted in reduced cell cycle progression associated with p21 upregulation and diminished Rb phosphorylation. Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness. Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice. CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors. In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size. These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential. Our data highlight a complex repertoire of actions providing a putative mechanism underlying the spectrum of biologic behaviors associated with thyroid cancer.	Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; Toronto Med Labs, Toronto, ON, Canada; Ontario Canc Inst, Toronto, ON M4X 1K9, Canada; Univ Toronto, Toronto, ON, Canada; Univ Hosp Hamburg Eppendorf, Dept Pathol, Hamburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Internal Med, Hamburg, Germany; Univ Hosp Hamburg Eppendorf, Dept Clin Chem, Toronto, ON, Canada; Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Asa, SL (corresponding author), Univ Toronto, Dept Pathol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	sylvia.asa@uhn.on.ca		Asa, Sylvia/0000-0001-8418-5054				Bamberger AM, 2006, AM J PATHOL, V168, P141, DOI 10.2353/ajpath.2006.050167; Bamberger AM, 2000, AM J PATHOL, V156, P1165, DOI 10.1016/S0002-9440(10)64985-1; Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; Beauchemin N, 1999, EXP CELL RES, V252, P243; Briese J, 2005, J CLIN ENDOCR METAB, V90, P5407, DOI 10.1210/jc.2004-2434; BRUMMER J, 1995, ONCOGENE, V11, P1649; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; DeLellis R, 2004, PATHOLOGY GENETICS T; Ebrahimnejad A, 2004, AM J PATHOL, V165, P1781, DOI 10.1016/S0002-9440(10)63433-5; Estrera VT, 1999, BIOCHEM BIOPH RES CO, V263, P797, DOI 10.1006/bbrc.1999.1443; Estrera VT, 2001, J BIOL CHEM, V276, P15547, DOI 10.1074/jbc.M008156200; Ezzat S, 1996, THYROID, V6, P409, DOI 10.1089/thy.1996.6.409; FAGIN JA, 1992, J CLIN ENDOCR METAB, V75, P1398, DOI 10.1210/jc.75.6.1398; Fournes B, 2001, ONCOGENE, V20, P219, DOI 10.1038/sj.onc.1204058; Garcia-Rostan G, 2001, AM J PATHOL, V158, P987, DOI 10.1016/S0002-9440(10)64045-X; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; HSIEH JT, 1995, CANCER RES, V55, P190; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Jhiang SM, 1996, ENDOCRINOLOGY, V137, P375, DOI 10.1210/en.137.1.375; Khoo MLC, 2002, ARCH OTOLARYNGOL, V128, P253, DOI 10.1001/archotol.128.3.253; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; Kinugasa T, 1998, INT J CANCER, V76, P148, DOI 10.1002/(SICI)1097-0215(19980330)76:1<148::AID-IJC23>3.3.CO;2-J; Kleinerman DI, 1996, CANCER RES, V56, P3431; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Kunath T, 1995, ONCOGENE, V11, P2375; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Liu W, 2005, MOL ENDOCRINOL, V19, P2349, DOI 10.1210/me.2005-0117; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Muenzner P, 2005, J CELL BIOL, V170, P825, DOI 10.1083/jcb.200412151; Muller MM, 2005, BLOOD, V105, P3925, DOI 10.1182/blood-2004-09-3618; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; OIKAWA S, 1992, BIOCHEM BIOPH RES CO, V186, P881, DOI 10.1016/0006-291X(92)90828-9; OLSEN A, 1994, GENOMICS, V23, P659, DOI 10.1006/geno.1994.1555; Piersanti M, 2003, ENDOCR PATHOL, V14, P183, DOI 10.1385/EP:14:3:183; PIGNATELLI M, 1994, HUM PATHOL, V25, P849, DOI 10.1016/0046-8177(94)90002-7; Plunkett TA, 2002, J CLIN ONCOL, V20, P4273, DOI 10.1200/JCO.2002.20.21.4273; Powell DJ, 1998, CANCER RES, V58, P5523; Prall F, 1996, J HISTOCHEM CYTOCHEM, V44, P35, DOI 10.1177/44.1.8543780; Riethdorf L, 1997, J HISTOCHEM CYTOCHEM, V45, P957, DOI 10.1177/002215549704500705; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Singer BB, 2000, CANCER RES, V60, P1236; STOFFEL A, 1993, J IMMUNOL, V150, P4978; Sugg SL, 1998, J CLIN ENDOCR METAB, V83, P4116, DOI 10.1210/jc.83.11.4116; Takanishi K, 1997, ONCOLOGY, V54, P231; Thies A, 2002, J CLIN ONCOL, V20, P2530, DOI 10.1200/JCO.2002.05.033; Wang L, 2000, CLIN CANCER RES, V6, P2988	50	53	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2747	2758		10.1038/sj.onc.1210077	http://dx.doi.org/10.1038/sj.onc.1210077			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17057731				2022-12-28	WOS:000246210600009
J	Tuupanen, S; Karhu, A; Jarvinen, H; Mecklin, JP; Launonen, V; Aaltonen, LA				Tuupanen, S.; Karhu, A.; Jarvinen, H.; Mecklin, J. P.; Launonen, V.; Aaltonen, L. A.			No evidence for dual role of loss of heterozygosity in hereditary non-polyposis colorectal cancer	ONCOGENE			English	Article						allele; LOH; HNPCC; MMR; tumor	MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; HMLH1 PROMOTER; COLON-CANCER; SOMATIC MUTATIONS; CELL-LINES; TUMORS; GERMLINE; GENE; HYPERMETHYLATION	Hereditary non-polyposis colorectal cancer (HNPCC) is caused by germline mutations in mismatch repair (MMR) genes, mostly MLH1 and MSH2. Somatic inactivation of the wild-type allele of the respective MMR gene is required for tumor development. Unexpectedly, a recent study utilizing DNA from paraffin-embedded tissue material detected frequent loss of the mutant MMR gene allele in HNPCC tumors. Dual role for loss of heterozygosity (LOH) was proposed. If somatic loss of the wild-type MMR gene allele had occurred through point mutation or promoter hypermethylation, frequent somatic deletions at the region of the MMR gene locus, perhaps targeting other relevant cancer genes, could quite commonly lead to loss of the mutant allele. To test this hypothesis, we studied a population-based series of 25 fresh-frozen HNPCC tumors with a germline mutation in MLH1 or MSH2 for LOH. Fourteen of the 25 tumors (56%) showed LOH at the respective locus, and all 14 losses targeted the wild-type allele (P=0.00006). These results strongly support the traditional two-hit model of HNPCC gene inactivation.	Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Surg 2, Helsinki, Finland; Cent Hosp Jyvaskyla, Dept Surg, Jyvaskyla, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Central Finland Central Hospital	Aaltonen, LA (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, Room B520a,POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	lauri.aaltonen@helsinki.fi	Mecklin, Jukka-Pekka/AAC-9650-2019; Mecklin, Jukka-Pekka/AAB-5378-2020; Aaltonen, Lauri/A-5375-2010	Mecklin, Jukka-Pekka/0000-0003-4895-2249; Aaltonen, Lauri/0000-0001-6839-4286; Karhu, Auli/0000-0002-7927-0796				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Aaltonen LA, 1998, NEW ENGL J MED, V338, P1481, DOI 10.1056/NEJM199805213382101; BENEZRA J, 1991, J HISTOCHEM CYTOCHEM, V39, P351, DOI 10.1177/39.3.1704393; Canzian F, 1996, CANCER RES, V56, P3331; Chadwick RB, 2001, J MED GENET, V38, P461, DOI 10.1136/jmg.38.7.461; Cunningham JM, 1998, CANCER RES, V58, P3455; Cunningham JM, 2001, AM J HUM GENET, V69, P780, DOI 10.1086/323658; de Abajo AS, 2006, ONCOGENE, V25, P2124, DOI 10.1038/sj.onc.1209233; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Kane MF, 1997, CANCER RES, V57, P808; Konishi M, 1996, GASTROENTEROLOGY, V111, P307, DOI 10.1053/gast.1996.v111.pm8690195; Kuismanen SA, 2000, AM J PATHOL, V156, P1773, DOI 10.1016/S0002-9440(10)65048-1; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lu SL, 1996, JPN J CANCER RES, V87, P279, DOI 10.1111/j.1349-7006.1996.tb00218.x; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Potocnik U, 2001, CANCER GENET CYTOGEN, V126, P85, DOI 10.1016/S0165-4608(00)00399-X; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Tannergard P, 1997, HUM GENET, V101, P51, DOI 10.1007/s004390050585; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Williams C, 1999, AM J PATHOL, V155, P1467, DOI 10.1016/S0002-9440(10)65461-2; Yuen ST, 2002, ONCOGENE, V21, P7585, DOI 10.1038/sj.onc.1205968	28	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2513	2517		10.1038/sj.onc.1210038	http://dx.doi.org/10.1038/sj.onc.1210038			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043646				2022-12-28	WOS:000245831000012
J	Imamichi, Y; Konig, A; Gress, T; Menke, A				Imamichi, Y.; Koenig, A.; Gress, T.; Menke, A.			Collagen type I-induced Smad-interacting protein 1 expression downregulates E-cadherin in pancreatic cancer	ONCOGENE			English	Article						pancreatic cancer; Smad-interacting protein 1 (SIP1); extracellular matrix (ECM); E-cadherin	TRANSCRIPTION FACTOR SNAIL; GENE-EXPRESSION; SIP1; BINDING; INVASION; FAMILY; TARGET; CELLS; CARCINOMAS; REPRESSION	Pancreatic cancer is a devastating disease with poor prognosis. Production of large quantities of extracellular matrix and early metastasis are characteristics of this disease. One important step in the development of various cancers is the loss of E-cadherin gene expression or inactivation of E-cadherin mediated cell-cell adhesion. It has been shown that collagen type I promotes down-regulation of E-cadherin expression, which correlates with enhanced cell migration and invasiveness. In this context, we elucidated the role of Smad-interacting protein 1 (SIP1), which has been discussed as a negative regulator of E-cadherin gene expression. We demonstrate that SIP1 upregulation shows an inverse relationship with E-cadherin in advanced pancreatic tumour stages. In Panc-1 cells, SIP1 expression can be induced by exposure to collagen type I in a src-dependent manner. In addition, overexpression of SIP1 reduces E-cadherin mRNA and protein levels. Taken together, these results suggest that SIP1 is involved in the progression of pancreatic cancer and plays a role in mediating signal transduction from collagen type I to downregulate E-cadherin expression.	Univ Hosp Ulm, Dept Internal Med 1, D-89081 Ulm, Germany; Univ Hosp Giessen & Marburg, Dept Gastroenterol Endocrinol & Metab, Marburg, Germany	Ulm University; University Hospital of Giessen & Marburg	Imamichi, Y (corresponding author), Univ Hosp Ulm, Dept Internal Med 1, Robert Koch Str 8, D-89081 Ulm, Germany.	yukiko.imamichi@uni-ulm.de		Gress, Thomas/0000-0002-9333-5461				Avizienyte E, 2005, CURR OPIN CELL BIOL, V17, P542, DOI 10.1016/j.ceb.2005.08.007; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Erickson AC, 2003, EXPERT OPIN THER TAR, V7, P71, DOI 10.1517/14728222.7.1.71; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Hajra KM, 2002, CANCER RES, V62, P1613; Heidenblut AM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh130; HENNIG G, 1995, ONCOGENE, V11, P475; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Maeda G, 2005, INT J ONCOL, V27, P1535; Menke A, 2001, CANCER RES, V61, P3508; Mikkers H, 2002, NAT GENET, V32, P459, DOI 10.1038/ng1102-459b; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; MOLLENHAUER J, 1987, Pancreas, V2, P14, DOI 10.1097/00006676-198701000-00003; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Seidel B, 2004, ONCOGENE, V23, P5532, DOI 10.1038/sj.onc.1207718; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; van Grunsven LA, 2003, J BIOL CHEM, V278, P26135, DOI 10.1074/jbc.M300597200; Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416	30	94	98	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2381	2385		10.1038/sj.onc.1210012	http://dx.doi.org/10.1038/sj.onc.1210012			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043655				2022-12-28	WOS:000245466000014
J	Bindra, RS; Glazer, PM				Bindra, R. S.; Glazer, P. M.			Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia	ONCOGENE			English	Article						Rad51; homologous recombination; hypoxia; E2F4/p130	CELL-CYCLE ARREST; DNA-REPAIR; DIFFERENTIAL REGULATION; POCKET PROTEINS; DOWN-REGULATION; STRESS; INSTABILITY; P107; DEPHOSPHORYLATION; E2F	We and others have shown that the dysregulation of DNA repair pathways can contribute to the phenomenon of hypoxia-induced genetic instability within the tumor microenvironment. Several studies have revealed that the recombinational repair genes, RAD51 and BRCA1, and the DNA mismatch repair genes, MLH1 and MSH2, are decreased in expression in response to hypoxic stress, prompting interest in elucidating the mechanistic basis for these responses. Here we report that the downregulation of RAD51 by hypoxia is specically mediated by repressive E2F4/p130 complexes that bind to a single E2F site in the proximal promoter of the gene. Intriguingly, this E2F site is conserved in the promoter of the BRCA1 gene, which is also regulated by a similar mechanism in hypoxia. Mechanistically, we have found that hypoxia induces substantial p130 dephosphorylation and nuclear accumulation, leading to the formation of E2F4/p130 complexes and increased occupancy of E2F4 and p130 at the RAD51 and BRCA1 promoters. These findings reveal a coordinated transcriptional program mediated by the formation of repressive E2F4/p130 complexes that represents an integral response to hypoxic stress. In addition, this co-regulation of key factors within the homology-dependent DNA repair pathway provides a further basis for understanding genetic instability in tumors and may guide the design of new therapeutic strategies for cancer.	Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Expt Radiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Geriatr, New Haven, CT 06520 USA	Yale University; Yale University; Yale University	Glazer, PM (corresponding author), Yale Univ, Sch Med, Dept Therapeut Radiol, POB 208040, New Haven, CT 06520 USA.	peter.glazer@yale.edu	Glazer, Peter/S-7651-2019	Bindra, Randip/0000-0003-1552-9057; Glazer, Peter/0000-0003-4525-5560	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R29ES005775, R01ES005775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007205] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05775] Funding Source: Medline; NIGMS NIH HHS [GM07205] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2004, MOL CELL BIOL, V24, P8504, DOI 10.1128/MCB.24.19.8504-8518.2004; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Chowdhury D, 2005, MOL CELL, V20, P801, DOI 10.1016/j.molcel.2005.10.003; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Coquelle A, 1998, MOL CELL, V2, P259, DOI 10.1016/S1097-2765(00)80137-9; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Garriga J, 2004, CELL CYCLE, V3, P1320, DOI 10.4161/cc.3.10.1183; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Iwanaga R, 2004, ONCOGENE, V23, P8581, DOI 10.1038/sj.onc.1207976; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Li CY, 2001, CANCER RES, V61, P428; Lin WC, 2001, GENE DEV, V15, P1833; Meng AX, 2005, RADIOTHER ONCOL, V76, P168, DOI 10.1016/j.radonc.2005.06.025; Mihaylova VT, 2003, MOL CELL BIOL, V23, P3265, DOI 10.1128/MCB.23.9.3265-3273.2003; North S, 2005, CANCER LETT, V218, P1, DOI 10.1016/j.canlet.2004.08.007; PAQUETTE B, 1994, CANCER RES, V54, P3173; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Reynolds TY, 1996, CANCER RES, V56, P5754; Roth ME, 2004, NAT BIOTECHNOL, V22, P418, DOI 10.1038/nbt948; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Stevceva L, 2004, CURR HIV RES, V2, P1, DOI 10.2174/1570162043485004; Stevens C, 2003, CELL CYCLE, V2, P435, DOI 10.4161/cc.2.5.462; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Thompson LH, 2002, MUTAT RES-FUND MOL M, V509, P49, DOI 10.1016/S0027-5107(02)00224-5; Voorhoeve PM, 1999, ONCOGENE, V18, P679, DOI 10.1038/sj.onc.1202289; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533; Yuan JL, 2000, CANCER RES, V60, P4372; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	40	121	122	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2048	2057		10.1038/sj.onc.1210001	http://dx.doi.org/10.1038/sj.onc.1210001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001309				2022-12-28	WOS:000245313400007
J	Naderi, A; Teschendorff, AE; Barbosa-Morais, NI; Pinder, SE; Green, AR; Powe, DG; Robertson, JFR; Aparicio, S; Ellis, IO; Brenton, JD; Caldas, C				Naderi, A.; Teschendorff, A. E.; Barbosa-Morais, N. I.; Pinder, S. E.; Green, A. R.; Powe, D. G.; Robertson, J. F. R.; Aparicio, S.; Ellis, I. O.; Brenton, J. D.; Caldas, C.			A gene-expression signature to predict survival in breast cancer across independent data sets	ONCOGENE			English	Article						breast cancer; microarray; prognosis; gene-signature; survival; Cox-clustering	MICROARRAY PLATFORMS; CLASSIFICATION; VALIDATION; PROGNOSIS; ADJUVANT	Prognostic signatures in breast cancer derived from microarray expression pro. ling have been reported by two independent groups. These signatures, however, have not been validated in external studies, making clinical application problematic. We performed microarray expression pro. ling of 135 early-stage tumors, from a cohort representative of the demographics of breast cancer. Using a recently proposed semisupervised method, we identified a prognostic signature of 70 genes that significantly correlated with survival ( hazard ratio (HR): 5.97, 95% confidence interval: 3.0-11.9, P = 2.7e-07). In multivariate analysis, the signature performed independently of other standard prognostic classifiers such as the Nottingham Prognostic Index and the 'Adjuvant!' software. Using two different prognostic classification schemes and measures, nearest centroid ( HR) and risk ordering (D-index), the 70-gene classifier was also found to be prognostic in two independent external data sets. Overall, the 70- gene set was prognostic in our study and the two external studies which collectively include 715 patients. In contrast, we found that the two previously described prognostic gene sets performed less optimally in external validation. Finally, a common prognostic module of 29 genes that associated with survival in both our cohort and the two external data sets was identified. In spite of these results, further studies that pro. le larger cohorts using a single microarray platform, will be needed before prospective clinical use of molecular classifiers can be contemplated.	Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Cambridge CB2 2XZ, England; Univ Cambridge, Dept Pathol, MRC, Hutchison Res Ctr, Cambridge CB2 2XZ, England; Univ Nottingham, Nottingham NG7 2RD, England; Nottingham City Hosp NHS Trust, Dept Mol Med Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Med & Surg Sci, Nottingham, England; Nottingham City Hosp NHS Trust, Dept Histopathol, Nottingham, England; Univ Lisbon, Fac Med, Inst Mol Med, P-1699 Lisbon, Portugal	University of Cambridge; University of Cambridge; University of Nottingham; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Nottingham University Hospital NHS Trust; Nottingham City Hospital; Universidade de Lisboa	Brenton, JD (corresponding author), Univ Cambridge, Canc Genom Program, Dept Oncol, Hutchison Res Ctr,MRC, Hills Rd, Cambridge CB2 2XZ, England.	jdb1003@cam.ac.uk; cc234@cam.ac.uk	Barbosa-Morais, Nuno L/I-2743-2013; Caldas, Carlos/A-7543-2008; Brenton, James D/B-3174-2008; Green, Andrew/AAF-1991-2020; Caldas, Carlos/U-7250-2019	Barbosa-Morais, Nuno L/0000-0002-1215-0538; Brenton, James D/0000-0002-5738-6683; Caldas, Carlos/0000-0003-3547-1489; Naderi, Ali/0000-0001-7142-7616; Green, Andrew/0000-0002-0488-5913; Aparicio, Samuel/0000-0002-0487-9599; /0000-0003-4167-8910; Ellis, Ian/0000-0001-5292-8474				Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108; Brenton JD, 2005, J CLIN ONCOL, V23, P7350, DOI 10.1200/JCO.2005.03.3845; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Cox D. R., 1984, ANAL SURVIVAL DATA; Dai HY, 2005, CANCER RES, V65, P4059, DOI 10.1158/0008-5472.CAN-04-3953; Degot S, 2004, J BIOL CHEM, V279, P33702, DOI 10.1074/jbc.M402754200; Eden P, 2004, EUR J CANCER, V40, P1837, DOI 10.1016/j.ejca.2004.02.025; Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469; GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834; Irizarry RA, 2005, NAT METHODS, V2, P345, DOI 10.1038/nmeth756; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Naderi A, 2005, MOL BIOTECHNOL, V30, P151, DOI 10.1385/MB:30:2:151; Naderi A, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-9; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Royston P, 2004, STAT MED, V23, P723, DOI 10.1002/sim.1621; Shen RL, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-94; Sollich P, 1996, ADV NEUR IN, V8, P190; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tan PK, 2003, NUCLEIC ACIDS RES, V31, P5676, DOI 10.1093/nar/gkg763; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1	25	187	195	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1507	1516		10.1038/sj.onc.1209920	http://dx.doi.org/10.1038/sj.onc.1209920			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936776				2022-12-28	WOS:000244558800016
J	Yoon, K; Zhu, S; Ewing, SJ; Smart, RC				Yoon, K.; Zhu, S.; Ewing, S. J.; Smart, R. C.			Decreased survival of C/EBP beta-deficient keratinocytes is due to aberrant regulation of p53 levels and function	ONCOGENE			English	Article						apoptosis; p53; C/EBP beta; keratinocytes	BINDING-PROTEIN-BETA; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; DEPENDENT PHOSPHORYLATION; EPITHELIAL-CELLS; GENE-EXPRESSION; STABILIZES P53; MDM2; DIFFERENTIATION; REPRESSION	Recent studies have identified roles for C/EBP beta in cellular survival and tumorigenesis, however, the mechanisms through which C/EBPb regulates these processes are not fully understood. Previously, we demonstrated that C/EBP beta(-/-) mice are resistant to carcinogen-induced skin tumorigenesis and in response to topical carcinogen treatment display a 17-fold increase in keratinocyte apoptosis compared to wild-type mice. Here, we have investigated the mechanisms through which C/EBPb regulates apoptosis in response to carcinogenic stress. Analysis of carcinogen-treated C/EBP beta(-/-) mouse skin revealed a striking increase in the number of p53 immunopositive keratinocytes in the epidermis of C/EBP beta(-/-) mice compared to wild-type mice and this increase was temporally associated with a concomitant anomalous increase in apoptosis. The increased levels of p53 were functional as Mdm2, Bcl-2, C/EBP alpha and p21 were differentially regulated in the epidermis of carcinogenic treated C/EBP beta(-/-) mice. The increase in p53 protein was not associated with an increase in p53 mRNA levels. To determine whether p53 is required for the increased apoptosis in C/EBPb-/- mice, C/EBP beta/p53 compound knockout mice were generated. Carcinogen-treated C/EBP beta/p53 compound knockout mice did not display increased apoptosis demonstrating p53 is required for the proapoptotic phenotype in C/EBP beta(-/-) mice. Our results demonstrate that altered keratinocyte survival in C/EBP beta(-/-) mice results from aberrant regulation of p53 protein and function and indicate C/EBP beta has a role in the negative regulation of p53 protein levels in response to carcinogen-induced stress.	N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Smart, RC (corresponding author), N Carolina State Univ, Dept Environm & Mol Toxicol, Cell Signaling & Canc Grp, Raleigh, NC 27695 USA.	rcsmart@unity.ncsu.edu		Smart, Robert/0000-0002-6767-6756	NATIONAL CANCER INSTITUTE [R29CA046637, R01CA046637] Funding Source: NIH RePORTER; NCI NIH HHS [CA46637] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Bundy LM, 2003, ONCOGENE, V22, P869, DOI 10.1038/sj.onc.1206216; Burkart AD, 2005, ENDOCRINOLOGY, V146, P1909, DOI 10.1210/en.2004-0842; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Di-Poi N, 2005, J BIOL CHEM, V280, P38700, DOI 10.1074/jbc.M507782200; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; Li WL, 2005, CANCER RES, V65, P2592, DOI 10.1158/0008-5472.CAN-04-1532; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Maytin EV, 1998, J INVEST DERMATOL, V110, P238, DOI 10.1046/j.1523-1747.1998.00123.x; Oh HS, 1998, J INVEST DERMATOL, V110, P939, DOI 10.1046/j.1523-1747.1998.00199.x; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rask K, 2000, INT J CANCER, V86, P337, DOI 10.1002/(SICI)1097-0215(20000501)86:3<337::AID-IJC6>3.3.CO;2-V; Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014; Sebastian T, 2005, EMBO J, V24, P3301, DOI 10.1038/sj.emboj.7600789; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shuman JD, 2004, MOL CELL BIOL, V24, P7380, DOI 10.1128/MCB.24.17.7380-7391.2004; Sterneck E, 2006, ONCOGENE, V25, P1272, DOI 10.1038/sj.onc.1209144; Sterneck E, 1997, GENE DEV, V11, P2153, DOI 10.1101/gad.11.17.2153; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wessells J, 2004, MOL CELL BIOL, V24, P3238, DOI 10.1128/MCB.24.8.3238-3250.2004; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhu SY, 2002, P NATL ACAD SCI USA, V99, P207, DOI 10.1073/pnas.012437299; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	35	19	19	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					360	367		10.1038/sj.onc.1209797	http://dx.doi.org/10.1038/sj.onc.1209797			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832342				2022-12-28	WOS:000243544000005
J	Oloumi, A; Syam, S; Dedhar, S				Oloumi, A.; Syam, S.; Dedhar, S.			Modulation of Wnt3a-mediated nuclear beta-catenin accumulation and activation by integrin-linked kinase in mammalian cells	ONCOGENE			English	Article						integrin-linked kinase; nuclear beta-catenin; Wnt; signal transduction	GLYCOGEN-SYNTHASE KINASE; AP-1 TRANSCRIPTION FACTOR; E-CADHERIN EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; THERAPEUTIC TARGET; WNT PATHWAY; PROTEIN; ADHESION; CANCER	The Wnt gene family encodes secreted signaling molecules that play important roles in tumorgenesis and embryogenesis. The canonical Wnt signaling pathway regulates target gene expression via the stabilization and nuclear translocation of the cytoplasmic pool of beta-catenin. The activation of integrin-linked kinase (ILK) is also known to regulate the stabilization and subsequent nuclear translocation of beta-catenin in several epithelial cell models. We now report that molecular and pharmacological inhibition of ILK activity in mammalian cells directly modulates Wnt signaling by suppressing the stabilization and nuclear translocation of beta-catenin, as well as beta-catenin/Lef-mediated transcription. Inhibition of ILK activity, but not phosphatidylinositol-3 kinase (PI3K) or MEK activities suppresses nuclear beta-catenin stabilization in cells stably expressing Wnt3a as well as in cells exposed to either Wnt3a conditioned media or purified Wnt3a. Furthermore, ILK inhibition reverses the Wnt3a-induced suppression of beta- catenin phosphorylation that accompanies beta-catenin stabilization. In addition, we show that ILK can be identified in a complex with Wnt pathway components such as adenomatous polyposis coli and GSK-3. Upon treatment of L cells with Wnt3a-CM, glycogen synthase kinase-3 (GSK-3b) becomes highly phosphorylated on Ser 9, which is completely abolished upon inhibition of ILK activity. However, acute exposure of L cells to purified Wnt3a does not result in the stimulation of GSK-3b Ser 9 phosphorylation, despite beta-catenin stabilization. Together our data demonstrate that ILK activity can modulate acute Wnt3a mediated b- catenin phosphorylation, stabilization and nuclear activation in a PI3K-independent manner, as well as the more prolonged PI3K-dependent secondary effects of Wnt signaling on GSK-3 phosphorylation. Finally, we suggest that a novel small molecule inhibitor of ILK, QLT-0267, may be a useful tool in the regulation of pathological Wnt signaling.	British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of British Columbia	Dedhar, S (corresponding author), Univ British Columbia, British Columbia Canc Res Ctr, Dept Biochem, 675 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@interchange.ubc.ca		Dedhar, Shoukat/0000-0003-4355-1657				Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Erdodi F, 2003, BIOCHEM BIOPH RES CO, V306, P382, DOI 10.1016/S0006-291X(03)00976-8; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Harte D, 1998, J NONLINEAR SCI, V8, P581, DOI 10.1007/s003329900060; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Li Y, 2001, BMC Mol Biol, V2, P2, DOI 10.1186/1471-2199-2-2; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Mills J, 2003, J NEUROSCI, V23, P1638; Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Novak A, 1999, CELL MOL LIFE SCI, V56, P523, DOI 10.1007/s000180050449; Oloumi A, 2004, BBA-MOL CELL RES, V1691, P1, DOI 10.1016/j.bbamcr.2003.12.002; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Pevarello P, 2004, J MED CHEM, V47, P3367, DOI 10.1021/jm031145u; Polakis P, 2002, CURR BIOL, V12, pR499, DOI 10.1016/S0960-9822(02)00969-7; Rosin-Arbesfeld R, 2003, EMBO J, V22, P1101, DOI 10.1093/emboj/cdg105; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; Shibamoto S, 1998, GENES CELLS, V3, P659; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Somasiri A, 2001, J CELL SCI, V114, P1125; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Torres MA, 2000, J CELL BIOL, V149, P1433, DOI 10.1083/jcb.149.7.1433; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Troussard AA, 2000, ONCOGENE, V19, P5444, DOI 10.1038/sj.onc.1203928; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Waltzer L, 1999, CANCER METAST REV, V18, P231, DOI 10.1023/A:1006321324190; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Willert K, 1999, GENE DEV, V13, P1768, DOI 10.1101/gad.13.14.1768; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Wu CY, 1998, J BIOL CHEM, V273, P528, DOI 10.1074/jbc.273.1.528; Yasunaga T, 2005, GENES CELLS, V10, P369, DOI 10.1111/j.1365-2443.2005.00841.x; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	61	80	81	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7747	7757		10.1038/sj.onc.1209752	http://dx.doi.org/10.1038/sj.onc.1209752			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799642				2022-12-28	WOS:000242830800009
J	Dalmay, T; Edwards, DR				Dalmay, T.; Edwards, D. R.			MicroRNAs and the hallmarks of cancer	ONCOGENE			English	Review						miRNAs; cancer; metastasis; invasion; angiogenesis; cell adhesion	TISSUE INHIBITOR; CELL-ADHESION; TRANSITION; PROFILES; HYPOXIA; GENES; SEED	It has become clear that particular microRNAs (miRNAs) function either as tumour suppressors or oncogenes, whose loss or overexpression, respectively, has diagnostic and prognostic significance. In several cases, miRNAs have been shown to affect target genes that are involved in the control of cell proliferation and apoptosis. However, malignant tumours display additional traits beyond the acquisition of enhanced growth potential and decreased cell death. Malignant disease is associated with altered tumour-host interactions leading to sustained angiogenesis and the ability to invade and metastasize. It is possible that miRNAs may act as master regulators of these aspects of tumour biology. Bioinformatic analysis of putative miRNA binding sites has indicated several novel potential gene targets of cancer-associated miRNAs that function in aspects of cell adhesion, neovascularization and tissue invasion. Among others, we speculate that miRNAs may find new roles in the regulation of E-cadherin, integrin alpha v beta 3, hypoxia-inducible factor-1 alpha, syndecan-1, lysyl oxidase, adamalysin metalloproteinase-17, tissue inhibitors of metalloproteinase-3, c-Met and CXCR-4 that underpin the tissue architectural changes associated with malignancy.	Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	University of East Anglia	Dalmay, T (corresponding author), Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England.	t.dalmay@uea.ac.uk; dylan.edwards@uea.ac.uk	Edwards, Dylan R/B-4734-2009; Dalmay, Tamas/E-1377-2011	Edwards, Dylan R/0000-0002-3292-2064; Dalmay, Tamas/0000-0003-1492-5429	Medical Research Council [G0100250] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Ahonen M, 2003, ONCOGENE, V22, P2121, DOI 10.1038/sj.onc.1206292; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; CRUZMUNOZ W, 2006, ONCOGENE        0515, DOI DOI 10.1038/SJ.ONC.1209663; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Esteller M, 2001, CANCER RES, V61, P3225; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu MCP, 2007, CANCER LETT, V247, P91, DOI 10.1016/j.canlet.2006.03.024; LU C, 1993, J CELL BIOL, V120, P1281, DOI 10.1083/jcb.120.5.1281; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Voorhoeve PM, 2006, CELL, V124, P1169, DOI 10.1016/j.cell.2006.02.037; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103	40	275	312	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6170	6175		10.1038/sj.onc.1209911	http://dx.doi.org/10.1038/sj.onc.1209911			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028596				2022-12-28	WOS:000241158900005
J	Avruch, J; Hara, K; Lin, Y; Liu, M; Long, X; Ortiz-Vega, S; Yonezawa, K				Avruch, J.; Hara, K.; Lin, Y.; Liu, M.; Long, X.; Ortiz-Vega, S.; Yonezawa, K.			Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase	ONCOGENE			English	Review						TOR; Rheb; TSC; S6K; raptor; leucine	P70 S6 KINASE; RAPAMYCIN-INDUCED INHIBITION; TUMOR-SUPPRESSOR COMPLEX; REPRESSOR PHAS-I; B-RAF KINASE; MAMMALIAN TARGET; TUBEROUS-SCLEROSIS; PROTEIN-KINASE; CELL-GROWTH; PHOSPHATIDYLINOSITOL 3-KINASE	Target of Rapamycin ( TOR), a giant protein kinase expressed by all eucaryotic cells, controls cell size in response to nutrient signals. In metazoans, cell and organismal growth is controlled by nutrients and the insulin/insulin-like growth factor (IGF) system, and the understanding of how these inputs coordinately regulate TOR signaling has advanced greatly in the past 5 years. In single-cell eucaryotes and Caenorhabditis elegans, TOR is a dominant regulator of overall mRNA translation, whereas in higher metazoans, TOR controls the expression of a smaller fraction of mRNAs that is especially important to cell growth. TOR signals through two physically distinct multiprotein complexes, and the control of cell growth is mediated primarily by TOR complex 1 (TORC1), which contains the polypeptides raptor and LST8. Raptor is the substrate binding element of TORC1, and the ability of raptor to properly present substrates, such as the translational regulators 4E-BP and p70 S6 kinase, to the TOR catalytic domain is essential for their TOR-catalysed phosphorylation, and is inhibited by the Rapamycin/FKBP-12 complex. The dominant proximal regulator of TORC1 signaling and kinase activity is the ras-like small GTPase Rheb. Rheb binds directly to the mTOR catalytic domain, and Rheb-GTP enables TORC1 to attain an active configuration. Insulin/IGF enhances Rheb GTP charging through the ability of activated Akt to inhibit the Rheb-GTPase-activating function of the tuberous sclerosis heterodimer (TSC1/TSC2). Conversely, energy depletion reduces Rheb-GTP charging through the ability of the adenosine monophosphate-activated protein kinase to phosphorylate TSC2 and stimulate its Rheb-GTPase activating function, as well as by HIF alpha-mediated transcriptional responses that act upstream of the TSC1/2 complex. Amino-acid depletion inhibits TORC1 acting predominantly downstream of the TSC complex, by interfering with the ability of Rheb to bind to mTOR. The components of the insulin/IGF pathway to TORC1 are now well established, whereas the elements mediating the more ancient and functionally dominant input of amino acids remain largely unknown.	Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Boston, MA 02114 USA; Kobe Univ, Grad Sch Med, Div Internal & Geriatr Med, Cyuo Ku, Kobe, Hyogo 657, Japan; Kobe Univ, Biosignal Res Ctr, Kobe, Hyogo, Japan	Harvard University; Massachusetts General Hospital; Kobe University; Kobe University	Avruch, J (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Diabet Res Lab, Simches Res Bldg 6408,185 Cambridge St, Boston, MA 02114 USA.	avruch@molbio.mgh.harvard.edu	Long, Samuel/AAR-8118-2021	Long, Samuel/0000-0001-7559-3232	NCI NIH HHS [CA73818] Funding Source: Medline; NIDDK NIH HHS [DK17776] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 2004, DNA REPAIR, V3, P883, DOI 10.1016/j.dnarep.2004.04.002; Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ali SM, 2005, J BIOL CHEM, V280, P19445, DOI 10.1074/jbc.C500125200; Arsham AM, 2003, J BIOL CHEM, V278, P29655, DOI 10.1074/jbc.M212770200; Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Avruch J, 2005, CURR OPIN CLIN NUTR, V8, P67, DOI 10.1097/00075197-200501000-00010; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200; BIERER BE, 1991, TRANSPLANT P, V23, P2850; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHEN RH, 1990, MOL CELL BIOL, V10, P3204, DOI 10.1128/MCB.10.6.3204; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Corradetti MN, 2005, J BIOL CHEM, V280, P9769, DOI 10.1074/jbc.C400557200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Dong JX, 2004, GENE DEV, V18, P2479, DOI 10.1101/gad.1240504; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dumont FJ, 1995, LIFE SCI, V58, P373, DOI 10.1016/0024-3205(95)02233-3; ERIKSON E, 1985, P NATL ACAD SCI USA, V82, P742, DOI 10.1073/pnas.82.3.742; ERIKSON E, 1986, J BIOL CHEM, V261, P350; Fang YM, 2003, CURR BIOL, V13, P2037, DOI 10.1016/j.cub.2003.11.021; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gautam N, 1998, CELL SIGNAL, V10, P447, DOI 10.1016/S0898-6568(98)00006-0; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Hu CD, 1995, J BIOL CHEM, V270, P30274, DOI 10.1074/jbc.270.51.30274; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; Kam Y, 2004, FASEB J, V18, P311, DOI 10.1096/fj.03-0731com; Karbowniczek M, 2004, J BIOL CHEM, V279, P29930, DOI 10.1074/jbc.M402591200; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kimura N, 2003, GENES CELLS, V8, P65, DOI 10.1046/j.1365-2443.2003.00615.x; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Long XM, 2005, J BIOL CHEM, V280, P23433, DOI 10.1074/jbc.C500169200; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mirshahi T, 2002, J BIOL CHEM, V277, P36345, DOI 10.1074/jbc.M205359200; NEMENOFF RA, 1988, J BIOL CHEM, V263, P19455; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1991, J BIOL CHEM, V266, P16281; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Radimerski T, 2002, GENE DEV, V16, P2627, DOI 10.1101/gad.239102; Reiling JH, 2004, GENE DEV, V18, P2879, DOI 10.1101/gad.322704; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; SEHGAL SN, 2003, TRANSPLANT P       S, V3, P75; Sekulic A, 2000, CANCER RES, V60, P3504; Smith EM, 2005, J BIOL CHEM, V280, P18717, DOI 10.1074/jbc.M414499200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sofer A, 2005, MOL CELL BIOL, V25, P5834, DOI 10.1128/MCB.25.14.5834-5845.2005; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Takahashi K, 2005, J BIOL CHEM, V280, P32768, DOI 10.1074/jbc.M506280200; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; VEZINA C, 1975, J ANTIBIOT, V28, P721, DOI 10.7164/antibiotics.28.721; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Wu SL, 2002, BBA-MOL CELL RES, V1542, P41, DOI 10.1016/S0167-4889(01)00164-1; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	128	246	260	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6361	6372		10.1038/sj.onc.1209882	http://dx.doi.org/10.1038/sj.onc.1209882			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041622				2022-12-28	WOS:000241380700003
J	White, MK; Khalili, K				White, M. K.; Khalili, K.			Interaction of retinoblastoma protein family members with large T-antigen of primate polyomaviruses	ONCOGENE			English	Review						polyomavirus; retinoblastoma; cell cycle; transformation; oncogenesis	SV40 LARGE-T; SUSCEPTIBILITY GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEINS; CELL-CYCLE CONTROL; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; VIRAL-DNA REPLICATION; PRB-RELATED PROTEINS; JC-VIRUS; BK VIRUS	The retinoblastoma gene product pRb and other members of the Rb family of pocket proteins have a central role in the regulation of cell cycle progression. Soon after its discovery, p Rb was found to interact with the transforming oncoproteins of DNA tumor viruses and this led to rapid advances in our understanding of the mechanisms of viral transformation and cell cycle progression. DNA viruses of the polyomavirus family have small, circular, double-stranded DNA genomes contained within non-enveloped icosahedral capsids and are highly tumorigenic in experimental animals. At least three types of polyomavirus infect humans: JC virus (JCV), BK virus (BKV) and Simian Vacuolating virus-40. The early region of these viruses encodes the transforming proteins large T-antigen and small t-antigen, which are involved in viral replication and also promote transformation of cells in culture and oncogenesis in vivo. Binding of T-antigen to pRb promotes the activation of the E2F family of transcription factors, which induce the expression of cellular genes required for S phase. In the context of lytic infection, this cell cycle progression is necessary for viral replication because polyomaviruses rely on S phase-specific host factors for their DNA synthesis. In the context of cellular transformation and tumorigenesis, T-antigen/pRB interaction is an indispensable event.	Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Khalili, K (corresponding author), Temple Univ, Sch Med, Ctr Neurovirol, Dept Neurosci, 1900 12th St,015-96,Room 203, Philadelphia, PA 19122 USA.	kamel.khalili@temple.edu						Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V352, P249, DOI 10.1038/352249a0; BANDARA LR, 1991, CELL, V65, P1053; Blais A, 2004, CURR OPIN GENET DEV, V14, P527, DOI 10.1016/j.gde.2004.07.003; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Cantalupo P, 2005, J VIROL, V79, P13094, DOI 10.1128/JVI.79.20.13094-13104.2005; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHITTENDEN T, 1991, COLD SPRING HARB SYM, V56, P187; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Cole Charles N., 1996, P917; Corallini A, 2001, HUMAN POLYOMAVIRUSES, P431; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Del Valle L, 2001, J CLIN PATHOL-MOL PA, V54, P331, DOI 10.1136/mp.54.5.331; DELVALLE L, 2001, HUMAN POLYOMAVIRUSES, P409; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frisque RJ, 2005, J NEUROVIROL, V14, P65; Frisque RJ, 2003, J NEUROVIROL, V9, P15, DOI 10.1080/13550280390195270; Frisque RJ, 2001, J NEUROVIROL, V7, P293, DOI 10.1080/13550280152537120; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Garcea RL, 2003, J VIROL, V77, P5039, DOI 10.1128/JVI.77.9.5039-5045.2003; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Hirsch HH, 2005, CLIN INFECT DIS, V41, P354, DOI 10.1086/431488; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Kelley WL, 1997, MOL MICROBIOL, V25, P913, DOI 10.1111/j.1365-2958.1997.mmi527.x; KHALILI K, 2005, POLYOMAVIRUSES HUMAN; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lin JY, 2003, J BIOL CHEM, V278, P46482, DOI 10.1074/jbc.M307044200; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; Ludlow JW, 1996, J VIROL METHODS, V59, P105, DOI 10.1016/0166-0934(96)02027-7; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MAYOL X, 1993, ONCOGENE, V8, P2561; NEVINS JR, 1991, COLD SPRING HARB SYM, V56, P157; ONEILL FJ, 1995, ONCOGENE, V10, P1131; PAGNANI M, 1988, INT J CANCER, V42, P405, DOI 10.1002/ijc.2910420317; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Prins C, 2001, J NEUROVIROL, V7, P250; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REICHEL R, 1987, CELL, V48, P501, DOI 10.1016/0092-8674(87)90200-5; ROBLES MTS, 1994, MOL CELL BIOL, V14, P2686, DOI 10.1128/MCB.14.4.2686; Stubdal H, 1996, J VIROL, V70, P2781, DOI 10.1128/JVI.70.5.2781-2788.1996; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sullivan CS, 2004, VIROLOGY, V320, P218, DOI 10.1016/j.virol.2003.10.035; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; Tevethia MJ, 1997, J VIROL, V71, P1888, DOI 10.1128/JVI.71.3.1888-1896.1997; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; Tyagarajan SK, 2005, J NEUROVIROL, V14, P43; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; White MK, 2004, VIROLOGY, V324, P1, DOI 10.1016/j.virol.2004.03.025; White MK, 2005, BRAIN RES REV, V50, P69, DOI 10.1016/j.brainresrev.2005.04.007; White MK, 2005, EUR J CANCER, V41, P2537, DOI 10.1016/j.ejca.2005.08.019; WHITE MK, 2004, GENE THER MOL BIOL, V8, P19; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WOLF DA, 1995, ONCOGENE, V10, P2067; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	89	45	45	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5286	5293		10.1038/sj.onc.1209618	http://dx.doi.org/10.1038/sj.onc.1209618			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936749				2022-12-28	WOS:000240064100014
J	Cheng, WC; Berman, SB; Ivanovska, I; Jonas, EA; Lee, SJ; Chen, Y; Kaczmarek, LK; Pineda, F; Hardwick, JM				Cheng, W. -C; Berman, S. B.; Ivanovska, I.; Jonas, E. A.; Lee, S. J.; Chen, Y.; Kaczmarek, L. K.; Pineda, F.; Hardwick, J. M.			Mitochondrial factors with dual roles in death and survival	ONCOGENE			English	Review						apoptosis; Fis1; CED-9; yeast; aging; virus	PROGRAMMED CELL-DEATH; DYNAMIN-RELATED GTPASE; CYTOCHROME-C RELEASE; WD REPEAT PROTEIN; PERMEABILITY TRANSITION; BH3-ONLY PROTEINS; REGULATES APOPTOSIS; CASPASE ACTIVATION; VITAL FUNCTIONS; BCL-2 HOMOLOGS	At least in mammals, we have some understanding of how caspases facilitate mitochondria-mediated cell death, but the biochemical mechanisms by which other factors promote or inhibit programmed cell death are not understood. Moreover, most of these factors are only studied after treating cells with a death stimulus. A growing body of new evidence suggests that cell death regulators also have 'day jobs' in healthy cells. Even caspases, mitochondrial fission proteins and pro-death Bcl-2 family proteins appear to have normal cellular functions that promote cell survival. Here, we review some of the supporting evidence and stretch beyond the evidence to seek an understanding of the remaining questions.	Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Yale Univ, Dept Endocrinol, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15260 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hardwick, JM (corresponding author), Johns Hopkins Sch Publ Hlth, Dept Mol Microbiol & Immunol, Rm E5140 BSPH,615 N Wolfe St, Baltimore, MD 21205 USA.	hardwick@jhu.edu	Berman, Sarah/I-2792-2014; Cheng, Wen-Chih/B-4088-2009	Berman, Sarah/0000-0002-5096-4962; 	NCI NIH HHS [R01 CA073581] Funding Source: Medline; NINDS NIH HHS [R01 NS037402, R01 NS034175, R01 NS045876] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037402, R01NS034175, R01NS045876] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434; BARANGER AM, 1995, NATURE, V376, P606, DOI 10.1038/376606a0; Basanez G, 2002, J BIOL CHEM, V277, P49360, DOI 10.1074/jbc.M206069200; Basanez G, 2001, J BIOL CHEM, V276, P31083, DOI 10.1074/jbc.M103879200; Basanez G, 1999, P NATL ACAD SCI USA, V96, P5492, DOI 10.1073/pnas.96.10.5492; Bellows DS, 2000, J VIROL, V74, P5024, DOI 10.1128/JVI.74.11.5024-5031.2000; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Blackstone NW, 1999, BIOESSAYS, V21, P84, DOI 10.1002/(SICI)1521-1878(199901)21:1<84::AID-BIES11>3.0.CO;2-0; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Borrello ME, 2005, ENDEAVOUR, V29, P43, DOI 10.1016/j.endeavour.2004.11.003; Breckenridge DG, 2003, J CELL BIOL, V160, P1115, DOI 10.1083/jcb.200212059; Cerveny KL, 2003, MOL BIOL CELL, V14, P4126, DOI 10.1091/mbc.E03-02-0092; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Colon-Ramos DA, 2003, MOL BIOL CELL, V14, P4162, DOI 10.1091/mbc.E03-03-0139; Dohm JA, 2004, PROTEINS, V54, P153, DOI 10.1002/prot.10524; Dyall SD, 2004, SCIENCE, V304, P253, DOI 10.1126/science.1094884; Engelberg-Kulka H, 2004, TRENDS MICROBIOL, V12, P66, DOI 10.1016/j.tim.2003.12.008; Engelberg-Kulka H, 2003, SCIENCE, V301, P467, DOI 10.1126/science.1088051; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fannjiang Y, 2004, GENE DEV, V18, P2785, DOI 10.1101/gad.1247904; Fannjiang Y, 2003, DEV CELL, V4, P575, DOI 10.1016/S1534-5807(03)00091-1; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; Foghsgaard L, 1997, J VIROL, V71, P7509, DOI 10.1128/JVI.71.10.7509-7517.1997; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Garrido C, 2004, CURR OPIN CELL BIOL, V16, P639, DOI 10.1016/j.ceb.2004.09.008; Goldstein JC, 2005, CELL DEATH DIFFER, V12, P453, DOI 10.1038/sj.cdd.4401596; Gonzalez-Pastor JE, 2003, SCIENCE, V301, P510, DOI 10.1126/science.1086462; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Griffin EE, 2005, J CELL BIOL, V170, P237, DOI 10.1083/jcb.200503148; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Hardwick J M, 1997, Adv Pharmacol, V41, P295, DOI 10.1016/S1054-3589(08)61063-7; Hardwick JM, 2002, MOL CELL, V10, P963, DOI 10.1016/S1097-2765(02)00751-7; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, NATURE, V369, P318, DOI 10.1038/369318a0; Herker E, 2004, J CELL BIOL, V164, P501, DOI 10.1083/jcb.200310014; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0; Ivanovska I, 2005, J CELL BIOL, V170, P391, DOI 10.1083/jcb.200503069; Jaattela M, 2002, ANN MED, V34, P480, DOI 10.1080/078538902321012423; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; Jagasia R, 2005, NATURE, V433, P754, DOI 10.1038/nature03316; James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200; Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2; Jeong SY, 2004, EMBO J, V23, P2146, DOI 10.1038/sj.emboj.7600225; Jin C, 2002, NAT REV MOL CELL BIO, V3, P453, DOI 10.1038/nrm832; Jonas EA, 2005, ANTIOXID REDOX SIGN, V7, P1092, DOI 10.1089/ars.2005.7.1092; Jonas EA, 2005, J BIOL CHEM, V280, P4491, DOI 10.1074/jbc.M410661200; Jonas EA, 2004, P NATL ACAD SCI USA, V101, P13590, DOI 10.1073/pnas.0401372101; Jonas EA, 2003, J NEUROSCI, V23, P8423; Karbowski M, 2002, J CELL BIOL, V159, P931, DOI 10.1083/jcb.200209124; Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260; Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082; Karren MA, 2005, J CELL BIOL, V171, P291, DOI 10.1083/jcb.200506158; Kennedy NJ, 1999, J EXP MED, V190, P1891, DOI 10.1084/jem.190.12.1891; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirsch DG, 1999, J BIOL CHEM, V274, P21155, DOI 10.1074/jbc.274.30.21155; Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294; Legros F, 2002, MOL BIOL CELL, V13, P4343, DOI 10.1091/mbc.E02-06-0330; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; Lewis J, 1999, NAT MED, V5, P832, DOI 10.1038/10556; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; LLERMEIER CD, 2006, CELL, V124, P549; Longo VD, 2005, NAT REV GENET, V6, DOI 10.1038/nrg1706; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Madeo F, 2002, CURR GENET, V41, P208, DOI 10.1007/s00294-002-0310-2; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; MARTINAC B, 1990, P NATL ACAD SCI USA, V87, P6228, DOI 10.1073/pnas.87.16.6228; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317; Naylor K, 2006, J BIOL CHEM, V281, P2177, DOI 10.1074/jbc.M507943200; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9; NICHOLLS DG, 2002, BIOENERGETICS, V3; Otsuga D, 1998, J CELL BIOL, V143, P333, DOI 10.1083/jcb.143.2.333; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Polster BM, 2004, J NEUROCHEM, V90, P1281, DOI 10.1111/j.1471-4159.2004.02572.x; Polster BM, 2004, BBA-MOL CELL RES, V1644, P211, DOI 10.1016/j.bbamcr.2003.11.001; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reiter J, 2005, J CELL BIOL, V168, P353, DOI 10.1083/jcb.200408071; Rine J, 2005, SCIENCE, V310, P1124, DOI 10.1126/science.1121310; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Seo SY, 2004, J BIOL CHEM, V279, P42240, DOI 10.1074/jbc.M406775200; Sesaki H, 1999, J CELL BIOL, V147, P699, DOI 10.1083/jcb.147.4.699; Severin FF, 2002, CURR BIOL, V12, pR233, DOI 10.1016/S0960-9822(02)00776-5; Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Strasser A, 2003, IMMUNOL REV, V193, P82, DOI 10.1034/j.1600-065X.2003.00036.x; Su H, 2005, SCIENCE, V307, P1465, DOI 10.1126/science.1104765; Suzuki M, 2003, J MOL BIOL, V334, P445, DOI 10.1016/j.jmb.2003.09.064; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tieu Q, 2000, J CELL BIOL, V151, P353, DOI 10.1083/jcb.151.2.353; Tieu Q, 2002, J CELL BIOL, V158, P445, DOI 10.1083/jcb.200205031; Tolkovsky AM, 2002, BIOCHIMIE, V84, P233, DOI 10.1016/S0300-9084(02)01371-8; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wickner RB, 1996, MICROBIOL REV, V60, P250, DOI 10.1128/MMBR.60.1.250-265.1996; Wilson-Annan J, 2003, J CELL BIOL, V162, P877, DOI 10.1083/jcb.200302144; Wissing S, 2004, J CELL BIOL, V166, P969, DOI 10.1083/jcb.200404138; Xue L, 2001, CURR BIOL, V11, P361, DOI 10.1016/S0960-9822(01)00100-2; Yu XC, 2005, STRUCTURE, V13, P1725, DOI 10.1016/j.str.2005.09.006; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	129	59	63	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4697	4705		10.1038/sj.onc.1209596	http://dx.doi.org/10.1038/sj.onc.1209596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892083				2022-12-28	WOS:000239687000007
J	Bruix, J; Hessheimer, AJ; Forner, A; Boix, L; Vilana, R; Llovet, JM				Bruix, J; Hessheimer, AJ; Forner, A; Boix, L; Vilana, R; Llovet, JM			New aspects of diagnosis and therapy of hepatocellular carcinoma	ONCOGENE			English	Review						hepatocellular carcinoma; early detection; diagnosis; treatment	RANDOMIZED CONTROLLED-TRIAL; PERCUTANEOUS RADIOFREQUENCY ABLATION; DONOR LIVER-TRANSPLANTATION; GAMMA-CARBOXY PROTHROMBIN; ETHANOL INJECTION; ALPHA-FETOPROTEIN; PROGNOSTIC PREDICTION; SURGICAL RESECTION; IMPROVES PROGNOSIS; IMAGING DIAGNOSIS	Hepatocellular carcinoma is one of the major cancer killers. It affects patients with chronic liver disease who have established cirrhosis, and currently is the most frequent cause of death in these patients. The main risk factors for its development are hepatitis B and C virus infection, alcoholism and aflatoxin intake. If acquistion of risk factors is not prevented and cirrhosis is established, the sole option to improve survival is to detect the tumor at an early stage when effective therapy may be indicated. Early detection plans should be based on hepatic ultrasonography every 6 months, whereas determination of tumor markers is not efficient. Upon detection of a hepatic nodule, there is a need to establish unequivocal diagnosis, either through biopsy or through the application of non-invasive criteria based on the specific radiology appearance of the tumor: fast arterial uptake of contrast followed by venous washout. Effective treatment for liver cancer includes surgical resection, liver transplantation and percutaneous ablation. These options provide a high rate of complete responses and are assumed to improve survival that should exceed 50% at 5 years. If the tumor is diagnosed at an advanced stage, the sole option that improves survival is transarterial chemoembolization. Ongoing research should further advance the time at diagnosis and identify new and effective options targeting molecular pathways governing tumor progression.	Univ Barcelona, BCLC Grp, Liver Unit, IDIBAPS,Digest Dis Inst,Hosp Clin, E-08036 Barcelona, Catalonia, Spain; Univ Barcelona, BCLC Grp, Dept Radiol, IDIBAPS,Hosp Clin, E-08036 Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Bruix, J (corresponding author), Univ Barcelona, BCLC Grp, Liver Unit, IDIBAPS,Digest Dis Inst,Hosp Clin, Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	bruix@ub.edu	Llovet, Josep M/D-4340-2014; Hessheimer, Amelia/N-1855-2019; Forner, Alejandro/C-8884-2016; Llovet, Josep M/ABB-6264-2021	Llovet, Josep M/0000-0003-0547-2667; Hessheimer, Amelia/0000-0002-7247-5051; Forner, Alejandro/0000-0002-9014-4950; Llovet, Josep M/0000-0003-0547-2667; Bruix, Jordi/0000-0002-9826-0753				Beaugrand M, 2005, SEMIN LIVER DIS, V25, P201, DOI 10.1055/s-2005-871199; BISMUTH H, 1993, TRANSPLANT P, V25, P1066; Bolondi L, 2003, J HEPATOL, V39, P1076, DOI 10.1016/S0168-8278(03)00349-0; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Bruix J, 2004, GASTROENTEROLOGY, V127, pS179, DOI 10.1053/j.gastro.2004.09.032; BRUIX J, 1994, HEPATOLOGY, V20, P643, DOI 10.1002/hep.1840200315; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep.20933; Bruix J, 2003, LIVER TRANSPLANT, V9, P700, DOI 10.1053/jlts.2003.50124; Bruix J, 1996, GASTROENTEROLOGY, V111, P1018, DOI 10.1016/S0016-5085(96)70070-7; Bruix J, 2001, J HEPATOL, V35, P421, DOI 10.1016/S0168-8278(01)00130-1; Bruix J, 2002, HEPATOLOGY, V35, P519, DOI 10.1053/jhep.2002.32089; Burrel M, 2003, HEPATOLOGY, V38, P1034, DOI 10.1053/jhep.2003.50409; Capurro M, 2003, GASTROENTEROLOGY, V125, P89, DOI 10.1016/S0016-5085(03)00689-9; DiStasi M, 1997, SCAND J GASTROENTERO, V32, P1168; Freeman RB, 2004, LIVER TRANSPLANT, V10, P7, DOI 10.1002/lt.20024; Garcia-Retortillo M, 2004, HEPATOLOGY, V40, P699, DOI 10.1002/hep.20357; Giorgio A, 2005, AM J ROENTGENOL, V184, P207, DOI 10.2214/ajr.184.1.01840207; Gondolesi GE, 2004, ANN SURG, V239, P142, DOI 10.1097/01.sla.0000109022.32391.eb; Grieco A, 2005, GUT, V54, P411, DOI 10.1136/gut.2004.048124; Grimaldi C, 1998, J CLIN ONCOL, V16, P411, DOI 10.1200/JCO.1998.16.2.411; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Ishizuka H, 1999, INTERNAL MED, V38, P927, DOI 10.2169/internalmedicine.38.927; IZUNO K, 1995, HEPATO-GASTROENTEROL, V42, P387; Jonas S, 2001, HEPATOLOGY, V33, P1080, DOI 10.1053/jhep.2001.23561; Kawasaki S, 2002, HEPATO-GASTROENTEROL, V49, P53; Koike Y, 2001, CANCER, V91, P561, DOI 10.1002/1097-0142(20010201)91:3<561::AID-CNCR1035>3.0.CO;2-N; Kumada T, 1999, J HEPATOL, V30, P125, DOI 10.1016/S0168-8278(99)80016-6; Lau WY, 1999, LANCET, V353, P797, DOI 10.1016/S0140-6736(98)06475-7; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Lencioni R, 2005, RADIOLOGY, V234, P961, DOI 10.1148/radiol.2343040350; Lencioni R, 2005, SEMIN LIVER DIS, V25, P162, DOI 10.1055/s-2005-871196; Lencioni RA, 2003, RADIOLOGY, V228, P235, DOI 10.1148/radiol.2281020718; Lin SM, 2004, GASTROENTEROLOGY, V127, P1714, DOI 10.1053/j.gastro.2004.09.003; Livraghi T, 1999, RADIOLOGY, V210, P655, DOI 10.1148/radiology.210.3.r99fe40655; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; LIVRAGHI T, 1995, RADIOLOGY, V197, P101, DOI 10.1148/radiology.197.1.7568806; Llovet JM, 2005, SEMIN LIVER DIS, V25, P181, DOI 10.1055/s-2005-871198; Llovet JM, 1999, SEMIN LIVER DIS, V19, P329, DOI 10.1055/s-2007-1007122; Llovet JM, 2002, GUT, V50, P123, DOI 10.1136/gut.50.1.123; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Llovet JM, 1998, HEPATOLOGY, V27, P1572, DOI 10.1002/hep.510270616; Llovet JM, 2001, HEPATOLOGY, V33, P1124, DOI 10.1053/jhep.2001.24233; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 1999, HEPATOLOGY, V30, P1434, DOI 10.1002/hep.510300629; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Majno P, 2005, J HEPATOL, V42, pS134, DOI 10.1016/j.jhep.2004.12.010; Marrero JA, 2005, HEPATOLOGY, V41, P707, DOI 10.1002/hep.20636; Marrero JA, 2003, HEPATOLOGY, V37, P1114, DOI 10.1053/jhep.2003.50195; Marrero JA, 2004, GASTROENTEROLOGY, V127, pS113, DOI 10.1053/j.gastro.2004.09.024; Mazzaferro V, 1996, NEW ENGL J MED, V334, P693, DOI 10.1056/NEJM199603143341104; Muto Y, 1996, NEW ENGL J MED, V334, P1561, DOI 10.1056/NEJM199606133342402; NAIMARK D, 1994, J GEN INTERN MED, V9, P702, DOI 10.1007/BF02599016; Paradis V, 2005, HEPATOLOGY, V41, P40, DOI 10.1002/hep.20505; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Sala M, 2005, SEMIN LIVER DIS, V25, P171, DOI 10.1055/s-2005-871197; Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465; Sala M, 2004, LIVER TRANSPLANT, V10, P1294, DOI 10.1002/lt.20202; Sharma P, 2004, LIVER TRANSPLANT, V10, P36, DOI 10.1002/lt.20012; Sherman M, 2001, J HEPATOL, V34, P603, DOI 10.1016/S0168-8278(01)00025-3; Shibata T, 2002, RADIOLOGY, V223, P331, DOI 10.1148/radiol.2232010775; Shiina S, 2005, GASTROENTEROLOGY, V129, P122, DOI 10.1053/j.gastro.2005.04.009; Shiratori Y, 2003, ANN INTERN MED, V138, P299, DOI 10.7326/0003-4819-138-4-200302180-00008; Steinmuller T, 2002, TRANSPLANT P, V34, P2263, DOI 10.1016/S0041-1345(02)03228-1; SUEHIRO T, 1994, CANCER-AM CANCER SOC, V73, P2464, DOI 10.1002/1097-0142(19940515)73:10<2464::AID-CNCR2820731004>3.0.CO;2-9; Takayama T, 1998, HEPATOLOGY, V28, P1241, DOI 10.1002/hep.510280511; Takayama T, 2000, LANCET, V356, P802, DOI 10.1016/S0140-6736(00)02654-4; Tateishi R, 2005, CANCER-AM CANCER SOC, V103, P1201, DOI 10.1002/cncr.20892; Todo S, 2004, ANN SURG, V240, P451, DOI 10.1097/01.sla.0000137129.98894.42; Torzilli G, 1999, ARCH SURG-CHICAGO, V134, P984, DOI 10.1001/archsurg.134.9.984; Trevisani F, 2001, J HEPATOL, V34, P570, DOI 10.1016/S0168-8278(00)00053-2; Trinchet JC, 2004, HEPATOLOGY, V40, P1361, DOI 10.1002/hep.20474; Yuen MF, 2002, HEPATOLOGY, V36, P687, DOI 10.1053/jhep.2002.35071; Zhang BH, 2004, J CANCER RES CLIN, V130, P417, DOI 10.1007/s00432-004-0552-0	74	123	132	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2006	25	27					3848	3856		10.1038/sj.onc.1209548	http://dx.doi.org/10.1038/sj.onc.1209548			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799626				2022-12-28	WOS:000238559600012
J	Donato, F; Gelatti, U; Limina, R; Fattovich, G				Donato, F.; Gelatti, U.; Limina, R. M.; Fattovich, G.			Southern Europe as an example of interaction between various environmental factors: a systematic review of the epidemiologic evidence	ONCOGENE			English	Review						hepatocellular carcinoma; risk factors; epidemiology; hepatitis B virus; hepatitis C virus; alcohol	HEPATITIS-C VIRUS; CHRONIC LIVER-DISEASE; GAMMA-GLUTAMYL-TRANSFERASE; HEPATOCELLULAR-CARCINOMA PATIENTS; NONALCOHOLIC FATTY LIVER; CHRONIC VIRAL-HEPATITIS; B SURFACE-ANTIGEN; CIGARETTE-SMOKING; RISK-FACTORS; NATURAL-HISTORY	Hepatitis B virus (HBV), hepatitis C virus (HCV) and alcohol consumption are major causes of hepatocellular carcinoma (HCC) worldwide. We performed a systematic review of epidemiologic studies carried out on HCC aetiology in Southern Europe, an area with an intermediate high prevalence of these agents as well as of putative risk factors such as tobacco smoking, diabetes and obesity. To retrieve the articles, we performed a Medline search for titles and abstracts of articles. After the Medline search, we reviewed the papers and reference lists to identify additional articles. A synergism between HCV infection and HBV infection, overt (hepatitis B virus antigen (HbsAg) positivity) or occult (HBsAg negativity with presence of HBV DNA in liver or serum), is suggested by the results of some studies. The pattern of the risk for HCC due to alcohol intake shows a continuous dose-effect curve without a definite threshold, although most studies found that HCC risk increased only for alcohol consumption above 40-60 g of ethanol per day. Some evidence supports a positive interaction of alcohol intake probably with HCV infection and possibly with HBV infection. A few studies found that coffee has a protective effect on HCC risk due to various risk factors. Some data also support a role of tobacco smoking, diabetes and obesity as single agents or preferably cofactors in causing HCC. In countries with a relatively high alcohol consumption and intermediate levels of HCV and HBV infections (1-3% of population infected by each virus), such as Mediterranean countries, the three main risk factors together account for about 85% of the total HCC cases, leaving little space to other known risk factors, such as haemochromatosis, and to new, still unrecognised, factors as independent causes of HCC.	Univ Brescia, Dipartimento Med Sperimentale & Applicata, Sez Igiene Epidemiol & Sanita Pubbl, Inst Hyg Epidemiol & Publ Hlth, I-25123 Brescia, Italy; Univ Verona, Dept Gastroenterol, I-37100 Verona, Italy	University of Brescia; University of Verona	Donato, F (corresponding author), Univ Brescia, Dipartimento Med Sperimentale & Applicata, Sez Igiene Epidemiol & Sanita Pubbl, Inst Hyg Epidemiol & Publ Hlth, Viale Europa 11, I-25123 Brescia, Italy.	donato@med.unibs.it	Donato, Francesco/AAQ-7477-2021; Gelatti, Umberto/H-7719-2012; Fattovich, giovanna/AAC-7083-2020	DONATO, Francesco/0000-0002-1402-1019				Adami HO, 1996, J NATL CANCER I, V88, P1472, DOI 10.1093/jnci/88.20.1472; ADAMI HO, 1992, INT J CANCER, V51, P898, DOI 10.1002/ijc.2910510611; Aizawa Y, 2000, CANCER, V89, P53, DOI 10.1002/1097-0142(20000701)89:1<53::AID-CNCR8>3.3.CO;2-Y; Becker U, 2002, HEPATOLOGY, V35, P868, DOI 10.1053/jhep.2002.32101; Bedogni G, 2005, HEPATOLOGY, V42, P44, DOI 10.1002/hep.20734; Bellentani S, 1997, GUT, V41, P845, DOI 10.1136/gut.41.6.845; Bellentani S, 2001, J HEPATOL, V35, P531, DOI 10.1016/S0168-8278(01)00151-9; BELLENTANI S, 1994, HEPATOLOGY, V20, P1442, DOI 10.1002/hep.1840200611; Bellentani S, 1999, GUT, V44, P874, DOI 10.1136/gut.44.6.874; BENVEGNU L, 1994, CANCER, V74, P2442, DOI 10.1002/1097-0142(19941101)74:9<2442::AID-CNCR2820740909>3.0.CO;2-#; Benvegnu L, 2004, GUT, V53, P744, DOI 10.1136/gut.2003.020263; Bhattacharya R, 2003, J CLIN GASTROENTEROL, V36, P242, DOI 10.1097/00004836-200303000-00012; Bosch FX, 2004, GASTROENTEROLOGY, V127, pS5, DOI 10.1053/j.gastro.2004.09.011; Braga C, 1997, EUR J CANCER, V33, P629, DOI 10.1016/S0959-8049(96)00500-X; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Bugianesi E, 2005, ALIMENT PHARM THER, V22, P40, DOI 10.1111/j.1365-2036.2005.02594.x; Bugianesi E, 2002, GASTROENTEROLOGY, V123, P134, DOI 10.1053/gast.2002.34168; Cacciola I, 1999, NEW ENGL J MED, V341, P22, DOI 10.1056/NEJM199907013410104; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; CASIGLIA E, 1993, EUR J EPIDEMIOL, V9, P293, DOI 10.1007/BF00146266; Chan HLY, 2002, AM J GASTROENTEROL, V97, P1211, DOI 10.1111/j.1572-0241.2002.05706.x; CHEN CJ, 1991, HEPATOLOGY, V13, P398, DOI 10.1002/hep.1840130303; Chen SY, 2002, INT J CANCER, V99, P14, DOI 10.1002/ijc.10291; Chen ZM, 2003, INT J CANCER, V107, P106, DOI 10.1002/ijc.11342; CHIARAMONTE M, 1998, CANCER, V85, P2132; Choudhury J, 2004, SEMIN LIVER DIS, V24, P349, DOI 10.1055/s-2004-860864; Corrao G, 2004, PREV MED, V38, P613, DOI 10.1016/j.ypmed.2003.11.027; Corrao G, 2001, ANN EPIDEMIOL, V11, P458, DOI 10.1016/S1047-2797(01)00223-X; Corrao G, 1997, J HEPATOL, V27, P470, DOI 10.1016/S0168-8278(97)80350-9; Corrao G, 1998, ALCOHOL ALCOHOLISM, V33, P381; CORRAO G, 1993, J CLIN EPIDEMIOL, V46, P601, DOI 10.1016/0895-4356(93)90032-V; Corrao G, 1998, J HEPATOL, V28, P608, DOI 10.1016/S0168-8278(98)80284-5; Corrao G, 1998, EUR J EPIDEMIOL, V14, P447, DOI 10.1023/A:1007411423766; Corrao G, 1998, HEPATOLOGY, V27, P914, DOI 10.1002/hep.510270404; Cotrim HP, 2000, AM J GASTROENTEROL, V95, P3018, DOI 10.1016/S0002-9270(00)02034-7; Coughlin SS, 2004, AM J EPIDEMIOL, V159, P1160, DOI 10.1093/aje/kwh161; Covolo L, 2005, CANCER CAUSE CONTROL, V16, P831, DOI 10.1007/s10552-005-2302-2; CRESPO J, 1994, AM J GASTROENTEROL, V89, P1147; Cuadrado A, 2005, OBES SURG, V15, P442, DOI 10.1381/0960892053576596; Davila JA, 2005, GUT, V54, P533, DOI 10.1136/gut.2004.052167; del Olmo JA, 1998, J CANCER RES CLIN, V124, P560, DOI 10.1007/s004320050215; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Donato F, 2002, AM J EPIDEMIOL, V155, P323, DOI 10.1093/aje/155.4.323; Donato F, 1997, HEPATOLOGY, V26, P579, DOI 10.1002/hep.510260308; DONATO F, 2005, DIGEST LIVER DIS, V37, pA47; El-Serag HB, 2004, GASTROENTEROLOGY, V126, P460, DOI 10.1053/j.gastro.2003.10.065; Evans AA, 2002, CANCER EPIDEM BIOMAR, V11, P369; Falck-Ytter Y, 2001, SEMIN LIVER DIS, V21, P17, DOI 10.1055/s-2001-12926; Fattovich G, 2004, GASTROENTEROLOGY, V127, pS35, DOI 10.1053/j.gastro.2004.09.014; FONG TL, 1991, HEPATOLOGY, V14, P64, DOI 10.1002/hep.1840140111; Gallus S, 2002, BRIT J CANCER, V87, P956, DOI 10.1038/sj.bjc.6600582; Gallus S, 2002, ANN EPIDEMIOL, V12, P202, DOI 10.1016/S1047-2797(01)00304-0; Gelatti U, 2005, J HEPATOL, V42, P528, DOI 10.1016/j.jhep.2004.11.039; Gelatti U, 2005, INT J CANCER, V115, P301, DOI 10.1002/ijc.20895; GOODMAN MT, 1995, EPIDEMIOLOGY, V6, P36, DOI 10.1097/00001648-199501000-00008; HADZIYANNIS S, 1995, INT J CANCER, V60, P627, DOI 10.1002/ijc.2910600510; Harris DR, 2001, ANN INTERN MED, V134, P120, DOI 10.7326/0003-4819-134-2-200101160-00012; Haslam DW, 2005, LANCET, V366, P1197, DOI 10.1016/S0140-6736(05)67483-1; Hassan MM, 2002, HEPATOLOGY, V36, P1206, DOI 10.1053/jhep.2002.36780; Heathcote EJ, 2004, GASTROENTEROLOGY, V127, pS294, DOI 10.1053/j.gastro.2004.09.044; Hezode C, 2003, GUT, V52, P126, DOI 10.1136/gut.52.1.126; Honjo S, 2001, J CLIN EPIDEMIOL, V54, P823, DOI 10.1016/S0895-4356(01)00344-4; Honjo S, 1999, ANN EPIDEMIOL, V9, P325, DOI 10.1016/S1047-2797(99)00013-7; Hu KQ, 2002, J VIRAL HEPATITIS, V9, P243, DOI 10.1046/j.1365-2893.2002.00344.x; Hui JM, 2003, HEPATOLOGY, V38, P420, DOI 10.1053/jhep.2003.50320; *IARC, 1994, IARC MON EV CARC RIS, V59; *IARC, 1988, ALC DRINK IARC MON, V44; IARC, 1991, IARC MON EV CARC RIS, V51; Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5; Inoue M, 2005, J NATL CANCER I, V97, P293, DOI 10.1093/jnci/dji040; Jee SH, 2004, JNCI-J NATL CANCER I, V96, P1851, DOI 10.1093/jnci/djh334; Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194; Kamper-Jorgensen M, 2004, J HEPATOL, V41, P25, DOI 10.1016/j.jhep.2004.03.002; Klatsky A L, 1993, Ann Epidemiol, V3, P375, DOI 10.1016/1047-2797(93)90064-B; KLATSKY AL, 1992, AM J EPIDEMIOL, V136, P1248, DOI 10.1093/oxfordjournals.aje.a116433; KOIKE K, 1995, J MED VIROL, V45, P236, DOI 10.1002/jmv.1890450222; Kuper H, 2000, INT J CANCER, V85, P498, DOI 10.1002/(SICI)1097-0215(20000215)85:4&lt;498::AID-IJC9&gt;3.0.CO;2-F; Kuper H, 2001, HEPATOLOGY, V34, P714, DOI 10.1053/jhep.2001.28233; Kuper HE, 2000, CANCER CAUSE CONTROL, V11, P171, DOI 10.1023/A:1008951901148; Kuriyama S, 2005, INT J CANCER, V113, P148, DOI 10.1002/ijc.20529; Kurozawa Y, 2005, BRIT J CANCER, V93, P607, DOI 10.1038/sj.bjc.6602737; Lagiou P, 2000, J NATL CANCER I, V92, P1096, DOI 10.1093/jnci/92.13.1096; LaVecchia C, 1997, INT J CANCER, V73, P204, DOI 10.1002/(SICI)1097-0215(19971009)73:2<204::AID-IJC7>3.0.CO;2-#; Lecube A, 2004, DIABETES CARE, V27, P1171, DOI 10.2337/diacare.27.5.1171; Liaw KM, 1998, TOB CONTROL, V7, P141, DOI 10.1136/tc.7.2.141; LIAW YF, 1995, HEPATOLOGY, V22, P1101, DOI 10.1016/0270-9139(95)90615-0; Liu BQ, 1998, BMJ-BRIT MED J, V317, P1411, DOI 10.1136/bmj.317.7170.1411; Loguercio C, 2000, ALCOHOL ALCOHOLISM, V35, P296, DOI 10.1093/alcalc/35.3.296; Mandayam S, 2004, SEMIN LIVER DIS, V24, P217, DOI 10.1055/s-2004-832936; Manno M, 2004, GASTROENTEROLOGY, V127, P756, DOI 10.1053/j.gastro.2004.06.021; Marchesini G, 2005, ANN MED, V37, P333, DOI 10.1080/07853890510011445; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; Marrero JA, 2004, GASTROENTEROLOGY, V126, P347, DOI 10.1053/j.gastro.2003.11.021; Marrero JA, 2002, HEPATOLOGY, V36, P1349, DOI 10.1053/jhep.2002.36939; Mastrangelo G, 2004, ENVIRON HEALTH PERSP, V112, P1188, DOI 10.1289/ehp.6972; McGlynn KA, 2005, BEST PRACT RES CL GA, V19, P3, DOI 10.1016/j.bpg.2004.10.004; McKillop IH, 2005, ALCOHOL, V35, P195, DOI 10.1016/j.alcohol.2005.04.004; Mehta SH, 2003, HEPATOLOGY, V38, P50, DOI 10.1053/jhep.2003.50291; Mehta SH, 2001, EPIDEMIOL REV, V23, P302, DOI 10.1093/oxfordjournals.epirev.a000808; MENDENHALL CL, 1991, HEPATOLOGY, V14, P581; Mizoue T, 2000, INT J EPIDEMIOL, V29, P232, DOI 10.1093/ije/29.2.232; MOLLER H, 1994, EUR J CANCER, V30A, P344, DOI 10.1016/0959-8049(94)90254-2; Monto A, 2004, HEPATOLOGY, V39, P826, DOI 10.1002/hep.20127; Morgan TR, 2004, GASTROENTEROLOGY, V127, pS87, DOI 10.1053/j.gastro.2004.09.020; Mori M, 2000, AM J EPIDEMIOL, V151, P131, DOI 10.1093/oxfordjournals.aje.a010180; Nair S, 2002, HEPATOLOGY, V36, P150, DOI 10.1053/jhep.2002.33713; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; NKONTCHOU G, 2006, IN PRESS CLIN GASTRO; Pan SY, 2004, AM J EPIDEMIOL, V159, P259, DOI 10.1093/aje/kwh041; Pessione F, 2001, HEPATOLOGY, V34, P121, DOI 10.1053/jhep.2001.25385; Peters MG, 2002, HEPATOLOGY, V36, pS220, DOI 10.1053/jhep.2002.36811; Pintus F, 1996, EUR J EPIDEMIOL, V12, P71, DOI 10.1007/BF00144431; Poikolainen K, 1997, AM J EPIDEMIOL, V146, P1019, DOI 10.1093/oxfordjournals.aje.a009230; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; PONTISSO P, 1993, GASTROENTEROLOGY, V105, P1529, DOI 10.1016/0016-5085(93)90161-5; Poschl G, 2004, ALCOHOL ALCOHOLISM, V39, P155, DOI 10.1093/alcalc/agh057; POWELL EE, 1990, HEPATOLOGY, V11, P74, DOI 10.1002/hep.1840110114; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Raimondo G, 2006, HEPATOLOGY, V43, P100, DOI 10.1002/hep.20944; Rapp K, 2005, BRIT J CANCER, V93, P1062, DOI 10.1038/sj.bjc.6602819; Ratziu V, 2005, ALIMENT PHARM THERAP, V22, P56, DOI 10.1111/j.1365-2036.2005.02598.x; Ratziu V, 2002, HEPATOLOGY, V35, P1485, DOI 10.1053/jhep.2002.33324; RATZIU V, 2005, FATTY LIVER DIS NASH, P263; Regev A, 1999, ALCOHOL CLIN EXP RES, V23, P1543, DOI 10.1111/j.1530-0277.1999.tb04679.x; Regimbeau Jean M, 2004, Liver Transpl, V10, pS69, DOI 10.1002/lt.20033; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rothman K, 1986, MODERN EPIDEMIOLOGY; RoudotThoraval F, 1997, HEPATOLOGY, V26, P485, DOI 10.1002/hep.510260233; Ruhl CE, 2005, GASTROENTEROLOGY, V129, P1928, DOI 10.1053/j.gastro.2005.08.056; Sagnelli E, 2005, J MED VIROL, V75, P522, DOI 10.1002/jmv.20313; Samanic C, 2004, CANCER CAUSE CONTROL, V15, P35, DOI 10.1023/B:CACO.0000016573.79453.ba; Sangiovanni A, 2004, GASTROENTEROLOGY, V126, P1005, DOI 10.1053/j.gastro.2003.12.049; Sharp DS, 1999, ANN EPIDEMIOL, V9, P391; Shi J, 2005, BRIT J CANCER, V92, P607, DOI 10.1038/sj.bjc.6602333; Shimada M, 2002, J HEPATOL, V37, P154, DOI 10.1016/S0168-8278(02)00099-5; Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056; Sorensen HT, 2003, J CLIN GASTROENTEROL, V36, P356, DOI 10.1097/00004836-200304000-00015; Sorensen HT, 1998, HEPATOLOGY, V28, P921, DOI 10.1002/hep.510280404; Squadrito G, 2006, CANCER-AM CANCER SOC, V106, P1326, DOI 10.1002/cncr.21702; Staretz ME, 1997, DRUG METAB DISPOS, V25, P154; STROFFOLINI T, 1992, J HEPATOL, V16, P360, DOI 10.1016/S0168-8278(05)80670-1; Stroffolini T, 2004, DIGEST LIVER DIS, V36, P56, DOI 10.1016/j.dld.2003.07.007; Sun CA, 2003, AM J EPIDEMIOL, V157, P674, DOI 10.1093/aje/kwg041; Sun ZT, 1999, HEPATOLOGY, V30, P379, DOI 10.1002/hep.510300204; Tanaka K, 1998, INT J EPIDEMIOL, V27, P438, DOI 10.1093/ije/27.3.438; TELI MR, 1995, LANCET, V346, P987, DOI 10.1016/S0140-6736(95)91685-7; Torbenson M, 2002, LANCET INFECT DIS, V2, P479, DOI 10.1016/S1473-3099(02)00345-6; Tverdal A, 2003, ANN EPIDEMIOL, V13, P419, DOI 10.1016/S1047-2797(02)00462-3; TZONOU A, 1991, INT J CANCER, V49, P377, DOI 10.1002/ijc.2910490311; VALLMAYANS M, 1990, INT J CANCER, V46, P378; Verlato G, 2003, DIABETES CARE, V26, P1047, DOI 10.2337/diacare.26.4.1047; Vineis P, 2004, JNCI-J NATL CANCER I, V96, P99, DOI 10.1093/jnci/djh014; Voigt Michael D, 2005, Clin Liver Dis, V9, P151, DOI 10.1016/j.cld.2004.10.003; Wang LY, 1998, AM J EPIDEMIOL, V147, P315; Wang LY, 2003, CANCER CAUSE CONTROL, V14, P241, DOI 10.1023/A:1023636619477; Wideroff L, 1997, J NATL CANCER I, V89, P1360, DOI 10.1093/jnci/89.18.1360; Wolk A, 2001, CANCER CAUSE CONTROL, V12, P13, DOI 10.1023/A:1008995217664; Wong RH, 2003, J OCCUP ENVIRON MED, V45, P379, DOI 10.1097/01.jom.0000063622.37065.fd; Yamanaka T, 2001, ANTICANCER RES, V21, P2937; YOSUYANAGI H, 2004, ALCOHOL CLIN EXP RES, V28, pS181; YU MC, 1991, JNCI-J NATL CANCER I, V83, P1820, DOI 10.1093/jnci/83.24.1820; Yu MC, 2004, GASTROENTEROLOGY, V127, pS72, DOI 10.1016/j.gastro.2004.09.018; Yu MW, 1997, AM J EPIDEMIOL, V145, P1039, DOI 10.1093/oxfordjournals.aje.a009060; Yuan JM, 2004, CANCER, V101, P1009, DOI 10.1002/cncr.20427; ZAVITSANOS X, 1992, CANCER RES, V52, P5364; Zen Y, 2001, PATHOL INT, V51, P127, DOI 10.1046/j.1440-1827.2001.01174.x; Zoli M, 1996, CANCER-AM CANCER SOC, V78, P977, DOI 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.0.CO;2-9	168	97	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3756	3770		10.1038/sj.onc.1209557	http://dx.doi.org/10.1038/sj.onc.1209557			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799617	Green Published			2022-12-28	WOS:000238559600003
J	Phang, BH; Sabapathy, K				Phang, B. H.; Sabapathy, K.			The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models	ONCOGENE			English	Article						codon 72 polymorphism; CRM1; growth inhibition; mouse cells; MDM2; p53	IN-VITRO; TUMOR SUPPRESSION; APOPTOSIS; CANCER; VARIANTS; MICE; DIFFERENTIATION; TRANSCRIPTION; CHEMOTHERAPY; INHIBITION	Human p53, unlike mouse p53, contains a polymorphic site at codon 72 in exon 4 encoding either an arginine amino acid ( 72R) or a proline residue ( 72P). The 72R form was shown to induce apoptosis better than the 72P form, partly owing to its ability to efficiently bind to the nuclear-export protein CRM1 and localize to the mitochondria. This polymorphism has also been associated with cancer predisposition and chemo-sensitivity. Further understanding of the in vivo significance of this polymorphism in carcinogenesis requires the generation of mouse models. We have thus evaluated if the polymorphism-specific effects of human p53 are retained in mouse cells. Though being transcriptionally active, both the human polymorphs were found to have lost their ability to differentially suppress growth and bind to CRM1 or MDM2 in mouse cells. Moreover, chimaeric proteins containing mouse exons 2-3 and human exons 4-11 have also lost the polymorphism-specific effects in human cells, suggesting that human exons 2-3 are important in regulating the polymorphism-specific effects. Furthermore, human p53 and the various chimaeric proteins were generally less effective in inhibiting growth of mouse cells compared to mouse p53, suggesting that mouse p53 is more potent than human p53 in suppressing growth, partly due to enhanced binding of MDM2 to human p53. The data together suggest that mouse cells may not provide an appropriate environment for the manifestation of the polymorphism-specific functional differences of human p53, and hence, cautions against the expression of full-length or chimaeric p53 proteins in mice to study the effects of the polymorphism.	Natl Canc Ctr, Lab Mol Carcinogenesis, Div Cellular & Mol Res, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Lab Mol Carcinogenesis, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Chen WP, 1998, VIROLOGY, V251, P217, DOI 10.1006/viro.1998.9431; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dudgeon C, 2006, CANCER RES, V66, P2928, DOI 10.1158/0008-5472.CAN-05-2063; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jardine LJ, 1999, ONCOGENE, V18, P7602, DOI 10.1038/sj.onc.1203137; Jaworski M, 2005, CARCINOGENESIS, V26, P1829, DOI 10.1093/carcin/bgi142; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Toh WH, 2005, J BIOL CHEM, V280, P17329, DOI 10.1074/jbc.M500044200; Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189	44	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2964	2974		10.1038/sj.onc.1210112	http://dx.doi.org/10.1038/sj.onc.1210112			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130838				2022-12-28	WOS:000246395400002
J	Ambrosini, G; Sambol, EB; Carvajal, D; Vassilev, LT; Singer, S; Schwartz, GK				Ambrosini, G.; Sambol, E. B.; Carvajal, D.; Vassilev, L. T.; Singer, S.; Schwartz, G. K.			Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1	ONCOGENE			English	Article						MDM2; nutlin-3a; E2F1; DNA damage; apoptosis	UBIQUITIN LIGASE ACTIVITY; DNA-DAMAGE; MDM2 ANTAGONISTS; E2F-1-INDUCED APOPTOSIS; S-PHASE; PATHWAY; PROTEIN; P73; DEGRADATION; ONCOPROTEIN	MDM2 is a critical negative regulator of the p53 tumor suppressor protein. Recently, small-molecule antagonists of MDM2, the Nutlins, have been developed to inhibit the p53-MDM2 interaction and activate p53 signaling. However, half of human cancers have mutated p53 and they are resistant to Nutlin treatment. Here, we report that treatment of the p53-mutant malignant peripheral nerve sheath (MPNST) and p53-null HCT116 cells with cisplatin (Cis) and Nutlin-3a induced a degree of apoptosis that was significantly greater than either drug alone. Nutlin-3a also increased the cytotoxicity of both carboplatin and doxorubicin in a series of p53-mutant human tumor cell lines. In the human dedifferentiated liposarcoma cell line (LS141) and the p53 wild-type HCT116 cells, Nutlin-3a induced downregulation of E2F1 and this effect appeared to be proteasome dependent. In contrast, in MPNST and HCTp53-/- cells, Nutlin-3a inhibited the binding of E2F1 to MDM2 and induced transcriptional activation of free E2F1 in the presence of Cis-induced DNA damage. Downregulation of E2F1 by small interfering RNA significantly decreased the level of apoptosis induced by Cis and Nutlin-3a treatment. Moreover, expression of a dominant-negative form of E2F1 rescued cells from apoptosis, whereas cells overexpressing wildtype E2F1 showed an increase in cell death. This correlated with the induction of the proapoptotic proteins p73 alpha and Noxa, which are both regulated by E2F1. These results indicate that antagonism of MDM2 by Nutlin-3a in cells with mutant p53 enhances chemosensitivity in an E2F1- dependent manner. Nutlin-3a therefore may provide a therapeutic benefit in tumors with mutant p53 provided it is combined with chemotherapy.	Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, Sarcoma Dis Management Program Lab, New York, NY 10021 USA; F Hoffmann La Roche & Co Ltd, Roche Res Ctr, Discovery Oncol, Nutley, NJ USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Roche Holding	Schwartz, GK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Lab New Drug Dev, 1275 York Ave, New York, NY 10021 USA.	Schwartg@mskcc.org		Singer, Samuel/0000-0001-9713-8230				Banerjee D, 1998, CANCER RES, V58, P4292; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Ganguli G, 2003, MOL CANCER RES, V1, P1027; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huang YY, 1997, CANCER RES, V57, P3640; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; JOHNSON AF, 1993, ECOSYSTEMS WORLD, V2, P365; Kojima K, 2005, BLOOD, V106, P3150, DOI 10.1182/blood-2005-02-0553; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; Lin WC, 2001, GENE DEV, V15, P1833; Loughran O, 2000, MOL CELL BIOL, V20, P2186, DOI 10.1128/MCB.20.6.2186-2197.2000; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Meng RD, 1999, INT J ONCOL, V14, P5; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Muller M J, 2001, Obes Rev, V2, P15; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Stuhmer T, 2005, BLOOD, V106, P3609, DOI 10.1182/blood-2005-04-1489; Tovar C, 2006, P NATL ACAD SCI USA, V103, P1888, DOI 10.1073/pnas.0507493103; Vassilev LT, 2005, J MED CHEM, V48, P4491, DOI 10.1021/jm058174k; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Wasylyk C, 1999, ONCOGENE, V18, P1921, DOI 10.1038/sj.onc.1202528; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhang Z, 2005, ONCOGENE, V24, P7238, DOI 10.1038/sj.onc.1208814	36	131	138	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3473	3481		10.1038/sj.onc.1210136	http://dx.doi.org/10.1038/sj.onc.1210136			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17146434				2022-12-28	WOS:000246799200003
J	Del Bello, B; Moretti, D; Gamberucci, A; Maellaro, E				Del Bello, B.; Moretti, D.; Gamberucci, A.; Maellaro, E.			Cross-talk between calpain and caspase-3/-7 in cisplatin-induced apoptosis of melanoma cells: a major role of calpain inhibition in cell death protection and p53 status	ONCOGENE			English	Article						apoptosis; cisplatin; melanoma cells; calpain; p53	KAPPA-B ACTIVATION; PROTEOLYTIC CLEAVAGE; PROTEASE FAMILIES; DEGRADATION; GLUTATHIONE; ALPHA; MODULATION; DEPLETION; MEMBRANE; RELEASE	The contribution of different proteolytic systems, in particular calpains and effector caspases, in apoptotic cell death is still controversial. In this paper, we show that during cisplatin-induced apoptosis of human metastatic melanoma cells, calpain activation, as measured in intact cells by two different fluorescent substrates, is an early event, taking place well before caspase-3/-7 activation, and progressively increasing during 48 h of treatment. Such activation appears to be independent from any intracellular calcium imbalance; in fact, an increase of cytosolic calcium along with emptying of the reticular stores occur only at very late stages, uniquely in frankly apoptotic, detached cells. Calpain activation proves to be an early and crucial event in the apoptotic machinery, as demonstrated by the significant protection of cell death in samples co-treated with the calpain inhibitors, MDL 28170, calpeptin and PD 150606, where a variable but significant reduction of both caspase-3/-7 activity and cell detachment is observed. Consistently, such a protective effect can be at least partially due to the impairment of cisplatin-induced p53 activation, occurring early in committed, preapoptotic cells. Furthermore, in late apoptotic cells, calpain activity is also responsible for the formation of a novel p53 proteolytic fragment (approximate to 26 kDa), whose function is so far to be elucidated.	Univ Siena, Dept Physiopathol & Expt Med, I-53100 Siena, Italy	University of Siena	Maellaro, E (corresponding author), Univ Siena, Dept Physiopathol & Expt Med, Via A Moro, I-53100 Siena, Italy.	maellaro@unisi.it	Moretti, Daniele/G-4082-2011; Gamberucci, Alessandra/P-5888-2017	Gamberucci, Alessandra/0000-0003-3373-0256				Arora AS, 1996, J CELL PHYSIOL, V167, P434, DOI 10.1002/(SICI)1097-4652(199606)167:3<434::AID-JCP7>3.0.CO;2-Q; Atencio IA, 2000, CELL GROWTH DIFFER, V11, P247; Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; Daniel KG, 2003, INT J MOL MED, V12, P247; Davies EV, 1998, BIOCHEM BIOPH RES CO, V248, P679, DOI 10.1006/bbrc.1998.9031; Del Bello B, 2004, EXP CELL RES, V293, P302, DOI 10.1016/j.yexcr.2003.10.024; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; Gao G, 2000, J CELL BIOCHEM, V80, P53; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Ghibelli L, 1998, FASEB J, V12, P479, DOI 10.1096/fasebj.12.6.479; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Gorka M, 2004, CELL BIOL INT, V28, P741, DOI 10.1016/j.cellbi.2004.07.003; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Kitagaki H, 2000, BIOSCI BIOTECH BIOCH, V64, P689, DOI 10.1271/bbb.64.689; Knepper-Nicolai B, 1998, J BIOL CHEM, V273, P30530, DOI 10.1074/jbc.273.46.30530; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kobayashi S, 2002, J BIOL CHEM, V277, P33968, DOI 10.1074/jbc.M203350200; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macho A, 1997, J IMMUNOL, V158, P4612; Maellaro E, 2003, BRIT J DERMATOL, V148, P1115, DOI 10.1046/j.1365-2133.2003.05301.x; Maellaro E, 2000, J CELL SCI, V113, P2671; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; Melloni E, 2000, J BIOL CHEM, V275, P82, DOI 10.1074/jbc.275.1.82; Melloni E, 1998, J BIOL CHEM, V273, P12827, DOI 10.1074/jbc.273.21.12827; Molinari M, 1996, ONCOGENE, V13, P2077; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Okorokov AL, 1997, ONCOL RES, V9, P267; Pariat M, 1997, MOL CELL BIOL, V17, P2806, DOI 10.1128/MCB.17.5.2806; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Porn-Ares MI, 1998, CELL DEATH DIFFER, V5, P1028, DOI 10.1038/sj.cdd.4400424; ROSSER BG, 1993, J BIOL CHEM, V268, P23593; SALAMINO F, 1993, BIOCHEM J, V290, P191, DOI 10.1042/bj2900191; Sato K, 2001, BIOL CHEM, V382, P743, DOI 10.1515/BC.2001.090; Schaecher K, 2004, NEUROCHEM RES, V29, P1443, DOI 10.1023/B:NERE.0000026410.56000.dd; Sedarous M, 2003, J BIOL CHEM, V278, P26031, DOI 10.1074/jbc.M302833200; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; Volbracht C, 2005, J NEUROCHEM, V93, P1280, DOI 10.1111/j.1471-4159.2005.03122.x; Wang JP, 2000, MOL CARCINOGEN, V29, P179, DOI 10.1002/1098-2744(200011)29:3<179::AID-MC7>3.0.CO;2-K; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; WU HY, 1994, J BIOL CHEM, V269, P20067; Zhang WL, 1996, J BIOL CHEM, V271, P18825, DOI 10.1074/jbc.271.31.18825; Zhu DM, 2000, CLIN CANCER RES, V6, P2456	59	52	52	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2007	26	19					2717	2726		10.1038/sj.onc.1210079	http://dx.doi.org/10.1038/sj.onc.1210079			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17130844				2022-12-28	WOS:000246210600006
J	Jacquel, A; Colosetti, P; Grosso, S; Belhacene, N; Puissant, A; Marchetti, S; Breittmayer, JP; Auberger, P				Jacquel, A.; Colosetti, P.; Grosso, S.; Belhacene, N.; Puissant, A.; Marchetti, S.; Breittmayer, J-P; Auberger, P.			Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition	ONCOGENE			English	Article						imatinib; PD166326; apoptosis; erythroid differentiation; caspases; CML	TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; SMALL-INTERFERING-RNA; IMATINIB MESYLATE STI571; K562 CELLS; MEGAKARYOCYTIC DIFFERENTIATION; GENE-EXPRESSION; C-KIT; ACTIVATION; CLEAVAGE	Imatinib targets the Bcr-Abl oncogene that causes chronic myelogenous leukemia (CML) in humans. Recently, we demonstrated that besides triggering apoptosis in K562 cells, imatinib also mediated their erythroid differentiation. Although both events appear to proceed concomitantly, it is not known at present whether or not imatinib-induced apoptosis and differentiation are interdependent processes. Hence, we investigated the requirements for Bcr-Abl inhibitor-mediated apoptosis and erythroid differentiation in several established and engineered CML cell lines. Imatinib triggered apoptosis and erythroid differentiation of different CML cell lines, but only apoptosis exhibited sensitivity to ZVAD-fmk inhibition. Conversely, the p38 mitogen-activated protein (MAP) kinase inhibitor, SB202190, significantly slowed down erythroid differentiation without affecting caspase activation. Furthermore, imatinib and PD166326, another Bcr-Abl inhibitory molecule, triggered erythroid differentiation of K562 cell clones, nevertheless resistant to Bcr-Abl inhibitor-induced apoptosis. Finally, short hairpin RNA inhibitor (shRNAi) silencing of caspase 3 efficiently inhibited caspase activity but had no effect on erythroid differentiation, whereas silencing of Bcr-Abl mimicked imatinib or PD166326 treatment, leading to increased apoptosis and erythroid differentiation of K562 cells. Taken together, our findings not only demonstrate that Bcr-Abl inhibitor-mediated apoptosis and differentiation are fully distinguishable events, but also that caspases are dispensable for erythroid differentiation of established CML cell lines.	Natl Contre Canc, INSERM U526, Equipe Labellisee Ligue, Cell Death Differentiat & Canc Team, F-06107 Nice, France; Univ Nice Sophia Antipolis, Nice, France; CHU Nice, Hop Archet, INSERM U576, Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm)	Auberger, P (corresponding author), Natl Contre Canc, INSERM U526, Equipe Labellisee Ligue, Cell Death Differentiat & Canc Team, 28 Ave Valombrose, F-06107 Nice, France.	auberger@unice.fr	Jacquel, Arnaud/O-1928-2017; Puissant, Alexandre/AAF-3875-2021; Colosetti, Pascal/ABH-4585-2020; PUISSANT, ALEXANDRE/O-9575-2016; Jacquel, Arnaud/AAJ-4760-2021; Marchetti, Sandrine/P-6479-2016; AUBERGER, Patrick/G-1491-2013	Jacquel, Arnaud/0000-0001-5062-8048; Puissant, Alexandre/0000-0002-3997-9282; PUISSANT, ALEXANDRE/0000-0002-3997-9282; Jacquel, Arnaud/0000-0001-5062-8048; Marchetti, Sandrine/0000-0001-8326-5730; AUBERGER, Patrick/0000-0002-2481-8275				Belhacene N, 1998, FASEB J, V12, P531; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Carlile GW, 2004, BLOOD, V103, P4310, DOI 10.1182/blood-2003-09-3362; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Dorsey JF, 2002, BLOOD, V99, P1388, DOI 10.1182/blood.V99.4.1388; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Herrant M, 2004, ONCOGENE, V23, P7863, DOI 10.1038/sj.onc.1208069; Huron DR, 2003, CLIN CANCER RES, V9, P1267; Jacquel A, 2006, ONCOGENE, V25, P781, DOI 10.1038/sj.onc.1209119; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Kawano T, 2004, MOL CELL BIOCHEM, V258, P25, DOI 10.1023/B:MCBI.0000012830.96393.b9; Kohmura K, 2004, J CELL PHYSIOL, V198, P370, DOI 10.1002/jcp.10426; Kolbus A, 2002, J EXP MED, V196, P1347, DOI 10.1084/jem.20020562; Krauss SW, 2005, BLOOD, V106, P2200, DOI 10.1182/blood-2005-04-1357; Kuzelova K, 2005, J CELL BIOCHEM, V95, P268, DOI 10.1002/jcb.20407; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Okada M, 2004, BLOOD, V103, P2299, DOI 10.1182/blood-2003-05-1605; Parmar S, 2004, J BIOL CHEM, V279, P25345, DOI 10.1074/jbc.M400590200; Perfettini JL, 2003, NAT IMMUNOL, V4, P308, DOI 10.1038/ni0403-308; Pettiford SM, 2003, LEUKEMIA, V17, P366, DOI 10.1038/sj.leu.2402767; Racke FK, 2001, J BIOL CHEM, V276, P522, DOI 10.1074/jbc.M005236200; Rangatia J, 2006, LEUKEMIA, V20, P68, DOI 10.1038/sj.leu.2403999; Roskoski R, 2003, BIOCHEM BIOPH RES CO, V309, P709, DOI 10.1016/j.bbrc.2003.08.055; Scherr M, 2003, BLOOD, V101, P1566, DOI 10.1182/blood-2002-06-1685; Steelman LS, 2004, LEUKEMIA, V18, P189, DOI 10.1038/sj.leu.2403241; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; WITHEY JM, 2005, LEUKEMIA RES, V30, P553; Wohlbold L, 2003, BLOOD, V102, P2236, DOI 10.1182/blood-2002-12-3899; Wolff NC, 2005, BLOOD, V105, P3995, DOI 10.1182/blood-2004-09-3534; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Zermati Y, 2001, J EXP MED, V193, P247, DOI 10.1084/jem.193.2.247	32	44	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 12	2007	26	17					2445	2458		10.1038/sj.onc.1210034	http://dx.doi.org/10.1038/sj.onc.1210034			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043649				2022-12-28	WOS:000245831000005
J	Perrin, D; Ballestar, E; Fraga, MF; Frappart, L; Esteller, M; Guerin, JF; Dante, R				Perrin, D.; Ballestar, E.; Fraga, M. F.; Frappart, L.; Esteller, M.; Guerin, J-F; Dante, R.			Specific hypermethylation of LINE-1 elements during abnormal overgrowth and differentiation of human placenta	ONCOGENE			English	Article						DNA methylation; repetitive elements; human; partial hydatidiform mole (PHM); triploid diandric embryos; 5-methylcytosine antibody	DNA METHYLATION; CPG ISLAND; 5-METHYLCYTOSINE CONTENT; HYPOMETHYLATION; CANCER; EXPRESSION; BRCA1; ASSOCIATION; PHENOTYPE; SEQUENCES	In human post-natal somatic cells, low global levels of DNA methylation have been associated with the hypomethylation of several repetitive elements, a feature that has been proposed to be a surrogate epigenetic marker. These data, mainly derived from the analysis of cancer cells, suggest a potential association between loss of cell-growth control and altered differentiation with hypomethylation of repetitive sequences. Partial hydatidiform moles (PHMs) can be used as an alternative model for investigating this association in a non-tumorigenic context. This gestational disease is characterized by abnormal overgrowth and differentiation of the placenta and spontaneous abortion. Here, we comprehensively analyse the DNA methylation of these trophoblastic tissues in both PHM and normal placenta at global and sequence-specific levels. Analysis of the global 5-methylcytosine content and immunohistochemistry indicate that PHM and normal placenta have identical global levels of DNA methylation. In contrast, bisulfite genomic sequencing shows that, whereas Alu, NBL2 and satellite 2 repetitive elements are equally methylated, LINE-1 sequences are hypermethylated in PHM tissues (similar to 2-fold relative to normal placenta). Interestingly, altered demethylation is also found in triploid diandric embryos that originate from dispermic fertilization of an oocyte, a common event responsible for most PHMs. In conclusion, alterations of DNA methylation do not seem to be randomly distributed in PHM, as several repeated elements remain unaltered, whereas LINE-1 sequences are hypermethylated. In addition, our findings suggest that the hypomethylation of repetitive elements in cancer is directly linked to the neoplasic process and not a simple consequence of loss of growth control observed in most of the cancer cells.	Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, F-69373 Lyon 08, France; Spanish Natl Canc Ctr CNIO, Canc Epigenet Lab, Madrid, Spain; Hop Edouard Herriot, Anat Pathol Lab, Lyon, France; Univ Lyon 1, Lab Biol Reprod & Dev, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; Centro Nacional de Investigaciones Oncologicas (CNIO); CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dante, R (corresponding author), Ctr Leon Berard, INSERM Unite 590, Oncol Mol Lab, 28 Rue Laennec, F-69373 Lyon 08, France.	dante@univ-lyon1.fr	Ballestar, Esteban/ABG-8561-2020; Fraga, Mario F/H-7824-2017; Esteller, Manel/L-5956-2014	Fraga, Mario F/0000-0001-8450-2603; Esteller, Manel/0000-0003-4490-6093; Ballestar, Esteban/0000-0002-1400-2440				[Anonymous], 2003, WHO CLASSIFICATION T; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137; Chen HZ, 2005, J SOC GYNECOL INVEST, V12, P214, DOI 10.1016/j.jsgi.2005.01.009; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832; FEINBERG AP, 1988, CANCER RES, V48, P1159; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P3087, DOI 10.1093/nar/11.10.3087; Genest DR, 2001, INT J GYNECOL PATHOL, V20, P315, DOI 10.1097/00004347-200110000-00001; Ghabreau L, 2004, VIRCHOWS ARCH, V445, P129, DOI 10.1007/s00428-004-1059-4; HJELLE BL, 1982, NUCLEIC ACIDS RES, V10, P3459, DOI 10.1093/nar/10.11.3459; Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222; JEANPIERRE M, 1994, ANN GENET-PARIS, V37, P163; Judson H, 2002, NATURE, V416, P539, DOI 10.1038/416539a; Lee C, 1997, HUM GENET, V100, P291, DOI 10.1007/s004390050508; Magdinier F, 2002, MOL HUM REPROD, V8, P630, DOI 10.1093/molehr/8.7.630; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Magdinier F, 2000, FASEB J, V14, P1585, DOI 10.1096/fj.14.11.1585; Morgan HD, 2005, HUM MOL GENET, V14, pR47, DOI 10.1093/hmg/ddi114; Nishiyama R, 2005, MOL CANCER RES, V3, P617, DOI 10.1158/1541-7786.MCR-05-0146; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Tsien F, 2002, CYTOGENET GENOME RES, V98, P13, DOI 10.1159/000068543; Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987; Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032; Young LE, 2004, ANIM REPROD SCI, V82-3, P61, DOI 10.1016/j.anireprosci.2004.05.020; Zaragoza MV, 2000, AM J HUM GENET, V66, P1807, DOI 10.1086/302951	32	39	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2518	2524		10.1038/sj.onc.1210039	http://dx.doi.org/10.1038/sj.onc.1210039			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043645				2022-12-28	WOS:000245831000013
J	Choi, SH; Mendrola, JM; Lemmon, MA				Choi, S. H.; Mendrola, J. M.; Lemmon, M. A.			EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer	ONCOGENE			English	Article						EGFR; ErbB; somatic mutations; constitutive activation; internalization; autoinhibition	EPIDERMAL-GROWTH-FACTOR; BREAST-CANCER; KINASE DOMAIN; TYROSINE KINASE; TRANSFORMATION; INHIBITOR; ONCOGENE; MUTANTS; PROGRESSION; EXPRESSION	Several somatic mutations within the tyrosine kinase domain of epidermal growth factor receptor (EGFR) have been identified that predict clinical response of non-small-cell lung carcinoma (NSCLC) patients to getfitnib. To test the hypothesis that these mutations cause constitutive EGF receptor signaling, and to investigate its mechanistic basis, we expressed representative examples in a null background and analysed their biochemical properties. Each mutation caused significant EGF-independent tyrosine phosphorylation of EGFR, and allowed the receptor to promote Ba/F3 cell mitogenesis in the absence of EGF, arguing that these are oncogenic mutations. Active mutated receptors are present at the cell surface and are fully competent to bind EGF. Recent structural studies show that the inactive EGFR tyrosine kinase domain is autoinhibited by intramolecular interactions between its activation loop and alpha C helix. We find that mutations predicted to disrupt this autoinhibitory interaction (including several that have not been described in NSCLC) elevate EGF-independent tyrosine kinase activity, thus providing new insight into how somatic mutations activate EGFR and other ErbB family members.	Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania	Lemmon, MA (corresponding author), Univ Penn, Sch Med, Dept Biochem & Biophys, 809C Stellar Chance Labs,422 Curie Blvd, Philadelphia, PA 19104 USA.	mlemmon@mail.med.upenn.edu		Lemmon, Mark/0000-0002-3379-5319	NATIONAL CANCER INSTITUTE [R01CA096768] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA096768, R01-CA096768] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amann J, 2005, CANCER RES, V65, P226; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; Dent R, 2006, CANCER TREAT REV, V32, P144, DOI 10.1016/j.ctrv.2006.01.005; DI FP, 1987, CELL, V51, P1063; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Ferguson KM, 2003, MOL CELL, V11, P507, DOI 10.1016/S1097-2765(03)00047-9; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HUDZIAK RM, 1991, J BIOL CHEM, V266, P24109; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238; Ozcan F, 2006, P NATL ACAD SCI USA, V103, P5735, DOI 10.1073/pnas.0601469103; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Sakai K, 2006, FASEB J, V20, P311, DOI 10.1096/fj.05-4034fje; SCHECHTER Y, 1979, NATURE, V278, P835, DOI 10.1038/278835a0; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Stamos J, 2002, J BIOL CHEM, V277, P46265, DOI 10.1074/jbc.M207135200; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Walker F, 2004, J BIOL CHEM, V279, P22387, DOI 10.1074/jbc.M401244200; Wood ER, 2004, CANCER RES, V64, P6652, DOI 10.1158/0008-5472.CAN-04-1168; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013	41	59	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1567	1576		10.1038/sj.onc.1209957	http://dx.doi.org/10.1038/sj.onc.1209957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16953218				2022-12-28	WOS:000244782500006
J	De Gregorio, G; Coppa, A; Cosentino, C; Ucci, S; Messina, S; Nicolussi, A; D'Inzeo, S; Di Pardo, A; Avvedimento, EV; Porcellini, A				De Gregorio, G.; Coppa, A.; Cosentino, C.; Ucci, S.; Messina, S.; Nicolussi, A.; D'Inzeo, S.; Di Pardo, A.; Avvedimento, E. V.; Porcellini, A.			The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals	ONCOGENE			English	Article						phosphoinositide-3-kinase; signal trasduction; thyropropin receptor; protein kinase A; cAMP	DEPENDENT PROTEIN-KINASE; STIMULATING HORMONE TSH; DNA-SYNTHESIS; RAS; ACTIVATION; PATHWAYS; FIBROBLASTS; RECEPTOR; 3-KINASE; CELLS	Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85 alpha(PI3K) phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH- induced cell cycle progression and was lethal in thyroid cells (FRTL-5). The aspartic version of the p85 alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal. The p85a PI3K wild type not the p85A bound PKA regulatory subunit RII beta in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85a PI3K to RIIb was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wildtype p85a PI3K but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factor-stimulated PI3K activity. We suggest that (1) TSH cAMP-induced PKA phosphorylates p85 alpha(PI3K) at serine 83, (2) phosphorylated p85 alpha(PI3K) binds RII beta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH - cAMP growth signals.	Univ Roma La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; IRCCs Neuromed, Dipartimento Patol Mol, Pozzilli, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; Univ Naples Federico II, CNR, Ist Edocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy	Sapienza University Rome; IRCCS Neuromed; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II	Porcellini, A (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena, I-00161 Rome, Italy.	avvedim@unina.it; antonio.porcellini@uniroma1.it	Porcellini, Antonio/E-1900-2011; Cosentino, Claudia/AAF-1100-2019; coppa, anna/N-3274-2016; Porcellini, Antonio/AAC-6097-2019; Di Pardo, Alba/AAC-9393-2020	Porcellini, Antonio/0000-0001-6882-9518; Di Pardo, Alba/0000-0002-9514-0086; coppa, anna/0000-0001-9758-5444				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; COSENTINO C, 2006, IN PRESS ONCOGENE; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Grieco D, 1996, SCIENCE, V271, P1718, DOI 10.1126/science.271.5256.1718; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Suh JM, 2003, J BIOL CHEM, V278, P21960, DOI 10.1074/jbc.M300805200; Wang XM, 2005, J BIOL CHEM, V280, P16705, DOI 10.1074/jbc.M501819200	16	42	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2039	2047		10.1038/sj.onc.1210011	http://dx.doi.org/10.1038/sj.onc.1210011			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17043656				2022-12-28	WOS:000245313400006
J	Erkeland, SJ; Aarts, LH; Irandoust, M; Roovers, O; Klomp, A; Valkhof, M; Gits, J; Eyckerman, S; Tavernier, J; Touw, IP				Erkeland, S. J.; Aarts, L. H.; Irandoust, M.; Roovers, O.; Klomp, A.; Valkhof, M.; Gits, J.; Eyckerman, S.; Tavernier, J.; Touw, I. P.			Novel role of WD40 and SOCS box protein-2 in steady-state distribution of granulocyte colony-stimulating factor receptor and G-CSF-controlled proliferation and differentiation signaling	ONCOGENE			English	Article						WD40 and SOCS box protein; G-CSF receptor; steady-state distribution; forward routing; proliferation-differentiation balance	NEUTROPENIA/ACUTE MYELOID-LEUKEMIA; DISTINCT CYTOPLASMIC REGIONS; UBIQUITIN; ACTIVATION; INTERNALIZATION; GROWTH; DOMAIN; SUPPRESSION; INDUCTION; SURVIVAL	Signals induced by granulocyte colony-stimulating factor (G-CSF), the major cytokine involved in neutrophil development, are tightly controlled by ligand-induced receptor internalization. Truncated G-CSF receptors(GCSF-Rs) that fail to internalize show sustained proliferation and defective differentiation signaling. Steady-state forward routing also determines cell surface levels of cytokine receptors, but mechanisms controlling this are poorly understood. Here, we show that WD40 and suppressor of cytokine signaling (SOCS) box protein-2 (Wsb-2), an SOCS box-containing WD40 protein with currently unknown function, bindsto the COOH-terminal region of G-CSF-R. Removal of this region did not affect internalization, yet resulted in increased membrane expression of G-CSF-R and enhanced proliferation signaling at the expense of differentiation induction. Conversely, Wsb-2 binding to the G-CSF-R reduced its cell surface expression and inhibited proliferation signaling. These effects depended on the SOCS box involved in ubiquitylation and on cytosolic lysines of G-CSF-R and imply a major role for ubiquitylation through the G-CSFR C-terminusin forward routing of the receptor. Importantly, the Wsb-2 gene iscommonly disrupted by virus integrations in mouse leukemia. We conclude that control of forward routing of G-CSF-R is essential for a balanced response of myeloid progenitors to G-CSF and suggest that disturbance of this balance may contribute to myeloid leukemia.	Erasmus Univ, Ctr Med, Dept Hematol, NL-3000 DR Rotterdam, Netherlands; Univ Ghent, Flanders Interuniv Inst Biotechnol, Dept Med Prot Res, Ghent, Belgium	Erasmus University Rotterdam; Ghent University	Touw, IP (corresponding author), Erasmus Univ, Ctr Med, Dept Hematol, POB 1738, NL-3000 DR Rotterdam, Netherlands.	i.touw@erasmusmc.nl	Tavernier, Jan/AAG-3636-2019	Erkeland, Stefan/0000-0002-1019-7957				Aarts LHJ, 2004, BLOOD, V103, P571, DOI 10.1182/blood-2003-07-2250; Aguilar RC, 2003, CURR OPIN CELL BIOL, V15, P184, DOI 10.1016/S0955-0674(03)00010-3; Avalos BR, 1996, BLOOD, V88, P761, DOI 10.1182/blood.V88.3.761.bloodjournal883761; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DEMETRI GD, 1991, BLOOD, V78, P2791; Dentice M, 2005, NAT CELL BIOL, V7, P698, DOI 10.1038/ncb1272; Dong F, 1998, J IMMUNOL, V161, P6503; Dong F, 2001, J IMMUNOL, V167, P6447, DOI 10.4049/jimmunol.167.11.6447; DONG F, 1993, MOL CELL BIOL, V13, P7774, DOI 10.1128/MCB.13.12.7774; Erkeland SJ, 2004, J VIROL, V78, P1971, DOI 10.1128/JVI.78.4.1971-1980.2004; Erkeland SJ, 2003, BLOOD, V101, P1111, DOI 10.1182/blood-2002-04-1207; Eyckerman S, 2001, NAT CELL BIOL, V3, P1114, DOI 10.1038/ncb1201-1114; Eyckerman Sven, 2002, Sci STKE, V2002, ppl18; FUKUNAGA R, 1993, CELL, V74, P1079, DOI 10.1016/0092-8674(93)90729-A; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Hermans MHA, 2003, BLOOD, V101, P2584, DOI 10.1182/blood-2002-07-2062; Hermans MHA, 1999, J EXP MED, V189, P683, DOI 10.1084/jem.189.4.683; Heuze ML, 2005, J BIOL CHEM, V280, P5468, DOI 10.1074/jbc.M413040200; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hilton DJ, 1998, P NATL ACAD SCI USA, V95, P114, DOI 10.1073/pnas.95.1.114; Hortner M, 2002, J IMMUNOL, V169, P1219, DOI 10.4049/jimmunol.169.3.1219; Hunter MG, 1999, BLOOD, V93, P440, DOI 10.1182/blood.V93.2.440.402k23_440_446; James P, 1996, GENETICS, V144, P1425; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; Kario E, 2005, J BIOL CHEM, V280, P7038, DOI 10.1074/jbc.M408575200; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KGS, 2003, EMBO J, V22, P5480; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; Neer EJ, 2000, P NATL ACAD SCI USA, V97, P960, DOI 10.1073/pnas.97.3.960; Reynolds A, 2006, RNA, V12, P988, DOI 10.1261/rna.2340906; Schnell JD, 2003, J BIOL CHEM, V278, P35857, DOI 10.1074/jbc.R300018200; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tavernier J, 2002, CLIN EXP ALLERGY, V32, P1397, DOI 10.1046/j.1365-2745.2002.01520.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Geijn GJM, 2004, BLOOD, V104, P667, DOI 10.1182/blood-2003-08-2913; van de Geijn GJM, 2004, REV PHYSIOL BIOCH P, V149, P53; van Zon A, 2002, BIOCHEM BIOPH RES CO, V291, P535, DOI 10.1006/bbrc.2002.6472; Ward AC, 1999, BLOOD, V93, P447, DOI 10.1182/blood.V93.2.447; Ward AC, 1999, J BIOL CHEM, V274, P14956, DOI 10.1074/jbc.274.21.14956	41	20	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					1985	1994		10.1038/sj.onc.1210004	http://dx.doi.org/10.1038/sj.onc.1210004			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17001306				2022-12-28	WOS:000245313400001
J	Kikuchi, R; Murakami, M; Sobue, S; Iwasaki, T; Hagiwara, K; Takagi, A; Kojima, T; Asano, H; Suzuki, M; Banno, Y; Nozawa, Y; Murate, T				Kikuchi, R.; Murakami, M.; Sobue, S.; Iwasaki, T.; Hagiwara, K.; Takagi, A.; Kojima, T.; Asano, H.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T.			Ewing's sarcoma fusion protein, EWS/Fli-1 and Fli-1 protein induce PLD2 but not PLD1 gene expression by binding to an ETS domain of 5 ' promoter	ONCOGENE			English	Article						Ewing's sarcoma; EWS/Fli-1; PLD; gene expression; promoter analysis	PHOSPHOLIPASE D2; CELL; SPECIFICITY; INHIBITION; FAMILY	It was reported that short interfering RNA (siRNA) of EWS/Fli-1 downregulated phospholipase D (PLD)2 in Ewing's sarcoma (EWS) cell line, suggesting that PLD2 is the target of aberrant transcription factor, EWS/Fli-1. Here, we further investigated the regulation of PLD2 gene expression by EWS/Fli-1 and Fli-1 in another EWS cell line, and also in EWS/Fli-1- or Fli-1-transfected cell line. EWS/Fli-1- or Fli-1-overexpressed cells showed higher PLD2 but not PLD1 protein expression and enhanced cell proliferation as compared to mock transfectant. The treatment of these cells with 1-butanol or siRNA of PLD2 inhibited cell growth, suggesting the pivotal role of PLD in cell growth promotion. PLD2 but not PLD1 mRNA level was also increased in EWS/Fli-1 or Fli-1-transfectants. After determining the transcription initiation points, we cloned the 50 promoter of both PLD1 and PLD2 and analysed promoter activities. Results showed that EWS/Fli-1 and Fli- 1 increase PLD2 gene expression by binding to an erythroblast transformation-specific domain (-126 to -120 bp from the transcription initiation site) of PLD2 promoter, which is the minimal and most powerful region. Electrophoresis mobility shift assay using truncated proteins showed that both DNA-binding domain and trans-activating domain were necessary for the enhanced gene expression of PLD2.	Nagoya Univ, Sch Hlth Sci, Higashi Ku, Nagoya, Aichi 4618673, Japan	Nagoya University	Murate, T (corresponding author), Nagoya Univ, Sch Hlth Sci, Higashi Ku, Daiko Minami 1-1-20, Nagoya, Aichi 4618673, Japan.	murate@met.nagoya-u.ac.jp	Kojima, Tetsuhito/I-6271-2014; Kikuchi, Ryosuke/AAX-4971-2021; Suzuki, Motoshi/I-7246-2014	Kojima, Tetsuhito/0000-0002-1905-1065; Suzuki, Motoshi/0000-0003-0682-5006				Arvand A, 2001, ONCOGENE, V20, P5747, DOI 10.1038/sj.onc.1204598; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; CARNERO A, 1994, ONCOGENE, V9, P1387; Dauphinot L, 2001, ONCOGENE, V20, P3258, DOI 10.1038/sj.onc.1204437; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Foster DA, 2003, MOL CANCER RES, V1, P789; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; LISCOVITCH M, 2000, BIOCHEM J, V345, P410; MAO XH, 1994, J BIOL CHEM, V269, P18216; Nakamura S, 2003, REC RES DEV MAGNET M, V1, P1; Nozawa S, 2005, J BIOL CHEM, V280, P27544, DOI 10.1074/jbc.M411626200; Oikawa T, 2004, CANCER SCI, V95, P626, DOI 10.1111/j.1349-7006.2004.tb03320.x; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; RAMUGOUNDER R, 2004, ONCOGENE, V23, P1; Redina OE, 1998, GENE, V222, P53, DOI 10.1016/S0378-1119(98)00465-X; REDINA OE, 1998, BIOCHEM J, V331, P173; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Sobue S, 2005, J NEUROCHEM, V95, P940, DOI 10.1111/j.1471-4159.2005.03399.x; Toretsky JA, 1997, J NEURO-ONCOL, V31, P9, DOI 10.1023/A:1005716926800; Truong AHL, 2000, ONCOGENE, V19, P6482, DOI 10.1038/sj.onc.1204042; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719	22	20	23	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	12					1802	1810		10.1038/sj.onc.1209973	http://dx.doi.org/10.1038/sj.onc.1209973			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964281				2022-12-28	WOS:000244955600014
J	Scharf, S; Zech, J; Bursen, A; Schraets, D; Oliver, PL; Kliem, S; Pfitzner, E; Gillert, E; Dingermann, T; Marschalek, R				Scharf, S.; Zech, J.; Bursen, A.; Schraets, D.; Oliver, P. L.; Kliem, S.; Pfitzner, E.; Gillert, E.; Dingermann, T.; Marschalek, R.			Transcription linked to recombination: a gene-internal promoter coincides with the recombination hot spot II of the human MLL gene	ONCOGENE			English	Article						MLL gene; acute leukaemia; transcription; gene-internal promoter	BREAKPOINT-CLUSTER REGION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHROMOSOMAL TRANSLOCATIONS; DNA CLEAVAGE; REARRANGEMENTS; EXPRESSION; INHIBITORS; ETOPOSIDE; APOPTOSIS; T(4/11)	The MLL gene is frequently involved in chromosomal translocations associated with high-risk acute leukaemia. Infant and therapy-related acute leukaemia patients display chromosomal breakpoints preferentially clustered in the telomeric portion of the MLL breakpoint cluster region (SCII). Here, we demonstrate that SCII colocalizes with a gene-internal promoter element in the mouse and human MLL gene, respectively. The mRNA generated encodes an N-terminally truncated version of MLL that still exhibits many functional regions, including the C-terminal SET-domain. Etoposide-induced DNA double-strand breaks colocalize with the binding site of RNA polymerase II and the transcription initiation region, but not with a nearby Topo II consensus sequence. Thus, the observed genomic instability of the human MLL gene is presumably linked to transcriptional processes. The consequences of this novel finding for the creation of chromosomal translocations, the biology of the MLL protein and for MLL-mediated acute leukaemia are discussed.	Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, D-60439 Frankfurt, Germany; Univ Oxford, Res Council Funct Genet Unit, Dept Physiol Anat & Genet, Oxford, England; Procompliance Verlag GmbH, Erlangen, Germany	Goethe University Frankfurt; University of Oxford	Marschalek, R (corresponding author), Univ Frankfurt, Inst Pharmaceut Biol, ZAFES, Bioctr, Marie Curie Str 9, D-60439 Frankfurt, Germany.	rolf.marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Pfitzner, Edith/AAU-7927-2021; Oliver, Peter/F-1453-2010; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Pfitzner, Edith/0000-0002-3484-9649; Dingermann, Theodor/0000-0002-2788-1085; Oliver, Peter/0000-0003-3347-2461				Andersen MK, 2001, BRIT J HAEMATOL, V114, P539, DOI 10.1046/j.1365-2141.2001.03000.x; Aplan PD, 1996, BLOOD, V87, P2649, DOI 10.1182/blood.V87.7.2649.bloodjournal8772649; Betti CJ, 2005, LEUKEMIA, V19, P2289, DOI 10.1038/sj.leu.2403966; Betti CJ, 2001, CANCER RES, V61, P4550; BLACKWELL TK, 1986, NATURE, V324, P585, DOI 10.1038/324585a0; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Gillert E, 1999, ONCOGENE, V18, P4663, DOI 10.1038/sj.onc.1202842; GOTO H, 1994, INT J HEMATOL, V60, P145; Hsieh JJD, 2003, CELL, V115, P293, DOI 10.1016/S0092-8674(03)00816-X; Khobta A, 2004, CANCER RES, V64, P2656, DOI 10.1158/0008-5472.CAN-03-1126; Libura J, 2005, BLOOD, V105, P2124, DOI 10.1182/blood-2004-07-2683; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nasr F, 1997, LEUKEMIA LYMPHOMA, V25, P399, DOI 10.3109/10428199709114180; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Reichel M, 1998, ONCOGENE, V17, P3035, DOI 10.1038/sj.onc.1202229; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Sim SP, 2001, J BIOL CHEM, V276, P31590, DOI 10.1074/jbc.M103962200; Stanulla M, 1997, MOL CELL BIOL, V17, P4070, DOI 10.1128/MCB.17.7.4070; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Yokoyama A, 2002, BLOOD, V100, P3710, DOI 10.1182/blood-2002-04-1015; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	28	43	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1361	1371		10.1038/sj.onc.1209948	http://dx.doi.org/10.1038/sj.onc.1209948			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16983345				2022-12-28	WOS:000244558800001
J	Spraggon, L; Dudnakova, T; Slight, J; Lustig-Yariv, O; Cotterell, J; Hastie, N; Miles, C				Spraggon, L.; Dudnakova, T.; Slight, J.; Lustig-Yariv, O.; Cotterell, J.; Hastie, N.; Miles, C.			hnRNP-U directly interacts with WT1 and modulates WT1 transcriptional activation	ONCOGENE			English	Article						hnRNP-U; WT1; zinc fingers; Wilms' tumour	WILMS-TUMOR GENE; RNA-POLYMERASE-II; SUPPRESSOR GENE; PROTEIN WT1; EXPRESSION; BINDING; RIBONUCLEOPROTEIN; INHIBITION; MUTATIONS; RECEPTOR	The Wilms' tumour suppressor gene, WT1, encodes a zinc-finger protein that is mutated in Wilms' tumours and highly expressed in a wide variety of other malignancies. WT1 is a transcription factor that is likely to have additional, post-transcriptional, regulatory roles, although the molecular mechanisms by which WT1 acts remain poorly understood. We have combined genetic and biochemical approaches to show, that endogenous WT1 binds to heterogeneous nuclear ribonuclear protein U (hnRNP-U), that this interaction does not require any other proteins or nucleic acids, involves the zinc-fingers of WT1 and the middle domain of hnRNP-U, and that hnRNP-U can modulate WT1 transcriptional activation of a bona. de WT1 target gene. These findings increase our knowledge of how WT1 exerts its transcriptional regulatory role and suggests that hnRNP-U may be a candidate Wilms' tumour gene at 1q44.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Newcastle Upon Tyne, Inst Human Genet, Int Ctr Life, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Columbia Univ, Coll Phys & Surg, New York, NY USA	University of Edinburgh; Newcastle University - UK; Columbia University	Hastie, N (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crew Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	nick.hastie@hgu.mrc.ac.uk	Spraggon, Lee/E-5900-2012	Dudnakova, Tatyana/0000-0002-8388-8871	Medical Research Council [MC_U127527180] Funding Source: Medline; MRC [MC_U127527180] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Barbaux S, 1997, NAT GENET, V17, P467, DOI 10.1038/ng1297-467; Bergmann L, 1997, LEUKEMIA LYMPHOMA, V25, P435, DOI 10.3109/10428199709039030; BRESLOW N, 1988, CANCER RES, V48, P1653; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; Caricasole A, 1996, P NATL ACAD SCI USA, V93, P7562, DOI 10.1073/pnas.93.15.7562; Carpenter B, 2004, MOL CELL BIOL, V24, P537, DOI 10.1128/MCB.24.2.537-549.2004; Challen G, 2005, PHYSIOL GENOMICS, V23, P159, DOI 10.1152/physiolgenomics.00043.2005; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Heilbronn R, 2003, NUCLEIC ACIDS RES, V31, P6206, DOI 10.1093/nar/gkg827; Kanai Y, 2004, NEURON, V43, P513, DOI 10.1016/j.neuron.2004.07.022; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; Kim MK, 1999, MOL CELL BIOL, V19, P6833; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Kukalev A, 2005, NAT STRUCT MOL BIOL, V12, P238, DOI 10.1038/nsmb904; Ladomery MR, 1999, J BIOL CHEM, V274, P36520, DOI 10.1074/jbc.274.51.36520; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Lee TH, 2002, J BIOL CHEM, V277, P44826, DOI 10.1074/jbc.M205667200; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Loeb DM, 2001, CANCER RES, V61, P921; Miles CG, 2003, MOL CELL BIOL, V23, P2608, DOI 10.1128/MCB.23.7.2608-2613.2003; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Natoli TA, 2002, MOL CELL BIOL, V22, P4433, DOI 10.1128/MCB.22.12.4433-4438.2002; Niksic M, 2004, HUM MOL GENET, V13, P463, DOI 10.1093/hmg/ddh040; Oji Y, 2004, NEOPLASMA, V51, P17; Oji Y, 2003, CANCER SCI, V94, P712, DOI 10.1111/j.1349-7006.2003.tb01507.x; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REDDY JC, 1995, J BIOL CHEM, V270, P29976; Rivera MN, 2005, NAT REV CANCER, V5, P699, DOI 10.1038/nrc1696; Roberts SGE, 2005, CURR OPIN GENET DEV, V15, P542, DOI 10.1016/j.gde.2005.08.004; RODECK U, 1994, INT J CANCER, V59, P78, DOI 10.1002/ijc.2910590116; ROMIG H, 1992, EMBO J, V11, P3431, DOI 10.1002/j.1460-2075.1992.tb05422.x; SCHAFER V, 1997, PFLANZENBAUWISS, V1, P133; Sim EUH, 2002, ONCOGENE, V21, P2948, DOI 10.1038/sj.onc.1205373; Wagner N, 2005, GENE DEV, V19, P2631, DOI 10.1101/gad.346405; Wagner N, 2004, J AM SOC NEPHROL, V15, P3044, DOI 10.1097/01.ASN.0000146687.99058.25; Wilhelm D, 2002, GENE DEV, V16, P1839, DOI 10.1101/gad.220102; Williams RD, 2004, GENE CHROMOSOME CANC, V41, P65, DOI 10.1002/gcc.20060; Yamagami T, 1996, BLOOD, V87, P2878, DOI 10.1182/blood.V87.7.2878.bloodjournal8772878; Zapata-Benavides P, 2002, BIOCHEM BIOPH RES CO, V295, P784, DOI 10.1016/S0006-291X(02)00751-9	44	25	28	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1484	1491		10.1038/sj.onc.1209922	http://dx.doi.org/10.1038/sj.onc.1209922			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16924231				2022-12-28	WOS:000244558800013
J	Turner, NC; Reis, JS; Russell, AM; Springall, RJ; Ryder, K; Steele, D; Savage, K; Gillett, CE; Schmitt, FC; Ashworth, A; Tutt, AN				Turner, N. C.; Reis-Filho, J. S.; Russell, A. M.; Springall, R. J.; Ryder, K.; Steele, D.; Savage, K.; Gillett, C. E.; Schmitt, F. C.; Ashworth, A.; Tutt, A. N.			BRCA1 dysfunction in sporadic basal-like breast cancer	ONCOGENE			English	Article						BRCA1; basal-like; breast cancer; ID4; metaplastic	PROMOTER REGION; METHYLATION; EXPRESSION; GENE; PHENOTYPE; HYPERMETHYLATION; CARCINOMAS; SUBTYPE; BARD1; ID4	Basal-like breast cancers forma distinct subtype of breast cancer characterized by the expression of markers expressed in normal basal/myoepithelial cells. Breast cancers arising in carriers of germline BRCA1 mutations are predominately of basal-like type, suggesting that BRCA1 dysfunction may play a role in the pathogenesis of sporadic basal-like cancers. We analysed 37 sporadic breast cancers expressing the basal marker cytokeratin 5/6, and age- and grade-matched controls, for downregulation of BRCA1. Although BRCA1 promoter methylation was no more common in basal-like cancers (basal 14% vs controls 11%, P = 0.72), BRCA1 messenger RNA expression was twofold lower in basal-like breast cancers compared to matched controls (P = 0.008). ID4, a negative regulator of BRCA1, was expressed at 9.1-fold higher levels in basal-like breast cancer (P < 0.0001), suggesting a potential mechanism of BRCA1 downregulation. BRCA1 downregulation correlated with the presence of multiple basal markers, revealing heterogeneity in the basal-like phenotype. Finally, we found that 63% of metaplastic breast cancers, a rare type of basal-like cancers, had BRCA1 methylation, in comparison to 12% of controls (P < 0.0001). The high prevalence of BRCA1 dysfunction identified in this study could be exploited in the development of novel approaches to targeted treatment of basal-like breast cancer.	Breakthrought Breast Canc Res Ctr, Chester Beatty Labs, Inst Canc Res, London SW3 6JB, England; Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4100 Oporto, Portugal; Univ Porto, Fac Med, P-4100 Oporto, Portugal; Breast Pathol Lab, London, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Universidade do Porto; Universidade do Porto	Tutt, AN (corresponding author), Breakthrought Breast Canc Res Ctr, Chester Beatty Labs, Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.	andrew.tutt@icr.ac.uk	Schmitt, Fernando/A-5270-2008	Schmitt, Fernando/0000-0002-3711-8681; Schmitt, Fernando/0000-0003-1006-6946; Turner, Nicholas/0000-0001-8937-0873; Tutt, Andrew/0000-0001-8715-2901	Cancer Research UK [A8363] Funding Source: Medline; Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Brody LC, 2005, NEW ENGL J MED, V353, P949, DOI 10.1056/NEJMcibr052331; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Fabbro M, 2002, J BIOL CHEM, V277, P21315, DOI 10.1074/jbc.M200769200; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Foulkes WD, 2004, J MED GENET, V41, P1, DOI 10.1136/jmg.2003.013805; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Furuta S, 2005, P NATL ACAD SCI USA, V102, P9176, DOI 10.1073/pnas.0503793102; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gillett CE, 2000, J PATHOL, V192, P549; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HUVOS AG, 1973, NEW YORK STATE J MED, V73, P1078; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Lambie H, 2003, J PATHOL, V200, P207, DOI 10.1002/path.1348; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Perez-Valles A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Reis JS, 2006, HISTOPATHOLOGY, V49, P10, DOI 10.1111/j.1365-2559.2006.02467.x; Ribeiro-Silva A, 2005, HISTOPATHOLOGY, V47, P458, DOI 10.1111/j.1365-2559.2005.02249.x; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Simpson PT, 2004, J PATHOL, V202, P274, DOI 10.1002/path.1530; Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Staff S, 2003, CANCER RES, V63, P4978; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538	35	443	466	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2126	2132		10.1038/sj.onc.1210014	http://dx.doi.org/10.1038/sj.onc.1210014			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016441				2022-12-28	WOS:000245313400014
J	Bai, Y; Liu, YJ; Wang, H; Xu, Y; Stamenkovic, I; Yu, Q				Bai, Y.; Liu, Y-j; Wang, H.; Xu, Y.; Stamenkovic, I.; Yu, Q.			Inhibition of the hyaluronan-CD44 interaction by merlin contributes to the tumor-suppressor activity of merlin	ONCOGENE			English	Article						CD44; hyaluronan; merlin; tumor suppressor; schwannoma growth	TYPE-2 GENE-PRODUCT; MEDIATES CONTACT INHIBITION; GERM-LINE MUTATIONS; MUTANT NF2 PROTEIN; NEUROFIBROMATOSIS TYPE-2; INCREASED EXPRESSION; SIGNALING PATHWAY; GLYCOPROTEIN CD44; HOMING RECEPTOR; CARCINOMA-CELLS	Mutation or loss of expression of merlin is responsible for neurofibromatosis type 2 (NF2), which is characterized by the development of schwannomas and other tumors of the nervous system. Like the ERM(ezrin-radixin-moesin) proteins, merlin interacts with CD44, a cell-surface receptor for hyaluronan (HA) that promotes tumorigenesis. However, the relationship between merlin and CD44 and the mechanism by which merlin exerts its tumor-suppressor function have not been elucidated. In the present study, we show that increased expression of wildtype merlin in Tr6BC1 schwannoma cells inhibits HA binding to CD44. Furthermore, we demonstrate that the residues required for this inhibitory effect and the interaction between CD44 and merlin lie within the first 50 amino acids of merlin. Overexpression of merlin inhibited subcutaneous growth of Tr6BC1 cells in immunocompromised Rag1 mice. In contrast, knocking down expression of endogenous merlin promoted tumor cell growth, as did overexpression of a merlin deletion mutant (merlinDel-1) that lacks the first 50 amino acids but not of other NH2-terminal deletion mutants. Together, our results demonstrate that inhibition of the CD44-HA interaction contributes to the tumor-suppressor function of merlin, and they suggest that merlin inhibits tumor growth, at least in part, by negatively regulating CD44 function.	Univ Penn, Sch Vet Med, Dept Pathobiol, Philadelphia, PA 19104 USA; Univ Lausanne, Inst Pathol, Div Expt Pathol, CH-1015 Lausanne, Switzerland	University of Pennsylvania; University of Lausanne	Yu, Q (corresponding author), Univ Penn, Sch Vet Med, Dept Pathobiol, 372E Old Vet,3800 Spruce St, Philadelphia, PA 19104 USA.	qyu@vet.upenne.edu			NCI NIH HHS [R01 CA116510, R01 CA135158] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALGRAIN M, 1993, J CELL BIOL, V120, P129, DOI 10.1083/jcb.120.1.129; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BIANCHI AB, 1994, NAT GENET, V6, P185, DOI 10.1038/ng0294-185; Chan HM, 2005, GENE DEV, V19, P196, DOI 10.1101/gad.1280205; Deguen B, 1998, HUM MOL GENET, V7, P217, DOI 10.1093/hmg/7.2.217; Evans DGR, 1998, J MED GENET, V35, P450, DOI 10.1136/jmg.35.6.450; EVANS DGR, 1992, Q J MED, V84, P603; Giovannini M, 2000, GENE DEV, V14, P1617; Giovannini M, 1999, GENE DEV, V13, P978, DOI 10.1101/gad.13.8.978; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUTMANN DH, 1994, CURR OPIN NEUROL, V7, P166, DOI 10.1097/00019052-199404000-00014; Gutmann DH, 1999, HUM MOL GENET, V8, P267, DOI 10.1093/hmg/8.2.267; Gutmann DH, 1997, NEUROLOGY, V49, P267, DOI 10.1212/WNL.49.1.267; Gutmann DH, 1999, J NEUROSCI RES, V58, P706, DOI 10.1002/(SICI)1097-4547(19991201)58:5<706::AID-JNR12>3.3.CO;2-Q; Hannon Gregory J, 2004, Methods Mol Biol, V257, P255, DOI 10.1385/1-59259-750-5:255; HARA T, 1994, CANCER RES, V54, P330; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Huynh DP, 1996, ONCOGENE, V13, P73; Kang BS, 2002, ACTA CRYSTALLOGR D, V58, P381, DOI 10.1107/S0907444901021175; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Khanna C, 2001, CANCER RES, V61, P3750; Kissil JL, 2003, MOL CELL, V12, P841, DOI 10.1016/S1097-2765(03)00382-4; Koga H, 1998, ONCOGENE, V17, P801, DOI 10.1038/sj.onc.1202010; LaJeunesse DR, 1998, J CELL BIOL, V141, P1589, DOI 10.1083/jcb.141.7.1589; Lallemand D, 2003, GENE DEV, V17, P1090, DOI 10.1101/gad.1054603; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; McClatchey AI, 2005, GENE DEV, V19, P2265, DOI 10.1101/gad.1335605; McClatchey AI, 1998, GENE DEV, V12, P1121, DOI 10.1101/gad.12.8.1121; MEREL P, 1995, GENE CHROMOSOME CANC, V12, P117, DOI 10.1002/gcc.2870120206; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Obremski VJ, 1998, J NEUROBIOL, V37, P487, DOI 10.1002/(SICI)1097-4695(199812)37:4<487::AID-NEU1>3.3.CO;2-2; Okada T, 2005, J CELL BIOL, V171, P361, DOI 10.1083/jcb.200503165; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Paddison Patrick J, 2004, Methods Mol Biol, V265, P85; Parry DM, 1996, AM J HUM GENET, V59, P529; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; RONG R, 2004, ONCOGENE, V4, P1; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Ruttledge MH, 1996, AM J HUM GENET, V59, P331; Sainio M, 1997, J CELL SCI, V110, P2249; Scoles DR, 1998, NAT GENET, V18, P354, DOI 10.1038/ng0498-354; SCREATON GR, 1993, J BIOL CHEM, V268, P12235; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; SHERMAN L, 1994, CURR OPIN CELL BIOL, V6, P726, DOI 10.1016/0955-0674(94)90100-7; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; STAMENKOVIC I, 1989, CELL, V56, P1057, DOI 10.1016/0092-8674(89)90638-7; Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379; Stickney JT, 2004, CANCER RES, V64, P2717, DOI 10.1158/0008-5472.CAN-03-3798; TROFATTER JA, 1993, CELL, V72, P1; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Yu Q, 2001, AM J PATHOL, V158, P563, DOI 10.1016/S0002-9440(10)63998-3; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Yu Q, 2000, GENE DEV, V14, P163; Yu YL, 2004, NAT MED, V10, P175, DOI 10.1038/nm966; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	68	63	66	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					836	850		10.1038/sj.onc.1209849	http://dx.doi.org/10.1038/sj.onc.1209849			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16953231				2022-12-28	WOS:000244063800005
J	Ivanov, SV; Salnikow, K; Ivanova, AV; Bai, L; Lerman, MI				Ivanov, S. V.; Salnikow, K.; Ivanova, A. V.; Bai, L.; Lerman, M. I.			Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13	ONCOGENE			English	Article						VHL; HIF-1; hypoxia; STRA13; STAT1; CASP1	RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR PROTEIN; INTERFERON-GAMMA; DEACETYLASE ACTIVITY; DOWN-REGULATION; TRANSCRIPTIONAL REPRESSOR; INDEPENDENT MECHANISMS; STRA13 EXPRESSION; INDUCED APOPTOSIS; CLASS-I	DEC1/STRA13 is a bHLH type transcriptional regulator involved with immune regulation, hypoxia response and carcinogenesis. We recently demonstrated that STRA13 interacts with STAT3 in the transcriptional activation of STAT-dependent promoters. Here, we pursue STRA13 involvement in the JAK/STAT pathway by studying its role in STAT1 expression. First, we showed that VHL deficiency or HIF-1 activation resulted in the repression of endogenous STAT1 mediated by STRA13. We then characterized the STAT1 proximal promoter to assess its response to STRA13 by transient coexpression in a luciferase reporter assay. Using sequential truncation and site-directed mutagenesis of the STAT1 promoter with STRA13 deletion constructs, we showed that the STRA13 C-terminal trans-activation domain, which is known to bind HDAC1, mostly determines the repressive activity. Involvement of HDAC activity in STAT1 regulation was validated by TSA inhibition and chromatin immuno-precipitation (ChIP) assay. Thus, we demonstrate that STRA13-mediated repression of STAT1 transcription utilizes an HDAC1-dependent mechanism. Furthermore, we show that targets of unphosphorylated STAT1, such as antigen presenting genes and CASP1, are also repressed by hypoxia possibly through the same STRA13-mediated mechanism. Thus, the newly discovered link between HIF-1 and STAT1 reveals a previously unknown role of STRA13 in hypoxia and carcinogenesis.	SAIC Frederick, Basic Res Program, Ft Detrick, MD 21702 USA; NCI, NIH, Frederick, MD 21701 USA; NYU, Med Ctr, Dept Cardiothorac Surg, New York, NY 10016 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); New York University; University of Michigan System; University of Michigan	Ivanov, SV (corresponding author), SAIC Frederick, Basic Res Program, B 560,POB B, Ft Detrick, MD 21702 USA.	Sergey.Ivanov@med.nyu.edu		Ivanov, Sergey/0000-0001-9770-7237	NATIONAL CANCER INSTITUTE [Z01BC008579] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Atkins D, 2004, J UROLOGY, V171, P885, DOI 10.1097/01.ju.0000094807.95420.fe; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bach EA, 1997, ANNU REV IMMUNOL, V15, P563, DOI 10.1146/annurev.immunol.15.1.563; Bai LC, 2003, NUCLEIC ACIDS RES, V31, P7264, DOI 10.1093/nar/gkg929; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; Chatterjee-Kishore M, 2000, EMBO J, V19, P4111, DOI 10.1093/emboj/19.15.4111; Darnell JE, 1998, J INTERF CYTOK RES, V18, P549, DOI 10.1089/jir.1998.18.549; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Dudley Andrew C, 2004, Cell Commun Signal, V2, P8, DOI 10.1186/1478-811X-2-8; Gastl G, 1996, J UROLOGY, V155, P361, DOI 10.1016/S0022-5347(01)66661-8; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Ivanova AV, 2005, CELL MOL LIFE SCI, V62, P471, DOI 10.1007/s00018-004-4423-2; Ivanova AV, 2004, J MOL BIOL, V340, P641, DOI 10.1016/J.Jmb.2004.05.025; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li YX, 2002, BIOCHEM J, V367, P413, DOI 10.1042/BJ20020514; Martin-Puig S, 2004, J BIOL CHEM, V279, P9504, DOI 10.1074/jbc.M310658200; Maxwell PH, 2004, CELL CYCLE, V3, P156; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Meyer T, 2002, EMBO J, V21, P344, DOI 10.1093/emboj/21.3.344; Miyazaki K, 2002, J BIOL CHEM, V277, P47014, DOI 10.1074/jbc.M204938200; Nusinzon I, 2003, P NATL ACAD SCI USA, V100, P14742, DOI 10.1073/pnas.2433987100; Osborne A, 1997, NUCLEIC ACIDS RES, V25, P5095, DOI 10.1093/nar/25.24.5095; Qing YL, 2004, J BIOL CHEM, V279, P41679, DOI 10.1074/jbc.M406413200; Sakamoto S, 2004, J BIOL CHEM, V279, P40362, DOI 10.1074/jbc.M406400200; Salnikow K, 2004, J BIOL CHEM, V279, P40337, DOI 10.1074/jbc.M403057200; Salnikow K, 2004, TOXICOL APPL PHARM, V196, P258, DOI 10.1016/j.taap.2004.01.003; Salnikow K, 2000, CANCER RES, V60, P38; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; Seimiya M, 2004, EUR J IMMUNOL, V34, P1322, DOI 10.1002/eji.200324700; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; St-Pierre B, 2002, J BIOL CHEM, V277, P46544, DOI 10.1074/jbc.M111652200; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; van den Elsen PJ, 2004, CURR OPIN IMMUNOL, V16, P67, DOI 10.1016/j.coi.2003.11.015; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wong LH, 2002, J BIOL CHEM, V277, P19408, DOI 10.1074/jbc.M111302200; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Xi SC, 2006, JNCI-J NATL CANCER I, V98, P181, DOI 10.1093/jnci/djj020; Yamamoto K, 2003, AUTOIMMUN REV, V2, P13, DOI 10.1016/S1568-9972(02)00121-0; Zagzag D, 2005, LAB INVEST, V85, P328, DOI 10.1038/labinvest.3700233; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	55	57	58	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 8	2007	26	6					802	812		10.1038/sj.onc.1209842	http://dx.doi.org/10.1038/sj.onc.1209842			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16878149				2022-12-28	WOS:000244063800002
J	Liu, SL; D Miller, A				Liu, S-L; D Miller, A.			Oncogenic transformation by the jaagsiekte sheep retrovirus envelope protein	ONCOGENE			English	Review						Jaagsiekte sheep retrovirus; envelope protein; transformation; lung cancer; signaling pathways; mouse model	OVINE PULMONARY ADENOCARCINOMA; MACROPHAGE-STIMULATING PROTEIN; LONG TERMINAL REPEAT; HUMAN BRONCHIOLOALVEOLAR CARCINOMA; BETARETROVIRUS ENV PROTEINS; RECEPTOR TYROSINE KINASE; LUNG EPITHELIAL-CELLS; ENZOOTIC NASAL TUMOR; RODENT FIBROBLASTS; PHOSPHATIDYLINOSITOL 3-KINASE	Retroviruses have played profound roles in our understanding of the genetic and molecular basis of cancer. Jaagsiekte sheep retrovirus (JSRV) is a simple retrovirus that causes contagious lung tumors in sheep, known as ovine pulmonary adenocarcinoma (OPA). Intriguingly, OPA resembles pulmonary adenocarcinoma in humans, and may provide a model for this frequent human cancer. Distinct from the classical mechanisms of retroviral oncogenesis by insertional activation of or virus capture of host oncogenes, the native envelope (Env) structural protein of JSRV is itself the active oncogene. A major pathway for Env transformation involves interaction of the Env cytoplasmic tail with as yet unidentified cellular adaptor(s), leading to the activation of PI3K/Akt and MAPK signaling cascades. Another potential mechanism involves the cell-entry receptor for JSRV, Hyaluronidase 2 (Hyal2), and the RON receptor tyrosine kinase, but the exact roles of these proteins in JSRV Env transformation remain to be better understood. Recently, a mouse model of lung cancer induced by JSRV Env has been developed, and the tumors in mice resemble those seen in sheep infected with JSRV and in humans. In this review, we summarize recent progress in our understanding the molecular mechanisms of oncogenic transformation by JSRV Env protein, and discuss the relevance to human lung cancer.	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA	McGill University; Fred Hutchinson Cancer Center	Liu, SL (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St,Lyman Duff Bldg,Room 608, Montreal, PQ H3A 2B4, Canada.	shan-lu.liu@mcgill.ca	Liu, Shan-Lu/L-5923-2016	Liu, Shan-Lu/0000-0003-1620-3817; Miller, Dusty/0000-0002-3736-3660				Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; Alberti A, 2002, J VIROL, V76, P5387, DOI 10.1128/JVI.76.11.5387-5394.2002; Alian A, 2000, VIROLOGY, V276, P161, DOI 10.1006/viro.2000.0550; Allen TE, 2002, J GEN VIROL, V83, P2733, DOI 10.1099/0022-1317-83-11-2733; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bai JR, 1999, VIROLOGY, V258, P333, DOI 10.1006/viro.1999.9728; Ballif BA, 2001, CELL GROWTH DIFFER, V12, P397; BARSKY SH, 1994, CANCER-AM CANCER SOC, V73, P1163, DOI 10.1002/1097-0142(19940215)73:4<1163::AID-CNCR2820730407>3.0.CO;2-J; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BONNE C., 1939, AMER JOUR CANCER, V35, P491; Cavanaugh JE, 2004, EUR J BIOCHEM, V271, P2056, DOI 10.1111/j.1432-1033.2004.04131.x; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chow YHJ, 2003, J VIROL, V77, P6341, DOI 10.1128/JVI.77.11.6341-6350.2003; Comoglio PM, 1996, GENES CELLS, V1, P347, DOI 10.1046/j.1365-2443.1996.37037.x; Cousens C, 2004, J VIROL, V78, P8506, DOI 10.1128/JVI.78.16.8506-8512.2004; Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Danilkovitch-Miagkova A, 2003, P NATL ACAD SCI USA, V100, P4580, DOI 10.1073/pnas.0837136100; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; De las Heras M, 2000, EUR RESPIR J, V16, P330, DOI 10.1034/j.1399-3003.2000.16b23.x; De Las Heras M, 2003, CURR TOP MICROBIOL, V275, P201; DeMartini JC, 2003, CURR TOP MICROBIOL, V275, P117; DeMartini JC, 2001, J VIROL, V75, P4239, DOI 10.1128/JVI.75.9.4239-4246.2001; Dirks C, 2002, J VIROL, V76, P2141, DOI 10.1128/JVI.76.5.2141-2149.2002; Duh FM, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-59; Fan H, 2003, CURR TOP MICROBIOL, V275, P139; Filippa N, 1999, MOL CELL BIOL, V19, P4989; Halbert CL, 2001, J VIROL, V75, P6615, DOI 10.1128/JVI.75.14.6615-6624.2001; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hecht SJ, 1996, P NATL ACAD SCI USA, V93, P3297, DOI 10.1073/pnas.93.8.3297; Hiatt KM, 2002, HUM PATHOL, V33, P680, DOI 10.1053/hupa.2002.125776; Hofacre A, 2004, J VIROL, V78, P10479, DOI 10.1128/JVI.78.19.10479-10489.2004; Ji L, 2002, CANCER RES, V62, P2715; Klymiuk N, 2003, J VIROL, V77, P11268, DOI 10.1128/JVI.77.20.11268-11273.2003; Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466; Liu SL, 2005, J VIROL, V79, P927, DOI 10.1128/JVI.79.2.927-933.2005; Liu SL, 2003, J VIROL, V77, P7924, DOI 10.1128/JVI.77.14.7924-7935.2003; Liu SL, 2003, J VIROL, V77, P2850, DOI 10.1128/JVI.77.5.2850-2858.2003; Maeda N, 2005, J VIROL, V79, P4440, DOI 10.1128/JVI.79.7.4440-4450.2005; Maeda N, 2003, J VIROL, V77, P9951, DOI 10.1128/JVI.77.18.9951-9959.2003; Maeda N, 2001, P NATL ACAD SCI USA, V98, P4449, DOI 10.1073/pnas.071547598; McGee-Estrada K, 2006, J VIROL, V80, P332, DOI 10.1128/JVI.80.1.332-341.2006; Mcgee-Estrada K, 2005, VIRUS GENES, V31, P257, DOI 10.1007/s11262-005-3239-y; McGee-Estrada K, 2002, VIROLOGY, V292, P87, DOI 10.1006/viro.2001.1247; Menzel EJ, 1998, CANCER LETT, V131, P3, DOI 10.1016/S0304-3835(98)00195-5; Miller Walter J, 2004, J Transl Med, V2, P4, DOI 10.1186/1479-5876-2-4; Mornex JF, 2003, CURR TOP MICROBIOL, V275, P225; Morozov VA, 2004, VIROLOGY, V327, P162, DOI 10.1016/j.virol.2004.05.028; Ortin A, 1998, VET IMMUNOL IMMUNOP, V61, P229, DOI 10.1016/S0165-2427(97)00149-9; Overbaugh J, 2001, MICROBIOL MOL BIOL R, V65, P371, DOI 10.1128/MMBR.65.3.371-389.2001; Palmarini M, 2000, J VIROL, V74, P5776, DOI 10.1128/JVI.74.13.5776-5787.2000; Palmarini M, 2000, J VIROL, V74, P8065, DOI 10.1128/JVI.74.17.8065-8076.2000; Palmarini M, 1999, J VIROL, V73, P6964, DOI 10.1128/JVI.73.8.6964-6972.1999; PALMARINI M, 1995, J GEN VIROL, V76, P2731, DOI 10.1099/0022-1317-76-11-2731; Palmarini M, 1996, J GEN VIROL, V77, P2991, DOI 10.1099/0022-1317-77-12-2991; Palmarini M, 2001, JNCI-J NATL CANCER I, V93, P1603, DOI 10.1093/jnci/93.21.1603; Palmarini M, 2001, J VIROL, V75, P11002, DOI 10.1128/JVI.75.22.11002-11009.2001; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Philbey AW, 2006, VIRUS RES, V117, P254, DOI 10.1016/j.virusres.2005.10.020; Rai SK, 2000, J VIROL, V74, P4698, DOI 10.1128/JVI.74.10.4698-4704.2000; Rai SK, 2001, P NATL ACAD SCI USA, V98, P4443, DOI 10.1073/pnas.071572898; Raz DJ, 2006, CLIN CANCER RES, V12, P3698, DOI 10.1158/1078-0432.CCR-06-0457; REDDEL RR, 1988, CANCER RES, V48, P1904; Rosenberg N., 1997, P475; Ruscetti SK, 1999, INT J BIOCHEM CELL B, V31, P1089, DOI 10.1016/S1357-2725(99)00074-6; Sable CL, 1997, FEBS LETT, V409, P253, DOI 10.1016/S0014-5793(97)00518-8; Sanna E, 2002, EUR J HISTOCHEM, V46, P273; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sharp J. M., 1990, Maedi-visna and related diseases., P177; Sharp JM, 2003, CURR TOP MICROBIOL, V275, P55; SHARP JM, 1983, J GEN VIROL, V64, P2323, DOI 10.1099/0022-1317-64-10-2323; Spencer TE, 2003, J VIROL, V77, P749, DOI 10.1128/JVI.77.1.749-753.2003; Summers C, 2002, J GEN VIROL, V83, P1753, DOI 10.1099/0022-1317-83-7-1753; Tam BYY, 2003, J BIOL CHEM, V278, P49610, DOI 10.1074/jbc.M308492200; Travis WD, 1999, INT HISTOLOGICAL CLA; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Varela M, 2006, VIROLOGY, V350, P347, DOI 10.1016/j.virol.2006.01.040; VERWOERD DW, 1980, ONDERSTEPOORT J VET, V47, P13; Vigdorovich V, 2005, J VIROL, V79, P79, DOI 10.1128/JVI.79.1.79-86.2005; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Wang MH, 2003, CARCINOGENESIS, V24, P1291, DOI 10.1093/carcin/bgg089; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; Wootton SK, 2005, NATURE, V434, P904, DOI 10.1038/nature03492; YORK DF, 1992, J VIROL, V66, P4930, DOI 10.1128/JVI.66.8.4930-4939.1992; Yousem SA, 2001, HUM PATHOL, V32, P1039, DOI 10.1053/hupa.2001.28249; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zavala G, 2003, VIROLOGY, V312, P95, DOI 10.1016/S0042-6822(03)00205-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	90	55	63	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					789	801		10.1038/sj.onc.1209850	http://dx.doi.org/10.1038/sj.onc.1209850			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909114				2022-12-28	WOS:000244063800001
J	Goldoni, S; Iozzo, RA; Kay, P; Campbell, S; McQuillan, A; Agnew, C; Zhu, JX; Keene, DR; Reed, CC; Iozzo, RV				Goldoni, S.; Iozzo, R. A.; Kay, P.; Campbell, S.; McQuillan, A.; Agnew, C.; Zhu, J-X; Keene, D. R.; Reed, C. C.; Iozzo, R. V.			A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity	ONCOGENE			English	Article						leucine-rich protein; decorin; kekkon1; epidermal growth factor receptor; tumor growth inhibition	LEUCINE-RICH PROTEOGLYCANS; FACTOR RECEPTOR; DECORIN BINDS; LUNG-CANCER; C-TERMINUS; GENE; PROTEIN; DROSOPHILA; GRB2; ENDOCYTOSIS	Leucine-rich repeats and immunoglobulin-like domains-1 (LRIG1) is a transmembrane protein with an ectodomain containing 15 leucine-rich repeats (LRRs) homologous to mammalian decorin and the Drosophila kekkon1 gene. In this study, we demonstrate that a soluble ectodomain of LRIG1, containing only the LRRs, inhibits ligand-independent epidermal growth factor receptor (EGFR) activation and causes growth inhibition of A431, HeLa and MDA-468 carcinoma cells. In contrast, cells that do not express detectable levels of EGFR fail to respond to soluble LRIG1. However, when a functional EGFR gene is introduced in these cells, they become growth-inhibited by soluble LRIG1 protein. Furthermore, we demonstrate the existence of high-affinity (K-d = 10 nM) binding sites on the A431 cells that can be competitively displaced (up to 75%) by molar excess of EGF. Even more powerful effects are obtained with a chimeric proteoglycan harboring the N-terminus of decorin, substituted with a single glycosaminoglycan chain, fused to the LRIG1 ectodomain. Both proteins also inhibit ligand-dependent activation of the EGFR and extracellular signal-regulated protein kinase 1/2 signaling in a rapid and dose-dependent manner. These results suggest a novel mechanism of action evoked by a soluble ectodomain of LRIG1 protein that could modulate EGFR signaling and its growth-promoting activity. Attenuation of EGFR activity without physical downregulation of the receptor could represent a novel therapeutic approach toward malignancies in which EGFR plays a primary role in tumor growth and survival.	Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; Shriners Hosp Children, Portland, OR 97201 USA; Thomas Jefferson Univ, Cellular Biol & Signaling Program, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Iozzo, RV (corresponding author), Thomas Jefferson Univ, Dept Pathol Anat & Cell Biol, Room 249 Jefferson Alumni Hall,1020 Locus St, Philadelphia, PA 19107 USA.	iozzo@mail.jci.tju.edu	Pranić, Shelly Melissa/E-1974-2017; Iozzo, Renato/AAS-1980-2020	Pranić, Shelly Melissa/0000-0001-5524-1723; Iozzo, Renato/0000-0002-5908-5112	NATIONAL CANCER INSTITUTE [R01CA047282, R01CA039481] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA47282, R01 CA39481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alvarado D, 2004, GENETICS, V167, P187, DOI 10.1534/genetics.167.1.187; Alvarado D, 2004, GENETICS, V166, P201, DOI 10.1534/genetics.166.1.201; Bailly M, 2000, MOL BIOL CELL, V11, P3873, DOI 10.1091/mbc.11.11.3873; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BERKERS JAM, 1991, J BIOL CHEM, V266, P922; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Carraway KL, 2001, CURR OPIN CELL BIOL, V13, P125, DOI 10.1016/S0955-0674(00)00188-5; Carter RE, 1998, J BIOL CHEM, V273, P35000, DOI 10.1074/jbc.273.52.35000; Cook PW, 1997, J CLIN INVEST, V100, P2286, DOI 10.1172/JCI119766; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; Derheimer FA, 2004, GENETICS, V166, P213, DOI 10.1534/genetics.166.1.213; ENNIS BW, 1989, MOL ENDOCRINOL, V3, P1830, DOI 10.1210/mend-3-11-1830; FILMUS J, 1987, MOL CELL BIOL, V7, P251, DOI 10.1128/MCB.7.1.251; FILMUS J, 1985, BIOCHEM BIOPH RES CO, V128, P898, DOI 10.1016/0006-291X(85)90131-7; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Ghiglione C, 2003, DEVELOPMENT, V130, P4483, DOI 10.1242/dev.00617; Ghiglione C, 1999, CELL, V96, P847, DOI 10.1016/S0092-8674(00)80594-2; Goldoni S, 2004, J BIOL CHEM, V279, P6606, DOI 10.1074/jbc.M310342200; Gonzalez EM, 2005, J BIOL CHEM, V280, P7080, DOI 10.1074/jbc.M409841200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Guo DS, 2004, GENOMICS, V84, P157, DOI 10.1016/j.ygeno.2004.01.013; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Holmlund C, 2004, GENE, V332, P35, DOI 10.1016/j.gene.2004.02.002; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mongiat M, 2001, J BIOL CHEM, V276, P10263, DOI 10.1074/jbc.M011493200; Musacchio M, 1996, DEV BIOL, V178, P63, DOI 10.1006/dbio.1996.0198; Nilsson J, 2003, CELL TISSUE RES, V312, P65, DOI 10.1007/s00441-003-0697-1; Nilsson J, 2001, BIOCHEM BIOPH RES CO, V284, P1155, DOI 10.1006/bbrc.2001.5092; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Reed CC, 2005, ONCOGENE, V24, P1104, DOI 10.1038/sj.onc.1208329; Reed CC, 2002, ONCOGENE, V21, P3688, DOI 10.1038/sj.onc.1205470; Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268; Santra M, 2002, J BIOL CHEM, V277, P35671, DOI 10.1074/jbc.M205317200; Schlessinger J, 2003, SCIENCE, V300, P750, DOI 10.1126/science.1082024; Sigismund S, 2005, P NATL ACAD SCI USA, V102, P2760, DOI 10.1073/pnas.0409817102; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5; Suzuki Y, 1996, J BIOL CHEM, V271, P22522, DOI 10.1074/jbc.271.37.22522; Suzuki Y, 2002, FEBS LETT, V521, P67, DOI 10.1016/S0014-5793(02)02824-7; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; WEBER W, 1984, SCIENCE, V224, P294, DOI 10.1126/science.6324343; YARDEN Y, 1985, J BIOL CHEM, V260, P315; Zhu JX, 2005, J BIOL CHEM, V280, P32468, DOI 10.1074/jbc.M503833200	62	58	71	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	3					368	381		10.1038/sj.onc.1209803	http://dx.doi.org/10.1038/sj.onc.1209803			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16847455				2022-12-28	WOS:000243544000006
J	Liu, Z; Li, H; Wu, X; Yoo, BH; Yan, SR; Stadnyk, AW; Sasazuki, T; Shirasawa, S; LaCasse, EC; Korneluk, RG; Rosen, KV				Liu, Z.; Li, H.; Wu, X.; Yoo, B. H.; Yan, S. R.; Stadnyk, A. W.; Sasazuki, T.; Shirasawa, S.; LaCasse, E. C.; Korneluk, R. G.; Rosen, K. V.			Detachment-induced upregulation of XIAP and cIAP2 delays anoikis of intestinal epithelial cells	ONCOGENE			English	Article						apoptosis; anoikis; XIAP; cIAP2; intestinal epithelial cells	NF-KAPPA-B; EPIDERMAL-GROWTH-FACTOR; RAS-INDUCED TRANSFORMATION; HUMAN PROSTATE-CANCER; ACID PHENETHYL ESTER; BCL-2 PROTEIN FAMILY; DOWN-REGULATION; INDUCED APOPTOSIS; SERINE-PROTEASE; CYTOCHROME-C	Detachment of normal epithelial cells from the extracellular matrix triggers apoptosis, a phenomenon called anoikis. Conversely, carcinoma cells tend to be relatively more anoikis- resistant than their normal counterparts, and this increased resistance represents a critical feature of the malignant phenotype. Mechanisms that control susceptibilityand resistance to anoikis are not fully understood. It is now known that detachment of non-malignant epithelial cells triggers both pro- and antiapoptotic signals, and it is the balance between these signals and the duration of detachment that determine further fate of the cells. Detachment- induced antiapoptotic events delay anoikis and if cells reattach relativelysoo n after detachment they survive. Direct regulators of apoptosis responsible for this delay of anoikis are unknown. We found that detachment of non-malignant intestinal epithelial cells triggers upregulation of inhibitors of apoptosis protein (IAP) family, such as X- chromosome- linked inhibitor of apoptosis protein and cellular inhibitor of apoptosis- 2 (cIAP2). We demonstrated that this upregulation requires detachment-dependent activation of the transcription factor nuclear factor-kappa B. We further observed that various IAP antagonists accelerate anoikis, indicating that upregulation of the IAPs delays detachment- triggered apoptosis. We conclude that the IAPs are important regulators of the balance between detachment- triggered life and death signals. Perhaps, not by coincidence, these proteins are often upregulated in carcinomas, tumors composed of cells that tend to be anoikis- resistant.	Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Biochem & Mol Biol, Atlantic Res Ctr, CRC, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4H7, Canada; Int Med Ctr Japan, Dept Pathol, Inst Res, Shinjyuku Ku, Tokyo, Japan; Childrens Hosp Eastern Ontario, Inst Res, Aegera Oncol Inc, Ottawa, ON K1H 8L1, Canada; Univ Ottawa, Childrens Hosp Eastern Ontario, Inst Res, Solange Gauthier Karsh Mol Genet Lab, Ottawa, ON, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	Dalhousie University; Dalhousie University; Dalhousie University; National Center for Global Health & Medicine - Japan; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa; Children's Hospital of Eastern Ontario; University of Ottawa	Rosen, KV (corresponding author), Dalhousie Univ, Dept Pediat, CRC, Atlantic Res Ctr, Room C-302,5849 Univ Ave, Halifax, NS B3H 4H7, Canada.	kirill.rosen@dal.ca		Rosen, Kirill/0000-0002-4317-9907; Stadnyk, Andrew/0000-0002-1940-8036				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Biswas DK, 2003, CANCER RES, V63, P290; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Coll MAL, 2005, ONCOGENE, V24, P1727, DOI 10.1038/sj.onc.1208379; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duxbury MS, 2004, ONCOGENE, V23, P465, DOI 10.1038/sj.onc.1207036; Duxbury MS, 2004, ONCOGENE, V23, P1448, DOI 10.1038/sj.onc.1207247; Farahani R, 1997, GENOMICS, V42, P514, DOI 10.1006/geno.1997.4742; Ferreira CG, 2001, CLIN CANCER RES, V7, P2468; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Gottfried Y, 2004, EMBO J, V23, P1627, DOI 10.1038/sj.emboj.7600155; Hofmann HS, 2002, J CANCER RES CLIN, V128, P554, DOI 10.1007/s00432-002-0364-z; Holcik M, 2002, BMC GENOMICS, V3, DOI 10.1186/1471-2164-3-5; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Jiang K, 2004, MOL CELL BIOL, V24, P5565, DOI 10.1128/MCB.24.12.5565-5576.2004; Kagawa S, 1997, ONCOGENE, V15, P1903, DOI 10.1038/sj.onc.1201362; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin MT, 2004, J BIOL CHEM, V279, P24015, DOI 10.1074/jbc.M402305200; Liu ZP, 2006, J BIOL CHEM, V281, P14738, DOI 10.1074/jbc.M508664200; Liu ZP, 2005, J BIOL CHEM, V280, P37383, DOI 10.1074/jbc.M503724200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Olson AL, 2001, AMBUL PEDIATR, V1, P91, DOI 10.1367/1539-4409(2001)001<0091:PCPRAP>2.0.CO;2; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; PAPADOPOULOS N, 1995, SCIENCE, V268, P1915, DOI 10.1126/science.7604266; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; RAK J, 1995, J CELL BIOL, V131, P1587, DOI 10.1083/jcb.131.6.1587; Rak Janusz, 1999, Neoplasia (New York), V1, P23, DOI 10.1038/sj.neo.7900001; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; RODENHUIS S, 1988, CANCER RES, V48, P5738; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2002, J BIOL CHEM, V277, P46123, DOI 10.1074/jbc.M207883200; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Rytomaa M, 2000, ONCOGENE, V19, P4461, DOI 10.1038/sj.onc.1203805; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; Scotlandi K, 2002, CANCER GENE THER, V9, P296, DOI 10.1038/sj.cgt.7700442; Shi Y, 2001, J UROLOGY, V166, P1514, DOI 10.1016/S0022-5347(05)65822-3; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254; Vachon PH, 2002, GASTROENTEROLOGY, V123, P1980, DOI 10.1053/gast.2002.37072; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang PB, 2003, J BIOL CHEM, V278, P19917, DOI 10.1074/jbc.M210337200; Watabe M, 2004, J BIOL CHEM, V279, P6017, DOI 10.1074/jbc.M306040200; Yamakita Y, 1999, J CELL BIOL, V144, P315, DOI 10.1083/jcb.144.2.315; Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810	69	44	48	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7680	7690		10.1038/sj.onc.1209753	http://dx.doi.org/10.1038/sj.onc.1209753			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16799641				2022-12-28	WOS:000242830800003
J	Tzircotis, G; Thorne, RF; Isacke, CM				Tzircotis, G.; Thorne, R. F.; Isacke, C. M.			Directional sensing of a phorbol ester gradient requires CD44 and is regulated by CD44 phosphorylation	ONCOGENE			English	Article						CD44; chemotaxis; phorbol ester; protein kinase C; protein kinase A; metastasis	DEPENDENT PROTEIN-KINASE; BREAST-CANCER CELLS; CYTOPLASMIC DOMAIN; ENDOTHELIAL-CELLS; UP-REGULATION; CYTOSKELETAL INTERACTION; FACILITATES INVASION; SELECTIVE INHIBITOR; TUMOR PROGRESSION; BONE-MARROW	Cancer progression is associated with enhanced directional cell migration, both of the tumour cells invading into the stroma and stromal cells infiltrating the tumour site. In cell-based assays to study directional cell migration, phorbol esters are frequently used as a chemotactic agent. However, the molecular mechanism by which these activators of protein kinase C (PKC) result in the establishment of a polarized migratory phenotype is not known. Here we show that CD44 expression is essential for chemotaxis towards a phorbol ester gradient. In an investigation of CD44 phosphorylation kinetics in resting and stimulated cells, Ser316 was identified as a novel site of phosphorylation following activation of PKC. PKC does not phosphorylate Ser316 directly, but rather mediates the activation of downstream Ser316 kinase(s). In transfection studies, a phosphorylation-deficient Ser316 mutant was shown to act in a dominant-negative fashion to impair chemotaxis mediated by endogenous CD44 in response to a phorbol ester gradient. Importantly, this mutation had no effect on random cell motility or the ability of cells to migrate directionally towards a cocktail of chemoattractants. These studies demonstrate that CD44 functions to provide directional cues to migrating cells without affecting the motility apparatus.	Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Isacke, CM (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	clare.isacke@icr.ac.uk		Isacke, Clare/0000-0002-9222-3345	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Alstergren P, 2004, CELL IMMUNOL, V231, P146, DOI 10.1016/j.cellimm.2005.01.007; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200; Caloca MJ, 1999, P NATL ACAD SCI USA, V96, P11854, DOI 10.1073/pnas.96.21.11854; CAMP RL, 1991, J CELL BIOL, V115, P1283, DOI 10.1083/jcb.115.5.1283; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cichy J, 2005, BBA-MOL CELL RES, V1745, P59, DOI 10.1016/j.bbamcr.2005.02.006; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Dingemans KP, 2002, LAB INVEST, V82, P313, DOI 10.1038/labinvest.3780425; Draffin JE, 2004, CANCER RES, V64, P5702, DOI 10.1158/0008-5472.CAN-04-0389; Dransfield DT, 1997, EMBO J, V16, P35, DOI 10.1093/emboj/16.1.35; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Eccles SA, 2005, CURR OPIN GENET DEV, V15, P77, DOI 10.1016/j.gde.2004.12.001; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; ESTENSEN RD, 1973, NATURE, V245, P458, DOI 10.1038/245458a0; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fujisaki T, 1999, CANCER RES, V59, P4427; GLASS DB, 1989, J BIOL CHEM, V264, P14579; Gomez-Mouton C, 2004, J CELL BIOL, V164, P759, DOI 10.1083/jcb.200309101; Herrera-Gayol A, 1999, EXP MOL PATHOL, V66, P99, DOI 10.1006/exmp.1999.2236; Herrera-Gayol A, 2001, INT J EXP PATHOL, V82, P193, DOI 10.1111/j.1365-2613.2001.iep196.x; ISACKE CM, 1986, IMMUNOGENETICS, V23, P326, DOI 10.1007/BF00398797; Jones GE, 2000, J LEUKOCYTE BIOL, V68, P593; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; Kim HR, 2004, CANCER RES, V64, P4569, DOI 10.1158/0008-5472.CAN-04-0202; Kobayashi H, 2002, INT J CANCER, V102, P379, DOI 10.1002/ijc.10710; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Lewis CA, 2001, BIOCHEM J, V357, P843, DOI 10.1042/0264-6021:3570843; Liu WS, 1998, CELL SIGNAL, V10, P529, DOI 10.1016/S0898-6568(98)00012-6; Martin TA, 2003, CRIT REV ONCOL HEMAT, V46, P165, DOI 10.1016/S1040-8428(02)00172-5; Miletti-Gonzalez KE, 2005, CANCER RES, V65, P6660, DOI 10.1158/0008-5472.CAN-04-3478; Mine S, 2003, EXP CELL RES, V288, P189, DOI 10.1016/S0014-4827(03)00184-8; Nagano O, 2004, J CELL BIOL, V165, P893, DOI 10.1083/jcb.200310024; NEAME SJ, 1995, J CELL SCI, V108, P3127; NEAME SJ, 1993, J CELL BIOL, V121, P1299, DOI 10.1083/jcb.121.6.1299; NEAME SJ, 1992, EMBO J, V11, P4733, DOI 10.1002/j.1460-2075.1992.tb05578.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peck D, 1998, J CELL SCI, V111, P1595; Peck D, 1996, CURR BIOL, V6, P884, DOI 10.1016/S0960-9822(02)00612-7; PERSCHL A, 1995, J CELL SCI, V108, P1033; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; PURE E, 1995, J EXP MED, V181, P55, DOI 10.1084/jem.181.1.55; Ratliff Timothy L, 2005, J Urol, V173, P1045, DOI 10.1016/S0022-5347(05)60440-5; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629; Van Haastert PJM, 2004, NAT REV MOL CELL BIO, V5, P626, DOI 10.1038/nrm1435; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Weber GF, 2002, CANCER RES, V62, P2281; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Xu Y, 2003, J BIOL CHEM, V278, P8661, DOI 10.1074/jbc.M208181200; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Zhao ZZ, 1996, J BIOL CHEM, V271, P22251, DOI 10.1074/jbc.271.36.22251; Zhu BQ, 2004, J CELL PHYSIOL, V198, P155, DOI 10.1002/jcp.10394; Zhu H, 2006, STEM CELLS, V24, P928, DOI 10.1634/stemcells.2005-0186; ZICHA D, 1991, J CELL SCI, V99, P769	64	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7401	7410		10.1038/sj.onc.1209724	http://dx.doi.org/10.1038/sj.onc.1209724			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785995				2022-12-28	WOS:000242419100009
J	Courtois, G; Gilmore, TD				Courtois, G.; Gilmore, T. D.			Mutations in the NF-kappa B signaling pathway: implications for human disease	ONCOGENE			English	Review						NF-kappaB; mutation; NEMO; CYLD; incontinentia pigmenti; lymphoma	MULTIPLE FAMILIAL TRICHOEPITHELIOMA; COMPARATIVE GENOMIC HYBRIDIZATION; ANHIDROTIC ECTODERMAL DYSPLASIA; CANDIDATE PROTOONCOGENE BCL-3; CHRONIC LYMPHOCYTIC-LEUKEMIA; CLASSICAL HODGKIN LYMPHOMA; TRANSCRIPTION FACTOR REL; BROOKE-SPIEGLER-SYNDROME; HUMAN BREAST-CANCER; X-LINKED DISORDER	The nuclear factor-kappa B (NF-kappa B) signaling pathway is a multi-component pathway that regulates the expression of hundreds of genes that are involved in diverse and key cellular and organismal processes, including cell proliferation, cell survival, the cellular stress response, innate immunity and in. ammation. Not surprisingly, mis-regulation of the NF-kappa B pathway, either by mutation or epigenetic mechanisms, is involved in many human and animal diseases, especially ones associated with chronic in. ammation, immunodeficiency or cancer. This review describes human diseases in which mutations in the components of the core NF-kappa B signaling pathway have been implicated and discusses the molecular mechanisms by which these alterations in NF-kappa B signaling are likely to contribute to the disease pathology. These mutations can be germline or somatic and include gene amplification (e. g., REL), point mutations and deletions (REL, NFKB2, IKBA, CYLD, NEMO) and chromosomal translocations (BCL-3). In addition, human genetic diseases are briefly described wherein mutations affect protein modifiers or transducers of NF-kappa B signaling or disrupt NF-kappa B-binding sites in promoters/enhancers.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Hop St Louis, INSERM, U697, Paris, France	Boston University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu		COURTOIS, Gilles/0000-0003-3117-9595	NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER; NCI NIH HHS [CA47763] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN H, 2002, MOL IMMUNOL, V38, P849; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Aradhya S, 2001, AM J HUM GENET, V68, P765, DOI 10.1086/318806; Aradhya S, 2001, HUM MOL GENET, V10, P2171, DOI 10.1093/hmg/10.19.2171; Arcaroli J, 2006, AM J RESP CRIT CARE, V173, P1335, DOI 10.1164/rccm.200603-341OC; Au WY, 2002, LEUKEMIA LYMPHOMA, V43, P813, DOI 10.1080/10428190290016935; AvetLoiseau H, 1997, BRIT J HAEMATOL, V97, P119, DOI 10.1046/j.1365-2141.1997.d01-2140.x; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Bargou RC, 1996, BLOOD, V87, P4340, DOI 10.1182/blood.V87.10.4340.bloodjournal87104340; Barth TFE, 1998, BLOOD, V91, P4321, DOI 10.1182/blood.V91.11.4321.411k08_4321_4330; Barth TFE, 2003, BLOOD, V101, P3681, DOI 10.1182/blood-2002-08-2577; Barth TFE, 2001, GENE CHROMOSOME CANC, V31, P316, DOI 10.1002/gcc.1150; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bea S, 2005, BLOOD, V106, P3183, DOI 10.1182/blood-2005-04-1399; Bea S, 2004, J CLIN ONCOL, V22, P3498, DOI 10.1200/JCO.2004.11.025; Bentz M, 1996, BLOOD, V88, P1437, DOI 10.1182/blood.V88.4.1437.bloodjournal8841437; Berlin AL, 2002, J AM ACAD DERMATOL, V47, P169, DOI 10.1067/mjd.2002.125949; Bignell GR, 2000, NAT GENET, V25, P160, DOI 10.1038/76006; Borm MEA, 2005, INT J IMMUNOGENET, V32, P401, DOI 10.1111/j.1744-313X.2005.00546.x; Boulton SJ, 2002, SCIENCE, V295, P127, DOI 10.1126/science.1065986; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1994, BIOCHEM PHARMACOL, V47, P145, DOI 10.1016/0006-2952(94)90448-0; Bowen S, 2005, J INVEST DERMATOL, V124, P919, DOI 10.1111/j.0022-202X.2005.23688.x; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Cabannes E, 1999, ONCOGENE, V18, P3063, DOI 10.1038/sj.onc.1202893; Canoz O, 2004, MODERN PATHOL, V17, P911, DOI 10.1038/modpathol.3800140; CEREB N, 1994, J IMMUNOL, V152, P3873; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen JY, 2005, GENES IMMUN, V6, P123, DOI 10.1038/sj.gene.6364158; Chen WY, 2006, BLOOD, V107, P2477, DOI 10.1182/blood-2005-07-2950; Chen YC, 2005, CANCER RES, V65, P11771, DOI 10.1158/0008-5472.CAN-05-2078; Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805-758; Ciana P, 1997, ONCOGENE, V14, P1805, DOI 10.1038/sj.onc.1201015; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Courtois G, 2003, J CLIN INVEST, V112, P1108, DOI 10.1172/JCI200318714; Courtois G, 2006, CELL DEATH DIFFER, V13, P843, DOI 10.1038/sj.cdd.4401841; Daroszewska A, 2005, CLIN SCI, V109, P257, DOI 10.1042/CS20050053; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; DEJARDIN E, 1995, ONCOGENE, V11, P1835; Derudder E, 2003, BIOCHEM BIOPH RES CO, V308, P744, DOI 10.1016/S0006-291X(03)01474-8; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Donnelly GB, 2001, BLOOD, V98, p302A; Emmerich F, 1999, BLOOD, V94, P3129, DOI 10.1182/blood.V94.9.3129.421k03_3129_3134; Emmerich F, 2003, J PATHOL, V201, P413, DOI 10.1002/path.1454; Epinat JC, 2000, ONCOGENE, V19, P599, DOI 10.1038/sj.onc.1203376; Fan YJ, 2004, ONCOGENE, V23, P1030, DOI 10.1038/sj.onc.1207221; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Filipe-Santos O, 2006, J EXP MED, V203, P1745, DOI 10.1084/jem.20060085; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Fukuhara N, 2006, CANCER SCI, V97, P499, DOI 10.1111/j.1349-7006.2006.00209.x; Fusco F, 2004, HUM MOL GENET, V13, P1763, DOI 10.1093/hmg/ddh192; Garcia JF, 2005, HISTOPATHOLOGY, V47, P101, DOI 10.1111/j.1365-2559.2005.02175.x; Gaspar DA, 2002, GENET EPIDEMIOL, V23, P364, DOI 10.1002/gepi.10189; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 1999, ONCOGENE, V18, P6925, DOI 10.1038/sj.onc.1203222; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Goff LK, 2000, BRIT J HAEMATOL, V111, P618, DOI 10.1046/j.1365-2141.2000.02352.x; Gutierrez PP, 2002, J INVEST DERMATOL, V119, P527, DOI 10.1046/j.1523-1747.2002.01839.x; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heinritz W, 2006, BRIT J DERMATOL, V154, P992, DOI 10.1111/j.1365-2133.2006.07142.x; Hidaka F, 2006, CLIN IMMUNOL, V119, P188, DOI 10.1016/j.clim.2006.01.005; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Houldsworth J, 1996, BLOOD, V87, P25; Houldsworth J, 2004, BLOOD, V103, P1862, DOI 10.1182/blood-2003-04-1359; Hu GF, 2003, J INVEST DERMATOL, V121, P732, DOI 10.1046/j.1523-1747.2003.12514.x; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Janssen R, 2004, J EXP MED, V200, P559, DOI 10.1084/jem.20040773; Joos S, 1996, BLOOD, V87, P1571, DOI 10.1182/blood.V87.4.1571.bloodjournal8741571; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Joos S, 2002, BLOOD, V99, P1381, DOI 10.1182/blood.V99.4.1381; Jungnickel B, 2000, J EXP MED, V191, P395, DOI 10.1084/jem.191.2.395; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; Kalaitzidis D, 2002, GENE CHROMOSOME CANC, V34, P129, DOI 10.1002/gcc.10051; Kang S, 2005, CANCER LETT, V217, P11, DOI 10.1016/j.canlet.2004.06.053; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Keightley AM, 1999, BLOOD, V93, P4277, DOI 10.1182/blood.V93.12.4277.412k03_4277_4283; Kim KE, 2000, ONCOGENE, V19, P1334, DOI 10.1038/sj.onc.1203432; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Krappmann D, 1999, ONCOGENE, V18, P943, DOI 10.1038/sj.onc.1202351; Levine A, 2005, AM J GASTROENTEROL, V100, P407, DOI 10.1111/j.1572-0241.2005.41126.x; LIN SC, 2006, IN PRESS CANC LETT; LU D, 1991, ONCOGENE, V6, P1235; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Luo WJ, 2004, LAB INVEST, V84, P1193, DOI 10.1038/labinvest.3700152; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mao X, 2003, J INVEST DERMATOL, V121, P618, DOI 10.1046/j.1523-1747.2003.12406.x; Mao X, 2003, GENE CHROMOSOME CANC, V37, P176, DOI 10.1002/gcc.10184; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; Martinez-Climent JA, 2003, BLOOD, V101, P3109, DOI 10.1182/blood-2002-07-2119; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; McKeithan TW, 1997, GENE CHROMOSOME CANC, V20, P64, DOI 10.1002/(SICI)1098-2264(199709)20:1<64::AID-GCC10>3.0.CO;2-F; Medvedev AE, 2003, J EXP MED, V198, P521, DOI 10.1084/jem.20030701; MIGLIAZZA A, 1994, BLOOD, V84, P3850, DOI 10.1182/blood.V84.11.3850.bloodjournal84113850; Mikkola ML, 2003, CYTOKINE GROWTH F R, V14, P211, DOI 10.1016/S1359-6101(03)00020-0; Mitchell TC, 2001, NAT IMMUNOL, V2, P397, DOI 10.1038/87692; Na SY, 1999, J BIOL CHEM, V274, P28491, DOI 10.1074/jbc.274.40.28491; NAKAGAWA M, 1995, CANCER GENET CYTOGEN, V79, P89, DOI 10.1016/0165-4608(94)00094-R; Neat MJ, 2001, GENE CHROMOSOME CANC, V32, P236, DOI 10.1002/gcc.1187; Nenci A, 2006, HUM MOL GENET, V15, P531, DOI 10.1093/hmg/ddi470; NERI A, 1991, CELL, V67, P1075, DOI 10.1016/0092-8674(91)90285-7; Neri A, 1996, LEUKEMIA LYMPHOMA, V23, P43, DOI 10.3109/10428199609054800; Niehues T, 2004, J ALLERGY CLIN IMMUN, V114, P1456, DOI 10.1016/j.jaci.2004.08.047; Ohno H, 2005, INT J HEMATOL, V82, P397, DOI 10.1532/IJH97.05045; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Orange JS, 2005, IMMUNOL REV, V203, P21, DOI 10.1111/j.0105-2896.2005.00221.x; Orange JS, 2004, J ALLERGY CLIN IMMUN, V114, P650, DOI 10.1016/j.jaci.2004.06.052; Palanisamy N, 2002, GENE CHROMOSOME CANC, V33, P114, DOI 10.1002/gcc.10016; Pallares J, 2004, J PATHOL, V204, P569, DOI 10.1002/path.1666; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Puel A, 2006, AM J HUM GENET, V78, P691, DOI 10.1086/501532; Qi H, 2003, CANCER RES, V63, P7076; Rao PH, 1998, BLOOD, V92, P234, DOI 10.1182/blood.V92.1.234.413k22_234_240; Rassidakis GZ, 2003, BLOOD, V102, P1146, DOI 10.1182/blood-2003-04-1366; Regamey A, 2003, J EXP MED, V198, P1959, DOI 10.1084/jem.20031187; Reiley W, 2004, J BIOL CHEM, V279, P55161, DOI 10.1074/jbc.M411049200; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; RIEHEMANN K, 1993, TRENDS BIOCHEM SCI, V18, P82, DOI 10.1016/0968-0004(93)90159-K; Rodig SJ, 2005, AM J SURG PATHOL, V29, P196, DOI 10.1097/01.pas.0000149689.75462.ff; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Rossouw M, 2003, LANCET, V361, P1871, DOI 10.1016/S0140-6736(03)13491-5; Ruiz-Ballesteros E, 2005, BLOOD, V106, P1831, DOI 10.1182/blood-2004-10-3898; Saha A, 2003, EUR J IMMUNOGENET, V30, P397, DOI 10.1111/j.1365-2370.2003.00423.x; Saito K, 2004, STRUCTURE, V12, P1719, DOI 10.1016/j.str.2004.07.012; Saleh M, 2004, NATURE, V429, P75, DOI 10.1038/nature02451; Salhi A, 2004, CANCER RES, V64, P5113, DOI 10.1158/0008-5472.CAN-04-0307; Savage KJ, 2003, BLOOD, V102, P3871, DOI 10.1182/blood-2003-06-1841; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Scheinfeld N, 2003, CLIN EXP DERMATOL, V28, P539, DOI 10.1046/j.1365-2230.2003.01344.x; Schlette E, 2005, AM J CLIN PATHOL, V123, P465, DOI 10.1309/6Q27Q3NDGV8LW1BU; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Smahi A, 2000, NATURE, V405, P466; Soma LA, 2006, HUM PATHOL, V37, P218, DOI 10.1016/j.humpath.2005.09.025; SPINK CF, 2006, IN PRESS CANC LETT; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; STARCZYNOWSKI DT, 2006, IN PRESS ONCOGENE; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Suzuki N, 2002, TRENDS IMMUNOL, V23, P503, DOI 10.1016/S1471-4906(02)02298-6; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tagawa H, 2005, BLOOD, V106, P1770, DOI 10.1182/blood-2005-02-0542; Takahashi H, 2006, BLOOD, V107, P844, DOI 10.1182/blood-2005-07-2827; THAKUR S, 1994, ONCOGENE, V9, P2335; Thomas RK, 2004, BRIT J HAEMATOL, V126, P50, DOI 10.1111/j.1365-2141.2004.05000.x; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; Tobin E, 2003, BRIT J DERMATOL, V149, P627, DOI 10.1046/j.1365-2133.2003.05543.x; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Udalova IA, 2000, MOL CELL BIOL, V20, P9113, DOI 10.1128/MCB.20.24.9113-9119.2000; van Heel DA, 2002, HUM MOL GENET, V11, P1281, DOI 10.1093/hmg/11.11.1281; Veillette A, 2006, NAT REV IMMUNOL, V6, P56, DOI 10.1038/nri1761; Viatour P, 2004, MOL CELL, V16, P35, DOI 10.1016/j.molcel.2004.09.004; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Werner CA, 1997, AM J PATHOL, V151, P335; Wessendorf S, 2003, ONCOGENE, V22, P1425, DOI 10.1038/sj.onc.1206297; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Wood KM, 1998, ONCOGENE, V16, P2131, DOI 10.1038/sj.onc.1201735; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Xiao QX, 2004, APPL IMMUNOHISTO M M, V12, P211, DOI 10.1097/00129039-200409000-00005; Yamato H, 2001, HISTOPATHOLOGY, V39, P163, DOI 10.1046/j.1365-2559.2001.01197.x; YANO T, 1993, BLOOD, V82, P1813, DOI 10.1182/blood.V82.6.1813.bloodjournal8261813; Yousaf N, 2005, ARTHRITIS RHEUM-US, V52, P2906, DOI 10.1002/art.21268; ZHANG JD, 1994, ONCOGENE, V9, P1931; Zhang XJ, 2004, J INVEST DERMATOL, V122, P658, DOI 10.1111/j.0022-202X.2004.22321.x; Zheng GY, 2004, HUM MUTAT, V23, P400, DOI 10.1002/humu.9231; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	181	385	401	1	52	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6831	6843		10.1038/sj.onc.1209939	http://dx.doi.org/10.1038/sj.onc.1209939			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072331				2022-12-28	WOS:000241666700011
J	De Falco, G; Comes, F; Simone, C				De Falco, G.; Comes, F.; Simone, C.			pRb: Master of differentiation. Coupling irreversible cell cycle withdrawal with induction of muscle-specification transcription	ONCOGENE			English	Review						retinoblastoma gene; cell cycle withdrawal; differentiation; myogenesis; MyoD; tissue-specific transcription	RETINOBLASTOMA PROTEIN; GENE-EXPRESSION; TUMOR-SUPPRESSOR; SKELETAL-MUSCLE; MYOD; E2F; INHIBITION; MYOGENESIS; COMPLEXES; REPRESSOR	The protein product of the retinoblastoma (RB) gene is necessary for the completion of the muscle differentiation program and for myogenic basic helix-loop-helix-dependent transcription. In fact, in addition to induction and maintenance of permanent cell cycle withdrawal through negative regulation of E2F-responsive genes involved in proliferation, pRb also plays a positive role in the activation of muscle-specific genes. In pRb(-/-) myocytes, the expression of late myogenic markers is defective and myoblast fusion into myotubes occurs without irreversible cell cycle exit. This evidence demonstrates only a partial functional redundancy between pRb and its relatives p107 and pRb2/p130, as these pRb(-/-) multinucleated cells, which display p107 levels higher than normal myotubes, respond to mitogens with cell cycle re-entry and DNA synthesis. At the molecular level, pRb myogenic functions are mediated by cooperation with MyoD, Myocyte enhancer factor 2 (MEF2), High mobility group box protein-1 (HBP1) and histone deacetylase1, affecting chromatin configuration and tissue-specific transcription, and by post-translational modi. cation in response to intracellular signaling cascades.	Univ Bari, Dept Biomed Childhood, Div Med Genet, I-70124 Bari, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA	Universita degli Studi di Bari Aldo Moro; University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Simone, C (corresponding author), Univ Bari, Dept Biomed Childhood, Div Med Genet, I-70124 Bari, Italy.	csimone@temple.edu	Simone, Cristiano/K-3452-2018	Simone, Cristiano/0000-0002-2628-7658				Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Bagella L, 1998, J CELL PHYSIOL, V177, P206, DOI 10.1002/(SICI)1097-4652(199811)177:2<206::AID-JCP2>3.3.CO;2-W; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FALLS HF, 1951, AMA ARCH OPHTHALMOL, V46, P367; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; GIANCINTI C, 2006, J CELL PHYSL, V206, P807; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; GRANA X, 1994, P NATL ACAD SCI USA, V91, P3834, DOI 10.1073/pnas.91.9.3834; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Guo K, 1997, J BIOL CHEM, V272, P791, DOI 10.1074/jbc.272.2.791; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; Iezzi S, 2004, DEV CELL, V6, P673, DOI 10.1016/S1534-5807(04)00107-8; Kitzmann M, 1999, MOL CELL BIOL, V19, P3167; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Lachner M, 2003, J CELL SCI, V116, P2117, DOI 10.1242/jcs.00493; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Magenta A, 2003, MOL CELL BIOL, V23, P2893, DOI 10.1128/MCB.23.8.2893-2906.2003; MARTELLI F, 1994, ONCOGENE, V9, P3579; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, ONCOGENE, V14, P1171, DOI 10.1038/sj.onc.1200941; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SELLERS WR, 1996, BIOCHIM BIOPHYS ACTA, V1288, P1; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Simone C, 2004, ONCOGENE, V23, P2177, DOI 10.1038/sj.onc.1207327; Simone C, 2006, J CELL PHYSIOL, V207, P309, DOI 10.1002/jcp.20514; Simone C, 2002, ONCOGENE, V21, P4158, DOI 10.1038/sj.onc.1205511; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Simone C, 2001, FRONT BIOSCI-LANDMRK, V6, pD1074; Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Smialowski P, 2005, BBA-PROTEINS PROTEOM, V1750, P48, DOI 10.1016/j.bbapap.2005.03.012; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983	52	68	69	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5244	5249		10.1038/sj.onc.1209623	http://dx.doi.org/10.1038/sj.onc.1209623			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936743				2022-12-28	WOS:000240064100008
J	De Falco, G; Giordano, A				De Falco, G.; Giordano, A.			pRb2/p130: A new candidate for retinoblastoma tumor formation	ONCOGENE			English	Review						cell cycle; cancer; RB family; retinoblastoma; pRb2/p130; tumor suppressors	ISOLATED UNILATERAL RETINOBLASTOMA; RB1 GENE-MUTATIONS; CELL-CYCLE; SUSCEPTIBILITY GENE; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; SPORADIC RETINOBLASTOMA; GROWTH SUPPRESSION; AMINO-TERMINUS; LARGE-T	Retinoblastoma is the most common primary intraocular tumor in childhood. Mutations in both the alleles of the RB1 gene represent the causative agent for the tumor to occur. It is becoming evident that, although these alterations represent key events in the genesis of retinoblastoma, they are not sufficient per se for the tumor to develop, and other additional genetic or epigenetic alterations must occur. A supportive role in the genesis of retinoblastoma has recently been proposed for the RB1-related gene RB2/p130. Additionally, several other genetic alterations involving different chromosomes have been described as relevant in the tumorigenic process. In this review we will analyse current knowledge about the molecular mechanisms involved in retinoblastoma, paying particular attention to the mechanisms of inactivation of the biological function of the retinoblastoma family of proteins.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Biolife Sci Bldg,Suite 333, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Adams PD, 1996, MOL CELL BIOL, V16, P6623; ARHEDEN K, 1988, CYTOGENET CELL GENET, V48, P174, DOI 10.1159/000132619; Bellan C, 2002, INVEST OPHTH VIS SCI, V43, P3602; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bremner R, 1997, AM J HUM GENET, V61, P556, DOI 10.1086/515499; BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467; CANO J, 1994, CANCER GENET CYTOGEN, V76, P112, DOI 10.1016/0165-4608(94)90459-6; Chen CF, 1996, MOL CELL BIOL, V16, P4691; CHEN CS, 1995, CYTOGENET CELL GENET, V69, P260, DOI 10.1159/000133976; Chen D, 2002, CANCER RES, V62, P967; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN TT, 2000, CRIT REV EUKAR GENE, V5, P79; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Choy KW, 2002, INVEST OPHTH VIS SCI, V43, P1344; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 2000, CANCER RES, V60, P372; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COWELL JK, 1992, CANCER GENET CYTOGEN, V64, P1, DOI 10.1016/0165-4608(92)90314-X; D'Andrilli G, 2004, CLIN CANCER RES, V10, P3098, DOI 10.1158/1078-0432.CCR-03-0524; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; De Falco G, 2003, ONCOGENE, V22, P6214, DOI 10.1038/sj.onc.1206637; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DESUTTER E, 1987, OPHTHALMIC PAED GEN, V8, P85, DOI 10.3109/13816818709028522; DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GREGER V, 1989, HUM GENET, V83, P155, DOI 10.1007/BF00286709; HALL JG, 1988, AM J HUM GENET, V43, P355; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HORSTHEMKE B, 1992, CANCER GENET CYTOGEN, V63, P1, DOI 10.1016/0165-4608(92)90055-D; Huang Q, 2003, MOL VIS, V9, P502; Imbert I, 2001, CANCER GENET CYTOGEN, V128, P141, DOI 10.1016/S0165-4608(01)00402-2; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAELIN A, 1955, ARCH J KLAUS STIFTUN, V30, P442; KATO J, 1993, GENE DEV, V7, P331; Klutz M, 1999, AM J HUM GENET, V64, P667, DOI 10.1086/302254; KNUDSON AG, 1973, PROG MED GENET, V9, P113; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; KUSNETSOVA LE, 1982, HUM GENET, V61, P201, DOI 10.1007/BF00296442; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Laj A, 1999, MOL CELL BIOL, V19, P6632; Lazzi S, 2002, HUM PATHOL, V33, P723, DOI 10.1053/hupa.2002.125372; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEE WH, 1984, NATURE, V309, P458, DOI 10.1038/309458a0; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Lohmann DR, 2004, AM J MED GENET C, V129C, P23, DOI 10.1002/ajmg.c.30024; Lohmann DR, 1997, AM J HUM GENET, V61, P282, DOI 10.1086/514845; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MURPHREE AL, 1984, SCIENCE, V223, P1028, DOI 10.1126/science.6320372; Mutti L, 1998, DEV BIOL STAND, V94, P47; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; OLIVEROS O, 1995, CANCER GENET CYTOGEN, V82, P155, DOI 10.1016/0165-4608(94)00212-T; ONADIM Z, 1992, P NATL ACAD SCI USA, V89, P6177, DOI 10.1073/pnas.89.13.6177; POGOSIANZ H E, 1986, Archiv fuer Geschwulstforschung, V56, P135; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; Sampieri K, 2006, J HUM GENET, V51, P209, DOI 10.1007/s10038-005-0348-3; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; SHEN WJ, 1995, J BIOL CHEM, V270, P20525, DOI 10.1074/jbc.270.35.20525; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIMIZU T, 1994, AM J HUM GENET, V54, P793; Sivakumaran T. A., 1997, Acta Geneticae Medicae et Gemellologiae, V46, P193; SQUIRE J, 1984, HUM GENET, V66, P46, DOI 10.1007/BF00275185; STERNER JM, 1995, J BIOL CHEM, V270, P9281, DOI 10.1074/jbc.270.16.9281; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Sterner JM, 1996, CELL GROWTH DIFFER, V7, P53; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; SUCKLING RD, 1982, BRIT J CANCER, V46, P729, DOI 10.1038/bjc.1982.265; TOGUCHIDA J, 1993, GENOMICS, V17, P535, DOI 10.1006/geno.1993.1368; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; TURLEAU C, 1995, CANCER GENET CYTOGEN, V16, P321; VOGEL FRIEDRICH, 1954, ZEITSCHR MENSCHL VERERBUNGS U KONSTITUTIONSLEHRE, V32, P308; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; Zeschnigk M, 1997, HUM MOL GENET, V6, P387, DOI 10.1093/hmg/6.3.387; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zheng L, 2002, CANCER RES, V62, P2498	94	15	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5333	5340		10.1038/sj.onc.1209614	http://dx.doi.org/10.1038/sj.onc.1209614			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936755				2022-12-28	WOS:000240064100020
J	Gabellini, C; Del Bufalo, D; Zupi, G				Gabellini, C.; Del Bufalo, D.; Zupi, G.			Involvement of RB gene family in tumor angiogenesis	ONCOGENE			English	Review						cancer; angiogenesis; retinoblastoma family proteins	ENDOTHELIAL GROWTH-FACTOR; STIMULATES AXONAL OUTGROWTH; RETINOBLASTOMA PROTEIN; IN-VITRO; BCL-2 OVEREXPRESSION; CELL-PROLIFERATION; FACTOR EXPRESSION; INTERFERON-BETA; UP-REGULATION; THROMBOSPONDIN-1 EXPRESSION	Angiogenesis, the development of new blood vessels from pre-existing vessels, represents a fundamental step in tumor progression and metastatization. The induction of vasculature is required for growth of the tumor mass, to ensure an adequate supply of oxygen and metabolites to the tumor beyond a critical size. Tumor angiogenesis is a highly regulated process that is controlled physiologically by the tumor microenvironment and genetically by alteration of several oncogenes or tumor suppressor genes. W e will focus on recent demonstrations regarding the involvement of the retinoblastoma family proteins ( phosphorylated retinoblastoma (pRb), p107 and pRb2/p130) at different levels of the angiogenic process. pRb and its homologs can regulate the expression of pro-and antiangiogenic factors, such as the vascular endothelial growth factor, through an E2F-dependent mechanism. Moreover, pRb is able to modulate also the transcriptional activity of several angiogenesis-related factors like HIF-1, Id2 and Oct-1. pRb2/p130 is required for both differentiation and mobilization of bone marrow-derived endothelial cell precursors and endothelial sprouting from neighboring vessels. The involvement of the pRb pathway in the angiogenesis process has also been demonstrated by different cellular models expressing viral oncoproteins, like human papilloma virus. Moreover, some natural and synthetic compounds demonstrate their antiangiogenetic activity with a mechanism of action involving pRb. Finally, the possible prognostic value of immunohistochemical evaluation of pRb and/or pRb2/p130 expression can represent a useful tool for the characterization of the angiogenic phenotype of specific tumor histotypes.	Regina Elena Inst Canc Res, Expt Chemotherapy Lab, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Zupi, G (corresponding author), Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Via Messi Oro 156, I-00158 Rome, Italy.	zupi@ifo.it	Del Bufalo, Donatella/AAC-1594-2021; Del Bufalo, Donatella/K-8673-2016; Gabellini, Chiara/M-2539-2014	Del Bufalo, Donatella/0000-0002-3148-6096; Del Bufalo, Donatella/0000-0002-3148-6096; Gabellini, Chiara/0000-0002-5544-1570				ABE J, 1994, CANCER RES, V54, P3407; ALBERT DM, 1984, RETINA-J RET VIT DIS, V4, P189, DOI 10.1097/00006982-198400430-00011; Amellem O, 1996, EXP CELL RES, V227, P106, DOI 10.1006/excr.1996.0255; Bale TL, 2002, P NATL ACAD SCI USA, V99, P7734, DOI 10.1073/pnas.102187099; Banerjee D, 2000, CANCER RES, V60, P2365; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Biroccio A, 2000, FASEB J, V14, P652, DOI 10.1096/fasebj.14.5.652; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Castano E, 1998, MOL CELL BIOL, V18, P5380, DOI 10.1128/MCB.18.9.5380; Chang KH, 1997, P NATL ACAD SCI USA, V94, P9040, DOI 10.1073/pnas.94.17.9040; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2004, CLIN CANCER RES, V10, P3509, DOI 10.1158/1078-0432.CCR-03-0662; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Claudio PP, 2001, CANCER RES, V61, P462; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Danielsen T, 1998, BRIT J CANCER, V78, P1547, DOI 10.1038/bjc.1998.722; Dasgupta P, 2004, MOL CELL BIOL, V24, P9527, DOI 10.1128/MCB.24.21.9527-9541.2004; DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dhanabal M, 1999, BIOCHEM BIOPH RES CO, V258, P345, DOI 10.1006/bbrc.1999.0595; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Farinelle S, 2000, J PHARMACOL TOXICOL, V43, P15, DOI 10.1016/S1056-8719(00)00080-0; Fels DR, 2005, TRENDS BIOCHEM SCI, V30, P426, DOI 10.1016/j.tibs.2005.06.009; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; GOHJI K, 1994, INT J CANCER, V58, P380, DOI 10.1002/ijc.2910580313; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Harada H, 2003, CANCER LETT, V191, P109, DOI 10.1016/S0304-3835(02)00592-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 2000, CURR OPIN CELL BIOL, V12, P685, DOI 10.1016/S0955-0674(00)00152-6; Heffelfinger SC, 2000, PATHOBIOLOGY, V68, P129, DOI 10.1159/000055913; Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; Iervolino A, 2002, FASEB J, V16, P1453, DOI 10.1096/fj.02-0122fje; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242; Jones MK, 1999, NAT MED, V5, P1418; Joshi B, 2005, ONCOGENE, V24, P2204, DOI 10.1038/sj.onc.1208206; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; KATO N, 1995, AM J OBSTET GYNECOL, V172, P601, DOI 10.1016/0002-9378(95)90579-0; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; Kerbel RS, 2000, CARCINOGENESIS, V21, P505, DOI 10.1093/carcin/21.3.505; Krtolica A, 1996, CANCER RES, V56, P1168; Kvanta A, 1996, EXP EYE RES, V63, P511, DOI 10.1006/exer.1996.0141; Lacy S, 1997, ONCOGENE, V14, P2395, DOI 10.1038/sj.onc.1201085; Lasorella A, 2005, MOL CELL BIOL, V25, P3563, DOI 10.1128/MCB.25.9.3563-3574.2005; Le Buanec H, 1999, BIOMED PHARMACOTHER, V53, P424, DOI 10.1016/S0753-3322(99)80122-X; Li J, 1996, ONCOGENE, V13, P2379; Li WY, 2000, MICROVASC RES, V59, P286, DOI 10.1006/mvre.1999.2221; LUDLOW JW, 1993, ONCOGENE, V8, P331; Ludovini V, 2004, LUNG CANCER, V46, P77, DOI 10.1016/j.lungcan.2004.03.018; Lyden D, 1999, NATURE, V401, P670, DOI 10.1038/44334; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madigan MC, 1997, ULTRASTRUCT PATHOL, V21, P95, DOI 10.3109/01913129709021310; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; Miyashita H, 2005, ENDOTHELIUM-J ENDOTH, V12, P163, DOI 10.1080/10623320500227101; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pai Rama, 2000, Molecular Cell Biology Research Communications, V4, P111, DOI 10.1006/mcbr.2000.0260; Pedram A, 1998, J BIOL CHEM, V273, P13966, DOI 10.1074/jbc.273.22.13966; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V176, P633, DOI 10.1016/S0006-291X(05)80231-1; Raffaella R, 2004, EXP CELL RES, V293, P331, DOI 10.1016/j.yexcr.2003.10.014; Rak J, 2000, CANCER RES, V60, P490; Ravi R, 2000, GENE DEV, V14, P34; Sanseverino F, 2006, CANCER BIOL THER, V5, P84, DOI 10.4161/cbt.5.1.2345; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sherif ZA, 2001, CANCER GENE THER, V8, P771, DOI 10.1038/sj.cgt.7700361; Sheu WHH, 2006, LIFE SCI, V78, P1520, DOI 10.1016/j.lfs.2005.07.046; Singh RK, 1996, J INTERF CYTOK RES, V16, P577, DOI 10.1089/jir.1996.16.577; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Suzuma K, 2002, P NATL ACAD SCI USA, V99, P721, DOI 10.1073/pnas.022644499; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Tashiro E, 2003, CANCER RES, V63, P424; Toma JG, 2000, J NEUROSCI, V20, P7648; Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816; Toussaint-Smith E, 2004, ONCOGENE, V23, P2988, DOI 10.1038/sj.onc.1207442; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trisciuoglio D, 2005, MOL BIOL CELL, V16, P4153, DOI 10.1091/mbc.E04-12-1087; Udagawa T, 2002, FASEB J, V16, P1361, DOI 10.1096/fj.01-0813com; Vidal A, 2005, P NATL ACAD SCI USA, V102, P6890, DOI 10.1073/pnas.0405823102; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Wegiel B, 2005, ONCOGENE, V24, P6385, DOI 10.1038/sj.onc.1208795; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yu JY, 2001, CIRC RES, V89, P1161, DOI 10.1161/hh2401.101909; Zhai YF, 1999, INT J CANCER, V82, P131, DOI 10.1002/(SICI)1097-0215(19990702)82:1<131::AID-IJC22>3.3.CO;2-F; Zhang HQ, 1999, CELL GROWTH DIFFER, V10, P457; Zhang SY, 2000, CANCER RES, V60, P5972; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051	110	38	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5326	5332		10.1038/sj.onc.1209631	http://dx.doi.org/10.1038/sj.onc.1209631			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936754				2022-12-28	WOS:000240064100019
J	Genovese, C; Trani, D; Caputi, M; Claudio, PP				Genovese, C.; Trani, D.; Caputi, M.; Claudio, P. P.			Cell cycle control and beyond: emerging roles for the retinoblastoma gene family	ONCOGENE			English	Review						cell cycle; retinoblastoma; DNA damage; DNA repair; chromatin remodelling	DOUBLE-STRAND BREAKS; DNA-DAMAGE; HISTONE DEACETYLASE; S-PHASE; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; KINASE-ACTIVITY; G(1) CONTROL; IN-VIVO; P107	Rb family proteins (pRb/p105, Rb2/p130 and p107) play a key role in cell cycle control and are worthily involved in transcription repression and tumor suppression. The mechanisms of transcriptional activation and repression by the Rb gene family has been extensively investigated: pRb, pRb2/p130 and p107 interact with different E2F family factors and can inhibit E2F responsive promoters, interfering with progression of cell cycle, gene transcription, initiation of apoptotic process and cell differentiation. Recent studies have indicated that Rb and Rb2/p130 may be involved in cellular response to DNA damage events, by influencing the transcription of factors involved in DNA repair pathways. In particular, evidences suggest that Rb loss and target gene deregulation impacts on the repair of UV-induced pyrimidine pyrimidone photoproducts (6-4 PP) by regulating the expression of several DNA damage factors involved in UV DNA damage repair processes, including proliferating cell nuclear antigen. Ongoing studies are focused on the mechanisms by which Rb family genes drive cell cycle exit following DNA damage induction, and how Rb gene family's interaction with chromatin remodeling factors can influence DNA repair dynamics.	Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Naples 2, Osp A Monaldi, Dipartimento Sci Cardio Toraciche & Resp, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Universita della Campania Vanvitelli	Claudio, PP (corresponding author), Temple Univ, Coll Sci & Technol, Sbarro Inst Canc Res & Mol Med, BioLife Sci Bldg Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	claudio@temple.edu	Claudio, Pier Paolo/AAW-7282-2021	Claudio, Pier Paolo/0000-0001-7790-1622				Angus SP, 2004, MOL CELL BIOL, V24, P5404, DOI 10.1128/MCB.24.12.5404-5420.2004; Avni D, 2003, MOL CELL, V12, P735, DOI 10.1016/S1097-2765(03)00355-1; Bartek J, 2003, NATURE, V421, P486, DOI 10.1038/421486a; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bosco EE, 2005, NUCLEIC ACIDS RES, V33, P1581, DOI 10.1093/nar/gki283; Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Crawford DF, 2001, J BIOL CHEM, V276, P37166, DOI 10.1074/jbc.M103414200; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Galderisi U, 2003, ONCOGENE, V22, P5208, DOI 10.1038/sj.onc.1206558; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Hallstrom TC, 2003, P NATL ACAD SCI USA, V100, P10848, DOI 10.1073/pnas.1831408100; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh JK, 2002, MOL CELL BIOL, V22, P78, DOI 10.1128/MCB.22.1.78-93.2002; Hunter N, 2001, NAT GENET, V27, P236, DOI 10.1038/85781; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jorl FP, 2005, CELL DEATH DIFFER, V12, P65, DOI 10.1038/sj.cdd.4401499; Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097-2765(03)00034-0; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Kulms D, 2002, J DERMATOL, V29, P189, DOI 10.1111/j.1346-8138.2002.tb00248.x; Lan ZD, 2002, J BIOL CHEM, V277, P8372, DOI 10.1074/jbc.M108906200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Markey MP, 2002, CANCER RES, V62, P6587; Mayhew Christopher N, 2004, Methods Mol Biol, V281, P3; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Munger K, 2003, P NATL ACAD SCI USA, V100, P2165, DOI 10.1073/pnas.0630419100; Naderi S, 2002, CELL CYCLE, V1, P193, DOI 10.4161/cc.1.3.125; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Paggi MG, 2001, CANCER RES, V61, P4651; Pastwa E, 2003, ACTA BIOCHIM POL, V50, P891; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Petrini JHJ, 2003, TRENDS CELL BIOL, V13, P458, DOI 10.1016/S0962-8924(03)00170-3; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Ruiz S, 2003, DEVELOPMENT, V130, P2341, DOI 10.1242/dev.00453; Sabelli PA, 2005, P NATL ACAD SCI USA, V102, P13005, DOI 10.1073/pnas.0506160102; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Sharova NP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P275, DOI 10.1007/s10541-005-0113-4; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Stiegler P, 1998, CANCER RES, V58, P5049; Taylor-Harding B, 2004, MOL CELL BIOL, V24, P9124, DOI 10.1128/MCB.24.20.9124-9136.2004; Tonini T, 2002, J CELL PHYSIOL, V192, P138, DOI 10.1002/jcp.10117; Wang JYJ, 2001, ACTA ONCOL, V40, P689; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	75	99	102	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5201	5209		10.1038/sj.onc.1209652	http://dx.doi.org/10.1038/sj.onc.1209652			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936738				2022-12-28	WOS:000240064100003
J	King, A; Selak, MA; Gottlieb, E				King, A.; Selak, M. A.; Gottlieb, E.			Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer	ONCOGENE			English	Review						mitochondria; tumour suppressor genes; hypoxia inducible factor; apoptosis	HYPOXIA-INDUCIBLE FACTOR; RENAL-CELL CANCER; COMPLEX-II; HEREDITARY PARAGANGLIOMA; PROLYL HYDROXYLASE; OXIDATIVE STRESS; FAMILIAL PHEOCHROMOCYTOMA; OXYGEN HOMEOSTASIS; ENZYMATIC-ACTIVITY; RESPIRATORY-CHAIN	The phenomenon of enhanced glycolysis in tumours has been acknowledged for decades, but biochemical evidence to explain it is only just beginning to emerge. A significant hint as to the triggers and advantages of enhanced glycolysis in tumours was supplied by the recent discovery that succinate dehydrogenase (SDH) and fumarate hydratase (FH) are tumour suppressors and which associated, for the first time, mitochondrial enzymes and their dysfunction with tumorigenesis. Further steps forward showed that the substrates of SDH and FH, succinate and fumarate, respectively, can mediate a 'metabolic signalling' pathway. Succinate or fumarate, which accumulate in mitochondria owing to the inactivation of SDH or FH, leak out to the cytosol, where they inhibit a family of prolyl hydroxylase enzymes (PHDs). Depending on the PHD inhibited, two newly recognized pathways that support tumour maintenance may ensue: affected cells become resistant to certain apoptotic signals and/or activate a pseudohypoxic response that enhances glycolysis and is conveyed by hypoxia-inducible factor.	Beatson Inst Canc Res, Canc Res UK, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; Cancer Research UK	Gottlieb, E (corresponding author), Beatson Inst Canc Res, Canc Res UK, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	e.gottlieb@beatson.gla.ac.uk	Gottlieb, Eyal/G-6450-2010	Gottlieb, Eyal/0000-0002-9770-0956				Ang SO, 2002, NAT GENET, V32, P614, DOI 10.1038/ng1019; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Baysal BE, 2004, J MED GENET, V41, P703, DOI 10.1136/jmg.2004.019224; Baysal BE, 2003, TRENDS ENDOCRIN MET, V14, P453, DOI 10.1016/j.tem.2003.08.004; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Benn DE, 2006, J CLIN ENDOCR METAB, V91, P827, DOI 10.1210/jc.2005-1862; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9; Chau NM, 2005, CANCER RES, V65, P4918, DOI 10.1158/0008-5472.CAN-04-4453; Dahia PLM, 2006, CURR OPIN ONCOL, V18, P1, DOI 10.1097/01.cco.0000198017.45982.06; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Dann CE, 2005, BIOCHEM BIOPH RES CO, V338, P639, DOI 10.1016/j.bbrc.2005.08.140; Dekker PBD, 2003, J PATHOL, V201, P480, DOI 10.1002/path.1461; Elson DA, 2001, GENE DEV, V15, P2520, DOI 10.1101/gad.914801; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Favier J, 2005, HORM RES, V63, P171, DOI 10.1159/000084685; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gimenez-Roqueplo AP, 2002, J CLIN ENDOCR METAB, V87, P4771, DOI 10.1210/jc.2002-020525; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Green DR, 2005, J CLIN INVEST, V115, P2610, DOI 10.1172/JCI26321; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009; Lee S, 2005, CANCER CELL, V8, P155, DOI 10.1016/j.ccr.2005.06.015; Lehtonen R, 2004, AM J PATHOL, V164, P17, DOI 10.1016/S0002-9440(10)63091-X; Maxwell PH, 2005, EXP PHYSIOL, V90, P791, DOI 10.1113/expphysiol.2005.030924; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Modica-Napolitano JS, 2004, MITOCHONDRION, V4, P755, DOI 10.1016/j.mito.2004.07.027; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Owen OE, 2002, J BIOL CHEM, V277, P30409, DOI 10.1074/jbc.R200006200; Pawlu C, 2005, FAM CANCER, V4, P49, DOI 10.1007/s10689-004-4227-4; Percy MJ, 2006, P NATL ACAD SCI USA, V103, P654, DOI 10.1073/pnas.0508423103; Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Raha S, 2000, TRENDS BIOCHEM SCI, V25, P502, DOI 10.1016/S0968-0004(00)01674-1; Robey RB, 2005, CELL CYCLE, V4, P654, DOI 10.4161/cc.4.5.1678; Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6; Schiavi F, 2005, JAMA-J AM MED ASSOC, V294, P2057, DOI 10.1001/jama.294.16.2057; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Schofield CJ, 2005, BIOCHEM BIOPH RES CO, V338, P617, DOI 10.1016/j.bbrc.2005.08.111; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Senoo-Matsuda N, 2001, J BIOL CHEM, V276, P41553, DOI 10.1074/jbc.M104718200; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Vanharanta S, 2006, HUM MOL GENET, V15, P97, DOI 10.1093/hmg/ddi431; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Wei MH, 2006, J MED GENET, V43, P18, DOI 10.1136/jmg.2005.033506; Welsh S, 2004, MOL CANCER THER, V3, P233; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; Zu XL, 2004, BIOCHEM BIOPH RES CO, V313, P459, DOI 10.1016/j.bbrc.2003.11.136	60	487	515	1	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4675	4682		10.1038/sj.onc.1209594	http://dx.doi.org/10.1038/sj.onc.1209594			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892081				2022-12-28	WOS:000239687000005
J	Kremsdorf, D; Soussan, P; Paterlini-Brechot, P; Brechot, C				Kremsdorf, D.; Soussan, P.; Paterlini-Brechot, P.; Brechot, C.			Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis	ONCOGENE			English	Review						hepatocellular carcinoma; hepatitis B virus; viral integration; HBx; HBSP	X PROTEIN HBX; CORE PROMOTER MUTATIONS; TRANSGENIC MOUSE MODEL; T-CELL EPITOPES; PRE-S MUTANT; SURFACE-ANTIGEN; IN-VIVO; INSERTIONAL MUTAGENESIS; GENE-EXPRESSION; LIVER-TUMORS	As discussed in detail in other chapters of this review, chronic hepatitis B (HBV) infection is a major risk factor for hepatocellular carcinoma (HCC). Most HCCs complicate the evolution of an active or inactive cirrhosis. However, some tumors occur on livers with minimal histological changes; the prevalence of such cases varies from one geographical region to the other, being much higher in the southern half of Africa (around 40% of HCCs) than in Asia, America and Europe, where at least 90% of HCCs are associated with the cirrhosis. This heterogeneity is probably a reflection of different environmental and genetic factors. This review will summarize the current knowledge on the mechanisms involved in HBV-related liver carcinogenesis. It will show in particular how viruses can be viewed as tools to discover and dissect new cellular pathways involved in cancer development and emphasize the potential synergistic effects between HBV and hepatitis C virus, as well as between viral infections and other environmental factors, such as alcohol.	INSERM, U812, Paris, France; Univ Paris 05, Fac Med, CHU Necker, Paris, France; Inst Pasteur, Paris, France; INSERM, U807, Paris, France; INSERM, U785, Villejuif, France; Univ Paris 11, Fac Med, Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Brechot, C (corresponding author), Univ Paris 11, INSERM, U785, Liver Hepatobiliary Ctr,Paul Brousse Hosp, F-94800 Villejuif, France.	brechot@vjf.inserm.fr	Kremsdorf, Dina/O-9797-2017; soussan, patrick/O-9801-2017	soussan, patrick/0000-0003-2706-7371; Paterlini- Brechot, Patrizia/0000-0001-7981-6325				Ahn JY, 2002, J GEN VIROL, V83, P2765, DOI 10.1099/0022-1317-83-11-2765; Andrisani OM, 1999, INT J ONCOL, V15, P373; Anthony PP, 2001, HISTOPATHOLOGY, V39, P109, DOI 10.1046/j.1365-2559.2001.01188.x; Aoki H, 1996, P NATL ACAD SCI USA, V93, P7300, DOI 10.1073/pnas.93.14.7300; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BANNASCH P, 1989, FALK SYMP, V51, P55; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bergametti F, 2002, J VIROL, V76, P6495, DOI 10.1128/JVI.76.13.6495-6501.2002; Bouchard MJ, 2004, J VIROL, V78, P12725, DOI 10.1128/JVI.78.23.12725-12734.2004; Bouchard MJ, 2003, J VIROL, V77, P7713, DOI 10.1128/JVI.77.14.7713-7719.2003; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; Brechot C, 2001, HEPATOLOGY, V34, P194, DOI 10.1053/jhep.2001.25172; Brechot C, 2000, SEMIN CANCER BIOL, V10, P211, DOI 10.1006/scbi.2000.0321; BRECHOT C, 1998, VIRAL HEPATITIS LIVE, P490; Bruni R, 2004, VIROLOGY, V329, P1, DOI 10.1016/j.virol.2004.08.008; Bruni R, 1999, VIROLOGY, V257, P483, DOI 10.1006/viro.1999.9678; BUENDIA MA, 1994, PRIMARY LIVER CANC E, P211; Cha MY, 2004, HEPATOLOGY, V39, P1683, DOI 10.1002/hep.20245; Chami M, 2000, ONCOGENE, V19, P2877, DOI 10.1038/sj.onc.1203605; Chan HLY, 2004, GUT, V53, P1494, DOI 10.1136/gut.2003.033324; CHEN C, 1986, BR J EXP PATHOL, V67, P1868; Chen CJ, 2006, JAMA-J AM MED ASSOC, V295, P65, DOI 10.1001/jama.295.1.65; Chen GG, 2005, J CLIN VIROL, V34, P7, DOI 10.1016/j.jcv.2005.01.006; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen YY, 2005, INT IMMUNOPHARMACOL, V5, P1839, DOI 10.1016/j.intimp.2005.06.004; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; CHISARI FV, 1995, HEPATOLOGY, V22, P1316, DOI 10.1016/0270-9139(95)90645-2; Choi YW, 2005, VIROLOGY, V332, P454, DOI 10.1016/j.virol.2004.11.019; Chun E, 2003, J IMMUNOL, V170, P1183, DOI 10.4049/jimmunol.170.3.1183; Chung MK, 1999, J IMMUNOTHER, V22, P279, DOI 10.1097/00002371-199907000-00001; Chung TW, 2004, FASEB J, V18, P1123, DOI 10.1096/fj.03-1429fje; CLEMENTI M, 1993, RES VIROLOGY, V144, P297, DOI 10.1016/S0923-2516(06)80044-0; Collier LS, 2005, NATURE, V436, P272, DOI 10.1038/nature03681; Cui F, 2006, PROTEOMICS, V6, P498, DOI 10.1002/pmic.200500218; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Fan YF, 2000, J GASTROEN HEPATOL, V15, P519, DOI 10.1046/j.1440-1746.2000.02187.x; Fan YF, 2001, HEPATOLOGY, V33, P277, DOI 10.1053/jhep.2001.21163; FARZA H, 1994, MOL CARCINOGEN, V9, P185, DOI 10.1002/mc.2940090402; FEITELSON MA, 1993, ONCOGENE, V8, P1109; FEITELSON MA, 2005, CANC LETT        SEP; Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528; GALLOWAY DA, 1983, NATURE, V302, P21, DOI 10.1038/302021a0; GERIN JL, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P556; Gong SS, 1996, J VIROL, V70, P2000, DOI 10.1128/JVI.70.3.2000-2007.1996; Guidotti LG, 2000, VIROLOGY, V273, P221, DOI 10.1006/viro.2000.0442; Guidotti LG, 1999, J EXP MED, V189, P1555, DOI 10.1084/jem.189.10.1555; Guidotti LG, 1999, SCIENCE, V284, P825, DOI 10.1126/science.284.5415.825; Gunther S, 1997, VIROLOGY, V238, P363, DOI 10.1006/viro.1997.8863; HAGEN TM, 1994, P NATL ACAD SCI USA, V91, P12808, DOI 10.1073/pnas.91.26.12808; Haller O, 1998, REV SCI TECH OIE, V17, P220, DOI 10.20506/rst.17.1.1084; HAN KH, 1993, HEPATOLOGY, V18, P1032; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; HESS J, 1988, MED MICROBIOL IMMUN, V177, P195, DOI 10.1007/BF00211219; Hessein M, 2005, TUMORI J, V91, P241, DOI 10.1177/030089160509100306; Hind O, 2002, J GASTROENTEROL, V37, P883, DOI 10.1007/s005350200149; Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171; Hsieh YH, 2004, CARCINOGENESIS, V25, P2023, DOI 10.1093/carcin/bgh207; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Hui AY, 2005, CURR OPIN INFECT DIS, V18, P400, DOI 10.1097/01.qco.0000180163.84271.5e; Hung L, 2004, FEBS LETT, V560, P210, DOI 10.1016/S0014-5793(04)00113-9; Huy TTT, 2003, J CLIN MICROBIOL, V41, P5449, DOI 10.1128/JCM.41.12.5449-5455.2003; Hwang GY, 2003, J CLIN MICROBIOL, V41, P5598, DOI 10.1128/JCM.41.12.5598-5603.2003; Hwang YK, 2002, VACCINE, V20, P3770, DOI 10.1016/S0264-410X(02)00297-9; Iavarone M, 2003, J HEPATOL, V39, P253, DOI 10.1016/S0168-8278(03)00217-4; Kanai Y, 1997, INT J CANCER, V71, P355; Kao JH, 2003, GASTROENTEROLOGY, V124, P327, DOI 10.1053/gast.2003.50053; Karla N, 2004, J BIOL CHEM, V279, P25313, DOI 10.1074/jbc.M400932200; KIM DG, 2005, METHOD MOL BIOL, V317, P141; Kim JH, 2003, J VIROL, V77, P7166, DOI 10.1128/JVI.77.13.7166-7173.2003; Kim KH, 2003, EMBO J, V22, P2104, DOI 10.1093/emboj/cdg210; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Kojiro M, 2005, SEMIN LIVER DIS, V25, P133, DOI 10.1055/s-2005-871193; Koo JS, 2005, INTERVIROLOGY, V48, P16, DOI 10.1159/000082090; KORBA BE, 1989, HEPATOLOGY, V9, P461, DOI 10.1002/hep.1840090321; Koziel MJ, 1999, SEMIN LIVER DIS, V19, P157, DOI 10.1055/s-2007-1007107; Kuang SY, 2004, P NATL ACAD SCI USA, V101, P3575, DOI 10.1073/pnas.0308232100; Kwun HJ, 2004, NUCLEIC ACIDS RES, V32, P2202, DOI 10.1093/nar/gkh553; Lakhtakia R, 2003, J GASTROEN HEPATOL, V18, P80, DOI 10.1046/j.1440-1746.2003.02902.x; Larkin J, 1999, NAT MED, V5, P907, DOI 10.1038/11347; Lee ATC, 2005, J BIOL CHEM, V280, P33525, DOI 10.1074/jbc.M506628200; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; Lee YI, 2004, J BIOL CHEM, V279, P15460, DOI 10.1074/jbc.M309280200; Leon B, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-60; Leupin O, 2005, J VIROL, V79, P4238, DOI 10.1128/JVI.79.7.4238-4245.2005; Leupin O, 2003, J VIROL, V77, P6274, DOI 10.1128/JVI.77.11.6274-6283.2003; LEVRERO M, 1991, HEPATOLOGY, V13, P143, DOI 10.1002/hep.1840130121; Li Donghua, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P383; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Lin X, 2005, WORLD J GASTROENTERO, V11, P4703, DOI 10.3748/wjg.v11.i30.4703; Lin Y, 1997, CANCER RES, V57, P5137; LONCAREVIC IF, 1990, VIROLOGY, V174, P158, DOI 10.1016/0042-6822(90)90064-X; LUGASSY C, 1987, J INFECT DIS, V155, P64, DOI 10.1093/infdis/155.1.64; Madden CR, 2001, J VIROL, V75, P3851, DOI 10.1128/JVI.75.8.3851-3858.2001; Malmassari S, 2005, MICROBES INFECT, V7, P626, DOI 10.1016/j.micinf.2004.12.022; Mathonnet G, 2004, MUTAT RES-FUND MOL M, V554, P305, DOI 10.1016/j.mrfmmm.2004.05.010; McMahon BJ, 2005, SEMIN LIVER DIS, V25, P3, DOI 10.1055/s-2005-915644; Melegari M, 2005, J VIROL, V79, P9810, DOI 10.1128/JVI.79.15.9810-9820.2005; MIAO J, 2005, CANC LETT       0628; Minami M, 1996, GASTROENTEROLOGY, V111, P691, DOI 10.1053/gast.1996.v111.pm8780574; Minami M, 2005, ONCOGENE, V24, P4340, DOI 10.1038/sj.onc.1208628; Moon EJ, 2003, FASEB J, V17, P382, DOI 10.1096/fj.03-0153fje; Moradpour D, 2005, EUR J GASTROEN HEPAT, V17, P477, DOI 10.1097/00042737-200505000-00002; MORGAN D, 1990, J VIROL, V64, P969, DOI 10.1128/JVI.64.3.969-976.1990; Murakami Y, 2005, GUT, V54, P1162, DOI 10.1136/gut.2004.054452; Murakami Y, 2004, J MED VIROL, V72, P203, DOI 10.1002/jmv.10547; Nakamoto Y, 1998, J EXP MED, V188, P341, DOI 10.1084/jem.188.2.341; Oon CJ, 2002, J GASTROEN HEPATOL, V17, pS491; Orito E, 2001, HEPATOLOGY, V33, P218, DOI 10.1053/jhep.2001.20532; Orito E, 2003, INTERVIROLOGY, V46, P408, DOI 10.1159/000075000; PANG R, 2005, CANC LETT       1017; Paradis V, 1998, HEPATOLOGY, V28, P953, DOI 10.1002/hep.510280409; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; Paterlini-Brechot P, 2003, ONCOGENE, V22, P3911, DOI 10.1038/sj.onc.1206492; Peng ZH, 2005, INT J ONCOL, V26, P467; Pollicino T, 2004, GASTROENTEROLOGY, V126, P102, DOI 10.1053/j.gastro.2003.10.048; PONTISSO P, 1984, BRIT MED J, V288, P1563, DOI 10.1136/bmj.288.6430.1563; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Pujol FH, 2005, J CLIN GASTROENTEROL, V39, P611, DOI 10.1097/01.mcg.0000170770.49394.92; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; RAIMONDO G, 1988, VIROLOGY, V166, P103, DOI 10.1016/0042-6822(88)90151-1; Reifenberg K, 2002, J GEN VIROL, V83, P991, DOI 10.1099/0022-1317-83-5-991; Robek MD, 2002, J VIROL, V76, P3570, DOI 10.1128/JVI.76.7.3570-3574.2002; Roberts LR, 2005, SEMIN LIVER DIS, V25, P212, DOI 10.1055/s-2005-871200; Romero R, 1996, HEPATOLOGY, V23, P17, DOI 10.1053/jhep.1996.v23.pm0008550037; ROSMORDUC O, 1995, HEPATOLOGY, V22, P10, DOI 10.1016/0270-9139(95)90346-1; Rosmorduc O, 1999, J GEN VIROL, V80, P1253, DOI 10.1099/0022-1317-80-5-1253; Sanchez-Prieto R, 1999, NAT MED, V5, P1076, DOI 10.1038/12516; SCHLUTER V, 1994, ONCOGENE, V9, P3335; SELL S, 1993, INT J DEV BIOL, V37, P189; Shin EC, 1999, INT J CANCER, V82, P587, DOI 10.1002/(SICI)1097-0215(19990812)82:4<587::AID-IJC19>3.0.CO;2-9; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; SMITH KT, 1988, VIROLOGY, V164, P39, DOI 10.1016/0042-6822(88)90617-4; Soussan P, 2000, J CLIN INVEST, V105, P55, DOI 10.1172/JCI8098; Soussan P, 2003, J HEPATOL, V38, P343, DOI 10.1016/S0168-8278(02)00422-1; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Tamori A, 2005, CLIN CANCER RES, V11, P5821, DOI 10.1158/1078-0432.CCR-04-2055; Tamori A, 1999, HEPATOLOGY, V29, P1429, DOI 10.1002/hep.510290520; Tanaka Y, 2004, BIOCHEM BIOPH RES CO, V318, P461, DOI 10.1016/j.bbrc.2004.04.046; Tang H, 2005, J VIROL, V79, P5548, DOI 10.1128/JVI.79.9.5548-5556.2005; Tennant BC, 2004, GASTROENTEROLOGY, V127, pS283, DOI 10.1053/j.gastro.2004.09.043; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; TERRE S, 1991, J VIROL, V65, P5539; TOSHKOV I, 1994, HEPATOLOGY, V20, P1162, DOI 10.1002/hep.1840200510; Tralhao JG, 2002, P NATL ACAD SCI USA, V99, P6991, DOI 10.1073/pnas.092657699; TRANSY C, 1992, P NATL ACAD SCI USA, V89, P3874, DOI 10.1073/pnas.89.9.3874; Tu H, 2001, CANCER RES, V61, P7803; Wang HC, 2005, HEPATOLOGY, V41, P761, DOI 10.1002/hep.20615; WANG WL, 1991, CANCER RES, V51, P4971; Wang Y, 2004, ONCOGENE, V23, P142, DOI 10.1038/sj.onc.1206889; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Xu ZM, 2002, J VIROL, V76, P2579, DOI 10.1128/JVI.76.5.2579-2584.2002; Yeh CT, 2000, ONCOGENE, V19, P5213, DOI 10.1038/sj.onc.1203903; Yoo YG, 2004, FEBS LETT, V577, P121, DOI 10.1016/j.febslet.2004.10.004; Yoo YG, 2004, J BIOL CHEM, V279, P36242, DOI 10.1074/jbc.M401290200; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Yotsuyanagi H, 2002, J HEPATOL, V37, P355, DOI 10.1016/S0168-8278(02)00180-0; Yu FL, 2005, J HEPATOL, V42, P520, DOI 10.1016/j.jhep.2004.11.031; Zhang JL, 2005, ARCH VIROL, V150, P721, DOI 10.1007/s00705-004-0446-0; Zhang SM, 2005, ARCH VIROL, V150, P1579, DOI 10.1007/s00705-005-0521-1; Zhang ZS, 2004, J VIROL, V78, P4566, DOI 10.1128/JVI.78.9.4566-4572.2004; Zhu HZ, 2004, EXP MOL PATHOL, V76, P44, DOI 10.1016/j.yexmp.2003.09.001; ZIEMER M, 1985, J VIROL, V53, P885, DOI 10.1128/JVI.53.3.885-892.1985; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	173	220	229	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3823	3833		10.1038/sj.onc.1209559	http://dx.doi.org/10.1038/sj.onc.1209559			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799624				2022-12-28	WOS:000238559600010
J	Kurosu, T; Tsuji, K; Kida, A; Koyama, T; Yamamoto, M; Miura, O				Kurosu, T.; Tsuji, K.; Kida, A.; Koyama, T.; Yamamoto, M.; Miura, O.			Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta	ONCOGENE			English	Article						BCR/ABL; imatinib; rottlerin; mitochondrial uncoupler; protein kinase C-delta	PERMEABILITY TRANSITION PORE; CHRONIC MYELOID-LEUKEMIA; DOMAIN MUTATIONS; RESISTANCE; INHIBITOR; ERYTHROPOIETIN; EVOLUTION; RESPONSES; COMPLEX; STI571	Although the BCR/ABL tyrosine kinase inhibitor imatinib is highly effective for treatment of chronic myeloid leukemia ( CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia ( ALL), relapse with emerging imatinib-resistance mutations in the BCR/ABL kinase domain poses a significant problem. Here, we demonstrate that rottlerin, a putative protein kinase C-delta ( PKC delta)-specific inhibitor, acts synergistically with imatinib to induce apoptosis of BCR/ABL-expressing K562 and Ton.B210 cells. However, rottlerin inhibited neither PKC delta nor BCR/ABL in these cells. On the other hand, rottlerin, previously characterized also as a mitochondrial uncoupler, transiently but significantly reduced mitochondrial membrane potential and gradually induced mitochondrial membrane permeabilization. Moreover, two other mitochondrial uncouplers, FCCP and DNP, very similarly induced apoptosis of BCR/ABL-expressing cells in a synergistic manner with imatinib. Imatinib synergistically enhanced mitochondrial membrane permeabilization induced by mitochondrial uncouplers, which led to release of cytochrome c into the cytoplasm and activation of caspases-3 and -9. Rottlerin also enhanced the cytotoxic effect of imatinib in leukemic cells from patients with CML blast crisis and Ph-positive ALL or a cell line expressing the imatinib-resistant E255K BCR/ABL mutant. The present study indicates that rottlerin synergistically enhances imatinib-induced apoptosis through its mitochondrial uncoupling effect independent of PKC delta and may contribute to the development of new treatment strategy to overcome the imatinib resistance and to cure the BCR/ABL expressing leukemias.	Tokyo Med & Dent Univ, Dept Hematol, Grad Sch Med, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Lab Mol Genet Hematol, Grad Sch Hlth Sci, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Miura, O (corresponding author), Tokyo Med & Dent Univ, Dept Hematol, Grad Sch Med, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	miura.hema@tmd.ac.jp		Yamamoto, Masahide/0000-0002-3142-8806; Miura, Osamu/0000-0002-0981-3054				Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Chin H, 1996, BLOOD, V88, P4415, DOI 10.1182/blood.V88.12.4415.bloodjournal88124415; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Durrant D, 2004, BIOCHEM BIOPH RES CO, V321, P905, DOI 10.1016/j.bbrc.2004.07.049; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Goldman JM, 2003, NEW ENGL J MED, V349, P1451, DOI 10.1056/NEJMra020777; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Harper J A, 2001, Obes Rev, V2, P255, DOI 10.1046/j.1467-789X.2001.00043.x; Hofmann WK, 2003, BLOOD, V102, P659, DOI 10.1182/blood-2002-06-1756; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Jin A, 2006, ONCOGENE, V25, P4332, DOI 10.1038/sj.onc.1209459; Klucher KM, 1998, BLOOD, V91, P3927, DOI 10.1182/blood.V91.10.3927.3927_3927_3934; Krauss S, 2005, NAT REV MOL CELL BIO, V6, P248, DOI 10.1038/nrm1592; Kreuzer KA, 2003, ANN HEMATOL, V82, P284, DOI 10.1007/s00277-003-0644-y; Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755; Liao YF, 2005, LIFE SCI, V77, P707, DOI 10.1016/j.lfs.2005.01.010; Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; O'Hare T, 2006, CURR OPIN GENET DEV, V16, P92, DOI 10.1016/j.gde.2005.11.002; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Poncet D, 2003, APOPTOSIS, V8, P521, DOI 10.1023/A:1025546525894; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014; Roche-Lestienne C, 2003, NEW ENGL J MED, V348, P2265, DOI 10.1056/NEJMc035089; Romanova LY, 1999, J CELL PHYSIOL, V179, P157, DOI 10.1002/(SICI)1097-4652(199905)179:2<157::AID-JCP6>3.0.CO;2-4; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Shah Neil P, 2005, Hematology Am Soc Hematol Educ Program, P183; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Temple MD, 2005, TRENDS CELL BIOL, V15, P319, DOI 10.1016/j.tcb.2005.04.003; Tillman DM, 2003, CANCER RES, V63, P5118; Weisberg E, 2005, CANCER CELL, V7, P129, DOI 10.1016/j.ccr.2005.01.007; Willis SG, 2005, BLOOD, V106, P2128, DOI 10.1182/blood-2005-03-1036; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753; Yamamoto M, 2004, BIOCHEM BIOPH RES CO, V319, P1272, DOI 10.1016/j.bbrc.2004.05.113; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	40	28	29	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2975	2987		10.1038/sj.onc.1210117	http://dx.doi.org/10.1038/sj.onc.1210117			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130834				2022-12-28	WOS:000246395400003
J	Mamidipudi, V; Dhillon, NK; Parman, T; Miller, LD; Lee, KC; Cartwright, CA				Mamidipudi, V.; Dhillon, N. K.; Parman, T.; Miller, L. D.; Lee, K. C.; Cartwright, C. A.			RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints	ONCOGENE			English	Article						RACK1; Src; colon cancer; cell cycle regulation	PROTEIN-KINASE-C; TYROSINE PHOSPHORYLATION; TRANSFORMED-CELLS; FAMILY KINASES; SAM68; RNA; PROGRESSION; ACTIVATION; SUBSTRATE; MITOSIS	Previously, we showed that Src tyrosine kinases are activated early in the development of human colon cancer and are suppressed as intestinal cells differentiate. We identified RACK1 as an endogenous substrate, binding partner and inhibitor of Src. Here we show (by over-expressing RACK1, depleting Src or RACK1 and utilizing cell-permeable peptides that perturb RACK1's interaction with Src) that RACK1 regulates growth of colon cells by suppressing Src activity at G(1) and mitotic checkpoints, and consequently delaying cell cycle progression. Activated Src rescues RACK1-inhibited growth of HT-29 cells. Conversely, inhibiting Src abolishes growth promoted by RACK1 depletion in normal cells. Two potential mechanisms whereby RACK1 regulates mitotic exit are identified: suppression of Src-mediated Sam68 phosphorylation and maintenance of the cyclin-dependent kinase (CDK) 1-cyclin B complex in an active state. Our results reveal novel mechanisms of cell cycle control in G1 and mitosis of colon cells. The significance of this work lies in the discovery of a mechanism by which the growth of colon cancer cells can be slowed, by RACK1 suppression of an oncogenic kinase at critical cell cycle checkpoints. Small molecules that mimic RACK1 function may provide a powerful new approach to the treatment of colon cancer.	Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University	Cartwright, CA (corresponding author), Stanford Univ, Sch Med, Dept Med, M211 Alway Bldg,300 Pasteur Dr, Stanford, CA 94305 USA.	chris.cartwright@stanford.edu			NIDDK NIH HHS [DK43743, DK56339] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK043743, R29DK043743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Bromann PA, 2004, ONCOGENE, V23, P7957, DOI 10.1038/sj.onc.1208079; Cartwright C, 1998, GASTROENTEROLOGY, V114, P1335, DOI 10.1016/S0016-5085(98)70443-3; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2002, ONCOGENE, V21, P7619, DOI 10.1038/sj.onc.1206002; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Di Fruscio M, 1999, P NATL ACAD SCI USA, V96, P2710, DOI 10.1073/pnas.96.6.2710; Dorn GW, 2002, ANNU REV PHYSIOL, V64, P407, DOI 10.1146/annurev.physiol.64.081501.155903; Fleury S, 2000, P NATL ACAD SCI USA, V97, P5393, DOI 10.1073/pnas.97.10.5393; Haegebarth A, 2004, J BIOL CHEM, V279, P54398, DOI 10.1074/jbc.M409579200; Itoh M, 2002, NUCLEIC ACIDS RES, V30, P5452, DOI 10.1093/nar/gkf673; Liu K, 2000, J BIOL CHEM, V275, P40195, DOI 10.1074/jbc.M006194200; Lukong KE, 2005, J BIOL CHEM, V280, P38639, DOI 10.1074/jbc.M505802200; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; Mamidipudi V, 2004, MOL CELL BIOL, V24, P6788, DOI 10.1128/MCB.24.15.6788-6798.2004; Mamidipudi V, 2004, FEBS LETT, V567, P321, DOI 10.1016/j.febslet.2004.03.125; Miller LD, 2004, ONCOGENE, V23, P5682, DOI 10.1038/sj.onc.1207735; Moasser MM, 1999, CANCER RES, V59, P6145; PARK J, 1995, MOL CELL BIOL, V15, P2374; Paul CP, 2002, NAT BIOTECHNOL, V20, P505, DOI 10.1038/nbt0502-505; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Porter Lisa A, 2003, Prog Cell Cycle Res, V5, P335; Riley D, 2001, ONCOGENE, V20, P5941, DOI 10.1038/sj.onc.1204826; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Taylor SJ, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-5; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WANG LL, 1995, J BIOL CHEM, V270, P2010, DOI 10.1074/jbc.270.5.2010	33	62	64	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2914	2924		10.1038/sj.onc.1210091	http://dx.doi.org/10.1038/sj.onc.1210091			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17072338				2022-12-28	WOS:000246210800011
J	Starczynowski, DT; Trautmann, H; Pott, C; Harder, L; Arnold, N; Africa, JA; Leeman, JR; Siebert, R; Gilmore, TD				Starczynowski, D. T.; Trautmann, H.; Pott, C.; Harder, L.; Arnold, N.; Africa, J. A.; Leeman, J. R.; Siebert, R.; Gilmore, T. D.			Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity	ONCOGENE			English	Article						c-Rel; Rel; NF-kB; malignant transformation; lymphoma; human mutation	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR REL; CHICKEN SPLEEN-CELLS; FACTOR-KAPPA-B; C-REL; HODGKINS LYMPHOMA; ACTIVATION; KINASE; PROLIFERATION; ABERRATIONS	The human c-rel proto-oncogene (REL) encodes a subunit of the nuclear factor-kappaB(NF-kappa B) transcription factor. In this report, we have identified an identical point mutation in two human B-cell lymphomas (follicular (FL) and mediastinal) that changes serine (Ser) 525 (TCA) to proline (Pro) (CCA) within the REL transactivation domain. This mutation was not identified in a similarly sized cohort of healthy individuals. In the mediastinal B-cell lymphoma, the mutation in REL is of germ-line origin. In both tumors, the S525P mutant allele is over-represented. REL-S525P shows enhanced in vitro transforming activity in chicken spleen cells. REL-S525P has a reduced ability to activate the human manganese superoxide dismutase (MnSOD) promoter in A293 cells; however, the MnSOD protein shows increased expression in REL-S525P-transformed chicken spleen cells as compared to wild-type REL-transformed cells. Ser525 is a site for phosphorylation by I kappa B kinase (IKK) in vitro. The S525P mutation reduces IKK alpha- and tumor necrosis factor (TNF)alpha-stimulated transactivation by a GAL4-REL protein. Furthermore, REL-S525P-transformed chicken spleen cells are more resistant to TNF alpha-induced cell death than cells transformed by wild-type REL. These results suggest that the S525P mutation contributes to the development of human B-cell lymphomas by affecting an IKK alpha-regulated transactivation activity of REL.	Boston Univ, Dept Biol, Boston, MA 02215 USA; Univ Kiel, Hosp Schleswig Holstein, Dept Med Hematol & Oncol, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Inst Human Genet, Kiel, Germany; Univ Kiel, Hosp Schleswig Holstein, Dept Gynecol & Obstet, Kiel, Germany	Boston University; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu	Arnold, Norbert/E-3012-2010; Siebert, Reiner/A-8049-2010	Arnold, Norbert/0000-0003-4523-8808; 	NCI NIH HHS [CA47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047763, R29CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown SL, 2002, ARTHRITIS RHEUM-US, V46, P3151, DOI 10.1002/art.10679; Bryder D, 2001, J EXP MED, V194, P941, DOI 10.1084/jem.194.7.941; Feuerhake F, 2005, BLOOD, V106, P1392, DOI 10.1182/blood-2004-12-4901; Fognani C, 2000, ONCOGENE, V19, P2224, DOI 10.1038/sj.onc.1203543; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Gilmore TD, 2001, ONCOGENE, V20, P7098, DOI 10.1038/sj.onc.1204898; Harris J, 2006, J IMMUNOL, V177, P2527, DOI 10.4049/jimmunol.177.4.2527; Harris NL, 1999, ANN ONCOL, V10, P1419, DOI 10.1023/A:1008375931236; Joos S, 2003, INT J CANCER, V103, P489, DOI 10.1002/ijc.10845; Kalaitzidis D, 2002, ONCOGENE, V21, P8759, DOI 10.1038/sj.onc.1206033; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kralova J, 2002, J VIROL, V76, P11960, DOI 10.1128/JVI.76.23.11960-11970.2002; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Liang MC, 2003, MOL PHARMACOL, V64, P123, DOI 10.1124/mol.64.1.123; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Martin AG, 2001, J BIOL CHEM, V276, P15840, DOI 10.1074/jbc.M011313200; Martin-Subero JI, 2003, LEUKEMIA, V17, P2214, DOI 10.1038/sj.leu.2403129; Martin-Subero JI, 2002, BLOOD, V99, P1474, DOI 10.1182/blood.V99.4.1474; MITTLEMANN F, 1995, INT SYSTEM HUMAN CYT; Neiman PE, 2003, ONCOGENE, V22, P1073, DOI 10.1038/sj.onc.1206070; Rhodes DR, 2005, NAT GENET, V37, P579, DOI 10.1038/ng1578; Sanchez-Valdepenas C, 2006, J IMMUNOL, V176, P4666, DOI 10.4049/jimmunol.176.8.4666; Sasaki CY, 2005, J BIOL CHEM, V280, P34538, DOI 10.1074/jbc.M504943200; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schlegelberger B, 1999, DIAGNOSTIC CYTOGENET, P151, DOI DOI 10.1007/978-3-642-59918-7_9; Starczynowski DT, 2005, ONCOGENE, V24, P7355, DOI 10.1038/sj.onc.1208902; Starczynowski DT, 2003, ONCOGENE, V22, P6928, DOI 10.1038/sj.onc.1206801; van Dongen JJM, 2003, LEUKEMIA, V17, P2257, DOI 10.1038/sj.leu.2403202; Yu SH, 2004, J MOL MED, V82, P621, DOI 10.1007/s00109-004-0559-7	29	23	23	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 26	2007	26	19					2685	2694		10.1038/sj.onc.1210089	http://dx.doi.org/10.1038/sj.onc.1210089			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CP	17072339				2022-12-28	WOS:000246210600003
J	Tarze, A; Deniaud, A; Le Bras, M; Maillier, E; Molle, D; Larochette, N; Zamzami, N; Jan, G; Kroemer, G; Brenner, C				Tarze, A.; Deniaud, A.; Le Bras, M.; Maillier, E.; Molle, D.; Larochette, N.; Zamzami, N.; Jan, G.; Kroemer, G.; Brenner, C.			GAPDH, a novel regulator of the pro-apoptotic mitochondrial membrane permeabilization	ONCOGENE			English	Article						apoptosis; mitochondria; VDAC; ANT; permeability transition; GAPDH	ADENINE-NUCLEOTIDE TRANSLOCASE; DEPENDENT ANION CHANNEL; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TRANSITION PORE; CELL-DEATH; ADENYLATE TRANSLOCATOR; OUTER-MEMBRANE; VIRAL PROTEIN; CYCLOPHILIN-D; CYTOCHROME-C	Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a pleiotropic enzyme that is overexpressed in apoptosis and in several human chronic pathologies. Here, we report that the protein accumulates in mitochondria during apoptosis, and induces the pro-apoptotic mitochondrial membrane permeabilization, a decisive event of the intrinsic pathway of apoptosis. GAPDH was localized by immunogold labeling and identified by matrix- assisted laser desorption/ionization-time of flight and nano liquid chromatography mass spectroscopy/mass spectroscopy in the mitochondrion of various tissues and origins. In isolated mitochondria, GAPDH can be imported and interact with the voltage-dependent anion channel (VDAC1), but not the adenine nucleotide translocase (ANT). The protein mediates a cyclosporin A-inhibitable permeability transition, characterized by a loss of the inner transmembrane potential, matrix swelling, permeabilization of the inner mitochondrial membrane and the release of two pro-apoptotic proteins, cytochrome and apoptosis-inducing factor (AIF). This novel function of GAPDH might have implications for the understanding of mitochondrial biology, oncogenesis and apoptosis.	Univ Versailles, SQY, CNRS VMR 8159, F-78035 Versailles, France; INRA, UMR, STLO, Rennes, France; IGR, CNRS UMR 8125, Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; INRAE; UNICANCER; Gustave Roussy	Brenner, C (corresponding author), Univ Versailles, SQY, CNRS VMR 8159, 45 Ave Etat Unis, F-78035 Versailles, France.	cbrenner@genetique.uvsq.fr	LAROCHETTE, Nathanael/R-4298-2017; Kroemer, Guido/AAY-9859-2020; Jan, Gwenael/K-6767-2014; Deniaud, Aurelien/L-5093-2019; KROEMER, Guido/B-4263-2013; Tarze, Agathe/R-4379-2018	LAROCHETTE, Nathanael/0000-0002-7936-678X; KROEMER, Guido/0000-0002-9334-4405; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591; Tarze, Agathe/0000-0001-6101-069X				Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Baker MA, 2004, J BIOL CHEM, V279, P4811, DOI 10.1074/jbc.M311020200; Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200; Belzacq AS, 2003, CANCER RES, V63, P541; BERNARDI P, 1992, J BIOL CHEM, V267, P2934; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Brassard J, 2004, VET MICROBIOL, V102, P87, DOI 10.1016/j.vetmic.2004.05.008; Brenner C, 2000, METHOD ENZYMOL, V322, P243; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Chuang DM, 1996, NAT MED, V2, P609, DOI 10.1038/nm0696-609; COLOMBINI M, 1983, J MEMBRANE BIOL, V74, P115, DOI 10.1007/BF01870500; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Cuezva JM, 2004, CARCINOGENESIS, V25, P1157, DOI 10.1093/carcin/bgh113; Fukuhara Y, 2001, NEUROREPORT, V12, P2049, DOI 10.1097/00001756-200107030-00051; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Gong YW, 1996, HEPATOLOGY, V23, P734, DOI 10.1053/jhep.1996.v23.pm0008666326; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; Han D, 2003, J BIOL CHEM, V278, P5557, DOI 10.1074/jbc.M210269200; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Ishida A, 2005, ARCH BIOCHEM BIOPHYS, V435, P134, DOI 10.1016/j.abb.2004.11.022; Ishitani R, 1996, J PHARMACOL EXP THER, V278, P447; Ishitani R, 1998, MOL PHARMACOL, V53, P701, DOI 10.1124/mol.53.4.701; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Korge P, 1999, EUR J BIOCHEM, V265, P273, DOI 10.1046/j.1432-1327.1999.00724.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laschet JJ, 2004, J NEUROSCI, V24, P7614, DOI 10.1523/JNEUROSCI.0868-04.2004; Le Bras M, 2005, HISTOL HISTOPATHOL, V20, P205, DOI 10.14670/HH-20.205; LEE AC, 1994, J BIOL CHEM, V269, P30974; Mazzola JL, 2003, BBA-GEN SUBJECTS, V1622, P50, DOI 10.1016/S0304-4165(03)00117-X; Mazzola JL, 2002, NEUROTOXICOLOGY, V23, P603, DOI 10.1016/S0161-813X(02)00062-1; Muller A, 2000, EMBO J, V19, P5332, DOI 10.1093/emboj/19.20.5332; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Patterson RL, 2005, P NATL ACAD SCI USA, V102, P1357, DOI 10.1073/pnas.0409657102; PFAFF E, 1968, EUR J BIOCHEM, V6, P66, DOI 10.1111/j.1432-1033.1968.tb00420.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Rostovtseva TK, 2004, J BIOL CHEM, V279, P13575, DOI 10.1074/jbc.M310593200; RYZLAK MT, 1988, BIOCHIM BIOPHYS ACTA, V954, P309, DOI 10.1016/0167-4838(88)90086-6; Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Shi Y, 2003, BIOCHEM BIOPH RES CO, V303, P475, DOI 10.1016/S0006-291X(03)00359-0; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shirakata Y, 2003, J BIOL CHEM, V278, P22071, DOI 10.1074/jbc.M301606200; Sirover MA, 1997, J CELL BIOCHEM, V66, P133, DOI 10.1002/(SICI)1097-4644(19970801)66:2<133::AID-JCB1>3.3.CO;2-V; SUNAGA K, 1995, NEUROSCI LETT, V200, P133, DOI 10.1016/0304-3940(95)12098-O; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; THINNES FP, 1994, BIOL CHEM H-S, V375, P315, DOI 10.1515/bchm3.1994.375.5.315; Tisdale EJ, 2004, J BIOL CHEM, V279, P54046, DOI 10.1074/jbc.M409472200; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001; Weaver JGR, 2005, J CLIN INVEST, V115, P1828, DOI 10.1172/JCI22954; Wu SL, 1999, BBA-MOL CELL RES, V1452, P68, DOI 10.1016/S0167-4889(99)00120-2; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zizi M, 1998, BIOPHYS J, V75, P704, DOI 10.1016/S0006-3495(98)77560-5	62	268	282	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 19	2007	26	18					2606	2620		10.1038/sj.onc.1210074	http://dx.doi.org/10.1038/sj.onc.1210074			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17072346				2022-12-28	WOS:000245831200008
J	Evans, MK; Yu, CR; Lohani, A; Mahdi, RM; Liu, X; Trzeciak, AR; Egwuagu, CE				Evans, M. K.; Yu, C-R; Lohani, A.; Mahdi, R. M.; Liu, X.; Trzeciak, A. R.; Egwuagu, C. E.			Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals	ONCOGENE			English	Article						breast-cancer cells; SOCS; breast cancer; STAT; BRCA1; DNA hypermethylation; interferon	ISLAND METHYLATOR PHENOTYPE; DNA-DAMAGE; IFN-GAMMA; BRCA1; TRANSCRIPTION; ACTIVATION; CARCINOMA; HYPERMETHYLATION; TUMORIGENESIS; COACTIVATOR	DNA-hypermethylation of SOCS genes in breast, ovarian, squamous cell and hepatocellular carcinoma has led to speculation that silencing of SOCS1 and SOCS3 genes might promote oncogenic transformation of epithelial tissues. To examine whether transcriptional silencing of SOCS genes is a common feature of human carcinoma, we have investigated regulation of SOCS genes expression by IFN gamma, IGF-1 and ionizing radiation, in a normal human mammary epithelial cell line (AG11134), two breast-cancer cell lines (MCF-7, HCC1937) and three prostate cancer cell lines. Compared to normal breast cells, we observe a high level constitutive expression of SOCS2, SOCS3, SOCS5, SOCS6, SOCS7, CIS and/or SOCS1 genes in the human cancer cells. In MCF-7 and HCC1937 breast-cancer cells, transcription of SOCS1 is dramatically up-regulated by IFN gamma and/or ionizing-radiation while SOCS3 is transiently down-regulated by IFN gamma and IGF-1, suggesting that SOCS genes are not silenced in these cells by the epigenetic mechanism of DNA-hypermethylation. We further show that the kinetics of SOCS1-mediated feedback inhibition of IFN gamma signaling is comparable to normal breast cells, indicating that the SOCS1 protein in breast-cancer cells is functional. We provide direct evidence that STAT3 pathways are constitutively activated in MCF-7 and HCC1937 cells and may drive the aberrant persistent activation of SOCS genes in breast-cancer cells. Our data therefore suggest that elevated expression of SOCS genes is a specific lesion of breast-cancer cells that may confer resistance to proinflammatory cytokines and trophic factors, by shutting down STAT1/STAT5 signaling that mediate essential functions in the mammary gland.	NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Evans, MK (corresponding author), NIA, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.	evansmi@grc.nia.nih.gov; egwuaguc@nei.nih.gov	Evans, Michele Kim/AAE-4776-2019	Evans, Michele/0000-0002-8546-2831; Yu, Cheng-Rong/0000-0001-7246-0362	NATIONAL EYE INSTITUTE [ZIAEY000372, Z01EY000372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000730] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Andrews HN, 2002, J BIOL CHEM, V277, P26225, DOI 10.1074/jbc.M201316200; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brender C, 2005, LEUKEMIA, V19, P209, DOI 10.1038/sj.leu.2403610; Campbell IL, 2005, BRAIN RES REV, V48, P166, DOI 10.1016/j.brainresrev.2004.12.006; Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; Coccia EM, 1999, ONCOGENE, V18, P2129, DOI 10.1038/sj.onc.1202536; Cui JQ, 1998, ONCOL REP, V5, P591; Darnell JE, 2005, NAT MED, V11, P595, DOI 10.1038/nm0605-595; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Le Provost F, 2005, BIOCHEM BIOPH RES CO, V338, P1696, DOI 10.1016/j.bbrc.2005.10.138; Medina D, 2005, ENDOCR-RELAT CANCER, V12, P483, DOI 10.1677/erc.1.00804; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Rottapel R, 2002, ONCOGENE, V21, P4351, DOI 10.1038/sj.onc.1205537; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Weber A, 2005, ONCOGENE, V24, P6699, DOI 10.1038/sj.onc.1208818; Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277; Welcsh PL, 2002, P NATL ACAD SCI USA, V99, P7560, DOI 10.1073/pnas.062181799; Yu CR, 2004, J IMMUNOL, V173, P737, DOI 10.4049/jimmunol.173.2.737	33	62	63	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1941	1948		10.1038/sj.onc.1209993	http://dx.doi.org/10.1038/sj.onc.1209993			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001312				2022-12-28	WOS:000245117700011
J	Neesse, A; Gangeswaran, R; Luettges, J; Feakins, R; Weeks, ME; Lemoine, NR; Crnogorac-Jurcevic, T				Neesse, A.; Gangeswaran, R.; Luettges, J.; Feakins, R.; Weeks, M. E.; Lemoine, N. R.; Crnogorac-Jurcevic, T.			Sperm-associated antigen 1 is expressed early in pancreatic tumorigenesis and promotes motility of cancer cells	ONCOGENE			English	Article						SPAG1; pancreatic adenocarcinoma; PanIN; lesions; motility	TESTIS ANTIGENS; CANCER/TESTIS ANTIGENS; SIGNALING PATHWAY; GENE-EXPRESSION; CARCINOMA; ADENOCARCINOMA; ACTIVATION; MIGRATION; PROTEINS; LINES	Sperm-associated antigen 1 (SPAG1) was recently identified in a rare form of infertility where anti-SPAG1 antibodies derived from the serum of an infertile woman were reported to cause sperm agglutination. Except for its expression and potential role in spermatogenesis, the function of SPAG1 is completely unknown. The unexpected finding of high levels of SPAG1 expression in pancreatic adenocarcinoma compared to normal pancreatic tissue in our previous cDNA array experiments prompted us to look in more detail at the expression and role of this gene in a panel of normal and malignant human tissues as well as in a larger series of pancreatic cancer specimens. We have generated an SPAG1-specific monoclonal antibody and showed high levels of SPAG1 protein in testis and in a large proportion of pancreatic ductal adenocarcinomas (PDAC). In the latter, SPAG1 expression was predominantly cytoplasmic and confined to malignant cells. Furthermore, the extent and intensity of SPAG1 expression was shown to be associated with stage and tumour nodal status, while analysis of precursor lesions, pancreatic intraepithelial neoplasias (PanINs), demonstrated its increased immunoreactivity with increasing PanIN grade, suggesting that SPAG1 is a novel marker of PDAC progression. Immunocytochemical analysis demonstrated colocalization of SPAG1 with microtubules, and their association was confirmed by co-immunoprecipitation; subsequent motility assays further substantiated a potential role of SPAG1 in cancer cell motility. Combined with the finding of its early expression in PDAC development, our data suggest that SPAG1 could contribute to the early spread and poor prognosis of pancreatic adenocarcinoma.	Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, London WC1M 6BQ, England; Klinikum Saarbrucken, Dept Pathol, Saarbrucken, Germany; Royal London Hosp, Dept Histopathol, London E1 1BB, England	Cancer Research UK; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital	Crnogorac-Jurcevic, T (corresponding author), Queen Marys Univ, Barts & London Sch Med & Dent, Canc Res UK, John Vane Sci Ctr,Mol Oncol Unit, Charterhouse Sq, London WC1M 6BQ, England.	t.c.jurcevic@qmul.ac.uk	weeks, Mark/AAT-7258-2021; Feakins, Roger/AAO-5570-2020; /C-2531-2011; Feakins, Roger/J-6782-2019	/0000-0002-6576-8809; 				Coral S, 2002, CLIN CANCER RES, V8, P2690; Crnogorac-Jurcevic T, 2003, J PATHOL, V201, P63, DOI 10.1002/path.1418; Cutillas PR, 2004, AM J PHYSIOL-RENAL, V287, pF353, DOI 10.1152/ajprenal.00018.2004; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Furukawa T, 1996, AM J PATHOL, V148, P1763; Gesierich S, 2005, CLIN CANCER RES, V11, P2840, DOI 10.1158/1078-0432.CCR-04-1935; Giehl K, 2000, ONCOGENE, V19, P2930, DOI 10.1038/sj.onc.1203612; Grutzmann R, 2005, ONCOGENE, V24, P5079, DOI 10.1038/sj.onc.1208696; Hustinx SR, 2004, CANCER BIOL THER, V3, P1254, DOI 10.4161/cbt.3.12.1238; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; Kalejs M, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-4; Kubuschok B, 2004, INT J CANCER, V109, P568, DOI 10.1002/ijc.20006; Lin W, 2001, MOL HUM REPROD, V7, P811, DOI 10.1093/molehr/7.9.811; Logsdon CD, 2003, CANCER RES, V63, P2649; Michl P, 2005, CANCER CELL, V7, P521, DOI 10.1016/j.ccr.2005.05.018; Missiaglia E, 2005, ONCOGENE, V24, P199, DOI 10.1038/sj.onc.1208018; Missiaglia E, 2004, INT J CANCER, V112, P100, DOI 10.1002/ijc.20376; Old L J, 2001, Cancer Immun, V1, P1; Sawai H, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-37; Scanlan Matthew J, 2004, Cancer Immun, V4, P1; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sigalotti L, 2002, BRIT J CANCER, V86, P979, DOI 10.1038/sj.bjc.6600174; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Takimoto M, 2002, BRIT J CANCER, V86, P1757, DOI 10.1038/sj.bjc.6600328; Taniuchi K, 2005, CANCER RES, V65, P3092, DOI 10.1158/0008.5472.CAN-04-3646; Tureci O, 1998, P NATL ACAD SCI USA, V95, P5211, DOI 10.1073/pnas.95.9.5211; Vasiliev JM, 2004, INT J DEV BIOL, V48, P425, DOI 10.1387/ijdb.041806jv; ZHANG ML, 1992, CHINESE MED J-PEKING, V105, P998; Zhang YT, 2004, CHINESE PHYS LETT, V21, P166, DOI 10.1088/0256-307X/21/1/050	30	24	28	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1533	1545		10.1038/sj.onc.1209961	http://dx.doi.org/10.1038/sj.onc.1209961			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16983343				2022-12-28	WOS:000244782500003
J	Pickering, BM; de Mel, S; Lee, M; Howell, M; Habens, F; Dallman, CL; Neville, LA; Potter, KN; Mann, J; Mann, DA; Johnson, PWM; Stevenson, FK; Packham, G				Pickering, B. M.; de Mel, S.; Lee, M.; Howell, M.; Habens, F.; Dallman, C. L.; Neville, L. A.; Potter, K. N.; Mann, J.; Mann, D. A.; Johnson, P. W. M.; Stevenson, F. K.; Packham, G.			Pharmacological inhibitors of NF-kappa B accelerate apoptosis in chronic lymphocytic leukaemia cells	ONCOGENE			English	Article						NF-kappa B; nuclear factor kappa B; Bcl-2; apoptosis; chronic lymphocytic leukaemia	CD38 EXPRESSION; BCL-X; SURVIVAL; ACTIVATION; CLL; PATHWAY; ZAP-70; GENES; BAFF; MODULATION	Nuclear factor-kappaB NF-kappa B) is a transcription factor that plays a critical role in the inappropriate survival of various types of malignant cells. Chronic lymphocytic leukaemia (CLL) is the most common B-cell malignancy in the Western world. Although overexpression and regulation of NF-kappa B has been described in CLL, its function remains unclear. Exposure of CLL cells to BAY117082 or Kamebakaurin, potent pharmacological inhibitors of the NF-kappa B pathway, accelerated apoptosis in approximately 70% of cases. Sensitivity to NF-kappa B pathway inhibitors was not related to the prognostic markers VH status, CD38 or Zap70 expression, or to the levels of nuclear NF-kappa B. Normal peripheral B cells were resistant to the apoptosis-inducing effects of these compounds. Cell death induced by the inhibitors was associated with activation of caspase-9 and -3, and loss of mitochondrial membrane polarization, but did not involve changes in the expression of Bcl-2 or Mcl-1. Inhibitors caused an increase in c-jun NH2-terminal kinase activity in CLL, but this did not appear to be important for apoptosis. Microarray analysis identified some potential novel NF-kappa B target genes, including interleukin-16- and the Bcl-2- related survival protein Bcl-w. These results demonstrate that a substantial proportion of CLL are dependent on NF-kappa B for enhanced survival and suggest that inhibition of NF-kappa B may have therapeutic potential.	Southampton Gen Hosp, Canc Res UK Clin Ctr, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Canc Sci Div, Mol Immunol Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair,Liver Grp, Southampton, Hants, England	Cancer Research UK; University of Southampton; University of Southampton; University of Southampton	Packham, G (corresponding author), Southampton Gen Hosp, Canc Res UK Clin Ctr, Somers Canc Res Bldg MP824,Tremona Rd, Southampton SO16 6YD, Hants, England.	g.k.packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Packham, Graham/0000-0002-9232-5691; Stevenson, Freda/0000-0002-0933-5021; Mann, Derek/0000-0003-0950-243X				Bernal A, 2001, BLOOD, V98, P3050, DOI 10.1182/blood.V98.10.3050; Brenner C, 2003, J CLIN IMMUNOL, V23, P73, DOI 10.1023/A:1022541009662; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Castro JE, 2005, BLOOD, V106, P2506, DOI 10.1182/blood-2005-03-1099; Chen LG, 2005, BLOOD, V105, P2036, DOI 10.1182/blood-2004-05-1715; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Cuni S, 2004, LEUKEMIA, V18, P1391, DOI 10.1038/sj.leu.2403398; Dallman C, 2005, METH MOLEC MED, V115, P1; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; DeMeester SL, 1998, SHOCK, V10, P1, DOI 10.1097/00024382-199807000-00001; Feuillard J, 2000, BLOOD, V95, P2068, DOI 10.1182/blood.V95.6.2068.2068; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Ghia P, 2000, ADV CANCER RES, V79, P157, DOI 10.1016/S0065-230X(00)79005-1; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Granziero L, 2001, BLOOD, V97, P2777, DOI 10.1182/blood.V97.9.2777; Hamblin TJ, 2002, BLOOD, V99, P1023, DOI 10.1182/blood.V99.3.1023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kern C, 2004, BLOOD, V103, P679, DOI 10.1182/blood-2003-02-0540; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Matsuda A, 2003, ONCOGENE, V22, P3307, DOI 10.1038/sj.onc.1206406; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Morabito F, 2001, LEUKEMIA RES, V25, P927, DOI 10.1016/S0145-2126(01)00049-2; Munzert G, 2002, BLOOD, V100, P3749, DOI 10.1182/blood.V100.10.3749; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Oakley F, 2003, J BIOL CHEM, V278, P24359, DOI 10.1074/jbc.M211051200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Packham G, 2005, IMMUNOLOGY, V114, P441, DOI 10.1111/j.1365-2567.2005.02117.x; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; Papa S, 2004, J CELL SCI, V117, P5197, DOI 10.1242/jcs.01483; Pedersen IM, 2002, BLOOD, V100, P1795, DOI 10.1182/blood.V100.5.1795.h81702001795_1795_1801; Pepper C, 1999, BRIT J HAEMATOL, V107, P611, DOI 10.1046/j.1365-2141.1999.01726.x; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Petlickovski A, 2005, BLOOD, V105, P4820, DOI 10.1182/blood-2004-07-2669; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Ran RQ, 2004, GENE DEV, V18, P1466, DOI 10.1101/gad.1188204; Ravid T, 2004, CURR BIOL, V14, pR898, DOI 10.1016/j.cub.2004.09.074; Ringshausen I, 2002, BLOOD, V100, P3741, DOI 10.1182/blood-2002-02-0539; Rodriguez A, 2004, CLIN CANCER RES, V10, P6796, DOI 10.1158/1078-0432.CCR-04-0753; Romano MF, 1998, BLOOD, V92, P990; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Rossi A, 1998, J BIOL CHEM, V273, P16446, DOI 10.1074/jbc.273.26.16446; Schattner EJ, 2000, LEUKEMIA LYMPHOMA, V37, P461, DOI 10.3109/10428190009058499; Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144; Scorrano L, 2003, BIOCHEM BIOPH RES CO, V304, P437, DOI 10.1016/S0006-291X(03)00615-6; Sembries S, 1999, BLOOD, V93, P624, DOI 10.1182/blood.V93.2.624.402k10_624_631; Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tran NL, 2005, J BIOL CHEM, V280, P3483, DOI 10.1074/jbc.M409906200; Viatour P, 2003, LEUKEMIA, V17, P1349, DOI 10.1038/sj.leu.2402982; Wiestner A, 2003, BLOOD, V101, P4944, DOI 10.1182/blood-2002-10-3306; Wilson KC, 2004, GROWTH FACTORS, V22, P97, DOI 10.1080/08977190410001704679; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zaninoni A, 2003, EXP HEMATOL, V31, P185, DOI 10.1016/S0301-472X(02)01046-9	58	66	68	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1166	1177		10.1038/sj.onc.1209897	http://dx.doi.org/10.1038/sj.onc.1209897			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16924235				2022-12-28	WOS:000244406400007
J	Chao, C; Goluszko, E; Lee, YT; Kolokoltsov, AA; Davey, RA; Uchida, T; Townsend, CM; Hellmich, MR				Chao, C.; Goluszko, E.; Lee, Y-T; Kolokoltsov, A. A.; Davey, R. A.; Uchida, T.; Townsend, C. M., Jr.; Hellmich, M. R.			Constitutively active CCK2 receptor splice variant increases Src-dependent HIF-1 alpha expression and tumor growth	ONCOGENE			English	Article						Src kinase; gastrin receptor; gastrointestinal cancer	CHOLECYSTOKININ-B/GASTRIN RECEPTOR; COLORECTAL-CANCER; TYROSINE KINASE; PREMALIGNANT EPITHELIA; PANCREATIC-CARCINOMA; BARRETTS-ESOPHAGUS; COLON CANCER; CELL-GROWTH; GASTRIN; ACTIVATION	Gastrointestinal (GI) cancers ectopically express multiple splice variants of the cholecystokinin-2 (CCK2)/gastrin receptor; however, their relative contributions to the cancer phenotype are unknown. The aim of this study was to compare the effects of CCK2 receptor (CCK2R) and CCK2i4svR expression on cell growth both in vitro and in vivo using a human epithelial cell model, HEK239. In vitro, receptor variant expression did not affect cell proliferation either in the absence or presence of agonist. However, in vivo, the expression of CCK2i4svR, but not CCK2R, increases HEK293 tumor growth in a constitutive, Src-dependent manner. Enhanced tumorigenicity of CCK2i4svR is associated with an Src- dependent increase in the transcription factor, hypoxia-inducible factor-1 alpha, its downstream target, vascular endothelial growth factor and tumor micro-vessel density, suggesting that CCK2i4svR may contribute to the growth and spread of GI cancers through agonist-independent mechanisms that enhance tumor angiogenesis.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Immunol & Microbiol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77550 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Hellmich, MR (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.	mhellmic@utmb.edu		Davey, Robert/0000-0001-9168-2892	NIDDK NIH HHS [R01 DK48345, R01 DK58119] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048345, R01DK058119] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aly A, 2004, BBA-REV CANCER, V1704, P1, DOI 10.1016/j.bbcan.2004.01.004; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; Chao C, 2005, J BIOL CHEM, V280, P33368, DOI 10.1074/jbc.M506337200; Choi KS, 2003, J BIOCHEM MOL BIOL, V36, P120; Ding WQ, 2002, CANCER RES, V62, P947; Dockray G, 2005, PFLUG ARCH EUR J PHY, V449, P344, DOI 10.1007/s00424-004-1347-5; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo Y S, 2000, J Hepatobiliary Pancreat Surg, V7, P276, DOI 10.1007/s005340070049; Harris JC, 2004, CANCER RES, V64, P1915, DOI 10.1158/0008-5472.CAN-03-2713; Hellmich MR, 2000, J BIOL CHEM, V275, P32122, DOI 10.1074/jbc.M005754200; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Iravani S, 1998, LAB INVEST, V78, P365; Ishizawar RC, 2004, J BIOL CHEM, V279, P23773, DOI 10.1074/jbc.M312368200; Iwase K, 1997, GASTROENTEROLOGY, V113, P782, DOI 10.1016/S0016-5085(97)70172-0; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Kolokoltsov AA, 2005, J VIROL, V79, P756, DOI 10.1128/JVI.79.2.756-763.2005; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; MCGREGOR DB, 1982, ANN SURG, V195, P219, DOI 10.1097/00000658-198202000-00017; McWilliams DF, 1998, GUT, V42, P795, DOI 10.1136/gut.42.6.795; MIYAKE A, 1995, BIOCHEM BIOPH RES CO, V208, P230, DOI 10.1006/bbrc.1995.1328; Moore TC, 2004, REGUL PEPTIDES, V120, P195, DOI 10.1016/j.regpep.2004.03.012; Noble PJM, 2003, AM J PHYSIOL-GASTR L, V284, pG75, DOI 10.1152/ajpgi.00300.2002; Olszewska-Pazdrak B, 2004, J BIOL CHEM, V279, P40400, DOI 10.1074/jbc.C400208200; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; SIRINEK KR, 1985, AM J SURG, V149, P35, DOI 10.1016/S0002-9610(85)80006-4; Smith AM, 2000, ALIMENT PHARM THERAP, V14, P1231, DOI 10.1046/j.1365-2036.2000.00842.x; SMITH JP, 1988, GASTROENTEROLOGY, V95, P1541; SMITH JP, 1995, AM J PHYSIOL-REG I, V268, pR135, DOI 10.1152/ajpregu.1995.268.1.R135; Smith JP, 1998, INT J ONCOL, V12, P411; Smith JP, 2002, INT J MOL MED, V10, P689; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thorburn CM, 1998, GASTROENTEROLOGY, V115, P275, DOI 10.1016/S0016-5085(98)70193-3; WATSON S, 1989, BRIT J CANCER, V59, P554, DOI 10.1038/bjc.1989.112; WEBER TK, 1992, J CLIN INVEST, V90, P815, DOI 10.1172/JCI115956; WINSETT OE, 1986, SURGERY, V99, P302; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068	38	28	32	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB	2007	26	7					1013	1019		10.1038/sj.onc.1209862	http://dx.doi.org/10.1038/sj.onc.1209862			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909104				2022-12-28	WOS:000244245400007
J	Mancini, A; El Bounkari, O; Norrenbrock, AF; Scherr, M; Schaefer, D; Eder, M; Banham, AH; Pulford, K; Lyne, L; Whetton, AD; Tamura, T				Mancini, A.; El Bounkari, O.; Norrenbrock, A-F; Scherr, M.; Schaefer, D.; Eder, M.; Banham, A. H.; Pulford, K.; Lyne, L.; Whetton, A. D.; Tamura, T.			FMIP controls the adipocyte lineage commitment of C2C12 cells by downmodulation of C/EBPalpha	ONCOGENE			English	Article						adipocyte/muscle differentiation; insulin signaling; C/EBP; mesenchymal stem cells; mRNA export complex	BINDING-PROTEIN-ALPHA; MITOTIC CLONAL EXPANSION; TRANSCRIPTIONAL REGULATION; REGULATED EXPRESSION; INTERACTING PROTEIN; ECTOPIC EXPRESSION; GENE-EXPRESSION; DIFFERENTIATION; GRANULOCYTE; BETA	Fms interacting protein ( FMIP) is a substrate for Fms tyrosine kinase, and a nuclear/cytoplasm shuttling protein with a leucine zipper. As the phosphorylation of FMIP is observed in insulin-stimulated preadipocytes, we examined the role of FMIP in adipocyte differentiation, using the mesenchymal multipotent stem cells, C2C12 cells, that can differentiate into adipocytes, muscle cells and osteoblasts. Ectopic expression of FMIP in C2C12 impairs the adipocyte differentiation induced by treatment with insulin, dexamethasone and 3-isobutyl-1-methylxanthine. These cells exhibit muscle phenotype with multinuclear morphology. Furthermore, knockdown of endogenous FMIP expression by small interfering RNA improves adipocytic lineage commitment of C2C12 cells, while impairing muscle differentiation. Upon stimulation with insulin, CCAAT/enhancer binding protein ( C/EBP)beta, but not C/EBPalpha, is upregulated in cells expressing ectopic FMIP, whereas in FMIP knockdown cells, C/EBPalpha is constitutively expressed. Ectopic expression of C/EBPalpha counteracts the effects of FMIP, whereas C/EBPalpha knockdown partially mimics the effects of FMIP in this system. Northern blot analysis and reverse transcriptase-polymerase chain reaction study reveal that ectopic FMIP-expressing cells do not contain the polyadenylated C/EBPalpha mRNA, but contain the C/EBPalpha pre-mRNA, suggesting that FMIP plays a role in RNA processing and/or export. Indeed, a member of the THO complex that plays a role in mRNA export, THOC1, is co-precipitated with FMIP. The data we have acquired on FMIP suggest that it is a target for tyrosine kinase receptors that potentiate mRNA export.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, Oxford OX3 9DU, England; Univ Manchester, Christie Hosp, Fac Med & Human Sci, Canc Studies Div, Manchester M13 9PL, Lancs, England	Hannover Medical School; University of Oxford; Christie NHS Foundation Trust; Christie Hospital; University of Manchester	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	tamura.teruko@mh-hannover.de	Banham, Alison H/B-2966-2009; Pulford, Karen/B-3609-2009	Pulford, Karen/0000-0002-2989-789X; WHETTON, ANTHONY D/0000-0002-1098-3878; Banham, Alison/0000-0002-3197-273X				CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Fux C, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh001; Gridley S, 2005, CELL SIGNAL, V17, P59, DOI 10.1016/j.cellsig.2004.05.013; Helftenbein G, 1996, ONCOGENE, V12, P931; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459; Jones LC, 2002, BLOOD, V99, P2032, DOI 10.1182/blood.V99.6.2032; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Koch A, 2005, ONCOGENE, V24, P3436, DOI 10.1038/sj.onc.1208558; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; Mancini A, 2004, ONCOGENE, V23, P6581, DOI 10.1038/sj.onc.1207841; MASON DY, 1983, TECHNIQUES IMMUNOCYT, P175; Masuda S, 2005, GENE DEV, V19, P1512, DOI 10.1101/gad.1302205; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Otto TC, 2005, CRIT REV BIOCHEM MOL, V40, P229, DOI 10.1080/10409230591008189; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Popernack PM, 2001, J HEMATOTH STEM CELL, V10, P631, DOI 10.1089/152581601753193841; Rehwinkel J, 2004, NAT STRUCT MOL BIOL, V11, P558, DOI 10.1038/nsmb759; Scherr M, 2002, BLOOD, V99, P709, DOI 10.1182/blood.V99.2.709; Scherr M, 2003, CELL CYCLE, V2, P251, DOI 10.4161/cc.2.3.376; Shi XM, 2003, EMBO REP, V4, P374, DOI 10.1038/sj.embor.embor805; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Tang QQ, 2003, P NATL ACAD SCI USA, V100, P850, DOI 10.1073/pnas.0337434100; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wang QF, 2002, BLOOD, V99, P2776, DOI 10.1182/blood.V99.8.2776; Zhang DE, 1997, P NATL ACAD SCI USA, V94, P569, DOI 10.1073/pnas.94.2.569; Zhang JW, 2004, P NATL ACAD SCI USA, V101, P43, DOI 10.1073/pnas.0307229101	32	29	31	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1020	1027		10.1038/sj.onc.1209853	http://dx.doi.org/10.1038/sj.onc.1209853			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16909111				2022-12-28	WOS:000244245400008
J	Cummins, JM; Velculescu, VE				Cummins, J. M.; Velculescu, V. E.			Implications of micro-RNA profiling for cancer diagnosis	ONCOGENE			English	Review						microRNAs; expression profiling; miRAGE; cancer; molecular diagnostics; biomarkers	EMBRYONIC STEM-CELLS; HUMAN LUNG CANCERS; DOWN-REGULATION; ADJUVANT CHEMOTHERAPY; EXPRESSION PROFILES; GENES; DIFFERENTIATION; MOUSE; ONCOGENES; GENOMICS	Micro-RNAs (miRNAs) are a large class of small noncoding RNAs that regulate protein expression in eucaryotic cells. Initially believed to be unique to the nematode Caenorhabditis elegans, miRNAs are now recognized to be important gene regulatory elements in multicellular organisms and have been implicated in a variety of disease processes, including cancer. Advances in expression technologies have facilitated the high-throughput analysis of small RNAs, identifying novel miRNAs and showing that these genes may be aberrantly expressed in various human tumors. These studies suggest that miRNA expression pro. ling can be correlated with disease pathogenesis and prognosis, and may ultimately be useful in the management of human cancer.	Johns Hopkins Univ, Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA	Johns Hopkins University	Velculescu, VE (corresponding author), Johns Hopkins Univ, Kimmel Canc Ctr, Ludwig Ctr Canc Genet & Therapeut, Baltimore, MD 21231 USA.	velculescu@jhmi.edu	Velculescu, Victor/ABF-4846-2020	Velculescu, Victor/0000-0003-1195-438X				AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Babak T, 2004, RNA, V10, P1813, DOI 10.1261/rna.7119904; Barad O, 2004, GENOME RES, V14, P2486, DOI 10.1101/gr.2845604; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253; Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Brigden ML, 1999, POSTGRAD MED, V105, P63, DOI 10.3810/pgm.1999.05.1.738; Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712; Calin GA, 2006, SEMIN ONCOL, V33, P167, DOI 10.1053/j.seminoncol.2006.01.010; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen CZ, 2005, NEW ENGL J MED, V353, P1768, DOI 10.1056/NEJMp058190; Ciafre SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gregory RI, 2005, CANCER RES, V65, P3509, DOI 10.1158/0008-5472.CAN-05-0298; Hall PA, 2005, HEMATOL ONCOL, V23, P49, DOI 10.1002/hon.748; Hammond SM, 2006, CURR OPIN GENET DEV, V16, P4, DOI 10.1016/j.gde.2005.12.005; HAYASHITA Y, 2005, CANCER RES, V65, P9628, DOI [DOI 10.1158/0008-5472.CAN-05-2352, 10.1158/0008-5472.CAN-05-2352]; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kasashima K, 2004, BIOCHEM BIOPH RES CO, V322, P403, DOI 10.1016/j.bbrc.2004.07.130; Kloosterman WP, 2006, NAT METHODS, V3, P27, DOI 10.1038/NMETH843; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Liang RQ, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni019; Lim LP, 2003, SCIENCE, V299, P1540, DOI 10.1126/science.1080372; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meltzer PS, 2005, NATURE, V435, P745, DOI 10.1038/435745a; Mendell JT, 2005, CELL CYCLE, V4, P1179, DOI 10.4161/cc.4.9.2032; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005; MORRIS JP, 2005, SCI STKE, pPE41; Muljo SA, 2005, J EXP MED, V202, P261, DOI 10.1084/jem.20050678; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Neely LA, 2006, NAT METHODS, V3, P41, DOI 10.1038/NMETH825; Nelson PT, 2004, NAT METHODS, V1, P155, DOI 10.1038/NMETH717; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Pallante P, 2006, ENDOCR-RELAT CANCER, V13, P497, DOI 10.1677/erc.1.01209; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Ramaswamy S, 2001, P NATL ACAD SCI USA, V98, P15149, DOI 10.1073/pnas.211566398; Raymond CK, 2005, RNA, V11, P1737, DOI 10.1261/rna.2148705; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Schmittgen TD, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh040; Service RF, 2006, SCIENCE, V311, P1544, DOI 10.1126/science.311.5767.1544; Shi R, 2005, BIOTECHNIQUES, V39, P519, DOI 10.2144/000112010; Shingara J, 2005, RNA, V11, P1461, DOI 10.1261/rna.2610405; Slack Frank J, 2006, Future Oncol, V2, P73, DOI 10.2217/14796694.2.1.73; Stegmaier K, 2004, NAT GENET, V36, P257, DOI 10.1038/ng1305; Suh MR, 2004, DEV BIOL, V270, P488, DOI 10.1016/j.ydbio.2004.02.019; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Thomson JM, 2004, NAT METHODS, V1, P47, DOI 10.1038/NMETH704; Varmus H, 2005, COLD SH Q B, V70, P1, DOI 10.1101/sqb.2005.70.039; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025	86	205	236	0	34	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6220	6227		10.1038/sj.onc.1209914	http://dx.doi.org/10.1038/sj.onc.1209914			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028602				2022-12-28	WOS:000241158900011
J	Hemmati, PG; Guner, D; Gillissen, B; Wendt, J; von Haefen, C; Chinnadurai, G; Dorken, B; Daniel, PT				Hemmati, P. G.; Guener, D.; Gillissen, B.; Wendt, J.; von Haefen, C.; Chinnadurai, G.; Doerken, B.; Daniel, P. T.			Bak functionally complements for loss of Bax during p14(ARF)-induced mitochondrial apoptosis in human cancer cells	ONCOGENE			English	Article						p14(ARF); Bax; Bak; p53; apoptosis; mitochondria	NF-KAPPA-B; REGULATED FORM; CYCLE ARREST; P53; ARF; DEATH; BCL-2; P19(ARF); ACTIVATION; INDUCTION	In contrast to the initial notion that the biological activity of p14(ARF) strictly depends on a functional mdm-2/p53 signaling axis, we recently demonstrated that p14ARF mediates apoptosis in a p53/Bax-independent manner. Here, we show that p14ARF induces breakdown of the mitochondrial membrane potential and cytochrome c release before triggering caspase-9- and caspase-3/7-like activities in p53/Bax-deficient DU145 prostate cancer cells expressing wild-type Bak. Re-expression of Bax in these cells failed to further enhance p14(ARF)-induced apoptosis, suggesting that p14(ARF)-induced apoptosis primarily depends on Bak but not Bax in these cells. To further de. ne the role of Bak and Bax in p14(ARF)-induced mitochondrial apoptosis, we employed short interference RNA for the knockdown of bak in isogeneic, p53 wildtype HCT116 colon cancer cells either proefficient or deficient for Bax. There, combined loss of Bax and Bak attenuated p14(ARF)-induced apoptosis whereas single loss of Bax or Bak was only marginally effective, as in the case of DU145. Notably, HCT116 cells deficient for Bax and Bak failed to release cytochrome c and showed attenuated activation of caspase-9 (LEHDase) and caspase-3/caspase-7 (DEVDase) upon p14ARF expression. These data indicate that p14ARF triggers apoptosis via a Bax/Bak-dependent pathway in p53-proficient HCT116, whereas Bax is dispensable in p53-deficient DU145 cells. Nevertheless, a substantial proportion of p14(ARF)-induced cell death proceeds in a Bax/Bak-independent manner. This is also the case for inhibition of clonogenic growth that occurs, at least in part, through an entirely Bax/Bak-independent mechanism.	Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, D-13125 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63103 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Saint Louis University	Daniel, PT (corresponding author), Univ Med Ctr Charite, Dept Hematol Oncol & Tumor Immunol, Campus Berlin Buch,Lindenberger Weg 80, D-13125 Berlin, Germany.	pdaniel@mdc-berlin.de		Gillissen, Bernhard/0000-0002-1815-2091	NCI NIH HHS [R01 CA033616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cartron PF, 2003, MOL CELL BIOL, V23, P4701, DOI 10.1128/MCB.23.13.4701-4712.2003; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; Gelinas W, 2005, GENE DEV, V19, P1263, DOI 10.1101/gad.1326205; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Groth A, 2000, J BIOL CHEM, V275, P27473; Hemmati PG, 2005, ONCOGENE, V24, P4114, DOI 10.1038/sj.onc.1208579; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAO L, 1995, CANCER RES, V55, P2995; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Qi Y, 2004, NATURE, V431, P712, DOI 10.1038/nature02958; QUELLE DE, 1995, CELL, V83, P993; Rocha S, 2005, CELL CYCLE, V4, P756, DOI 10.4161/cc.4.6.1739; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Scholz C, 2005, ONCOGENE, V24, P7031, DOI 10.1038/sj.onc.1208868; Scholz C, 2005, ONCOGENE, V24, P1904, DOI 10.1038/sj.onc.1208233; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2004, CELL, V116, P235, DOI 10.1016/S0092-8674(03)01075-4; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shmueli A, 2005, CELL, V121, P963, DOI 10.1016/j.cell.2005.06.018; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Suzuki H, 2003, BIOCHEM BIOPH RES CO, V312, P1273, DOI 10.1016/j.bbrc.2003.11.071; Theodorakis P, 2002, CANCER RES, V62, P3373; von Haefen C, 2003, ONCOGENE, V22, P2236, DOI 10.1038/sj.onc.1206280; von Haefen C, 2004, ONCOGENE, V23, P8320, DOI 10.1038/sj.onc.1207971; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200; Yarbrough WG, 2002, CANCER RES, V62, P1171; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009; Zong WX, 2004, GENE DEV, V18, P1272, DOI 10.1101/gad.1199904	48	34	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6582	6594		10.1038/sj.onc.1209668	http://dx.doi.org/10.1038/sj.onc.1209668			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16847458				2022-12-28	WOS:000241569700003
J	Balmer, A; Zografos, L; Munier, F				Balmer, A.; Zografos, L.; Munier, F.			Diagnosis and current management of retinoblastoma	ONCOGENE			English	Review						retinoblastoma; tumor suppressor gene; diagnosis; management	DIFFUSE INFILTRATING RETINOBLASTOMA; TRANSGENIC MURINE RETINOBLASTOMA; RISK-FACTORS; SUBCONJUNCTIVAL CARBOPLATIN; HEREDITARY RETINOBLASTOMA; BILATERAL RETINOBLASTOMA; NONOCULAR TUMORS; PARENTAL AGE; SURVIVORS; RETINOCYTOMA	Retinoblastoma represents the prototypic model for inherited cancers. The RB1 gene was the first tumor suppressor gene to be identified. It represents the most frequent primary eye cancer in children under 15 years old, habitually occurring in infancy, even in utero, but can be observed in older children or young adults. Many other retinal lesions may also simulate retinoblastoma. The two major presenting signs are leukocoria and strabismus, but other ocular or general signs may be observed. A highly malignant tumor, retinoblastoma can nowadays be cured. The heritable form, however, carries a high risk of second nonocular tumors. Treatment in the early stages of disease holds a good prognosis for survival and salvage of visual function. In very late stages, however, the prognosis for ocular function and even survival is jeopardized.	Jules Gonin Univ Eye Hosp, Ocular Oncol Serv, Lausanne, Switzerland		Balmer, A (corresponding author), Hop Ophtalmique Jules Gonin, Ave France 15, CH-1004 Lausanne, Switzerland.	aubin.balmer@bluewin.ch						Abramson D H, 1989, Acta Ophthalmol Suppl, V194, P3; Abramson D H, 1999, Ophthalmic Genet, V20, P193, DOI 10.1076/opge.20.3.193.2284; Abramson DH, 1998, OPHTHALMOLOGY, V105, P573, DOI 10.1016/S0161-6420(98)94006-4; Abramson DH, 2001, OPHTHALMOLOGY, V108, P1868, DOI 10.1016/S0161-6420(01)00713-8; Abramson DH, 1996, RETINA-J RET VIT DIS, V16, P232, DOI 10.1097/00006982-199616030-00009; AERTS I, 2005, INT RET S INT SOC GE; BALMER A, 1993, OPHTHALMIC PAED GEN, V14, P33, DOI 10.3109/13816819309087621; BALMER A, 1991, OPHTHALMIC PAED GEN, V12, P131, DOI 10.3109/13816819109029394; BALMER A, 2002, TUMEURS INTRAOCULAIR, P587; Balmer A, 2002, TUMEURS INTRAOCULAIR, P485; Balmer A, 2002, TUMEURS INTRAOCULAIR, P481; BEAVERSON K, 2001, 10 INT C OC ONC AMST, P202; BINDER PS, 1974, AM J OPHTHALMOL, V77, P674, DOI 10.1016/0002-9394(74)90530-3; Chan Helen S L, 2005, Ophthalmol Clin North Am, V18, P55, DOI 10.1016/j.ohc.2004.11.002; Chantada G L, 1999, Ophthalmic Genet, V20, P133, DOI 10.1076/opge.20.3.133.2277; Chevez-Barrios P, 2005, J CLIN ONCOL, V23, P7927, DOI 10.1200/JCO.2004.00.1883; Conway R Max, 2005, Ophthalmol Clin North Am, V18, P25, DOI 10.1016/j.ohc.2004.08.006; DERKINDEREN DJ, 1990, AM J OPHTHALMOL, V110, P605, DOI 10.1016/S0002-9394(14)77056-4; Fletcher O, 2004, JNCI-J NATL CANCER I, V96, P357, DOI 10.1093/jnci/djh058; GALLIE BL, 1984, OPHTHALMOLOGY, V91, P666; GALLIE BL, 1982, OPHTHALMOLOGY, V89, P1393; GIRARD B, 1989, J FR OPHTALMOL, V12, P369; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Khelfaoui F, 1996, CANCER-AM CANCER SOC, V77, P1206, DOI 10.1002/(SICI)1097-0142(19960315)77:6<1206::AID-CNCR30>3.3.CO;2-Q; Kivela T, 1999, J CLIN ONCOL, V17, P1829, DOI 10.1200/JCO.1999.17.6.1829; KOPELMAN JE, 1987, OPHTHALMOLOGY, V94, P371; Linn Murphree A, 2005, Ophthalmol Clin North Am, V18, P41; MAATKIEVIT JA, 1993, PRENATAL DIAG, V13, P377, DOI 10.1002/pd.1970130510; MAHONEY MC, 1990, OPHTHALMOLOGY, V97, P1143; MARGO C, 1983, ARCH OPHTHALMOL-CHIC, V101, P1519, DOI 10.1001/archopht.1983.01040020521003; MATSUNAGA E, 1990, HUM GENET, V84, P155; MESSMER EP, 1991, OPHTHALMOLOGY, V98, P136; MILLER RW, 1969, J PEDIATR, V75, P685, DOI 10.1016/S0022-3476(69)80466-X; MORGAN G, 1971, BRIT J OPHTHALMOL, V55, P600, DOI 10.1136/bjo.55.9.600; MUNIER F, 2002, TUMEURS INTRAOCULAIR, P466; Murray TG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1286, DOI 10.1001/archopht.1997.01100160456013; REESE A B, 1963, Trans Am Acad Ophthalmol Otolaryngol, V67, P164; Scat Y, 1996, J FR OPHTALMOL, V19, P83; Shields CL, 1997, J PEDIAT OPHTH STRAB, V34, P165; SHIELDS CL, 1993, BRIT J OPHTHALMOL, V77, P544, DOI 10.1136/bjo.77.9.544; Shields CL, 1999, ARCH OPHTHALMOL-CHIC, V117, P885; SHIELDS CL, 1991, OPHTHALMOLOGY, V98, P395; SHIELDS CL, 1993, OPHTHALMOLOGY, V100, P216; Simpson Joe Leigh, 2005, J Natl Cancer Inst Monogr, P87; Singh AD, 2000, ARCH OPHTHALMOL-CHIC, V118, P199; Uusitalo MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P41; Van Quill KR, 2005, OPHTHALMOLOGY, V112, P1151, DOI 10.1016/j.ophtha.2004.11.060; Xu Hong-Ji, 2003, Ophthalmol Clin North Am, V16, P621, DOI 10.1016/S0896-1549(03)00065-8; Xu KP, 2004, AM J OPHTHALMOL, V137, P18, DOI 10.1016/S0002-9394(03)00872-9; ZOGRAFOS L, 2002, TUMEURS INTRAOCULAIR, P21	50	84	95	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5341	5349		10.1038/sj.onc.1209622	http://dx.doi.org/10.1038/sj.onc.1209622			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936756				2022-12-28	WOS:000240064100021
J	Khidr, L; Chen, PL				Khidr, L.; Chen, P-L			RB, the conductor that orchestrates life, death and differentiation	ONCOGENE			English	Review						RB; differentiation; E2F; EID-1	RETINOBLASTOMA GENE-PRODUCT; TUMOR-SUPPRESSOR PROTEIN; SKELETAL-MUSCLE CELLS; ADIPOCYTE DIFFERENTIATION; S-PHASE; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; INHIBITS TRANSACTIVATION; SUSCEPTIBILITY GENE; RESTRICTION POINT	The retinoblastoma susceptibility gene was the first tumor suppressor gene identified in humans and the first tumor suppressor gene knocked out by targeted deletion in mice. RB serves as a transducer between the cell cycle machinery and promoter-specific transcription factors, its most documented activity being the repression of the E2F family of transcription factors, which regulate the expression of genes involved in cell proliferation and survival. Recent investigations of RB function suggest that it works as a fundamental regulator to coordinate pathways of cellular growth and differentiation. In this review, we unravel the novel role of an equally important aspect of RB in downregulating the differentiation inhibitor EID-1 during cellular differentiation by teasing apart the signal, which elicit differentiation and limit cell cycle progression, since the molecular mechanisms relating to RB activation of differentiation is much less understood. We review the various roles for RB in differentiation of neurons, muscle, adipose tissue, and the retina. In addition, we provide an update for the current models of the role of RB in cell cycle to entry and exit, extending the view toward chromatin remodeling and expose the dichotomies in the regulation of RB family members. We conclude with a discussion of a novel RB regulatory network, incorporating the dynamic contribution of EID family proteins.	Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Chen, PL (corresponding author), Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.	plchen@uci.edu	Chen, Phang-Lang/J-5031-2013					Ait-Si-Ali S, 2004, EMBO J, V23, P605, DOI 10.1038/sj.emboj.7600074; Barbie DA, 2004, MOL CELL BIOL, V24, P595, DOI 10.1128/MCB.24.2.595-607.2004; Bavner A, 2005, NUCLEIC ACIDS RES, V33, P3561, DOI 10.1093/nar/gki667; Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; BENEDICT WF, 1983, SCIENCE, V219, P973, DOI 10.1126/science.6336308; Black EP, 2003, CANCER RES, V63, P3716; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; CHEN PL, 1995, CELL GROWTH DIFFER, V6, P199; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2000, P NATL ACAD SCI USA, V97, P10826, DOI 10.1073/pnas.190343597; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; COPPOLA JA, 1990, ONCOGENE, V5, P1731; Cvekl A, 2004, INT J DEV BIOL, V48, P829, DOI 10.1387/ijdb.041866ac; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Delehouzee S, 2005, GENES CELLS, V10, P717, DOI 10.1111/j.1365-2443.2005.00873.x; Dick FA, 2003, MOL CELL, V12, P639, DOI 10.1016/S1097-2765(03)00344-7; DOU QP, 1993, CANCER RES, V53, P1493; Dyer MA, 2005, NAT REV CANCER, V5, P91, DOI 10.1038/nrc1545; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eckner R, 1996, BIOL CHEM, V377, P685; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FERGUSON KL, 2005, EMBO J; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Goodman RH, 2000, GENE DEV, V14, P1553; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; Hannan KM, 2000, ONCOGENE, V19, P3487, DOI 10.1038/sj.onc.1203690; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; Higgins C, 1996, J VIROL, V70, P745, DOI 10.1128/JVI.70.2.745-752.1996; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Ji AM, 2003, GENE, V318, P35, DOI 10.1016/j.gene.2003.06.001; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KATO J, 1993, GENE DEV, V7, P331; Krutzfeldt M, 2005, MOL CELL, V18, P213, DOI 10.1016/j.molcel.2005.03.009; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lee EY, 2002, CANCER CELL, V2, P463, DOI 10.1016/S1535-6108(02)00207-6; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacLellan WR, 2000, MOL CELL BIOL, V20, P8903, DOI 10.1128/MCB.20.23.8903-8915.2000; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Mantela J, 2005, DEVELOPMENT, V132, P2377, DOI 10.1242/dev.01834; MAYOL X, 1993, ONCOGENE, V8, P2561; McDonnell TJ, 1999, J PATHOL, V188, P322, DOI 10.1002/(SICI)1096-9896(199907)188:3<322::AID-PATH372>3.0.CO;2-F; Miyake S, 2000, MOL CELL BIOL, V20, P8889, DOI 10.1128/MCB.20.23.8889-8902.2000; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; NEVINS JR, 1992, SCIENCE, V258, P424; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Nicolas E, 2003, MOL CELL BIOL, V23, P1614, DOI 10.1128/MCB.23.5.1614-1622.2003; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Novitch BG, 1999, CURR BIOL, V9, P449, DOI 10.1016/S0960-9822(99)80210-3; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; OBEYESEKERE MN, 1995, ONCOGENE, V11, P1199; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pradhan S, 2002, EMBO J, V21, P779, DOI 10.1093/emboj/21.4.779; RAY SK, 1992, MOL CELL BIOL, V12, P4327, DOI 10.1128/MCB.12.10.4327; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RILEY DJ, 1994, ANNU REV CELL BIOL, V10, P1, DOI 10.1146/annurev.cb.10.110194.000245; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Rodier G, 2005, J CELL BIOL, V168, P55, DOI 10.1083/jcb.200404146; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; Sandmoller A, 1996, MOL CELL BIOL, V16, P5846; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; Scime A, 2005, CELL METAB, V2, P283, DOI 10.1016/j.cmet.2005.10.002; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; Slack RS, 1998, J CELL BIOL, V140, P1497, DOI 10.1083/jcb.140.6.1497; Takahashi Y, 2000, GENE DEV, V14, P804; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wells J, 2002, P NATL ACAD SCI USA, V99, P3890, DOI 10.1073/pnas.062047499; WINDLE JJ, 1990, NATURE, V343, P665, DOI 10.1038/343665a0; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	116	81	82	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5210	5219		10.1038/sj.onc.1209612	http://dx.doi.org/10.1038/sj.onc.1209612			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936739				2022-12-28	WOS:000240064100004
J	Macaluso, M; Montanari, M; Giordano, A				Macaluso, M.; Montanari, M.; Giordano, A.			Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes	ONCOGENE			English	Review						pocket proteins; pRb1/p105; pRb2/p130; p107; gene transcription; E2Fs; chromatin remodeling nzymes	DEPENDENT TRANSCRIPTIONAL REPRESSION; S-PHASE ENTRY; CELL-CYCLE; RETINOBLASTOMA PROTEIN; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; E2F FAMILY; POCKET PROTEINS; G(1) CONTROL; DNA-REPAIR	The pRb family proteins (pRb1/105, p107, pRb2/p130), collectively referred to as pocket proteins, are believed to function primarily as regulators of the mammalian cell cycle progression, and suppressors of cellular growth and proliferation. In addition, different studies suggest that these pocket proteins are also involved in development and differentiation of various tissues. Several lines of evidence indicate that generally pRb-family proteins function through their effect on the transcription of E2F-regulated genes. In fact, each of Rb family proteins binds to distinct members of the E2F transcription factors, which regulate the expression of genes whose protein products are necessary for cell proliferation and to drive cell-cycle progression. Nevertheless, pocket proteins can affect the G1/S transition through E2F-independent mechanisms. More recently, a broad range of evidences indicate that pRb-family proteins associate with a wide variety of transcription factors and chromatin remodeling enzymes forming transcriptional repressor complexes that control gene expression. This review focuses on the complex regulatory mechanisms by which pRb-family proteins tell genes when to switch on and off.	Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Univ Palermo, Dept Oncol, Sect Oncol, Palermo, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Siena; University of Palermo	Giordano, A (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA.	giordano@temple.edu	Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X				Araki K, 2003, ONCOGENE, V22, P7632, DOI 10.1038/sj.onc.1206840; Aslanian A, 2004, GENE DEV, V18, P1413, DOI 10.1101/gad.1196704; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Balciunaite E, 2005, MOL CELL BIOL, V25, P8166, DOI 10.1128/MCB.25.18.8166-8178.2005; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Black EP, 2003, CANCER RES, V63, P3716; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Claudio P, 2002, GENOME BIOL, V3; Claudio PP, 1996, CANCER RES, V56, P2003; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Dimova DK, 2003, GENE DEV, V17, P2308, DOI 10.1101/gad.1116703; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Galderisi U, 2001, MOL CELL NEUROSCI, V17, P415, DOI 10.1006/mcne.2000.0949; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Ginsberg D, 2004, DEV CELL, V6, P742, DOI 10.1016/j.devcel.2004.05.012; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; Gunawardena RW, 2004, J BIOL CHEM, V279, P29278, DOI 10.1074/jbc.M400395200; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; He S, 2000, MOL CELL BIOL, V20, P363, DOI 10.1128/MCB.20.1.363-371.2000; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Iavarone A, 1999, MOL CELL BIOL, V19, P916; ISHIDA S, 2001, MOL CELL BIOL, V16, P47; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; KATO J, 1993, GENE DEV, V7, P331; La Sala D, 2003, ONCOGENE, V22, P3518, DOI 10.1038/sj.onc.1206487; Lee KY, 1999, MOL CELL BIOL, V19, P7724; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Macaluso M, 2005, ANN ONCOL, V16, P20, DOI 10.1093/annonc/mdi903; Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578; MACALUSO M, 2006, CELL DEATH DIFF 0106; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morrison AJ, 2002, MOL CELL BIOL, V22, P856, DOI 10.1128/MCB.22.3.856-865.2002; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mulligan GJ, 1998, MOL CELL BIOL, V18, P206, DOI 10.1128/MCB.18.1.206; Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4; Nguyen DX, 2005, J CELL BIOCHEM, V94, P870, DOI 10.1002/jcb.20375; Paggi MG, 1996, J CELL BIOCHEM, V62, P418; Paggi MG, 2001, CANCER RES, V61, P4651; Parakati R, 2005, J BIOL CHEM, V280, P21284, DOI 10.1074/jbc.M410744200; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Spencer C, 2005, GENE EXPR PATTERNS, V5, P687, DOI 10.1016/j.modgep.2005.02.003; Stiegler P, 1998, CANCER RES, V58, P5049; Stirzaker C, 2004, CANCER RES, V64, P3871, DOI 10.1158/0008-5472.CAN-03-3690; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; TAMARU H, 2003, NAT GENET, V12, P177; Taubert S, 2004, MOL CELL BIOL, V24, P4546, DOI 10.1128/MCB.24.10.4546-4556.2004; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Trouche D, 1997, P NATL ACAD SCI USA, V94, P11268, DOI 10.1073/pnas.94.21.11268; Tsantoulis PK, 2005, EUR J CANCER, V41, P2403, DOI 10.1016/j.ejca.2005.08.005; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Vignali M, 2000, MOL CELL BIOL, V20, P1899, DOI 10.1128/MCB.20.6.1899-1910.2000; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	84	111	117	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5263	5267		10.1038/sj.onc.1209680	http://dx.doi.org/10.1038/sj.onc.1209680			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936746				2022-12-28	WOS:000240064100011
J	Maeda, M; Johnson, E; Mandal, SH; Lawson, KR; Keim, SA; Svoboda, RA; Caplan, S; Wahl, JK; Wheelock, MJ; Johnson, KR				Maeda, M.; Johnson, E.; Mandal, S. H.; Lawson, K. R.; Keim, S. A.; Svoboda, R. A.; Caplan, S.; Wahl, J. K., III; Wheelock, M. J.; Johnson, K. R.			Expression of inappropriate cadherins by epithelial tumor cells promotes endocytosis and degradation of E-cadherin via competition for p120(ctn)	ONCOGENE			English	Article						cadherin; endocytosis; p120(ctn)	MICROVASCULAR ENDOTHELIAL-CELLS; SQUAMOUS CARCINOMA-CELLS; N-CADHERIN; MESENCHYMAL TRANSITIONS; DOWN-REGULATION; CANCER CELLS; ADHERENS JUNCTIONS; PLASMA-MEMBRANE; P120 CATENIN; VE-CADHERIN	Cadherin cell-cell adhesion proteins play an important role in modulating the behavior of tumor cells. E-cadherin serves as a suppressor of tumor cell invasion, and when tumor cells turn on the expression of a non-epithelial cadherin, they often express less E-cadherin, enhancing the tumorigenic phenotype of the cells. Here, we show that when A431 cells are forced to express R-cadherin, they dramatically downregulate the expression of endogenous E- and P-cadherin. In addition, we show that this downregulation is owing to increased turnover of the endogenous cadherins via clathrin-dependent endocytosis. p120(ctn) binds to the juxtamembrane domain of classical cadherins and has been proposed to regulate cadherin adhesive activity. One way p120(ctn) may accomplish this is to serve as a rheostat to regulate the levels of cadherin. Here, we show that the degradation of E-cadherin in response to expression of R-cadherin is owing to competition for p120(ctn).	Univ Nebraska, Med Ctr, Dept Oral Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Ctr, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Wheelock, MJ (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 987696 Nebraska Med Ctr, Omaha, NE 68198 USA.	mwheelock@unmc.edu		Keim, Sarah/0000-0002-7965-9267	NATIONAL CANCER INSTITUTE [P30CA036727] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR018759] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012308] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051188] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09746, P30-CA36727] Funding Source: Medline; NCRR NIH HHS [P20-RR018759] Funding Source: Medline; NIDCR NIH HHS [R01-DE12308] Funding Source: Medline; NIGMS NIH HHS [R01-GM51188] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Behrens J, 1999, CANCER METAST REV, V18, P15, DOI 10.1023/A:1006200102166; Bussemakers MJG, 2000, INT J CANCER, V85, P446, DOI 10.1002/(SICI)1097-0215(20000201)85:3<446::AID-IJC23>3.3.CO;2-2; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Dahl U, 2002, MOL CELL BIOL, V22, P1474, DOI 10.1128/MCB.22.5.1474-1487.2002; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Giroldi Laurence A., 2000, Morphologie, V84, P31; Grignani F, 1998, CANCER RES, V58, P14; Guilford P, 1999, MOL MED TODAY, V5, P172, DOI 10.1016/S1357-4310(99)01461-6; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Hazan RB, 1996, CELL ADHES COMMUN, V4, P399, DOI 10.3109/15419069709004457; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Islam S, 2000, J CELL BIOCHEM, V78, P141, DOI 10.1002/(SICI)1097-4644(20000701)78:1<141::AID-JCB13>3.0.CO;2-R; Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643; Johnson E, 2004, J BIOL CHEM, V279, P31041, DOI 10.1074/jbc.M400024200; JOHNSON KR, 1993, EXP CELL RES, V207, P252, DOI 10.1006/excr.1993.1191; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Kowalczyk AP, 2004, CURR OPIN CELL BIOL, V16, P522, DOI 10.1016/j.ceb.2004.07.001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le TL, 2002, AM J PHYSIOL-CELL PH, V283, pC489, DOI 10.1152/ajpcell.00566.2001; Le TL, 1999, J CELL BIOL, V146, P219, DOI 10.1083/jcb.146.1.219; MATSUNAMI H, 1993, J CELL SCI, V106, P401; Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; Nieman MT, 1999, J CELL SCI, V112, P1621; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Palacios F, 2005, MOL CELL BIOL, V25, P389, DOI 10.1128/MCB.25.1.389-402.2005; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Paterson AD, 2003, J BIOL CHEM, V278, P21050, DOI 10.1074/jbc.M300082200; Peifer M, 2003, J CELL BIOL, V163, P437, DOI 10.1083/jcb.200310090; Pishvaian MJ, 1999, CANCER RES, V59, P947; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; SUBTIL A, 1994, J CELL SCI, V107, P3461; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Tomita K, 2000, CANCER RES, V60, P3650; Vernon AE, 2004, CURR BIOL, V14, pR719, DOI 10.1016/j.cub.2004.08.048; Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305; Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; Xiao KY, 2005, MOL BIOL CELL, V16, P5141, DOI 10.1091/mbc.E05-05-0440; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Xiao KY, 2003, J BIOL CHEM, V278, P19199, DOI 10.1074/jbc.M211746200	48	48	53	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2006	25	33					4595	4604		10.1038/sj.onc.1209396	http://dx.doi.org/10.1038/sj.onc.1209396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16786001				2022-12-28	WOS:000239457500009
J	Lee, JS; Thorgeirsson, SS				Lee, J-S; Thorgeirsson, S. S.			Comparative and integrative functional genomics of HCC	ONCOGENE			English	Review						DNA microarray; gene expression profile; hepatocellular carcinoma (HCC); comparative functional genomics; integrative functional genomics	GENE-EXPRESSION PROFILES; HEPATITIS-B-VIRUS; HEPATOCELLULAR-CARCINOMA; BETA-CATENIN; PEROXISOME PROLIFERATORS; MOLECULAR-FEATURES; NATURAL-HISTORY; WIDE ANALYSIS; MOUSE MODELS; LUNG-CANCER	Global gene expression pro. ling of hepatocellular carcinoma (HCC) is a promising new technology that has already refined the diagnosis and prognostic predictions of HCC patients. This has been accomplished by identifying genes whose expression pattern is associated with clinicopathological features of HCC tumors. Molecular characterization of HCC from gene expression pro. ling studies will undoubtedly improve the prediction of treatment responses, selection of treatments for specific molecular subtypes of HCC and ultimately the clinical outcome of HCC patients. The research focus is now shifting toward the identification of genetic determinants that are components of the specific regulatory pathways altered in cancers, and that may constitute novel therapeutic targets. Here we review the recent advances in gene expression pro. ling of HCC and discuss the future strategies for analysing large and complicated data sets from microarray studies and how to integrate these with diverse genomic data.	NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Thorgeirsson, SS (corresponding author), NCI, Lab Expt Carcinogenesis, Ctr Canc Res, NIH, 37 Convent Dr,Bldg 37,Room 4146, Bethesda, MD 20892 USA.	snorri_thorgeirsson@nih.gov			NATIONAL CANCER INSTITUTE [Z01SC010385] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Bruix J, 2004, CANCER CELL, V5, P215, DOI 10.1016/S1535-6108(04)00058-3; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; CALVET X, 1990, HEPATOLOGY, V12, P753, DOI 10.1002/hep.1840120422; Calvisi DF, 2004, GASTROENTEROLOGY, V126, P1374, DOI 10.1053/j.gastro.2004.02.014; Calvisi DF, 2001, CANCER RES, V61, P2085; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; Cheung C, 2004, CANCER RES, V64, P3849, DOI 10.1158/0008-5472.CAN-04-0322; Chevret S, 1999, J HEPATOL, V31, P133, DOI 10.1016/S0168-8278(99)80173-1; Cooper GM, 2003, CURR OPIN GENET DEV, V13, P604, DOI 10.1016/j.gde.2003.10.001; Dave SS, 2004, NEW ENGL J MED, V351, P2159, DOI 10.1056/NEJMoa041869; Davila JA, 2004, GASTROENTEROLOGY, V127, P1372, DOI 10.1053/j.gastro.2004.07.020; Eddy SR, 2002, CELL, V109, P137, DOI 10.1016/S0092-8674(02)00727-4; EL SH, 1999, NEW ENGL J MED, V340, P745; El-Serag HB, 2004, GASTROENTEROLOGY, V127, pS27, DOI 10.1053/j.gastro.2004.09.013; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hardison RC, 1997, GENOME RES, V7, P959, DOI 10.1101/gr.7.10.959; Hsu HC, 2000, AM J PATHOL, V157, P763, DOI 10.1016/S0002-9440(10)64590-7; Iizuka N, 2003, LANCET, V361, P923, DOI 10.1016/S0140-6736(03)12775-4; Kim BY, 2004, BBA-MOL BASIS DIS, V1739, P50, DOI 10.1016/j.bbadis.2004.07.004; KIMURA M, 1968, NATURE, V217, P624, DOI 10.1038/217624a0; KING JL, 1969, SCIENCE, V164, P788, DOI 10.1126/science.164.3881.788; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Lee JS, 2005, CARCINOGENESIS, V26, P1013, DOI 10.1093/carcin/bgi030; Lee JS, 2004, NAT GENET, V36, P1306, DOI 10.1038/ng1481; Lee JS, 2004, HEPATOLOGY, V40, P667, DOI 10.1002/hep.20375; Lee JS, 2002, HEPATOLOGY, V35, P1134, DOI 10.1053/jhep.2002.33165; Lee JS, 2004, GASTROENTEROLOGY, V127, pS51, DOI 10.1053/j.gastro.2004.09.015; Lenhard Boris, 2003, J Biol, V2, P13, DOI 10.1186/1475-4924-2-13; Llovet JM, 1999, HEPATOLOGY, V29, P62, DOI 10.1002/hep.510290145; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Manghisi G, 1998, HEPATOLOGY, V28, P751; Mao TL, 2001, J PATHOL, V193, P95, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH720>3.0.CO;2-3; McNeil C, 1998, J NATL CANCER I, V90, P882, DOI 10.1093/jnci/90.12.882; Murphy WJ, 2004, TRENDS GENET, V20, P631, DOI 10.1016/j.tig.2004.09.005; Nam SW, 2005, HEPATOLOGY, V42, P809, DOI 10.1002/hep.20878; Neo SY, 2004, HEPATOLOGY, V39, P944, DOI 10.1002/hep.20105; Okabe H, 2001, CANCER RES, V61, P2129; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RAO MS, 1984, CANCER RES, V44, P1072; REDDY JK, 1983, CRC CR REV TOXICOL, V12, P1, DOI 10.3109/10408448309029317; Roepman P, 2005, NAT GENET, V37, P182, DOI 10.1038/ng1502; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Sargent LM, 1999, AM J PATHOL, V154, P1047, DOI 10.1016/S0002-9440(10)65357-6; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Tan CK, 2003, J CLIN ONCOL, V21, P2294, DOI 10.1200/JCO.2003.03.151; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wistuba II, 2001, SEMIN ONCOL, V28, P3, DOI 10.1053/sonc.2001.25738; Wong CM, 2001, CANCER-AM CANCER SOC, V92, P136, DOI 10.1002/1097-0142(20010701)92:1<136::AID-CNCR1301>3.0.CO;2-R; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843	69	98	100	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	27					3801	3809		10.1038/sj.onc.1209561	http://dx.doi.org/10.1038/sj.onc.1209561			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	056XY	16799621				2022-12-28	WOS:000238559600007
J	Buschbeck, M; Uribesalgo, I; Ledl, A; Gutierrez, A; Minucci, S; Muller, S; Di Croce, L				Buschbeck, M.; Uribesalgo, I.; Ledl, A.; Gutierrez, A.; Minucci, S.; Muller, S.; Di Croce, L.			PML4 induces differentiation by Myc destabilization	ONCOGENE			English	Article						cancer; differentiation; gene repression; Myc; promyelocytic leukemia protein; protein degradation	RAR-ALPHA; ACUTE-LEUKEMIA; C-MYC; UBIQUITIN; EXPRESSION; DEGRADATION; PATHOGENESIS; ASSOCIATION; PROTEASOMES; BINDING	Opposing functions like oncogene and tumor suppressions have been established for c-Myc and promyelocytic leukemia (PML) protein, respectively. Myc is known to inhibit differentiation of hematopoietic precursor cells, and here we report that PML promotes cell differentiation. We further demonstrate that PML and Myc form a complex in vivo. The interaction of the two proteins leads to the destabilization of Myc in a manner dependent on the really interesting new gene (RING) domain of PML. Although several PML isoforms are able to interact with Myc, the ability to destabilize Myc is specific for PML4. Importantly, the PML-induced destabilization resulted in a reduction of promoter-bound Myc on Myc-repressed genes. Thereby, PML induced the re-activation of Myc-repressed target genes including the tumor, suppressive genes of the cell cycle inhibitors cdkn1a/p21 and cdkn2b/ p15. Together, these results establish PML-mediated destabilization of Myc and the derepression of cell cycle inhibitor genes as an important regulatory mechanism that allows cell differentiation and prevents aberrant proliferation driven by uncontrolled Myc activity.	PRBB, CRG, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Max Planck Inst Biochem, D-82152 Martinsried, Germany; IEO, Milan, Italy	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; Max Planck Society; IRCCS European Institute of Oncology (IEO)	Di Croce, L (corresponding author), ICREA, C Dr Aiguaer 88, Barcelona 08003, Spain.	luciano.dicroce@crg.es	Gutierrez, Arantxa/K-8213-2015; Di Croce, Luciano/E-7759-2015; Minucci, Saverio/J-9669-2012; Buschbeck, Marcus/J-8204-2017	Gutierrez, Arantxa/0000-0001-9033-3834; Di Croce, Luciano/0000-0003-3488-6228; Buschbeck, Marcus/0000-0002-3218-4567; Muller, Stefan/0000-0002-8792-7700	ICREA Funding Source: Custom	ICREA(ICREA)		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Amati B, 2004, P NATL ACAD SCI USA, V101, P8843, DOI 10.1073/pnas.0403046101; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Buschbeck M, 2005, EMBO REP, V6, P63, DOI 10.1038/sj.embor.7400316; Cairo S, 2005, ONCOGENE, V24, P2195, DOI 10.1038/sj.onc.1208338; Di Croce L, 2005, HUM MOL GENET, V14, pR77, DOI 10.1093/hmg/ddi109; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; Kalejta RF, 2003, P NATL ACAD SCI USA, V100, P3263, DOI 10.1073/pnas.0538058100; Kanatani Y, 1999, CELL GROWTH DIFFER, V10, P705; Lafarga M, 2002, MOL BIOL CELL, V13, P2771, DOI 10.1091/mbc.E02-03-0122; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Rockel TD, 2005, J CELL SCI, V118, P5231, DOI 10.1242/jcs.02642; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Smith KP, 2004, J CELL BIOCHEM, V93, P1282, DOI 10.1002/jcb.20273; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Strudwick S, 2002, LEUKEMIA, V16, P1906, DOI 10.1038/sj.leu.2402724; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Villa R, 2006, P NATL ACAD SCI USA, V103, P1400, DOI 10.1073/pnas.0509343103; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145	29	33	34	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3415	3422		10.1038/sj.onc.1210128	http://dx.doi.org/10.1038/sj.onc.1210128			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17146439				2022-12-28	WOS:000246579600011
J	Mehta, SA; Christopherson, KW; Bhat-Nakshatri, P; Goulet, RJ; Broxmeyer, H; Kopelovich, L; Nakshatri, H				Mehta, S. A.; Christopherson, K. W.; Bhat-Nakshatri, P.; Goulet, R. J., Jr.; Broxmeyer, He; Kopelovich, L.; Nakshatri, H.			Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion	ONCOGENE			English	Article						CXCR4; p53; breast cancer; invasion; PRIMA-1	GENE-EXPRESSION; MUTANT P53; GROWTH SUPPRESSION; METASTASIS; TRANSCRIPTION; REPRESSION; MIGRATION; APOPTOSIS; PRIMA-1; AP-1	Chemokine receptor CXCR4 and its ligand CXCL12 are suggested to be involved in migration, invasion and metastasis of breast cancer cells. Mutation of the tumor suppressor gene p53 in breast cancer is associated with metastasis and aggressive clinical phenotype. In this report, we demonstrate that wild type but not the dominant-negative mutant (V143A)or cancer-specific mutants (R175H or R280K) of p53 repress CXCR4 expression. Recently described cancer-specific p53 isoform, Delta 133p53, also failed to repress CXCR4 promoter activity. Short-interfering RNA-mediated depletion of p53 increased endogenous CXCR4 expression in MCF-7 breast cancer cells that contain wild-type p53. Basal CXCR4 promoter activity in HCT116 colon carcinoma cells deleted of p53 [HCT116(p53KO)] was 10-fold higher compared to that in parental HCT116 cells with functional wild-type p53. Deletion analysis of CXCR4 promoter identified a seven-base pair p53-repressor element homologous to cyclic AMP/AP-1 response (CRE/AP-1) element. Electrophoretic mobility shift and chromatin immunoprecipitation assays revealed binding of ATF-1 and cJun to the CRE/AP-1 element. The p53 rescue drug PRIMA-1 reduced CXCR4 mRNA and cell surface expression in MDA-MB-231 cells, which express R280K mutant p53. CP-31398, another p53 rescue drug, similarly reduced cell surface levels of CXCR4. PRIMA-1-mediated decrease in CXCR4 expression correlated with reduced invasion of MDA-MB-231 cells through matrigel. These results suggest a mechanism for elevated CXCR4 expression and metastasis of breast cancers with p53 mutations or isoform expression. We propose that p53 rescue drugs either alone or in combination with chemotherapeutic drugs may be effective in reducing CXCR4-mediated metastasis.	Indiana Univ, Sch Med, Dept Microbiol & Immunol, Bloomington, IN 47405 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Bloomington, IN 47405 USA; Natl Canc Inst, DCP, CADRG, Bethesda, MD USA; Walther Canc Inst, Indianapolis, IN USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Walther Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Walther Cancer Institute	Nakshatri, H (corresponding author), Indiana Canc Res Inst, Dept Surg Biochem & Mol Biol, R4-202,1044 W Walnut St,R4-268, Indianapolis, IN 46202 USA.	hnakshat@iupui.edu		Nakshatri, Harikrishna/0000-0001-8876-0052	NCI NIH HHS [N01-CN-15133, R01 CA89153] Funding Source: Medline; NHLBI NIH HHS [R01 HL67384] Funding Source: Medline; NIDDK NIH HHS [R01 DK53674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089153] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachelder RE, 2002, CANCER RES, V62, P7203; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 2002, CANCER RES, V62, P1129; Bykov VJN, 2002, CARCINOGENESIS, V23, P2011, DOI 10.1093/carcin/23.12.2011; Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282; Cabioglu N, 2005, CLIN EXP METASTAS, V22, P39, DOI 10.1007/s10585-005-3222-y; Caruz A, 1998, FEBS LETT, V426, P271, DOI 10.1016/S0014-5793(98)00359-7; CASEY G, 1991, ONCOGENE, V6, P1791; Dong Y, 2002, EXP CELL RES, V276, P328, DOI 10.1006/excr.2002.5534; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gupta GP, 2005, COLD SH Q B, V70, P149, DOI 10.1101/sqb.2005.70.018; Helbig G, 2003, J BIOL CHEM, V278, P21631, DOI 10.1074/jbc.M300609200; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Khan MZ, 2005, MOL CELL NEUROSCI, V30, P58, DOI 10.1016/j.mcn.2005.05.007; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Kim E, 2003, ONCOGENE, V22, P7716, DOI 10.1038/sj.onc.1207155; Kucia M, 2005, STEM CELLS, V23, P879, DOI 10.1634/stemcells.2004-0342; Lee BC, 2005, CANCER RES, V65, P2840, DOI 10.1158/0008-5472.CAN-04-3309; Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206; Liang ZX, 2005, CANCER RES, V65, P967; Matteucci E, 2005, EXP CELL RES, V310, P176, DOI 10.1016/j.yexcr.2005.07.008; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531; Moriuchi M, 1999, J IMMUNOL, V162, P5986; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Salvucci O, 2006, BREAST CANCER RES TR, V97, P275, DOI 10.1007/s10549-005-9121-8; Scian MJ, 2004, CANCER RES, V64, P7447, DOI 10.1158/0008-5472.CAN-04-1568; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sheridan C, 2006, EXP HEMATOL, V34, P1085, DOI 10.1016/j.exphem.2006.03.013; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Sun YB, 2004, J CELL BIOCHEM, V92, P258, DOI 10.1002/jcb.20044; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864	38	91	92	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3329	3337		10.1038/sj.onc.1210120	http://dx.doi.org/10.1038/sj.onc.1210120			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130833				2022-12-28	WOS:000246579600003
J	Bowie, ML; Troch, MM; Delrow, J; Dietze, EC; Bean, GR; Ibarra, C; Pandiyan, G; Seewaldt, VL				Bowie, M. L.; Troch, M. M.; Delrow, J.; Dietze, E. C.; Bean, G. R.; Ibarra, C.; Pandiyan, G.; Seewaldt, V. L.			Interferon regulatory factor-1 regulates reconstituted extracellular matrix (rECM)-mediated apoptosis in human mammary epithelial cells	ONCOGENE			English	Article						mammary epithelial cells; IRF-1; apoptosis; extracellular matrix; tamoxifen	INDUCED NUCLEAR FACTORS; CREB-BINDING PROTEIN; PROMOTER ELEMENT; GROWTH; EXPRESSION; IRF-1; TAMOXIFEN; ARREST; ALPHA; FASLODEX	Interactions between extracellular matrix (ECM) and mammary epithelial cells are critical for mammary gland homeostasis and apoptotic signaling. Interferon regulatory factor-1 (IRF-1) is a transcriptional regulator that promotes apoptosis during mammary gland involution and p53-independent apoptosis. We have recently shown that rapid cell surface tamoxifen (Tam) signa ling promotes apoptosis in normal human mammary epithelial cells that were acutely damaged by expression of human papillomavirus type-16 E6 protein (*HMEC-E6). Apoptosis was mediated by recruitment of CREB-binding protein (CBP) to the gamma-activating sequence (GAS) element of the IRF-1 promoter, induction of IRF-1 and caspase-1/-3 activation. Here, we show that growth factor-depleted, reconstituted ECM (rECM), similar to Tam, promotes apoptosis in *HMEC-E6 cells through induction of IRF-1. Apoptosis was temporally associated with recruitment of CBP to the GAS element of the IRF-1 promoter, induction of IRF-1 expression and caspase-1/-3 activation. Small interfering RNA-mediated suppression of IRF-1 protein expression in *HMEC-E6 cells blocked (1) induct ion of IRF-1, (2) caspase-1/-3 activation and (3) apoptosis. These observations demonstrate that IRF-1 promotes rECM-mediated apoptosis and provide evidence that both rECM and rapid Tam signaling transcriptionally activate IRF-1 through recruitment of CBP to the IRF- 1 GAS promoter complex.	Duke Univ, Dept Med, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Dept Genom Shared Resources, Seattle, WA 98104 USA; Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University; Fred Hutchinson Cancer Center; Duke University	Seewaldt, VL (corresponding author), Duke Univ, Dept Med, Box 2628,MRSB, Durham, NC 27710 USA.	seewa001@mc.duke.edu			NATIONAL CANCER INSTITUTE [R01CA114068, P50CA068438, R01CA088799, P30CA014236, R01CA098441] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA114068, R01CA098441, P30CA14236, P50CA68438, R01CA088799] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberdam D, 2000, MICROSC RES TECHNIQ, V51, P228, DOI 10.1002/1097-0029(20001101)51:3<228::AID-JEMT3>3.0.CO;2-9; Bouker KB, 2005, CARCINOGENESIS, V26, P1527, DOI 10.1093/carcin/bgi113; Bouker KB, 2004, CANCER RES, V64, P4030, DOI 10.1158/0008-5472.CAN-03-3602; Bowie ML, 2004, ONCOGENE, V23, P8743, DOI 10.1038/sj.onc.1208120; DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304; Dietze EC, 2005, J CELL SCI, V118, P5005, DOI 10.1242/jcs.02616; Dietze EC, 2004, ONCOGENE, V23, P3851, DOI 10.1038/sj.onc.1207480; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; Goodman RH, 2000, GENE DEV, V14, P1553; Gu ZP, 2002, CANCER RES, V62, P3428; Henderson YC, 1997, BRIT J HAEMATOL, V96, P566, DOI 10.1046/j.1365-2141.1997.d01-2057.x; IMAM AMA, 1990, NUCLEIC ACIDS RES, V18, P6573, DOI 10.1093/nar/18.22.6573; KELLY JM, 1986, EMBO J, V5, P1601, DOI 10.1002/j.1460-2075.1986.tb04402.x; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Kim PKM, 2004, ONCOGENE, V23, P1125, DOI 10.1038/sj.onc.1207023; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351; PARRINGTON J, 1993, EUR J BIOCHEM, V214, P617, DOI 10.1111/j.1432-1033.1993.tb17961.x; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Pizzoferrato E, 2004, CANCER RES, V64, P8381, DOI 10.1158/0008-5472.CAN-04-2223; Porta C, 2005, ONCOGENE, V24, P605, DOI 10.1038/sj.onc.1208204; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Romeo G, 2002, J INTERF CYTOK RES, V22, P39, DOI 10.1089/107999002753452647; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 2001, J CELL BIOL, V155, P471, DOI 10.1083/jcb.200011001; Stupack DG, 2002, J CELL SCI, V115, P3729, DOI 10.1242/jcs.00071; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tanaka N, 1996, NATURE, V382, P816, DOI 10.1038/382816a0; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Yokota S, 2004, J VIROL, V78, P4591, DOI 10.1128/JVI.78.9.4591-4598.2004	36	10	10	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2007	26	14					2017	2026		10.1038/sj.onc.1210013	http://dx.doi.org/10.1038/sj.onc.1210013			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016442				2022-12-28	WOS:000245313400004
J	Concannon, CG; Koehler, BF; Reimertz, C; Murphy, BM; Bonner, C; Thurow, N; Ward, MW; Villunger, A; Strasser, A; Kogel, D; Prehn, JHM				Concannon, C. G.; Koehler, B. F.; Reimertz, Claus; Murphy, B. M.; Bonner, C.; Thurow, N.; Ward, M. W.; Villunger, A.; Strasser, A.; Koegel, D.; Prehn, J. H. M.			Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway	ONCOGENE			English	Article						proteasome; apoptosis; epoxomicin; Bcl-2 family; BH3-only protein; p53	NF-KAPPA-B; UBIQUITIN-PROTEIN LIGASE; PHASE-I TRIAL; BH3-ONLY PROTEINS; MULTIPLE-MYELOMA; TARGET GENES; GLIOMA-CELLS; SOLID TUMORS; C-MYC; P53	The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA- dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.	Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, Dublin 2, Ireland; Johann Wolfgang Goethe Univ Clin, Ctr Neurol & Neurosurg, Frankfurt, Germany; Innsbruck Med Univ, Bioctr, Div Expt Pathophysiol & Immunol, Innsbruck, Austria; Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Royal College of Surgeons - Ireland; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Medical University of Innsbruck; Walter & Eliza Hall Institute	Prehn, JHM (corresponding author), Royal Coll Surgeons Ireland, Dept Physiol & Med Phys, 123 St Stephens Green, Dublin 2, Ireland.	prehn@rcsi.ie	Strasser, Andreas/C-7581-2013; Murphy, Brona/P-2544-2019; Prehn, Jochen HM/A-3928-2010; Concannon, Caoimhin/B-2075-2010; Murphy, Brona/D-4873-2012; Pattou, Francois/O-6151-2017; Bonner, Caroline/A-9819-2015	Strasser, Andreas/0000-0002-5020-4891; Murphy, Brona/0000-0002-6740-8858; Prehn, Jochen HM/0000-0003-3479-7794; Murphy, Brona/0000-0002-6740-8858; Pattou, Francois/0000-0001-8388-3766; Bonner, Caroline/0000-0002-4430-8280; Ward, Manus/0000-0002-7085-9668; Kogel, Donat/0000-0003-1209-0210				Adams J, 2002, CURR OPIN ONCOL, V14, P628, DOI 10.1097/00001622-200211000-00007; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Aghajanian C, 2002, CLIN CANCER RES, V8, P2505; Amiri KI, 2004, CANCER RES, V64, P4912, DOI 10.1158/0008-5472.CAN-04-0673; Anan A, 2006, HEPATOLOGY, V43, P335, DOI 10.1002/hep.21036; Biswas SC, 2005, NEUROCHEM RES, V30, P839, DOI 10.1007/s11064-005-6877-5; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Ceballos E, 2005, ONCOGENE, V24, P4559, DOI 10.1038/sj.onc.1208652; Chauhan D, 2005, ANNU REV PHARMACOL, V45, P465, DOI 10.1146/annurev.pharmtox.45.120403.100037; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Dang CV, 1999, MOL CELL BIOL, V19, P1; Ganten TM, 2005, HEPATOLOGY, V42, P588, DOI 10.1002/hep.20807; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HANADA M, 1992, J ANTIBIOT, V45, P1746, DOI 10.7164/antibiotics.45.1746; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kikuchi S, 2003, BRAIN RES, V964, P228, DOI 10.1016/S0006-8993(02)04030-1; Kurland JF, 2001, INT J CANCER, V96, P327, DOI 10.1002/ijc.1040; Kuwana T, 2005, MOL CELL, V17, P525, DOI 10.1016/j.molcel.2005.02.003; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marshansky V, 2001, J IMMUNOL, V166, P3130, DOI 10.4049/jimmunol.166.5.3130; Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274; Meiners S, 2003, J BIOL CHEM, V278, P21517, DOI 10.1074/jbc.M301032200; Melino G, 2005, CELL DEATH DIFFER, V12, P1155, DOI 10.1038/sj.cdd.4401740; Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403; MITSIADES N, 2002, MOL SEQUELAE PROTEAS, V99, P14374; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nikrad M, 2005, MOL CANCER THER, V4, P443; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Papandreou CN, 2004, J CLIN ONCOL, V22, P2108, DOI 10.1200/JCO.2004.02.106; Park DJ, 2004, ANN MED, V36, P296, DOI 10.1080/07853890410029031; Qin JZ, 2005, CANCER RES, V65, P6282, DOI 10.1158/0008-5472.CAN-05-0676; Reimertz C, 2003, J CELL BIOL, V162, P587, DOI 10.1083/jcb.200305149; Reimertz C, 2001, J NEUROCHEM, V78, P1256, DOI 10.1046/j.1471-4159.2001.00503.x; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Villunger A, 2003, BLOOD, V101, P2393, DOI 10.1182/blood-2002-07-2132; Wagenknecht B, 2000, J NEUROCHEM, V75, P2288, DOI 10.1046/j.1471-4159.2000.0752288.x; Wagenknecht B, 1999, CELL PHYSIOL BIOCHEM, V9, P117, DOI 10.1159/000016308; Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001; Wong HK, 2005, MOL CELL BIOL, V25, P8732, DOI 10.1128/MCB.25.19.8732-8747.2005; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Yan CH, 2005, EMBO J, V24, P2425, DOI 10.1038/sj.emboj.7600712; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	55	76	79	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1681	1692		10.1038/sj.onc.1209974	http://dx.doi.org/10.1038/sj.onc.1209974			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16983338				2022-12-28	WOS:000244955600002
J	Yang, G; Rosen, DG; Colacino, JA; Mercado-Uribe, I; Liu, J				Yang, G.; Rosen, D. G.; Colacino, J. A.; Mercado-Uribe, I.; Liu, J.			Disruption of the retinoblastoma pathway by small interfering RNA and ectopic expression of the catalytic subunit of telomerase lead to immortalization of human ovarian surface epithelial cells	ONCOGENE			English	Article						human ovarian surface epithelial cells; immortalization; siRNA; pRb; hTERT	HUMAN-PAPILLOMAVIRUS TYPE-16; GENOMIC INSTABILITY; GENE-EXPRESSION; CANCER; GROWTH; PROTEIN; P53; TRANSFORMATION; RETROVIRUS; BREAST	The risk of developing ovarian cancer is about 1% over a lifetime, but it is the most deadly gynecologic cancer, in part due to lack of diagnostic markers for early-stage disease and cell model system for studying early neoplastic changes. Most existing immortal human ovarian surface epithelial cells were achieved by using viral protein such as SV40 T/t antigen or E6/E7, which inactivate multiple cellular pathways. In the current study, we used a small interfering RNA ( siRNA) against the retinoblastoma gene (pRb) and ectopic expression of human telomerase reverse transcriptase ( hTERT) to immortalize the primary ovarian epithelial cell line OSE137 and two additional human ovarian surface epithelial cells. The immortalized OSE137 showed increased telomerase activity, lengthened telomeres, increased G(2)/M phase, altered cell-cycle regulatory proteins but nontumorigenic. As both Rb and hTERT pathways are commonly altered in human ovarian cancer and these genetic changes are faithfully modeled in these cells without using viral protein, these immortal cells represent an authentic in vitro model system with which to study the initiation and progression of human ovarian cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jliu@mdanderson.org			NCI NIH HHS [CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Baege AC, 2002, AM J PATHOL, V160, P1251, DOI 10.1016/S0002-9440(10)62552-7; Band V, 1998, INT J ONCOL, V12, P499; Bantounas I, 2004, J MOL ENDOCRINOL, V33, P545, DOI 10.1677/jme.1.01582; BERNUES J, 1991, GENE, V108, P269, DOI 10.1016/0378-1119(91)90444-G; Chun YM, 2002, ANN OTO RHINOL LARYN, V111, P507, DOI 10.1177/000348940211100606; D'Andrilli G, 2004, CLIN CANCER RES, V10, P8132, DOI 10.1158/1078-0432.CCR-04-0886; Davies BR, 2003, EXP CELL RES, V288, P390, DOI 10.1016/S0014-4827(03)00218-0; Duensing S, 2002, ONCOGENE, V21, P6241, DOI 10.1038/sj.onc.1205709; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Gao QS, 2001, J VIROL, V75, P4459, DOI 10.1128/JVI.75.9.4459-4466.2001; Hashiguchi Y, 2001, HUM PATHOL, V32, P988, DOI 10.1053/hupa.2001.27115; Hayflick L, 1973, TISSUE CULTURE METHO, P220, DOI DOI 10.1016/B978-0-12-427150-0.50060-7; Hu YM, 2005, J BIOL CHEM, V280, P39485, DOI 10.1074/jbc.M503296200; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Jarrard DF, 1999, CANCER RES, V59, P2957; Kauff ND, 2005, JNCI-J NATL CANCER I, V97, P1382, DOI 10.1093/jnci/dji281; Kusakari T, 2003, BRIT J CANCER, V89, P2293, DOI 10.1038/sj.bjc.6601423; Kusume T, 1999, CLIN CANCER RES, V5, P4152; Lenferink AEG, 2000, P NATL ACAD SCI USA, V97, P9609, DOI 10.1073/pnas.160564197; Liu J, 2001, CANCER CYTOPATHOL, V93, P390, DOI 10.1002/cncr.10141; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lundberg AS, 2002, ONCOGENE, V21, P4577, DOI 10.1038/sj.onc.1205550; McDougall J K, 2001, Dev Biol (Basel), V106, P267; McDougall JK, 2001, DEV BIOL BASEL, V106; MCDOUGALL JK, 2001, DEV BIOL BASEL, V106, P272; Noble JR, 2004, ONCOGENE, V23, P3116, DOI 10.1038/sj.onc.1207440; Ouellette MM, 2000, HUM MOL GENET, V9, P403, DOI 10.1093/hmg/9.3.403; Ozols RF, 2004, CANCER CELL, V5, P19, DOI 10.1016/S1535-6108(04)00002-9; Plug-Demaggio AW, 2002, ONCOGENE, V21, P7507, DOI 10.1038/sj.onc.1205903; Prowse A, 2003, ACS A CLIN ONCOL SER, P49; Rosen DG, 2005, CLIN CANCER RES, V11, P632; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; SANKARANARAYANA.R, 2006, BEST PRACT RES CLIN, V20, P1; Takebayashi T, 2003, J BIOL CHEM, V278, P14897, DOI 10.1074/jbc.M210849200; Tammela J, 2004, Minerva Ginecol, V56, P495; Terasawa K, 1999, CANCER LETT, V142, P207, DOI 10.1016/S0304-3835(99)00170-6; Vasey PA, 2003, BRIT J CANCER, V89, pS23, DOI 10.1038/sj.bjc.6601497; Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zou GM, 2005, BIOL CELL, V97, P211	41	16	20	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1492	1498		10.1038/sj.onc.1209905	http://dx.doi.org/10.1038/sj.onc.1209905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16953228				2022-12-28	WOS:000244558800014
J	Prabhu, S; Saadat, D; Zhang, M; Halbur, L; Fruehauf, JP; Ong, ST				Prabhu, S.; Saadat, D.; Zhang, M.; Halbur, L.; Fruehauf, J. P.; Ong, S. T.			A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation	ONCOGENE			English	Article						CML; eIF4F; mTOR; cap-dependent translation	CHRONIC MYELOGENOUS LEUKEMIA; CAP-DEPENDENT TRANSLATION; IMATINIB MESYLATE STI571; P70 S6 KINASE; MAMMALIAN TARGET; CYTOGENETIC RESPONSES; CYCLIN D2; RAPAMYCIN; BCR/ABL; INHIBITOR	The oncogenic kinase Bcr-Abl is thought to cause chronic myelogenous leukemia (CML) by altering the transcription of specific genes with growth- and survival-promoting functions. Recently, Bcr-Abl has also been shown to activate an important regulator of protein synthesis, the mammalian target of rapamycin ( mTOR), which suggests that dysregulated translation may also contribute to CML pathogenesis. In this study, we found that both Bcr-Abl and the rapamycin-sensitive mTORC1 complex contribute to the phosphorylation ( inactivation) of 4E-BP1, an inhibitor of the eIF4E translation initiation factor. Experiments with rapamycin and the Bcr-Abl inhibitor, imatinib mesylate, in Bcr-Abl-expressing cell lines and primary CML cells indicated that Bcr-Abl and mTORC1 induced formation of the translation initiation complex, eIF4F. This was characterized by reduced 4E-BP1 binding and increased eIF4G binding to eIF4E, two events that lead to the assembly of eIF4F. One target transcript is cyclin D3, which is regulated in Bcr-Abl-expressing cells by both Bcr-Abl and mTORC1 in a translational manner. In addition, the combination of imatinib and rapamycin was found to act synergistically against committed CML progenitors from chronic and blast phase patients. These experiments establish a novel mechanism of action for Bcr-Abl, and they provide insights into the modes of action of imatinib mesylate and rapamycin in treatment of CML. They also suggest that aberrant cap-dependent mRNA translation may be a therapeutic target in BcrAbl-driven malignancies.	Univ Calif Irvine, Dept Med, Div Hematol Oncol, Irvine, CA 92697 USA; Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Irvine, CA 92697 USA; Univ Calif Irvine, Canc Res Inst, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Immunol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Ong, ST (corresponding author), Univ Calif Irvine, Dept Med, Div Hematol Oncol, 839 Med Sci Court,116 Sprague Hall, Irvine, CA 92697 USA.	ongt@uci.edu		Ong, S. Tiong/0000-0001-9460-3483	NCI NIH HHS [1R21 CA105514, R21 CA112936-01A1, R21 CA112936, R01 CA107041-02, R01 CA107041-01A1, 1R21 CA112936, R21 CA105514, R01 CA107041, 1R01 CA107041] Funding Source: Medline; NIBIB NIH HHS [R01 EB004436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA107041, R21CA112936, R21CA105514] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB004436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Altmann M, 1997, EMBO J, V16, P1114, DOI 10.1093/emboj/16.5.1114; Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Bushell M, 2000, CELL DEATH DIFFER, V7, P628, DOI 10.1038/sj.cdd.4400699; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Chou T C, 1994, Contrib Gynecol Obstet, V19, P91; Chu S, 2004, BLOOD, V103, P3167, DOI 10.1182/blood-2003-04-1271; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Decker T, 2003, BLOOD, V101, P278, DOI 10.1182/blood-2002-01-0189; Deininger MWN, 2003, PHARMACOL REV, V55, P401, DOI 10.1124/pr.55.3.4; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2003, BLOOD, V101, P690, DOI 10.1182/blood.V101.2.690; Edinger AL, 2003, CANCER RES, V63, P8451; Fruman DA, 2002, P NATL ACAD SCI USA, V99, P359, DOI 10.1073/pnas.012605099; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Hentze MW, 1997, SCIENCE, V275, P500, DOI 10.1126/science.275.5299.500; Hleb M, 2004, J BIOL CHEM, V279, P31948, DOI 10.1074/jbc.M400638200; Holtz MS, 2002, BLOOD, V99, P3792, DOI 10.1182/blood.V99.10.3792; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Iervolino A, 2002, MOL CELL BIOL, V22, P2255, DOI 10.1128/MCB.22.7.2255-2266.2002; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jena N, 2002, CANCER RES, V62, P535; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; La Rosee P, 2002, CANCER RES, V62, P7149; Low WK, 2005, MOL CELL, V20, P709, DOI 10.1016/j.molcel.2005.10.008; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Ly C, 2003, CANCER RES, V63, P5716; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Meier-Kriesche HU, 2000, CLIN THER, V22, pB93, DOI 10.1016/S0149-2918(00)89026-8; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Morley SJ, 1997, RNA, V3, P1085; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Notari M, 2006, BLOOD, V107, P2507, DOI 10.1182/blood-2005-09-3732; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ottmann OG, 2002, BLOOD, V100, P1965, DOI 10.1182/blood-2001-12-0181; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Parmar S, 2005, BLOOD, V106, P2436, DOI 10.1182/blood-2004-10-4003; Perrotti D, 2005, CELL DEATH DIFFER, V12, P534, DOI 10.1038/sj.cdd.4401606; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 2002, BLOOD, V99, P3530, DOI 10.1182/blood.V99.10.3530; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Trotta R, 2003, CANCER CELL, V3, P145, DOI 10.1016/S1535-6108(03)00020-5; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016	61	42	46	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1188	1200		10.1038/sj.onc.1209901	http://dx.doi.org/10.1038/sj.onc.1209901			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16936779	Green Accepted			2022-12-28	WOS:000244406400009
J	Marzec, M; Kasprzycka, M; Liu, X; Raghunath, PN; Wlodarski, P; Wasik, MA				Marzec, M.; Kasprzycka, M.; Liu, X.; Raghunath, P. N.; Wlodarski, P.; Wasik, M. A.			Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf	ONCOGENE			English	Article						NPM/ALK tyrosine kinase; MEK/ERK pathway; T-cell lymphoma	NON-HODGKINS-LYMPHOMA; ANAPLASTIC LYMPHOMA; CONSTITUTIVE ACTIVATION; REGULATED KINASE; CELL LYMPHOMA; DEPENDENT PATHWAY; INDUCED APOPTOSIS; MULTIPLE-MYELOMA; PROTEIN-KINASES; ALK	The mechanisms of cell transformation mediated by the highly oncogenic, chimeric NPM/ALK tyrosine kinase remain only partially understood. Here we report that cell lines and native tissues derived from the NPM/ALK-expressing T-cell lymphoma (ALK+ TCL) display phosphorylation of the extracellular signal-regulated protein kinase (ERK) 1/2 complex. Transfection of BaF3 cells with NPM/ALK induces phosphorylation of EKR1/2 and of its direct activator mitogen-induced extracellular kinase (MEK) 1/2. Depletion of NPM/ALK by small interfering RNA (siRNA) or its inhibition by WHI-154 abrogates the MEK1/2 and ERK1/2 phosphorylation. The NPM/ALK-induced MEK/ERK activation is independent of c-Raf as evidenced by the lack of MEK1/2 and ERK1/2 phosphorylation upon c-Raf inactivation by two different inhibitors, RI and ZM336372, and by its siRNA-mediated depletion. In contrast, ERK1/2 activation is strictly MEK1/2 dependent as shown by suppression of the ERK1/2 phosphorylation by the MEK1/2 inhibitor U0126. The U0126-mediated inhibition of ERK1/2 activation impaired proliferation and viability of the ALK+ TCL cells and expression of antiapoptotic factor Bcl-xL and cell cycle-promoting CDK4 and phospho-RB. Finally, siRNA-mediated depletion of both ERK1 and ERK2 inhibited cell proliferation, whereas depletion of ERK 1 (but not ERK2) markedly increased cell apoptosis. These findings identify MEK/ERK as a new signaling pathway activated by NPM/ALK and indicate that the pathway represents a novel therapeutic target in the ALK-induced malignancies.	Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania	Wasik, MA (corresponding author), Univ Penn, Med Ctr, Dept Pathol & Lab Med, 3400 Spruce St,7-106 Founders Pavil, Philadelphia, PA 19104 USA.	wasik@mail.med.upenn.edu	Marzec, Michal/O-6387-2016	Marzec, Michal/0000-0001-9698-6019; Wlodarski, Pawel/0000-0002-0683-1791	NCI NIH HHS [R01-CA89194, R01-CA96856] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA096856, R01CA089194] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Chiarle R, 2005, NAT MED, V11, P623, DOI 10.1038/nm1249; Chiarle R, 2003, BLOOD, V101, P1919, DOI 10.1182/blood-2002-05-1343; Crockett DK, 2004, ONCOGENE, V23, P2617, DOI 10.1038/sj.onc.1207398; Epling-Burnett PK, 2004, ONCOGENE, V23, P9220, DOI 10.1038/sj.onc.1208122; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Hoyle PE, 2000, LEUKEMIA, V14, P642, DOI 10.1038/sj.leu.2401720; Kim SC, 1999, BLOOD, V93, P3893, DOI 10.1182/blood.V93.11.3893.407k14_3893_3899; Kuefer MU, 1997, BLOOD, V90, P2901, DOI 10.1182/blood.V90.8.2901; Marzec M, 2005, LAB INVEST, V85, P1544, DOI 10.1038/labinvest.3700348; Matsumoto S, 2005, J BIOL CHEM, V280, P25687, DOI 10.1074/jbc.M412784200; Milella M, 2001, J CLIN INVEST, V108, P851, DOI 10.1172/JCI200112807; Morgan MA, 2001, BLOOD, V97, P1823, DOI 10.1182/blood.V97.6.1823; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Pratt G, 2002, J CLIN PATHOL-MOL PA, V55, P273, DOI 10.1136/mp.55.5.273; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; SHIOTA M, 1994, ONCOGENE, V9, P1567; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Tanaka T, 1996, MOL CELL BIOL, V16, P3967; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Ussar S, 2004, J BIOL CHEM, V279, P43861, DOI 10.1074/jbc.M406240200; Wan WH, 2006, BLOOD, V107, P1617, DOI 10.1182/blood-2005-08-3254; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Wasik Mariusz A, 2002, Am J Clin Pathol, V118 Suppl, pS81; Wlodarski P, 2005, CANCER RES, V65, P7800, DOI 10.1158/0008-5472.CAN-04-4180; Wu WS, 2006, CANCER LETT, V239, P27, DOI 10.1016/j.canlet.2005.07.034; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	34	68	72	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					813	821		10.1038/sj.onc.1209843	http://dx.doi.org/10.1038/sj.onc.1209843			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909118				2022-12-28	WOS:000244063800003
J	Eguchi, T; Takaki, T; Itadani, H; Kotani, H				Eguchi, T.; Takaki, T.; Itadani, H.; Kotani, H.			RB silencing compromises the DNA damage-induced G2/M checkpoint and causes deregulated expression of the ECT2 oncogene	ONCOGENE			English	Article						ECT2; RB; cytokinesis; DNA damage	CELL-CYCLE PROGRESSION; EXCHANGE FACTOR ECT2; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR; E2F; RHO; CYTOKINESIS; FAMILY; GENE; REPLICATION	As alterations in retinoblastoma (RB)/E2F pathway are commonly found in human cancers, the molecular mechanism underlying cell cycle deregulation caused by the mutations in the RB/E2F pathway needs to be investigated extensively. Compared with good understanding of RB/E2F functions in G1-S cell cycle progression, it is not fully understood how an abrogated RB pathway affects the G2-M phase of the cell cycle. Here, we report that disruption of RB accelerated G2-M progression in the presence of DNA damage by elevating the expression of a set of mitotic regulatory genes. We generated RB(+)- and (-)-matched cells using short hairpin RNA. In the RB(-) cells, the G2/M checkpoint mediated by a DNA-damaging agent was over-ridden. With microarray analysis, we found that the expression of key G2-M regulatory genes was upregulated in RB(-) cells. In particular, we demonstrated that the proto-oncogene ECT2 was directly regulated by E2Fs. Furthermore, suppression of ECT2 expression by small interfering RNA in RB(-) cells resulted in cytokinesis arrest, suggesting that RB(-) cells lack the regulation of E2F-mediated cytokinesis. These results indicate that aberrant ECT2 expression, observed in various human tumors, could be the direct result of RB/E2F pathway deficiency, thereby contributing to cell division in cancers.	Merck Res Lab, Banyu Tsukuba Res Inst, Funct Genom, Tsukuba, Ibaraki 3002611, Japan	Merck & Company	Kotani, H (corresponding author), Merck Res Lab, Banyu Tsukuba Res Inst, Funct Genom, Tsukuba, Ibaraki 3002611, Japan.	hidehito_kotani@merck.com						Black EP, 2003, CANCER RES, V63, P3716; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1; Clemens F, 2005, TOXICOL APPL PHARM, V206, P138, DOI 10.1016/j.taap.2005.02.009; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jiang YY, 2004, J BIOL CHEM, V279, P40511, DOI 10.1074/jbc.M404496200; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Mayhew CN, 2005, CANCER RES, V65, P4568, DOI 10.1158/0008-5472.CAN-04-4221; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Namba R, 2004, MOL CANCER RES, V2, P453; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Saito S, 2004, J BIOL CHEM, V279, P7169, DOI 10.1074/jbc.M306725200; Saito S, 2003, J CELL BIOCHEM, V90, P819, DOI 10.1002/jcb.10688; Sakata H, 2000, HEPATOLOGY, V32, P193, DOI 10.1053/jhep.2000.8271; SCHULZE A, 1994, ONCOGENE, V9, P3475; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Wang JYJ, 2001, ACTA ONCOL, V40, P689; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Westwick JK, 1998, J BIOL CHEM, V273, P16739, DOI 10.1074/jbc.273.27.16739; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603; Yen CC, 2005, WORLD J GASTROENTERO, V11, P1267, DOI 10.3748/wjg.v11.i9.1267; Young AP, 2003, ONCOGENE, V22, P7209, DOI 10.1038/sj.onc.1206804	41	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					509	520		10.1038/sj.onc.1209810	http://dx.doi.org/10.1038/sj.onc.1209810			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862181				2022-12-28	WOS:000243731600004
J	La Ferla-Bruhl, K; Westhoff, MA; Karl, S; Kasperczyk, H; Zwacka, RM; Debatin, KM; Fulda, S				La Ferla-Bruehl, K.; Westhoff, M. A.; Karl, S.; Kasperczyk, H.; Zwacka, R. M.; Debatin, K. M.; Fulda, S.			NF-kappa B-independent sensitization of glioblastoma cells for TRAIL-induced apoptosis by proteasome inhibition	ONCOGENE			English	Article						NF-kappa B; TRAIL; cytotoxic drugs; apoptosis; proteasome inhibition	CANCER-CELLS; GENE-EXPRESSION; BETULINIC ACID; LIGAND TRAIL; ACTIVATION; GROWTH; DEATH; RESISTANCE; THERAPY; POTENTIATION	The transcription factor nuclear factor-kappaB (NF-kappa B) is a key regulator of stress-induced transcriptional activation and has been implicated in mediating primary or acquired apoptosis resistance in various cancers. In the present study, we therefore investigated the role of NF-kappa B in regulating apoptosis in malignant glioma, a prototypic tumor refractory to current treatment approaches. Here, we report that constitutive NF-KB DNA-binding activity was tow or moderate in eight different glioblastoma cell fines compared to Hodgkin's lymphoma cells, known to harbor aberrant constitutive NF-kappa B activity. Specific inhibition of NF-kappa B by overexpression of inhibitor of kappa B (I kappa B)a superrepressor did not enhance spontaneous apoptosis of glioblastoma cells. Also, overexpression of I kappa B alpha superrepressor had no significant impact on apoptosis induced by two prototypic classes of apoptotic stimuli, that is, chemotherapeutic drugs or death-inducing ligands such as TNF-related apoptosis inducing ligand (TRAIL), which are known to trigger NF-kappa B activation as part of a cellular stress response. Similarly, inhibition of NF-kappa B by the proteasome inhibitor MG132 did not increase doxorubicin (Doxo)-induced apoptosis of glioblastoma cells, although it prevented DNA binding of NF-kappa B complexes in response to Doxo. Interestingly, proteasome inhibition significantly sensitized glioblastoma cells for TRAIL-induced apoptosis. These findings indicate that the characteristic antiapoptotic function of NF-KB reported for many cancers is not a primary feature of glioblastoma and thus, specific NF-KB inhibition may not be effective for chemosensitization of glioblastoma. Instead, proteasome inhibitors, which enhanced TRAIL-induced apoptosis in an NF-kappa B-independent manner, may open new perspectives to increase the efficacy of TRAIL-based regimens	Univ Childrens Hosp, D-89075 Ulm, Germany; Univ Ulm, Div Gene Therapy, Ulm, Germany	Ulm University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ulm University	Fulda, S (corresponding author), Univ Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Westhoff, Mike-Andrew/ABA-9272-2021; Debatin, Klaus-Michael/J-9704-2014	Westhoff, Mike-Andrew/0000-0003-3256-7100; Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417; Zwacka, Ralf/0000-0003-2821-0387				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baumann B, 2002, J BIOL CHEM, V277, P44791, DOI 10.1074/jbc.M208003200; Bentires-Alj M, 1999, CANCER RES, V59, P811; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Darnell JE, 2002, NAT REV CANCER, V2, P740, DOI 10.1038/nrc906; Denk A, 2001, J BIOL CHEM, V276, P28451, DOI 10.1074/jbc.M102698200; Fulda S, 1997, CANCER RES, V57, P4956; Gurney JG, 2001, CURR OPIN ONCOL, V13, P160, DOI 10.1097/00001622-200105000-00005; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Hermisson M, 2003, CELL DEATH DIFFER, V10, P1078, DOI 10.1038/sj.cdd.4401269; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Huang S, 2000, CLIN CANCER RES, V6, P2573; Jeremias I, 1998, EUR CYTOKINE NETW, V9, P687; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279; Kasperczyk H, 2005, ONCOGENE, V24, P6945, DOI 10.1038/sj.onc.1208842; Kasuga C, 2004, CANCER SCI, V95, P840, DOI 10.1111/j.1349-7006.2004.tb02191.x; Kim S, 2004, CELL MOL LIFE SCI, V61, P1075, DOI 10.1007/s00018-004-3477-5; Lashinger LM, 2005, CANCER RES, V65, P4902, DOI 10.1158/0008-5472.CAN-04-3701; Leverkus M, 2003, MOL CELL BIOL, V23, P777, DOI 10.1128/MCB.23.3.777-790.2003; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; Nagai S, 2002, J NEUROSURG, V96, P909, DOI 10.3171/jns.2002.96.5.0909; Nencioni A, 2005, CLIN CANCER RES, V11, P4259, DOI 10.1158/1078-0432.CCR-04-2496; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nikrad M, 2005, MOL CANCER THER, V4, P443; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Sayers TJ, 2003, BLOOD, V102, P303, DOI 10.1182/blood-2002-09-2975; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang WX, 1999, CLIN CANCER RES, V5, P119; Weaver KD, 2003, J NEURO-ONCOL, V61, P187, DOI 10.1023/A:1022554824129; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zwacka RM, 2000, J GENE MED, V2, P334, DOI 10.1002/1521-2254(200009/10)2:5<334::AID-JGM129>3.0.CO;2-Q	39	31	31	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 25	2007	26	4					571	582		10.1038/sj.onc.1209841	http://dx.doi.org/10.1038/sj.onc.1209841			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16909119				2022-12-28	WOS:000243731600009
J	Baert, JL; Beaudoin, C; Monte, D; Degerny, C; Mauen, S; de Launoit, Y				Baert, J-L; Beaudoin, C.; Monte, D.; Degerny, C.; Mauen, S.; de Launoit, Y.			The 26S proteasome system degrades the ERM transcription factor and regulates its transcription-enhancing activity	ONCOGENE			English	Article						ETS; ERM; transcription factor; 26S proteasome; degradation; ubiquitin; regulation of transcription	UBIQUITIN-MEDIATED PROTEOLYSIS; FAMILY MEMBER ERM; ACTIVATION DOMAIN; TARGET GENES; ETS-DOMAIN; PEA3 GROUP; ORNITHINE-DECARBOXYLASE; EXPRESSION PATTERNS; DNA-BINDING; DEGRADATION	ERM is a member of the ETS transcription factor family. High levels of the corresponding mRNA are detected in a variety of human breast cancer cell lines, as well as in aggressive human breast tumors. As ERM protein is almost undetectable in these cells, high degradation of this transcription factor has been postulated. Here we have investigated whether ERM degradation might depend on the proteasome pathway. We show that endogenous and ectopically expressed ERM protein is short-lived protein and undergoes proteasome- dependent degradation. Deletion mutagenesis studies indicate that the 61 C-terminal amino acids of ERM are critical for its proteolysis and serve as a degradation signal. Although ERM conjugates with ubiquitin, this post-translational modi. cation does not depend on the C-terminaldomain. We have used an Ets-responsive ICAM-1 reporter plasmid to show that the ubiquitin - proteasome pathway can affect transcriptional function of ERM. Thus, ERM is subject to degradation via the 26S proteasome pathway, and this pathway probably plays an important	Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, F-59021 Lille, France; Univ Libre Bruxelles, Fac Med, Mol Virol Lab, Brussels, Belgium	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Universite Libre de Bruxelles	de Launoit, Y (corresponding author), Univ Lille 1, Inst Pasteur Lille, CNRS, Inst Biol Lille,UMR 8161,Univ Lille 2,IFR 142, 1 Rue Prof Calmette, F-59021 Lille, France.	yvan.delaunoit@ibl.fr		monte, didier/0000-0002-0613-6203				Alvarez-Castelao B, 2005, FEBS LETT, V579, P4797, DOI 10.1016/j.febslet.2005.07.060; Baert JL, 2002, J BIOL CHEM, V277, P1002, DOI 10.1074/jbc.M107139200; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Blanquart C, 2002, J BIOL CHEM, V277, P37254, DOI 10.1074/jbc.M110598200; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Chotteau-Lelievre A, 2001, MECH DEVELOP, V108, P191, DOI 10.1016/S0925-4773(01)00480-4; Chotteau-Lelievre A, 2003, DEV BIOL, V259, P241, DOI 10.1016/S0012-1606(03)00182-9; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Conaway RC, 2002, SCIENCE, V296, P1254, DOI 10.1126/science.1067466; Dalton WS, 2004, SEMIN ONCOL, V31, P3, DOI 10.1053/j.seminoncol.2004.10.012; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Deroo BJ, 2002, MOL CELL BIOL, V22, P4113, DOI 10.1128/MCB.22.12.4113-4123.2002; Galang CK, 2004, J BIOL CHEM, V279, P11281, DOI 10.1074/jbc.M311887200; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Janknecht R, 1996, ONCOGENE, V13, P1745; Kurosu T, 2004, CURR BIOL, V14, P1112, DOI 10.1016/j.cub.2004.06.020; Laget MP, 1996, ONCOGENE, V12, P1325; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; LELIEVRE AC, 2004, CLIN CANCER RES, V19, P7297; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Maurer P, 2003, ONCOGENE, V22, P3319, DOI 10.1038/sj.onc.1206572; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Murakami Y, 1999, MOL CELL BIOL, V19, P7216; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Peloponese JM, 2004, J VIROL, V78, P11686, DOI 10.1128/JVI.78.21.11686-11695.2004; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Pollenz RS, 2002, CHEM-BIOL INTERACT, V141, P41, DOI 10.1016/S0009-2797(02)00065-0; Prakash S, 2004, NAT STRUCT MOL BIOL, V11, P830, DOI 10.1038/nsmb814; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Tworkowski KA, 2002, ONCOGENE, V21, P8515, DOI 10.1038/sj.onc.1205976; Zhang MS, 2003, EMBO J, V22, P1488, DOI 10.1093/emboj/cdg158	42	16	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					415	424		10.1038/sj.onc.1209801	http://dx.doi.org/10.1038/sj.onc.1209801			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832340				2022-12-28	WOS:000243544000010
J	Huang, H; Wang, H; Sinz, M; Zoeckler, M; Staudinger, J; Redinbo, MR; Teotico, DG; Locker, J; Kalpana, GV; Mani, S				Huang, H.; Wang, H.; Sinz, M.; Zoeckler, M.; Staudinger, J.; Redinbo, M. R.; Teotico, D. G.; Locker, J.; Kalpana, G. V.; Mani, S.			Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole	ONCOGENE			English	Article						drug metabolism; transcriptional regulation; orphan nuclear receptors	PREGNANE-X-RECEPTOR; CYP3A4 GENE-EXPRESSION; XENOBIOTIC RECEPTOR; TRANSCRIPTIONAL REGULATION; COACTIVATOR PGC-1-ALPHA; CLINICAL-RELEVANCE; ACID SENSOR; BINDING; AGENTS; LIGAND	Individual variation in drug metabolism is a major cause of unpredictable side effects during therapy. Drug metabolism is controlled by a class of orphan nuclear receptors (NRs), which regulate expression of genes such as CYP (cytochrome) 3A4 and MDR-1 (multi-drug resistance-1), that are involved in this process. We have found that xenobiotic-mediated induction of CYP3A4 and MDR-1 gene transcription was inhibited by ketoconazole, a commonly used antifungal drug. Ketoconazole mediated its effect by inhibiting the activation of NRs, human pregnenolone X receptor and constitutive androstene receptor, involved in regulation of CYP3A4 and MDR-1. The effect of ketoconazole was specific to the group of NRs that control xenobiotic metabolism. Ketoconazole disrupted the interaction of the xenobiotic receptor PXR with the co-activator steroid receptor co-activator-1. Ketoconazole treatment resulted in delayed metabolism of tribromoethanol anesthetic in mice, which was correlated to the inhibition of PXR activation and downmodulation of cyp3a11 and mdr-1 genes and proteins. These studies demonstrate for the first time that ketoconazole represses the coordinated activation of genes involved in drug metabolism, by blocking activation of a specific subset of NRs. Our results suggest that ketoconazole can be used as a pan-antagonist of NRs involved in xenobiotic metabolism in vivo, which may lead to novel strategies that improve drug effect and tolerance.	Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Bristol Myers Squibb Co, Wallingford, CT 06492 USA; Univ Kansas, Dept Toxicol, Lawrence, KS 66045 USA; Univ N Carolina, Dept Chem, Chapel Hill, NC USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Bristol-Myers Squibb; University of Kansas; University of North Carolina; University of North Carolina Chapel Hill; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Mani, S (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Oncol, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Chanin 302D-1, Bronx, NY 10461 USA.	smani@montefiore.org		Kalpana, Ganjam/0000-0003-4111-0604				Albers M, 2005, MOL CELL PROTEOMICS, V4, P205, DOI 10.1074/mcp.M400169-MCP200; BEETENS JR, 1986, BIOCHEM PHARMACOL, V35, P883, DOI 10.1016/0006-2952(86)90072-9; Berthold DR, 2005, J CLIN ONCOL, V23, P8247, DOI 10.1200/JCO.2005.03.1435; Bhalla S, 2004, J BIOL CHEM, V279, P45139, DOI 10.1074/jbc.M405423200; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Bourdoncle A, 2005, J MOL BIOL, V347, P921, DOI 10.1016/j.jmb.2005.01.048; Ding XS, 2005, J PHARMACOL EXP THER, V312, P849, DOI 10.1124/jpet.104.076331; Dresser GK, 2000, CLIN PHARMACOKINET, V38, P41, DOI 10.2165/00003088-200038010-00003; Dussault I, 2003, P NATL ACAD SCI USA, V100, P833, DOI 10.1073/pnas.0336235100; ELLSWORTH JL, 1994, BBA-LIPID LIPID MET, V1210, P321, DOI 10.1016/0005-2760(94)90236-4; Eloranta JJ, 2005, METHOD ENZYMOL, V400, P511, DOI 10.1016/S0076-6879(05)00028-5; Evans RM, 2005, MOL ENDOCRINOL, V19, P1429, DOI 10.1210/me.2005-0046; Fujino T, 2003, J STEROID BIOCHEM, V87, P247, DOI 10.1016/j.jsbmb.2003.09.008; Gnerre C, 2004, PHARMACOGENETICS, V14, P635, DOI 10.1097/00008571-200410000-00001; Hamaguchi Taizo, 2002, Nihon Ishinkin Gakkai Zasshi, V43, P95, DOI 10.3314/jjmm.43.95; Handschin C, 2005, ARCH BIOCHEM BIOPHYS, V433, P387, DOI 10.1016/j.abb.2004.08.030; Johnson DR, 2006, MOL PHARMACOL, V69, P99, DOI 10.1124/mol.105.013375; Kanda N, 2002, J INVEST DERMATOL, V119, P590, DOI 10.1046/j.1523-1747.2002.01864.x; Kanda N, 2002, J INVEST DERMATOL, V119, P174, DOI 10.1046/j.1523-1747.2002.01804.x; KIM SG, 1992, MOL PHARMACOL, V42, P273; Kliewer SA, 2002, ENDOCR REV, V23, P687, DOI 10.1210/er.2001-0038; Lee HS, 2002, J BIOCHEM, V131, P399, DOI 10.1093/oxfordjournals.jbchem.a003115; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Li TG, 2005, AM J PHYSIOL-GASTR L, V288, pG74, DOI 10.1152/ajpgi.00258.2004; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Mani S, 2005, CLIN CANCER RES, V11, P6359, DOI 10.1158/1078-0432.CCR-05-0252; Matheny CJ, 2004, DRUG METAB DISPOS, V32, P1008; Miquel M, 1999, PHARMACOL BIOCHEM BE, V64, P89, DOI 10.1016/S0091-3057(99)00070-2; Pascussi JM, 2001, EUR J BIOCHEM, V268, P6346, DOI 10.1046/j.0014-2956.2001.02540.x; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; Sohn YC, 2003, MOL ENDOCRINOL, V17, P366, DOI 10.1210/me.2002-0150; Sonoda J, 2003, CURR DRUG METAB, V4, P59, DOI 10.2174/1389200033336739; STALLA GK, 1988, ENDOCRINOLOGY, V122, P618; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; Tabb MM, 2004, ENVIRON HEALTH PERSP, V112, P163, DOI 10.1289/ehp.6560; TAKAGI K, 1989, J BIOL CHEM, V264, P12352; Takeshita A, 2002, J BIOL CHEM, V277, P32453, DOI 10.1074/jbc.M111245200; Tzanakakis GN, 2002, J GASTROINTEST CANC, V32, P23, DOI 10.1385/IJGC:32:1:23; Undevia SD, 2005, NAT REV CANCER, V5, P447, DOI 10.1038/nrc1629; Venkatakrishnan K, 2000, CLIN PHARMACOKINET, V38, P111, DOI 10.2165/00003088-200038020-00002; Wei P., 2002, Pharmacogenomics Journal, V2, P117, DOI 10.1038/sj.tpj.6500087; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Xie W, 2000, GENE DEV, V14, P3014, DOI 10.1101/gad.846800; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Yamamoto A, 2000, J Dermatol, V27, P598; Yong WP, 2005, CLIN CANCER RES, V11, P6699, DOI 10.1158/1078-0432.CCR-05-0703; Zhu ZR, 2004, J BIOMOL SCREEN, V9, P533, DOI 10.1177/1087057104264902	50	168	180	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					258	268		10.1038/sj.onc.1209788	http://dx.doi.org/10.1038/sj.onc.1209788			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819505				2022-12-28	WOS:000243398300009
J	Basseres, DS; Baldwin, AS				Basseres, D. S.; Baldwin, A. S.			Nuclear factor-kappa B and inhibitor of kappa B kinase pathways in oncogenic initiation and progression	ONCOGENE			English	Review						NF-kappa B; IKK; cancer; cancer therapy; inhibitors; signal transduction	PANCREATIC-CANCER CELLS; MULTIPLE-MYELOMA CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC LYMPHOCYTIC-LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; HUMAN-MELANOMA CELLS; HUMAN BREAST-CANCER; PROTEASOME INHIBITION; TRANSCRIPTION FACTOR	Abundant data support a key role for the transcription factor nuclear factor-kappa B (NF-kappa B) signa ling pathway in controlling the initiation and progression of human cancer. NF-kappa B and associated regulatory proteins such as I kappa B kinase (IKK) are activated downstream of many onco-proteins and there is much evidence for the activation of NF-kappa B-dependent target genes in a variety of solid tumors and hematologic malignancies. This review focuses on the mechanisms by which the NF-kappa B pathway is activated in cancer and on the oncogenic functions controlled by activated NF-kappa B. Additionally, the effects of NF-kappa B activation in tumors relative to cancer therapy are also discussed.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu	Bassères, Daniela S/C-6623-2013	Bassères, Daniela S/0000-0001-7745-3567				ADLI M, 2006, IN PRESS J BIOL CHEM; Albanese C, 2003, MOL BIOL CELL, V14, P585, DOI 10.1091/mbc.02-06-0101; Anto RJ, 2002, CARCINOGENESIS, V23, P143, DOI 10.1093/carcin/23.1.143; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Asano T, 2004, ONCOGENE, V23, P8571, DOI 10.1038/sj.onc.1207902; Ashikawa K, 2004, BIOCHEM PHARMACOL, V67, P353, DOI 10.1016/j.bcp.2003.08.039; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Biswas DK, 2000, P NATL ACAD SCI USA, V97, P8542, DOI 10.1073/pnas.97.15.8542; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Braun T, 2006, BLOOD, V107, P1156; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Burstein E, 2003, CURR OPIN CELL BIOL, V15, P732, DOI 10.1016/j.ceb.2003.10.005; Campbell KJ, 2004, MOL CELL, V13, P853, DOI 10.1016/S1097-2765(04)00131-5; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chauhan D, 2005, CANCER CELL, V8, P407, DOI 10.1016/j.ccr.2005.10.013; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; Cilloni D, 2006, LEUKEMIA, V20, P61, DOI 10.1038/sj.leu.2403998; Clevers H, 2004, CELL, V118, P671, DOI 10.1016/j.cell.2004.09.005; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Cusack JC, 2001, CANCER RES, V61, P3535; Dajee M, 2003, NATURE, V421, P639, DOI 10.1038/nature01283; Dhawan P, 2002, CANCER RES, V62, P7335; Dhawan P, 2002, J BIOL CHEM, V277, P7920, DOI 10.1074/jbc.M112210200; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Eddy SF, 2005, CANCER RES, V65, P11375, DOI 10.1158/0008-5472.CAN-05-1602; Farhana L, 2005, CANCER RES, V65, P4909, DOI 10.1158/0008-5472.CAN-04-4124; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Frelin C, 2005, BLOOD, V105, P804, DOI 10.1182/blood-2004-04-1463; Fujioka S, 2003, CLIN CANCER RES, V9, P346; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; Furman RR, 2000, J IMMUNOL, V164, P2200, DOI 10.4049/jimmunol.164.4.2200; Garcea G, 2005, PANCREATOLOGY, V5, P514, DOI 10.1159/000087493; Garcia MG, 2005, LEUKEMIA RES, V29, P1425, DOI 10.1016/j.leukres.2005.05.004; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Gustin JA, 2004, J BIOL CHEM, V279, P1615, DOI 10.1074/jbc.M306976200; Guzman ML, 2005, BLOOD, V105, P4163, DOI 10.1182/blood-2004-10-4135; Hammerman PS, 2004, CANCER RES, V64, P8341, DOI 10.1158/0008-5472.CAN-04-2284; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanson JL, 2004, CANCER RES, V64, P7248, DOI 10.1158/0008-5472.CAN-03-3898; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Hinz M, 2001, BLOOD, V97, P2798, DOI 10.1182/blood.V97.9.2798; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; Ho WC, 2005, CANCER RES, V65, P4273, DOI 10.1158/0008-5472.CAN-04-3494; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang S, 2000, CANCER RES, V60, P5334; Huang S, 2000, CLIN CANCER RES, V6, P2573; Huang SY, 2002, AM J PATHOL, V161, P125, DOI 10.1016/S0002-9440(10)64164-8; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Ikenoue T, 2003, CANCER RES, V63, P8132; Jiang YX, 2001, ONCOGENE, V20, P2254, DOI 10.1038/sj.onc.1204293; Jin FS, 2005, CANCER RES, V65, P6354, DOI 10.1158/0008-5472.CAN-04-4061; Jung YJ, 2003, FASEB J, V17, P2115, DOI 10.1096/fj.03-0329fje; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kashatus D, 2006, GENE DEV, V20, P225, DOI 10.1101/gad.1352206; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Kim HJ, 2006, CELL DEATH DIFFER, V13, P738, DOI 10.1038/sj.cdd.4401877; Kim JH, 2005, CANCER RES, V65, P6312, DOI 10.1158/0008-5472.CAN-04-4193; Kim JH, 2005, NATURE, V434, P921, DOI 10.1038/nature03452; Kirchner D, 2003, EXP HEMATOL, V31, P504, DOI 10.1016/S0301-472X(03)00069-9; Kordes U, 2000, LEUKEMIA, V14, P399, DOI 10.1038/sj.leu.2401705; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kucharczak J, 2003, ONCOGENE, V22, P8961, DOI 10.1038/sj.onc.1207230; Lam LT, 2005, CLIN CANCER RES, V11, P28; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; Liptay S, 2003, INT J CANCER, V105, P735, DOI 10.1002/ijc.11081; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Massoumi R, 2006, CELL, V125, P665, DOI 10.1016/j.cell.2006.03.041; Mathas S, 2003, BLOOD, V102, P1028, DOI 10.1182/blood-2002-04-1154; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mrowietz U, 1999, BRIT J CANCER, V79, P1025, DOI 10.1038/sj.bjc.6690164; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Mukhopadhyay A, 2001, ONCOGENE, V20, P7597, DOI 10.1038/sj.onc.1204997; Munzert G, 2004, LEUKEMIA LYMPHOMA, V45, P1181, DOI 10.1080/10428190310001657326; Nadiminty N, 2006, P NATL ACAD SCI USA, V103, P7264, DOI 10.1073/pnas.0509808103; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nasr R, 2005, ONCOGENE, V24, P419, DOI 10.1038/sj.onc.1208212; Nawata R, 2003, ONCOGENE, V22, P7774, DOI 10.1038/sj.onc.1206901; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Ni H, 2001, BRIT J HAEMATOL, V115, P279, DOI 10.1046/j.1365-2141.2001.03102.x; Niu JG, 2004, J BIOL CHEM, V279, P16452, DOI 10.1074/jbc.M309789200; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Palmby TR, 2004, MOL CANCER RES, V2, P702; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2004, TRENDS CELL BIOL, V14, P64, DOI 10.1016/j.tcb.2003.12.004; Pianetti S, 2001, ONCOGENE, V20, P1287, DOI 10.1038/sj.onc.1204257; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Rajkumar SV, 2003, SEMIN HEMATOL, V40, P17, DOI 10.1053/j.seminhematol.2003.09.007; Ramaswamy S, 2003, LANCET, V361, P1576, DOI 10.1016/S0140-6736(03)13322-3; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Richardson PG, 2004, ANN MED, V36, P304, DOI 10.1080/07853890410030877; Robe PA, 2004, CLIN CANCER RES, V10, P5595, DOI 10.1158/1078-0432.CCR-03-0392; Rocha S, 2005, EMBO J, V24, P1157, DOI 10.1038/sj.emboj.7600608; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Ryan KM, 2000, NATURE, V404, P892, DOI 10.1038/35009130; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schneider G, 2006, INT J CANCER, V118, P2405, DOI 10.1002/ijc.21637; Shishodia S, 2005, BIOCHEM PHARMACOL, V70, P700, DOI 10.1016/j.bcp.2005.04.043; Shishodia S, 2004, J IMMUNOL, V173, P2011, DOI 10.4049/jimmunol.173.3.2011; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Singh RK, 1999, MELANOMA RES, V9, P383, DOI 10.1097/00008390-199908000-00007; Sitcheran R, 2005, EMBO J, V24, P510, DOI 10.1038/sj.emboj.7600555; Small GW, 2004, MOL PHARMACOL, V66, P1478, DOI 10.1124/mol.104.003400; Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028; Stark LA, 2005, MOL CELL BIOL, V25, P5985, DOI 10.1128/MCB.25.14.5985-6004.2005; Subhashini J, 2005, CANCER LETT, V224, P31, DOI 10.1016/j.canlet.2004.11.002; Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008-5472.CAN-04-4125; Takada Y, 2004, ONCOGENE, V23, P9247, DOI 10.1038/sj.onc.1208169; Tanaka A, 2005, BLOOD, V105, P2324, DOI 10.1182/blood-2004-08-3247; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Ueda Y, 2006, PIGM CELL RES, V19, P112, DOI 10.1111/j.1600-0749.2006.00304.x; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Westerheide SD, 2001, MOL CELL BIOL, V21, P8428, DOI 10.1128/MCB.21.24.8428-8436.2001; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yin D, 2005, ONCOGENE, V24, P344, DOI 10.1038/sj.onc.1208225; Zaninoni A, 2003, EXP HEMATOL, V31, P185, DOI 10.1016/S0301-472X(02)01046-9; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou ZC, 2005, J CENT SOUTH UNIV T, V12, P1, DOI 10.1007/s11771-005-0190-y	153	552	574	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6817	6830		10.1038/sj.onc.1209942	http://dx.doi.org/10.1038/sj.onc.1209942			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072330	Green Submitted			2022-12-28	WOS:000241666700010
J	De Virgilio, C; Loewith, R				De Virgilio, C.; Loewith, R.			Cell growth control: little eukaryotes make big contributions	ONCOGENE			English	Review						target of rapamycin (TOR); TOR complexes (TORC1, TORC2); anabolism; catabolism; longevity; cell polarity	DEPENDENT PROTEIN-KINASE; AMINO-ACID PERMEASE; REGULATES GENE-EXPRESSION; CHRONOLOGICAL LIFE-SPAN; TOR SIGNALING NETWORK; P70 S6 KINASE; SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; TRANSLATION INITIATION; ACTIN CYTOSKELETON	The story of rapamycin is a pharmaceutical fairytale. Discovered as an antifungal activity in a soil sample collected on Easter Island, this macrocyclic lactone and its derivatives are now billion dollar drugs, used in, and being evaluated for, a number of clinical applications. Taking advantage of its antifungal property, the molecular Target Of Rapamycin, TOR, was.rst described in the budding yeast Saccharomyces cerevisiae. TORs encode large, Ser/Thr protein kinases that reside in two distinct, structurally and functionally conserved, multi-protein complexes. In yeast, these complexes coordinate many different aspects of cell growth. TOR complex 1, TORC1, promotes protein synthesis and other anabolic processes, while inhibiting macroautophagy and other catabolic and stress response processes. TORC2 primarily regulates cell polarity, although additional readouts of this complex are beginning to be characterized. TORC1 appears to be activated by nutrient cues and inhibited by stresses and rapamycin; however, detailed mechanisms are not known. In contrast, TORC2 is insensitive to rapamycin and physiological regulators of this complex have yet to be defined. Given the unsurpassed resources available to yeast researchers, this simple eukaryote continues to contribute to our understanding of eukaryotic cell growth in general and TOR function in particular.	Univ Geneva, CMU, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland; Univ Geneva, Dept Biol Mol, CH-1211 Geneva, Switzerland	University of Geneva; University of Geneva	Loewith, R (corresponding author), Univ Geneva, CMU, Dept Microbiol & Med Mol, CH-1211 Geneva, Switzerland.	Claudio.DeVirgilio@medecine.unige.ch; Robbie.Loewith@molbio.unige.ch	Loewith, Robbie J/S-6289-2016; De Virgilio, Claudio/B-4707-2012	Loewith, Robbie J/0000-0002-2482-603X; De Virgilio, Claudio/0000-0001-8826-4323				Abeliovich H, 2003, MOL BIOL CELL, V14, P477, DOI 10.1091/mbc.E02-07-0413; Ai WD, 2002, MOL CELL, V10, P1295, DOI 10.1016/S1097-2765(02)00695-0; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Albig AR, 2001, MOL BIOL CELL, V12, P3428, DOI 10.1091/mbc.12.11.3428; ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Araki T, 2005, GENES GENET SYST, V80, P325, DOI 10.1266/ggs.80.325; Audhya A, 2004, EMBO J, V23, P3747, DOI 10.1038/sj.emboj.7600384; Ayscough KR, 2005, PROTOPLASMA, V226, P81, DOI 10.1007/s00709-005-0107-5; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barbe E., 1996, MEDITERR POLIT, V1, P25; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Beck T, 2001, Results Probl Cell Differ, V32, P231; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Beeler T, 1998, J BIOL CHEM, V273, P30688, DOI 10.1074/jbc.273.46.30688; Berset C, 1998, P NATL ACAD SCI USA, V95, P4264, DOI 10.1073/pnas.95.8.4264; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Bosotti R, 2000, TRENDS BIOCHEM SCI, V25, P225, DOI 10.1016/S0968-0004(00)01563-2; Brengues M, 2005, SCIENCE, V310, P486, DOI 10.1126/science.1115791; Budovskaya YV, 2004, J BIOL CHEM, V279, P20663, DOI 10.1074/jbc.M400272200; Bultynck G, 2006, MOL CELL BIOL, V26, P4729, DOI 10.1128/MCB.01973-05; Butcher RA, 2006, NAT CHEM BIOL, V2, P103, DOI 10.1038/nchembio762; Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cameroni E, 2004, CELL CYCLE, V3, P462; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CARDENAS ME, 1995, EMBO J, V14, P5892, DOI 10.1002/j.1460-2075.1995.tb00277.x; Carvalho J, 2003, J BIOL CHEM, V278, P16878, DOI 10.1074/jbc.M300429200; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chen EJ, 2003, J CELL BIOL, V161, P333, DOI 10.1083/jcb.200210141; Chen EJ, 2002, P NATL ACAD SCI USA, V99, P14837, DOI 10.1073/pnas.232591899; Chen JCY, 2006, CURR GENET, V49, P281, DOI 10.1007/s00294-005-0055-9; Cherkasova VA, 2003, GENE DEV, V17, P859, DOI 10.1101/gad.1069003; Claypool JA, 2004, MOL BIOL CELL, V15, P946, DOI 10.1091/mbc.E03-08-0594; Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032; Coller J, 2005, CELL, V122, P875, DOI 10.1016/j.cell.2005.07.012; Colomina N, 2003, MOL CELL BIOL, V23, P7415, DOI 10.1128/MCB.23.20.7415-7424.2003; Cosentino GP, 2000, MOL CELL BIOL, V20, P4604, DOI 10.1128/MCB.20.13.4604-4613.2000; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2001, J BIOL CHEM, V276, P34441, DOI 10.1074/jbc.M103601200; Damelin M, 2002, MOL CELL, V9, P563, DOI 10.1016/S1097-2765(02)00475-6; Dames SA, 2005, J BIOL CHEM, V280, P20558, DOI 10.1074/jbc.M501116200; Danaie P, 1999, BIOCHEM J, V340, P135, DOI 10.1042/0264-6021:3400135; De Craene JO, 2001, J BIOL CHEM, V276, P43939, DOI 10.1074/jbc.M102944200; De Virgilio C, 2006, INT J BIOCHEM CELL B, V38, P1476, DOI 10.1016/j.biocel.2006.02.013; De Wever V, 2005, EMBO J, V24, P4115, DOI 10.1038/sj.emboj.7600871; DEAN RT, 1977, BIOCHEM J, V168, P603, DOI 10.1042/bj1680603; deHart AKA, 2003, MOL BIOL CELL, V14, P4676, DOI 10.1091/mbc.E03-05-0323; deHart AKA, 2002, J CELL BIOL, V156, P241, DOI 10.1083/jcb.200107135; Dennis PB, 2001, SCIENCE, V294, P1102, DOI 10.1126/science.1063518; Desai BN, 2002, P NATL ACAD SCI USA, V99, P4319, DOI 10.1073/pnas.261702698; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Dilova I, 2004, J BIOL CHEM, V279, P46527, DOI 10.1074/jbc.M409012200; Drenan RM, 2004, J BIOL CHEM, V279, P772, DOI 10.1074/jbc.M305912200; Dubouloz F, 2005, MOL CELL, V19, P15, DOI 10.1016/j.molcel.2005.05.020; Duvel K, 2003, MOL CELL, V11, P1467, DOI 10.1016/S1097-2765(03)00228-4; DUVEL K, 2004, TOR TARGET RAPAMYCIN, P20; Edinger AL, 2005, BIOCHEM SOC T, V33, P225, DOI 10.1042/BST0330225; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Fadri M, 2005, MOL BIOL CELL, V16, P1883, DOI 10.1091/mbc.e04-07-0564; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Gatherar IM, 2004, FUNGAL GENET BIOL, V41, P463, DOI 10.1016/j.fgb.2003.12.004; Gelperin D, 2002, GENETICS, V161, P1453; Giannattasio S, 2005, J BIOL CHEM, V280, P42528, DOI 10.1074/jbc.M509187200; Ginalski K, 2004, TRENDS BIOCHEM SCI, V29, P522, DOI 10.1016/j.tibs.2004.08.006; Gorner W, 2002, EMBO J, V21, P135, DOI 10.1093/emboj/21.1.135; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; Griffioen G, 2000, J BIOL CHEM, V275, P1449, DOI 10.1074/jbc.275.2.1449; Gstaiger M, 2003, SCIENCE, V302, P1208, DOI 10.1126/science.1088401; Hall DB, 2006, MOL CELL BIOL, V26, P3672, DOI 10.1128/MCB.26.9.3672-3679.2006; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Harris TE, 2006, EMBO J, V25, P1659, DOI 10.1038/sj.emboj.7601047; Harris Thurl E, 2003, Sci STKE, V2003, pre15; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 2001, J CELL BIOL, V153, P649, DOI 10.1083/jcb.153.4.649; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Hilti N, 1999, CURR GENET, V35, P585, DOI 10.1007/s002940050456; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Ho HL, 2005, CURR GENET, V47, P273, DOI 10.1007/s00294-005-0570-8; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; Hresko RC, 2005, J BIOL CHEM, V280, P40406, DOI 10.1074/jbc.M508361200; Huang J, 2004, P NATL ACAD SCI USA, V101, P16594, DOI 10.1073/pnas.0407117101; Humphrey EL, 2004, CHEM BIOL, V11, P295, DOI 10.1016/j.chembiol.2004.03.001; Iiboshi Y, 1999, BIOCHEM BIOPH RES CO, V260, P534, DOI 10.1006/bbrc.1999.0920; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kamada Y, 2005, MOL CELL BIOL, V25, P7239, DOI 10.1128/MCB.25.16.7239-7248.2005; Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kennedy BK, 2005, CELL, V123, P548, DOI 10.1016/j.cell.2005.11.002; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kim DH, 2003, MOL CELL, V11, P895, DOI 10.1016/S1097-2765(03)00114-X; Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200; KOLTIN Y, 1991, MOL CELL BIOL, V11, P1718, DOI 10.1128/MCB.11.3.1718; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; Krogan NJ, 2004, MOL CELL, V13, P225, DOI 10.1016/S1097-2765(04)00003-6; Kubota H, 2003, J BIOL CHEM, V278, P20457, DOI 10.1074/jbc.C300133200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; Kunz JB, 2004, J BIOL CHEM, V279, P9987, DOI 10.1074/jbc.M307905200; Kuruvilla FG, 2001, P NATL ACAD SCI USA, V98, P7283, DOI 10.1073/pnas.121186898; Leao AN, 2003, FEMS YEAST RES, V4, P131, DOI 10.1016/S1567-1356(03)00070-9; Lee S, 2005, MOL BIOL CELL, V16, P4572, DOI 10.1091/mbc.E05-04-0342; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Levin DE, 2005, MICROBIOL MOL BIOL R, V69, P262, DOI 10.1128/MMBR.69.2.262-291.2005; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 2003, MOL CELL, V12, P401, DOI 10.1016/S1097-2765(03)00285-5; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Loewith Robbie, 2004, VVolume 42, P139; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660; Mach KE, 2000, GENETICS, V155, P611; MacLean M, 2001, YEAST, V18, P499, DOI 10.1002/yea.701; Magasanik B, 2002, GENE, V290, P1, DOI 10.1016/S0378-1119(02)00558-9; MAGER WH, 1995, MICROBIOL REV, V59, P506, DOI 10.1128/MMBR.59.3.506-531.1995; Marion RM, 2004, P NATL ACAD SCI USA, V101, P14315, DOI 10.1073/pnas.0405353101; Martin DE, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-148; Martin DE, 2004, CELL, V119, P969, DOI 10.1016/j.cell.2004.11.047; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Matsuo T, 2003, EMBO J, V22, P3073, DOI 10.1093/emboj/cdg298; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mayordomo I, 2002, J BIOL CHEM, V277, P35650, DOI 10.1074/jbc.M204198200; McMahon LP, 2005, MOL ENDOCRINOL, V19, P175, DOI 10.1210/me.2004-0305; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Muller O, 2000, J CELL BIOL, V151, P519, DOI 10.1083/jcb.151.3.519; Nakaji T, 1999, CANCER LETT, V147, P139, DOI 10.1016/S0304-3835(99)00285-2; Nakase Y, 2006, GENETICS, V173, P569, DOI 10.1534/genetics.106.056895; Ng HH, 2002, GENE DEV, V16, P806, DOI 10.1101/gad.978902; Oakes ML, 2006, MOL CELL BIOL, V26, P3889, DOI 10.1128/MCB.26.10.3889-3901.2006; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Pedruzzi I, 2003, MOL CELL, V12, P1607, DOI 10.1016/S1097-2765(03)00485-4; Peng T, 2002, MOL CELL BIOL, V22, P5575, DOI 10.1128/MCB.22.15.5575-5584.2002; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Pichler H, 2004, BBA-BIOMEMBRANES, V1666, P51, DOI 10.1016/j.bbamem.2004.05.011; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697; Pruyne D, 2004, ANNU REV CELL DEV BI, V20, P559, DOI 10.1146/annurev.cellbio.20.010403.103108; Raught B, 2000, EMBO J, V19, P434, DOI 10.1093/emboj/19.3.434; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Reinders A, 1998, GENE DEV, V12, P2943, DOI 10.1101/gad.12.18.2943; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Rempola B, 2000, MOL GEN GENET, V262, P1081, DOI 10.1007/PL00008651; Robaglia C, 2004, BIOCHEM SOC T, V32, P581, DOI 10.1042/BST0320581; Roberg KJ, 1997, GENETICS, V147, P1569; Roberts P, 2003, MOL BIOL CELL, V14, P129, DOI 10.1091/mbc.E02-08-0483; Roelants FM, 2004, MICROBIOL-SGM, V150, P3289, DOI 10.1099/mic.0.27286-0; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Rohde JR, 2003, MOL CELL BIOL, V23, P629, DOI 10.1128/MCB.23.2.629-635.2003; Roosen J, 2005, MOL MICROBIOL, V55, P862, DOI 10.1111/j.1365-2958.2004.04429.x; Rubio-Texeira M, 2006, MOL BIOL CELL, V17, P3031, DOI 10.1091/mbc.E05-07-0669; Rudra D, 2005, EMBO J, V24, P533, DOI 10.1038/sj.emboj.7600553; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; Santhanam A, 2004, EUKARYOT CELL, V3, P1261, DOI 10.1128/EC.3.5.1261-1271.2004; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, J BIOL CHEM, V280, P39505, DOI 10.1074/jbc.M506096200; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sattler T, 2000, J CELL BIOL, V151, P529, DOI 10.1083/jcb.151.3.529; Schawalder SB, 2004, NATURE, V432, P1058, DOI 10.1038/nature03200; Schmelzle T, 2004, MOL CELL BIOL, V24, P338, DOI 10.1128/MCB.24.1.338-351.2004; Schmelzle T, 2002, MOL CELL BIOL, V22, P1329, DOI 10.1128/MCB.22.5.1329-1339.2002; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Schmidt A, 1998, EMBO J, V17, P6924, DOI 10.1093/emboj/17.23.6924; Schroder W, 2005, CELL SIGNAL, V17, P761, DOI 10.1016/j.cellsig.2004.10.015; Schroder W, 2004, GENE, V339, P17, DOI 10.1016/j.gene.2004.07.001; Scott C, 2000, BIOPHARM-APPL T BIO, V13, P8; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Sekiguchi T, 2001, J BIOL CHEM, V276, P7246, DOI 10.1074/jbc.M004389200; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Shitamukai A, 2004, J BIOL CHEM, V279, P3651, DOI 10.1074/jbc.M306098200; STAN R, 1994, J BIOL CHEM, V269, P32027; Swinnen E, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-3; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Tabuchi M, 2006, MOL CELL BIOL, V26, P5861, DOI 10.1128/MCB.02403-05; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; TODA T, 1988, GENE DEV, V2, P517, DOI 10.1101/gad.2.5.517; Torres J, 2002, J BIOL CHEM, V277, P43495, DOI 10.1074/jbc.M205408200; Uesono Y, 1997, J BIOL CHEM, V272, P16103, DOI 10.1074/jbc.272.26.16103; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Urano J, 2005, MOL MICROBIOL, V58, P1074, DOI 10.1111/j.1365-2958.2005.04877.x; Van Belle D, 2001, CURR OPIN CELL BIOL, V13, P389, DOI 10.1016/S0955-0674(00)00226-X; Van Hoof C, 2005, BIOCHEM J, V386, P93, DOI 10.1042/BJ20040887; van Slegtenhorst M, 2004, J BIOL CHEM, V279, P12706, DOI 10.1074/jbc.M313874200; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Wade JT, 2004, NATURE, V432, P1054, DOI 10.1038/nature03175; Wang LH, 2003, P NATL ACAD SCI USA, V100, P11249, DOI 10.1073/pnas.1534805100; Wang XM, 1998, BIOCHEM J, V334, P261, DOI 10.1042/bj3340261; Wang Z, 2001, MOL CELL BIOL, V21, P5742, DOI 10.1128/MCB.21.17.5742-5752.2001; Wanke V, 2005, EMBO J, V24, P4271, DOI 10.1038/sj.emboj.7600889; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Wedaman KP, 2003, MOL BIOL CELL, V14, P1204, DOI 10.1091/mbc.E02-09-0609; Weindruch R., 1988, RETARDATION AGING DI; Weisman R, 2003, CURR TOP MICROBIOL, V279, P85; Wilkinson MG, 1999, EMBO J, V18, P4210, DOI 10.1093/emboj/18.15.4210; WOYCHIK NA, 1990, GENE DEV, V4, P313, DOI 10.1101/gad.4.3.313; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Wullschleger S, 2005, J BIOL CHEM, V280, P30697, DOI 10.1074/jbc.M505553200; Xie MW, 2005, P NATL ACAD SCI USA, V102, P7215, DOI 10.1073/pnas.0500297102; Xu G, 1998, J BIOL CHEM, V273, P28178, DOI 10.1074/jbc.273.43.28178; Yan GH, 2006, EMBO J, V25, P3546, DOI 10.1038/sj.emboj.7601239; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; Zhang Y, 2006, GENETICS, V172, P355, DOI 10.1534/genetics.105.051979; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng Y, 2005, MOL BIOL CELL, V16, P2119, DOI 10.1091/mbc.e04-09-0797; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	239	181	184	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	48					6392	6415		10.1038/sj.onc.1209884	http://dx.doi.org/10.1038/sj.onc.1209884			24	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096MH	17041625	Green Published			2022-12-28	WOS:000241380700006
J	Skapek, SX; Pan, YR; Lee, EYHP				Skapek, S. X.; Pan, Y-R; Lee, E. Y-H P.			Regulation of cell lineage specification by the retinoblastoma tumor suppressor	ONCOGENE			English	Review						tumor suppressor gene; retinoblastoma susceptibility gene; cellular differentiation	SKELETAL-MUSCLE CELLS; C-ELEGANS; CAENORHABDITIS-ELEGANS; RNA INTERFERENCE; GENE FAMILY; TRANSCRIPTIONAL COACTIVATOR; ADIPOCYTE DIFFERENTIATION; DEFINITIVE ERYTHROPOIESIS; SOMATIC INACTIVATION; VULVAL DEVELOPMENT	Early studies of the retinoblastoma gene (RB) have uncovered its critical role as a regulator of the G(1)/S cell cycle phase progression. Surprisingly, genetic approaches in mammals and nematodes have also shown RB controls cell lineage specification and aspects of differentiation. The RB gene product accomplishes this by diverse mechanisms such as by interacting with tissue-specific transcription factors, enhancing RNA interference, and modifying chromatin structure. We review recent studies uncovering novel mechanisms by which RB works in several cell lineages and we provide perspectives on how these new findings might relate to RB tumor suppression.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92717 USA	St Jude Children's Research Hospital; University of California System; University of California Irvine; University of California System; University of California Irvine	Skapek, SX (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	steve.skapek@stjude.org						Anderson KL, 1998, BLOOD, V91, P3702, DOI 10.1182/blood.V91.10.3702; Ashe M, 2004, J BIOL CHEM, V279, P664, DOI 10.1074/jbc.M308810200; Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012; Camarda G, 2004, J CELL BIOL, V167, P417, DOI 10.1083/jcb.200408164; Cardoso C, 2005, DEV BIOL, V278, P49, DOI 10.1016/j.ydbio.2004.10.014; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chen D, 2004, CANCER CELL, V5, P539, DOI 10.1016/j.ccr.2004.05.025; Chen G, 1996, J BIOL CHEM, V271, P9567, DOI 10.1074/jbc.271.16.9567; Chen PL, 1996, GENE DEV, V10, P2794, DOI 10.1101/gad.10.21.2794; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Cloud JE, 2002, MOL CELL BIOL, V22, P2663, DOI 10.1128/MCB.22.8.2663-2672.2002; COLLINS J, 1987, NATURE, V328, P726, DOI 10.1038/328726a0; Couteau F, 2002, EMBO REP, V3, P235, DOI 10.1093/embo-reports/kvf051; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ebel C, 2004, NATURE, V429, P776, DOI 10.1038/nature02637; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fay DS, 2003, DEVELOPMENT, V130, P3319, DOI 10.1242/dev.00561; FERGUSON EL, 1989, GENETICS, V123, P109; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GODBOUT R, 1983, NATURE, V304, P451, DOI 10.1038/304451a0; Grishok A, 2005, P NATL ACAD SCI USA, V102, P17360, DOI 10.1073/pnas.0508989102; Grishok A, 2005, GENE DEV, V19, P683, DOI 10.1101/gad.1247705; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Hall IM, 2002, SCIENCE, V297, P2232, DOI 10.1126/science.1076466; Hansen JB, 2004, P NATL ACAD SCI USA, V101, P4112, DOI 10.1073/pnas.0301964101; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Hu NP, 1997, CANCER RES, V57, P4123; HU NP, 1994, ONCOGENE, V9, P1021; Hub MS, 2004, J CELL BIOL, V166, P865, DOI 10.1083/jcb.200403004; Iavarone A, 2004, NATURE, V432, P1040, DOI 10.1038/nature03068; IAVARONE A, 1994, GENE DEV, V8, P1270, DOI 10.1101/gad.8.11.1270; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kawane K, 2001, SCIENCE, V292, P1546, DOI 10.1126/science.292.5521.1546; Kelly WG, 2002, DEVELOPMENT, V129, P479; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee KY, 1999, MOL CELL BIOL, V19, P7724; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lu XW, 1998, CELL, V95, P981, DOI 10.1016/S0092-8674(00)81722-5; MAANDAG ECR, 1994, EMBO J, V13, P4260, DOI 10.1002/j.1460-2075.1994.tb06746.x; MacPherson D, 2004, GENE DEV, V18, P1681, DOI 10.1101/gad.1203304; Maison C, 2004, NAT REV MOL CELL BIO, V5, P296, DOI 10.1038/nrm1355; Mansouri A, 1998, NAT GENET, V19, P87, DOI 10.1038/ng0598-87; Mantela J, 2005, DEVELOPMENT, V132, P2377, DOI 10.1242/dev.01834; MAYOL X, 1993, ONCOGENE, V8, P2561; Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4; Miccadei S, 2005, ONCOGENE, V24, P6993, DOI 10.1038/sj.onc.1208861; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Myers TR, 2005, DEV CELL, V8, P117, DOI 10.1016/j.devcel.2004.11.015; Nikitin AY, 1999, P NATL ACAD SCI USA, V96, P3916, DOI 10.1073/pnas.96.7.3916; Novitch BG, 1996, J CELL BIOL, V135, P441, DOI 10.1083/jcb.135.2.441; Papadimou E, 2005, EMBO J, V24, P1750, DOI 10.1038/sj.emboj.7600652; Picard F, 2002, CELL, V111, P931, DOI 10.1016/S0092-8674(02)01169-8; Puigserver P, 1998, EUR J CELL BIOL, V77, P117, DOI 10.1016/S0171-9335(98)80079-4; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Qiu XH, 2006, DEV BIOL, V291, P239, DOI 10.1016/j.ydbio.2005.11.045; Rekhtman N, 2003, MOL CELL BIOL, V23, P7460, DOI 10.1128/MCB.23.21.7460-7474.2003; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Sage C, 2005, SCIENCE, V307, P1114, DOI 10.1126/science.1106642; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Skapek SX, 1996, MOL CELL BIOL, V16, P7043; Skapek SX, 2001, ONCOGENE, V20, P6742, DOI 10.1038/sj.onc.1204876; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Takahashi C, 2004, MOL CELL BIOL, V24, P10406, DOI 10.1128/MCB.24.23.10406-10415.2004; Takahashi C, 2003, MOL CELL BIOL, V23, P5256, DOI 10.1128/MCB.23.15.5256-5268.2003; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973; Wang D, 2005, NATURE, V436, P593, DOI 10.1038/nature04010; Wikenheiser-Brokamp KA, 2004, DEVELOPMENT, V131, P4299, DOI 10.1242/dev.01232; WIKENHEISERBROK.KA, 2006, CELL MOL LIFE SCI; Wildwater M, 2005, CELL, V123, P1337, DOI 10.1016/j.cell.2005.09.042; WILLIAMS BO, 1994, EMBO J, V13, P4251, DOI 10.1002/j.1460-2075.1994.tb06745.x; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Wylie C, 1999, CELL, V96, P165, DOI 10.1016/S0092-8674(00)80557-7; Yuan SSF, 2002, BIOCHEM BIOPH RES CO, V296, P1019, DOI 10.1016/S0006-291X(02)02032-6; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zhang JK, 2004, CELL CYCLE, V3, P952; Zhang JK, 2004, NAT GENET, V36, P351, DOI 10.1038/ng1318; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	99	29	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5268	5276		10.1038/sj.onc.1209710	http://dx.doi.org/10.1038/sj.onc.1209710			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936747				2022-12-28	WOS:000240064100012
J	Fulda, S; Debatin, KM				Fulda, S.; Debatin, K. -M			Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy	ONCOGENE			English	Review						apoptosis; death receptor; mitochondria; cancer; chemotherapy	DRUG-INDUCED APOPTOSIS; STRUCTURE-BASED DESIGN; CYTOCHROME-C RELEASE; X-LINKED INHIBITOR; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; APO-1/FAS RECEPTOR/LIGAND SYSTEM; SERINE-PROTEASE OMI/HTRA2; TRAIL-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; NF-KAPPA-B	Apoptosis or programmed cell death is a key regulator of physiological growth control and regulation of tissue homeostasis. One of the most important advances in cancer research in recent years is the recognition that cell death mostly by apoptosis is crucially involved in the regulation of tumor formation and also critically determines treatment response. Killing of tumor cells by most anticancer strategies currently used in clinical oncology, for example, chemotherapy, gamma-irradiation, suicide gene therapy or immunotherapy, has been linked to activation of apoptosis signal transduction pathways in cancer cells such as the intrinsic and/or extrinsic pathway. Thus, failure to undergo apoptosis may result in treatment resistance. Understanding the molecular events that regulate apoptosis in response to anticancer chemotherapy, and how cancer cells evade apoptotic death, provides novel opportunities for a more rational approach to develop molecular-targeted therapies for combating cancer.	Univ Ulm, Childrens Hosp, D-89075 Ulm, Germany	Ulm University	Fulda, S (corresponding author), Univ Ulm, Childrens Hosp, Eythstr 24, D-89075 Ulm, Germany.	simone.fulda@uniklinik-ulm.de	Fulda, Simone/D-5864-2011; Debatin, Klaus-Michael/J-9704-2014	Debatin, Klaus-Michael/0000-0002-8397-1886; Fulda, Simone/0000-0002-0459-6417				Adrain C, 1999, J BIOL CHEM, V274, P20855, DOI 10.1074/jbc.274.30.20855; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Arnt CR, 2002, J BIOL CHEM, V277, P44236, DOI 10.1074/jbc.M207578200; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bartling B, 2004, EXP CELL RES, V298, P83, DOI 10.1016/j.yexcr.2004.04.007; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Bouillet P, 2002, J CELL SCI, V115, P1567; Bratton SB, 2001, EMBO J, V20, P998, DOI 10.1093/emboj/20.5.998; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Brown M, 2003, CANCER BIOL THER, V2, P477, DOI 10.4161/cbt.2.5.450; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Cande C, 2004, ONCOGENE, V23, P1514, DOI 10.1038/sj.onc.1207279; Cande C, 2002, J CELL SCI, V115, P4727, DOI 10.1242/jcs.00210; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chuntharapai A, 2001, J IMMUNOL, V166, P4891, DOI 10.4049/jimmunol.166.8.4891; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 2000, J NATL CANCER I, V92, P1042, DOI 10.1093/jnci/92.13.1042; Cotter FE, 2004, SEMIN ONCOL, V31, P18, DOI 10.1053/j.seminoncol.2004.10.014; Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Debatin KM, 2003, SEMIN CANCER BIOL, V13, P149, DOI 10.1016/S1044-579X(02)00132-3; Decaudin D, 1998, INT J ONCOL, V12, P141; Dechant MJ, 2004, INT J CANCER, V109, P661, DOI 10.1002/ijc.20008; Degterev A, 2003, ONCOGENE, V22, P8543, DOI 10.1038/sj.onc.1207107; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1997, BLOOD, V90, P935, DOI 10.1182/blood.V90.3.935.935_935_943; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Friesen C, 1997, LEUKEMIA, V11, P1833, DOI 10.1038/sj.leu.2400827; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Fulda S, 2004, CURR CANCER DRUG TAR, V4, P569, DOI 10.2174/1568009043332763; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Fulda S, 1997, CANCER RES, V57, P3823; Fulda S, 1998, INT J CANCER, V76, P105; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Fulda S, 2001, ONCOGENE, V20, P1063, DOI 10.1038/sj.onc.1204141; Fulda S, 2000, CANCER RES, V60, P3947; Gautschi O, 2001, J NATL CANCER I, V93, P463, DOI 10.1093/jnci/93.6.463; Gliniak B, 1999, CANCER RES, V59, P6153; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Hao CH, 2001, CANCER RES, V61, P1162; Hao ZY, 2005, CELL, V121, P579, DOI 10.1016/j.cell.2005.03.016; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Houghton JA, 1997, P NATL ACAD SCI USA, V94, P8144, DOI 10.1073/pnas.94.15.8144; Huang YH, 2003, J BIOL CHEM, V278, P49517, DOI 10.1074/jbc.M310061200; Hyer ML, 2000, MOL THER, V2, P348, DOI 10.1006/mthe.2000.0139; Ichikawa K, 2001, NAT MED, V7, P954, DOI 10.1038/91000; Igney FH, 2002, J LEUKOCYTE BIOL, V71, P907; Jansen B, 2000, LANCET, V356, P1728, DOI 10.1016/S0140-6736(00)03207-4; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kataoka T, 1998, J IMMUNOL, V161, P3936; Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515; Kidd JF, 2002, J BIOL CHEM, V277, P6504, DOI 10.1074/jbc.M106802200; Kinoshita H, 2000, INT J CANCER, V88, P986, DOI 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Knudson CM, 2001, CANCER RES, V61, P659; Konishi A, 2003, CELL, V114, P673, DOI 10.1016/S0092-8674(03)00719-0; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Maecker HL, 2002, CANCER CELL, V2, P139, DOI 10.1016/S1535-6108(02)00095-8; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; McNeish IA, 2003, EXP CELL RES, V286, P186, DOI 10.1016/S0014-4827(03)00073-9; Meng RD, 2000, MOL THER, V1, P130, DOI 10.1006/mthe.2000.0025; Meng RD, 2001, EXP CELL RES, V262, P154, DOI 10.1006/excr.2000.5073; Micheau O, 1999, BIOCHEM BIOPH RES CO, V256, P603, DOI 10.1006/bbrc.1999.0391; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Milella M, 2004, CLIN CANCER RES, V10, P7747, DOI 10.1158/1078-0432.CCR-04-0908; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagane M, 2000, CANCER RES, V60, P847; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Ng CP, 2002, MOL CANCER THER, V1, P1051; Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+; Nitsch R, 2000, LANCET, V356, P827, DOI 10.1016/S0140-6736(00)02659-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Okano H, 2003, INT J MOL MED, V12, P25; Olsson A, 2001, LEUKEMIA, V15, P1868, DOI 10.1038/sj.leu.2402287; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pai SI, 1998, CANCER RES, V58, P3513; Petak I, 2003, CELL DEATH DIFFER, V10, P211, DOI 10.1038/sj.cdd.4401132; Pitti RM, 1998, NATURE, V396, P699, DOI 10.1038/25387; Pollack IF, 2001, CLIN CANCER RES, V7, P1362; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Roth W, 2001, CANCER RES, V61, P2759; Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090; Saelens X, 2004, ONCOGENE, V23, P2861, DOI 10.1038/sj.onc.1207523; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schimmer AD, 2004, CANCER CELL, V5, P25, DOI 10.1016/S1535-6108(03)00332-5; Sheikh MS, 1999, ONCOGENE, V18, P4153, DOI 10.1038/sj.onc.1202763; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Stassi G, 2005, CANCER RES, V65, P6668, DOI 10.1158/0008-5472.CAN-04-4009; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Sun HY, 2004, J AM CHEM SOC, V126, P16686, DOI 10.1021/ja047438+; Sun HY, 2005, BIOORG MED CHEM LETT, V15, P793, DOI 10.1016/j.bmcl.2004.11.008; Sun HY, 2004, J MED CHEM, V47, P4147, DOI 10.1021/jm0499108; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Suzuki Y, 2004, CELL DEATH DIFFER, V11, P208, DOI 10.1038/sj.cdd.4401343; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Talos F, 2005, CANCER RES, V65, P9971, DOI 10.1158/0008-5472.CAN-05-1084; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tortora G, 2003, CLIN CANCER RES, V9, P1566; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Trencia A, 2004, J BIOL CHEM, V279, P46566, DOI 10.1074/jbc.M406317200; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; van Noesel MM, 2002, CANCER RES, V62, P2157; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Vaux DL, 2003, BIOCHEM BIOPH RES CO, V304, P499, DOI 10.1016/S0006-291X(03)00622-3; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Villunger A, 1997, CANCER RES, V57, P3331; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang SL, 2003, P NATL ACAD SCI USA, V100, P15095, DOI 10.1073/pnas.2435285100; Wang ZL, 2004, J BIOL CHEM, V279, P48168, DOI 10.1074/jbc.M405022200; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yamanaka K, 2005, MOL CANCER THER, V4, P1689, DOI 10.1158/1535-7163.MCT-05-0064; Yang L, 2003, CANCER RES, V63, P6815; Yang LL, 2003, CANCER RES, V63, P831; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zangemeister-Wittke U, 2000, CLIN CANCER RES, V6, P2547; Zhao J, 2006, CANCER GENE THER, V13, P420, DOI 10.1038/sj.cgt.7700910; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	169	1633	1712	6	210	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2006	25	34					4798	4811		10.1038/sj.onc.1209608	http://dx.doi.org/10.1038/sj.onc.1209608			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892092				2022-12-28	WOS:000239687000016
J	Chebotaev, D; Yemelyanov, A; Zhu, L; Lavker, RM; Budunova, I				Chebotaev, D.; Yemelyanov, A.; Zhu, L.; Lavker, R. M.; Budunova, I.			The tumor suppressor effect of the glucocorticoid receptor in skin is mediated via its effect on follicular epithelial stem cells	ONCOGENE			English	Article						epidermis; stem cells; glucocorticoid receptor; skin carcinogenesis	LABEL-RETAINING CELLS; GROWTH-FACTOR; TRANSCRIPTION FACTORS; KAPPA-B; CARCINOGENESIS; APOPTOSIS; ERYTHROPOIESIS; IDENTIFICATION; DEXAMETHASONE; PROLIFERATION	Glucocorticoids are potent inhibitors of mouse skin tumorigenesis. The glucocorticoid control of cellular functions is mediated via the glucocorticoid receptor ( GR), a well-known transcription factor. Recently, we generated transgenic mice overexpressing GR under control of the keratin5 ( K5) promoter, and showed that K5. GR animals are resistant to skin carcinogenesis. Follicular epithelial stem cells ( SCs), located in the bulge region of the hair follicle, are believed to be one of the target cells for skin carcinogenesis. We found that the number of putative hair follicle SC detected as label-retaining cells was significantly less in the K5. GR transgenics compared to wild type ( w.t.) littermates. We also showed that GR overexpression led to a reduction in the clonogenicity of the follicular epithelial SCs. We evaluated the global effect of GR on gene expression in a population of follicular SC-enriched bulge keratinocytes isolated by fluorescence activated cell sorting. We found that GR affected the expression of numerous bulge SC 'signature' genes, genes involved in the maintenance of SC and progenitor cells of non-epidermal origin and proapoptotic genes. Our findings underscore the important role of GR signaling in the homeostasis of follicular epithelial SCs, and suggest that the reduction in their number may underlie the tumor suppressor effect of GR in the skin.	Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Bioinformat Core, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University	Budunova, I (corresponding author), Northwestern Univ, Feinberg Med Sch, Dept Dermatol, Ward Bldg 9-332,303 E Chicago Ave, Chicago, IL 60611 USA.	i-budunova@northwestern.edu		Zhu, Lihua/0000-0001-7416-0590				Bauer A, 1999, GENE DEV, V13, P2996, DOI 10.1101/gad.13.22.2996; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BICKENBACH JR, 1984, J INVEST DERMATOL, V82, P618, DOI 10.1111/1523-1747.ep12261460; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Blanpain C, 2006, ANNU REV CELL DEV BI, V22, P339, DOI 10.1146/annurev.cellbio.22.010305.104357; Budunova IV, 1997, MOL CARCINOGEN, V18, P177, DOI 10.1002/(SICI)1098-2744(199703)18:3<177::AID-MC7>3.3.CO;2-U; Budunova IV, 2003, ONCOGENE, V22, P3279, DOI 10.1038/sj.onc.1206383; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Daniel PT, 2001, LEUKEMIA, V15, P1022, DOI 10.1038/sj.leu.2402169; Davies TH, 2005, BIOCHEMISTRY-US, V44, P2030, DOI 10.1021/bi048503v; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; Derfoul A, 2006, STEM CELLS, V24, P1487, DOI 10.1634/stemcells.2005-0415; Dumitriu B, 2006, BLOOD, V108, P1198, DOI 10.1182/blood-2006-02-004184; Fuchs E, 2001, DEV CELL, V1, P13, DOI 10.1016/S1534-5807(01)00022-3; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; Hubler TR, 2004, CELL STRESS CHAPERON, V9, P243, DOI 10.1379/CSC-32R.1; Ito C, 2003, BONE MARROW TRANSPL, V32, P391, DOI 10.1038/sj.bmt.1704152; Lavker RM, 2003, J INVEST DERM SYMP P, V8, P28, DOI 10.1046/j.1523-1747.2003.12169.x; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Li BG, 2005, INT J BIOCHEM CELL B, V37, P2207, DOI 10.1016/j.biocel.2005.04.008; Li GY, 2003, J BIOL CHEM, V278, P41779, DOI 10.1074/jbc.M305350200; Ligon KL, 2006, P NATL ACAD SCI USA, V103, P7853, DOI 10.1073/pnas.0511001103; Lu JH, 2006, FEBS LETT, V580, P3539, DOI 10.1016/j.febslet.2006.05.031; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; MORRIS RJ, 1985, J INVEST DERMATOL, V84, P277, DOI 10.1111/1523-1747.ep12265358; Morris RJ, 2000, J CLIN INVEST, V106, P3, DOI 10.1172/JCI10508; Necela Brian M, 2004, Proc Am Thorac Soc, V1, P239, DOI 10.1513/pats.200402-005MS; Owens DM, 2003, NAT REV CANCER, V3, P444, DOI 10.1038/nrc1096; Perez P, 2001, FASEB J, V15, P2030, DOI 10.1096/fj.00-0772fje; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; SCHWARZ JA, 1977, CHEM-BIOL INTERACT, V17, P331, DOI 10.1016/0009-2797(77)90096-5; Schwarz-Romond T, 2002, GENE DEV, V16, P2073, DOI 10.1101/gad.230402; Smith E, 2004, J LEUKOCYTE BIOL, V75, P973, DOI 10.1189/jlb.1103554; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Trempus CS, 2003, J INVEST DERMATOL, V120, P501, DOI 10.1046/j.1523-1747.2003.12088.x; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; VERMA AK, 1983, CANCER RES, V43, P3045; Ward AC, 2000, LEUKEMIA, V14, P973, DOI 10.1038/sj.leu.2401808; Yao RS, 2004, ONCOGENE, V23, P7746, DOI 10.1038/sj.onc.1207985; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066	44	18	20	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					3060	3068		10.1038/sj.onc.1210108	http://dx.doi.org/10.1038/sj.onc.1210108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17146443				2022-12-28	WOS:000246395400011
J	Hernandez-Vargas, H; Palacios, J; Moreno-Bueno, G				Hernandez-Vargas, H.; Palacios, J.; Moreno-Bueno, G.			Molecular profling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis	ONCOGENE			English	Article						docetaxel; cDNA microarrays; taxanes; aberrant mitosis; mitotic arrest	MITOTIC CATASTROPHE; GENE-EXPRESSION; HELA-CELLS; MICROTUBULE; ARREST; DEATH; P53; PROTEIN; TAXOTERE; BCL-2	Among microtubule-targeting agents, docetaxel has received recent interest owing to its good therapeutic index. Clinical trials have underlined its potential for the treatment of advanced breast cancer, although little is known about its molecular mode of action in this context. We characterized the molecular changes induced by docetaxel in two well-known human breast carcinoma cell lines. Two mechanisms of action according to drug concentration were suggested by a biphasic sensitivity curve, and were further validated by cell morphology, cell cycle and cell death changes. Two to four nanomolar docetaxel induced aberrant mitosis followed by late necrosis, and 100 nM docetaxel induced mitotic arrest followed by apoptosis. Passing through mitosis phase was a requirement for hypodiploidy to occur, as shown by functional studies in synchronized cells and by combining docetaxel with the proteasome inhibitor MG132. Transcriptional pro. ling showed differences according to cell line and docetaxel concentration, with cell cycle, cell death and structural genes commonly regulated in both cell lines. Although p53 targets were mainly induced with low concentration of drug in MCF7 cells, its relevance in the dual mechanism of docetaxel cytotoxicity was ruled out by using an isogenic shp53 cell line. Many of the genes shown in this study may contribute to the dual mechanism by which docetaxel inhibits the growth of breast cancer cells at different concentrations. These findings provide a basis for rationally enhancing docetaxel therapy, considering lower concentrations, and better drug combinations.	Spanish Natl Canc Ctr, CNIO, Mol Pathol Programme, Breast & Gynaecol Canc Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Moreno-Bueno, G (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Unidad Biol Mol & Celular Canc, Arturo Duperier 4, E-28029 Madrid, Spain.	jose.palacios.sspa@juntadeand.alucia.es; gmoreno@iib.uam.es	Palacios, Jose/AAV-3765-2020; Moreno-Bueno, Gema/K-9354-2016	Moreno-Bueno, Gema/0000-0002-5030-6687; Hernandez-Vargas, Hector/0000-0001-6045-2103				Aapro M, 1996, ANTI-CANCER DRUG, V7, P33, DOI 10.1097/00001813-199608002-00009; Avramis VI, 1998, ANTICANCER RES, V18, P2327; Baker SD, 2004, CLIN CANCER RES, V10, P1976, DOI 10.1158/1078-0432.CCR-0842-03; Berchem GJ, 1999, ANTICANCER RES, V19, P535; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Blagosklonny MV, 2002, MOL CANCER THER, V1, P937; Blagosklonny MV, 1996, CANCER RES, V56, P1851; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Boudny V, 2002, BRIT J CANCER, V86, P463, DOI 10.1038/sj.bjc.6600080; Brown I, 2004, BREAST CANCER RES, V6, pR601, DOI 10.1186/bcr918; Caraglia M, 2005, FRONT BIOSCI, V10, P2566, DOI 10.2741/1720; CARMICHAEL J, 1987, CANCER RES, V47, P936; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Chen JG, 2003, CANCER RES, V63, P7891; Consolini R, 1998, J CLIN ONCOL, V16, P907, DOI 10.1200/JCO.1998.16.3.907; Dieras V, 1996, ANTI-CANCER DRUG, V7, P47, DOI 10.1097/00001813-199608002-00012; Escuin D, 2005, CANCER RES, V65, P9021, DOI 10.1158/0008-5472.CAN-04-4095; Fabbri F, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-6; Fumoleau P, 1996, ANN ONCOL, V7, P165; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Giannakakou P, 2001, ONCOGENE, V20, P3806, DOI 10.1038/sj.onc.1204487; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Haldar S, 1997, CANCER RES, V57, P229; Hernandez-Vargas H, 2006, INT J CANCER, V119, P1164, DOI 10.1002/ijc.21938; Jordan MA, 1996, CANCER RES, V56, P816; Li YW, 2004, NEOPLASIA, V6, P158, DOI 10.1593/neo.03391; Mansilla S, 2006, CELL CYCLE, V5, P53, DOI 10.4161/cc.5.1.2267; Montero A, 2005, LANCET ONCOL, V6, P229, DOI 10.1016/S1470-2045(05)70094-2; Moreno-Bueno G, 2003, CANCER RES, V63, P5697; Morse DL, 2005, MOL CANCER THER, V4, P1495, DOI 10.1158/1535-7163.MCT-05-0130; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Paoletti A, 1997, J CELL SCI, V110, P2403; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Tarsounas M, 2004, CELL, V117, P337, DOI 10.1016/S0092-8674(04)00337-X; Torres K, 1998, CANCER RES, V58, P3620; Veronesi U, 2005, LANCET, V365, P1727, DOI 10.1016/S0140-6736(05)66546-4; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; Wang Q, 2004, ONCOGENE, V23, P426, DOI 10.1038/sj.onc.1207040; Yoo GH, 2002, CLIN CANCER RES, V8, P3910; Zeng S, 2000, CLIN CANCER RES, V6, P3766	42	116	117	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 3	2007	26	20					2902	2913		10.1038/sj.onc.1210102	http://dx.doi.org/10.1038/sj.onc.1210102			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17099726				2022-12-28	WOS:000246210800010
J	Hurley, PJ; Wilsker, D; Bunz, F				Hurley, P. J.; Wilsker, D.; Bunz, F.			Human cancer cells require ATR for cell cycle progression following exposure to ionizing radiation	ONCOGENE			English	Article						ATR; IR; cell cycle; S-phase stasis; Chk1; Seckel	DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; S-PHASE; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; SECKEL-SYNDROME; CHECKPOINT PATHWAY; HUMAN CHK1; REPLICATION; DEFECTS	The vast majority of cancer cells have defective checkpoints that permit the cell cycle to progress in the presence of double-strand DNA breaks (DSBs) caused by ionizing radiation (IR) and radiomimetic drugs. ATR (ataxia telangiectasia-mutated and Rad3-related) has recently been shown to be activated by DSBs, although the consequences of this activity are largely unknown. In this report, we use advanced gene targeting methods to generate biallelic hypomorphic ATR mutations in human colorectal cancer cells and d demonstrate that progression of the cancer cell cycle after IR treatment requires ATR. Cells with mutant ATR accumulated a defined point at the beginning of the S phase after IR treatment and were unable to progress beyond that point, where as cells at later stages of the S phase during the time of irradiation progresseda and completed DNA replication. The prolonged arrest of ATR mutant cancer cells did not involve the ataxia telangiectasia mutated-dependent S-phase checkpoint, but rather closely resembled a previously characterized form of cell cycle arrest termed S-phase stasis. As ATR strongly contributed to clonogenic survival after IR treatment, these data suggest that blocking ATR activity might be a useful strategy for inducing S-phase stasis and promoting the radiosensitization of checkpoint deficient cancer cells.	Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, Baltimore, MD 21231 USA	Johns Hopkins University	Bunz, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Radiat Oncol & Mol Radiat Sci, 1550 Orleans St,Room 453, Baltimore, MD 21231 USA.	fbunz@jhmi.edu			NATIONAL CANCER INSTITUTE [R01CA104253] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA104253] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Alderton GK, 2004, HUM MOL GENET, V13, P3127, DOI 10.1093/hmg/ddh335; Bernardi R, 2000, ONCOGENE, V19, P2447, DOI 10.1038/sj.onc.1203564; Borel F, 2002, J CELL SCI, V115, P2829; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jirmanova L, 2005, CELL CYCLE, V4, P1428, DOI 10.4161/cc.4.10.2055; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kumar S, 2004, J BIOL CHEM, V279, P43574, DOI 10.1074/jbc.M407819200; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; McGowan CH, 2004, CURR OPIN CELL BIOL, V16, P629, DOI 10.1016/j.ceb.2004.09.005; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; O'Driscoll M, 2004, DNA REPAIR, V3, P1227, DOI 10.1016/j.dnarep.2004.03.025; OConnor PM, 1997, CANCER RES, V57, P4285; Osborn AJ, 2002, TRENDS CELL BIOL, V12, P509, DOI 10.1016/S0962-8924(02)02380-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Seckel H.P.G., 1960, BIRD HEADED DWARFS S; Shechter D, 2004, NAT CELL BIOL, V6, P648, DOI 10.1038/ncb1145; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Syljuasen RG, 2005, MOL CELL BIOL, V25, P3553, DOI 10.1128/MCB.25.9.3553-3562.2005; Topaloglu O, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni160; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	38	43	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 19	2007	26	18					2535	2542		10.1038/sj.onc.1210049	http://dx.doi.org/10.1038/sj.onc.1210049			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YI	17043640				2022-12-28	WOS:000245831200001
J	Herzig, M; Savarese, F; Novatchkova, M; Semb, H; Christofori, G				Herzig, M.; Savarese, F.; Novatchkova, M.; Semb, H.; Christofori, G.			Tumor progression induced by the loss of E-cadherin independent of beta-catenin/Tcf-mediated Wnt signaling	ONCOGENE			English	Article						beta-catenin; cell adhesion; E-cadherin; Tcf; tumorigenesis; Wnt signaling	EPITHELIAL-MESENCHYMAL TRANSITION; CELL-ADHESION; TRANSGENIC MICE; SUPPRESSOR GENE; CANCER CELLS; TUMORIGENESIS; EXPRESSION; INVASION; OVEREXPRESSION; MUTATIONS	E-cadherin-mediated cell-cell adhesion is frequently lost during the development of malignant epithelial cancers. Employing a transgenic mouse model of beta-cell carcinogenesis (Rip1Tag2) we have previously shown that the loss of E-cadherin is a rate-limiting step in the progression from adenoma to carcinoma. However, the mere loss of cell adhesion may not be sufficient and additional signals are required to cause tumor cells to permeate the basal membrane and to invade surrounding tissue. Besides being an important component of the E-cadherin cell-adhesion complex, beta-catenin plays a critical role in canonical Wnt signaling. We report here that beta-catenin-mediated Wnt signaling does not contribute to tumor progression in Rip1Tag2 mice. E-cadherin downregulates beta-catenin/Tcf-mediated transcriptional activity by sequestrating beta-catenin into E-cadherin cell-adhesion complexes even in the presence of activated Wnt signaling. Upon loss of E-cadherin expression, beta-catenin is degraded and Tcf/beta-catenin-mediated transcriptional activity is not induced. Moreover, forced expression of constitutive-active beta-catenin or genetic ablation of Tcf/beta-catenin transcriptional activity in tumor cells of Rip1Tag2 transgenic mice does not affect tumor progression. Together, the data indicate that signals other than beta-catenin/Tcf-mediated Wnt signaling are induced by the loss of E-cadherin during tumor progression in Rip1Tag2 transgenic mice.	Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, CH-4058 Basel, Switzerland; Res Inst Mol Pathol, A-1030 Vienna, Austria; Lund Univ, Stem Cell Ctr, Lund, Sweden	University of Basel; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Lund University	Christofori, G (corresponding author), Univ Basel, Biomed Ctr, Dept Clin Biol Sci, Inst Biochem & Genet, Mattenstr 28, CH-4058 Basel, Switzerland.	gerhard.christofori@unibas.ch						BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; Brembeck FH, 2006, CURR OPIN GENET DEV, V16, P51, DOI 10.1016/j.gde.2005.12.007; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Crnic I, 2004, CANCER RES, V64, P8630, DOI 10.1158/0008-5472.CAN-04-2523; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gottardi CJ, 2004, J CELL BIOL, V167, P339, DOI 10.1083/jcb.200402153; Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Harada N, 2002, CANCER RES, V62, P1971; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Herzig M, 1999, BIOL CHEM, V380, P203, DOI 10.1515/BC.1999.028; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuphal F, 2006, EXP CELL RES, V312, P457, DOI 10.1016/j.yexcr.2005.11.007; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Orsulic S, 1999, J CELL SCI, V112, P1237; Perez-Moreno M, 2003, CELL, V112, P535, DOI 10.1016/S0092-8674(03)00108-9; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Romagnolo B, 1999, CANCER RES, V59, P3875; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Stockinger A, 2001, J CELL BIOL, V154, P1185, DOI 10.1083/jcb.200104036; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; van de Wetering M, 2001, CANCER RES, V61, P278; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wicki A, 2006, CANCER CELL, V9, P261, DOI 10.1016/j.ccr.2006.03.010	33	99	105	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 5	2007	26	16					2290	2298		10.1038/sj.onc.1210029	http://dx.doi.org/10.1038/sj.onc.1210029			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17043652				2022-12-28	WOS:000245466000005
J	Hasegawa, M; Kawase, K; Inohara, N; Imamura, R; Yeh, WC; Kinoshita, T; Suda, T				Hasegawa, M.; Kawase, K.; Inohara, N.; Imamura, R.; Yeh, W. -C; Kinoshita, T.; Suda, T.			Mechanism of ASC-mediated apoptosis: Bid-dependent apoptosis in type II cells	ONCOGENE			English	Article						apoptosis; ASC; CARD12; caspase; Bid; Bax	NF-KAPPA-B; RECEPTOR-INDUCED APOPTOSIS; INTERLEUKIN-8 PRODUCTION; CONTAINING PROTEIN; FAMILY MEMBER; C-FLIP; ACTIVATION; DEATH; CASPASE-1; PATHWAY	Apoptosis-associated speck-like protein containing a CARD (ASC) is an adaptor molecule that mediates apoptotic and inflammatory signals, and implicated in tumor suppression. However, the mechanism of ASC-mediated apoptosis has not been well elucidated. Here, we investigated the molecular mechanisms of ASC-mediated apoptosis in several cell lines using a caspase recruitment domain 12-Nod2 chimeric protein that transduces the signal from muramyl dipeptide into ASC-mediated apoptosis. Experiments using dominant-negative mutants, small-interfering RNAs and peptide inhibitors for caspases indicated that caspase-8 was generally required for ASC-mediated apoptosis, whereas a requirement for caspase-9 depended on the cell type. In addition, caspase-like apoptosis-regulatory protein (CLARP)/Fas-like inhibitor protein, a natural caspase-8 inhibitor, suppressed ASC-mediated apoptosis, and Clarp-/- mouse embryonic fibroblasts were highly sensitive to ASC-mediated apoptosis. Bax-deficient HCT116 cells were resistant to ASC-mediated apoptosis as reported previously, although we failed to observe colocalization of ASC and Bax in cells. Like Fas-ligand-induced apoptosis, the ASC- mediated apoptosis was inhibited by Bcl-2 and/orBcl-XL in type-II but not type-I cell lines. Bid was cleaved upon ASC activation, and suppression of endogenous Bid expression using small-interfering RNAs in type-II cells reduced the ASC- mediated apoptosis. These results indicate that ASC, like death receptors, mediates two types of apoptosis depending on the cell type, in a manner involving caspase-8.	Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, Kanazawa, Ishikawa 9200934, Japan; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Toronto, Dept Med Biophys, Toronto, ON M4X 1K9, Canada	Kanazawa University; University of Michigan System; University of Michigan; University of Toronto	Suda, T (corresponding author), Kanazawa Univ, Inst Canc Res, Ctr Dev Mol Target Drugs, 13-1 Takaramachi, Kanazawa, Ishikawa 9200934, Japan.	sudat@kenroku.kanazawa-u.ac.jp	IMAMURA, Ryu/D-8433-2015					Bullani RR, 2001, J INVEST DERMATOL, V117, P360, DOI 10.1046/j.0022-202x.2001.01418.x; Damiano JS, 2004, J IMMUNOL, V173, P6338, DOI 10.4049/jimmunol.173.10.6338; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Elnemr A, 2001, INT J ONCOL, V18, P311; Geddes BJ, 2001, BIOCHEM BIOPH RES CO, V284, P77, DOI 10.1006/bbrc.2001.4928; Gumucio DL, 2002, CLIN EXP RHEUMATOL, V20, pS45; Hasegawa M, 2005, J BIOL CHEM, V280, P15122, DOI 10.1074/jbc.M412284200; Imamura R, 2004, J BIOL CHEM, V279, P46415, DOI 10.1074/jbc.M403226200; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Jesenberger V, 2000, J EXP MED, V192, P1035, DOI 10.1084/jem.192.7.1035; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Masumoto J, 2003, BIOCHEM BIOPH RES CO, V303, P69, DOI 10.1016/S0006-291X(03)00309-7; Mathas S, 2004, J EXP MED, V199, P1041, DOI 10.1084/jem.20031080; McConnell BB, 2004, APOPTOSIS, V9, P5, DOI 10.1023/B:APPT.0000012117.32430.0c; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Ohtsuka T, 2004, NAT CELL BIOL, V6, P121, DOI 10.1038/ncb1087; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Wang YT, 2004, INT IMMUNOL, V16, P777, DOI 10.1093/intimm/dxh081; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Zender L, 2003, P NATL ACAD SCI USA, V100, P7797, DOI 10.1073/pnas.1330920100	31	43	45	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1748	1756		10.1038/sj.onc.1209965	http://dx.doi.org/10.1038/sj.onc.1209965			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	16964285	Green Submitted			2022-12-28	WOS:000244955600009
J	Gerber, AN; Wilson, CW; Li, YJ; Chuang, PT				Gerber, A. N.; Wilson, C. W.; Li, Y-J; Chuang, P-T			The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting MyoD-mediated transcriptional activation	ONCOGENE			English	Review						Gli; MyoD; hedgehog; cancer; rhabdomyosarcoma; development	LOOP-HELIX PROTEINS; SONIC HEDGEHOG; SKELETAL-MUSCLE; SIGNALING PATHWAY; TERMINAL DIFFERENTIATION; BRANCHING MORPHOGENESIS; REPRESSOR FUNCTIONS; FAMILY-MEMBERS; UP-REGULATION; DNA-BINDING	The mechanism by which activation of the Hedgehog (Hh) pathway modulates differentiation and promotes oncogenesis in specific tissues is poorly understood. We therefore, analysed rhabdomyosarcomas from mice that were haploinsufficient for the Hh-binding protein, Hip1, or for the Hh receptor, Patched 1 (Ptch1). Transfection of the Hh-regulated transcription factor Gli1, which is expressed in a subset of mouse and human rhabdomyosarcomas, suppressed differentiation of myogenic rhabdomyosarcoma lines generated from Hip1(+/+) and Ptch1(+/+) mice. The closely related factor, Gli2, had similar effects. Gli1 and Gli2 inhibited myogenesis by repressing the capacity of MyoD to activate transcription. Deletion analysis of Gli1 indicated that multiple domains of Gli1 are required for efficient inhibition of MyoD. Gli1 reduced the ability of MyoD to heterodimerize with E12 and bind DNA, providing one mechanism whereby the Gli proteins modulate the activity of MyoD. This novel activity of Gli proteins provides new insights into how Hh signaling modulates terminal differentiation through inhibition of tissue-specific factors such as MyoD. This mechanism may contribute to the broad role of Hh signaling and the Gli proteins in differentiation decisions and cancer formation.	Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94158 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Chuang, PT (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.	pao-tien.chuang@ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL077159, R01HL067822, U01HL066600, T35HL007715] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL077159-01A1, HL067822, K08 HL077159, K08HL07715, U01 HL066600, R01 HL067822, HL66600, T35 HL007715] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Altaba ARI, 1999, DEVELOPMENT, V126, P3205; Amthor H, 1999, DEVELOPMENT, V126, P1041; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Azmi S, 2003, J BIOL CHEM, V278, P20098, DOI 10.1074/jbc.M210427200; Bai CYB, 2001, DEVELOPMENT, V128, P5161; BALL DW, 1993, P NATL ACAD SCI USA, V90, P5648, DOI 10.1073/pnas.90.12.5648; Barr FG, 2001, ONCOGENE, V20, P5736, DOI 10.1038/sj.onc.1204599; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; BENGAL E, 1994, P NATL ACAD SCI USA, V91, P6221, DOI 10.1073/pnas.91.13.6221; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Bren-Mattison Y, 2002, DEV BIOL, V242, P130, DOI 10.1006/dbio.2001.0528; Briscoe J, 2005, DEV CELL, V8, P143, DOI 10.1016/j.devcel.2005.01.008; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Buckingham M, 2003, J ANAT, V202, P59, DOI 10.1046/j.1469-7580.2003.00139.x; Chen MH, 2004, GENE DEV, V18, P641, DOI 10.1101/gad.1185804; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chuang PT, 1999, NATURE, V397, P617, DOI 10.1038/17611; Chuang PT, 2003, GENE DEV, V17, P342, DOI 10.1101/gad.1026303; Chuang PT, 2003, TRENDS CELL BIOL, V13, P86, DOI 10.1016/S0962-8924(02)00031-4; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dai Z, 2004, CURR TOP MED CHEM, V4, P1347; di Magliano MP, 2003, NAT REV CANCER, V3, P903, DOI 10.1038/nrc1229; Dodou E, 2003, MECH DEVELOP, V120, P1021, DOI 10.1016/S0925-4773(03)00178-3; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Duprez D, 1998, DEVELOPMENT, V125, P495; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Gerber AN, 1997, GENE DEV, V11, P436, DOI 10.1101/gad.11.4.436; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; GORLIN RJ, 1987, MEDICINE, V66, P98, DOI 10.1097/00005792-198703000-00002; Guo CS, 2003, J BIOL CHEM, V278, P22615, DOI 10.1074/jbc.M301943200; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; Hahn H, 1999, J MOL MED-JMM, V77, P459, DOI 10.1007/s001099900018; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jeong JH, 2005, DEVELOPMENT, V132, P143, DOI 10.1242/dev.01566; Kappler R, 2004, ONCOGENE, V23, P8785, DOI 10.1038/sj.onc.1208133; Kappler R, 2003, J PATHOL, V200, P348, DOI 10.1002/path.1361; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Keller C, 2004, GENE DEV, V18, P2608, DOI 10.1101/gad.1243904; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Koleva M, 2005, CELL MOL LIFE SCI, V62, P1863, DOI 10.1007/s00018-005-5072-9; Kruger M, 2001, DEVELOPMENT, V128, P743; Kuang S, 2006, J CELL BIOL, V172, P103, DOI 10.1083/jcb.200508001; Li Xiaopeng, 2004, BMC Dev Biol, V4, P9, DOI 10.1186/1471-213X-4-9; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Lu QR, 2000, NEURON, V25, P317, DOI 10.1016/S0896-6273(00)80897-1; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Mal A, 2003, P NATL ACAD SCI USA, V100, P1735, DOI 10.1073/pnas.0437843100; Marigo V, 1996, DEVELOPMENT, V122, P1225; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McDermott A, 2005, DEVELOPMENT, V132, P345, DOI 10.1242/dev.01537; McMahon AP, 2003, CURR TOP DEV BIOL, V53, P1, DOI 10.1016/S0070-2153(03)53002-2; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; Nagy A., 2003, MANIPULATING MOUSE E; Narumi O, 2000, J BIOL CHEM, V275, P3510, DOI 10.1074/jbc.275.5.3510; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Olguin HC, 2004, DEV BIOL, V275, P375, DOI 10.1016/j.ydbio.2004.08.015; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2001, MOL CELL, V8, P885, DOI 10.1016/S1097-2765(01)00373-2; Relaix F, 2006, J CELL BIOL, V172, P91, DOI 10.1083/jcb.200508044; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; Sambrook J., 2001, MOL CLONING LAB MANU, Vthird edition; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sirri V, 2003, ONCOGENE, V22, P5658, DOI 10.1038/sj.onc.1206690; Sun JX, 2001, J BIOL CHEM, V276, P18591, DOI 10.1074/jbc.M101163200; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Teboul L, 2003, GENE DEV, V17, P2870, DOI 10.1101/gad.1117603; Tiffin N, 2003, BRIT J CANCER, V89, P327, DOI 10.1038/sj.bjc.6601040; Toftgard R, 2000, CELL MOL LIFE SCI, V57, P1720, DOI 10.1007/PL00000654; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Verzi MP, 2002, DEV BIOL, V249, P174, DOI 10.1006/dbio.2002.0753; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Watson Joseph, 2004, Ear Nose Throat J, V83, P716; Weiner HL, 2002, CANCER RES, V62, P6385; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; Wolff C, 2003, CURR BIOL, V13, P1169, DOI 10.1016/S0960-9822(03)00461-5; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496	101	41	47	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2007	26	8					1122	1136		10.1038/sj.onc.1209891	http://dx.doi.org/10.1038/sj.onc.1209891			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139BG	16964293	Green Accepted			2022-12-28	WOS:000244406400003
J	Lebedeva, IV; Su, ZZ; Emdad, L; Kolomeyer, A; Sarkar, D; Kitada, S; Waxman, S; Reed, JC; Fisher, PB				Lebedeva, I. V.; Su, Z-Z; Emdad, L.; Kolomeyer, A.; Sarkar, D.; Kitada, S.; Waxman, S.; Reed, J. C.; Fisher, P. B.			Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells	ONCOGENE			English	Article						mda-7/IL-24; K-ras single-chain antibody; K-ras AS; bipartite adenovirus; colorectal carcinoma; Bcl-family of proteins	DIFFERENTIATION-ASSOCIATED GENE-7; MELANOMA-DIFFERENTIATION; BCL-2 EXPRESSION; IN-VITRO; BYSTANDER ACTIVITY; MDA-7/IL-24; MDA-7; PROTEIN; LINES; ADENOVIRUS	Melanoma differentiation-associated gene-7/interleukin-24 (mda-7/IL-24) is a cancer-specific, growth-suppressing and apoptosis-inducing gene with broad-spectrum antitumor activity. However, when administered by means of a replication-incompetent adenovirus, Ad.mda-7, several colorectal carcinoma cell lines are resistant to its antiproliferative and antisurvival effects. We have presently endeavored to determine if K-ras mutations, present in similar to 40-50% of colorectal cancers and which may mediate resistance to chemotherapy and radiotherapy, represent a predisposing genetic factor mitigating reduced sensitivity to Ad.mda-7. To suppress ras expression, three structurally different replication-incompetent adenoviral vectors were engineered that express (1) an intracellular, neutralizing single-chain antibody (scAb) to p21 ras (Ad.K-ras scAb), (2) an antisense (AS) K-ras gene (Ad.K-ras AS) or (3) both mda-7/IL-24 and a K-ras AS gene in a single bipartite virus (Ad.m7.KAS). Simultaneous inhibition of K-ras and expression of mda-7/IL-24 enhanced killing of colorectal carcinoma cells with mutated K-ras, but not with wild-type K-ras. The extent of killing depended on the degree of K-ras downregulation, with Ad.K-ras AS being generally more efficient than Ad.K-ras scAb in combination with Ad.mda-7. These findings support an effective dual-combinatorial approach for the therapy of colorectal cancers that employs a unique cancer-specific suppressor gene (mda-7/IL-24) with targeted inhibition of oncogene (ras) expression.	Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Med Ctr, Herbert Irving Comprehens Canc Ctr,Dept Urol, New York, NY USA; Mt Sinai Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA; Burnham Inst, La Jolla, CA USA; Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Neurosurg, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA	Columbia University; Columbia University; Icahn School of Medicine at Mount Sinai; Sanford Burnham Prebys Medical Discovery Institute; Columbia University	Fisher, PB (corresponding author), Columbia Univ, Herbert Irving Comprehens Canc Ctr, Dept Pathol, Coll Phys & Surg,Med Ctr, New York, NY 10032 USA.	pbf1@columbia.edu	Lebedeva, Irina V/A-3156-2008	Lebedeva, Irina V/0000-0002-1693-9392	NCI NIH HHS [R01 CA097318, R01 CA098712] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097318, R01CA098712] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964; Aoki K, 1997, MOL CARCINOGEN, V20, P251, DOI 10.1002/(SICI)1098-2744(199710)20:2<251::AID-MC12>3.0.CO;2-9; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; BOS JL, 1989, CANCER RES, V49, P4682; Brand K, 1999, GENE THER, V6, P1054, DOI 10.1038/sj.gt.3300914; Canevari S, 2002, J NATL CANCER I, V94, P1031; Cardinale A, 1998, FEBS LETT, V439, P197, DOI 10.1016/S0014-5793(98)01369-6; Chada S, 2006, CANCER GENE THER, V13, P490, DOI 10.1038/sj.cgt.7700915; Chada S, 2004, MOL THER, V10, P1085, DOI 10.1016/j.ymthe.2004.08.020; Chada S, 2004, INT IMMUNOPHARMACOL, V4, P649, DOI 10.1016/j.intimp.2004.01.017; Cochet O, 1998, CANCER RES, V58, P1170; Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127; Fisher PB, 2003, CANCER BIOL THER, V2, pS23; GUPTA P, 2006, IN PRESS PHARM THER; HAGUE A, 1994, ONCOGENE, V9, P3367; Holmes Matthew, 2003, Methods Mol Biol, V234, P1; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Jiang HP, 1995, ONCOGENE, V11, P2477; KINOSHITA T, 1995, ONCOGENE, V10, P2207; Kita K, 1999, INT J CANCER, V80, P553, DOI 10.1002/(SICI)1097-0215(19990209)80:4<553::AID-IJC12>3.0.CO;2-6; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V148, P1567; Krajewski S, 1997, CLIN CANCER RES, V3, P199; Lebedeva IV, 2006, CANCER RES, V66, P2403, DOI 10.1158/0008-5472.CAN-05-3510; Lebedeva IV, 2005, ONCOGENE, V24, P585, DOI 10.1038/sj.onc.1208183; Lebedeva IV, 2003, ONCOGENE, V22, P8758, DOI 10.1038/sj.onc.1206891; Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; MUKHOPADHYAY T, 1991, CANCER RES, V51, P1744; Oida Y, 2005, MOL CANCER THER, V4, P291; Ramesh R, 2003, CANCER RES, V63, P5105; Russell JS, 1999, CANCER RES, V59, P5239; Russo P, 2002, INT J CANCER, V100, P266, DOI 10.1002/ijc.10461; Sarkar D, 2005, P NATL ACAD SCI USA, V102, P14034, DOI 10.1073/pnas.0506837102; Sarkar D, 2005, CANCER RES, V65, P9056, DOI 10.1158/0008-5472.CAN-05-1261; SARKAR D, IN PRESS ANTIINFLAMM; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SKLAR MD, 1988, CANCER RES, V48, P793; Su ZZ, 2006, ONCOGENE, V25, P2339, DOI 10.1038/sj.onc.1209271; Su ZZ, 1997, P NATL ACAD SCI USA, V94, P9125, DOI 10.1073/pnas.94.17.9125; Su ZZ, 2001, P NATL ACAD SCI USA, V98, P10332, DOI 10.1073/pnas.171315198; Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062; Su ZZ, 2005, ONCOGENE, V24, P7552, DOI 10.1038/sj.onc.1208911; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021; Viale Pamela Hallquist, 2005, Clin J Oncol Nurs, V9, P541, DOI 10.1188/05.CJON.541-552; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Ward RL, 1997, CANCER, V79, P1106, DOI 10.1002/(SICI)1097-0142(19970315)79:6<1106::AID-CNCR8>3.0.CO;2-D; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Yacoub A, 2004, CANCER BIOL THER, V3, P739, DOI 10.4161/cbt.3.8.968; Yacoub A, 2003, CANCER BIOL THER, V2, P347, DOI 10.4161/cbt.2.4.422; Yacoub A, 2003, CLIN CANCER RES, V9, P3272; YOUNG IT, 1977, J HISTOCHEM CYTOCHEM, V25, P935, DOI 10.1177/25.7.894009; Zhao LL, 2005, HUM GENE THER, V16, P845, DOI 10.1089/hum.2005.16.845	60	23	27	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					733	744		10.1038/sj.onc.1209813	http://dx.doi.org/10.1038/sj.onc.1209813			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16924242				2022-12-28	WOS:000243902200010
J	Rosner, M; Freilinger, A; Hengstschlager, M				Rosner, M.; Freilinger, A.; Hengstschlaeger, M.			Akt regulates nuclear/cytoplasmic localization of tuberin	ONCOGENE			English	Article						TSC2; tuberin; Akt; S6K; cell cycle	SCLEROSIS GENE-2 PRODUCT; TUMOR-SUPPRESSOR COMPLEX; MAMMALIAN TARGET; PHOSPHORYLATION; TSC2; RAPAMYCIN; PROTEIN; GROWTH; P27(KIP1); HAMARTIN	The autosomal dominantly inherited disease tuberous sclerosis (TSC) affects similar to 1 in 6000 individuals and is characterized by the development of tumors, named hamartomas, in different organs. TSC1, encoding hamartin, and TSC2, encoding tuberin are tumor suppressor genes responsible for TSC. Hamartin and tuberin form a complex, of which tuberin is assumed to be the functional component. The TSC proteins have been implicated in the control of cell cycle by activating the cyclin-dependent kinase inhibitor p27 and in cell size regulation by inhibiting the mammalian target of rapamycin (mTOR)/p70S6K cascade. Phosphorylation of S939 and T1462 by Akt downregulates tuberin's potential to inhibit mTOR/ p70S6K. Here, we show that this tuberin phosphorylation by Akt does not affect tuberin-mediated control of p27 protein amounts. This demonstrates that regulating p27 protein amounts and mTOR/p7OS6K are separable functions of tuberin. Furthermore, we found that phosphorylation by Akt triggers upregulation of cytoplasmic and downregulation of nuclear tuberin. In cycling cells with high Akt activity, tuberin is predominantly localized to the cytoplasm. In arrested GO cells with downregulated Akt activity, a significant proportion of tuberin is localized to the nucleus. Upon re-entry into the normal ongoing cell cycle, nuclear localization of tuberin is downregulated parallel to the activation of Akt. Recently, the mTOR/p7OS6K cascade has been demonstrated to exist in both the cytoplasm and nucleus. We here also found that tuberin harbors the potential to regulate p70S6K activity in both the cytoplasm and nucleus. This description of functional tuberin in the cytoplasm and the nucleus together with our observation of Akt-controlled and cell cycle-regulated tuberin localization are of particular interest for a further understanding of tuberin's function as a gate keeper of the GO cell status as well as of Akt's activity to control cell proliferation.	Med Univ Vienna, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at						Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Astrinidis A, 2006, HUM MOL GENET, V15, P287, DOI 10.1093/hmg/ddi444; Bachmann RA, 2006, J BIOL CHEM, V281, P7357, DOI 10.1074/jbc.M512218200; Chong-Kopera H, 2006, J BIOL CHEM, V281, P8313, DOI 10.1074/jbc.C500451200; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Furuya F, 2006, P NATL ACAD SCI USA, V103, P1780, DOI 10.1073/pnas.0510849103; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kim JE, 2000, P NATL ACAD SCI USA, V97, P14340, DOI 10.1073/pnas.011511898; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Pasumarthi KBS, 2000, CIRC RES, V86, P1069, DOI 10.1161/01.RES.86.10.1069; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2004, AMINO ACIDS, V27, P119, DOI 10.1007/s00726-004-0119-z; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wienecke R, 1996, ONCOGENE, V13, P913; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097; Zhang XW, 2002, J BIOL CHEM, V277, P28127, DOI 10.1074/jbc.M202625200	43	48	48	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					521	531		10.1038/sj.onc.1209812	http://dx.doi.org/10.1038/sj.onc.1209812			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862180				2022-12-28	WOS:000243731600005
J	Zhang, P; Castedo, M; Tao, Y; Violot, D; Metivier, D; Deutsch, E; Kroemer, G; Bourhis, J				Zhang, P.; Castedo, M.; Tao, Y.; Violot, D.; Metivier, D.; Deutsch, E.; Kroemer, G.; Bourhis, Jean			Caspase independence of radio-induced cell death	ONCOGENE			English	Article						apoptosis; delayed cell death; mitotic catastrophe; micronucleation; polyploidization	RADIATION-INDUCED APOPTOSIS; MITOTIC CATASTROPHE; CLONOGENIC SURVIVAL; MITOCHONDRIAL; CANCER; P53; SENESCENCE; EXPRESSION; CHK2	Colon carcinoma cells subjected to gamma-irradiation (4 Gy) manifest signs of apoptosis (caspase activation, chromatin condensation, phosphatidylserine (PS) exposure on the cell surface, sub-diploid DNA content), correlating with their radiosensitivity, which is increased in cells lacking the 14-3-3 sigma protein as compared to wild-type controls. Inhibition of caspases byaddition of Z-Val-Ala-DLAsp (OMe)-fluoromethylketone, by stable transfection with the Baculovirus gene coding for p35, or by Bax knockout reduced all signs of apoptosis, yet failed to suppress radio-induced micro- and multinucleation. Moreover, pharmacological caspase inhibition, p35 expression or Bax knockout had no effect on the clonogenic survival that was reduced by gamma-irradiation and caspase inhibition failed to abolish the increased radiosensitivity of 14-3-3 sigma-deficient cells. Micro- and multinucleation was detectable among non-apoptotic cells lacking PS exposure, as well as among cells undergoing apoptosis. Moreover, a fraction of micro- or multinucleated cells manifested caspase activation, and videomicroscopic analyses revealed that such cells could succumb to caspase-dependent apoptosis. Altogether, these results suggest that genomic instability induced by gamma-irradiation can trigger apoptosis, although apoptosis is dispensable for radio-induced clonogenic death.	Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, F-94805 Villejuif, France; Inst Gustave Roussy, UPRES EA 2710, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Kroemer, G (corresponding author), Inst Gustave Roussy, Ctr Natl Rech Sci, UMR 8125, Pavillon Rech 1,38 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020	KROEMER, Guido/0000-0002-9334-4405; tao, yungan/0000-0002-6916-5263; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697; Zhang, Ping/0000-0002-3043-8738				Adams JM, 2003, GENE DEV, V17, P2481, DOI 10.1101/gad.1126903; Albertini RJ, 2000, MUTAT RES-REV MUTAT, V463, P111, DOI 10.1016/S1383-5742(00)00049-1; Andreau K, 2004, J BIOL CHEM, V279, P55937, DOI 10.1074/jbc.M406411200; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Bulavin DV, 1999, ONCOGENE, V18, P5611, DOI 10.1038/sj.onc.1202945; BUSH C, 1993, BRIT J CANCER, V67, P102, DOI 10.1038/bjc.1993.17; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; Castedo M, 1996, J IMMUNOL, V157, P512; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Date T, 2003, HUM GENE THER, V14, P947, DOI 10.1089/104303403766682214; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Ferri KF, 2000, J EXP MED, V192, P1081, DOI 10.1084/jem.192.8.1081; Golstein P, 2005, CELL DEATH DIFFER, V12, P1490, DOI 10.1038/sj.cdd.4401607; Gourdier I, 2004, ONCOGENE, V23, P7449, DOI 10.1038/sj.onc.1208047; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Guo GZ, 1998, INT J RADIAT BIOL, V73, P297, DOI 10.1080/095530098142392; Held KD, 1997, APOPTOSIS, V2, P265, DOI 10.1023/A:1026485003280; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hirsch T, 1997, ONCOGENE, V15, P1573, DOI 10.1038/sj.onc.1201324; Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Kroemer G, 2005, NAT MED, V11, P725, DOI 10.1038/nm1263; Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Mariya Y, 1997, RADIAT RES, V147, P29, DOI 10.2307/3579439; Methot N, 2004, J EXP MED, V199, P199, DOI 10.1084/jem.20031791; MULLER WU, 1995, STEM CELLS, V13, P199; Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412; Olive PL, 1997, INT J RADIAT BIOL, V71, P695, DOI 10.1080/095530097143707; Perfettini JL, 2005, J EXP MED, V201, P279, DOI 10.1084/jem.20041502; Prise KM, 2005, LANCET ONCOL, V6, P520, DOI 10.1016/S1470-2045(05)70246-1; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Schmitt CA, 2003, NAT REV CANCER, V3, P286, DOI 10.1038/nrc1044; Schulze-Bergkamen H, 2004, SEMIN ONCOL, V31, P90, DOI 10.1053/j.seminoncol.2003.11.006; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; Vidair CA, 1996, CANCER RES, V56, P4116; Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989; ZHIVOTOVSKY B, 2004, NAT REV MOL CELL BIO, V117, P4461	46	24	26	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2006	25	59					7758	7770		10.1038/sj.onc.1209744	http://dx.doi.org/10.1038/sj.onc.1209744			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	116VE	16862186				2022-12-28	WOS:000242830800010
J	Borgne, A; Versteege, I; Mahe, M; Studeny, A; Leonce, S; Naime, I; Rodriguez, M; Hickman, JA; Meijer, L; Golsteyn, RM				Borgne, A.; Versteege, I.; Mahe, M.; Studeny, A.; Leonce, S.; Naime, I.; Rodriguez, M.; Hickman, J. A.; Meijer, L.; Golsteyn, R. M.			Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment	ONCOGENE			English	Article						mitotic catastrophe; cyclins; cyclin-dependent kinases; roscovitine; CYC202; seliciclib; camptothecin	DEPENDENT KINASE-ACTIVITIES; DAMAGE-INDUCED APOPTOSIS; CANCER-CELL-LINES; DNA-DAMAGE; HEMATOPOIETIC-CELLS; MITOTIC CATASTROPHE; PROTEIN-KINASES; TUMOR-CELLS; DEATH; PHOSPHORYLATION	We have studied the role of cyclins and cyclin-dependent kinase (CDK) activity in apoptosis induced by camptothecin (CPT). In this model, 22% of the cells stain for annexin-V at 24 h and then proceed to be 93% positive by 72 h. This time window permits the analysis of cyclins in cells that are committed to apoptosis but not yet dead. We provide evidence that cyclin protein levels and then associated kinase levels increase after CPT treatment. Strikingly, cyclin B1 and cyclin E1 proteins are present at the same time in CPT treated HT29 cells. Although cyclin B1 and E1 CDK complexes are activated in CPT treated cells, only the cyclin B1 complex is required for apoptosis since reduction of cyclin B1 by RNAi or roscovitine treatment reduces the number of annexin-V-stained cells. We have detected poorly organized chromosomes and phosphorylated histone H3 epitopes at the time of maximum cyclin B1/CDK kinase activity in CPT-treated cells, which suggests that these cells enter a mitotic catastrophe. Understanding which CDKs are required for apoptosis may allow us to better adapt CDK inhibitors for use as anti-cancer compounds.	Inst Rech Servier, F-78290 Croissy Sur Seine, France; CNRS, Biol Stn, Roscoff, France	Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS)	Golsteyn, RM (corresponding author), Inst Rech Servier, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.	roy.golsteyn@fr.netgrs.com	MEIJER, Laurent/ABE-7465-2021	, laurent/0000-0003-3511-4916				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Borgne Annie, 2003, Prog Cell Cycle Res, V5, P453; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DE LA, 1997, J CELL BIOCHEM, V64, P579; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Golsteyn RM, 2005, CANCER LETT, V217, P129, DOI 10.1016/j.canlet.2004.08.005; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Hyzy M, 2005, BIOCHEM PHARMACOL, V69, P801, DOI 10.1016/j.bcp.2004.11.028; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Leonce S, 2001, MOL PHARMACOL, V60, P1383, DOI 10.1124/mol.60.6.1383; Li KY, 2003, CANCER RES, V63, P3593; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Maity A, 1996, ONCOGENE, V13, P1647; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; Price PM, 2004, AM J PHYSIOL-RENAL, V286, pF378, DOI 10.1152/ajprenal.00192.2003; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Shao RG, 1997, CANCER RES, V57, P4029; Shen Manli, 2002, Zhonghua Zhongliu Zazhi, V24, P215; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; SHIMIZU T, 1995, CANCER RES, V55, P228; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	56	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7361	7372		10.1038/sj.onc.1209718	http://dx.doi.org/10.1038/sj.onc.1209718			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785996				2022-12-28	WOS:000242419100005
J	De Bosscher, K; Vanden Berghe, W; Haegeman, G				De Bosscher, K.; Vanden Berghe, W.; Haegeman, G.			Cross-talk between nuclear receptors and nuclear factor kappa B	ONCOGENE			English	Review						NF-kappaB; hormone; nuclear receptor; glucocorticoid receptor; estrogen receptor; PPAR	TUMOR-NECROSIS-FACTOR; INTERLEUKIN-6 GENE-EXPRESSION; LIGAND-BINDING DOMAIN; HUMAN PROSTATE-CANCER; HISTONE ACETYLTRANSFERASE ACTIVITY; SMOOTH-MUSCLE-CELLS; RNA-POLYMERASE-II; GLUCOCORTICOID-RECEPTOR; ESTROGEN-RECEPTOR; ANDROGEN-RECEPTOR	A variety of studies have shown that some activated nuclear receptors (NRs), especially the glucorticoid receptor, the estrogen receptor and peroxisome proliferator-activated receptor, can inhibit the activity of the transcription factor nuclear factor kappa B (NF-kappa B), which plays a key role in the control of genes involved in inflammation, cell proliferation and apoptosis. This review describes the molecular mechanisms of cross-talk between NRs and NF-kappa B and the biological relevance of this crosstalk. The importance and mechanistic aspects of selective NR modulation are discussed. Also included are future research prospects, which will lead to a new era in the field of NR research with the aim of specifically inhibiting NF-kappa B-driven gene expression for anti-inflammatory, anti-tumor and immune-modulatory purposes.	Univ Ghent, Dept Biol Mol, LEGEST, B-9000 Ghent, Belgium	Ghent University	De Bosscher, K (corresponding author), Univ Ghent, Dept Biol Mol, LEGEST, B-9000 Ghent, Belgium.	karolien.debosscher@ugent.be	Berghe, Wim Vanden/S-6425-2018; Vanden Berghe, Wim/HGE-4696-2022	Berghe, Wim Vanden/0000-0003-0161-7355; De Bosscher, Karolien/0000-0001-5059-9718				Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; Adcock IM, 1997, BIOCHEM SOC T, V25, pS154, DOI 10.1042/bst025154s; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; An JP, 1999, P NATL ACAD SCI USA, V96, P15161, DOI 10.1073/pnas.96.26.15161; Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baek SH, 2004, BIOCHEM BIOPH RES CO, V319, P707, DOI 10.1016/j.bbrc.2004.04.169; Barnes PJ, 2006, EUR J PHARMACOL, V533, P2, DOI 10.1016/j.ejphar.2005.12.052; Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Bellentani S, 2005, EUR J GASTROEN HEPAT, V17, P137, DOI 10.1097/00042737-200502000-00001; BELLIDO T, 1995, J CLIN INVEST, V95, P2886, DOI 10.1172/JCI117995; Belvisi MG, 2001, PULM PHARMACOL THER, V14, P221, DOI 10.1006/pupt.2001.0284; Belvisi MG, 2001, J IMMUNOL, V166, P1975, DOI 10.4049/jimmunol.166.3.1975; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Bird A, 2003, NAT IMMUNOL, V4, P208, DOI 10.1038/ni0303-208; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Bjornstrom L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486; Borras C, 2005, AGING CELL, V4, P113, DOI 10.1111/j.1474-9726.2005.00151.x; Bosisio D, 2006, EMBO J, V25, P798, DOI 10.1038/sj.emboj.7600977; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; Buratowski S, 2003, NAT STRUCT BIOL, V10, P679, DOI 10.1038/nsb0903-679; Burkhart BA, 2005, J BIOL CHEM, V280, P6349, DOI 10.1074/jbc.M411147200; Cacquevel M, 2004, CURR DRUG TARGETS, V5, P529, DOI 10.2174/1389450043345308; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Chakalova L, 2005, NAT REV GENET, V6, P669, DOI 10.1038/nrg1673; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chaudhary LR, 1996, J BIOL CHEM, V271, P16591, DOI 10.1074/jbc.271.28.16591; Chen JG, 2006, MOL ENDOCRINOL, V20, P1, DOI 10.1210/me.2005-0192; Cheung E, 2003, EMBO J, V22, P600, DOI 10.1093/emboj/cdg037; Cinar B, 2005, CANCER RES, V65, P2547, DOI 10.1158/0008-5472.CAN-04-3411; Clarkl DE, 2001, EMBO J, V20, P3484, DOI 10.1093/emboj/20.13.3484; Coghlan MJ, 2003, MOL ENDOCRINOL, V17, P860, DOI 10.1210/me.2002-0355; Condon JC, 2006, MOL ENDOCRINOL, V20, P764, DOI 10.1210/me.2005-0242; Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100; Cutolo M, 2004, AUTOIMMUN REV, V3, P193, DOI 10.1016/j.autrev.2003.08.003; Cutolo M, 2003, CLIN EXP RHEUMATOL, V21, P687; Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014; Davie JR, 1999, J CELL BIOCHEM, P141; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006; De Bosscher K, 2000, J NEUROIMMUNOL, V109, P16, DOI 10.1016/S0165-5728(00)00297-6; De Bosscher K, 2003, NUCLEAR FACTOR KB: REGULATION AND ROLE IN DISEASE, P221; De Bosscher K, 2005, P NATL ACAD SCI USA, V102, P15827, DOI 10.1073/pnas.0505554102; De Bosscher K, 2001, MOL ENDOCRINOL, V15, P219, DOI 10.1210/me.15.2.219; de Kloet ER, 2005, NAT REV NEUROSCI, V6, P463, DOI 10.1038/nrn1683; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DeFranco DB, 2000, CRIT REV EUKAR GENE, V10, P39; DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, EMBO REP, V2, P42, DOI 10.1093/embo-reports/kve007; Delerive P, 2002, MOL ENDOCRINOL, V16, P1029, DOI 10.1210/me.16.5.1029; Delfino FJ, 2003, MOL CELL ENDOCRINOL, V201, P1, DOI 10.1016/S0303-7207(03)00005-4; Dijsselbloem N, 2004, BIOCHEM PHARMACOL, V68, P1171, DOI 10.1016/j.bcp.2004.05.036; Doucas V, 2000, P NATL ACAD SCI USA, V97, P11893, DOI 10.1073/pnas.220413297; Dutnall RN, 2003, MOL CELL, V12, P3, DOI 10.1016/S1097-2765(03)00282-X; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Egan KM, 2004, SCIENCE, V306, P1954, DOI 10.1126/science.1103333; Eissenberg JC, 2006, CURR OPIN GENET DEV, V16, P184, DOI 10.1016/j.gde.2006.02.004; Espinosa L, 2003, MOL BIOL CELL, V14, P491, DOI 10.1091/mbc.E02-07-0404; Eun CS, 2006, DIGEST DIS SCI, V51, P693, DOI 10.1007/s10620-006-3193-0; Forman BM, 1996, ANN NY ACAD SCI, V804, P266, DOI 10.1111/j.1749-6632.1996.tb18621.x; Foster JS, 2001, TRENDS ENDOCRIN MET, V12, P320, DOI 10.1016/S1043-2760(01)00436-2; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Francastel C, 2000, NAT REV MOL CELL BIO, V1, P137, DOI 10.1038/35040083; Fujita N, 2004, MOL ENDOCRINOL, V18, P2937, DOI 10.1210/me.2004-0258; Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4; Galien R, 1997, NUCLEIC ACIDS RES, V25, P2424, DOI 10.1093/nar/25.12.2424; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Glass CK, 2000, GENE DEV, V14, P121; Glyn J, 1998, J ROY SOC MED, V91, P513, DOI 10.1177/014107689809101004; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Gururaj AE, 2006, CLIN CANCER RES, V12, p1001S, DOI 10.1158/1078-0432.CCR-05-2110; Haffner SM, 2006, J CARDIOVASC PHARM, V47, P469; Hager GL, 2000, BIOCHEM SOC T, V28, P405, DOI 10.1042/0300-5127:0280405; Hall JM, 2005, MOL INTERV, V5, P343, DOI 10.1124/mi.5.6.7; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Heldring N, 2004, MOL CELL BIOL, V24, P3445, DOI 10.1128/MCB.24.8.3445-3459.2004; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hoberg JE, 2006, MOL CELL BIOL, V26, P457, DOI 10.1128/MCB.26.2.457-471.2006; Hofbauer LC, 1999, EUR J ENDOCRINOL, V140, P271, DOI 10.1530/eje.0.1400271; Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933; Hofmann TG, 2002, BIOL CHEM, V383, P1947, DOI 10.1515/BC.2002.219; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Jehn BM, 1997, CRIT REV EUKAR GENE, V7, P179, DOI 10.1615/CritRevEukarGeneExpr.v7.i1-2.100; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Jordan VC, 2004, CANCER CELL, V5, P207, DOI 10.1016/S1535-6108(04)00059-5; Jordan VC, 2002, CANCER CELL, V1, P215, DOI 10.1016/S1535-6108(02)00050-8; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Joseph SB, 2003, CURR OPIN PHARMACOL, V3, P192, DOI 10.1016/S1471-4892(03)00009-2; Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kao HY, 2001, J BIOL CHEM, V276, P47496, DOI 10.1074/jbc.M107631200; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katzenellenbogen BS, 2002, SCIENCE, V295, P2380, DOI 10.1126/science.1070442; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; KIAN TM, 2004, MOL BIOL CELL, V15, P1262; Kim MY, 2006, MOL ENDOCRINOL, V20, P1479, DOI 10.1210/me.2005-0531; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Kong EH, 2005, P NATL ACAD SCI USA, V102, P3593, DOI 10.1073/pnas.0407189102; Kwon HJ, 2004, MOL CELL BIOL, V24, P9317, DOI 10.1128/MCB.24.21.9317-9326.2004; Lanz RB, 2003, MOL CELL BIOL, V23, P7163, DOI 10.1128/MCB.23.20.7163-7176.2003; Lanz RB, 2002, P NATL ACAD SCI USA, V99, P16081, DOI 10.1073/pnas.192571399; Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Leclercq G, 2006, CURR CANCER DRUG TAR, V6, P39, DOI 10.2174/156800906775471716; Lee DY, 2006, J BIOL CHEM, V281, P8476, DOI 10.1074/jbc.M511093200; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Leung TH, 2004, CELL, V118, P453, DOI 10.1016/j.cell.2004.08.007; Lewis BA, 2003, J CELL SCI, V116, P3667, DOI 10.1242/jcs.00734; Li AC, 2004, J CLIN INVEST, V114, P1564, DOI 10.1172/JCI200418730; Li JW, 2002, MOL CELL BIOL, V22, P5688, DOI 10.1128/MCB.22.16.5688-5697.2002; Liden J, 2000, BIOCHEM BIOPH RES CO, V273, P1008, DOI 10.1006/bbrc.2000.3079; Liden J, 1997, J BIOL CHEM, V272, P21467, DOI 10.1074/jbc.272.34.21467; Liu JM, 1999, MOL ENDOCRINOL, V13, P355, DOI 10.1210/me.13.3.355; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Manavathi B, 2006, J CELL PHYSIOL, V207, P594, DOI 10.1002/jcp.20551; Maret A, 1999, ENDOCRINOLOGY, V140, P2876, DOI 10.1210/en.140.6.2876; MARKHAM A, 1995, DRUGS, V50, P317, DOI 10.2165/00003495-199550020-00008; Martens C, 2005, MOL ENDOCRINOL, V19, P885, DOI 10.1210/me.2004-0333; McDonnell DP, 2002, SCIENCE, V296, P1642, DOI 10.1126/science.1071884; McKay LI, 2000, MOL ENDOCRINOL, V14, P1222, DOI 10.1210/me.14.8.1222; McKenna NJ, 2002, ENDOCRINOLOGY, V143, P2461, DOI 10.1210/endo.143.7.8892; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Mendelson CR, 2005, J STEROID BIOCHEM, V93, P113, DOI 10.1016/j.jsbmb.2004.12.027; Metivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Miao F, 2006, MOL ENDOCRINOL, V20, P1562, DOI 10.1210/me.2005-0365; Miner JN, 2002, BIOCHEM PHARMACOL, V64, P355, DOI 10.1016/S0006-2952(02)01121-8; Miska EA, 2001, NUCLEIC ACIDS RES, V29, P3439, DOI 10.1093/nar/29.16.3439; Miura T, 2001, J BIOL CHEM, V276, P47371, DOI 10.1074/jbc.M107098200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Murayama A, 2006, EMBO J, V25, P1081, DOI 10.1038/sj.emboj.7601012; Nakajima Y, 1996, PROSTATE, V29, P296; Natoli G, 2006, CELL DEATH DIFFER, V13, P693, DOI 10.1038/sj.cdd.4401880; Natoli G, 2005, NAT IMMUNOL, V6, P439, DOI 10.1038/ni1196; Necela BM, 2003, TRENDS PHARMACOL SCI, V24, P58, DOI 10.1016/S0165-6147(02)00046-9; NELSON HCM, 1995, CURR OPIN GENET DEV, V5, P180, DOI 10.1016/0959-437X(95)80006-9; Neve BP, 2000, BIOCHEM PHARMACOL, V60, P1245, DOI 10.1016/S0006-2952(00)00430-5; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Ogawa S, 2004, P NATL ACAD SCI USA, V101, P14461, DOI 10.1073/pnas.0405786101; Olivier S, 2006, MOL PHARMACOL, V69, P1615, DOI 10.1124/mol.105.020479; Pacifici R, 1996, J BONE MINER RES, V11, P1043; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Panta GR, 2004, MOL CELL BIOL, V24, P1823, DOI 10.1128/MCB.24.5.1823-1835.2004; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Paumelle R, 2006, CIRC RES, V98, P361, DOI 10.1161/01.RES.0000202706.70992.95; Pearce ST, 2003, J BIOL CHEM, V278, P7630, DOI 10.1074/jbc.M211129200; Perissi V, 2005, NAT REV MOL CELL BIO, V6, P542, DOI 10.1038/nrm1680; Perissi V, 2004, CELL, V116, P511, DOI 10.1016/S0092-8674(04)00133-3; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Phillips A, 1997, MOL CELL BIOL, V17, P5952, DOI 10.1128/MCB.17.10.5952; Pratt MAC, 2003, MOL CELL BIOL, V23, P6887, DOI 10.1128/MCB.23.19.6887-6900.2003; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Ramirez-Carrozzi VR, 2006, GENE DEV, V20, P282, DOI 10.1101/gad.1383206; Ray A, 1995, ANN NY ACAD SCI, V762, P79; RAY A, 1994, J BIOL CHEM, V269, P12940; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Reichardt HM, 2000, ADV PHARMACOL, V47, P1; Reily MM, 2006, EMBO J, V25, P108, DOI 10.1038/sj.emboj.7600919; Resche-Rigon M, 1998, CURR OPIN CHEM BIOL, V2, P501, DOI 10.1016/S1367-5931(98)80126-9; Robinson-Rechavi M, 2003, J CELL SCI, V116, P585, DOI 10.1242/jcs.00247; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rogatsky I, 2002, P NATL ACAD SCI USA, V99, P16701, DOI 10.1073/pnas.262671599; Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Roux S, 1999, J BIOL CHEM, V274, P10059, DOI 10.1074/jbc.274.15.10059; Salojin KV, 2006, J IMMUNOL, V176, P1899, DOI 10.4049/jimmunol.176.3.1899; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schotta Gunnar, 2004, Novartis Found Symp, V259, P22; Schulz M, 2002, J BIOL CHEM, V277, P26238, DOI 10.1074/jbc.M203268200; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Sheppard KA, 1998, J BIOL CHEM, V273, P29291, DOI 10.1074/jbc.273.45.29291; Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Smoak KA, 2004, MECH AGEING DEV, V125, P697, DOI 10.1016/j.mad.2004.06.010; Sowers JR, 2003, AM J CARDIOL, V91, p14B; Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Stavreva DA, 2004, MOL CELL BIOL, V24, P2682, DOI 10.1128/MCB.24.7.2682-2697.2004; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart S, 2000, NATURE, V408, P46, DOI 10.1038/35040690; Straus DS, 2000, P NATL ACAD SCI USA, V97, P4844, DOI 10.1073/pnas.97.9.4844; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Suh JH, 2002, PROSTATE, V52, P183, DOI 10.1002/pros.10082; SUPAKAR PC, 1995, J BIOL CHEM, V270, P837, DOI 10.1074/jbc.270.2.837; Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002; Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974; TOBLER A, 1992, BLOOD, V79, P45; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vanden Berghe W, 1999, MOL PHARMACOL, V56, P797; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Vanden Berghe W, 2006, CANCER RES, V66, P4852, DOI 10.1158/0008-5472.CAN-05-2957; VANDENBERGHE W, 2006, BIOCHEM PHARMACOL, DOI DOI 10.1016/J.BQ.2006.07.012; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vina J, 2005, FEBS LETT, V579, P2541, DOI 10.1016/j.febslet.2005.03.090; Wang JC, 2006, GENE DEV, V20, P689, DOI 10.1101/gad.1400506; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; West AG, 2005, HUM MOL GENET, V14, pR101, DOI 10.1093/hmg/ddi104; Widen C, 2003, BIOCHEM J, V373, P211, DOI 10.1042/BJ20030175; Wissink S, 1997, J BIOL CHEM, V272, P22278, DOI 10.1074/jbc.272.35.22278; Wissink S, 2001, MOL ENDOCRINOL, V15, P543, DOI 10.1210/me.15.4.543; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu J, 2004, MOL ENDOCRINOL, V18, P53, DOI 10.1210/me.2002-0373; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Wu YL, 2005, MOL CELL, V18, P413, DOI 10.1016/j.molcel.2005.04.014; Xu W, 2004, GENE DEV, V18, P144, DOI 10.1101/gad.1141704; Xu W, 2003, METHOD ENZYMOL, V364, P205; Yamada T, 2006, MOL CELL, V21, P227, DOI 10.1016/j.molcel.2005.11.024; Yamamoto Y, 2004, TRENDS BIOCHEM SCI, V29, P72, DOI 10.1016/j.tibs.2003.12.003; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977; Zhou YM, 2005, INT J BIOCHEM CELL B, V37, P1130, DOI 10.1016/j.biocel.2004.09.006; [No title captured], DOI DOI 10.1126/STKE.2882005PE27	252	207	211	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6868	6886		10.1038/sj.onc.1209935	http://dx.doi.org/10.1038/sj.onc.1209935			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072333				2022-12-28	WOS:000241666700013
J	Gilmore, TD				Gilmore, T. D.			Introduction to NF-kappa B: players, pathways, perspectives	ONCOGENE			English	Review						NF-kappaB; IkappaB; IKK; Rel; signal transduction; transcription factor	DNA-BINDING SUBUNIT; V-REL; SIGNALING PATHWAY; CROSS-TALK; ONCOGENE; DORSAL; ACTIVATION; DROSOPHILA; PROTEIN; KBF1	This article serves as an introduction to the collection of reviews on nuclear factor-kappaB (NF-kappa B). It provides an overview of the discovery and current status of NF-kappa B as a research topic. Described are the structures, activities and regulation of the proteins in the NF-kappa B family of transcription factors. NF-kappa B signaling is primarily regulated by inhibitor kappa B (I kappa B) proteins and the I kappa B kinase complex through two major pathways: the canonical and non-canonical NF-kappa B pathways. The organization and focus of articles included in the following reviews are described, as well as likely future areas of research interest on NF-kappa B.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Gilmore, TD (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	gilmore@bu.edu						BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bubici C, 2006, ONCOGENE, V25, P6731, DOI 10.1038/sj.onc.1209936; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; De Bosscher K, 2006, ONCOGENE, V25, P6868, DOI 10.1038/sj.onc.1209935; Dutta J, 2006, ONCOGENE, V25, P6800, DOI 10.1038/sj.onc.1209938; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; Gilmore TD, 2006, ONCOGENE, V25, P6887, DOI 10.1038/sj.onc.1209982; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943; Hiscott J, 2006, ONCOGENE, V25, P6844, DOI 10.1038/sj.onc.1209941; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; Minakhina S, 2006, ONCOGENE, V25, P6749, DOI 10.1038/sj.onc.1209940; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; STEPHENS RM, 1983, P NATL ACAD SCI-BIOL, V80, P6229, DOI 10.1073/pnas.80.20.6229; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; STEWARD R, 1988, CELL, V55, P487, DOI 10.1016/0092-8674(88)90035-9; WILHELMSEN KC, 1984, J VIROL, V52, P172, DOI 10.1128/JVI.52.1.172-182.1984; [No title captured]; [No title captured]	25	1680	1777	1	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6680	6684		10.1038/sj.onc.1209954	http://dx.doi.org/10.1038/sj.onc.1209954			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072321				2022-12-28	WOS:000241666700001
J	Pfeffer, S; Voinnet, O				Pfeffer, S.; Voinnet, O.			Viruses, microRNAs and cancer	ONCOGENE			English	Review						virus; RNA silencing; microRNA; cancer; oncogene; cellular transformation	SMALL INTERFERING RNA; RETRACTED ARTICLE. SEE; ANTIVIRAL IMMUNITY; VIRAL SUPPRESSOR; IDENTIFICATION; PROTEINS; EXPRESSION; INFLUENZA; BINDING; LOCUS	Viruses represent one of the main factors that cause normal cells to proliferate and to become malignant: up to 15% of all human cancers are associated with single or multiple virus infections, and several viruses have been recognized as causal agents of specific types of cancer. Viruses have evolved many strategies to prevent infected cells from becoming apoptotic and to evade the innate and adaptive immune responses of their hosts. The recent discovery that Epstein-Barr virus and other herpesviruses produce their own sets of micro (mi) RNAs brings an additional layer of complexity in this ongoing host-virus arms race and changes our initial views of the antiviral roles of RNA silencing in plants and insects. It seems that, rather than being inhibited by this process, many mammalian viruses can usurp or divert the host RNA silencing machinery to their advantage. Viral-encoded miRNAs can act both in cis, to ensure accurate expression of viral genomes, and in trans, to modify the expression of host transcripts. Here, we review the current knowledge on viral miRNAs and discuss how mammalian viruses can also perturb host miRNA expression. Those recent findings provide new insights into the role of viruses and miRNAs in cancer development.	CNRS, Inst Biol Mol Plantes, UPR 2357, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Voinnet, O (corresponding author), CNRS, Inst Biol Mol Plantes, UPR 2357, 12,Rue Gen Zimmer, F-67084 Strasbourg, France.	sebastien.pfeffer@ibmp-ulp.u-strasbg.fr; olivier.voinnet@ibmp-ulp.u-strasbg.fr	Pfeffer, Sébastien/H-3212-2019; Pfeffer, Sebastien/A-6512-2010	Pfeffer, Sébastien/0000-0002-8458-348X; Pfeffer, Sebastien/0000-0002-8458-348X; Voinnet, Olivier/0000-0001-6982-9544				AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Aparicio O, 2006, J VIROL, V80, P1376, DOI 10.1128/JVI.80.3.1376-1384.2006; Bergmann M, 2000, J VIROL, V74, P6203, DOI 10.1128/JVI.74.13.6203-6206.2000; Bucher E, 2004, J GEN VIROL, V85, P983, DOI 10.1099/vir.0.19734-0; Cai Xuezhong, 2006, PLoS Pathogens, V2, P236, DOI 10.1371/journal.ppat.0020023; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Cai XZ, 2005, P NATL ACAD SCI USA, V102, P5570, DOI 10.1073/pnas.0408192102; Chapman EJ, 2004, GENE DEV, V18, P1179, DOI 10.1101/gad.1201204; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cui C, 2006, J VIROL, V80, P5499, DOI 10.1128/JVI.00200-06; Cullen BR, 2006, NAT IMMUNOL, V7, P563, DOI 10.1038/ni1352; Deleris A, 2006, SCIENCE, V313, P68, DOI 10.1126/science.1128214; Ding SW, 2004, VIRUS RES, V102, P109, DOI 10.1016/j.virusres.2004.01.021; Dunn W, 2005, CELL MICROBIOL, V7, P1684, DOI 10.1111/j.1462-5822.2005.00598.x; Dunoyer P, 2004, PLANT CELL, V16, P1235, DOI 10.1105/tpc.020719; Galiana-Arnoux D, 2006, NAT IMMUNOL, V7, P590, DOI 10.1038/ni1335; Gottwein E, 2006, J VIROL, V80, P5321, DOI 10.1128/JVI.02734-05; Grey F, 2005, J VIROL, V79, P12095, DOI 10.1128/JVI.79.18.12095-12099.2005; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Gupta A, 2006, NATURE, V442, P82, DOI 10.1038/nature04836; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Khalili K, 2003, ONCOGENE, V22, P5181, DOI 10.1038/sj.onc.1206559; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kliche S, 2001, MOL CELL, V7, P833, DOI 10.1016/S1097-2765(01)00227-1; Lakatos L, 2006, EMBO J, V25, P2768, DOI 10.1038/sj.emboj.7601164; Lecellier CH, 2005, SCIENCE, V308, P557, DOI 10.1126/science.1108784; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Li WX, 2004, P NATL ACAD SCI USA, V101, P1350, DOI 10.1073/pnas.0308308100; Lu SH, 2004, J VIROL, V78, P12868, DOI 10.1128/JVI.78.23.12868-12876.2004; Macrae AI, 2001, J VIROL, V75, P5315, DOI 10.1128/JVI.75.11.5315-5327.2001; Mallory AC, 2002, P NATL ACAD SCI USA, V99, P15228, DOI 10.1073/pnas.232434999; Merai Z, 2006, J VIROL, V80, P5747, DOI 10.1128/JVI.01963-05; MOORE PS, 2001, FIELDS VIROLOGY, V2, P2803; Navarro L, 2006, SCIENCE, V312, P436, DOI 10.1126/science.1126088; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Obbard DJ, 2006, CURR BIOL, V16, P580, DOI 10.1016/j.cub.2006.01.065; Pearce M, 2005, J VIROL, V79, P14457, DOI 10.1128/JVI.79.22.14457-14464.2005; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Pfeffer S, 2004, SCIENCE, V304, P734, DOI 10.1126/science.1096781; Sadler R, 1999, J VIROL, V73, P5722, DOI 10.1128/JVI.73.7.5722-5730.1999; Samols MA, 2005, J VIROL, V79, P9301, DOI 10.1128/JVI.79.14.9301-9305.2005; Sano M, 2006, FEBS LETT, V580, P1553, DOI 10.1016/j.febslet.2006.01.085; Skaletskaya A, 2001, P NATL ACAD SCI USA, V98, P7829, DOI 10.1073/pnas.141108798; Soderberg-Naucler C, 2006, J INTERN MED, V259, P219, DOI 10.1111/j.1365-2796.2006.01618.x; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Speck SH, 1999, CURR OPIN MICROBIOL, V2, P403; Sullivan CS, 2005, NATURE, V435, P682, DOI 10.1038/nature03576; Sullivan CS, 2005, MOL CELL, V20, P3, DOI 10.1016/j.molcel.2005.09.012; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Tognon M, 2003, ONCOGENE, V22, P5192, DOI 10.1038/sj.onc.1206550; Vargason JM, 2003, CELL, V115, P799, DOI 10.1016/S0092-8674(03)00984-X; Voinnet O, 2005, NAT REV GENET, V6, P206, DOI 10.1038/nrg1555; Wang XH, 2006, SCIENCE, V312, P452, DOI 10.1126/science.1125694; Watanabe T, 2006, GENE DEV, V20, P1732, DOI 10.1101/gad.1425706; Xiang Y, 2002, J VIROL, V76, P5251, DOI 10.1128/JVI.76.10.5251-5259.2002; Yang WD, 2006, NAT STRUCT MOL BIOL, V13, P13, DOI 10.1038/nsmb1041; Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213; Yeung ML, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-81	65	79	92	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6211	6219		10.1038/sj.onc.1209915	http://dx.doi.org/10.1038/sj.onc.1209915			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028601				2022-12-28	WOS:000241158900010
J	Antoniou, AC; Easton, DF				Antoniou, A. C.; Easton, D. F.			Models of genetic susceptibility to breast cancer	ONCOGENE			English	Review						polygenic inheritance; genetic model; twin studies; mathematical model; association; linkage	ATAXIA-TELANGIECTASIA; MAMMOGRAPHIC DENSITY; LINKAGE ANALYSIS; EARLY-ONSET; FAMILY-HISTORY; GROWTH-HORMONE; ATM MUTATIONS; RISK-FACTORS; BRCA1; AGE	One of the most important risk factors for breast cancer is family history of the disease, indicating that genetic factors are important determinants of breast cancer risk. A number of breast cancer susceptibility genes have been identified, the most important being BRCA1 and BRCA2. However, it is estimated that all the currently known breast cancer susceptibility genes accounts for less than 25% of the familial aggregation of breast cancer. In this paper, we review the evidence for other breast cancer susceptibility genes arising from twin studies, pedigree analysis and studies of phenotypes associated with breast cancer, and the progress towards finding other breast cancer susceptibility genes through linkage and association studies. Taken together, the available evidence indicates that susceptibility to breast cancer is mediated through variants in many genes, each conferring a moderate risk of the disease. Such a model of susceptibility has implications for both risk prediction and for future gene identification studies.	Univ Cambridge, Genet Epidemiol Unit, Dept Publ Hlth & Primary Care, Strangeways Res Lab,Canc Res UK, Cambridge CB1 8RN, England	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge	Antoniou, AC (corresponding author), Univ Cambridge, Genet Epidemiol Unit, Dept Publ Hlth & Primary Care, Strangeways Res Lab,Canc Res UK, Worts Causeway, Cambridge CB1 8RN, England.	antonis@srl.cam.ac.uk						Ahmed M, 2006, ONCOGENE, V25, P5906, DOI 10.1038/sj.onc.1209873; AMOS CI, 1991, CANCER RES, V51, P1793; Andrieu N, 2006, JNCI-J NATL CANCER I, V98, P535, DOI 10.1093/jnci/djj132; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Antoniou AC, 2002, BRIT J CANCER, V86, P76, DOI 10.1038/sj.bjc.6600008; Antoniou AC, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1365; Antoniou AC, 2004, BRIT J CANCER, V91, P1580, DOI 10.1038/sj.bjc.6602175; Antoniou Antonis C, 2006, Future Oncol, V2, P257, DOI 10.2217/14796694.2.2.257; Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2; Bernstein JL, 2003, BRIT J CANCER, V89, P1513, DOI 10.1038/sj.bjc.6601289; BISHOP DT, 1988, GENET EPIDEMIOL, V5, P151, DOI 10.1002/gepi.1370050303; Boardman LA, 1998, ANN INTERN MED, V128, P896, DOI 10.7326/0003-4819-128-11-199806010-00004; BORRESEN AL, 1992, CANCER RES, V52, P3234; Boyd NF, 2005, LANCET ONCOL, V6, P798, DOI 10.1016/S1470-2045(05)70390-9; Boyd NF, 2002, NEW ENGL J MED, V347, P886, DOI 10.1056/NEJMoa013390; BOYD NF, 1995, J NATL CANCER I, V87, P670, DOI 10.1093/jnci/87.9.670; *BREAST CANC ASS C, 2006, IN PRESS J NATL CANC; Breast Canc Linkage Consortium, 1999, JNCI-J NATL CANCER I, V91, P1310; BYRNE C, 1995, J NATL CANCER I, V87, P1622, DOI 10.1093/jnci/87.21.1622; Canzian F, 2005, CANCER EPIDEM BIOMAR, V14, P2316, DOI 10.1158/1055-9965.EPI-04-0874; Cavaciuti E, 2005, GENE CHROMOSOME CANC, V42, P1, DOI 10.1002/gcc.20101; Chenevix-Trench G, 2002, JNCI-J NATL CANCER I, V94, P205, DOI 10.1093/jnci/94.3.205; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Cui JS, 2001, AM J HUM GENET, V68, P420, DOI 10.1086/318187; de Bruin JP, 2001, HUM REPROD, V16, P2014, DOI 10.1093/humrep/16.9.2014; de Jong MM, 2002, J MED GENET, V39, P225, DOI 10.1136/jmg.39.4.225; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Dunning AM, 2004, JNCI-J NATL CANCER I, V96, P936, DOI 10.1093/jnci/djh167; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; FitzGerald MG, 1997, NAT GENET, V15, P307, DOI 10.1038/ng0397-307; Fletcher O, 2005, CANCER EPIDEM BIOMAR, V14, P2; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GARBER JE, 1991, CANCER RES, V51, P6094; Harvey JA, 2004, RADIOLOGY, V230, P29, DOI 10.1148/radiol.2301020870; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hemminki K, 2002, INT J CANCER, V99, P873, DOI 10.1002/ijc.10441; Hong CC, 2004, BREAST CANCER RES TR, V88, P217, DOI 10.1007/s10549-004-0780-7; HOPPER JL, 1992, AM J EPIDEMIOL, V136, P1138, DOI 10.1093/oxfordjournals.aje.a116580; Hunter DJ, 2001, OSTEOPOROSIS INT, V12, P406, DOI 10.1007/s001980170110; Jaquish CE, 1997, METABOLISM, V46, P988, DOI 10.1016/S0026-0495(97)90266-3; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kok HS, 2005, HUM REPROD UPDATE, V11, P483, DOI 10.1093/humupd/dmi024; Lalloo F, 2003, LANCET, V361, P1101, DOI 10.1016/S0140-6736(03)12856-5; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Mack TM, 2002, BRIT J CANCER, V87, P294, DOI 10.1038/sj.bjc.6600429; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mitchell G, 2006, CANCER RES, V66, P1866, DOI 10.1158/0008-5472.CAN-05-3368; Mulhall C, 2005, CANCER EPIDEM BIOMAR, V14, P2648, DOI 10.1158/1055-9965.EPI-04-0374; Murabito JM, 2005, J CLIN ENDOCR METAB, V90, P3427, DOI 10.1210/jc.2005-0181; Nelen MR, 1996, NAT GENET, V13, P114, DOI 10.1038/ng0596-114; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Olsen JH, 2001, JNCI-J NATL CANCER I, V93, P121, DOI 10.1093/jnci/93.2.121; Pankow JS, 1997, J NATL CANCER I, V89, P549, DOI 10.1093/jnci/89.8.549; Pe'er I, 2006, NAT GENET, V38, P663, DOI 10.1038/ng1816; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Pharoah PDP, 2004, NAT REV CANCER, V4, P850, DOI 10.1038/nrc1476; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Rebbeck TR, 2002, NEW ENGL J MED, V346, P1616, DOI 10.1056/NEJMoa012158; Risch N, 2001, CANCER EPIDEM BIOMAR, V10, P733; Roberts SA, 1999, AM J HUM GENET, V65, P784, DOI 10.1086/302544; Seitz S, 1997, BRIT J CANCER, V76, P983, DOI 10.1038/bjc.1997.497; SIDRANSKY D, 1992, CANCER RES, V52, P2984; Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330; Snieder H, 1998, J CLIN ENDOCR METAB, V83, P1875, DOI 10.1210/jc.83.6.1875; Stone J, 2006, CANCER EPIDEM BIOMAR, V15, P612, DOI 10.1158/1055-9965.EPI-05-0127; Swerdlow AJ, 1997, LANCET, V350, P1723, DOI 10.1016/S0140-6736(97)05526-8; SWIFT M, 1986, AM J HUM GENET, V39, P573; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Thompson D, 2002, JNCI-J NATL CANCER I, V94, P1358, DOI 10.1093/jnci/94.18.1358; Thompson Deborah, 2005, Hum Mutat, V25, P594, DOI 10.1002/humu.9344; Treloar SA, 1998, LANCET, V352, P1084, DOI 10.1016/S0140-6736(05)79753-1; Tyrer J, 2004, STAT MED, V23, P1111, DOI 10.1002/sim.1668; Vaittinen P, 2000, INT J CANCER, V88, P998, DOI 10.1002/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0; van Asselt KM, 2004, FERTIL STERIL, V82, P1348, DOI 10.1016/j.fertnstert.2004.04.047; van Duijnhoven FJB, 2005, CANCER EPIDEM BIOMAR, V14, P2655, DOI 10.1158/1055-9965.EPI-05-0398; Velde ERT, 2002, HUM REPROD UPDATE, V8, P141, DOI 10.1093/humupd/8.2.141; Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Ziv E, 2004, CANCER EPIDEM BIOMAR, V13, P2090; Ziv E, 2003, J NATL CANCER I, V95, P556, DOI 10.1093/jnci/95.7.556	86	192	200	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2006	25	43					5898	5905		10.1038/sj.onc.1209879	http://dx.doi.org/10.1038/sj.onc.1209879			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TS	16998504				2022-12-28	WOS:000240765900010
J	Lee, MG; Huh, JS; Chung, SK; Lee, JH; Byun, DS; Ryu, BK; Kang, MJ; Chae, KS; Lee, SJ; Lee, CH; Kim, JI; Chang, SG; Chi, SG				Lee, M. -G; Huh, J. -S; Chung, S. -K; Lee, J. -H; Byun, D. -S; Ryu, B. -K; Kang, M. -J; Chae, K. -S; Lee, S. -J; Lee, C. -H; Kim, J. I.; Chang, S. -G; Chi, S. -G			Promoter CpG hypermethylation and downregulation of XAF1 expression in human urogenital malignancies: implication for attenuated p53 response to apoptotic stresses	ONCOGENE			English	Article						xAF1; promoter hypermethylation; CpG site; urogenital cancer; apoptosis; p53	XIAP-ASSOCIATED FACTOR-1; HUMAN BLADDER-CANCER; X-LINKED INHIBITOR; IAP; GENE; PROTEINS; CELLS; FAMILY; IDENTIFICATION; IMMUNOTHERAPY	XIAP-associated factor 1 (XAF1) is a new candidate tumor suppressor, which has been known to exert proapoptotic effects by interfering with the caspase-inhibiting activity of XIAP. To explore the XAF1' s candidacy for a suppressor in urogenital tumorigenesis, we investigated the XAF1 status in a series of cancer cell lines and primary tumors derived from the bladder, kidney and prostate. Expression of XAF1 transcript was undetectable or extremely low in 60% (3/5) of bladder, 66% (10/15) of kidney, and 100% (3/3) prostate cancer cell lines. Abnormal reduction of XAF1 was also found in 33% (18/55) of primary bladder and 40% (8/20) of primary kidney tumors, and showed a correlation with advanced stage and high grade of bladder tumor. Hypermethylation at 14 CpG sites in the 50 proximal region of the XAF1 promoter was highly prevalent in cancers versus adjacent normal or benign tissues and tightly associated with reduced gene expression. XAF1 expression enhanced the apoptotic response of tumor cells to chemotherapeutic agents, such as etoposide or 5-FU. While XAF1 expression did not influence the subcellular distribution or expression of XIAP, it elevated the protein stability of p53 and its target gene expression. Moreover, the apoptosis-sensitizing and growth suppression function of XAF1 was markedly impeded by blockade of p53 function. Collectively, our study demonstrates that epigenetic alteration of XAF1 is frequent in human urogenital cancers and may contribute to the malignant progression of tumors by rendering tumor cells a survival advantage partially through the attenuated p53 response to apoptotic stresses.	Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea; Jeju Natl Univ, Coll Med, Dept Urol, Cheju, South Korea; Kyung Hee Univ, Sch Med, Dept Urol, Seoul, South Korea	Korea University; Jeju National University; Kyung Hee University	Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.	chi6302@korea.ac.kr	Kang, Min-Ju/AAY-8706-2021	KANG, MIN-JU/0000-0001-5040-1388				Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Asselin E, 2001, CANCER RES, V61, P1862; Benedict WF, 2004, MOL THER, V10, P525, DOI 10.1016/j.ymthe.2004.05.027; Byun DS, 2003, CANCER RES, V63, P7068; Chi SG, 1998, GASTROENTEROLOGY, V115, P1084, DOI 10.1016/S0016-5085(98)70078-2; Chi SG, 1999, CANCER RES, V59, P2791; CHI SG, 1994, J NATL CANCER I, V86, P926, DOI 10.1093/jnci/86.12.926; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fong WG, 2000, GENOMICS, V70, P113, DOI 10.1006/geno.2000.6364; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; JACKSON AM, 1995, CLIN EXP IMMUNOL, V99, P369, DOI 10.1111/j.1365-2249.1995.tb05560.x; Leaman DW, 2002, J BIOL CHEM, V277, P28504, DOI 10.1074/jbc.M204851200; Lee MG, 2001, CANCER RES, V61, P6688; Li J, 1998, ENDOCRINOLOGY, V139, P1321, DOI 10.1210/en.139.3.1321; Liston P, 2001, NAT CELL BIOL, V3, P128, DOI 10.1038/35055027; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Ludwig AT, 2004, CANCER RES, V64, P3386, DOI 10.1158/0008-5472.CAN-04-0374; Luo Y, 1999, J IMMUNOL, V162, P2399; Ng KCP, 2004, J INVEST DERMATOL, V123, P1127, DOI 10.1111/j.0022-202X.2004.23467.x; Papageorgiou A, 2004, CANCER RES, V64, P8973, DOI 10.1158/0008-5472.CAN-04-1909; Perrelet D, 2004, J NEUROSCI, V24, P3777, DOI 10.1523/JNEUROSCI.0413-04.2004; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sasaki H, 2000, CANCER RES, V60, P5659; Siegelin M, 2005, NEUROBIOL DIS, V20, P509, DOI 10.1016/j.nbd.2005.04.006; Steidl C, 2002, J PATHOL, V198, P115, DOI 10.1002/path.1175; Sun CH, 1999, NATURE, V401, P818, DOI 10.1038/44617; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Tamm I, 2000, CLIN CANCER RES, V6, P1796; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tomita Y, 2003, INT J CANCER, V104, P400, DOI 10.1002/ijc.10956; Tricoli JV, 1996, GENE CHROMOSOME CANC, V15, P108, DOI 10.1002/(SICI)1098-2264(199602)15:2<108::AID-GCC5>3.0.CO;2-7; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X	37	68	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 21	2006	25	42					5807	5822		10.1038/sj.onc.1209867	http://dx.doi.org/10.1038/sj.onc.1209867			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	087TR	16909101				2022-12-28	WOS:000240765800011
J	Gaussmann, A; Wenger, T; Eberle, I; Bursen, A; Bracharz, S; Herr, I; Dingermann, T; Marschalek, R				Gaussmann, A.; Wenger, T.; Eberle, I.; Bursen, A.; Bracharz, S.; Herr, I.; Dingermann, T.; Marschalek, R.			Combined effects of the two reciprocal t(4; II) fusion proteins MLL . AF4 and AF4 . MLL confer resistance to apoptosis, cell cycling capacity and growth transformation	ONCOGENE			English	Article						MLL; AF4; acute leukemia; t(4;11) fusion proteins; Nanog	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD ACUTE-LEUKEMIA; CARCINOMA IN-SITU; CHROMOSOMAL REARRANGEMENT; EXPRESSION; MLL-AF4; GENE; PLURIPOTENCY; NANOG; COOPERATION	The reciprocal chromosomal translocation t(4;11) is correlated with infant, childhood, adult and therapy-related high-risk acute leukemia. Here, we investigated the biological effects of MLL (.) AF4, AF4 (.) MLL or the combination of both reciprocal fusion proteins in a conditional in vitro cell culture model system. Several parameters like cell growth, cell cycling capacity, apoptotic behavior and growth transformation were investigated under physiological and stress conditions. Co-transfected cells displayed the highest resistance against apoptotic triggers, cell cycling capacity and loss-of-contact inhibition. These analyses were complemented by gene expression profiling experiments and specific gene signatures were established for each of the three cell lines. Interestingly, co-transfected cells strongly upregulate the homeobox gene Nanog. In combination with Oct4, the Nanog homeoprotein is steering maintenance of pluripotency and self-renewal in embryonic stem cells. Transcription of Nanog and other stem cell factors, like Oct4 and Bmi1, was verified in biopsy material of t(4;11) patient cells which express both reciprocal t(4;11) fusion genes. In conclusion, the presence of both reciprocal MLL fusion proteins confers biological properties known from t(4;11) leukemia, suggesting that each of the two fusion proteins contribute specific properties and, in combination, also synergistic effects to the leukemic phenotype.	Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, ZAFES, D-60439 Frankfurt, Germany; Heidelberg Univ, Dept Surg, Heidelberg, Germany; German Canc Res Ctr, Heidelberg, Germany	Goethe University Frankfurt; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)	Marschalek, R (corresponding author), Goethe Univ Frankfurt, Bioctr, Inst Pharmaceut Biol, ZAFES, Max Von Laue Str 9, D-60439 Frankfurt, Germany.	rolf.marschalek@em.uni-frankfurt.de	Marschalek, Rolf/D-3404-2011; Dingermann, Theodor/M-6970-2014	Marschalek, Rolf/0000-0003-4870-3445; Dingermann, Theodor/0000-0002-2788-1085				Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; Andersson A, 2005, P NATL ACAD SCI USA, V102, P19069, DOI 10.1073/pnas.0506637102; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Caslini C, 2004, LEUKEMIA, V18, P1064, DOI 10.1038/sj.leu.2403321; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; CHEN W, 2006, IN RPESS BLOOD  0321; Dordelmann M, 1999, BLOOD, V94, P1209, DOI 10.1182/blood.V94.4.1209.416k05_1209_1217; DOWNING JR, 1994, BLOOD, V83, P330, DOI 10.1182/blood.V83.2.330.bloodjournal832330; FELIX CA, 1995, BLOOD, V85, P3250, DOI 10.1182/blood.V85.11.3250.bloodjournal85113250; GREIL J, 1994, BRIT J HAEMATOL, V86, P275, DOI 10.1111/j.1365-2141.1994.tb04726.x; Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102; Hoei-Hansen CE, 2005, HISTOPATHOLOGY, V47, P48, DOI 10.1111/j.1365-2559.2005.02182.x; Ivanova N, 2006, NATURE, V442, P533, DOI 10.1038/nature04915; JANSSEN JWG, 1994, BLOOD, V84, P3835, DOI 10.1182/blood.V84.11.3835.bloodjournal84113835; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kersey JH, 1998, LEUKEMIA, V12, P1561, DOI 10.1038/sj.leu.2401148; LANGE B, 1987, BLOOD, V70, P192; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; LOH YH, 2006, IN PRESS NAT GENET, V5; Metzler M, 2006, ONCOGENE, V25, P3093, DOI 10.1038/sj.onc.1209636; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Mitterbauer-Hohendanner G, 2004, EUR J CLIN INVEST, V34, P12, DOI 10.1111/j.0960-135X.2004.01366.x; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; SO ECW, 2004, ASH ABST, V467; STONG RC, 1985, BLOOD, V65, P21, DOI 10.1182/blood.V65.1.21.21; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Takeda S, 2006, GENE DEV, V20, P2397, DOI 10.1101/gad.1449406; Taranger CK, 2005, MOL BIOL CELL, V16, P5719, DOI 10.1091/mbc.e05-06-0572; Terranova R, 2006, P NATL ACAD SCI USA, V103, P6629, DOI 10.1073/pnas.0507425103; Thomas M, 2005, BLOOD, V106, P3559, DOI 10.1182/blood-2005-03-1283; Xia ZB, 2005, P NATL ACAD SCI USA, V102, P14028, DOI 10.1073/pnas.0506464102; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0; Zhang FQ, 2006, M&SOM-MANUF SERV OP, V8, P273, DOI 10.1287/msom.1060.0108	38	38	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 17	2007	26	23					3352	3363		10.1038/sj.onc.1210125	http://dx.doi.org/10.1038/sj.onc.1210125			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	169GB	17130830				2022-12-28	WOS:000246579600005
J	Mayelzadeh, F; Martinez, JD				Mayelzadeh, F.; Martinez, J. D.			DNA binding and selective gene induction by different forms of the p53 protein	ONCOGENE			English	Article						conformation; transactivation; chromatin immunoprecipitation	WILD-TYPE P53; MUTANT P53; CELLS; LOCALIZATION; ACTIVATION; EXPRESSION; MUTATIONS; COMPLEX; GROWTH	P53 is a tumor suppressor gene that plays a crucial role in suppressing tumorigenesis by inducing either cell cycle arrest or apoptosis in cells with DNA damage. In more than 50% of tumors p53 is inactivated by gene mutations. However, there have also been reports of tumor cells in which p53 remains wild type and is present in elevated concentrations. Here we utilized a set of mutant cell lines, which, unlike the parental A1-5 cell line, which expresses a mouse tsp53 and becomes growth arrested at 32 degrees C, are capable of growth at this same incubation temperature. We found that the tsp53 in the two cell lines, ALTR-17 and ALTR-24, was identical to the parental A1-5s and concentrated in the nucleus at 32 degrees C. Examination of both lines revealed that p21 was induced at 32 degrees C, although to a lesser extent than in parental cells and that the p21 genes were not mutated. Interestingly, evaluation of the conformation of tsp53 using conformation-specific antibodies showed that the protein existed in different forms, which were found to bind DNA using chromatin immunoprecipitation assays and which we showed could induce expression of a p21 reporter construct. We conclude that the tsp53 may exist in various forms capable of binding DNA.	Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA; Univ Arizona, Genet Grad Interdisciplinary Program, Tucson, AZ USA; Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ USA	Arizona Center Cancer Care; University of Arizona; University of Arizona; University of Arizona	Martinez, JD (corresponding author), Univ Arizona, Arizona Canc Ctr, 1515 N Campbell Ave,POB 245024, Tucson, AZ 85724 USA.	jmartinez@azcc.arizona.edu			NATIONAL CANCER INSTITUTE [R01CA090776] Funding Source: NIH RePORTER; NCI NIH HHS [CA090776] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARENJEE S, 2004, MOL CELL BIOL, V24, P2052; BARTEK J, 1990, ONCOGENE, V5, P893; Benchimol S, 2001, CELL DEATH DIFFER, V8, P1049, DOI 10.1038/sj.cdd.4400918; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; Martinez JD, 1997, ONCOGENE, V14, P2511, DOI 10.1038/sj.onc.1201095; McLure KG, 1999, EMBO J, V18, P763, DOI 10.1093/emboj/18.3.763; MOLL R, 1992, AM J PATHOL, V140, P427; Qiao DH, 2001, CARCINOGENESIS, V22, P957, DOI 10.1093/carcin/22.6.957; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watts GS, 2004, NEOPLASIA, V6, P187, DOI 10.1593/neo.03292; Wolff A, 2001, ONCOGENE, V20, P1307, DOI 10.1038/sj.onc.1204251; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	24	4	4	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2007	26	21					2955	2963		10.1038/sj.onc.1210110	http://dx.doi.org/10.1038/sj.onc.1210110			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130840	Green Accepted			2022-12-28	WOS:000246395400001
J	Iwamaru, A; Kondo, Y; Iwado, E; Aoki, H; Fujiwara, K; Yokoyama, T; Mills, GB; Kondo, S				Iwamaru, A.; Kondo, Y.; Iwado, E.; Aoki, H.; Fujiwara, K.; Yokoyama, T.; Mills, G. B.; Kondo, S.			Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells	ONCOGENE			English	Article						rapamycin; autophagy; glioma; mTOR; siRNA	TUMOR-SUPPRESSOR; CANCER-THERAPY; GROWTH-CONTROL; MTOR; INHIBITION; PATHWAY; KINASE; AKT; TOR; BECLIN-1	The mammalian target of rapamycin ( mTOR) plays a central role in regulating the proliferation of malignant glioma cells, and mTOR-specific inhibitors such as rapamycin analogs are considered as promising therapy for malignant gliomas. However, the efficacy of mTOR inhibitors alone in the treatment of patients with malignant gliomas is only modest, potentially because these agents rather than acting as mTOR kinase inhibitors instead interfere with the function of only mTOR/raptor (regulatory-associated protein of mTOR) complex and thus do not perturb all mTOR functions. The purpose of this study was to determine whether global inhibition of the mTOR molecule enhances the antitumor effect of rapamycin on malignant glioma cells. We showed that rapamycin induced autophagy and that inhibition of autophagy by small interfering RNA ( siRNA) directed against autophagy-related gene Beclin 1 attenuated the cytotoxicity of rapamycin in rapamycin-sensitive tumor cells, indicating that the autophagy was a primary mediator of rapamycin's antitumor effect rather than a protective response. Exogenous expression of an mTOR mutant interfering with its kinase activity markedly enhanced the incidence of rapamycin-induced autophagy. Moreover, silencing of mTOR with siRNA augmented the inhibitory effect of rapamycin on tumor cell viability by stimulating autophagy. Importantly, not only rapamycin-sensitive malignant glioma cells with PTEN mutations but also rapamycin-resistant malignant glioma cells with wild-type PTEN were sensitized to rapamycin by mTOR siRNA. These results indicate that rapamycin-induced autophagy is one of the agent's antitumor effects and that silencing or inhibiting mTOR kinase activity could enhance the effectiveness of rapamycin.	Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Houston, TX 77030 USA; Univ Texas, Grad Sch Biomed Sci, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; Baylor College of Medicine	Kondo, S (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Neurosurg, 1515 Holcombe Blvd,Unit BSRB 1004, Houston, TX 77030 USA.	seikondo@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA108558, R01CA088936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 088936, CA 108558] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi J, 1999, J NEUROSURG, V91, P822, DOI 10.3171/jns.1999.91.5.0822; Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj/cdd/4400978; Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002; Daido S, 2005, CANCER RES, V65, P4368, DOI 10.1158/0008-5472.CAN-04-4202; Edinger AL, 2003, CANCER RES, V63, P8451; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521; Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Hosoi H, 1999, CANCER RES, V59, P886; Huang S, 2003, CURR OPIN PHARMACOL, V3, P371, DOI 10.1016/S1471-4892(03)00071-7; Ito H, 2005, HUM GENE THER, V16, P685, DOI 10.1089/hum.2005.16.685; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200; Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Mitchell P, 2005, LANCET NEUROL, V4, P413, DOI 10.1016/S1474-4422(05)70118-6; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Nepomuceno RR, 2003, CANCER RES, V63, P4472; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0; Oldham S, 2003, TRENDS CELL BIOL, V13, P79, DOI 10.1016/S0962-8924(02)00042-9; Peralba JM, 2003, CLIN CANCER RES, V9, P2887; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Sekulic A, 2000, CANCER RES, V60, P3504; Shi YJ, 2005, MOL CANCER THER, V4, P1533, DOI 10.1158/1535-7163.MCT-05-0068; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Surawicz TS, 1998, J NEURO-ONCOL, V40, P151, DOI 10.1023/A:1006091608586; Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222	48	127	127	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1840	1851		10.1038/sj.onc.1209992	http://dx.doi.org/10.1038/sj.onc.1209992			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17001313				2022-12-28	WOS:000245117700002
J	Lau, L; Hansford, LM; Cheng, LS; Hang, M; Baruchel, S; Kaplan, DR; Irwin, MS				Lau, L.; Hansford, L. M.; Cheng, L. S.; Hang, M.; Baruchel, S.; Kaplan, D. R.; Irwin, M. S.			Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; cyclooxygenase inhibitor; p53; HDM2; chemosensitivity	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE COX-2 INHIBITOR; P53 GENE-MUTATIONS; CANCER CELL-LINES; ANTICANCER AGENTS; NUCLEAR EXCLUSION; GROWTH-INHIBITION; NITRIC-OXIDE; MDM2; HDM2	Cyclooxygenase-2 (COX-2) is upregulated in many tumors including neuroblastoma, and its overexpression has been implicated in resistance to p53-dependent apoptosis. Although p53 is rarely mutated in neuroblastoma, the p53 protein is rendered inactive via several mechanisms including sequestration in the cytoplasm. Here, we show that COX inhibitors inhibit the growth of neuroblastoma and when combined with low doses of chemotherapy, exert synergistic effects on neuroblastoma cells. Following COX inhibitor treatment, HDM2, which targets p53 for ubiquitin-mediated degradation, is downregulated, resulting in an attenuation of p53 ubiquitination and an increase in p53 half-life. The level of HDM2 phosphorylation at ser166, which influences both HDM2 and p53 subcellular distribution, is markedly diminished in response to COX inhibitors and is associated with increased p53 nuclear localization. Combining COX inhibitors with low-dose chemotherapy potentiates apoptosis and p53 stability, nuclear localization, and activity. p53 knockdown by siRNA resulted in the rescue of COX-inhibitor-treated cells, indicating that COX inhibitor-induced apoptosis is, at least in part, p53-dependent. Taken together, these results provide the first evidence that COX inhibitors enhance chemosensitivity in neuroblastoma via downregulating HDM2 and augmenting p53 stability and nuclear accumulation.	Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Canc Res Program, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Irwin, MS (corresponding author), Hosp Sick Children, Dept Pediat & Canc Res, Div Haematol Oncol, Black Wing 9th Floor,555 Univ Ave, Toronto, ON M5G 1X8, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970				Arico S, 2002, J BIOL CHEM, V277, P27613, DOI 10.1074/jbc.M201119200; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Bianco R, 2005, CURR CANCER DRUG TAR, V5, P51, DOI 10.2174/1568009053332681; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Carr J, 2006, CANCER RES, V66, P2138, DOI 10.1158/0008-5472.CAN-05-2623; Choi EM, 2005, BIOCHEM BIOPH RES CO, V328, P1107, DOI 10.1016/j.bbrc.2005.01.072; CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432-1033.1981.tb06218.x; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Corcoran CA, 2005, ONCOGENE, V24, P1634, DOI 10.1038/sj.onc.1208353; CORVI R, 1995, ONCOGENE, V10, P1081; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Fischer PM, 2004, TRENDS PHARMACOL SCI, V25, P343, DOI 10.1016/j.tips.2004.04.011; Gasparini G, 2003, LANCET ONCOL, V4, P605, DOI 10.1016/S1470-2045(03)01220-8; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hida T, 2000, CLIN CANCER RES, V6, P2006; HOSOI G, 1994, CANCER, V73, P3087, DOI 10.1002/1097-0142(19940615)73:12<3087::AID-CNCR2820731230>3.0.CO;2-9; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; IMAMURA J, 1993, CANCER RES, V53, P4053; Inoue T, 2005, FEBS LETT, V579, P4978, DOI 10.1016/j.febslet.2005.08.006; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; KOMURO H, 1993, CANCER RES, V53, P5284; Liu XH, 2005, J BIOL CHEM, V280, P3817, DOI 10.1074/jbc.M406577200; LOOK AT, 1991, J CLIN ONCOL, V9, P581, DOI 10.1200/JCO.1991.9.4.581; Lu WG, 2000, ONCOGENE, V19, P232, DOI 10.1038/sj.onc.1203262; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Moos PJ, 2000, P NATL ACAD SCI USA, V97, P9215, DOI 10.1073/pnas.160241897; Nikolaev AY, 2003, CELL, V112, P29, DOI 10.1016/S0092-8674(02)01255-2; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Parashar B, 2005, J NEURO-ONCOL, V71, P141, DOI 10.1007/s11060-004-1721-3; Parashar B, 2006, J NEURO-ONCOL, V78, P129, DOI 10.1007/s11060-005-9079-8; Rodriguez-Lopez AM, 2001, MOL PHARMACOL, V59, P135, DOI 10.1124/mol.59.1.135; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Subbaramaiah K, 1999, J BIOL CHEM, V274, P10911, DOI 10.1074/jbc.274.16.10911; Swamy MV, 2003, CANCER RES, V63, P5239; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Trifan OC, 2002, CANCER RES, V62, P5778; Tweddle DA, 2001, AM J PATHOL, V158, P2067, DOI 10.1016/S0002-9440(10)64678-0; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; VOGAN K, 1993, CANCER RES, V53, P5269; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang X, 2003, CELL DEATH DIFFER, V10, P468, DOI 10.1038/sj.cdd.4401181; Wang XJ, 2002, J BIOL CHEM, V277, P15697, DOI 10.1074/jbc.M112068200; Waskewich C, 2002, CANCER RES, V62, P2029; Weber HO, 2005, ONCOGENE, V24, P1965, DOI 10.1038/sj.onc.1208389; Winters ME, 2005, CANCER RES, V65, P3853, DOI 10.1158/0008-5472.CAN-04-1989; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175	54	34	34	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1920	1931		10.1038/sj.onc.1209981	http://dx.doi.org/10.1038/sj.onc.1209981			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983334				2022-12-28	WOS:000245117700009
J	Olmeda, D; Jorda, M; Peinado, H; Fabra, A; Cano, A				Olmeda, D.; Jorda, M.; Peinado, H.; Fabra, A.; Cano, A.			Snail silencing effectively suppresses tumour growth and invasiveness	ONCOGENE			English	Article						snail; E-cadherin; EMT; MET; tumorigenicity; invasion	TRANSCRIPTION FACTOR SNAIL; EPITHELIAL-MESENCHYMAL TRANSITIONS; CELL-ADHESION MOLECULE; E-CADHERIN EXPRESSION; GENE-EXPRESSION; REPRESSOR SNAIL; SUPERFAMILY; PROGRESSION; JUNCTIONS; INVASION	The transcription factor Snail has been recently proposed as an important mediator of tumour invasion because of its role in downregulation of E-cadherin and induction of epithelial-mesenchymal transitions (EMT). This behaviour has led to the consideration of Snail as a potential therapeutic target to block tumour progression. In this report, we provide evidence for this hypothesis. We show that silencing of Snail by stable RNA interference in MDCK-Snail cells induces a complete mesenchymal to epithelial transition (MET), associated to the upregulation of E-cadherin, downregulation of mesenchymal markers and inhibition of invasion. More importantly, stable interference of endogenous Snail in two independent carcinoma cell lines leads to a dramatic reduction of in vivo tumour growth, accompanied by increased tumour differentiation and a significant decrease in the expression of MMP-9 and angiogenic markers and invasiveness. These results indicate that use of RNA interference can be an effective tool for blocking Snail function, opening the way for its application in new antiinvasive therapies.	UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, Madrid 28029, Spain; IDIBELL, Inst Invest Bellvitge, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Cano, A (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Dept Bioquim, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Peinado, Hector/A-6417-2013; Jordà, Mireia/Z-4519-2019; Olmeda, David/L-4270-2017	Peinado, Hector/0000-0002-4256-3413; Olmeda, David/0000-0001-5513-5621; Jorda, Mireia/0000-0003-3709-1850				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Behrens J, 1992, Semin Cell Biol, V3, P169; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Espineda CE, 2004, MOL BIOL CELL, V15, P1364, DOI 10.1091/mbc.E03-09-0646; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Ikenouchi J, 2003, J CELL SCI, V116, P1959, DOI 10.1242/jcs.00389; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Martinez-Estrada OM, 2006, BIOCHEM J, V394, P449, DOI 10.1042/BJ20050591; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2004, J CELL SCI, V117, P2827, DOI 10.1242/jcs.01145; Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Sefton M, 1998, DEVELOPMENT, V125, P3111; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cb.09.110193.002545; Sugimachi K, 2003, CLIN CANCER RES, V9, P2657; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	37	208	220	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1862	1874		10.1038/sj.onc.1209997	http://dx.doi.org/10.1038/sj.onc.1209997			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043660				2022-12-28	WOS:000245117700004
J	Cosentino, C; Di Domenico, M; Porcellini, A; Cuozzo, C; De Gregorio, G; Santillo, MR; Agnese, S; Di Stasio, R; Feliciello, A; Migliaccio, A; Avvedimento, EV				Cosentino, C.; Di Domenico, M.; Porcellini, A.; Cuozzo, C.; De Gregorio, G.; Santillo, M. R.; Agnese, S.; Di Stasio, R.; Feliciello, A.; Migliaccio, A.; Avvedimento, E. V.			p85 regulatory subunit of PI3K mediates cAMP-PKA and estrogens biological effects on growth and survival	ONCOGENE			English	Article						cAMP; PI3K; p21Ras; growth	CELL-CYCLE PROGRESSION; STIMULATING-HORMONE; SIGNALING PATHWAY; KINASE; ACTIVATION; RECEPTOR; FIBROBLASTS; EXPRESSION; BETA; TOR	Cyclic adenosine 3050 monophosphate (cAMP) and protein kinase A (PKA) cooperate with phosphatidylinositol 30 kinase (PI3K) signals in the control of growth and survival. To determine the molecular mechanism(s) involved, we identified and mutagenized a specific serine (residue 83) in p85 alpha(PI3K), which is phosphorylated in vivo and in vitro by PKA. Expression of p85 alpha(PI3K) mutants (alanine or aspartic substitutions) significantly altered the biological responses of the cells to cAMP. cAMP protection from anoikis was reduced in cells expressing the alanine version p85 alpha(PI3K). These cells did not arrest in G1 in the presence of cAMP, whereas cells expressing the aspartic mutant p85D accumulated in G1 even in the absence of cAMP. S phase was still efficiently inhibited by cAMP in cells expressing both mutants. The binding of PI3K to Ras p21 was greatly reduced in cells expressing p85A in the presence or absence of cAMP. Conversely, expression of the aspartic mutant stimulated robustly the binding of PI3K to p21 Ras in the presence of cAMP. Mutation in the Ser 83 inhibited cAMP, but not PDGF stimulation of PI3K. Conversely, the p85D aspartic mutant amplified cAMP stimulation of PI3K activity. Phosphorylation of Ser 83 by cAMP - PKA in p85 alpha(PI3K) was also necessary for estrogen signaling as expression of p85A or p85D mutants inhibited or amplified, respectively, the binding of estrogen receptor to p85 alpha and AKT phosphorylation induced by estrogens. The data presented indicate that: (1) phosphorylation of Ser 83 in p85a PI3K is critical for cAMP - PKA induced G1 arrest and survival in mouse 3T3. broblasts; (2) this site is necessary for amplification of estrogen signals by cAMP - PKA and related receptors. Finally, these data suggest a general mechanism of PI3K regulation by cAMP, operating in various cell types and under different conditions.	CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Naples, Italy; CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Cellulaire, Naples, Italy; Univ Naples 2, Dipartimento Patol Gen, Naples, Italy; Univ Roma La Sapienza, Dipartimento Sperimentale & Patol, I-00161 Rome, Italy; INM Neuromed, Pozzilli, Italy; Univ Naples Federico II, Dipartimento Neurosci, Sez Fisiol, Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); Universita della Campania Vanvitelli; Sapienza University Rome; IRCCS Neuromed; University of Naples Federico II	Avvedimento, EV (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Mol, Via S Pansini 5, Naples, Italy.	avvedim@unina.it	Porcellini, Antonio/E-1900-2011; Porcellini, Antonio/AAC-6097-2019; Cosentino, Claudia/AAF-1100-2019; Migliaccio, Antimo/AAB-3376-2019	Porcellini, Antonio/0000-0001-6882-9518; Migliaccio, Antimo/0000-0002-4197-2055; Feliciello, Antonio/0000-0002-7932-2170; Di Domenico, Marina/0000-0002-6201-4200				Affaitati A, 2003, J BIOL CHEM, V278, P4286, DOI 10.1074/jbc.M209941200; Alvarez B, 2003, J BIOL CHEM, V278, P26466, DOI 10.1074/jbc.M300663200; Ariga M, 2000, BIOCHEM J, V348, P409, DOI 10.1042/0264-6021:3480409; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Ciullo I, 2001, ONCOGENE, V20, P1186, DOI 10.1038/sj.onc.1204219; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; DEGREGORIA G, 2006, IN PRESS ONCOGENE; Feliciello A, 2000, J BIOL CHEM, V275, P303, DOI 10.1074/jbc.275.1.303; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Houslay MD, 2000, MOL PHARMACOL, V58, P659, DOI 10.1124/mol.58.4.659; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KNECHT M, 1984, ENDOCRINOLOGY, V115, P41, DOI 10.1210/endo-115-1-41; Kurokawa K, 1998, CELL STRUCT FUNCT, V23, P357, DOI 10.1247/csf.23.357; Lee Y. Z., 1998, Annals of Noninvasive Electrocardiology, V3, P244, DOI 10.1111/j.1542-474X.1998.tb00350.x; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; Maier U, 1999, J BIOL CHEM, V274, P29311, DOI 10.1074/jbc.274.41.29311; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; Porcellini A, 2003, J BIOL CHEM, V278, P40621, DOI 10.1074/jbc.M307501200; Rohde JR, 2004, MOL CELL BIOL, V24, P8332, DOI 10.1128/MCB.24.19.8332-8341.2004; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Zurita-Martinez SA, 2005, EUKARYOT CELL, V4, P63, DOI 10.1128/EC.4.1.63-71.2005	23	58	59	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2095	2103		10.1038/sj.onc.1210027	http://dx.doi.org/10.1038/sj.onc.1210027			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016431				2022-12-28	WOS:000245313400011
J	Thullberg, M; Gad, A; Beeser, A; Chernoff, J; Stromblad, S				Thullberg, M.; Gad, A.; Beeser, A.; Chernoff, J.; Stromblad, S.			The kinase-inhibitory domain of p21-activated kinase 1 (PAK1) inhibits cell cycle progression independent of PAK1 kinase activity	ONCOGENE			English	Article						p21-activated kinase 1 (PAK1); cell cycle; cyclin D1; Rac; GTPase	BREAST-CANCER CELLS; ADAPTER PROTEIN; D1 EXPRESSION; BUDDING-YEAST; ALPHA-PAK; ACTIVATION; PHOSPHORYLATION; CDC42; REVEALS; FAMILY	p21-activated kinase 1 (PAK1) is a mediator of downstream signaling from the small GTPases Rac and Cdc42. In its inactive state, PAK1 forms a homodimer where two kinases inhibit each other in trans. The kinase inhibitory domain ( KID) of one molecule of PAK1 binds to the kinase domain of its counterpart and keeps it inactive. Therefore, the isolated KID of PAK1 has been widely used to specifically inhibit and study PAK function. Here, we show that the isolated KID induced a cell cycle arrest with accumulation of cells in the G1 phase of the cell cycle with an inhibition of cyclin D1 and D2 expression. This cell cycle arrest required the intact KID and was also induced by a mutated KID unable to block PAK1 kinase activity. Furthermore, the KID-induced cell cycle arrest could not be rescued by the expression of a constitutively active PAK1-T423E mutant, concluding that this arrest occurs independently of PAK1 kinase activity. Our results suggest that PAK1 through its KID inhibits cyclin D expression and thereby enforces a cell cycle arrest. Our results also call for serious precaution in the use of KID to study PAK function.	Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden; Fox Chase Canc Ctr, Tumor Cell Biol Program, Philadelphia, PA 19111 USA; Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden	Karolinska Institutet; Fox Chase Cancer Center; Karolinska Institutet	Thullberg, M (corresponding author), Karolinska Inst, Dept Biosci & Nutr, S-14157 Huddinge, Sweden.	minna.thullberg@ki.se	Gad, Annica/X-8294-2018; Chernoff, Jonathan/I-7631-2014; Gad, Annica/H-8758-2017	Gad, Annica/0000-0002-1098-9129; Chernoff, Jonathan/0000-0002-4803-7836; Gad, Annica/0000-0002-1098-9129; Stromblad, Staffan/0000-0002-1236-6339				Adam L, 2000, J BIOL CHEM, V275, P12041, DOI 10.1074/jbc.275.16.12041; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Balasenthil S, 2004, J BIOL CHEM, V279, P1422, DOI 10.1074/jbc.M309937200; Bartek J, 1999, J PATHOL, V187, P95, DOI 10.1002/(SICI)1096-9896(199901)187:1<95::AID-PATH249>3.0.CO;2-#; Bekri S, 1997, CYTOGENET CELL GENET, V79, P125, DOI 10.1159/000134699; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Chi S, 2004, BIOCHEM BIOPH RES CO, V319, P683, DOI 10.1016/j.bbrc.2004.05.042; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; Dadke D, 2003, CANCER RES, V63, P8837; DerMardirossian C, 2004, MOL CELL, V15, P117, DOI 10.1016/j.molcel.2004.05.019; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Holly SP, 1999, J CELL BIOL, V147, P845, DOI 10.1083/jcb.147.4.845; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lee SH, 2001, J BIOL CHEM, V276, P25066, DOI 10.1074/jbc.M010892200; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Li F, 2002, EMBO REP, V3, P767, DOI 10.1093/embo-reports/kvf157; Li WQ, 2001, J BIOL CHEM, V276, P34728, DOI 10.1074/jbc.M103496200; Li Z, 2003, CELL, V114, P215, DOI 10.1016/S0092-8674(03)00559-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Nheu T, 2004, CELL CYCLE, V3, P71; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Schraml P, 2003, AM J PATHOL, V163, P985, DOI 10.1016/S0002-9440(10)63458-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; Sundberg-Smith LJ, 2005, J BIOL CHEM, V280, P2055, DOI 10.1074/jbc.M406013200; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Thiel DA, 2002, CURR BIOL, V12, P1227, DOI 10.1016/S0960-9822(02)00931-4; Thullberg M, 2000, ONCOGENE, V19, P2870, DOI 10.1038/sj.onc.1203579; Vadlamudi RK, 2000, J BIOL CHEM, V275, P36238, DOI 10.1074/jbc.M002138200; Weiss EL, 2000, NAT CELL BIOL, V2, P677, DOI 10.1038/35036300; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; Zenke FT, 1999, J BIOL CHEM, V274, P32565, DOI 10.1074/jbc.274.46.32565; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035	41	38	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1820	1828		10.1038/sj.onc.1209983	http://dx.doi.org/10.1038/sj.onc.1209983			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001318				2022-12-28	WOS:000244955600016
J	Yang, MH; Chang, SY; Chiou, SH; Liu, CJ; Chi, CW; Chen, PM; Teng, SC; Wu, KJ				Yang, M-H; Chang, S-Y; Chiou, S-H; Liu, C-J; Chi, C-W; Chen, P-M; Teng, S-C; Wu, K-J			Overexpression of NBS1 induces epithelial-mesenchymal transition and co-expression of NBS1 and Snail predicts metastasis of head and neck cancer	ONCOGENE			English	Article						head and neck cancer; epithelial-mesenchymal transition; metastasis; NBS1; Snail	TRANSCRIPTION FACTOR SNAIL; SQUAMOUS-CELL CARCINOMAS; DISTANT METASTASES; TUMOR-CELLS; EXPRESSION; INVASION; GENE; INVOLVEMENT; REPRESSOR; COMPLEX	Major causes of head and neck squamous cell carcinoma (HNSCC)-related deaths are cervical node and distant metastasis. We previously demonstrated that overexpression of the DNA double-strand break repair protein Nijmegen breakage syndrome 1 (NBS1) is a prognostic marker of advanced HNSCCs. Epithelial-mesenchymal transition (EMT) was demonstrated to be the major mechanism responsible for mediating invasiveness and metastasis of late-stage cancers. We therefore investigated the role of NBS1 overexpression in mediating EMT and metastasis. NBS1 overexpression was associated with metastasis of HNSCC patients using tissue microarray immunohistochemistry approach. Induction of EMT was observed in an NBS1-overexpressing HNSCC cell line (FADUNBS), whereas short-interference RNA ( siRNA)mediated repression of endogenous NBS1 reversed the shift of EMT markers. Increased migration/invasiveness of FADUNBS was shown by in vitro and in vivo assays. NBS1 overexpression upregulated the expression of an EMT regulator Snail and its downstreamtarget matrix metalloproteinase-2. EMT phenotypes and increased migration/invasiveness of FADUNBS cells were reversed by siRNA-mediated repression of Snail expression or a phosphatidylinositol 3-kinase-specific inhibitor. In HNSCC samples, co-expression of NBS1/Snail in primary tumors correlated with metastasis and the worst prognosis. These results indicate that NBS1 overexpression induces EMT through the upregulation of Snail expression, and coexpression of NBS1/Snail predicts metastasis in HNSCCs.	Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan; Vet Gen Hosp, Dept Med, Div Med Oncol, Taipei, Taiwan; Vet Gen Hosp, Genom Med Res Ctr, Taipei, Taiwan; Vet Gen Hosp, Dept Otolaryngol, Taipei, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei, Taiwan; Taipei Mackay Mem Hosp, Dept Dent, Taipei, Taiwan; Natl Yang Ming Univ, Dept Pharmacol, Taipei 112, Taiwan; Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Mackay Memorial Hospital; National Yang Ming Chiao Tung University; National Taiwan University	Wu, KJ (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155 Linong St,Sect 2, Taipei 112, Taiwan.	kjwu2@ym.edu.tw	Wu, Kou-Juey/P-4654-2015; Yang, Muh-Hwa/AAE-4691-2020	TENG, SHU-CHUN/0000-0002-6492-2560				Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bentz BG, 2000, HEAD NECK-J SCI SPEC, V22, P71, DOI 10.1002/(SICI)1097-0347(200001)22:1<71::AID-HED11>3.0.CO;2-G; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Chiang YC, 2003, J BIOL CHEM, V278, P19286, DOI 10.1074/jbc.M212043200; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Ferlito A, 2001, ORL J OTO-RHINO-LARY, V63, P189, DOI 10.1159/000055738; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kandel ES, 2002, MOL CELL BIOL, V22, P7831, DOI 10.1128/MCB.22.22.7831-7841.2002; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; LEEMANS CR, 1993, CANCER, V71, P452, DOI 10.1002/1097-0142(19930115)71:2<452::AID-CNCR2820710228>3.0.CO;2-B; Lu WS, 2004, CANCER LETT, V214, P205, DOI 10.1016/j.canlet.2003.08.012; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; *ROC DEP HLTH EX Y, 2005, CANC REG ANN REP TAI; Sauter ER, 1999, CLIN CANCER RES, V5, P775; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsai HJ, 2006, J BIOL CHEM, V281, P13717, DOI 10.1074/jbc.M600649200; Yang MH, 2006, CLIN CANCER RES, V12, P507, DOI 10.1158/1078-0432.CCR-05-1231; Yokoyama K, 2003, INT J ONCOL, V22, P891; Zhang Y, 2005, CANCER RES, V65, P5544, DOI 10.1158/0008-5472.CAN-04-4368; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	26	123	125	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2007	26	10					1459	1467		10.1038/sj.onc.1209929	http://dx.doi.org/10.1038/sj.onc.1209929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936774				2022-12-28	WOS:000244558800010
J	Rasola, A; Fassetta, M; De Bacco, F; D'Alessandro, L; Gramaglia, D; Di Renzo, M; Comoglio, PM				Rasola, A.; Fassetta, M.; De Bacco, F.; D'Alessandro, L.; Gramaglia, D.; Di Renzo, M. F.; Comoglio, P. M.			A positive feedback loop between hepatocyte growth factor receptor and beta-catenin sustains colorectal cancer cell invasive growth	ONCOGENE			English	Article						apoptosis; beta-catenin; colorectal carcinoma; hepatocyte growth factor; invasive growth	WNT SIGNALING PATHWAY; NF-KAPPA-B; C-MET; SCATTER-FACTOR; CARCINOMA-CELLS; COLON-CANCER; APOPTOSIS; EXPRESSION; GENE; OVEREXPRESSION	Overexpressed or activated hepatocyte growth factor receptor, encoded by the MET proto-oncogene, was found in the majority of colorectal carcinomas (CRCs), whose stepwise progression to malignancy requires transcriptional activation of beta-catenin. We here demonstrate that a functional crosstalk between Met and beta-catenin signaling sustains and increases CRC cell invasive properties. Hepatocyte growth factor (HGF) stimulation prompts beta-catenin tyrosine phosphorylation and dissociation from Met, and upregulates beta-catenin expression via the phosphatidylinositol 3- kinase pathway in conditions that mimic those found by the invading and metastasizing cells. Additionally, a transcriptionally active form of beta-catenin, known to be oncogenic, enhances Met expression. Furthermore, HGF treatment increases the activity of the beta-catenin-regulated T-cell factor transcription factor in cells expressing the wild-type or the oncogenic beta-catenin. In the mirror experiments, either Met or beta-catenin knocking down also reduces their protein level. In biological assays, beta-catenin knocking down abrogates the HGF-induced motile phenotype, whereas active beta-catenin fosters ligand-independent cell scattering. Met and beta-catenin also cooperate in promoting entry into the cell cycle and in protecting cells from apoptosis. In conclusion, Met and beta-catenin pathways are mutually activated in CRC cells. This might generate a self-amplifying positive feedback loop resulting in the upregulation of the invasive growth properties of CRC cells.	Univ Padua, Dept Biomed Sci, I-25121 Brescia, Italy; Univ Turin, Sch Med, Div Mol Oncol, I-10124 Turin, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, IRCC,Lab Canc Genet, Candiolo, Italy	University of Padua; University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin	Rasola, A (corresponding author), Univ Padua, Dept Biomed Sci, Viale Giuseoppe Colombo 3, I-25121 Brescia, Italy.	rasola@bio.unipd.it	DI RENZO, Maria Flavia/B-6091-2012; GRAMAGLIA, DANIELA/A-6354-2012	DI RENZO, Maria Flavia/0000-0002-5093-3373; Comoglio, Paolo/0000-0002-7056-5328; Rasola, Andrea/0000-0003-4522-3008; Gramaglia, Daniela/0000-0001-6259-0059				Arakaki N, 1998, BIOCHEM BIOPH RES CO, V245, P211, DOI 10.1006/bbrc.1998.8397; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boon EMJ, 2005, BRIT J CANCER, V92, P1078, DOI 10.1038/sj.bjc.6602405; Boon EMJ, 2002, CANCER RES, V62, P5126; Bowers DC, 2000, CANCER RES, V60, P4277; Corso S, 2005, TRENDS MOL MED, V11, P284, DOI 10.1016/j.molmed.2005.04.005; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; Derksen PWB, 2003, LEUKEMIA, V17, P764, DOI 10.1038/sj.leu.2402875; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Edlund S, 2005, MOL CELL BIOL, V25, P1475, DOI 10.1128/MCB.25.4.1475-1488.2005; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fan SJ, 2005, ONCOGENE, V24, P1749, DOI 10.1038/sj.onc.1208327; Fazekas K, 2001, CLIN EXP METASTAS, V18, P639, DOI 10.1023/A:1013136303880; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Gao M, 2001, J BIOL CHEM, V276, P47257, DOI 10.1074/jbc.M106791200; Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2; Gramaglia D, 2004, CELL DEATH DIFFER, V11, P342, DOI 10.1038/sj.cdd.4401326; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Harris TJC, 2005, TRENDS CELL BIOL, V15, P234, DOI 10.1016/j.tcb.2005.03.002; Henderson BR, 2002, EMBO REP, V3, P834, DOI 10.1093/embo-reports/kvf181; Herynk MH, 2003, CLIN EXP METASTAS, V20, P291, DOI 10.1023/A:1024024218529; Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020; Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567; Kim K, 2000, MOL BIOL CELL, V11, P3509, DOI 10.1091/mbc.11.10.3509; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Lal BC, 2005, CLIN CANCER RES, V11, P4479, DOI 10.1158/1078-0432.CCR-05-0166; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lustig B, 2003, J CANCER RES CLIN, V129, P199, DOI 10.1007/s00432-003-0431-0; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Matteucci E, 2003, ONCOGENE, V22, P4062, DOI 10.1038/sj.onc.1206519; Monga SPS, 2002, CANCER RES, V62, P2064; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Papkoff J, 1998, BIOCHEM BIOPH RES CO, V247, P851, DOI 10.1006/bbrc.1998.8888; Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815; Rasola A, 2004, CANCER RES, V64, P1744, DOI 10.1158/0008-5472.CAN-03-2383; Rasola A, 2001, CYTOMETRY, V45, P151, DOI 10.1002/1097-0320(20011001)45:2<151::AID-CYTO1157>3.0.CO;2-I; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Takeuchi H, 2003, CLIN CANCER RES, V9, P1480; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; van Es JH, 2003, CURR OPIN GENET DEV, V13, P28, DOI 10.1016/S0959-437X(02)00012-6; van Gijn ME, 2001, EXP CELL RES, V265, P46, DOI 10.1006/excr.2001.5174; Vigna E, 2000, J GENE MED, V2, P308; Wielenga VJM, 2000, AM J PATHOL, V157, P1563, DOI 10.1016/S0002-9440(10)64793-1; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	49	89	92	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	7					1078	1087		10.1038/sj.onc.1209859	http://dx.doi.org/10.1038/sj.onc.1209859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	136SW	16953230				2022-12-28	WOS:000244245400014
J	Borczuk, AC; Cappellini, GCA; Kim, HK; Hesdorffer, M; Taub, RN; Powell, CA				Borczuk, A. C.; Cappellini, G. C. A.; Kim, H. K.; Hesdorffer, M.; Taub, R. N.; Powell, C. A.			Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors	ONCOGENE			English	Article						mesothelioma; microarray analysis; bortezomib; drug therapy combination	PLEURAL MESOTHELIOMA; PHASE-II; EXPRESSION; GEMCITABINE; CANCER; CELL; COMBINATION; DOCETAXEL; OVEREXPRESSION; CISPLATIN	Malignant mesothelioma is an aggressive neoplastic proliferation derived from cells lining serosal membranes. The biological and clinical characteristics of epithelial type malignant mesothelioma are distinct from those of biphasic and sarcomatous type tumors. The goal of our study was to examine the molecular basis for this distinction. Microarray analysis confirmed that the molecular signatures of epithelial and biphasic histologic subtypes were distinct. Among the differentially expressed functional gene categories was the ubiquitin-proteasome pathway, which was upregulated in biphasic tumors. Cytotoxicity experiments indicated that 211H cells derived from biphasic tumors were synergistically sensitive to sequential combination regimens containing the proteasome inhibitor bortezomib and oxaliplatin. The mechanism of this synergistic response, which was not detected in cells of epithelial tumor origin, was apoptosis. Together, our results identify the ubiquitin-proteasome pathway as a biomarker of poor prognosis biphasic peritoneal mesothelioma tumors and suggest that proteasome inhibitors could increase the effectiveness of cytotoxic chemotherapy in this subset of patients.	Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Powell, CA (corresponding author), Columbia Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Coll Phys & Surg,Dept Med, 630 W 168th St,Box 91, New York, NY 10032 USA.	cap6@columbia.edu	Borczuk, Alain/AAI-8226-2021; Powell, Charles A/C-8663-2011; BORCZUK, alain/AHA-5172-2022; Borczuk, Alain/AFU-5278-2022	Borczuk, Alain/0000-0001-6807-8064; Powell, Charles A/0000-0003-3509-891X; Borczuk, Alain/0000-0001-6807-8064				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2003, CANCER TREAT REV, V29, P3, DOI 10.1016/S0305-7372(03)00081-1; Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Borczuk AC, 2005, AM J RESP CRIT CARE, V172, P729, DOI 10.1164/rccm.200504-615OC; Borczuk AC, 2005, CLIN CANCER RES, V11, P3303, DOI 10.1158/1078-0432.CCR-04-1884; Borczuk AC, 2003, AM J PATHOL, V163, P1949, DOI 10.1016/S0002-9440(10)63553-5; Fally BN, 2003, J SURG RES, V113, P88, DOI 10.1016/S0022-4804(03)00201-4; Fizazi K, 2003, J CLIN ONCOL, V21, P349, DOI 10.1200/JCO.2003.05.123; Gentiloni N, 1997, J CLIN GASTROENTEROL, V24, P276, DOI 10.1097/00004836-199706000-00023; GOLDBLUM J, 1995, AM J SURG PATHOL, V19, P1124, DOI 10.1097/00000478-199510000-00003; Gordon GJ, 2005, AM J PATHOL, V166, P1827, DOI 10.1016/S0002-9440(10)62492-3; Gordon GJ, 2003, J NATL CANCER I, V95, P598, DOI 10.1093/jnci/95.8.598; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Khalil N, 2001, THORAX, V56, P907, DOI 10.1136/thorax.56.12.907; Kim H, 2003, AM J RESP CELL MOL, V29, P694, DOI 10.1165/rcmb.2003-0061OC; Kitagawa Y, 1996, AM J RESP CELL MOL, V15, P45, DOI 10.1165/ajrcmb.15.1.8679221; Lee JJ, 1996, CANCER EPIDEM BIOMAR, V5, P191; Leu KM, 2004, J CLIN ONCOL, V22, P1706, DOI 10.1200/JCO.2004.08.043; Lopez-Rios F, 2006, CANCER RES, V66, P2970, DOI 10.1158/0008-5472.CAN-05-3907; McShane LM, 2002, BIOINFORMATICS, V18, P1462, DOI 10.1093/bioinformatics/18.11.1462; Mohamed Faheez, 2002, Curr Treat Options Oncol, V3, P375, DOI 10.1007/s11864-002-0003-6; Nawrocki ST, 2004, MOL CANCER THER, V3, P59; Nowak AK, 2002, BRIT J CANCER, V87, P491, DOI 10.1038/sj.bjc.6600505; Pass HI, 2004, CLIN CANCER RES, V10, P849, DOI 10.1158/1078-0432.CCR-0607-3; Rajkumar SV, 2005, J CLIN ONCOL, V23, P630, DOI 10.1200/JCO.2005.11.030; REILE H, 1990, ANAL BIOCHEM, V187, P262, DOI 10.1016/0003-2697(90)90454-H; Ricotti L, 2003, CLIN CANCER RES, V9, P900; Robinson BW, 2004, SEMIN ONCOL, V31, P2, DOI 10.1053/j.seminoncol.2004.03.021; Schenkein David P, 2005, Clin Lung Cancer, V7 Suppl 2, pS49, DOI 10.3816/CLC.2005.s.008; Schutte Wolfgang, 2003, Clin Lung Cancer, V4, P294, DOI 10.3816/CLC.2003.n.009; Sebbag G, 2000, BRIT J SURG, V87, P1587, DOI 10.1046/j.1365-2168.2000.01571.x; Singhal S, 2003, CLIN CANCER RES, V9, P3080; Sugarbaker Paul H, 2003, Surg Oncol Clin N Am, V12, P605, DOI 10.1016/S1055-3207(03)00045-0; Tallarida RJ, 2001, J PHARMACOL EXP THER, V298, P865; Taub R N, 2000, Curr Treat Options Oncol, V1, P303, DOI 10.1007/s11864-000-0046-5; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Voorhees PM, 2003, CLIN CANCER RES, V9, P6316	37	40	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					610	617		10.1038/sj.onc.1209809	http://dx.doi.org/10.1038/sj.onc.1209809			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16862182				2022-12-28	WOS:000243731600013
J	Duensing, A; Liu, Y; Spardy, N; Bartoli, K; Tseng, M; Kwon, JA; Teng, X; Duensing, S				Duensing, A.; Liu, Y.; Spardy, N.; Bartoli, K.; Tseng, M.; Kwon, J-A; Teng, X.; Duensing, S.			RNA polymerase II transcription is required for human papillomavirus type 16 E7-and hydroxyurea-induced centriole overduplication	ONCOGENE			English	Article						HPV-16 E7; hydroxyurea; centrioles; RNA polymerase II; cyclin A	CENTROSOME DUPLICATION; GENOMIC INSTABILITY; CELLS; CYCLE; AMPLIFICATION; TRANSFORMATION; DISSOCIATION; REPRODUCTION; REPLICATION; PROTEINS	Aberrant centrosome numbers are detected in virtually all human cancers where they can contribute to chromosomal instability by promoting mitotic spindle abnormalities. Despite their widespread occurrence, the molecular mechanisms that underlie centrosome amplification are only beginning to emerge. Here, we present evidence for a novel regulatory circuit involved in centrosome overduplication that centers on RNA polymerase II (pol II). We found that human papillomavirus type 16 E7(HPV-16 E7)- and hydroxyurea (HU)-induced centriole overduplication are abrogated by alpha-amanitin, a potent and specific RNA pol II inhibitor. In contrast, normal centriole duplication proceeded undisturbed in alpha-amanitin-treated cells. Centriole overduplication was significantly reduced by siRNA-mediated knock down of CREB-binding protein (CBP), a transcriptional co-activator. We identifi ed cyclin A2 as a key transcriptional target of RNA pol II during HU-induced centriole overduplication. Collectively, our results show that ongoing RNA pol II transcription is required for centriole overduplication whereas it may be dispensable for normal centriole duplication. Given that many chemotherapeutic agents function through inhibition of transcription, our results may help to develop strategies to target centrosome-mediated chromosomal instability for cancer therapy and prevention.	Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Biochem & Mol Genet Grad Program, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Duensing, S (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Mol Virol Program, Res Pavil Suite 1-8,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	duensing@pitt.edu		Duensing, Anette/0000-0002-0168-4067	NATIONAL CANCER INSTITUTE [R01CA112598] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA112598-03, R01 CA112598] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bai VU, 2005, J CELL PHYSIOL, V204, P381, DOI 10.1002/jcp.20422; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; BRAUDE PR, 1979, DEV BIOL, V68, P440, DOI 10.1016/0012-1606(79)90216-1; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bushnell DA, 2002, P NATL ACAD SCI USA, V99, P1218, DOI 10.1073/pnas.251664698; Caldeira S, 2000, ONCOGENE, V19, P821, DOI 10.1038/sj.onc.1203375; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; Derheimer FA, 2005, EUR J CANCER, V41, P2569, DOI 10.1016/j.ejca.2005.08.012; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Doxsey S, 2002, MOL CELL, V10, P439, DOI 10.1016/S1097-2765(02)00654-8; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Duensing S, 2005, CELL BIOL INT, V29, P352, DOI 10.1016/j.cellbi.2005.03.005; Duensing S, 2004, ONCOGENE, V23, P8206, DOI 10.1038/sj.onc.1208012; Duensing S, 2001, BBA-REV CANCER, V1471, pM81, DOI 10.1016/S0304-419X(00)00025-1; Duensing S, 2001, CANCER RES, V61, P2356; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faivre J, 2002, ONCOGENE, V21, P1493, DOI 10.1038/sj.onc.1205215; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; GIRDHAM CH, 1991, GENE DEV, V5, P1786, DOI 10.1101/gad.5.10.1786; Gong XQ, 2004, J BIOL CHEM, V279, P27422, DOI 10.1074/jbc.M402163200; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Hahn S, 2004, NAT STRUCT MOL BIOL, V11, P394, DOI 10.1038/nsmb763; Hinchcliffe EH, 2001, GENE DEV, V15, P1167, DOI 10.1101/gad.894001; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Janknecht R, 1996, NATURE, V383, P22, DOI 10.1038/383022a0; Jiang Y, 2004, MOL CELL, V14, P375, DOI 10.1016/S1097-2765(04)00234-5; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDermott KM, 2006, PLOS BIOL, V4, P350, DOI 10.1371/journal.pbio.0040051; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; PHILLIPS SG, 1976, J CELL BIOL, V70, P9, DOI 10.1083/jcb.70.1.9; Salisbury JL, 1999, BIOL CELL, V91, P451, DOI 10.1016/S0248-4900(99)80086-0; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; TOMMASINO M, 1993, ONCOGENE, V8, P195; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; UZAWA M, 1995, DEV BIOL, V171, P51, DOI 10.1006/dbio.1995.1259; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y	50	17	20	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2007	26	2					215	223		10.1038/sj.onc.1209782	http://dx.doi.org/10.1038/sj.onc.1209782			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819507	Green Accepted			2022-12-28	WOS:000243398300005
J	Vidal, GA; Clark, DE; Marrero, L; Jones, FE				Vidal, G. A.; Clark, D. E.; Marrero, L.; Jones, F. E.			A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities	ONCOGENE			English	Article						EGFR-family; STAT5A; apoptosis; nuclear translocation; transactivation	TYROSINE KINASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; NEU ONCOGENE; TRANSMEMBRANE DOMAIN; POINT MUTATION; MAMMARY-GLAND; EXPRESSION; PROTEIN; ACTIVATION	In the normal breast, ERBB4 regulates epithelial differentiation and functions as a nuclear chaperone for signal transducer and activator of transcription (STAT) 5A, thereby stimulating milk-gene expression. In addition, ERBB4 functions as a proapoptotic protein, suppressing the growth of malignant cells. We hypothesize that these ERBB4 activities can be marshaled to suppress the growth of breast tumors. To this end, we have created an ERBB4 allele harboring an activating transmembrane mutation (ERBB4-CA) by substituting isoleucine 658 for glutamic acid. This base substitution forms a valine-glutamic acidglycine activation domain first identified in oncogenic ERBB2/HER2/Neu. Ectopic expression of ERBB4-CA in HEK293T cells resulted in a fivefold increase in receptor tyrosine phosphorylation. Functionally, ERBB4-CA exhibited higher levels of nuclear translocation than wild-type ERBB4, leading to significantly enhanced ERBB4-induced STAT5A simulation of the beta-casein promoter. Activated ERBB4 has been demonstrated to induce cell killing of breast tumor cells. Significantly, ERBB4-CA potentiated the proapoptotic function of ERBB4 in each breast, prostate and ovarian cancer cell line tested. Untransformed cell lines were resistant to both ERBB4 and ERBB4-CA-mediated apoptosis underscoring the potential utility of active ERBB4 signaling for the therapeutic intervention of human cancer.	Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, New Orleans, LA 70112 USA; Tulane Univ, Hlth Sci Ctr, Dept Struct & Cellular Biol, Tulane Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Gene Therapy Program, Morphol & Imaging Core Lab, New Orleans, LA 70112 USA	Tulane University; Tulane University; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Jones, FE (corresponding author), Tulane Univ, Hlth Sci Ctr, Tulane Canc Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.	fjones@tulane.edu		Vidal, Gregory/0000-0003-3325-6224	NATIONAL CANCER INSTITUTE [R01CA096717, R01CA095783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA95783, R01 CA96717] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARGMANN CI, 1988, P NATL ACAD SCI USA, V85, P5394, DOI 10.1073/pnas.85.15.5394; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Barnes NLP, 2005, CLIN CANCER RES, V11, P2163, DOI 10.1158/1078-0432.CCR-04-1633; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Clark DE, 2005, J BIOL CHEM, V280, P24175, DOI 10.1074/jbc.M414044200; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2003, CELL CYCLE, V2, P555, DOI 10.4161/cc.2.6.598; Kew TY, 2000, BRIT J CANCER, V82, P1163, DOI 10.1054/bjoc.1999.1057; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; SEGATTO O, 1988, MOL CELL BIOL, V8, P5570, DOI 10.1128/MCB.8.12.5570; Srinivasan R, 1998, J PATHOL, V185, P236, DOI 10.1002/(SICI)1096-9896(199807)185:3<236::AID-PATH118>3.0.CO;2-7; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tidcombe H, 2003, P NATL ACAD SCI USA, V100, P8281, DOI 10.1073/pnas.1436402100; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	21	31	33	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					462	466		10.1038/sj.onc.1209794	http://dx.doi.org/10.1038/sj.onc.1209794			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832345				2022-12-28	WOS:000243544000015
J	Hamai, A; Richon, C; Meslin, F; Faure, F; Kauffmann, A; Lecluse, Y; Jalil, A; Larue, L; Avril, MF; Chouaib, S; Mehrpour, M				Hamai, A.; Richon, C.; Meslin, F.; Faure, F.; Kauffmann, A.; Lecluse, Y.; Jalil, A.; Larue, L.; Avril, M. F.; Chouaib, S.; Mehrpour, M.			Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: relationship to Bcl-2 family and caspase activation	ONCOGENE			English	Article						human melanoma; metastasis; apoptosis; gene expression profiling; TRAIL; tyrosine kinase	TYROSINE KINASE INHIBITOR; IN-VIVO EFFICACY; INDUCED APOPTOSIS; BCR-ABL; LUNG-CANCER; LIGAND; PROTEIN; BAX; SENSITIZES; RECEPTORS	In order to de. ne genetic determinants of primary and metastatic melanoma cell susceptibility to tumor necrosis factor-related apoptosis-inducing ligand ( TRAIL), we have applied oligonucleotide microarrays to TRAIL-sensitive primary T1 cells and TRAIL-resistant metastatic G1 cells treated or not with TRAIL. T1 and G1 cells are isogenic melanoma cell subclones. We examined 22 000 spots, 4.2% of which displayed differential expression in G1 and T1 cells. Cell susceptibility to TRAIL-mediated apoptosis was found to be correlated with gene expression signatures in this model. Some of the differentially expressed genes were identified as involved in ATP-binding and signaling pathways, based on previously published data. Further analysis provided evidences that c-kit was overexpressed in G1 cells while it was absent in T1 cells. The c-kit inhibitor, imatinib, did not restore TRAIL sensitivity, excluding a role for c-kit in TRAIL resistance in G1 cells. Surprisingly, imatinib inhibited cell proliferation and TRAIL-mediated apoptosis in melanoma cells. We investigated the possible involvement of several molecules, including c-ABL, platelet-derived growth factor receptor (PDGFR), cellular FADD-like interleukin-1 alpha-converting enzyme-like inhibitory protein (c-FLIP)(L/S), Fas-associated DD kinase, p53, p21(WAF1), proteins of B-cell leukemia/lymphoma 2 (Bcl-2) family and cytochrome c. Imatinib did not modulate the expression or activation of its own targets, such as c-ABL, PDGFR alpha and PDGFR beta, but it did affect the expression of c-FLIPL, BCL2-associated X protein (Bax) and Bcl-2. Moreover, c-FLIPL knockdown sensitized T1 cells to TRAIL-mediated apoptosis, with a sensitivity similar to that of cells previously treated with imatinib. More notably, we found that the resistance to TRAIL in G1 cells was correlated with constitutive c-FLIPL recruitment to the DISC and the inhibition of caspase 8, 3 and 9 processing. Moreover, c-FLIPL knockdown partly restored TRAIL sensitivity in G1 cells, indicating that the expression level of c-FLIPL and its interaction with TRAIL receptor2 play a crucial role in determining TRAIL resistance in metastatic melanoma cells. Our results also show that imatinib enhances TRAIL-induced cell death independently of BH3-interacting domain death agonist translocation, in a process involving the Bax: Bcl-X-L ratio, Bax: Bcl-X-L/Bcl-2 translocation, cytochrome c release and caspase activation. Our data indicate that imatinib sensitizes T1 cells by directly downregulating c-FLIPL, with the use of an alternative pathway for antitumor activity, because PDGFRa is not activated in T1 cells and these cells do not express c-kit, c-ABL or PDGFR beta. Caspase cascade activation and mitochondria also play a key role in the imatinib-mediated sensitization of melanoma cells to the proapoptotic action of TRAIL.	Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, F-94805 Villejuif, France; Inst Curie, INSERM, U520, Lab Biol Cellulaire Immun Antitumorale, Paris, France; Inst Gustave Roussy, CNRS, UMR 8125, Lab Genet Oncol,PRI, F-94805 Villejuif, France; Inst Curie, CNRS, UMR 146, F-91405 Orsay, France; Chinese Acad Sci, Lab Apoptosis & Canc Biol, Natl Key Lab Biomembrane & Membrane Biotechnol, Inst Zool, Beijing, Peoples R China	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Chinese Academy of Sciences; Institute of Zoology, CAS	Mehrpour, M (corresponding author), Inst Gustave Roussy, INSERM, U753, Labs Immunol Tumeurs Humaines,PRI, Rue Camille Desmoulins, F-94805 Villejuif, France.	mehrpour@igr.fr	Larue, Lionel/F-7355-2013; Mehrpour, Maryam/D-8640-2017; Larue, Lionel/I-6532-2016; Chouaib, Salem/F-7939-2016; faure, florence/P-9064-2016	faure, florence/0000-0002-8359-4283; RICHON, Catherine/0000-0002-3556-3941; JALIL, Abdelali/0000-0003-2710-8735				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; All-Ericsson C, 2004, INVEST OPHTH VIS SCI, V45, P2075, DOI 10.1167/iovs.03-1196; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Barnhart BC, 2003, ONCOGENE, V22, P8634, DOI 10.1038/sj.onc.1207103; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Carcelain G, 1997, INT J CANCER, V72, P241, DOI 10.1002/(SICI)1097-0215(19970717)72:2<241::AID-IJC7>3.0.CO;2-R; Carr KM, 2003, ONCOGENE, V22, P3076, DOI 10.1038/sj.onc.1206448; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cory GOC, 2002, NATURE, V418, P732, DOI 10.1038/418732a; Debatin KM, 2004, ONCOGENE, V23, P2950, DOI 10.1038/sj.onc.1207558; Decaudin D, 2005, INT J CANCER, V113, P849, DOI 10.1002/ijc.20652; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Diarra-Mehrpour M, 2004, CANCER RES, V64, P719, DOI 10.1158/0008-5472.CAN-03-1735; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dufour E, 1997, J IMMUNOL, V158, P3787; El-Deiry WS, 2001, CELL DEATH DIFFER, V8, P1066, DOI 10.1038/sj.cdd.4400943; Eriksson L, 2004, ANAL BIOANAL CHEM, V380, P419, DOI 10.1007/s00216-004-2783-y; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Hasegawa J, 1996, CANCER RES, V56, P1713; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Hersey P, 2001, NAT REV CANCER, V1, P142, DOI 10.1038/35101078; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ivanov VN, 2005, ONCOGENE, V24, P616, DOI 10.1038/sj.onc.1208125; Ivanov VN, 2003, ONCOGENE, V22, P3152, DOI 10.1038/sj.onc.1206456; Jin TG, 2004, J BIOL CHEM, V279, P55594, DOI 10.1074/jbc.M401056200; Johnston JB, 2003, ONCOGENE, V22, P8356, DOI 10.1038/sj.onc.1207004; Kelley SK, 2001, J PHARMACOL EXP THER, V299, P31; Kim KM, 2005, ONCOGENE, V24, P355, DOI 10.1038/sj.onc.1208213; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Krystal GW, 2000, CLIN CANCER RES, V6, P3319; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Leverkus M, 2000, CANCER RES, V60, P553; Mikhailov V, 2003, J BIOL CHEM, V278, P5367, DOI 10.1074/jbc.M203392200; Muhlethaler-Mottet A, 2004, ONCOGENE, V23, P5415, DOI 10.1038/sj.onc.1207704; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Nimmanapalli R, 2002, ONCOGENE, V21, P8584, DOI 10.1038/sj.onc.1206086; Pandiella A, 2003, BRIT J HAEMATOL, V123, P858, DOI 10.1046/j.1365-2141.2003.04706.x; Poncet D, 2004, J BIOL CHEM, V279, P22605, DOI 10.1074/jbc.M308408200; Sattler M, 2004, LEUKEMIA RES, V28, pS11, DOI 10.1016/j.leukres.2003.10.004; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Strasser A, 2005, NAT REV IMMUNOL, V5, P189, DOI 10.1038/nri1568; Taylor JR, 2006, ONCOGENE, V25, P147, DOI 10.1038/sj.onc.1209007; Thomas WD, 1998, J IMMUNOL, V161, P2195; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Uziel O, 2005, BRIT J CANCER, V92, P1881, DOI 10.1038/sj.bjc.6602592; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang SL, 2003, ONCOGENE, V22, P8628, DOI 10.1038/sj.onc.1207232; Weeraratna AT, 2004, ONCOGENE, V23, P2264, DOI 10.1038/sj.onc.1207337; Wei MC, 2000, GENE DEV, V14, P2060; Wendt J, 2005, ONCOGENE, V24, P4052, DOI 10.1038/sj.onc.1208580; Wittnebel S, 2005, EUR CYTOKINE NETW, V16, P123; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamaguchi K, 2005, ONCOGENE, V24, P5868, DOI 10.1038/sj.onc.1208742	59	34	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 7	2006	25	58					7618	7634		10.1038/sj.onc.1209738	http://dx.doi.org/10.1038/sj.onc.1209738			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114GU	16983347				2022-12-28	WOS:000242655500007
J	Malhi, H; Gores, GJ				Malhi, H.; Gores, G. J.			TRAIL resistance results in cancer progression: a TRAIL to perdition?	ONCOGENE			English	Editorial Material						TRAIL; NF-kappa B; meta stasis; invasion; cFLIP; Mcl-1	NF-KAPPA-B; CHOLANGIOCARCINOMA CELLS; INDUCED APOPTOSIS; RECEPTORS; DEATH; LIGAND; INHIBITION; PROTEIN; FLIP	Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL, APO-2L) is a mediator of cell death that preferentially targets cancer cells. The potential of TRAIL as a chemotherapeutic agent is limited, however, because of the emergence of TRAIL resistance. Furthermore, recent studies have demonstrated that alternative TRAIL signaling is unmasked in TRAIL resistant cells. In these cells, the predominant effect of TRAIL receptor activation is the activation of nuclear factor-kappa B (NF-kappa B), which promotes tumor metastases and invasion. TRAIL resistance can occur at the level of the death inducing signaling complex via upregulation of cFLIP or via an increase in antiapoptotic proteins of the Bcl-2 family. A paradigm emerges from this information, that chemotherapy, targeting NF-kappa B, cFLIP, or antiapoptotic proteins of the Bcl-2 family, in combination with TRAIL maybe more rational than TRAIL therapy alone.	Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA	Mayo Clinic	Gores, GJ (corresponding author), Mayo Clin, Coll Med, Miles & Shirley Fiterman Ctr Digest Dis, Div Gastroenterol & Hepatol, 200 1st St SW, Rochester, MN 55905 USA.	gores.gregory@mayo.edu						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; BUDD RC, NAT REV IMMUNOL, V6, P196; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Ishimura N, 2006, AM J PHYSIOL-GASTR L, V290, pG129, DOI 10.1152/ajpgi.00242.2005; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Kimberley FC, 2004, CELL RES, V14, P359, DOI 10.1038/sj.cr.7290236; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Okano H, 2003, LAB INVEST, V83, P1033, DOI 10.1097/01.LAB.0000079328.76631.28; Peter ME, 2005, BBA-REV CANCER, V1755, P25, DOI 10.1016/j.bbcan.2005.01.001; Sayers TJ, 2006, CANCER IMMUNOL IMMUN, V55, P76, DOI 10.1007/s00262-005-0676-3; Taniai M, 2004, CANCER RES, V64, P3517, DOI 10.1158/0008-5472.CAN-03-2770; TRAUZOLDK A, 2006, IN PRESS ONCOGENE; Truneh A, 2000, J BIOL CHEM, V275, P23319, DOI 10.1074/jbc.M910438199; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	17	66	71	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7333	7335		10.1038/sj.onc.1209765	http://dx.doi.org/10.1038/sj.onc.1209765			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785986				2022-12-28	WOS:000242419100001
J	Gerondakis, S; Grumont, R; Gugasyan, R; Wong, L; Isomura, I; Ho, W; Banerjee, A				Gerondakis, S.; Grumont, R.; Gugasyan, R.; Wong, L.; Isomura, I.; Ho, W.; Banerjee, A.			Unravelling the complexities of the NF-kappa B signalling pathway using mouse knockout and transgenic models	ONCOGENE			English	Review						NF-kappa B; IKK; I kappa B; knockout mice; transgenics	REL TRANSCRIPTION FACTORS; CELL-INTRINSIC EXPRESSION; SEVERE LIVER DEGENERATION; C-H TRANSCRIPTION; MATURE T-CELLS; MICE LACKING; IKK-BETA; TARGETED DISRUPTION; DENDRITIC CELLS; GERMINAL CENTER	The nuclear factor-kappa B (NF-kappa B) signalling pathway serves a crucial role in regulating the transcriptional responses of physiological processes that include cell division, cell survival, differentiation, immunity and inflammation. Here we outline studies using mouse models in which the core components of the NF-kappa B pathway, namely the I kappa B kinase subunits (IKK alpha, IKK beta and NEMO), the I kappa B ;proteins (I kappa B alpha, I kappa B beta, I kappa B epsilon and Bcl-3) and the five NF-kappa B transcription factors (NF-kappa B1, NF-kappa B2, c-Rel, RelA and RelB), have been genetically manipulated using transgenic and knock out technology.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Gerondakis, S (corresponding author), Walter & Eliza Hall Inst Med Res, 1G Royal Parade, Melbourne, Vic 3050, Australia.	gerondakis@wehi.edu.au	Wong, W. Wei-Lynn/A-6851-2015	Wong, W. Wei-Lynn/0000-0003-3155-1211				Alcamo E, 2002, J EXP MED, V195, P233, DOI 10.1084/jem.20011885; Alcamo E, 2001, J IMMUNOL, V167, P1592, DOI 10.4049/jimmunol.167.3.1592; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1038/nm1185; Aronica MA, 1999, J IMMUNOL, V163, P5116; Artis D, 2005, J IMMUNOL, V174, P7154, DOI 10.4049/jimmunol.174.11.7154; Artis D, 2003, J IMMUNOL, V170, P1995, DOI 10.4049/jimmunol.170.4.1995; Attar RM, 1998, MOL CELL BIOL, V18, P477, DOI 10.1128/MCB.18.1.477; Aune TM, 1999, J IMMUNOL, V162, P5805; Banerjee A, 2006, P NATL ACAD SCI USA, V103, P3274, DOI 10.1073/pnas.0511113103; Banerjee D, 2005, IMMUNITY, V23, P445, DOI 10.1016/j.immuni.2005.09.012; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; Beinke S, 2004, BIOCHEM J, V382, P393, DOI 10.1042/BJ20040544; Bendall HH, 1999, MOL IMMUNOL, V36, P187, DOI 10.1016/S0161-5890(99)00031-0; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Caamano J, 1999, J IMMUNOL, V163, P4453; Caamano J, 2000, J IMMUNOL, V165, P5720, DOI 10.4049/jimmunol.165.10.5720; Caamano JH, 1998, J EXP MED, V187, P185, DOI 10.1084/jem.187.2.185; Cai DS, 2004, CELL, V119, P285, DOI 10.1016/j.cell.2004.09.027; Cai DS, 2005, NAT MED, V11, P183, DOI 10.1038/nm1166; Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Cariappa A, 2000, J EXP MED, V192, P1175, DOI 10.1084/jem.192.8.1175; Carlsen H, 2002, J IMMUNOL, V168, P1441, DOI 10.4049/jimmunol.168.3.1441; Carrasco D, 1996, EMBO J, V15, P3640, DOI 10.1002/j.1460-2075.1996.tb00733.x; Carrasco D, 1997, J EXP MED, V186, P279, DOI 10.1084/jem.186.2.279; Carrasco D, 1998, J EXP MED, V187, P973, DOI 10.1084/jem.187.7.973; Castglioni P, 2002, SCAND J IMMUNOL, V56, P219, DOI 10.1046/j.1365-3083.2002.01144.x; Chaisson ML, 2002, J CLIN INVEST, V110, P193, DOI 10.1172/JCI200215295; Chen CL, 2000, J IMMUNOL, V165, P5418, DOI 10.4049/jimmunol.165.10.5418; Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849; Chen XX, 2005, MOL CELL BIOL, V25, P3209, DOI 10.1128/MCB.25.8.3209-3219.2005; Cheng JD, 1998, J EXP MED, V188, P1055, DOI 10.1084/jem.188.6.1055; Cheng SH, 2003, ONCOGENE, V22, P8472, DOI 10.1038/sj.onc.1206917; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Corn RA, 2005, J IMMUNOL, V175, P2102, DOI 10.4049/jimmunol.175.4.2102; Corn RA, 2003, J IMMUNOL, V171, P1816, DOI 10.4049/jimmunol.171.4.1816; Courtois G, 2006, ONCOGENE, V25, P6831, DOI 10.1038/sj.onc.1209939; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dawn B, 2001, J MOL CELL CARDIOL, V33, P161, DOI 10.1006/jmcc.2000.1291; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Elewaut D, 2003, J EXP MED, V197, P1623, DOI 10.1084/jem.20030141; Esslinger CW, 1997, J IMMUNOL, V158, P5075; Ferreira V, 1999, J IMMUNOL, V162, P6442; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Franzoso G, 1997, IMMUNITY, V6, P479, DOI 10.1016/S1074-7613(00)80291-5; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; Fridmacher V, 2003, J NEUROSCI, V23, P9403; Gadjeva M, 2004, J IMMUNOL, V173, P5786, DOI 10.4049/jimmunol.173.9.5786; GELINAS C, 2006, ONCOGENE, V25, P6800; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Gerondakis S, 2003, SEMIN IMMUNOL, V15, P159, DOI 10.1016/S1044-5323(03)00036-8; Gerondakis S, 1996, P NATL ACAD SCI USA, V93, P3405, DOI 10.1073/pnas.93.8.3405; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Gilmore TD, 2004, ONCOGENE, V23, P2275, DOI 10.1038/sj.onc.1207410; Goudeau B, 2003, P NATL ACAD SCI USA, V100, P15800, DOI 10.1073/pnas.2535880100; Graham B, 2005, CELL CYCLE, V4, P1342, DOI 10.4161/cc.4.10.2047; Grigoriadis G, 1996, EMBO J, V15, P7099, DOI 10.1002/j.1460-2075.1996.tb01101.x; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848; Grumont R, 2004, IMMUNITY, V21, P19, DOI 10.1016/j.immuni.2004.06.004; Grumont R, 2001, J EXP MED, V194, P1021, DOI 10.1084/jem.194.8.1021; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Grumont RJ, 2002, MOL CELL, V10, P1283, DOI 10.1016/S1097-2765(02)00779-7; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Guerin S, 2002, EUR J IMMUNOL, V32, P1; Gugasyan R, 2004, MOL CELL BIOL, V24, P5733, DOI 10.1128/MCB.24.13.5733-5745.2004; Hatada EN, 2003, J IMMUNOL, V171, P761, DOI 10.4049/jimmunol.171.2.761; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Hettmann T, 2000, J IMMUNOL, V165, P5004, DOI 10.4049/jimmunol.165.9.5004; Hettmann T, 1999, J EXP MED, V189, P145, DOI 10.1084/jem.189.1.145; Hilliard BA, 2002, J CLIN INVEST, V110, P843, DOI 10.1172/JCI200215254; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Horwitz BH, 1999, J IMMUNOL, V162, P1941; Horwitz BH, 1997, IMMUNITY, V6, P765, DOI 10.1016/S1074-7613(00)80451-3; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hunter RB, 2004, J CLIN INVEST, V114, P1504, DOI 10.1172/JCI200421696; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Ishikawa H, 1997, J EXP MED, V186, P999, DOI 10.1084/jem.186.7.999; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Kaltschmidt B, 2006, MOL CELL BIOL, V26, P2936, DOI 10.1128/MCB.26.8.2936-2946.2006; Kanters E, 2004, BLOOD, V103, P934, DOI 10.1182/blood-2003-05-1450; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kim S, 2003, P NATL ACAD SCI USA, V100, P1203, DOI 10.1073/pnas.0337707100; Klement JF, 1996, MOL CELL BIOL, V16, P2341; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Lamhamedi-Cherradi SE, 2003, J IMMUNOL, V171, P4886, DOI 10.4049/jimmunol.171.9.4886; Lavon I, 2000, NAT MED, V6, P573, DOI 10.1038/75057; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; Levenson JM, 2004, J NEUROSCI, V24, P3933, DOI 10.1523/JNEUROSCI.5646-03.2004; Li M, 2001, J BIOL CHEM, V276, P1185, DOI 10.1074/jbc.M006647200; Li QT, 2005, P NATL ACAD SCI USA, V102, P12425, DOI 10.1073/pnas.0505997102; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 2003, J IMMUNOL, V170, P4630, DOI 10.4049/jimmunol.170.9.4630; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Lind MH, 2004, P NATL ACAD SCI USA, V101, P4972, DOI 10.1073/pnas.0307106101; Liou HC, 2003, BIOESSAYS, V25, P767, DOI 10.1002/bies.10306; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Luedde T, 2005, J CLIN INVEST, V115, P849, DOI 10.1172/JCI200523493; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Magness ST, 2004, J IMMUNOL, V173, P1561, DOI 10.4049/jimmunol.173.3.1561; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mason NJ, 2004, J IMMUNOL, V172, P3704, DOI 10.4049/jimmunol.172.6.3704; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Meffert MK, 2003, NAT NEUROSCI, V6, P1072, DOI 10.1038/nn1110; Memet S, 1999, J IMMUNOL, V163, P5994; Mintern JD, 2002, J IMMUNOL, V168, P3283, DOI 10.4049/jimmunol.168.7.3283; Mora AL, 2003, CELL DEATH DIFFER, V10, P1032, DOI 10.1038/sj.cdd.4401257; Norlin S, 2005, DIABETES, V54, P125, DOI 10.2337/diabetes.54.1.125; O'Donnell SM, 2005, J CLIN INVEST, V115, P2341, DOI 10.1172/JCI22428; O'Keeffe M, 2005, BLOOD, V106, P3457, DOI 10.1182/blood-2004-12-4965; Ong ST, 1998, ONCOGENE, V16, P2333, DOI 10.1038/sj.onc.1201771; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park JM, 2005, IMMUNITY, V23, P319, DOI 10.1016/j.immuni.2005.08.010; Pasparakis M, 2002, J EXP MED, V196, P743, DOI 10.1084/jem.20020907; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Pizzi M, 2002, J BIOL CHEM, V277, P20717, DOI 10.1074/jbc.M201014200; Pizzi M, 2005, CELL DEATH DIFFER, V12, P761, DOI 10.1038/sj.cdd.4401598; Pohl T, 2002, P NATL ACAD SCI USA, V99, P4514, DOI 10.1073/pnas.072071599; Prendes M, 2003, J IMMUNOL, V171, P3963, DOI 10.4049/jimmunol.171.8.3963; Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724; Romieu-Mourez R, 2003, MOL CELL BIOL, V23, P5738, DOI 10.1128/MCB.23.16.5738-5754.2003; Rudolph D, 2000, GENE DEV, V14, P854; Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081; Rupec RA, 2005, IMMUNITY, V22, P479, DOI 10.1016/j.immuni.2005.02.009; Samson SI, 2004, BLOOD, V103, P4573, DOI 10.1182/blood-2003-08-2975; Sanjabi S, 2000, P NATL ACAD SCI USA, V97, P12705, DOI 10.1073/pnas.230436397; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Schmidt-Supprian M, 2004, P NATL ACAD SCI USA, V101, P4566, DOI 10.1073/pnas.0400885101; Schmidt-Supprian M, 2003, IMMUNITY, V19, P377, DOI 10.1016/S1074-7613(03)00237-1; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; Schwabe RF, 2006, AM J PHYSIOL-GASTR L, V290, pG583, DOI 10.1152/ajpgi.00422.2005; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Sivakumar V, 2003, J EXP MED, V197, P1613, DOI 10.1084/jem.20022234; Snapper CM, 1996, J IMMUNOL, V156, P183; Speirs K, 2004, J IMMUNOL, V172, P752, DOI 10.4049/jimmunol.172.2.752; Speirs K, 2002, J IMMUNOL, V168, P4406, DOI 10.4049/jimmunol.168.9.4406; Strasser A, 1999, EUR J IMMUNOL, V29, P928, DOI 10.1002/(SICI)1521-4141(199903)29:03<928::AID-IMMU928>3.3.CO;2-G; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tato CM, 2006, INT IMMUNOL, V18, P505, DOI 10.1093/intimm/dxh391; Tato CM, 2003, J IMMUNOL, V170, P3139, DOI 10.4049/jimmunol.170.6.3139; Thomas R, 2005, ARTHRITIS RES THER, V7, P170, DOI 10.1186/ar1784; van Hogerlinden M, 1999, CANCER RES, V59, P3299; Voll RE, 2000, IMMUNITY, V13, P677, DOI 10.1016/S1074-7613(00)00067-4; Wang Y, 2004, CANCER RES, V64, P6240, DOI 10.1158/0008-5472.CAN-04-0591; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 2003, IMMUNOL REV, V195, P91, DOI 10.1034/j.1600-065X.2003.00064.x; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wu L, 1998, IMMUNITY, V9, P839, DOI 10.1016/S1074-7613(00)80649-4; Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yang H, 2002, TRANSPLANTATION, V74, P291, DOI 10.1097/00007890-200208150-00002; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004; Zanetti M, 2003, ANN NY ACAD SCI, V987, P249, DOI 10.1111/j.1749-6632.2003.tb06056.x; Zhang JY, 2004, GENE DEV, V18, P17, DOI 10.1101/gad.1160904; Zheng Y, 2003, J EXP MED, V197, P861, DOI 10.1084/jem.20021610	184	234	245	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 30	2006	25	51					6781	6799		10.1038/sj.onc.1209944	http://dx.doi.org/10.1038/sj.onc.1209944			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	100KD	17072328				2022-12-28	WOS:000241666700008
J	Zeng, Y				Zeng, Y.			Principles of micro-RNA production and maturation	ONCOGENE			English	Review						micro-RNA; micro-RNA processing; Drosha; precursor miRNAs	DOUBLE-STRANDED-RNA; MEDIATES NUCLEAR EXPORT; STRUCTURAL BASIS; HUMAN DICER; BINDING; GENE; IDENTIFICATION; INTERFERENCE; BIOGENESIS; PROTEIN	Micro-RNAs ( miRNAs) are a class of approximately 22-nucleotide non-coding RNAs expressed in multicellular organisms. They are first transcribed in a similar manner to pre-mRNAs. The transcripts then go through a series of processing steps, including endonucleolytic cleavage, nuclear export and a strand selection procedure, to yield the single-stranded mature miRNA products. The transcription and processing of miRNAs determines the abundance and the sequence of mature miRNAs and has important implications for the function of miRNAs.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Zeng, Y (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	zengx033@umn.edu						Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803; Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Andersson MG, 2005, J VIROL, V79, P9556, DOI 10.1128/JVI.79.15.9556-9565.2005; Aukerman MJ, 2003, PLANT CELL, V15, P2730, DOI 10.1105/tpc.016238; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Blow MJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r27; Bohnsack MT, 2004, RNA, V10, P185, DOI 10.1261/rna.5167604; Bracht J, 2004, RNA, V10, P1586, DOI 10.1261/rna.7122604; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Conaco C, 2006, P NATL ACAD SCI USA, V103, P2422, DOI 10.1073/pnas.0511041103; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Du TT, 2005, DEVELOPMENT, V132, P4645, DOI 10.1242/dev.02070; Eliceiri GL, 1999, CELL MOL LIFE SCI, V56, P22, DOI 10.1007/s000180050003; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Feinbaum R, 1999, DEV BIOL, V210, P87, DOI 10.1006/dbio.1999.9272; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Gwizdek C, 2003, J BIOL CHEM, V278, P5505, DOI 10.1074/jbc.C200668200; Haase AD, 2005, EMBO REP, V6, P961, DOI 10.1038/sj.embor.7400509; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hiraguri A, 2005, PLANT MOL BIOL, V57, P173, DOI 10.1007/s11103-004-6853-5; Houbaviy HB, 2005, RNA, V11, P1245, DOI 10.1261/rna.2890305; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Ishizuka A, 2002, GENE DEV, V16, P2497, DOI 10.1101/gad.1022002; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Johnson SM, 2003, DEV BIOL, V259, P364, DOI 10.1016/S0012-1606(03)00202-1; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kurihara Y, 2006, RNA, V12, P206, DOI 10.1261/rna.2146906; Kurihara Y, 2004, P NATL ACAD SCI USA, V101, P12753, DOI 10.1073/pnas.0403115101; Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921; Lai EC, 2005, GENE DEV, V19, P1067, DOI 10.1101/gad.1291905; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062; Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2006, EMBO J, V25, P522, DOI 10.1038/sj.emboj.7600942; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lee Y, 2002, EMBO J, V21, P4663, DOI 10.1093/emboj/cdf476; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li JJ, 2005, CURR BIOL, V15, P1501, DOI 10.1016/j.cub.2005.07.029; Lim LP, 2003, GENE DEV, V17, P991, DOI 10.1101/gad.1074403; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Luciano DJ, 2004, RNA, V10, P1174, DOI 10.1261/rna.7350304; Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; MacRae IJ, 2006, SCIENCE, V311, P195, DOI 10.1126/science.1121638; Mallory AC, 2004, EMBO J, V23, P3356, DOI 10.1038/sj.emboj.7600340; Maniataki E, 2005, GENE DEV, V19, P2979, DOI 10.1101/gad.1384005; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Papp I, 2003, PLANT PHYSIOL, V132, P1382, DOI 10.1104/pp.103.021980; Park MY, 2005, P NATL ACAD SCI USA, V102, P3691, DOI 10.1073/pnas.0405570102; Pfeffer S, 2005, NAT METHODS, V2, P269, DOI 10.1038/NMETH746; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Shen BZ, 2004, SCIENCE, V306, P997, DOI 10.1126/science.1103521; Sokol NS, 2005, GENE DEV, V19, P2343, DOI 10.1101/gad.1356105; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tam W, 2001, GENE, V274, P157, DOI 10.1016/S0378-1119(01)00612-6; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Yu B, 2005, SCIENCE, V307, P932, DOI 10.1126/science.1107130; Zeng Y, 2003, RNA, V9, P112, DOI 10.1261/rna.2780503; Zeng Y, 2005, EMBO J, V24, P138, DOI 10.1038/sj.emboj.7600491; Zeng Y, 2005, J BIOL CHEM, V280, P27595, DOI 10.1074/jbc.M504714200; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	97	203	248	1	39	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2006	25	46					6156	6162		10.1038/sj.onc.1209908	http://dx.doi.org/10.1038/sj.onc.1209908			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	093HL	17028594				2022-12-28	WOS:000241158900003
J	Fantin, VR; Leder, P				Fantin, V. R.; Leder, P.			Mitochondriotoxic compounds for cancer therapy	ONCOGENE			English	Review						mitochondria; cancer; therapy; cell death; peptide; conjugate	PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; PERIPHERAL BENZODIAZEPINE-RECEPTORS; DIAZEPAM-BINDING INHIBITOR; SMALL-MOLECULE INHIBITORS; CELL-CYCLE ARREST; BCL-X-L; TUMOR-CELLS; IN-VIVO; CARCINOMA-CELLS	One of the hallmarks of cancer cells is their increased resistance to apoptosis induction. Alterations in many apoptosis regulators belonging to the intrinsic pathway confer emerging neoplastic cells with a selective growth advantage in the hostile tumor microenvironment. The realization that those same defects contribute to resistance to radiation and chemotherapeutic agents have prompted the unrelenting search for mitochondria-targeted compounds for the treatment of cancer. Mitochondria play a central role in the process of cell death. They serve as integrators of upstream effector mechanisms. Most importantly, mitochondrial outer membrane permeabilization becomes a commitment point during cell death. Thus, strategies aimed at directly triggering this event by either blocking the activity of antiapoptotic factors or by interfering with vital mitochondrial functions may help to overcome resistance to standard cancer therapy.	Merck & Co Inc, Boston, MA USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Howard Hughes Med Inst, Boston, MA 02115 USA	Merck & Company; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Fantin, VR (corresponding author), Merck & Co Inc, Boston, MA USA.	valeria_fantin@merck.com						ANDERSON WM, 1989, BIOCHEM INT, V19, P673; Andre N, 2002, FEBS LETT, V532, P256, DOI 10.1016/S0014-5793(02)03691-8; Beinlich A, 2000, BIOCHEM PHARMACOL, V60, P397, DOI 10.1016/S0006-2952(00)00325-7; Belzacq AS, 2001, ONCOGENE, V20, P7579, DOI 10.1038/sj.onc.1204953; BENZ CC, 1990, MOL PHARMACOL, V37, P840; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; Borner C, 2003, MOL IMMUNOL, V39, P615, DOI 10.1016/S0161-5890(02)00252-3; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brewis ND, 2003, MOL THER, V7, P262, DOI 10.1016/S1525-0016(02)00054-0; Britten CD, 2000, CLIN CANCER RES, V6, P42; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; Chahboune N, 2006, BIOORGAN MED CHEM, V14, P1089, DOI 10.1016/j.bmc.2005.09.036; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cb.04.110188.001103; Chernyak BV, 1996, EUR J BIOCHEM, V238, P623, DOI 10.1111/j.1432-1033.1996.0623w.x; Chevrollier A, 2005, J BIOENERG BIOMEMBR, V37, P307, DOI 10.1007/s10863-005-8642-5; Chiba Y, 1998, ANTICANCER RES, V18, P1047; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Costantini P, 2000, ONCOGENE, V19, P307, DOI 10.1038/sj.onc.1203299; Csordas G, 2002, EMBO J, V21, P2198, DOI 10.1093/emboj/21.9.2198; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Decaudin D, 2002, CANCER RES, V62, P1388; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dharap SS, 2003, PHARMACEUT RES, V20, P889, DOI 10.1023/A:1023839319950; Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Eiznhamer DA, 2004, IDRUGS, V7, P359; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enyedy IJ, 2001, J MED CHEM, V44, P4313, DOI 10.1021/jm010016f; EPAND RM, 1995, BIOPOLYMERS, V37, P319, DOI 10.1002/bip.360370504; Fantin VR, 2005, CANCER RES, V65, P6891, DOI 10.1158/0008-5472.CAN-05-0395; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Forte M, 2005, J BIOENERG BIOMEMBR, V37, P121, DOI 10.1007/s10863-005-6565-9; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Geschwind JFH, 2002, CANCER RES, V62, P3909; Goldsmith KC, 2005, CANCER LETT, V228, P133, DOI 10.1016/j.canlet.2005.01.048; Gonzalez-Polo RA, 2005, ONCOGENE, V24, P7503, DOI 10.1038/sj.onc.1208907; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Guo PG, 2001, CANCER CHEMOTH PHARM, V48, P169, DOI 10.1007/s002800100284; Halestrap AP, 2003, CURR MED CHEM, V10, P1507, DOI 10.2174/0929867033457278; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hsu CA, 1997, BLOOD, V89, P4470, DOI 10.1182/blood.V89.12.4470; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Jameel JKA, 2004, BREAST, V13, P452, DOI 10.1016/j.breast.2004.08.004; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; Javadpour MM, 1996, J MED CHEM, V39, P3107, DOI 10.1021/jm9509410; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kadenbach B, 2003, BBA-BIOENERGETICS, V1604, P77, DOI 10.1016/S0005-2728(03)00027-6; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kandela IK, 2003, BIOTECH HISTOCHEM, V78, P157, DOI 10.1080/10520290310001597050; Kang DC, 2005, CURR MED CHEM, V12, P429, DOI 10.2174/0929867053363081; KATZ Y, 1990, CLIN SCI, V78, P155, DOI 10.1042/cs0780155; Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282; Kitada S, 2003, J MED CHEM, V46, P4259, DOI 10.1021/jm030190z; Kitada S, 2002, ONCOGENE, V21, P3459, DOI 10.1038/sj.onc.1205327; Kolonin MG, 2004, NAT MED, V10, P625, DOI 10.1038/nm1048; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; Korsmeyer SJ, 2000, CELL DEATH DIFFER, V7, P1166, DOI 10.1038/sj.cdd.4400783; Kroemer G, 2002, BIOCHIMIE, V84, P103, DOI 10.1016/S0300-9084(02)01382-2; Kroemer G, 1999, JNCI-J NATL CANCER I, V91, P743, DOI 10.1093/jnci/91.9.743; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; Lacerda SHD, 2005, PHOTOCHEM PHOTOBIOL, V81, P1430, DOI 10.1562/2005-08-05-RA-639; LINDEN M, 1982, FEBS LETT, V141, P189, DOI 10.1016/0014-5793(82)80044-6; Liu H, 2001, BIOCHEMISTRY-US, V40, P5542, DOI 10.1021/bi002426w; Lo S, 2005, INT J ONCOL, V27, P337; Maaser K, 2001, BRIT J CANCER, V85, P1771, DOI 10.1054/bjoc.2001.2181; MAJIMA E, 1994, BIOCHEMISTRY-US, V33, P9530, DOI 10.1021/bi00198a019; MAJIMA E, 1995, J BIOL CHEM, V270, P29548, DOI 10.1074/jbc.270.49.29548; Marchetti P, 1999, CANCER RES, V59, P6257; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MIETTINEN H, 1995, CANCER RES, V55, P2691; MIYASHITA T, 1993, BLOOD, V81, P151; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; ModicaNapolitano JS, 1996, CANCER RES, V56, P544; Moretti JL, 2005, EUR J NUCL MED MOL I, V32, P836, DOI 10.1007/s00259-005-1840-x; NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pani G, 2004, CURR MED CHEM, V11, P1299, DOI 10.2174/0929867043365297; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pedersen PL, 2002, BBA-BIOENERGETICS, V1555, P14, DOI 10.1016/S0005-2728(02)00248-7; Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004; Propper DJ, 1999, ANN ONCOL, V10, P923, DOI 10.1023/A:1008336904585; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; REED JC, 1990, P NATL ACAD SCI USA, V87, P3660, DOI 10.1073/pnas.87.10.3660; REED JC, 1990, CANCER RES, V50, P6565; Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Schadendorf D, 1996, J CELL BIOL, V135, P1889, DOI 10.1083/jcb.135.6.1889; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; SINGH G, 1992, PHARMACOL THERAPEUT, V54, P217, DOI 10.1016/0163-7258(92)90033-V; Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; SUMMERHAYES IC, 1982, P NATL ACAD SCI-BIOL, V79, P5292, DOI 10.1073/pnas.79.17.5292; Sutter AP, 2002, INT J CANCER, V102, P318, DOI 10.1002/ijc.10724; TEICHER BA, 1986, BIOCHEM PHARMACOL, V35, P3365, DOI 10.1016/0006-2952(86)90437-5; Trapp S, 2005, EUR BIOPHYS J BIOPHY, V34, P959, DOI 10.1007/s00249-005-0472-1; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Venturini I, 1999, LIFE SCI, V65, P2223, DOI 10.1016/S0024-3205(99)00487-7; Vieira Helena L. A., 2002, Oncogene, V21, P1963, DOI 10.1038/sj.onc.1205270; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Walter RB, 2005, BLOOD, V106, P3584, DOI 10.1182/blood-2005-02-0711; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wang JL, 2000, CANCER RES, V60, P1498; Weissig V, 2004, MITOCHONDRION, V3, P229, DOI 10.1016/j.mito.2003.11.002; Xu L, 2005, MOL CANCER THER, V4, P197; Yamada Y, 2005, INT J PHARMACEUT, V303, P1, DOI 10.1016/j.ijpharm.2005.06.009; Yin H, 2005, J AM CHEM SOC, V127, P10191, DOI 10.1021/ja050122x; Zamzami N, 2005, CELL DEATH DIFFER, V12, P1478, DOI 10.1038/sj.cdd.4401682; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440	117	113	116	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2006	25	34					4787	4797		10.1038/sj.onc.1209599	http://dx.doi.org/10.1038/sj.onc.1209599			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QD	16892091				2022-12-28	WOS:000239687000015
